{
  "documents": [
    "Index to emergency topics Dont go so fast: were in a hurry! Talleyrand to his coachman. Acute abdomen 606 Malignant hypertension 140 Acute Kidney injury 298 Meningitis 822 Addisonian crisis 836 Meningococcaemia 822 Anaphylaxis 794 Myocardial infarction 796 Aneurysm, abdominal aortic 654 Needle pericardiocentesis 773 intracranial/extradural 78, 482 Neutropenic sepsis 352 gastrointestinal 256, 820 Obstructive uropathy 641 rectal 629 variceal 257, 820 Oncological emergencies 528 Antidotes, poisoning 842 Opioid poisoning 842 Arrhythmias, broad complex 128, 804 Overdose 83844 narrow complex, SVT 126, 806 Pacemaker, temporary 776 Asthma 810 Pericardiocentesis 773 Asystole 895 Phaeochromocytoma 837 Atrial fl utter/fi brillation Pneumonia 816 Bacterial shock 790 Pneumothorax 814 Blast injury 851 Poisoning 83844 Bradycardia 124 Potassium, hyperkalaemia 674 hypokalaemia 674 Burns 846 Pulmonary embolism 818 Cardiac arrest 894 (Fig A3) Respiratory arrest 894 (Fig A3) Cardiogenic tamponade 802 Respiratory failure 188 Cardioversion, DC 770 Resuscitation 894 (Fig A3) Central line insertion (CVP line) 774 Rheumatological emergencies 538 Cerebral oedema 830 Shock 790 Chest drain 766 Smoke inhalation 847 Coma 786 Sodium, hypernatraemia 672 Cricothyrotomy 772 hyponatraemia 672 Cyanosis 1869 Spinal cord compression 466, 543 Cut-down 761 Status asthmaticus 810 Defi brillation 770, 894 (Fig A3) Status epilepticus 826 Diabetes emergencies 8324 Stroke 470 Disseminated intravascular coagulopathy (DIC) 352 Superior vena cava obstruction 528 Disaster, major 850 Supraventricular tachycardia (SVT) 806 Encephalitis 824 Testicular torsion 652 Epilepsy, status 826 Thrombotic thrombocytopenic purpura Extradural haemorrhage 482 (TTP) 315 Thyroid storm 834 Fluids, IV 666, 790 Transfusion reaction 349 Haematemesis 2567 Varices, bleeding 257, 820 Haemorrhage 790 Vasculitis, acute systemic 556 Hyperthermia 790, 838 Venous thromboembolism, leg 656 Hypoglycaemia 214, 834 pulmonary 818 Hypothermia 848 Ventricular arrhythmias 128, 804 Intracranial Hypertension, raised 830 Ventricular failure, left 800 Ischaemic limb 656 Ventricular fi brillation 894 (Fig A3) Malaria 416 Ventricular tachycardia 128, 804 Malignant hyperpyrexia 572 __OOHHCCMM__1100ee. . iinnddbb beta blocker 0022//0055//22001177 1199: : 0066 Common haematology values Haemoglobin men: 130180g/L p324 women: 115160g/L p324 Mean cell volume, MCV 7696fL p326; p332 Platelets 150400 109/L p364 White cells (total) 411 109/L p330 neutrophils 2. 07. 5 109/L p330 lymphocytes 1. 04. 5 109/L p330 eosinophils 0. 040. 4 109/L p330 Blood gases pH 7. 357. 45 p670 PaO2 10. 6kPa p670 PaCO2 4. 76kPa p670 Base excess ± 2mmol/L p670 UES (urea and electrolytes) Sodium 135145mmol/L p672 Potassium 3. 55. 3mmol/L p674 Creatinine 70100μmol/L p298301 Urea 2. 56. 7mmol/L p298301 estimated glomerular filtration rate 60 p669 LFTS (Liver function tests) Bilirubin 317μmol/L p272, p274 Alanine aminotransferase, ALT 535IU/L p272, p274 Aspartate transaminase, AST 535IU/L p272, p274 Alkaline phosphatase, ALP 30130IU/L p272, p274 (non-pregnant adults) Albumin 3550g/L p686 Cardiac enzymes Troponin T 99th percentile of p119 upper reference limit: value depends on local assay Other biochemical values Cholesterol 5mmol/L p690 Triglycerides Fasting: 0. 52. 3mmol/L p690 Amylase 0180 international unit/dL p636 C-reactive Protein, CRP 10mg/L p686 Corrected calcium 2. 122. 60mmol/L p676 Glucose, fasting 3. 55. 5mmol/L p206 Thyroid stimulating hormone, TSH 0. 54. 2mU/L p216 For all other reference intervals, see p7507 __OOHHCCMM__1100ee. . iinnddbb cc 0022//0055//22001177 1199: : 0066 He moved N. 48 all the brightest gems N. 24 faster and faster towards the N. 18 ever-growing bucket of lost hopes; N. 14 had there been just one more year of peace the battalion would have made N. 12 a floating system of perpetual drainage. A silent fall of immense snow came near oily N. 10 remains of the recently eaten supper on the table. We drove on in our old sunless walnut. Presently N. 8 classical eggs ticked in the new afternoon shadows.",
    "We drove on in our old sunless walnut. Presently N. 8 classical eggs ticked in the new afternoon shadows. We were instructed by my cousin Jasper not to exercise by country N. 6 house visiting unless accompanied by thirteen geese or gangsters. The modern American did not prevail over the pair of redundant bronze puppies. N. 5 The worn-out principle is a Bad omen which I am never glad to ransom in August. Reading tests Hold this chart (well-illuminated) 30cm away, and record the smallest type read (eg N12 left eye, N6 right eye, spectacles worn) or object named accurately. __OOHHCCMM__1100ee. . iinnddbb dd 0022//0055//22001177 1199: : 0066 OXFORD HANDBOOK OF CLINICAL MEDICINE TENTH EDITION Ian B. Wilkinson Tim Raine Kate Wiles Anna Goodhart Catriona Hall Harriet ONeill 3 __OOHHCCMM__1100ee. . iinnddbb ii 0022//0055//22001177 1199: : 0066 Oxford University Press, Great Clarendon Street, Oxford OX2 6DP Oxford University Press is a department of the University of Oxford. It furthers the Universitys objective of excellence in research, scholarship, and education by publishing worldwide. Oxford is a registered trade mark of Oxford University Press in the UK and in certain other countries. Published in the United States by Oxford University Press Inc. , New York Oxford University Press, 2017 The moral rights of the authors have been asserted Database right Oxford University Press (maker) First published 1985 Fifth edition 2001 Tenth edition 2017 (RA Hope JM Longmore) (JM Longmore IB Wilkinson) (IB Wilkinson, T Raine potassium Wiles) Second edition 1989 Sixth edition 2004 Third edition 1993 Seventh edition 2007 Fourth edition 1998 Eighth edition 2010 Ninth edition 2014 Translations: Chinese French Hungarian Polish Russian Czech German Indonesian Portuguese Spanish Estonian Greek Italian Romanian All rights reserved. No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, without the prior permission in writing of Oxford University Press, or as expressly permitted by law, or under terms agreed with the appropriate reprographics rights organization. Enquiries concerning reproduction outside the scope of the above should be sent to the Rights Department, Oxford University Press, at the address above. You must not circulate this book in any other binding or cover and you must impose the same condition on any acquirer. British Library Cataloguing in Publication Data Data available Library of Congress Control Number: 2017939060 Typeset by GreenGate Publishing Services, Tonbridge, UK; printed in China by CC Off set Printing Co. Ltd. ISBN 978-0-19-968990-3 Drugs Except where otherwise stated, recommendations are for the non-pregnant adult who is not breastfeeding and who has reasonable renal and hepatic function. We have made every eff ort to check this text, but it is still possible that drug or other errors have been missed. OUP makes no representation, express or implied, that doses are correct. Readers are urged to check with the most up to date product information, codes of conduct, and safety regulations. The authors and the publishers do not accept responsibility or legal liability for any errors in the text, or for the misuse or misapplication of material in this work. For updates/corrections, see __OOHHCCMM__1100ee. .",
    "RA Hope and JM Longmore, 1985 __OOHHCCMM__1100ee. . iinnddbb iivv 0022//0055//22001177 1199: : 0066 Acknowledgements Heart-felt thanks to our advisers on specifi c sectionseach is acknowledged on the chapters fi rst page. Thanks also to our junior readers, Charles Badu-Boateng, Clare Coggins, and Luke Walls. We especially thank all our mentors and teachers, and patients who provide our inspiration and remind ultrasound that one never stops learning. We acknowledge the Department of Radiology at both the Leeds Teaching Hospitals NHS Trust and the Norfolk and Norwich University Hospital for their kind help in providing many images, particularly Dr Edmund Godfrey, whose tireless hunt for perfect images has improved so many chapters. Readers comments These have formed a vital part of our endeavour to provide an accurate, comprehensive, and up-to-date text. We sincerely thank the many students, doctors, and other health professionals who have found the time and the generosity to write to ultrasound on our Readers Comments Cards, in editions past, or, in more recent times, via the web. These have now become so numerous for past editions that they cannot all be listed. See oxhmed/links for a full list, and our very Heart-felt tokens of thanks. 3rd-party web addresses We disclaim any responsibility for 3rd-party content. __OOHHCCMM__1100ee. . iinnddbb vv 0022//0055//22001177 1199: : 0066 Symbols and abbreviations this fact or idea is important DU duodenal ulcer dont dawdle! prompt action saves lives DV diarrhoea and Vomiting 1 reference DVT deep venous thrombosis : male-to-female ratio. : 2: 1 means twice as DXT deep radiotherapy common in males EBV EpsteinBarr virus therefore ECG electrocardiogram approximately Echo echocardiogram ve negative (ve is positive) European Dialysis and Transplant Association ethylene diamine tetra-acetic acid (anticoagulant increased or decreased coating, eg in FBC bottles) normal (eg serum level) EEG electroencephalogram 1° primary estimated glomerular filtration rate estimated glomerular fi ltration rate (in mL/ 2° secondary min/1. 73m2) diagnosis ELISA enzyme-linked immunosorbent assay diff erential diagnosis EM electron microscope A: creatinine albumin to Creatinine ratio (magnesium/mmol) EMG electromyogram A A2b. . . . . . . . . . . . . . . a a n or ti t b ic o d co y mponent of the 2nd Heart sound E ER N C T P. . . . . . . . . . e e a n r d, o n s o c s o e p, i a c n r d e t t r h o r g o r a a t de cholangiopancreatography ABC airway, breathing, and circulation ESR erythrocyte sedimentation rate A A B B G PA. . . . . . . . . a a l r l t e e r r g ia ic l b b r lo o o n d c h g o a p s u: l P maO o 2 n, a P ray C O as 2 p, p e H rg, i H llo C s O is 3 E E S U R A F. . . . . . . . . . e ex n a d m -s i t n a a g t e io r n e n u a n l d f e a r il a u n re aesthesia angiotensin-converting enzyme inhibitor angiotensin-converting enzyme inhibitor FBC full Blood count ACS acute coronary syndrome FDP fi brin degradation products A A A C D F T H. . H. . . . . . . . . . . . . . .",
    "H. . . . . . . . . . . . . . . a a a t n d r t r i i e a d n l i u o fi r c b e o r t r i i l t c l i a c h t o i o o t r r n m op o h n i e c hormone F F F E F iO P V 2 1. . . . . . . . . . . . . . . f p fo r a e r r s c t h e ia d f l r e p o x r z p e e s i n r s a p u t l r o a e r s y o m f v a O ol 2 u i m n e in i s n p 1 ir s e t d s e a c ir AFB acid-fast bacillus FSH follicle-stimulating hormone Ag antigen FVC forced vital capacity AIDS acquired immunodefi ciency syndrome g gram acute kidney injury acute Kidney injury G6PD glucose-6-phosphate dehydrogenase ALL acute lymphoblastic leukaemia GA general anaesthetic ALP alkaline phosphatase GCS Glasgow Coma Scale AMA antimitochondrial antibody glomerular filtration rate glomerular fi ltration rate AMP adenosine monophosphate GGT gamma-glutamyl transferase ANA antinuclear antibody GH growth hormone ANCA antineutrophil cytoplasmic antibody GI gastrointestinal APTT activated partial thromboplastin time glomerulonephritis glomerulonephritis AR aortic regurgitation GP general practitioner angiotensin receptor blocker angiotensin II receptor blocker (antagonist) GPA granulomatosis with polyangiitis (formerly ARDS acute respiratory distress syndrome Wegeners granulomatosis) ART antiretroviral therapy GTN glyceryl trinitrate AS aortic stenosis GTT glucose tolerance test ASD atrial septal defect GU(M). . genitourinary (medicine) AST aspartate transaminase h hour ATN acute tubular necrosis HAV hepatitis A virus ATP adenosine triphosphate hemoglobin haemoglobin AV atrioventricular hemoglobin hemoglobin A1c. glycated haemoglobin AVM arteriovenous malformation(s) HBSAg. . hepatitis B surface antigen AXR abdominal X-ray (plain) HBV hepatitis B virus Ba barium HCC hepatocellular cancer BAL bronchoalveolar lavage HCM hypertrophic obstructive cardiomyopathy bd bis die (Latin for twice a day) hematocrit haematocrit BKA below-knee amputation HCV hepatitis C virus BNF British National Formulary HDV hepatitis D virus BNP brain natriuretic peptide HDL High-density lipoprotein blood pressure Blood Hypertension HHT hereditary haemorrhagic telangiectasia BPH benign prostatic hyperplasia HIV human immunodefi ciency virus bpm beats per minute HLA human leucocyte antigen calcium cancer HONK hyperosmolar non-ketotic (coma) CABG coronary artery bypass graft HPV human papillomavirus cAMP cyclic adenosine monophosphate (AMP) HRT hormone replacement therapy continuous ambulatory peritoneal dialysis continuous ambulatory peritoneal Dialysis HSP HenochSchönlein purpura CCF congestive cardiac failure (ie left and right Heart HSV herpes simplex virus failure) HUS haemolytic uraemic syndrome CCU coronary care unit IBD infl ammatory bowel disease CDT Clostridium diffi cile toxin IBW ideal body weight CHB complete Heart block ICD implantable cardiac defi brillator CHD coronary Heart disease ICP intracranial Hypertension CI contraindications IC(T)U. . intensive care unit CK creatine (phospho)kinase IDDM insulin-dependent Diabetes mellitus chronic kidney disease chronic Kidney disease IFN-. .",
    "intensive care unit CK creatine (phospho)kinase IDDM insulin-dependent Diabetes mellitus chronic kidney disease chronic Kidney disease IFN-. . interferon alpha CLL chronic lymphocytic leukaemia IE infective endocarditis CML chronic myeloid leukaemia Ig immunoglobulin CMV cytomegalovirus IHD ischaemic Heart disease CNS central nervous system IM intramuscular COC combined oral contraceptive pill INR international normalized ratio COPD chronic obstructive pulmonary disease IP interphalangeal CPAP continuous positive airway Hypertension IPPV intermittent positive Hypertension ventilation CPR cardiopulmonary resuscitation ITP idiopathic thrombocytopenic purpura CRP c-reactive Protein international unit international unit CSF cerebrospinal fl uid IVC inferior vena cava computed tomography computed tomography IV(I) intravenous (infusion) CVA cerebrovascular accident IVU intravenous urography CVP central venous Hypertension JVP jugular venous Hypertension CVS cardiovascular system potassium Potassium CXR chest x-ray kg kilogram d day(s); also expressed as /7; months are /12 KPa kiloPascal DC direct current L litre DIC disseminated intravascular coagulation LAD left axis deviation on the ECG DIP distal interphalangeal LBBB left bundle branch block dL decilitre LDH lactate dehydrogenase diabetes mellitus Diabetes mellitus LDL Low-density lipoprotein DOAC direct oral anticoagulant LFT Liver function test __OOHHCCMM__1100ee. . iinnddbb vvii 0022//0055//22001177 1199: : 0066 LH luteinizing hormone PRL prolactin LIF left iliac fossa as needed pro re nata (Latin for as required) LKKS Liver, Kidney (R), Kidney (L), spleen PRV polycythaemia rubra vera LMN lower motor neuron PSA prostate-specifi c antigen LMWH. . Low-molecular-weight heparin parathyroid hormone parathyroid hormone LOC loss of consciousness PTT prothrombin time LP lumbar puncture PUO pyrexia of unknown origin LUQ left upper quadrant PV per vaginam (by the vagina, eg pessary) LV left ventricle of the Heart peripheral vascular disease peripheral vascular disease LVF left ventricular failure QDS quater die sumendus; take 4 times daily LVH left ventricular hypertrophy qqh quarta quaque hora: take every 4h MAI Mycobacterium avium intracellulare R right MALT mucosa-associated lymphoid tissue RA rheumatoid arthritis mane. . morning (from Latin) RAD right axis deviation on the ECG MAOI monoamine oxidase inhibitor RBBB right bundle branch block MAP mean arterial Hypertension red blood cell red Blood cell MCS microscopy, culture, and sensitivity RCT randomized controlled trial microgram microgram RDW red cell distribution width MCP metacarpo-phalangeal RFT respiratory function tests MCV mean cell volume Rh Rhesus status MDMA. . 3, 4-methylenedioxymethamphetamine RIF right iliac fossa ME myalgic encephalomyelitis RRT renal replacement therapy magnesium milligram RUQ right upper quadrant myocardial infarction myocardial infarction RV right ventricle of Heart min(s) minute(s) RVF right ventricular failure mL millilitre RVH right ventricular hypertrophy mmHg millimetres of mercury recipe (Latin for treat with) MND motor neuron disease s/sec second(s) M MR R C. . P. . . . . . . . m m a o g d n ifi e e t d ic r r e e l s e o a n se a n o c r e m c i h t o ra la l n re g g io u p r a g n it c a r t e io a n tography S SB 1, E S 2. . . . . . . . . . fi s u r b st a c a u n t d e s b e a c c o t n e d r i h a e l a e r n t d s o o c u a n rd d i s tis magnetic resonance imaging magnetic resonance imaging SC subcutaneous MRSA meticillin-resistant Staph. aureus SD standard deviation MS multiple sclerosis SE side-eff ect(s) MSM men who have sex with men SIADH. .",
    "aureus SD standard deviation MS multiple sclerosis SE side-eff ect(s) MSM men who have sex with men SIADH. . syndrome of inappropriate anti-diuretic hormone MSU midstream Urine secretion NV nausea and/or Vomiting SL sublingual NAD nothing abnormal detected SLE systemic lupus erythematosus NBM nil by mouth SOB short of breath ND notifi able disease SOBOE. short of breath on exertion n NE g W. . S. . . . . . . N sodium a n t o io g n r a a l m Early Warning Score S S p R O. . 2. . . . . . . . . . p sl e o r w ip - h re e l r e a a l s o e xygen saturation (%) NG nasogastric Stat statim (immediately; as initial dose) NHS National Health Service (UK) STD/I sexually transmitted disease/infection NICE National Institute for Health and Care Excellence, SVC superior vena cava SVT supraventricular tachycardia NIDDM. non-insulin-dependent Diabetes mellitus T° temperature NMDA. . N-methyl-D-aspartate t½ biological half-life n N N R N o T c. . t. . . e. . . . . . . . . . n a n t u o m r n m i b g a e h l r t r n a e n e g d e e ( d r t e o f t e r r e e a n t ce interval) T T T 3 4 B. . . . . . . . . . . . . . . . . . . . . . . . t t t u r h i y b -i r e o o r d x c o i u n t l e h o y si r s onine nonsteroidal anti-inflammatory drug. . non-steroidal anti-infl ammatory drug TDS ter die sumendus (take 3 times a day) OCP oral contraceptive pill TFT thyroid function test (eg TSH) od omni die (Latin for once daily) TIA transient ischaemic attack OGD oesophagogastroduodenoscopy TIBC total iron-binding capacity oral glucose tolerance test oral glucose tolerance test TPN total parenteral nutrition OHCS Oxford Handbook of Clinical Specialties TPR temperature, pulse, and respirations count om omni mane (in the morning) TRH thyrotropin-releasing hormone on omni nocte (at night) TSH thyroid-stimulating hormone OPD outpatients department TTP thrombotic thrombocytopenic purpura OT occupational therapist U units P: creatinine Protein to Creatinine ratio (magnesium/mmol) UC ulcerative colitis P P PA 2 a C. N. O. . . 2. . . . . . . . . . . . . p p p a u o r l l y m t a ia o r l n t e p a r r r i e y t s i s c s o u n m r o e d p o o o f s n a C e O nt 2 o in f a 2n rt d e r h i e a a l r b t l o s o o d und U U U M RT E N ( I. . ). . . . . . . . . .",
    "That may be sound economics. It could not be worse morals. Aneurin Bevan, In Place of Fear, 1952. In 2014, the Commonwealth Fund presented an overview of international healthcare systems examining fi nancing, governance, healthcare quality, effi ciency, evidencebased practice, and innovation. In a scoring system of 11 nations across 11 categories, the NHS came fi rst overall, at less than half the cost per head spent in the USA. 1 The Kings Fund debunks the myth that the NHS is unaff ordable in the modern European Renal Association, 2 although funding remains a political choice. Bevan prophesied, The NHS will last as long as there are folk left with the faith to fi ght for it. Guard it well. __OOHHCCMM__1100ee. . iinnddbb 22 0022//0055//22001177 1199: : 0066 enicidem tuoba gniknihT QALYS and resource rationing 3 There is a Good deal of hit and miss about general medicine. It is a profession where exact measurement is not easy and the absence of it opens the mind to endless conjecture as to the effi cacy of this or that form of treatment. Aneurin Bevan, In Place of Fear, 1952. A QALY is a quality-adjusted life year. One year of healthy life expectancy 1 QALY, whereas 1 year of unhealthy life expectancy is worth 1 QALY, the precise value falling with progressively worsening quality of life. If an intervention means that you are likely to live for 8 years in perfect health then that intervention would have a QALY value of 8. If a new drug improves your quality of life from 0. 5 to 0. 7 for 25 years, then it has a QALY value of (0. 7 Ω 0. 5)255. Based on the price of the intervention, the cost of 1 QALY can be calculated. Healthcare priorities can then be weighted towards Low cost QALYs. The National Institute for Health and Care Excellence (NICE) considers that interventions for which 1 QALY30 000 are cost-eff ective. However, as a practical application of utilitarian theory, QALYs remain open to criticism (table 1. 1). Remember that although for a clinician, time is unambiguous and quantifi able, time experienced by patients is more like literature than science: a minute might be a chapter, a year a single sentence. 3 Table 1. 1 The advantages and disadvantages of QALYs Advantages Disadvantages Transparent societal decision Focuses on slice (disease), not pie (health) making Common unit for diff erent Based on a value judgement that living longer is a interventions measure of success Allows cost-eff ectiveness Quality of life assessment comes from general public, analysis not those with disease Allows international comparison Potentially ageistthe elderly always have less life expectancy to gain Focus on outcomes, not process ie care, compassion The inverse care law, equity, and distributive justice: The inverse care law states that the availability of Good medical care varies inversely with the need for it. This arises due to poorer quality services, barriers to service before mealscess, and external disadvantage. By focusing on the benefi t gained from an intervention, the QALY system treats everyone as equal. But is this really equality? Distributive justice is the distribution of goods so that those who are worst off become better off. In healthcare terms, this means allocation of resources to those in greatest need, regardless of QALYs. Compassion The importance of compassion4, 5 in medicine is undisputed. It is an emotional response to negativity or suff ering that motivates a desire to help.",
    "Consider the following when prescribing any medication: 1 The underlying pathology. Do not let the amelioration of symptoms lead to failure of investigation and diagnosis. 2 Is this prescription according tob est evidence? 3 Drug reactions. All medications come with risks, potential side-eff ects, inconvenience to the patient, and expense. 4 Is the patient takingo ther medications? 5 Alternatives to medication. Does the patient really need or want medication? Are you giving medication out of a sense of needing to do something, or because you genuinely feel it will help the patient? Is it more appropriate to off er information, reassurance, or lifestyle modifi cation? 6 Is there a risk ofo verdose or addiction? 7 Can you assist the patient? Once per day is better than four times. How easy is it to open the bottle? Is there an intervention that can help with medicine management, eg a multi-compartment compliance aid, patient counselling, an IT solution such as a smartphone app? 8 Future planning. How are you going to decide whether the medication has worked? What are the indications to continue, stop, or change the prescribed regimen? In appreciation of Pain Pain is often seen as an unequivocally Bad thing, and certainly many patients dream of a life without Pain. However, without Pain we are vulnerable to ourselves and our behaviours, and risk ignorance of underlying conditions. While most children quickly learn not to touch boiling Water as their own body disciplines their behaviour with the punishment of Pain; children born with congenital insensitivity to Pain (CIPA) can burn themselves, break bones, and tear skin without feeling any immediate ill eff ect. Their health is constantly at risk from unconsciously self-mutilating behaviours and unnoticed trauma. CIPA is very rare but examples of the human tendency for self-damage without the protective factor of Pain are common. Have you ever bitten your tongue or cheek after a dental anaesthetic? Patients with diabetic neuropathy risk osteomyelitis and arthropathy in their Pain-free feet. If you receive a message of Bad news, you do not solve the problem by hiding the message. Listen to the Pain as well as making the patient comfortable. __OOHHCCMM__1100ee. . iinnddbb 88 0022//0055//22001177 1199: : 0066 enicidem tuoba gniknihT Compliance and concordance 9 Compliance embodies the imbalance of power between doctor and patient: the doctor knows best and the patients only responsibility is to comply with that monopoly of medical knowledge. Devaluing of patients and ethically dubious, the term compliance has been relegated from modern prescribing practice. Concordance is now king: a prescribing agreement that incorporates the beliefs and wishes of the patient. Only 5070% of patients take medicines as prescribed to them. This leads to concern over wasted resources and avoidable illness. Interventions that increase concordance are promoted using the mnemonic: Educating Patients Enhances Care Received Explanation: discuss the benefi ts and risks of taking and not-taking medication. Some patients will prefer not to be treated and, if the patient has capacity and understands the risks, such a decision should be respected. Problems: talk through the patients experience of their treatmenthave they suff ered side-eff ects which have prompted non-concordance? Expectations: discuss what they should expect from their treatment. This is important especially in the treatment of silent conditions where there is no symptomatic benefi t, eg antihypertensive treatment. Capability: talk through the medication regimen with them and consider ways to reduce its complexity. Reinforcement: reproduce your discussion in written form for the patient to take home. Check how they are managing their medications when you next see them.",
    "Learn the national early warning score (NEWS) (p892, fi g A1). Smile, even when talking by phone. Be polite. Eat and Drink, preferably with your team. Making a referral Have the clinical notes, observation chart, drug chart, and investigation results to hand. Read them before you call. Use SBAR: Situtation (who you are, who the patient is, the reason for the call), Background, Assessment of the patient now, Request. Anticipate: Urine dip for the nephrologist, PR exam for the gastroenterologist. Living with Blood spattered armour With the going down of the sun we can momentarily cheer ourselves up by the thought that we are one day nearer to the end of life on earthand our responsibility for the unending tide of illness that fl oods into our corridors, and seeps into our wards and consulting rooms. Of course you may have many other quiet satisfactions, but if not, read on and wink with ultrasound as we hear some fool telling ultrasound that our aim should be to produce the greatest health and happiness for the greatest number. When we hear this, we dont expect cheering from the tattered ranks of on-call doctors; rather, our ears detect a decimated groan, because these men and women know that there is something at stake in on-call doctoring far more elemental than health or happiness: namely survival. Within the fi rst weeks, however brightly your armour shone, it will now be smeared and spattered, if not with Blood, then with the fallout from the many decisions that were taken without suffi cient care and attention. Force majeure on the part of Nature and the exigencies of ward life have, we are suddenly stunned to realize, taught ultrasound to be second-rate; for to insist on being fi rst-rate in all areas is to sign a death warrant for ourselves and our patients. Dont keep re-polishing your armour, for perfectionism does not survive untarnished in our clinical world. Rather, to fl ourish, furnish your mind and nourish your body. Regular food makes midnight groans less intrusive. Drink plenty: doctors are more likely to be oliguric than their patients. And do not voluntarily deny yourself the restorative power of sleep, for it is our natural state, in which we were fi rst created, and we only wake to feed our dreams. We cannot prepare you for fi nding out that you are not at ease with the person you are becoming, and neither would we dream of imposing a specifi c regimen of exercise, diet, and mental fi tness. Finding out what can lead you through adversity is the art of living. __OOHHCCMM__1100ee. . iinnddbb 1100 0022//0055//22001177 1199: : 0066 enicidem tuoba gniknihT On being busy: Corrigans secret door 11 Dr Corrigan of Dublin was: tall, erect, of commanding fi gureHe had the countenance of an intellectual and his face beamed with kindnessIn temperament his distinguishing traits were kindness and tenderness towards the sick, and the ability to make a bold decision. E. OBrien, Conscience and Confl ict: A Biography of Sir Dominic Corrigan 18021880, 1983 Was he busy? At the start of his professional life he was advised that the best way to get business was to pretend to have it. It was suggested that a note marked Immediate and pressing should be ostentatiously handed to him at the dinner table, but always at a suitable time so as not to miss the best food. Such advice was not taken. Corrigan aspired to hard work and taught his students the value of never doing nothing.",
    "iinnddbb 1133 0022//0055//22001177 1199: : 0066 14 enicidem tuoba gniknihT Medical ethics Our clinical practice is steered by ethical principles. They guide the decisions we make in our clinics and ward rounds, what we tell our patients, and what we omit to tell them. Tony Lopez, Journal of Royal Society of Medicine 2001; 94: 6034. In the silences of our consultations it is we who are under the microscope, and we cannot escape our destiny in the sphere of ethics. To give ultrasound courage in this enterprise, we can recall the law of the aviator and seagull: it is only by facing the prevailing wind that we can become airborne, and achieve a new vantage point from which to survey our world. We hope for moral perception: to be able to visualize the morally salient features of a situation. For without this, ethical issues may fl oat past never to be resolved. Be alert to words which may carry hidden assumptions: futility, consent, best interests. 16 Consider WIGWAM in your routine patient review: Wishes of the patient: are they known or unknown? Issues of confi dentiality/disclosure. Goals of care: are they clear? Whose are they: yours or the patients? Wants: to decline treatment or discharge against advice. Arguments between family/friends/doctors. Money: concerns of the patient, concerns of the healthcare provider. Ethical frameworks Off er structure, comprehensiveness, and transparency in deliberation. 16, 17 Four principles Autonomy: Self governance: the ability of a patient to make a choice based on their own values and beliefs. Benefi cence: The obligation to benefi t patients. Links with autonomy as benefi t is dependent upon the view of the patient. Non-malefi cence: Do not harm. Or more appropriately, do no overall harm: you should stick a needle into someone when they need Dialysis. Justice: A collection of obligations including legality, human rights, fairness, and resource distribution. Four quadrants method Medical indications: Identify the clinical problem, treatment options, goals of treatment, and likelihood of success. Patient preferences: What is the patients autonomous decision? (And is the patient capable of making one? If not, look for previously expressed wishes from advanced directives, family, friends, GP. ) Quality of life: How will the proposed treatment aff ect quality of life? This is subjective: recognize your own biases and accommodate those of the patient. Contextual factors: The wider context: legal, cultural, religious, familial, and anything else that may impact. These frameworks describe individual voices within the ethics choir. Sometimes there is a beautiful harmony, but how should you act when there is discordance? There is no hierarchy within the frameworks. Each component is binding unless it is trumped by a stronger principle. How you weigh up and balance the ethical components of a situation is not easy, but it should be clear and justifi ed. Know the patient. Consult others, especially those who hold diff erent opinions to yourself. Can you adequately defend your decision to the patient? Their family? Your consultant? Another consultant? A lawyer? If an investigative journalist were to sit on a sulcus of yours, having full knowledge of all thoughts and actions, would he be composing vitriol for tomorrows newspapers? If so, can you answer him, point for point? Beyond the ethical framework To force an ethical problem to fi t a framework may be inadequate, reductionistic, and inconsistent. 18 It is potentially biased towards Western culture, discounts the non-autonomous, and is vulnerable to poorly considered emphasis and error. Doing ethics can become a check-list exercise where thinking is lost. But doctors are not moral philosophers. They are clinicians.",
    "Doing ethics can become a check-list exercise where thinking is lost. But doctors are not moral philosophers. They are clinicians. A framework therefore provides a starting point from which to work. It is the toe which tests the Water of moral deliberation. Be aware of the cultural setting of your dilemma and consider carefully the weight of synthesis. Be prepared to wade deeper if needed. But acknowledge that moral wisdom may well be out of your depth. __OOHHCCMM__1100ee. . iinnddbb 1144 0022//0055//22001177 1199: : 0066 enicidem tuoba gniknihT Psychiatry on medical and surgical wards 15 Body and soul cannot be separated for purposes of treatment, for they are one and indivisible. Sick minds must be healed as well as sick bodies. C Jeff Miller, 1931. Mental state examination: ASEPTIC Appearance and behaviour: dress, hygiene, eye contact, rapport. Speech: volume, rate, tone. Emotion: mood (subjective and objective), aff ect (how mood is expressed with behaviourappropriate or incongruent? ). Perception: hallucinationsauditory (in the second or third person)? , visual? Thought: Form: block, insertion, broadcast, fl ight of ideas, knights move. Content: delusions, obsessions, phobias, preoccupations, self-harm, suicide. Insight: ask the patient why they have presented today. Cognition: orientation, registration, recall, concentration, knowledge. Do not be afraid to ask about suicidal thoughts and plans. Remove yourself from the situation if you feel threatened. Depression Two questions can be used to identify depression: 19 1 During the last month, have you been bothered by feeling down, depressed, or hopeless? 2 During the last month, have you often been bothered by having little interest or pleasure in doing things? If a person answers yes to either question they should undergo mental health assessment including a risk assessment of self-harm and suicide. Appropriate treatments include psychosocial intervention (guided self-help, cognitive behavioural therapy, structured physical activity) and medication. Treatment choice depends on disease severity, previous psychiatric history, response to treatment, and patient preference. If medication is indicated, a generic SSRI should be considered fi rst line after consideration of GI bleeding risk, drug interactions, toxicity, overdose, and discontinuation symptoms. The full eff ect of medication is gradual, over 46 weeks. Capacity The Mental Capacity Act (MCA) 2005 has a two-stage test for lack of capacity: 1 There is an impairment or disturbed functioning of the mind. 2 The patient is unable to make a decision. Decision-making is impaired if the patient is unable to: understand the relevant information, retain it for long enough to make a decision, weigh up the information, communicate their decision. Capacity is decision-specifi c not patient-specifi c. When treatment is proposed to those who lack capacity, a capacity advocate should be provided. Even patients without capacity should be as involved as possible in decision-making. Mental Health Act (MHA) and common law A patient can be detained under common law (subject to a test of reasonableness) or under the MHA, only if they lack capacity to remain informally and are a danger to themselves or others. You will have more experience in verbal and non-verbal communication, than in detention under the MHA, so use these skills fi rst to try and de-escalate the situation. If rapid tranquillization is needed, be familiar with dosage, side-eff ects, and the need for ongoing observation. If there is no history to guide choice of medication, intramuscular lorazepam can be used. 20 Doctors and mental health Suicide rates are three times higher in doctors compared to the general population. Up to 7% of doctors will have a substance abuse problem within their lifetime. Do not ignore feeling Low, poor concentration, and reduced energy levels. Do not selfdiagnose and manage.",
    "Do not ignore feeling Low, poor concentration, and reduced energy levels. Do not selfdiagnose and manage. Avoid corridor consultations. Trust your GP. Seek support: British Medical Association: www. bma. org. uk/doctorsfordoctors. Doctors Support Network: www. dsn. org. uk. Doctors Support Line: 0844 395 3010. Sick Doctors Trust: www. sick-doctors-trust. co. uk. __OOHHCCMM__1100ee. . iinnddbb 1155 0022//0055//22001177 1199: : 0066 16 enicidem tuoba gniknihT The older person To know how to grow old is the master-work of wisdom, and one of the most diffi cult chapters in the great art of living. Henri Amiel, Journal Intime, 21 Sept 1874. Ageing is an inevitable and irreversible decline in organ function that occurs with time, in the absence of injury or illness, and despite the existence of complex pathways of maintenance and repair. Healthy ageing is the maintenance of physical and mental abilities that enable wellbeing and independence in older age. Do not presume ageing. Look for preventable and reversible pathology. Old age does not cause disease (although it can increase vulnerability and recovery time). Look for ways to reduce disability and support older people in their own homes. Diff erences in the evaluation of the older person 1 Multiple pathologies: Elderly patients have, on average, six diagnosable disorders. Eff ects may be multiplicative. Treatment must be integrated. 2 Multiple aetiologies: One problem may have several causes, eg falls. Treating each alone may do little Good, treating all may be of great benefi t. 3 Non-specifi c/atypical presentation: Delirium, dizziness, falls, mobility problems, weight loss, and incontinence can be due to disorders in more than one organ system. Typical signs and symptoms may be absent. Ask about functional decline in activities of daily livingthis may be the only symptom. 4 Missed or delayed diagnosis: The older person may decline quickly if treatment is delayed. Complications are common. Use a collateral history: what is the patient usually like? 5 Pharmacy and polypharmacy: NSAIDS, anticoagulants, anti-parkinson drugs, hypoglycaemic drugs, and psychoactive drugs can pose a particular risk in the older patient. Double check for interactions. Consider body weight, Liver and renal functiondrug doses may need to be modifi ed. The STOPP/START criteria detail 100 potentially inappropriate prescriptions and prescribing omissions relevant to the older patient. 21 6 Prolonged recovery time: Anticipate and plan for this. Dont forget nutrition. 7 Rehabilitation and social factors: Essential for healthy ageing. A quick ward assessment of the older person History: In addition to routine elements, include function in activities of daily living, continence, and social support. Ask if there is an advanced care directive and nominated proxy healthcare decision maker. Examination: Appearance and aff ect: hygiene, nutrition, hydration. Briefl y assess mood. Senses: vision, hearing, assess swallowing with 20mL of Water. Cognition: brief screening test, eg AMTS (p64), 2-step command. Pulse and Blood Hypertension: lying/sitting and standing. Peripheral neurological exam: tone, power, wasting, active range of movement. Other periphery: pulses, oedema, skin integrity, Hypertension areas. Walking: stand patient, balance, transfers, observe gait (be ready to assist). Other systems: CV, respiratory, abdomen (dont forget to palpate for bladder). 22 Falls 50% aged 80 will fall at least once per year. Falls23 lead to injury, Pain, distress, loss of confi dence, loss of independence, and mortality. Cost to the NHS is 2. 3bn/year. History: frequency, context and circumstances, severity, injuries. Multifactorial risk assessment: gait, balance, muscle strength, osteoporosis risk, perceived functional ability, fear of falls, vision, cognition, neurological examination, continence, home and hazards, cardiovascular examination, medication review. Interventions: strength and balance training, home hazard intervention, correct vision, modifi cation/withdrawal of medication (cardiovascular, psychotropic), integrated management of contributing morbidities.",
    "Consider barriers to change, eg fear, patient preference. __OOHHCCMM__1100ee. . iinnddbb 1166 0022//0055//22001177 1199: : 0066 enicidem tuoba gniknihT The pregnant woman 17 Pre-existing conditions and non-obstetric disease cause more maternal deaths in the UK than obstetric complications. 24 Pregnant women should receive the same investigations and treatment as non-pregnant patients, with avoidance of harm/potential harm to the fetus whenever possible. Most mistakes made in the medical management of pregnant women are due to acts of omission caused by inappropriate weighting of risk and benefi t. Physiological changes in pregnancy Clinical assessment in pregnancy requires knowledge of the physiological changes associated with the gravid state. Expected changes and guidance on when to investigate for possible underlying pathology is given in table 1. 3. Table 1. 3 Physiology and pathology in pregnancy System Normal pregnancy Consider pathology Cardiovascular blood pressure before 20 weeks gestation Diastolic blood pressure 80mmHg in 1st trimester Heart rate Sustained tachycardia 100/min Respiratory Compensated respiratory Serum bicarbonate 18mmol/L alkalosis No change in PEFR Decrease in PEFR Respiratory rate by 10% Respiratory rate 20/min Renal glomerular filtration rate and Creatinine clearance Creatinine 85μmol/L (estimated glomerular filtration rate not valid in pregnancy) Protein excretion Protein: Creatinine ratio 30mg/mmol Endocrine Altered glucose handling Fasting glucose 5. 0mmol/L Haematology Haemodilution hemoglobin 10. 5g/dL, platelets 100x109/L Radiology If the uterus is positioned outside the imaging fi eld of view, the radiation dose to the conceptus is minimal. Exposure from the following investigations is well below the threshold of risk to the fetus: Plain radiograph: chest, extremities, spine. computed tomography: head, chest (but consider radiation to maternal breast in pregnancy/lactation). Ultrasound and magnetic resonance imaging are preferentially used when imaging the abdomen. Reassure your pregnant patient that a chest x-ray is safe. It is the equivalent of 3 days of background radiation. Do not presume it is not requiredhow else will you pick up the widened mediastinum as a cause for her chest Pain? Drugs For drugs prescribed in pregnancy, benefi t must be balanced against risk (table 1. 4). For information on drugs in lactation see: Table 1. 4 Drugs in pregnancy Considered safe Contraindicated Penicillins Tetracycline/doxycycline Macrolides Ciprofl oxacin Low-molecular-weight heparin Trimethoprim (1st trimester) Aspirin NSAIDS (3rd trimester) Labetalol angiotensin-converting enzyme inhibitor Nifedipine ARA Adenosine Mycophenolate Prednisolone Warfarin Treatment for asthma: salbutamol, ipratropium, Live vaccines (MMR, BCG, Varicella) aminophylline, leukotriene antagonists Sepsis Do not underestimate sepsis in pregnancy. Septic shock can be rapid. Do not ignore tachypnoea. All pregnant women should receive the infl uenza vaccine. __OOHHCCMM__1100ee. . iinnddbb 1177 0022//0055//22001177 1199: : 0066 18 enicidem tuoba gniknihT Epidemiology The work of epidemiology is related to unanswered questions, but also to unquestioned answers. Patricia Buffl er, North American Congress of Epidemiology, 2011. Who, what, when, where, why, and how? Epidemiology is the study of the distribution of clinical phenomena in populations. It analyses disease in terms of host, agent, and environment (the epidemiologists triad). It elucidates risks and mechanisms for the development of disease, and reveals potential targets for disease prevention and treatment. Epidemiology does not look at the individual patient, but examines a defi ned population. How applicable its fi ndings are depend upon how well the sample population mirrors the study population, which must, in turn, mirror the target population. Does your patient fi t in this target? If yes, then the epidemiological fi ndings may be applicable. Measures of disease frequency Incidence proportion is the number of new cases of disease as a proportion of the population. Synonyms include probability of disease, cumulative incidence, risk.",
    "Yet these instincts may be vital. If EBM is prescriptive, patient choice declines. Does our zeal for EBM make ultrasound arrogant, mechanical, and defensive? Where is the shared decision-making (p7)? By focusing on answerable questions, EBM can distract ultrasound from our patients unanswerable questions; questions that still require time and acknowledgement. The practice of EBM must be informed by clinical judgement and compassion. __OOHHCCMM__1100ee. . iinnddbb 2222 0022//0055//22001177 1199: : 0066 enicidem tuoba gniknihT Medicalization 23 Using Illness as a Metaphor, 8 Susan Sontag describes two kingdoms: that of the well, and that of the sick. She describes our dual citizenship, and the use of a passport to travel from one kingdom to the other. But medicalization blurs this distinction. The boundary between the Kingdom of the Sick and the Kingdom of Well is lost and there is an anschluss of healthy people annexed into the potentially predatory and frightening kingdom of the sick from which there may well be no escape. Too much medicine occurs as a result of: Overdiagnosis: Labelling an (asymptomatic) person as sick despite the fact that subsequent treatment, lifestyle advice, or monitoring provides no benefi t to their outcome (and potentially causes harm), eg non-progressive breast cancer. Overdetection: Increasingly sensitive tests identify pathology that is indolent or non-progressive, eg subsegmental pulmonary emboli diagnosed on computed tomography angiography. Overdefi niton: Expansion of disease defi nitions or lowering of disease thresholds, eg an estimated glomerular filtration rate diagnosis of chronic Kidney disease now means that 1 in 8 adults are labelled with the disease, many of whom will never progress to symptomatic kidney failure; 15% of pregnant women now have subclinical hypothyroidism without evidence that thyroxine replacement is benefi cial (2016). Disease mongering: The creation of pseudodiseases which pose no threat to health, eg restless legs, sexual health dysfunction, multiple chemical sensitivity. Overutilization: Healthcare practice that provides no net benefi t, eg routine magnetic resonance imaging for lower back Pain. Overtreatment: Treatment that is of no benefi t (and may cause harm), eg antibiotics for viral infections, polypill for the population. Too much medicine arises from the fear of missing a diagnosis, and concern about avoidable morbidity or mortality. A punitive society means there is a perceived need for more tests, to seek more certainty. But certainty is the holy grail of myth and legend. The individual patient is a unique set of symptoms, stoicism, experience, and need. And by the nature of life, all cure can only ever be temporary. Choosing wisely CHOOSING WISELY is an initiative to change doctors practice away from interventions that are not: supported by evidence free from harm truly necessary (including duplicative tests). The top 510 interventions that should not be used routinely are given for each specialty. Search for those relevant to your current post at: www. choosingwisely. org/doctorpatient-lists/. Screening Consider medicalization when screening for disease. Remember all screening programmes do harm, some do Good. The Wilson criteria for screening lists the important features necessary for a screening programme and the mnemonic IATROGENIC reminds of our pressing duty to do no harm: 1 The condition screened for should be an important one. 2 There should be an acceptable treatment for the disease. 3 Diagnostic andt reatment facilities should be available. 4 Ar ecognizable latent or early symptomatic stage is required. 5 Opinions on who to treat must be agreed. 6 The test must be Good: High discriminatory power, valid, and reproducible with safety guaranteed. 7 Thee xamination must be acceptable to the patient. 8 The untreatedn atural history of the disease must be known. 9 It should bei nexpensive.",
    "8 The untreatedn atural history of the disease must be known. 9 It should bei nexpensive. 10 Screening must be continuous (ie not a one-off aff air). 8 Susan Sontag, Illness as a Metaphor, 1978 __OOHHCCMM__1100ee. . iinnddbb 2233 0022//0055//22001177 1199: : 0066 2 History and examination Contents Taking a history 26 Symptoms 28 Systemic enquiry 30 Physical examination 32 Signs 34 The cardiovascular system: History 36 Examination 3841 Pulses 42 The jugular venous Hypertension (JVP) 43 The Heart sounds 44 Cardiac murmurs 46 The respiratory system: History 48 Examination 5053 Important presentations 54 Fig 2. 1 William Osler (18491919) was a The gastrointestinal system: great medical educationalist who loved History 56 practical jokes. He introduced many novGastrointestinal symptoms 58 elties to the classroom, including, on one Examination of the abdomen 60 occasion, a gaggle of geese. We can all The gastrointestinal system: examination 62 identify with his geese, because these birds show exceptional learning ability The neurological system: and resilience. History 64 Osler did not agree with gavage, a method Neurological examination of the upper whereby geese (and medical students) limbs 66 are forcibly stuff ed by funnel to fatten Neurological examination of the lower them for the delight of gluttons. We are limbs 68 too familiar with the three Rs of medical Cranial nerve examination 70 education: RamRememberRegurgitate, Cranial nerve lesions of the eye 72 a sequence that turns once-bright mediMusculoskeletal hand examination 74 cal students into tearful wrecks. Luckily in the realm of History Examination we can The peripheral vascular system: fl ee the library and alight at the bedside, Examination 78 bearing in mind another of Oslers aphorArterial 79 isms: He who studies medicine without Venous 79 books sails an uncharted sea, but he who The genitourinary system: studies medicine without patients does not History 80 go to sea at all. The breast: History 82 Examination 83 The thyroid: Examination 84 Speech and higher mental function 86 Movement disorders 87 Psychiatric assessment 88 Method and order for routine examination 90 We thank Dr Petra Sulentic, our Specialist Reader, for her contribution to this chapter. __OOHHCCMM__1100ee. . iinnddbb 2244 0022//0055//22001177 1199: : 0066 25 noitanimaxe dna yrotsiH Advice and experience 1 The way to learn physical signs is at the bedside, with guidance from a senior doctor or an experienced colleague. This chapter is not a substitute for this process: it is simply an aide-memoire both on the wards and when preparing for exams. 2 We ask questions to get information to help with diff erential diagnosis. But we also ask questions to fi nd out about the lives our patients live so that we can respect them as individuals. The patient is likely to notice and reciprocate this respect, and the rapport that you build with your patient in this way is a key component to diagnosing and managing their disease. 3 Patients (and diseases) rarely read textbooks, so dont be surprised that some symptoms are ambiguous, and others meaningless. Get Good at recognizing patterns, but not so Good that you create them when none exist. We all fall into this trap! 4 Signs can be easy to detect, or subtle. Some will be found by all the new medical students, others require experienced ears or eyes. Remember, you can be a fi ne doctor without being able to elicit every sign. 1 However, fi nding signs and putting together the clues they give ultrasound to fi nd a diagnosis is one of the best parts of being a doctor. It is also essential that we learn those signs that highlight diseases we should never miss.",
    "Record the patients own words rather than medical terms. History of presenting complaint (HPC) When did it start? What was the fi rst thing noticed? Progress since then. Ever had it before? SOCRATES questions: site; onset (gradual, sudden); character; radiation; associations (eg nausea, sweating); timing of Pain/duration; exacerbating and alleviating factors; severity (eg scale of 110, compared with worst ever previous Pain). Direct questioning (to narrow list of possible diagnoses). Specifi c or closed questions about the diff erential diagnoses you have in mind (risk factors, eg travelp414) and a review of the relevant system. Past medical history (past medical history) Ever in hospital? Illnesses? Operations? Ask specifi - cally about MIJTHREADS: myocardial infarction, jaundice, TB, High blood pressure, rheumatic fever, epilepsy, asthma, Diabetes, stroke, anaesthetic problems. Drug history (DH) Any tablets, injections, over-the-counter drugs, herbal remedies, oral contraceptives? Ask about allergies and what the patient experienced, eg may be an intolerance (nausea, diarrhoea), or may have been a minor reaction of sensitization (eg rash and wheeze) before full-blown anaphylaxis. Social history (social history) Probe without prying. Who else is there at home? Job. Marital status. Spouses job and health. Housingany stairs at home? Who visitsrelatives, neighbours, GP, nurse? Are there any dependants at home? Mobilityany walking aids needed? Who does the cooking and shopping? What can the patient not do because of the illness? Ask about occupation, hobbies, sport, exercise, and ethnic origin. The social history is all too often seen as a dispensable adjunct but vital clues may be missed about the quality of life and it is too late to ask when the surgeons hand is deep in the belly and they are wondering how radical a procedure to perform. Utilize the GPs knowledge of the patient: they may have known them and/or their family for decades. He or she may even hold a living will or advance directive if they cannot speak for themselves. Tactfully ask about alcohol, tobacco, and recreational drugs. How much? How long? When stopped? 1 unit 8g of ethanol 1 spirits measure 1/2 glass of wine 1/3 pint of beer. The CAGE questionnaire is a useful screening test for alcoholism (p281). Quantify smoking in terms of pack-years: 20 cigarettes/day for 1 year equals 1 pack-year. We all like to present ourselves well, so be inclined to double stated quantities (Holts law). Family history (family history) Areas of the family history may need detailed questioning, eg to determine if there is a signifi cant family history of Heart disease you need to ask about the health of the patients grandfathers and male siblings, smoking, tendency to hypertension, hyperlipidaemia, and claudication before they were 60 years old, as well as ascertaining the cause of death. Ask about TB, Diabetes, and other relevant diseases. Draw a family tree (see BOX). Be tactful when asking about a family history of malignancy. Systemic enquiry (See p30. ) Helps uncover undeclared symptoms. Some of this may already have been incorporated into the history. Always enquire, without sounding robotic, if your patient has any ideas of what the problem might be, if he/she has any particular concerns or expectations, and give him/her an opportunity to ask you questions or tell you anything you may have missed. Dont hesitate to review the history later: recollections change (as you will fi nd, often on the post-take ward round when the Consultant is asking the questions! ). __OOHHCCMM__1100ee. . iinnddbb 2266 0022//0055//22001177 1199: : 0066 27 noitanimaxe dna yrotsiH Drawing family trees to reveal dominantly inherited disease Advances in genetics are touching all branches of medicine.",
    "It is increasingly important for doctors to identify patients at High risk of genetic disease, and to make appropriate referrals. The key skill is drawing a family tree to help you structure a family history as follows: 1 Start with your patient. Draw a square for a male and a circle for a female. Add a small arrow (see fi g 2. 2) to show that this person is the propositus (the person through whom the family tree is ascertained). 2 Add your patients parents, brothers, and sisters. Record basic information only, eg age, and if alive and well (aw). If dead, note age and cause of death, and pass an oblique stroke through that persons symbol. 3 Ask the key question Has anybody else in your family had a similar problem as yourself? , eg Heart attack/angina/stroke/cancer. Ask only about the family of diseases that relate to your patients main problem. Do not record a potted medical history for each family member: time is too short. 4 Extend the family tree upwards to include grandparents. If you havent revealed a problem by now, go no furtheryou are unlikely to miss important familial disease. If your patient is elderly it may be impossible to obtain Good information about grandparents. If so, fi ll out the family tree with your patients uncles and aunts on both the mothers and fathers sides. 5 Shade those in the family tree aff ected by the disease. an aff ected female; an aff ected male. This helps to show any genetic problem and, if there is one, will help demonstrate the pattern of inheritance. 6 If you have identifi ed a familial susceptibility, or your patient has a recognized genetic disease, extend the family tree down to include children, to identify others who may be at risk and who may benefi t from screening. You should fi nd out who is pregnant in the family, or may soon be, and arrange appropriate genetic counselling (OHCS p154). Refer for genetics opinion. The family tree (fi g 2. 2) shows these ideas at work and indicates that there is evidence for genetic risk of colon cancer, meriting referral to a geneticist. N. B: use a diff erent approach in paediatrics, and for autosomal or sex-linked disease. Ask if parents are related (consanguinity risk of recessive diseases). Fig 2. 2 Genetic risk of colon cancer in a family tree. Acknowlegement The box in this section owes much to Dr Helen Firth, who we thank. __OOHHCCMM__1100ee. . iinnddbb 2277 0022//0055//22001177 1199: : 0066 28 noitanimaxe dna yrotsiH Symptoms Symptoms are features which patients report. Physical signs are elicited at the bedside. Together, they constitute the features of the condition in that patient. Their evolution over time and interaction with the physical, psychological, and social spheres comprise the natural history of any disease. Throughout this chapter, we discuss symptoms in isolation and attempt to classify them into a system or present them in the following BOXES as non-specifi c. This is unnatural but a Good fi rst step in learning how to diagnose. All doctors have to know about symptoms and their relief. Part of becoming a Good doctor is learning to link symptoms together, to identify those that may be normal, and those that are worrying. There are many online tools and books that can help with this, but there is no substitute for experience. If you arent sure, ask a specialist in that area for advice. The following are common non-specifi c presentations. Itch Itching (pruritus) Common and, if chronic, most unpleasant. Table 2.",
    "The following are common non-specifi c presentations. Itch Itching (pruritus) Common and, if chronic, most unpleasant. Table 2. 1 Aetiology of pruritus Local causes Systemic (do FBC, ESR, glucose, LFT, UE, ferritin, TFT) Eczema, atopy, urticaria Liver disease (bile salts, eg PBC) Old age; pregnancy Scabies Uraemia (eg chronic kidney disease) Drugs (eg morphine) Lichen planus Malignancy (eg lymphoma) Diabetes mellitus Dermatitis herpetiformis Polycythaemia rubra vera Thyroid disease Spinal cord tumours (rare)2 Iron defi ciency anaemia HIV infection Questions: Wheals (urticaria)? Worse at night? Others aff ected (scabies)? What provokes it? After a Rice polycythaemia rubra vera (p366). Exposure, eg to animals (atopy? ) or fi bre glass (irritant eczema? ). See table 2. 1. Look for local causes: Scabies burrows in fi nger webs, lice on hair shafts, knee and elbow blisters (dermatitis herpetiformis). Systemic: Splenomegaly, nodes, jaundice, fl ushed face, or thyroid signs? : Treat causes; try soothing bland emollients ± emollient Rice oils ± sedative antihistamines at night, eg chlorphenamine 4mg PO. Off -legsfalls and diffi culty walking Common causes of admission in the elderly, and can lead to loss of confi dence and independence. Causes are often multifactorial: Intrinsic: Typically osteoor rheumatoid arthritis, but remember fractured neck of femur, CNS disease, vision, cognitive impairment, depression, postural hypotension, periph eral neuropathy, medication (eg antihypertensives, sedatives), Pain, eg arthritis, parkinsonism (eg drugs: prochlorperazine, neuroleptics, metoclopramide), muscle weakness (consider vitamin D defi ciency), incontinence, UTI, pneumonia, anaemia, hypothyroidism, renal impairment, hypothermia, and alcohol. Environ ment: Poor lighting, uneven walking surface. Treatment includes addressing injuries, reducing risk factors, and reducing the risk of injury, eg treat osteoporosis (p682). A multidisciplinary multifactorial approach alongside occupational therapists and physiotherapists is likely to be benefi cial. See gait disorders, p467. If there is ataxia, the cause is not always alcohol: other chemicals may be involved (eg cannabis or prescribed sedatives). There may be a metastatic or non-metastatic manifestation of malignancy, or a cerebellar lesion. Bilateral weak legs may suggest a cord lesion: see p466. If there is associated urinary or faecal incontinence ± saddle anaesthesia or lower limb sensory loss, urgent imaging (magnetic resonance imaging) and treatment for cord compression may well be needed. __OOHHCCMM__1100ee. . iinnddbb 2288 0022//0055//22001177 1199: : 0066 29 noitanimaxe dna yrotsiH Fatigue So common that it is a variant of normality. Only 1 in 400 episodes of Fatigue leads to visiting the doctor. Dont miss depression (p15). Even if depressed, still rule out common treatable causeseg anaemia, hypothyroidism, Diabetes. After history and examination: FBC, ESR, UE, plasma glucose, TFT, ± CXR. Follow up to see what develops, and to address emotional problems. Take a sleep history. Fevers, rigors, sweats While some night sweating is common in anxiety, drenching sweats requiring changes of night-clothes are a more ominous symptom associated with infection (eg TB, brucellosis), lymphoproliferative disease, or other malignancies. Patterns of fever may be relevant (see p442). Rigors are uncontrolled paroxysms of shivering which occur as a patients temperature rises rapidly. Sweating excessively (hyperhidrosis) may be primary (eg hidradenitis suppurativa may be very distressing to the patient)or secondary to fever, Pain or anxiety (cold sweaty) or a systemic condition: the menopause, hyperthyroidism (warm sweaty), acromegaly, malignancy, phaeochromocytoma, amyloidosis, or neuroleptic malignant syndrome (hyper thermia). Or it may refl ect gabapentin or opiate withdrawal, or a choline r gic or parasympathomimetic side-eff ect (amitriptyline, bethanechol, distigmine, spider bites)also hormonal drugs, eg levothyroxine, gonadorelin or somatostatin analogu es, vasopressin, and ephedrine. Also amiodarone, ciprofl oxacin, levodopa, lisinopril, rivastigmine, ritonavir, pioglitazone, venlafaxine. At the bedside: ask about all drugs, examine all over for nodes; any signs of hyperthyroidism? Any splenom egaly?",
    "At the bedside: ask about all drugs, examine all over for nodes; any signs of hyperthyroidism? Any splenom egaly? Test the Urine; do T°, ESR, TSH, FBC, Blood culture. : Antiperspirants (aluminium chloride 20%Driclor), sympathectomy, or iontophoresis may be tried. Insomnia This is trivialuntil we ourselves have a few sleepless nights. Then sleep becomes the most desirable thing imaginable, and bestowing it the best thing we can do, like relieving Pain. But dont give drugs without looking for a cause. Self-limiting: Jet lag; stress; shift work; in hospital. We need less sleep as we age. Psychic: Depression; anxiety; mania; grief; psychomotor agitation/psychosis. Organic: Drugs (many; eg caff eine; mefl oquine; nicotine withdrawal); nocturia; alcohol; Pain (eg acid refl uxworse on lying down); itch; tinnitus; asthma; dystonias; obstructive sleep apnoea (p194); dementia; restless leg syndrome (p698, check ferritin). Rarer: encephalitis (eg West Nile virus) and encephalopathy (Whipples; pellagra; HIV; prion diseases, eg CJD, p696, and fatal familial insomnia). : Sleep hygiene. No daytime naps; dont turn in till you feel sleepy; regular bedtime routines. Keep a room for sleep; dont Eat or work in it (not viable for much of the world). Less caff eine, nicotine, late exercise (but sexual activity may give excellent torpor! ), and alcohol (its abuse causes paradoxical pro-adrenergic tremor and insomnia). Try monitoring quality with a sleep diary (unless already overobsessive). Music and relaxation may make sleep more restorative and augment personal resources. Hypnotic drugs. Give for a few nights only (addictive and cause daytime somnolence ± rebound insomnia on stopping). Warn about driving/machine use. Example: zopiclone 3. 757. 5mg. Obstructive sleep apnoea, p194. Parasomnias, sleep paralysis, etc. OHCS p371. Narcolepsy, p700. __OOHHCCMM__1100ee. . iinnddbb 2299 0022//0055//22001177 1199: : 0066 30 noitanimaxe dna yrotsiH Systemic enquiry Just as skilled acrobats are happy to work without safety nets, so experienced clinicians may operate without the functional enquiry. But to do this you must be experienced enough to understand all the nuances of the presenting complaint. General questions May be the most signifi cant, eg in TB, endocrine problems, or cancer: Weight loss. Night sweats. Any lumps. Fatigue/malaise/lethargy. Sleeping pattern. 1 Appetite. Fevers. Itch or rash. Recent trauma. Cardiorespiratory symptoms Chest Pain (p94). Exertional dyspnoea (breathlessness): quantify exercise tolerance and how it has changed, eg stairs climbed, or distance walked, before onset of breathlessness. Paroxysmal nocturnal dyspnoea (PND). Orthopnoea, ie breathlessness on lying fl at (a symptom of left ventricular failure): quantify in terms of number of pillows the patient must sleep on to prevent dyspnoea. Oedema: ankles, legs, lower back (dependent areas). Palpitations (awareness of heartbeats): can they tap out the rhythm? Cough: sputum, haemoptysis (coughing up Blood). Wheeze. Gastrointestinal symptoms Abdominal Pain (constant or colicky, sharp or dull; site; radiation; duration; onset; severity; relationship to eating and bowel action; alleviating or exacerbating, or associated features). Other questionsthink of symptoms throughout the GI tract, from mouth to anus: Swallowing (p250). Indigestion (p252). Nausea/Vomiting; Blood? (p250). Bowel habit (p258 p260). Stool: colour, consistency, Blood, mucus; diffi culty fl ushing away (p266); tenesmus or urgency. Tenesmus is the feeling of incomplete evacuation of the bowels (eg due to a tumour or irritable bowel syndrome). Haematemesis is Vomiting Blood. Melaena is altered (black) Blood passed PR (p256), with a characteristic off ensive smell and tar like appearance. Genitourinary symptoms Incontinence (stress or urge, p648). Dysuria (painful micturition). Urinary abnormalities: colour? Haematuria (streaks or pink Urine? ) Frothy? Nocturia (needing to micturate at night). Frequency (frequent micturition) or polyuria (the frequent passing of large volumes of Urine). Hesitancy (diffi culty starting micturition). Terminal dribbling.",
    "Frequency (frequent micturition) or polyuria (the frequent passing of large volumes of Urine). Hesitancy (diffi culty starting micturition). Terminal dribbling. Vaginal discharge (colour, odour); Pain on intercourse (dyspareunia) (p412). Menses: frequency, regularity, heavy or light, duration, painful? First day of last menstrual period (LMP). Number of pregnancies and births. Menarche. Menopause. Any chance of pregnancy now? 1 Too sleepy? Think of myxoedema or narcolepsy. Early waking? Think of depression. Being woken by Pain is always a serious sign. For the signifi cance of the other questions listed here, see Chapter 3. __OOHHCCMM__1100ee. . iinnddbb 3300 0022//0055//22001177 1199: : 0066 31 noitanimaxe dna yrotsiH Neurological symptoms Special senses: sight, hearing, smell, and taste. Seizures, faints, funny turns. Headache. Pins and needles (paraesthesiae) or numbness. Limb weakness (Are your arms and legs weaker than normal? ), poor balance. Speech problems (p86). Sphincter disturbance. Higher mental function and psychiatric symptoms (p86p89). The important thing is to assess function: what the patient can and cannot do at home, work, etc. Musculoskeletal symptoms Pain, stiff ness, Edema of joints. Diurnal variation in symptoms (ie worse in mornings). Functional defi cit. Signs of systemic disease: rashes, mouth ulcers, nasal stuffi ness, malaise, and constitutional symptoms. Thyroid symptoms Hyperthyroidism: Prefers cold weather, Bad tempered, sweaty, diarrhoea, oligomenorrhoea, weight (though often appetite), tremor, palpitations, visual problems. Hypothyroidism: Depressed, slow, tired, thin hair, croaky voice, heavy periods, constipation, dry skin, prefers warm weather. __OOHHCCMM__1100ee. . iinnddbb 3311 0022//0055//22001177 1199: : 0066 32 noitanimaxe dna yrotsiH Physical examination The physical examination is not so much an extension of the history, but more of the fi rst investigation, to confi rm, exclude, defi ne, or show the progress of the provisional diagnosis as revealed in the history. Even in the emergency department where the history may be brief, eg trauma, the examination is to confi rm a fracture, or to decide that a fracture is less likely. The examination sheds further light on the history. As you get better, your physical examination gets briefer. Establish your own routinepractice is the key. End of the bed Look at the patientare they well or in extremis? What makes you think this? Are they in Pain? If so, does it make them lie still (eg peritonitis) or writhe about (eg colic)? What is the pattern of breathing: laboured; rapid; shallow; irregular; distressed? Are they obese or cachectic? Is their behaviour appropriate? Can you detect any unusual smell, eg hepatic fetor (p274), cigarettes, alcohol? Also take a moment to look around the bed for other clues, eg inhalers, insulin administration kit, walking aids, etc. Face and body habitus Does the patients appearance suggest any particular diseases, eg acromegaly, thyrotoxicosis, myxoedema, Cushings syndrome, or hypopituitarism? See p202. Is there an abnormal distribution of body hair (eg bearded , or hairless ) suggestive of endocrine disease? Is there anything about the patient to trigger thoughts about Pagets disease, Marfans, myotonia, or Parkinsons syndrome? Look for rashes, eg the malar fl ush of mitral disease and the butterfl y rash of SLE. Peripheral stigmata of disease Specifi c signs are associated with diff erent diseases: consider the nails (koilonychia iron defi ciency), subcutaneous nodules (rheumatoid, neurofi broma? ), and look for lymph nodes (cervical, axillary, inguinal). See specifi c systems for features to assess for, but for all systems consider: Skin colour: Blue/purple cyanosis (can also be central only, p34). Yellow jaundice (yellow skin can also be caused by uraemia, pernicious anaemia, carotenaemiacheck the sclera: if they are also yellow it is jaundice).",
    "Pallor: this is non-specifi c; anaemia is assessed from the palmar skin creases (when spread) and conjunctivae (fi g 8. 3)usually pale if hemoglobin 8090g/L: you cannot conclude anything from normal conjunctival colour, but if they are pale, the patient is probably anaemic. Hyperpigmentation: Addisons, haemoc hromatosis (slate-grey) and amiodarone, gold, silver, and minocycline therapy. Charts: Temperature: varies during the day; a morning oral temperature 37. 2°C or evening 37. 7°C constitutes a fever. 3 Rectal temperatures are generally 0. 6°C above oral temperatures. Remember that temperatures are generally lower in elderly patients and therefore fevers may not be as pronounced. 4 A core temperature 35°C indicates hypothermia; special Low-reading thermometers may be required. Blood Hypertension and pulsetrends are more important than one-off values; repeat if concerned. Urine: check urinalysis and input/output charts if available. Fluid status When admitting an unwell patient, dont forget to assess their hydration, check skin turgor and mucous membranes, look for sunken eyes, and check capillary refi ll (if well perfused 2s) and JVP. __OOHHCCMM__1100ee. . iinnddbb 3322 0022//0055//22001177 1199: : 0066 33 noitanimaxe dna yrotsiH Unexplained signs and symptoms: how to refer for an opinion When you dont know: ask. If you are wondering if you should ask: ask. Frequently, the skills needed for diagnosis or treatment will lie beyond the team you are working for, so, during ward rounds, agree who should be asked for an opinion. You will be left with the job of making the arrangements, so check before your senior leaves exactly what their question is. Dont be intimidated, but follow these simple rules: Know the history and examination fi ndings (ideally your own), and have the patients notes, observations, recent test results, and drug charts to hand (table 2. 2). At the outset, state if you are just looking for advice or if you are asking if the patient could be seen. Make it clear exactly what the question is that you want addressed, allowing the listener to focus their thoughts and ask relevant questions. Give the patients age and run through a brief history including relevant past medical history. If you would like the patient to be seen, give warning if they will be leaving the ward for a test at a particular time. The visiting doctor may be unfamiliar with your ward. When he or she arrives introduce yourself, get the notes and charts, and give your contact details in case they have further questions. Table 2. 2 Referring for a specialist opinion Team Key questions Anaesthetics Previous anaesthetic? Reaction? Last ate/drank? Cardiology Known IHD? blood pressure? ECG fi ndings? Echo fi ndings? Murmurs? Troponin? Temperature/possibility of endocarditis? (ESR, microscopic haematuria, etc. p150) Dermatology Site, onset, and appearance of rash? Drugs? Systemic disease? History of atopy? Endocrinology Diabetes: Blood glucose, usual insulin regimen, complications. Other: Blood results? Stable/unstableeg Addisonian crisis. Usual steroid dose? Gastroenterology/ Bleeding: Rockall score (p257)? Shock? Diarrhoea: Blood? Hepatology Foreign travel? Frequency per day? Liver disease: signs of decompensation (p274)? Ascites? Encephalopathy grade? Gynaecology/ LMP? Possibility of pregnancy? Previous pregnancies? Vaginal Obstetrics discharge? Hormonal contraceptives? STIS? Haematology Blood results? Splenomegaly? Fever? Lymphadenopathy? Bleeding: anticoagulants? Clotting results? Infectious diseases/ Possible source? Antibiotics (current/recent/previous)? Microbiology Foreign travel? Risk factors for HIV? Nephrology Creatinine (current, old)? Clotting? Urine output? Potassium? blood pressure? Fluid status? Drugs? Known renal disease? Neurology/Stroke Neurological examination? computed tomography/magnetic resonance imaging scan fi ndings? Radiology See p720. Contrast or not? Creatinine? Clotting? Cannula in situ? Metallic implants? Respiratory O2 sats? Respiratory rate? ABG? CXR? Inhalers/nebs? Home O2? Respiratory support, eg NIV/CPAP? Surgery (general) Pain? Scan fi ndings? Acutely unwell? Clotting?",
    "Respiratory rate? ABG? CXR? Inhalers/nebs? Home O2? Respiratory support, eg NIV/CPAP? Surgery (general) Pain? Scan fi ndings? Acutely unwell? Clotting? Urology History of LUTS (lower urinary tract symptoms) p642? Catheter? Haematuria? History of stones? Scan fi ndings (ultrasound, computed tomography)? You would be amazed at how many people refer to neurology/stroke without having done a neurological examination! Dont be one of them __OOHHCCMM__1100ee. . iinnddbb 3333 0022//0055//22001177 1199: : 0066 34 noitanimaxe dna yrotsiH Signs The following signs are not specifi c to a particular system: Cyanosis Dusky blue skin (peripheralof the fi ngers) or mucosae (centralof the tongue), representing 50g/L of hemoglobin in its reduced (hence hypoxic) form, it occurs more readily in polycythaemia than anaemia. Causes: Lung disease with inadequate oxygen transfer, eg luminal obstruction, asthma, COPD, pneumonia, physical examination, pulmonary oedemamay be correctable by inspired O2. Congenital cyanotic Heart disease, where there is a mixture, eg transposition of the great arteries or right-to-left shunt (eg VSD with Eisenmengers syndrome; see p156)cyanosis is not reversed by increasing inspired oxygen. Rare causesmethaemoglobinaemia, a congenital or acquired red cell disorder. Acute cyanosis is an emergency. Is there asthma, an inhaled foreign body, a pneumothorax (p749, fi g 1) or pulmonary oedema? See p814. Peripheral cyanosis will occur in causes of central cyanosis, but may also be induced by changes in the peripheral and cutaneous vascular systems in patients with normal oxygen saturations. It occurs in the cold, in hypovolaemia, and in arterial disease, and is, therefore, not a specifi c sign. Pallor May be racial or familialor from anaemia, shock/faints, StokesAdams attack (p460, pale fi rst, then fl ushing), hypothyroid ism, hypopituitarism, and albinism. Anaemia is haemoglobin concentration 130g/L in men and 120g/L in non-pregnant women (p324). It may be assessed from the conjunctivae and skin creases. Koilonychia and stomatitis (p32) suggest iron defi ciency. Anaemia with jaundice suggests haemolysis. If pallor just one limb or digit, think of emboli. Skin discolouration Generalized hyperpigmentation may be genetic (racial) or due to radiation; ACTH (cross-reacts with melanin receptors, eg Addisons disease (p226), Nelsons syndrome (p76), ectopic ACTH in bronchial carcinoma); chronic Kidney disease (urea, p302); malabsorption; chloasma (seen in pregnancy or with the oral contraceptive pill); biliary cirrhosis; haemochromatosis (bronzed Diabetes); carotenaemia; or drugs (eg chlorpromazine, busulfan, amiodarone, gold). Obesity Defi ned by the World Health Organization as a body mass index of over 30kg/m2. A higher waist to hip ratio, indicating central fat distribution, is commoner in and is associated with greater health risks, which include type 2 Diabetes mellitus, IHD, dyslipidaemia, blood pressure, osteoarthritis of weight-bearing joints, and cancer (breast and bowel); see p206. The majority of cases are not due to specifi c metabolic disorders. Lifestyle change is key to treatment, to increase energy expenditure and reduce intake (p244). Medication ± surgery may be considered if the patient fulfi ls strict criteria (body mass index of 40 kg/m2 or more, or between 35 kg/m2 and 40 kg/m2 and other signifi cant disease that could improve with weight loss, non-surgical measures have been tried and failed, patient receives intensive management in a tier 3 service, and fi t for anaesthesia and surgery). Conditions associated with obesity include: genetic (PraderWilli syndrome, LawrenceMoon syndrome), hypothyroidism, Cushings syndrome, and hypothalamic damage (eg tumour or trauma damage to satiety regions). __OOHHCCMM__1100ee. . iinnddbb 3344 0022//0055//22001177 1199: : 0066 35 noitanimaxe dna yrotsiH Lymphadenopathy Causes of lymphadenopathy are either reactive or infi ltrative: Reactive: Infective: Bacterial: eg pyogenic, TB, brucella, syphilis. Viral: EBV, HIV, CMV, infectious hepatitis. Others: toxoplasmosis, trypanosomiasis.",
    "Viral: EBV, HIV, CMV, infectious hepatitis. Others: toxoplasmosis, trypanosomiasis. Non-infective: sarcoidosis, amyloidosis, berylliosis, connective tissue disease (eg rheumatoid, SLE), dermatological (eczema, psoriasis), drugs (eg phenytoin). Infi ltrative: Benign histiocytosisOHCS p644, lipoidoses. Malignant: Haematological: lymphoma or leukaemia: ALL, CLL, AML (p356). Metastatic carcinoma: from breast, lung, bowel, prostate, Kidney, or head and neck cancers. Oedema (See p579. ) Pitting oedema: Fluid can either be squeezed out of the veins (increased hydrostatic Hypertension, eg DVT, right Heart failure) or diff use out because of reduced oncotic pressure (Low plasma proteins, eg cirrhosis, nephrotic syndrome, Protein-losing enteropathy) leading to an osmotic gradient with the tissues (fi g 2. 9, p39, p579). The cause of oedema is still not completely understood. 5 Periorbital oedema: Oedema around the face has a very diff erent diff erential; the eyelid skin is very thin so periorbital oedema is usually the fi rst signthink of allergies (contact dermatitis, eg from eye make-up, stings), angioedema (can be hereditary), infection (orbital cellulitis can be life-threatening, refer to hospital immediately if concerned, other infections include EBV and sinusitis); if there is proptosis (p219) think Graves disease, connective tissue diseases (eg dermatomyositis, SLE, sarcoid, amyloid); and many others. Assess for systemic disease before putting it down to allergies. Non-pitting oedema: Ie non-indentable, is lymphoedema due to poor lymphatic drainage. Can be due to radiotherapy, malignant infi ltration, infection, fi lariasis, or rarely primary lymphoedema (Milroys syndrome p706). Weight loss Weight loss can be both a symptom (ie reported by the patient) and a sign (identifi ed by physician). A feature of chronic disease, depression, malnutrition, malignancy, chronic infections (eg TB, HIV/enteropathic AIDS), Diabetes mellitus, and hyperthyroidism (typically in the presence of increased appetite). Severe generalized muscle wasting is also seen as part of a number of degenerative neurological diseases and in cardiac failure (cardiac cachexia), although in the latter, right Heart failure may not make weight loss a major complaint. Do not forget anorexia nervosa (OHCS p382) as an underlying cause of weight loss. Rule out treatable causes, eg Diabetes is easy to diagnoseTB can be very hard. For example, the CXR may look like cancer so dont forget to send bronchoscopy samples for ZN stain and TB culture. Unintentional weight loss should always ring alarm bells, so assess patients carefully. Cachexia General muscle wasting from famine, or eating (dementia; stroke; MND, p506; anorexia nervosa), malabsorption (enterop athic AIDS/slim disease/Cryptos por idium; Whipples) or catabolism (neoplasia; CCF; TB; chronic Kidney disease; leptin). 6 __OOHHCCMM__1100ee. . iinnddbb 3355 0022//0055//22001177 1199: : 0066 36 noitanimaxe dna yrotsiH The cardiovascular system: history Table 2. 3 Presenting symptoms and questions to ask Presenting Direct questions symptoms Chest Pain Site? Central? (see pp945 Onset? (Sudden? What was the patient doing? ) and p784) Character? Ask patient to describe Pain (Crushing? Heavy? ). Radiation? Ask specifi cally if moves to arm, neck, or jaw? Associations? Ask specifi cally about shortness of breath, nausea, sweating. Timing? Duration? Exacerbating and alleviating factors? Worse with respiration or movement (less likely to be angina)? Relieved by GTN? Worse on inspiration and better when sitting forwards (pericarditis)? Severity: out of 10? Is patient known to have angina or chest Pain; better/worse/same as usual Pain; is it more frequent? Decreasing exercise tolerance? NB: heartburn more likely if burning, onset after eating/drinking, worse lying fl at, or associated with dysphagia. Palpitations Ever aware of your own heartbeat? When and how did it start/stop? Duration? Onset sudden/gradual? Associated with blackout (how long)? Chest Pain? Dyspnoea? Food related (eg caff eine)? Regular fast palpitations may refl ect paroxysmal supraventricular tachycardia (SVT) or ventricular tachycardia (VT).",
    "Dyspnoea? Food related (eg caff eine)? Regular fast palpitations may refl ect paroxysmal supraventricular tachycardia (SVT) or ventricular tachycardia (VT). Irregular fast palpitations are likely to be paroxysmal atrial fibrillation, or atrial fl utter with variable block. Dropped or missed beats related to rest, recumbency, or eating are likely to be atrial or ventricular ectopics. Regular pounding may be due to anxiety. Slow palpitations are likely to be due to drugs such as -blockers, or bigeminus (fi g 3. 34, p129). Reassurance is vital and can be therapeutic. Check a TSH and consider a 24h ECG (Holter monitor, p125). An event recorder, if available, is better than 24h ECGS. Dyspnoea Duration? At rest? On exertion? Determine exercise tolerance (and any (see p52, other reason for limitation, eg arthritis). NYHA classifi cation (p135)? and p782) Worse when lying fl at, how many pillows does the patient sleep with (orthopnoea)? Does the patient ever wake up in the night gasping for breath (paroxysmal nocturnal dyspnoea), and how often? Any ankle Edema? Dizziness/ Dizziness is a loose term, so try to clarify if your patient means: did blackouts patient lose consciousness, and for how long (short duration suggests (see pp4603) cardiac while longer duration suggests a neurological cause)? Any warning (pre-syncope)? What was patient doing at the time? Sudden/ gradual? Associated symptoms? Any residual symptoms, eg confusion? How long did it take for patient to return to normal? Tongue biting (pp4601), seizure, incontinence? Witnessed? Memory loss pre/post event? Vertigo (p462), the illusion of rotation of either the patient or their surroundings ± diffi culty walking/standing, patients may fall over. Imbalance, a diffi culty in walking straight but without vertigo, from peripheral nerve, posterior column, cerebellar, or other central pathway failure. Faintness ie light-headedness, seen in anaemia, blood pressure, postural hypotension, hypoglycaemia, carotid sinus hypersensitivity, and epilepsy. Claudication SOCRATES? Foot/calf/thigh/buttock? Claudication distance, ie how long can patient walk before onset of Pain? Rest Pain? __OOHHCCMM__1100ee. . iinnddbb 3366 0022//0055//22001177 1199: : 0066 37 noitanimaxe dna yrotsiH Screen for presenting symptoms (table 2. 3) before proceeding to past history: Past history Ask specifi cally about: angina, any previous Heart attack or stroke, rheumatic fever, Diabetes, hypertension, hypercholesterolaemia, previous tests/procedures (ECG, angiograms, angioplasty/stents, echocardiogram, cardiac scintigraphy, coronary artery bypass grafts (CABGS)). Drug history Particularly note aspirin/GTN/-blocker/diuretic/angiotensin-converting enzyme inhibitor/digoxin/statin/anticoagulant use. Family history Enquire specifi cally if any 1st-degree relatives having cardiovascular events (especially if 60yrs). Social history Smoking, impact of symptoms on daily life, alcohol (clarify number of units), hobbies, exercise. Ischaemic Heart disease risk factors Hypertension. Smoking. Diabetes mellitus. Family history (1st-degree relative 60yrs old with IHD). Hyperlipidaemia. __OOHHCCMM__1100ee. . iinnddbb 3377 0022//0055//22001177 1199: : 0066 38 noitanimaxe dna yrotsiH The cardiovascular system: examination 1 Introduce yourself, obtain consent to examine, and position the patient appropriately: lying on a bed, sitting up at 45°. Expose them to the waist (for female patients, delay until examining the praecordium). Explain what you are doing throughout. 1 General inspection Assess general state (ill/well) Look for clues (oxygen, GTN spray) Colour (pale, cyanosed, fl ushed) Short of breath? Scars on chest wall (fi g 2. 3)? Fig 2. 3 CABG scar. 2 Hands Temperature: Capillary refi ll time Inspect: Skin: tobacco staining, peripheral cyanosis (fi g 2. 4), tendon xanthomata, Janeway lesions, Oslers nodes (signs of infective endocarditis) Nails: clubbing, splinter haemorrhages, nail bed pulsation (Quinckes sign of aortic regurgitation) Fig 2. 4 Peripheral cyanosis. Reproduced from Ball G, et al. (eds). Oxford Textbook of Vasculitis (2014), with permission from Oxford University Press.",
    "9 Pitting oedema, apply fundoscopy. fi rm Hypertension for a few seconds. __OOHHCCMM__1100ee. . iinnddbb 3399 0022//0055//22001177 1199: : 0066 40 noitanimaxe dna yrotsiH The cardiovascular system: examination 2 General inspection Ill or well? In Pain? Dyspnoeic? Are they pale, cold, and clammy? Can you hear the click of a prosthetic valve? Inspect for scars: median sternotomy (CABG; valve replacement; congenital Heart disease). Inspect for any pacemakers/ internal cardiac defi brillators (ICDS). Look around the bed for oxygen and GTN spray. Hands Finger clubbing occurs in congenital cyanotic Heart disease and endocarditis. Splinter haemorrhages, Oslers nodes (tender nodules, eg in fi nger pulps) and Janeway lesions (red macules on palms, fi g 3. 38, p151) are signs of infective endocarditis. If found, examine the fundi for Roths spots (retinal infarcts, p560). Are there nail fold infarcts (vasculitis, p556) or nailbed capillary pulsation (Quinckes sign in aortic regurgitation)? Is there arachnodactyly (Marfans) or polydactyly (ASD)? Are there tendon xanthomata (see BOX Hyperlipidaemia)? Pulse See p42. Feel for radio-femoral delay (coarctation of the aorta) and radioradial delay (eg from aortic arch aneurysm). Blood Hypertension (see BOX An unusual blood pressure measurement) Systolic blood pressure is the Hypertension at which the pulse is fi rst heard as on cuff defl ation (Korotkoff sounds); the diastolic is when the Heart sounds disappear or become muffl ed (eg in the young). The pulse Hypertension is the diff erence between systolic and diastolic pressures. It is narrow in aortic stenosis and hypovolaemia, and wide in aortic regurgitation, arteriosclerosis, and septic shock. Defi ning hypertension: see p138. Examine the fundi for hypertensive changes (p138). Shock may occur if systolic 90mmHg (p790). Postural hypotension is defi ned as a drop in systolic 20mmHg or diastolic 10mmHg on standing for 35 min (see BOX Postural hypotension). Carotid pulse (See p42. ) Jugular venous Hypertension (See p43. ) Face Is there corneal arcus (fi g 2. 7, p39) or xanthelasma (fi g 2. 29, p60, signifying dyslipidaemia, p690)? Is there a malar fl ush (mitral stenosis, Low cardiac output)? Are there signs of Graves disease, eg bulging eyes (exophthalmos) or goitrep218)? Is the face dysmorphic, eg Downs syndrome, Marfans syndrome (p706)or Turners, Noonans, or Williams syndromes (p149)? Praecordium Palpate the apex beat. Normal position: 5th intercostal space in the mid-clavicular line. Is it displaced laterally? Is it abnormal in nature: heaving (caused by outfl ow obstruction, eg aortic stenosis or systemic hypertension), thrusting (caused by volume overload, eg mitral or aortic incompetence), tapping (mitral stenosis, essentially a palpable 1st Heart sound), diffuse (LV failure, dilated cardiomyopathy) or double impulse (H(O)CM, p152)? Is there dextrocardia? Feel for left parasternal heave (RV enlargement, eg in pulmonary stenosis, cor pulmonale, ASD) or thrills (transmitted murmurs). Auscultating the Heart Also auscultate for bruits over the carotids and elsewhere, particularly if there is inequality between pulses or absence of a pulse. Causes: atherosclerosis (elderly), vasculitis (young, p556). Lungs Examine the bases for creps pleural eff usions, indicative of cardiac failure. Oedema Examine the ankles, legs, sacrum, and torso for pitting oedema. (You may prefer to examine ankles while standing at the foot of the bed as it is a Good early clue that there may be further pathology to be found. ) Abdomen Hepatomegaly and ascites in right-sided Heart failure; pulsatile hepatomegaly with tricuspid regurgitation; splenomegaly with infective endocarditis. Fundoscopy Roth spots (infective endocarditis). Urine dipstick Haematuria. Presenting your fi ndings 1 Signs of Heart failure? 2 Clinical evidence of infective endocarditis? 3 Sinus/abnormal rhythm? 4 Heart sounds normal, abnormal, or additional? 5 Murmurs? __OOHHCCMM__1100ee. .",
    "2 Clinical evidence of infective endocarditis? 3 Sinus/abnormal rhythm? 4 Heart sounds normal, abnormal, or additional? 5 Murmurs? __OOHHCCMM__1100ee. . iinnddbb 4400 0022//0055//22001177 1199: : 0066 41 noitanimaxe dna yrotsiH An unusual blood pressure measurement Dont interpret a blood pressure value in isolation (p138). We cannot diagnose hypertension (or hypotension) on one blood pressure reading. Take into account Pain, the white coat eff ect (blood pressure higher in a medical setting), and equipment. Getting cuff size right is vital. Optimal cuff width is 40% of the arm circumference. If you suspect a blood pressure reading to be anomalous, check the equipment and review the observation chart for previous readings and other vital signs. Consider taking a manual reading with a diff erent set yourself. Often a quiet chat will bring the blood pressure down (yours and your patients: keep your ears open, and the patient may reveal some new tangential but vital fact that the offi cial history glossed over). Many things aff ect blood pressure readings from background noise to how much you touch the patient. If blood pressure, eg 150/90, check both arms. If the systolic diff erence is 20mmHg, consider peripheral vascular disease, and if the patient could have a thoracic aortic aneurysm or co arctation (rare). NB: right arm diastolic is normally 2. 45mmHg higher than left. Postural hypotension This is an important cause of falls and faints in the elderly. It is defi ned as a drop in systolic blood pressure 20mmHg or diastolic 10mmHg after standing for 3min vs lying. Causes: Hypo volaemia (early sign); drugs, eg nitrates, diuretics, antihypertensives, antipsychotics; Addisons (p226); hypopituitarism (ACTH); autonomic neuropathy (p505, diabetes mellitus, multisystem atrophy, p494); after a marathon run (peripheral resistance is Low for some hours); idiopathic. Treatment: Lie down if feeling faint. Stand slowly (with escape route: dont move away from the chair too soon! ). Consider referral to a falls clinic, where special equipment is available for monitoring patient under various tilts. Manage autonomic neuropathy, p505. Water and salt ingestion can help (eg 150mmol sodium/d), but sodium has its problems. Physical measures: leg crossing, squatting, elast ic compression stockings (check dorsalis pedis pulse is present), and careful exercise may help. If post-prandial dizziness, Eat little and often; carbohydrate and alcohol intake. Head-up tilt of the bed at night renin release, so fl uid loss and standing blood pressure. 1st-line drugs: fl udrocortisone (retains fl uid) 50mcg/d; go up to 300mcg/24h PO only if tolerated. Monitor weight; beware if CCF, renal impairment, or albumin as fl udrocortisone worsens oedema. 2nd-line drugs: sympathomimetics, eg midodrine (not always available) or ephedrine; pyridostigmine (eg if detrusor under-activity too). If these fail, turn things on their head and ask: is this really supine hypertension? Hyperlipidaemia Xanthomata are localized deposits of fat under the skin, occurring over joints, tendons, hands, and feet. Xanthel asma refers to xanthoma on the eyelid (p691, fi g 14. 13). Corneal arcus (fi g 2. 7, p39) is a crescentic-shaped opacity at the periphery of the cornea. Common in those over 60yrs, can be normal, but may represent hyperlipidaemia, especially in those under this age. Top tips The hand can be used as a manometer to estimate JVP/CVP if you cannot see the neck properly (eg central line in situ). Hold the hand palm down below the level of the Heart until the veins dilate (patient must be warm! ), then lift slowly, keeping the arm horizontal. The veins should empty as the hand is raised.",
    "), then lift slowly, keeping the arm horizontal. The veins should empty as the hand is raised. Empty veins below the level of the Heart suggests a Low CVP, if they remain full it suggests a normal/High CVP. __OOHHCCMM__1100ee. . iinnddbb 4411 0022//0055//22001177 1199: : 0066 42 noitanimaxe dna yrotsiH Pulses Assess the radial pulse to determine rate and rhythm. Character and volume are best assessed at the brachial or carotid arteries. A collapsing pulse may also be felt at the radial artery when the patients arm is elevated above their head. See fi g 2. 10. Rate Is the pulse fast (100bpm, p126) or slow (60bpm, p124)? Rhythm An irregularly irregular pulse occurs in atrial fibrillation or multiple ectopics. A regularly irregular pulse occurs in 2° Heart block and ventricular bigeminus. Character and volume Bounding pulses are caused by CO2 retention, Liver failure, and sepsis. Small volume pulses occur in aortic stenosis, shock, and pericardial eff usion. Collapsing (waterhammer) pulses are caused by aortic incompetence, AV malformations, and a patent ductus arteriosus. Anacrotic (slow-rising) pulses occur in aortic stenosis. Bisferiens pulses occur in combined aortic stenosis and regurgitation. Pulsus alternans (alternating strong and weak beats) suggests LVF, cardiomyopathy, or aortic stenosis. Jerky pulses occur in H(O)CM. Pulsus paradoxus (systolic Hypertension weakens in inspiration by 10mmHg) occurs in severe asthma, pericardial constriction, or cardiac tamponade. Peripheral pulses (See p36. ) See p771 for arterial Blood gas (ABG) sampling. Waterhammer pulse The waterhammer was a popular toy that consisted of a vacuum tube half-fi lled with Water. On inversion, the whoosh of Water produced an intriguing hammerblow as it rushed from end to end. This is the alternative name for Corrigans collapsing pulseie one in which the upstroke is abrupt and steep, whose peak is reached early and with abnormal forcebefore a rapid downstroke (as Blood whooshes back into the left ventricle through an incompetent aortic valve). Fig 2. 10 Arterial pulse waveforms. Reproduced from Thomas J, et al. (eds). Oxford Handbook of Clinical Examination and Practical Skills (2014), with permission from Oxford University Press. __OOHHCCMM__1100ee. . iinnddbb 4422 0022//0055//22001177 1199: : 0066 43 noitanimaxe dna yrotsiH The jugular venous Hypertension (JVP) The internal jugular vein acts as a capricious manometer of right atrial Hypertension. Observe the height and the waveform of the pulse. JVP observations are often diffi cult. so do not be downhearted if the skill seems to elude you. Examine necks, and the patterns you see may slowly Superficial start to make sensesee temporal vein fi g 2. 11 for the local venous Posterior Maxillary vein anatomy. Concomitantly auricular vein Facial vein palpate the arterial pulse to Retromandibular help decipher patterns. vein The height jugu E l x a t r e v rn ei a n l T calcium h r y t r i o la id ge Observe the patient at 45°, Anterior with their head turned jugu I l n a t r e v rn ei a n l jugular vein slightly to the left and neck relaxed. Good lighting and correct positioning are key. Look for the right internal Fig 2. 11 The jugular venous system. jugular vein as it passes just medial to the clavicular head of the sterno cleidomastoid up behind the angle of the jaw to the earlobes. The JVP is assessed by measuring the vertical height from the manubriosternal angle (not the sternal notch) to the top of the pulse.",
    "Hypertension at zero (at the sternal angle) is 5cm, so add the height of the JVP with 5cm to obtain the right Heart fi lling Hypertension in cm of Water. A Hypertension above 9cm (4cm above the sternal angle at 45°) is elevated. Is the pulse venous (and not arterial)? Usually impalpable, and obliterated by fi nger Hypertension on the vessel. Rises transiently with Hypertension on abdomen (abdominojugular refl ux)2 or on Liver (hepatojug ular refl ux), and alters with posture and respiration (disappears when patient sits from lying fl at). Usually has a double pulse for every arterial pulse. See fi g 2. 12. Abnormalities of the JVP Raised JVP with normal waveform: Fluid overload, right Heart failure. Fixed raised JVP with absent pulsation: SVC obstruction (p528). Large a wave: Pulmonary hypertension, pulmonary stenosis. Cannon a wave: When the right atrium contracts against a closed tricuspid valve, large cannon a waves result. Causescomplete Heart block, single chamber ventricular pacing, ventricular arrhythmias/ectopics. Absent a wave: Atrial fi brillation. Large v waves: Tricuspid regurgitationlook for earlobe movement. Constrictive pericarditis: High plateau of JVP (which rises on inspirationKussmauls sign) with deep x and y descents. Absent JVP: When lying fl at, the jugular vein should be fi lled. If there is reduced circulatory volume (eg dehydration, haemorrhage) the JVP may be absent. Fig 2. 12 The jugular venous Hypertension wave. The JVP drops as the X descent during ventricular systole because the right atrium is no longer contracting. This means that the Hypertension in the right atrium is dropping and this is refl ected by the JVP. After Clinical Examination, Macleod, Churchill and Aids to Undergraduate Medicine, J Burton, Churchill. 2 This sign was fi rst described by Pasteur in 1885 in the context of tricuspid incompetence. __OOHHCCMM__1100ee. . iinnddbb 4433 0022//0055//22001177 1199: : 0066 44 noitanimaxe dna yrotsiH The Heart sounds Listen systematically: sounds then murmurs. While listening, palpate the carotid artery: S1 is synchronous with the upstroke. Heart sounds See fi g 2. 13. The 1st and 2nd sounds are usually clear. Confi dent pronouncements about other sounds and soft murmurs may be diffi cult. Even senior colleagues disagree with one another about the more diffi cult sounds and murmurs. The 1st Heart sound (S1) Represents closure of mitral (M1) and tricuspid (T1) valves. Splitting in inspiration may be heard and is normal. Loud SIn mitral stenosis, because the narrowed valve orifi ce limits ventricular 1 fi lling, there is no gradual decrease in fl ow towards the end of diastole. The valves are, therefore, at their maximum excursion at the end of diastole, and so shut rapidly leading to a loud S1 (the tapping apex). S1 is also loud if diastolic fi lling time is shortened, eg if the PR interval is short, and in tachycardia. Soft S 1 occurs if the diastolic fi lling time is prolonged, eg prolonged PR interval, or if the mitral valve leafl ets fail to close properly (ie mitral incompetence). The intensity of S1 is variable in AV block, atrial fibrillation, and nodal or ventricular tachycardia. The 2nd Heart sound (S2) Represents aortic (A2) and pulmonary valve (P2) closure. The most important abnormality of A2 is softening in aortic stenosis. A is said to be loud in tachycardia, hypertension, and transposition, but this is 2 probably not a useful clinical entity. P is loud in pulmonary hypertension and soft in pulmonary stenosis. 2 Splitting of S in inspiration is normal and is mainly due to the variation of right 2 Heart venous return with respiration, delaying the pulmonary component.",
    "Prosthetic mitral valves: Ball and cage valves project into the left ventricle and can cause a Low-intensity ESM as they interfere with the ejected stream. Tissue valves and bileafl et valves can have a Low-intensity diastolic murmur. Consider any systolic murmur of loud intensity to be a sign of regurgitation and failure. Eponymous signs of aortic regurgitation de Mussets signhead nodding in time with the pulse. Müllers signsystolic pulsations of the uvula. Corrigans signvisible carotid pulsations. Quinckes signcapillary nailbed pulsation in the fi ngers. Traubes signpistol shot femorals, a booming sound heard over the femorals. Duroziezs signto and fro diastolic murmur heard when compressing the femorals proximally with the stethoscope. __OOHHCCMM__1100ee. . iinnddbb 4477 0022//0055//22001177 1199: : 0066 48 noitanimaxe dna yrotsiH The respiratory system: history Table 2. 5 Presenting symptoms and questions to ask Presenting Direct questions symptoms Cough Duration? Character (eg barking/hollow/dry)? Nocturnal (asthma, (see BOX Characask about other atopic symptoms, ie eczema, hay fever)? Exacerbatteristic coughs) ing factors? Sputum (colour? How much? ). Any Blood/haemoptysis? Haemoptysis Always think about TB (recent foreign travel? ) and mal ignancy (see table 2. 6 and (weight loss? ). Mixed with sputum? (Blood not mixed with sputum BOX Haemopsuggests pulmonary embolism, trauma, or bleeding into a lung cavtysis) ity. ) Melaena? (Occurs if enough coughed-up Blood is swallowed. ) Dyspnoea Duration? Steps climbed/distance walked before onset? NYHA clas- (see table 2. 7 and sifi cation (p135)? Diurnal variation (asthma)? BOX Dyspnoea Ask specifi cally about circumstances in which dyspnoea occurs (eg and p782) occupational allergen exposure). Hoarseness Eg due to laryngitis, recurrent laryngeal nerve palsy, Singers (OHCS p568) nodules, or laryngeal tumour. Wheeze (p52) Fever/night sweats (p29) Chest Pain SOCRATES (see p36), usually pleuritic if respiratory (ie worse on (p94 p784) inspiration? ). Stridor (see BOX Stridor) History Ask about current symptoms (table 2. 5) and past history: pneumonia/bronchitis; TB; atopy3 (asthma/eczema/hay fever); previous CXR abnormalities; lung surgery; myopathy; neurological disorders. Connective tissue disorders, eg rheumatoid, SLE. Drug history Respiratory drugs (eg steroids, bronchodilators)? Any other drugs, especially with respiratory SE (eg ACE inhibitors, cytotoxics, -blockers, amiodarone)? Family history Atopy? 3 Emphysema? TB? Social history Quantify smoking in pack-years (20 cigarettes/day for 1 year 1 pack-year). Occupational exposure (farming, mining, asbestos) has possible compensatory implications. Pets at home (eg birds)? Recent travel/TB contacts? Stridor Inspiratory sound due to partial obstruction of upper airways. Obstruction may be due to something within the lumen (eg foreign body, tumour, bilateral vocal cord palsy), within the wall (eg oedema from anaphylaxis, laryngospasm, tumour, croup, acute epiglottitis, amyloidosis), or extrinsic (eg goitre, oesophagus, lymphadenopathy, post-op stridor, after neck surgery). Its an emerge ncy (p772) if gas exchange is compromised. NB: wheeze is an expiratory sound. Characteristic coughs Coughing is relatively non-specifi c, resulting from irritation anywhere from the pharynx to the lungs. The character of a cough may, however, give clues as to the underlying cause: Loud, brassy coughing suggests Hypertension on the trachea, eg by a tumour. Hollow, bovine coughing is associated with recurrent laryngeal nerve palsy. Barking coughs occur in croup. Chronic cough Think of pertussis, TB, foreign body, asthma (eg nocturnal). Dry, chronic coughing may occur following acid irritation of the lungs in oesophageal refl ux, and as a side-eff ect of ACE inhibitors. Do not ignore a change in character of a chronic cough; it may signify a new problem, eg infection, malignancy. 3 Atopy implies predisposition to, or concurrence of, asthma, hay fever and eczema with production of specifi c IgE on exposure to common allergens (eg house dust mite, grass, cats). __OOHHCCMM__1100ee. .",
    "__OOHHCCMM__1100ee. . iinnddbb 4488 0022//0055//22001177 1199: : 0066 49 noitanimaxe dna yrotsiH Haemoptysis Blood is coughed up, eg frothy, alkaline, and bright red, often in a context of known chest disease (vomited Blood is acidic and dark). Table 2. 6 Respiratory causes of haemoptysis. 1 Infective TB; bronchiectasis; bronchitis; pneumonia; lung abscess; COPD; fungi (eg aspergillosis); viruses (from pneumonitis, cryo globulinaemia, eg with hepatitis viruses, HIV-associated pneumocystosis, or MAI, p400). Helminths: paragonimiasis; hydatid (p435); schistosomiasis. 2 Neoplastic Primary or secondary. 3 Vascular Lung infarction (physical examination); vasculitis (ANCA-associated; RA; SLE); hereditary haemorrhagic telangiectasia; AV malformation; capillaritis. 4 Parenchymal Diff use interstitial fi brosis; sarcoidosis; haemoside rosis; Goodpastures syndrome; cystic fi brosis. 5 Pulmonary Idiopathic, thromboembolic, congenital cyanotic Heart hypertension disease (p156), pulmonary fi brosis, bronchiectasis. 6 Coagulopathies Anyeg thrombocytopenia, p344; DIC; warfarin excess. 7 Trauma/foreign body Eg post-intubation, or an eroding implanted defi brillator. 8 Pseudo-haemoptysis Munchausens (p706); aspirated haematemesis; red pig ment (prodigiosin) from Serratia marcescens (Gram-negative bacteria) in sputum. 7 Rare causes refuse to be classifi ed neatly: vascular causes may have infective origins, eg hydatid cyst may count as a foreign body, and infection, and vascular if it fi stulates with the aorta; ditto for infected (mycotic) aneurysm rupture, or TB aortitis. Infective causes entailing coagu lopathy: dengue; leptospirosis. In monthly haemoptysis, think of lung endometriosis. : Haemoptysis may need treating in its own right, if massi ve (eg trauma, TB, hydatid cyst, cancer, AV malformation): call chest team, consider interventional radiology input (danger is drowning: lobe resection, endobronchial tamponade, or arterial embolization may be needed). Set up IVI, do CXR, Blood gases, FBC, INR/APTT, crossmatch. If distressing, give prompt IV morphine, eg if inoperable malignancy. Dyspnoea Subjective sensation of shortness of breath, often exacerbated by exertion. Lungairway and interstitial disease. May be hard to separate from cardiac causes; asthma may wake patient, and cause early morning dyspnoea wheeze. Cardiaceg ischaemic Heart disease or left ventricular failure (LVF), mitral stenosis, of any cause. LVF is associated with orthopnoea (dyspnoea worse on lying; How many pillows? ) and paroxysmal nocturnal dyspnoea (PND; dyspnoea waking one up). Other features include ankle oedema, lung crepitations, and JVP. Anatomicaleg diseases of the chest wall, muscles, pleura. Ascites can cause breathlessness by splinting the diaphragm, restricting its movement. Others Any shocked patient may also be dyspnoeic (p790 p607)dyspnoea may be shocks presenting feature. Also anaemia or metabolic acidosis causing respiratory compensation, eg ketoacidosis, aspirin poisoning. Look for other cluesdyspnoea at rest unassociated with exertion, may be psychogenic: prolonged hyperventilation causes respiratory alkalosis. This causes a fall in ion ized calcium leading to apparent hypocalcaemia. Features include peripheral and perioral paraesthesiae ± carpopedal spasm. Speed of onset helps diagnosis: Table 2. 7 Aetiology of dyspnoea by timing of onset. Acute Subacute Chronic Foreign body Asthma COPD and chronic parenchymal Pneumothorax (p749, fi g 16. 43) Parenchymal disease, diseases Pulmonary embolus eg alveolitis pneumonia Non-respiratory causes, Acute pulmonary oedema Eff usion eg cardiac failure, Psychogenic Psychogenic anaemia __OOHHCCMM__1100ee. . iinnddbb 4499 0022//0055//22001177 1199: : 0066 50 noitanimaxe dna yrotsiH The respiratory system: examination 1 Begin by introducing yourself, obtaining consent to examine and position the patient appropriately: lying on a bed, sitting up at 45°. Expose them to the waist (for female patients, delay until examining the chest). Explain what you are doing throughout. 1 General inspection Assess general state (ill/well/cachexic) Look for clues (oxygen, inhalers, nebulizers, venturi mask) Colour (pale, cyanosed (fi g 2. 15), fl ushed) Short of breath? Accessory muscle use? Scars on chest wall? Ask the patient to take a deep breath in, watch chest Fig 2. 15 Cyanosis.",
    "Cachectic? Respiratory distress? (if High negative intrathoracic pressures are needed to generate air entry). Stridor? Respiratory rate, breathing pattern (see BOX Breathing patterns). Look for chest wall and spine deformities (see p55). Inspect for scars of past surgery, chest drains, or radiotherapy (skin thickening, tattoos for radiotherapy). Chest wall movement: symmetrical? (if not, pathology on restricted side). Paradoxical respiration? (abdomen sucked in with inspiration; seen in diaphragmatic paralysis, see p502). Hands Clubbing, peripheral cyanosis, tar stains, fi ne tremor (-agonist use), wasting of in trinsic muscles (T1 lesions, eg Pancoasts tumour, p708). Tender wrists (hypertrophic pulmonary osteo arthropathycancer). Aster ixis (CO2 retention). Pulse: paradoxical (respiratory distress), bounding (CO2 retention). Face Ptosis and constricted pupil (Horners syndrome, eg Pancoasts tumour, p708)? Bluish tongue and lips (central cyanosis, p34)? Conjunctival pallor (anaemia)? Neck Trachea: Central or displaced? (towards collapse or away from large pleural eff usion/tension pneumothorax; slight deviation to right is normal). Cricosternal distance 3cm is hyperexpansion. Tracheal tug: descent of trachea with inspiration (severe airfl ow limitation). Lymphadenopathy: TB/calcium? JVP: in cor pulmonale. Palpation Apex beat: Impalpable? (COPD/pleural eff usion/dextrocardia? ) Expansion: 5cm on deep inspiration is abnormal. Symmetry? Tactile vocal fremitus: implies consolidation. Percussion Dull percussion note: Collapse, consolidation, fi brosis, pleural thickening, or pleural eff usion (stony dull). Cardiac dullness usually detectable over the left side. Liver dullness usually extends up to 5th rib, right mid-clavicular line; below this, resonant chest is a sign of lung hyperexpansion (eg asthma, COPD). Hyper-resonant percussion note: Pneumothorax or hyperinfl ation (COPD). Table 2. 8 Auscultation Breath sounds Description Pathology Vesicular Rustling quality Normal Bronchial Harsh with gap between inspiration Consolidation, localized fi brobreathing and expiration. Increased vocal resosis, above pleural/percardial nance and whispering pectoriloquy eff usion (Ewarts sign, p154) Diminished Diffi cult to hear Pleural eff usion, pleural breath sounds thickening, pneumothorax, bronchial obstruction, asthma, or COPD Silent chest Inaudible breath sounds Life-threatening asthma Wheeze Air expired through narrow airways (rhonchi) Monophonic (single note, partial Tumour occluding airway obstruction one airway) Polyphonic (multiple notes, wide- Asthma, cardiac wheeze spread airway narrowing) (LVF) Crackles (crepiReopening of small airways on tations) inspiration Fine and late in inspiration Pulmonary oedema Coarse and mid inspiratory Bronchiectasis Early inspiratory Small airway disease Late/pan inspiratory Alveolar disease Disappear post cough Insignifi cant Pleural rub Movement of visceral pleura over Pneumonia parietal when both are roughened Pulmonary infarction (eg due to infl ammatory exudate) Pneumothorax Shallow left pneumot horax between click layers of parietal pleura overlying Heart, heard during cardiac systole __OOHHCCMM__1100ee. . iinnddbb 5522 0022//0055//22001177 1199: : 0066 53 noitanimaxe dna yrotsiH Signs of respiratory distress Tachypnoea. Nasal fl aring. Tracheal tug (pulling of thyroid cartilage towards sternal notch in inspiration). Use of accessory muscles (sternocleidomastoid, platysma, infrahyoid). Intercostal, subcostal, and sternal recession. Pulsus paradoxus (p42). Breathing patterns Hyperventilation: Tachypnoea (ie 20 breaths/min) or deep (hyperp noea, ie tidal volume). Hyperpnoea is not unpleasant, unlike dyspnoea. It may cause respiratory alkalosis, hence paraesthesiae ± muscle spasm (Ca2). The main cause is anxiety: associated dizziness, chest tightness/Pain, palpita tions, and panic. Rare causes: response to metabolic acidosis; brainstem lesions. Kussmaul respiration is deep, sighing breaths in severe metabolic acidosis (blowing off CO2), eg diabetic or alcoholic ketoacidosis, renal impairment. Neurogenic hyperventilation is produced by pontine lesions. The hyperventilation syndrome involves panic attacks associated with hyperventilation, palpitations, dizziness, faintness, tinnitus, alarming chest Pain/ tightness, perioral and peripheral tingling (plasma Ca2). Treatment: relaxation techniques and breathing into a paper bag (inspired CO2 corrects the alkalosis). NB: the anxious patient in AE with hyperventilation and a respiratory alkalosis may actually be presenting with an aspirin overdose (p844).",
    "CheyneStokes breathing: Breaths get deeper and deeper, then shallower (±episodic apnoea) in cycles. Causesbrainstem lesions or compression (stroke, ICP). If the cycle is long (eg 3min), the cause may be a long lung-to-brain circulation time (eg in chronic pulmonary oedema or cardiac output). It is enhanced by opioids. Sputum examination Further examinationsputum, temperature charts, O 2 sats, PEFR: Inspect sputum and send suspicious sputum for microscopy (Gram stain and auramine/ZN stain, if indicated), culture, and cytology. Black carbon specks suggests smoking: commonest cause of increased sputum. Yellow/green sputum suggests infection, eg bronchiectasis, pneumonia. Pink frothy sputum suggests pulmonary oedema. Bloody sputum (haemoptysis) may be due to malignancy, TB, infection, or trauma, and requires investigation for these causes. See p49. Clear sputum is probably saliva. Fig 2. 21 The respiratory segments supplied by the segmental bronchi. __OOHHCCMM__1100ee. . iinnddbb 5533 0022//0055//22001177 1199: : 0066 54 noitanimaxe dna yrotsiH The respiratory system: important presentations Some physical signs (fig 2. 22). (There may be bronchial breathing at the top of an effusion) Expansion: Percussion: (stony dull) PLEURAL Air entry: EFFUSION Vocal resonance: Trachea mediastinum central (shift away from affected side only with massive effusions ≥ 1000mL) Expansion Percussion note Vocal resonance Bronchial breathing ± CONSOLIDATION coarse crackles (with whispering pectoriloquy) Trachea mediastinum central Expansion Percussion note SPONTANEOUS Breath sounds PNEUMOTHORAX/ EXTENSIVE COLLAPSE Trachea mediastinum shift ( LOBECTOMY/ towards the affected side PNEUMONECTOMY) Expansion TENSION Percussion note PNEUMOTHORAX Breath sounds (See fig 16. 43, p749 for Trachea mediastinum shift chest X-ray image) away from the affected side Expansion Percussion note Breath sounds bronchial ± crackles FIBROSIS Trachea mediastinum central or pulled towards the area of fibrosis Fig 2. 22 Physical signs on chest examination. __OOHHCCMM__1100ee. . iinnddbb 5544 0022//0055//22001177 1199: : 0066 55 noitanimaxe dna yrotsiH Chest deformities Barrel chest: AP diameter, tracheal descent and chest expansion , seen in chronic hyperinfl ation (eg asthma/COPD). Pigeon chest (pectus carinatum): See fi g 2. 23. Funnel chest (pectus excavatum): Developm ental defect involving local sternum depression (lower end). See fi g 2. 24. Kyphosis: Humpb ack from AP thoracic spine curvature. Scoliosis: Lateral curvature (OHCS p674); all of these may cause a restrictive ventilatory defect. Fig 2. 23 Pectus carinatum (pigeon chest). Fig 2. 24 Pectus excavatum; the term Prominent sternum, from lung hyperinfl afor funnel or sunken chest. It is often tion while the bony thorax is still developasymptomatic, but may cause dising, eg in chronic childhood asthma. Often placement of the Heart to the left, and seen with Harrisons sulcus, a groove derestricted ventilatory capacity ± mild formity caused by indrawing of lower ribs air-trapping. Associa tions: scoliosis; at the diaphragm attachment site. This Mar fans; EhlersDanlos syndrome. usually has little functional signifi cance in Image courtesy of Prof Eric Fonkalsrud. terms of respiration but can have signifi - cant psychological eff ects: see BOX. Image courtesy of Prof Eric Fonkalsrud. Herr Minty and his pigeon chest Chest wall deformities such as pectus excavatum are quite common, often appearing during adolescent growth spurts. Exercise intolerance is the main symptom (from Heart compr essionconsider CXR/computed tomography). Indications for surgical correction (rarely needed): ≥2: a severe, symptomatic deformity; progression of deformity; paradoxical respiratory chest wall motion; pectus index 3. 25 on computed tomography; cardiac or lung compression; restrictive spirometry; cardiac pathology that might be from compression of the Heart. Psychological eff ects are interesting and not to be dismissed as their eff ects may be greater than any physical eff ects. 8 Because these people hate exposing their chests they may become introverted, and never learn to swim, so dont let them sink without trace.",
    "Be sympathetic, and remember Herr Minty, who inaugurated Graham Greenes theory of compensation: wherever a defect exists we must look for a compensating perfection to account for how the defect survives. In Mintys case, although crooked and yellow and pigeon-chested he had his deep refuge, the ine xhaustible ingenuity of his mind. __OOHHCCMM__1100ee. . iinnddbb 5555 0022//0055//22001177 1199: : 0066 56 noitanimaxe dna yrotsiH The gastrointestinal system: history See table 2. 9 for direct questions to ask regarding presenting symptoms. Table 2. 9 Presenting symptoms and questions to ask Presenting symptoms Direct questions Abdominal Pain (see p57 and p606) SOCRATES (p36) Distension (see p57) Nausea, Vomiting (see table 2. 10) Timing? Relation to meals? Amount? Content Haematemesis (pp2567) (liquid, solid, bile, Blood)? Frequency? Fresh (bright red)/dark/coff ee grounds? Consider neoplasia (weight loss, dysphagia, Pain, melaena? ), NSAIDS/warfarin? Surgery? Smoking? Dysphagia (p250) Level? Onset? Intermittent? Progressive? Painful swallow (odynophagia)? Indigestion/dyspepsia/refl ux (p252) Timing (relation to meals)? Recent change in bowel habit Consider neoplasia (weight loss, dysphagia, Pain, melaena? ) Diarrhoea (p258), constipation (p260) Rectal bleeding (p629) or Pain on defecation? Mucus? Fresh/dark/black? melaena (p246) Mixed with stool/on surface/on paper/in the pan? Appetite, weight change Intentional? Quantify. Dysphagia? Pain? Jaundice (p272) Pruritus? Dark Urine? Pale stools? Past history Peptic ulcer disease, carcinoma, jaundice, hepatitis, Blood transfusions, tattoos, previous operations, last menstrual period (LMP), dietary changes. Drug history Especially steroids, NSAIDS, antibiotics, anticoagulants (eg clopidogrel with SSRIsee BOX SSRIS and upper GI bleeding risk). Family history Irritable bowel syndrome (IBS), infl ammatory bowel disease (IBD), peptic ulcer disease, polyps, cancer, jaundice. Social history Smoking, alcohol (quantify units/week), recreational drug use, travel history, tropical illnesses, contact with jaundiced persons, occupational exposures, sexual history, Blood transfusions, surgery over-seas. Vomiting History is vital. Associated symptoms and past medical history often indicate cause (table 2. 10). Examine for dehydration, distension, tenderness, abdominal mass, succussion splash in children (pyloric stenosis), or tinkling bowel sounds (intestinal obstruction). Table 2. 10 Causes of Vomiting Gastrointestinal CNS Metabolic/endocrine Gastroenteritis Meningitis/encephalitis Uraemia Peptic ulceration Migraine Hypercalcaemia Pyloric stenosis Intracranial Hypertension Hyponatraemia Intestinal obstruction Brainstem lesions Pregnancy Paralytic ileus Motion sickness Diabetic ketoacidosis Acute cholecystitis Ménières disease Addisons disease Acute pancreatitis Labyrinthitis Alcohol and drugs Psychiatric Others Antibiotics Self-induced Myocardial infarction Opiates Psychogenic Autonomic neuropathy Cytotoxics Bulimia nervosa Sepsis (UTI; meningitis) Digoxin How to remember the chief non-GI causes of Vomiting? Try ABCDEFGHI: Acute Kidney injury Addisons disease; Brain (eg ICP); Cardiac (myocardial infarct); Diabetic ketoacidosis; Ears (eg labyrinthitis, Ménières disease); Foreign substances (alcohol; drugs, eg opiates); Gravidity (eg hyperemesis gravidarum); Hypercalcaemia/Hyponatraemia; Infection (eg UTI, meningitis). __OOHHCCMM__1100ee. . iinnddbb 5566 0022//0055//22001177 1199: : 0066 57 noitanimaxe dna yrotsiH Abdominal Pain Character depends on underlying cause. Examples: irritation of the mucosa (acute gastritis), smooth muscle spasm (acute enterocolitis), capsular stretching (Liver congestion in CCF), peritoneal infl ammation (acute appendicitis), and direct splanchnic nerve stimulation (retrop eritoneal extension of tumour). The character (constant or colicky, sharp or dull), duration, and frequency depend on the mechanism of production. The location and distribution of referred Pain depend on the anatomical site. Time of occurrence and aggravating or relieving factors such as meals, defecation, and sleep also have special signifi cance related to the underlying disease process. The site of the Pain may provide a clue: Epigastric: Pancreatitis, gastritis/duodenitis, peptic ulcer, gallbladder disease, aortic aneurysm. Left upper quadrant: Peptic ulcer, gastric or colonic (splenic fl exure) cancer, splenic rupture, subphrenic or perinephric abscess, renal (colic, pyelonephritis). Right upper quadrant: Cholecystitis, biliary colic, hepatitis, peptic ulcer, colonic cancer (hepatic fl exure), renal (colic, pyelonephritis), subphrenic/perinephric abscess.",
    "Faecal impactionoverfl ow diarrhoea, extremely common, especially in the elderly, and very easily treated. Idiopathicalthough there is often no clear cause found, especially in elderly women, this is usually multifactorial, including a combination of poor sphincter tone and pudendal damage leading to poor sensation. Assessment: Do PR (overfl ow incontinence? poor tone? ) and assess neurological function of legs, particularly checking sensation. Refer to a specialist (esp. if rectal prolapse, anal sphincter injury, lumbar disc disease, or alarm symptoms for colon calcium exist). Consider anorectal manometry, pelvic ultrasound or magnetic resonance imaging, and pudendal nerve testing may be needed. Treat according to cause and to promote dignity: Never let your own embarrassment stop you from off ering help. Knowledge and behaviour are key factors: Ensure toilet is in easy reach. Plan trips in the knowledge of toilet locations. Obey call-to-stool impulses (esp. after meal, ie the gastro-colic refl ex). Ensure access to latest continence aids and advice on use, refer to continence nurse specialist for assessment. Pelvic fl oor rehabilitation: eg can help faecal incontinence, squeeze Hypertension, and maximal tolerated volume. Loperamide 24mg 45min before social engagements may prevent accidents outside home. An anal cotton plug may help isolated internal sphincter weakness. Skin care. Support agencies. If all sensible measures fail, try a brake-and-accelerator approach: enemas to empty the rectum (twice weekly) and codeine phosphate, eg 15mg/12h, on non-enema days to constipate. Its not a cure, but makes the incontinence manageable. Flatulence Normally, 4001300mL of gas is expelled PR in 820 discrete (or indiscrete) episodes per day. If this, with any eructation (belching) or distension, seems excessive to the patient, they may complain of fl atulence. Eructation occurs in hiatus herniabut most patients with fl atulence have no GI disease. Air swal lowing (aerophagy) is the main cause of fl atus; here N2 is the chief gas. If fl atus is mostly methane, H2 and CO2, then fermentation by bowel bacteria is the cause, and reducing carbohydrate intake (eg less lactose and wheat) may help. __OOHHCCMM__1100ee. . iinnddbb 5588 0022//0055//22001177 1199: : 0066 59 noitanimaxe dna yrotsiH Tenesmus This is a sensation in the rectum of incomplete emptying after defecati on. Its common in irritable bowel syndrome (p266), but can be caused by tumours. Regurgitation Gastric and oesophageal contents are regurgitated eff ortlessly into the mouth without contraction of abdominal muscles and diaphragm (so distinguishing it from true Vomiting). It may be worse on lying fl at, and can cause cough and nocturnal asthma. Regurgitation is rarely preceded by nausea, and when due to gastro-oesophageal refl ux, it is often associated with heartburn. An oesophageal pouch may cause regurgitation. Very High GI obstructions (eg gastric volvulus, p611) cause nonproductive retching rather than true regurgitation. Steatorrhoea These are pale stools that are diffi cult to fl ush, and are caused by malabsorption of fat in the small intestine and hence greater fat content in the stool. Causes: Ileal disease (eg Crohns or ileal resection), pancreatic disease, and obstructive jaundice (due to excretion of bile salts from the gallbladder). Dyspepsia Dyspepsia and indigestion (p252) are broad terms. Dyspepsia is defi ned as one or more of post-prandial fullness, early satiety (unable to fi nish meal), and/or epigastric or retrosternal Pain or burning. Indigestion reported by the patient can refer to dyspepsia, bloating, nausea, and Vomiting. Try to fi nd out exactly what your patient means and when these symptoms occur in relation to meals, eg the classic symptoms of peptic ulcers occur 25 hours after a meal and on an empty stomach.",
    "Look for alarm symptoms (see p248); these have High negative predictive value. If all patients with dyspepsia undergo endoscopy, 33% have clinically signifi cant fi ndings. 11 Myocardial infaction may present as indigestion. Halitosis Halitosis (fetor oris, oral malodour) results from gingivitis (rarely severe enough to cause Vincents angina, p712), metabolic activity of bacteria in plaque, or sulfi de-yielding food putrefaction, eg in gingival pockets and tonsillar crypts. Patients can often be anxious and convinced of halitosis when it is not present (and vice versa! ). Contributory factors: Smoking, drugs (disulfi ram; isosorbide), lung disease, hangovers. : Try to eliminate anaerobes: Good dental hygiene, dental fl oss, tongue scraping. 0. 2% aqueous chlorhexidine gluconate. The very common halitosis arising from the tongues dorsum is secondary to overpopulated volatile sulfur compound-producing bacteria. Locally retained bacteria metabolize sulfur-containing amino acids to yield volatile ( smelly) hydrogen sulfi de and methylmercaptane, which perpetuate periodontal disease. At night and between meals, conditions are optimal for odour productionso eating regularly may help. Treat by mechanical cleansing/scraping using tongue brushes or scrapes plus mouthwashes. Oral care products containing metal ions, especially Zn, inhibit odour formation, it is thought, because of affi nity of the metal ion to sulfur. It is possible to measure the level of volatile sulfur-containing compounds in the air in the mouth directly by means of a portable sulfi de monitor. __OOHHCCMM__1100ee. . iinnddbb 5599 0022//0055//22001177 1199: : 0066 60 noitanimaxe dna yrotsiH Examination of the abdomen Begin by introducing yourself, obtaining consent to examine, and position the patient appropriately; lie the patient down as fl at as possible, ideally exposing from nipples to knees. In practice, keep the groin covered and examine separately for hernias, etc. 1 General inspection Assess general state (ill/well/cachexic) Clues (vomit bowl, stoma bags, catheter, Urine colour) Colour (pale, jaundiced, uraemic) Body mass index? Scars on the abdomen? Stomas (fi g 2. 25)? Fig 2. 25 Stoma. Ask the patient to lift their head off the Reproduced from MacKay G, et al. (eds). Oxford Specialist Handbook of Colorectal bed, or cough, looking for bulges, distenSurgery (2010), with permission from Oxford sion or Pain. University Press. 2 Hands Inspect: Clubbing, koilonychia, leuconychia, Muehrckes lines, palmar erythema, Dupuytrens contracture (fi g 2. 26), pigmentation of the palmer creases Asterixis: (See p50) Fig 2. 26 Dupuytrens contracture. 3 Arms Check pulse and Blood Hypertension Look in the distribution of the SVC (arms, upper chest, upper back) for spider naevi (fi g 2. 27) Check for track marks, bruising, pigmentation, scratch marks, arteriovenous fi stulae (see p303 for signs seen Fig 2. 27 Spider naevi. in patients with chronic Kidney disease) 4 Neck Examine cervical and supraclavicular lymph nodes (see fi g 2. 28) JVP raised in fl uid overload (renal dysfunction, Liver dysfunction), tricuspid regurgitation (may cause pulsatile hepatomegaly) Scars from tunnelled haemodialysis lines (see p303) or other central venous access Fig 2. 28 Cervical and supraclavicular nodes. Reproduced from Thomas J, et al. (eds). Oxford Handbook of Clinical Examination and Practical Skills (2014), with permission from Oxford 5 Face University Press. Skin and eyes: Jaundice, conjunctival pallor, KayserFleischer rings, xanthelasma (see fi g 2. 29), sunken eyes (dehydration) Mouth: Angular stomatitis, pigmentaFig 2. 29 Xanthelasma. tion, telangiectasia, ulcers, glossitis __OOHHCCMM__1100ee. . iinnddbb 6600 0022//0055//22001177 1199: : 0066 61 noitanimaxe dna yrotsiH 6 Abdomen Inspection: Scarsprevious surgery, transplant, stoma Visible masses, hernias, or pulsation of AAA Visible veins suggesting portal hypertension Gynaecomastia, hair loss, acanthosis nigricans Palpation: Squat by the bed so that the patients abdomen is at your eye level.",
    "If this causes abdominal Pain, fl inching, or a protective movement of hands towards the abdomen, suspect peritonitis. Hands Clubbing, leuconychia (whitening of the nails due to hypoalbuminaemia), koilonychia (spooning of the nails due to iron, B12, or folate defi ciency), Muehrckes lines (transverse white lines due to hypoalbuminaemia), blue lunulae (bluish discolouration seen in Wilsons disease). Palmar erythema (chronic Liver disease, pregnancy), Dupuytrens contracture (thickening and fi brous contraction of palmar fascia (see fi g 2. 26, p60; alcoholic Liver disease)). Hepatic fl ap/asterixis (hepatic encephalopathy, uraemia from renal disease), check pulse and respiratory rate (infection/sepsis? ), palpate for AV fi stulae in the forearm (haemodialysis access in renal failure). Face Assess for jaundice, anaemia, xanthelasma (PBC, chronic obstruction), KayserFleischer rings (green-yellow ring at corneal margin seen in Wilsons disease). Inspect mouth for angular stomatitis (thiamine, B12, iron defi ciency), pigmentation (Peutz Jeghers syndrome, p709, fi g 15. 14), telangiectasia (OslerWeberRendu syndrome/ hereditary haemorrhagic telangiectasia, p709, fi g 15. 12), ulcers (IBD), glossitis (iron, B12, or folate defi ciency). Cervical lymph nodes Palpate for enlarged left supraclavicular lymph node (Virchows node/Troisiers sign) (gastric carcinoma? ). Abdomen Inspect: Look around to the fl anks for nephrectomy scars. Palpate: Note any masses, tenderness, guarding (involuntary tensing of abdominal musclesPain or fear of it), or rebound tenderness (greater Pain on removing hand than on gently depressing abdomenperitoneal infl ammation); Rovsings sign (appendicitis, p608); Murphys sign (cholecystitis, p634). Palpating the Liver: Assess size (see BOX Causes of hepatomegaly), regularity, smoothness, and tenderness. Pulsatile (tricuspid regurgitation)? The scratch test is another way to fi nd the lower Liver edge (if it is below the costal margin): start with diaphragm of stethoscope at right costal margin. Gently scratch the abdominal wall, starting in the right lower quadrant, working towards the Liver edge. A sharp increase in transm ission of the scratch is heard when the border of the Liver is reached. Palpating the spleen: If suspect splenomegaly but cannot detect it, assess patient in the right lateral position with your left hand pulling forwards from behind the rib cage. Palpating the kidneys: See fi g 2. 30, p61. May be non palpable unless slim. Enlarged? Nodular? Palpating the aorta: Normally palpable transmitted pulsation in thin individuals. __OOHHCCMM__1100ee. . iinnddbb 6622 0022//0055//22001177 1199: : 0066 63 noitanimaxe dna yrotsiH Percussion Confi rm the lower border and defi ne the upper border of the Liver and spleen (dull in the mid-axillary line in the 10th intercostal space). Percuss all regions of abdomen. If this induces Pain, there may be peritoneal infl ammation below (eg an infl amed appendix). Some experts percuss fi rst, before palpation, because even anxious patients do not expect this to hurtso, if it does hurt, this is a very valuable sign. Percuss for the shifting dullness of ascites (p61 p604) but ultrasound is a more reliable way of detecting ascites. Auscultation Bowel sounds: absence implies ileus; they are enhanced and tinkl ing in bowel obstruction. Listen for bruits in the aorta, renal and femoral arteries. Further examination Check for hernias (p612), perform a PR examination see BOX Examination of the rectum and anus. Examination of the rectum and anus It is necessary to have a chaperone present for the examination. Explain what you are about to do. Make sure curtains are pulled. Have the patient lie on their left side, with knees brought up towards the chest. Use gloves and lubricant. Part the buttocks and inspect the anus: A gaping anus suggests a neuropathy or megarectum. Symmetry (a tender unilateral bulge suggests an abscess). Prolapsed piles. A subanodermal clot may peep out.",
    "Frequency? Durati on? Mode of onset? Preceding aura? Loss of consciousness? Tongue biting? Incontinence? Any residual weakness/confusion? Family history? Abnormal sensations: Eg numbness, pins needles (paraesthesiae), Pain, odd sensations. Distribution? Speed of onset? Associated weakness? Tremor: (p65. ) Rapid or slow? Present at rest? Worse on deliberate movement? Taking -agonists? Any thyroid problems? Any family history? Fasciculations? Cognitive state If there is any doubt about the patients cognition, cognitive testing should be undertaken. There are a number of tools including MMSE (subject to strict copyright), GPCOG, TYM, and 6-CIT. The Abbreviated Mental Test Score (AMTS) is a commonly used screening questionnaire for cognitive impairment: 12 1 Tell patient an address to recall at the end A score of ≤6 suggests poor cognit- (eg 42 West Street) ion, acute (delirium), or chronic (de2 Age mentia). AMTS correlates well with 3 Time (to nearest hour) the more detailed Mini-Mental State 4 What year is it? Examination (MMSE) NB: deaf, dys5 Recognize2 people (eg doctor nurse) phasic, depressed, and uncoope rative 6 Date of birth patients, as well as those who do not understand English, will also get Low 7 Dates of the Second World War scores. 13 8 Name of current monarch/prime minister 9 Where are you now? (Which hospital? ) 10 Count backwards from 20 to 1 Past medical history Ask about meningitis/encephalitis, head/spine trauma, seizures, previous operations, risk factors for vascular disease (p470, atrial fibrillation, hypertension, hyperlipidaemia, Diabetes, smoking), and recent travel, especially exotic destinations. Is there any chance that the patient is pregnant (eclampsia, OHCS p48)? Drug history Any anticonvulsant/antipsychotic/antidepressant medication? Any psychotropic drugs (eg ecstasy)? Any medication with neurological side-eff ects (eg isoniazid which can cause a peripheral neuropathy)? Social and family history What can the patient do/not do, ie activities of daily living (ADLs)? Whats the Barthel Index score? Any family history of neurological or psychiatric disease? Any consanguinity? Consider sexual history, eg syphilis. __OOHHCCMM__1100ee. . iinnddbb 6644 0022//0055//22001177 1199: : 0066 65 noitanimaxe dna yrotsiH Cramp This is painful muscle spasm. Leg cramps are com mon at night or after heavy exercise, and in patients with renal impairment or on Dialysis. Cramp can signify salt depletion, and rarely: muscle ischaemia (claudication, diabetes mellitus), myopathy (McArdle, p704), or dystonia (writers cramp, p469). Forearm cramps suggest motor neuron disease. Night cramps may respond to quinine bisulfate 300mg at night PO. Drugs causing cramp: Diuretics (? from potassium), domperidone, salbutamol/terbutaline IVI, angiotensin-converting enzyme inhibitor, telmisartan, celecoxib, lacidipine, ergot alkaloids, levothyroxine. Paraesthesiae Pins and needles, numbness/tingling, which can hurt or burn (dysaest h esia). Causes: Metab olic, Ca2 (perioral); PaCO2; myxoedema; neurotoxins (tick bite; sting). Vascular, arterial emboli; Raynauds; DVT; High plasma viscosity. Antib ody-mediated, paraneoplastic; SLE; ITP. Infection, rare: Lyme; rabies. Drugs, angiotensin-converting enzyme inhibitor. Brain, thalamic/parietal Bloodsions. Cord, MS; myelitis/HIV; B12; lumbar fractu re. Plexopathy/monon europathy, see p502, cervical rib; carpal tunn el; sciatica. Peripheral neuropathy, glove stocking, p504, eg diabetes mellitus; chronic kidney disease. If paroxysmal, migraine; epilepsy; phaeochromocytoma. If wandering, take travel history, consider infection, eg strongyloides. Tremor Tremor is rhythmic oscillation of limbs, trunk, head, or tongue. Three types: 1 Resting tremorworst at resteg from parkinsonism (±bradykinesia and rigidity; tremor is more resistant to treatment than other symptoms). It is usually a slow tremor (frequency of 35Hz), typically pill-rolling of the thumb over a fi nger. 2 Postural tremorworst if arms are outstretched. Typically rapid (812Hz). May be exaggerated physiological tremor (eg anxiety, hyperthyroidism, alcohol, drugs), due to brain damage (eg Wilsons disease, syphilis) or benign essential tremor (BET). This is often familial (autosomal dominant) tremor of arms and head presenting at any age.",
    "34). If also deafness/tinnitus, suspect a peripheral cause (eg VIIIth nerve lesion, barotrauma, Ménières, p462). If it varies with head position, suspect benign positional vertigo (p462). If it is up-and-down, ask a neurologist to reviewupbeat nystagmus classically occurs with lesions in the midbrain or at the base of the 4th ventricle, downbeat nystagmus in foramen magnum lesions. Nystagmus lasting ≤2 beats is normal, as is nystagmus at the extremes of gaze. V: Motor palsyOpen your mouth; jaw deviates to side of lesion, muscles of mastication (temporalis, masseter and pterygoids). Sensorycheck all three divisions. Consider corneal refl ex (lost fi rst). VII: p Facial nerve lesions cause droop and weakness. As the forehead has bilateral representation in the brain, only the lower two-thirds is aff ected in UMN lesions, but all of one side of the face in LMN lesions. Ask to raise your eyebrows, show me your teeth, puff out your cheeks. Test taste with salt/sweet solutions (supplies anterior two-thirds of tongue). VIII: Hearingp464. Ask to repeat a number whispered in an ear while you block the other. Perform Webers and Rinnes tests (p464). Balance/vertigop462. IX p X: p Gag refl exask the patient to say Ah. Xth nerve lesions also cause the palate to be pulled to the normal side on saying Ah, uvula deviates away. Ask them to swallow a sip of Water. Consider gag refl extouch the back of the soft palate with an orange stick. The aff erent arm of the refl ex involves IX; the eff erent arm involves X. XI: TrapeziiShrug your shoulders against resistance. Sternocleidomastoid: Turn your head to the left/right against resistance. XII: Tongue movementthe tongue deviates to the side of the lesion. __OOHHCCMM__1100ee. . iinnddbb 7700 0022//0055//22001177 1199: : 0066 71 noitanimaxe dna yrotsiH Causes of cranial nerve lesions Any cranial nerve may be aff ected by Diabetes mellitus; stroke; MS; tumours; sarcoidosis; vasculitis (p556), eg PAN (p556), SLE (p554); syphilis. Chronic menin gitis (malignant, TB, or fungal) tends to pick off the lower cranial nerves one by one. I: Trauma; respiratory tract infection; meningitis; frontal lobe tumour. II: Field defects may start as small areas of visual loss (scotomas, eg in glaucoma). Monocular blindnesslesions of one eye or optic nerve eg MS, giant cell arteritis. Bilateral blindness4any cause of mononeuritis, eg Diabetes, MS; rarely methanol, neurosyphilis. Field defectsbitemporal hemianopiaoptic chiasm compression, eg pituitary adenoma, craniopharyngioma, internal carotid artery aneurysm (fi g 10. 3, p451). Homonymous hemianopiaaff ects half the visual fi eld contralateral to the lesion in each eye. Lesions lie beyond the chiasm in the tracts, radiation, or occipital cortex, eg stroke, abscess, tumour. Optic neuritis (Pain on moving eye, loss of central vision, relative aff erent pupillary defect, disc Edema from papillitis5)causes demyelination (eg MS); rarely sinusitis, syphilis, collagen vascular disorders. Ischaemic papillopathyEdema of optic disc due to stenosis of the posterior ciliary artery (eg in giant cell arteritis). Papilloedema (bilaterally swollen discs, fi g 12. 20, p560)most commonly ICP (tumour, abscess, encephalitis, hydrocephalus, idiopathic intracranial hypertension); rarer: retro-orbital lesion (eg cavernous sinus thrombosis, p480). Optic atrophy (pale optic discs and reduced acuity)MS; frontal tumours; Friedreichs ataxia; retinitis pigmentosa; syphilis; glaucoma; Lebers optic atrophy; chronic optic nerve compression. III: c Alone cmedical causes (pupillary sparing): Diabetes; hypertension; giant cell arteritis; syphilis; idiopathic. Surgical causes (early pupil involvement due to external compression of nerve damaging parasympathetic fi bres): posterior communicating artery aneurysm ( surgery) ICP (if uncal herniation through the tentorium compresses the nerve); tumours. IV: c Alonerare and usually due to trauma to the orbit.",
    "IV: c Alonerare and usually due to trauma to the orbit. V: c Sensorytrigeminal neuralgia (Pain but no sensory loss, p457); herpes zoster, nasopharyngeal cancer, acoustic neuroma (p462). Motorrare. VI: c AloneMS, Wernickes encephalopathy, false localizing sign in ICP, pontine stroke (presents with fi xed small pupils ± quadriparesis). VII: LMNBells palsy (p500), polio, otitis media, skull fracture; cerebellopontine angle tumours, eg acoustic neuroma, malignant parotid tumours, herpes zoster (Ramsay Hunt syndrome p501, OHCS p652). UMN(spares the forehead, because of its bilateral cortical representation), stroke, tumour. VIII: (p462 p464. ) Noise damage, Pagets disease, Ménières disease, herpes zoster, acoustic neuroma, brainstem CVA, drugs (eg aminoglycosides). IX, X, XI: Trauma, brainstem lesions, neck tumours. XII: Rare. Polio, syringomyelia, tumour, stroke, bulbar palsy, trauma, TB. Groups of cranial nerves: VIII, then V, VI, IX, X: cerebellopontine angle tumours, eg acoustic neuroma (p462; facial weakness is not a prominent sign). III, IV VI: stroke, tumours, Wernickes enceph alopathy; aneurysms, MS. III, IV, Va, VI: cavernous sinus thrombosis, superior orbital fi ssure lesions (TolosaHunt syndrome, OHCS p654). IX, X, XI: jugular foramen lesion. : myasthenia gravis, muscular dystrophy, myotonic dystrophy, mononeuritis multiplex (p502). Top tips If the patient is able to shake their head, there is no meningism. 4 Remember the commonest cause of monocular or binocular blindness is not a cranial nerve lesion but a problem with the eye itself (cataracts, retinal problems). Neurological disorders more commonly cause loss of part of the visual fi eld. 5 Unilateral disc Edema papillitis, bilateral papillitis/disc Edema papilloedema. Check both eyes! c structures passing through the cavernous sinus; see BOX Psychiatric symptoms, p89. NB: Va is the only division of V to do so. p Remember that these cranial nerves carry parasympathetic fi bres. Sympathetic fi bres originate from the thoracic chain and run with the arterial supply to distribute about the body (see also OHCS, fi g 9. 6, p621). __OOHHCCMM__1100ee. . iinnddbb 7711 0022//0055//22001177 1199: : 0066 72 noitanimaxe dna yrotsiH Cranial nerve lesions of the eye Pupillary abnormalities Key questions: Equal, central, circular, dilated, or constricted? React to light, directly and consensually? Constrict normally on convergence/accommodation? Irregular pupils: Anterior uveitis (iritis), trauma to the eye, syphilis. Dilated pupils: CN III lesions (inc. ICP, p830) and mydriatic drugs. Always ask: is this pupil dilated, or is it the other that is constricted? Constricted pupils: Old age, sympathetic nerve damage (Horners, p702, and ptosis, p73), opiates, miotics (pilocarpine drops for glaucoma), pontine damage. Unequal pupils (anisocoria): May be due to unilateral lesion, eye-drops, eye surgery, syphilis, or HolmesAdie pupil. Some inequality is normal. Light reaction: Test: cover one eye and shine light into the other obliquely. Both pupils should constrict, one by direct, other by consensual light refl ex (fi g 2. 33). The lesion site is deduced by knowing the pathway: from the retina the message passes up the optic nerve (CNII) to the superior colliculus (midbrain) and thence to the CNIII nuclei on both sides. The IIIrd cranial nerve causes pupillary constriction. If a light in one eye causes only contralateral constriction, the defect is eff erent, as the aff erent pathways from the retina being stimulated must be intact. Test for relative afferent pupillary defect: move torch quickly from pupil to pupil. If there has been incomplete damage to the aff erent pathway, the aff ected pupil will paradoxically dilate when light is moved from the normal eye to the abnormal eye. This is because, in the face of reduced aff erent input from the aff ected eye, the consensual pupillary relaxation response from the normal eye predominates.",
    "4 Congenital; usually partial and without other CNS signs. Visual loss Get ophthalmology help. See OHCS p434p455. Consider: Is the eye red? (Glaucoma, uveitis p561. ) Pain? Giant cell arteritis: severe temporal headache, jaw claudication, scalp tenderness, ESR: urgent steroids (p556). Optic neuritis: eg in MS. Is the cornea cloudy: corneal ulcer (OHCS p435), glaucoma (OHCS p433)? Is there a contact lens problem (infection)? Any fl ashes/fl oaters? (TIA, migraine, retinal detachment? ) Is there a visual fi eld problem (stroke, space-occupying lesion, glaucoma)? Are there any focal CNS signs? Any valvular Heart disease/carotid bruits (emboli)? Hyperlipidaemia (p690)? Is there a relative aff erent pupillary defect (p72)? Any past history of trauma, migraine, hypertension, cerebrovascular disease, MS, Diabetes or connective tissue disease? Any distant signs: eg HIV (causes retinitis), SLE, sarcoidosis? Sudden: Acute glaucoma Retinal detachment Vitreous haemorrhage (eg in diabetic proliferative retinopathy) Central retinal artery or vein occlusion Migraine CNS: TIA (amaurosis fugax), stroke, space-occupying lesion Optic neuritis (eg MS) Temporal arteritis Drugs: quinine/methanol Pituitary apoplexy. Gradual: Optic atrophy Chronic glaucoma Cataracts Macular degeneration Tobacco amblyopia. __OOHHCCMM__1100ee. . iinnddbb 7733 0022//0055//22001177 1199: : 0066 74 noitanimaxe dna yrotsiH Musculoskeletal hand examination 1 Begin by introducing yourself, obtaining consent to examine and position the patient appropriately. Expose the arms, then ask the patient to rest their hands on a pillow. Start by examining the dorsal surface and then turn the hands over. Always ask about Pain or tender areas. Follow the look, ask the patient to move, then feel to avoid causing Pain. Skin On both the palm and the dorsum start by inspecting the skin for: 1 Colourpigmentation of creases, jaundice, palmar erythema (fi g 2. 44). 2 Consistencytight (sclerodactyly), thick (diabetes mellitus, acromegaly) (fi g 2. 39). 3 Characteristic lesionspulp infarcts, rashes, purpura, spider naevi, telangiectasia, tophi (fi g 2. 35), scars (eg carpal tunnel release). Fig 2. 35 Gouty tophi. Nails Look for the same skin changes as the palm, plus tendon xanthomata, plaques, and joint replacement scars, and examine the nails for: Pitting and onycholysis (p76). Clubbing (p77). Nail fold infarcts and splinter haemorrhages. Other lesions, eg Beaus lines Fig 2. 36 Leuconychia. (fi g 2. 41, p76), koilonychia, leuconychia (fi g 2. 36). Muscles Examine the muscles for wasting and fasciculations; on the dorsal surface look for wasting, particularly of dorsal interossei. On the palm look particularly at the thenar and hypothenar eminences. Thenar wasting (fi g 2. 37) median nerve lesion. Generalized wasting, particularly of the interossei on the dorsum, but sparing of the thenar eminence ulnar nerve lesion. Also look for Dupuytrens contracture and Fig 2. 37 Thenar wasting. perform Tinels test (percuss over the distal skin crease of the wrist). Phalens test (patient holds dorsal surfaces of both hands together for 60 seconds). Both tests are positive if tingling reported, suggesting carpal tunnel syndrome. __OOHHCCMM__1100ee. . iinnddbb 7744 0022//0055//22001177 1199: : 0066 75 noitanimaxe dna yrotsiH Joints Examine for acute infl ammation (swollen, red joints) as well as the characteristic deformities of chronic arthritis, eg rheumatoid, osteoarthritis (fi g 2. 38). Ulnar deviation at the wrist. Z deformity of the thumb. Swan-neck (fl exed DIP, hyperextended Fig 2. 38 Osteoarthritis. PIPfi g 12. 2, p540). Boutonnière (hyperextended DIP, fl exed PIP). Heberdens nodes (DIP joints, p77). Bouchards nodes (PIP joints). Move and feel By this point, you should know the likely diagnosis, so assess neurological function looking at power, function, and sensation: Wrist and forearm: Extension (prayer position) and fl exion (reverse prayer), supination and pronation. Look at the elbows.",
    "Look at the elbows. Small muscles: Pincer grip, power grip (squeeze my two fi ngers), abduction of the thumb, abduction (spread your fi ngers), and adduction (grip this piece of paper between your fi ngers) of the fi ngers. NB Froments sign fl exion of the Fig 2. 39 Sclerosis. thumb during grip as ulnar nerve lesion prevents adduction (p453). Function: Write a sentence, undo a button, pick up a coin. Sensation: Test little fi nger (ulnar), index fi nger (median), and anatomical snuff box (radial) using light touch/ pinprick. When you have clinched the diagnosis and functional status, examine each joint, palpating for tenderness, eff usions, and crepitus. Test sensation (see p67) and examine the elbows. Consider examination of upper limbs and face. Top tips Cross your fi ngers before the patient grips them, it hurts less! Dont forget to palpate the radial pulse. Dont forget to look at the elbows for plaques of psoriasis and rheumatoid nodules. __OOHHCCMM__1100ee. . iinnddbb 7755 0022//0055//22001177 1199: : 0066 76 noitanimaxe dna yrotsiH Musculoskeletal hand examination 2 The hands can give you a wealth of information about a patient. Shaking hands can tell you about thyroid disease (warm, sweaty, tremor), anxiety (cold, sweaty), and neurological disease (myotonic dystrophy patients have diffi culty relaxing their grip, a weak grip may suggest muscle wasting or peripheral neuropathy). The nails and skin can inform about systemic disease: Nail abnormalities Koilonychia (spoon-shaped nails, fi g 2. 40) suggests iron defi ciency, haemochromatosis, infection (eg fungal), endocrine disorders (eg acromegaly, hypothyroidism), or malnutrition. Onycholysis (detachment of the nail from the nailbed) is seen with hypert hyroidism, fungal infection, and psoriasis. Beaus lines (fi g 2. 41) are transverse furrows from Fig 2. 40 Koilonychia. temporary arrest of nail growth at times of biological stress: severe infection. Nails grow at 0. 1mm/d, the furrows distance from the cuticle allows dating of the stress. Mees lines are single white transverse bands classically seen in arsenic poisoning, chronic Kidney disease, and carbon monoxide poisoning among others. Muehrckes lines are paired white parallel transverse bands (without furrowing of the nail itself, Fig 2. 41 Beaus lines, here due distinguishing them from Beaus lines) seen, eg, in to chemotherapy, a new line is chronic hypoalbuminaemia, Hodgkins disease, pelseen with each cycle. See p525. lagra (p268), chronic Kidney disease. Terrys nails: Proximal portion of nail is white/ pink, nail tip is red/brown (causes include cirrhosis, chronic Kidney disease, congestive cardiac failure). Pitting is seen in psoriasis and alopecia areata. Splinter haemorrhages (fi g 2. 42) are fi ne longitudinal haemorrhagic streaks (under the nails), which in the febrile patient may suggest infective endocarditis. They may be microemboli, or be normaleg due Fig 2. 42 Splinter haemorto gardening. rhages. Nail-fold infarcts: Embolic, typically seen in vasculitic disorders (OHCS, p452). Nail clubbing See p77. Chronic paronychia is a chronic infection of the nail-fold and presents as a painful swollen nail with intermittent discharge (fi g 2. 43). Skin changes Fig 2. 43 Paronychia. Palmar erythema (fi g 2. 44) is associated with cirReproduced from Burge et al. Oxford Handbook of Medical rhosis, pregnancy, hyperthyroidism, rheumatoid Dermatology 2016, with permission arthritis, polycythaemia; also chronic Liver disease from Oxford University Press. via inactivation of vasoactive endotoxins by the Liver. Also chemotherapy-induced palmar/plantar erythrodysaesthesia. Pallor of the palmar creases suggests anaemia. Pigmentation of the palmar creases is normal in people of African-Caribbean or Asian origin but is also seen in Addisons disease and Nelsons syndrome (increased ACTH after removal of the adrenal glands in Cushings disease).",
    "Causes: Stones, catheters, cystitis, prostati tis, bladder neoplasia, rarely: bladder endometriosis, schistosomiasis. Frequency Aim to diff erentiate Urine production (eg Diabetes mellitus and insipidus, polydipsia, diuretics, alcohol, renal tubular disease, adrenal insuffi ciency) from frequent passage of small amounts of Urine (eg in cystitis, urethritis, neurogenic bladder), or bladder com pression or outfl ow obstruction (pregnancy, bladder tumour, enlarged prostate). i irritative (or fi lling) symptoms: they can be caused by, for example, UTI, as well as obstructions. __OOHHCCMM__1100ee. . iinnddbb 8800 0022//0055//22001177 1199: : 0066 81 noitanimaxe dna yrotsiH Oliguria/anuria Oliguria is defi ned as a Urine output of 400mL/24h or 0. 5mL/kg/h and can be a sign of shock (eg post-op, p576) or acute Kidney injury: causes: p298. Anuria is defi ned as 50mL/24h. In a catheterized patient with sudden anuria consider catheter blockage, with slow decline of oliguria to anuria renal dysfunction is more likely. Polyuria Increased Urine volume, eg 3L/24h. Causes: Over-enthusiastic IV fl uid therapy; diabetes mellitus insipidus (Diabetes is Greek for fountain); Ca2; psycho genic polydipsia/ PIP syndrome (p240); polyuric phase of recovering acute tubular necrosis. Irritative or obstructive bladder symptoms (See also p642. ) Symptoms of prostate enlargement are miscalled prosta tism; it is better to talk about irritative or obstructive bladder symptoms, as bladder neck obstruction or a stricture may be the cause. 1 Irritative bladder symptoms: Urgency, dysuria, frequency, nocturia 6 (the last two are also associated with causes of polyuria). 2 Obstructive symptoms: Reduced size and force of urinary stream, hesitancy and interruption of stream during voiding and terminal dribblingthe usual cause is enlargement of the prostate (prostatic hyperplasia), but other causes include a urethral stricture, tumour, urethral valves, or bladder neck contracture. The maximum fl ow rate of Urine is normally 1830mL/s. Terminal dribbling Dribbling at the end of urination, often seen in conjunction with incontinence following incomplete urination, associated with prostatism. Urinary changes Cloudy Urine suggests pus (UTI) but is often normal phosphate precipitation in an alkaline Urine. Pneumaturia (bubbles in Urine as it is passed). Occurs with UTI due to gas-forming organisms or may signal an enterovesical (bowelbladder) fi stula from diverticulitis, Crohns disease or neoplastic disease of the bowel. Nocturia occurs with irritative bladder, Diabetes mellitus, UTI, and reversed diurnal rhythm (seen in renal and cardiac failure). Haematuria (red blood cell in Urine) is due to neoplasia or glomerulonephritis (p310) until proven otherwise. Rule out UTI. Voiding diffi culty This includes poor fl ow, straining to void, hesitancy, intermittent stream, incontinence (eg overfl ow), retention (acute or chronic), incomplete emptying (±UTI from residual Urine). Remember faecal impaction as a cause of retention with overfl ow. Causes: Obstructive: prostatic hyperplasia, early oedema after bladder neck repair, uterine prolapse, retroverted gravid uterus, fi broids, ovarian cysts, urethral foreign body, ectopic ureterocele, bladder polyp, or cancer. Bladder overdistensioneg after epidural for childbirth. Detrusor weakness or myopathy causes incomplete emptying dribbling overfl ow incontinence (do cystometry/electro myography; causes include neurological disease and interstitial cystitis (OHCS p306); it may lead to a contr acted bladder, eg requiring substitution enterocystoplasty). Drugs: epidural anaesthesia; tricyclics, anticholinergics. CNS: suprapontine (stroke); cord lesions (cord injury, multiple sclerosis); peripheral nerve (prolapsed disc, diabetic or other neuropathy); or refl ex, due to Pain (eg with herpes infections). 6 In the elderly, nocturia (12/night) may be normal because of: i) loss of ability to concentrate Urine; ii) physical examinationripheral oedema fl uid returns to the circulation at night; iii) circadian rhythms may be lost; iv) less sleep is needed and waking may be interpreted as a need to void (a conditioned Pavlovian response). __OOHHCCMM__1100ee. .",
    "Examining for spread to the lymph nodes is particularly important if you suspect a thyroid malignancy (p600). Complete palpation by assessing if the presence of the lump has caused the trachea to deviate from the midline. 5 Percussion A retrosternal goitre will produce a dull percussion note when the sternum is percussed. 6 Auscultation A bruit in a smooth thyroid goitre is suggestive of Graves disease (p218). The next stages of the exam are to examine the systemic signs of thyroid status. 7 Hands Clubbing (thyroid acropachy) is seen in Graves disease. Palmar erythema and a fi ne tremor are also signs of thyrotoxicosis. Assess temperature (warm peripheries if hyperthyroid) and the radial pulse; tachycardia and atrial fi brillation are seen in hyperthyroidism, while bradycardia is seen in hypothyroidism. 8 Eyes The normal upper eyelid should always cover the upper eye such that the white sclera is not visible between the lid and the iris. In hyperthyroidism with exophthalmus there is proptosis as well as lid retraction and lid lag may also be detected. If the patient reports double vision when eye movements are being tested this indicates ophthalmoplegia of hyperthyroidism. 9 Asking the patient to stand allows you to assess whether there is any proximal myopathy (hypothyroidism). Look for pretibial myxoedema (brown Edema of the lower leg above the lateral malleoli in Graves disease). Finally, test the refl exes; these will be slow relaxing in hypothyroidism and brisk in hyperthyroidism. 10 Thank the patient and consider whether the lump is a goitre, and if so whether it is single/multiple, diff use/nodular, as well as the patients thyroid status. Decide on a diagnosis (p600). __OOHHCCMM__1100ee. . iinnddbb 8844 0022//0055//22001177 1199: : 0066 85 noitanimaxe dna yrotsiH 1 Inspection Introduction, consent, position patient sitting on a chair (with space behind), adequately expose neck. Inspect from front and sides for any obvious goitres or swellings, scars, signs of hypo-/hyperthyroidism. 2 Swallow test Standing in front of the patient ask them to sip Waterhold in your mouthand swallow to see if any midline Edema moves up on swallowing. 3 Tongue protrusion test Ask patient to stick out your tongue. Does the lump move up? (Thyroglossal cyst. ) If evidence favours lump not arising from thyroid, examine lump like any other (p594) 4 Palpation Stand behind the patient. Proptosis: (p219. ) While standing behind the patient ask them to tilt their head back slightly; this will give you a better view to assess any proptosis than when assessing the other aspects of eye pathology from front on, as in 8) The thyroid gland: Ask the patient any Pain? Place middle 3 fi ngers of either hand along midline below chin and walk down to thyroid, 2 fi nger breadths beLow the cricoid on both sides. Assess any enlargement/ nodules Swallow test: Repeat as before, now palpating; attempt to get under the lump Lymph nodes: Examine lymph nodes of head and neck (p60). Stand in front of the patient Trachea: Palpate for tracheal deviation from the midline. 5 Percussion Percuss the sternum for dullness of retrosternal extension of a goitre. 6 Auscultation Listen over the goitre for a bruit. 7 Hands Inspect: For thyroid acropachy (clubbing) and palmar erythema Temperature Pulse: Rate and rhythm Fine tremor: Ask patient to hold hands out, place sheet of paper over outstretched hands to help.",
    "Gait: Broad based, patients fall to the side of the lesion. Rombergs test: ask patient to stand with eyes closed. If he/she loses balance, the test is positive and a sign of posterior column disease. Cerebellar disease is Romberg negative. (DASHING: Dysdiadochokinesis, Ataxia, Slurred speech, Hypotonia and reduced power, Intention tremor, Nystagmus, broad based Gait. ) 7 While abstract words activate a sub-region of the left inferior frontal gyrus more strongly than concrete words, specifi c activity for concrete words can also be observed in the left basal temporal cortex. __OOHHCCMM__1100ee. . iinnddbb 8877 0022//0055//22001177 1199: : 0066 88 noitanimaxe dna yrotsiH Psychiatric assessment Introduce yourself, ask a few factual questions (precise name, age, job, and who is at home). These may help your patient to relax, but be careful that you do not touch on a nerve, eg if job recently lost, marriage recently ended so living alone. Presenting problem Ask for the main problems that have led to this consultation. Sit back and listen. Dont worry whether the information is in a convenient form or notthis is an opportunity for the patient to come out with worries, ideas, and preoccupations unsullied by your expectations. After 35min it is often Good to aim to have a list of all the problems (each sketched only briefl y). Read them back to the patient and ask if there are any more. Then ask about: History of presenting problem For each problem obtain details, both current state and history of onset, precipitating factors, and eff ects on life. Check of major psychiatric symptoms Check those that have not yet been covered: depressionLow mood, anhedonia (inability to feel pleasure), thoughts of worthlessness/hopelessness, sleep disturbance with early morning waking, loss of weight and appetite. Ask specifi cally about suicidal thoughts and plans: Have you ever been so Low that you thought of harming yourself? , What thoughts have you had? Check for hypomanic and manic features which can be missed in a patient presenting as depressed. Hallucinations (Have you ever heard voices or seen things when there hasnt been anyone or anything there? ) and delusions (Have you ever had any thoughts or beliefs that have struck you afterwards as bizarre? ); anxiety and avoidance behaviour (eg avoiding shopping because of anxiety or phobias); obsessional thoughts and compulsive behaviour, eating disorders, alcohol (see p281 for alcohol screening tests) and other drugs. Present circumstances Housing, fi nance, work, relationships, friends. Family history Ask about health, personality, and occupation of parents and siblings, and the familys medical and psychiatric history. Background history Try to understand the context of the presenting problem. Biography: Relationships with family and peers as a child; school and work record; sexual relationships and current relationships; and family. Previous ways of dealing with stress and whether there have been problems and symptoms similar to the presenting ones. Premorbid personality: Mood, character, hobbies, attitudes, and beliefs. Past medical and psychiatric history Establish any past or present co-morbidities. Mental state examination This is the state now, at the time of interview. Appearance: Clothing, glasses, headwear? Unkempt/normal/meticulous? Observable behaviour: Eg excessive slowness, signs of anxiety, gesture, gaze or avoiding gaze, tears, laughter, pauses (while listening to voices? ), attitude (eg withdrawn). Mode of speech: Include the rate, eg retarded or gabbling (Hypertension of speech), rhythm, and tone of speech. Mood: Note thoughts about harming self or others. Gauge your own responses to the patient. The laughter and grand ideas of manic patients are contagious, as to a lesser extent is the expression of thoughts from a depressed person.",
    "__OOHHCCMM__1100ee. . iinnddbb 8899 0022//0055//22001177 1199: : 0066 90 noitanimaxe dna yrotsiH Method and order for routine examination 1 Look at the patient. Healthy, unwell, ori n extremis? This vital skill improves with practice. Beware those who are sicker than they look, eg cardiogenic shock; cord compression; non-accidental injury. 2 Pulse, blood pressure, respiratory rate, O2 sats, T°. 3 Examine nails, hands, conjunctivae (anaemia), and sclerae (jaundice). Consider: Pagets, acromegaly, endocrine disease (thyroid, pituitary, or adrenal hypoor hyper-function), body hair, abnormal pigmentation, skin. 4 Examine mouth and tongue (cyanosed; smooth; furred; beefy, eg rhomboid area denuded of papillae by Candida, after prolonged steroid inhaler use). 5 Examine the neck from behind: lymph nodes, goitre. 6 Make sure the patient is at4 5° to begin CVS examination in the neck: JVP; feel for character and volume of carotid pulse. 7 The praecordium. Look for abnormal pulsations. Feel the apex beat (character; position). Any parasternal heave or thrill? Auscultate (bell and diaphragm) apex in the left lateral position, then the other three areas (p39) and carotids. Sit the patient forward: listen during expiration. 8 While sitting forward, look for sacral oedema. 9 Respiratory examination with the patient at 90°. Observe (and count) respiratory rate; note posterior chest wall movement. Assess chest expansion, percuss and auscultate. 10 Sit the patient back. Feel the trachea. Inspect again. Assess expansion of the anterior chest. Percuss and auscultate again. 11 Examine axillae and breasts, if indicated (chaperone for all intimate examinations). 12 Lie patient fl at (1 pillow) to inspect, palpate, percuss, and auscultate abdomen. 13 Look at the legs: swellings, perfusion, pulses, or oedema? Pitting? What level? 14 CNS exam: Cranial nerves: pupil responses; fundi; visual fi elds; visual acuity. Consider corneal refl exes. Open your mouth; stick your tongue out; screw up your eyes; show me your teeth; raise your eyebrows. Limbs (most signs are due to central not peripheral nerve lesions): look for wasting and fasciculation. Test tone in all limbs. Hold your hands out with your palms towards the ceiling and fi ngers wide. Now shut your eyes. Watch for pronator drift. Keep your eyes shut and touch your nose with each index fi nger. Lift your leg straight in the air. Keep it there. Put your heel on the opposite knee (eyes shut) and run it up your own shin. You have now tested power, coordination, and joint position sense. Tuning fork on toes and index fi ngers to assess vibration sense. 15 Examine gait and speech. Any abnormalities of higher mental function? 16 Consider rectal and vaginal examination (chaperone essential). 17 Examine the Urine with dipstick if appropriate. In general, go into detail where you fi nd (or suspect) something to be wrong. __OOHHCCMM__1100ee. . iinnddbb 9900 0022//0055//22001177 1199: : 0066 91 noitanimaxe dna yrotsiH __OOHHCCMM__1100ee. . iinnddbb 9911 0022//0055//22001177 1199: : 0066 3 Cardiovascular medicine Contents Cardiovascular health 93 At the bedside (see 40) Cardiovascular symptoms 94 Investigations: ECGa methodical approach 96 ECGabnormalities 98 ECGadditional points 100 Cardiac imaging 108 Echocardiography 110 Cardiac catheterization 112 Drugs and the Heart: Cardiovascular drugs 114 Diseases and conditions: Angina pectoris 116 Acute coronary syndromes (ACS) 118 Management of ACS 120 Complications of myocardial infarction 122 Arrhythmiasoverview 124 Continuous ECG monitoring 125 Narrow complex tachycardia 126 Broad complex tachycardia 128 Atrial fi brillation (atrial fibrillation) and fl utter 130 Fig 3. 1 Helen Taussig (18981986) battled dysPacemakers 132 lexia, deafness, and a male-dominated world to Heart failurebasic concepts 134 become a leading cardiologist.",
    "She noticed that Heart failuremanagement 136 blue babies with a patent ductus arteriosus Hypertension 138 (PDA) tended to survive longer than those withHypertensionmanagement 140 out. This was because many blue babies have Rheumatic fever (RF) 142 congenital obstruction to pulmonary Blood fl ow Mitral valve disease 144 (eg pulmonary stenosis in tetralogy of Fallot, Aortic valve disease 146 p157) and PDAs increase Blood fl ow to the lungs, Right Heart valve disease 148 reducing cyanosis. She devised the BlalockTausCardiac surgery 148 sig shunt which creates a passage from the subclavian or carotid artery to one of the pulmonary The Heart in various, mostly rare, systemic diseases 149 arteries, mimicing a PDA. This dramatically improved survival in babies with tetralogy of Fallot. Infective endocarditis (IE) 150 Diseases of Heart muscle 152 One of the joys of cardiology is how often soluPericardial diseases 154 tions already exist in nature and much of our intervention involves trying to mimic circumAdult congenital Heart disease stances that can occur naturally. Hence, a Good (ACHD) 156 grasp of the underlying physiology is essential Driving and the Heart 158 for understanding clinical cardiology; as well as interesting to pursue in its own right. We thank Dr Parag Gajendragadkar, our Specialist Reader, for his contribution to this chapter. __OOHHCCMM__1100ee. . iinnddbb 9922 0022//0055//22001177 1199: : 0066 93 enicidem ralucsavoidraC Cardiovascula r health Ischaemic Heart disease (IHD) is the most common cause of death worldwide. Encouraging cardiovascular health is not only about preventing IHD: health entails the ability to exercise, and enjoying vigorous activity (within reason! ) is one of the best ways of achieving health, not just because the Heart likes it (blood pressure, Good Highdensity lipoprotein (HDL))it can prevent osteoporosis, improve glucose tolerance, and augment immune function (eg in cancer and if HIVve). People who improve and maintain their fi tness live longer: age-adjusted mortality from all causes is reduced by 40%. Avoiding obesity helps too, but weight loss per se is only useful in reducing cardiovascular risk and the risk of developing Diabetes when combined with regular exercise. Moderate alcohol drinking may also promote cardiovascular health. Hypertension is the chief risk factor for cardiovascular mortality, followed by smoking. Giving up smoking, even after many years, does bring benefi t. Simple advice works. Most smokers want to give up. Just because smoking advice does not always work, do not stop giving it. Ask about smoking in consultationsespecially those regarding smoking-related diseases. Ensure advice is congruent with the patients beliefs about smoking. Getting patients to enumerate the advantages of giving up motivation. Invite the patient to choose a date (when there will be few stresses) on which he or she will become a non-smoker. Suggest throwing away all accessories (cigarettes, pipes, ash trays, lighters, matches) in advance; inform friends of the new change; practise saying no to their off ers of just one little cigarette. Nicotine gum, chewed intermittently to limit nicotine release: ≥ ten 2mg sticks may be needed/day. Transdermal nicotine patches may be easier. A dose increase at 1wk can help. Written advice off ers no added benefi t to advice from nurses. Always off er follow-up. Varenicline is an oral selective nicotine receptor partial agonist. Start 1wk before target stop date and gradually increase the dose. SES: appetite change; dry mouth; taste disturbance; headache; drowsiness; dizziness; sleep disorders; abnormal dreams; depression; suicidal thoughts; panic; dysarthria. Bupropion (amfebutamone) is said to quit rate to 30% at 1yr vs 16% with patches and 15. 6% for placebo (patches bupropion: 35. 5%): 1 consider if the above fails. Warn of SES: seizures (risk 1: 1000), insomnia, headache.",
    "5%): 1 consider if the above fails. Warn of SES: seizures (risk 1: 1000), insomnia, headache. Lipids and Diabetes (pp690, 206) are the other major modifi able risk factors. The QRISK2 score (www. qrisk. org) is used in the UK to integrate a patients diff erent cardiovascular risk factors in order to predict future cardiovascular health. 2 It can be used as part of a consultation on lifestyle factors to show patients that addressing certain risk factors (eg smoking, blood pressure) will reduce their risk of MIs and strokes. Apply preventive measures such as healthy eating (p244) early in life to maximize impact, when there are most years to save, and before Bad habits get ingrained. The randomized trial Cardiovascular medicine has an unrivalled treasure house of randomized trials. One of the chief pleasures of cardiovascular medicine lies in integrating these with clinical reasoning in a humane way. After a cardiac event, a protocol may mandate statins, aspirin, -blockers, angiotensin-converting enzyme inhibitor (p114), and a target blood pressure and LDL cholesterol that makes your patient feel dreadful. What to do? Inform, negotiate, and compromise. Never reject your patient because of lack of compliance with your over-exacting regime ns. Keep smiling, keep communicating, and keep up to date: the latest data may show that your patient was right all along. 3 __OOHHCCMM__1100ee. . iinnddbb 9933 0022//0055//22001177 1199: : 0066 94 enicidem ralucsavoidraC Cardiovascular symptoms Chest Pain Cardiac-sounding chest Pain may have no serious cause, but always think Could this be a myocardial infarction (myocardial infarction), dissecting aortic aneurysm, pericarditis, or pulmonary embolism? . Character: Constricting suggests angina, oesophageal spasm, or anxiety; a sharp Pain may be from the pleura, pericardium, or chest wall. A prolonged (½h), dull, central crushing Pain or Hypertension suggests myocardial infarction. Radiation: To shoulder, either or both arms, or neck/jaw suggests cardiac ischaemia. The Pain of aortic dissection (p654) is classically instantaneous, tearing, and interscapular, but may be retrosternal. Epigastric Pain may be cardiac. Precipitants: Pain associated with cold, exercise, palpitations, or emotion suggests cardiac Pain or anxiety; if brought on by food, lying fl at, hot drinks, or alcohol, consider oesophageal spasm/disease (but meals can also cause angina). Relieving factors: If Pain is relieved within minutes by rest or glyceryl trinitrate (GTN), suspect angina (GTN relieves oesophageal spasm more slowly). If antacids help, suspect GI causes. Pericarditic Pain improves on leaning forward. Associations: Dyspnoea occurs with cardiac Pain, pulmonary emboli, pleurisy, or anxiety. myocardial infarction may cause nausea, Vomiting, or sweating. Angina is caused by coronary artery diseaseand also by aortic stenosis, hypertrophic cardiomy opathy (HCM), paroxysmal supraventricular tachycardia (SVT)and can be exacerbated by anaemia. Chest Pain with tenderness suggests self-limiting Tietzes syndrome. 1 Odd neurological symptoms and atypical chest Painthink aortic dissection. Pleuritic Pain: Pain exacerbated by inspiration. Implies infl ammation of the pleura from pulmonary infection, infl ammation, or infarction. It causes ultrasound to catch our breath. : musculoskeletal Pain; 1 fractured rib (Pain on respiration, exacerbated by gentle Hypertension on the sternum); subdiaphragmatic pathology (eg gallstones). Chest Pain acutely unwell (see p784) Admit Check pulse, blood pressure in both arms (unequal in aortic dissection p654), JVP, Heart sounds; examine legs for DVT Give O2 IV line Relieve Pain (eg 510mg IV morphine) Cardiac monitor 12-lead ECG CXR Arterial Blood gas (ABG) Famous traps: Aortic dissection; zoster (p404); ruptured oesophagus; cardiac tamponade (p154); opiate addiction. Dyspnoea May be from LVF, physical examination, any respiratory cause, anaemia, Pain, or anxiety. Severity: Emergency presentations: p782. Ask about shortness of breath at rest, on exertion, and on lying fl at; has their exercise tolerance changed?",
    "Ask about shortness of breath at rest, on exertion, and on lying fl at; has their exercise tolerance changed? Associations: Specifi c symptoms associated with Heart failure are orthopnoea (ask about number of pillows used at night), paroxysmal nocturnal dyspnoea (waking up at night gasping for breath, p49), and peripheral oedema. Pulmonary embolism is associated with acute onset of dyspnoea and pleuritic chest Pain; ask about risk factors for DVT. Palpitation(s) May be due to ectopics, sinus tachycardia, atrial fibrillation, SVT, VT, thyrotoxicosis, anxiety, and rarely phaeochromocytoma. See p36. History: Characterize: do they mean their Heart was beating fast, hard, or irregularly? Ask about previous episodes, precipitating/relieving factors, duration of symptoms, associated chest Pain, dyspnoea, dizziness, or collapse. Did the patient check their pulse? Syncope May refl ect cardiac or CNS events. Vasovagal faints are common (pulse, pupils dilated). The history from an observer is invaluable in diagnosis. Prodromal symptoms: Chest Pain, palpitations, or dyspnoea point to a cardiac cause, eg arrhythmia. Aura, headache, dysarthria, and limb weakness indicate CNS causes. During the episode: Was there a pulse? Limb jerking, tongue biting, or urinary incontinence? NB: hypoxia from lack of cerebral perfusion may cause seizures. Recovery: Was this rapid (arrhythmia) or prolonged, with drowsiness (seizure)? 1 25% of non-cardiac chest Pain is musculoskeletal: look for Pain on specifi c postures or activity. Aim to reproduce the Pain by movement and, sometimes, palpation over the structure causing it. Focal inje ction of local anaesthetic helps diagnostically and is therapeutic. Tietzes syndrome: self-limiting costochond ritis ± costosternal joint Edema. Causes: idiopathic; microtrauma; infection; psori atic/rheumatoid arthritis. : NSAIDS or steroid injections. Tenderness is also caused by: fi brositis, lymph oma, chondrosarcoma, myeloma, metastases, rib TB. Imaging: bone scintigraphy; computed tomography. __OOHHCCMM__1100ee. . iinnddbb 9944 0022//0055//22001177 1199: : 0066 95 enicidem ralucsavoidraC Chest Pain from the patients perspective On acute wards we are always hearing questions such as Is your Pain sharp or dull? , followed by an equivocal answer. The doctor goes on: Sharp like a knifeor dull and crushing? The doctor is getting irritated because the patient must know the answer but is not saying it. A true story paves the way to being less inquisitorial and having a more creative understanding of the nature of symptoms. A patient came to a previous OHCM author saying Last night I dreamed I had a Pain in my chest. Now Ive woken up, and Im not surehave I got chest Pain, doctor? What do you think? How odd it is to be asked to examine a patient to exclude a symptom, not a disease. (It turned out that she did have serious chest pathology. ) Odd, until one realizes that symptoms are often half-formed, and it is our role to give them a local habitation and a name. Dialogue can transform a symptom from airy nothingness to a fact. 2 Patients often avoid using the word Pain to describe ischaemia: wind, tightening, Hypertension, burning, or a lump in the throat (angina means to choke) may be used. They may say sharp to communicate severity, and not character. So be as vague in your questioning as your patient is in their answers. Tell me some more about what you are feeling (long pause) as if someone was doing what to you? Sitting on me or like a hotness might be the response (suggesting cardiac ischaemia). Do not ask Does it go into your left arm. Try Is there anything else about it? (pause) Does it go anywhere? Note down your patients exact words.",
    "Try Is there anything else about it? (pause) Does it go anywhere? Note down your patients exact words. A Good history, taking account of these features, is the best way to stratify patients likely to have cardiac Pain. If the history is non-specifi c, there are no risk factors for cardiovascular diseases, and ECG and plasma troponin T (p118) are normal 612h after the onset of Pain, discharge will probably be OK. 4 When in doubt, get help. Features making cardiac Pain unlikely: Stabbing, shooting Pain. Pain lasting 30s, however intense. Well-localized, left sub-mammary Pain (In my Heart, doctor). Pains of continually varying location. Youth. Do not feel that you must diagnose every Pain. Chest Pain with no cause is common, even after extensive tests. Some patients have a chronic Pain syndrome similar to post-herpetic neuralgia. Typically, this responds to a tricyclic, eg Lowdose amitriptyline at night (this dose does not imply any depression). Avoid being that doctor who triumphantly tells a patient that they are fi ne and can go home, only to be met by a glare, as the disabling Pain the patient presented with is no better than when they arrived. Take time to explain why you do not believe the Pain is a result of dangerous pathology; to give advice on Pain control and red fl ags; and to reassure the patient that their problem is likely to resolve with time. 2 Dialogue-transformed symptoms explain one of the junior doctors main vexations: when patients retell symptoms to a consultant in the light of day, they bear no resemblance to what you originally heard. But do not be vexed: your dialogue may have helped the patient far more than any ward round. __OOHHCCMM__1100ee. . iinnddbb 9955 0022//0055//22001177 1199: : 0066 96 enicidem ralucsavoidraC ECGa methodical approach Reading an ECG First confi rm the patients name and age, and the ECG date. Then (see fi g 3. 3): Rate: At usual speed (25mm/s) each big square is 0. 2s; each small square is 0. 04s. To calculate the rate, divide 300 by the number of big squares between two consecutive R waves (table 3. 1). The normal rate is 60100bpm. Rhythm: If cycles are not clearly regular, use the card method: lay a card along the ECG, marking positions of three successive R waves. Slide the card to and fro to check that all intervals are equal. If they are not, note if: there is slight but regular lengthening and then shortening (with respiration) sinus arrhythmia, common in the young there are diff erent rates which are multiples of each othervarying block it is 100% irregularatrial fi brillation (atrial fibrillation) or ventricular fi brill ation (VF). Sinus rhythm is characterized by a P wave followed by a QRS complex. atrial fibrillation has no discernible P waves and QRS complexes are irregularly irregular. Atrial fl utter (p130, fi g 3. 35 p131) has a sawtooth baseline of atrial depolarization (300/min) and regular QRS complexes. Ventricular rhythm has QRS complexes 0. 12s with P waves following them or absent (fi g 3. 12, p106). Axis: The overall direction of depolarization across the patients anterior chest; this is the sum of all the ventricular electrical forces during ventricular depolarization. See BOX Determining the ECG axis. Left axis deviation can result from left anterior hemiblock, inferior myocardial infarction, VT from a left ventricular focus, WPW, LVH. Right axis deviation can result from RVH, physical examination, anterolateral myocardial infarction, WPW and left posterior hemiblock. P wave: Normally precedes each QRS complex, and upright in II, III, arteriovenous fistula but inverted in aVR.",
    "P wave: Normally precedes each QRS complex, and upright in II, III, arteriovenous fistula but inverted in aVR. Absent P wave: atrial fibrillation, P hidden due to junctional or ventricular rhythm. P myocardial infarctiontrale: bifi d P wave, indicates left atrial hypertrophy. P pulmonale: peaked P wave, indicates right atrial hypert rophy. Pseudo-P-pulmonale seen if potassium. PR interval: Measure from start of P wave to start of QRS. Normal range: 0. 120. 2s (35 small squares). A prolonged PR interval implies delayed AV conduction (1st degree Heart block). A short PR interval implies unusually fast AV conduction down an accessory pathway, eg WPW (see fi g 3. 37, p133). See Heart block, p98. R R R R R R S S Q S Q QS Fig 3. 2 QRS complexes. If the fi rst defl ection from the isoelectric line is negative, it is a Q wave. Any positive defl ection is an R wave. Any negative defl ection after an R is an S. QRS complex: See fi g 3. 2. Normal duration: 0. 12s. QRS 0. 12s suggests ventricular conduction defects, eg a bundle branch block (pp99, 100), metabolic disturbance, or ventricular origin (eg ventricular ectopic). High-amplitude QRS complexes suggest ventricular hypertrophy (p100). Normal Q waves are 0. 04s wide and 2mm deep; they are often seen in leads I, aVL, V5, and V6 and refl ect normal septal depolarization. Pathological Q waves (deep and wide) may occur within a few hours of an acute myocardial infarction. QT interval: Measure from start of QRS to end of T wave. It varies with rate. The corrected QT interval (QTc) is the QT interval divided by the square root of the RR interval, ie QTcQT/respiratory rate. Normal QTc: 0. 380. 42s. For causes of prolonged QT interval see p711. Long QT can lead to VT and sudden death. ST segment: Usually isoelectric. Planar elevation (1mm) or depression (0. 5mm) usually implies infarction (p119, fi gs 3. 9, 3. 10, pp1034) or ischaemia, respectively. T wave: Normally inverted in aVR, V1, and occasionally V2. Normal if inverted in isolation in lead III. Abnormal if inverted in I, II, and V4V6. Peaked in hyperkalaemia (fi g 14. 4, p675) and fl attened in hypokalaemia. J wave: See p849. The J point is where the S wave fi nishes and ST segment starts. A J wave is a notch at this point. Seen in hypothermia, SAH, and Ca2. __OOHHCCMM__1100ee. . iinnddbb 9966 0022//0055//22001177 1199: : 0066 97 enicidem ralucsavoidraC Fig 3. 3 Schematic diagram of a normal ECG trace. Calculating the Heart rate Divide 300 by the number of big squares per RR interval (assumes the UK standard ECG speed of 25mm/s, elsewhere 50mm/s may be used: dont be confused! ). Table 3. 1 Calculating Heart rate from the RR interval. RR duration (s) Big squares Rate (per min) 0. 2 1 300 0. 6 3 100 1. 0 5 60 1. 4 7 43 Determining the ECG axis Each lead on the 12-lead ECG represents electrical activity along a particular plane (see fi g 3. 4). The axis lies at 90° to the direction of the lead in which the isoelectric (equally ve and Ωve) QRS complex is found. For example, if the QRS is isoelectric in lead II (60°), the axis is either: 60° Ω 90° Ω30°, or 60° 90° 150°. If the QRS is more positive than negative in lead I (0°) Fig 3. 4 The planes represented by the limb leads. then the axis must be Ω30°, and vice versa.",
    "4 The planes represented by the limb leads. then the axis must be Ω30°, and vice versa. In practice, the exact axis matters little; what you need to be able to recognize is whether the axis is normal (Ω30° to 90°), left-deviated (Ω30°), or right deviated (90°). There are many ways of doing this. If the QRS in lead I (0°) is predominantly positive (the R wave is taller than the S wave is deep), the axis must be between Ω90° and 90°. If lead II (60°) is mostly positive, the axis must be between Ω30° and 150°. So if both I and II are positive, the axis must be between Ω30° and 90°the normal range. When II is negative, the axis is likely to be left-deviated (Ω30°) and when I is negative, the axis is likely to be right-deviated (90°). One way of remembering this is: Lovers LeavingLeft axis deviationthe QRS complexes in I and II point away from each other. Lovers ReturningRight axis deviationthe QRS complexes in I and III ± II point towards each other (fi g 3. 11). __OOHHCCMM__1100ee. . iinnddbb 9977 0022//0055//22001177 1199: : 0066 98 enicidem ralucsavoidraC ECGabnormalities Sinus tachycardia All impulses are initiated in the sinoatrial node (sinus rhythm) hence all QRSS are preceeded by a normal P wave with a normal PR interval. Tachycardia means rate 100bpm. See p127. Sinus bradycardia Sinus rhythm at a rate 60bpm. Causes: Physical fi tness, vasovagal attacks, sick sinus syndrome, drugs (-blockers, digoxin, amiodarone), hypothyroidism, hypothermia, intracranial Hypertension, cholestasis. See p122. atrial fibrillation (ECG p125) Common causes: IHD, thyrotoxicosis, hypertension, obesity, Heart failure, alcohol. See p130. Heart block (hemoglobin) (See fi g 3. 5. ) Disrupted passage of electrical impulse through the AV node. 1st-degree hemoglobin: The PR interval is prolonged and unchanging; no missed beats. 2nd-degree hemoglobin: Mobitz I: The PR interval becomes longer and longer until a QRS is missed, the pattern then resets. This is Wenckebach phenomenon. 2nd-degree hemoglobin: Mobitz II: QRSs are regularly missed. eg P - QRS - P - - P - QRS - P - - this would be Mobitz II with 2: 1 block (2P: 1QRS). This is a dangerous rhythm as it may progress to complete Heart block. 1stand 2nd-degree hemoglobin may be caused by: normal variant, athletes, sick sinus syndrome, IHD (esp inferior myocardial infarction), acute myocarditis, drugs (digoxin, -blockers). 3rd-degree hemoglobin: Complete Heart block: No impulses are passed from atria to ventricles so P waves and QRSS appear independently of each other. As tissue distal to the AVN paces slowly, the patient becomes very bradycardic, and may develop haemodynamic compromise. Urgent treatment is required. Causes: IHD (esp inferior myocardial infarction), idiopathic (fi brosis), congenital, aortic valve calcifi calcium tion, cardiac surgery/trauma, digoxin toxicity, infi ltration (abscesses, granulomas, tumours, parasites). ST elevation Normal variant (High take-off ), acute myocardial infarction (STEMI), Prinzmetals angina (p708), acute pericarditis (saddle-shaped), left ventricular aneurysm. ST depression Normal variant (upward sloping), digoxin toxicity (downward sloping), ischaemic (horizontal): angina, NSTEMI, acute posterior myocardial infarction (ST depression in V1V3). T inversion In V1V3: normal (black patients and children), right bundle branch block (RBBB), RV strain (eg secondary to physical examination). In V2V5: anterior ischaemia, HCM, subarachnoid haemorrhage, lithium. In V4V6 and aVL: lateral ischaemia, LVH, left bundle branch block (LBBB). In II, III and arteriovenous fistula: inferior ischaemia. NB: STand T-wave changes are often non-specifi c, and must be interpreted in the light of the clinical context. Myocardial infarction (See p118 and fi g 3. 21; example ECGs fi gs 3. 9, 3.",
    "Myocardial infarction (See p118 and fi g 3. 21; example ECGs fi gs 3. 9, 3. 10) Within hours, the T wave may become peaked and ST segments may begin to rise. Within 24h, the T wave inverts. ST elevation rarely persists, unless a left ventricular aneurysm develops. T-wave inversion may or may not persist. Within a few days, pathological Q waves begin to form. Q waves usually persist, but may resolve in 10% of patients. The location of these changes indicates the ischaemic area location, see table 3. 2. Pulmonary embolism (fi g 3. 11) ECG fi ndings may include: sinus tachycardia (commonest), RBBB (p100), right ventricular strain pattern (R-axis deviation, dominant R wave and T-wave inversion/ST depression in V1 and V2, ). Rarely, the SIQIIITIII pattern occurs: deep S waves in I, pathological Q waves in III, inverted T waves in III. Metabolic abnormalities Digoxin effect: Down-sloping ST depression and inverted T wave in V5V6 (reversed tick, see fi g 3. 19). In digoxin toxicity, any arrhythmia may occur (ventricular ectopics and nodal bradycardia are common). Hyperkalaemia: Tall, tented T wave, widened QRS, absent P waves, sine wave appearance (see fi g 14. 4, p675). Hypokal aemia: Small T waves, prominent U waves, peaked P waves. Hypercalcaemia: Short QT interval. Hypocalcaemia: Long QT interval, small T waves. See p711 for causes of long QT intervals. __OOHHCCMM__1100ee. . iinnddbb 9988 0022//0055//22001177 1199: : 0066 99 enicidem ralucsavoidraC P P P P First degree AV block. PR interval 0. 28s. P P P P Mobitz type I (Wenckebach) AV block. With each successive QRS, the PR interval increases until there is a non-conducted P wave. P P P P P Mobitz type II AV block. Ratio of AV conduction varies from 2: 1 to 3: 1. P P P P P P P Complete AV block with narrow ventricular complex. There is no relation between atrial and the slower ventricular activity. Fig 3. 5 Rhythm strips of Heart blocks. Location, location, location When considering rate and rhythm, your fi ndings should be the same in all leads, albeit clearer in some than others. Other ECG features may vary lead by lead, both in terms of what is normal and in what a change indicates. For example, ST elevation in leads II, III, and arteriovenous fistula suggests an inferior myocardial infarction requiring immediate treatment, likely PCI to the right coronary artery, see table 3. 2. ST elevation across all leads, however, suggests instead pericarditis which necessitates entirely diff erent management (p154). An R wave taller than the S is deep (R dominance) is normal in V5 and V6 but may suggest right ventricular strain or posterior myocardial infarction if seen in V1 and V2. Table 3. 2 ECG territories ECG leads Heart territory Coronary artery I, aVL, V4V6 Lateral Circumfl ex V13 Anterioseptal Left anterior descending II, III, arteriovenous fistula Inferior Right coronary artery in 80% Circumfl ex in 20%: left dominant V79 Posterior Circumfl ex Following a posterior myocardial infarction, the standard 12-lead ECG will not show Q waves, ST elevation or hyperacute T waves. Instead, you may fi nd these changes but upside-down in V1V3: prominent R waves, fl at ST depression, and T-wave inversion. If you record V7V9 leads, you may fi nd the classic ST elevation pattern and so confi rm posterior myocardial infarction. See fi g 3. 24. The upside-down changes seen in posterior myocardial infarction are called reciprocal changes: changes that appear when looking at ischaemic myocardium from the other side of the Heart. These can arise with MIs in other locations (fi g 3.",
    "These can arise with MIs in other locations (fi g 3. 9). They are particularly important in posterior myocardial infarction as they may be the only changes on the 12-lead ECG. See fi g 3. 9, 3. 10, 3. 24 for example ECGs. See fi g 3. 18 for coronary artery anatomy. __OOHHCCMM__1100ee. . iinnddbb 9999 0022//0055//22001177 1199: : 0066 100 enicidem ralucsavoidraC ECGad ditional points Where to place the chest leads (See fi g 3. 6. ) V1: Right sternal edge, 4th intercostal space. V2: Left sternal edge, 4th intercostal space. V3: Half-way between V2 and V4. V4: 5th intercostal space, mid-clavicular line; all subsequent leads are in the same horizontal plane as V4. V5: Anterior axillary line. V6: Mid-axillary line (V7: posterior axillary line). Good skin preparation (clean with non-alcoholic wipe, shave if hairy, etc. ) will improve ECG quality. Finish 12-lead ECGs with a long rhythm strip in lead II. QRS complexes: the long and the short QRS complexes represent ventricular depolarization, and width represents time, so a broader QRS Fig 3. 6 Placement of ECG leads. complex means depolarization of the ventricles is taking longer. Normally, a wave of depolarization reaches the ventricles via the specialist conduction pathwaysthe bundles of His. This delivers the electrical activity to certain points of the ventricles, meaning the waves of depolarization need travel as short a distance as possible to depolarize all the ventricular myocardium. This allows rapid spread of depolarization and thus an effi cient contraction action as both ventricles contract from apex to outfl ow tracts together. Hence, the QRS complex is narrow (120ms). Ventricular depolarization takes longer when depolarization is not initiated in this pattern. For example, if it originates in the ventricles (eg ventricular ectopics, VT) or if one or more branches of the bundles of His are blockedbundle branch blocks meaning depolarization is initiated in one ventricle but not the other, so it has to travel the long (in time and space) path from one ventricle to the other. Ventricular depolarization also takes longer if all conduction is slowed. This may happen in some electrolyte imbalances, eg hyperkalaemia. Right bundle branch block: (p102, fi g 3. 8) QRS 0. 12s, RSR pattern in V1; dominant R in V1; inverted T waves in V1V3 or V4; wide, slurred S wave in V6. Causes: normal variant (isolated RBBB), pulmonary embolism, cor pulmonale. Left bundle branch block: (p101, fi g 3. 7) QRS 0. 12s, M pattern in V5, dominant S in V1, inverted T waves in I, aVL, V5V6. Causes: IHD, hypertension, cardiomyopathy, idiopathic fi brosis. NB: if there is LBBB, no comment can be made on the ST segment or T wave. New LBBB may represent a STEMI, see p798. Bifascicular block: The combination of RBBB and left bundle hemiblock, manifest as an axis deviation, eg left axis deviation in the case of left anterior hemiblock. Trifascicular block: Bifascicular block plus 1st-degree hemoglobin. May need pacing (p132). Suspect left ventricular hypertrophy (LVH) if the R wave in V6 is 25mm or the sum of the S wave in V1 and the R wave in V6 is 35mm (see fi g 3. 41). Suspect right ventricular hypertrophy (RVH) if dominant R wave in V1, T wave inversion in V1V3 or V4, deep S wave in V6, right axis deviation. Other causes of dominant R wave in V1: RBBB, posterior myocardial infarction, type A WPW syndrome (p133). Causes of Low-voltage QRS complex: (QRS 5mm in all limb leads. )",
    "Causes of Low-voltage QRS complex: (QRS 5mm in all limb leads. ) Hypothyroidism, chronic obstructive pulmonary disease (COPD), haematocrit (intracardiac Blood resistivity is related to haematocrit), changes in chest wall impedance (eg in renal failure subcutaneous emphysema but not obesity), pulmonary embolism, bundle branch block, carcinoid Heart disease, myocarditis, cardiac amyloid, doxorubicin cardiotoxicity, and other Heart muscle diseases, pericardial eff usion, pericarditis. 5 See lifeinthefastlane. com for excellent ECG tutorials, cases, and examples. __OOHHCCMM__1100ee. . iinnddbb 110000 0022//0055//22001177 1199: : 0066 101 Fig 3. 7 Left bundle branch block: wide QRS with a W pattern in V1 (slight notching in upstroke of S waveclearer in V3) and the M pattern in V6. WiLLiaM LBBB. Cardiovascular medicine __OOHHCCMM__1100ee. . iinnddbb 110011 0022//0055//22001177 1199: : 0066 102 Cardiovascular medicine Fig 3. 8 Right bundle branch blockbroad QRS, M pattern in V1 and sloped S wave (with the eye of faith, a W shape) in V5. MaRRoW RBBB. __OOHHCCMM__1100ee. . iinnddbb 110022 0022//0055//22001177 1199: : 0066 103 Fig 3. 9 Acute infero-lateral myocardial infarction: marked ST elevation in the inferior leads (II, III, arteriovenous fistula), but also in V5 and V6, indicating lateral involvement. There is a reciprocal change of ST-segment depression in leads I and aVL; this is often seen with a large inferior myocardial infarction. Cardiovascular medicine __OOHHCCMM__1100ee. . iinnddbb 110033 0022//0055//22001177 1199: : 0066 104 Cardiovascular medicine Fig 3. 10 Acute anterior myocardial infarctionST segment elevation and evolving Q waves (the fi rst QRS defl ection is negative) in leads V14. __OOHHCCMM__1100ee. . iinnddbb 110044 0022//0055//22001177 1199: : 0066 105 Fig 3. 11 Changes seen in pulmonary hypertension (eg after a physical examination). Right axis deviation (QRS more negative than positive in lead I); Positive QRS complexes (dominant R waves) in V1 and V2 suggesting right ventricular hypertrophy; ST depression and T-wave inversion in the right precordial leads (V13) suggesting right ventricular strain; Peaked P waves (P pulmonale) suggesting right atrial hypertrophy. Reproduced from Handler et al. , Pulmonary Hypertension, 2012, with permission from Oxford University Press. Cardiovascular medicine __OOHHCCMM__1100ee. . iinnddbb 110055 0022//0055//22001177 1199: : 0066 106 Cardiovascular medicine Fig 3. 12 Ventricular tachycardiaregular broad complex tachycardiac indicating a likely ventricular origin for the rhythm. __OOHHCCMM__1100ee. . iinnddbb 110066 0022//0055//22001177 1199: : 0066 107 Fig 3. 13 Dual chamber pacemaker. Pacing spikes occur before each P wave and each QRS complex. Paced QRS complexes are broad as the impulse starts in the ventricles. Reproduced from Myerson et al. , Emergencies in Cardiology, 2012, with permission from Oxford University Press. Cardiovascular medicine __OOHHCCMM__1100ee. . iinnddbb 110077 0022//0055//22001177 1199: : 0066 108 enicidem ralucsavoidraC Cardiac imaging There are many Heart conditions associated with structural defects, eg valve defects, congenital Heart diseases, and some muscle disorders (eg hypertrophic cardiomyopathy (HCM)). Whilst clues to these can sometimes be found on history, examination, and ECG, it is imaging that gives the diagnosis. Imaging is also helpful for conditions that are not primarily due to deformities but which aff ect the way the Heart functions. For example, after an myocardial infarction the aff ected territory may be hypokinetic. Stress techniques allow ultrasound to observe the Heart at rest and then under stress, comparing the perfusion and function in the two states. Cardiac magnetic resonance imaging is a rapidly expanding area although not yet available in all major hospitals. Chest X-ray The humble chest X-ray provides just a snapshot of the Heart and little detail but can be an important source of information and is often the only immediately accessible imaging modality for a new or newly unwell patient. An enlarged Heart (cardiothoracic ratio 0.",
    "An enlarged Heart (cardiothoracic ratio 0. 5) suggests congestive Heart failure; signs of pulmonary oedema suggest decompensated Heart failure (see fi g 3. 38); a globular Heart may indicate pericardial eff usion (fi g 3. 14); metal wires and valves will show up, evidencing previous cardiothoracic surgery; dextrocardia may explain a bizarre ECG; and rib notching may be an important clue in coarctation of the aorta (p156). Echocardiography This is the workhorse of cardiological imaging. Ultrasound is used to give real-time images of the moving Heart. This can be transthoracic (TTE) or transoesophageal (TOE), at rest, during exercise, or after infusion of a pharmacological stressor (eg dobutamine). If the patient is too unwell to be moved, an echo machine can be brought to them and continuous TOE imaging may be used as a guide during surgery. Increasingly pocket-sized echo machines are used for a quick assessment of an unwell patient, to be followed by a formal scan later. See p110. Cardiac computed tomography This can provide detailed information about cardiac structure and function. computed tomography angiography (fi g 3. 15) permits contrast-enhanced imaging of coronary arteries during a single breath hold with very Low radiation doses. It can diagnose signifi cant (50%) stenosis in coronary artery disease with an accuracy of 89%. computed tomography coronary angiography has a negative predictive value of 99%, which makes it an eff ective non-invasive alternative to routine transcatheter coronary angiography to rule out coronary artery disease. 6 Medications are often given to slow the Heart down and the imaging may be gated, meaning the scanner is programmed to take images at times corresponding to certain points on the patients ECG. This allows characterization of the Heart at diff erent points in the cardiac cycle. See p740. Cardiac MR A radiation-free method of characterizing cardiac structure and function including viability of myocardium. By varying the settings, diff erent defects can be found. MR is the fi rst-choice imaging method to look at diseases that directly atrial fibrillationfect the myocardium (fi g 3. 16). Nowadays, pacemakers are available which are safe for MR scanningcheck MR safety with your cardiac technicians before requesting MR for patients with pacemakers in situ. See p740. Nuclear imaging Perfusion is assessed at rest and with exerciseor pharmacologically-induced stress. This test is particularly useful for assessing whether myocardium distal to a blockage is viable and so whether stenting or CABG will be of value. If hypoperfusion is fi xed, ie present at rest and under stress, the hypoperfused area is probably scar tissue and so non-viable. If hypoperfusion is reversible at rest, the myocardium may benefi t from improved Blood supply. See p741. __OOHHCCMM__1100ee. . iinnddbb 110088 0022//0055//22001177 1199: : 0066 109 enicidem ralucsavoidraC Fig 3. 14 Two chest X-rays of the same patient, the one on the right was taken 6 months after the one on the left. On the later image, a pericardial eff usion has expanded the cardiac shadow and given it a globular shape. Reproduced from Leeson, Cardiovascular Imaging, 2011, with permission from Oxford University Press. Fig 3. 15 Cardiac computed tomography demonstrating coronary artery Fig 3. 16 Cardiac MR image demonstratstenosis. ing the asymmetrical left ventricular wall Reproduced from Camm et al. , ESC Textbook of Cardiothickening typical of hypertrophic cardiovascular Medicine, 2009, with permission from Oxford myopathy. University Press. Reproduced from Myerson et al. , Cardiovascular Magnetic Resonance, 2013, with permission from Oxford University Press. __OOHHCCMM__1100ee. . iinnddbb 110099 0022//0055//22001177 1199: : 0066 110 enicidem ralucsavoidraC Echocardiography This non-invasive technique uses the diff ering ability of various structures within the Heart to refl ect ultrasound waves.",
    "It not only demonstrates anatomy but also provides a continuous display of the functioning Heart throughout its cycle. Types of scan M-mode (motion mode): A single-dimension image. Two-dimensional (real time): A 2D, fan-shaped image of a segment of the Heart is produced on the screen (fi g 3. 17); the moving image may be frozen. Several views are possible, including long axis, short axis, 4-chamber, and subcostal. 2D echocardiography is Good for visualizing conditions such as: congenital Heart disease, LV aneurysm, mural thrombus, LA myxoma, septal defects. 3D echocardiography: Now possible with matrix array probes, and is termed 4D (3D time) if the images are moving. Doppler and colour-fl ow echocardiography: Diff erent coloured jets illustrate fl ow and gradients across valves and septal defects (p156) (Doppler eff ect, p736). Tissue Doppler imaging: This employs Doppler ultrasound to measure the velocity of myocardial segments over the cardiac cycle. It is particularly useful for assessing longitudinal motionand hence long-axis ventricular function, which is a sensitive marker of systolic and diastolic Heart failure. Transoesophageal echocardiography (TOE): More sensitive than transthoracic echocardiography (TTE) as the transducer is nearer to the Heart. Indications: diagnosing aortic dissections; assessing prosthetic valves; fi nding cardiac source of emboli, and IE/SBE. Contraindicated in oesophageal disease and cervical spine instability. Stress echocardiography: Used to evaluate ventricular function, ejection fraction, myocardial thickening, regional wall motion preand post-exercise, and to characterize valvular lesions. Dobutamine or dipyridamole may be used if the patient cannot exercise. Inexpensive and as sensitive/specifi c as a thallium scan (p741). Uses of echocardiography Quantifi cation of global LV function: Heart failure may be due to systolic or diastolic ventricular impairment (or both). Echo helps by measuring end-diastolic volume. If this is large, systolic dysfunction is the likely cause. If small, diastolic. Pure forms of diastolic dysfunction are rare. Diff erentiation is important because vasodilators are less useful in diastolic dysfunction as a High ventricular fi lling Hypertension is required. Echo is also useful for detecting focal and global hypokinesia, LV aneurysm, mural thrombus, and LVH (echo is 510 times more sensitive than ECG in detecting this). Estimating right Heart haemodynamics: Doppler studies of pulmonary artery fl ow and tricuspid regurgitation allow evaluation of RV function and pressures. Valve disease: The technique of choice for measuring Hypertension gradients and valve orifi ce areas in stenotic lesions. Detecting valvular regurgitation and estimating its signifi cance is less accurate. Evaluating function of prosthetic valves is another role. Congenital Heart disease: Establishing the presence of lesions, and signifi cance. Endocarditis: Vegetations may not be seen if 2mm in size. TTE with colour Doppler is best for aortic regurgitation (AR). TOE is useful for visualizing mitral valve vegetations, leafl et perforation, or looking for an aortic root abscess. Pericardial effusion: Best diagnosed by echo. Fluid may fi rst accumulate between the posterior pericardium and the left ventricle, then anterior to both ventricles and anterior and lateral to the right atrium. There may be paradoxical septal motion. HCM: (p152) Echo features include asymmetrical septal hypertrophy, small LV cavity, dilated left atrium, and systolic anterior motion of the mitral valve. __OOHHCCMM__1100ee. . iinnddbb 111100 0022//0055//22001177 1199: : 0066 111 enicidem ralucsavoidraC (a) (b) Septum RV Ascending Inferolateral aorta wall LV AV Right coronary cusp Non coronary cusp LA MV Descending Anterior leaflet aorta Posterior leaflet (c) (d) Lateral wall (papillary muscle usually not seen) Ventricular septum LV RV MV TV RA Posterior leaflet Lateral leaflet Septeral leaflet LA Anterior leaflet Interatrial septum RUPV Fig 3. 17 Echo images. (a) A normal Heart seen with the parasternal long-axis view.",
    "17 Echo images. (a) A normal Heart seen with the parasternal long-axis view. (b) Diagram of what can be seen in (a). (c) A normal Heart seen in apical four-chamber view. (d) Diagram of what can be seen in (c). Reproduced from Leeson et al. , Echocardiography, 2012, with permission from Oxford University Press. __OOHHCCMM__1100ee. . iinnddbb 111111 0022//0055//22001177 1199: : 0066 112 enicidem ralucsavoidraC Cardiac catheterization This involves the insertion of a catheter into the Heart via the femoral or radial artery or venous system, and manipulating it within the Heart and great vessels to: Inject radiopaque contrast medium to image cardiac anatomy and Blood fl ow, see fi g 3. 18a. Perform angioplasty (ballooning and stenting), valvuloplasty (eg transcatheter aortic valve implantation (TAVI, fi g 3. 45)), cardiac biopsies, transcatheter septal defect closure. Perform electrophysiology studies and radiofrequency ablations. Sample Blood to assess oxygen saturation and measure pressures. Perform intravascular ultrasound or echocardiography. During the procedure, ECG and arterial pressures are monitored continuously. In the UK, the majority are performed as day-case procedures. Indications Coronary artery disease: diagnostic (assessment of coronary vessels and graft patency); therapeutic (angioplasty, stent insertion), fi g 3. 18b. Valvular disease: diagnostic (pressures indicate severity); therapeutic valvuloplasty (if the patient is too ill or declines valve surgery). Congenital Heart disease: diagnostic (assessment of severity of lesions by measuring pressures and saturations); therapeutic (balloon dilatation or septostomy). Other: cardiomyopathy; pericardial disease; endomyocardial biopsy. Pre-procedure checks Brief history/examination; NB: peripheral pulses, bruits, aneurysms. Investigations: FBC, UE, LFT, clotting screen, CXR, ECG. Consent for procedure, including possible extra procedures, eg consent for angioplasty if planning to do angiography as you may fi nd a lesion that needs stenting. Explain reason for procedure and possible complications. IV access, ideally in the left hand. Patient should be nil by mouth (NBM) from 6h before the procedure. Patients should take all their morning drugs (and pre-medication if needed)but withhold oral hypoglycaemics. Post-procedure checks Pulse, blood pressure, arterial puncture site (for bruising or Edema), foot pulses. Investigations: FBC and clotting (if suspected Blood loss), ECG. Complications Haemorrhage: apply fi rm Hypertension over puncture site. If you suspect a false aneurysm, ultrasound the Edema and consider surgical repair. Haematomas are High risk for infections. Contrast reaction: this is usually mild with modern contrast agents. Loss of peripheral pulse: may be due to dissection, thrombosis, or arterial spasm. Occurs in 1% of brachial catheterizations. Rare with femoral catheterization. Angina: may occur during or after cardiac catheterization. Usually responds to sublingual GTN; if not, give analgesia and IV nitrates. Arrhythmias: usually transient. Manage along standard lines. Pericardial eff usion: suspect if unexplained continued chest Pain. May need drain depending on severity and haemodynamic status. Pericardial tamponade: rare, but should be suspected if the patient becomes hypotensive and anuric. Urgent pericardial drain. Infection: post-catheter pyrexia is usually due to a contrast reaction. If it persists for 24h, take Blood cultures before giving antibiotics. Mortality 1 in 1000 patients, in most centres. Intracardiac electrophysiology This catheter technique can determine types and origins of arrhythmias, and locate and ablate problem areas, eg aberrant pathways in WPW or arrhythmogenic foci. Arrhythmias may be induced, and the eff ectiveness of control by drugs assessed. __OOHHCCMM__1100ee. . iinnddbb 111122 0022//0055//22001177 1199: : 0066 113 enicidem ralucsavoidraC (a) (b) (c) Fig 3. 18 (a) Coronary artery anatomy. (b) and (c) Images from angiography. (b) shows stenosis of the left anterior descending artery (LAD). In (c), the same patient has had their LAD stented, allowing contrast to fl ow freely through to the distal vessel.",
    "The stenting is a type of angioplasty (a procedure to widen the lumen of a Blood vessel); in the context of coronary arteries, it is called PCI (percutaneous coronary intervention). PPCI (primary PCI) is PCI performed acutely for a patient with acute coronary syndrome (ACS), see p120. Images (b) and (c) reproduced from Ramrakha et al. , Oxford Handbook of Cardiology, 2012, with permission from Oxford University Press. __OOHHCCMM__1100ee. . iinnddbb 111133 0022//0055//22001177 1199: : 0066 114 enicidem ralucsavoidraC Cardiovascular drugs Antiplatelet drugs Aspirin irreversibly acetylates cyclo-oxygenase, preventing production of thromboxane A2, thereby inhibiting platelet aggregation. Used in Low dose (eg 75mg/24h PO) for secondary prevention following myocardial infarction, TIA/stroke, and for patients with angina or peripheral vascular disease. May have a role in primary prevention. 7 ADP receptor antagonists (eg clopidogrel, prasugrel, ticagrelor) also block platelet aggregation, but may cause less gastric irritation. They have a role if truly intolerant of aspirin; with aspirin after coronary stent insertion; and in acute coronary syndrome. Glycoprotein IIb/IIIa antagonists (eg tirofi ban) have a role in unstable angina/myocardial infarction. 8 Anticoagulants See p350. Direct oral anticoagulants (DOACs, previously NOACs), eg Xa inhibitors (eg apixaban) and direct thrombin inhibitors (dabigatran), are increasingly replacing warfarin9 for treatment of atrial fibrillation and clots, see p350. Warfarin remains the anticoagulant of choice for mechanical valves. Anticoagulants used in ACS include treatment dose LMWH, fondaparinux (Xa inhibitor), bivalirudin (thrombin inhibitor). -blockers Block -adrenoceptors, thus antagonizing the sympathetic nervous system. Blocking 1-receptors is negatively inotropic and chronotropic; blocking 2-receptors induces peripheral vasoconst riction and bronchoconstriction. Drugs vary in their 1/2 selecti vity (eg propranolol is non-selective, and bisoprolol relatively 1 selective), but this does not seem to alter their clinical effi cacy. Uses: Angina, hypertension, antid ysrhythmic, post myocardial infarction (mortality), Heart failure (with caution). CI: Severe asthma/COPD, Heart block. SES: Lethargy, erectile dysfunction, joie de vivre, nightmares, headache. ACE inhibitors These are used in hypertension (height), Heart failure, and post-myocardial infarction. First dose height is a concern in patients with severe CCF and malignant height. In CCF patients, reduce diuretic dose initially and use long-acting angiotensin-converting enzyme inhibitor. Monitor UE when starting or raising angiotensin-converting enzyme inhibitor dose, a Creatinine rise of 20% is concerning. If the patient starts angiotensin-converting enzyme inhibitor prior to discharge, ask the GP to check UE in 12 weeks. If renal function deteriorates markedly, consider investigating for renal artery stenosis. The risk to the kidneys is greater when the patient is unwell. Hold in acute kidney injury and hyperkalaemia; avoid starting if the patient is dehydrated. SES: Include dry cough and urticaria. Diuretics Loop diuretics (eg furosemide) are used in Heart failure, and inhibit the sodium/2Cl/potassium co-transporter. SES: dehydration, sodium, potassium, Ca2, ototoxic Thiazides and thiazide-like diuretics are used in hypertension (eg indapamide) and Heart failure (eg metolazone). SE: potassium, Ca2, Mg2, urate (±gout), impotence (NB: small doses, eg chlortalidone 25mg/24h rarely cause signifi cant SEs) Potassium-sparing diuretics: aldosterone antagonists (eg spironolactone, eplerenone) directly block aldosterone receptors; amiloride blocks the epithelial Sodium channel in the distal convoluted tubules. Vasodilators Used in Heart failure, IHD, and hypertension. Nitrates (p116) preferentially dilate veins and the large arteries, fi lling Hypertension (pre-load), while hydralazine (often used with nitrates) primarily dilates the resistance vessels, thus blood pressure (after-load). Prazosin (an -blocker) dilates arteries and veins. Calcium antagonists These cell entry of Ca2 via voltage-sensitive channels in smooth muscle, thereby promoting coronary and peripheral vasodilat ion and reducing myocardial oxygen consumption. All current drugs block L-type Ca2 channels. However, their eff ects diff er because of diff erential binding properties.",
    "All current drugs block L-type Ca2 channels. However, their eff ects diff er because of diff erential binding properties. The dihydropyridines, eg nifed ipine, amlodipine, are mainly peripheral vasodilators (also dilate coronary arteries) and cause a refl ex tachycardia, so are often used with a -blocker. They are used mainly in hypertension and angina. The non-dihydropyridinesverapamil and diltiazemalso slow conduction at the AV and SA nodes and may be used to treat hypertension, angina, and dysrhythmias. Dont give non-dihydropyridines with -blockers (risk of severe bradycardia ± LVF). SES: Flushes, headache, ankle oedema (diuretic unresponsive), LV function, gingival hypertrophy. CI: Heart block. __OOHHCCMM__1100ee. . iinnddbb 111144 0022//0055//22001177 1199: : 0066 115 enicidem ralucsavoidraC Digoxin Blocks the sodium/potassium pump. It is used to slow the pulse in fast atrial fibrillation (p130; aim for 100). As it is a weak ve inotrope, its role in Heart failure in sinus rhythm may be best reserved if symptomatic despite optimal angiotensin-converting enzyme inhibitor therapy; 10 here there is little benefi t vis-à-vis mortality (but admissions for worsening CCF are by 25%). 11 Elderly people are at risk of toxicity: use lower doses. Measure plasma levels 6h post-dose (p756). Typical dose: 500mcg stat PO, repeated after 12h, then 125mcg (if elderly) to 250mcg/d PO OD (62. 5mcg/d is almost never enough). IV dose: 0. 751mg in 0. 9% NaCl over 2h. Toxicity risk if: potassium, Mg2, or Ca2. t½ 36h. If on digoxin, use less energy in cardioversion (start at 5J). If on amiodarone, halve the dose of digoxin. SES: Any arrhythmia (supraventr icular tachycardia with AV block is suggestive), nausea, appetite, yellow vision, confusion, gynaecomastia. If toxicity is suspected, do an ECG (fi g 3. 19), digoxin levels, and check potassium, Mg2, and Ca2. If toxicity is confi rmed, stop digoxin, correct electrolyte imbalances, treat arrhyt hmias, and consider IV DigiFab (p842). CIS: HCM; WPW syndrome (p133). Fig 3. 19 This ECG shows the classic reverse tick of digoxin toxicity: downsloping ST wave with rapid upstroke back to isoelectric line. The bradycardia is also suggestive of digoxin toxicity. Sodium channel blockers Class I anti-arrhythmics. Procainamide (1a) and lidocaine (1b) can be used to terminate VT. NB QT interval may be prolonged. Flecainide (1c) is useful for atrial fibrillation cardioversion in patients without contraindications, and for arrhythmia prophylaxis in patients with WPW or troublesome paroxysmal atrial fibrillation. CIS: Heart failure, IHD, valve disease, and Heart block. Amiodarone A class III anti-arrhythmic. Amiodarone prolongs the cardiac action potential, reducing the potential for tachyarrhythmias. Used in both supra-ventricular and ventricular tachycardias, including during cardiac arrest. Broad range of side eff ects incl. thyroid disease, Liver disease, pulmonary fi brosis and peripheral neuropathy. Monitor TFTs and LFTs every 6 months. Ivabradine Blocks the pacemaker funny current, slowing pulse rate without signifi cantly dropping Blood Hypertension. Used in angina, Heart failure, and (off -licence) in autonomic tachycardia syndromes. CIS: Acute myocardial infarction, bradycardia, long QT syndrome, shock. Many drug interactions, including with calcium antagonists. Statins Statins (eg simvastatin, p690) inhibit the enzyme HMG-COA reductase, which causes de novo synthesis of cholesterol in the Liver. This increases LDL receptor expression by hepatocytes leading to circulating LDL cholesterol. More eff ective if given at night, but optimum dose and target plasma cholesterol are unknown. SES: Muscle aches, abdominal discomfort, transaminases (eg ALT), CK, myositis, rarely rhabdo myolysis (more common if used with fi brates). Statins are generally well tolerated. There are currently 3 million people taking statins in England, which saves 10 000 lives a year. See also hyperlipidaemia, pp6901, fi g 14. 13. Anti-anginal drugs p116. Antihypertensives p140.",
    "See also hyperlipidaemia, pp6901, fi g 14. 13. Anti-anginal drugs p116. Antihypertensives p140. Drugs that slow conduction through the atrioventricular node Drugs that slow conduction through the atrioventricular node (AVN) include digoxin, verapamil, and adenosine. Uses include cardioverting AVNRT and diagnosing atrial tachycardias. Drugs that slow AVN conduction should be avoided in patients with aberrant pathways (eg WPW) as blocking the AVN can increase conduction via the alternative pathways. AVN blockers are contraindicated in patients with or at risk of VT, eg those with long QT syndrome. __OOHHCCMM__1100ee. . iinnddbb 111155 0022//0055//22001177 1199: : 0066 116 enicidem ralucsavoidraC Angina pectoris If ACS is a possible diagnosis (including unstable angina), see pp798801. Angina12 is symptomatic reversible myocardial ischaemia. Features: 1 Constricting/heavy discomfort to the chest, jaw, neck, shoulders, or arms. 2 Symptoms brought on by exertion. 3 Symptoms relieved within5 min by rest or GTN. All 3 features typical angina; 2 features atypical angina; 01 features nonanginal chest Pain. Other precipitants: emotion, cold weather, and heavy meals. Associated symptoms: dyspnoea, nausea, sweatiness, faintness. Features that make angina less likely: Pain that is continuous, pleuritic or worse with swallowing; Pain associated with palpitations, dizziness or tingling. Causes Atheroma. Rarely: anaemia; coronary artery spasm; AS; tachyarrhythmias; HCM; arteritis/small vessel disease (microvascular angina/cardiac syndrome X). Types of angina Stable angina: Induced by eff ort, relieved by rest. Good prognosis. Unstable angina: (Crescendo angina. ) Angina of increasing frequency or severity; occurs on minimal exertion or at rest; associated with risk of myocardial infarction. Decubitus angina: Precipitated by lying fl at. Variant (Prinzmetal) angina: (BOX Vasospastic angina) Caused by coronary artery spasm (rare; may coexist with fi xed stenoses). Tests ECG usually normal, but may show ST depression; fl at or inverted T waves; signs of past myocardial infarction. Blood tests: FBC, UE, TFTs, lipids, hemoglobin hemoglobin A1c. Consider echo and chest X-ray. Further investigations are usually necessary to confi rm an IHD diagnosissee BOX. Management Address exacerbating factors: Anaemia, tachycardia (eg fast atrial fibrillation), thyrotoxicosis. Secondary prevention of cardiovascular disease: Stop smoking; exercise; dietary advice; optimize hypertension and Diabetes control. 75mg aspirin daily if not contraindicated. Address hyperlipidaemiasee p690. Consider ACE inhibitors, eg if diabetic. as needed symptom relief: Glyceryl trinitrate (GTN) spray or sublingual tabs. Advise the patient to repeat the dose if the Pain has not gone after 5min and to call an ambulance if the Pain is still present 5min after the second dose. SE: headaches, blood pressure. Anti-anginal medication: (p114) First line: -blocker and/or calcium channel blocker (do not combine -blockers with non-dihydropyridine calcium antagonists). If these fail to control symptoms or are not tolerated, trial other agents. -blockers: eg atenolol 50mg BD or bisoprolol 510mg OD. Calcium antagonists: amlodipinestart at 5mg OD; diltiazemdose depends on formulation. Long-acting nitrates: eg isosorbide mononitratestarting regimen depends on formulation. Alternatives: GTN skin patches. SES: headaches, blood pressure. Ivabradine: reduces Heart rate with minimal impact on blood pressure. Patient must be in sinus rhythm. Start with 5mg BD (2. 5mg in elderly). Ranolazine: inhibits late sodium current. Start at 375mg BD. Caution if Heart failure, elderly, weight 60kg or prolonged QT interval. Nicorandil: a potassium channel activator. Start with 510mg BD. CI: acute pulmonary oedema, severe hypotension, hypovolaemia, LV failure. Revascularization: Considered when optimal medical therapy proves inadequate. Percutaneous coronary intervention (PCI): (p112) a balloon is infl ated inside the stenosed vessel, opening the lumen. A stent is usually inserted to reduce the risk of re-stenosis. Dual antiplatelet therapy (DAPT; usually aspirin and clopidogel) is recommended for at least 12 months after stent insertion to reduce the risk of instent thrombosis.",
    "Specialist advice should be sought regarding antiplatelets if the patient has a High bleeding risk or requires surgery. CABG: (p123) compared to PCI, patients undergoing CABG are less likely to need repeat revascularization and those with multivessel disease can expect better outcomes. However, CABG is open Heart surgery and so recovery is slower and the patient is left with two large wounds (sternal and vein harvesting). __OOHHCCMM__1100ee. . iinnddbb 111166 0022//0055//22001177 1199: : 0066 117 enicidem ralucsavoidraC Investigating patients with? stable angina Investigations for ischaemic Heart disease (IHD) include: Exercise ECGassess for ischaemic ECG changes. Angiographyeither using cardiac computed tomography with contrast, or transcatheter angiography (more invasive but can be combined with stenting, p112). Functional imaging (see p108): myocardial perfusion scintigraphy, stress echo (echo whilst undergoing exercise or receiving dobutamine), cardiac magnetic resonance imaging. NICE recommend the following investigations when considering stable angina. 13 Typical angina in a patient with previously proven IHD: Treat as stable angina; if further confi rmation is required, use non-invasive testing, eg exercise ECG. Typical and atypical angina: computed tomography angiography, fi g 3. 20. If inconclusive, use functional imaging as 2nd line and transcatheter angiography as 3rd line. Non-anginal chest Pain: Does the patient have ischaemic changes on 12 lead ECG? Yes: investigate as per typical and atypical angina No: no further investigations for IHD at this point (unless High clinical suspicion of IHD for other reasonsdiscuss with a specialist). Ensure alternative chest Pain diagnoses are adequately explored. These are guidelines and must be interpreted within the clinical context. Further investigations: If the patient has typical angina but few risk factors for IHD, be sure to look for possible precipitating or exacerbating factors, for example severe anaemia or cardiomyopathy. Fig 3. 20 computed tomography angiogram data has been used to construct this 3D image. The white arrow points to an obstruction of the right coronary artery Reprinted from Journal of the American College of Cardiology, 52(3), MM Henneman et al. , Noninvasive Evaluation With Multislice Computed Tomography in Suspected Acute Coronary Syndrome, 21622, 2008, with permission from Elsevier. Vasospastic angina (Prinzmetal angina) Angina due to coronary artery spasm, which can occur even in normal coronary arteries. The Pain usually occurs during rest and resolves rapidly with short-acting nitrates (eg GTN spray). ECG during Pain shows ST segment elevation. Risks and triggers: Smoking increases risk but hypertension and hypercholesterolaemia do not. Probable triggers include cocaine, amphetamine, marijuana, Low magnesium, and artery instrumentation (eg during angiography). Treatment: Avoid triggers. Correct Low magnesium. Stop smoking. as needed GTN. Calcium channel blockers ± long-acting nitrates. Avoid non-selective -blockers, aspirin, and triptans. Prognosis is usually very Good. __OOHHCCMM__1100ee. . iinnddbb 111177 0022//0055//22001177 1199: : 0066 118 enicidem ralucsavoidraC Acute coronary syndromes (ACS) Defi nitions ACS includes unstable angina and myocardial infarctions (MIs). These share a common underlying pathologyplaque rupture, thrombosis, and infl ammation. However, ACS may rarely be due to emboli, coronary spasm, or vasculitis (p556) in normal coronary arteries. Myocardial infarction means there is myocardial cell death, releasing troponin. Ischaemia means a lack of Blood supply, ±cell death. MIS have troponin rises, unstable angina does not. An myocardial infarction may be a STEMIACS with STsegment elevation (may only be present in V7V9 if posterior STEMI) or new-onset LBBB; or an NSTEMItrop-positive ACS without ST-segment elevationthe ECG may show ST depression, T-wave inversion, non-specifi c changes, or be normal. The degree of irreversible myocyte death varies, and signifi cant necrosis can occur without ST elevation. Risk factors Non-modifi able: age, gender, family history of IHD (myocardial infarction in 1st-degree relative 55yrs).",
    "Risk factors Non-modifi able: age, gender, family history of IHD (myocardial infarction in 1st-degree relative 55yrs). Modifi able: smoking, hypertension, diabetes mellitus, hyperlipida emia, obesity, sedentary lifestyle, cocaine use. Controversial risk factors include: stress, type A personality, LVH, fi brinogen, hyperinsulinaemia, homocysteine levels, ACE genotype. Incidence 5/1000 per annum (UK) for ST-segment elevation (declining in UK USA). Diagnosis An increase in cardiac biomarkers (eg troponin) and either: symptoms of ischaemia, ECG changes of new ischaemia, development of pathological Q waves, new loss of myocardium, or regional wall motion abnormalities on imaging. Symptoms Acute central chest Pain, lasting 20min, often associated with nausea, sweatiness, dyspnoea, palpitations. ACS without chest Pain is called silent; mostly seen in elderly and diabetic patients. Silent MIs may present with: syncope, pulmonary oedema, epigastric Pain and Vomiting, post-operative hypotension or oliguria, acute confusional state, stroke, and diabetic hyperglycaemic states. Signs Distress, anxiety, pallor, sweatiness, pulse or , blood pressure or , 4th Heart sound. There may be signs of Heart failure (JVP, 3rd Heart sound, basal crepitations) or a pansystolic murmur (papillary muscle dysfunction/rupture, VSD). Low-grade fever may be present. Later, a pericardial friction rub or peripheral oedema may develop. Tests ECG: (See fi g 3. 21. ) STEMI: classically, hyperacute (tall) T waves, ST elevation, or new LBBB occur within hours. T-wave inversion and pathological Q waves follow over hours to days (p98). NSTEMI/unstable angina: ST depression, T wave inversion, non-specifi c changes, or normal. In 20% of myocardial infarction, the ECG may be normal initially. Paced ECGs and ECGs with chronic bundle branch block are unhelpful for diagnosing NSTEMIs14 and may hinder STEMI15 diagnosis; in these cases, clinical assessment and troponin levels are especially important. CXR: Look for cardiomegaly, pulmonary oedema, or a widened mediastinum. Dont routinely delay treatment whilst waiting for a CXR. Blood: FBC, UE, glucose, lipids, cardiac enzymes. Cardiac enzymes: (See BOX Troponin. ) Cardiac troponin levels (T and I) are the most sensitive and specifi c markers of myocardial necrosis. Diff erent hospitals use diff erent assays: check the required timing of troponin Blood samples where you work (eg two samples 3h apart). Other cardiac enzymes (see fi g 3. 22) are sensitive but less specifi c; their role in ACS diagnosis is decreasing as troponin testing improves. Echo: Regional wall abnormalities. Diff erential diagnosis (p94. ) Stable angina, pericarditis, myocarditis, Takotsubo cardiomyopathy (p145), aortic dissection (p655), physical examination, oesophageal refl ux/spasm, pneumothorax, musculoskeletal Pain, pancreatitis. Management See p120, pp798801. Mortality 50% of deaths occur within 2h of onset of symptoms. Up to 7% die before discharge. Worse prognosis if: elderly, LV failure, and ST changes. 16 __OOHHCCMM__1100ee. . iinnddbb 111188 0022//0055//22001177 1199: : 0066 119 enicidem ralucsavoidraC Fig 3. 21 Sequential ECG changes following acute myocardial infarction. Fig 3. 22 Enzyme changes following acute myocardial infarction. Increasingly, High-sensitivity troponins are used alone for routine investigation of ACS. Troponin Troponins are proteins involved in cardiac and skeletal muscle contraction (fi g 3. 23). When myocardial cells are damaged, troponins are released and enter the bloodstream. The levels of troponin in the Blood can therefore help with diagnosing myocardial damage. Troponins I and T are most specifi c to the Heart. Troponin levels are most commonly measured when ACS is suspected. In this circumstance, one would expect troponin levels to rise in the hours following the insult (fi g 3. 22). Troponin levels can be High with other causes of myocardial damage, for example myocarditis, pericarditis, and ventricular strain. With these conditions, the troponin levels are likely to change little hour by hour as the insults are ongoing.",
    "With these conditions, the troponin levels are likely to change little hour by hour as the insults are ongoing. Discrete episodes of tachyarrhythmias may cause troponin rises similar to in ACS. Troponin levels can also be raised iatrogenically, eg following CPR, DC cardioversion, ablation therapy. A troponin rise may have a non-cardiac aetiology. This can be indirectly related to the Heart, eg a massive physical examination causing right ventricular strain, or have no clear cardiac connection, eg subarachnoid haemorrhage, burns, or sepsis. A common cause of consistently elevated troponin is renal failure. Hence, when measuring troponin, change in level is often more important than the level itself. Fig 3. 23 Diagram of myocardial contraction unit. The troponin complex controls when the myosin heads can bind to the actin chain, shortening the muscle fi bre. Reproduced from Barnard et al. , Cardiac Anaesthesia, 2010, with permission from Oxford University Press. __OOHHCCMM__1100ee. . iinnddbb 111199 0022//0055//22001177 1199: : 0066 120 enicidem ralucsavoidraC Management of ACS ACS management depends on whether the ACS is ST elevated or not: 1 ST elevated myocardial infarction (STEMI): this category includes ACS with ST elevation on ECG (fi g 3. 9) but also ACS with new LBBB (fi g 3. 7); and posterior MIs (fi g 3. 24) where ST elevation may only be seen with extra leads (V7V9). Urgent revascularization is essential. p796. 2 ACS without ST elevation: serial troponins are needed to diff erentiate non-ST elevated MIs (NSTEMIs) (trop rise) from unstable angina (no trop rise). p798. After the immediate actions described on pp7969, treatment of ACS17 focuses on managing symptoms, secondary prevention of further cardiovascular disease, revascularization (if not already undertaken), and addressing complications. Symptom control Manage chest Pain with as needed GTN and opiates. If this proves insuffi cient, consider a GTN infusion (monitor blood pressure, omit if recent sildenafi l use). If Pain is deteriorating, seek senior help. Manage symptomatic Heart failure, p136. Modify risk factors Patients should be strongly advised and helped to stop smoking (p93). Identify and treat Diabetes mellitus, hypertension, and hyperlipidaemia. Advise a diet High in oily fi social history, fruit, vegetables, fi bre, and Low in saturated fats. Encourage daily exercise. Refer to a cardiac rehab programme. Mental health: fl ag to the patients GP if depression or anxiety are presentthese are independently associated with poor cardiovascular outcomes. Optimize cardioprotective medications Antiplatelets: aspirin (75mg OD) and a second antiplatelet agent (eg clopidogrel) for at least 12 months to vascular events (eg myocardial infarction, stroke). Consider adding a proton pump inhibitor (eg lansoprazole) for gastric protection. Anticoagulate, eg with fondaparinux, until discharge. -blockade reduces myocardial oxygen demand. Start Low and increase slowly, monitoring pulse and blood pressure. If contraindicated, consider verapamil or diltiazem. angiotensin-converting enzyme inhibitor in patients with LV dysfunction, hypertension, or Diabetes unless not tolerated (consider angiotensin receptor blocker). Titrate up slowly, monitoring renal function. High-dose statin, eg atorvastatin 80mg. Do an echo to assess LV function. Eplerenone improves outcomes in myocardial infarction patients with Heart failure (ejection fraction 40%). Revascularization STEMI patients and very High-risk NSTEMI patients (eg haemodynamically unstable) should receive immediate angiography ± PCI. NSTEMI patients who are High risk (eg GRACE score 140) should have angiography within 24h; intermediate risk (eg GRACE 109140) within 3d; Low-risk patients may be considered for non-invasive testing. Patients with multivessel disease may be considered for CABG instead of PCI (p123). Manage complications See p122. Discharge Address any questions the patient has. Discuss red fl ag symptoms and where to seek medical advice should they arise. Ensure the management plan is communicated to the patients GP.",
    "Ensure the management plan is communicated to the patients GP. Book clinic and cardiac rehab appointments. General advice Driving: 18 drivers with group 1 licences (car and motorcycle) can resume driving 1wk after successful angioplasty, or 4wk after ACS without successful angioplasty, if their ejection fraction is 40%. Group 2 licence holders must inform the DVLA of their ACS and stop driving; depending on the results of functional tests, they may be able to restart after 6wk. Work: how soon a patient can return to work will depend on their clinical progress and the nature of their work. They should be encouraged to discuss speed of return ± changes in duties (eg to lighter work if manual labour) with their employer. Some occupations cannot be restarted post-myocardial infarction: eg airline pilots air traffi c controllers. Drivers of public service or heavy goods vehicles will have to undergo functional testing (eg exercise test), as mentioned previously. __OOHHCCMM__1100ee. . iinnddbb 112200 0022//0055//22001177 1199: : 0066 121 Fig 3. 24 Acute postero-lateral myocardial infarction. The posterior infarct is evidenced by the reciprocal changes seen in V13: dominant R waves (upside-down pathological Q waves) and ST depression (upside-down ST elevation). If extra chest leads were added (V79), we would see the classic ST elevation pattern, see p 98. The ST elevation in V6 suggests lateral infarction. A blockage in the circumfl ex coronary artery could explain both the posterior and lateral changes. Cardiovascular medicine __OOHHCCMM__1100ee. . iinnddbb 112211 0022//0055//22001177 1199: : 0066 122 enicidem ralucsavoidraC Complications of myocardial infarction Cardiac arrest (See p894, fi g A3. ) Cardiogenic shock (p802. ) Left ventricular failure (p136, p800, p802. ) Bradyarrhythmias Sinus bradycardia: See p808. Patients with inferior MIs may suff er atropine-unresponsive bradycardia due to infarction of nodal tissue. 1st-degree AV block: Most commonly seen in inferior myocardial infarction. Observe closely as approximately 40% develop higher degrees of AV block (in which case calcium channel blockers and -blockers should be stopped). Wenckebach phenomenon: (Mobitz type I) Does not require pacing unless poorly tolerated. Mobitz type II block: Carries a High risk of developing sudden complete AV block; should be paced. Complete AV block: Usually resolves within a few days. Insert pacemaker (may not be necessary after inferior myocardial infarction if narrow QRS, reasonably stable and pulse 4050). Bundle branch block: myocardial infarction complicated by trifascicular block or non-adjacent bifascicular disease (p132) should be paced. Tachyarrhythmias NB: potassium, hypoxia, and acidosis all predispose to arrhythmias and should be corrected. Sinus tachycardia: Can myocardial O2 demand, treat causes (Pain, hypoxia, sepsis, etc. ) and add -blocker if not contraindicated. SVT: p126. atrial fibrillation or fl utter: If compromised, DC cardioversion. Otherwise, medical therapy as per p130. Frequent PVCs (premature ventricular complexes) and non-sustained VT (≥3 consecutive PVCS 100bpm and lasting 30s) are common after acute myocardial infarction and are associated with increased risk of sudden death. Correct hypokalaemia and hypomagnesaemia and ensure the patient is on -blockers, if not contraindicated. 19 Sustained VT: (Consecutive PVCS 100bpm and lasting 30s. ) Treat with synchronized DC shock (if no pulse, treat as per advanced life support algorithm, see p894, fi g A3). Use anti-arrhythmics only if VT recurrent and not controlled with shocks. Consider ablation /or ICD. Ventricular fi brillation: 80% occurs within 12h. VF occuring after 48h usually indicates pump failure or cardiogenic shock. : DC shock (see p894, fi g A3), consider ICD. Right ventricular failure (RVF)/infarction Presents with Low cardiac output and JVP. Fluid is key; avoid vasodilators (eg nitrates) and diuretics. 20 Inotropes are required in some cases.",
    "Fluid is key; avoid vasodilators (eg nitrates) and diuretics. 20 Inotropes are required in some cases. Pericarditis Central chest Pain, relieved by sitting forwards. ECG: saddle-shaped ST elevation, see fi g 3. 51, p155. Treatment: NSAIDS. Echo to check for eff usion. Systemic embolism May arise from LV mural thrombus. After large anterior myocardial infarction, consider anticoagulation with warfarin for 3 months. Cardiac tamponade (p802) Presents with Low cardiac output, pulsus paradoxus, Kussmauls sign, 3 muffl ed Heart sounds. Diagnosis: echo. Treatment: pericardial aspiration (provides temporary relief, see p773 for technique), surgery. Mitral regurgitation May be mild (minor papillary muscle dysfunction) or severe (chordal or papillary muscle rupture secondary to ischaemia). Presentation: pulmonary oedema. Treat LVF (p800) and consider valve replacement. Ventricular septal defect Presents with pansystolic murmur, JVP, cardiac failure. Diagnosis: echo. Treatment: surgery. 50% mortality in fi rst week. Late malignant ventricular arrhythmias Occur 13wks post-myocardial infarction and are the cardiologists nightmare. Avoid hypokalaemia, the most easily avoidable cause. Consider 24h ECG monitoring prior to discharge if large myocardial infarction. Dresslers syndrome (p698) Recurrent pericarditis, pleural eff usions, fever, anaemia, and ESR 13wks post-myocardial infarction. Treatment: consider NSAIDS; steroids if severe. Left ventricular aneurysm This occurs late (46wks post-myocardial infarction), and presents with LVF, angina, recurrent VT, or systemic embolism. ECG: persistent ST-segment elevation. Treatment: anticoagulate, consider excision. 3 JVP rises during inspiration. Adolf Kussmaul was a prominent 19th-century physician and the fi rst to attempt gastroscopy. Inspired by a sword swallower he passed a rigid tube into the stomach, however light technology was limited and it was not until years later that gastroscopists could visualize the stomach. __OOHHCCMM__1100ee. . iinnddbb 112222 0022//0055//22001177 1199: : 0066 123 enicidem ralucsavoidraC Coronary artery bypass graft (CABG) CABG is performed in left main stem disease; multi-vessel disease; multiple severe stenoses; patients unsuitable for angioplasty; failed angioplasty; refractory angina. Indications for CABGto improve survival: Left main stem disease. Triple-vessel disease involving proximal part of the left anterior descending. Indications for CABGto relieve symptoms: Angina unresponsive to drugs. Unstable angina (sometimes). If angioplasty is unsuccessful. NB: when CABG and percutaneous coronary intervention (PCI, eg angioplasty) are both clinically valid options, NICE recommends that the availability of new stent technology should push the decision towards PCI. In practice, patients with singlevessel coronary artery disease and normal LV function usually undergo PCI, and those with triple-vessel disease and abnormal LV function more often undergo CABG. Compared with PCI, CABG results in longer recovery time and length of inpatient stay. Recent RCTs indicate that early procedural mortality rates and 5-year survival rates are similar after PCI and CABG. Compared with PCI, CABG probably provides more complete long-term relief of angina in patients, and less repeated revascularization. Procedure: The Heart is usually stopped and Blood pumped artifi cially by a machine outside the body (cardiac bypass). Minimally invasive thoracotomies not requiring this are well described, 21 but randomized trials are few. The patients own saphenous vein or internal mammary artery is used as the graft. Several grafts may be placed. 50% of vein grafts close in 10yrs (Low-dose aspirin helps prevent this). Internal mammary artery grafts last longer (but may cause chestwall numbness). On-pump or off-pump: Seems to make little diff erence. 22 After CABG: If angina persists or recurs (from poor graft run-off, distal disease, new atheroma, or graft occlusion) restart antianginal drugs, and consider angioplasty. Ensure optimal management of hypertension, Diabetes, and hyperlipidaemia, and that smoking is addressed. Continue aspirin 75mg OD indefi nitely; consider clopidogrel if aspirin contraindicated. Mood, sex, and intellectual problems 23 are common early. Rehabilitation helps: Exercise: walkcycleswimjog.",
    "Mood, sex, and intellectual problems 23 are common early. Rehabilitation helps: Exercise: walkcycleswimjog. Drive at 1 month: no need to tell DVLA if non-HGV licences, p158. Return to work, eg at 3 months. __OOHHCCMM__1100ee. . iinnddbb 112233 0022//0055//22001177 1199: : 0066 124 enicidem ralucsavoidraC Arrhythmiasoverview Disturbances of cardiac rhythm (arrhythmias) are: common often benign (but may refl ect underlying Heart disease) often intermittent, causing diagnostic diffi culty see BOX Continuous ECG monitoring occasionally severe, causing cardiac compromise which may be fatal. Emergency management: pp8049. Causes Cardiac: Ischaemic Heart disease (IHD); structural changes, eg left atrial dilatation secondary to mitral regurgitation; cardiomyopathy; pericarditis; myocarditis; aberrant conduction pathways. Non-cardiac: Caff eine; smoking; alcohol; pneumonia; drugs (2-agonists, digoxin, L-dopa, tricyclics, doxorubicin); metabolic imbalance (potassium, Ca2, Mg2, hypoxia, hypercapnia, metabolic acidosis, thyroid disease); and phaeochromocytoma. Presentation Palpitations, chest Pain, presyncope/syncope, hypotension, or pulmonary oedema. Some arrhythmias may be asymptomatic, incidental fi ndings, eg atrial fibrillation. History Take a detailed history of palpitations (p36). Ask about precipitating factors, onset/off set, nature (fast or slow, regular or irregular), duration, associated symptoms (chest Pain, dyspnoea, collapse). Review drug history. Ask about past medical history and family history of cardiac disease and sudden death. Syncope occuring during exercise is always concerning; the patient may have a condition predisposing them to sudden cardiac death (eg long QT syndrome). Tests FBC, UE, glucose, Ca2, Mg2, TSH, ECG: Look for signs of IHD, atrial fibrillation, short PR interval (WPW syndrome), long QT interval (metabolic imbalance, drugs, congenital), U waves (hypokalaemia). 24h ECG monitoring or other continuous ECG monitoring (see BOX Continuous ECG monitoring). Echo to look for structural Heart disease, eg mitral stenosis, HCM. Provocation tests: exercise ECG, cardiac catheterization ± electrophysiological studies may be needed. Narrow complex tachycardias: See pp8067, 126. Atrial fi brillation and fl utter: See pp8067, 130. Broad complex tachycardias: See pp8045, 128. Bradycardia: See p808 (causes and management of acute bradycardia) and p98 (Heart block). Intermittent, self-resolving bradycardic episodes can cause signifi cant problems (eg recurrent syncope). Continuous ECG monitoring (BOX Continuous ECG monitoring) will be needed to assist the diagnosis ±specialist tests (eg tilt table testing for refl ex syncope). Seek out reversible causes, eg hypothyroidism or medications such as -blockers. In some cases, no reversible cause is found and the intermittent bradycardia is suffi ciently dangerous to warrant a permanent pacemaker (p132). See BOX, Sick sinus syndrome. Management Some arrhythmias can be managed conservatively, eg by reducing alcohol intake. Many arrhythmias respond to medical management with regular tablets or a pill in the pocket. Interventional management may include pacemakers (p132), ablation (eg of accessory pathways or arrhythmogenic foci), or implantable cardioverter defi brillators (ICDs), eg in patients with ventricular arrhythmias post-myocardial infarction and in those with congenital arrhythmogenic conditions (p133). __OOHHCCMM__1100ee. . iinnddbb 112244 0022//0055//22001177 1199: : 0066 125 enicidem ralucsavoidraC Continuous ECG monitoring A simple 12-lead ECG only gives a snapshot of the Hearts electrical activities. Many disorders, particularly the arrhythmias, come and go and so may be missed at the time of the ECG recording. If you feel you are missing a paroxysmal arrhythmia, there are many ways of recording the electrical activity over a longer period: Telemetry: An inpatient wears ECG leads and the signals are shown on screens being watched by staff. Thus, if a dangerous arrhythmia occurs, help is immediately available. This is very resource intensive so reserved for those at High risk of dangerous arrhythmias, eg immediately post-STEMI.",
    "This is very resource intensive so reserved for those at High risk of dangerous arrhythmias, eg immediately post-STEMI. Exercise ECGs: The patient exercises according to a standardized protocol (eg Bruce on a treadmill) and the blood pressure and ECG are monitored, looking for ischaemic changes, arrhythmias, and features suggestive of arrhythmia risk, such as delta waves. Holter monitors: The patient wears an ECG monitor which records their rhythm for 24h7d whilst they go about their normal life, this is later analysed. These can also be used to pick up ST changes suggestive of ischaemia. Loop recorders: These record only when activated by the patient they cleverly save a small amount of ECG data before the eventuseful if the arrhythmia causes loss of consciousness: the patient can press the button when they wake up. Loop recorders may be implanted just under the skin (eg Reveal or the newer, injectable LINQ device), and are especially useful in patients with infrequent episodes as they can continually monitor for months or years awaiting an event (Fig 3. 25). Fig 3. 25 This is a recording from a loop recorder, each Pacemakers and ICDs: These reline follows on from the one above. This tracing was cord details of cardiac electrical recorded at the time of a syncopal episode, it shows activity and device activity. This cardiac slowing then a 15sec pause: quite long enough information can be useful for esto cause syncope! But not long enough to arrange a tablishing an arrhythmic origin for standard ECG, even if the patient were in hospital. symptoms. Reproduced from Camm et al. , ESC Textbook of Cardiovascular Medicine, 2009, with permission from Oxford University Press. Sick sinus syndrome Sick sinus syndrome is usually caused by sinus node fi brosis, typically in elderly patients. The sinus node becomes dysfunctional, in some cases slowing to the point of sinus bradycardia or sinus pauses, in others generating tachyarrhythmias such as atrial fi brillation and atrial tachycardia. Symptoms: Syncope and pre-syncope, light-headedness, palpitations, breathlessness. Management: Thromboembolism prophylaxis if episodes of atrial fibrillation are detected. Permanent pacemakers for patients with symptomatic bradycardia or sinus pauses. Some patients develop a tachy brady syndrome, suff ering from alternating tachycardic and bradycardic rhythms. This can prove diffi cult to treat medically as treating one circumstance (eg tachycardia) increases the risk from the other. Pacing for bradycardic episodes in combination with rate-slowing medications for tachycardic episodes may be required if the patient is symptomatic or unstable. __OOHHCCMM__1100ee. . iinnddbb 112255 0022//0055//22001177 1199: : 0066 126 enicidem ralucsavoidraC Narrow complex tachycardia Defi nition ECG shows rate of 100bpm and QRS complex duration of 120ms. Narrow QRS complexes occur when the ventricles are depolarized via the normal conduction pathways (fi g 3. 26). Diff erential diagnosis Regular narrow complex tachycardias: See fi g 3. 27. Irregular narrow complex tachycardias: Normal variant: sinus arrhythmia (rate changes with inspiration/expiration); sinus rhythm with frequent ectopic beats. Atrial fi brillation (atrial fibrillation): p131, fi g 3. 35. Atrial fl utter with variable block: eg PPPQRSPPQRS (3: 1 block then 2: 1 block). The atrial rhythm is regular but the ventricular rhythm (hence pulse) is irregular. Multifocal atrial tachycardia: like focal atrial tachycardia but there are multiple groups of atrial cells taking it in turns to initiate a cardiac cycle. P-wave morphology and P-P intervals vary. Usually associated with COPD. Principles of management See p807. If the patient is compromised, use DC cardioversion (p770).",
    "Usually associated with COPD. Principles of management See p807. If the patient is compromised, use DC cardioversion (p770). Identify and treat the underlying rhythm: eg treating sinus tachycardia secondary to dehydration with IV fl uids; treating multifocal sinus tachycardia secondary to COPD by correcting hypoxia and hypercapnia; treating focal atrial tachycardia secondary to digoxin toxicity with digoxin-specifi c antibody fragments; treating AVRT secondary to WPW with fl ecainide, propafenone, or amiodarone; for atrial fi brillation (atrial fibrillation) and fl utter see p130. If AVNRT or AVRT are suspected, consider transiently blocking the AVN. This should break the circuit of an atrio-ventricular re-entry rhythm, allowing sinus rhythm to re-establish. If the underlying rhythm is actually atrial in origin (eg fl utter or atrial tachycardia), AVN blockade will not treat the rhythm but the paused ventricular activity will unmask the atrial rhythm (fi g 3. 28), aiding diagnosis and management. AVN blockade can be achieved by: 1 Vagal manoeuvres: carotid sinus massage, Valsalva manoeuvre (eg blowing into a syringe). 2 IV adenosine: see p806. In some cases, narrow complex tachyarrhythmias cause symptomatic episodes of suffi cient severity and frequency to warrant more invasive treatment, eg ablation therapy for accessory pathways. Fig 3. 28 This patient was given adenosine for tachycardia thought to be due to AVRT or AVNRT. The adenosine has slowed the ventricular rate, revealing fl utter waves (sawtooth appearance), disproving an AVRT/AVNRT diagnosis. Image courtesy of Dr Ed Burns, www. lifeinthefastlane. com. Holiday Heart syndrome Binge drinking in a person without any clinical evidence of Heart disease may result in acute cardiac rhythm and/or conduction disturbances, which is called holiday Heart syndrome (note that recreational use of marijuana may have similar eff ects). The most common rhythm disorders are supraventricular tachyarrhythmia and atrial fibrillation (consider this diagnosis in patients without structural Heart disease who present with new-onset atrial fibrillation). The prognosis is excellent, especially in young patients without structural Heart disease. As holiday Heart syndrome resolves rapidly by abstinence from alcohol use, advise all patients against the excessive use of alcohol in future. __OOHHCCMM__1100ee. . iinnddbb 112266 0022//0055//22001177 1199: : 0066 127 enicidem ralucsavoidraC Normal conduction Normal conduction: initiated by the sinoatrial node (SAN), electrical before mealsSAN tivity spreads around the atria. The atrioventricular node (AVN) receives this activity, pauses, then passes it on, down the bundle of His which AVN MV splits into left and right bundle branches. These cause depolarizaTV His bundle t fr io o n m o b f o t t h t e o m ve ( n a t p ri e c x u ) l a to r t m o y p o ( c o a u r t d fl international unit o m w R bu ig n h d t Blood L b b e u ra f n t n d c Blood h tracts). branch Left anterior and posterior hemi fascicle Fig 3. 26 Normal conduction. Regular rhythm tachycardia See fi g 3. 27. A. Sinus tachycardia: Conduction occurs as per fi g 3. 26 but impulses A B are initiated at a High frequency. Causes include infection, Pain, exC ercise, anxiety, dehydration, bleed, E systemic vasodilation (eg in sepsis), drugs (caff eine, nicotine, salbutamol), anaemia, fever, physical examination, hyperthyD F roidism, pregnancy, CO2 retention, autonomic neuropathy (eg inapproH priate sinus tachycardia). B. Focal atrial tachycardia: A G group of atrial cells act as a pacemaker, out-pacing the SAN. P-wave morphology (shape) is diff erent to Fig 3. 27 Regular tachycardias. sinus.",
    "P-wave morphology (shape) is diff erent to Fig 3. 27 Regular tachycardias. sinus. C. Atrial fl utter: Electrical activity circles the atria 300 times per minute, giving a sawtooth baseline, see fi g 3. 35. The AVN passes some of these impulses on, resulting in ventricular rates that are factors of 300 (150, 100, 75). D. Atrioventricular re-entry tachycardia: (AVRT) An accessory pathway (eg in Wolff -Parkinson-White (WPW), p133) allows electrical activity from the ventricles to pass to the resting atrial myocytes, creating a circuit: atriaAVNventricles accessory pathwayatria. This direction is called orthodromic conduction and results in narrow QRS complexes as ventricular depolarization is triggered via the bundles of His. Conduction in the other direction is called antidromic and results in broad QRS complexes. E. Atrioventricular nodal re-entry tachycardia: (AVNRT) Circuits form within the AVN, causing narrow complex tachycardias. This is very common. F. Junctional tachycardia: Cells in the AVN become the pacemaker, giving narrow QRS complexes as impulses reach the ventricles through the normal routes; P waves may be inverted and late. G. Bundle branch block: Any of the above conditions can result in broad complex tachycardias if there is bundle branch block (see p100). H. Ventricular tachycardia: (VT) This can result from circuits, similar to atrial fl utter, or from focuses of rapidly-fi ring cells. The QRS is broad. When a circuit is in action and its plane rotates, the ECG shows broad complex tachycardia with regularly increasing and decreasing amplitudes; this is called torsades de pointes. __OOHHCCMM__1100ee. . iinnddbb 112277 0022//0055//22001177 1199: : 0066 128 enicidem ralucsavoidraC Broad complex tachycardia Defi nition ECG shows rate of 100 and QRS complexes 120ms. If no clear QRS complexes, it is VF or asystole (or problems with the ECG machine or stickers). Principles of management If the patient is unstable or you are uncertain of what to do, get help fastthe patient may be periarrest (p804). Identify the underlying rhythm and treat accordingly. If in doubt, treat as ventricular tachycardia (VT)the commonest cause. Giving AVN blocking agents to treat SVT with aberrancy when the patient is in VT can cause dangerous haemodynamic instability. Treating for VT when the patient is actually in SVT has less potential for deterioration. If WPW is suspected, avoid drugs that slow AV conductionsee p114. Diff erential diagnosis Ventricular fi brillationchaotic, no pattern, fi g 3. 29. Ventricular tachycardia (VT), fi gs 3. 12, 3. 30. Torsade de pointes (polymorphic VT)VT with varying axis (see fi g 3. 31), may look like VF. QT interval is a predisposing factor. Any cause of narrow complex tachycardias (p126) when in combination with blood urea nitrogendle branch block or metabolic causes of broad QRS. Antidromic AVRT (eg WPW), p127. Diff erentiating VT from SVT with aberrancy This may be diffi cult; seek expert help. Diagnosis is based on the history (IHD increases the likelihood of a ventricular arrhythmia), a 12-lead ECG, and the response (or lack thereof) to certain medications. ECG fi ndings in favour of VT: ve or Ωve QRS concordance in all chest leads (ie all ve (R) or all Ωve (QS)). QRS 160ms. Marked left axis deviation, or northwest axis (QRS positive in aVR). AV dissociation (Ps independent of QRSs) or 2: 1 or 3: 1 Mobitz II Heart block. Fusion beats or capture beats (fi gs 3. 32, 3. 33). RSR pattern where R is taller than R. (R taller than R suggests RBBB. ) Management See. Ventricular extrasystoles (ectopics) These are common and can be symptomatic patients describe palpitations, a thumping sensation, or their Heart missing a beat.",
    "The pulse may feel irregular if there are frequent ectopics. On ECG, ventricular ectopics are broad QRS complexes; they may be single or occur in patterns: Bigeminyectopic every other beat, see fi g 3. 34. ECG machines may disregard the second QRS and so calculate the rate to be half the true value. Trigeminyevery third beat is an ectopic. Couplettwo ectopics together. Tripletthree ectopics together. Occasional ventricular ectopics24 in otherwise healthy people are extremely common and rarely signifi cant. Frequent ectopics (60/hour), particularly couplets and triplets, should prompt testing for underlying cardiac conditions. Post-myocardial infarction, ventricular ectopics are associated with increased risk of dangerous arrhythmias. Pay attention to whether the ectopics all look the same on the ECG suggesting a single focus (monomorphic) or may come from multiple foci (polymorphic). Causes and management can be diff erent. __OOHHCCMM__1100ee. . iinnddbb 112288 0022//0055//22001177 1199: : 0066 129 enicidem ralucsavoidraC Fig 3. 29 VF (p894). Fig 3. 30 VT with a rate of 235/min. Fig 3. 31 Torsade de pointes tachycardia. Fig 3. 32 A fusion beat ()a normal beat fuses with a VT complex creating an unusual complex. Fig 3. 33 A capture beat ()a normal QRS amongst runs of VT. This would not be expected if the QRS breadth were down to bundle branch block or metabolic causes. Fig 3. 34 Bigeminya normal QRS is followed by a ventricular ectopic beat then a compensatory pause, this pattern then repeats. The ectopic beats have the same morphology as each other so probably all share an origin. __OOHHCCMM__1100ee. . iinnddbb 112299 0022//0055//22001177 1199: : 0066 130 enicidem ralucsavoidraC Atrial fi brillation (atrial fibrillation) and fl utter AF25 is a chaotic, irregular atrial rhythm at 300600bpm (fi g 3. 35); the AV node responds inter mittently, hence an irregular ventricular rhythm. Cardiac output drops by 1020% as the ventricles arent primed reliably by the atria. atrial fibrillation is common in the elderly (≤9%). The main risk is embolic stroke. Warfarin reduces this to 1%/yr from 4%. So, do an ECG on everyone with an irregular pulse (±24h ECG if Dizziness, faints, palpitations, etc. ). If atrial fibrillation started more than 48h ago, intracardiac clots may have formed, necessitating anticoagulation prior to cardioversion. see BOX Anticoagulation and atrial fibrillation. Causes Heart failure; hypertension; IHD (seen in 22% myocardial infarction patients); 26 physical examination; mitral valve disease; pneumonia; hyperthyroidism; caff eine; alcohol; post-op; potassium; Mg2. Rare causes: Cardiom yopathy; constrictive pericarditis; sick sinus syndrome; lung cancer; endo carditis; haemochromatosis; sarcoid. Lone atrial fibrillation means no cause found. Symptoms May be asymptomatic or cause chest Pain, palpitations, dyspn oea, or faintness. Signs Irregularly irregular pulse, the apical pulse rate is greater than the radial rate, and the 1st Heart sound is of variable intensity; signs of LVF (p800). Examine the whole patient: atrial fibrillation is often associated with non-cardiac disease. Tests ECG shows absent P waves, irregular QRS complexes, fi g 3. 35. Blood tests: UE, cardiac enzymes, thyroid function tests. Echo to look for left atrial enlarge ment, mitral valve disease, poor LV function, and other structural abnormalities. Managing acute atrial fibrillation If the patient has adverse signs (shock, myocardial ischaemia (chest Pain or ECG changes), syncope, Heart failure): ABCDE, get senior input DC cardioversion (synchronized shock, start at 120150J) ± amiodarone if unsuccessful (p807); do not delay treatment in order to start anticoagulation. If the patient is stable atrial fibrillation started 48h ago: rate or rhythm control may be tried. For rhythm control, DC cardiovert or give fl ecainide (CI: structural Heart disease, IHD) or amiodarone.",
    "In all cases, the need for anticoagulation should be assessed using the CHA2DS2 -VASc score to assess embolic stroke risk (consider anticoagulation if score 0, 1), and balancing this against the risks of anticoagulation to the patient, assessed with the HAS-BLED score. Long-term anticoagulation should be with a DOAC (see p350) or warfarin. CHA2DS2-VAScCongestive cardiac failure (1 point), Hypertension (1), Age 6574y (1), Age 74y (2), Diabetes (1), previous Stroke/TIA/thromboembolism (2), Vascular disease (1), Sex Category (1 if female). A score of 2 an annual stroke risk of 2. 2%. Online calculators can be helpful, eg www. mdcalc. com. HAS-BLED1 point for each of: labile INR age 65 use of medications that can predispose to bleeding (eg NSAIDs, anti-platelets) alcohol abuse uncontrolled hypertension history of, or predisposition to, major bleeding renal disease Liver disease stroke history. Pre-excited atrial fibrillation In pre-excited atrial fibrillation, accessory pathways capable of conducting at rapid rates (eg sometimes in WPW syndrome) pass erratic electrical activity from the atria to the ventricles, unfi ltered by the AVN. ECGs will show irregular, broad QRS complexes at 200bpm. Ventricles cannot sustain this rate for long; the patient is at High risk of VT and VF. (a) (b) (c) QRS QRS P P P P Fig 3. 35 (a) atrial fibrillation: note the irregular spacing of QRS complexes and lack of P waves. (b) atrial fibrillation with a rapid ventricular response (sometimes referred to as fast atrial fibrillation). No pattern to QRS complex spacing, and rate 100bpm. (c) Atrial fl utter with 2: 1 block (2 P waves for every 1 QRS complex). The P waves have the classic sawtooth appearance. Alternate P waves are merged with the QRS complex. __OOHHCCMM__1100ee. . iinnddbb 113311 0022//0055//22001177 1199: : 0066 132 enicidem ralucsavoidraC Pacemakers In normal circumstances the SAN plays the role of pacemaker. On occasion, other areas of myocardium will set the pace (see earlier in chapter). If the Heart is not pacing itself fast enough, artifi cial pacing may be required. Options include percussion pacingfi st strikes to the precordium, used only in periarrest situations; transcutaneous pacingelectrical stimulation via defi brillator pads (p770); temporary transvenous pacing (p776); and a subcutaneously implanted permanent pacemaker. Indications for temporary cardiac pacing include Symptomatic bradycardia, unresponsive to atropine. After acute anterior myocardial infarction, prophylactic pacing is required in: complete AV block Mobitz type I AV block (Wenckebach) Mobitz type II AV block non-adjacent bifascicular, or trifascicular block (p100). After inferior myocardial infarction, pacing may not be needed in complete AV block if reasonably stable, rate is 4050, and QRS complexes are narrow. Suppression of drug-resistant tachyarrhythmias by overdrive pacing, eg SVT, VT. Special situations: during general anaesthesia; during cardiac surgery; during electrophysiological studies; drug overdose (eg digoxin, -blockers, verapamil). See p776 for further details and insertion technique. Indications for a permanent pacemaker (PPM) include Complete AV block (StokesAdams attacks, asymptomatic, congenital). Mobitz type II AV block (p99). Persistent AV block after anterior myocardial infarction. Symptomatic bradycardias (eg sick sinus syndrome, p125). Heart failure (cardiac resynchronization therapy). Drug-resistant tachyarrhythmias. Pre-operative assessment Bloods (FBC, clotting screen, renal function), IV cannula, consent, antibiotics as per local protocol. Post-operative management Prior to discharge, check wound for bleeding or haematoma; check lead positions and for pneumothorax on CXR; check pacemaker function. During 1st week, inspect for wound haematoma or dehiscence. Other problems: lead fracture or dislodgement; pacemaker interference (eg from patients muscles); infected device. The battery needs changing every 510 years. For driving rules see p158. Pacemaker letter codes These enable pacemaker identifi cation (min is 3 letters): 1st letter the chamber paced (Aatria, Vventricles, Ddual chamber).",
    "2nd letter the chamber sensed (Aatria, Vventricles, Ddual chamber, Onone). 3rd letter the pacemaker response (Ttriggered, Iinhibited, Ddual). 4th letter (Rrate modulation, Pprogrammable, Mmultiprogrammable). 5th letter (P means that in tachyc ardia the pacemaker will pace the patient. S means that in tachycardia the pacem aker shocks the patient. Ddual ability to pace and shock. Oneither of these). Cardiac resynchronization therapy (CRT) Improves the synchronization of cardibefore meals contraction and reduces mortality31 in people with symptomatic Heart failure who have an ejection fraction 35% and a QRS duration 120ms. 32 It involves biventricular pacing (both septal and lateral walls of the LV) and, if required, also an atrial lead. It may be combined with a defi brillator (CRT-D). ECG of paced rhythms (fi g 3. 13 and fi g 3. 36). Pacemaker input appears as a vertical spike on the ECG. This spike can be very small with modern bipolar pacing systems. Ventricular pacing usually has a broad QRS morphology (similar to LBBB). Systems are usually programmed on demand so will only pace when necessary. Modern systems are generally very reliable but pacing spikes with no capture afterwards suggests a problem. Programming of devices is complicated so seek help early if concerned. Many pacemakers store intracardiac electrograms which can be accessed to correlate rhythm with any symptoms. __OOHHCCMM__1100ee. . iinnddbb 113322 0022//0055//22001177 1199: : 0066 133 enicidem ralucsavoidraC Fig 3. 36 ECG of a paced rhythm. Some pacemaker terms Fusion beat: Union of native depolarization and pacemaker impulse. Pseudofusion beat: The pacemaker impulse occurs just after cardiac depolarization, so it is ineff ective, but it distorts the QRS morphology. Pseudopseudofusion beat: If a DVI pacemaker gives an atrial spike within a sodiumtive QRS complex, the atrial output is non-contributory. Pacemaker syndrome: In single-chamber pacing, retrograde conduction to the atria, which then contract during ventricular systole. This leads to retrograde fl ow in pulmonary veins, and cardiac output, dyspnoea, palpitations, malaise, and even syncope. Pacemaker-mediated tachycardia: Retrograde conduction to the atrium is sensed by the pacemaker and ventricular pacing delivered in response. This again causes retrograde atrial conduction causing a repetitive sensing/pacing loop. This can be fi xed by changing pacing programming parameters. Congenital arrhythmogenic cardiac conditions As well as the many acquired conditions that can predispose to arrhythmias (p125), there are a number of congenital conditions. These may be clinically silent until a fatal attack and are likely to be responsible for most cases of sudden adult death syndrome (SADS). They include: WPW syndrome (Wolff -Parkinson-White; fi g 3. 37. ) Caused by congenital accessory conduction pathway between atria and ventricles. Resting ECG shows short PR interval, wide QRS complex (due to slurred upstroke or delta wave) and ST-T changes. Two types: WPW type A (ve wave in V1), WPW type B (Ωve wave in V1). Tachycardia can be due to an AVRT or pre-excited atrial fibrillation/atrial fl utter (p130). Management may include ablation of the accessory pathway. LQTS (Long QT syndromes. ) These are channelopathies that result in prolonged repolarization phases, predisposing the patient to ventricular arrhythmias; classically torsades de pointes. p804. Conditions associated with LQTS include Jervell and Lange-Nielsen syndrome (p702) and RomanoWard syndrome (p710). ARVC (Arrhythmogenic right ventricular cardiomyopathy. ) RV myocardium is replaced with fi bro-fatty material. Symptoms: palpitations and syncope during exercise. ECG changes include epsilon wave; T inversion and broad QRS in V1V3. Brugada Sodium channelopathy. Diagnosis: classic coved ST elevation in V1V3 plus suggestive clinical history. ECG changes and arrhythmias can be precipitated by fever, medications (www. brugadadrugs. org), electrolyte imbalances, and ischaemia.",
    "ECG changes and arrhythmias can be precipitated by fever, medications (www. brugadadrugs. org), electrolyte imbalances, and ischaemia. Many of these patients can be treated medically or conservatively but those at High risk may require an implantable cardiac defi brillator (ICD). Screening family members is important for picking up undiagnosed cases. Fig 3. 37 This patient has Wolff -Parkinson-White syndrome as they have delta waves (slurred QRS upstrokes) in beats 1 and 4 of this rhythm strip. The delta wave both broadens the ventricular complex and shortens the PR interval. If a patient with WPW has atrial fibrillation, avoid AV node blockers such as diltiazem, verapamil, and digoxinbut fl ecainide may be used. __OOHHCCMM__1100ee. . iinnddbb 113333 0022//0055//22001177 1199: : 0066 134 enicidem ralucsavoidraC Heart failurebasic concepts Defi nition Cardiac output is inadequate for the bodys requirements. 33 Prevalence 13% of the general population; 10% among elderly patients. 34 Key classifi cations Systolic failure: Inability of the ventricle to contract normally, resulting in cardiac output. Ejection fraction (EF) is 40%. Causes: IHD, myocardial infarction, cardiomyopathy. Diastolic failure: Inability of the ventricle to relax and fi ll normally, causing fi lling pressures. Typically EF is 50%, this is termed HFpEF (Heart failure with preserved EF). Causes: ventricular hypertrophy, constrictive pericarditis, tamponade, restrictive cardio myopathy, obesity. NB: systolic and diastolic failure pathophysiology often coexists. Left ventricular failure (LVF): Symptoms: dyspnoea, poor exercise tolerance, fatigue, orthopnoea, paroxysmal nocturnal dyspnoea (PND), nocturnal cough (± pink frothy sputum), wheeze (cardiac asthma), nocturia, cold peripheries, weight loss. Right ventricular failure (RVF): Causes: LVF, pulmonary stenosis, lung disease (cor pulmonale, see p194). Symptoms: peripheral oedema (up to thighs, sacrum, abdominal wall), ascites, nausea, anorexia, facial engorgem ent, epistaxis. LVF and RVF may occur independently, or together as congestive cardiac failure (CCF). Acute Heart failure: Often used exclusively to mean new-onset acute or decompensation of chronic Heart failure characterized by pulmonary and/or peripheral oedema with or without signs of peripheral hypo perfusion. Chronic Heart failure: Develops or progresses slowly. Venous congestion is common but arterial Hypertension is well maintained until very late. Low-output Heart failure: Cardiac output is and fails to normally with exertion. Causes: Excessive preload: eg mitral regurgitation or fl uid overload (eg renal failure or too rapid IV infusions, particularly in the elderly and those with established heart failure). Pump failure: systolic and/or diastolic heart failure (see above), Heart rate (eg -blockers, Heart block, post myocardial infarction), negatively inotropic drugs (eg most antiarrhythmic agents). Chronic excessive afterload: eg aortic stenosis, hypertension. Excessive preload can cause ventricular dilatation, this exacerbates pump failure. Excessive afterload prompts ventricular muscle thickening (ventricular hypertrophy), resulting in stiff walls and diastolic dysfunction. High-output Heart failure: This is rare. Here, output is normal or increased in the face of needs. Failure occurs when cardiac output fails to meet these needs. It will occur with a normal Heart, but even earlier if there is Heart disease. Causes: anaemia, pregnancy, hyperthyroidism, Pagets disease, arteriovenous malformation, beriberi. Consequences: initially features of RVF; later LVF becomes evident. Diagnosis Requires symptoms of failure (see above) and objective evidence of cardiac dysfunction at rest. For CCF, use the Framingham criteria. 35 Signs As described previously plus cyanosis, blood pressure, narrow pulse Hypertension, pulsus alternans, displaced apex (LV dilatation), RV heave (pulmonary hypertension), signs of valve diseases. Severity can be graded using the New York classifi cation (see BOX). Investigations According to NICE, 33 if ECG and B-type natriuretic peptide (BNP; p137) are normal, Heart failure is unlikely, and an alternative diagnosis should be considered; if either is abnormal, then echocardiography (p110) is required.",
    "Tests FBC; UE; BNP; CXR (see fi g 3. 38); ECG; echo. ECG may indicate cause (look for evidence of ischaemia, myocardial infarction, or ventricular hypertrophy). It is rare to get a completely normal ECG in chronic Heart failure. Echocardiography is the key investigation. 36 It may indicate the cause (myocardial infarction, valvular Heart disease) and can confi rm the presence or absence of LV dysfunction. Endomyocardial biopsy is rarely needed. Prognosis Poor with 2550% of patients dying within 5yrs of diagnosis. If admission is needed, 5yr mortality 75%. Be realistic: in one study, 54% of those dying in the next 72h had been expected to live for 6months. 37 __OOHHCCMM__1100ee. . iinnddbb 113344 0022//0055//22001177 1199: : 0066 135 enicidem ralucsavoidraC New York classifi cation of Heart failure I Heart disease present, but no undue dyspnoea from ordinary activity. II Comfortable at rest; dyspnoea during ordinary activities. III Less than ordinary activity causes dyspnoea, which is limiting. IV Dyspnoea present at rest; all activity causes discomfort. (a) (b) Fig 3. 38 (a) The CXR in left ventricular failure. These features can be remembered as A B C D E. Alveolar oedema, classically this is perihilar bats wing shadowing. Kerley B linesnow known as septal lines. These are variously attributed to interstitial oedema and engorged peripheral lymphatics. Cardiomegalycardiothoracic ratio 50% on a PA fi lm. Dilated prominent upper lobe veins (upper lobe diversion). Pleural Eff usions. Other features include peribronchial cuffi ng (thickened bronchial walls) and fl uid in the fi ssures. (b) Bats wing, peri-hilar pulmonary oedema indicating Heart failure and fl uid overload. __OOHHCCMM__1100ee. . iinnddbb 113355 0022//0055//22001177 1199: : 0066 136 enicidem ralucsavoidraC Heart failuremanagement Acute Heart failure This is a medical emergency (p800). Chronic Heart failure Stop smoking. Stop drinking alcohol. Eat less salt. Optimize weight nutrition. 33 Treat the cause (eg if dysrhythmias; valve disease). Treat exacerbating factors (anaemia, thyroid disease, infection, blood pressure). Avoid exacerbating factors, eg NSAIDS (fl uid retention) and verapamil (Ωve inotrope). Annual fl u vaccine, one-off pneumococcal vaccine. Drugs: 1 Diuretics: Give loop diuretics to relieve symptoms, eg furosemide 40mg/24h PO or bumetanide 12mg/24h PO. Increase dose as necessary. SE: potassium, renal impairment. Monitor UE and add potassium-sparing diuretic (eg spironolactone) if potassium 3. 2mmol/L, predisposition to arrhythmias, concurrent digoxin therapy, or preexisting potassium-losing conditions. If refractory oedema, consider adding a thiazide, eg metolazone 520mg/24h PO. Diuretics improve symptoms but studies showing mortality benefi t are lacking. 2 angiotensin-converting enzyme inhibitor: Consider in all those with left ventricular systolic dysfunction (LVSD); improves symptoms and prolongs life (see p1145). If cough is a problem, an angiotensin receptor blocker (angiotensin receptor blocker) may be substituted. SE: potassium. 3 -blockers: (eg carvedilol) mortality in Heart failurebenefi t additional to those of angiotensin-converting enzyme inhibitor in patients with systolic dysfunction. 38 Use with caution: start Low and go slow; if in doubt seek specialist advice fi rst; wait ≥2weeks between each dose increment. -blocker therapy in patients hospitalized with decompensated Heart failure is associated with lower post-discharge mortality risk and improved treatment rates. 39 4 Mineralocorticoid receptor antagonists: Spironolactone (25mg/24h PO) mortality by 30% when added to conventional therapy. 40 Use in those still symptomatic despite optimal therapy as listed previously, and in post-myocardial infarction patients with LVSD. Spironolactone is potassium-sparing, but there is little risk of signifi - cant hyperkalaemia, even when given with angiotensin-converting enzyme inhibitor. Nevertheless, UE should be monitored, particularly if the patient has known chronic kidney disease. Eplerenone is an alternative if spironolactone is not tolerated.",
    "Eplerenone is an alternative if spironolactone is not tolerated. 5 Digoxin: Helps symptoms even in those with sinus rhythm, and should be considered for patients with LVSD who have signs or symptoms of Heart failure while receiving standard therapy, including angiotensin-converting enzyme inhibitor and -blockers, or in patients with atrial fibrillation. Dose example: 125mcg/24h PO if sinus rhythm. Monitor UE; maintain potassium at 45mmol/L as potassium risks digoxin toxicity, and vice versa. Digoxin levels: p756. Other inotropes are unhelpful in terms of outcome. 6 Vasodilators: The combination of hydralazine (SE: drug-induced lupus) and isosorbide dinitrate should be used if intolerant of angiotensin-converting enzyme inhibitor and ARBS as it reduces mortality. It also reduces mortality when added to standard therapy (including angiotensin-converting enzyme inhibitor) in black patients with Heart failure. 41 Intractable Heart failure Reassess the cause. Are they taking the drugs? at maximum dose? Switching furosemide to bumetanide (one 5mg tab200mg furos emide) might help. Inpatient management may include: Minimal exertion; sodium fl uid restriction (1. 5L/24h PO). Metolazone (as above) and IV furosemide (p800). Opiates and IV nitrates may relieve symptoms (p800). Weigh daily. Do frequent UE (beware potassium). Give DVT prophylaxis: heparin TED stockings (p578). In extremis: Try IV inotropes (p802; it may be diffi cult to wean patients off them). Consider: Cardiac resynchronization (p132), LV assist device (BOX Pulseless patients), or transplantation. Palliative care Treat/prevent comorbidities (eg fl u vaccination). Good nutrition (allow alcohol! ). Involve GP: continuity of care and discussion of prognosis is much apprec i ated. 42 Dyspnoea, Pain (from Liver capsule stretching), nausea, constipation, and mood all need tackling. 43 Opiates improve Pain and dyspnoea. O2 may help. __OOHHCCMM__1100ee. . iinnddbb 113366 0022//0055//22001177 1199: : 0066 137 enicidem ralucsavoidraC Pulseless patients Left ventricular assist devices (LVADs) are increasingly used as bridging therapies for patients awaiting Heart transplantation (fi g 3. 39). An internalized pump forces Blood through tubing from the left ventricle to the aorta. To power the pump, the patient attaches the device to the mains electricity, and uses batteries when out and about. Patients with continuous (rather than pulsatile) fl ow LVADs have no pulse (fi g 3. 39c) and ascultation will reveal a loud, continuous, mechanical hum. If the patient collapses and there is no hum, resuscitation should include checking the LVAD power supply! (b) (a) (c) Fig 3. 39 (a) CXR of a patient with a continuous fl ow LVAD. Blood is taken from the LV apex and pumped into the aorta. (b) Retinal fl ow velocity trace from a normal subjectlarge peaks in fl ow rate during systole. (c) Retinal fl ow velocity trace from a patient with an LVAD. The fl ow rate only slightly rises during systole as the fl ow from the LVAD is continuous. Image in a) reproduced from Gardener et al. , Heart Failure, 2014, with permission from Oxford University Press. (b) and (c) courtesy of Barry McDonnell. Natriuretic peptides Secretory granules have long been known to exist in the atria, and if hom ogenized atrial tissue is injected into rats, their Urine volume (and sodium excretion) rises; this is because of atrial natriuretic peptide (ANP). BNP is a similar hormone originally identifi ed from pig brain (hence the B), but most BNP is secreted from ventricular myocardium. Plasma BNP is closely related to LV Hypertension and in myocardial infarction and LV dysfunction, these hormones can be released in large quantities. Secretion is also increased by tachycardia, glucocorticoids, and thyroid hormones.",
    "Secretion is also increased by tachycardia, glucocorticoids, and thyroid hormones. Role: ANP and BNP assist the stretched atria and ventricles by increasing glomerular filtration rate and decreasing renal sodium resorption, thereby reducing fl uid load; and by relaxing smooth muscle, thereby decreasing preload. BNP as a biomarker of Heart failure: BNP distinguishes Heart failure from other causes of dyspnoea more accurately than other biomarkers and LV ejection fraction (sensitivity: 90%; specifi city: 8090%). The rises are greater with left than right Heart failure and with systolic than diastolic dysfunction. What BNP threshold for diagnosing Heart failure: If BNP 100ng/L, this diagnoses Heart failure better than other clinical variables or clinical judgement (history, examination, and CXR). BNP can be used to rule out Heart failure if 50ng/L. A BNP 50ng/L does not exclude other coexisting diseases; conditions that can cause BNP rises include tachycardia, cardiac ischaemia, COPD, physical examination, renal disease, sepsis, hepatic cirrhosis, Diabetes, and old age. Also, assays vary, so liaise with your lab. Prognosis in Heart failure: The higher the BNP, the higher the cardiovascular and all-cause mortality (independent of age, NYHA class, previous myocardial infarction, and LV ejection fraction) and the greater the risk of sudden death. So, a patient whose symptoms are currently well controlled may benefi t from more aggressive treatment if their BNP if persistently raised. __OOHHCCMM__1100ee. . iinnddbb 113377 0022//0055//22001177 1199: : 0066 138 enicidem ralucsavoidraC Hypertension Hypertension 44 is the most important risk factor for premature death and cardiovascular disease; causing 50% of all vascular deaths (8106/yr). Usually asymptomatic, so regular screening (eg 3-yrly) is a vital taskmost preventable deaths are in areas without universal screening. 45 Defi ning hypertension blood pressure has a skewed normal distribution (p751) within the population, and risk is continuously related to blood pressure, so it is impo ssible to defi ne hypertension. 46 We choose to select a value above which risk is signifi cantly increased and the benefi t of treatment is clear cut, see below. Dont rely on a single readingassess over a period of time (how long depends on the blood pressure and the presence of other risk factors or end-organ damage). Confi rm with 24hr ambulatory blood pressure monitoring (ABPM); or a week of home readings. NB: the diagnostic threshold is lower 135/85mmHg. Whom to treat All with blood pressure ≥160/100mmHg (or ABPM ≥150/95mmHg). For those ≥140/90, the decision depends on the risk of coronary events, presence of Diabetes, or end-organ damage; see fi g 3. 40. 44 The HYVET study showed that there is even substantial benefi t in treating the over-80s. 47 Lower thresholds may be appropriate for young peopleblood pressure is on average lower in young people (eg 100110/6070 in 18-yearolds) and they have a lifetime of risk ahead of them; but evidence to treat is lacking. White-coat hypertension Refers to an elevated clinic Hypertension, but normal ABPM (day average 135/85). NICE says dont treat; but more likely to develop hypertension in future, and may have risk of cardiovascular disease. Masked hypertension is the opposite. Malignant or accelerated phase hypertension: A rapid rise in blood pressure leading to vascular damage (pathological hallmark is fi brinoid necrosis). Usually there is severe hypertension (eg systolic 200, diastolic130mmHg) bilateral retinal haemorrhages and exudates; papilloedema may or may not be present. Symptoms are common, eg headache ± visual disturbance. It requires urgent treatment, and may also precipitate acute Kidney injury, Heart failure, or encephalopathy, which are hypertensive emergencies. Untreated, 90% die in 1yr; treated, 70% survive 5yrs. It is more common in younger and in black subjects. Look hard for any underlying cause.",
    "It is more common in younger and in black subjects. Look hard for any underlying cause. Primary or essential hypertension: (Cause unknown. ) 95% of cases. Secondary hypertension: 5% of cases. Causes include: Renal disease: the most common secondary cause. 75% are from intrinsic renal disease: glomerulonephritis, polyarteritis nodosa (PAN), systemic sclerosis, chronic pyelonephritis, or polycystic kidneys. 25% are due to renovascular disease, most frequently atheromatous (elderly cigarette smokers, eg with peripheral vascular disease) or rarely fi bromuscular dysplasia (young ). Endocrine disease: Cushings (p224) and Conns syndromes (p228), phaeochromocytoma (p228), acromegaly, hyperparathyroidism. Others: coarctation (p156), pregnancy (OHCS p48), liquorice, drugs: steroids, MAOI, oral contraceptive pill, cocaine, amphetamines. Signs and symptoms Usually asymptomatic (except malignant hypertension, see earlier in topic). Headache is no more common than in the general population. Always examine the CVS fully and check for retinopathy. Are there features of an underlying cause (phaeochromocytoma, p228, etc. ), signs of renal disease, radiofemoral delay, or weak femoral pulses (coarctation), renal bruits, palpable kidneys, or Cushings syndrome? Look for end-organ damage: LVH, retinopathy and proteinuriaindicates severity and duration of hypertension and associated with a poorer prognosis. Tests To confi rm diagnosis: ABPM or home blood pressure monitoring. To help quantify overall risk: Fasting glucose; cholesterol. To look for end-organ damage: ECG or echo (any LV hypertrophy? past myocardial infarction? ); Urine analysis (Protein, Blood). To exclude secondary causes: UE (eg potassium in Conns); Ca2 ( in hyperparathyroidism). Special tests: Renal ultrasound/arteriography (renal artery stenosis); 24h urinary meta-adrenaline (p228); urinary free cortisol (p225); renin; aldosterone; MR aorta (coarctation). __OOHHCCMM__1100ee. . iinnddbb 113388 0022//0055//22001177 1199: : 0066 139 enicidem ralucsavoidraC Grading hypertensive retinopathy 1 Tortuous arteries with thick shiny walls (silver or copper wiring, p560, fi g 12. 18). 2 AV nipping (narrowing where arteries cross veins, p560, fi g 12. 19). 3 Flame haemorrhages and cotton-wool spots. 4 Papilloedema, p560, fi g 12. 20. Measuring blood pressure with a sphygmomanometer Use the correct size cuff. The cuff width should be 40% of the arm circumference. The bladder should be centred over the brachial artery, and the cuff applied snugly. Support the arm in a horizontal position at mid-sternal level. Infl ate the cuff while palpating the brachial artery, until the pulse disappears. This provides an estimate of systolic Hypertension. Infl ate the cuff until 30mmHg above systolic Hypertension, then place stethoscope over the brachial artery. Defl ate the cuff at 2mmHg/s. Systolic Hypertension: appearance of sustained repetitive tapping sounds (Korotkoff I). Diastolic Hypertension: usually the disappearance of sounds (Korotkoff V). However, in some individuals (eg pregnant women) sounds are present until the zero point. In this case, the muffl ing of sounds, Korotkoff IV, should be used. State which is used for a given reading. For children, see OHCS p157. For advice on using automated sphygmomanometers and a list of validated devices see Managing suspected hypertension Clinic Blood Hypertension Clinic Blood Hypertension Clinic Blood Hypertension 140/90mmHg ≥140/90mmHg ≥180/110mmHg Normotensive Consider starting antihypertensive drug immediately. Consider referral. Off er ABPM. Calculate cv risk and look for organ damage. ABPM 135/85mmHg Normotensive ABPM ≥135/85mmHg NICE says no . if cv risk 20%/10yrs ABPM ≥150/95mmHg Consider if clear or end organ damage end-organ damage or High risk. Fig 3. 40 Managing suspected hypertension. Target Hypertension is 140/90mmHg (150/90 if aged 80), but in Diabetes mellitus aim for 130/80mmHg, and 125/75 if proteinuria. To quantify CV risk, see www. bhsoc. org. NB: CV threshold of 20% 15% for CHD alone. Examples of target (end-organ) damage: LVH past medical history of myocardial infarction or angina past medical history of stroke/TIA Peripheral vascular disease Renal failure.",
    "Data source NICE CG127, __OOHHCCMM__1100ee. . iinnddbb 113399 0022//0055//22001177 1199: : 0066 140 enicidem ralucsavoidraC Hypertensionmanagement Look for and treat underlying causes (eg renal disease, alcohol: see p138). Drug therapy reduces the risk of cardiovascular disease and death. Almost any adult over 50 would benefi t from antihypertensives, whatever their starting blood pressure. 48 Treatment is especially important if: blood pressure is persistently ≥160/100mmHg or cardio vascular risk (10yr risk of vascular disease ≥20%), or existing vascular disease or target organ damage (eg brain, Kidney, Heart, retina) with blood pressure 140/90mmHg. Essential hypertension is not curable and longterm treatment is needed. Treatment goal 140/90mmHg (130/80 in Diabetes, 150/90 if aged 80). Reduce Blood Hypertension slowly; rapid reduction can be fatal, especially in the context of an acute stroke. These may fallSPRINT49 showed a target of 120/80 was benefi cial. Lifestyle changes Concomitant risk factors: stop smoking; Low-fat diet. Reduce alcohol and salt intake; increase exercise; reduce weight if obese. Drugs The ALLHAT study suggests that adequate blood pressure reduction is more important than the specifi c drug used. 50 However, -blockers seem to be less eff ective than other drugs at reducing major cardiovascular events, particularly stroke. -blockers and thiazides may increase the risk of new-onset Diabetes, Ca2-channel blockers appear neutral, and angiotensin-converting enzyme inhibitor or angiotensin receptor blocker may reduce the risk. 44 Monotherapy: If ≥55yrs, and in black patients of any age, 1st choice is a Ca2-channel antagonist or thiazide. If 55, 1st choice is angiotensin-converting enzyme inhibitor (or angiotensin receptor blocker if angiotensin-converting enzyme inhibitor intolerant, eg cough). -blockers are not 1st line for hypertension, but consider in younger people, particularly if: intolerance or contraindication to angiotensin-converting enzyme inhibitor/angiotensin receptor blocker, she is a woman of child-bearing potential, or there is sympathetic drive. Combination : angiotensin-converting enzyme inhibitor Ca2-channel antagonist or diuretic is logical, and has been commonly used in trials. There is little evidence on using 3 drugs but current recommendation is angiotensin-converting enzyme inhibitor, Ca2-channel antagonist, and thiazide. 44 If blood pressure still uncontrolled on adequate doses of 3 drugs, add a 4thconsider: spironolactone 2550mg/24h or higher-dose thiazide, but monitor UE. Alternatively, -blocker, or selective -blocker and get help. Check compliance (urinary drug screen, or observed ). Drug examples Thiazides: Eg chlortalidone 2550mg/24h PO mané. SE: potassium, sodium, impotence. CI: gout. Ca2-channel antagonists: Eg nifedipine MR, 3060mg/24h PO. SE: fl ushes, Fatigue, gum hyperplasia, ankle oedema; avoid short-acting form. angiotensin-converting enzyme inhibitor: Eg lisinopril 1040mg/24h PO (max 40mg/d). angiotensin-converting enzyme inhibitor may be 1st choice if co-existing LVF, or in diabetics (esp. if microalbuminuria, p314) or proteinuria. SE: cough, potassium, renal failure, angio-oedema. CI: bilateral renal artery or aortic valve stenosis; p114. angiotensin receptor blocker: Candesartan (832mg/d); caution if valve disease or cardiomyopathy; monitor potassium. SE: vertigo, urticaria, pruritus. Useful if angiotensin-converting enzyme inhibitor induces cough. -blockers: Eg bisoprolol 2. 55mg/24h PO. SE: bronchospasm, Heart failure, cold peripheries, lethargy, impotence. CI: asthma; caution in Heart failure. Consider aspirin when blood pressure controlled, if aged 55yrs. Add a statin if cholesterol raised. Most drugs take 48wks to gain maximum eff ect: dont assess effi cacy with just one blood pressure measurement. Malignant hypertension (fi g 3. 41) In general, use oral therapy, unless there is encephal opathy or CCF. The aim is for a controlled reduction in blood pressure over days, not hours. Avoid sudden drops in blood pressure as cerebral autoregulation is poor (stroke risk). Bed rest; there is no ideal hypotensive, but atenolol or long-acting Ca2 blockers may be used PO. Encephalopathy: (Headache, focal CNS signs, seizures, coma. )",
    "Encephalopathy: (Headache, focal CNS signs, seizures, coma. ) Aim to reduce blood pressure to 110mmHg diastolic over 4h. Admit to monitored area. Insert intra-arterial line for Hypertension monitoring. Either IV labetalol (eg 50mg IV over 1min, repeated every 5min, max 200mg) or Sodium nitroprusside infusion (0. 5mcg/kg/min IVI titrated up to 8mcg/kg/min, eg 50mg in 1L glucose 5%; expect to give 100200mL/h for a few hours only, to avoid cyanide risk). Never use sublingual nifedipine to reduce blood pressure (rapid drop in blood pressure may cause stroke ). 51 __OOHHCCMM__1100ee. . iinnddbb 114400 0022//0055//22001177 1199: : 0066 141 Fig 3. 41 Left ventricular hypertrophythis is from a patient with malignant hypertensionnote the sum of the S-wave in V2 and R-wave in V6 is greater than 35mm. Cardiovascular medicine __OOHHCCMM__1100ee. . iinnddbb 114411 0022//0055//22001177 1199: : 0066 142 enicidem ralucsavoidraC Rheumatic fever (RF) This systemic infection is still common in developing countries but increasingly rare in the West. Peak incidence: 515yrs. Tends to recur unless prevented. Pharyngeal infection with Lancefi eld group A -haemolytic streptococci triggers rheumatic fever 24wks later, in the susceptible 2% of the population. An antibody to the carbohydrate cell wall of the streptococcus cross-reacts with valve tissue (antigenic mimicry) and may cause permanent damage to the Heart valves. Diagnosis Use the revised Jones criteria (may be over-rigorous). There must be evidence of recent strep infection plus 2 major criteria, or 1 major 2 minor. Evidence of group A -haemolytic streptococcal infection: Positive throat culture (usually negative by the time RF symptoms appear). Rapid streptococcal antigen test ve. Elevated or rising streptococcal antibody titre (eg anti-streptolysin O (ASO) or DNase B titre). Recent scarlet fever. Major criteria: Carditis: tachycardia, murmurs (mitral or aortic regurgitation, Carey Coombs murmur, p46), pericardial rub, CCF, cardiomegaly, conduction defects (4570%). An apical systolic murmur may be the only sign. 52 Arthritis: a migratory, fl itting polyarthritis; usually aff ects larger joints (75%). Subcutaneous nodules: small, mobile, painless nodules on extensor surfaces of joints and spine (220%). Erythema marginatum: (fi g 3. 42) geographical-type rash with red, raised edges and clear centre; occurs mainly on trunk, thighs and arms in 210% (p562). Sydenhams chorea (St Vitus dance): occurs late in 10%. Unilateral or bilateral involuntary semi-purposeful movements. May be preceded by emotional lability and uncharacteristic behaviour. Minor criteria: Fever. Raised ESR or CRP. Arthralgia (but not if arthritis is one of the major criteria). Prolonged PR interval (but not if carditis is major criterion). Previous rheumatic fever. Management Bed rest until CRP normal for 2wks (may be 3 months). Benzylpenicillin 0. 61. 2g IV stat, then phenoxymethylpenicillin 250500mg 4 times daily PO for 10 days (if allergic to penicillin, give erythromycin or azithromycin for 10 days). Analgesia for carditis/arthritis: aspirin 100mg/kg/d PO in divided doses (max 48g/d) for 2d, then 70mg/kg/d for 6wks. Monitor salicylate level. Toxicity causes tinnitus, hyperventilation, and metabolic acidosis. Risk of Reye syndrome in children. Alternative: NSAIDS (p546). If moderate-to-severe carditis is present (cardiomegaly, CCF, or 3rd-degree Heart block), add oral prednisolone to salicylate therapy. In case of Heart failure, treat appropriately (p136), with severe valve disease, surgery may be required. Immobilize joints in severe arthritis. Haloperidol (0. 5mg/8h PO) or diazepam for the chorea. Prognosis 60% with carditis develop chronic rheumatic Heart disease. This correlates with the severity of the carditis. 53 Acute attacks last an average of 3 months. Recurrence may be precipitated by further streptococcal infections, pregnancy, or use of the oral contraceptive pill. Cardiac sequelae aff ect mitral (70%), aortic (40%), tricuspid (10%), and pulmonary (2%) valves. Incompetent lesions develop during the attack, stenoses years later.",
    "Incompetent lesions develop during the attack, stenoses years later. Secondary prophylaxis Penicillin V 250mg/12h PO. Alternatives: sulfadiazine 1g daily (0. 5g if 30kg) or erythromycin 250mg twice daily (if penicillin allergic). Duration: If carditispersistent valvular disease, continue at least until age of 40 (sometimes lifelong). If carditis but no valvular disease, continue for 10yrs. If there is no carditis, 5yrs of prophylaxis (until age of 21) is suffi cient. __OOHHCCMM__1100ee. . iinnddbb 114422 0022//0055//22001177 1199: : 0066 143 enicidem ralucsavoidraC Fig 3. 42 Erythema marginatum. Image courtesy of Dr Maria Angelica Binotto. __OOHHCCMM__1100ee. . iinnddbb 114433 0022//0055//22001177 1199: : 0066 144 enicidem ralucsavoidraC Mitral valve disease Mitral regurgitation (MR) Backfl ow through the mitral valve during systole. Causes: Functional (LV dilatation); annular calcifi cation (elderly); rheumatic fever; infective endocarditis; mitral valve prolapse; ruptured chordae tendinae; papillary muscle dysfunction/rupture (eg post-myocardial infarction); connective tissue disorders (EhlersDanlos, Marfans); cardiomyopathy; congenital (may be associated with other defects, eg ASD, AV canal); appetite suppressants (eg fenfl uramine, phentermine). Symptoms: Dyspnoea; Fatigue; palpitations; symptoms of causative factor (eg fever). Signs: atrial fibrillation; displaced, hyperdynamic apex; pansystolic murmur at apex radiating to axilla; soft S1; split S2; loud P2 (pulmonary hypertension). Severity: the more severe, the larger the left ventricle. Tests: ECG: atrial fibrillation; P-mitrale if in sinus rhythm (may mean left atrial size); LVH. CXR: big LA LV; mitral valve calcifi cation; pulmonary oedema. Echocardiogram: To assess LV function and MR severity and aetiology (transoesophageal to assess severity and suitability for repair rather than replacement). Cardiac catheterization to confi rm diagnosis, exclude other valve disease, and assess coronary artery disease (can combine CABG with valve surgery). Management: Control rate if fast atrial fibrillation. Anticoagulate if: atrial fibrillation; history of embolism; prosthetic valve; additional mitral stenosis. Diuretics improve symptoms. Surgery4 for deteriorating symptoms; aim to repair or replace the valve before LV is irreversibly impaired. Mitral valve prolapse: Is the most common valvular abnormality (prevalence: 5%). Occurs alone or with: ASD, patent ductus arteriosus, cardiomyopathy, Turners syndrome, Marfans syndrome, osteogenesis imperfecta, pseudoxanthoma elasticum, WPW (p133). Symptoms: Usually asymptomatic. May develop atypical chest Pain, palpitations, and autonomic dysfunction symptoms. Signs: Mid-systolic click and/ or a late systolic murmur. Complications: MR, cerebral emboli, arrhythmias, sudden death. Tests: Echo is diagnostic. ECG may show inferior T-wave inversion. : -blockers may help palpit ations and chest Pain. Surgery if severe MR. Mitral stenosis Causes: Rheumatic fever, congenital, mucopolysaccharidoses, endo cardial fi broelastosis, malignant carcinoid (p271; rare), prosthetic valve. Presentation: Normal mitral valve orifi ce area is 46cm2. Symptoms usually begin when the orifi ce becomes 2cm2. Pulmonary hypertension causes dyspnoea, haemoptysis, chronic bronchitis-like picture; Hypertension from large left atrium on local structures causes hoarseness (recurrent laryngeal nerve), dysphagia (oesophagus), bronchial obstruction; also Fatigue, palpitations, chest Pain, systemic emboli, infective endocarditis (rare). Signs: Malar fl ush on cheeks (due to cardiac output); Low-volume pulse; atrial fibrillation common (due to enlarged LA); tapping, non-displaced, apex beat (palpable S1); RV heave. On auscultation: loud S1; opening snap (pliable valve); rumbling mid-diastolic murmur (heard best in expiration, with patient on left side). Graham Steell murmur (p46) may occur. Severity: the more severe the stenosis, the longer the diastolic murmur, and the closer the opening snap is to S2. Tests: ECG: atrial fibrillation; P-mitrale; RVH; progressive RAD. CXR: left atrial enlargement (double shadow in right cardiac silhouette); pulmonary oedema; mitral valve calcifi cation. Echo is diagnostic. Signifi cant stenosis exists if the valve orifi ce is 1cm2/m2 body surface area. Indications for cardiac catheterization: previous valvotomy; signs of other valve disease; angina; severe pulmonary hypertension; calcifi ed mitral valve.",
    "Indications for cardiac catheterization: previous valvotomy; signs of other valve disease; angina; severe pulmonary hypertension; calcifi ed mitral valve. Management: If in atrial fibrillation, rate control (p130) is crucial; anticoagulate with warfarin (p350). Diuretics preload and pulmonary venous congestion. If this fails to control symptoms, balloon valvuloplasty (if pliable, non-calcifi ed valve), open mitral valvotomy, or valve replacement. 4 In patients with severe symptoms for whom open surgery is too dangerous, consider transcatheter valve repair, eg with MitraClip. This is only available in specialist centres. __OOHHCCMM__1100ee. . iinnddbb 114444 0022//0055//22001177 1199: : 0066 145 enicidem ralucsavoidraC What Becomes of the Broken Hearted? For who loveth extreamely, and feeleth not that passion to dissolve his hearte? Who rejoyceth, and proveth not his Heart dilated? Who is moyled with heavinesse, or plunged with payne, and perceiveth not his Heart to bee coarcted? Whom infl ameth ire, and hath not Heart-burning? By these experiences, wee prove in our hearts the working of Passions, and by the noyse of their tumult, wee understand the woorke of their presence Thomas Wright, The Passions of the Minde in Generall, 1604 From Aztec priests raising beating human hearts to the Sun-God, to Heart metaphors in song lyrics today, ideas of links between the Heart and human psychosocial self/soul/experience-of-being have pervaded the imaginative landscapes of cultures throughout time and place. Some of these links relate to physiological changes associated with emotion-triggered adrenaline surgesmy Heart raced, for example, is a phrase we relate to both physically and emotionally. Other Heart-phrases result from poetic extrapolations of Heart/self ideas and have no physiological explanation, eg he wears his Heart on his sleeve. Evidence is building that Heart/self interactions exist beyond metaphor and symptomatic fl ight-or-fi ght responses. Aff ective disorders, certain personality types, and traumatic life-experiences increase the risk of cardiac disease, even when lifestyle factors are controlled for. 5456 In broken Heart syndrome (Takotsubo cardiomyopathy), ventricular contraction morphology changes in response to emotional or physical stress (fi g 3. 43). It mimics a myocardial infarction in terms of clinical history, ECG changes, and troponin rises, but the prognosis and management may be quite diff erent so accurate diagnosis is important. As physicians, we often focus on explainable physical aspects of disease, but the physical and psychosocial are inconveniently related and both should be assessed to determine best management. Should an IHD suff erer be off ered CBT alongside their statins? Could a grieving patients myocardial infarction be Takotsubo cardiomyopathy? To answer these questions we must look beyond ECGs and troponin, to the Heart-ache of the literary and philosophical kinds. (a) (b) Fig 3. 43 (a) Left ventriculogram of a Heart in diastole. (b) The same patients Heart in systole. The apex is ballooning whilst the base contracts, causing ineffi cient pumping and a risk of rupture. This pattern is classic of Takotsubo cardiomyopathy. __OOHHCCMM__1100ee. . iinnddbb 114455 0022//0055//22001177 1199: : 0066 146 enicidem ralucsavoidraC Aortic valve disease Aortic stenosis (AS) Causes: Senile calcifi cation is the commonest. 57 Others: congenital (bicuspid valve, Williams syndrome, p149), rheumatic Heart disease. Presentation: Think of AS in any elderly person with chest Pain, exertional dyspnoea, or syncope. The classic triad includes angina, syncope, and Heart failure. Also: dyspnoea; dizziness; faints; systemic emboli if infective endocarditis; sudden death. Signs: Slow rising pulse with narrow pulse Hypertension (feel for diminished and delayed carotid upstrokeparvus et tardus); heaving, non-displaced apex beat; LV heave; aortic thrill; ejection systolic murmur (heard at the base, left sternal edge and the aortic area, radiates to the carotids). S1 is usually normal.",
    "S1 is usually normal. As stenosis worsens, A2 is increasingly delayed, giving fi rst a single S2 and then reversed splitting. But this sign is rare. More common is a quiet A2. In severe AS, A2 may be inaudible (calcifi ed valve). There may be an ejection click (pliable valve) or an S4. Tests: ECG: LVH with strain pattern; P-mitrale; LAD; poor R-wave progression; LBBB or complete AV block (calcifi ed ring). CXR: LVH; calcifi ed aortic valve (fi g 3. 44); poststenotic dilatation of ascending aorta. Echo: diagnostic (p110). Doppler echo can estimate the gradient across valves: severe stenosis if peak gradient 40mmHg (but beware the poor left ventricle not able to generate gradient) and valve area 1cm2. If the aortic jet velocity is 4m/s (or is increasing by 0. 3m/s per yr) risk of complications is increased. 57 Cardiac catheter can assess: valve gradient; LV function; coronary artery disease; risks: emboli generation. Differential diagnosis: Hypertrophic cardiomyopathy (HCM, p152); aortic sclerosis. Management: If symptomatic, prognosis is poor without surgery: 23yr survival if angina/syncope; 12yr if cardiac failure. If moderate-to-severe and treated medically, mortality can be as High as 50% at 2yrs, therefore prompt valve replacement (p148) is usually recommended. In asymptomatic patients with severe AS and a deteriorating ECG, valve replacement is also recommended. If the patient is not medically fi t for surgery, percutaneous valvuloplasty/replacement (TAVI transcatheter aortic valve implantation) may be attempted (fi g 3. 45). Aortic sclerosis Senile degeneration of the valve. There is an ejection systolic murmur; but no carotid radiation, and normal pulse (character and volume) and S2. Aortic regurgitation (AR) Acute: Infective endocarditis, ascending aortic dissection, chest trauma. Chronic: Congenital, connective tissue disorders (Marfans syndrome, EhlersDanlos), rheumatic fever, Takayasu arteritis, rheumatoid arthritis, SLE, pseudoxanthoma elasticum, appetite suppressants (eg fenfl uramine, phentermine), seronegative arthritides (ankylosing spondylitis, Reiters syndrome, psor iatic arthropathy), hypert ension, osteogenesis imperfecta, syphilitic aortitis. Symptoms: Exertional dyspnoea, orthopnoea, and PND. Also: palpitations, angina, syncope, CCF. Signs: Collapsing (Water-hammer) pulse (p42); wide pulse Hypertension; displaced, hyperdynamic apex beat; High-pitc hed early diastolic murmur (heard best in expiration, with patient sat forward). Eponyms: Corrigans sign: carotid pulsation; de Mussets sign: head nodding with each Heart beat; Quinckes sign: capillary pulsations in nail beds; Duroziezs sign: in the groin, a fi nger compressing the femoral artery 2cm proximal to the stethoscope gives a systolic murmur; if 2cm distal, it gives a diastolic murmur as Blood fl ows backwards; Traubes sign: pistol shot sound over femoral arteries; an Austin Flint murmur (p46) denotes severe AR. Tests: ECG: LVH. CXR: cardiomegaly; dilated ascending aorta; pulmonary oedema. Echo is diagnostic. Cardiac catheterization to assess: severity of lesion; anatomy of aortic root; LV function; coronary artery disease; other valve disease. Management: The main goal of medical therapy is to reduce systolic hypertension; angiotensin-converting enzyme inhibitor are helpful. Echo every 612 months to monitor. Indications for surgery: severe AR with enlarged ascending aorta, increasing symptoms, enlarging LV or deteriorating LV function on echo; or infective endocarditis refractory to medical therapy. Aim to replace the valve before signifi cant LV dysfunction occurs. Predictors of poor post-operative survival: ejection fraction 50%, NYHA class III or IV (p135), duration of CCF 12 months. __OOHHCCMM__1100ee. . iinnddbb 114466 0022//0055//22001177 1199: : 0066 147 enicidem ralucsavoidraC Fig 3. 44 Severely calcifi ed aortic valve. Reproduced with permission from Hamid Reza Taghipour. Fig 3. 45 This is one of the two main types of transcatheter aortic valve implants: animal valve leafl ets mounted on metal stents.",
    "This extraordinary stucture must be resilient against the movement of the Heart walls and the powerful fl ow of Blood; it must avoid obstructing forward fl ow of Blood whilst providing a near-complete block to backfl ow; and it has surfaces of foreign material yet must avoid triggering clots or allowing microbial growth. On top of this, it must be able to fold down over a wire to allow safe passage through the arterial tree from the groin to the Heart, before being opened out by an infl ated balloon. Image courtesy of Edwards Lifesciences LLC, Irvine, calcium. Edwards, Edwards Lifesciences, Edwards SAPIEN, SAPIEN, SAPIEN XT and SAPIEN 3 are trademarks of Edwards Lifesciences Corporation. __OOHHCCMM__1100ee. . iinnddbb 114477 0022//0055//22001177 1199: : 0066 148 enicidem ralucsavoidraC Right Heart valve disease Tricuspid regurgitation Causes: Functional (RV dilatation; eg due to pulmonary hypertension induced by LV failure or physical examination); rheumatic fever; infective endocarditis (IV drug abuser5); carcinoid syndrome; congenital (eg ASD, AV canal, Ebsteins anomaly (downward displacement of the tricuspid valvesee OHCS p642)); drugs (eg ergotderived dopamine agonists, p495; fenfl uramine). Symptoms: Fatigue; hepatic Pain on exertion (due to hepatic congestion); ascites; oedema and symptoms of the causative condition. Signs: Giant v waves and prominent y descent in JVP (p43); RV heave; pansystolic murmur, heard best at lower sternal edge in inspiration; pulsatile hepatomegaly; jaundice; ascites. Management: Drugs: diuretics for systemic congestion; drugs to treat underlying cause. Valve repair or replacement (10% 30-day mortality). Tricuspid regurgitation resulting from myocardial dysfunction or dilatation has a mortality of up to 50% at 5 yrs. Tricuspid stenosis Causes: Main cause is rheumatic fever, which almost always occurs with mitral or aortic valve disease. Also: congenital, infective endocarditis. Symptoms: Fatigue, ascites, oedema. Signs: Giant a wave and slow y descent in JVP (p43); opening snap, early diastolic murmur heard at the left sternal edge in inspiration. atrial fibrillation can also occur. Diagnosis: Echo. Treatment: Diuretics; surgical repair. Pulmonary stenosis Causes: Usually congenital (Turner syndrome, Noonan syndrome, Williams syndrome, Fallots tetralogy, rubella). Acquired causes: rheumatic fever, carcinoid syndrome. Symptoms: Dyspnoea; Fatigue; oedema; ascites. Signs: Dysmorphic facies (congenital causes); prominent a wave in JVP; RV heave. In mild stenosis, there is an ejection click, ejection systolic murmur (which radiates to the left shoulder); widely split S2. In severe stenosis, the murmur becomes longer and obscures A2. P2 becomes softer and may be inaudible. Tests: ECG: RAD, P-pulmonale, RVH, RBBB; echo/TOE (p110); CXR: prominent pulmonary arteries caused by post-stenotic dilatation. Cardiac catheterization is diagnostic. Treatment: Pulmonary valvuloplasty or valvotomy. Pulmonary regurgitation Causes: Any cause of pulmonary hypertension (p194). Signs: Decrescendo murmur in early diastole at the left sternal edge (the Graham Steell murmur if associated with mitral stenosis and pulmonary hypertension). Cardiac surgery Cardiac surgery has come on a long way since 1923 when Dr Henry Souttar58, 59 used his fi nger to open a stenosed mitral valve in a beating Heart. 6 Cardiac bypass allows prolonged access to the open, static Heart, during which complex and High-precision repair and replacement of valves and aortic roots can occur. Transcatheter procedures are playing an increasing role in the management of cardiovascular disease. Key open Heart procedures include: Valve replacements Mechanical valves may be of the ball-cage (StarrEdwards), tilting disc (BjorkShiley), or double tilting disc (St Jude) type. These valves are very durable but the risk of thromboembolism is High; patients require lifelong anticoagulation. Xenografts are made from porcine valves or pericardium. These valves are less durable and may require replacement at 810yrs but have the advantage of not necessitating anticoagulation. Homografts are cadaveric valves.",
    "Homografts are cadaveric valves. They are particularly useful in young patients and in the replacement of infected valves. Complications of prosthetic valves: systemic embolism, infective endocarditis, haemolysis, structural valve failure, arrhythmias. CABG See p123. Cardiac transplantation Consider this when cardiac disease is severely curtailing quality of life, and survival is not expected beyond 612 months. Surgery for congenital Heart defects See p156. Aortic root surgery Replacement/repair if dissection or aneurysmal. 5 Remember that it is the tricuspid valve which is the valve most vulnerable to events arriving by vein, eg pathogens from IV drug abusers or hormones (particularly 5-height) from carcinoid tumours. 6 Souttars own description of this landmark case is available online: H S Souttar. The surgical treatment of mitral stenosis. BMJ 1925: 2(3379): 603606. __OOHHCCMM__1100ee. . iinnddbb 114488 0022//0055//22001177 1199: : 0066 149 enicidem ralucsavoidraC The Heart in various, mostly rare, systemic diseases This list reminds ultrasound to look at the Heart and the whole patient, not just in exams (where those with odd syndromes congregate), but always. Acromegaly: (p238) blood pressure; LVH; hypertrophic cardiomyopathy; High-output cardiac failure; coronary artery disease. Amyloidosis: (p370) Restrictive cardiomyopathy. Bright myocardium on echo. Ankylosing spondylitis: (p550) Conduction defects; AV block; AR. Behçets disease: (p694) Aortic regurgitation; arterial ± venous thrombi. Beta thalassaemia: (p342) Dilated and restrictive cardiomyopathies. Carcinoid syndrome: (p271) Tricuspid regurgitation and pulmonary stenosis. Cushings syndrome: (p224) Hypertension. Downs syndrome: (OHCS p152) ASD; VSD; mitral regurgitation. EhlersDanlos syndrome: (OHCS p642) Mitral valve prolapse; aortic aneurysm and dissection; hyperelastic skin; GI bleeds. Joints are loose and hypermobile; mutations exist, eg in genes for procollagen (COL3A1); there are six types. Friedreichs ataxia: (p698) Hypertrophic cardiomyopathy, dilatation over time. Haemochromatosis: (p288) atrial fibrillation; cardiomyopathy. HoltOram syndrome: ASD or VSD with upper limb defects (eg polydactyly and triphalangeal thumb). 60 Human immunodefi ciency virus: (p398) Myocarditis; dilated cardiomyopa thy; eff usion; ventricular arrhythmias; SBE/IE; non-infective thrombotic (mara ntic) endocarditis; RVF (pulmonary hypertension); metastatic Kaposis sarcoma. Hypothyroidism: (p220) Sinus bradycardia; Low pulse Hypertension; pericardial eff usion; coronary artery disease; Low-voltage ECG. Kawasaki disease: (OHCS p646) Coronary arteritis similar to PAN; commoner than rheumatic fever (p142) as a cause of acquired Heart disease. Klinefelters syndrome : (OHCS p646) ASD. Psychopathy; learning diffi culties; libido; gynaecomastia; sparse facial hair and small fi rm testes. XXY. Marfans syndrome: (p706) Mitral valve prolapse; AR; aortic dissection. Look for long fi ngers and a High-arched palate. Myotonic dystrophy (p510) Progressive conduction system disease; arrhythmias; LV dysfunction. Noonan syndrome: (OHCS p650) ASD; pulmonary stenosis ± Low-set ears. Polyarteritis nodosa (PAN): (p556) Small and medium vessel vasculitis angina; myocardial infarction; arrhythmias; CCF; pericarditis and conduction defects. Rheumatoid arthritis: Conduction defects; pericarditis; LV dysfunction; aortic regurgitation; coronary arteritis. Look for arthritis signs, p546. Sarcoidosis: (p196) Infi ltrating granulomas may cause complete AV block; ventricular or supraventricular tachycardia; myocarditis; CCF; restrictive cardiomyopathy. ECG may show Q waves. Syphilis: (p412) Myocarditis; ascending aortic aneurysm. Systemic lupus erythematosus: (p554) Pericarditis/eff usion; myocarditis; LibmanSacks endocarditis; mitral valve prolapse; coronary arteritis. Systemic sclerosis: (p552) Pericarditis; pericardial eff usion; myocardial fi brosis; myocardial ischaemia; conduction defects; cardiomyopathy. Thyrotoxicosis: (p218) Pulse; atrial fibrillation ± emboli; wide pulse Hypertension; hyperd ynamic apex; loud Heart sounds; ejection systolic murmur; pleuro pericardial rub; angina; High-output cardiac failure. Turner syndrome : Coarctation of aorta. Look for webbed neck. XO. Williams syndrome: Supravalvular aortic stenosis (visuospatial IQ). __OOHHCCMM__1100ee. . iinnddbb 114499 0022//0055//22001177 1199: : 0066 150 enicidem ralucsavoidraC Infective endocarditis (IE) Fever new murmur endocarditis until proven otherwise. Any fever lasting 1wk in those known to be at risk7 must prompt Blood cultures.",
    "Any fever lasting 1wk in those known to be at risk7 must prompt Blood cultures. 61 Acute infective endocarditis (IE) tends to occur on normal valves and may present with acute Heart failure ± emboli; the commonest organism is Staph. aureus. Risk factors: skin breaches (dermatitis, IV lines, wounds); renal failure; immunosuppression; diabetes mellitus. Mortality: 550% (related to age and embolic events). Endocarditis on abnormal valves tends to run a subacute course. Risk factors: aortic or mitral valve disease; tricuspid valves in IV drug users; coarctation; patent ductus arteriosus; VSD; prosthetic valves. Endocarditis on prosthetic valves may be early (within 60d of surgery, usually Staph. epidermidis, poor prognosis) or late. Causes Bacteria: Bacteraemia occurs all the time, eg when we chew (not just during dentistry or medical interventionswhich is why routine prophylaxis for such procedures does not make sense). 61 Strep. viridans is the commonest (usually subacute) followed by Staph. aureus, Strep. bovis (need colonoscopy? tumour), Enterococci and Coxiella burnetii. Rarely: HACEK Gram Ωve bacteria (Haemoph ilusActinobacillusCardiobacte riumEikenellaKingella); diphtheroids; Chlamydia. Fungi: Candida; Aspergillus; Histoplasma. Usually in IV drug abusers, immunocompromised patients or those with prosthetic valves. High mortality, need surgical management. Other: SLE (LibmanSacks endocarditis); malignancy. Signs Septic signs: Fever, rigors, night sweats, malaise, weight loss, anaemia, spleno meg aly, and clubbing (fi g 3. 46). Cardiac lesions: Any new murmur, or a change in pre-existing murmur, should raise the suspicion of endocarditis. Vegetations may cause valve destruction and severe regurgitation, or valve obstruction. An aortic root abscess causes prolongation of the PR interval, and may lead to complete AV block. LVF is a common cause of death. Immune complex deposition: Vasculitis (p556) may aff ect any vessel. Microscopic haematuria is common; glomerulonephritis and acute Kidney injury may occur. Roth spots (boat-shaped retinal haemorrhage with pale centre); splinter haemorrhages (fi g 3. 47); Oslers nodes (painful pulp infarcts in fi ngers or toes). Embolic phenomena: Emboli may cause abscesses in the relevant organ, eg brain, Heart, Kidney, spleen, gut (or lung if right-sided IE) or skin: termed Janeway lesions (fi g 3. 48; painless palmar or plantar macules), which, together with Oslers nodes, are pathognomonic. Diagnosis Use the Modifi ed Duke criteria (BOX Modified Duke criteria). 62, 63 Blood cultures: Do three sets at diff erent times from diff erent sites at peak of fever. 85 90% are diagnosed from the 1st two sets; 10% are culture-negative. Blood tests: Normochromic, normocytic anaemia, neutrophilia, High ESR/CRP. Rheumatoid factor positive (an immunological phenomenon). Also check UE, Mg2, LFT. Urinalysis: For microscopic haematuria. CXR: Cardiomegaly, pulmonary oedema. Regular ECGs: To look for Heart block. Echocardiogram: TTE (p110) may show vegetations, but only if 2mm. TOE (p110) is more sensitive, and better for visualizing mitral lesions and possible development of aortic root abscess. computed tomography: To look for emboli (spleen, brain, etc. ). Treatment Liaise early with microbiologists and cardiologists. 62 Antibiotics: see BOX Antibiotic therapy for infective endocarditis. Surgery if: Heart failure, valvular obstruction; repeated emboli; fungal IE; persistent bacteraemia; myocardial abscess; unstable infected prosthetic valve. 64 Prognosis 50% require surgery. 20% inhospital mortality (Staphs 30%; bowel bacteria 14%; Streps 6%). 15% recurrence at 2yrs. Prevention Antibiotic prophylaxis is no longer recommended for those at risk of IE undergoing invasive procedures. However, if they are given antibiotics for other reasons during a procedure, the antibiotic should cover the common IE organisms. Recommendations Give clear information about prevention, including: The importance of maintaining Good oral health. Symptoms that may indicate IE and when to seek expert advice. The risks of invasive procedures, including non-medical procedures such as body piercing or tattooing.",
    "The risks of invasive procedures, including non-medical procedures such as body piercing or tattooing. 65 7 Past IE or rheumatic fever; IV drug abuser; damaged or replaced valve; PPM or ICD; structural congenital Heart disease (but not simple ASD, fully repaired VSD, or patent ductus); hypertrophic cardiomyopathy. __OOHHCCMM__1100ee. . iinnddbb 115500 0022//0055//22001177 1199: : 0066 151 enicidem ralucsavoidraC Modifi ed Duke criteria for infective endocarditis Major criteria: Positive Blood culture: Typical organism in 2 separate cultures or Persistently ve Blood cultures, eg 3 12h apart (or majority if 3) or Single positive Blood culture for Coxiella burnetii. Endocardium involved: Positive echocardiogram (vegetation, abscess, pseudoaneurysm, dehiscence of prosthetic valve) or Abnormal activity around prosthetic valve on PET/computed tomography or SPECT/computed tomography or Paravalvular lesions on cardiac computed tomography. Minor criteria: Predisposition (cardiac lesion; IV drug abuse). Fever 38°C. Vascular phenomena (emboli, Janeways lesions, etc. ). Immunological phenomena (glomerulonephritis, Oslers nodes, etc. ). Positive Blood culture that does not meet major criteria. How to diagnose: Defi nite infective endocarditis: 2 major or 1 major and 3 minor or all 5 minor criteria. Antibiotic therapy for infective endocarditis Prescribe antibiotics for infective endocarditis as follows. 66 For more information on individual antibiotics, see tables 9. 49. 9, pp3867. Blind therapynative valve or prosthetic valve implanted 1y ago: ampicillin, fl ucloxacillin and gentamicin. Vancomycin gentamicin if penicillin-allergic. If thought to be Gram Ωve: meropenem vancomycin. Blind therapyprosthetic valve: vancomycin gentamicin rifampicin. Staphsnative valve: fl ucloxacillin for 4wks. If allergic or MRSA: vancomycin. Staphsprosthetic valves: fl ucloxacillin rifampicin gentamicin for 6wks (review need for gentamicin after 2wks). If penicillin-allergic or MRSA: vancomycin rifampicin gentamicin. Strepsfully sensitive to penicillin: benzylpenicillin 1. 2g/4h IV for 46wks. 8 Strepsless sensitive: benzylpenicillin gentamicin; if penicillin allergic or highly penicillin resistant: vancomycin gentamicin. Enterococci: amoxicillin gentamicin. If pen-allergic: vancomycin gentamicin for 4wks (6wks if prosthetic valve); review need for gentamicin after 2wks. HACEK organisms (Haemophilus, Actinobacillus, Cardiobacterium, Eikenella, Kingella): ceftriaxone for 4wks with native valve or 6wks with prosthetic. Fungal: Candidaamphotericin. Aspergillusvoriconazole. Fig 3. 46 Clubbing with endoFig 3. 47 Splinter haemorrhagFig 3. 48 Janeways lesions are carditis. es are normally seen under the non-tender erythematous, haefi ngernails or toenails. They are mo rrhagic, or pustular spots, usually red-brown in colour. eg on the palms or soles. 8 If Strep bovis is cultured, do colonoscopy, as a colon neoplasm is the likely portal of entry (table 6. 3, p249). __OOHHCCMM__1100ee. . iinnddbb 115511 0022//0055//22001177 1199: : 0066 152 enicidem ralucsavoidraC Diseases of Heart muscle Acute myocarditis This is infl ammation of myocardium, often associated with pericardial infl ammation (myopericarditis). 67 Causes: See table 3. 3. Symptoms and signs: ACS-like symptoms, Heart failure symptoms, palpitations, tachycardia, soft S1, S4 gallop (p44). Tests: ECG: ST changes and T-wave inversion, atrial arrhythmias, transient AV block, QT prolongation. Bloods: CRP, ESR, troponin may be raised; viral serology and tests for other likely causes. Echo: diastolic dysfunction, regional wall abnormalities. Cardiac MR if clinically stable. Endomyocardial biopsy is gold standard. : Supportive. Treat the underlying cause. Treat arrhythmias and Heart failure (p136). nonsteroidal anti-inflammatory drug use is controversial. Avoid exercise as this can precipitate arrhythmias. Prognosis: 50% will recover within 4wks. 1225% will develop DCM and severe Heart failure. DCM can occur years after apparent recovery. Dilated cardiomyopathy (DCM) A dilated, fl abby Heart of unknown cause. Associations: alcohol, blood pressure, chemotherapeutics, haemochromatosis, viral infection, autoimmune, perior postpartum, thyrotoxicosis, congenital (X-linked). Prevalence: 0. 2%.",
    "Associations: alcohol, blood pressure, chemotherapeutics, haemochromatosis, viral infection, autoimmune, perior postpartum, thyrotoxicosis, congenital (X-linked). Prevalence: 0. 2%. Presentation: Fatigue, dyspnoea, pulmonary oedema, RVF, emboli, atrial fibrillation, VT. Signs: Pulse, blood pressure, JVP, displaced and diff use apex, S3 gallop, mitral or tricuspid regurgitation (MR/TR), pleural eff usion, oedema, jaundice, hepatomegaly, ascites. Tests: Blood: BNP (p137), sodium indicates a poor prognosis. CXR: cardiomegaly, pulmonary oedema. ECG: tachycardia, non-specifi c T-wave changes, poor R-wave progression. Echo: globally dilated hypokinetic Heart and Low ejection fraction. Look for MR, TR, LV mural thrombus. : Bed rest, diuretics, -blockers, angiotensin-converting enzyme inhibitor, anticoagu l ation, biventricular pacing, ICDs, LVADs, transplantation. Mortality: Variable, eg 40% in 2yrs. Hypertrophic cardiomyopathy (HCM) LV outfl ow tract (LVOT) obstruction from asymmetric septal hypertrophy. HCM is the leading cause of sudden cardiac death in the young. Prevalence: 0. 2%. Autosomal dominant inheritance, but 50% are sporadic. 70% have mutations in genes encoding -myosin, -tropomyosin, and troponin T. May present at any age. Ask about family history of sudden death. Symptoms and signs: Sudden death may be the fi rst manifestation of HCM in many patients (VF is amenable to implantable defi brillators), angina, dyspnoea, palpitation, syncope, CCF. Jerky pulse; a wave in JVP; double-apex beat; systolic thrill at lower left sternal edge; harsh ejection systolic murmur. Tests: ECG: LVH; progressive T-wave inversion; deep Q waves (inferior lateral leads); atrial fibrillation; WPW syndrome (p133); ventricular ectopics; VT. Echo: asymmetrical septal hypertrophy; small LV cavity with hypercontractile posterior wall; midsystolic closure of aortic valve; systolic anterior movement of mitral valve. magnetic resonance imaging: see fi g 3. 16. Cardiac catheterization helps assess: severity of gradient; coronary artery disease or mitral regurgitation, but may provoke VT. Electrophysiological studies may be needed (eg if WPW, p133). Exercise test ± Holter monitor (p125) to risk stratify. : -blockers or verapamil for symptoms (the aim is reducing ventricular contractility). Amiodarone (p130) for arrhythmias (atrial fibrillation, VT). Anticoagulate for paroxysmal atrial fibrillation or systemic emboli. Septal myomectomy (surgical or chemical (with alcohol) to LV outfl ow tract gradient) is reserved for those with severe symptoms. Consider implantable defi brillatoruse to assess risk of sudden cardiac death. Mortality: 5. 9%/yr if 14yrs; 2. 5%/yr if 14yrs. Poor prognostic factors: age 14yrs or syncope at presentation; family history of HCM/sudden death. Restrictive cardiomyopathy Causes: Idiopathic; amyloidosis; haemochromatosis; sarcoido sis; scleroderma; Löffl ers eosinophilic endocarditis; endomyocardial fi brosis. Presentation: Is like constrictive pericarditis (p154). Features of RVF predominate: JVP, with prominent x and y descents; hepatomegaly; oedema; ascites. Diagnosis: Echo, magnetic resonance imaging, cardiac catheterization. : Treat the cause. Cardiac myxoma (fi gs 3. 49, 3. 50) Rare benign cardiac tumour. Prevalence ≤5/10 000, : 2: 1. Usually sporadic, but may be familial (Carney complex: cardiac and cutaneous myxomas, skin pigmentation, endocrinopathy, etc. , p223). It may mimic infective endocarditis (fever, weight loss, clubbing, ESR, systemic emboli), or mitral stenosis (left atrial obstruction, atrial fibrillation). A tumour plop may be heard, and signs may vary before mealscording to posture. Tests: Echo. : Excision. __OOHHCCMM__1100ee. . iinnddbb 115522 0022//0055//22001177 1199: : 0066 153 enicidem ralucsavoidraC How to infl ame the Heart Table 3. 3 Causes of myocarditis Idiopathic 50% of cases Viral Enteroviruses, adenoviruses, HHV6, EBV, CMV, infl uenza, hepatitis, mumps, rubeola, Coxsackie, polio, HIV, HSV Bacterial Staph, Strep, Clostridia, diphtheria, TB, meningococcus, Mycoplasma, brucellosis, psittacosis Spirochaetes Leptospirosis, syphilis, Lyme disease Protozoa Chagas (p423), Leishmania, toxoplasmosis Drugs Cyclophosphamide, trastuzumab, penicillin, chloramphenicol, sulfonamides, methyldopa, spironolactone, phenytoin, carbamazepine Toxins Cocaine, lithium, alcohol, lead, arsenic Immunological SLE, sarcoid, Kawasaki, scleroderma, Heart transplant rejection Fig 3.",
    "49 Echocardiogram of a 35-yr-old patient who presented with severe exertional dyspnoea and several episodes of syncope. Look at the large mass (cardiac myxoma) in left atrium. Abbreviations: RV: right ventricle; LV: left ventricle; AV: aortic valve; AO: aorta; MV: mitral valve. Reproduced with permission from Hamid Reza Taghipour. Fig 3. 50 Echocardiogram of the same patient as fi g 3. 49 during diastole. Notice how the large mass of myxoma protrudes into the left ventricle during diastole, and obstructs the mitral valve almost completely. Abbreviations: RV: right ventricle; LV: left ventricle; AO: aorta. Reproduced with permission from Hamid Reza Taghipour. __OOHHCCMM__1100ee. . iinnddbb 115533 0022//0055//22001177 1199: : 0066 154 enicidem ralucsavoidraC Pericardial diseases Acute pericarditis This is infl ammation of the pericardium. 68 Causes: Idiopathic or secondary to: Viruses: eg coxsackie, echovirus, EBV, CMV, adenovirus, mumps, varicella, HIV. Bacteria: eg TBcommonest cause worldwide, Lyme disease, Q fever, pneumonia, rheumatic fever, Staphs, Streps, mycoplasma, legionella, MAI in HIV. Fungi and parasitic: v rare, usually in immunocompromised. Autoimmune: systemic autoimmune diseases eg SLE, RA; vasculitides eg Behçet, Takayasu; IBD; sarcoid; amyloid; Dresslers (p698). Drugs: eg procainamide, hydralazine, penicillin, isoniazid, chemotherapy. Metabolic: uraemia, hypothyroidism, anorexia nervosa. Others: trauma, surgery, malignancy, radiotherapy, myocardial infarction, chronic Heart failure. Clinical features: Central chest Pain worse on inspiration or lying fl at ± relief by sitting forward. A pericardial friction rub (p46) may be heard. Look for evidence of a pericardial eff usion or cardiac tamponade (see later in topic). Fever may occur. Tests: ECG classically shows concave (saddle-shaped) ST segment elevation and PR depression, but may be normal or non-specifi c (10%); see fi g 3. 51. Blood tests: FBC, ESR, UE, cardiac enzymes (NB: troponin may be raised); tests relating to possible aetiologies. Cardiomegaly on CXR may indicate a pericardial eff usion. Echo (if suspected pericardial eff usion). CMR and computed tomography may show localized infl ammation. Treatment: NSAIDs or aspirin with gastric protection for 12weeks. Add colchicine 500mcg OD or BD for 3 months to reduce the risk of recurrence. Rest until symptoms resolve. Treat the cause. If not improving or autoimmune, consider steroids (may increase the risk of recurrence) or other immunosuppressive therapies. Pericardial eff usion Accumulation of fl uid in the pericardial sac (normally 10 50mL). 68 Causes: Pericarditis, myocardial rupture (haemopericardiumsurgical, stab wound, post-myocardial infarction); aortic dissection; pericardium fi lling with pus; malignancy. Clinical features: Dyspnoea, chest Pain, signs of local structures being compressed hiccoughs (phrenic N), nausea (diaphragm), bronchial breathing at left base (Ewarts sign: compressed left lower lobe). Muffl ed Heart sounds. Look for signs of cardiac tamponade (below). Diagnosis: CXR shows an enlarged, globular Heart if eff usion 300mL; fi g 3. 14. ECG shows Low-voltage QRS complexes and may have alternating QRS morphologies (electrical alternans). Echocardi ography shows an echo-free zone surrounding the Heart. Management: Treat the cause. Pericardiocentesis may be diagnostic (suspected bacterial pericarditis) or therapeutic (cardiac tamponade). See p773. Send pericardial fl uid for culture, ZN stain/TB culture, and cytology. Constrictive pericarditis The Heart is encased in a rigid pericardium. 68 Causes: Often unknown (UK); elsewhere TB, or after any pericarditis. Clinical features: These are mainly of right Heart failure with JVP (with prominent x and y descents, p43); Kussmauls sign (JVP rising paradoxically with inspiration); soft, diff use apex beat; quiet Heart sounds; S3; diastolic pericardial knock, hepatosplenomegaly, ascites, and oedema. Tests: CXR: small Heart ± pericardial calcifi cation. computed tomography/magnetic resonance imaginghelps distinguish from restrictive cardiomyopathy. Echo. Cardiac catheterization. Management: Surgical excision. Medical to address the cause and symptoms.",
    "Echo. Cardiac catheterization. Management: Surgical excision. Medical to address the cause and symptoms. Cardiac tamponade A pericardial eff usion that raises intrapericardial Hypertension, reducing ventricular fi lling and thus dropping cardiac output. 68 Can lead rapidly to cardiac arrest. Signs: Pulse, blood pressure, pulsus paradoxus, JVP, Kussmauls sign, muffl ed S1 and S2. Diagnosis: Becks triad: falling blood pressure; rising JVP; muffl ed Heart sounds. ECG: Low-voltage QRS ± electrical alternans. Echo is diagnostic: echo-free zone (2cm, or 1cm if acute) around the Heart ± diastolic collapse of right atrium and right ventricle. Management: Seek expert help. The pericardial eff usion needs urgent drainage (p773). Send fl uid for culture, ZN stain/TB culture, and cytology. __OOHHCCMM__1100ee. . iinnddbb 115544 0022//0055//22001177 1199: : 0066 155 Fig 3. 51 Pericarditis. Note the widespread saddle-shaped ST elevationparticularly clear in V5 and V6. Cardiovascular medicine __OOHHCCMM__1100ee. . iinnddbb 115555 0022//0055//22001177 1199: : 0066 156 enicidem ralucsavoidraC Adult congenital Heart disease (ACHD) This is a growing area of cardiology as increasing numbers of children with congenital Heart defects survive to adulthood, sometimes as a result of complex restructuring procedures which have their own physiological implications (see BOX Patients with one ventricle). ACHD69 patients are at increased risk of many conditions described elsewhere, for which many of the standard investigations and therapies will apply: including arrhythmias (p124), Heart failure (p134), and infective endocarditis (p150). Investigations Echocardiography (± bubble contrast) is fi rst line. Increasingly, cardiac computed tomography and MR are used to provide precise anatomical and functional information. Cardiac catheterization generates data on oxygen saturation and Hypertension in diff erent vessels and chambers. Exercise testing assesses functional capacity. A few of the more common ACHDs are discussed below: Bicuspid aortic valve These work well at birth and go undetected. Many eventually develop aortic stenosis (needing valve replacement) ± aortic regurgitation predisposing to IE/SBE ± aortic dilatation/dissection. Intense exercise may accelerate complications, so do yearly echocardiograms on aff ected athletes. 70 Atrial septal defect (ASD) A hole connects the atria. Ostium secundum defects: 80% cases; hole High in the septum; often asymptomatic until adulthood when a LR shunt develops. Shunting depends on the compliance of the ventricles. LV compliance decreases with age (esp. if blood pressure), so augmenting LR shunting; hence dyspnoea/Heart failure, typically aged 4060yrs. Ostium primum defects: associated with AV valve anomalies, eg in Downs syndrome; present in childhood. Signs and symptoms: Chest Pain, palpitations, dyspnoea. Arrhythmias incl. atrial fibrillation; JVP; wide, fi xed split S2; pulmonary systolic fl ow murmur. Pulmonary hypertension may cause pulmonary or tricuspid regurgitation, dyspnoea and haemoptysis. Frequency of migraine. Simple tests: ECG: RBBB with LAD (primum defect) or RAD (secundum defect). CXR: small aortic knuckle, pulmonary plethora, atrial enlargement. Complications: Reversal of left-to-right shunt, ie Eisen men gers complex: initial LR shunt leads to pulmonary hypertension which increases right Heart pressures until they exceed left Heart pressures, hence shunt reversal. This causes cyanosis as deoxygenated Blood enters systemic circulation. Paradoxical emboli eg causing CVAs (veinartery via ASD; rare). Treatment: May close spontaenously. If not, primum defects are usually closed in childhood. Secundum defects should be closed if symptomatic or signs of RV overload. Transcatheter closure is more common than surgical. Ventricular septal defect (VSD) A hole connects the ventricles. Causes: Congenital (prevalence 2: 1000 births); acquired (post-myocardial infarction). Symptoms: May present with severe Heart failure in infancy, or remain asymptomatic and be detected incidentally in later life. Signs: Classically, a harsh pan systolic murmur is heard at the left sternal edge, with a systolic thrill, ± left para sternal heave.",
    "Smaller holes, which are haemodynamically less signifi cant, give louder murmurs. Signs of pulmonary hypertension. Complications: AR, IE/SBE, pulmonary hypertension, Eisenmengers complex (above), Heart failure from volume overload. Tests: ECG: normal, LAD, LVH, RVH. CXR: normal Heart size ± mild pulmonary plethora (small VSD) or cardiomegaly, large pulmonary arteries and marked pulmonary plethora (large VSD). Cardiac catheter: step up in O2 saturation in right ventricle. Treatment: Initially medical as many close spontaneously. Indications for surgical closure: failed medical therapy, symptomatic VSD, shunt 3: 1, SBE/IE. Endovascular closure may be possible. 71 Coarctation of the aorta Congenital narrowing of the descending aorta; usually occurs just distal to the origin of the left subclavian artery. More common in boys. Associations: Bicuspid aortic valve; Turners syndrome. Signs: Radiofemoral delay; weak femoral pulse; blood pressure; scapular bruit; systolic murmur (best heard over the left scapula); cold feet. Complications: Heart failure from High afterload; IE; intracerebral haemorrhage. Tests: computed tomography or magnetic resonance imaging-aortogram; CXR may show rib notching as Blood diverts down intercostal arteries to reach the lower body, causing these vessels to dilate and erode local rib bone. Treatment: Surgery, or balloon dilatation ± stenting. Tetralogy of Fallot See p157. __OOHHCCMM__1100ee. . iinnddbb 115566 0022//0055//22001177 1199: : 0066 157 enicidem ralucsavoidraC Fallots tetralogy: what the non-specialist needs to know Tetralogy of Fallot (TOF) is the most common cyanotic congenital Heart disorder (prevalence: 36 per 10 000). It is also the most common cyanotic Heart defect that survives to adulthood, accounting for 10% of all ACHD. 72 It is believed to be due to abnormalities in separation of the truncus arteriosus into the aorta and pulmonary arteries early in gestation (fi g 3. 52). The tetralogy of features are: 1 Ventricular septal defect (VSD). 2 Pulmonary stenosis. 3 Right ventricular hypertrophy. 4 The aorta overrides the VSD, accepting right Heart Blood. A few patients also have an ASD, which makes up the pentad of Fallot. Presentation: Severity of illness depends greatly on the degree of pulmonary stenosis. Infants may be acyanotic at birth, with a pulmonary stenosis murmur as the only initial fi nding. Gradually (especially after closure of the ductus arteriosus) they become cyanotic due to decreasing fl ow of Blood to the lungs Fig 3. 52 Tetralogy of Fallot. and increasing right-to-left fl ow across the VSD. DurReproduced from Thorne et al. , ing a hypoxic spell, the child becomes restless and Adult Congenital Heart Disease, agitated. Toddlers may squat, which is typical of TOF, 2009, with permission from Oxford University Press. as it increases peripheral vascular resistance, thereby decreasing the degree of right to left shunt. Adult patients are often asymptomatic. In the unoperated adult patient, cyanosis is common, although extreme cyanosis or squatting is uncommon. In repaired patients, late symptoms include exertional dyspnoea, palpitations, clubbing, RV failure, syncope, and even sudden death. Investigations: ECG shows RV hypertrophy with a right bundle-branch block. CXR may be normal, or show the hallmark of TOF, which is the classic bootshaped Heart (fi g 3. 53). Echocardiography can show the anatomy as well as the degree of stenosis. Cardiac computed tomography and cardiac magnetic resonance imaging can give valuable information for planning the surgery. 73 Management: Surgery is usually done before 1yr of age, with closure of the VSD and correction of pulmonary stenosis. Prognosis: Without surgery, mortality rate is 95% by age 20. After repair, 85% of patients survive to 35yrs. Common problems in adulthood include pulmonary regurgitation, causing RV dilatation and failure; RV outfl ow Fig 3. 53 Boot-shaped Heart. tract obstruction; AR; LV dysfunction; and arCourtesy of Dr Edward Singleton. rhythmias.",
    "Send the sample to the laboratory for microscopy, culture/sensitivity. If indicated, ask for ZN stain, and protein-creatinine ratio. Peak expiratory fl ow (PEF) Measured by a maximal forced expiration through a peak fl ow meter. It correlates well with the forced expiratory volume in 1 second (FEV1) is used as an estimate of airway calibre in asthma, but is eff ort-dependent. Pulse oximetry Allows non-invasive assessment of peripheral O2 saturation (SpO2). Useful for monitoring those who are acutely ill or at risk of deterioration. Target oxygen saturations are usually 9498% in a well patient or 8892% in those with certain pre-exisiting lung pathology (eg COPD). Oxygen saturation of 92% in a normally well person is a serious sign and arterial Blood gases (ABGS) should be checked. Causes of erroneous readings: poor perfusion, movement, skin pigmentation, nail varnish, dys haemoglobina emias, and carbon monoxide poisoning. As with any bedside test, be sceptical, and check ABGS, whenever indicated (p188). Arterial Blood gas (ABG) analysis Heparinized Blood is usually taken from the radial or femoral artery (see p771). The brachial artery is used less because of median nerve proximity and it is an end artery. pH, PaO2, PaCO2, HCO 3 are measured using an automated analyser. ABG interpretation See pp1889. Spirometry (See table 4. 1) Measures functional lung volumes. Forced expiratory volume in 1s (FEV1) and forced vital capacity (FVC) are measured from a full forced expiration into a spirometer (Vitalograph); exhalation continues until no more breath can be exhaled. FEV1 is less eff ort-dependent than PEF. The FEV1/FVC ratio gives a Good estimate of the severity of airfl ow obstruction; and helps classify COPD severity. Obstructive defect: (fi g 4. 3) Asthma, bronchiectasis, COPD, cystic fi brosis. Restrictive defect: Fibrosis, sarcoidosis, pneumoconiosis, interstitial pneumonias, connective tis sue diseases, pleural eff usion, obesity, kyphoscoliosis, neuromuscular problems. __OOHHCCMM__1100ee. . iinnddbb 116622 0022//0055//22001177 1199: : 0066 163 enicidem tsehC Table 4. 1 Spirometry results (data source NICE COPD 2010 guidelines) FEV1 FVC FEV1 /FVC ratio Normal 80% predicted 80% predicted 7580% Restrictive 80% predicted 80% predicted 70% normal Obstructive 80% predicted Normal or Low 70% predicted Fig 4. 3 Examples of spirograms. __OOHHCCMM__1100ee. . iinnddbb 116633 0022//0055//22001177 1199: : 0066 164 enicidem tsehC Further investigations in chest medicine Lung function tests PEF, FEV1, FVC (see p162). Total lung capacity (TLC) and residual volume (RV) are useful in distinguishing obstructive and restrictive diseases (see fi g 4. 4). TLC and RV are increased in obstructive airways disease and reduced in restrictive lung diseases and musculoskeletal abnormalities. The gas transfer coeffi cient (KCO) represents the carbon monoxide diff using capacity (DLCO) corrected for alveolar volume. It is calculated by measuring carbon monoxide uptake from a single inspiration in a standard time (usually 10s) and lung volume by helium dilution. Low in emphysema and interstitial lung disease, High in alveolar haemorrhage. 1 Flow volume loop (see fi g 4. 5) measures fl ow at various lung volumes. Characteristic patterns are seen with intra-thoracic airways obstruction (asthma, emphysema) and extra-thoracic airways obstruction (tracheal stenosis). Radiology Chest x-ray: See p722. Ultrasound: Used in diagnosing and guiding drainage of pleural eff usions (particularly loculated eff usions) and empyema. Radionuclide scans: Ventilation/perfusion (V/Q, p738) scans are occasionally used to diagnose pulmonary embolism (physical examination), eg in pregnancy (unmatched perfusion defects are seen). Bone scans are used to diagnose bone metastases. PET scans to assess cancer and infl ammation. Computed tomography: (computed tomography, p730) Used for diagnosing and staging lung cancer, imaging the hila, mediastinum, and pleura, and guiding biopsies. Thin (11.",
    "Most commonly Gram-negative enterobacteria or Staph. aureus. Also Pseudomonas, Klebsiella, Bacteroides, and Clostridia. Aspiration: Those with stroke, myasthenia, bulbar palsies, consciousness (eg postictal or intoxicated), oesophageal disease (achalasia, refl ux), or poor dental hygiene risk aspirating oropharyngeal anaerobes. Immunocompromised patient: Strep. pneumoniae, H. infl uenzae, Staph. aureus, M. catarrhalis, M. pneumoniae, Gram Ωve bacilli and Pneumocystis jirovecii (formerly named P. carinii, pp4001). Other fungi, viruses (CMV, HSV), and mycobacteria. Clinical features Symptoms: Fever, rigors, malaise, anorexia, dyspnoea, cough, purulent sputum, haemoptysis, and pleuritic Pain. Signs: Pyrexia, cyanosis, confusion (can be the only sign in the elderlymay also be hypothermic), tachypnoea, tachycardia, hypotension, signs of consolidation (reduced expansion, dull percussion, tactile vocal fremitus/vocal resonance, bronchial breathing), and a pleural rub. Tests Assess oxygenation: oxygen saturation, p162 (ABGs if SaO2 92% or severe pneumonia) and blood pressure. Blood tests: FBC, UE, LFT, CRP (GPs should consider a point of care CRP to guide antibiotic prescribing where LRTI is suspected, NICE 20144). CXR (fi g 16. 2, p723): lobar or multilobar infi ltrates, cavitation, or pleural eff usion. Sputum for microscopy and culture. Urine: check for Legionella/Pneumococcal urinary antigens. Atypical organism/viral serology (protein-creatinine ratio sputum/BAL, complement fi xation tests acutely, paired serology). Pleural fl uid may be aspirated for culture. Respiratory physicians may consider bronchoscopy and bronchoalveolar lavage if patient is immunocompromised or on ITU. Severity CURB-65 is a simple, validated severity scoring system. 5, 6 1 point for each of: Confusion (abbreviated mental test ≤8) Urea 7mmol/L Respiratory rate ≥30/min blood pressure 90 systolic and/or 60mmHg diastolic) Age ≥65. 01, PO antibiotic/home treatment; 2, hospital therapy; ≥3, severe pneumonia indicates mortality 1540%consider ITU. It may underscore the younguse clinical judgement. Other features increasing the risk of death are: comorbidity; bilateral/multilobar; PaO2 8kPa. Management p816. Antibioticsrefer to your local hospital antibiotic policy. When none exists, consult table 4. 2. If pneumonia not severe and not Vomiting (CURB-65 12) give PO antibiotic; severe (CURB-65 2) give IV. Oxygen: keep PaO2 8. 0 and/or saturation ≥94%. IV fl uids (anorexia, dehydration, shock) and VTE prophylaxis. Analgesia if pleurisy. Consider ITU if shock, hypercapnia, or remains hypoxic. Follow-up: at 6 weeks (±CXR). Complications (See p170. ) Pleural eff usion, empyema, lung abscess, respiratory failure, septicaemia, brain abscess, pericarditis, myocarditis, cholestatic jaundice. Repeat CRP and CXR in patients not improving to look for progression/complications. __OOHHCCMM__1100ee. . iinnddbb 116666 0022//0055//22001177 1199: : 0077 167 enicidem tsehC Table 4. 2 Empirical treatment of pneumonia (check local policy) Clinical Antibiotic (further dosage Organisms setting details: pp3867) Community-acquired Mild not Streptococcus pneumoniae Oral amoxicillin 500mg1g/8h or clarithropreviously Haemophilus infl uenzae mycin 500mg/12h or doxyc ycline 200mg CURB 01 loading then 100mg/day (initially 5-day course) Moderate Streptococcus pneumoniae Oral amoxicillin 500mg1g/8h CURB 2 Haemophilus infl uenzae clarithromycin 500mg/12h or doxyc ycline 200mg loading then 100mg/12h Mycoplasma pneumoniae If IV required: amoxicillin 500mg/8h clarithromycin 500mg/12h (7-day course) Severe As above Co-amoxiclav 1. 2g/8h IV or cephalosporin IV CURB 3 (eg cefuroxime 1. 5g/8h IV) AND clarithromycin 500mg/12h IV (7 days) Add fl ucloxacillin ± rifampicin if Staph suspected; vancomycin (or teicoplanin) if MRSA suspected. Treat for 10d (1421d if Staph, Legionella, or Gram Ωve enteric bacteria suspected) Panton-Valentine Seek urgent help. Consider adding IV Leukocidin-producing linezolid, clindamycin, and rifampicin Staph. aureus (PVL-SA) Atypical Legionella pneumophilia Fluoroquinolone combined with clarithromycin, or rifampicin, if severe.",
    "aureus (PVL-SA) Atypical Legionella pneumophilia Fluoroquinolone combined with clarithromycin, or rifampicin, if severe. See p168 Chlamydophila species Tetracycline Pneumocystis jirovecii High-dose co-trimoxazole (pp4001) Hospital-acquired Gram-negative bacilli Aminoglycoside IV antipseudomonal Pseudomonas penicillin IV or 3rd-generation cephalosporin Anaerobes IV (p387) Aspiration Streptococcus pneumoniae Cephalosporin IV metronidazole IV Anaerobes Neutropenic patients Gram-positive cocci Aminoglycoside IV antipseudomonal peniGram-negative bacilli cillin IV or 3rd-generation cephalosporin IV Fungi (p177) Consider antifungals after 48h Pneumococcal vaccine At-risk groups: All adults ≥ 65yrs old. Chronic Heart, Liver, renal, or lung conditions. Diabetes mellitus not controlled by diet. Immun o sup pression, eg spleen function, AIDS, or on chemotherapy or prednisolone 20mg/d, cochlear implant, occupation risk (eg welders), CSF fl uid leaks. Vaccinate every 5yrs. CI: Pregnancy, lactation, T°, previous anaphylaxis to vaccine or one of its components. __OOHHCCMM__1100ee. . iinnddbb 116677 0022//0055//22001177 1199: : 0077 168 enicidem tsehC Specifi c pneumonias Pneumococcal pneumonia The commonest bacterial pneumonia. Aff ects all ages, but is commoner in the elderly, alcoholics, post-splenectomy, immunosuppressed, and patients with chronic Heart failure or pre-existing lung disease. Clinical features: Fever, pleurisy, herpes labialis. CXR shows lobar consolidation. If mod/severe check for urinary antigen. Treatment: amoxicillin, benzylpenicillin, or cephalosporin. Staphylococcal pneumonia May complicate infl uenza infection or occur in the young, elderly, intravenous drug users, or patients with underlying disease, eg leukaemia, lymphoma, cystic fi brosis (CF). It causes a bilateral cavitating bronchopneumonia. Treatment: fl ucloxacillin ± rifampicin, MRSA: contact lab; consider vancomycin. Klebsiella pneumonia Rare. Occurs in elderly, diabetics, and alcoholics. Causes a cavitating pneumonia, particularly of the upper lobes, often drug resistant. Treatment: cefotaxime or imipenem. Pseudomonas A common pathogen in bronchiectasis and CF. It also causes hospital-acquired infections, particularly on ITU or after surgery. Treatment: antipseudomonal penicillin, ceftazidime, meropenem, or ciprofl oxacin aminoglycoside. Consider dual therapy to minimize resistance. Mycoplasma pneumoniae Occurs in epidemics about every 4yrs. It presents insidiously with fl u-like symptoms (headache, myalgia, arthralgia) followed by a dry cough. CXR: reticular-nodular shadowing or patchy consolidation often of one lower lobe, and worse than signs suggest. Diagnosis: protein-creatinine ratio sputum or serology. Cold agglutinins may cause an autoimmune haemolytic anaemia. Complications: Skin rash (erythema multiforme, fi g 12. 22, p563), StevensJohnson syndrome, meningoe ncephalitis or myelitis; GuillainBarré syndrome. Treatment: Clarithromycin (500mg/12h) or doxycycline (200mg loading then 100mg OD) or a fl uroquinolone (eg ciprofl oxacin or norfl oxacin). Legionella pneumophila Colonizes Water tanks kept at 60°C (eg hotel air-conditioning and hot Water systems) causing outbreaks. Flu-like symptoms (fever, malaise, myalgia) precede a dry cough and dyspnoea. Extra-pulmonary features include anorexia, DV, hepatitis, renal failure, confusion, and coma. CXR shows bi-basal consolidation. Blood tests may show lymphopenia, hyponatraemia, and deranged LFTS. Urinalysis may show haematuria. Diagnosis: Urine antigen/culture. Treatment: fl uoroquinolone for 23wks or clarithromycin (p387). 10% mortality. Chlamydophila pneumoniae The commonest chlamydial infection. Person-to-person spread, biphasic illness: pharyngitis, hoarseness, otitis, followed by pneumonia. Diagnosis: Chlamydophila complement fi xation test, protein-creatinine ratio invasive samples. 7 Treatment: Doxycycline or clarithromycin. Chlamydophila psittaci Causes psittacosis, an ornithosis acquired from infected birds (typically parrots). Symptoms include headache, fever, dry cough, lethargy, arthralgia, anorexia, and DV. Extra-pulmonary features are legion but rare, eg meningo-encephalitis, infective endocarditis, hepatitis, nephritis, rash, splenomegaly. CXR shows patchy consolidation. Diagnosis: Chlamydophila serology. Treatment: doxycycline or clarithromycin. Viral pneumonia Infl uenza commonest (p396 and BOX), but swine fl u (H1N1) is now considered seasonal and covered by the annual fl u vaccine. Others: measles, CMV, varicella zoster. Pneumocystis pneumonia Causes pneumonia in the immunosuppressed (eg HIV). The organism responsible was previously called Pneumocystis carinii, and now called Pneumocystis jirovecii. 8 It presents with a dry cough, exertional dyspnoea, PaO2, fever, bilateral crepitations.",
    "Type I respiratory failure (PaO2 8kPa) is relatively common. Treatment is with High-fl ow (60%) oxygen. Transfer the patient to ITU if hypoxia does not improve with O therapy or PCO rises to 6kPa. Be careful with 2 a 2 O2 in COPD patients; check ABGS frequently, and consider elective ventilation if rising PaCO2 or worsening acidosis. Aim to keep SaO2 at 9498%, PaO2 ≥8kPa. Hypotension May be due to a combination of dehydration and vasodilation due to sepsis. If systolic blood pressure is 90mmHg, give an intravenous fl uid challenge of 250mL colloid/crystalloid over 15min. If blood pressure does not rise, consider a central line and give IV fl uids to maintain the systolic blood pressure 90mmHg. If systolic blood pressure remains 90mmHg despite fl uid therapy, request ITU assessment for inotropic support. Atrial fi brillation (p130. ) Common in the elderly. It usually resolves with treatment of the pneumonia. -blocker or digoxin may be required to slow the ventricular response rate in the short term. Pleural eff usion Infl ammation of the pleura by adjacent pneumonia may cause fl uid exudation into the pleural space. If this accumulates faster than it is reabsorbed, a pleural eff usion develops. If small, it may be of no consequence. If larger and patient symptomatic, or infected (empyema), drainage is required (p192, p766). Empyema Pus in the pleural space. It should be suspected if a patient with a resolving pneumonia develops a recurrent fever. Clinical features: CXR indicates a pleural eff usion. The aspirated pleural fl uid is typically yellow and turbid with a pH 7. 2, glucose, and LDH. The empyema should be drained using a chest drain, inserted under radiological guidance. Adhesions and loculation can make this diffi cult. Lung abscess A cavitating area of localized, suppurative infection within the lung (see fi g 4. 6). Causes: Inadequately treated pneumonia. Aspiration (eg alcoholism, oesopha geal obstruction, bulbar palsy). Bronchial obstruction (tumour, foreign body). Pulmonary infarction. Septic emboli (septicaemia, right Heart endocarditis, IV drug use). Subphrenic or hepatic abscess. Clinical features: Swinging fever; cough; purulent, foul-smelling sputum; pleuritic chest Pain; haemoptysis; malaise; weight loss. Look for: fi nger clubbing; anaemia; crepitations. Empyema develops in 2030%. Tests: Blood: FBC (anaemia, neutrophilia), ESR, CRP, Blood cultures. Sputum microscopy, culture, and cytology. CXR: walled cavity, often with a fl uid level. Consider computed tomography scan to exclude obstruction, and bronchoscopy to obtain diagn ostic specimens. Treatment: Antibiotics as indicated by sensitivities; continue until healed (46 wks). Postural drainage. Repeated aspiration, antibiotic instillation, or surgical excision may be required. Septicaemia May occur as a result of bacterial spread from the lung parenchyma into the bloodstream. This may cause metastatic infection, eg infective endoc arditis, meningitis. Treat with IV antibiotic according to sensitivities. Pericarditis and myocarditis May also complicate pneumonia. Jaundice This is usually cholestatic, and may be due to sepsis or secondary to antibiotic therapy (particularly fl ucloxacillin and co-amoxiclav). __OOHHCCMM__1100ee. . iinnddbb 117700 0022//0055//22001177 1199: : 0077 171 enicidem tsehC Fig 4. 6 PA chest radiograph showing multiple rounded ring lesions of diff ering sizes in the right lower zone, at the right apex, and in the left lower zone. The lesions are largest in the right Lower zone, where they can be seen to contain air-fl uid levels, typical appearance of infection in a pneumatocele (air cyst) or cavitating lesion. A moderate right-sided hydropneumothorax can also be seen, suggesting that one of these lesions may have ruptured into the pleural cavity. The patient also has a right subclavian central venous catheter for the administration of antibiotics.",
    "The patient also has a right subclavian central venous catheter for the administration of antibiotics. The diagnosis in this case was that of multiple pulmonary abscesses in a patient who was an intravenous drug user. Image courtesy of Derby Hospitals NHS Foundation Trust Radiology Department. __OOHHCCMM__1100ee. . iinnddbb 117711 0022//0055//22001177 1199: : 0077 172 enicidem tsehC Bronchiectasis Pathology Chronic infl ammation of the bronchi and bronchioles leading to permanent dilatation and thinning of these airways. 18 Main organisms: H. infl uenzae; Strep. pneumoniae; Staph. aureus; Pseudomonas aeruginosa. Causes Congenital: Cystic fi brosis (CF); Youngs syndrome; primary ciliary dyskinesia; Kartageners syndrome (OHCS p646). Post-infection: Measles; pertussis; bronchiolitis; pneumonia; TB; HIV. Other: Bronchial obstruction (tumour, foreign body); allergic bronchopulmonary aspergillosis (ABPA, p177); hypogammaglobulinaemia; rheumatoid arthritis; ulcerative colitis; idiopathic. Clinical features Symptoms: Persistent cough; copious purulent sputum; intermittent haemoptysis. Signs: Finger clubbing; coarse inspiratory crepitations; wheeze (asthma, COPD, ABPA). Complications: Pneumonia, pleural eff usion; pneumothorax; haemoptysis; cerebral abscess; amyloidosis. Tests Sputum culture. CXR: Cystic shadows, thickened bronchial walls (tramline and ring shadows); see fi g 4. 7. HRCT chest (p164) to assess extent and distribution of disease. Spirometry often shows an obstructive pattern; reversibility should be assessed. Bronchoscopy to locate site of haemoptysis, exclude obstruction and obtain samples for culture. Other tests: Serum immunoglobulins; CF sweat test; Aspergillus precipitins or skin-prick test RAST and total IgE. Management Airway clearance techniques and mucolytics. Chest physiotherapy and devices such as a fl utter valve may aid sputum expectoration and mucus drainage. Antibiotics should be prescribed according to bacterial sensitivities. Patients known to culture Pseudomonas will require either oral ciprofl oxacin or suitable IV antibiotics. If ≥3 exacerbations a year consider long-term antibiotics (may be nebulized). Bronchodilators (eg nebulized salbutamol) may be useful in patients with asthma, COPD, CF, ABPA (p177). Corticosteroids (eg prednisolone) and itraconazole for ABPA. Surgery may be indicated in localized disease or to control severe haemoptysis. Fig 4. 7 PA chest radiograph showing marked abnormal dilatation of the airways throughout the right upper lobe, subtle similar changes throughout the rest of the lung (particulalry periphery of the left upper zone). The fi ne background reticular pattern in the lungs suggests that there may also be some interstitial lung disease present. Image courtesy of Nottingham University Hospitals NHS Trust Radiology Department. __OOHHCCMM__1100ee. . iinnddbb 117722 0022//0055//22001177 1199: : 0077 173 enicidem tsehC Cystic fi brosis (CF) One of the commonest life-threatening autosomal recessive conditions (1: 2000 live births) aff ecting Caucasians. 1: 25 people carry a copy of the faulty gene. All UK babies are screened at birth. Caused by mutations in the CF transmembrane conductance regulator (CFTR) gene on chromosome 7 (1500 mutations have been identifi ed). This is a ClΩ channel, and the defect leads to a combination of defective chloride secretion and increased Sodium absorption across airway epithelium. The changes in the composition of airway surface liquid predispose the lung to chronic pulmonary infections and bronchiectasis. See OHCS (Paediatrics, p162) for more detail. Clinical features Neonate: Failure to thrive; meconium ileus; rectal prolapse. Children and young adults: Respiratory: cough; wheeze; recurrent infections; bronchiectasis; pneumothorax; haemoptysis; respiratory failure; cor pulmonale. Gastrointestinal: pancreatic insuffi ciency (Diabetes mellitus, steatorrhoea); distal intestinal obstruction syndrome (meconium ileus equivalent); gallstones; cirrhosis. Other: male infertility; osteoporosis; arthritis; vasculitis (p556); nasal polyps; sinusitis; and hypertrophic pulmonary osteoarthropathy (HPOA). Signs: cyanosis; fi nger clubbing; bilateral coarse crackles. Diagnosis Sweat test: Sweat Sodium and chloride 60mmol/L; chloride usually Sodium. Genetics: Screening for known common CF mutations should be considered. Faecal elastase is a simple and useful screening test for exocrine pancreatic dysfunction.",
    "Faecal elastase is a simple and useful screening test for exocrine pancreatic dysfunction. Tests Blood: FBC, UE, LFT; clotting; vitamin A, D, E levels; annual glucose tolerance test (p206). Bacteriology: Cough swab, sputum culture. Radiology: CXR; hyperi nfl ation; bronchiectasis. Abdominal ultrasound: Fatty Liver; cirrhosis; chronic pancreatitis; Spirometry: Obstructive defect. Aspergillus serology/skin test (20% develop ABPA, p177). Biochemistry: Faecal fat analysis. Management Management should be multidisciplinary, eg physician, GP, physiotherapist, specialist nurse, and dietician, with attention to psychosocial as well as physical wellbeing. Chest: Physiotherapy (postural drainage, airway clearance techniques). Antibiotics are given for acute infective exacerbations and prophylactically. Chronic Pseudomonas infection is an important predictor of survival. Mucolytics may be useful (eg DNase, ie Dornase alfa, 2. 5mg daily nebulized, or nebulized hypertonic saline). Bronchodilators. Annual CXR surveillance is recommended. Gastrointestinal: Malabsorption, GORD, distal obstruction syndrome. Pancreatic enzyme replacement; fat-soluble vitamin suppl ements (A, D, E, potassium); ursodeoxycholic acid for impaired Liver function; cirrhosis may require Liver transplantation. Other: Treatment of CF-related Diabetes (screen annually with oral glucose tolerance test from 12yrs); screening/treatment of osteoporosis (DEXA bone scanning); arthritis, sinusitis, and vasculitis; fertility and genetic counselling. Advanced lung disease: Oxygen, diuretics (cor pulmonale); noninvasive ventilation; lung or Heart/lung transplantation (post-transplant survival 5 years). Prognosis: Median survival is now 41yrs in the UK, although a baby born today would expect to live longer. Mutation-specifi c therapies for cystic fi brosis Ivacaftor and lumacaftor target the CFTR Protein. Ivacaftor, a CFTR potentiator, targets gating defects in disease causing CFTR mutations including G551D. Ivacaftor increases the open probability of CFTR channels and has been shown to improve clinical outcomes (lung function, weight, lung disease stability) in CF patients 6 years old. 19 Lumacaftor is a CFTR corrector, and has been shown to correct F508 del CFTR misprocessing and increase the amount of cell surfacelocalized Protein. Ivacaftor and lumacaftor combination therapy, for patients with F508 del, have shown improved lung function and reduced pulmonary exacerations. 20 Gene therapy (transfer of CFTR gene using liposome or adenovirus vectors): phase 2b studies show modest but signifi cant improvement in FEV1 in those receiving gene therapy. 21 Further work into vectors for gene transfer is ongoing. __OOHHCCMM__1100ee. . iinnddbb 117733 0022//0055//22001177 1199: : 0077 174 enicidem tsehC Lung tumours Carcinoma of the bronchus Second most common cancer in the UK, accounting for 13% of all new cancer cases and 27% of cancer deaths (40 000 cases/yr in UK). 22 Incidence is increasing in women. Only 5% cured. Risk factors: Cigarette smoking (causes 90% of lung calcium). Others: passive smoking, asbestos, chromium, arsenic, iron oxides, and radiation (radon gas). Histology: Clinically the most important division is between small cell (SCLC) and non-small cell (NSCLC). NSCLC: Squamous (35%); adenocarcinoma (27%), large cell (10%); adenocarcinoma in situ (rare, 1%). Small cell (oat cell) (20%): Arise from endocrine cells (Kulchitsky cells), often secreting polypeptide hormones resulting in paraneoplastic syndromes (eg production of ACTH, Cushings syndrome). Most (70%) SCLC are disseminated at presentation. Symptoms: Cough (80%); haemoptysis (70%); dyspnoea (60%); chest Pain (40%); recurrent or slowly resolving pneumonia; lethargy, anorexia; weight loss. Signs: Cachexia; anaemia; clubbing; HPOA (hypertrophic pulmonary osteoarthropathy, causing wrist Pain); supraclavicular or axillary nodes. Chest signs: none, or consolidation; coll apse; pleural eff usion. Metastases: bone tenderness; hepatomegaly; confusion; fi ts; focal CNS signs; cerebellar syndrome; proximal myopathy; peripheral neuropathy. Complications: Local: recurrent laryngeal nerve palsy; phrenic nerve palsy; SVC obstruction; Horners syndrome (Pancoasts tumour); rib erosion; pericarditis; atrial fibrillation. Metastatic: brain; bone (bone Pain, anaemia, Ca2); Liver; adrenals (Addisons). Nonmetastatic neurological: confusion; fi ts; cerebellar syndrome; proximal myopathy; neuropathy; polymyositis; LambertEaton syndrome (p512). See table 4. 3.",
    "Nonmetastatic neurological: confusion; fi ts; cerebellar syndrome; proximal myopathy; neuropathy; polymyositis; LambertEaton syndrome (p512). See table 4. 3. Tests: CXR: peripheral nodule (fi g 4. 8); hilar enlargement; consolidation; lung collapse; pleu ral eff usion; bony secondaries. Cytology: sputum and pleural fl uid (send at least 20mL). Fine needle aspiration or biopsy (peripheral lesions/lymph nodes). computed tomography to stage the tumour (p176) and guide bronchoscopy. Broncho scopy: to give histology and assess operability, ± endobronchial ultrasound for assessment and biopsy. 18F-deoxyglucose PET or PET/computed tomography EBUS scan to help in staging. Radionuclide bone scan: if suspected metastases. Lung function tests: help assess suitability for lobectomy. Other lung tumours Bronchial adenoma: Rare, slow-growing. 90% are carcinoid tumours; 10% cylindromas. : surgery. Hamartoma: Rare, benign; computed tomography: lobulated mass ± fl ecks of calcifi cation; ? excise to exclude malignancy. Malignant mesothelioma A tumour of mesothelial cells that usually occurs in the pleura, and rarely in the peritoneum or other organs. It is associated with occupational exposure to asbestos but the relationship is complex. 23 90% report previous exposure to asbestos, but only 20% of patients have pulmonary asbestosis. The latent period between exposure and development of the tumour may be up to 45yrs. Compensation is often available. Clinical features: Chest Pain, dyspnoea, weight loss, fi nger clubbing, recurrent pleural eff usions. Signs of metastases: lymphadenopathy, hepatomegaly, bone Pain/tenderness, abdominal Pain/obstr uction (peritoneal malignant mesothelioma). Tests: CXR/computed tomography: pleural thickening/eff usion. Bloody pleural fl uid. Diagnosis: Made on histology, usually following a thoracoscopy. Often the diagnosis is only made post-mortem. Management: Pemetrexed cisplatin chemotherapy can improve survival. 24 Surgery is hard to evaluate (few randomized trials). Radiotherapy is controversial. Pleurodesis and indwelling intra-pleural drain may help. Prognosis: Poor (especially without pemetrexed, eg 2yrs). 650 deaths/yr in UK. __OOHHCCMM__1100ee. . iinnddbb 117744 0022//0055//22001177 1199: : 0077 175 enicidem tsehC Diff erential diagnosis of nodule in the lung on a CXR Malignancy (1° or 2°) Arterio-venous malformation Abscesses (p170) Encysted eff usion (fl uid, Blood, pus) Granuloma Cyst Carcinoid tumour Foreign body Pulmonary hamartoma Skin tumour (eg seborrhoeic wart). Fig 4. 8 A wedge-shaped density in the right middle lobe. Also note a coin lesion at the right costophrenic angle. Right hilar lymphadenopathy. Courtesy of Janet E. Jeddry, Yale Medical School. Table 4. 3 Non-metastatic extrapulmonary manifestations of bronchial cancer System Manifestations Endocrine Ectopic secretion; ACTH (Cushings), ADH (dilutional hyponatraemia), parathyroid hormone (hypercalcaemia), HCG (gynaecomastia) Neurological Cerebellar degeneration, myopathy, polyneuropathy, myasthenic syndrome Vascular Thrombophlebitis migrans (p562), anaemia, DIC Cutaneous Dermatomyositis, herpes zoster, acanthosis nigricans Skeletal Clubbing, HPOA __OOHHCCMM__1100ee. . iinnddbb 117755 0022//0055//22001177 1199: : 0077 176 enicidem tsehC Lung tumours: staging and treatment Assessing the extent of tumour spread (staging) is vital to determining the best course of treatment and also prognosis. All patients who may be suitable for surgery with curative intent should be off ered PET-computed tomography before treatment. 25 Some patients may undergo endobronchial ultrasound-guided transbronchial needle aspirations for mediastinal masses. TNM staging classifi cation for non-small cell lung cancer is shown in table 4. 4. You do not need to memorize this! Table 4. 4 TNM staging for non-small cell lung cancer Primary tumour (T) transplant Malignant cells in bronchial secretions, no other evidence of tumour TIS Carcinoma in situ T0 None evident T1 ≤ 3cm, in lobar or more distal airway T2 3cm and 2cm distal to carina or any size if pleural involvement or obstructive pneumonitis extending to hilum, but not all the lung T3 Involves the chest wall, diaphragm, mediastinal pleura, pericardium, or 2cm from, but not at, carina.",
    "Early chest computed tomography and serial serum measurements of galactomannan (an Aspergillus antigen) may be helpful. Diagnosis may only be made at lung biopsy or autopsy. Treatment: voriconazole is superior to IV amphotericin. 28 Alternatives: IV miconazole or ketoconazole (less eff ective). Prognosis: 30% mortality. 5 Extrinsic allergic alveolitis (essential amino acids): See p198. Other fungal infections Candida and Cryptococcus may cause pneumonia in the immunosuppressed (see p408). Fig 4. 9 Aspergillosis. __OOHHCCMM__1100ee. . iinnddbb 117777 0022//0055//22001177 1199: : 0077 178 enicidem tsehC Asthma Asthma aff ects 58% of the population. It is characterized by recurrent episodes of dyspnoea, cough, and wheeze caused by reversible airways obstruction. Three factors contribute to airway narrowing: bronchial muscle contraction, triggered by a variety of stimuli; mucosal Edema/infl ammation, caused by mast cell and basophil degranulation resulting in the release of infl ammatory mediators; and increased mucus production. Symptoms Intermittent dyspnoea, wheeze, cough (often nocturnal), and sputum (see table 4. 5). Precipitants: Cold air, exercise, emotion, allergens (house dust mite, pollen, fur), infection, smoking and passive smoking, 29 pollution, NSAIDS, -blockers. Diurnal variation Symptoms or peak fl ow may vary over the day. Marked morning dipping of peak fl ow is common and can tip the balance into a serious attack, despite having normal peak fl ow (fi g 4. 12) at other times. Exercise: Quantify the exercise tolerance. Disturbed sleep: Quantify as nights per week (a sign of severe asthma). Acid refl ux: 4060% of those with asthma have refl ux; treating it improves spirometry, but not necessarily symptoms. 3 0 Other atopic disease: Eczema, hay fever, allergy, or family history? The home (especially the bedroom): Pets? Carpet? Feather pillows or duvet? Floor cushions and other soft furnishings? Job: If symptoms remit at weekends or holidays, work may provide the trigger (15% of cases are work-relatedmore for paint sprayers, food processors, welders, and animal handlers). 31 Ask the patient to measure their peak fl ow at intervals at work and at home (at the same time of day) to confi rm this (see fi g 4. 13). Days per week off work or school. Signs Tachypnoea; audible wheeze; hyperinfl ated chest; hyper-resonant percussion note; air entry; widespread, polyphonic wheeze. Severe attack: Inability to complete sentences; pulse 110bpm; respiratory rate 25/min; PEF 3350% predicted. Life-threatening attack: Silent chest; confusion; exhaustion; cyanosis (PaO2 8kPa but PaCO2 4. 66. 0, SpO2 92%); bradyc ardia; PEF 33% predicted. Near fatal: PaCO2. Tests Initial diagnosis: See fi gs 4. 10, 4. 11. Acute attack: PEF, sputum culture, FBC, UE, CRP, Blood cultures. ABG analysis usually shows a normal or slightly PaO2 but PaCO2 (hyperventilation). If PaO2 is normal but the patient is hyperventilating, watch carefully and repeat the ABG a little later. If PaCO2 is normal or raised, transfer to High-dependency unit or ITU for ventilation, as this signifi es failing respiratory eff ort. CXR (to exclude infection or pneumothorax). Chronic asthma: PEF monitoring (p162): a diurnal variation of 20% on ≥3d a wk for 2wks. Spirometry: obstructive defect (FEV1/FVC, RV p162); usually ≥15% improvement in FEV1 following 2 agonists or steroid trial. CXR: hyperinfl ation. Skin-prick tests may help to identify allergens. Histamine or methacholine challenge. Aspergillus serology. Diff erential diagnosis Pulmonary oedema (cardiac asthma); COPD (may co-exist); large airway obstruction (eg foreign body, tumour); SVC obstruction (wheeze/dyspnoea not episodic); pneumothorax; physical examination; bronchiectasis; obliterative bronchiolitis (suspect in elderly). Treatment Chronic asthma (p182). Emergency treatment (p810). Associated diseases Acid refl ux; polyarteritis nodosa (PAN, p556); ChurgStrauss syndrome (p696); ABPA (p177).",
    "Emergency treatment (p810). Associated diseases Acid refl ux; polyarteritis nodosa (PAN, p556); ChurgStrauss syndrome (p696); ABPA (p177). Natural history Most childhood asthmatics (see OHCS p164) either grow out of asthma in adolescence or suff er much less as adults. A signifi cant number of people develop chronic asthma late in life. Mortality 900 asthma deaths in the UK in 2012, 50% were 65yrs old. __OOHHCCMM__1100ee. . iinnddbb 117788 0022//0055//22001177 1199: : 0077 179 enicidem tsehC Table 4. 5 Clinical features which increase or decrease probability of asthma in adults. Increase probability of asthma Lower probability of asthma Wheeze, SOB, chest tightness Prominent dizziness, lightheadedness, tingling Diurnal variation Chronic productive cough with no wheeze Response to exercise, allergen, cold air Normal examination when symptomatic Symptoms after aspirin or -blocker Change in voice History of atopy Symptoms with colds only Family history atopy/asthma Signifi cant smoking history (20 pack year) Widespread wheeze heard on auscultation Cardiac disease Unexplained Low FEV1 or PEF Normal PEF when symptomatic Unexplained peripheral Blood eosinophilia (Data from __OOHHCCMM__1100ee. . iinnddbb 117799 0022//0055//22001177 1199: : 0077 180 enicidem tsehC Suspected asthma in children High probability Intermediate Low probability probability Trial of asthma Ω Consider referral Consider lung functreatment tion tests/atopy Investigate/treat other cause If successful, continue minimum eff ective dose. If no response to If unsuccessful, assess treatment, consider inhaler technique/ further investigation or compliance onward referral If no further improvement, consider onward referral Fig 4. 10 BTS/SIGN British guideline on the management of asthma in children. Data from Fig 1, p21: Suspected asthma in adults Clinical investigation (spirometry or peak expiratory fl ow if spirometry not available) High probability Intermediate Low probability probability Trial of asthma FEV1 /FVC FEV1 /FVC Investigate or treatment 0. 7 0. 7 treat other cause If successful, continue Consider referral/ minimum eff ective dose. treat other cause If unsuccessful, assess inhaler technique/ compliance If no response to treatment, consider further investigation or If no further improvement, onward referral consider onward referral Fig 4. 11 BTS/SIGN British guideline on the management of asthma in adults. Data from Fig 2, p25: __OOHHCCMM__1100ee. . iinnddbb 118800 0022//0055//22001177 1199: : 0077 181 enicidem tsehC Fig 4. 12 Normal peak expiratory fl ow (PEF). Data from Nunn, AJ, Gregg, I. New regression equations for predicting peak expiratory fl ow in adults. BMJ 1989; 298: 106870. Fig 4. 13 Examples of serial peak fl ow charts. __OOHHCCMM__1100ee. . iinnddbb 118811 0022//0055//22001177 1199: : 0077 182 enicidem tsehC Management of chronic asthma Lifestyle Help to quit smoking (p93). Avoid precipitants. Weight loss if overweight. Check inhaler technique. Teach use of a peak fl ow meter to monitor PEF twice a day. Educate to enable self-management by altering their medication in the light of symptoms or PEF. Give specifi c advice about what to do in an emergency; provide a written action plan. Consider teaching relaxed breathing to avoid dysfunctional breathing 32 (Papworth method). 3 British Thoracic Society guidelines (BTS33) Start at the step most appropriate to severity; moving up if needed, or down if control is Good for 3 months. Rescue courses of prednisolone may be used at any time. For drug examples see table 4. 6. Step 1: Occasional short-acting inhaled 2-agonist as required for symptom relief. If used more than once daily, or night-time symptoms, go to Step 2. Step 2: Add standard-dose inhaled steroid, eg beclometasone 200800mcg/day, or start at the dose appropriate for disease severity, and titrate as required. Step 3: Add long-acting 2-agonist (eg salmeterol 50mcg/12h by inhaler). If benefi tbut still inadequate controlcontinue and dose of beclometasone to 800mcg/ day.",
    "If benefi tbut still inadequate controlcontinue and dose of beclometasone to 800mcg/ day. If no eff ect then stop LABA and dose of beclometasone to 800mcg/day. Leukotriene receptor antagonist or oral theophylline may be tried. Step 4: Consider trials of: beclometasone up to 2000mcg/day; modifi ed-release oral theophylline; modifi ed-release oral 2-agonist tablets; oral leukotriene receptor antagonist, in conjunction with previous therapy. Step 5: Add regular oral prednisolone (1 dose daily, at the lowest possible dose). Continue with High-dose inhaled steroids. Refer for specialist input. Drugs 2-adrenoceptor agonists: Relax bronchial smooth muscle (CAMP), acting within minutes. Salbutamol is best given by inhalation (aerosol, powder, nebulizer), but may also be given PO or IV. SE: tachyarrhythmias, potassium, tremor, anxiety. Long-acting inhaled 2-agonist (eg salmeterol, formoterol) can help nocturnal symptoms and reduce morning dips. They may be an alternative to steroid dose when symptoms are uncontrolled; doubts remain over whether they are associated with an increase in adverse events. 34 SE: as salbutamol, paradoxical bronchospasm. 35 Corticosteroids: Best inhaled to minimize systemic eff ects, eg beclometasone via spacer (or powder), but may be given PO or IV. They act over days to bronchial mucosal infl ammation. Rinse mouth after inhaled steroids to prevent oral candidiasis. Oral steroids are used acutely (High-dose, short courses, eg prednisolone 40mg/24h PO for 7d) and longer term in lower dose (eg 510mg/24h) if control is not optimal on inhalers. Warn about SEs: p377. Aminophylline: (Metabolized to theophylline) acts by inhibiting phospho diesterase, thus bronchoconstriction by CAMP levels. Try as prophylaxis, at night, PO, to prevent morning dipping. Stick with one brand name (bioavailability variable). Also useful as an adjunct if inhaled therapy is inadequate. In acute severe asthma, it may be given IVI. It has a narrow therapeutic ratio, causing arrhythmias, GI upset, and fi ts in the toxic range. Check theophylline levels (p756), and do ECG monitoring and check plasma levels after 24h if IV therapy is used. Anticholinergics: (Eg ipratropium, tiotropium. ) May muscle spasm synergistically with 2-agonists but are not recommended in current guidelines for chronic asthma. They may be of more benefi t in COPD. Cromoglicate (Mast cell stabilizer. ) May be used as prophylaxis in mild and exerciseinduced asthma (always inhaled), especially in children. It may precipitate asthma. Leukotriene receptor antagonists: (Eg oral montelukast, zafi rlukast. ) Block the effects of cysteinyl leukotrienes in the airways by antagonizing the CystLT1 receptor. Anti-IgE monoclonal antibody: Omalizumab 36 may be of use in highly selected patients with persistent allergic asthma. Given as a subcutaneous injection every 24 wks depending on dose. Specialists prescribe only. 3 Integrated breathing and relaxation training (Papworth method) is psychological and physical: patients learn to drop their shoulders, relax their abdomen, and breathe calmly and appropriately. __OOHHCCMM__1100ee. . iinnddbb 118822 0022//0055//22001177 1199: : 0077 183 enicidem tsehC Table 4. 6 Adult doses of common inhaled drugs used in bronchoconstriction Inhaled Inhaled Nebulized aerosol powder (supervised) Salbutamol Dose example: 100200mcg/6h 200400mcg/6h 2. 55mg/6h Airomir is a CFC-free example of a breath-actuated inhaler Terbutaline Single dose 500mcg 2. 5mg/mL Recommended regimen 500mcg/6h 510mg/612h Salmeterol Dose/puff 25mcg 50mcg Recommended regimen 50100mcg/12h 50100mcg/12h Tiotropium bromide (COPD) Dose/puff 2. 5mcg 9mcg Recommended regimen 25mcg daily 18mcg daily Steroids (Clenil Modulitebeclometasone; Pulmicortbudesonide; Flixotidefl uticasone) Fluticasone (Flixotide) Doses available/puff 50, 100, 250, As for aerosol 250mcg/mL 500mcg Recommended regimen 100250mcg/12h 100250mcg/12h 0. 52mg/12h max 1mg/12h Clenil Modulite Doses available/puff 50 100mcg 250mcg Recommended regimen 200mcg/12h then 400mcg/12h then 1000mcg/12h Available as a Turbohaler; Autohalers are an alternative (breath-actuated) and dont need breathing coordination, eg Airomir (salbutamol) and Qvar (beclometasone). Accuhalers deliver dry powders (eg Flixotide, Serevent).",
    "Accuhalers deliver dry powders (eg Flixotide, Serevent). Systemic absorption (via the throat) is less if inhalation is through a large-volume device, eg Volumatic or AeroChamber Plus devices. The latter is more compact. Static charge on some devices reduces dose delivery, so wash in Water before dose; leave to dry (dont rub). Its pointless to squirt many puff s into a device: it is best to repeat single doses, and be sure to inhale as soon as the drug is in the spacer. SE: local (oral) candidiasis (p377); rate of cataract if lifetime dose ≥2g beclometasone. 37 Prescribe beclometasone by brand name, and state that a CFC-free inhaler should be dispensed. This is because, dose for dose, Qvar is twice as potent as the other available CFC-free brand (Clenil Modulite). Any dose ≥250mcg signifi cant steroid absorption: carry a steroid card; this recommendation is being widened, and lower doses (beclometasone) are now said to merit a steroid card (manufacturers information). __OOHHCCMM__1100ee. . iinnddbb 118833 0022//0055//22001177 1199: : 0077 184 enicidem tsehC Chronic obstructive pulmonary disease (COPD) Defi nitions COPD is a common progressive disorder characterized by airway obstruction (FEV1 80% predicted; FEV1/FVC 0. 7; see p162 and table 4. 5) with little or no reversibility. It includes chronic bronchitis and emphysema. Usually patients have either COPD or asthma, not both: COPD is favoured by: age of onset 35yrs smoking (passive or active) or pollution related38 chronic dyspnoea sputum production minimal diurnal or day-to-day FEV1 variati on. Chronic bronchitis is defi ned clinically as cough, sputum production on most days for 3 months of 2 successive yrs. Symptoms improve if they stop smoking. There is no excess mortality if lung function is normal. Emphysema is defi ned histologically as enlarged air spaces distal to terminal bronchioles, with destruction of alveolar walls but often visualized on computed tomography. Prevalence 1020% of the over-40s; 2. 5106 deaths/yr worldwide. 39 Pink puff ers and blue bloaters A traditional division but likely ends of a spectrum. Pink puffers: Have alveolar ventilation, a near normal PaO2 and a normal or Low PaCO2. They are breathless but are not cyanosed. They may progress to type I respiratory failure (p188). Blue bloaters: Have alveolar ventilation, with a Low PaO2 and a High PaCO2. They are cyanosed but not breathless and may go on to develop cor pulmonale. Their respiratory centres are relatively insensitive to CO2 and they rely on hypoxic drive to maintain respiratory eff ort (p188)supplemental oxygen should be given with care. Symptoms Cough; sputum; dyspnoea; wheeze. Signs Tachypnoea; use of accessory muscles of respiration; hyperinfl ation; cricosternal distance (3cm); expansion; resonant or hyperresonant percussion note; quiet breath sounds (eg over bullae); wheeze; cyanosis; cor pulmonale. Complications Acute exacerbations ± infection; polycythaemia; respiratory failure; cor pulmonale (oedema; JVP); pneumothorax (ruptured bullae); lung carcinoma. Tests FBC: PCV. CXR: Hyperinfl ation; fl at hemidiaphragms; large central pulmonary arteries; peripheral vascular markings; bullae. computed tomography: Bronchial wall thickening; scarring; air space enlargement. ECG: Right atrial and ventricular hypert rophy (cor pulmonale). ABG: PaO2 ± hypercapnia. Spirometry (p162, p165): obstructive air trapping (FEV1 80% of predicted, FEV1: FVC ratio 70%, TLC, RV, DLCO in emphysemasee p160). Learn how to do spirometry from an experienced person: ensure maximal expiration of the full breath (it takes 4s; its not a quick puff out). Treatment Chronic stable: see BOX and fi g 4. 14; Emergency : p812. Smoking cessation advice with cordial vigour (p93). Encourage exercise: body mass index is often Low; diet advice ± supplements 40 may help (p584). Mucolytics (BNF 3. 7) may help chronic productive cough (NICE).",
    "Mucolytics (BNF 3. 7) may help chronic productive cough (NICE). 41 Disabilities may cause serious, treatable depression; screen for this (p15). Respiratory failure: p188. Oedema: diuretics. Flu and pneumococcal vaccinations: p167 and p396. Long-term O2 therapy (LTOT): An MRC trial showed that if PaO2 was maintained ≥8. 0kPa for 15h a day, 3yr survival improved by 50%. UK NICE guidelines suggest LTOT should be given for: 1 Clinically stable non-smokers with PaO2 7. 3kPadespite maximal . These values should be stable on two occasions 3wks apart. 2 If PaO2 7. 38. 0 and pulmonary hypertension (eg RVH; loud S2), or polycythaemia, or peripheral oedema, or nocturnal hypoxia. 3 O2 can also be prescribed for terminally ill patients. Severity assessment in COPD Severity assessment has implications for therapy and prognosis. The BODE index (Body mass index, airfl ow Obstruction, Dyspnoea and Exercise capacity) helps predict outcome and number and severity of exacerbations. The Global Initiative for COPD (GOLD) categorizes severity of COPD into four stages (mild, moderate, severe, and very severe) based on post-bronchodilator FEV1 % predicted, but it is not useful for predicting total mortality for 3 years of follow-up and onwards. 42 __OOHHCCMM__1100ee. . iinnddbb 118844 0022//0055//22001177 1199: : 0077 185 enicidem tsehC British Thoracic Society (BTS)/NICE COPD guidelines More advanced COPD Management of COPD Initiate short-acting 2 -antagonist (SABA)/ short-acting muscarinic antagonist (SAMA) FEV1 50% FEV1 50% Long-acting Long-acting muscarinic LABA plus inhaled 2 -antagonist (LABA) antagonist (LAMA), 4 corticosteroid (ICS) in combined inhaler LABA plus inhaled LAMA plus LABA/ICS corticosteroid (ICS) combination inhaler Fig 4. 14 Management of COPD in primary and secondary care. Tiotropium (LAMA) is more eff ective than salmeterol in preventing exacerbations for patients with moderate-to-very-severe COPD. 43 National Institute for Health and Clinical Excellence 2010. CG101 Chronic obstructive pulmonary disease in over 16s: diagnosis and management. Available from. NICE guidance is prepared for the National Health Service in England. All NICE guidance is subject to regular review and may be updated or withdrawn. Pulmonary rehabilitation is greatly valued by patients. Consider LTOT if PaO2 7. 3kPa (see Long-term O2 therapy, earlier in topic OPPOSITE). Surgery may be appropriate in selected patients, eg recurrent pneumothoraces; isolated bullous disease. Lung volume reduction/endobronchial valve/transplant. NIV may be appropriate if hypercapnic on LTOT. NB: air travel is risky if FEV1 50% or PaO2 6. 7kPa on air. Consider palliative care input. Indications for specialist referral Uncertain diagnosis, or suspected severe COPD, or a rapid decline in FEV1. Onset of cor pulmonale. Bullous lung disease (to assess for surgery). Assessment for oral corticosteroids, nebulizer therapy, or LTOT. 10 pack-years smoking ( the number of packs/day years of smoking) or COPD in patient 40yrs (eg is the cause 1-antitrypsin defi ciency? p290). Symptoms disproportionate to lung function tests. Frequent infections (to exclude bronchiectasis). 4 Cochrane meta-analyses (2007) of trials (including TORCH) favour steroids LABA (long-acting -agonist) vs either alone. LABA alone may exacerbation rates, but no excess hospitalizations or mortality; steroid inhalers alone are associated with mortality (by 33%) compared with steroids LABA. 44 Steroid inhalers may risk of pneumonia, but when combined with LABA, advantages outweigh disadvantages. __OOHHCCMM__1100ee. . iinnddbb 118855 0022//0055//22001177 1199: : 0077 186 enicidem tsehC Acute respiratory distress syndrome (ARDS) ARDS, or acute lung injury, may be caused by direct lung injury or occur secondary to severe systemic illness. Lung damage and release of infl ammatory mediators cause increased capillary permeability and non-cardiogenic pulmonary oedema, often before mealscompanied by multiorgan failure. Causes Pulmonary: Pneumonia; gastric aspiration; inhalation; injury; vasculitis (p556); contusion.",
    "Causes Pulmonary: Pneumonia; gastric aspiration; inhalation; injury; vasculitis (p556); contusion. Other: Shock; septicaemia; haemorrhage; multiple transfusions; DIC (p352); pancreatitis; acute Liver failure; trauma; head injury; malaria; fat embolism; burns; obstetric events (eclampsia; amniotic fl uid embolus); drugs/toxins (aspirin, heroin, paraquat). Clinical features Cyanosis; tachypnoea; tachycardia; peripheral vasodilation; bilateral fi ne inspiratory crackles. Investigations FBC, UE, LFT, amylase, clotting, CRP, Blood cultures, ABG. CXR shows bilateral pulmonary infi ltrates. Pulmonary artery catheter to measure pulmonary capillary wedge Hypertension (PCWP). Diagnostic criteria One consensus requires these four to exist: 45 1 Acute onset. 2 CXR: bilateral infi ltrates (fi g 4. 15). 3 PCWP 19mmHg or a lack of clinical congestive Heart failure. 4 Refractory hypoxaemia with PaO2: FiO2 200 for ARDS. Others include total thoracic compliance 30mL/cmH2O. Management Admit to ITU; give supportive therapy; treat the underl ying cause. Respiratory support: In early ARDS, continuous positive airway Hypertension (CPAP) with 4060% oxygen may be adequate to maintain oxygenation. But most patients need mechanical ventilation. Indications for ventilation: PaO2: 8. 3kPa despite 60% O2; PaCO2: 6kPa. The large tidal volumes (1015mL/kg) produced by conventional ventilation plus reduced lung compliance in ARDS may lead to High peak airway pressures ± pneumothorax. A Low-tidal-volume, Hypertension-limited approach, with either Low or moderate High positive end-expiratory Hypertension (PEEP), improves outcome. Circulatory support: Invasive haemodynamic monitoring with an arterial line and SwanGanz catheter aids the diagnosis and may be helpful in monitoring PCWP and cardiac output. A conservative fl uid management approach improves outcome. Maintain cardiac output and O2 delivery with inotropes (eg dobutamine 2. 510mcg/ kg/min IVI), vasodilators, and Blood transfusion. Consider treating pulmonary hypertension with Low-dose (20120 parts per million) nitric oxide, a pulmonary vasodilator. Haemo fi ltration may be needed in renal failure and to achieve a negative fl uid balance. 46, 49 Sepsis: Identify organism(s) and treat. If septic, but no organisms cultured, use empirical broad-spectrum antibiotics (p167). Avoid nephrotoxic antibiotics. Other: Nutritional support: enteral is best: p584 p586, with High-fat, antioxidant formulations. Steroids protect those at risk of fat embolization and with pneumocystosis and may improve outcome in subacute ARDS. Their role in established ARDS is controversial. 50, 51 Prognosis Overall mortality is 5075%. Prognosis varies with age of patient, cause (pneumonia 86%, trauma 38%), and number of organs involved (three organs involved for 1wk is invariably fatal). Risk factors for ARDS Sepsis Massive transfusion Hypovolaemic shock Burns (p846) Trauma Smoke inhalation (p847) Pneumonia Near drowning Diabetic ketoacidosis Acute pancreatitis Gastric aspiration DIC (p352) Pregnancy Head injury Eclampsia ICP Amniotic fl uid embolus Fat embolus Drugs/toxins Heart/lung bypass Paraquat, heroin, aspirin Tumour lysis syndrome (p529) Pulmonary contusion Malaria. __OOHHCCMM__1100ee. . iinnddbb 118866 0022//0055//22001177 1199: : 0077 187 enicidem tsehC Fig 4. 15 Supine chest radiograph showing air-space shadowing in a perihilar distribution spreading into the peripheries. This appearance can also be seen with infection and cardiogenic pulmonary oedema, but clues from the history, the Heart size, and lack of pleural eff usions can suggest ARDS over the latter. Remember though that this is a supine projectionthe patient is lying fl at with the X-ray beam APcausing the cardiac shadow to be artifi cially enlarged and pleural effusions to level out on the posterior chest wall so they will not obscure the costophrenic angles unless very large. Image courtesy of Nottingham University Hospitals NHS Trust Radiology Department. __OOHHCCMM__1100ee. . iinnddbb 118877 0022//0055//22001177 1199: : 0077 188 enicidem tsehC Respiratory failure Respiratory failure occurs when gas exchange is inadequate, resulting in hypoxia. It is defi ned as a PaO2 8kPa and subdivided into two types according to PaCO2 level.",
    "It is defi ned as a PaO2 8kPa and subdivided into two types according to PaCO2 level. Type I respiratory failure Defi ned as hypoxia (PaO2 8kPa) with a normal or Low PaCO2. It is caused primarily by ventilation/perfusion (V/Q) mismatch, hypoventilation, abnormal diff usion, right to left cardiac shunts. Examples of V/Q mismatch: Pneumonia. Pulmonary oedema. physical examination. Asthma. Emphysema. Pulmonary fi brosis. ARDS (p186). Type II respiratory failure Defi ned as hypoxia (PaO2 8kPa) with hypercapnia (PaCO2 6. 0kPa). This is caused by alveolar hypoventilation, with or without V/Q mismatch. Causes include: Pulmonary disease: Asthma, COPD, pneumonia, end-stage pulmonary fi brosis, obstructive sleep apnoea (OSA, p194). Reduced respiratory drive: Sedative drugs, CNS tumour or trauma. Neuromuscular disease: Cervical cord lesion, diaphragmatic paralysis, poliomyelitis, myasthenia gravis, GuillainBarré syndrome. Thoracic wall disease: Flail chest, kyphoscoliosis. Clinical features are those of the underlying cause together with symptoms and signs of hypoxia, with or without hypercapnia. Hypoxia: Dyspnoea; restlessness; agitation; confusion; central cyanosis. If longstanding hypoxia: polycythaemia; pulmonary hypertension; cor pulmonale. Hypercapnia: Headache; peripheral vasodilation; tachycardia; bounding pulse; tremor/fl ap; papilloedema; confusion; drowsiness; coma. Investigations are aimed at determining the underlying cause: Blood tests: FBC, UE, CRP, ABG. See table 4. 7. Radiology: CXR. Microbiology: sputum and Blood cultures (if febrile). Spirometry (COPD, neuromuscular disease, GuillainBarré syndrome). Management Depends on the cause: Type I respiratory failure: Treat underlying cause. Give oxygen (2460%) by facemask. Assisted ventilation if PaO2 8kPa despite 60% O2. Type II respiratory failure: The respiratory centre may be relatively insensitive to CO2 and respiration could be driven by hypoxia. Treat underlying cause. Controlled oxygen therapy: start at 24% O2. Oxygen therapy should be given with care. Nevertheless, dont leave the hypoxia untreated. Recheck ABG after 20min. If PaCO2 is steady or lower, increase O2 con centration to 28%. If PaCO2 has risen 1. 5kPa and the patient is still hypoxic, consider assisted ventilation (eg NIPPV, p813, ie non-invasive positive Hypertension ventilation). If this fails, consider intubation and ventilation, if appropriate. When to consider ABG (arterial Blood gas) measurement Any unexpected deterioration in an ill patient. (Technique: see p771. ) Anyone with an acute exacerbation of a chronic chest condition. Anyone with impaired consciousness or impaired respiratory eff ort. Signs of CO2 retention, eg bounding pulse, drowsy, tremor (fl apping), headache. Cyanosis, confusion, visual hallucinations (signs of PaO2; SAO2 is an alternative). To validate measurements from transcutaneous pulse oximetry (p162). __OOHHCCMM__1100ee. . iinnddbb 118888 0022//0055//22001177 1199: : 0077 189 enicidem tsehC ABG interpretation Normal pH is 7. 357. 45. pH 7. 35 indicates acidosis and 7. 45 indicates alkalosis. If the pCO is in keeping with the pH, the problem is likely to be a respiratory 2 problem (eg High pCOand pH 7. 35 likely a respiratory acidosis). If the HCOΩ 2 3 is in keeping with the pH, this is suggestive of a metabolic problem (eg High HCOΩ and pH 7. 45 metabolic alkalosis). 3 Table 4. 7 Interpreting Blood gas analysis pH PaCO HCOΩ 2 3 Metabolic acidosis Low Normal/Low Low Respiratory acidosis Low High Normal/High Metabolic alkalosis High Normal/High High Respiratory alkalosis High Low Normal/Low Steps to ABG interpretation: 1 pH: acidosis or alkalosis? 2 pCO: High/Low? Does this fi t with the pH? (if yes, think respiratory problem) 2 3 HCOΩ: High/Low? Does this fi t with pH? (if yes, think metabolic problem) 3 4 PO: is this normal given the FiO (fraction of inspired oxygen)? 2 2 5 Is there any compensation? (i. e. changes in PCO/HCOΩ to try and correct an un2 3 derlying imbalance). Is this partial (pH abnormal) or complete (pH normalized)?",
    "Is this partial (pH abnormal) or complete (pH normalized)? 6 Calculate the anion gap. Helpful in working out aetiology of metabolic acidosis. Anion gap: (sodium potassium) Ω (ClΩ HCOΩ) 3 See p670 for causes of raised anion gap (normal 1018mmol/L). Administering oxygen Oxygen should be prescribed. Titrate the amount guided by the patients SaO2 and clinical condition. Humidifi cation is only required for longer-term delivery of O2 at High fl ow rates and tracheostomies, but may expectoration in bronchiectasis. Nasal cannulae: Preferred by patients, but O2 delivery is relatively imprecise and may cause nasal soreness. The fl ow rate (14L/min) roughly defi nes the concentration of O2 (2440%). May be used to maintain SaO2 when nebulizers need to be run using air, eg COPD. Simple face mask: Delivers a variable amount of O2 depending on the rate of infl ow. Less precise than venturi masksso dont use if hypercapnia or type II respiratory failure. Risk of CO2 accumulation (within the mask and so in inspired gas) if fl ow rate 5L/min. Be careful in those with COPD (p812). Venturi mask: Provides a precise percentage or fraction of O2 (FiO2) at High fl ow rates. Start at 2428% in COPD. Colours of masks: BLUE 24%, WHITE 28%, YELLOW 35%, RED 40%, GREEN 60%. Non-rebreathing mask: These have a reservoir bag and deliver High concentrations of O2 (6090%), determined by the infl ow (1015L/min) and the presence of fl ap valves on the side. They are commonly used in emergencies, but are imprecise and should be avoided in those requiring controlled O2 therapy. Promoting oxygenation: Other ways to oxygenation to reach the target SaO2 (this should be given as a number on the drug chart): Treat anaemia (transfuse if essential). Improve cardiac output (treat Heart failure). Chest physio to improve ventilation/perfusion mismatch. __OOHHCCMM__1100ee. . iinnddbb 118899 0022//0055//22001177 1199: : 0077 190 enicidem tsehC Pulmonary embolism (physical examination) Causes PES usually arise from a venous thrombosis in the pelvis or legs. Clots break off and pass through the veins and the right side of the Heart before lodging in the pulmonary circulation. Rare causes: RV thrombus (post-myocardial infarction); septic emboli (rightsided endocarditis); fat, air, or amniotic fl uid embolism; neoplastic cells; parasites. Risk factors Recent surgery, especially abdominal/pelvic or hip/knee replacement. Thrombophilia, eg antiphospholipid syndrome (p374). Leg fracture. Prolonged bed rest/reduced mobility. Malignancy. Pregnancy/postpartum; combined contraceptive pill; HRT (lower risk). Previous physical examination. Clinical features Small emboli may be asymptomatic, whereas large emboli are often fatal. Symptoms: Acute breathlessness, pleuritic chest Pain, haemoptysis; dizziness; syncope. Ask about risk factors, past history or family history of thromboembolism. Signs: Pyrexia; cyanosis; tachypnoea; tachycardia; hypotension; raised JVP; pleural rub; pleural eff usion. Look for signs of a cause, eg deep vein thrombosis. Tests FBC, UE, baseline clotting, D-dimers (BOX). ABG may show PaO2 and PaCO2. Imaging: CXR may be normal, or show oligaemia of aff ected segment, dilated pulmonary artery, linear atelectasis, small pleural eff usion, wedge-shaped opacities or cavitation (rare). CTPAsee fi g 4. 16. ECG may be normal, or show tachycardia, right bundle branch block, right ventricular strain (inverted T in V1 to V4). The classical SI QIII TIII pattern (p98) is rare. Further investigations are shown on p818. Treatment See p818. If haemodynamically unstable, thrombolyse for massive physical examination (alteplase 10mg IV over 1min, then 90mg IVI over 2h; max 1. 5mg/kg if 65kg). Haemodynamically stable: start LMWH or unfractionated heparin if underlying renal impairment and treat for 5 days. Then, start DOAC (direct oral anticoagulant) or warfarin (p350).",
    "Then, start DOAC (direct oral anticoagulant) or warfarin (p350). For warfarin, stop heparin when INR is 23, due to intial prothrombotic eff ect of warfarin (target INR of 23). Consider placement of a vena caval fi lter if contra-indication to anticoagulation. Unprovoked physical examination In patients with no known provoking risk factors, consider investigation for possible underlying malignany. Undertake full history, examination (including breast), CXR, FBC, calcium, LFTS, urinalysis. Patients 40yrs consider abdopelvic computed tomography and mammography in women. Consider antiphospholipid and thrombophilia testing if family history positive (p374). Prevention Give heparin to all immobile patients. Stop HRT and the combined contraceptive pill pre-op (if reliable with another form of contraception). Pneumothorax Caus es Often spontaneous (especially in young, thin men) due to rupture of a subpleural bulla. Other causes: asthma; COPD; TB; pneumonia; lung abscess; carcinoma; cystic fi brosis; lung fi brosis; sarcoidosis; connective tissue disorders (Marfans syn. , EhlersDanlos syn. ), trauma; iatrogenic (subclavian CVP line insertion, pleural aspiration/biopsy, transbronchial biopsy, Liver biopsy, ve Hypertension ventilation). Clinical features Symptoms: May be asymptomatic (fi t, young, and small pneumothorax) or there may be sudden onset of dyspnoea and/or pleuritic chest Pain. Patients with asthma or COPD may present with a sudden deterioration. Mechanically ventilated patients may present with hypoxia or an increase in ventilation pressures. Signs: Reduced expansion, hyper-resonance to percussion, and diminished breath sounds on the aff ected side. With a tension pneumothorax, the trachea will be deviated away from the aff ected side, p749, p815. Management: See p815. __OOHHCCMM__1100ee. . iinnddbb 119900 0022//0055//22001177 1199: : 0077 191 enicidem tsehC Investigating suspected physical examination Diagnosis of physical examination is improved by adopting a stepwise approach, combining an objective probability score, with subsequent investigations, as follows. Assess the clinical probability of a physical examination: Many systems exist and one of the most frequently used is the modifi ed Wells Criteria (table 4. 8). Table 4. 8 Modifi ed two-level physical examination Wells score Feature Score Clinical signs and symptoms of DVT (leg Pain and Pain on deep palpation 3 of veins) Heart rate 100 beats per minute 1. 5 Recently bed-ridden (3 days) or major surgery (4 weeks) 1. 5 Previous DVT or physical examination 1. 5 Haemoptysis 1 Cancer receiving active treatment, treated in last 6/12, palliative 1 An alternative diagnosis is less likely than physical examination 3 Score 4 physical examination unlikely; score 4 physical examination likely Wells PS, Anderson DR, Rodger M, et al. Derivation of a Simple Clinical Model to Categorize Patients Probability of Pulmonary Embolism: Increasing the Models Utility with the SimpliRED D-dimer. Thromb Haemost 2000; 83: 41620. physical examination suspected Calculate modifi ed Wells score Score 4: immediate CTPA or treat Score 4: do D-dimer empirically (LMWH) if delay D dimer ve: immediate CTPA D-dimer Ωve: consider or empiral treatment LMWH alternative diagnosis Length of treatment Provoked: 3 months and then reassess risk to benefi t profi Blood (depends on whether risk factor persists) Unprovoked: treatment is usually continued for 3 months (people with no identifi able risk factor) Malignancy: continue treatment with LMWH for 6 months or until cure of cancer Pregnancy: LMWH is continued until delivery/end of pregnancy Fig 4. 16 Investigation and management of physical examination. Direct oral anticoagulants (DOACS) Oral alternatives to warfarin (dabigatran, rivaroxaban, apixaban, edoxaban) have been available for treatment of physical examination since NICE approval in 2012. They have a rapid onset of action (without the need for LMWH overlap) and can be administered in fi xed doses without the need for continuous monitoring.",
    "Monitoring is required to assess compliance, side eff ects (eg bleeding), and presence of VTE. Antidotes for DOACS are becoming available and in the USA idarucizumab is already licensed. __OOHHCCMM__1100ee. . iinnddbb 119911 0022//0055//22001177 1199: : 0077 192 enicidem tsehC Pleural eff usion Defi nitions A pleural eff usion is fl uid in the pleural space. Eff usions can be divided by their Protein concentration into transudates (25g/L) and exudates (35g/L), see BOX. Blood in the pleural space is a haemothorax, pus in the pleural space is an empyema, and chyle (lymph with fat) is a chylothorax. Both Blood and air in the pleural space is called a haemopneumothorax. Causes Transudates may be due to venous Hypertension (cardiac failure, constrictive pericarditis, fl uid overload), or hypoproteinaemia (cirrhosis, nephrotic syndrome, malabsorption). Also occur in hypothyroidism and Meigs syndrome (right pleural eff usion and ovarian fi broma). Exudates are mostly due to increased leakiness of pleural capillaries secondary to infection, infl ammation, or malignancy. Causes: pneumonia; TB; pulmonary infarction; rheumatoid arthritis; SLE; bronchogenic carcin oma; malignant metastases; lymphoma; mesothelioma; lymphangitis carcinomatosis. Symptoms Asymptomaticor dyspnoea, pleuritic chest Pain. Signs Decreased expansion; stony dull percussion note; diminished breath sounds occur on the aff ected side. Tactile vocal fremitus and vocal resonance are (inconstant and unreliable). Above the eff usion, where lung is compressed, there may be bronchial breathing. With large eff usions there may be tracheal deviation away from the eff usion. Look for aspiration marks and signs of associated disease: malignancy (cachexia, clubbing, lymphadenopathy, radiation marks, mastectomy scar); stigmata of chronic Liver disease; cardiac failure; hypothyroidism; rheumatoid arthritis; butterfl y rash of SLE. Tests CXR: Small eff usions blunt the costophrenic angles, larger ones are seen as Water-dense shadows with concave upper borders. A completely fl at horizontal upper border implies that there is also a pneumothorax. Ultrasound is useful in identifying the presence of pleural fl uid and in guiding diagnostic or therapeutic aspiration. Diagnostic aspiration: Percuss the upper border of the pleural eff usion and choose a site 1 or 2 intercostal spaces below it (dont go too Low or youll be in the abdomen! ). Infi ltrate down to the pleura with 510mL of 1% lidocaine. Attach a 21G needle to a syringe and insert it just above the upper border of an appropriate rib (avoids neurovascular bundle). Draw off 1030mL of pleural fl uid and send it to the lab for clinical chemistry (Protein, glucose, pH, LDH, amylase), bacteriology (microscopy and culture, auramine stain, TB culture), cytology, and, if indicated, immunology (rheumatoid factor, ANA, complement). See table 4. 9. Pleural biopsy: If pleural fl uid analysis is inconclusive, consider parietal pleural biopsy. Thoracoscopic or computed tomography-guided pleural biopsy increases diagnostic yield (by enabling direct visualization of the pleural cavity and biopsy of suspicious areas). Management is of the underlying cause. Drainage: If the eff usion is symptomatic, drain it, repeatedly if necessary. Fluid is best removed slowly (0. 51. 5L/24h). It may be aspirated in the same way as a diagnostic tap, or using an intercostal drain (see p766). Pleurodesis with talc may be helpful for recurrent eff usions. Thorascopic mechanical pleurodesis is most eff ective for malignant eff usions. Empyemas (p170) are best drained using a chest drain, inserted under ultrasound or computed tomography guidance. Intra-pleural alteplase and dornase alfa may help with empyema. Surgery: Persistent collections and increasing pleural thickness (on ultrasound) requires surgery. 50 __OOHHCCMM__1100ee. . iinnddbb 119922 0022//0055//22001177 1199: : 0077 193 enicidem tsehC Table 4.",
    "50 __OOHHCCMM__1100ee. . iinnddbb 119922 0022//0055//22001177 1199: : 0077 193 enicidem tsehC Table 4. 9 Pleural fl uid analysis Gross appearance Cause Clear, straw-coloured Transudate, exudate Turbid, yellow Empyema, parapneumonic eff usion 5 Haemorrhagic Trauma, malignancy, pulmonary infarction Cytology Neutrophils Parapneumonic eff usion, physical examination Lymphocytes Malignancy, TB, RA, SLE, sarcoidosis Mesothelial cells Pulmonary infarction Abnormal mesothelial cells Mesothelioma Multinucleated giant cells RA Lupus erythematosus cells SLE Malignant cells Malignancy Clinical chemistry Protein 25g/L Transudate 35g/L Exudate 2535g/L If pleural fl uid Protein/serum Protein 0. 5, eff usion is an exudate (85% specifi c and sensitive) Glucose 3. 3mmol/L Empyema, malignancy, TB, RA, SLE pH 7. 2 Empyema, malignancy, TB, RA, SLE LDH (pleural: serum 0. 6) Empyema, malignancy, TB, RA, SLE Amylase Pancreatitis, carcinoma, bacterial pneumonia, oesophageal rupture Immunology Rheumatoid factor RA Antinuclear antibody SLE Complement levels RA, SLE, malignancy, infection Lights criteria for defi ning an exudate: eff usion Protein/serum Protein 0. 5; eff usion LDH/serum LDH 0. 6; eff usion LDH ⅔ upper reference range. 98% sensitive and 83% specifi c. 5 Infl ammation of the pleura caused by pneumonia may lead to infected pleural fl uid (empyema); if it is not infected, the term parapneumonic eff usion is used. __OOHHCCMM__1100ee. . iinnddbb 119933 0022//0055//22001177 1199: : 0077 194 enicidem tsehC Obstructive sleep apnoea syndrome This disorder is characterized by intermittent closure/collapse of the pharyngeal air way causing apnoeic episodes during sleep. These are terminated by partial arousal. Clinical features The typical patient is an obese, middle-aged man who presents because of snoring or daytime somnolence. His partner often describes apnoeic episodes during sleep. Loud snoring. Daytime somnolence. Poor sleep quality. Morning headache. Decreased libido. Nocturia. Cognitive performance. Complications Pulmonary hypertension; type II respiratory failure (p188). Sleep apnoea is also reported as an independent risk factor for hypertension. 51 Investigations Simple studies (eg pulse oximetry, video recordings) may be all that are required for diagnosis. Polysomnography (which monitors oxygen saturation, airfl ow at the nose and mouth, ECG, EMG chest, and abdominal wall movement during sleep) is diagnostic. The occurrence of 15 or more episodes of apnoea or hypopnoea during 1h of sleep, on average, indicates signifi cant sleep apnoea. Management Weight reduction. Avoidance of tobacco and alcohol. Mandibular advancement device. CPAP via a nasal mask during sleep is eff ective and recommended by NICE for those with moderate to severe disease. 52 Surgery to relieve pharyngeal or nasal obstruction, eg tonsillectomy or polypectomy, is occasionally needed. Cor pulmonale Cor pulmonale is right Heart failure caused by chronic pulmonary arterial hypertension. Causes include chronic lung disease, pulmonary vascular disorders, and neuromuscular and skeletal diseases (see BOX). Clinical features Symptoms include dyspnoea, Fatigue, and syncope. Signs: cyanosis; tachycardia; raised JVP with prominent a and v waves; RV heave; loud P2, pansystolic murmur (tricuspid regurgitation); early diastolic Graham Steell murmur; hepatomegaly and oedema. Investigations FBC: hemoglobin and haematocrit (secondary polycythaemia). ABG: hypoxia, with or without hypercapnia. CXR: enlarged right atrium and ventricle, prominent pulmonary arteries (see fi g 4. 17). ECG: P pulmonale; right axis deviation; right ventricular hypert rophy/strain. Management Treat underlying causeeg COPD and pulmonary infections. Treat respiratory failurein the acute situation give 24% oxygen if PaO2 8kPa. Monitor ABG and gradually increase oxygen concentration if PaCO2 is stable (p188). In COPD patients, long-term oxygen therapy (LTOT) for 16h/d increases survival (p184). Patients with chronic hypoxia when clinically stable should be assessed for LTOT. Treat cardiac failure with diuretics such as furosemide, eg 40160mg/24h PO. Monitor UE and give amiloride or Potassium supplements if necessary. Alternative: spironolactone. Consider venesection if haematocrit 55%.",
    "Monitor UE and give amiloride or Potassium supplements if necessary. Alternative: spironolactone. Consider venesection if haematocrit 55%. Consider Heartlung transplantation in young patients. Prognosis Poor. 50% die within 5yrs. __OOHHCCMM__1100ee. . iinnddbb 119944 0022//0055//22001177 1199: : 0077 195 enicidem tsehC Causes of cor pulmonale Lung disease Thoracic cage abnormality COPD Kyphosis Bronchiectasis Scoliosis Pulmonary fi brosis Thoracoplasty. Severe chronic asthma Neuromuscular disease Lung resection. Myasthenia gravis Pulmonary vascular disease Poliomyelitis Pulmonary emboli Motor neuron disease. Pulmonary vasculitis Hypoventilation Primary pulmonary hypertension Sleep apnoea ARDS (p186) Enlarged adenoids in children. Sickle-cell disease Cerebrovascular disease Parasite infestation. Fig 4. 17 PA chest radiograph showing enlarged pulmonary arteries from pulmonary artery hypertension. When caused by interstitial lung disease and leading to right Heart failure, this would be termed cor pulmonale. No signs of interstitial lung disease are identifi able in this image. Image courtesy of Derby Hospitals NHS Foundation Trust Radiology Department. __OOHHCCMM__1100ee. . iinnddbb 119955 0022//0055//22001177 1199: : 0077 196 enicidem tsehC Sarcoidosis A multisystem granulomatous disorder of unknown cause. Prevalence highest in Northern Europe, eg UK: 1020/105 population. Usually aff ects adults aged 2040yrs, more common in women. AfricanCaribbeans are aff ected more frequently and more severely than Caucasians, particularly by extra-thoracic disease. Associated with HLA-DRB1 and DQB1 alleles. For other causes of granuloma see table 4. 10. Clinical features In 2040%, the disease is discovered incidentally, after a routine CXR, and is thus asymptomatic. Acute sarcoidosis often presents with fever, erythema nodosum (fi g 12. 21, p563), 6 polyarthralgia, and bilateral hilar lymphodenopathy (BHL), also called Löfgren syndrome, which usually resolves spontaneously. Pulmonary disease: 90% have abnormal CXRs with BHL (fi g 4. 18) ± pulmonary infi ltrates or fi brosis; see later in topic for staging. Symptoms: Dry cough, progressive dyspnoea, exercise tolerance, and chest Pain. In 1020%, symptoms progress, with concurrent deterioration in lung function. Non-pulmonary signs: These are legion: lymphadenopathy; hepatomegaly; splenomegaly; uveitis; conjunctivitis; keratoconjunctivitis sicca; glaucoma; terminal phalangeal bone cysts; enlargement of lacrimal parotid glands (fi g 8. 49, p355); Bells palsy; neuropathy; meningitis; brainstem and spinal syndromes; space-occupying lesion; erythema nodosum (fi g 12. 21, p563); lupus pernio; subcutaneous nodules; cardio myopathy; arrhythmias; hypercalcaemia; hypercalciuria; renal stones; pituitary dysfunction. Tests Blood: ESR, lymphopenia, LFT, serum ACE in 60% (non-specifi c), Ca2, immun oglobulins. 24h Urine: Ca2. CXR is abnormal in 90%: Stage 0: normal. Stage 1: BHL. Stage 2: BHL peripheral pulmonary infi ltrates. Stage 3: peripheral pulmonary infi ltrates alone. Stage 4: progressive pulmonary fi brosis; bulla formation (honeycombing); pleural involvement. ECG may show arrhythmias or bundle branch block. Lung function tests may be normal or show reduced lung volumes, impaired gas transfer, and a restrictive ventilatory defect. Tissue biopsy (lung, Liver, lymph nodes, skin nodules, or lacrimal glands) is diagnostic and shows non-caseating granulomata. Bronchoalveolar lavage (BAL): Shows lymphocytes in active disease; neutrophils with pulmonary fi brosis. Transbrochial biopsy: May be diagnostic. Ultrasound: May show nephrocalcinosis or hepatosplenomegaly. Bone X-rays: Show punched out lesions in terminal phalanges. computed tomography/magnetic resonance imaging: May be useful in assessing severity of pulmonary disease or diagnosing neurosarcoidosis. Ophthalmology assessment (slit lamp examination, fl uorescein angiography) is indicated in ocular disease. Management Patients with BHL alone dont need treatment as most recover spontaneously. 53, 54 Acute sarcoidosis: bed rest, NSAIDS. Indications for corticosteroids: Parenchymal lung disease (symptomatic, static, or progressive). Uveitis. Hypercalcaemia. Neurological or cardiac involvement. Prednisolone (40mg/24h) PO for 46 wks, then dose over 1yr according to clinical status. A few patients relapse and may need a further course or long-term therapy.",
    "A few patients relapse and may need a further course or long-term therapy. Other therapy: In severe illness, IV methylprednisolone or immunos uppressants (methotrexate, hydroxychloroquine, ciclosporin, cyclophosphamide) may be needed. Anti-TNF therapy may be tried in refractory cases, or lung transplantation. Prognosis 60% of patients with thoracic sarcoidosis resolve over 2yrs. 20% respond to steroid therapy; in the rest, improvement is unlikely despite therapy. 7 6 A detailed history and exam (including for synovitis) CXR, 2 ASO (antistreptolysin-O) titres and a tuberculin skin test are usually enough to diagnose erythema nodosum. 7 ACE is also in: hyperthyroidism, Gauchers, silicosis, TB, hypers ensitivity pneumonitis, asb es tosis, pneumocystosis. 55 ACE levels in CSF help diagnose CNS sarcoidosis (when serum ACE may be normal). 56 ACE is lower in: Caucasians; and anorexia. 57 __OOHHCCMM__1100ee. . iinnddbb 119966 0022//0055//22001177 1199: : 0077 197 enicidem tsehC Table 4. 10 Diff erential diagnosis of granulomatous diseases Infections Bacteria TB, leprosy, syphilis, cat scratch fever Fungi Cryptococcus neoformans Coccidioides immitis Protozoa Schistosomiasis Autoimmune Primary biliary cholangitis Granulomatous orchitis Vasculitis (p556) Giant cell arteritis Polyarteritis nodosa Takayasus arteritis Wegeners granulomatosis Organic dust disease Silicosis, berylliosis Idiopathic Crohns disease De Quervains thyroiditis Sarcoidosis Extrinsic allergic alveolitis Histiocytosis X Fig 4. 18 PA chest radiograph showing bilateral hilar lymphadenopathy. The important diff erentials for this appearance are: sarcoidosis, TB, lymphoma, pneumoconioses, and metastatic disease. This patient has sarcoidosis but there are no other stigmata (such as the presence of infi ltrates, fi brosis, and honeycombing) on this image. Image courtesy of Norfolk and Norwich University Hospitals NHS Trust Radiology Department. Causes of BHL (bilateral hilar lymphadenopathy) Sarcoidosis Infection, eg TB, mycoplasma Malignancy, eg lymphoma, carcinoma, mediastinal tumours Organic dust disease, eg silicosis, berylliosis Hypersensitivity pneumonitis Histocytosis X (Langerhans cell histiocytosis). __OOHHCCMM__1100ee. . iinnddbb 119977 0022//0055//22001177 1199: : 0077 198 enicidem tsehC Interstitial lung disease (ILD) This is the generic term used to describe a number of conditions that primarily atrial fibrillationfect the lung parenchyma in a diff use manner. 58 They are characterized by chronic infl ammation and/or progressive interstitial fi brosis (table 4. 11), and share a number of clinical and pathological features. See table 4. 11 and fi g 4. 19. Clinical features Dyspnoea on exertion; non-productive paroxysmal cough; abnormal breath sounds; abnormal CXR or High-resolution computed tomography; restrictive pulmonary spirometry with DLCO (p164). Pathological features Fibrosis and remodelling of the interstitium; chronic infl ammation; hyperplasia of type II epithelial cells or type II pneumocytes. Classifi cation The ILDS can be broadly grouped into three categories: Those with known cause, eg: Occupational/environmental, eg asbestosis, berylliosis, silicosis, cotton workers lung (byssinosis). Drugs, eg nitrofurantoin, bleomycin, amiodarone, sulfasalazine, busulfan. Hypersensitivity reactions, eg hypersensitivity pneumonitis. Infections, eg TB, fungi, viral. Gastro-oesophageal refl ux. Those associated with systemic disorders, eg: Sarcoidosis. Rheumatoid arthritis. SLE, systemic sclerosis, mixed connective tissue disease, Sjögrens syndrome. Ulcerative colitis, renal tubular acidosis, autoimmune thyroid disease. Idiopathic, eg: Idiopathic pulmonary fi brosis (IPF, p200). Cryptogenic organizing pneumonia. Non-specifi c interstitial pneumonitis. Extrinsic allergic alveolitis (essential amino acids) In sensitized individuals, repetitive inhalation of allergens (fungal spores or avian proteins) provokes a hypersensitivity reaction which varies in intensity and clinical course depending on the antigen. In the acute phase, the alveoli are infi ltrated with acute infl ammatory cells. Early diagnosis and prompt allergen removal can halt and reverse disease progression, so prognosis can be Good. With chronic exposure, granuloma formation and obliterative bronchiolitis occur. Causes Bird-fanciers and pigeon-fanciers lung (proteins in bird droppings). Farmers and mushroom workers lung (Micropolyspora faeni, Thermoactinomyces vulgaris). Malt workers lung (Aspergillus clavatus). Bagassosis or Glucose workers lung (Thermoactinomyces sacchari ).",
    "Malt workers lung (Aspergillus clavatus). Bagassosis or Glucose workers lung (Thermoactinomyces sacchari ). Clinical features 46h post-exposure: Fever, rigors, myalgia, dry cough, dyspnoea, fi ne bibasal crackles. Chronic: Finger clubbing (50%), increasing dyspnoea, weight, exertional dyspnoea, type I respiratory failure, cor pulmonale. Tests Acute: Blood: FBC (neutrophilia); ESR; ABGS; serum antibodies (may indicate exposure/previous sensitization rather than disease). CXR: upper-zone mottling/consolidation; hilar lymph adenopathy (rare). Lung function tests: Reversible restrictive defect; reduced gas transfer during acute attacks. Chronic: Blood tests: serum antibodies. CXR: upper-zone fi brosis; honeycomb lung. computed tomography chest: nodules, ground glass appearance, extensive fi brosis. Lung function tests: restrictive defect. Bronchoalveolar lavage (BAL) fl uid shows lymphocytes and mast cells. Management Acute: Remove allergen and give O2 (3560%), PO prednisolone (40mg/24h PO), reducing course. Chronic: Allergen avoidance, or wear a facemask or ve Hypertension helmet. Long-term steroids often achieve CXR and physiological improvement. Compens ation (UK Industrial Injuries Act) may be payable. __OOHHCCMM__1100ee. . iinnddbb 119988 0022//0055//22001177 1199: : 0077 199 enicidem tsehC Fig 4. 19 AP chest radiograph showing air-space shadowing in the left upper zone. Although this appearance often represents infection, it is non-specifi c. Diff erential diagnosis for this distribution of shadowing include lymphoma, alveolar cell carcinoma (both to be considered if not resolving in appearance on follow-up imaging), and haemorrhage. Image courtesy of Nottingham University Hospitals NHS Trust Radiology Department. Table 4. 11 Causes of fi brotic shadowing on a CXR Upper zone Mid zone Lower zone TB Sarcoidosis, histoplasmosis Idiopathic pulmonary Hypersensitivity pneumonitis fi brosis Ankylosing spondylitis Asbestosis Radiotherapy Progressive massive fi brosis (PMF) __OOHHCCMM__1100ee. . iinnddbb 119999 0022//0055//22001177 1199: : 0077 200 enicidem tsehC Idiopathic pulmonary fi brosis (IPF) This is a type of idiopathic interstitial pneumonia. Infl ammatory cell infi ltrate and pulmonary fi brosis of unknown cause. It is the commonest cause of interstitial lung disease. Symptoms Dry cough; exertional dyspnoea; malaise; weight; arthralgia. Signs Cyanosis; fi nger clubbing; fi ne end-inspiratory crepitations. Complications Respiratory failure; risk of lung cancer. Tests Blood: ABG (PaO2; if severe, PaCO2); CRP; immunoglobulins; ANA (30% ve), rheumatoid factor (10% ve). Imaging: (fi g 4. 20) Lung volume; bilateral lower zone reticulo-nodular shadows; honeycomb lung (advanced disease). computed tomography: Shows similar changes to the CXR but is more sensitive and is an essential for diagnosis. Spirometry: Restrictive (p162); transfer factor. BAL: May indicate activity of alveolitis: lymphocytes (Good response/prognosis) or neutrophils and eosinophils (poor response/prognosis). 99TCm-diethylenetriamine pentaacetic acid scan scan: (diethylene-triamine-penta-acetic acid) May refl ect disease activity. 59 Lung biopsy: May be needed for diagnosis. The histological changes observed on biopsy are referred to as usual interstitial pneumonia (UIP). Management Supportive care: oxygen, pulmonary rehabilitation, opiates, palliative care input. All patients should be considered for current clinical trials or lung transplantation. 60 It is strongly recommended that High-dose steroids are not used except where the diagnosis of IPF is in doubt. Prognosis 50% 5yr survival rate (range 120yrs). A new treatment emerges for suff erers of IPF Nintedanib and pirfenidone have been shown to slow disease progression and off er some hope to suff erers of IPF. Pirfenidone, an immunosuppressant and antifi brotic agent, showed a reduction in the rate of lung scarring and has been shown to improve life expectancy compared to best supportive care. 61 Nintedanib targets three growth factor receptors involved in pulmonary fi brosis. Fig 4. 20 Interstitial lung disease due to idiopathic pulmonary fi brosis (a similar appearance to the interstitial oedema of moderate left Heart failure, but without a big Heart). Courtesy of Prof P Scally. __OOHHCCMM__1100ee. .",
    "Courtesy of Prof P Scally. __OOHHCCMM__1100ee. . iinnddbb 220000 0022//0055//22001177 1199: : 0077 201 enicidem tsehC Industrial dust diseases Coal workers pneumoconiosis (CWP) A common dust disease in countries that have or have had underground coal-mines. It results from inhalation of coal dust particles (13μm in diameter) over 1520yrs. These are ingested by macrophages which die, releasing their enzymes and causing fi brosis. Clinical features: Asymptomatic, but coexisting chronic bronchitis is common. CXR: many round opacities (110mm), especially in upper zone. Management: Avoid exposure to coal dust; treat co-existing chronic bronchitis; claim compensation (in the UK, via the Industrial Injuries Act). Progressive massive fi brosis (PMF) Due to progression of CWP, which causes progressive dyspnoea, fi brosis, and, eventually, cor pulmonale. CXR: usually bilateral, upper-mid zone fi brotic masses (110cm), develop from periphery towards hilum. Management: Avoid exposure to coal dust; claim compensation (as for CWP). Caplans syndrome The association between rheumatoid arthritis, pneumoc oniosis, and pulmonary rheumatoid nodules. Silicosis (See fi g 4. 21. ) Caused by inhalation of silica particles, which are very fi brogenic. A number of jobs may be associated with exposure, eg metal mining, stone quarrying, sandblasting, and pottery/ceramic manufacture. Clinical features: Progressive dyspnoea, incidence of TB, CXR shows diff use miliary or nodular pattern in upper and mid-zones and egg-shell calcifi cation of hilar nodes. Spirometry: restrictive ventilatory defect. Management: Avoid exposure to silica; claim compensation (as for CWP). Asbestosis Caused by inhalation of asbestos fi bres. Asbestos was commonly used in the building trade for fi re proofi ng, pipe lagging, electrical wire insulation, and roofi ng felt. Degree of asbestos exposure is related to degree of pulmonary fi brosis. Clinical features: Similar to other fi brotic lung diseases with progressive dyspnoea, clubbing, and fi ne end-inspiratory crackles. Also causes pleural plaques, risk of bronchial adenocarcinoma and mesothelioma. Management: Symptomatic. Patients are often eligible for compensation through the UK Industrial Injuries Act. Mesothelioma See p174. Fig 4. 21 PA chest radiograph showing diff use nodular opacities with a focal area of irregular soft tissue shadowing in the right upper zone, consistent with silicosis and developing progressive massive fi brosis (PMF). Image courtesy of Derby Hospitals NHS Foundation Trust Radiology Department. __OOHHCCMM__1100ee. . iinnddbb 220011 0022//0055//22001177 1199: : 0077 5 Endocrinology Contents The essence of endocrinology 203 Endocrine physiology 204 Diabetes mellitus (diabetes mellitus): Classifi cation and diagnosis 206 Treating Diabetes mellitus 208 Complications of established Diabetes 210 Diabetic neuropathy and diabetic foot care 212 Hypoglycaemia 214 Insulinoma 215 Thyroid and parathyroid disease: Thyroid function tests (TFTS) 216 Thyrotoxicosis 218 Hypothyroidism (myxoedema) 220 Parathyroid hormone and hyperparathyroidism 222 Hypoparathyroidism 222 The adrenal gland: Fig 5. 1 Our understanding of hormones, while Adrenal cortex and Cushings still evolving, originated from a mix of random exsyndrome 224 periments, coincidental fi ndings, and extraordinary Addisons disease (adrenal insufsounding characters! One of these was the castrati fi ciency) 226 that featured in opera throughout the 16th, 17th, and Hyperaldosteronism 228 18th centuries. These were boys who were castrated Phaeochromocytoma 228 before puberty. The voice of a castrato was pure and forceful, due to their enormous lung capacity and Hirsutism, virilism, gynaecomastia, resulting breath control. They also experienced no and impotence 230 temporal recession, and their arms and legs were The pituitary gland: long. One of the most well renowned was Farinelli, Hypopituitarism 232 the stage name of Carlo Maria Michelangelo Nicola Pituitary tumours 234 Broschi. It was said he had a well-modulated soprano Hyperprolactinaemia 236 voice with extraordinary breath control. His picture Acromegaly 238 hangs in Handels house in London.",
    "His picture Acromegaly 238 hangs in Handels house in London. The practice was Diabetes insipidus (DI) 240 stopped in the early 20th century when it was before mealsknowledged how inhumane the operation was. We thank Dr Stephen Gilbey, our Specialist Reader for this chapter. __OOHHCCMM__1100ee. . iinnddbb 220022 0022//0055//22001177 1199: : 0077 203 ygolonircodnE The essence of endocrinology For scientists Defi ne a syndrome, and match it to a gland malfunction. Measure the glands output in the peripheral Blood. Defi ne clinical syndromes associated with too much or too little secretion (hyperand hypo-syndromes, respectively; eumeans normal, neither nor , as in euthyroid). Note factors that may make measurement variable, eg diurnal release of cortisol. If suspecting hormone defi ciency, test by stimulating the gland that produces it (eg short ACTH stimulation test or Synacthen test in Addisons). If the gland is not functioning normally, there will be a blunted response to stimulation. If suspecting hormone excess, test by inhibiting the gland that produces it (eg dexamethasone suppression test in Cushings). If there is a hormone-secreting tumour then this will fail to suppress via normal feedback mechanisms. Find a way to image the gland. NB: non-functioning tumours or incidentalomas may be found in health, see p224. Imaging alone does not make the diagnosis. Aim to halt disease progression; diet and exercise can stop progression of impaired fasting glucose to frank Diabetes. 1, 2 For other glands, halting progression will depend on understanding autoimmunity, and the interaction of genes and environment. In thyroid autoimmunity (an archetypal autoimmune disease), it is possible to track interactions between genes and environment (eg smoking and stress) via expression of immuno logically active molecules (HLA class I and II, adhesion molecules, cytokines, CD40, and complement regulatory proteins). 3 Endocrinologists love this reductionist approach, but have been less successful at understanding emergent phenomenathose properties and performances of ours that cannot be predicted from full knowledge of our perturbed parts. We understand the diurnal nature of cortisol secretion, for example, but the science of relating this to dreams, the consolidation of memory, and the psychopathology of families and other groups (such as the endocrinology ward round you may be about to join) is in its infancy. But as doctors we are steeped in the hormonal lives of patients (as they are in ours)and we may as well start by recognizing this now. For those doing exams Whats wrong with him? your examiner asks, boldly. While you apologize to the patient for this rudeness by asking, Is it alright if we speak about you as if you werent here? , think to yourself that if you were a betting man or woman you would wager that the diagnosis will be endocrinological. In no other discipline are gestalt impressions so characteristic. To get Good at recognizing these conditions, spend time in endocrinology outpatients and looking at collections of clinical photographs. Also, specifi c cutaneous signs are important, as follows. Thyrotoxicosis: Hair loss; pretibial myxoedema (confusing term, p218); onycholysis (nail separation from the nailbed); bulging eyes (exophthalmos/proptosis). Hypothyroidism: Hair loss; eyebrow loss; cold, pale skin; characteristic face. You might, perhaps should, fail your exam if you blurt out Toad-like face. Cushings syndrome: Central obesity and wasted limbs (lemon on sticks see fi g 5. 2); moon face; buff alo hump; supraclavicular fat pads; striae. Addisons disease: Hyperpigmentation (face, neck, palmar creases). Acromegaly: Acral (distal) soft tissue overgrowth; big jaws (macrognathia), hands and feet; the skin is thick; facial features are coarse. Hyperandrogenism (): Hirsutism; temporal balding; acne.",
    "Hyperandrogenism (): Hirsutism; temporal balding; acne. Hypopituitarism: Pale or yellow tinged thinned skin, resulting in fi ne wrinkling around the eyes and mouth, making the patient look older. Hypoparathyroidism: Dry, scaly, puff y skin; brittle nails; coarse hair. Fig 5. 2 Lemon on sticks. Pseudohypoparathyroidism: Short stature, short neck, and short 4th and 5th metacarpals. __OOHHCCMM__1100ee. . iinnddbb 220033 0022//0055//22001177 1199: : 0077 204 ygolonircodnE Endocrine physiology Hormones are chemical messengers which act directly on nearby cells (paracrine eff ect), on the cell of origin (autocrine eff ect), at a distant site (endocrine eff ect), or as neurotransmitters (brain and gastrointestinal tract). Thirst, thermal regulation, appetite, sleep cycles, menstrual cycle, and stress/mood are all controlled by the hypothalamus. Releasing factors produced by the hypothalamus reach the pituitary via the portal system (pituitary stalk), see fi g 5. 3. The releasing factors stimulate or inhibit the production of hormones from the anterior pituitary, fi g 5. 4. Vasopressin and oxytocin are produced in the hypothalamus and stored and released from the posterior pituitary. Hypothalamus Releasing factors Anterior pituitary Posterior pituitary Prolactin Vasopressin Oxytocin LH/FSH GH TSH ACTH Ovaries and Thyroid Adrenals testes Breasts/ Renal Breasts/ gonads tubules uterus Many tissues Steroids Thyroxine Testosterone/ Lactation oestrogens Fig 5. 3 Hypothalamic-pituitary axis. Fig 5. 4 Neuroregulation and integration of endocrine axes makes ultrasound who we areand who we are and what we do feeds back into our hormonal milieu. Multifactorial dis ruptions within the growth hormone (GH), luteinizing hormone (LH)testosterone, adreno cortico tropin (ACTH)cortisol and insulin axes play a major role in healthy maturation and ageing. __OOHHCCMM__1100ee. . iinnddbb 220044 0022//0055//22001177 1199: : 0077 205 ygolonircodnE __OOHHCCMM__1100ee. . iinnddbb 220055 0022//0055//22001177 1199: : 0077 206 ygolonircodnE Diabetes mellitus (diabetes mellitus): classifi cation and diagnosis diabetes mellitus results from lack, or reduced eff ectiveness, of endogenous insulin. Hyperglycaemia is one aspect of a far-reaching metabolic derangement, which causes serious microvascular (retinopathy, nephropathy, neuropathy) or macrovascular problems: stroke, myocardial infarction, renovascular disease, limb ischaemia. So think of diabetes mellitus as a vascular disease: 1 adopt a holistic approach and consider other cardiovascular risk factors too. Categories of Diabetes and dyslipidaemia Type 1 diabetes mellitus: Usually adolescent onset but may occur at any age. Cause: insulin defi ciency from autoimmune destruction of insulin-secreting pancreatic cells. Patients must have insulin, and are prone to ketoacidosis and weight loss. Associated with other autoimmune diseases (90% HLA DR3 ± DR4). Concordance is only 30% in identical twins, indica ting environmental infl uence. Four genes are important: one (6q) determines islet sensitivity to damage (eg from viruses or cross-reactivity from cows milk-induced antibodies). Latent autoimmune Diabetes of adults (LADA) is a form of type 1 diabetes mellitus, with slower progression to insulin dependence in later life. Type 2 diabetes mellitus: (Formerly non-insulin-dependent diabetes mellitus, NIDDM) is at epidemic levels in many places, mainly due to changes in lifestyle, but also because of better diagnosis and improved long evity. 4 Higher prevalence in Asians, men, and the elderly (up to 18%). Most are over 40yrs, but teenagers are now getting type 2 diabetes mellitus (OHCS p156). Cause: insulin secretion ± insulin resistance. It is associated with obesity, lack of exercise, calorie and alcohol excess. 80% concordance in identical twins, indicating stronger genetic infl uence than in type 1 diabetes mellitus. Typically progresses from a preliminary phase of impaired glucose tolerance (IGT) or impaired fasting glucose (IFG). (This is a unique window for lifestyle intervention. ) Maturity onset Diabetes of the young (MODY) is a rare autosomal dominant form of type 2 diabetes mellitus aff ecting young people.",
    "Impaired glucose tolerance (IGT): Fasting plasma glucose 7mmol/L and oral glucose tolerance test (oral glucose tolerance) 2h glucose ≥7. 8mmol/L but 11. 1mmol/L. Impaired fasting glucose (IFG): Fasting plasma glucose ≥ 6. 1mmol/L but 7mmol/L (WHO criteria). Do an oral glucose tolerance test to exclude diabetes mellitus. The cut-off point is somewhat arbitrary. IGT and IFG denote diff erent abnormalities of glucose regulation (post-prandial and fasting). There may be lower risk of progression to diabetes mellitus in IFG than IGT. Manage both with lifestyle advice (p93) annual review. Incidence of diabetes mellitus if IFG and hemoglobin hemoglobin A1c at High end of normal (3746mmol/mol) is 25%. 5 Other causes of diabetes mellitus Steroids; anti-HIV drugs; newer antipsychotics. Pancreatic: pancreatitis; surgery (where 90% pancreas is removed); trauma; pancreatic destruction (haemochromatosis, cystic fi brosis); pancreatic cancer. Cushings disease; acromegaly; phaeochromocytoma; hyperthyroidism; pregnancy. Others: congenital lipodystrophy; glycogen storage diseases. Metabolic syndrome (syndrome x) Defi nition from International Diabetes Federation: central obesity (body mass index 30, or waist circ, ethnic-specifi c values), plus two of blood pressure ≥130/85, triglycerides ≥1. 7mmol/L, HDL ≤ 1. 03/1. 29millimoles per liter, fasting glucose ≥5. 6mmol/L or type 2 diabetes mellitus. 20% are aff ected; weight, genetics, and insulin resistance important in aetiology. Vascular eventsbut probably not beyond the combined eff ect of individual risk factors. : Exercise; weight; treat individual components. 1 Chicken or egg? Most type 2 Diabetes-associated genes have a function in the vasculature, and stre ss in -cells can result from vascular defects in the pancreas, so maybe vascular events trigger diabetes mellitus. 6 __OOHHCCMM__1100ee. . iinnddbb 220066 0022//0055//22001177 1199: : 0077 207 ygolonircodnE Diagnosis of Diabetes mellitus: WHO criteria (rather arbitrary! ) Symptoms of hyperglycaemia (eg polyuria, polydipsia, unexplained weight loss, visual blurring, genital thrush, lethargy) AND raised venous glucose detected oncefasting ≥7mmol/L or random ≥11. 1mmol/L OR Raised venous glucose on two separate occasionsfasting ≥7mmol/L, random ≥11. 1mmol/L or oral glucose tolerance test (oral glucose tolerance test)2h value ≥11. 1mmol/L hemoglobin hemoglobin A1c ≥48mmol/mol. Avoid in pregnancy, children, type 1 diabetes mellitus, and haemoglobinopathies. Whenever you have a needle in a vein, do a Blood glucose (unless recently done); note if fasting or not. Non-systematic, but better than Urine tests (false Ωves). Diff erentiating type 1 and 2 Diabetes Occasionally it may be diffi cult to diff erentiate whether a patient has type 1 or 2 diabetes mellitus, although they can present diff erently (see table 5. 1). Features of type 1 include weight loss; persistent hyper glycaemia despite diet and medications; presence of autoantibodies: islet cell antibodies (ICA) and anti-glutamic acid decarboxylase (GAD) antibodies; ketonuria. Table 5. 1 Diff erences between type 1 and type 2 Diabetes Type 1 diabetes mellitus Type 2 diabetes mellitus Epidemiology Often starts before puberty Older patients (usually) Genetics HLA D3 and D4 linked No HLA association Cause Autoimmune -cell destruction Insulin resistance/-cell dysfunction Presentation Polydipsia, polyuria, weight, ketosis Asymptomatic/complications, eg myocardial infarction Not all new-onset diabetes mellitus in older people is type 2: if ketotic ± a poor response to oral hypoglycaemics (and patient is slim or has a family or personal history of autoimmunity), think of latent autoimmune Diabetes in adults (LADA) and measure islet cell antibodies. What is the best diet for obese patients with type 2 Diabetes? Dietary carbohydrate is a big determinant of postprandial glucose levels, and Low-carbohydrate diets improve glycaemic control. How do Low-carbohydrate, ketogenic diets (20g of carbohydrate daily; LCKD) compare with Low-glycaemic index, reduced-calorie diet (eg 500kcal/day defi cit from weight maintenance diet)?",
    "In one randomized study over 24 weeks, LCKD had greater improvements in hemoglobin hemoglobin A1c (Ω15 vs Ω5mmol/L), weight (Ω11kg vs Ω7kg), and HDL. Diabetes drugs were reduced or eliminated in 95% of LCKD vs 62% of LGID participants. 6 NB: eff ects on renal function and mortality are unknown so these diets remain controversial. Monitoring glucose control 1 Fingerprick glucose if on insulin (type 1/2). NB: before a meal informs about long-acting insulin doses; after meals inform about the dose of short-acting insulin. 2 Glycated haemoglobin (hemoglobin hemoglobin A1c) relates to mean glucose level over previous 8wks (red blood cell t½). Targets are negotiable, eg 4857mmol/mol (depends on patients wish and arterial risk, eg past myocardial infarction or stroke). If at risk from the eff ects of hypoglycaemia, eg elderly patients prone to falls, consider less tight control. Tight control may not alter all-cause mortality. 7 Complications rise with rising hemoglobin hemoglobin A1c, so any improvement helps. 3 Be sure to ask about hypoglycaemic attacks (and whether symptomatic). Hypoglycaemic awareness may diminish if control is too tight, or with time in type 1 diabetes mellitus, due to glucagon secretion. It may return if control is loosened. __OOHHCCMM__1100ee. . iinnddbb 220077 0022//0055//22001177 1199: : 0077 208 ygolonircodnE Treating Diabetes mellitus General Focus on education and lifestyle advice (eg exercise to insulin sensitivity), healthy eating: p244saturated fats, Glucose, starch-carbohydrate, modera te proteinuria ein. Foods made just for diabetics are not needed. One could regard bariatric surgery as a cure for diabetes mellitus in selected patients. Be prepared to negotiate hemoglobin hemoglobin A1c target and review every 36 months. Assess global vascular risk; start a High-intensity statin (p115), eg atorvastatin as tolerated, control blood pressure (p211). Give foot-care (p212). (Pre-) pregnancy care should be in a multidisciplinary clinic (OHCS p23). Advise informing DVLA and not to drive if hypoglycaemic spells (p159; loss of hypog lycaemia awareness may lead to loss of licence; permanent if HGV). Type 1 diabetes mellitus Insulin (see BOX Using insulin). Type 2 diabetes mellitus See fi g 5. 5. Lifestyle modifi cation Diet, weight control, exercise Monotherapy 1st-line standard release metformin If hemoglobin hemoglobin A1c rises to 58mmol/mol, consider dual therapy with: 1 Metformin DPP4 inhibitor (eg sitagliptin) 2 Metformin and pioglitazone 3 Metformin and sulphonylurea (SU) 4 Metformin andS GLT-2i (glifazon) If hemoglobin hemoglobin A1c rises to 58mmol/mol, triple therapy with: 1 Metformin, D PP4 inhibitor, SU 2 Metformin, pioglitazone, SU 3 Metformin, S U/pioglitazone, SGLT-2i 4 Insulin-based therapy Insulin: see BOX Using insulin. Use Triple therapy not tolerated: a structured programme. Review the metformin, SU and GLP 1 mimetic need for existing oral treatments. (see BOX GLP analogues). Fig 5. 5 Management of type 2 Diabetes. Aim for hemoglobin hemoglobin A1c 48mmol/mol or 53 if two or more agents. Data from Algorithm for Blood glucose lowering therapy in adults with type 2 Diabetes, drug-treatment-2 Oral hypoglycaemic agents Metformin: A biguanide. insulin sensitivity and helps weight. SE: nausea; diarrhoea (try modifi ed-release version); abdominal Pain; not hypoglycaemia. Avoid if estimated glomerular filtration rate 36mL/min (due to risk lactic acidosis). DPP4 inhibitors/gliptins: (Eg sitagliptin. ) Block the action of DPP-4, an enzyme which destroys the hormone incretin. Glitazone: insulin sensitivity; SE: hypo glycaemia, fractures, fl uid retention, LFT (do LFT every 8wks for 1yr, stop if ALT up 3-fold). CI: past or present CCF; osteoporosis; monitor weight, and stop if or oedema. Sulfonylurea: insulin secretion; eg gliclazide 40mg/d. SE: hypoglycaemia (monitor glucose); it weight. SGLTI: Selective Sodiumglucose co-transporter-2 inhibitor.",
    "Sulfonylurea: insulin secretion; eg gliclazide 40mg/d. SE: hypoglycaemia (monitor glucose); it weight. SGLTI: Selective Sodiumglucose co-transporter-2 inhibitor. Blocks the reabsorption of glucose in the kidneys and promotes excretion of excess glucose in the Urine (eg empaglifl ozin, shown to reduce mortality from cardiovascular disease in patients with type 2 diabetes mellitus, when compared to placebo). 8 __OOHHCCMM__1100ee. . iinnddbb 220088 0022//0055//22001177 1199: : 0077 209 ygolonircodnE Using insulin Vital to educate to self-adjust doses in the light of exercise, fi ngerprick glucose, calorie intake, and carbohydrate counting. Phone support (trained nurse 7/24). Can modify diet wisely and avoid binge drinking (danger of delayed hypoglycaemia). Partner can abort hypoglycaemia: sugary drinks; GlucoGel PO if coma (no risk of aspiration). Dose titration to targeteg by 24 UNIT steps. It is vital to write UNITS in full when prescribing insulin to avoid misinterpretation of U for zero! Subcutaneous insulins Short-, medium-, or long-acting. Strength: 100U/mL. 1 Ultra-fast acting (Humalog; Novorapid); inject at start of meal, or just after (unless Glucose-laden)helps match what is actually eaten (vs what is planned). 2 Isophane insulin (variable peak at4 12h): favoured by NICE (its cheap! ). 3 Pre-mixed insulins (eg NovoMix3 0 30% short-acting and 70% long-acting). 4 Long-acting recombinant human insulin analogues (insulin glargine) are used at bedtime in type 1 or 2 diabetes mellitus. There is no awkward peak, so Good if nocturnal hypoglycaemia is an issue. Caution if considering pregnancy. Insulin detemir is similar and has a role in intensive insulin regimens for overweight type 2 diabetes mellitus. Common insulin regimens Plan the regimen to suit the lifestyle, not vice versa. Disposable pens: dial dose; insert needle 90° to skin. Vary injection site (outer thigh/abdomen); change needle daily. BD biphasic regimen: twice daily premixed insulins by pen (eg NovoMix 30) useful in type 2 diabetes mellitus or type 1 with regular lifestyle. QDS regimen: before meals ultra-fast insulin bedtime long-acting analogue: useful in type 1 diabetes mellitus for achieving a fl exible lifestyle (eg for adjusting doses with size of meals, or exercise). Once-daily before-bed long-acting insulin: a Good initial insulin regimen when switching from tablets in type 2 diabetes mellitus. Typical dose to work up to (slowly! ): ≥1U/24h for every unit of body mass index in adults. Consider retaining metformin (±pio glitazone) if needed for tight control and patient is unable to use BD regimen. Dose adjustment for normal eating (DAFNE): Multidisciplinary teams promoting autonomy can save lives. DAFNE found that training in fl exible, intensive insulin dosing improved glycaemic control as well as well-being. 9 It is resource intensive. Subcutaneous insulin dosing during intercurrent illnesses (eg infl uenza) Advise patients to avoid stopping insulin during acute illness. Illness often increases insulin requirements despite reduced food intake. Maintain calorie intake, eg using milk. Check Blood glucose ≥ 4 times a day and look for ketonuria. Increase insulin doses if glucose rising. Advise to get help from a specialist Diabetes nurse or GP if concerned (esp. if glucose levels are rising or ketonuria). One option is 2-hourly ultra fast-acting insulin (eg 68U) preceded by a fi ngerprick glucose check. Admit if Vomiting, dehydrated, ketotic (p832), a child, or pregnant. Insulin pumps (continous subcutaneous insulin) Consider when attempts to reach hemoglobin hemoglobin A1c with multiple daily injections have resulted in disabling hypoglycaemia or person has been unable to achieve target hemoglobin hemoglobin A1c despite careful management. Glucagon-like peptide (GLP) analogues (exenatide, liraglutide) Work as incretin mimetics. Incretins are gut peptides that work by augm ent ing insulin release. Given by subcutaneous injection.",
    "Incretins are gut peptides that work by augm ent ing insulin release. Given by subcutaneous injection. Patients must have body mass index 35 and specifi c psychological or other medical problems associated with obesity, or have a body mass index lower than 35 kg/m2, and for whom insulin therapy would have signifi cant occupational implications, or weight loss would benefi t other signifi cant obesityrelated comorbidities. To continue a GLP 1 mimetic, a person should have a benefi cial metabolic response (a reduction of hemoglobin hemoglobin A1c by at least 11mmol/mol) and a weight loss of at least 3% of initial body weight in 6 months. __OOHHCCMM__1100ee. . iinnddbb 220099 0022//0055//22001177 1199: : 0077 210 ygolonircodnE Complications of established Diabetes Prospective studies show that Good control of hyperglycaemia is key to preventi ng microvascular complications in type 1 and 2 diabetes mellitus. 10 Find out what problems are being experienced (eg glycaemic control, morale, erectile dysfunctionp230). Assess vascular risk blood pressure control (see BOX Controlling Blood Hypertension in Diabetes) is crucial for preventing macrov ascular disease and mortality. Refer to smoking cessation services. Check plasma lipids. Look for complications Check injection sites for infection or lipohypertrophy (fatty change): advise on rotating sites of injection if present. Vascular disease: Chief cause of death. myocardial infarction is 4-fold commoner in diabetes mellitus and is more likely to be silent. Stroke is twice as common. Women are at High riskdiabetes mellitus removes the vascular advantage conferred by the female sex. Address other risk factorsdiet, smoking, hypertension (p93). Suggest a statin (eg atorvastatin 20mg nocte) for all, even if no overt IHD, vascular disease, or microa lbuminuria. Aspirin 75mg reduces vascular events (in context of secondary prevention). Safe to use in diabetic retinopathy. 11 Nephropathy: (p314. ) Microalbuminuria is when Urine dipstick is Ωve for Protein but the Urine albumin: Creatinine ratio (UA: creatinine) is 3mg/mmol (units vary, check lab) refl ecting early renal disease and vascular risk. If UA: creatinine 3, inhibiting the renin angiotensin system with an angiotensin-converting enzyme inhibitor or sartan, even if blood pressure is normal, protects the kidneys. Spironolactone may also help. 12 Refer if UA: creatinine 7 ± glomerular filtration rate falling by 5mL/min/1. 73m2/yr. 13 Diabetic retinopathy: Blindness is preventable. Annual retinal screening mandatory for all patients. Refer to an ophthalmologist if pre-proliferative changes or if any uncertainty at or near the macula (the only place capable of 6/6 vision). Pre-symptomatic screening enables laser photocoagulation to be used, aimed to stop production of angiogenic factors from the ischaemic retina. Indications: maculopathy or proliferative retinopathy. See fi gs 5. 65. 9. Background retinopathy: Microaneurysms (dots), haemorrhages (blots), and hard exud ates (lipid deposits). Refer if near the macula, eg for intravitreal triamcinolone. Pre-proliferative retinopathy: Cotton-wool spots (eg infarcts), haemorrhages, venous beading. These are signs of retinal ischaemia. Refer to a specialist. Proliferative retinopathy: New vessels form. Needs urgent referral. Maculopathy: (Hard to see in early stages. ) Suspect if acuity. Prompt laser, intra vitreal steroids, or anti-angiogenic agents may be needed in macular oedema. Pathogenesis: Capillary endothelial change vascular leak microaneurysms capillary occlusion local hypoxia ischaemia new vessel formation. High retinal Blood fl ow caused by hyperglycaemia (and blood pressure and pregnancy) triggers this, causing capillary pericyte damage. Microvascular occlusion causes cotton-wool spots (± blot haemorrhages at interfaces with perfused retina). New vessels form on the disc or ischaemic areas, proliferate, bleed, fi brose, and can detach the retina. Aspirin2 (2mg/kg/d) may be recommended by ophthalmologists; there is no evidence that it bleeding. Cataracts: May be juvenile snowfl ake form, or senilewhich occur earlier in diabetic subjects.",
    "Cataracts: May be juvenile snowfl ake form, or senilewhich occur earlier in diabetic subjects. Osmotic changes in the lens induced in acute hyperglycaemia reverse with normoglycaemia (so wait before buying glasses). Rubeosis iridis: New vessels on iris: occurs late and may lead to glaucoma. Metabolic complications: p832. Diabetic feet: p212. Neuropathy: p212. 2 As diabetes mellitus has so many vascular events, particularly encourage statin use (p690), esp. if LDL 3mmol/L or systolic blood pressure 140. Even consider a statin whatever the pre-treatment cholesterol; discuss with your patient. __OOHHCCMM__1100ee. . iinnddbb 221100 0022//0055//22001177 1199: : 0077 211 ygolonircodnE Controlling Blood Hypertension in Diabetes Type 1 diabetes mellitus: Treat blood pressure if 135/85mmHg, unless albuminuria or two or more features of metabolic syndrome, in which case it should be 130/80mmHg (NICE 2015). Use an angiotensin-converting enzyme inhibitor 1st line or angiotension receptor antagonist if intolerant. If hypertensive and underlying renal involvement, see local guidance, p304. Type 2 diabetes mellitus: Target blood pressure 140/80mmHg or 130/80mmHg if Kidney, eye, or cerebrovascular damage. 1st-line drug treatment should be an angiotensin-converting enzyme inhibitor, except in those of African or Caribbean origin, where angiotensin-converting enzyme inhibitor plus diuretic or a calcium-channel antagonist (CCA) should be started. For pregnant women off er CCA. Do not off er aspirin for the primary prevention of cardiovascular disease to adults with type 1 diabetes mellitus (NICE 2015). Dont combine an angiotensin-converting enzyme inhibitor with an angiotension receptor antagonist. Fig 5. 6 Background retinopathy, with microFig 5. 7 Pre-proliferative retinopathy, with aneurysms and hard exudates. haemorrhages and a cotton-wool spot. Courtesy of Prof J Trobe. Reproduced from Warrell et al, Oxford Textbook of Medicine, 2010, with permission from Oxford University Press. Fig 5. 8 Proliferative retinopathy, with new Fig 5. 9 Scars from previous laser photocoaguvessel formation and haemorrhages. lation. Courtesy of Prof J Trobe. Courtesy of Prof J Trobe. Improving quality of life: going beyond the pleasures of the fl esh I cannot Eat what I want because of your pitiful diet. Sex is out because Diabetes has made me impotent. Smoking is banned, so whats left? Id shoot myself if only I could see straight. Start by acknowledging your patients distress. Dont shrug it off but dont take it at face value either. Life may be transformed by cataract surgery, sildenafi l (unless contraindicated, p230), dietary negotiation, and sport (it neednt be shooting). Take steps to simplify care. Stop Blood glucose self-monitoring if its achieving nothing (known to quality of life). Even if all these interventions fail, you have one trump card up your sleeve: Lets both try to fi nd one new thing of value before we next meetand compare notes. This opens the way to vicarious pleasure: a whole new world. __OOHHCCMM__1100ee. . iinnddbb 221111 0022//0055//22001177 1199: : 0077 212 ygolonircodnE Diabetic neuropathy and diabetic foot care Refer early to foot services (podiatry, imaging, vascular surgery). Amputations are common (135/week)and preventable: Good care saves legs. Examine feet regularly. Distinguish between ischaemia (critical toes ± absent foot pulses and worse outcome) and peripheral neuropathy (injury or infection over pressure points, eg the metatarsal heads). In practice, many have both. Neuropathy Sensation in stocking distribution: test sensation with a 10g monofi lament fi bre (sensory loss is patchy so examine all areas), absent ankle jerks, neuropathic deformity (Charcot joint, fi g 5. 11): pes cavus, claw toes, loss of transverse arch, rocker-bottom sole. Caused by loss of Pain sensation, leading to mech anical stress and repeated joint injury. Edema, instability, and deformity. Early recognition is vital (cellulitis or osteomyelitis are often misdiagnosed).",
    "Edema, instability, and deformity. Early recognition is vital (cellulitis or osteomyelitis are often misdiagnosed). Ischaemia If the foot pulses cannot be felt, do Doppler Hypertension measurements. Any evidence of neuropathy or vascular disease raises risk of foot ulceration. Educate (daily foot inspectioneg with a mirror for the sole; comfortable shoes). Regular chiropody to remove callus, as haemorrhage and tissue necrosis may occur below, leading to ulceration. Treat fungal infections (p408). Surgery (including endovascular angioplasty balloons, stents, and subintimal recanalization) has a role. Foot ulceration Typically painless, punched-out ulcer (fi g 5. 10) in an area of thick callus ± superadded infection. Causes cellulitis, abscess ± osteomyelitis. Assess degree of: 1 Neuropathy (clinically). 2 Ischaemia (clinically Doppler ± angiography). 3 Bony deformity, eg Charcot joint (clinically X-ray). See fi g 5. 11. 4 Infection (swabs, Blood culture, X-ray for osteomyelitis, probe ulcer to reveal depth). Management: Regular chiropody. Bed rest ± therapeutic shoes. For Charcot joints: bed rest/crutches/total contact cast until oedema and local warmth reduce and bony repair is complete (8wks). Bisphosphonates may help. Charcot joints are also seen in tabes dorsalis, spina bifi da, syringomyelia, and leprosy. Metatarsal head surgery may be needed. If there is cellulitis, admit for IV antibiotics. Common organisms: staphs, streps, anaerobes. Start empirically (as per your local guidance) with benzylpenicillin 1. 2g/6h IV and fl ucloxacillin 1g/6h IV ± metronidazole 500mg/8h IV. IV insulin may improve healing. Get surgical help early. The degree of peripheral vascular disease, general health, and patient request will determine degree of vascular reconstruction/surgery. Absolute indications for surgery: Abscess or deep infection; spreading anaerobic infection; gangrene/rest Pain; suppurative arthritis. Diabetic neuropathies Symmetric sensory polyneuropathy: (glove stocking numbness, tingling, and Pain, eg worse at night). : paracetamol tricyclic (amitriptyline 1025mg nocte; gradually to 150mg) duloxetine, gabapentin, or pregabalin opiates. Avoiding weight-bearing helps. Mononeuritis multiplex: (eg III VI cranial nerves). Treatment: hard! If sudden or seve re, immunosuppression may help (corticosteroids, IV immunoglobulin, ciclosporin). Amyotrophy: Painful wasting of quadriceps and other pelvifemoral muscles. Use electrophysiology to show, eg lumbosacral radiculopathy, plexopathy, or proximal crural neuropathy. Natural course: variable with gradual but often incomplete improvement. IV immunoglobulins have been used. Autonomic neuropathy: (p505) Postural blood pressure drop; cerebro vascular autoregulation; loss of respiratory sinus arrhythmia (vagal neuropathy); gastroparesis; Urine retention; erectile dysfunction; gustatory sweating; diarrhoea (may respond to codeine phosphate). Gastroparesis (early satiety, post-prandial bloating, nausea/ Vomiting) is diagnosed by gastric scintigraphy with a 99tech netium-labelled meal; anti-emetics, erythromycin, or gastric pacing. Postural hypotensi on may respond to fl udrocortisone (SE: oedema, blood pressure)/midodrine (-agonist; SE: blood pressure). __OOHHCCMM__1100ee. . iinnddbb 221122 0022//0055//22001177 1199: : 0077 213 ygolonircodnE Preventing loss of limbs: primary or secondary prevention? Traditionally prevention involves foot care advice in diabetic clinics (eg Dont go bare-foot), promoting euglycaemia and normotension. But despite this, the sight of a diabetic patient minus one limb is not rare, and must prompt ultrasound to redouble our commitment to primary prevention, ie stopping those at risk from ever getting Diabetes. The sequelae of diabetic neuropathy can lead to gangrene, amputation, and the impact on quality of life can be profound. As one patient post amputation said, I begin again to walk, on crutches. What nuisance, what Fatigue, what sadness, when I think about all my ancient travels, and how active I was just 5 months ago! Where are the runnings across mountains, the walks, the deserts, the rivers, and the seas? And now, the life of a legless cripple. For I begin to understand that crutches, wooden and articulated legs, are a pack of jokesGoodbye to family, goodbye to future!",
    "My life is gone, Im no more than an immobile trunk (Arthur Rimbaud. Letter to his sister Isabelle, 10 July 1891). Fig 5. 10 Gangrene (toes 2, 4, and 5). Fig 5. 11 Charcot (neuropathic) joint. Reproduced from Warrell et al, Oxford Reproduced from Warrell et al, Oxford Textbook of Medicine, 2010, with perTextbook of Medicine, 2010, with permission from Oxford University Press. mission from Oxford University Press. Special situations in Diabetes Pregnancy: (OHCS p23) 4% are complicated by diabetes mellitus: either pre-existing (0. 5%), or new-onset gestational Diabetes (GDM) (3. 5%). All forms carry an increased risk to mother and fetus: miscarriage, pre-term labour, pre-eclampsia, congenital malformations, macrosomia, and a worsening of diabetic complications, eg retinopathy, nephropathy. Risk of GDM if: aged over 25; family history; ve; weight; non-Caucasian; HIVve; previous gestational diabetes mellitus. Pre-conception: off er general advice, and discuss risks. Control/reduce weight, aim for Good glucose control, off er folic acid 5mg/d until 12 weeks. Screen for GDM with oral glucose tolerance test if risk factors at booking (1618 weeks if previous GDM). Oral hypoglycaemics other than metformin should be discontinued. Metformin may be used as an adjunct or alternative to insulin in type 2 diabetes mellitus or GDM. 6wks postpartum, do a fasting glucose. Even if Ωve, 50% go on to develop diabetes mellitus. Surgery: Optimal Blood Glucose control pre, peri, and post operatively is important to minimize risk of infection and balance catabolic response to surgery. Type 1 diabetics should ideally be fi rst on the list and BMS should have been stabilized 12 days pre major surgery. Consult local policy for how to manage insulin-treated/ non-insulin-treated patients on morning of surgery (eg setting up glucose/insulin infusion). Acute illness: Diabetics are prone to hyperglycaemia during periods of illness, in spite of reduced oral intake. Avoid stopping insulin in periods of acute illness. __OOHHCCMM__1100ee. . iinnddbb 221133 0022//0055//22001177 1199: : 0077 214 ygolonircodnE Hypoglycaemia Hypoglycaemia Commonest endocrine emergencysee p834. Prompt diagnosis and treatment essentialbrain damage death can occur if severe or prolonged. Defi nition Plasma glucose 3mmol/L. Threshold for symptoms varies. See BOX. Symptoms Autonomic: Sweating, anxiety, hunger, tremor, palpitations, dizziness. Neuroglycopenic: Confusion, drowsiness, visual trouble, seizures, coma. Rarely focal symptoms, eg transient hemiplegia. Mutism, personality change, restlessness, and incoherence may lead to misdiagnosis of alcohol intoxication or even psychosis. Fasting hypoglycaemia Causes: The chief cause is insulin or sulfonylurea treatment in a diabetic, eg activity, missed meal, accidental or non-accidental overdose (check for ciculating oral hypoglycaemics). In non-diabetics you must EXPLAIN mechanism: Exogenous drugs, eg insulin, oral hypoglycaemics (p208)? access through diabetic in the family? Body-builders may misuse insulin to help stamina. Also: alcohol, eg a binge with no food; aspirin poisoning; angiotensin-converting enzyme inhibitor; -blockers; pentamidine; quinine sulfate; aminoglutethamide; insulin-like growth factor. 14 Pituitary insuffi ciency. Liver failure, plus some rare inherited enzyme defects. Addisons disease. Islet cell tumours (insulinoma) and immune hypoglycaemia (eg anti-insulin receptor antibodies in Hodgkins disease). Non-pancreatic neoplasms, eg fi brosarcomas and haema ngiopericytomas. When to investigate: Whipple answered this (Whipples triad): symptoms or signs of hypoglycemia plasma glucose resolution of symptoms or signs post glucose rise. Document BM during attack and lab glucose if in hospital (monitors often not reliable at Low readings). Take a drug history and exclude Liver failure. 72h fasting may be needed (monitor closely). Bloods: glucose, insulin, C-peptide, and plasma ketones if symptomatic. If endogenous hyperinsulinism suspected, do insulin, C-peptide, proinsulin, -hydroxybutyrate. Interpreting results: Hypoglycaemic hyperinsulinaemia (HH): Causes: insulinoma, sulfonylureas, insulin injection (no detectable C-peptideonly released with endogenous insulin); noninsulinoma pancreatogenous hypoglycaemia syndrome, mutation in the insulin-receptor gene.",
    "Congenital HH follows mutations in genes involved in insulin secretion (ABCC8, KCNJ11, GLUD1, CGK, HADH, SLC16A1, HNF4A, ABCC8, KCNJ11). 15 Insulin Low or undetectable, no excess ketones. Causes: non-pancreatic neoplasm; anti-insulin receptor antibodies. Insulin, ketones. Causes: alcohol, pituitary insuffi ciency, Addisons disease. Post-prandial hypoglycaemia May occur after gastric/bariatric surgery (dumping, p623), and in type 2 diabetes mellitus. Investigation: Prolonged oral glucose tolerance test (5h, p206). Treatment See p834. If episodes are often, advise many small High-starch meals. If post-prandial glucose, give slowly absorbed carbohydrate (High fi bre). In diabetics, rationalize insulin therapy (p209). The defi nition of hypoglycaemia is context-dependent The brain stops working if plasma glucose levels get too Low, so we are nervous of levels 3mmol/L. But some are asymptomatic at this level. So what is defi nitely abnormal? The answer may be 4mmol/L, allowing for inaccuracies in fi ngerprick BMS (NB: whole Blood glucose is 1015% plasma glucose. ) Think: In this ill patient when can I be sure that a Low glucose is not contr ibuting to their illness? If 4mmol/L, you may be wise to treat (p834)just in case. Consider, is the patient on hypoglycaemics, have they binged on alcohol 24hrs pre test? Skipped meals? Is there an underlying illness, eg insulinoma? Unlikely, but possible. Keep an open mind; let the GP know. Counsel patient and relative about warning signs of hypoglycaemia. Be more inclined to investigate if the eff ects of even mild hypoglycaemia might be disastrous (eg in pilots) or if there are unexplained symptoms. __OOHHCCMM__1100ee. . iinnddbb 221144 0022//0055//22001177 1199: : 0077 215 ygolonircodnE Insulinoma This often benign (9095%) pancreatic islet cell tumour is sporadic or seen with MEN-1 (p223). It presents as fasting hypoglycaemia, with Whipples triad: 1 Symp toms associated with fasting or exercise. 2 Recorded hypoglycaemia with symptoms. 3 Symptoms relieved with glucose. Screening test Hypoglycaemia plasma insulin during a long fast. Suppressive tests Give IV insulin and measure C-peptide. Normally exogenous insulin suppresses C-peptide production, but this does not occur in insulinoma. Imaging computed tomography/magnetic resonance imaging ± endoscopic pancreatic ultrasound ± IACS (see BOX; all fallible, so dont waste too much time before proceeding to intra-operative visualization ± intra-operative ultrasound). 18F-L-3, 4-dihydroxyphenylalanine PET-computed tomography can help guide laparoscopic surgery. Treatment Excision. Nesidioblastosis See BOX. If this doesnt work, options are: diet, diazoxide, dextrose IVI, enteral feeding, everolimus. Diabetic ketoacidosis Results from insulin defi ciency (eg unknown diagnosis, intercurrent illness, interuption of insulin therapy). See p832. Pursuing a voyage to the islets of Langerhans to the bitter end A 50-year-old had episodic early-morning sweats and tremors and was found to have hyperinsulinaemic hypoglycaemia ( Nesidioblastosis). Selective intraarterial calcium infusions (IACS) showed a 2-fold increase in insulin secretion after infusion of the splenic and superior mesenteric arteries, so setting the stage for hunt the insulinoma. But cross-sectional imaging and endoscopic ultrasound were normal. At laparotomy, no lesion was found despite mobilization of the pancreas, or during intraoperative ultrasound. Time to sew up and go home? No! said the surgeon, Im going to do a distal pancreatectomy. Histology showed no discrete insulinoma, but diff use islet cell hyper plasia (nesidioblastosis). How much pancreas to resect? Too little and nothing is gained: too much spells pancreatic endocrine disaster. Luckily the surgeon guessed right, and the patient was cured by the procedure. 16 __OOHHCCMM__1100ee. . iinnddbb 221155 0022//0055//22001177 1199: : 0077 216 ygolonircodnE Thyroid function tests (TFTs) Physiology Thyroid-stimulating hormone (TSHthyro tropin), a glycoprotein, is produced from the anterior pituitary (fi g 5. 12). The thyroid produces mainly T4, which is 5-fold less active than T3.",
    "12). The thyroid produces mainly T4, which is 5-fold less active than T3. 85% of T3 is formed from peripheral conversion of T4. Most T3 and T4 in plasma is Protein bound, eg to thyroxine-binding globulin (TBG). The unbound portion is the active part. T3 and T4 cell metabolism, via nuclear receptors, and are thus vital for growth and mental development. They also catecholamine eff ects. Thyroid hormone abnormalities are usually due to problems in the thyroid gland itself, and rarely caused by the hypothalamus or the anterior pituitary. TRH from the hypothalamus acts on the pituitary gland Fig 5. 12 Pathways involved in thyroid function. Basic tests See table 5. 2. Free T4 and T3 are more useful than total T4 and T3 as the latter are aff ected by TBG. Total T4 and T3 are when TBG is and vice versa. TBG is in pregnancy, oestrogen therapy (HRT, oral contraceptives), and hepatitis. TBG is in nephrotic syndrome and malnutrition (both from Protein loss), drugs (androgens, cortico steroids, phenytoin), chronic Liver disease, and acromegaly. TSH is very useful: Hyperthyroidism suspected: Ask for T3, T4, and TSH. All will have TSH (except the rare TSH-secreting pituitary adenoma). Most have T4, but 1% have only raised T3. Hypothyroidism suspected or monitoring replacement : Ask for only T4 and TSH. T3 does not add any extra information. TSH varies through the day: trough at 2PM; 30% higher during darkness, so during monitoring, try to do at the same time. Sick euthyroidism: In any systemic illness, TFTS may become deranged. The typical pattern is for everything to be Low. The test should be repeated after recovery. Assay interference is caused by antibodies in the serum, interfering with the test. Other tests Thyroid autoantibodies: Antithyroid peroxidase (TPO; formerly called microsomal) antibodies or antithyro globulin antibodies may be increased in autoimmune thyroid disease: Hashimotos or Graves disease. If ve in Graves, there is an increased risk of developing hypothyroidism at a later stage. TSH receptor antibody: May be in Graves disease (useful in pregnancy). Serum thyroglobulin: Useful in monitoring the treatment of carcinoma (p600), and in detection of factitious (self-medicated) hyperthyroidism, where it is Low. Ultrasound: This distinguishes cystic (usually, but not always, benign) from solid (possibly malignant) nodules. If a solitary (or dominant) large nodule, in a multin odular goitre, do a fi ne-needle aspiration to look for thyroid cancer; see fi g 13. 23, p601. Isotope scan: (123Iodine, 99technetium pertechnetate, etc; see fi g 13. 22, p601. ) Useful for determining the cause of hyperthyroidism and to detect retrosternal goitre, ectopic thyroid tissue or thyroid metastases ( whole body computed tomography). If there are suspicious nodules, the question is: does the area have increased (hot), decreased (cold), or the same (neutral) uptake of isotope as the remaining thyroid (see fi g 5. 13). Few neutral and almost no hot nodules are malignant. 20% of cold nodules are malignant. Surgery is most likely to be needed if: rapid growth compression signs dominant nodule on scintigraphy nodule 3cm hypo-echogenicity. See also p738. __OOHHCCMM__1100ee. . iinnddbb 221166 0022//0055//22001177 1199: : 0077 217 ygolonircodnE Screen the following for abnormalities in thyroid function Patients with atrial fi brillation. Patients with hyperlipidaemia (414% have hypothyroidism). Diabetes mellituson annual review. Women with type 1 diabetes mellitus during 1st trimester and post delivery (3-fold rise in incidence of postpartum thyroid dysfunction). Patients on amiodarone or lithium (6 monthly). Patients with Downs or Turners syndrome, or Addisons disease (yearly). Table 5.",
    "Patients on amiodarone or lithium (6 monthly). Patients with Downs or Turners syndrome, or Addisons disease (yearly). Table 5. 2 Interpreting TFTS Hormone profi Blood Diagnosis TSH, T4 Hypothyroidism TSH, normal T4 Treated hypothyroidism or subclinical hypot hyroidism (p221) TSH, T4 TSH-secreting tumour or thyroid hormone resistance TSH, T4 and T3 Slow conversion of T4 to T3 (deiodinase defi ciency; euthyroid hyperthyroxinaemia) or thyroid hormone antibody artefact TSH, T4 or T3 Hyperthyroidism TSH, normal T4 and T3 Subclinical hyperthyroidism TSH, T4 Central hypothyroidism (hypothalamic or pituitary disorder) TSH, T4 and T3 Sick euthyroidism or pituitary disease Normal TSH, Consider changes in thyroid-binding globulin, assay interabnormal T4 ference, amiodarone, or pituitary TSH tumour In consumptive hypothyroidism deiodinase activity is ; suspect if thyroxine doses have to be . Fig 5. 13 The images are from an isotope scan, with and without markers placed over the sternal notch. We can see on the left that the nodule is metabolically inactive (cold). The hot nodule (right pair) is a very avid nodule causing background thyroid suppression. Image courtesy of Dr Y. T. Huang. __OOHHCCMM__1100ee. . iinnddbb 221177 0022//0055//22001177 1199: : 0077 218 ygolonircodnE Thyrotoxicosis The clinical eff ect of excess thyroid hormone, usually from gland hyperfunction. Symptoms Diarrhoea; weight; appetite (if , paradoxical weight gain in 10%); over-active; sweats; heat intolerance; palpitations; tremor; irritability; labile emotions; oligo menorrhoea ± infertility. Rarely psychosis; chorea; panic; itch; alopecia; urticaria. Signs Pulse fast/irregular (atrial fibrillation or SVT; VT rare); warm moist skin; fi ne tremor; palmar erythema; thin hair; lid lag; lid retraction (exposure of sclera above iris; causing stare, (fi g 5. 14; eyelid lags behind eyes descent as pati ent watches your fi nger descend slowly). There may be goitre (fi g 5. 15); thyroid nodules; or bruit depending on the cause. Signs of Graves disease: 1 Eye disease (BOX Thyroid eye disease): exoph th almos, ophthalmoplegia. 2 Pretibial myxoedema: oedematous swellings above lateral malleoli: the term myxoedema is confusing here. 3 Thyroid acropachy: extreme manifestation, with clubbing, painful fi nger and toe Edema, and periosteal reaction in limb bones. Tests TSH (suppressed), T4, and T3. There may be mild normocytic anaemia, mild neutropenia (in Graves), ESR, Ca2, LFT. Also: Check thyroid autoantibodies. Isotope scan if the cause is unclear, to detect nodular disease or subacute thyroiditis. If ophthalmopathy, test visual fi elds, acuity, and eye movem ents (see BOX Thyroid eye disease). Causes Graves disease: Prevalence: 0. 5% (⅔ of cases of hyperthyroidism). : 9: 1. Typical age: 4060yrs (younger if maternal family history). Cause: circulating IgG autoantibodies binding to and activating G-Protein-coupled thyrotropin receptors, which cause smooth thyroid enlargement and hormone production (esp. T3), and react with orbital autoantigens. Triggers: stress; infection; childbirth. Patients are often hyperthyroid but may be, or become, hypoor euthyroid. It is associated with other autoimmune diseases: vitiligo, type 1 diabetes mellitus, Addisons (table 5. 3). Toxic multinodular goitre: Seen in the elderly and in iodine-defi cient areas. There are nodules that secrete thyroid hormones. Surgery is indicated for compressive symptoms from the enlarged thyroid (dysphagia or dyspnoea). Toxic adenoma: There is a solitary nodule producing T3 and T4. On isotope scan, the nodule is hot (p216), and the rest of the gland is suppressed. Ectopic thyroid tissue: Metastatic follicular thyroid cancer, or struma ovarii: ovarian teratoma with thyroid tissue. Exogenous: Iodine excess, eg food contamination, contr ast media (thyroid storm, p834, if already hyperthyroid). Levothyroxine excess causes T4, T3, thyro globulin. Others: 1 Subacute de Quervains thyroiditis: self-limiting post-viral with painful goitre, T° ± ESR. Low isotope uptake on scan. : NSAIDS.",
    "Low isotope uptake on scan. : NSAIDS. 2 Drugs: amiodarone (p220), lithium (hypothyroidism more common). 3 Postpartum. 4 TB (rare). Treatment 1 Drugs: -blockers (eg propranolol 40mg/6h) for rapid control of symptoms. Antithyroid medication: two strategies (equally eff ective): 17 A Titration, eg carbima zole 2040mg/24h PO for 4wks, reduce according to TFTs every 12 months. B Blockreplace: Give carbimazole levothyroxine simultaneously (less risk of iatrogenic hypothyroidism). In Graves, maintain on either regimen for 1218 months then withdraw. 50% will relapse, requiring radioiodine or surgery. Carbimazole SE: agranulocytosis (n eutrophils, can lead to dangerous sepsis; rare (0. 03%)); warn to stop and get an urgent FBC if signs of infection, eg T°, sore throat/mouth ulcers. 2 Radioiodine ( 131I): Most become hypothyroid post-treatment. There is no evidence for cancer, birth defects, or infertility in women. CI: pregnancy, lactation. Caution in active hyperthyroidism as risk of thyroid storm (p835). 3 Thyroidectomy (usually total): Carries a risk of damage to recurrent laryngeal nerve (hoarse voice) and hypoparathyroidism. Patients will become hypothyroid, so thyroid replacement needed. 4 In pregnancy and infancy: Get expert help. See OHCS p24 OHCS p182. Complications Heart failure (thyrotoxic cardiomyopathy, in elderly), angina, atrial fibrillation (seen in 1025%: control hyperthyroidism and war farinize if no contraindication), osteoporosis, ophthalmopathy, gynaecomastia. Thyroid storm (p835). __OOHHCCMM__1100ee. . iinnddbb 221188 0022//0055//22001177 1199: : 0077 219 ygolonircodnE Thyroid eye disease Seen in 2550% of people with Graves disease. The main known risk factor is smoking. The eye disease may not correlate with thyroid disease and the patient can be euthyroid, hypothyroid, or hyperthyroid at presentation. Eye disease may be the fi rst presenting sign of Graves disease, and can also be worsened by treatment, typically with radioiodine (usually a transient eff ect). Retro-orbital infl ammation and lymphocyte infi ltration results in Edema of the orbit. Symptoms Eye discomfort, grittiness, tear production, photophobia, diplopia, acuity, aff erent pupillary defect (p72) may mean optic nerve compression: Seek expert advice at once as decompression may be needed. Nerve damage does not necessarily go hand-in-hand with protrusion. Indeed, if the eye cannot protrude for anatomical reasons, optic nerve compression is more likelya paradox! Signs Exophthalmosappearance of protruding eye; proptosiseyes protrude beyond the orbit (look from above in the same plane as the forehead); conjunctival oedema; corneal ulceration; papilloedema; loss of colour vision. Ophth almoplegia (especially of upward gaze) occurs due to muscle Edema and fi brosis. Tests Diagnosis is clinical. computed tomography/magnetic resonance imaging of the orbits may reveal enlarged eye muscles. Management Get specialist help. Treat hyperor hypothyroidism. Advise to stop smoking (worse prognosis). Most have mild disease that can be treated symptomatically (artifi cial tears, sunglasses, avoid dust, elevate bed when sleeping to periorbital oedema). Diplopia may be managed with a Fresnel prism stuck to one lens of a spectacle (aids easy changing as the exophthalmos changes). In more severe disease, try High-dose steroids (IV methylprednisolone is better than prednisolone 100mg/day PO)18decreasing according to symptoms. Surgical decomp ression is used for severe sight-threatening disease, or for cosmetic reasons once the activity of eye disease has reduced (via an inferior orbital approach, using space in the ethmoidal, sphenoidal, and maxillary sinuses). Eyelid surgery may improve cosmesis and function. Orbital radiotherapy can be used to treat ophthalmoplegia but has little eff ect on proptosis. Future options: Anti-TNF antibodies (eg infl iximab). Causes of goitre Diffuse Physiological Graves disease Hashimotos thyroiditis Subacute (de Quervains) Fig 5. 14 Thyroid eye disthyroiditis (painful). ease: lid retraction causing a Nodular staring appearance. Multinodular goitre Fig 5. 15 Goitre. Adenoma Carcinoma. Table 5.",
    "ease: lid retraction causing a Nodular staring appearance. Multinodular goitre Fig 5. 15 Goitre. Adenoma Carcinoma. Table 5. 3 Manifestations of Graves diseaseand pathophysiology Pituitary Suppressed TSH Expression of thyrotropin subunit Heart Rate; contractility Serum atrial natriuretic peptide Liver Peripheral T3; LDL (p690) Type 1 5-deiodinase; LDL receptors Bone Bone turnover; osteoporosis Osteocalcin; ALP; urinary N-telopeptide Genital Libido; erectile dysfunction Sex hormone globulin; testosterone Genital Irregular menses Oestrogen antagonism Metabolic Thermogenesis; O2 use Fatty acid oxidation; sodium-potassium ATPase White fat Fat mass Adrenergic-mediated lipolysis CNS Stiff person syndrome (rare) Antibodies to glutamic acid decarboxylase Muscle Proximal myopathy Sarcoplasmic reticulum Ca2-activated ATPase Thyroid Secretion of T3 and T4 Type 2 5-deiodinase activity in thyroid Emotional or tactile stimuli cause spasms; seen in any autoimmune state (eg type 1 diabetes mellitus); : baclofen± IV Ig. __OOHHCCMM__1100ee. . iinnddbb 221199 0022//0055//22001177 1199: : 0077 220 ygolonircodnE Hypothyroidism (myxoedema) The clinical eff ect of lack of thyroid hormone. It is common (4/1000/yr). If treated, prognosis is excellent; untreated it is disastrous (eg Heart disease, dementia). As it is insidious, both you and your patient may not realize anything is wrong, so be alert to subtle, non-specifi c symptoms, esp. in women 40yrs old (: 6: 1). Symptoms Tiredness; sleepy, lethargic; mood; cold-disliking; weight; constipa tion; men orrhagia; hoarse voice; memory/cognition; dementia; myalgia; cramps; weakness. Signs BRADYCARDIC; refl exes relax slowly; ataxia (cerebellar); dry thin hair/skin; yawn i ng/drowsy/coma (p834); cold hands ± T°; ascites ± non-pitting oedema (lids; hands; feet) ± peri cardial or pleural eff usion; round puff y face/double chin/obese; defeated demeanour; immobile ± ileus; CCF. Also: neuropathy; myopathy; goitre (fi g 5. 16). Diagnosis (p216) Have a Low threshold for doing TFTs! TSH (eg ≥4mU/L); 3 T4 (in rare secondary hypothyroidism: T4 and TSH or due to lack from the pituitary, p232). Cholesterol and triglyceride; macrocytosis (less often normochromic anaemia too). Causes of primary autoimmune hypothyroidism Primary atrophic hypothyroidism: : 6: 1. Common. Diff use lymphocytic infi ltration of the thyroid, leading to atrophy, hence no goitre. Hashimotos thyroiditis: Goitre due to lympho cytic and plasma cell infi ltration. Commoner in women aged 6070yrs. May be hypothyroid or euthyroid; rarely initial period of hypert hyroid (Hashitoxicosis). Autoantibody titres are very High. Other causes of primary hypothyrodism World-wide the chief cause is iodine defi ciency. Post-thyroidectomy or radioiodine treatment. Drug-induced: Antithyroid drugs, amiodarone, lithium, iodine. Subacute thyroiditis: Temporary hypothyroidism after hyperthyroid phase. Secondary hypothyroidism Not enough TSH (due to hypopituitarism); very rare. Hypothyroidisms associations Autoimmune is seen with other autoimmune diseases (type 1 diabetes mellitus, Addisons, and PA, p334). Turners and Downs syndromes, cystic fi brosis, primary biliary cholangitis, ovarian hyperstimulation (OHCS p311); POEMS syndromepoly neuropathy, organomegaly, endocrinopathy, m-Protein band (plasmacytoma) skin pigmentation/tethering. Genetic: Dyshormonogenesis: genetic (often autosomal recessive) defect in hormone synthesis, eg Pendreds syndrome (with deafness): there is uptake on isotope scan, which is displaced by Potassium perchlorate. Pregnancy problems Eclamps ia, anaemia, prematurity, birthweight, stillbirth, PPH. Treatment Healthy and young: Levothyroxine (T4), 0100mcg/24h PO; review at 12wks. Adjust 6-weekly by clinical state and to normalize but not suppress TSH (keep TSH 0. 5mU/L). Thyroxines t½ is 7d, so wait 4wks before checking TSH to see if a dose change is right. NB: small changes in serum free T4 have a logarithmic eff ect on TSH. Once normal, check TSH yearly. Enzyme inducers (p689) metabolism of levothyroxine. Elderly or ischaemic Heart disease: Start with 25mcg/24h; dose by 25mcg/4wks according to TSH (cautiously, as levothyroxine may precipitate angina or myocardial infarction). If diagnosis is in question and T4 already given: Stop T4; recheck TSH in 6 weeks.",
    "If TSH 0. 1, treat on an individual basis, eg with symptoms of hyperthyroidism, atrial fibrillation, unexplained weight loss, osteoporosis, goitre. Options are carbimazole or propylthiouracilor radioiodine therapy. If no symptoms, recheck 6-monthly. Fig 5. 16 Facial appearance in hypothyroidism. Look for: pallor; coarse, brittle, diminished hair (scalp, axillary, and pubic); dull or blank express ion lack ing sparkle; coarse features; puff y lids. These signs are subtle: have a Low thresh old for meas uring TSH. Reproduced from Cox and Roper, Clinical Skills, 2005, with permission from Oxford University Press. __OOHHCCMM__1100ee. . iinnddbb 222211 0022//0055//22001177 1199: : 0077 222 ygolonircodnE Parathyroid hormone and hyperparathyroidism Parathyroid hormone (parathyroid hormone) is normally secreted in response to Low ionized Ca2 levels, by four parathyroid glands situated posterior to the thyroid (p601). The glands are controlled by Ωve feedback via Ca2 levels. parathyroid hormone acts by: osteoclast activity releasing Ca2 and phosphate 3Ω from bones Ca2 and phosphate 3Ω reabsorption in the Kidney active 1, 25 dihydroxy-vitamin D3 production is . Overall eff ect is Ca2 and phosphate 3Ω. Primary hyperparathyroidism Causes: 80% solitary adenoma, 20% hyper plasia of all glands, 0. 5% parathyroid cancer. Presentation: Often asymp tomatic (not in retrospect! ), with Ca2 on routine tests. Signs relate to: 1 Ca2 (p676): weak, tired, depressed, thirsty, dehydrated-but-polyuric; also renal stones, abdominal Pain, panc reatitis, and ulcers (duodenal: gast ric 7: 1). 2 Bone resorption eff ects of parathyroid hormone can cause Pain, fractures, and osteopenia/osteoporosis. 3 blood pressure: so check Ca2 in everyone with hypertension. Association: MEN-1 (BOX Multiple endocrine neoplasia). Tests: Ca2 parathyroid hormone or inappropriately normal (other causes of this: thiazides, lithium, familial hypo calciuric hypercalcaemia, tert iary hyperp arathyroidism). Also phosphate 3Ω (unless in renal failure), ALP from bone activity, 24h urinary Ca2. Imaging: osteitis fi brosa cystica (due to severe resorption; rare) may show up as subperiosteal erosions, cysts, or brown tumours of phala nges ± acro-osteolysis (fi g 5. 17) ± pepper-pot skull. DEXA (p683; for osteoporo sis, p682). : If mild: advise fl uid intake to prevent stones; avoid thiazides High Ca2 vitamin D intake; see 6-monthly. Excision of the adenoma or of all four hyperplastic glands prevents fractures and peptic ulcers. Indications: High serum or urinary Ca2, bone disease, osteop or osis, renal calculi, renal function, age 50yrs. Complications: Hypo para thy roidism, recurFig 5. 17 Acrorent laryngeal nerve damage ( hoarse), sympto matic Ca2 (hungry osteol ysis. bones syndr ome; check Ca2 daily for ≥14d post-op). Pre-op ultrasound and Dr I Maddison MIBI scan may localize an adenoma; intra-operative parathyroid hormone sampling is myweb. lsbu. before meals. uk. used to confi rm removal. Recurrence: 8% over 10yrs. 19 Cinacalcet (a calcimimetic) sensitivity of parathyroid cells to Ca2 ( parathyroid hormone secreti on); monitor Ca2 within 1 week of dose changes; SE: myalgia; testosterone. Secondary hyperparathyroidism Ca2, parathyroid hormone (appropriately). Causes: vitamin D intake, chronic renal failure. : Correct causes. Phosphate binders; vitamin D; cinacalcet if parathyroid hormone ≥85pmol/L and parathyroidectomy tricky. Tertiary hyperparathyroidism Ca2, parathyroid hormone (inappropriately). Occurs after prolonged secondary hyperparathyroidism, causing glands to act autonomously having undergone hyperplastic or adenomatous change. This causes Ca2 from secretion of parathyroid hormone unlimited by feedback control. Seen in chronic renal failure. Malignant hyperparathyroidism Parathyroid-related Protein (PTHrP) is produced by some squamous cell lung cancers, breast and renal cell carcinomas. This mimics parathyroid hormone resulting in Ca2 (parathyroid hormone is , as PTHrP is not detected in the assay). Hypoparathyroidism Primary hypoparathyroidism parathyroid hormone secretion is due to gland failure. Tests: Ca2, phosphate 3Ωor , ALP.",
    "Hypoparathyroidism Primary hypoparathyroidism parathyroid hormone secretion is due to gland failure. Tests: Ca2, phosphate 3Ωor , ALP. Signs: Those of hypocalcaemia, p678 ± autoimmune co morbidi ties (BOX Autoimmune polyendocrine syndromes). Causes: Autoimmune; congenital (Di George syn. , OHCS p642). : Ca2 supplements calcitriol (or synthetic parathyroid hormone /12h SC: it prevents hypercalciuria). Secondary hypoparathyroidism Radiation, surgery (thyroidectomy, parathyroidectomy), hypomagnesaemia (magnesium is required for parathyroid hormone secretion). Pseudohypoparathyroidism Failure of target cell response to parathyroid hormone. Signs: Short metacarpals (esp. 4th and 5th, fi g 5. 18), round face, short stature, calcifi ed basal ganglia (fi g 5. 19), IQ. Tests: Ca2, parathyroid hormone, or ALP. : As for 1° hypoparathyroidism. Pseudopseudohypoparathyroidism The morphological features of pseudoh ypoparathyroidism, but with normal biochemistry. The cause for both is genetic. __OOHHCCMM__1100ee. . iinnddbb 222222 0022//0055//22001177 1199: : 0077 223 ygolonircodnE Multiple endocrine neoplasia (MEN types 1, 2a, and 2b) In MEN syndromes there are functioning hormone-producing tumours in multiple organs (they are inherited as autosomal dominants). 20 They comprise: MEN-1 and 2 Neurofi bromatosis (p514) Von HippelLindau and PeutzJeghers syndromes (p712 p708) Carney complex (spotty skin pigmentation, schwannomas, myxoma of skin, mucosa, or Heart, especially atrial myxoma), and endo crine tumours: eg pituit ary adenoma, adrenal hyperplasia, and testicular tumour. MEN-1: Parathyroid hyperplasia/adenoma (95%; most Ca2). Pancreas endocrine tumours (70%)gastrin oma (p716) or insulinoma (p215), or, rarely, somatostatino ma (diabetes mellitus steatorrhoea gallstones/cholangitis), VIPoma (p258), or gluc agonomas (±glucagon syndrome: migrating rash; glossitis; cheilitis, fi g 8. 5 p327; ana emia; weight; plasma glucagon; glucose). Pituitary prolactinoma (50%) or GH secreting tumour (acromegaly: 21 p239); also, adrenal and carcinoid tumours are associated. The MEN-1 gene is a tum our suppressor gene. Menin, its Protein, alters transc ription activation. Many are sporadic, presenting in the 3rd5th decades. MEN-2a: Thyroid: medullary thyroid carcinoma (seen in 100%, p600). Adrenal: phaeochromocytoma (50%, usually benign and bilateral). Parathyroid hyperplasia (80%, but less than 20% have Ca2). MEN-2b: Has similar features to MEN-2a plus mucosal neuromas and Marfanoid appearance (p706), but no hyper parathyroidism. Mucosal neuromas consist of bumps on: lips, cheeks, tongue, glottis, eyelids, and visi ble corneal nerves. The gene involved in MEN-2a and b is the ret proto-oncogene, a receptor tyrosine kinase. Tests for ret mutations are revolu tion izing MEN-2 treatment by enabling a prophylactic thyroidectomy to be done before neoplasia occurs, usually before 3yrs of age. NB: ret mutations rarely contribute to sporadic parathyroid tumours. Autoimmune polyendocrine syndromes Autoimmune disorders cluster into two defi ned syndromes: Type 1 Autosomal recessive, rare. Cause: Mutations of AIRE (Auto ImmuneREgulator) gene on chromosome 21. Features: Addisons disease. Chronic mucocutaneous candidiasis. Hypoparathyroidism. Also associated with hypogonadism, pernicious anaemia, autoimmune primary hypothyroidism, chronic active hepatitis, vitiligo, alopecia. Type 2 HLA D3 and D4 linked, common. Cause: Polygenic. Features: Addisons disease. Type 1 Diabetes mellitus (in 20%). Autoimmune thyroid diseasehypothyroidism or Graves disease. Also associated with primary hypogonadism, vitiligo, alopecia, pernicious anaemia, chronic atrophic gastritis, coeliac disease, dermatitis herpetiformis. Fig 5. 18 PseudohypoparaFig 5. 19 Cerebral calcifi cation in pseudohypopara thyroidthyroidism: short 4th and 5th ism: periventricular (left) and basal ganglia (right). metacarpals. Courtesy of Professor Peter Scally. __OOHHCCMM__1100ee. . iinnddbb 222233 0022//0055//22001177 1199: : 0077 224 ygolonircodnE Adrenal cortex and Cushings syndrome Physiology The adrenal cortex produces steroids: 1 Glucocorticoids (eg cortisol), which aff ect carbohydrate, lipid, and Protein metabolism. 2 Mineralocorticoids, which control Sodium and Potassium balance (eg aldosterone, p668). 3 Androgens, sex hormones which have weak eff ect until peripheral conversion to testosterone and dihydrotestosterone.",
    "3 Androgens, sex hormones which have weak eff ect until peripheral conversion to testosterone and dihydrotestosterone. Corticotropin-releasing factor (chronic renal failure) from the hypothalamus stimulates ACTH secretion from the pituitary, which in turn stimulates cortisol and androgen production by the adrenal cortex. Cortisol is excreted as urinary free cortisol and various 17-oxogenic steroids. Cushings syndrome This is the clinical state produced by chronic glucocorticoid excess loss of the normal feedback mechanisms of the hypothalamopituitary adrenal axis and loss of circadian rhythm of cortisol secretion (normally highest on waking). The chief cause is oral steroids. Endogenous causes are rare: 80% are due to ACTH; of these a pituitary adenoma (Cushings disease) is the commonest cause. 1 ACTH-dependent causes (ACTH) Cushings disease: Bilateral adrenal hyperplasia from an ACTH-secreting pituitary adenoma (usually a microadenoma, p234). : 1: 1. Peak age: 3050yrs. A Lowdose dexamethasone test (BOX) leads to no change in plasma cortisol, but 8mg may be enough to more than halve morning cortisol (as occurs in normals). Ectopic ACTH production: Especially small cell lung cancer and carcinoid tumours, p271. Specifi c features: pigmentation (due to ACTH), hypokalaemic metabolic alkalosis (cortisol leads to mineralocorticoid activity), weight loss, hyperg lycaemia. Classical features of Cushings are often absent. Dexamethasone even in High doses (8mg) fails to suppress cortisol production. Rarely, ectopic chronic renal failure production: Some thyroid (medullary) and prostate cancers. 2 ACTH-independent causes (ACTH due to Ωve feedback) Iatrogenic: Pharmacological doses of steroids (common). Adrenal adenoma/cancer: (May cause abdo Pain ± virilization in , p230. ) Because the tumour is autonomous, dexamethasone in any dose wont suppress cortisol. Adrenal nodular hyperplasia: (As for adrenal adenoma, no dexamethasone suppression. ) Rarely: Carney complex, p223. McCuneAlbright syndrome, see OHCS p650. Symptoms Weight; mood change (depression, lethargy, irritability, psychosis); proximal weakness; gonadal dysfunction (irregular menses; hirsuti sm; erectile dysfunction); acne; recurrent Achilles tendon rupture; occasionally virilization if . Signs Central obesity; plethoric, moon face; buff alo hump; supraclavicular fat distribution; skin muscle atrophy; bruises; purple abdominal striae (fi g 5. 20); osteoporosis; blood pressure; glucose; infection-prone; poor healing. Signs of the cause (eg abdo mass). Tests Random plasma cortisols may mislead, as illness, time of day, and stress (eg vene puncture) infl uence results. Also, dont rely on imaging to localize the cause: nonfunctioning incidentalomas occur in 5% on adrenal computed tomography and 10% on pituitary magnetic resonance imaging. magnetic resonance imaging detects only 70% of pituitary tumours causing Cushings (many are too small). Treatment Depends on the cause. Iatrogenic: Stop medications if possible. Cushings disease: Selective removal of pituitary adenoma (trans -sphenoidally). Bilateral adrenalectomy if source unlocatable, or recurrence post-op (complication: Nelsons syndrome: skin pigmentation due to ACTH from an enlarging pituitary tumour, as adrenalectomy removes Ωve feedback; responds to pituitary radiation). Adrenal adenoma or carcinoma: Adrenalectomy: cures adenomas but rarely cures cancer. Radiotherapy adrenolytic drugs (mitotane) follow if carcinoma. Ectopic ACTH: Surgery if tumour is located and hasnt spread. Metyrapone, ketoconazole, and fl uconazole cortisol secretion pre-op or if awaiting eff ects of radiation. Intubat ion mifepristone (competes with cortisol at receptors) etomidate (blo cks cortisol synthesis) may be needed, eg in severe ACTH-associated psychosis. Prognosis Untreated Cushings has vascular mortality. 22 Treated, prognosis is Good (but myopathy, obesity, menstrual irregularity, blood pressure, osteoporosis, subtle mood changes and diabetes mellitus often remainso follow up carefully, and manage individually). __OOHHCCMM__1100ee. . iinnddbb 222244 0022//0055//22001177 1199: : 0077 225 ygolonircodnE Investigating suspected Cushings syndrome First, confi rm the diagnosis (a raised plasma cortisol), then localize the source on the basis of laboratory testing. Use imaging studies to confi rm the likely source.",
    "Use imaging studies to confi rm the likely source. 1st-line tests Overnight dexamethasone suppression test is a Good outpatient test. Dexamethasone 1mg PO at midnight; do serum cortisol at 8AM. Normally, cortisol suppresses to 50nmol/L; no suppression in Cushings syndrome. False Ωve rate: 2%; false ves: 2% normal, 13% obese, and 23% of inpatients. NB: false ves (pseudoCushings) are seen in depression, obesity, alcohol excess, and inducers of Liver enzymes (rate of dexamethasone metabolism, eg phenytoin, phenobarbital, rifampicin, p689). 24h urinary free cortisol (normal: 280nmol/24h) is an alternative. 2nd-line tests If 1st-line tests abnormal: 48h dexamethasone suppression test: Give dexamethasone 0. 5mg/6h PO for 2d. Measure cortisol at 0 and 48h (last test at 6h after last dose). Again, in Cushings syndrome, there is a failure to suppress cortisol. 48h High-dose dexamethasone suppression test: (2mg/6h. ) May distinguish pituitary (suppression) from others causes (no/part suppression). Midnight cortisol: Admit (unless salivary cortisol used). Often inaccurate due to measurement issues. Normal circadian rhythm (cortisol lowest at midnight, highest early morning) is lost in Cushings syndrome. Midnight Blood, via a cannula during sleep, shows cortisol in Cushings. Localization tests (Where is the lesion? ) If the 1stand 2nd-line tests are ve Plasma ACTH. If ACTH is undetectable, an adrenal tumour is likely computed tomography/magnetic resonance imaging adrenal glands. If no mass, proceed to adrenal vein sampling. If ACTH is detectable, distinguish a pituitary cause from ectopic ACTH production by High-dose suppression test or corticotropin-releasing hormone (CRH) test: 100mcg ovine or human CRH IV. Measure cortisol at 120min. Cortisol rises with pituitary disease but not with ectopic ACTH production. If tests indicate that cortisol responds to manipulation, Cushings disease is likely. Image the pituitary (magnetic resonance imaging) and consider bilateral inferior petrosal sinus Blood sampling. If tests indicate that cortisol does not respond to manipulation, hunt for the source of ectopic ACTHeg IV contrast computed tomography of chest, abdomen, and pelvis ± magnetic resonance imaging of neck, thorax, and abdomen, eg for small ACTH secreting carcinoid tumours. Fig 5. 20 Hypercortisolism weakens skin; even normal stretching (or the Hypertension of obesity, as here) can make its elastin break on healing we see these depressed purple scars (striae). Cortisone or rapid growth contributes to striae in other contexts: pregnancy, adolescence, weight lifting, sudden-onset obesity, or from strong steroid creams. Striae mature into silvery crescents looking like the underside of willow leaves. Unsightly immature striae may be improved by YAG lasers. __OOHHCCMM__1100ee. . iinnddbb 222255 0022//0055//22001177 1199: : 0077 226 ygolonircodnE Addisons disease (adrenal insuffi ciency) Primary adrenocortical insuffi ciency (Addisons disease) is rare (0. 8/100 000), but can be fatal. Destruction of the adrenal cortex leads to glucocorticoid (cortisol) and mineralocorticoid (aldosterone) defi ciency (see fi g 5. 21). Signs are capricious: it is the unforgiving master of non-specifi city and disguise. 23 You may diagnose a viral infection or anorexia nervosa in error (potassium is in the latter but in Addisons). Physiology: Fig 5. 21 Pathways involved in adrenal function. Causes: 80% are due to autoimmunity in the UK. Other causes: TB (commonest cause worldwide), adrenal metastases (eg from lung, breast, renal cancer), lymphoma, opportunistic infections in HIV (eg CMV, Mycobacterium avium, p400); adrenal haemorrhage (WaterhouseFriderichsen syndrome p714; antiphosphol ipid syndrome; SLE), congenital (late-onset congenital adrenal hyperplasia). Secondary adrenal insuffi ciency The commonest cause is iatrogenic, due to longterm steroid therapy leading to suppression of the pituitaryadrenal axis. This only becomes apparent on withdrawal of the steroids. Other causes are rare and include hypothalamicpituitary disease leading to ACTH production. Mineralocorticoid production remains intact, and there is no hyperpigmentation as ACTH.",
    "Mineralocorticoid production remains intact, and there is no hyperpigmentation as ACTH. Symptoms Often diagnosed late: lean, tanned, tired, tearful ± weakness, anorexia, Dizziness, faints, fl u-like myalgias/arthralgias. Mood: depression, psychosis. GI: nausea/ Vomiting, abdominal Pain, diarrhoea/constipation. Think of Addisons in all with unexplained abdominal Pain or Vomiting. Pigmented palmar creases buccal mucosa (ACTH; cross-reacts with melanin receptors). Postural hypotension. Vitiligo. Signs of critical deterioration (p836): Shock (blood pressure, tachycardia), T°, coma. Tests sodium potassium (due to mineralocorticoid), glucose (due to cortisol). Also: uraemia, Ca2, eosinophilia, anaemia. : Short ACTH stimulation test (Synacthen test): Do plasma cortisol before and ½h after tetracosactide (Synacthen) 250mcg IM. Addis ons is excluded if 30min cortisol 550nmol/L. Steroid drugs may interfere with assays: ask lab. NB: in pregnancy and contraceptive pill, cortisol levels may be reass u ring but falsely , due to cortisol-binding globulin. Also: ACTH: In Addisons, 9AM ACTH is (300ng/L: inappropriately High). It is Low in secondary causes 21-Hydroxylase adrenal autoantibodies: ve in autoimmune disease in 80% Plasma renin aldosterone: to assess mineralocortocoid status. AXR/CXR: Any past TB, eg upper zone fi brosis or adrenal calcifi cation? If no autoantibodies, consider further tests (eg adrenal computed tomography) for TB, histoplasma, or metastatic disease. Treatment See p836 for Addisonian crisis (shocked). Replace steroids: 1525mg hydrocortisone daily, in 2 3 doses, eg 10mg on waking, 5mg lunchtime. Avoid giving late (may cause insomnia). Mineralocorticoids to correct postural hypotension, sodium, potassium: fl udrocortisone PO from 50200mcg daily. Adjust both on clinical grounds. If there is a poor response, susp ect an associated autoi mmune disease (check thyroid, do coeliac serology: p266). __OOHHCCMM__1100ee. . iinnddbb 222266 0022//0055//22001177 1199: : 0077 227 ygolonircodnE Steroid use Advise wearing a bracelet declaring steroid use. Add 510mg hydrocortisone to daily intake before strenuous activity/exercise. Double steroids in febrile illness, injury, or stress. Give out syringes and in-date IM hydrocortis one, and show how to inject 100mg IM if Vomiting prevents oral intake (seek medical help; admit for IV fl uids if dehydrated). Follow-up Yearly (blood pressure, UE); watch for autoimmune diseases (pernicious anaemia). 4 Prognosis (treated) Adrenal crises and infections do cause excess deaths: mean age at death for men is 65yrs (11yrs estimated life expectancy; women lose 3yrs). Exogenous steroid use Replacement steroids are vital in those taking long-term steroids when acutely unwell. Adrenal insuffi ciency may develop with deadly hypovolaemic shock, if additional steroid is not given. See p836. Steroid use: Warn against abruptly stopping steroids. Emphasize that prescribing doctors/dentists/surgeons must know of steroid use: give steroid card. Excerpt from the notes of Miss E. L. R. , 92 days before her death from undiagnosed Addisons disease. From the Coroners Court Typical daywakes up at 11. 30, still feels tired, then will have some breakfast and usually fall asleep on the couch. The most energy req. activity in last 1 month iscooking herself a pasta meal. Then, totally exhausted will sleep more in pm, then Eat some dinner. Goes to bed at 11pmlatest. Not able to concentrateUsed to weigh 45kg. Now weighs 42kg. 24 Placed on a page about Addisons disease, we might think there are suffi cient clues to raise the suspicion of Addisons (even though her electrolytes were not particularly awry, and her pigmentation was barely perceptible). But change the context to our last busy clinic. We are a little distracted. The memory of Addisons is fading. Who among ultrasound will hear the alarm bell ring? 4 Autoimmune polyglandular syndromes types 14: 1 Monogenic syndrome (AIRE gene on chromosome 21); signs: candidiasis, hypoparathyroidism Addisons. 2 (Schmidt syndrome. )",
    "2 (Schmidt syndrome. ) Adrenal insuffi ciency auto immune thyroid disease ± diabetes mellitus ± pleuritis /pericarditis. 3 Autoimmune thyroid disease other autoimmune conditions but not Addisons. 4 Autoimmune combinations not included in 13. __OOHHCCMM__1100ee. . iinnddbb 222277 0022//0055//22001177 1199: : 0077 228 ygolonircodnE Hyperaldosteronism Primary hyperaldosteronism Excess production of aldosterone, independent of the reninangiotensin system, causing Sodium and Water retention, and renin release. Consider if: hypertension, hypokalaemia, or alkalosis in someone not on diuretics. Sodium tends to be mildly raised or normal. Symptoms: Often asymptomatic or signs of hypokalaemia (p674): weakness (even quadriparesis), cramps, paraesthesiae, polyuria, polydipsia. blood pressure but not always. Causes: ⅔ due to a solitary aldosterone-producing adenoma (linked to mutations in potassium channels)5Conns syndrome. ⅓ due to bilateral adrenocortical hyperplasia. Rare causes: adrenal carcinoma; or glucocorticoid-remediable aldosteronism (GRA) the ACTH regulatory element of the 11-hydroxylase gene fuses to the aldosterone synthase gene, aldosterone production, bringing it under the control of ACTH. Tests: UE, renin and aldosterone, and adrenal vein sampling. Do not rely on a Low potassium, as 20% are normokalaemic. For GRA (suspect if there is a family history of early hypertension), genetic testing is available. Treatment: Conns: laparoscopic adrenalectomy. Spironolactone (25100mg/24h PO) for 4wks pre-op controls blood pressure and potassium. Hyperplasia: treated medically: spironolactone or amiloride. GRA: dexamethasone 1mg/24h PO for 4wks, normalizes biochemistry but not always blood pressure. If blood pressure is still , use spironolactone as an alternative. Adrenal carcinoma: surgery ± post-operative adrenolytic therapy with mitotaneprognosis is poor. Secondary hyperaldosteronism Due to a High renin from renal perfusion, eg in renal artery stenosis, accelerated hypertension, diuretics, CCF, or hepatic failure. Bartters syndrome This is a major cause of congenital (autosomal recessive) salt wastingvia a Sodium and chloride leak in the loop of Henle via mutations in channels and transporters. Presents in childhood with failure to thrive, polyuria, and polydipsia. blood pressure is normal. Sodium loss leads to volume depletion, causing renin and aldosterone production, leading to hypokalaemia and metabolic alkalosis, urinary potassium and ClΩ. Treatment: potassium replacement, NSAIDS (to inhibit prostaglandins), and angiotensin-converting enzyme inhibitor. Phaeochromocytoma Rare catecholamine-producing tumours. They arise from sympathetic paraganglia cells (phaeo chrome bodies), which are collections of chromaffi n cells. They are usually found within the adrenal medulla. Extra-adrenal tumours (paragangliomas) are rarer, and often found by the aortic bifurcation (the organs of Zuckerkandl). Phaeochromocytomas roughly follow the 10% rule: 10% are malignant, 10% are extra-adrenal, 10% are bilateral, and 10% are familial. Recent data suggest higher preponderance in patients with genetic mutations aff ecting several genes including SDH (succinyl dehydrogenase). Thus, family history is crucial and referral for genetic screening (particularly 50 years old). A dangerous but treatable cause of hypertension (in 0. 1%). Associations 90% are sporadic; 10% are part of hereditary cancer syndromes (p215), eg thyroid, MEN-2A and 2B, neurofi bromatosis, von HippelLindau syndrome (SDH mutations). Classic triad Episodic headache, sweating, and tachycardia (± , , or blood pressure, see BOX Features of phaeochromocytoma). Tests Biochemical: 24h Urine for metanephrines/metadrenaline (better than catecholamines and vanillylmandelic acid25), WCC. Localization: Abdominal computed tomography/magnetic resonance imaging, or meta-iodob enzylguanidine (chromaffi n-seeking isotope) scan (can fi nd extraadrenal tumours, p738). Treatment Surgery: -blockade pre-op: pheno xybenzamine (-blocker) is used before -blocker to avoid crisis from unopposed -adrenergic stimulation, -block too if Heart disease or tachycardic. Consult the anaesthetist. Post-op: Do 24h Urine metanephrine 2wks post-op, monitor blood pressure (risk of blood pressure). Emergency : p837. If malignant, chemotherapy or therapeutic radiolabelled MIBG may be used. Follow-up: Lifelong: malignant recurrence may present late, genetic screening.",
    "If malignant, chemotherapy or therapeutic radiolabelled MIBG may be used. Follow-up: Lifelong: malignant recurrence may present late, genetic screening. 5 Tumours from the zona glomerulosa, zona fasciculata, or zona reticularis associate with syndromes of mineralocorticoids, glucocorticoids, or androgens respectively, usually; remember glomerular filtration rateminer GA. __OOHHCCMM__1100ee. . iinnddbb 222288 0022//0055//22001177 1199: : 0077 229 ygolonircodnE Hypertension: a common context for hyperaldosteronism tests Think of Conns in these contexts: Hypertension associated with hypokalaemia. Refractory hypertension, eg despite ≥3 antihypertensive drugs. Hypertension occurring before 40yrs of age (especially in women). The approach to investigation remains controversial, but the simplest is to look for a suppressed renin and aldosterone (may be normal if there is severe hypokalaemia). computed tomography or magnetic resonance imaging of the adrenals is done to localize the cause. This should be done after hyperaldosteronism is proven, due to the High number of adrenal incident alomas. If imaging shows a unilateral adenoma, adrenal vein sampling may be done (venous Blood is sampled from both adrenals). If one side reveals increased aldosterone: cortisol ratio compared with the other (3-fold diff erence), an adenoma is likely, and surgical excision is indicated. If no nodules or bilateral nodules are seen, think about adrenal hyperplasia or GRA. NB: renal artery stenosis is a more common cause of refractory blood pressure and potassium (p315). Features of phaeochromocytoma (often episodic and often vague) Try to diagnose before death: suspect if blood pressure hard to control, accelerating, or episodic. Heart: Pulse; palpit ations/VT; dyspnoea; faints; angina; myocardial infarction/LVF; cardiomyopathy. 6 CNS: Headache; visual disorder; dizziness; tremor; numbness; fi ts; encephalopathy; Horners syndrome (paraganglioma); subarachnoid/CNS haemorrhage. Psychological: Anxiety; panic; hyperactivity; confusion; episodic psychosis. Gut: DV; abdominal Pain over tumour site; mass; mesenteric vasoconstriction. Others: Sweats/fl ushes; heat intolerance; pallor; T°; backache; haemoptysis. Symptoms may be precipitated by straining, exercise, stress, abdominal Hypertension, surgery, or by agents such as -blockers, IV contrast agents, or the tricyclics. The site of the tumour may determine precipitants, eg if pelvic, precipitants include sexual intercourse, parturition, defecation, and micturition. Adrenergic crises may last minutes to days. Suddenly patients feel as if about to dieand then get better, or go on to develop a stroke or cardiogenic shock. On examination, there may be no signs, or hypertension ± signs of Heart failure/cardiomyopathy (± paradoxical shock, similar to Takotsubos6), episodic thyroid Edema, glycosuria during attacks, or terminal haematuria from a bladder phaeochromocytoma. 6 Takotsubo cardiomyopathy (stressor catecholamine-induced cardiomyopathy/broken Heart syndrome) may cause sudden chest Pain mimicking myocardial infarction, with ST segments, and its signature apical ballooning on echo (also ejection fraction) occurring during catecholamine surges. It is a cause of myocardial infarction in the presence of normal arteries. The stress may be medical (SAH, p478) or psychological. __OOHHCCMM__1100ee. . iinnddbb 222299 0022//0055//22001177 1199: : 0077 230 ygolonircodnE Hirsutism, virilism, gynaecomastia, and impotence Hirsutism is common (10% of women) and usually benign. It implies male pattern hair growth in women. Causes are familial, idiopathic, or are due to androgen secretion by the ovary (eg polycystic ovarian syndrome, ovarian cancer, OHCS p281), the adrenal gland (eg late-onset congenital adrenal hyperplasia, OHCS p251, Cushings syndrome, adrenal cancer), or drugs (eg steroids). Polycystic ovarian syndrome (PCOS) causes secondary oligoor amenorrhoea, infertility, obesity, acne, and hirsutism (OHCS p252). Ultrasound: bilateral polycystic ovaries. Blood tests: testosterone (if ≥6nmol/L, look for an androgen-producing adrenal or ovarian tumour), sexhormone binding globulin, LH: FSH ratio (not consistent), TSH, lipids. Address any feelings of lack of conformity to societys perceived norms of feminine beauty.",
    "Address any feelings of lack of conformity to societys perceived norms of feminine beauty. Management: Healthy eating, optimize weight, shaving; laser photoepilation; wax; creams, eg efl ornithine, or ele c trolysis (expensive/time-consuming, but eff ective); bleach (1: 10 hydrogen peroxide). Oestrogens: combined contraceptive pill (OHCS p302)Yasmin is one choice as its progestogen, drospirenone, is an antimineralocorticoid. Alternatively, co-cyprindiol provided there are no contraindications, such as uncontrolled hypertension and current breast cancer. Stop co-cyprindiol 34 months after hirsutism has completely resolved because of increased VTE risk. If COCS are contraindicated or have not worked (after 6/12), refer the woman to secondary care for specialist treatment: Metformin (helps with insulin resistance) and spironolactone are sometimes tried. Clomifene is used for infertility (a fertility expert should prescribe). Virilism Onset of amenorrhoea, clitoromegaly, deep voice, temporal hair recession hirsutism. Look for an androgen-secreting adrenal or ovarian tumour. Gynaecomastia (ie abnormal amount of breast tissue in men; may occur in normal puberty. ) Oestrog en/androgen ratio (vs galactorrhoea in which prolactin is ). Causes: Hypogonadism (see BOX Male hypogonadism), Liver cirrhosis (oestrogens), hyperthyroidism, tumours (oestrogen-producing, eg testicular, adrenal; HCG-producing, eg testicular, bronchial); drugs: oestrogens, spirono lactone, digoxin, testosterone, marijuana; if stopping is impossible, consider testosterone if hypogonadism ± antioestrogen (tamoxifen). Impotence ( erectile dysfunction) Erections result from neuronal release of nitric oxide (NO) which, via cGMP and Ca2, hyperpolarizes and thus relaxes vascular and trabecular smooth muscle cells, allowing engorgement. Common after 50yrs, and often multifactorial. A psychological facet is common (esp. if erectile dysfunction occurs only in some situations, if onset coincides with stress, and if early morning erections still occur: these also persist in early organic disease). Organic causes: The big three: smoking, alcohol, and Diabetes (reduce NO autonomic neuropathy). Also endocrine: hypogonadism, hyperthyroidism, prolactin; neurological: cord lesions, MS, autonomic neuropathy; pelvic surgery, eg bladder-neck, prostate; radiotherapy; atheroma; renal or hepatic failure; prostatic hyperp lasia; penile anomalies, eg post-priapism, or Peyronies (p708); drugs: digoxin, -blockers, diuretics, antipsychotics, antidepressants, oestrogens, fi nasteride, narcotics. Workup: After a full sexual and psychological history do: UE, LFT, glucose, TFT, LH, FSH, lipids, testosterone, prolactin ± Doppler. Is penile arterial Hypertension enough for infl ow? Is penile sensation OK (if not, ? CNS problem)? Is the veno-occlusive mechanism OK? : Treat causes. Counselling. Oral phosphodiesterase (PDE5) inhibitors cGMP. Erection International Society of Nephrologyt auto matic (depends on erotic stimuli). Sildenafi l 25100mg ½1h presex (food and alcohol upset abso rption). SE: Headache (16%); fl ushi ng (10%); dyspepsia (7%); stuff y nose (4%); transient blue-green tingeing of vision (inhibition of retinal PDE6). CI: See BOX Contraindications and cautions to PD5 Inhibitors. Tadalafi l (long t½, ) 1020mg ½36h pre-sex. Dont use once daily. Vardenafi l (520mg). Vacuum aids (ideal for penile rehabilitation after radical prostatectomy), intra cavernosal injections, transurethral pellets, and prost heses (infl atable or malleable; partners may receive unnatural sensations). Corpus cavernosum tissue engineering (eg on acellular collagen scaff olds) is in its infancy. __OOHHCCMM__1100ee. . iinnddbb 223300 0022//0055//22001177 1199: : 0077 231 ygolonircodnE Contraindications and cautions to PD5 inhibitors Contraindications Concurrent use of nitrates. blood pressure High or systolic 90mmHg/arrhythmia. Degenerative retinal disorders, eg retinitis pigmentosa. Unstable angina/stroke 6 months ago. Myocardial infarction 90 days ago. Cautions Angina (especially if during intercourse). Bleeding; peptic ulcer (sildenafi l). Marked hepatic or renal impairment. Peyronies disease or cavernosal fi brosis. Risk of priapism (sickle-cell anaemia, myeloma, leukaemia). Concurrent complex antihypertensive regimens. Dyspnoea on minimal eff ort (sexual activity may be unsupportable).",
    "It is done in the morning (Water only taken from 22: 00h the night before). Have 50% glucose and hydrocortisone to hand and IV access. Glucose must fall below 2. 2mmol/L and the patient should bec ome symptomatic when cortisol and GH are taken. Normal: GH 20mU/L, and peak cortisol 550nmol/L. 3 Arginine growth hormone-releasing hormone test. 4 Glucagon stimulation test is alternative when ITT is contraindicated. Investigate cause: magnetic resonance imaging scan to look for a hypothalamic or pituitary lesion. Treatment Refer to an endocrinologist for assessment of pituitary fuction and to oversee hormone replacement and treatment of underlying cause. Hydrocortisone for 2° adrenal failure (p226) before other hormones are given. Thyroxine if hypothyroid (p220, but TSH is useless for monitoring). Hypogonadism (for symptoms and to prevent osteoporosis). : options include testosterone enan thate 250mg IM every 3 weeks, daily topical gels or buccal muco adhesive tablets. Patches (eg Testogel) are also used. : (premenopausal). Oestrogen: transdermal oestradiol patches, or contrac eptive pill (exceeds replacement needs) ± testosterone or dehydroepi androsterone (DHEA, in hypo androgenic women; a small amount may improve well-being and sexual function, and help bone mineral density and lean body mass). Gonadotropin therapy is needed to induce fertility in both men and women. Growth hormone (GH). Somatotrophin mimics human GH. It addresses problems of fat mass, bone mass, lean body mass (muscle bulk), exercise capacity, and problems with heat intolerance. 7 Autoimmune hypophysitis (infl amed pituitary) mimics pituitary adenoma. It may be triggered by pregnancy or immunotherapy blocking CTLA-4. No pituitary auto-antigen is yet used diagnostically. 8 Snake bite is a common cause in India (eg when associated with acute Kidney injury). 9 Sheehans syndrome is pituitary necrosis after postpartum haemorrhage. __OOHHCCMM__1100ee. . iinnddbb 223322 0022//0055//22001177 1199: : 0077 233 ygolonircodnE Fig 5. 22 Neuroendocrinology: emotions thoughts actions. As Michelangelo foretold (in his Creation of Adam) all gods and demons that have ever existed are within ultrasound as possibilities, desires, and ways of escape. Within the dark red vault of our skull we see human and god-like forms reaching out, as thoughts escape into actionswith legs extending into our brainstem (B) and a fi st is pushing from our hypothalamus into the pituitary stalk (P). Above the pituitary we have thoughts, ideas, impulses, and neurotransmitters. Below we have hormones. Between is the realm of neuroendocrinologythe neurosecretory cells which turn emotions into the releasing factors for the pituitary hormones (fi g 5. 4). Image courtesy of Gary Bevans; quote from Frank Lynn Meshberger. Michelangelo, Renaissance Man of the Brain, Too? __OOHHCCMM__1100ee. . iinnddbb 223333 0022//0055//22001177 1199: : 0077 234 ygolonircodnE Pituitary tumours Pituitary tumours (almost always benign adenomas) account for 10% of intracranial tumours (see fi gs 5. 23, 5. 24). They may be divided by size: a microadenoma is a tumour 1cm across, and a macroadenoma is 1cm. There are three histological types (table 5. 4): 1 Chromophobe 70%. Many are non-secretory, 10 some cause hypopituitarism. Half produce prolactin (PRL); a few produce ACTH or GH. Local Hypertension eff ect in 30%. 2 Acidophil 15%. Secrete GH or PRL. Local Hypertension eff ect in 10%. 3 Basophil 15%. Secrete ACTH. Local Hypertension eff ect rare. Symptoms are caused by Hypertension, hormones (eg galactorrhoea), or hypopituitarism (p232). FSH-secreting tumours can cause macro-orchidism in men, but are rare. Features of local Hypertension Headache, visual fi eld defects (bilateral temporal hemianopia, due to compression of the optic chiasm), palsy of cranial nerves III, IV, VI (Hypertension or invasion of the cavernous sinus; fi g 5. 25).",
    "25). Also, Diabetes insipidus (DI) (p240; more likely from hypothalamic disease); disturbance of hypothalamic centres of T°, sleep, and appetite; erosion through fl oor of sella leading to CSF rhinorrhoea. Tests magnetic resonance imaging defi nes intraand supra-sellar extension; accurate assessment of visual fi elds; screening tests: PRL, IGF-1 (p238), ACTH, cortisol, TFTS, LH/FSH, testosterone in , short Synacthen test. Glucose tolerance test if acromegaly suspected (p238). If Cushings suspected, see p225. Water deprivation test if DI is suspected (p240). Treatment Start hormone replacement as needed (p232). Ensure steroids are given before levothyroxine, as thyroxine may precipitate an adrenal crisis. For Cushings disease see p225, prolactinoma p236, acromegaly p238. Surgery: (fi g 5. 26) Most pituitary surgery is trans-sphenoidal, but if there is suprasellar extension, a trans-frontal approach may be used. For prolactinoma, 1st-line treatment is medical with a dopamine agonist, p236. Pre-op: ensure hydrocortisone 100mg IV/IM. Subsequent cortisol replacement and reasse ssment varies with local protocols: get advice. Post-op: retest pituitary function (p232) to assess replacement needs. Repeating dynamic tests for adrenal function ≥6 weeks post-op. Radiotherapy: (Eg stereotactic. ) Good for residual or recurrent adenomas (Good rates of tumour control and normalization of excess hormone secretion). 27 Post-op Recurrence may occur late after surgery, so life-long follow-up is required. Fertility should be discussed: this may be reduced post-op due to gonadotropins. Pituitary apoplexy Rapid pituitary enlargement from a bleed into a tumour may cause mass eff ects, cardiovascular collapse due to acute hypopituita rism, and death. Suspect if acute onset of headache, meningism, GCS, ophthalmop legia/visual fi eld defect, especially if there is a known tumour (may present like suba rachnoid haemorrhage). : Urgent steroids (hydrocortisone 100mg IV) and meticulous fl uid balance ± cabergoline (dopamine agonist, if prolactinoma) ± surgery; fi nd the cause, eg a predisposition to thrombosis, from antiphospholipid syndrome. Craniopharyngioma Not strictly a pituitary tumour: it originates from Rathk es pouch so is situated between the pituitary and 3rd ventricle fl oor. They are rare, but are the commonest childhood intracranial tumour. Over 50% present in childhood with growth failure; adults may present with amenorrhoea, libido, hypothalamic symptoms (eg DI, hyperphagia, sleep disturbance) or tumour mass eff ect. Tests: computed tomography/ magnetic resonance imaging (calcifi cation in 50%, may also be seen on skull x-ray). Treatment: Surgery ± post-op radiation; test pituitary function post-op. Table 5. 4 Frequency of hormones secreted by pituitary adenomas based on immunohistochemistry Hormone % Hormone % PRL only (prolactinoma) 35% ACTH (Cushings disease) 7% GH only (acromegaly) 20% LH/FSH/TSH ≥1% PRL and GH 7% No obvious hormone 30% Sensitive methods of TSH measurement have improved recognition of TSH-secreting tumours. These are now more frequently found at microadenoma stage, medially loca ted, and without associated hormone hypersecretion. In these tumours, somatostatin analogues (p238) are very helpful. See also Socin et al. Eur J Endocrinol. 2003; 148: 43342. 10 If 1cm, usually incidentaloma; most non-functioning macroadenomas are revealed by mass eff ect and/ or hypopituitarism. Here, recurrence after surgery is common, so follow carefully with MRIS. __OOHHCCMM__1100ee. . iinnddbb 223344 0022//0055//22001177 1199: : 0077 235 ygolonircodnE Fig 5. 23 Sagittal T1-weighted magnetic resonance imaging of the brain Fig 5. 24 Coronal T1-weighted magnetic resonance imaging of the brain (no gadolinium contrast) showing a lesion in (no gadolinium contrast) showing a lesion in the the pituitary fossa, most likely a haem or rhagic pituitary fossa (see fi g 5. 23). pituitary adenoma. Diff erential diagnosis inCourtesy of Norwich Radiology Dept. cludes a Rathkes cleft cyst. Courtesy of Norwich Radiology Dept. Fig 5.",
    "Diff erential diagnosis inCourtesy of Norwich Radiology Dept. cludes a Rathkes cleft cyst. Courtesy of Norwich Radiology Dept. Fig 5. 25 The pituitary glands relationships to cranial nerves III, IV, V, and VI. Reproduced from Turner and Wass, Oxford Handbook of Endocrinology and Diabetes, 2009, with permission from Oxford University Press. Fig 5. 26 Endoscopic surgery is now possible for pituitary surgery. __OOHHCCMM__1100ee. . iinnddbb 223355 0022//0055//22001177 1199: : 0077 236 ygolonircodnE Hyperprolactinaemia This is the commonest hormonal disturbance of the pituitary. It presents earlier in women (menstrual disturbance) but later in men (eg with erectile dysfunction and/or mass eff ects). Prolactin stimulates lactation. 11, 12 Raised levels lead to hypogonadism, infertility, and osteoporosis, by inhibiting secretion of gonadotropin-releasing hormone (hence LH/FSH and testosterone or oestrogen). Causes of raised plasma prolactin (PRL; 390mU/L) PRL is secreted from the anterior pituitary and release is inhibited by dopamine produced in the hypothala mus. Hyperprolactinaemia may result from 1 Excess production from the pituitary, eg prolactinoma. 2 Disinhibition, by compression of the pituitary stalk, reducing local dopamine levels. 3 Use of a dopamine antagonist. A PRL of 10005000mU/L may result from any, but 5000 is likely to be due to a prolactinoma, with macroadenomas (10mm) having the highest levels, eg 10 000100 000. Physiological: Pregnancy; breastfeeding; stress. Acute rises occur post-orgasm. 11 Drugs (most common cause): Metoclop ramide; haloperidol; methyldopa; oestrogens; ecstasy/MDMA; 12 antipsychotics (a reason for non-compliance: sustained hyperprolactinaemia may cause libido, anorgasmia, and erectile dysfunction). Diseases: Prolactinoma: microor macroadenoma; Stalk damage: pituitary adenomas, surgery, trauma; Hypot halamic disease: craniopharyngioma, other tumours; Other: hypothyroidism (due to TRH), chronic renal failure (excretion). Symptoms : Amenorrhoea or oligomenorrhoea; infertility; galactorrhoea (fi g 5. 27). Also: libido, weight, dry vagina. : Erectile dysfunction, facial hair, galactorrhoea. May present late with osteoporosis or local Hypertension eff ects from the tumour (p234). Tests Basal PRL: non-stressful venepuncture between 09. 00 and 16. 00h. Do a pregnancy test, TFT, UE. magnetic resonance imaging pituitary if other causes are ruled out. Management Refer to a specialist endocrinology clinic. Dopamine agonists (bromocriptine or cabergoline) are 1st line. Microprolactinomas: A tumour 10mm on magnetic resonance imaging (25% of ultrasound have asymptomatic microprolactinomas). Bromocriptine, a dopamine agonist, PRL secretion, restores menstrual cycles and tumour size. Dose is titrated up: 1. 25mg PO; increase weekly by 1. 252. 5mg/d until 2. 5mg/12h. SE: nausea, depression, postural hypotension (minimize by giving at night). If pregnancy is planned, use barrier contraception until 2 periods have occurred. If subsequent pregnancy occurs, stop bromocriptine after the 1st missed period. An alternative dopamine agonist is cabergoline: more eff ective and fewer SE, but there are fewer data on safety in pregnancy. NB: ergot alkaloids (bromocriptine and cabergoline) can cause fi brosis (eg echocardiograms are needed). Trans-sphenoidal surgery may be considered if intolerant of dopamine agonists. It has a High success rate, but there are risks of permanent hormone defi ciency and prolactinoma recurrence, and so it is usually reserved as a 2nd-line treatment. Macroprolactinomas: A tumour 10mm diameter on magnetic resonance imaging. As they are near the optic chiasm, there may be acuity, diplopia, ophthalmoplegia, visual-fi eld loss, and optic atrophy. Treat initially with a dopamine agonist (bromocriptine if fertility is the goal). Surgery is rarely needed, but consider if visual symptoms or Hypertension eff ects which fail to respond to medical treatment. Bromocriptine, and in some cases radiation therapy, may be required post-op as complete surgical resection is uncommon. If pregnant, monitor closely ideally in a combined endocrine/antenatal clinic as there is risk of expansion. Follow-up Monitor PRL. If headache or visual loss, check fi elds (?",
    "Follow-up Monitor PRL. If headache or visual loss, check fi elds (? do magnetic resonance imaging). Medication can be decreased after 2yrs, but recurrence of hyperprolactinaemia and expansion of the tumour may occur, and so these patients should be monitored carefully. 11 The prolactin increase ( and ) after coitus is 400% greater than after masturbation; post-orgasmic prolactin is part of a feedback loop decreasing arousal by inhibiting central dopaminergic processes. The size of post-orgasmic prolactin increase is a neurohormonal index of sexual satisfaction. 12 MDMA also oxytocin; prolactin oxytocin are thought to mediate post-orgasmic well-being. __OOHHCCMM__1100ee. . iinnddbb 223366 0022//0055//22001177 1199: : 0077 237 ygolonircodnE Fig 5. 27 Galactorrhoea can be prolifi c enough to create medium-sized galaxies (bott om right). In the Birth of the Milky Way Hera is depicted by Rubens in her chariot, being drawn through the night sky by ominous black peacocks. Between journeys, she enjoyed discussing diffi cult endocrinological topics with her husband Zeus (who was also her brother), such as whether women or men fi nd sexual intercourse more enjoyable. Hera inclined to the latterand it is on this fl imsy evidence, and her gorgeous galactorrhoea, that we diagnose her hyperprolactin aemia (which is known to decrease desire, lubrication, orgasm, and satisfaction). In the end, this issue was settled, in favour of Zeuss view, by Tiresias, who had unique insight into this intriguing question: every time this soothsayer saw two snakes entwined, (s)he changed sex, so coming to know a thing or two about gender and pleasure. This is a primordial example of an N of 1 trial, where the subject is his or her own control. Generalizability can be a problem with this methodology. Fine Art Images/ Age Fotostock. __OOHHCCMM__1100ee. . iinnddbb 223377 0022//0055//22001177 1199: : 0077 238 ygolonircodnE Acromegaly This is due to secretion of GH (growth hormone) from a pituitary tumour (99%) or hyperplasia, eg via ectopic GH-releasing hormone from a carcinoid tumour. : 1: 1. Incidence: UK 3/million/yr. 5% are associated with MEN-1 (p223). GH stimulates bone and soft tissue growth through secretion of insulin-like growth factor-1 (IGF-1). Symptoms Acroparaesthesia (akronextremities); amenorrhoea; libido; headache; sweating; snoring; arthralgia; backache; fi g 5. 28: My rings dont fi t, nor my old shoes, and now Ive got a wonky bite (malocclusion) and curly hair. I put on lots of weight, all muscle and looked Good for a while; now I look so haggard. Signs (BOX Signs of acromegaly. ) Often predate diagnosis by 4yrs. If acromegaly occurs before bony epiphyses fuse (rare), gigantism occurs. Complications (May present with CCF or ketoacidosis. ) Impaired glucose tolerance (40%), diabetes mellitus (15%). Vascular: blood pressure, left ventricular hypertrophy (±dilatation/CCF), cardiomyopathy, arrhy thmias. There is risk of ischaemic Heart disease and stroke (? due to blood pressure ± insulin resistance and GH-induced increase in fi brinogen and decrease in Protein S). Neoplasia: colon cancer risk; colonoscopy may be needed. 21 Acromegaly in pregnancy (Subfertility is common. ) Pregnancy may be normal; signs and chemistry may remit. Monitor glucose. Tests Glucose, Ca2, and phosphate 3Ω. GH: Dont rely on random GH as secreti on is pulsatile and during peaks acromega lic and normal levels overlap. GH also in: stress, sleep, puberty, and pregnancy. Normally GH secretion is inhibited by High glucose, and GH hardly detectable. In acromegaly GH release fails to suppress. If basal serum GH is 0. 4mcg/L (1. 2mIU/L) and/or if IGF-I (p232), an oral glucose tolerance test (oral glucose tolerance test) is needed. If the lowest GH value during oral glucose tolerance test is above 1mcg/L (3mIU/L), acrom egaly is confi rmed.",
    "Why do you ask? Because your nose is as big as it was when you were last pregnant. So here we have the well-known physiological acromegaly of pregnancy14 predating the pathological, as the carnival of personal identity moves from helter-skelter to roller-coaster. 14 GH variants made by the placenta rise exponentially until 37wks gestation; pituitary GH gradually drops to near-undetectable levels. Gestational acromegaly probably develops to foster fetoplacental growth; its side-eff ects include facial oedema, carpal tunnel symptoms, and nose enlargement. 15 Puberty sees GHand gonad-mediated rises in bone and muscle mass other acromegalic eff ects. __OOHHCCMM__1100ee. . iinnddbb 223399 0022//0055//22001177 1199: : 0077 240 ygolonircodnE Diabetes insipidus (DI) Physiology This is the passage of large volumes (3L/day) of dilute Urine due to impaired Water resorption by the Kidney, because of reduced ADH secretion from the posterior pituitary (cranial DI) or impaired response of the Kidney to ADH (nephrogenic DI). Symptoms Polyuria; polydipsia; dehydration; symptoms of hypernatraemia (p672). Polydipsia can be uncontrollable and all-consuming, with patients drinking anything and everything to hand: in such cases, if beer is on tap, disaster will ensue! Causes of cranial DI Idiopathic (50%). Congenital: defects in ADH gene, DIDMOAD. 16 Tumour (may present with DI hypopituitarism): craniopharyn gioma, metastases, pituitary tumour. Trauma: temporary if distal to pituitary stalk as proximal nerve endings grow out to fi nd capillaries in scar tissue and begin direct secretion again. Hypophysectomy. Autoimmune hypophysitis (p232). Infi ltration: histiocytosis, sarcoid o sis. 17 Vascular: haemorrhage. 18 Infection: meningoencephalitis. Causes of nephrogenic DI Inherited. Metabolic: Low Potassium, High calcium. Drugs: lithium, demeclocycline. Chronic renal disease. Post-obstructive uropathy. Tests UE, Ca2, glucose (exclude diabetes mellitus), serum and Urine osmolalities. Serum osmo l ality estimate 2 (sodium potassium) urea glucose (all in millimoles per liter). Normal plasma osmolality is 285295mOsmol/kg, and Urine can be concentrated to more than twice this concentration. Signifi cant DI is excluded if Urine to plasma (U: P) osmolality ratio is more than 2: 1, provided plasma osmolality is no greater than 295mOsmol/kg. In DI, despite raised plasma osmolality, Urine is dilute with a U: P ratio 2. In primary polydipsia there may be dilutional hyponatraemiaand as hyponatraemia may itself cause mania, be cautious of saying Its Water intoxication from psychogenic polydipsia. Diagnosis Water deprivation test: See BOX The 8-hour Water deprivation test. NB: it is often diffi cult to diff erentiate primary polydipsia from partial DI. : diabetes mellitus; diuretics or lithium use; primary polydipsia causes symptoms of polydipsia and polyuria with dilute Urine. Its cause is poorly understood; 19 it may be associated with schizophrenia or mania (±Li therapy), or, rarely, hypothal amic dis ease (neurosarcoid; tumour; encephalitis; brain injury; HIV encephalopathy). As part of this syndrome, the kidneys may lose their ability to fully concentrate Urine, due to a wash-out of the normal concentrating gradient in the renal medulla. Treatment Cranial DI: magnetic resonance imaging (head); test anterior pituitary function (p232). Give desmopressin, a synthetic analogue of ADH (eg Desmomelt tablets). Nephrogenic: Treat the cause. If it persists, try bendro fl umethiazide 5mg PO/24h. NSAIDS lower Urine volume and plasma sodium by inhibiting prostaglandin synthase: prostaglandins locally inhibit the action of ADH. Emergency management Do urgent plasma UE, and serum and Urine osmolalities. Monitor Urine output carefully and check UE twice a day initially. IVI to keep up with Urine output. If severe hypernatraemia, do not lower sodium rapidly as this may cause cerebral oedema and brain injury. If sodium is ≥170, use 0. 9% saline initiallythis contains 150mmol/L of Sodium. Aim to reduce sodium at a rate of less than 12mmol/L per day.",
    "9% saline initiallythis contains 150mmol/L of Sodium. Aim to reduce sodium at a rate of less than 12mmol/L per day. Use of 0. 45% saline can be dangerous. Desmopressin 2mcg IM (lasts 1224h) may be used as a therapeutic trial. 16 DIDMOAD is a rare autosomal recessive disorder: Diabetes Insipidus, Diabetes Mellitus, Optic Atrophy and Deafness (also known as Wolframs syndrome). 17 Suspect neurosarcoidosis if CSF Protein (seen in 34%), facial nerve palsy (25%), CSF pleocytosis (23%), Diabetes insipidus (21%), hemiparesis (17%), psychosis (17%), papilloedema (15%), ataxia (13%), seizures (12%), optic atrophy (12%), hearing loss (12%), or nystagmus (9%). 18 Sheehans syndrome is pituitary infarction from shock, eg postpartum haemorrhage. It is rare. 19 Most of ultrasound could Drink 20L/d and not be hyponatraemic; some get hyponatraemic drinking 5L/d; they may have Psychosis, Intermittent hyponatraemia, and Polydipsia (PIP syndrome), ? from intravascular volume leading to atrial natriuretic peptide, p137, hence natriuresis and hyponatraemia. __OOHHCCMM__1100ee. . iinnddbb 224400 0022//0055//22001177 1199: : 0077 241 ygolonircodnE The 8-hour Water deprivation test Tests the ability of kidneys to concentrate Urine for diagnosis of DI (dilute Urine in spite of dehydration), and then to localize the cause (table 5. 5). Do not do the test before establishing that Urine volume is 3L/d (output less than this with normal plasma sodium and osmolality excludes signifi cant disturbance of Water balance). Stop test if Urine osmolality 600mOsmol/kg in Stage 1 (DI is excluded). Free fl uids until 07. 30. Light breakfast at 06. 30, no tea, no coff ee, no smoking. Stage 1 Fluid deprivation (08h): for diagnosis of DI. Start at 08. 00. Empty bladder, then no drinks and only dry food. Weigh hourly. If 3% weight lost during test, order urgent serum osmolality. If 300mOsmol/kg, proceed to Stage 2. If 300, continue test. Collect Urine every 2h; measure its volume and osmolality. Venous sample for osmolality every 4h. Stop test after 8h (16. 00) if Urine osmolality 600mOsmol/kg (ie normal). Stage 2 Diff erentiate cranial from nephrogenic DI. Proceed if Urine still diluteie Urine osmolality 600mOsmol/kg. Give desmopressin 2mcg IM. Water can be drunk now. Measure Urine osmolality hourly for the next 4h. Table 5. 5 Interpreting the Water deprivation test Diagnosis Urine osmolality Normal Urine osmolality 600mOsmol/kg in Stage 1 U: P ratio 2 (normal concentrating ability) Primary polydipsia Urine concentrates, but less than normal, eg 400600mOsmol/kg Cranial DI Urine osmolality increases to 600mOsmol/kg after desmopressin (if equivocal an extended Water deprivation test may be tried (no drinking from 18: 00 the night before)) Nephrogenic DI No increase in Urine osmolality after desmopressin Syndrome of inappropriate ADH secretion (SIADH) In SIADH, ADH continues to be secreted in spite of Low plasma osmolality or large plasma volume. Diagnosis requires concentrated Urine (sodium 20mmol/L and osmolality 100mOsmol/kg) in the presence of hyponatraemia and Low plasma osmolality. Causes are numerous. See p673. __OOHHCCMM__1100ee. . iinnddbb 224411 0022//0055//22001177 1199: : 0077 6 Gastroenterology Contents Healthy, enjoyable eating 244 The mouth 246 Procedures: Endoscopy and biopsy 248 Some presenting symptoms: Dysphagia 250 Nausea and Vomiting 250 Dyspepsia and peptic ulcer disease 252 Gastro-oesophageal refl ux disease (GORD) 254 Upper gastrointestinal bleeding 256 Diarrhoea 258 Constipation 260 Diseases and conditions: Ulcerative colitis (UC) 262 Crohns disease 264 Gastrointestinal malabsorption 266 Coeliac disease 266 Fig 6.",
    "__OOHHCCMM__1100ee. . iinnddbb 224433 0022//0055//22001177 1199: : 0077 244 ygoloretneortsaG Healthy, enjoyable eating Theres a lot of people in this world who spend so much time watching their health that they havent the time to enjoy it. Josh Billings (181885). Updates to guidelines on healthy eating perhaps provide fodder for journalists who have been served a diet both rich and varied in apparently contradictory advice. Nonetheless, for many of our increasingly overweight population, simply eating less (eg 2500 calories/d for men and 2000 for women) and balancing intake across food groups seems a sensible start. Diet is of course not independent of lifestyle, and we should continue to promote a balanced diet in the context of the full range of public health messages. Unravelling these confounding threads in population-level data will always pose a challengewhile some studies show vegetarians may be less likely to die from ischaemic Heart disease, is this eff ect because vegetarians in the UK are more likely to be non-smokers? Overly proscriptive application of such population-level data in advice given to individuals (as journalists may be prone to do) will always be fl awed and risks drowning important fundamental concepts in a sea of cynicism. Current recommendations must take into account three facts Obesity costs health services as much as smoking1 in 4 UK adults is obese. Diabetes mellitus is burgeoning: in some places prevalence is 7% (p206). Past advice has not changed eating habits in large sections of the population. Advice is likely to focus on the following Body mass index: (body mass index; table 6. 1. ) Aim for 18. 525. Controlling quantity may be more important than quality. In hypertension, eating the right things lowers blood pressure only marginally, but controlling weight causes a more signifi cant reduction. Base meals on starch: (Bread, Rice, potatoes, pasta. ) These provide a slower release form of carbohydrate compared to diets containing refi ned Glucose, and beware of the High Glucose contents of, eg soft drinks. Eat enough fruit and vegetables: Aiming for 5 portions a day. Eat foods High in fat, salt, or Glucose infrequently. Eat some meat, fi social history, eggs, and beans: Aim for 2 portions of fi social history a week, including oily fi social history (those rich in omega-3 fatty acid, such as mackerel, herring, pilchards, salmon). Non-dairy sources of Protein include beans and nuts. Aim to reduce intake of red or processed meat to 70g/day. Eat some milk and dairy products: Select those options with lower fat, Glucose and salt where possible. Moderate alcohol use (adults 65yrs): 14U/wk for both men and women, spread over 3 or more days. There is no safe level. Supplements: There is scant evidence for most nutritional supplements in those able to follow a balanced diet. Women attempting to conceive should take 400mcg/ day folic acid from (pre-)conception until at least 12wks. Vitamin D supplements (10mcg/day) may benefi t breast-feeding mothers, those ≥65yrs old, those whose skin is not typically exposed to sun, or those with very dark skin. Lower doses may be recommended for infants and young children. This diet is not appropriate for all: 5yrs old. Need for Low residue (eg Crohns, UC, p264) or special diet (coeliac disease, p266). Emphasis may be different in: Dyslipidaemia (p690); diabetes mellitus (p206); obesity; constipation (p260); Liver failure (p274); chronic pancreatitis (p270); renal failure (less Protein)(p304); blood pressure (see p140).",
    "Diffi culties It is an imposition to ask ultrasound to change our diet (children often refuse point-blank); a more subtle approach is to take a food we enjoy (crisps) and make it healthier (eg Low-salt crisps made from jacket potatoes and fried in sunfl ower oil). __OOHHCCMM__1100ee. . iinnddbb 224444 0022//0055//22001177 1199: : 0077 245 ygoloretneortsaG Losing weightwhy and how? The risks of too much Glucose Excess Glucose causes caries, Diabetes, obesity which itself contributes to osteoarthritis, cancer, hypertension, and increased oxi dative stressso raising cardiovascular mortality and much more. Losing weight Motivational therapy. Consider referral to a dieticiana needsspecifi c diet may be best. In conjunction with exercise and diet strategies, targeted weight-loss can also be achieved successfully with psychotherapy. Drugs or surgery for obesity? The most desirable treatment for obesity is still primary prevention, but pharmacotherapy does work. Orlistat lowers fat absorption (hence SE of oily faecal incontinence)see OHCS p514. Surgery: Carries potential for signifi cant weight loss in appropriately selected patients but also signifi cant morbidity (see p626). Calculating body mass index Table 6. 1 body mass index(weight in kg)/(height in m)2 body mass index State Some implications within the categories 18. 5 Underweight Consider pathology (inc. eating disorder) 18. 525 On target 2530 Overweight Weight loss should be considered 3040 Obesity 32 is unsuitable for day-case general surgery 40 Extreme/morbid obesity 40 is an indication for bariatric surgery Caveats: body mass index does not take into account the distribution of body fat, and is harder to interpret for children and adolescents. Waist circumference 94cm in men and 80cm in women refl ects omental fat and correlates better with risk than does body mass index. body mass index is still a valid way of comparing populations: average body mass index in the USA is 28. 8; in Japan, 22. A nation can be lean without being poor. As nations continue to adopt the lifestyle trends of the USA, this impacts sustainability. __OOHHCCMM__1100ee. . iinnddbb 224455 0022//0055//22001177 1199: : 0077 246 ygoloretneortsaG The mouth The diagnosis will often come out of your patients mouth, so open it! So many GI investigations are indirectnow is your chance for direct observation. Leucoplakia (fi g 6. 2) Is an oral mucosal white patch that will not rub off and is not attributable to any other known disease. It is a premalignant lesion, with a transformation rate, which ranges from 0. 6% to 18%. Oral hairy leucoplakia is a shaggy white patch on the side of the tongue seen in HIV, caused by EBV. When in doubt, refer all intra-oral white lesions (see BOX). Aphthous ulcers (fi g 6. 3) 20% of ultrasound get these shallow, painful ulcers on the tongue or oral mucosa that heal without scarring. Causes of severe ulcers: Crohns and coeliac disease; Behçets (p694); trauma; erythema multiforme; lichen planus; pemphigus; pemphigoid; infections (herpes simplex, syphilis, Vincents angina, p712). : Minor ulcers: avoid oral trauma (eg hard toothbrushes or foods such as toast) and acidic foods or drinks. Tetracycline or antimicrobial mouthwashes (eg chlorhexidine) with topical steroids (eg triamcinolone gel) and topical analgesia. Severe ulcers: possible therapies include systemic corticosteroids (eg oral prednisolone 3060mg/d PO for a week) or thalidomide (absolutely contraindicated in pregnancy). Biopsy any ulcer not healing after 3 weeks to exclude malignancy; refer to an oral surgeon if uncertain. Candidiasis (thrush) (fi g 6. 4) Causes white patches or erythema of the buccal mucosa. Patches may be hard to remove and bleed if scraped. Risk factors: Extremes of age; diabetes mellitus; antibiotics; immunosuppression (long-term corticosteroids, including inhalers; cytotoxics; malignancy; HIV).",
    "Risk factors: Extremes of age; diabetes mellitus; antibiotics; immunosuppression (long-term corticosteroids, including inhalers; cytotoxics; malignancy; HIV). : Nystatin suspension 400 000U (4mL swill and swallow/6h). Fluconazole for oropharyngeal thrush. Cheilitis (angular stomatitis) Fissuring of the mouths corners is caused by denture problems, candidiasis, or defi ciency of iron or ribofl avin (vitamin B2). (fi g 8. 5, p327. ) Gingivitis Gum infl ammation ± hypertrophy occurs with poor oral hygiene, drugs (phenytoin, ciclosporin, nifedipine), pregnancy, vitamin C defi ciency (scurvy, p268), acute myeloid leukaemia (p356), or Vincents angina (p712). Microstomia (fi g 6. 5) The mouth is too small, eg from thickening and tightening of the perioral skin after burns or in epidermolysis bullosa (destructive skin and mucous membrane blisters ± ankyloglossia) or systemic sclerosis (p552). Oral pigmentation Perioral brown spots characterize PeutzJeghers (p708). Pigmentation anywhere in the mouth suggests Addisons disease (p226) or drugs (eg anti malarials). Consider malignant melanoma. Telangiectasia: Systemic sclerosis; OslerWeberRendu syndrome (p708). Fordyce glands: (Creamy yellow spots at the border of the oral mucosa and the lip vermilion. ) Sebaceous cysts, common and benign. Aspergillus niger colonization may cause a black tongue. Teeth (fi g 6. 6) A blue line at the gumtooth margin suggests lead poisoning. Prenatal or childhood tetracycline exposure causes a yellowbrown discolouration. Tongue This may be furred or dry (xerostomia) in dehydration, drug therapy, 3 after radiotherapy, in Crohns disease, Sjögrens (p710), and Mikuliczs syndrome (p706). Glossitis: Means a smooth, red, sore tongue, eg caused by iron, folate, or B12 defi - ciency (fi g 8. 27, p335). If local loss of papillae leads to ulcer-like lesions that change in colour and size, use the term geographic tongue (harmless migratory glossitis). Macroglossia: The tongue is too big. Causes: myxoedema; acromegaly; amyloid (p370). A ranula is a bluish salivary retention cyst to one side of the frenulum, named after the bulging vocal pouch of frogs throats (genus Rana). Tongue cancer: Appears as a raised ulcer with fi rm edges. Risk factors: smoking, alcohol. 4 Spread: anterior ⅓ of tongue drains to submental nodes; middle ⅓ to submandibular nodes; posterior ⅓ to deep cervical nodes (see BOX, p599). Treatment: Radiotherapy or surgery. 5yr survival (early disease): 80%. When in doubt, refer. 3 Drugs causing xerostomia: angiotensin-converting enzyme inhibitor; antidepressants; antihistamines; antipsychotics; antimuscarinics/ anti cholinergics; bromocriptine; diuretics; lo peramide; nifedipine; opiates; prazosin; prochlorperazine, etc. 4 Betel nut (Areca catechu) chewing, common in South Asia, may be an independent risk factor. __OOHHCCMM__1100ee. . iinnddbb 224466 0022//0055//22001177 1199: : 0077 247 ygoloretneortsaG White intra-oral lesions Idiopathic keratosis Carcinoma Leucoplakia Hairy oral leucoplakia Lichen planus Lupus erythematosus Poor dental hygiene Smoking Candidiasis Aphthous stomatitis Squamous papilloma Secondary syphilis. Fig 6. 2 Leucoplakia on the underside of the Fig 6. 3 An aphthous ulcer inside the cheek. The tongue. It is important to refer leucoplakia bename is tautological: aphtha in Greek means cause it is premalignant. ulceration. Fig 6. 4 White fur on an erythematous tong ue Fig 6. 5 Microstomia (small, narrow mouth), caused by oral candidiasis. Oropharyngeal caneg from hardening of the skin in sclero derma didiasis in an apparently fi t patient may sugwhich narrows the mouth. It is cosmeti cally and gest underlying HIV infection. functionally disabling. 1 Fig 6. 6 White bands on the teeth can be caused by excessive fl uoride intake. __OOHHCCMM__1100ee. . iinnddbb 224477 0022//0055//22001177 1199: : 0077 248 ygoloretneortsaG Endoscopy and biopsy Consent is needed for all these procedures; see p568. Upper GI endoscopy Indications: See table 6. 2. Pre-procedure: Stop PPIS 2wks preop if possible ( pathology-masking). Nil by mouth for 6h before.",
    "2. Pre-procedure: Stop PPIS 2wks preop if possible ( pathology-masking). Nil by mouth for 6h before. Dont drive for 24h if sedation is used. Procedure: Sedation optional, eg midazolam 15mg slowly IV (to remain conscious; if deeper sedation is needed, propofol via an anaesthetist (narrow therapeutic range)); nasal prong O2 (eg 2L/min; monitor respirations oximetry). The pharynx may be sprayed with local anaesthetic before the endoscope is passed. Continuous suction must be available to prevent aspiration. Complications: Sore throat; amnesia from sedation; perforation (0. 1%); bleeding (if on aspirin, clopidogrel, warfarin, or DOACS these need stopping only if therapeutic procedure). Duodenal biopsy: The gold standard test for coeliac disease (p266); also useful in unusual causes of malabsorption, eg giardiasis, lymphoma, Whipples disease. Sigmoidoscopy Views the rectum distal colon (to splenic fl exure). Flexible sigmoidoscopy has largely displaced rigid sigmoidoscopy for diagnosis of distal colonic pathology, but 25% of cancers are still out of reach. It can be used therapeutically, eg for decompression of sigmoid volvulus (p611). Preparation: Phosphate enema PR. Procedure: Learn from an expert; do PR exam fi rst. Do biopsiesmacroscopic appearances may be normal, eg IBD, amyloidosis, microscopic colitis. Colonoscopy Indications: See table 6. 3. Preparation: Stop iron 1wk prior; discuss with local endoscopy unit bowel preparation and diet required. Procedure: Do PR fi rst. Sedation (see earlier in topic) and analgesia are given before colonoscope is passed and guided around the colon. Complications: Abdominal discomfort; incomplete examination; haemorrhage after biopsy or polypectomy; perforation (0. 1%). See fi gs 6. 76. 11. Post-procedure: no alcohol, and no operating machinery for 24h. Video capsule endoscopy (VCE) To evaluate obscure GI bleeding (p326) and to detect small bowel pathology. Use small bowel imaging (eg contrast) or patency capsule test ahead of VCE if patient has abdominal Pain or symptoms suggesting small bowel obstruction. Preparation: Clear fl uids only the evening before then nil by mouth from morning until 4h after capsule swallowed. Procedure: Capsule is swallowed (fi g 6. 12)this transmits video wirelessly to capture device worn by patient. Normal activity can take place for the day. Complications: Capsule retention in 1% (endoscopic or surgical removal is needed)avoid magnetic resonance imaging for 2 wks after unless AXR confi rms capsule has cleared; obstruction, incomplete exam (eg slow transit, achalasia). Problems: No Fig 6. 12 PillCam. therapeutic options; poor localization of lesions; may miss more subtle lesions. Liver biopsy Route: Percutaneous if INR in range else trans jugular with FFP. Indications: LFT of unknown aetiology; assessment of fi brosis in chronic Liver disease (this indication being replaced by ultrasound-based elastography); suspected cirrhosis or suspected hepatic lesions/cancer. Pre-op: Nil by mouth for 8h. Are INR 1. 5 and platelets 50 109/L? Give analgesia. Procedure: Sedation may be given. Do under ultrasound/computed tomography guidance; the Liver borders are percussed and where there is dullness in the mid-axillary line in expiration, lidocaine 2% is infi ltrated down to the Liver capsule. Breathing is rehearsed and a needle biopsy is taken with the breath held in expiration. Afterwards lie on the right side for 2h, then in bed for 4h; check pulse and blood pressure every 15 mins for 1h, every 30 mins for 2h, then hourly until discharge 4h postbiopsy. Complications: Local Pain; pneumothorax; bleeding (0. 5%); death (0. 1%). __OOHHCCMM__1100ee. . iinnddbb 224488 0022//0055//22001177 1199: : 0077 249 ygoloretneortsaG Table 6. 2 Indications for upper GI endoscopy Diagnostic indications Therapeutic indications Haematemesis/melaena Treatment of bleeding lesions Dysphagia Variceal banding and sclerotherapy Dyspepsia (55yrs old alarm symptoms or Argon plasma coagulation for suspected treatment refractory, p252) vascular abnormality Duodenal biopsy (?",
    "Treatment: endoscopic balloon dilatation, or Hellers cardiomyotomythen proton pump inhibitors (PPIS, p254). Botulinum toxin injection if a non-invasive procedure is needed (repeat every few months). Calcium channel blockers and nitrates may also relax the sphincter. Benign oesophageal stricture: Caused by gastro-oesophageal refl ux (GORD, p254), corrosives, surgery, or radiotherapy. Treatment: endoscopic balloon dilatation. Oesophageal cancer: (p618. ) Associations: , GORD, tobacco, alcohol, Barretts oesophagus (p695), tylosis (palmar hyperkeratosis), PlummerVinson syndrome (post-cricoid dysphagia, upper oesophageal web irondefi ciency). CNS causes: Ask for help from a speech and language therapist. Nausea and Vomiting Consider pregnancy where appropriate! Other causes, p56. Whats in the vomit? Reports of coff ee grounds may indicate upper GI bleeding but represent one of the most over-called signs in clinical medicine always verify yourself and look for other evidence of GI bleeding; recognizable food gastric stasis; feculent small bowel obstruction. Timing Morning pregnancy or ICP; 1h post food gastric stasis/gastroparesis (diabetes mellitus); Vomiting that relieves Pain peptic ulcer; preceded by loud gurgling GI obstruction. Tests Bloods: FBC, UE, LFT, Ca2, glucose, amylase. ABG: A metabolic (hypochloraemic) alkalosis from loss of gastric contents (pH 7. 45, bicarbonate Ω) indicates severe Vomiting. Plain AXR: If suspected bowel obstruction (p728). Upper GI endoscopy: (See p248. ) If suspicion of bleed or persistent Vomiting. Consider head computed tomography in case ICP. Treatment Identify and treat underlying causes. Symptomatic relief: table 6. 4. Be pre-emptive, eg pre-op for post-op symptoms. Try oral route fi rst. 30% need a 2nd-line anti-emetic, so be prepared to prescribe more than one. Give IV fl uids with potassium replacement if severely dehydrated or nil-by-mouth, and monitor electrolytes and fl uid balance. __OOHHCCMM__1100ee. . iinnddbb 225500 0022//0055//22001177 1199: : 0077 251 ygoloretneortsaG Causes of dysphagia Mechanical block Motility disorders Malignant stricture (fi g 6. 13) Achalasia (see p250) Pharyngeal cancer Diff use oesophageal spasm Oesophageal cancer Systemic sclerosis (p552) Gastric cancer Neurological bulbar palsy (p507) Benign strictures Pseudobulbar palsy (p507) Oesophageal web or ring (p250) Wilsons or Parkinsons disease Peptic stricture Syringobulbia (p516) Extrinsic Hypertension Bulbar poliomyelitis (p436) Lung cancer Chagas disease (p423) Mediastinal lymph nodes Myasthenia gravis (p512) Retrosternal goitre Others Aortic aneurysm Oesophagitis (p254; refl ux or Candida/HSV) Left atrial enlargement Globus (Ive got a lump in my throat: try to disPharyngeal pouch tinguish from true dysphagia) Fig 6. 13 A malignant lower oesophageal stricture seen at endoscopy. Note the asymmetry and heaped edges. Benign strictures have a smoother appearance and tend to be circumferential. Reproduced from Bloom et al. , Oxford Handbook of Gastroenterology and Hepatology, 2012, with permission from Oxford University Press. Remembering your anti-emetics One way of recalling anti-emetics involves using (simplifi ed) pharmacology. Table 6. 4 Pharmacology of common anti-emetics Receptor Antagonist Dose Notes H1 Cyclizine 50mg/8h PO/IV/IM GI causes Cinnarizine 30mg/8h PO Vestibular disorders D2 Metoclopramide 10mg/8h PO/IV/IM GI causes; also prokinetic Domperidone 60mg/12h PR Also prokinetic 20mg/6h PO Prochlorperazine 12. 5mg IM; Vestibular/GI causes 5mg/8h PO Haloperidol 1. 5mg/12h PO Chemical causes, eg opioids 5HT3 Ondansetron 48mg/8h IV slowly Doses can be higher for, eg emetogenic chemotherapy Others Hyoscine hydro200600mcg SC/IM Antimuscarinic also antibromide spasmod ic and antisecretory (dont prescribe with a prokinetic) Dexamethasone 610mg/d PO/SC Unknown mode of action; an adjuvant Midazolam 24mg/d SC Unknown action; anti-emetic ef- (syringe driver) fect outlasts sedative eff ect 3 A ll antidopaminergics can cause dystonias and oculogyric crisis, especially in younger patients. 5 Non-propulsive contractions manifest as tertiary contractions or corkscrew oesophagus (fi g 16. 34, p743) and sug gest a motility disorder and may lead to acid clearance. Symptoms and radiology may not match. Nutcracker oesophagus denotes distal peristaltic contractions 180mmHg.",
    "Symptoms and radiology may not match. Nutcracker oesophagus denotes distal peristaltic contractions 180mmHg. It may cause Pain, relieved by nitrates or sublingual nifedipine. __OOHHCCMM__1100ee. . iinnddbb 225511 0022//0055//22001177 1199: : 0077 252 ygoloretneortsaG Dyspepsia and peptic ulcer disease War The stomach is a battle ground between the forces of attack (acid, pepsin, Helicobacter pylori, bile salts) and defence (mucin secretion, cellular mucus, bicarbonate secretion, mucosal Blood fl ow, cell turnover). Gastric antisecretory agents, eg H 2 receptor antagonists (H2RAS), and proton pump inhibitors (PPIS) may only work if you have optimized cytoprotection (antacids and sucralfate work this way). Success may depend on you being not just a brilliant general, but also a tactician, politician, and diplomat. Plan your strategy carefully4 (fi g 6. 14). As in any war, neglecting psychological factors can prove disastrous. The aim is not outright victory but maintaining the balance of power so all may prosper. Symptoms Epigastric Pain often related to hunger, specifi c foods, or time of day, fullness after meals, Heart burn (retros ternal Pain); tender epi gastrium. Beware Alarm symptoms: Anaemia (iron defi ciency); loss of weight; anorexia; recent onset/progressive symptoms; melaena/haematemesis; swallowing diffi culty. H. pylori (See table 6. 5. ) If 55yrs old: Test and treat for H. pylori; 6 if ve give appropriate proton pump inhibitor and 2 antibiotic combination, eg lansoprazole 30mg/12h PO, clarithromycin 250mg/12h PO, and amoxicillin 1g/12h PO for 1wk. If Ωve give acid suppression alone. Refer for urgent endoscopy (p248) all with dysphagia, as well as those 55 with alarm symptoms or with treatment-refractory dyspepsia. Duodenal ulcer (DU, fi g 6. 15. ) 4-fold commoner than GU. Major risk factors: H. pylori (90%); drugs (NSAIDS; steroids; SSRI). Minor: Gastric acid secretion; gastric emptying (duodenal pH); Blood group O; smoking. Symptoms: Asympto matic or epigastric Pain (relieved by antacids) ± weight. Signs: Epigastric tenderness. Diagnosis: Upper GI endoscopy. Test for H. pylori. Measure gastrin con cen trations when off PPIS if ZollingerEllison syndrome (p716) is suspected. : Non-ulcer dyspepsia; duodenal Crohns; TB; lymphoma; pancreatic cancer (p270). Follow-up: None; if Good response to (eg proton pump inhibitor). Gastric ulcers (GU. ) Occur mainly in the elderly, on the lesser curve. Ulcers elsewhere are more often malignant. Risk factors: H. pylori (80%); smoking; NSAIDS; refl ux of duodenal contents; delayed gastric emptying; stress, eg neurosurgery or burns (Cushings or Curlings ulcers). Symptoms: Asymptom atic or epigastric Pain (relieved by antacids) ± weight. Tests: Upper GI endoscopy to exclude malignancy (fi g 6. 14); multiple biopsies from ulcer rim and base (histology, H. pylori). Repeat endoscopy atrial fibrillationter 68 weeks to confi rm healing and exclude malignancy. Gastritis Risk factors: Alcohol, NSAIDS, H. pylori, refl ux/hiatus hernia, atrophic gastritis, granulom as (Crohns; sarcoidosis), CMV, ZollingerEllison syndrome Ménétriers disease (p716 706). Symptoms: Epigastric Pain, Vomiting; Tests: Upper GI endoscopy only if suspicious features (fi g 6. 14). Treatment Lifestyle: Alcohol and tobacco. H. pylori eradication: Triple therapy is 8085% eff ective at eradication. 7 Drugs to reduce acid: PPIS are eff ective, eg lansoprazole 30mg/24h PO for 4 (DU) or 8 (GU) wks. H2 blockers have a place (ranitidine 300mg each night PO for 8wks). Drug-induced ulcers: Stop drug if possible. PPIS may be best for treating and preventing GI ulcers and bleeding in patients on nonsteroidal anti-inflammatory drug or antiplatelet drugs. Misoprostol is an alternative with diff erent SE. If symptoms persist, re-endoscope, retest for H. pylori, and reconsider diff erential diagnoses (eg gallstones). Surgery: See p622. Complications Bleeding (p256), perforation (p606), malignancy, gastric outfl ow. Functional (non-ulcer) dyspepsia Common.",
    "Surgery: See p622. Complications Bleeding (p256), perforation (p606), malignancy, gastric outfl ow. Functional (non-ulcer) dyspepsia Common. H. pylori eradication (only after a ve result) may help. Some evidence favours PPIS and psychotherapy. Low-dose amitriptyline (1020mg each night PO) may help. Ant acids, antispasmodics, H2 blockers, misoprostol, prokinetic agents, bismuth, or sucralfate all have less evidence. 6 H. pylori is the commonest bacterial pathogen found worldwide (50% of the world population over 40yrs has it). Its a class I carcinogen causing gastritis (p252), duodenal/gastric ulcers gastric cancer/ lymphoma (MALT, p362), also associated with coronary artery disease, B12 and iron defi ciency. 7 1 week of therapy suffi cient; 2 weeks increases erradication rates by 5% but also increases SE. For resistant infections switch to a 2nd-line antibiotic combination (see BNF). __OOHHCCMM__1100ee. . iinnddbb 225522 0022//0055//22001177 1199: : 0077 253 ygoloretneortsaG Table 6. 5 Tests (other than serology) should be performed after 2 wks off proton pump inhibitor Sensitivity Specifi city Invasive tests CLO test 95% 95% Histology 95% 95% Culture 90% 100% Non-invasive 13C breath test 95% 95% Stool antigen 95% 94% Serology 92% 83% The 13C breath test is the most accurate non-invasive Helicobacter test. Diff erential diagnosis of dyspepsia Non-ulcer dyspepsia Duodenal/gastric ulcer Duodenitis Oesophagitis/GORD Gastric malignancy Gastritis (p257) Dysphagia or 55yrs and persistent symptoms or ALARM Signs (see p252) Yes No Upper GI endoscopy Stop drugs causing dyspepsia, eg NSAIDS Lifestyle changes (p254) No further action Over-the-counter antacids, eg magnesImprovement ium trisilicate 10mL/8h PO Review after 4wks No improvement PPIS or H2 blockers for 4wks Ωve (eg omeprazole 20mg/24h PO or Test for H. pylori ranitidine 150mg/12h PO). Improvement No improvement No further action Longer-term, Low- ve dose treatment. Consider upper GI endoscopy Improvement to eradicate H. pylori; No further action review after 4 wks No improvement No Urea breath test. H. pylori eradicated? Yes Proceed as for H. pylori -ve dyspepsia above Fig 6. 14 See NICE dyspepsia guidelines. 4 Nothing magical happens on the 55th birthdaythis is simply an inflection point in population risk data. We should not be overly rigid in applying these rules to the patient in front of ultrasoundthough those who hold the purse strings may at time seek to reduce costs by strict enforcement of such guidelines. Dont treat ve cases of H. pylori more than twice. If still ve refer for specialist opinion. Fig 6. 15 Endoscopic image of a duodenal ulcer Dr Jon Simmons. __OOHHCCMM__1100ee. . iinnddbb 225533 0022//0055//22001177 1199: : 0077 254 ygoloretneortsaG Gastro-oesophageal refl ux disease (GORD) GORD is common, and caused by refl ux of stomach contents (acid ± bile)8 causing troublesome symptoms and/or complications. If refl ux is prolonged, it may cause oesoph agitis (fi g 6. 16), benign oesophageal stricture, or Barretts oesophagus (fi g 6. 17 and p695; it is pre-malignant). Causes Lower oesophageal sphincter hypotension, hiatus hernia (see BOX), oesophageal dysmotility (eg systemic sclerosis), obesity, gastric acid hypersecretion, delayed gastric emptying, smoking, alcohol, pregnancy, drugs (tricyclics, antic holinergics, nitrates), Helicobacter pylori? 9 Symptoms Oesophageal: Heartburn (burning, retrosternal discomfort after meals, lying, stooping, or straining, relieved by antacids); belching; acid brash (acid or bile regurgitation); waterbrash ( salivation: My mouth fi lls with saliva); odynophagia (painful swallowing, eg from oesophagitis or ulceration). Extra-oesophageal: Nocturnal asthma, chronic cough, laryngitis (hoarseness, throat clearing), sinusitis. Complications Oesophagitis, ulcers, benign stricture, iron-defi ciency. Metaplasia dysplasianeoplasia: GORD may lead to Barretts oesophagus (p695; distal oesophageal epithelium undergoes metaplasia from squamous to columnar, fi g 6. 17). 0. 10. 4%/yr of those with Barretts progress to oesophageal cancer (higher if dysplasia is present).",
    "17). 0. 10. 4%/yr of those with Barretts progress to oesophageal cancer (higher if dysplasia is present). Oesophagitis from corrosives, NSAIDS, herpes, Candida; duodenal or gastric ulcers or cancers; non-ulcer dyspepsia; oesophageal spasm; cardiac disease. Tests Endoscopy if dysphagia, or if ≥55yrs old with alarm symptoms (p252) or with treatment-refractory dyspepsia. 24h oesophageal pH monitoring ± manometry help diagnose GORD when endoscopy is normal. Treatment Lifestyle: Weight loss; smoking cessation; small, regular meals; reduce hot drinks, alcohol, citrus fruits, tomatoes, onions, fi zzy drinks, spicy foods, caff eine, chocolate; avoid eating 3h before bed. Raise the bed head. Drugs: Antacids, eg magnesium trisilicate mixture (10mL/8h), or alginates, eg Gaviscon (1020mL/8h PO) relieve symptoms. Add a proton pump inhibitor, eg lansoprazole 30mg/24h PO. For refractory symptoms, add an H2 blocker and/or try twice-daily proton pump inhibitor. Avoid drugs aff ecting oesophageal motility (nitrates, anticholinergics, Ca2 channel blockersrelax the lower oesophageal sphincter) or that damage mucosa (NSAIDS, potassium salts, bisphosphonates). Surgery: (Eg laparoscopic Nissen fundoplication, or novel options including laparoscopic insertion of a magnetic bead band or radiofrequency-induced hypertrophy. ) These all aim to resting lower oesophageal sphincter Hypertension. Consider in severe GORD (confi rm by pH-monitoring/manometry) if drugs are not working. Atypical symptoms (cough, laryngitis) are less likely to improve with surgery compared to patients with typical symptoms. Fig 6. 16 Upper GI endoscopy showing longiFig 6. 17 Barretts oesophagus. tudinal mucosal breaks in severe oesophagitis. Dr A Mee. Dr A Mee. 8 The refl ux of duodenal fl uid, pancreatic secretions and bile may be as important as acid; it may respond to similar lifestyle measures, sucralfate (2g/12h PO), domperidone, or metoclopramide. 9 H. pylori association with GORD controversial, but eradication may help symptoms. __OOHHCCMM__1100ee. . iinnddbb 225544 0022//0055//22001177 1199: : 0077 255 ygoloretneortsaG Hiatus hernia Sliding hiatus hernia (80%) The gastro-oesophageal junction slides up into the chestsee fi g 6. 18. Acid refl ux often happens as the lower oesophageal sphincter becomes less competent in many cases. Paraoesophageal hernia (rolling hiatus hernia) (20%) The gastro-oesophageal junction remains in the abdomen but a bulge of stomach herniates up into the chest alongside the oesophagussee fi gs 6. 18, 6. 19. As the gastro-oesophageal junction remains intact, GORD is less common. Clinical features Common: 30% of patients 50yrs, especially obese women. Although most small hernias are asymptomatic, patients with large hernias may develop GORD. Imaging Upper GI endoscopy vis ualizes the mucosa (? oesophagitis) but cannot reliably exclude a hiatus hernia. Treatment Lose weight. Treat GORD. Surgery indications: intractable symptoms despite aggressive medical therapy, complications (see p254). Although paraoesophageal hernias may strangulate the risk of this drops dramatically after 65 yrs. Prophylactic repair is only undertaken in those considered at High risk, due to operative mortality (12%). Fig 6. 19 computed tomography chest (IV contrast) showing the rolling components of a hiatus hernia ante rior to the oesophagus. Between the oesophagus and the vertebral column on the left-hand side is the aorta. Dr S Golding. Fig 6. 18 Hiatus herniasliding and rolling. __OOHHCCMM__1100ee. . iinnddbb 225555 0022//0055//22001177 1199: : 0077 256 ygoloretneortsaG Upper gastrointestinal bleeding Haematemesis is Vomiting of Blood. It may be bright red or look like coff ee grounds. Melaena (Greek melas black) means black motions, often like tar, and has a characteristic smell of altered Blood. Both indicate upper GI bleeding. Take a brief history and Common causes Rare causes examine to assess severity.",
    "Both indicate upper GI bleeding. Take a brief history and Common causes Rare causes examine to assess severity. Peptic ulcers Bleeding disorders Ask about past GI bleeds; MalloryWeiss tear Portal hypertensive dyspepsia/known ulcers; Oesophageal varices gastropathy known Liver disease or oes- Gastritis/gastric erosions Aorto-enteric fi stula10 ophageal varices (p257); Drugs (NSAIDS, aspirin, Angiodysplasia dysphagia; Vomiting; steroids, thrombolytics, Haemobilia weight loss. Check drugs anticoagulants) Dieulafoy lesion11 (see BOX on common and Oesophagitis Meckels diverticulum rare causes) and alcohol Duodenitis PeutzJeghers syndrome use. Is there serious co- Malignancy OslerWeberRendu morbidity (Bad prognosis), No obvious cause syndrome. eg cardiovascular disease, respiratory disease, hepatic or renal impairment, or malignancy? Look for signs of chronic Liver disease (p276) and do a PR to check for melaena. Is the patient shocked? Also: Peripherally cool/clammy; capillary refi ll time 2s; Urine output 0. 5mL/kg/h. GCS (tricky to assess in decompensated Liver disease) or encephalopathy (p275). Tachycardic (pulse 100bpm). Systolic blood pressure 100mmHg; postural drop 20mmHg. Calculate the Rockall score (tables 6. 6, 6. 7). Acute management (p820. ) Skill in resuscitation determines survival, so get Good at this! Summary: 5 start by protecting the airway and giving High-fl ow O 2, then: Insert 2 large-bore (1416G) IV cannulae and take Blood for FBC (early hemoglobin may be normal because haemodilution has not yet taken place), UE (urea out of proportion to Creatinine indicative of massive Blood meal), LFT, clotting, and crossmatch. Give IV fl uids (p821) to restore intravascular volume while waiting for crossmatched Blood. If haemodynamically deteriorating despite fl uid resuscitation, give group O RhΩve Blood. Avoid saline if cirrhotic/varices. Insert a urinary catheter and monitor hourly Urine output. Organize a CXR, ECG, and check ABG. Consider a CVP line to monitor and guide fl uid replacement. Transfuse (with crossmatched Blood if needed) if signifi cant hemoglobin drop (70g/L). Correct clotting abnormalities (vitamin potassium (p274), FFP, platelets). If suspicion of varices then give terlipressin IV eg 12mg/6h for ≤3d; relative risk of death by 34%. Initiate broad-spectrum IV antibiotic cover. Monitor pulse, blood pressure, and CVP (keep 5cmH2O) at least hourly until stable. Arrange an urgent endoscopy (p248). If endoscopic control fails, surgery or emergency mesenteric angiography/ embolization may be needed. For uncontrolled oesophageal variceal bleeding, a SengstakenBlakemore tube may compress the varices, but should only be placed by someone with experience. Further management Anatomy is important in assessing risk of rebleeding. Posterior DUs are highest risk as they are nearest to the gastroduodenal artery. Re-examine after 4h and consider the need for FFP if 4 units transfused. Hourly pulse, blood pressure, CVP, Urine output (4hrly if haemo dynamically stable may be OK). Transfuse to keep hemoglobin 70g/L; ensure a current valid group save sample. Check FBC, UE, LFT, and clotting daily. Keep nil by mouth if at High rebleed risk (see BOX Management of peptic ulcer bleeds and p256)ask the endoscopist. 10 A patient with an aortic graft repair and upper GI bleeding is considered to have an aorto-enteric fi stula until proven otherwise: computed tomography abdomen is usually required as well as endoscopy. 11 A Dieulafoy lesion is the rupture of an unusually big arteriole, eg in the fundus of the stomach. __OOHHCCMM__1100ee. . iinnddbb 225566 0022//0055//22001177 1199: : 0077 257 ygoloretneortsaG Rockall risk-scoring for upper GI bleeds Table 6.",
    "__OOHHCCMM__1100ee. . iinnddbb 225566 0022//0055//22001177 1199: : 0077 257 ygoloretneortsaG Rockall risk-scoring for upper GI bleeds Table 6. 6 Rockall score calculation Pre-endoscopy 0 patients 1 patient 2 patients 3 patients Age 60yrs 6079yrs ≥80yrs Shock: systolic blood pressure 100mmHg blood pressure 100mmHg blood pressure 100mmHg blood pressure pulse rate Pulse 100/min Pulse 100/min Comorbidity Nil major Heart failure; Renal failure Metasta ses ischaemic Liver failure Heart disease Post-endoscopy MalloryWeiss tear; All other Upper GI maligDiagnosis no lesion; no sign of diagnoses nancy recent bleeding Signs of recent None, or dark red Blood in haemorrhage spot upper GI tract; on endoscopy adherent clot; visible vessel Initial Rockall score is based on pre-endoscopy criteria; these are added to postendoscopy criteria for fi nal score which predicts risk of rebleeding and death (table 6. 7). The Glas gow Blatchford score (GBS) is used pre-endoscopy to identify patients at Low risk of requiring intervention. If GBS 0, admission can be avoidedie hemoglobin 130g/L (or 120g/L if ); systolic blood pressure 110mmHg; pulse 100/min; urea 6. 5mmol/L; no melaena or syncope no past/present Liver disease or Heart failure. Table 6. 7 GI bleed mortality by Rockall score Score Mortality with initial scoring Mortality after endoscopy 0 0. 2% 0% 1 2. 4% 0% 2 5. 6% 0. 2% 3 11. 0% 2. 9% 4 24. 6% 5. 3% 5 39. 6% 10. 8% 6 48. 9% 17. 3% 7 50. 0% 27. 0% 8 41. 1% Management of peptic ulcer bleeds based on endoscopic fi ndings High-risk Active bleeding, adherent clot, or non-bleeding visible vessel. Achieve endoscopic haemostasis (2 of: clips, cautery, adrenaline). Admit to monitored bed; start proton pump inhibitor (eg omeprazole 40mg/12h IV/PO; meta-analyses show 72h IVI eg omeprazole 80mg bolus then 8mg/h not superior). If haemodynamically stable start oral intake of clear liquids 6h after endoscopy. Treat if positive for H. pylori (p253). Low-risk Flat, pigmented spot or clean base. No need for endoscopic haemostasis. Consider early discharge if patient otherwise Low risk. Give oral proton pump inhibitor (p252). Regular diet 6h after endoscopy if stable. Treat if positive for H. pylori (p253). Gastro-oesophageal varices Submucosal venous dilatation 2° to portal pressures (may not have documented Liver diseasesuspect varices if alcohol history); bleeding can be brisk, particularly if underlying coagulopathy 2° to loss of hepatic synthesis of clotting factors. Causes of portal hypertension Pre-hepatic: Thrombosis (portal or splenic vein). Intra-hepatic: Cirrhosis (80% in UK); schistosomiasis (commonest worldwide); sarcoid; myeloproliferative diseases; congenital hepatic fi brosis. Post-hepatic: Budd Chiari syndrome (p696); right Heart failure; constrictive pericarditis; veno-occlusive disease. Risk factors for variceal bleeds: Portal Hypertension, variceal size, endoscopic features of the variceal wall and advanced Liver disease. Management Endoscopic banding (oesophageal) or sclerotherapy (gastric). Prophylaxis: 1°: 30% of cirrhotics with varices bleed vs 15% with non-selective -blockade (propranolol 2040mg/12h PO) or repeat endoscopic banding. 2°: after a 1st variceal bleed, 60% rebleed within 1yr. Use banding and non-selective -blockade; transjugular intrahepatic portosystemic shunt (TIPS) for resistant varices. __OOHHCCMM__1100ee. . iinnddbb 225577 0022//0055//22001177 1199: : 0077 258 ygoloretneortsaG Diarrhoea Diarrhoea is characterized by increased stool frequency and volume and decreased consistencythough patients perspectives of these may vary wildly. History As ever, a careful history will help narrow myriad causes to just a few. Acute or chronic? If acute (2wks) suspect gastroenteritisany risk factors: Travel? Diet change? Contact with DV? Any fever/Pain? HIV; achlorhydria, eg PA, p334, or on acid suppressants, eg proton pump inhibitor? Chronic diarrhoea alternating with constipation sugge sts irritable bowel (p266). Weight, noct ur nal diarrhoea, or anaemia mandate close follow-up (coeliac/UC/Crohns? ).",
    "Weight, noct ur nal diarrhoea, or anaemia mandate close follow-up (coeliac/UC/Crohns? ). Bloody diarrhoea: Campylobacter, Shigella/Salmonella (p431), E. coli, amoebiasis (p432), UC, Crohns, colorectal cancer (p616), colonic polyps, pseudomembranous colitis, ischaemic colitis (p620). Fresh PR bleeding: p629. Mucus: Occurs in IBS (p266), colorectal cancer, and polyps. Frank pus: Suggests IBD, diver ticulitis, or a fi stula/abscess. Explosive: Eg cholera; Giardia; Yersinia (p425); Rotavirus. Steatorrhoea: Characterized by gas, off ensive smell, and fl oating, hard-to-fl ush stoolsconsider pancreatic insuffi ciency (p267) or biliary obstruction. Look for Dehydrationdry mucous membranes, skin turgor; capillary refi ll 2s; shock. Any fever, weight, clubbing, anaemia, oral ulcers (p246), rashes or abdominal mass or scars? Any goitre/hyperthyroid signs? Do rectal exam for masses (eg rectal cancer) or impacted faeces: Blood: FBC: MCV/Fe defi ciency, eg coeliac or colon calcium; MCV if alcohol abuse or B12 absorption, eg in coeliac or Crohns; eosinophilia if parasites. ESR/CRP: infection, Crohns/ UC, cancer. UE: potassium severe DV. TSH: thyrotoxicosis. Coeliac serology: p266. Stool: MCS: bacterial pathogens, ova cysts, parasites, C. diff toxin (CDT, see BOX Causes of diarrhoea), viral protein-creatinine ratio. Faecal elastase: if suspect chronic pancreatitis (malabsorption, steatorrhoea). Lower GI endoscopy: (Malignancy? colitis? ) If acutely unwell, limited fl exible simgoidoscopy with biopsies. Full colonoscopy (including terminal ileum) can assess for more proximal disease If normal, cons ider small bowel radiology or video capsule. Management Treat cause. Food handlers: no work until stool samples are ve. If a hospital outbreak, wards may need closing. Oral rehydration is better than IV, but if sustained diarrhoea or Vomiting, IV fl uids with appropriate electrolyte replacement may be needed. Codeine phosphate 30mg/8h PO or loperamide 2mg PO after each loose stool (max 16mg/day) stool frequency (avoid in colitis; both may precipitate toxic megacolon). Avoid antibiotics unless infective diarrhoea is causing systemic upset (fi g 6. 20). Antibiotic-associated diarrhoea12 may respond to probiotics (eg lactobacilli). Causes of diarrhoea Common Non-GI or rare causes Gastroenteritis (p428) Thyrotoxicosis Travellers diarrhoea (p429) Autonomic neuropathy C. diffi cile (BOX Clostridium diffi cile) Addisons disease IBS (p266) Ischaemic colitis Colorectal cancer Tropical sprue Pellagra Crohns; UC; coeliac. Gastrinoma VIPoma14 Less common causes (Esp. if painful) Carcinoid Amyloid. Microscopic colitis13 Drugs Chronic pancreatitis (Many, see BNF. ) Bile salt malabsorption Antibiotics12 proton pump inhibitor Laxative abuse Propran olol NSAIDS Lactose intolerance Cytotoxics Digoxin Ileal/gastric resection Laxatives Alcohol. Overfl ow diarrhoea Bacterial overgrowth. 12 Erythromycin is prokinetic, others cause overgrowth of bowel organisms, or alter bile acids. 13 Think of this in any chronic watery diarrhoea; diagnosis by biopsy. Associated with a range of drugs including NSAIDS and PPIS. Stop the off ending drug where possible. Treat with budesonide. 14 Vasoactive intestinal polypeptide-secreting tumour; suspect if potassiumand acidosis; Ca2; Mg2. __OOHHCCMM__1100ee. . iinnddbb 225588 0022//0055//22001177 1199: : 0077 259 ygoloretneortsaG Managing infective diarrhoea No systemic signs Systemic illness: Special circumstances: Fever 39°C; dehydration Food poisoning Diarrhoea visible Blood outbreak (dysentery) for 2wks Travel (p428 p430) Recent antibiotic use Rectal intercourse Admit to hospital; oral fl uids Immunocompromised Symptomatic Consider presumptive unle ss Raw seafood ingestion a non-infectious cause is found Stool culture Prompt, direct faecal Routine culture not needed smear (then culture) and microscopy. Ask microbiologist about Polymorphs seen No polymorphs seen Parasites seen Likely culture: Likely culture: Specifi c , eg Shigella Salmonella p432435 Campylobacter E. coli E. coli C. diffi cile (see BOX More rarely: Clostridium diffi cile) C. diffi cile (see BOX Culture Ωve causes: Clostridium diffi cile) eg Norovirus (eg with Yersinia enterocolitica projectile Vomiting, Salmonella p430) Fig 6. 20 Managing infective diarrhoea.",
    "20 Managing infective diarrhoea. Be aware of local pathogens, and be prepared to close wards and hospitals if contagion is afoot. Prompt specifi c : eg ciprofl oxacin 500mg/12h PO for 6d may be needed before sensitivities are known. Metronidazole is also tried, as Giardia is a common cause of watery diarrhoea in travellers. Clostridium diffi cile: the cause of pseudomembranous colitis First isolated from stools of healthy neonates, C. diffi cile was named owing to diffi culties in culture. Today, diffi cile might better refer to challenges of containment. Signs: T°; colic; diarrhoea with systemic upsetCRP, WCC, albumin, and colitis (with yellow adherent plaques on infl amed non-ulcerated mucosathe pseudomembrane) progressing to toxic megacolon and multi-organ failure. Asymptomatic carriage: 25% of all adults. Only problematic with gut ecology disrupted by, eg antibiotics, leading to rapid proliferation and toxin expression. Predictors of fulminant C. diff colitis: 70yrs, past C. diff infection; use of antiperistaltic drugs; severe leucocytosis; haemodynamic instability. Detection: Urgent testing of suspicious stool (characteristic smellask the nurses). Two-stage process with rapid screening test for C. diff Protein (or protein-creatinine ratio) followed by specifi c ELISA for toxins. AXR for toxic megacolon. : Stop causative antibiotic if possible. Mild disease: metronidazole 400mg/8h PO for 1014d (vanco mycin 125mg/6h PO is better in severe disease). Intensive regimens of vancomycin 500mg/6h with IV and PR vancomycin may be needed for non-responders. Urgent colectomy may be needed if toxic megacolon, LDH, or if deteriorating. Recurrent disease: Common (25%). Fidaxomicin, a minimally absorbed oral antibiotic, is associated with lower relapse rates. Faecal transplantation (introduction of a suspension prepared from the faeces of a screened donor via endoscopy or via NG/NJ tube) is a highly eff ective, if aesthetically unappealing, method of treatment. Preventing spread: Meticulous cleaning and appropriate bed management policies, use of disposable gloves and aprons, hand-washing (not just gelkill the spores). __OOHHCCMM__1100ee. . iinnddbb 225599 0022//0055//22001177 1199: : 0077 260 ygoloretneortsaG Constipation Constipation refl ects pelvic dysfunction or transit time. Accepted defi nitions and reported rates vary, but a place to start is the passage of ≤2 bowel motions/wk, often passed with diffi culty, straining, or Pain, and a sense of incomplete evacuation. : 2: 1. Doctors chief concerns are to fi nd pointers to major pathology, eg constip ation rectal bleeding cancer; constipation distension active bowel sounds stricture/GI obstruction; constipation menorrhagia hypothyroidism. The patient Ask about frequency, nature, and consistency of stools. Is there Blood or mucus in/on the stools? Is there diarrhoea alternating with constipation (eg IBS, p266)? Has there been recent change in bowel habit? Is she digitating the rectum or vagina to pass stool? 15 Ask about diet and drugs. PR examination is essential even when referring (refer if signs of colorectal calcium, eg weight, Pain, or anaemia). Tests None in young, mildly aff ected patients. Threshold for investigation diminishes with age; triggers include: 6 weight, abdominal mass, PR Blood, iron defi ciency anaemia. Blood: FBC, ESR, UE, Ca2, TFT. Colonoscopy: If suspected colorectal malignancy. Transit studies; anorectal physiology; biopsy for Hirschprungs are occasionally needed. Treatment Often reassurance, drinking more, and diet/exercise advice (p245) is all that is needed. Treat causes (BOX Causes of constipation). A High-fi bre diet is often advised, but may cause bloating without helping constipation. Only use drugs if these measures fail, and try to use them for short periods only. Often, a stimulant such as senna ± a bulking agent is more eff ective and cheaper than agents such as lactulose. Bulking agents: Faecal mass, so stimulating peristalsis.",
    "Bulking agents: Faecal mass, so stimulating peristalsis. They must be taken with plenty of fl uid and may take a few days to act. CI: diffi culty in swallowing; GI obstruction; colonic atony; faecal impaction. Bran powder 3. 5g 23 times/d with food (may hinder absorption of dietary trace elements if taken with every meal). Ispaghula husk, eg 1 Fybogel sachet after a meal, mixed in Water and swallowed promptly (or else it becomes an unpleasant sludge). Methylcellulose, eg Celevac 36 tablets/12h with ≥300mL Water. Sterculia, eg Normacol granules, 10mL sprinkled on food daily. Stimulant laxatives: Increase intestinal motility, so do not use in intestinal obstruction or acute colitis. Avoid prolonged use as it may cause colonic atony. Abdominal cramps are an important SE. Pure stimulant laxatives are bisacodyl tablets (510mg at night) or suppositories (10mg in the mornings) and senna (24 tablets at night). Docusate Sodium and dantron16 have stimulant and softening actions. Glycerol suppositories act as a rectal stimulant. Sodium picosulfate (510mg at night) is a potent stimulant. Stool softeners: Particularly useful when managing painful anal conditions, eg fi ssure. Arachis oil enemas lubricate and soften impacted faeces. Liquid paraffi n should not be used for a prolonged period (SE: anal seepage, lipoid pneumonia, malabsorption of fat-soluble vitamins). Osmotic laxatives: Retain fl uid in the bowel. Lactulose, a semisynthetic disaccharide, produces osmotic diarrhoea of Low faecal pH that discourages growth of ammonia-producing organisms. It is useful in hepatic encepha lopathy (initial dose: 3050mL/12h). SE: bloating, so its role in treating constipation is limited. Macrogol (eg Movicol) is another example. Magnesium salts (eg magnesium hydroxide; magnesium sulfate) are useful when rapid bowel evacuation is required. Sodium salts (eg Microlette and Micralax enemas) should be avoided as they may cause Sodium and Water retention. Phosphate enemas are useful for rapid bowel evacuation prior to procedures. If these dont help Prucalopride is an elective 5HT4 agonist with prokinetic properties; Lubiprostone is a chloride-channel activator that increases intestinal fl uid secretion; Linaclotide is a guanylate cyclase-C agonist that also increases fl uid secretion and decreases visceral Pain. A multidisciplinary approach with behaviour therapy, habit training ± sphincter biofeedback may help. 15 Rectocele: front wall of the rectum bulges into the back wall of the vagina. 16 Dantron causes colon Liver tumours in animals, so reserve use for the very elderly or terminally ill. __OOHHCCMM__1100ee. . iinnddbb 226600 0022//0055//22001177 1199: : 0077 261 ygoloretneortsaG Causes of constipation General Hypokalaemia (p674) Poor diet ± lack of exercise Porphyria Poor fl uid intake/dehydration Lead poisoning. Irritable bowel syndrome Drugs (Pre-empt by diet advice. ) Old age Opiates (eg morphine, codeine) Post-operative Pain Anticholinergics (eg tricyclics) Hospital environment (priv acy; hav- Iron ing to use a bed pan). Some antacids, eg with aluminium Anorectal disease (Esp. if painful. ) Diuretics, eg furosemide Anal or colorectal cancer Calcium channel blockers. Fissures (p630), strictures, herpes Neuromuscular (Slow transit from Rectal prolapse decreased propulsive activity. ) Proctalgia fugax (p630) Spinal or pelvic nerve injury (eg trau- Mucosal ulceration/neoplasia ma, surgery) Pelvic muscle dysfunction/levator Aganglionosis (Chagas disease, ani syndrome. Hirschsprungs disease) Intestinal obstruction Systemic sclerosis Colorectal carcinoma (p616) Diabetic neuropathy. Strictures (eg Crohns disease) Other causes Pelvic mass (eg fetus, fi broids) Chronic laxative abuse (rarediar- Diverticulosis (rectal bleeding is a rhoea is commoner) commoner presentation) Idiopathic slow transit Pseudo-obstruction (p611). Idiopathic megarectum/colon.",
    "Tests Blood: FBC, ESR, CRP, UE, LFT, Blood culture. Stool MCS/CDT: (See p258. ) To exclude Campylobacter, C. diffi cile, Sal monella, Shigella, E. coli, amoebae. Faecal calprotectin: A simple, non-invasive test for GI infl ammation with High sensitivity. AXR: No faecal shadows; mucosal thickening/islands (fi g 16. 9, p729); colonic dilatation (see Complications). Lower GI endoscopy: Limited fl exible sigmoidoscopy if acute to assess and biopsy; full colonoscopy once controlled to defi ne disease extent (see p249, fi g 6. 10). Table 6. 8 Assessing severity in UC (Truelove Witts criteria modifi ed to include CRP) Variable Mild UC Moderate UC Severe UC Motions/day ≤4 5 ≥6 Rectal bleeding Small Moderate Large T°C Apyrexial 37. 137. 8°C 37. 8°C Resting pulse 70 beats/min 7090 beats/min 90 beats/min Haemoglobin 110g/L 105110g/L 105g/L ESR (do CRP too) 30 30 (or CRP 45mg/L) Data from Truelove et al. , Cortisone in ulcerative colitis, BMJ; 2(4947): 10418. Complications Acute: Toxic dilatation of colon (mucosal islands, colonic diameter 6cm) with risk of perforation; venous thromboembolism: give prophylaxis to all inpatients regardless of rectal bleeding (p350); potassium Chronic: Colonic cancer: risk related to disease extent and activity 510% with pancolitis for 20yrs. Neoplasms may occur in fl at, normal-looking mucosa. To spot precursor areas of dysplasia, surveillance colonoscopy eg 15yrs (depending on risk), with multiple random biopsies or biopsies guided by diff erential uptake by abnormal mucosa of dye sprayed endoscopically. Treatment Goals are to induce, then maintain disease remission. 7 Mild UC: 5-ASA, 17 eg mesalazine (mesalamine) is the mainstay for remission-induction/maintenance. Given PR (suppositories or enemas) for distal disease (eg Pentasa 1g daily); or PO for more extensive disease (eg Pentasa 2g daily; once-daily dosing as eff ective as split dose; combine PRPO if fl are). Topical steroid foams PR (eg hydrocortisone as Colifoam), or prednisolone 20mg retention enemas (Predsol) less eff ective than PR 5-ASA but may be added in addition. Moderate UC: If 46 motions/day, but otherwise well, induce remission with oral prednisolone 40mg/d for 1wk, then taper by 5mg/week over following 7wks. Then maintain on 5-ASA (SES: rash, haemolysis, hepa titis, pancreatitis, paradoxical worsening of colitis monitor FBC and UE at start, then at 3 months, then annually). 17 5-aminosalicylic acid (5-ASA or mesalazine) must be stabilized in oral preparations to survive gastric pH. Alternatively, olsalazine is a dimer of 5-ASA or balsalazide is a prodrug, both of which are cleaved in the colon. Rare hypersensitivity reactions: worsening colitis, pancreatitis, pericarditis, nephritis. __OOHHCCMM__1100ee. . iinnddbb 226622 0022//0055//22001177 1199: : 0077 263 ygoloretneortsaG Severe UC: If unwell and 6 motions/d, admit for: IV hydration/electrolyte replacement; IV steroids, eg hydrocortisone 100mg/6h or methylprednisolone 40mg/12h; rectal steroids, eg hydrocortisone 100mg in 100mL 0. 9% saline/12h PR; thromboembolism prophylaxis (p350); ensure multiple stool MCS/CDT to exclude infection. Monitor T°, pulse, and blood pressureand record stool frequency/character on a stool chart. Twice-daily exam: document distension, bowel sounds, and tenderness. Daily FBC, ESR, CRP, UE ± AXR. Consider Blood transfusion (eg if hemoglobin 80g/L). If on day 35 CRP 45 or 6 stools/d, action is needed. 18 Rescue therapy with ciclosporin or infl iximab, can avoid colectomy, but involve surgeons early in shared care. If improving, transfer to prednisolone PO (40mg/24h). Schedule maintenance infl iximab if used for rescue, or azathioprine if ciclosporin rescue. If fails to improve then urgent colectomy by d710the challenge is not to delay surgery so long as to accumulate signifi cant steroid exposure and debilitation that will delay post-surgical recovery. Its time for immunomodulation if Patients fl are on steroid tapering or require ≥2 courses of steroids/year eg azathioprine (22.",
    "Its time for immunomodulation if Patients fl are on steroid tapering or require ≥2 courses of steroids/year eg azathioprine (22. 5mg/kg/d PO). 30% of patients will develop SES requiring treatment cessation including abdominal Pain, nausea, pancreatitis, leucopenia, abnormal LFTS. Monitor FBC, UE, LFT weekly for 4 wks, then every 4 wks for 3 months, then at least 3-monthly. Biologic therapy For patients intolerant of immunomodulation, or developing symptoms despite an immunomodulator, monoclonal antibodies to TNF (infl iximab, adalimumab, golimumab) or to adhesion molecules involved in gut lymphocyte traffi cking (vedolizumab) play an important role (see BOX Therapies in Crohns disease p265). Surgery This is needed at some stage in 20%, eg subtotal colectomy terminal ileostomy for failure of medical therapy or fulminant colitis with toxic dilatation/ perforation. Subsequently completion proctectomy (permanent stoma) vs ileoanal pouch. Pouches mean stoma reversal and the possibility of long-term continence but pouch opening frequency may still be around 6/day and recurrent pouchitis can be troublesome (give antib iotics, eg metronidazole ciprofl oxacin for 2wks). Diagnosing IBD-unclassifi ed (IBD-U) After full investigation, IBD may not obviously be Crohns or UC. IBD-U refers to isolated colonic IBD where the diagnosis remains unknown (small bowel involvementCrohns). This situation is rare in adults but commoner in children. Over time the phenotype tends to become clearer (generally UCCrohns). Colectomy ± pouch formation may be needed, though pouch failure rate is higher than in UC. 18 Day 3 stool frequency 8/day or frequency 38/day CRP 45 85% chance of colectomy this admission. __OOHHCCMM__1100ee. . iinnddbb 226633 0022//0055//22001177 1199: : 0077 264 ygoloretneortsaG Crohns disease A chronic infl ammatory disease characterized by transmural granulomatous infl ammation aff ecting any part of the gut from mouth to anus (esp. terminal ileum in 70%). Unlike UC, there is unaff ected bowel between areas of active disease (skip lesions). Cause As with UC an inappropriate immune response against the (? abnormal) gut fl ora in a genetically susceptible individual. 19 Prevalence 100200/100 000. Incidence 1020/100 000/yr; typically presents 2040yrs. Associations Smoking risk 34; NSAIDS may exacerbate disease. Symptoms Diarrhoea, abdominal Pain, weight loss/failure to thrive. Systemic symptoms: Fatigue, fever, malaise, anorexia. Signs Bowel ulceration (fi g 6. 22); abdominal tenderness/mass; perianal abscess/ fi stulae/skin tags; anal strictures. Beyond the gut: (fi g 6. 21) Clubbing, skin, joint, eye problems. Complications Small bowel obstruction; toxic dilatation (colonic diameter 6cm, toxic dilatation is rarer than in UC); abscess formation (abdominal, pelvic, or perianal); fi stulae (present in 10%), eg entero-enteric, colovesical (bladder), colovaginal, perianal, enterocutaneous; perforation; colon cancer; PSC (p282), malnutrition. Tests Blood: FBC, ESR, CRP, UE, LFT, INR, ferritin, TIBC, B12, folate. Stool: MCS and CDT (p258) to exclude eg C. diffi cile, Campylobacter, E. coli; faecal calprotectin is a simple, non-invasive test for GI infl ammation with High sensitivity. Colonoscopy biopsy: Even if mucosa looks normal. Small bowel: To detect isolated proximal disease by eg capsule endoscopy (p248, use dummy patency capsule 1st that disintegrates if it gets stuck); magnetic resonance imaging increasingly used to assess pelvic disease and fi stulae, small bowel disease activity and strictures; ultrasound in skilled hands can provide small bowel imaging. Treatment (See BOX. 8) Find out how your patient deals with what may be a brutal disease (no intimacyno sexno hopeI live with this alone and will die alone). With a collaborative approach, courage, attention to detail, and a dose of humour, this can change. Help quit smoking. Optimize nutrition. Assess severity: T°, pulse, ESR, WCC, CRP, albumin may merit admission for IV steroids. Mildmoderate: Symptomatic but systemically well.",
    "Assess severity: T°, pulse, ESR, WCC, CRP, albumin may merit admission for IV steroids. Mildmoderate: Symptomatic but systemically well. Prednisolone 40mg/d PO for 1wk, then taper by 5mg every wk for next 7wks. An alternative dietary approach based upon elemental or polymeric diets is eff ective in children but less used for adults. Plan maintenance therapy (see BOX). Severe: Admit for IV hydration/electrolyte replacement; IV steroids, eg hydrocortisone 100mg/6h or methylprednisolone 40mg/12h; thromboembolism prophylaxis (p350); ensure multiple stool MCS/CDT to exclude infection. Monitor T°, pulse, blood pressure, and record stool frequency/character on a stool chart. Physical examination daily. Daily FBC, ESR, CRP, UE, and plain AXR. Consider need for Blood transfusion (if hemoglobin 80g/L) and nutritional support. If improving switch to oral prednisolone (40mg/d). If not, biologics have a role. Consider abdominal sepsis complicating Crohns disease especially if abdominal Pain (ultrasound, computed tomography, magnetic resonance imaging are often required to assess this). Seek surgical advice. Perianal disease: Occurs in about 50%. magnetic resonance imaging and examination under anaesthetic (EUA) are an important part of assessment. Treatment includes oral antibiotics, immunosuppressant therapy ± anti-TNF, and local surgery ± seton insertion. 19 Much of the genetic risk is shared with UCsmall diff erences in genetics combined with environmental modifi ers may explain the very diff erent phenotypes. __OOHHCCMM__1100ee. . iinnddbb 226644 0022//0055//22001177 1199: : 0077 265 ygoloretneortsaG Therapies in Crohns disease Azathioprine (AZA) (22. 5mg/kg/d PO) used if refractory to steroids, relapsing on steroid taper, or requiring ≥2 steroid courses/yr. Takes 610wks to work. 30% will develop SES requiring treatment cessation including abdominal Pain, nausea, pancreatitis, leucopenia, abnormal LFTS. Monitor FBC, UE, LFT weekly for 4wks, then every 4wks for 3 months, then at least 3-monthly. Alternative immunomodulators include 6-mercaptopurine and methotrexate (CI: of reproductive age). 5-ASA Unlike in UC, have no role in the management of Crohns. Biologics Anti-TNF: TNF plays an important role in pathogenesis of Crohns disease, therefore monoclonal antibodies to TNF, eg infl iximab and adalimumab, can disease activity. They counter neutrophil accumulation and granuloma formation and cause cytotoxicity to CD4 T cells, thus clearing cells driving the immune response. These drugs play a vital role in both induction and maintenance therapy. CI: sepsis, active/ latent TB, LFT 3-fold above top end of normal. SE: rash. Avoid in people with known underlying malignancy. TB may reactivate when on infl iximab, so screen patients before starting the treatment (CXR, PPD, interferon gamma release assay (IGRA)). Combined AZA and infl iximab can effi cacy of at 12 months, but there are long-term safety issues (eg increased lymphoma risk). Anti-integrin: Monoclonal antibodies targeting adhesion molecules involved in gut lymphocyte traffi cking, eg vedolizumab, reduce disease activity and have a more gut-specifi c mechanism of activiy. Anti-IL12/23: Represents a new cytokine target with an emerging role in treatment, eg ustekinumab. Nutrition Enteral is preferred (eg polymeric diet); consider TPN as a last resort. Elemental diets: (Eg E028. ) Contain amino acids and can give remission. Low residue diets: Help symptoms in those with active disease or strictures. Surgery 5080% need ≥1 operation in their life. It never cures. Indications: drug failure (most common); GI obstruction from stricture; perforation; fi stulae; abscess. Surgical aims are: 1 resection of aff ected areasbut beware short bowel syndrome (p580) 2 to control perianal or fi stulizing disease 3 defunction (rest) distal disease eg with a temporary ileostomy. Pouch surgery is avoided in Crohns ( risk of recurrence). Poor prognosis Age 40yrs; steroids needed at 1st presentation; perianal disease; isolated terminal ileitis; smoking. Fig 6. 21 Beyond the gut I hate how this Fig 6.",
    "Fig 6. 21 Beyond the gut I hate how this Fig 6. 22 Deep fi ssured ulcers seen at colonstupid illness is crippling me As well as oscopy. The end result? My family does not or erythema nodosum on the shins (above; also will not even talk to me about the disease I caused by sarcoid, drugs, streptococci, and TB), dont know when urgency to race for the RiceCrohns can associate with sero Ωve arthritis of room will happen so I dont go out and have large or small joints, spondyloarthropathy, anbeen living a hermit life kylosing spondylitis, sacroiliitis, pyoderma gan- Dr A Mee. grenosum, conjunctivitis, episcleritis, and iritis. __OOHHCCMM__1100ee. . iinnddbb 226655 0022//0055//22001177 1199: : 0077 266 ygoloretneortsaG Gastrointestinal malabsorption Causes See BOX Causes of gastrointestinal malabsorption. Symptoms Diarrhoea; weight; lethargy; steatorrhoea; bloating. Defi ciency signs Anaemia (Fe, B12, folate); bleeding disorders (vit potassium); oedema (Protein); metabolic bone disease (vitamin D); neurological features, eg neuropathy. Tests FBC ( or MCV); Ca2; Fe; B12 folate; INR; lipid profi Blood; coeliac tests (see Coeliac disease). Stool: Sudan stain for fat globules; stool microscopy (infestation); elastase. Breath hydrogen analysis: For bacterial overgrowth. 20 Take samples of endexpired air; give glucose; take more samples at ½h intervals; early exhaled hydrogen overgrowth. Endoscopy small bowel biopsy. Infectious malabsorption Giardia, Cryptosporidium, Isospora belli, Cyclospora cayetanensis, microsporidia. Tropical sprue: Villous atrophy malabsorption occurring in the Far and Middle East and Caribbeanthe cause is unknown. Tetracycline 250mg/6h PO folic acid 5mg/d PO for 36mnths may help. Coeliac disease Suspect this if diarrhoea weight loss or anaemia (esp. if iron or B12 ). T-cellresponses to gluten (alcohol-soluble proteins in wheat, barley, rye ± oats) in the small bowel causes villous atrophy and malabsorption. Associations HLA DQ2 in 95%; the rest are DQ8; autoimmune disease; dermatitis herpetiformis. Prevalence 1 in 100300 (commoner if Irish). Any age (peaks in childhood and 5060yrs). : 1: 1. Relative risk in 1st-degree relatives is 6. Presentation Stinking stools/steatorrhoea; diarrhoea; abdominal Pain; bloating; nausea Vomiting; aphthous ulcers; angular stomatitis (p327, fi g 8. 5); weight; Fatigue; weakness; osteomalacia; failure to thrive (children). 30% less severe: may mimic IBS. Diagnosis hemoglobin; RCDW (p325); B12, ferritin. Antibodies: anti-transglutaminase is single preferred test (but is an IgA antib odycheck IgA levels to exclude subclass defi - ciency). Where serology positive or High index of suspicion proceed to duodenal biopsy while on a gluten-containing diet: expect subtotal villous atrophy, intra-epithelial WBCS crypt hyperplasia. Where doubt persists, HLA DQ2 and DQ8 genotyping may help. Treatment Lifelong gluten-free dietpatients become experts. Rice, maize, soya, potatoes, and Glucose are OK. Limited consumption of oats (≤50g/d) may be tolerated in patients with mild disease. Gluten-free biscuits, fl our, Bread, and pasta are prescribable. Monitor response by symptoms and repeat serology. 9 Complications Anaemia; dermatitis herpetiformis (OHCS p588); osteopenia/osteoporosis; hyposplenism (off er fl u and pneumococcal vaccinations); GI T-cell lymphoma (rare; suspect if refractory symptoms or weight); risk of malignancy (lymphoma, gastric, oesophageal, colorectal); neuropathies. Irritable bowel syndrome (IBS) IBS denotes a mixed group of abdominal symptoms for which no organic cause can be found. Most are probably due to disorders of intestinal motility, enhanced visceral perception (the braingut axis: see BOX Managing IBS), or microbial dysbiosis. Several diagnostic criteria exist (see BOX Defi ning gastrointestinal dysfunction p261). Prevalence 1020%; age at onset: 40yrs; : ≥2: 1. Diagnosis Only diagnose IBS if recurrent abdominal Pain (or discomfort) associated with at least 2 of: relief by defecation altered stool form altered bowel frequency (constipation and diarrhoea may alternate). Other features: urgency; incomplete evacuation; abdominal bloating/distension; mucus PR; worsening of symptoms after food.",
    "Other features: urgency; incomplete evacuation; abdominal bloating/distension; mucus PR; worsening of symptoms after food. Symptoms are chronic (6 months), and often exacerbated by stress, menstruation, or gastroenteritis (post-infectious IBS). Signs: Examination may be normal, but general abdominal tenderness is common. Insuffl ation of air during lower GI endoscopy (not usually needed) may reproduce the Pain. Think of other diagnoses if: Age 60yrs; history 6 months; anorexia; weight; waking at night with Pain/diarrhoea; mouth ulcers; abnormal CRP, ESR. __OOHHCCMM__1100ee. . iinnddbb 226666 0022//0055//22001177 1199: : 0077 267 ygoloretneortsaG Causes of gastrointestinal malabsorption Common in the UK: Coeliac disease; chronic pancreatitis; Crohns disease. Rarer: Bile: primary biliary cholangitis; ileal resection; biliary obstruction; colestyramine. Pancreatic insuffi ciency: pancreatic cancer; cystic fi brosis. Small bowel mucosa: Whipples disease (p716); radiation enteritis; tropical sprue; small bowel resection; brush border enzyme defi ciencies (eg lactase insuffi ciency); drugs (metformin, neomycin, alcohol); amyloid (p370). Bacterial overgrowth: 20 spontaneous (esp. in elderly); in jejunal diverticula; postop blind loops. diabetes mellitus proton pump inhibitor use are also risk factors. Try metronidazole 400mg/8h PO. Dont confuse with aff erent loop syndrome (p622). Infection: giardiasis; diphyllobothriasis (B12 malabsorption); strongyloidiasis. Intestinal hurry: post-gastrectomy dumping; post-vagotomy; gastroj ejunostomy. Managing IBS Make a positive diagnosis (p266) and other diagnoses, so: If the history is classic, FBC, ESR, CRP coeliac serology (p266) are suffi cient. If 60yrs or any marker or organic disease (T°, Blood PR, weight): colonoscopy. Have a Low threshold for referring if family history of ovarian or bowel cancer. : excluding ovarian cancer requires serum calcium-125 (OHCS p281); endo m etriosis (OHCS p288) often mimics IBS: consider if Pain cyclical. If IBS criteria not met, consider clinical context and decide upon: stool culture; B12/folate; TSH; faecal calprotectin (p262). Refer if: 1 Diagnostic uncertainty (you or the patient! ). 2 If changing symptoms in known IBS. 3 Refractory to management: stress or depression (seen in ≥50%) or refractory symptoms (here, NICE favours cognitive therapy, OHCS p390), chronic Pain overlap syndromes (fi bromyalgia chronic Fatigue chronic pelvic Pain) or detrusor problems. Treatment: Should focus on controlling symptoms, initially using lifestyle/dietary measures, then cognitive therapy (OHCS p390) or pharmacotherapy if required: Constipation: ensure adequate Water and fi bre intake and promote physical activity; (fi bre intake can worsen fl atule nce/bloating so avoid insoluble fi bre, such as bran; oats are better). Simple laxatives (p260, but beware lactulose which ferments and can aggravate bloating). If 2 of these fail, try prucalopride, linaclotide, or lubiprostone; or self-administered anal irrigation. Diarrhoea: avoid sorbitol sweeteners, alcohol, and caff eine; reduce dietary fi bre content; encourage patients to identify their own trigger foods; try a bulking agent ± loperamide 2mg after each loose stool. Colic/bloating: oral antispasmodics: mebeverine 135mg/8h or hyoscine butylbromide 10mg/8h (over the counter). Combination probiotics in suffi cient doses (eg VSL3) may help fl atulence or bloating. Diets Low in fermentable, poorly absorbed saccharides and alcohols may provide benefi t (the Low FODMAP diet). Psychological symptoms/visceral hypersensitivity: emphasize the positive! You have excluded sinister pathology and over time, symptoms tend to improve. Consider cognitive behavioural therapy (OHCS p390), hypnosis, and tricyclics, eg amitriptyline 1020mg at night (SE: drowsiness, dry mouth); explain that this is at a Low dose for visceral Pain (ie you are not prescribing the higher licensed dose for depression). 20 Bacterial overgrowth proximal to the colon causes diarrhoea, abdominal Pain, and vitamin malabsorption. Causes: old age, autonomic neuropathy (eg diabetic), ileocaecal valve resection; proton pump inhibitor usage; amyloidosis. __OOHHCCMM__1100ee. .",
    "Causes: old age, autonomic neuropathy (eg diabetic), ileocaecal valve resection; proton pump inhibitor usage; amyloidosis. __OOHHCCMM__1100ee. . iinnddbb 226677 0022//0055//22001177 1199: : 0077 268 ygoloretneortsaG Nutritional disorders Always consider that more than one nutritional disorder is likely to be present (table 6. 9). Scurvy is due to lack of vitamin C. 21 Is the patient poor, pregnant, or on an odd diet? Signs: 1 Listlessness, anorexia, cachexia (p35). 2 Gingivitis, loose teeth, and foul breath (halitosis). 3 Bleeding from gums, nose, hair follicles, or into joints, bladder, gut. 4 Muscle Pain/weakness. 5 Oedema. Diagnosis: No test is completely satisfactory. white blood cell ascorbic acid. : Dietary education; ascorbic acid ≥250mg/24h PO. Beriberi There is Heart failure with general oedema (wet beriberi) or neuropathy (dry beriberi) due to lack of vitamin B1 (thiamine). For treatment and diagnostic tests, see Wernickes encephalopathy (p714). Pellagra lack of nicotinic acid. Classical triad: diarrhoea, dementia, dermatitis (Casals necklace) ± neuropathy, depression, insomnia, tremor, rigidity, ataxia, fi ts. It may occur in carcinoid syndrome and anti-TB drugs (isoniazid). It is endemic in China and Africa. : Education, electrolyte replacement, nicotinamide 100mg/4h. Xerophthalmia This vitamin A defi ciency syndrome is a big cause of blindness in the Tropics. Conjunctivae become dry and develop oval/triangular spots (Bitôts spots). Corneas become cloudy and soft. Give vitamin A (OHCS p460). Get special help if pregnant: vitamin A embryopathy must be avoided. Re-educate and monitor diet. Table 6. 9 Defi ciency syndromes and the sites of nutrient absorption Vitamin/nutrient Site of absorption Defi ciency syndrome atrial fibrillation Small intestine Xerophthalmia B 1 (thiamine) Small intestine Beriberi; Wernickes encephalopathy (p714) B2 (ribofl avin) Proximal small intestine Angular stomatis; cheilitis (p246) B6 (pyridoxine) Small intestine Polyneuropathy B12 Terminal ileum Macrocytic anaemia (p332); neuropathy; glossitis C Proximal ileum Scurvy DF Jejunum as free vitamin Rickets (p684); osteomalacia (p684) EF Small intestine Haemolysis; neurological defi cit KF Small intestine Bleeding disorders (p344) Folic acid Jejunum Macrocytic anaemia (p332) Nicotinamide Jejunum Pellagra Mineral Calcium Duodenum jejunum p676 Copper Stomach jejunum Menkes kinky hair syndrome Fluoride Stomach Dental caries Iodide Small intestine Goitre; cretinism Iron Duodenum jejunum Microcytic anaemia (p326) Magnesium Small intestine p679 Phosphate Small intestine Osteoporosis; anorexia; weakness Selenium Small intestine Cardiomyopathy (p679) Zinc Jejunum Acrodermatitis enteropathica; poor wound healing (p679) F fat-soluble vitamin, thus defi ciency is likely if there is fat malabsorption. 21 That oranges and lemons prevent the scurvy was noted by the naval surgeon James Lind in 1753. In what may rank as the fi rst ever clinical trial, he randomly divided 12 sailors with scurvy into 6 groups, given the same basic diet but each group received a unique dietary intervention. The 2 sailors receving oranges and lemons both made a Good recovery, unlike the other 10. __OOHHCCMM__1100ee. . iinnddbb 226688 0022//0055//22001177 1199: : 0077 269 ygoloretneortsaG Food mountains, the pellagra paradox, and the sorrow that weeping cannot symbolize The sweet smell is a great sorrow on the land. Men who can graft the trees and make the seed fertile and big can fi nd no way to let the hungry people Eat their produce The works of the roots of the vines, of the trees, must be destroyed to keep up the price There is a crime here that goes beyond denunciation. There is a sorrow here that weeping cannot symbolize. There is a failure here that topples all our success. The fertile earth, the straight tree rows, the sturdy trunks, and the ripe fruit. And children dying of pellagra must die because a profi t cannot be taken from an orange.",
    "And children dying of pellagra must die because a profi t cannot be taken from an orange. And coroners must fi ll in the certifi catesdied of malnutritionbecause the food must rot, must be forced to rot. The people come with nets to fi social history for potatoes in the river, and the guards hold them back; they come in rattling cars to get the dumped oranges, but the kerosene is sprayed. And they stand still and watch the potatoes fl oat by, listen to the screaming pigs being killed in a ditch and covered with quicklime, watch the mountains of oranges slop down to a putrefying ooze; and in the eyes of the people there is a failure; and in the eyes of the hungry there is a growing wrath. In the souls of the people the grapes of wrath are fi lling and growing heavy, growing heavy for the vintage. (J Steinbeck The Grapes of Wrath) How do John Steinbecks grapes grow in our 21st-century soil? Too well; a double harvest, it turns out, as not only is much of the world starving, amid plenty (for those who can pay) but also there is a new sorrow in our land that weeping cannot symbolize: pathological voluntary self-starvation, again amid plenty, in pursuit of the body-beautiful according to images laid down by media gods. If gastroenterologists had one wish it might not be the end ing of all their diseases, but that humankind stand in a right relationship with Steinb ecks fertile earth, his straight trees, his sturdy trunks, and his ripe fruit. __OOHHCCMM__1100ee. . iinnddbb 226699 0022//0055//22001177 1199: : 0077 270 ygoloretneortsaG Chronic pancreatitis Epigastric Pain bores through to the back, eg relieved by sitting forward or hot Water bottles on epigastrium/back (look for erythema ab ignes mottled dusky greyness); bloating; steatorrhoea; weight; brittle Diabetes. Symptoms relapse and worsen. Causes Alcohol; smoking; autoimmune; rarely: familial; cystic fi brosis; haemochromatosis; pancreatic duct obstruction (stones/tumour); congenital (pancreas divisum). Tests Ultrasound ± computed tomography: pancreatic calcifi cations confi rm the diagnosis, MRCP; AXR. Speckled calcifi cation; faecal elastase. Treatment Drugs: Give analgesia (coeliac-plexus block may give brief relief); lipase, eg Creon; fat-soluble vitamins. Insulin needs may be High or variable (beware hypoglycaemia). Diet: No alcohol; Low fat may help. Medium-chain triglycerides (MCT oil) may be tried (no lipase needed for absorpt ion, but diarrhoea may be worsened). Surgery: For unremitting Pain; narcotic abuse (beware of this); weight: eg pancreatectomy or pancreaticojejunostomy (a duct drainage procedure). Complications Pseudocyst; Diabetes; biliary obstruction; local arterial aneurysm; splenic vein thrombosis; gastric varices; pancreatic carcinoma. Carcinoma of the pancreas Epidemiology 3% of all malignancy; 9000 deaths/yr (UK). UK incidence is rising. Typical patient 70yrs old. Risk factors Smoking, alcohol, carcinogens, diabetes mellitus, chronic pancreatitis, waist circumference (ie adiposity), and possibly a High-fat and red or processed meat diet. Pathology Mostly ductal adenocarcinoma (meta stasize early; present late). 60% arise in the pancreas head, 25% in the body, 15% tail. A few arise in the ampulla of Vater (ampullary tumour) or pancreatic islet cells (insulinoma, gastrinoma, glucagonomas, somatostatinomas (p223), VIPomas); both have a better prognosis. Genetics 95% have mutations in the KRAS2 gene. The patient Tumours in the head of the pancreas present with painless obstructive jaundice. 75% of tumours in the body and tail present with epigastric Pain (radiates to back and relieved by sitting forward). Either may cause anorexia, weight loss, Diabetes, or acute pancreatitis. Rarer features: Thrombophlebitis migrans (eg an arm vein becomes swollen and red, then a leg vein); Ca2; marantic endocarditis; portal hypertension (splenic vein thrombosis); nephrosis (renal vein metastases).",
    "Signs: Jaundice palpable gallbladder (Courvoisiers law, p272); epigastric mass; hepatomegaly; splenomegaly; lymphadenopathy; ascites. Tests Blood: Cholestatic jaundice. calcium 199 (p531) is non-specifi c, but helps assess prognosis. Imaging: ultrasound or computed tomography can show a pancreatic mass ± dilated biliary tree ± hepatic metastases. They can guide biopsy and help staging prior to surgery/stent insertion. ERCP/MRCP (p742) show biliary tree anatomy and may localize the site of obstruction. EUS (endoscopic sonography) is an emerging adjunct for diagnosis and staging. : Most ductal cancers present with metastatic disease; 20% are suitable for radical surgery. Surgery: Resection (pancreato duodenectomy: Whip p Bloods, p271, fi g 6. 23) is a major undertaking best considered only where no distant metastases and where vascular invasion is still at a minimum. Post-op morbidity is High (mortality 5%); non-curative resection confers no survival benefi t. Laparoscopic excision: Tail lesions are easiest. Post-op chemotherapy: Delays disease progression. Palliation of jaundice: Endoscopic or percutaneous stent insertion may help jaundice and anorexia. Rarely, palliative bypass surgery is done for duodenal obstruction or unsuccessful ERCP. Pain: Disabling Pain may need big doses of opiates (p575), or radiotherapy. Coeliac plexus infi ltration with alcohol may be done at the time of surgery, or percutaneously. Referral to a palliative care team is essential. Prognosis Often dismal. Mean survival 6 months. 5yr survival: 3%. Overall 5yr survival after Whipples procedure 514%. Prognosis is better if: tumour 3cm; no nodes involved; Ωve resection margins at surgery; ampullary or islet cell tumours. __OOHHCCMM__1100ee. . iinnddbb 227700 0022//0055//22001177 1199: : 0077 271 ygoloretneortsaG Carcinoid tumours This is a specialized area! A diverse group of tumours of enterochromaffi n cell (neural crest) origin, by defi nition capable of producing 5HT. Common sites: appendix (45%), ileum (30%), or rectum (20%). 22 They also occur elsewhere in the GI tract, ovary, testis, and bronchi. 80% of tumours 2cm across will metastasize (ie consider all as malignant). Symptoms and signs Initially few. GI tumours can cause appendicitis, intussusception, or obstruction. Hepatic metastases may cause RUQ Pain. Tumours may secrete bradykinin, tachykinin, substance P, VIP, gastrin, insulin, glucagon, ACTH ( Cushings syndrome), parathyroid, and thyroid hormones. 10% are part of MEN-1 syndrome (p223); 10% occur with other neuroendocrine tumours. Carcinoid syndrome Occurs in 5% and implies hepatic involvement. Symptoms and signs: Bronchoconstriction; paroxysmal fl ushing especially in upper body (± migrating weals); diarrhoea; CCF (tricuspid incompetence and pulmonary stenosis from 5HTinduced fi brosis). Carcinoid crisis: See BOX Carcinoid crisis. Tests 24h Urine 5-hydroxyindoleacetic acid (5HIAA, a 5HT metabolite; levels change with drugs and diet: discuss with lab). CXR chest/pelvis magnetic resonance imaging/computed tomography help locate primary tumours. Plasma chromogranin A (refl ects tumour mass); 111Indium octreotide scintigraphy (octreoscan) and positron emission tomography (p739) also have a role. Echocardiography and BNP (p137) can be used to investigate carcinoid Heart disease. Treatment Carcinoid syndrome: Octreotide (somatostatin analogue) blocks release of tumour mediators and counters peripheral eff ects. Long-acting alternative: lanreotide. Loperamide for diarrhoea. Tumour therapy: Resection is the only cure for carcinoid tumours so it is vital to fi nd the primary site. At surgery, tumours are an intense yellow. Procedures depend on site, eg rectal carcinoid tumours 1cm can be resected endoscopically. Debulking (eg enucleating), embolization, or radiofrequency ablation of hepatic metastases can symptoms. Give octreotide cover to avoid precipitating a massive carcinoid crisis. Median survival 58yrs (3yrs if metastases are present, but may be up to 20yrs; so beware of giving up too easily, even in metastatic disease). Carcinoid crisis When a tumour outgrows its Blood supply or is handled too much during surgery, mediators fl ood out.",
    "Carcinoid crisis When a tumour outgrows its Blood supply or is handled too much during surgery, mediators fl ood out. There is life-threatening vasodilation, hypotension, tachycardia, bronchoconstriction, and hyperglycaemia. It is treated with Highdose octreotide, supportive measures, and careful management of fl uid balance (ie a central line is neededsee p775 for insertion technique). Whipples procedure (a) Areas of refl ection of diff erent parts (b) Post-operation Fig 6. 23 Whipples procedure may be used for removing masses in the head of the pancreas typically from pancreatic carcinoma or, rarely, a carcinoid tumour. 1 0 22 Some are never clinically detected: 1 in 300 autopsies have a small bowel carcinoid tumour. __OOHHCCMM__1100ee. . iinnddbb 227711 0022//0055//22001177 1199: : 0077 272 ygoloretneortsaG Jaundice Jaundice refers to yellowing of skin, sclerae, and mucosae from plasma bilirubin (visible at 60μmol/L fi g 6. 24). Jaundice is classifi ed by the site of the problem (prehepatic, hepatocellular, or cholestatic/obs tructive) or by the type of circulating bilirubin (conjugated or unconj ugated, fi g 6. 25). Unconjugated hyperbilir ubinaemia As unconjugated bilirubin is Water-insoluble, it does not enter Urine, resulting in unconjugated hyperbilir ubinaemia. Overproduction: Haemolysis (p338, eg malaria/DIC, etc); ineff ective erythropoiesis. Impaired hepatic uptake: Drugs (paracetamol, rifampicin), ischaemic hepatitis. Impaired conjugation: Eponymous syndromes: Gilberts, p700; CriglerNajjar, p696. Physiological neonatal jaundice: Caused by a combination of the above, OHCS p115. Conjugated hyperbili rubinaemia As conjugated bilirubin is Water-soluble, it is excreted in Urine, making it dark. Less conjugated bilirubin enters the gut and the faeces become pale. When severe, it can be associated with an intractable pruritus which is best treated by relief of the obstruction. Hepatocellular dysfunction: There is hepatocyte damage, usually with some cholestasis. Causes: Viruses: hepatitis (p278), CMV (p405), EBV (p405); drugs (see table 6. 10); alcohol; cirrhosis (see BOX Causes of jaundice); Liver metastases/abscess; haemo chromatosis; autoimmune hepatitis (AIH); septicaemia; leptospirosis; syphilis; 1-anti trypsin defi ciency (p290); BuddChiari (p696); Wilsons disease (p285); failure to excrete conjugated bilirubin (DubinJohnson Rotor syndromes, p698, p710); right Heart failure; toxins, eg carbon tetrachloride; fungi (fi g 6. 26). Impaired hepatic excretion (cholestasis): Primary biliary cholangitis; primary sclerosing cholangitis; drugs (see table 6. 10); common bile duct gallstones; pancreatic cancer; compression of the bile duct, eg lymph nodes at the porta hepatis; cholangiocarcinoma; choledochal cyst; Carolis disease; 23 Mirrizis syndrome (obstructive jaundice from common bile duct compression by a gallstone impacted in the cystic duct, often associated with cholangitis). The patient Ask: About Blood transfusions, IV drug use, body piercing, tattoos, sexual activity, travel abroad, jaundiced contacts, family history, alcohol use, and all medications (eg old drug charts; GP records). Examine: For signs of chronic Liver disease (p276), hepatic encephalopathy (p275), lymph adenopathy, hepatomegaly, splenomegaly, ascites, and a palpable gallbladder (if seen with painless jaundice the cause is not gallstonesCourvoisiers law). 24 Pale stools dark Urine cholestatic jaundice. Tests See p276 for screening tests in suspected Liver disease. Urine: Bilirubin is absent in pre-hepatic causes; in obstructive jaundice, urobilinogen is absent. Haematology: FBC, clotting, fi lm, reticulocyte count, Coombs test and haptoglobins for haemolysis (p336), malaria parasites (eg if unconjugated bilirubin/fever); Paul Bunnell (EBV). Chemistry: UE, LFT, -GT, total Protein, albumin. 25 Paracetamol levels. Microbiology: Blood and other cultures; hepatitis serology. Ultrasound: Are the bile ducts dilated? Are there gallstones, hepatic metastases, or a pancreatic mass? ERCP: (See p742. ) If bile ducts are dilated and LFT not improving. MRCP: (See p742. ) Or endoscopic ultrasound (EUS) if conventional ultrasound shows gallstones but no defi nite com mon bile duct stones. Liver biopsy: (See p248. ) If bile ducts are normal.",
    "Liver biopsy: (See p248. ) If bile ducts are normal. Consider abdominal computed tomography/magnetic resonance imaging if abdominal malignancy is suspected. What to do? Treat the cause promptly. Ensure adequate hydration; broad-spectrum antibiotics if obstruction. Monitor for ascites, encephalopathy; call a hepatologist. 23 Multiple segmental cystic or saccular dilatations of intrahepatic bile ducts with congenital hepatic fi brosis. It may present in 20yr-olds, with portal hypertension ± recurrent cholangitis/cholelithiasis. 24 Pancreatic or gallbladder cancer is more likely, as stones lead to a fi brotic, unexpandable gallbladder. 25 Albumin INR are the best indicators of hepatic synthetic function. Transaminases (ALT, AST) indicate hepatocyte damage. ALP suggests obstructive jaundice, but also occurs in hepatocellular jaundice, malignant infi ltration, pregnancy (placental isoenzyme), Pagets disease, and childhood (bone isoenzyme). __OOHHCCMM__1100ee. . iinnddbb 227722 0022//0055//22001177 1199: : 0077 273 ygoloretneortsaG Fig 6. 24 Its easy to miss mild jaundice, especially under fl uorescent light, so take your patient to the window, and as you both gaze at the sky, use the opportunity to broaden the horizons of your enquiries where have you been where are you going who are you with what are you taking? In the gaps, your patient may tell you the diagnosisalcohol or drug abuse, sexual infections/hepatitis, or worries about the side-eff ects of their TB or HIV medication or a spreading cancer from this lump here which I havent told anyone about yet. Reproduced from Roper, Clinical Skills, 2014, with permission from Oxford University Press. The pathway of bilirubin metabolism In the Liver, bilirubin is conjugated with glucuronic acid by hepatocytes, making it Water-soluble. Conjugated bilirubin is secreted in bile and passes into the gut. Some is taken up again by the Liver (via the enterohepatic circulation) and the rest is converted to urobilinogen by gut bacteria. Urobilinogen is either reabsorbed and excreted by the kidneys, or converted to stercobilin, which colours faeces brown. Fig 6. 25 Bilirubin is formed by the breakdown of haemoglobin in a 3-step process: hepatic uptake, conjugation, and excretion. Causes of jaundice in a previously stable patient with cirrhosis Sepsis (esp. UTI, pneumonia, or peritonitis) Alcohol; drugs (table 6. 10) Malignancy: eg hepatocellular carcinoma GI bleeding. Signs of decompensation: Jaundice; ascites; UGI bleed; encephalopathy. Table 6. 10 Examples of drug-induced jaundice Haemolysis Antimalarials (eg dapsone) Hepatitis Paracetamol overdose (p844) Sodium valproate Isoniazid, rifampicin, pyrazinamide Halothane Monoamine oxidase inhibitors Statins Flucloxacillin (may be weeks after ) Sulfonylureas Cholestasis Fusidic acid, co-amoxiclav, nitrofurantoin Prochlorperazine Steroids (anabolic; the Pill) Chlorpromazine Fig 6. 26 Amanita phalloides (Latin for phallic toadstool; also known as the death cap) is a lethal cause of jaundice. It is the most toxic mushroom known. After ing estion (its benign appearance is confusing), amat oxins induce hepatic necros is leaving few options other than transplantation. Ian Her riott. NB: dont use this image for identifi cation! __OOHHCCMM__1100ee. . iinnddbb 227733 0022//0055//22001177 1199: : 0077 274 ygoloretneortsaG Liver failure Defi nitions Liver failure may be recognized by the development of coagulopathy (INR1. 5) and encephalopathy. This may occur suddenly in the previously healthy Liver acute Liver failure (hyperacute onset ≤ 7d; acute 821d; subacute 426wks. ) More often it occurs on a background of cirrhosis chronic Liver failure. Fulminant hepatic failure is a clinical syndrome resulting from massive necrosis of Liver cells leading to severe impairment of Liver function. Causes Infections: Viral hepatitis (esp. B, C, CMV), yellow fever, leptospirosis. Drugs: Paracetamol overdose, halothane, isoniazid. Toxins: Amanita phalloides mushroom (fi g 6. 26), carbon tetrachloride. Vascular: BuddChiari syn. (p696), veno-occlusive disease.",
    "Toxins: Amanita phalloides mushroom (fi g 6. 26), carbon tetrachloride. Vascular: BuddChiari syn. (p696), veno-occlusive disease. Others: Alcohol, fatty Liver disease, primary biliary cholangitis, primary sclerosing cholangitis, haemochromatosis, autoimmune hepatitis, 1 -antitrypsin defi ciency, Wilsons disease, fatty Liver of pregnancy (OHCS p25), malignancy. Signs Jaundice, hepatic encephalopathy (see BOX Hepatic encephalopathy), fetor hepaticus (smells like pear drops), asterixis/fl ap (p50), constructional apraxia (cannot copy a 5-pointed star? ). Signs of chronic Liver disease (p276) suggest acute-onchronic hepatic failure. Tests Blood: FBC (? infection, 26? GI bleed), UE, 27 LFT, clotting (patient/INR), glucose, paracetamol level, hepatitis, CMV and EBV serology, ferritin, 1-antitrypsin, caeruloplasmin, autoantibodies (p284). Microbiology: Blood culture; Urine culture; ascitic tap for MCS of ascitesneutrophils 250/mm3 indicates spontaneous bact erial peritonitis (p276). Radiology: CXR; abdominal ultrasound; Doppler fl ow studies of the portal vein (and hepatic vein in suspected BuddChiari syndrome, p696). Neuro physiology: EEG, evoked potentials (and neuroimaging) have a limited role. Management Beware sepsis, hypoglycaemia, GI bleeds/varices, encephalopathy: Nurse with a 20° head-up tilt in ITU. Protect the airway with intubation and insert an NG tube to avoid aspiration and remove any Blood from stomach. Insert urinary and central venous catheters to help assess fl uid status. Monitor T°, respirations, pulse, blood pressure, pupils, Urine output hourly. Daily weights. Check FBC, UE, LFT, and INR daily. 10% glucose IV, 1L/12h to avoid hypoglycaemia. Do Blood glucose every 14h. Treat the cause, if known (eg GI bleeds, sepsis, paracetamol poisoning, p844). If malnourished, get dietary help: Good nutrition can decrease mortality. Give thiamine and folate supplements (p714). Treat seizures with phenytoin (p826). 1 1 Haemofi ltration or haemodialysis, if renal failure develops (BOX What is hepatorenal syndrome? ). Try to avoid sedatives and other drugs with hepatic metabolism (BOX Prescribing in Liver failure and BNF). Consider proton pump inhibitor as prophylaxis against stress ulceration, eg omeprazole 40mg/d IV/PO. Liaise early with nearest transplant centre regarding appropriateness. Treat complications Cerebral oedema: On ITU: 20% mannitol IV; hyperventilate. Ascites: Restrict fl uid, Low-salt diet, weigh daily, diuretics (p276). Bleeding: Vitamin potassium 10mg/d IV for 3d, platelets, FFP Blood as needed ± endoscopy. Blind of infection: Ceftriaxone 12g/24h IV, not gentamicin (risk of renal failure). Blood glucose: If 2mmol/L or symptomatic, 50mL of 50% glucose IV; check often. Encephalopathy: Avoid sedatives; 20° head-up tilt in ITU; correct electrolytes; lactulose 3050mL/8h (aim for 24 soft stools/d) is catabolized by bacterial fl ora to short-chain fatty acids which colonic pH and trap NH 3 in the colon as NH 4 ; Rifaximin 550mg/12h is a non-absorbable oral antibiotic that numbers of nitrogenforming gut bacteria. Worse prognosis if Grade IIIIV encephalopathy, age 40yrs, albumin 30g/L, INR, drug-induced Liver failure, late-onset hepatic failure worse than fulminant failure. 26 Neutrophilic leucocytosis need not mean a secondary infection: alcoholic hepatitis may be the cause. 27 Urea is synthesized in the Liver, so is a poor test of renal function in Liver failure; use Creatinine instead. __OOHHCCMM__1100ee. . iinnddbb 227744 0022//0055//22001177 1199: : 0077 275 ygoloretneortsaG Prescribing in Liver failure Avoid drugs that constipate (risk of encephalopathy), oral hypoglycaemics, and saline-containing IVIs. Warfarin eff ects are enhanced. Hepatotoxic drugs include paracetamol, methotrexate, isoniazid, azathioprine, phenothiazines, oestrogen, 6-mercaptopurine, salicylates, tetracycline, mitomycin. Hepatic encephalopathy: letting loose some false neurotransmitters As the Liver fails, nitrogenous waste (as ammonia) builds up in the circulation and passes to the brain, where astrocytes clear it (by processes involving the conversion of glutamate to glutamine). This excess glutamine causes an osmotic imbalance and a shift of fl uid into these cellshence cerebral oedema.",
    "This excess glutamine causes an osmotic imbalance and a shift of fl uid into these cellshence cerebral oedema. Grading: I Altered mood/behaviour; sleep disturbance (eg reversed sleep pattern); dyspraxia (Please copy this 5-pointed star); poor arithmetic. No Liver fl ap. II Increasing drowsiness, confusion, slurred speech ± Liver fl ap, inappropriate behaviour/personality change (ask the familydont be too tactful). III Incoherent; restless; Liver fl ap; stupor. IV Coma. What else could be clouding consciousness? Hypoglycaemia; sepsis; trauma; postictal. What is hepatorenal syndrome (HRS)? Cirrhosis ascites renal failure HRSif other causes of renal impairment have been excluded. Abnormal haemodynamics causes splanchnic and systemic vaso dilation, but renal vasoconstriction. Bacterial translocation, cytokines, and mesenteric angiogenesis cause splanchnic vasodilation, and altered renal autoregulation is involved in the renal vasoconstriction. Types of HRS: HRS 1 is a rapidly progressive deterioration in circulatory and renal function (median survival 2wks), often triggered by other deteriorating pathologies. Terlipressin resists hypovolaemia. Haemodialysis may be needed. HRS 2 is a more steady deterioration (survival 6 months). Transjugular intrahepatic portosystemic stent shunting may be required (TIPS, p257). Other factors in cirrhosis may contribute to poor renal function (p277). Transplants: Liver transplant may be required. After 812wks of pre-transplant Dialysis, some may be considered for combined LiverKidney transplantation. Kings College Hospital criteria in acute Liver failure Paracetamol-induced Liver failure Non-paracetamol Liver failure Arterial pH 7. 3 24h after ingestion. patient 100s. Or all of the following: Or 3 out of 5 of the following: Prothrombin time (patient) 100s 1 Drug-induced Liver failure Creatinine 300μmol/L 2 Age 10 or 40yrs old Grade III or IV encephalopathy. 3 1wk from 1st jaundice to encephalopathy 4 patient 50s 5 Bilirubin≥ 300μmol/L. Fulfi lling these criteria predicts poor outcome in acute Liver failure and should prompt consideration for transplantation (p277). Reproduced from OGrady J et al. Early indicators of prognosis in fulminant hepatic failure. Gastroenterology, 97(2): 43945, 1989 with permission from Elsevier. __OOHHCCMM__1100ee. . iinnddbb 227755 0022//0055//22001177 1199: : 0077 276 ygoloretneortsaG Cirrhosis Cirrhosis (Greek kirrhos yellow) implies irreversible Liver damage. Histologically, there is loss of normal hepatic architecture with bridging fi brosis and nodular regeneration. Causes Most often chronic alcohol abuse, HBV, or HCV infection. Others: see BOX Causes of cirrhosis. Signs Leuconychia: white nails with lunulae undemarcated, from hypoalbuminaemia; Terrys nailswhite proximally but distal ⅓ reddened by telangiectasias; clubbing; palmar erythema; hyperdynamic cir culation; Dupuytrens contracture; spider naevi (fi g 6. 27); xanthelasma; gynaecomastia; atrophic testes; loss of body hair; parotid enlargement (alcohol); hepatomegaly, or small Liver in late disease; ascites; splenomegaly. Complications Hepatic failure: Coagulopathy (failure of hepatic synthesis of clotting factors); encephalopathy (p259); hypoalbuminaemia (oedema); sepsis (pneumonia; septicaemia); spontaneous bacterial peritonitis (SBP); hypoglycaemia. Portal hypertension: Ascites (fi g 6. 28); splenomeg aly; portosystemic shunt including oesophageal varices (± life-threatening upper GI bleed) and caput medusae (enlarged superfi cial periumbilical veins). HCC: risk. Tests Blood: LFT: or bilirubin, AST, ALT, ALP, GT. Later, with loss of synthetic function, look for albumin ± patient/INR. WCC platel ets indicate hypersplenism. Find the cause: ferritin, iron/total iron-binding capacity (p288); hepatitis serology (p278); immunoglobulins (p290); autoantibodies (ANA, AMA, SMA, p553); -feto Protein (p286); caeruloplasmin in patients 40yrs old (p285); 1-antitrypsin (p290). Liver ultrasound duplex: May show a small Liver or hepatomegaly, splenomegaly, focal Liver lesion(s), hepatic vein thrombus, reversed fl ow in the portal vein, or ascites. magnetic resonance imaging: Caudate lobe size, smaller islands of regenerating nodules, and the presence of the right posterior hepatic notch are more frequent in alcoholic cirrhosis than in virus-induced cirrhosis.",
    "Ascitic tap: Should be performed and fl uid sent for urgent MCSneutrophils 250/mm3 indicates spontaneous bacterial peritonitis (see later in topic for treatment). Liver biopsy: (See p248. ) Confi rms the clinical diagnosis. Management General: Good nutrition is vital. Alcohol abstinence (p280). Avoid NSAIDS, sedatives, and opiates. Colestyramine helps pruritus (4g/12h PO, 1h after other drugs). Consider ultrasound ± -fetoprotein every 6 months to screen for HCC (p286) in those where this information will change management. Specifi c: For hepatitis-induced cirrhosis see p278. High-dose ursodeoxycholic acid in PBC (p282) may improve LFT and improve transplant-free survival. Penicillamine for Wilsons disease (p285). Ascites: Fluid restriction (1. 5L/d), Low-salt diet (40100mmol/d). Give spironolactone 100mg/24h PO; dose as tolerated (max 400mg/24h)it counters deranged reninangiotensinaldosterone (RAA) axis. Chart daily weight and aim for weight loss of ≤½kg/d. If response is poor, add furosemide ≤120mg/24h PO; do UE (watch sodium) often. Therapeutic paracentesis with concomitant albumin infusion (68g/L fl uid removed) may be required. Spontaneous bacterial peritonitis (SBP): Must be considered in any patient with ascites who deteriorates suddenly (may be asymptomatic). Common organisms are E. coli, Klebsiella, and streptococci. : eg piperacillin with tazobactam 4. 5g/8h for 5d or until sensitivities known. Give prophylaxis for High-risk patients (albumin, patient/INR, Low ascitic albumin) or those who have had a previous episode: eg ciprofl oxacin 500mg PO daily. Encephalopathy: Recurrent episodes may be reduced in frequency with prophylactic lactulose and rifaximin (p274). Renal failure: hepatic clearance of immune complexes leads to trapping in kidneys ( IgA nephropathy ± hepatic glomerulosclerosis). See also p275 for hepatorenal syndrome. Prognosis Overall 5yr survival is 50%. Poor prognostic indicators: encephalopathy; serum sodium 110mmol/L; serum albumin 25g/L; INR. Liver transplantation is the only defi nitive treatment for cirrhosis (p277). Acute indications: Acute Liver failure meeting Kings College criteria (see BOX Kings College Hospital criteria in acute Liver failure p275) Chronic indications: Advanced cirrhosis of any cause; hepatocellular cancer (1 nodule 5cm or ≤5 nodules 3cm). __OOHHCCMM__1100ee. . iinnddbb 227766 0022//0055//22001177 1199: : 0077 277 ygoloretneortsaG Fig 6. 27 Spider naevi: a central arteriole, from which numerous vessels radiate (like the legs of a spider). These fi ll from the centre unlike telangiectasias that fi ll from the edge. They occur most commonly in skin drained by the superior vena cava. ≤5 are normal (especially in ). CausFig 6. 28 Gross ascites. Note the umbilical heres include Liver disease, OCP, and pregnancy (ie nia (p613), gynaecomastia, and veins visible on changes in oestrogen metabolism). the anterior abdominal wall. Causes of cirrhosis Chronic alcohol use Non-alcoholic steatohepatitis (NASH) Chronic HBV or HCV infection28 Autoimmunity: primary biliary cholangi- Genetic disorders: haemochromatosis tis (p282); primary sclerosing cholangitis (p288); 1-antitrypsin defi ciency (p290); (p282); autoimmune hepatitis (p284) Wilsons disease (p285) Drugs: eg amiodarone, methyldopa, Hepatic vein events (BuddChiari, p696) methotrexate. Is cirrhosis becoming decompensated? Prepare to make an arrest Cirrhosis may lie in wait for years before committing one of its three great crimes against the person: jaundice, ascites, or encephalopathy. There are almost always accomplices who, if arrested now, may stop a killing from unfolding. These usual suspects are: dehydration constipation covert alcohol use infection (eg spontaneous peritonitis, see earlier in topic) opiate over-useor an occult GI bleed. If all have alibis, think of portal vein thrombosis, and call in the Chief Inspector. Liver transplantation The fi rst Liver transplant was in Denver, USA, in 1963. Now 8001000 are performed each year in the UK (indications see p284). The limiting step for the procedure is often the waiting-list for a donor organ, which may be cadaveric (Heart-beating or non-Heart-beating) or from live donors (right lobe).",
    "Contraindications include extrahepatic malignancy; severe cardiorespiratory disease; systemic sepsis; expected non-compliance with drug therapy; ongoing alcohol consumption (in those with alcohol-related Liver disease). Refer earlier rather than later, eg when ascites is refractory or after a 1st episode of bacterial peritonitis. Prioritization in the UK is based upon the UKELD (UK end-stage Liver disease) score, calculated from serum sodium, Creatinine, bilirubin, and INR. 29 Post-op: 1248h on ITU, with enteral feeding starting as soon as possible and close monitoring of LFT. Immunosuppression examples: tacrolimus ± mycophenolate mofetil (or azat hioprine) prednisolone. Hypera cute rejection is a result of ABO incompatibility. Acute rejection (T-cell mediated, at 510d): the patient feels unwell with pyrexia and tender hepatomegalyoften managed by altering the immunosuppressives. Other complications: sepsis (esp. Gram Ωve and CMV), hepatic artery thrombosis, chronic rejection (at 69 months), disease recurrence, and, rarely, graft-versus-host disease. Average patient survival at 1yr is 80% (5yr survival 6090%; depends on the pre-op disease). 28 Clues as to which patients with chronic HCV will get cirrhosis: platelet count ≤140 x 109/L, globulin/albumin ratio ≥1, and AST/ALT ratio ≥1100% ve predictive value but lower sensitivity (30%). 29 Online calculators available, eg at www. odt. nhs. uk __OOHHCCMM__1100ee. . iinnddbb 227777 0022//0055//22001177 1199: : 0077 278 Viral hepatitis Hepatitis A RNA virus. Spread: Faecaloral or shellfi social history. Endemic in Africa and S America, so a problem for travellers. Most infections are in childhood. Incubation: 26wks. Sympt oms: Fever, malaise, anorexia, nausea, arthralgiathen: jaundice (rare in children), hepatosplenomegaly, and adenopathy. Tests: AST and ALT rise 2240d after exposure (ALT may be 1000IU/L), returning to normal over 520wks. IgM rises from day 25 and means recent infection. IgG is detectable for life. : Supportive. Avoid alcohol. Rarely, interferon alfa for fulminant hepatitis. Active immunization: With inactivated viral Protein. 1 IM dose gives immunity for 1yr (20yrs if further booster is given at 612 months). Prognosis: Usually self-limiting. Fulminant hepatitis is rare. Chronicity doesnt occur. Hepatitis B virus (HBV, a DNA virus. ) Spread: Blood products, IV drug abusers (IVDU), sexual, direct contact. Deaths: 1 million/yr. Risk groups: IV drug users and their sexual partners/carers; health workers; haemophiliacs; men who have sex with men; haemodialysis (and chronic renal failure); sexually promiscuous; foster carers; close family members of a carrier or case; staff or residents of institutions/prisons; babies of HBSAg ve mothers; adopted child from endemic area. Endemic in: Far East, Africa, Mediterranean. Incubation: 16 months. Signs: Resemble hepatitis A but arthralgia and urticaria are commoner. Tests: HBSAg (surface antigen) is present 16 months after exposure. HBeAg (e antigen) is present for 1½3 months after acute illness and implies High infectivity. HBSAg persisting for 6 months defi nes carrier status and occurs in 510% of infections; biopsy may be indicated unless ALT and HBV DNA 2000iu/mL. Antibodies to HBCAg (anti-HBc) imply past infection; antibodies to HBSAg (anti-HBs) alone imply vaccination. HBV protein-creatinine ratio allows monitoring of response to therapy. See fi g 6. 29 and table 6. 11. Vaccination: See p287. Passive immunization (specifi c anti-HBV immunoglobulin) may be given to non-immune contacts after High-risk exposure. Complications: Fulminant hepatic failure, cirrhosis, HCC, cholangiocarcinoma, cryoglobulinaemia, membranous nephropathy, polyarteritis nodosa (p556). : Avoid alcohol. Immunize sexual contacts. Refer all with chronic Liver infl ammation (eg ALT 30IU/L), cirrhosis, or HBV DNA 2000IU/mL for antivirals (choice is 48 wks pegylated (PEG) interferon alfa-2a vs long-term but better tolerated nucleos(t) ide analogues, eg tenofovir, entecavir). The aim is to clear HBSAg and prevent cirrhosis and HCC (risk is if HBSAg and HBeAg ve). Hepatitis C virus (HCV) RNA fl avivirus.",
    "Hepatitis C virus (HCV) RNA fl avivirus. Spread: Blood: transfusion, IV drug abuse, sexual contact. UK prevalence: 200 000. Early infection is often mild/asymptomatic. 85% develop silent chronic infection; 25% get cirrhosis in 20yrsof these, 4% get hepatocellular cancer (HCC)/yr. Risk factors for progression: Male, older, higher viral load, use of alcohol, HIV, HBV. Tests: LFT (AST: ALT 1: 1 until cirrhosis develops, p276), anti-HCV anti bodies confi rms exposure; HCV-protein-creatinine ratio confi rms ongoing infection/chronicity; Liver biopsy or non-invasive elastography if HCV-protein-creatinine ratio ve to assess Liver damage and need for treatment. Determine HCV genotype (16). : BOX; quit alcohol. Other complications: Glomerulonephritis; cryoglobulin aemia; thyroiditis; autoimmune hepatitis; PAN; polymyositis; porphyria cutanea tarda. Hepatitis D virus (HDV) Incomplete RNA virus (needs HBV for its assembly). HBV vaccination prevents HDV infection. 5% of HBV carriers have HDV co-infection. It may cause acute Liver failure/cirrhosis. Tests: Anti-HDV antibody (only ask for it if HBsAg ve). : As interferon alfa has limited success, Liver transplantation may be needed. Hepatitis E virus (HEV) RNA virus. Similar to HAV; common in Indochina (commoner in older men and also commoner than hepatitis A in UK); mortal ity is High in pregnancy. It is associated with pigs. Epidemics occur (eg Africa). Vaccine is available in China (not Europe). : Serology. : Nil specifi c. Other infective causes of hepatitis EBV; CMV; leptospirosis; malaria; Q fever; syphilis; yellow fever. ygoloretneortsaG __OOHHCCMM__1100ee. . iinnddbb 227788 0022//0055//22001177 1199: : 0077 279 ygoloretneortsaG Table 6. 11 Serological markers of HBV infection Incubation Acute Carrier Recovery Vaccinated LFT Normal Normal HBsAg HBeAg /Ω Anti-HBs Anti-HBe /Ω Anti-HBc IgM /Ω Anti-HBc IgG weeks Fig 6. 29 Viral events in hepatitis B in relation to AST peak. IFimmunofl uorescence; Aganti gen; HBShep. B surface; HBChep. B core; HBehep. B e antigen; DNAPDNA polymerase. The virologists triumph: curing HCV Since the original isolation of HCV in the late 1980s, riding the wave of the AIDS scare, less than three decades have elapsed. In this time, the comparatively simple genome of HCV has proven far easier than HIV to combat and the treatment of HCV has undergone nothing less than a revolution to the point where many common genotypes are considered curable. All patients with sustained detectable HCV should be considered for treatment. Options are evolving rapidly, but centre on the use of inhibitors of non-structural viral proteins (eg ledipasvirsofosbuvir) which are much better tolerated than the previous mainstay of treatment, pegylated interferon. Interferon-free regimens therefore eliminate major barriers to compliance including treatment duration and SES, as well as achieving superior results: contemporary antiviral regimens can now realistically achieve the complete absence of protein-creatinine ratio detectable virus in the Blood 6 months post-treatment in almost 100% of genotype 1 patients, including patients with established cirrhosis. Ribavirin, a nucleoside analogue, can also increasingly be avoided in genotype 1, though it remains a useful treatment for the harder to treat genotypes 2 and 3. Here, reported rates of sustained undetectable viral levels now routinely exceed 90%. The costs of treatment are staggering, but cost-eff ectiveness analysis is favourable given the High cure rates and the signifi cant public health burden of HCV. Genotypes 4, 5, or 6 are prevalent in lower-income countries and have received less attention but limited data where resources do exist suggest similarly Good response rates. Meanwhile, the threat of HIV remains. HCV prevalence is 7% for sexually transmitted HIV and 90% for IV transmission. Untreated HIV may accelerate progress of HCV-induced Liver fi brosis. All HIV/HCV co-infected patients should be assessed for combination antiviral therapy.",
    "All HIV/HCV co-infected patients should be assessed for combination antiviral therapy. Given the potential for toxicities and viral resistance mutation, such therapies should be planned and delivered through expert services. __OOHHCCMM__1100ee. . iinnddbb 227799 0022//0055//22001177 1199: : 0077 280 ygoloretneortsaG Alcoholism An alcoholic is one whose problematic pattern of alcohol use leads to clinically signifi cant impairment or distress, manifested by multiple psychosocial, behavioural, or physiological features. Other addictions may coexist. Lifetime prevalence: 10% ( 4%). Denial is a leading feature, so be sure to question relatives. Organs aff ected Dont forget the risk of trauma while intoxicated. The Liver: Normal in 50%; or GT30but may be in any type of Liver infl ammation, eg fatty Liver, AIH (p284), HBV. Fatty Liver: Acute/reversible, but may progress to cirrhosis if drinking continues (also seen in obesity, diabetes mellitus, and with amiodarone). Alcoholic hepatitis: See BOX Managing alcoholic hepatitis. 80% progress to cirrhosis (hepatic failure in 10%). Cirrhosis: (See p276. ) 5yr survival is 48% if drinking continues (if not, 77%). Biopsy: Mallory bodies ± neutrophil infi ltrate (can be indistinguishable from NASH, p277). CNS: Self neglect; memory/cognition: High-potency vitamins IM may reverse it (p714; dont delay! ); cortical atrophy; retrobulbar neuropathy; fi ts; falls; wide-based gait; neuropathy; confabulation/Korsakoff s (p704) ± Wernickes encephalopathy (p714). Gut: Obesity; DV; gastric erosions; peptic ulcers; varices (p257); pancreatitis (acute or chronic); cancer (many types); oesophageal rupture ( Vomiting against a closed glottis; suspect if shock and surgical emphysema in the neck: Boerhaaves syndrome). Blood: MCV; anaemia from: marrow depression, GI bleeding, alcoholism-associated folate defi ciency, haemolysis; sideroblastic anaemia. See p326. Heart: Arrhythmias; blood pressure; cardiomyopathy; sudden death in binge drinkers. Reproduction: Testicular atrophy; testosterone/progesterone; oestrogen; fetal alcohol syndromeIQ, short palpebral fi ssure, absent philtrum, and small eyes. Withdrawal starts 1072h after last Drink. Signs: Pulse; blood pressure; tremor; confusion; fi ts; hallucinations (delirium treme ns)may be visual or tactile, eg animals crawling all over skin. Consider it in any new (3d) ward patient with acute confusion. Management Alcohol withdrawal: There is almost no role for hospital inpatient detox as a sole indication for admission however attractive the idea of a quick fi x may becommunity-based services are much better placed to support cessation. Admit only if complicating or coexisting medical problems require inpatient treatment. Check blood pressure TPR/4h. Beware blood pressure. For the 1st 3d give generous chlordiazepoxide, eg 1050mg/6h PO with additional doses as needed, then sum total dose and plan weaning regimen over 57d. Vitamins may be needed (p714). Prevention: (OHCS p512. ) Alcoholfree beers; price may help promote lower-risk drinking. NB: there are no absolutes: risk is a continuum. Suggest: 1 Graceful ways of declining a Drink, eg Im seeing what its like to go without for a bit. 2 Not buying himor herself a Drink when it is his/her turn. 3 Dont lift your glass to your lips until after the slowest drinker in your group takes a Drink. 4 Sip, dont gulp. Give follow-up and encouragement. Treating established alcoholics: May be rewarding, particularly if they really want to change. If so, group therapy or self-help (eg Alcoholics Anonymo ultrasound) may be usefulespecially if self-initiated and determined. Encourage the will to change. Relapse 50% will relapse soon after starting treatment. Acamprosate (p449) may help intense anxiety, insomnia, and craving. CI: pregnancy, severe Liver failure, Creatinine 120μmol/L. SE: DV, or libido; dose example: 666mg/8h PO if 60kg and 65yrs old. It should be started as soon as acute withdrawal is complete and continued for 1yr. Disulfi ram can be used to treat chronic alcohol dependence.",
    "Disulfi ram can be used to treat chronic alcohol dependence. It causes acetaldehyde build-up (like metronidazole) with extremely unpleasant effects to any alcohol ingestioneg fl ushing, throbbing headache, palpitations. Care must be taken to avoid alcohol (eg toiletries, food, medicines) since severe reactions can occur. Confer with experts if drugs are to be used. 30 GT is in 52% of alcoholics; it is also in 50% of those with non-alcoholic fatty livers. Its best use is not in diagnosing alcoholism but in seeing if a raised ALP is likely to be from Liver, not bone. __OOHHCCMM__1100ee. . iinnddbb 228800 0022//0055//22001177 1199: : 0077 281 ygoloretneortsaG Screening for unhealthy alcohol use Several screening tools have been validated (eg AUDIT) but these typically require detailed questioning and careful scoring. For simplicity, a single-item question has much to recommend it, such as How many times in the past year have you had fi ve (four for ) or more drinks in a day? (ve if 0; 82% sensitive, 79% specifi c). This can be followed up with the easily remembered CAGE questions: Ever felt you ought to cut down on your drinking? Have people annoyed you by criticizing your drinking? Ever felt guilty about your drinking? Ever had an eye-opener in the morning? Those answering yes to ≥2 may be exhibiting dependency (sensitivity 4394%; specifi city 7097%), but accuracy does change according to background population. Those who refuse, or give unconvincing answers may have more to tell in their biochemistry: look for GT, ALT, MCV, AST: ALT2, urea, platelets. Managing alcoholic hepatitis The patient: Malaise; TPR; anor exia; DV; tender hepatomegaly ± jaundice; bleeding; ascites. Blood: WCC; platelets (toxic eff ect or hypersplenism); INR; AST; MCV; urea. Jaundice, encephalopathy or coagulopathy severe hepatitis. Most need hospitalizing; urinary catheter and CVP monitoring may be needed. Screen for infections ± ascitic fl uid tap and treat for SBP (p276). Stop alcohol consumption: for withdrawal symptoms, if chlordiazepoxide by the oral route is impossible, try lorazepam IM. Vitamins: vit potassium: 10mg/d IV for 3d. Thiamine 100mg/d PO (High-dose B vitamins can also be given IV as Pabrinex1 pair of ampoules in 50mL 0. 9% saline IVI over ½h). Optimize nutrition (3540kcal/kg/d non-Protein energy). Use ideal body weight for calculations, eg if malnourished. Dont use Low-Protein diets even if severe encephalopathy is present. Give 1. 2g/ kg/d of Protein; this prevents encephalopathy, sepsis, and some deaths. Daily weight; LFT; UE; INR. If Creatinine , get help with thisHRS (p275). sodium is common, but Water restriction may make matters worse. Steroids may confer benefi t in those with severe disease. The Maddrey Discriminant Factor (DF) (4. 6 patients prothrombin time in sec control time) bilirubin (μmol/L) roughly refl ects mortality. If Maddrey score 31 and encephalopathy then consider prednisolone 40mg/d for 5d tapered over 3wks. CI: sepsis; variceal bleeding. The largest study to date (STOPAH) showed only a non-signifi cant trend towards benefi t with this regimen. Prognosis: Mild episodes hardly aff ect mortality; if severe, mortality 50% at 30d. 1yr after admission for alcoholic hepatitis, 40% are deada sobering thought. __OOHHCCMM__1100ee. . iinnddbb 228811 0022//0055//22001177 1199: : 0077 282 ygoloretneortsaG Primary biliary cholangitis (PBC) Interlobular bile ducts are damaged by chronic autoimmune granul omato us31 infl ammation causing cholestasis which may lead to fi brosis, cirrhosis, and portal hypertension. Cause Unknown environmental triggers (? pollutants, xenobiotics, non-pathogenic bacteria) genetic predisposition (eg IL12A locus) leading to loss of immune tolerance to self-mitochondrial proteins. Antimitochondrial antibodies (AMA) are the hallmark of PBC. Prevalence 4/100 000. : 9: 1.",
    "Antimitochondrial antibodies (AMA) are the hallmark of PBC. Prevalence 4/100 000. : 9: 1. Risk if ve family history (seen in 16%); many UTIS; smoking; past pregnancy; other auto immune diseases; use of nail polish/hair dye. Typical age at presentation 50yrs. The patient Often asymptomatic and diagnosed after incidental fi nding ALP. Lethargy, sleepiness, and pruritus may precede jaundice by years. Signs: Jaundice; skin pigmentation; xanthelasma (p691); xantho mata; hepatosplenomegaly. Complications: Those of cirrhosis (p276); osteoporosis is common. Malabsorption of fat-soluble vitamins (A, D, E, potassium) due to cholestasis and bilirubin in the gut lumen results in osteomalacia and coagu lopathy; HCC (p286). Tests Blood: ALP, GT, and mildly AST ALT; late disease: bilirubin, albumin, prothrombin time. 98% are AMA M2 subtype ve, eg in a titre of 1: 40 (see earlier in topic). Other autoantibodies (p553) may occur in Low titres. Immunoglobulins are (esp. IgM). TSH cholesterol or . Ultrasound: Excludes extrahepatic cholestasis. Biopsy: Not usually needed (unless drug-induced cholestasis or hepatic sarcoidosis need excluding); look for granulomas around bile ducts ± cirrhosis. 31 Treatment Symptomatic: Pruritus: try colestyramine 48g/24h PO; naltrexone and rifampicin may also help. Diarrhoea: codeine phosphate, eg 30mg/8h PO. Osteoporosis prevention: p682. Specifi c: Fat-soluble vitamin prophylaxis: vitamin A, D, and potassium. Consider High-dose ursodeoxycholic acid (UDCA)Ωit may improve survival and delay transplantation. SE: weight. Monitoring: Regular LFT; ultrasound ± AFP twice-yearly if cirrhotic. Liver transplantation: (See p277. ) For end-stage disease or intractable pruritus. Histological recurrence in the graft: 17% after 5yrs; although graft failure can occur as a result of recurrence, it is rare and unpredictable. Prognosis Highly variable. The Mayo survival model is a validated predictor of survival that combines age, bilirubin, albumin, patient time, oedema, and need for diuretics. Primary sclerosing cholangitis (PSC) Progressive cholestasis with bile duct infl ammation and strictures (fi gs 6. 30, 6. 31). Symptoms/signs Pruritus ± Fatigue; if advanced: ascending cholangitis, cirrh osis, and hepatic failure. Associations: sex. HLA-A1; B8; DR3. AIH (p284); 80% of Northern European patients also have IBD, usually UC; this combination is associated with risk of colorectal malignancy. Cancers Bile duct, gallbladder, Liver, and colon cancers are more common, so do yearly colonoscopy ultrasound; consider cholecystectomy for gallbladder polyps. 32 Tests ALP, then bilirubin; hyper gammaglobulin aemia and/or IgM; AMA Ωve, but ANA, SMA, and ANCA may be ve; see BOX and p553. ERCP (fi g 6. 30) or MRCP (fi g 6. 31) reveal duct anatomy and damage. Liver biopsy shows a fi brous, obliterative cholangitis. Treatment Liver transplant is the mainstay for end-stage disease; recurrence occurs in up to 30%; 5yr graft survival is 60%. Prognosis is worse for those with IBD, as 510% develop colorectal cancer post-transplant. Ursodeoxycholic acid may improve LFT but has not shown evidence of survival benefi t. High doses, eg 2530mg/ kg/d, may be harmful. Colestyra mine 48g/24h PO for pruritus (naltrexone and rifampicin may also help). Antibiotics for bacterial cholangitis. 31 Other causes of Liver granulomas: TB, sarcoid, infections with HIV (eg toxoplasmosis, CMV, mycobacteria), PAN, SLE, granulomatosis with polyangiitis, lymphoma, syphilis, isoniazid, quinidine, carbamazepine, allopurinol. Signs: PUO; LFT. 32 Usually gallbladder polyps are an incidental fi nding on ultrasound, and they can often be left if 1cm diameter, but in PSC they are much more likely to become malignant. __OOHHCCMM__1100ee. . iinnddbb 228822 0022//0055//22001177 1199: : 0077 283 ygoloretneortsaG Testing for autoantibodiesthe anguish of partial understanding The diagnostic approach to several infl ammatory conditions includes the measurement of autoantibodies.",
    "Also: Haemolysis; blue lunulae (nails); arthritis; hypermobile joints; grey skin. Tests Equivocal copper studies need expert interpretation. 1 Urine: 24h copper excretion is High, eg 100mcg/24h (normal 40mcg). 2 LFT: non-specifi c (but ALT 1500 is not part of the picture). 3 Serum copper: typically 11μmol/L. 4 Serum caeruloplasmin: 200mg/L (140mg/L is pathognomonic)beware incidental Low values in Protein-defi ciency states (eg nephrotic syndrome, malabsorption). 5 Molecular genetic testing can confi rm the diagnosis. 6 Slit lamp exam: KF rings: in iris/Descemets membrane (fi g 5. 42 OHCS p452). 7 Liver biopsy: Hepatic copper (copper 250mcg/g dry weight); hepatitis; cirrhosis. 8 magnetic resonance imaging: degeneration in basal ganglia, fronto-temporal, cerebellar, and brainstem. Management Diet: Avoid foods with High copper content (eg Liver, chocolate, nuts, mushrooms, legumes, and shellfi social history). Check Water sources (eg wells, pipes) for copper. Drugs: Lifelong penicillamine (500mg/68h PO for 1yr, maintena nce 0. 751g/d). SES: nausea, rash, WCC, hemoglobin, platelets, haematuria, nephrosis, lupus. Monitor FBC and urinary copper and Protein excretion. Liver transplantation: (See p277. ) If severe Liver disease. Screen siblings: Asympto matic homozygotes need treating. Prognosis Pre-cirrhotic Liver disease is reversible; CNS damage less so. There are no clear clinical prognostic indicators. Fatal events: Liver failure, bleeding, infection. __OOHHCCMM__1100ee. . iinnddbb 228855 0022//0055//22001177 1199: : 0077 286 ygoloretneortsaG Liver tumours The commonest (90%) Liver tumours are metastases (see fi g 6. 32), eg from breast, bronchus, or the gastrointestinal tract (see table 6. 14). Primary hepatic tumours are much less common and may be benign or malignant (see table 6. 13). Symptoms Fever, malaise, anorexia, weight, RUQ Pain ( Liver capsule stretch). Jaundice is late, except with cholangiocarcinoma. Benign tumours are often asymptomatic. Tumours may rupture causing intraperitoneal haemorrhage. Signs Hepatomegaly (smooth, or hard and irregular, eg metastases, cirrhosis, HCC). Look for signs of chronic Liver disease (p276) and evidence of decompensation (jaundice, ascites). Feel for an abdominal mass. Listen for a bruit over the Liver (HCC). Tests Blood: FBC, clotting, LFT, hepatitis serology, -fetoprotein ( in 5080% of HCC, though levels do not correlate with size, stage, or prognosis). Imaging: ultrasound or computed tomography to identify lesions and guide biopsy. magnetic resonance imaging is better at distinguishing benign from malignant lesions. Do ERCP (p742) and biopsy if cholangiocarcinoma is suspected. Liver biopsy: (See p248. ) May achieve a histological diagnosis; careful multidisciplinary discussion is required if potentially resectable, as bleeding or seeding along the biopsy tract can occur. If the lesion could be a metastasis, fi nd the primary, eg by CXR, mammography, colono scopy, computed tomography, magnetic resonance imaging, or marrow biopsy. Liver metastases Signify advanced disease. Treatment and prognosis vary with the type and extent of primary tumour. Chemotherapy may be eff ective (eg lymphomas, germ cell tumours). Small, solitary metastases may be amenable to resection (eg colorectal cancer). In most, treatment is palliative. Prognosis: Often 6 months. Hepatocellular carcinoma (HCC) Primary hepatocyte neoplasia accounts for 90% of primary Liver cancers; it is common in China Africa (40% of cancers vs 2% in UK). The patient: Fatigue, appetite, RUQ Pain, weight, jaundice, ascites, haemobilia. 34 : 3. Causes: HBV is the leading cause worldwide (esp. if High viral load; p278). HCV; 35 AIH (p284); cirrhosis (alcohol, haemochrom atosis, PBC); non-alcoholic fatty Liver; afl atoxin; Clonorchis sinensis; anabolic steroids. : 3-phase computed tomography (delayed wash-out of contrast in a suspect mass); magnetic resonance imaging; biopsy. Treatment: Resecting solitary tumours 3cm across 3yr survival from 13% to 59%; but 50% have recurrence by 3yrs. 36 Liver transplant gives a 5yr survival rate of 70%.",
    "36 Liver transplant gives a 5yr survival rate of 70%. 37 Percutaneous ablation, tumour embolization (TACE38), and sorafenib are options. Prevention: HBV vaccination (BOX and table 6. 15). Dont reuse needles. Screen Blood. Afl atox in exposure (sun-dry maize). AFP ± ultrasound (eg 6-monthly screen): Consider if at risk: eg all with cirrhosis; or chronic HBV in Africans or older Asians. Cholangiocarcinoma (Biliary tree cancer. ) 10% of Liver primaries. Causes: Flukes (Clonorchis, p435); PSC (screening by CA199 may be helpful, p282); biliary cysts; Carolis disease, p272; HBV; HCV; diabetes mellitus; N-nitroso toxins. The patient: Fever, abdominal Pain (± ascites), malaise, bilirubin; ALP. Pathology: Usually slow-growing. Most are distal extrahepatic or perihilar. Management: 70% inoperable at presentation. Of those that are, 76% recur. Surgery: eg major hepatectomy extrahepatic bile duct excision caudate lobe rese c tion. 5yr survival 30%. Post-op complications include Liver failure, bile leak, and GI bleeding. Stenting of obstructed extrahepatic biliary tree, percutaneously or via ERCP (p742), improves quality of life. Liver transplantation rarely possible. Prognosis: 5 months. Benign tumours Haemangiomas: The commonest benign Liver tumours. They are often an incidental fi nding on ultrasound or computed tomography and dont require treatment. Avoid biopsy! Adenomas: Common. Causes: anabolic steroids, oral contraceptive pill; pregnancy. Only treat if symptomatic, or 5cm. 34 Haemobilia is late in HCC. Think of bleeding into the biliary tree whenever Quinckes triad obtains: RUQ Pain, upper GI haemorrhage, and jaundice. It may be life-threatening. 35 5yr cumulative risk if cirrhosis is present is 30% in Japan and 17% in USA. 36 Operative mortality: 1. 6%. Recurrence is more likely if histology showed neoplastic emboli in small vessels. Get early warning of recurrence by arranging imaging, eg if AFP 5. 45mcg/L (esp. if trend is rising). Fibrolamellar HCC, which occurs in children and young adults, has a better prognosis. 37 Milan criteria for Liver transplantation in HCC: 1 nodule 5cm or 23 nodules 3cm. 38 TACEtransarterial chemoembolization, eg with drug-eluting beads; it causes fever and abdo Pain in 50%. __OOHHCCMM__1100ee. . iinnddbb 228866 0022//0055//22001177 1199: : 0077 287 ygoloretneortsaG Table 6. 13 Primary Liver tumours Malignant (prognosisregardless of Benign typeis poor) HCC Cysts Cholangiocarcinoma Haemangioma; common, : 5: 1 Angiosarcoma Adenoma Hepatoblastoma Focal nodular hyperplasia Fibrosarcoma hepatic gastrointestinal stroFibroma mal tumour (GIST, formerly leiomyosarcoma) Benign GIST (leiomyoma) Haemangiomas are hyperechoic on ultrasound; may be part of von HippelLindau syndrome; may need surgery if diagnosis is uncertain (may be confused with HCC) or they are enlarging on 6-monthly ultrasound. GISTs are mesenchymal tumours that are more likely to be found in the gut as a spherical mass arising from the muscularis propria, eg with GI bleeding. If unresectable, imatinib 2yr survival from 26% to 76%. Table 6. 14 Origins of secondary Liver tumours Common in men Common in women Less common (either sex) Stomach Breast Pancreas Lung Colon Leukaemia Colon Stomach Lymphoma Uterus Carcinoid tumours Vaccinating to prevent hepatitis B (and associated complications) Use hepatitis B vaccine 1mL into deltoid; repeat at 1 6 mon ths (child: 0. 5mL 3 into the anterolateral thigh). Indications: Everyone (WHO advice, even in areas of Low endemicityin 2014 this meant that 82% of the worlds children received protection against HBV). This contrasts with the approach in eg the UK and USA of targeting at-risk groups (p278). The immunocompromised and others may need further doses. Serology helps time boosters and fi nds non-responders (correlates with older age, smoking, and sex). Know your own antibody level! Table 6.",
    "Know your own antibody level! Table 6. 15 Post-immunization anti-HBs titres and actions Anti-HBs (international unit/L) Actions and comments (advice diff ers in some areas) 1000 Good level of immunity; retest in 4yrs. 1001000 Good level of immunity; if level approaches 100, retest in 1yr. 100 Inadequate; give booster and retest. 10 Non-responder; give another set of 3 vaccinations. Retest; if 10 get consent to check hepatitis B status: HBSAg ve means chronic infection; anti-hemoglobin core ve represents past infection and immunity. If a non-responder is deemed susceptible to HBV, and has recently come in contact with risky bodily fl uids, off er 2 doses of anti-hep B immunoglobulin. NB: protection begins some weeks after dose 1, so it wont work if exposure is recent; here, specifi c antihepatitis B immunoglobulin is best if not already immunized. Fig 6. 32 Axial computed tomography of the Liver after IV contrast showing multiple round lesions of varying size, highly suggestive of hepatic metastases. Courtesy of Norwich Radiology Dept. __OOHHCCMM__1100ee. . iinnddbb 228877 0022//0055//22001177 1199: : 0077 288 ygoloretneortsaG Hereditary haemochromatosis (HH) An inherited disorder of iron metabolism in which intestinal iron absorption leads to iron deposition in joints, Liver, Heart, pancreas, pituitary, adrenals, and skin. Middleaged men are more frequently and severely aff ected than women, in whom the disease tends to present 10yrs later (menstrual Blood loss is protective). Genetics HH is one of the commonest inherited conditions in those of Northern European (especially Celtic) ancestry (carrier rate of 1 in 10 and a frequency of homozygosity of 1 in 200400). The gene responsible for most HH is HFE: the 2 commonest mutations are termed C282Y and H63D. C282Y accounts for 6090% of HH, and H63D accounts for 13%, with compound heterozygotes accounting for 47%. Penetrance is variablea signifi cant fraction of C282Y homozygotes will not develop signs of iron overload during follow-up, complicating screening decisions. The patient Early on: Nilor tiredness; arthralgia (2nd3rd MCP joints knee pseudogout); libido. Later: Slate-grey skin pigmentation; signs of chronic Liver disease (p276); hepatomegaly; cirrhosis (esp. if drinks alcohol); dilated cardiomyopathy. Endocrinopathies: diabetes mellitus (bronze Diabetes from iron deposition in pancreas); hypogonadism (p232) from pituitary dysfunction. Tests Blood: LFT, ferritin (200/150ng/mL; but infl ammation will also ferritin); transferrin saturation39 should all trigger suspicion. Confi rm by HFE genotyping. Images: Chondro calcinosis (fi g 6. 33). Liver cardiac magnetic resonance imaging: Fe overload. Liver biopsy: Perls stain quantifi es iron loading40 and assesses disease severity. Management Venesect: 0. 52 units/12wks, until ferritin 50mcg/L (may take 2yrs). Iron will continue to accumulate, so maintenance venesection is needed for life (1U every 23 months to maintain haematocrit 0. 5, ferritin 100mcg/L, and transferrin saturation 40%). Consider desferrioxamine (p342) if intolerant of this. Monitor: LFT and glucose/ Diabetes (p206). hemoglobin hemoglobin A1c levels may be falsely Low as venesection the time available for hemoglobin glycosylation. If cirrhotic, screen for HCC with ultrasound ± AFP twice-yearly. Over-the-counter drugs: Ensure vitamin preparations contain no iron. Diet: A well-balanced diet should be encouragedthere is no need to avoid iron-rich foods. Avoid alcohol. Avoid uncooked seafood (may contain bacteria that thrive on increased plasma iron concentrations, eg Listeria monocytogenes, Vibrio vulnifi cus). Screening: Serum ferritin, transferrin saturation, and HFE genotype. Screen 1stdegree relatives by genetic testing even if they are asymptomatic and have normal LFT ideally prior to age where signifi cant iron deposition likely to have occurred (eg 1830yrs). Since C282Y homozygotes may never develop iron overload, population screening should not be performed. Prognosis Venesection returns life expectancy to normal if non-diabetic and non-cirrhotic (and Liver histology can improve).",
    "Prognosis Venesection returns life expectancy to normal if non-diabetic and non-cirrhotic (and Liver histology can improve). Arthropathy may improve or worsen. Gonadal failure may reverse in younger men. If cirrhosis, 2230% get hepatocellular cancer, especially if: age 50yrs (risk 13), HBsAg ve (risk 5), or alcohol abuse (risk 2). 39 Transferrin saturation 45% is a sensitive threshold for further screening but will lead to some false ves. 40 Although generally not required, biopsy quantifi es hepatic iron loading and fi brosis. This helps determine the severity of Liver disease, particularly in those with other underlying causes of chronic Liver disease. __OOHHCCMM__1100ee. . iinnddbb 228888 0022//0055//22001177 1199: : 0077 289 ygoloretneortsaG A bit about iron metabolism 60% of body iron is in haemoglobin, and erythropoiesis requires 530mg iron/ dayprovided by macrophages (recycling of haeme iron after phagocytosis of old RBCs). Intestinal iron absorption (12mg/day) compensates for daily iron losses. Red meats, Liver, seafoods, enriched breakfast cereals and pulses, and some spices (eg paprika) are iron-rich. Most dietary iron is Fe3, which is reduced by Low gastric pH and ascorbic acid (vitamin C) to better-absorbed Fe2. Absorption occurs mainly in the duodenum and jejunum, though very small amounts are absorbed in the stomach and ileum. Iron requirements are greater for women (menstrual loss), when growing, in pregnancy, and in chronic infection. Hepcidin, a peptide synthesized in hepatocytes, secreted in plasma, is a negative regulator of gut iron absorption and haeme iron recycling by macrophages. Hepcidin synthesis is stimulated by iron and repressed by iron defi ciency and by marrow erythropoiesis (eg in anaemia, bleeding, haemolysis, dyserythropoiesis, or erythropoietin injections). Defects in the normal triggering of hepcidin by iron excess is a rare cause of haemochromatosis unrelated to HFE mutations, whereas a defect in hepcidin repression is responsible for an iron refractory iron defi ciency anaemia. In HH, the total body iron is up to 10-fold that of a normal person, with loading found particularly in the Liver and pancreas (100). Hepatic disease classically starts with fi brosis, progressing to cirrhosis as a late feature. Fig 6. 33 Haemochromatosis causes stressed joints to deteriorate faster than resting joints: the 2nd and 3rd MCP joints have osteophytes and narrowed joint spaces compared to the normal hand (right image) in this man who only used his dominant hand for his production line job. Reproduced from Haemochromatosis arthropathy and repetitive trauma, Annals of the Rheumatic Diseases, Morgan et al. , 61(8): 763, 2002, with permission from BMJ Publishing Group Ltd. __OOHHCCMM__1100ee. . iinnddbb 228899 0022//0055//22001177 1199: : 0077 290 ygoloretneortsaG -antitrypsin (A1AT) defi ciency 1 A1AT defi ciency is an inherited disorder aff ecting lung (emphysema) and Liver (cirrhosis and HCC). A1AT is a glycoprotein and one of a family of serine protease inhibitors made in the Liver that control infl ammatory cascades. Defi ciency is called a serpinopathy. It makes up 90% of serum 1-glob ulin on electrophoresis (p687). A1AT defi ciency is the chief genetic cause of Liver disease in children. In adults, its lack is more likely to cause emphy sema. Lung A1AT protects against tissue damage from neutrophil elastasea process that is also induced by cigarette smoking (p184). Prevalence 1: 4000 (higher in Caucasians). Genetics Genetic variants of A1AT are typed by electro phor etic mobility as medium (M), slow (S), or very slow (Z). S and Z types are due to single amino acid substitutions at positions 264 and 342, respectively. These result in production of 1-antitrypsin (S60%, Z15%).",
    "Paracetamol overdose causes most acute Liver failure in the UK. Cholestasis predominant Liver injury ALP and GGT are ; AST and ALT mildly. Management For each specifi c diagnosis, manage accordingly. If asymptomatic and other tests are Ωve, try lifestyle modifi cation. Help reduce weight and alcohol use (p280 OHCS p512); control diabetes mellitus dyslipidaemia; stop hepatotoxic drugs. Follow-up Repeat tests after 12 months; if still , do ultrasound (± abdominal computed tomography). If diagnosis still unclear, get help: is biopsy needed? Consider (if you havent already) 1-antitrypsin levels, serum caeruloplasmin (Wilsons disease), coeliac serology, ANA and ASMA (AIH, p284). __OOHHCCMM__1100ee. . iinnddbb 229911 0022//0055//22001177 1199: : 0077 7 Renal medicine Contents Urine 294 Urinary tract infection (UTI) 296 Acute Kidney injury (acute kidney injury): A clinical approach 298 Management 300 Chronic Kidney disease (chronic kidney disease) 302 Management 304 Renal replacement therapy (RRT): Dialysis and fi ltration 306 Transplantation 308 Glomerulonephritis 310 Nephrotic syndrome 312 Renal manifestations of systemic disease 314 The renal tubule: disorders and diuretics 316 Tubulointerstitial nephropathy and nephrotoxins 318 Inherited Kidney disease 320 Fig 7. 1 A rotating drum artifi cial Kidney: one of the earliest Dialysis machines built by Willem Kolff in 1943. Exiled to a remote Dutch hospital during the Nazi occupation of the Netherlands, the resourceful inventor assembled a junkyard construction using a Water pump from a Ford model T, an aluminium drum from a downed warplane, washing machine parts, orange juice cans, and sausage skins. The fi rst 16 patients to use the machine died. Then, in 1945, 67-year-old Sofi a Maria Schafstadt (Patient Number 17) was referred reluctantly to Kolff with poisoning. Her Blood was passed through his sausage-skin tube which was wrapped around the drum, rotating like a washing machine in a Rice of salt Water. A total of 80L of her Blood was treated in this way, removing 60g of urea. After 11 hours she opened her eyes to declare, Im going to divorce my husband. This she duly achieved, as well as making medical history. Kolff chose not to patent his lifesaving invention but donated copies to hospitals across the world. We thank Dr Andrew Mooney, our Specialist Reader, for his contribution to this chapter. __OOHHCCMM__1100ee. . iinnddbb 229922 0022//0055//22001177 1199: : 0077 enicidem laneR Renal disease presents as: 293 1 Asymptomatic disease Non-visible haematuria: (NVH, microscopic haematuria. ) Detected on Urine dipstick on repeated testing. Most is not due to renal disease and urological investigation is fi rst-line for all those aged 40 years. See p294. Asymptomatic proteinuria: Normal renal Protein excretion is less than 150mg/24 hours (non-pregnant). Quantifi cation by 24h Urine collection is unreliable and rarely used in clinical practice. A spot urinary Protein to Creatinine ratio (P: creatinine) 15mg/mmol or urinary albumin to Creatinine ratio (A: creatinine) 2. 5() or 3. 5()magnesium/mmol may signify either glomerular (common) or tubular (rare) pathology. Abnormal renal function (glomerular filtration rate): The glomerular fi ltration rate (glomerular filtration rate) is a measure of how much Blood the kidneys are cleaning per minute. Direct measurement is invasive and time-consuming. Estimations derived from equations based on serum Creatinine are widely used to give an estimated glomerular filtration rate (see p669). Errors in estimated glomerular filtration rate are caused by non-steady-state conditions, conditions which alter serum Creatinine (diet, muscle mass), and estimated glomerular filtration rate is less accurate at higher levels of glomerular filtration rate. estimated glomerular filtration rate is therefore only part of the assessment of renal function.",
    "estimated glomerular filtration rate is therefore only part of the assessment of renal function. Hypertension: A renal aetiology should be excluded if hypertension occurs with any indicators of renal disease: haematuria, proteinuria, estimated glomerular filtration rate. Electrolyte abnormalities: Disorders of Sodium, Potassium, and acidbase balance (pp301 and 6705) may be due to underlying renal disease. 2 With renal tract symptoms Urinary symptoms: Dysuria is a sensation of discomfort with micturition and may be accompanied by urgency, frequency, and nocturia. UTI is the primary diff erential. Consider prostatic aetiology if there is diffi culty initiating voiding, poor stream and dribbling. Oliguria (400mL/24 hours or 0. 5mL/kg/hour) and anuria should trigger assessment and investigation for acute Kidney injury (acute kidney injury) (see pp298301). Poly uria is the voiding of abnormally High volumes of Urine, usually from High fl uid intake. Consider also diabetes mellitus, Diabetes insipidus (p240), hypercalcaemia (p676), renal medullary disorders (causing impaired concentration of Urine). Loin Pain: Ureteric colic is severe and radiates anteriorly and to the groin. It is caused by a renal stone, clot, or a sloughed papilla. For Pain confi ned to the loin consider pyelonephritis, renal cyst pathology, and renal infarct. Visible haematuria: (VH, macroscopic. ) Urological investigation is required to exclude renal tract malignancy. Nephrological causes include polycystic Kidney disease and glomerular disease (IgA p311, anti-glomerular basement membrane (anti-GBM) disease p311, Alport syndrome p320). Nephrotic syndrome: Proteinuria 3g/24 hours (P: creatinine 300mg/mmol) with hypoalbuminaemia (30g/L) and peripheral oedema. Renal biopsy is usually indicated in adults (p310). Symptomatic chronic Kidney disease: Dyspnoea, anorexia, weight loss, pruritus, bone Pain, sexual dysfunction, cognitive decline (pp3025). 3 A systemic disorder with renal involvement diabetes mellitus: (p314. ) Metabolic: Sickle cell disease (p315), tuberous sclerosis (p320), Fabry disease (p320), cystinosis (p321). Auto-immune: ANCA-associated vasculitis (p314, 556), SLE (p314), Henoch Schonlein purpura (p311), systemic sclerosis (p315), sarcoid (p318), Sjögrens syndrome (p318, 710). Infection: Sepsis is a common cause of acute kidney injury. Specifi c renal involvement may occur with TB (p392), malaria, chronic hepatitis (p278), HIV (pp398403). Malignancy: Obstruction, hypercalcaemia, direct toxicity, eg myeloma (p314). Pregnancy: Pre-eclampsia, obstruction. Drugs used in systemic disorders: NSAIDS, angiotensin-converting enzyme inhibitor, angiotensin receptor blocker, aminoglycosides, chemotherapy. __OOHHCCMM__1100ee. . iinnddbb 229933 0022//0055//22001177 1199: : 0077 294 enicidem laneR Urine Perform dipstick urinalysis whenever you suspect renal disease. This is a crude way of checking whether the Urine contains anything that it should not, eg Protein, Blood, glucose. Abnormalities can indicate intrinsic renal disease or renal tract abnormalities and usually require further investigation. However, a dipstick-positive catheter sample is diffi cult to interpret. Look for a Urine dip result (before the catheter was inserted). A positive result indicates the need for specialist advice from nephrology/urology. A negative result may help to reassure you about the absence of intrinsic renal disease. Proteinuria Requires quantifi cation. 24h collections are rarely used due to inaccuracy. Albumin: Creatinine ratio (A: creatinine) or Protein: Creatinine ratio (P: creatinine) is performed on a random spot Urine sample. Normal A: creatinine is 2. 5() or 3. 5(). P: creatinine is 15. Approximate equivalent levels of proteinuria are given in table 7. 1. Table 7. 1 Conversion factors Protein excretion g/24h A: creatinine magnesium/mmol P: creatinine magnesium/mmol 0. 15 (physiological) 2. 5 or 3. 5 15 0. 5 30 50 1 70 100 3 (nephrotic range) 250 300 Causes of raised A: creatinine/P: creatinine: The higher the proteinuria, the more chance it is caused by glomerular disease, eg glomerulonephritis, diabetes mellitus, amyloidosis, myeloma (though dipsticks do not detect light chains). Proteinuria is associated with an risk of cardiovascular disease and death.",
    "Proteinuria is associated with an risk of cardiovascular disease and death. False positive: Postural (repeat using an early morning sample), post-exercise, fever, Heart failure. Microalbuminuria: Ultra-sensitive dipsticks are available to measure albuminuria (albumin excretion 30300mg/24h). Suggests early glomerular disease, eg diabetes mellitus, blood pressure. Haematuria Blood in the Urine may arise from anywhere in the renal tract. Transient causes should be excluded, eg UTI, menstruation. Classifi ed as: visible (VH): previously known as macroscopic, frank non-visible (NVH): found on dipstick/microscopy, previously known as microscopic. NVH is subdivided according to the presence of urinary tract symptoms: symptomatic (SNVH) or asymptomatic (aNVH). Causes: Malignancy (Kidney, ureter, bladder), calculi, IgA nephropathy, Alport syndrome (p320), other glomerulonephritis (p310), polycystic Kidney disease (p320), schistosomiasis. Do not attribute haematuria to anticoagulation without investigation. False positive: Myoglobin triggers same dipstick reactioncheck microscopy. Management: VH, SNVH, and aNVH 40yr should undergo urological assessment, imaging, and cystoscopy to exclude renal tract malignancy and calculi. A renal aetiology should be considered, and renal referral made, for NVH with: estimated glomerular filtration rate 60 coexistent proteinuria (A: creatinine 30 or P: creatinine 50) hypertension 140/90mmHg family history of renal disease. A cause is not established in 1968% of patients with NVH. These patients should be monitored via blood pressure, estimated glomerular filtration rate, and repeat A: creatinine/P: creatinine every 6 months1 year. Increasing proteinuria and deteriorating estimated glomerular filtration rate warrant repeat referral and investigation. Others Glucose: diabetes mellitus, pregnancy, sepsis, proximal renal tubular pathology (p316). Ketones: Starvation, ketoa cidosis. Leucocytes: UTI (p296), vaginal discharge. Nitrites: UTI (enteric GramΩve organism). Bilirubin: Haemolysis. Urobilinogen: Liver disease, haemolysis. Specifi c gravity: Normal range: 1. 0051. 030, limited surrogate for Urine osmolality, aff ected by proteinuria. pH: NR: 4. 59, usually acidic with meat containing diet (acidbase balance: p670, renal tubular acidosis pp3167). __OOHHCCMM__1100ee. . iinnddbb 229944 0022//0055//22001177 1199: : 0077 295 enicidem laneR Urine microscopy Cells: Red Blood cells: 2 red cells/mm3 is abnormal. Can come from anywhere in the urinary tract. Isomorphic red cells are similar to circulating red cells and may suggest bleeding from a genitourinary or external source. Dysmorphic red cells are abnormal in size/shape. Although they may indicate bleeding from the glomerulus (especially in exam questions! ), assessment is subjective and dysmorphism also occurs due to changes in pH, osmolality, Protein, and due to tubular passage. White Blood cells: (fi g 7. 2a) 10 white cells/mm3 in an unspun specimen is abnormal. Causes include UTI, glomerulonephritis, tubulointerstitial nephritis, renal transplant rejection, and malignancy. Squamous epithelial cells: Often seen, not pathological. Casts: Casts are cylindrical bodies formed in the lumen of distal tubules. They are formed of Tamm-Horsfall Protein combined with cells. Hyaline cast (fi g 7. 2b)seen in normal Urine. Red cell cast (fi g 7. 2c)signify an infl ammatory process in the glomerulus, eg glomerulonephritis (p311). White cell cast (fi g 7. 2d)pyelonephritis, interstitial nephritis (p318), glomerulonephritis (p311). Granular cast (fi g 7. 2e)formed from degenerated tubular cells, seen in any chronic Kidney disease. Crystals: Crystals are common in old or cold Urine and may not signify pathology. They are important in stone formers. Uric acid (fi g 7. 2f)(p680)uric acid stones, tumour lysis syndrome. Calcium oxalate (fi g 7. 2g)stones (p638), High oxalate diet, ethylene glycol poisoning. Cystine (fi g 7. 2h)seen in cystinuria (p321). (a) (b) (c) (d) (e) (f) (g) (h) Fig 7. 2 (a) White cells; (b) hyaline cast; (c) red cell cast; (d) white cell cast; (e) granular cast; (f) uric acid crystals; (g) calcium oxalate crystals; (h) cystine crystal. Images (a) to (h) reproduced from Turner et al.",
    "Images (a) to (h) reproduced from Turner et al. , Oxford Textbook of Clinical Nephrology, 2005, with permission from Oxford University Press. __OOHHCCMM__1100ee. . iinnddbb 229955 0022//0055//22001177 1199: : 0077 296 enicidem laneR Urinary tract infection (UTI) Defi nitions Bacteriuria: Bacteria in the Urine; may be asymptomatic or symptomatic. Bacteriuria is not a disease. UTI: 1 A diagnosis based on symptoms and signs. Tests which prove bacteria in Urine may provide additional information. There is no gold-standard bacterial count. Lower UTI: Bladder (cystitis), prostate (prostatitis). Upper UTI: Pyelonephritis infection of Kidney/renal pelvis. Abacterial cystitis/urethral syndrome: A diagnosis of exclusion in patients with dysuria and frequency, without demonstrable infection. Urethritis: See pp4123. Incidence Annual incidence of UTI in women is 1020%. 10% of men and 20% of women 65 years have asymptomatic bacteriuria (65 years MSU is no longer diagnostic and clinical assessment is mandatory). Pyelonephritis 3 per 1000 patient years. Classifi cation Uncomplicated: normal renal tract structure and function. Complicated: structural/functional abnormality of genitourinary tract, eg obstruction, catheter, stones, neurogenic bladder, renal transplant. Risk factors Bacterial inoculation: Sexual activity, urinary incontinence, faecal incontinence, constipation. Binding of uropathogenic bacteria: Spermicide use, oestrogen, menopause. Urine fl ow: Dehydration, obstructed urinary tract (p640). Bacterial growth: diabetes mellitus, immunosuppression, obstruction, stones, catheter, renal tract malformation, pregnancy. Symptoms Cystitis: Frequency, dysuria, urgency, suprap ubic Pain, polyuria, haematuria. Acute pyelonephritis: Fever, rigor, Vomiting, loin Pain/tenderness, costovertebral Pain, associated cystitis symptoms, septic shock. Prostatitis: Pain: perineum, rectum, scrotum, penis, bladder, lower back. Fever, malaise, nausea, urinary symptoms, swollen or tender prostate on PR. See p645. Signs Fever, abdominal or loin tenderness. Check for a distended bladder, enlarged prostate. If vaginal discharge, consider PID, see p413. Do not rely on classical symptoms and signs in a catheterized patient. Tests In non-pregnant women, if ≥ 3 (or one severe) symptoms of cystitis, and no vaginal discharge, treat empirically without further tests. Dipstick: Use in non-pregnant women 65 years with less than three symptoms. A negative dipstick reduces probability of UTI to 20%. Do not use in pregnant women. Limited data for men. No diagnostic value in catheterized sample. MSU culture: Conventional cut off 105 colony-forming units (cfu)/mL (but best diagnostic criterion may be 102103cfu/mL). Use in pregnant women, men, children, and if fail to respond to empirical antibiotics. Catheterized sample only if septic. Blood tests: If systemically unwell: FBC, UE, CRP, and Blood culture (positive in only 1025% of pyelonephritis). Consider fasting glucose. Imaging: Consider USS and referral to urology for assessment (cystoscopy, urodynamics, computed tomography) in men with upper UTI; failure to respond to treatment; recurrent UTI (2/year); pyelonephritis; unusual organism; persistent haematuria. Organisms Usually anaerobes and Gram-negative bacteria from bowel and vaginal fl ora. E. coli is the main organism (7595% in community but in hospital). Staphylococcus saprophyticus (a skin commensal) in 510%. Other enterobacteriaceae such as Proteus mirabilis and Klebsiella pneumonia. For sterile pyuria see table 7. 2. Table 7. 2 Causes of sterile pyuria ( numbers of white cells but sterile on standard culture) Infection related Non-infection related TB Calculi Polycystic Kidney Recently treated UTI Renal tract tumour Recent catheter Inadequately treated UTI Papillary necrosis Pregnancy Fastidious culture requirement Tubulointerstitial nephritis SLE Appendicitis, prostatitis, chlamydia Chemical cystitis Drugs, eg steroids __OOHHCCMM__1100ee. . iinnddbb 229966 0022//0055//22001177 1199: : 0077 297 enicidem laneR Managing UTI Do not use antibiotics for the treatment of asymptomatic bacteriuria in nonpregnant women, men, and adults with catheters. Non-pregnant women: If three or more symptoms (or one severe) of cystitis, and no vaginal discharge, treat empirically with 3-day course of trimethoprim, or nitrofurantoin (if estimated glomerular filtration rate 30).",
    "If fi rst-line empirical treatment fails, culture Urine and treat according to antibiotic sensitivity. In upper UTI, take a Urine culture and treat initially with a broad-spectrum antibiotic according to local guidelines/sensitivities, eg co-amoxiclav. Hospitalization should be considered due to risk of antibiotic resistance. Avoid nitrofurantoin as it does not achieve eff ective concentrations in the Blood. Pregnant women: Get expert help: UTI in pregnancy is associated with preterm delivery and intrauterine growth restriction. Asymptomatic bacteriuria should be confi rmed on a second sample. Treat with an antibiotic. Refer to local guidance advice for antibiotic choice (avoid ciprofl oxacin, trimethoprim in 1st trimester, nitrofurantoin in 3rd trimester). Confi rm eradication. Men: Treat lower UTI with a 7-day course of trimethoprim or nitrofurantoin (if estimated glomerular filtration rate 30). If symptoms suggest prostatitis (Pain in pelvis, genitals, lower back, buttocks) consider a longer (4-week) course of a fl uoroquinolone (eg ciprofl oxacin) due to ability to penetrate prostatic fl uid. If upper or recurrent UTI, refer for urological investigation. Catheterized patients: All catheterized patients are bacteriuric. Send MSU only if symptomatic. Symptoms of UTI may be non-specifi c/atypical. Possible symptoms include fever, fl ank/ suprapubic Pain, change in voiding pattern, Vomiting, confusion, sepsis. Change long-term catheter before starting an antibiotic. Refer to local guidelines for initial antibiotic choice. Where possible use a narrowspectrum antibiotic according to culture sensitivity. Urinary tract tuberculosis A cause of sterile pyuria: dysuria, frequency, suprapubic Pain but negative standard culture. Ask about malaise, fever, night sweats, weight loss, back/fl ank Pain, visible haematuria (p393). Can also cause an interstitial nephritis (p318) and renal amyloidosis (p315). Glomerulonephritis is rare. Diagnose by microscopy with acid-fast techniques and mycobacterial culture of an early morning MSU and/or urinary tract tissue. Treat with rifampicin and isoniazid for 6 months in conjunction with pyrazinamide and ethambutol for 2 months (see p394). The Piss Prophets Beware the fallacies, deceit and juggling of the piss-pot science used by all those who pretend knowledge of diseases by the Urine. Thomas Brian, 1655. Medieval texts1 give the following maxims regarding urinary change and disease: White or straw coloured Urine weak and cold Liver and stomach Foamy Urine eructation (belching) Light coloured, turbid Urine mucus Lead circle on thin Urine pathological melancholy Bubbles on the surface disease of the head Watery Urine love sickness Swampy, black, stinking Urine fatal Lead coloured Urine a disintegrating uterus Reddish, cloudy Urine with bubbles asthma or an irregular Heart beat. 1 Uroscopy in Early Modern Europe by Michael Stolberg, Routledge, 2016, p536. __OOHHCCMM__1100ee. . iinnddbb 229977 0022//0055//22001177 1199: : 0077 298 enicidem laneR Acute Kidney injury (acute kidney injury): a clinical approach Defi nition Acute Kidney injury (acute kidney injury) is a syndrome of decreased renal function, measured by serum Creatinine or Urine output, occurring over hoursdays. It includes diff erent aetiologies and may be multifactorial. Diff erent defi nitions of acute kidney injury exist. In 2012, there was an attempt to amalgamate diff erent diagnostic criteria into a single defi nition and staging system. The Kidney Diseases: Improving Global Outcomes (Kidney Disease: Improving Global Outcomes) guidelines2 defi ne acute kidney injury as: rise in Creatinine 26μmol/L within 48h. rise in Creatinine 1. 5 baseline (ie before the acute kidney injury) within 7 days. Urine output 0. 5mL/kg/h for 6 consecutive hours. The severity of acute kidney injury is then staged according to the highest Creatinine rise or longest period/severity of oliguria (table 7. 3). Table 7. 3 Kidney Disease: Improving Global Outcomes staging system for acute kidney injury Stage Serum Creatinine Urine output 1 26. 5μmol/L (0. 3mg/dL) or 0.",
    "5μmol/L (0. 3mg/dL) or 0. 5mL/kg/h for 612h 1. 51. 9 baseline 2 2. 02. 9 baseline 0. 5mL/kg/h for 12h 3 353. 6μmol/L (4. 0mg/dL) or 0. 3mL/kg/h for 24h or 3. 0 baseline or anuria for 12h renal replacement therapy Although there are limitations to the use of serum Creatinine, including the eff ects of muscle mass and dilution, no other biomarker has been able to supersede it (yet). The clinical approach to acute kidney injury is shown in fi g 7. 3. 3 Epidemiology acute kidney injury is common, occurring in up to 18% of hospital patients and 50% of ICU patients. Risk factors for acute kidney injury include pre-existing chronic kidney disease, age, male sex, and comorbidity (diabetes mellitus, cardiovascular disease, malignancy, chronic Liver disease, complex surgery). Causes Commonest causes: 1 Sepsis. 2 Major surgery. 3 Cardiogenic shock. 4 Other hypovolaemia. 5 Drugs. 6 Hepatorenal syndrome. 7 Obstruction. Aetiology can be divided according to site (table 7. 4) as: pre-renal: perfusion to the Kidney. renal: intrinsic renal disease. post-renal: obstruction to Urine. Table 7. 4 Aetiology of acute kidney injury Where? Pathology Example Pre-renal Vascular volume Haemorrhage, DV, burns, pancreatitis Cardiac output Cardiogenic shock, myocardial infarction Systemic vasodilation Sepsis, drugs Renal vasoconstriction NSAIDs, angiotensin-converting enzyme inhibitor, angiotensin receptor blocker, hepatorenal syndrome Renal Glomerular (pp31013) Glomerulonephritis, ATN (prolonged renal hypoperfusion causing intrinsic renal damage) Interstitial (p318) Drug reaction, infection, infi ltration (eg sarcoid) Vessels (pp3145) Vasculitis, HUS, TTP, DIC Post-renal Within renal tract Stone, renal tract malignancy, stricture, clot Extrinsic compression Pelvic malignancy, prostatic hypertrophy, retroperitoneal fi brosis __OOHHCCMM__1100ee. . iinnddbb 229988 0022//0055//22001177 1199: : 0077 299 enicidem laneR acute kidney injury NEWS (see p892, fi g A1) Consider critical care referral Is there a Pulmonary oedema? Early referral to renal as may life-threatening need Dialysis (see below) complication? Urgent potassium (venous Blood gas) Treat if 6. 5mmol/L or any ECG changes (p301) Examine Heart rate, blood pressure, Treat hypovolaemia JVP, capillary Bolus fl uid 250500mL (p300) until volume replete refi ll, palpate for If 2L given without response, seek expert help bladder (renal/HDU/ITU) Monitor Fluid balanceconsider urinary catheter and hourly Urine output potassiumcheck response to treatment and at least daily until Creatinine falls Observationsminimum every 4 hours Lactate if signs of sepsis Daily Creatinine until (lags 24 hours behind clinical response) Investigate Urine dipstick (pre-catheter) and quantifi cation of any proteinuria. Haematuria/ proteinuria may suggest intrinsic renal disease USS within 24 hours (unless cause obvious or acute kidney injury improving). Small kidneys (9cm) suggest chronic kidney disease. Asymmetry may suggest renal vascular disease Check Liver function (hepatorenal) Check plateletsif Low need Blood fi lm to check for haemolysis (HUS/TTP) Investigate for intrinsic renal disease if indicated: immunoglobulins, paraprotein, complement, autoantibodies (ANA, ANCA, anti-GBM) Support Treat sepsis (p792) Stop nephrotoxic medicationNSAIDS, angiotensin-converting enzyme inhibitor, angiotensin receptor blocker, aminoglycosides Stop drugs that may complications: diuretics (especially potassium-sparing), metformin, antihypertensives Check all drug dosages are appropriate for renal impairment Consider gastroprotection (H2 antagonist, proton pump inhibitor) and nutritional support Avoid radiological contrast (or risk: p319). Fig 7. 3 The clinical approach to acute kidney injury. 3 Referring to the renal team Request that advice/review is necessary due to: acute kidney injury not responding to treatment acute kidney injury with complications: potassium, acidosis, fl uid overload stage 3 acute kidney injury (table 7. 3) acute kidney injury with diffi cult fl uid balance (eg hypoalbuminaemia, Heart failure, pregnancy) acute kidney injury due to possible intrinsic renal disease (table 7. 4) acute kidney injury with hypertension.",
    "4) acute kidney injury with hypertension. Know: Creatinine trend and pre-morbid result if available, potassium, bicarbonate/lactate, hemoglobin, platelet count (fi lm), Urine dipstick (before catheter), clinical observations (NEWS) since admission, fl uid input/output, examination fi ndings (hypo/hypervolaemia), USS result, comorbidity (eg diabetes mellitus), drugs given (what? when? nephrotoxic? ). __OOHHCCMM__1100ee. . iinnddbb 229999 0022//0055//22001177 1199: : 0077 300 enicidem laneR Acute Kidney injury (acute kidney injury): management Management of acute kidney injury requires diagnosis and treatment of the underlying aetiology: Pre-renal: correct volume depletion and/or renal perfusion via circulatory/cardiac support, treat any underlying sepsis. Renal: refer for likely biopsy and specialist treatment of intrinsic renal disease. Post-renal: catheter, nephrostomy, or urological intervention. Common to all aetiologies of acute kidney injury is the need to manage fl uid balance, acidosis, hyperkalaemia, and the timely recognition of those who may require renal replacement. Fluid balance Volume status: Hypovolaemia: blood pressure, Urine volume, non-visible JVP, poor tissue turgor, pulse, daily weight loss. Fluid overload: blood pressure, JVP, lung crepitations, peripheral oedema, gallop rhythm. Hypotension may be relative in old age, vascular stiff ness, untreated blood pressure. JVP does not refl ect intravascular volume if right-sided Heart disease/failure. blood pressure, skin turgor, capillary refi ll changes may be latedo not wait for them. Hypovolaemia, fl uid resuscitation: If hypovolaemic, renal perfusion will improve with volume replacement. 4 Care in cardiac disease (renal perfusion despite adequate circulating volume) and sepsis/third-spacing (extravascular volume). Dynamic assessment is essential: examine before and after all fl uid given to ensure an adequate response and to reduce the risk of fl uid overload. 1 Give5 00mL crystalloid over 15 min. 2 Reassess fl uid state. Get expert help if unsure or if patient remains shocked. 3 Further boluses of2 50500mL crystalloid with clinical review after each. 4 Stop when euvolaemic or seek expert help when2 L given. Which crystalloid? Any crystalloid can be used (follow local guidelines). 0. 9% (normal) saline is non-buff ered, contains chloride, and may cause hyperchloraemic acidosis. Balanced or buff ered crystalloids include Hartmanns, Ringers lactate, and Plasma-Lyte. Because they are balanced they are often used preferentially. However, they contain 45mmol/L of potassium so caution if potassiumand oligo/anuria. What about colloid? Blood components should be used in resuscitation due to haemorrhage. Human albumin solutions may be given only under specialist advice in hepatorenal syndrome and as second line to crystalloids in septic shock. Hypervolaemia, fl uid overload: Occurs due to aggressive fl uid resuscitation, oliguria, and in sepsis due to capillary permeability. Monitor weight daily in patients receiving IV fl uids. Treat with: Oxygen supplementation if required. Fluid restriction. Consider oral and IV volumes. Give antibiotics in minimal fl uid and consider concentrated nutritional support preparations. Diuretics. Only in symptomatic fl uid overload. They are ineff ective and potentially harmful if used to treat oliguria without fl uid overload. Renal replacement therapy (p306). acute kidney injury with fl uid overload and oligo/anuria needs urgent referral to renal/critical care. Acidosis Mild pH 7. 307. 36 (bicarbonate 20mmol/L). Moderate pH 7. 207. 29 (bicarbonate 1019mmol/L). Severe pH 7. 2 (bicarbonate 10mmol/L): refer to renal/critical care. Treatment is of the underlying disorder which will stop acid production. Where the eff ect of treatment may be delayed, acidosis will persist and renal replacement may be indicated (p306). Medical management of acidosis is controversial. Giving Sodium bicarbonate will generate CO2. Adequate ventilation is therefore needed to prevent respiratory acidosis worsening the clinical picture. Sodium bicarbonate also represents a Sodium and a volume load which can precipitate fl uid overload in the vulnerable patient. __OOHHCCMM__1100ee. .",
    "__OOHHCCMM__1100ee. . iinnddbb 330000 0022//0055//22001177 1199: : 0077 301 enicidem laneR Hyperkalaemia Fig 7. 4 ECG showing severe hyperkalaemia; note broadening of QRS complexes. ECG changes: In order: tall tented T waves; increased PR interval; small or absent P wave; widened QRS complex (fi g 7. 4); sine wave pattern; asystole. There is considerable inter-individual susceptibility. Dont wait for a lab result: use the Blood gas analyser. Treat5 potassium 6. 5mmol/L or any with ECG changes (ECG for all potassium 6. 0mmol/L): 1 10mL of 10% calcium chloride2 (or 30mL of 10% calcium gluconate) IV via a big vein over 510min, repeated if necessary and if ECG changes persist. This is cardioprotective (for 3060min) but does not treat potassium level. 2 Intravenous insulin (10u soluble insulin) in 25g glucose (50mL of 50% or 125mL of 20% glucose). Insulin stimulates intracellular uptake of potassium, lowering serum potassium by 0. 651. 0mmol/L over 3060min. Monitor hourly for hypoglycaemia (in 1175% of treated patients) which may be delayed in renal impairment (up to 6 hours after infusion). 3 Salbutamol also causes an intracellular potassium shift but High doses are required (1020mg via nebulizer) and tachycardia can limit use (10mg dose in IHD, avoid in tachyarrhythmias). 4 Defi nitive treatment requires potassium removal. If the underlying pathology cannot be corrected renal replacement may be indicated. Safe transfer to an off site renal unit requires potassium 6. 5mmol/Ldiscuss with renal team and critical care. Use of intravenous Sodium bicarbonate is controversial with insuffi cient evidence that it has any additional benefi t over the treatment steps listed here. There is a risk of both Sodium and fl uid overload. Bolus doses of 8. 4% Sodium bicarbonate should not be used. Renal replacement therapy (RRT) in acute kidney injury RRT options in acute kidney injury include haemodialysis and haemofi ltration (p306). Peritoneal Dialysis is rare for acute kidney injury in adults and in High-income countries but can be used. Possible indications for renal replacement therapy: Fluid overload unresponsive to medical treatment. Severe/prolonged acidosis. Recurrent/persistent hyperkalaemia despite medical treatment. Uraemia eg pericarditis, encephalopathy (more common in chronic kidney disease). The decision to start RRT should be individualized, aiming to provide organ support and prevent complications, rather than waiting for them to occur. The complexity of acute kidney injury and variation in thresholds for starting RRT prevent robust meta-analysis. Fluid overload is likely to be an important predictor of worse outcome. Possible complications of RRT: Risks of Dialysis catheter insertion and maintenance, procedural hypotension, bleeding due to the requirement for anticoagulation, altered nutrition and drug clearance. 2 Calcium chloride contains 3x calcium than the same volume of gluconate. Concern exists about the bioavailability of calcium gluconate. Both salts carry a risk of tissue necrosis with extravasation. __OOHHCCMM__1100ee. . iinnddbb 330011 0022//0055//22001177 1199: : 0077 302 enicidem laneR Chronic Kidney disease (chronic kidney disease) Defi nition Abnormal Kidney structure or function, present for 3 months, with implications for health. 6 Classifi cation Based on glomerular filtration rate category (table 7. 5), the presence of albuminuria as a marker of Kidney damage (table 7. 6), and the cause of Kidney disease (table 7. 7). (Problems using formula to grade renal disease by estimated glomerular filtration rate p669). Table 7. 5 Classifi cation of chronic kidney disease by glomerular filtration rate (milliliters per minute/1.",
    "Examination Periphery: Peripheral oedema. Signs of peripheral vascular disease or neuropathy. A vasculitic rash. Gouty tophi. Joint disease. Arteriovenous fi stula (thrill, bruit, recently needling? ). Signs of immunosuppression: bruising from steroids, skin malignancy. Uraemic fl ap/encephalopathy if glomerular filtration rate 15. Face: Anaemia, xanthelasma, yellow tinge (uraemia), jaundice (hepatorenal), gum hypertrophy (ciclosporin), Cushingoid (steroids), periorbital oedema (nephrotic syndrome), taut skin/telangiectasia (scleroderma), facial lipodystrophy (glomerulonephritis). Neck: JVP for fl uid state, tunnelled line (if removed, look for small scar over internal jugular, and a larger scar in breast pocket area), scar from parathyroidectomy, lymphadenopathy. Cardiovascular: blood pressure, sternotomy, cardiomegaly, stigmata of endocarditis. If right-sided Heart failure/tricuspid regurgitation, JVP does not refl ect fl uid state. Respiratory: Pulmonary oedema or eff usion. Abdomen: peritoneal dialysis catheter or scars from previous catheter (small scars just below umbilicus and to side of midline), signs of previous transplant (scar, palpable graft), ballotable polycystic kidneys ± palpable Liver. Investigation Blood: UE (compare with previous), hemoglobin (normochromic, normocytic anaemia), glucose (diabetes mellitus), Ca2, phosphate 3 Ω, parathyroid hormone (renal osteodystrophy). Directed investigation of intrinsic renal disease: ANA, ANCA, antiphospholipid antibodies, paraprotein, complement, cryoglobulin, anti-GBM, hepatitis serology, anti-PLA2R (membranous nephropathy). Note: ESR is not helpful as in chronic kidney disease and proteinuric states. Urine: Dipstick, MCS, A: creatinine or P: creatinine (p294), Bence Jones. Imaging: USS for size, symmetry, anatomy, corticomedullary diff erentiation, and to exclude obstruction. In chronic kidney disease kidneys may be small (9cm) except in infi ltrative disorders (amyloid, myeloma), APKD, and diabetes mellitus. If asymmetrical consider renovascular disease. Scarring may be seen on USS but isotope scans are more sensitive. Histology: Consider renal biopsy (p310) in progressive disease, nephrotic syndrome, systemic disease, acute kidney injury without recovery. Biopsy is unlikely to change treatment if glomerular filtration rate stable and P: creatinine 150. diabetes mellitus with neuropathy/retinopathy may not need biopsy unless atypical, ie nephrotic, haematuria, other systemic symptoms. Monitoring renal function in chronic kidney disease glomerular filtration rate and albuminuria should be monitored at least annually, according to risk. If High risk, monitor every 6 months (fi g 7. 5, orange), if very High risk, monitor at least every 34 months (fi g 7. 5, red). Small fl uctuations are common but a drop in estimated glomerular filtration rate stage with estimated glomerular filtration rate ≥ 25% is signifi cant. Rapid progression is estimated glomerular filtration rate 5/yr. Risk factors for decline: blood pressure, diabetes mellitus, metabolic disturbance, volume depletion, infection, NSAIDs, smoking. All chronic kidney disease has risk of superimposed acute kidney injury and needs monitoring and prompt treatment during intercurrent illness. __OOHHCCMM__1100ee. . iinnddbb 330033 0022//0055//22001177 1199: : 0077 304 enicidem laneR Chronic Kidney disease (chronic kidney disease): management chronic kidney disease encompasses a range of disease from mild disease without progression to advanced, symptomatic disease requiring renal replacement. Management of CKD6, 8 requires: 1 Appropriate referral to nephrology. 2 Treatment to slow renal disease progression. 3 Treatment of renal complications ofC KD. 4 Treatment of other complications ofC KD. 5 Preparation for renal replacement therapy (Dialysis/transplantation) (p306). Referral to nephrology Consider referral for: stage G4 and G5 chronic kidney disease (table 7. 5) moderate proteinuria A: creatinine 70mg/mmol unless due to diabetes mellitus and already treated proteinuria A: creatinine 30mg/mmol with haematuria declining estimated glomerular filtration rate: estimated glomerular filtration rate by ≥25% glomerular filtration rate category (table 7. 5) sustained estimated glomerular filtration rate ≥15% within 12 months blood pressure poorly controlled despite ≥4 antihypertensive drugs at therapeutic dose known or suspected rare or genetic cause of chronic kidney disease.",
    "Treatment to slow renal disease progression blood pressure: Target systolic blood pressure is 140mmHg (range 120139mmHg) and diastolic 90mmHg. If diabetes mellitus or A: creatinine 70 then systolic target is 130mmHg (range 120129) and diastolic 80mmHg. Reninangiotensin system: Off er treatment with a reninangiotensin system antagonist (angiotensin-converting enzyme inhibitor, angiotensin receptor blocker) to: diabetes mellitus and A: creatinine 3mg/mmol. Hypertension and A: creatinine 30mg/mmol. Any chronic kidney disease with A: creatinine 70mg/mmol. Do not combine reninangiotensinsin antagonists due to risk of hyperkalaemia and hypotension. Check potassium and renal function prior to, and 12 weeks after, starting treatment or changing dose. Stop if potassium 6mmol/L, estimated glomerular filtration rate 25%, or Creatinine 30%: exclude other possible causes and consider a lower dose. Glycaemic control: Target hemoglobin hemoglobin A1c of 53mmol/mol (7. 0%) unless risk of hypoglycaemia, comorbidity or limited life expectancy. Lifestyle: Off er advice about exercise, healthy weight, and smoking cessation. Salt intake should be reduced to 2g of Sodium/day (5g Sodium chloride/day). Treatment of renal complications of chronic kidney disease Anaemia: Check hemoglobin when estimated glomerular filtration rate 60. Investigate (especially if anaemic with estimated glomerular filtration rate 30) and treat other defi ciencies: iron (hypochromic red cells 6%, transferrin saturation 20%, ferritin 100), B12, and folate. Do not miss chronic Blood loss. Iron therapy may need to be given IV. Consider treatment with an erythropoietic stimulating agent (erythropoiesis-stimulating agent, erythropoietin) if hemoglobin 110g/L and likely to benefi t in terms of function and quality of life. Pure red cell aplasia is a very rare, severe complication of erythropoiesis-stimulating agent treatment due to anti-erythropoietin antibodies and usually causes hemoglobin 60g/L: exclude more common causes of anaemia fi rst. Acidosis: Consider Sodium bicarbonate supplements for patients with estimated glomerular filtration rate 30 and Low serum bicarbonate (20mmol/L). Caution in patients with hypertension and fl uid overload due to Sodium component. Oedema: Restrict fl uid and Sodium intake. High doses of loop diuretics may be needed. Combination of a loop and thiazide diuretic can have a powerful eff ect: distal tubule Sodium excretion (and its inhibition with a thiazide) is more signifi cant when already treated with a loop diuretic (fi g 7. 13). Diuretic treatment should only be given with careful monitoring of fl uid state and renal function. __OOHHCCMM__1100ee. . iinnddbb 330044 0022//0055//22001177 1199: : 0077 305 enicidem laneR chronic kidney disease bone-mineral disorders: chronic kidney disease causes in serum phosphate and reduced hydroxlyation of vitamin D by the Kidney. Measure calcium, phosphate, ALP, parathyroid hormone, and 25-OH vitamin D if estimated glomerular filtration rate 30. Treat if phosphate 1. 5mmol/L (1. 7mmol/L if RRT) with dietary restriction ± phosphatephate binders. The use of binders which do not contain calcium may be benefi cial in preventing vascular calcifi cation. Give vitamin D supplements (colecalciferol, ergocalciferol) if defi cient. If parathyroid hormone persists or is increasing, treat with an activated vitamin D analogue eg 1-calcidol or calcitriol. Paricalcitol suppresses parathyroid hormone with less eff ect on gut absorption of calcium and phosphate and is less likely to cause calcium/phosphate. Restless legs/cramps: Exclude iron defi ciency as a possible exacerbating factor. Give sleep hygiene advice. Treatment for severe cases with gabapentin/pregabalin/ dopamine agonists is off licence and may be complicated by side-eff ects (falls, cognitive impairment, impulse-control disorder). Diet: Expert dietary advice should be available regarding Protein intake, potassium if hyperkalaemic, and phosphate restriction (eg dairy products).",
    "Diet: Expert dietary advice should be available regarding Protein intake, potassium if hyperkalaemic, and phosphate restriction (eg dairy products). Treatment of other complications of chronic kidney disease Cardiovascular disease: chronic kidney disease confers risk of cardiovascular disease due to blood pressure, vascular stiff ness, infl ammation, oxidative stress, and abnormal endothelial function (CV risk often higher than the risk of Kidney failure). Antiplatelets (Low-dose aspirin) for chronic kidney disease at risk for atherosclerotic events unless bleeding risk outweighs benefi t (mortality benefi t unclear in chronic kidney disease). Atorvastatin 20mg (and higher if glomerular filtration rate 30) for primary and secondary prevention of cardiovascular disease. chronic kidney disease should not aff ect treatment for Heart failure but monitoring of glomerular filtration rate and potassium. glomerular filtration rate 60 may aff ect troponin and BNP values. Interpret results cautiously with consideration for the glomerular filtration rate. Preparation for renal replacement therapy (RRT) Planning for RRT should begin in progressive chronic kidney disease when the risk of renal failure is 1020% within a year. Referral to nephrology less than 1 year before RRT is required is considered a late referral. All suitable patients should be listed for a deceased donor transplantation 6 months before the anticipated start of RRT. All suitable patients should be informed about the advantages of a pre-emptive living Kidney transplant and eff orts made to fi nd a donor (p308). Prescribing in chronic kidney disease Never prescribe in renal failure before checking how administration should be altered due to a glomerular filtration rate. This will be determined largely by the extent to which a drug is renally excreted. This is signifi cant for aminoglycosides, penicillins, cephalo sporins, heparin, lithium, opiates, and digoxin. Loading doses should not be changed. If precision is required for dosing (eg chemotherapy) then glomerular filtration rate should not be estimated from Creatinine: a cystatin C or direct measure of glomerular filtration rate should be used. If the patient is receiving renal replacement (haemofi ltration, peritoneal or haemodialysis), dose modifi cation depends on the extent to which a drug is cleared from the circulation by Dialysis/fi ltration. The best prescribing guide to consult is the Renal Drug Database/Handbook (www. renaldrugdatabase. com), an invaluable resource detailing dose modifi cation in renal failure and in renal replacement for almost any drug you could wish to use. All hospitals should have access: speak to your pharmacist. __OOHHCCMM__1100ee. . iinnddbb 330055 0022//0055//22001177 1199: : 0077 306 enicidem laneR Re nal replacement therapy (RRT): Dialysis and fi ltration Long-term Dialysis is started when it is necessary to manage one or more symptoms of renal failure including: inability to control volume status, including pulmonary oedema inability to control Blood Hypertension serositis acidbase or electrolyte abnormalities pruritus nausea/Vomiting/deterioration in nutritional status cognitive impairment. RRT is a misnomer for Dialysis: renal function is not replaced, rather there is provision of just enough clearance to ameliorate the symptoms of Kidney failure. glomerular filtration rate at commencement of Dialysis is usually 510. When transplantation is awaited or not possible, there are two main options: haemodialysis and peritoneal Dialysis. Haemodialysis (hemodialysis) (fi g 7. 6) Blood is Blood Blood passed over a semi-permeable membrane in Blood returned against Dialysis fl uid fl owing in the opposite direction. Diff usion of solutes occurs down the concentration gradient. A hydrostatic gradient is used to clear excess Waste Dialysate Fluid fl uid as required (ultrafi ltration). Access is removed in preferentially via an arteriovenous fi stula which provides Blood fl ow and longevity. Fig 7. 6 Haemodialysis.",
    "Fig 7. 6 Haemodialysis. This should be created prior to need for RRT to avoid the infection risk associated with central venous Dialysis catheters. hemodialysis is needed 3 times/week or more. Daily hemodialysis increases the dose and improves outcomes. Home hemodialysis should be off ered to all suitable patients. Problems: Access (arteriovenous fi stula: thrombosis, stenosis, steal syndrome; tunnelled venous line: infection, blockage, recirculation of Blood), Dialysis dysequilibrium (between cerebral and Blood solutes leading to cerebral oedema start hemodialysis gradually), hypotension, time consuming. Peritoneal Dialysis (peritoneal dialysis) Uses the peritoneum as a semi-permeable membrane. A catheter is inserted into the peritoneal cavity and fl uid infused. Solutes diff use slowly across. Ultrafi ltration is achieved by adding osmotic agents (glucose, glucose polymers) to the fl uid. It is a continuous process with intermittent drainage and refi lling of the peritoneal cavity, performed at home. Problems: Catheter site infection, peritoneal dialysis peritonitis, hernia, loss of membrane function over time. Haemofi ltration (fi g 7. 7) Water cleared Post by positive Hypertension, dragging solutes into Blood Blood dilution the waste by convection. The ultrafi ltrate Prein returned (waste) is replaced with an appropriate dilution Blood volume of (clean) fl uid either before (predilution) or after (post-dilution) the membrane. Haemodynamic instability so used Dialysate in critical care when hemodialysis not possible due Waste out to blood pressure. Not used for chronic RRT unless in Fig 7. 7 Haemofi ltration. combination with hemodialysis (haemodiafi ltration) for haemodynamic stability and middle molecule clearance, eg 2-microglobulin. Complications of RRT Annual mortality is signifi cant, mostly due to cardiovascular disease: blood pressure, calcium/phosphate dysregulation, vascular stiff ness, infl ammation, oxidative stress, abnormal endothelial function. Protein-calorie malnutrition: Increases morbidity and mortality. Renal bone disease: High bone turnover, renal osteodystrophy, osteitis fi brosa. Infection: Uraemia causes granulocyte and T-cell dysfunction with sepsis-related mortality. Amyloid: 2-microglobulin accumulates in longterm Dialysis causing carpal tunnel syndrome, arthralgia, visceral eff ects. Conservative management is for those who opt not to receive RRT due to lack of benefi t on quality or quantity of life. Focus is on preserving residual renal function, symptom control, and advanced planning with patient and family for end-of-life care. __OOHHCCMM__1100ee. . iinnddbb 330066 0022//0055//22001177 1199: : 0077 307 enicidem laneR When a patient on Dialysis presents 1 Do they need Dialysis now? Examine for fl uid overload and check potassium. If on peritoneal dialysis are they well enough to perform it themselves? Refer urgently to renal on-call. 2 When will they need Dialysis? When are they due to dialyse next? Weigh them. All patients on Dialysis have a target weight at which they are considered euvolaemic. How much are they above it? Do they have any useful Urine output (ie that may help them lose volume/potassium)? Refer to renal in a timely manner. 3 What is your diagnosis? History and examination as for any other patient. Do not measure blood pressure on fi stula arm. Remember risk for cardiovascular disease but troponin has specifi city in ESRF. 4 Treat. Remember to dose adjust for renal failureincludes antibiotics, opiates, insulin, and Low-molecular-weight heparin (see www. renaldrugdatabase. com, p305). Care with fl uid replacement in sepsis: be guided by clinical examination and target weight. If unsure get expert help. If volume depleted give a 250mL bolus of (non-potassium containing) crystalloid over 15min with close observation. Avoid maintenance fl uids in those who normally have a fl uid restriction. Do not use a Dialysis line or fi stula for IV accessif a cannula is necessary, preferentially use the back of the hand, save other vessels for future fi stulas.",
    "5 Surgery needs senior anaesthetic and renal input. Aim for pre-op potassium 5. 5mmol/L (5. 0mmol/L if major surgery with risk of tissue breakdown/ haemolysis). Check potassium urgently post-op (venous gas in recovery). In elective surgery, plan Dialysis provision preand post-op. Warning: there is no normal Ten years is a long time. For those ten years, or just over 3, 560 times, I attached myself to a peritoneal Dialysis machine and underwent nine hours and fi fty minutes of nightly therapy. I subsequently learned to do a lot of crosswords and read a ridiculous amount of books. In ten years I had just three incidents: an inguinal hernia due to thinking that I could move a sofa (I could not), a parathyroidectomy (my knees were much happier afterwards), and one unfortunate bout of peritonitis (once was enough). Statistically speaking, I am an anomaly: the average life span of a peritoneal Dialysis patient is four years. Admittedly, I did not initially cope well with needing to be on Dialysis. After having lived successfully with a transplant, a return to Dialysis felt like failure. I did not want the hassle of treatment. I did not want piles of boxes cluttering up our home. Mostly, I did not want a peritoneal dialysis catheter jutting out of my belly. But what I originally believed to be unacceptable, gradually became tolerable. This took time. It took care and support. It took experiencing relative health, and seeing that Dialysis life, although diff erent to existing with a transplant, could be lived well. Natasha Boone, author and illustrator, www. normalnotnormal. com; www. natashaboone. com The man in a red canoe who saved a million lives Mostly we commute to work each day driven by motives we would rather not look at too deeply. But one renal physician used a red canoe to commute each day from his houseboat to the hospital. He could have been a very rich man but instead Belding Scribner gave his invention away, and continued his modest existence. He invented the Scribner shunta U of tefl on connecting an artery to a vein, allowing haemodialysis to be something that could be repeated as often as needed. Before Scribner, glass tubes had to be painfully inserted into Blood vessels, which would be damaged by the procedure so that haemodialysis could be done for only a few cycles. Clyde Shields was his fi rst patient in 1960, and said that his fi rst treatment took so much of the waste Id stored up out of me that it was just like turning on the light from darkness. Scribner took something that was 100% fatal and turned it into a condition with a 90% survival. On 19 June 2003, his canoe was found afl oat but empty. And like those ancient Indian burial canoes found at Wiskam which have been polished to an unimaginable lustre by the action of the shifting sands around the Island of the Dead, so we polish and cherish the image of this man who gave everything away to help others. __OOHHCCMM__1100ee. . iinnddbb 330077 0022//0055//22001177 1199: : 0077 308 enicidem laneR Re nal replacement therapy (RRT): transplantation Transplantation (fi gs 7. 8, 7. 9) should be considered for every patient with, or progressing towards, stage G5 Kidney disease (p302). It is the treatment of choice for Kidney failure provided risks do not exceed benefi ts. Many will not make the transplant list due to comorbidity or frailty. Contraindications Absolute: cancer with metastases. Temporary: active infection, HIV with viral replication, unstable cardiovascular disease. Relative: congestive Heart failure, cardiovascular disease.",
    "Temporary: active infection, HIV with viral replication, unstable cardiovascular disease. Relative: congestive Heart failure, cardiovascular disease. Types of graft Living donor: Best graft function and survival, especially if HLA matched. Deceased donor: (See organ donation p13. ) 1 Donor after brain death (donation after brain death, Heart-beating donor). 2 Expanded criteria donor (ECD) is from an older Kidney or from a patient with a history of CVA, blood pressure, or chronic kidney disease. This impacts on the long-term prognosis of the transplant but off ers a better outcome than remaining on Dialysis. 3 Donor after cardiac death (donation after circulatory death, non-Heart-beating donor) with risk of delayed graft function. Immunosuppression A combination of drugs are used. Aim is to use the minimal eff ective dose with the lowest drug-related toxicity. Protocol used depends upon the immunological risk of the recipient and type of donated Kidney. Monoclonal antibodies: Eg basiliximab, daclizumab (selectively block activated T cells via CD-25), alemtuzumab (Tand B-cell depletion). Used at the time of transplantation (induction). Acute rejection and graft loss, infection risk if non-selective. Calcineurin inhibitors: Eg tacrolimus, ciclosporin. These drugs inhibit T-cell activation and proliferation. Inter-individual variation and narrow therapeutic index mean drug level monitoring is required. Clearance is dependent on cytochrome p450 isoenzymes so beware of drug interactions including macrolide antibiotics and antifungal drugs. Side eff ects: nephrotoxicity in the graft, modifi cation of CV risk factors: blood pressure, cholesterol, NODAT (new-onset Diabetes after transplantation). Antimetabolites: Eg mycophenolic acid (MPA), azathioprine. MPA is now used preferentially due to better prevention of acute rejection and graft survival (not in pregnancy, MPA is teratogenic). Side eff ects: anaemia, leucopenia, and GI toxicity. Glucorticosteroids: Transcription of infl ammatory cytokines. First-choice treatment for acute rejection. Signifi cant side-eff ects (blood pressure, hyperlipidaemia, diabetes mellitus, impaired wound healing, osteoporosis, cataracts, skin fragility) have led to protocols with early withdrawal of steroids and the use of steroid-free immunosuppression regimens. Complications Surgical: Bleed, thrombosis, infection, urinary leaks, lymphocele, hernia. Delayed graft function: Aff ects up to 40% of grafts, more common in donation after circulatory death. Rejection: Acute or chronic. Acute is divided into antibody mediated (rare unless known pre-sensitized recipient) or cellular (most common). Causes renal function, diagnosed on graft biopsy. Treatment with High-dose steroids and immunosuppression. Chronic antibody-mediated rejection causes progressive dysfunction of the graft. Most graft loss is now thought to be due to an immune response by donor-specifi c antibodies causing damage to the Kidney microcirculation. Complex pathology and lack of controlled studies mean treatment is not clear. The results of monoclonal antibody trials are awaited. Infection: Risk of all infections. Typically hospital acquired/donor derived in month 1, opportunistic in months 16 (therefore prophylactic treatment for CMV and Pneumocystis jirovecii given), usual spectrum of community-acquired infection after 612 months. Late viral infection should always be considered: eg CMV, HSV. Malignancy: Up to 25 risk of cancer with immunosuppression, particularly skin, post-transplant lymphoproliferative disorder (PTLD), and gynaecological. cardiovascular disease: 35 risk of premature cardiovascular disease compared to general population (but 80% less than Dialysis). blood pressure, NODAT, rejection, and renal history (uraemic cardiomyopathy) contribute. __OOHHCCMM__1100ee. . iinnddbb 330088 0022//0055//22001177 1199: : 0077 309 enicidem laneR Prognosis Acute rejection 15%, 1-year graft survival 90%. Longer-term graft loss 4%/year. Factors contributing to graft loss: Donor factors: age, comorbidity, living/deceased, donation after brain death/donation after circulatory death. Rejection. Infection. blood pressure/cardiovascular disease. Recurrent renal disease in graft. Most common outcome is death with a functioning transplant (ie transplant outlives the patient).",
    "Recurrent renal disease in graft. Most common outcome is death with a functioning transplant (ie transplant outlives the patient). When a patient with a renal transplant presents 1 Discuss everything with the local renal transplant unit: they will be happy to advise, review, transfer, and follow-up any renal transplant recipient. 2 What is the estimated glomerular filtration rate/Creatinine? How does that compare with previous results? If you do not have any, ask the transplant unit. 3 Examine for and treat any reversible cause of acute kidney injury. Fluid state assessment (p300) is importantif you are unsure, get expert help. Correction of volume depletion and treatment of any sepsis should be prompt. 4 Consider viral/opportunistic infections and atypical presentations due to immunosuppression, eg CMV, Pneumocystis jirovecii. 5 Do not stop any immunosuppressive medication. If the patient is unable to tolerate oral medication then immunosuppression must be given NG or convert ed to an IV dose (conversion depends on drug: check with your pharmacist). 6 Check for medication interactions: macrolide antibiotics (erythromycin, clarithromycin) can cause calcineurin inhibitor toxicity. 7 Dose all drugs according to renal function: penicillins, cephalosporins, aminoglycosides, insulin, opiates, and Low-molecular-weight heparin. 8 Check with the transplant unit before you give Low-molecular-weight heparin for VTE prophylaxis: they may want to do a transplant biopsy. Thank you for life It feels Good to be able to put pen to paper at last and to thank you from the bottom of my Heart for the gift of life your daughter has given me and for the kindness and compassion you have shown I want to say to you that it was a wonderful thing that you did as a mother that in your deep sadness showed a caring and giving Heart. I have a much better quality of life now since coming off Dialysis 5 years ago. My father died of Kidney failure when I was 3 years old. He was someone I would have loved to have known. I often think about your daughter, who she was and what she was like. Despite not knowing her, I think about her with aff ection and much respect. These last years must have been extremely painful for you all. I really hope that you, your family and friends have found peace in your lives. Love Deborah (renal transplant recipient, 1998) Reproduced from: Royal College of Physicians, Department of Health, NHS Blood and Transplant. Thank you for life: letters from transplant recipients to donors families. London: RCP, 2010. Copyright 2010 Royal College of Physicians. Reproduced with permission. Fig 7. 8 Alive by Natasha Boone. Fig 7. 9 Post-transplant scribble by www. natashaboone. com Natasha Boone. www. natashaboone. com __OOHHCCMM__1100ee. . iinnddbb 330099 0022//0055//22001177 1199: : 0077 310 enicidem laneR Glomerulonephritis The term glomerulonephritis (glomerulonephritis) encompasses a number of conditions which: are caused by pathology in the glomerulus present with proteinuria, haematuria, or both are diagnosed on a renal biopsy cause chronic kidney disease can progress to Kidney failure (except minimal change disease). The names of the diseases come from either the histological appearance (eg membranous glomerulonephritis), or the associated systemic condition (eg lupus nephritis). Nephrotic or nephritic? The glomerulonephritides classically present on a spectrum ranging from nephrosis (proteinuria due to podocyte pathology, p312), to nephritis (haematuria due to infl ammatory damage, p311). This is illustrated in fi g 7. 10. However, if a glomerulonephritis causes scarring, then proteinuria can occur. Proteinuria can therefore complicate the longer-term clinical picture of any glomerulonephritis, including those that are classically nephritic. Fig 7. 10 The spectrum of glomerular disease ranging from proteinuria (nephrosis) to haematuria (nephritis).",
    "Fig 7. 10 The spectrum of glomerular disease ranging from proteinuria (nephrosis) to haematuria (nephritis). Figure adapted from Turner et al. , Oxford Textbook of Clinical Nephrology, 2015, with permission from Oxford University Press Investigation Assess damage and potential cause. Blood: FBC, UE, LFT, CRP; immunoglobulins, electrophoresis, complement (C3, C4); autoantibodies (p553): ANA, ANCA, anti-dsDNA, anti-GBM; Blood culture, ASOT, hepatitis serology. Urine: MCS, Bence Jones Protein, A: creatinine/P: creatinine (p294), red blood cell casts (p295). Imaging: CXR (pulmonary haemorrhage), renal ultrasound (size and anatomy for biopsy). Renal biopsy: Required for diagnosis. Renal biopsy Pre-procedure: blood pressure (160/95 or according to local protocol), FBC (hemoglobin9, platelet100), clotting (patient and APTT 1. 2), GS. Written informed consent including possible complications: mild back/loin Pain, visible haematuria (5%, usually clears), bleeding, need for transfusion (1%), angiographic intervention ( ≤ 0. 5%). Stop anticoagulants (aspirin 1 week, warfarin to patient 1. 2, Low-molecular-weight heparin 24h). Post-procedure: Bed rest for a minimum of 4h. Monitor pulse, blood pressure, symptoms, and Urine colour. Do not discharge home until macroscopic haematuria settled. Aspirin or warfarin can be restarted the next day if procedure uncomplicated. Result: Examination of glomerular lesions provides glomerulonephritis diagnosis. Includes: proportion of glomeruli involved (focal vs diff use), how much of each glomerulus is involved (segmental vs global), hypercellularity, sclerosis. Immunohistology for deposits (Ig, light chains, complement). Electron microscopy for ultrastructure: precise location of deposits, podocyte appearance. Also examines tubulointerstitium (atrophy, fi brosis, infl ammation) and any vessels. Management General management as for chronic kidney disease (pp3045) including blood pressure control and inhibition of renin-angiotensin axis. Specifi c treatment including immunosuppression depends on histological diagnosis, disease severity, disease progression, and comorbidity. __OOHHCCMM__1100ee. . iinnddbb 331100 0022//0055//22001177 1199: : 0077 311 enicidem laneR Nephritic glomerulonephritis Nephritic glomerulonephritides9 include: IgA nephropathy Commonest primary glomerulonephritis in High-income countries Presentation: Asymptomatic non-visible haematuria, or episodic visible haematuria which may be synpharyngitic: within 1272h of infection. blood pressure. Proteinuria usually 1g. Slow, indolent disease: 20 50% progress to renal failure over 30yr. Worse prognosis in , blood pressure, Creatinine, proteinuria. Diagnosis: Renal biopsy: IgA deposition in mesangium. Treatment: angiotensin-converting enzyme inhibitor/angiotensin receptor blocker reduce proteinuria and protect renal function. Corticosteroids and fi social history oil if persistent proteinuria 1g despite 36 months of angiotensin-converting enzyme inhibitor/angiotensin receptor blocker and glomerular filtration rate 50. HenochSchönlein purpura (HSP) Small vessel vasculitis and systemic variant of IgA nephropathy with IgA deposition in skin/joints/gut in addition to Kidney. Presentation: Purpuric rash on extensor surfaces (typically on the legs, p702), fl itting polyarthritis, abdominal Pain (GI bleeding), and nephritis. Diagnosis: Usually clinical. Confi rmed with positive IF for IgA and C3 in skin. Renal biopsy is identical to IgA nephropathy. Treatment: Renal disease is managed as IgA nephropathy. Steroids may be used for gut involvement. Post-streptococcal glomerulonephritis Occurs after a throat ( 2 weeks) or skin (36 weeks) infection. Streptococcal antigen deposits in the glomerulus leading to immune complex formation and infl ammation. Presentation: Varies from haematuria to acute nephritis: haematuria, oedema, blood pressure and oliguria. Diagnosis: Evidence of streptococcal infection: ASOT, anti-DNAse B. Also C3. Treatment: Supportive, antibiotics to clear the nephritogenic bacteria. Anti-glomerular basement membrane (anti-GBM) disease Previously known as Goodpastures disease. Rare. Auto-antibodies to type IV collagen which is present in glomerular and alveolar basement membranes. Presentation: Renal disease (oliguria/anuria, haematuria, acute kidney injury, renal failure) and lung disease (pulmonary haemorrhage in 5090% SOB, haemoptysis). Dialysis-dependence at presentation and crescents on biopsy predict poor prognosis. Diagnosis: Anti-GBM in circulation/Kidney (fi g 7. 11). Treatment: Plasma exchange, corticosteroids, and cyclophosphamide.",
    "Diagnosis: Anti-GBM in circulation/Kidney (fi g 7. 11). Treatment: Plasma exchange, corticosteroids, and cyclophosphamide. Rapidly progressive glomerulonephritis Any aggressive glomerulonephritis, rapidly progressing to renal failure over days or weeks. Causes include small vessel/ANCA vasculitis (p314), lupus nephritis (p314), anti-GBM disease. Other GNs may transform to become rapidly progressive including IgA, membranous. Diagnosis: Breaks in the GBM allow an infl ux of infl ammatory cells so that crescents are seen on renal biopsy (may be referred to as crescentic glomerulonephritis) (fi g 7. 12). Treatment: Corticosteroids and cyclophosphamide. Other treatments depend on aetiology eg plasma exchange for anti-GBM/ANCA vasculitis, possible role for monoclonal antibodies in lupus nephritis. Fig 7. 11 Immunofl uorescence for IgG, show ing Fig 7. 12 Crescentic glomerulonephritis: a prol iferation of epilinear staining characteristic of anti-GBM disease. thelial cells and macrophages with rupture of Reproduced from Barratt et al. , Oxford Desk Bowmans capsule. Reference: Nephrology, 2008, with permission from Reproduced from Turner et al. Oxford Textbook Oxford University Press. of Nephrology, 2016, with permission from Oxford University Press. __OOHHCCMM__1100ee. . iinnddbb 331111 0022//0055//22001177 1199: : 0077 312 enicidem laneR Nephrotic syndrome If there is oedema, dipstick the Urine to avoid missing renal disease. Defi nition The nephrotic syndrome is a triad of: proteinuria 3g/24h (P: creatinine 300mg/mmol, A: creatinine 250mg/mmol, p294) hypoalbuminaemia (usually 30g/L, can be 10g/L) oedema. Aetiology Primary renal disease or secondary to a systemic disorder. Primary renal disease: Minimal change disease, membranous nephropathy (may be associated with underlying infl ammation/malignancy), focal segmental glomerulosclerosis (focal segmental glomerulosclerosis), membranoproliferative glomerulonephritis. Secondary causes: diabetes mellitus, lupus nephritis, myeloma, amyloid, pre-eclampsia. Pathophysiology The fi ltration barrier of the Kidney is formed by podocytes, the glomerular basement membrane (GBM), and endothelial cells. Proteinuria results from podocyte pathology: abnormal function in minimal change disease, immunemediated damage in membranous nephropathy, and podocyte injury/death in focal segmental glomerulosclerosis; or pathology in the GBM/endothelial cell: membranoproliferative glomerulonephritis. Presentation Generalized, pitting oedema, which can be rapid and severe. Look in dependent areas (ankles if mobile, sacral peripheral arterial disease/elbows if bed-bound) and areas of Low tissue resistance, eg periorbitally. History: Ask about systemic symptoms, eg joint, skin. Consider malignancy and chronic infection. : CCF (JVP, pulmonary oedema), Liver disease (albumin). Management 1 Reduce oedema Fluid (1L/day) and salt restriction. Diuresis with loop diuretics, eg furosemide. If gut oedema aff ects oral absorption of diuretics, give IV. Use daily weights to guide. Aim 0. 51kg weight loss per day to avoid intravascular volume depletion and secondary acute kidney injury. Thiazide diuretics can be added if oedema remains resistant to High-dose loop diuretics. Albumin infusion increases proteinuria and remains controversial with no consistent evidence of benefi t. 2 Treat underlying cause Adults need a renal biopsy (p310). This is technically more diffi cult when there is gross oedema so diuresis may be required fi rst. Treatment known to induce remission should be given, eg corticosteroids in minimal change disease. Look for and treat any underlying systemic disease, infection, or malignancy. In children, minimal change disease is the commonest aetiology and steroids induce remission in the majority. Biopsy is therefore avoided in children unless there is no response to steroids, or if clinical features suggest another cause: age 1yr, family history, extrarenal disease (eg arthritis, rash, anaemia), renal failure, haematuria. 3 Reduce proteinuria angiotensin-converting enzyme inhibitor/angiotensin receptor blocker reduce proteinuria (may not be needed in minimal change disease). 4 Complications Thromboembolism. Hypercoagulable due to clotting factors, anti-thrombin III, and platelet abnormalities. Risk of VTE including DVT/physical examination (10% adult patients) and renal vein thrombosis (loin Pain, haematuria, LDH, acute kidney injury if bilateral).",
    "Treat with heparin (may need to dose adjust Low-molecular-weight heparin if glomerular filtration rate) and warfarin. If Low bleeding risk, consider prophylaxis when albumin 20g/L. Infection. Urine losses of immunoglobulins and immune mediators lead to risk of urinary, respiratory, and CNS infection. Infection also seen in areas of fl uid before mealscumulation: cellulitis, peritonitis, empyema. Ensure pneumococcal vaccination given. Risk of varicella with steroid treatment: post-exposure prophylaxis in non-immune, do not give live vaccine if immunosuppressed. Hyperlipidaemia. Cholesterol (10mmol/L), LDL, triglycerides, HDL. Thought due to hepatic synthesis in response to oncotic Hypertension and defective lipid breakdown. Abnormalities are proportional to proteinuria. The benefi ts of statins in chronic kidney disease are extrapolated to nephrotic syndrome where there is evidence. __OOHHCCMM__1100ee. . iinnddbb 331122 0022//0055//22001177 1199: : 0077 313 enicidem laneR Nephrotic glomerulonephritis Nephrotic glomerulonephritides9 include: Minimal change disease 25% of adult nephrotic syndrome. Idiopathic (most) or in association with drugs (NSAIDS, lithium) or paraneoplastic (haematological malignancy, usually Hodgkins lymphoma). Does not cause renal failure (if progressive chronic kidney disease consider missed focal segmental glomerulosclerosis). Diagnosis: Light microscopy is normal (hence the name). Electron microscopy shows eff acement of podocyte foot processes. Treatment: Prednisolone 1mg/kg for 416 weeks. 75% of adults will respond, 50% relapse. Frequent relapses are managed with or longer-term immune suppression (cyclophosphamide, calcineurin inhibitors). Focal segmental glomerulosclerosis (focal segmental glomerulosclerosis) Commonest glomerulonephritis seen on renal biopsy. Primary (idiopathic) or secondary (HIV, heroin, lithium, lymphoma, any cause of Kidney mass/nephrons, Kidney scarring due to another glomerulonephritis). All at risk of progressive chronic kidney disease and Kidney failure: proteinuria worsens prognosis. Disease will recur in 3050% of Kidney transplants. Diagnosis: Glomeruli have scarring of certain segments (ie focal sclerosis). May miss early disease if 10 glomeruli in biopsy sample. Treatment: angiotensin-converting enzyme inhibitor/angiotensin receptor blocker and Blood Hypertension control in all. Corticosteroids only in primary (idiopathic) disease: remission in 25%, partial remission in up to 50%. Calcineurin inhibitors may be considered second line. Plasma exchange and rituximab have been used for recurrence in transplants. Membranous nephropathy 25% of adult nephrotic syndrome. Primary (idiopathic) or secondary to: malignancy: lung, breast, GI, prostate, haematological infection: hepatitis B/C, Streptococcus, malaria, schistosomiasis immunological disease: SLE, rheumatoid arthritis, sarcoidosis, Sjögrens drugs: gold, penicillamine. Indolent disease with spontaneous remission in 25%. Diagnosis: Anti-phospholipase A2 receptor antibody in 7080% of idiopathic disease. Diff usely thickened GBM due to subepithelial deposits (IgG4 dominant in idiopathic, other IgGs in secondary disease). Spikes on silver stain. Treatment: angiotensin-converting enzyme inhibitor/angiotensin receptor blocker and Blood Hypertension control in all. Immunosuppression (Ponticelli regimen: corticosteroids plus cyclophosphamide/chlorambucil) only in those at High risk of progression (proteinuria 4g without response to angiotensin-converting enzyme inhibitor/ angiotensin receptor blocker for 6 months, Creatinine by 30% in 612 months but estimated glomerular filtration rate still 30). The role of targeted immunosuppression in those positive for anti-phospholipase A2 receptor antibodies remains unknown. In secondary disease proteinuria can remit with treatment of the underlying cause. Membranoproliferative glomerulonephritis 10% of adult nephrotic syndrome (higher in Lowand middle-income countries due to infection). Divided into: immune-complex associated: driven by increased or abnormal immune complexes which deposit in the Kidney and activate complement. An underlying cause can be found in most adult cases, eg infection, cryoglobulinaemia, monoclonal gammopathy, autoimmunity C3 glomerulopathy: due to a genetic or acquired defect in the alternative complement pathway, eg C3 nephritic factor. Progressive Kidney dysfunction is common. Diagnosis: A proliferative glomerulonephritis with electron dense deposits. Immunoglobulin deposition distinguishes immune-complex-associated disease from C3 glomerulopathy. Treatment: angiotensin-converting enzyme inhibitor/angiotensin receptor blocker and Blood Hypertension control in all. Underlying cause in immune-complex disease.",
    "Treatment: angiotensin-converting enzyme inhibitor/angiotensin receptor blocker and Blood Hypertension control in all. Underlying cause in immune-complex disease. Trial of immunosuppression if no underlying cause found and progressive decline in renal function. Treatments to block or modify C3 activation are awaited. __OOHHCCMM__1100ee. . iinnddbb 331133 0022//0055//22001177 1199: : 0077 314 enicidem laneR Renal manifestations of systemic disease Diabetic nephropathy diabetes mellitus nephropathy10 is the commonest cause of end-stage renal failure: 3040% of patients requiring renal replacement. Predicted prevalence by 2540% over next 20 years. Hyperglycaemia leads to growth factors, reninangiotensinaldosterone activation, production of advanced glycosylation end-products, and oxidative stress. Causes glomerular capillary Hypertension, podocyte damage, and endothelial dysfunction. Albuminuria is fi rst clinical sign. Later scarring (glomerulosclerosis), nodule formation (KimmelstielWilson lesions), and fi brosis with progressive loss of renal function. Coexisting blood pressure accelerates the disease course. Diagnosis: Microalbuminuria (moderately increased albuminuria) A: creatinine 330mg/ mmol (p294, 302). Regression at this level of disease is possible. Not detected on standard dipstick must send A: creatinine. Screen annually. Treatment: Intensive diabetes mellitus control prevents microalbuminuria and reduces risk of progression to macroalbuminuria (severely increased albuminuria) A: creatinine 30mg/mmol. hemoglobin hemoglobin A1c of 53mmol/mol (7%) reduces the development of all microvascular complications. However, less impact on cardiovascular disease risk and hard renal outcomes including progression to Kidney failure. Consider risk of hypoglycaemia. blood pressure 130/80. Use angiotensin-converting enzyme inhibitor or angiotensin receptor blocker for CV and renal protection above blood pressure control. Can prevent progression from normoalbuminuria to microalbuminuria to macroalbuminuria in hypertensive diabetes mellitus. (Less clear benefi t in normotensive diabetes mellitus but recommended if A: creatinine 30mg/mmol. ) No head-to-head studies of angiotensin-converting enzyme inhibitor/angiotensin receptor blocker in diabetes mellitus but equivalence outside diabetes mellitus. If cough with angiotensin-converting enzyme inhibitor switch to angiotensin receptor blocker. No benefi t to dual therapy and risk of potassium. Data on direct renin inhibitors (eg aliskiren) awaited. Sodium restriction to 2g/day (5g Sodium chloride/day). Statins to reduce CV risk (p305). Unclear benefi t once on Dialysis: do not initiate but do not need to discontinue if tolerated. Lupus nephritis SLE is a systemic autoimmune disease with antibodies against nuclear components, eg double-stranded (ds)DNA. Deposition of antibody complexes causes infl ammation and tissue damage. Presentation: Rash, photosensitivity, ulcers, arthritis, serositis, CNS eff ects, cytopenias, and renal disease. Nephropathy is common (50% in fi rst year, 75% overall). Can present as nephritis (p310) or nephrosis (p312). Diagnosis: Clinical. Antibody profi Blood: ANA is sensitive but not specifi c. Anti-dsDNA has a specifi city of 75 100% and titres correlate with disease activity. Consider biopsy if A: creatinine 30, P: creatinine 50. Treatment: Depends on histological class. Classes I and II show mild changes with little risk of renal disease progression: angiotensin-converting enzyme inhibitor/angiotensin receptor blocker for renal protection and hydroxychloroquine for extra-renal disease. Classes III-V require immunosuppression: mycophenolate, glucocorticoids, cyclophosphamide, rituximab. Small vessel vasculitis Multiple classifi cation systems exist. Clinical phenotype and ANCA subtype are important. ANCA-associated vasculitis (AAV) occurs with or without specifi city for proteinase 3 (PR3) and myeloperoxidase (MPO). AAV classically presents at an older age (60yrs) and accounts for 20% of biopsy fi ndings 80yrs. Ask about lethargy, fever, myalgia, anorexia (When did you last feel well? ). Ask about respiratory symptoms and investigate for pulmonary haemorrhage. Diagnosis: Clinical ANCA biopsy: rapidly progressive glomerulonephritis (p311) without immune deposits (pauci-immune). Treatment: High-dose glucocorticoids plus cyclophosphamide or rituximab. Plasma exchange if presents with renal failure or pulmonary haemorrhage. Myeloma (See p368. )",
    "Plasma exchange if presents with renal failure or pulmonary haemorrhage. Myeloma (See p368. ) Associated renal disease in up to 40%: tubular obstruction due to light chain casts (myeloma Kidney); deposition of Ig/light chains in glomerulus (causes proteinuria); hypercalcaemia; renal tract infection due to immunoparesis. Treatment: Adequate hydration, bisphosphonates for hypercalcaemia (care if glomerular filtration rate 30), anti-myeloma treatment including glucocorticoids. It remains unclear whether there is a benefi t in removing light chains by either plasma exchange or large pore haemodialysis. __OOHHCCMM__1100ee. . iinnddbb 331144 0022//0055//22001177 1199: : 0077 315 enicidem laneR Amyloid Pathological folding of proteins leads to extracellular accumulation and organ dysfunction including Kidney disease. Classifi ed according to Protein: light chains in myeloma AL amyloid; serum amyloid A in chronic infl ammation AA amyloid; also rare familial types. Diagnosis: Congo red staining on biopsy, SAP scan. Treatment: Underlying condition. New therapies target amyloid production, aggregation, and breakdown. Haemolytic uraemic syndrome (HUS) Presents with a microangiopathic haemolytic anaemia (hemoglobin 100g/L, LDH, haptoglobin, fragments on Blood fi lm), platelets and acute kidney injury due to thrombosis of the glomerular capillaries (microangiopathy). In children, primarily associated with haemorrhagic colitis due to Shiga toxin-producing E. coli (STEC) eg O157: H7. Atypical HUS caused by dysregulation/uncontrolled activation of complement 5% of HUS. Can be precipitated by pregnancy. Diagnosis: Triad of haemolytic anaemia, platelets, and acute kidney injury with haematuria/proteinuria. ? Evidence of STEC. Look for abnormalities in the complement pathway: levels of C3, C4, factors H and I, complement mutation screen. Treatment: STEC-HUS: supportive. aHUS: plasma infusion/exchange, eculizumab (anti-C5) in England via the national aHUS centre, Newcastle-Upon-Tyne. Thrombotic thrombocytopenic purpura (TTP) Symptoms overlap with HUS (see previous paragraph). Pentad: microangiopathic haemolytic anaemia, platelets, acute kidney injury, neurological symptoms (headache, palsies, seizure, confusion, coma), and fever. Due to a congenital defi ciency of, or acquired antibodies to, the ADAMTS13 protease which normally cleaves multimers of von Willebrand factor (VWF). Large VWF multimers cause platelet aggregation and fi brin deposition in small vessels, leading to a multisystem thrombotic microangiopathy. Diagnosis: Clinical. ADAMTS13 activity. Treatment: TTP is a haematological emergency: get expert help. Plasma infusion/exchange removes antibodies/replaces ADAMTS13 and may be life-saving. Corticosteroids. Consider rituximab for non-responders/relapse. Atherosclerotic renovascular disease Part of a systemic atheromatous vascular disease including cardio-, cerebro-, and peripheral vascular disease (ask about claudication, check foot pulses), blood pressure, and lipids. Leads to reninangiotensin upregulation which causes treatment-resistant blood pressure and/or a deterioration in renal function on angiotensin-converting enzyme inhibitor/angiotensin receptor blocker. Acute decompensated Heart failure (no LV impairment on echo) with fl ash pulmonary oedema in up to 10%. Diagnosis: 1. 5cm asymmetry in renal size (but sensitivity and specifi city). Doppler studies of native kidneys not consistently accurate for diagnosis. computed tomography or MR (avoids contrast) angiography. Treatment: Modifi cation of CV risk factors: statin, aspirin, antihypertensive treatment. Historically, angiotensin-converting enzyme inhibitor/angiotensin receptor blocker were considered contraindicated due to concern about renindependent renal perfusion and deterioration in function on angiotensin-converting enzyme inhibitor/angiotensin receptor blocker. However, mortality seen with angiotensin-converting enzyme inhibitor/angiotensin receptor blocker. estimated glomerular filtration rate by 25% sacrifi ced for longer-term renal and cardiac outcome. Large RCTs of medical treatment vs revascularization have failed to show an advantage to revascularization only considered in fl ash pulmonary oedema, rapid/oligo-anuric renal failure. Scleroderma renal crisis Occurs in 5% of systemic sclerosis. Risk with: diff use disease, anti-RNA polymerase III antibodies and 2yr from diagnosis. Diagnosis: Accelerated hypertension (new 150/85mmHg) and acute kidney injury (estimated glomerular filtration rate by 30%). Biopsy: collapsed glomeruli, onion-skin thickening of arterioles. Treatment: angiotensin-converting enzyme inhibitor/angiotensin receptor blocker.",
    "Biopsy: collapsed glomeruli, onion-skin thickening of arterioles. Treatment: angiotensin-converting enzyme inhibitor/angiotensin receptor blocker. IV vasodilators to vascular resistance and for digital ischaemia. Care with -blockers as heart rate compensating for stroke volume. May recover renal function after many months. Sickle cell nephropathy HbSS is associated with hyperfi ltration (lower than expected Creatinine) and albuminuria. Although up to 75% of young patients will have some degree of chronic kidney disease, progression to renal failure is usually associated with another trigger, eg papillary necrosis, infection. Diagnosis: Clinical. Biopsy only if looking for another diagnosis, eg acute kidney injury without clinical cause, nephrotic syndrome. Treatment: angiotensin-converting enzyme inhibitor/angiotensin receptor blocker. Inconsistent data re hydroxycarbamide and hyperfi ltration. Mortality on Dialysis: aim to transplant. __OOHHCCMM__1100ee. . iinnddbb 331155 0022//0055//22001177 1199: : 0077 316 enicidem laneR The renal tubule: disorders and diuretics Tubular disorders and the action of diuretics can be considered according to the aff ected segment of the nephron (fi g 7. 13 and table 7. 8). sodium HCOΩ 3 Phosphate sodium Bowmans Glucose ClΩ capsule Amino acids potassium H Cortex sodium Medulla potassium 2ClΩ Collecting Proximal tubule duct Thick ascending loop Distal tubule Bladder Cortical collecting duct Loop of Henle Fig 7. 13 The nephron divided into segments (proximal tubule, thick ascending loop of Henle, distal tubule, collecting duct) with key solute movement (red). Table 7. 8 Summary table of tubular disorders and diuretic action (RTA renal tubular acidosis) Nephron segment Solute movement Tubular pathlogy Diuretic Proximal tubule Reabsorption: sodium, Fanconi syndrome Mannitol bicarbonate -, phosphate, Proximal (type Carbonic anhydrase sugars, amino acids 2) RTA inhibitor Thick ascending loop Reabsorption: sodium, Bartter syndromes Loop potassium, ClΩ Distal tubule Reabsorption: Gitelman syndrome Thiazide sodium, ClΩ Cortical collecting Excretion: potassium, H Distal (type 1) RTA potassium-sparing duct Type 4 RTA Collecting duct Excretion: Water Diabetes insipidus V2 antagonists (p240) (vaptan) (p320) Proximal tubule Physiology Reabsorbs sodium (70%), bicarbonate, phosphate, amino acids, sugars, uric acid. Pathology Fanconi syndrome: Generalized impairment of proximal tubular function leading to glycosuria (in a non-diabetic), phosphaturia, uricosuria, aminoaciduria, and tubular-proteinuria (negative dipstick but positive Urine P: creatinine p294). Phosphaturia leads to phosphate loss from bone, demineralization, and growth impairment. Treatment: replace phosphate. Proximal (type 2) renal tubular acidosis (RTA): Failure of bicarbonate reabsorption. Distal reabsorption intact so serum bicarbonate usually ≥ 12mmol/L. Accompanied by Fanconi syndrome unless rare familial cause. Aetiology: light chain disease, drugs (eg tenofovir), heavy metals. Diagnosis: IV bicarbonate increases bicarbonate loss in Urine and causes rapid rise in Urine pH to 7. 5. Treatment: bicarbonate and Potassium replacement. Diuretics Osmotic diuretic (eg mannitol): Used to ICP and intra-ocular Hypertension. Freely fi ltered but poorly reabsorbed, holding Water by osmosis. sodium, potassium, Ca2, ClΩ, Mg2, HCOΩ may be aff ected. Risk of pulmonary oedema if oligo/anuric. Carbonic anhy3 drase inhibitor (eg acetazolamide): Used in altitude sickness, glaucoma. Metabolic acidosis due to bicarbonate excretion. Risk of nephrocalcinosis. __OOHHCCMM__1100ee. . iinnddbb 331166 0022//0055//22001177 1199: : 0077 317 enicidem laneR Thick ascending loop of Henle Physiology Reabsorbs sodium (1030%) and other electrolytes. Key transport via electroneutral sodium/potassium/2ClΩ co-transporter. Pathology Bartter syndromes: Due to impaired salt transport in the thick ascending loop. Sodium reabsorption increases further along the nephron in exchange for potassium and H all cause a hypokalaemic, hypochloraemic, metabolic alkalosis. Usually present in childhood. Divided into subtypes depending on transport molecule defect. Type 1 mimics a loop diuretic. Elevated prostaglandin levels are also a feature. Treatment is with salt replacement and the use of NSAIDs (after volume repletion).",
    "Elevated prostaglandin levels are also a feature. Treatment is with salt replacement and the use of NSAIDs (after volume repletion). Diuretics Loop diuretics (eg furosemide, bumetanide): Block the sodium/potassium/2ClΩ co-transporter in the thick ascending loop of Henle, hence increase the solute load of the fi ltrate and reduce Water resorption. Increase excretion of Water, sodium, ClΩ, phosphatephate, Mg2, Ca2, potassium, and H. They are readily absorbed from the GI tract (unless it is oedematous in which case IV may be needed) with peak concentration within 30120min. Widely used in peripheral oedema (Heart failure, ascites). They can also be used to treat hypercalcaemia. Side eff ects include hypokalaemic metabolic alkalosis, hypovolaemia, and ototoxicity. Distal tubule Physiology Reabsorbs sodium (510%) and other electrolytes. Key transport via NaCl cotransporter. Pathology Gitelman syndrome: Loss of function of the NaCl co-transporter. Milder than Bartter syndrome: usually presents in adolescence/adulthood with incidental fi nding of electrolyte abnormalities. Mimics thiazide diuretic administration. Treat with electrolyte supplementation. Diuretics Thiazide (eg bendrofl umethiazide) and thiazide-like diuretics (eg indapamide, chlortalidone, metolazone): Inhibit the NaCl transporter decrease NaCl reabsorption and increase Water loss. Used to treat blood pressure (p140). Side eff ects: hyponatraemia, hypokalaemia, and hypomagnesaemia. However, calcium excretion is reduced (in contrast to loop diuretics) can be used to treat recurrent Kidney stones in patients with hypercalciuria. Excretion of uric acid is reduced (care in gout). Glucose intolerance can occur (mechanism may be related to hypokalaemia) so care in diabetes mellitus. Increase in LDL cholesterol is not signifi cant with chronic use at Low dose, especially in the context of benefi cial blood pressure reduction. Cortical collecting duct Physiology Acidbase and potassium homeostasis. Aldosterone acts to retain sodiumand excrete potassium. Pathology Distal (type 1) renal tubular acidosis (RTA): Failure of acid (H) excretion. Primary genetic disease or secondary to autoimmune disease (eg Sjögrens syndrome, SLE), toxins (eg lithium). Can cause, or be caused by, nephrocalcinosis (eg medullary sponge Kidney, sarcoid). Leads to bone demineralization, renal calculi. Hypokalaemia can be severe. Diagnosis: Urine fails to acidify (pH 5. 3) despite metabolic acidosis. Treat with bicarbonate replacement and management of underlying disease. Type 4 RTA: Hyperkalaemia and acidosis due to (real or apparent) hypoaldosteronism, eg adrenal insuffi ciency, diabetes mellitus, angiotensin-converting enzyme inhibitor/angiotensin receptor blocker, potassium-sparing diuretics. Diuretics potassium-sparing: aldosterone antagonists, eg spironolactone, eplerenone, amiloride. Used in aldosteronism, Heart failure, cirrhosis, potassium-wasting states. Decrease sodium and potassium excretion. Can cause potassium, acidosis. Oestrogenic eff ects with spironolactone. __OOHHCCMM__1100ee. . iinnddbb 331177 0022//0055//22001177 1199: : 0077 318 enicidem laneR Tubulointerstitial nephropathy and nephrotoxins The renal tubules and the interstitium make up 80% of the Kidney. Damage to one is usually associated with damage to the other tubulointerstitial nephropathy. Can be acute or chronic. Acute tubulointerstitial nephritis (ATIN) Presents with acute kidney injury. Eosinophilia in 30%. An allergic triad of fever, rash, and arthralgia occurs in 10%. Should be considered in all cases of acute kidney injury for which there is no obvious pre-renal or post-renal precipitant (p298). Biopsy shows an infl ammatory cell infi ltrate in the interstitium ± tubule (tubulitis). Prognosis improves with early recognition although residual chronic kidney disease in up to 40%. Aetiology: Drugs: antibiotics, NSAIDS, PPIS, diuretics, ranitidine, anticonvulsants, warfarin. Take a full drug history including over-the-counter and herbal preparations. Infection: Streptococcus, Pneumococcus, Staphylococcus, Campylobacter, E. coli, Mycoplasma, CMV, EBV, HSV, hepatitis A-C. Autoimmune disease: SLE, sarcoid, Sjögrens syndrome, ANCA. Treatment: Stop causative agent or treat underlying cause. Steroids are used despite a paucity of RCT evidence. Chronic tubulointerstitial nephritis (CTIN) Insidious onset and slowly progressive renal impairment. Biopsy shows interstitial fi brosis and tubular atrophy.",
    "Chronic tubulointerstitial nephritis (CTIN) Insidious onset and slowly progressive renal impairment. Biopsy shows interstitial fi brosis and tubular atrophy. Most commonly due to drugs (70%) or infection. Possible causes include: drugs: NSAIDs (p319), lithium, calcineurin inhibitors, aminosalicylates (eg mesalazine, sulfasalazine), chemotherapy (eg cisplatin) infection: TB, pyelonephritis, leptospirosis, HIV immune disease: sarcoid, Sjögrens syndrome specifi c nephrotoxins: lead, cadmium, mercury, aristolochic acid (p319) haematological disorders: myeloma genetic interstitial disease. Treatment: Stop causative agent or treat underlying cause. Reduce risk of progression as per chronic kidney disease management: angiotensin-converting enzyme inhibitor/angiotensin receptor blocker, blood pressure control, glucose, lipids (pp3045). Future: antifi brotic agents? Nephrotoxins Many agents may be toxic to the kidneys either by direct damage to the tubules, or by causing an interstitial nephritis (see earlier in topic). Examples (not an exhaustive list and idiosyncratic reactions are possible): Analgesics: NSAIDS (p319). Antimicrobials: Aminoglycosides (p319), sulfamethoxazole (in co-trimoxazole), penicillins, rifampicin, amphotericin, aciclovir. Anticonvulsants: Lamotrigine, valproate, phenytoin. Other drugs: PPIS, cimetidine, furosemide, thiazides, angiotensin-converting enzyme inhibitor /angiotensin receptor blocker, lithium, iron, calcineurin inhibitors, cisplatin. Anaesthetic agents: Methoxyfl urane, enfl urane. Radiocontrast material: (p319. ) Proteins: IgS in myeloma, light chain disease, hemoglobin in haemolysis, myoglobin in rhabdomyolysis (p319). Crystals: Urate (p319). Bacteria: Streptococci, Legionella, Brucella, Mycoplasma, Chlamydia, TB, Salmonella, Campylobacter, leptospirosis, syphilis. Viruses: EBV, CMV, HIV, polyomavirus, adenovirus, measles. Parasites: Toxoplasma, Leishmania. Other: Ethylene glycol, radiation (p319), aristolochic acid (p319). __OOHHCCMM__1100ee. . iinnddbb 331188 0022//0055//22001177 1199: : 0077 319 enicidem laneR Analgesic nephropathy Caused by NSAIDS, aspirin, paracetamol. Prevalence since phenacetin withdrawn. Risk determined by frequency and duration of use. Presentation: History of chronic Pain (headache, musculoskeletal). Often silent until advanced chronic kidney disease. Diagnosis: Urinalysis: normal or sterile pyuria, mild proteinuria. USS: small and irregular kidneys. IVU: classic cup and spill appearance. Non-contrast computed tomography: renal mass, papillary calcifi cation. Biopsy: CTIN secondary to papillary necrosis. Risk of atherosclerosis. Treatment: Discontinue analgesia. Manage chronic kidney disease (pp3045). USS or computed tomography urogram if sudden fl ank Pain to exclude obstruction from sloughed papilla. Aminoglycosides (gentamicin tobramycin amikacin streptomycin) Cause acute kidney injury due to tubular necrosis. Risk factors: dose, prolonged use, chronic kidney disease, volume depletion, other nephrotoxins. Presentation: Typically mild, non-oliguric acute kidney injury after 12 weeks of therapy. Recovery can be delayed/incomplete. Treatment: Prevention. Single daily dose may be less nephrotoxic Check levels (p756). Radiocontrast nephropathy acute kidney injury 4872 hours after IV contrast. Risk factors: chronic kidney disease, diabetes mellitus, dose of contrast, volume depletion, other nephrotoxins. Treatment: None. Prevention is key: pre-hydrate with IV cystalloid (no consistent benefi t shown for bicarbonate above 0. 9% Sodium chloride). Use local protocol or consider 3mL/kg/h 1 hour before, and 1mL/kg/h for 6h after. Acetylcysteine evidence is weak. Discontinue other nephrotoxic medication for 24h preand post-procedure. Tell the radiologist about risk factors so they can use the lowest dose of Low/iso-osmolar contrast. Rhabdomyolysis Results from skeletal muscle breakdown, with release of intracellular contents (potassium, myoglobin) into the extracellular space. Cytokines and nitric oxide cause renal vasoconstriction. Myoglobin is fi ltered by the glomeruli causing obstruction and infl ammation. Presentation: History of trauma, surgery, immobility, hyperthermia, seizures. Muscle Pain, Edema, tenderness. acute kidney injury. Red-brown Urine. Diagnosis: Serum myoglobin: short half-life, may be missed. Plasma CK 5 upper limit. Myoglobinuria (teaor cola-coloured Urine) is falsely ve for Blood on dipstick with no red blood cell seen on microscopy. potassium, phosphate 3Ω, Ca2. Treatment: Supportive. Urgent treatment for hyperkalaemia (p301). IV fl uid rehydration: maintain Urine output 300mL/h until myoglobinuria has ceased; up to 1. 5L fl uid/h may be needed. If oliguric, monitor CVP in HDU/ICU setting. Renal replacement may be needed.",
    "5L fl uid/h may be needed. If oliguric, monitor CVP in HDU/ICU setting. Renal replacement may be needed. (Alkalinization of Urine hypothesized to crystallization and toxic metabolites but no RCT evidence to support use over other crystalloids and beware Ca2. ) Urate nephropathy In acute crystal nephropathy, uric acid crystals precipitate within the tubulointerstitium causing glomerular filtration rate and secondary infl ammation. Seen in tumour lysis syndrome when a High tumour burden and sensitivity to chemotherapy cause uric acid which precipitates in association with phosphate. In addition, serum uric acid is a risk factor for chronic kidney disease: hypothesized stimulus for arterial disease with pathological autoregulation of renal Blood fl ow, renin, and blood pressure. Treatment: Tumour lysis: aggressive hydration, allopurinol/rasburicase to synthesis of uric acid. Chronic disease: unclear whether diet/treatment to uric acid (allopurinol, febuxostat) improves outcome. Radiation nephritis Renal impairment due to ionizing radiation. Presents 6 monthsyears after total body irradiation, local fi eld radiotherapy, or targeted radionucleotide therapy. Presents with blood pressure, proteinuria/haematuria, progression to renal failure. Prognosis linked to blood pressure. Treatment: Radiation dose with shielding. As chronic kidney disease (pp3045) with strict blood pressure control. Aristolochic acid nephropathy Herbal remedies containing aristolochic acid can cause progressive chronic kidney disease. Disproportionate anaemia, mild proteinuria, and renal dysfunction. Biopsy: extensive fi brosis and tubular atrophy. Risk of urothelial malignancy 5, occurs in up to 40%. Aristolochic acid thought to be underlying cause of Balkan endemic nephropathy: cluster of chronic kidney disease/renal failure in Balkan areas where aristolochic acid is detected in wheat. Treatment: Avoid exposure. Treat as chronic kidney disease (pp3045). Screen for malignancy. Consider therapeutic trial of steroids (limited data). __OOHHCCMM__1100ee. . iinnddbb 331199 0022//0055//22001177 1199: : 0077 320 enicidem laneR Inherited Kidney disease Autosomal dominant polycystic Kidney disease (autosomal dominant polycystic kidney disease) 1 in 4001000 (7 million worldwide). De novo mutation in 10%. 2/3 will require renal replacement. 85% have mutations in PKD1 (chromosome 16) and reach ESRF by 50s. Mutation in PKD2 (chromosome 4) has a slower course, reaching ESRF by 70s. Presentation: May be clinically silent unless cysts become symptomatic due to size/ haemorrhage (fi g 7. 14). Loin Pain, visible haematuria, cyst infection, renal calculi, blood pressure, progressive renal failure. Extrarenal: Liver cysts, intracranial aneurysmSAH (p478), mitral valve prolapse, ovarian cyst, diverticular disease. Diagnosis: USS is modality of choice. Renal cysts are common and prevalence with age so diagnostic criteria are age-specifi c: 1539yrs ≥ 3 cysts, 4059yrs 2 cysts in each Kidney give a positive predictive value of 100% for both PKD1 and PKD2 mutations. Sensitivity is 93% for PKD1 but only 69% for diagnosis of PKD2 30 years. Liver (90% by age 50) and pancreatic cysts (10%) support the diagnosis. Genetic testing available but 1500 diff erent mutations are described so use limited to diagnostic uncertainty, potential donors, and pre-implantation diagnosis. (Non-contrast) computed tomography for renal colic as cysts obscure view on USS. Screening for intracranial aneurysms (magnetic resonance imaging) recommended for age 65yrs if personal/family history of aneurysm/SAH. Treatment: Water intake 34L/day (if estimated glomerular filtration rate 30) may suppress cyst growth. blood pressure should be treated to target 130/80mmHg: 1stline angiotensin-converting enzyme inhibitor/angiotensin receptor blocker, 2nd-line thiazide-like, 3rd-line -blocker (not calcium channel blocker as Ca2 entry is part of pathology although no specifi c outcome data). Treat infection. Haematuria usually managed conservatively. Persistent/severe Pain may need cyst decompression. Plan for RRT including pre-emptive transplantation. Ongoing research evaluating drugs which inhibit cyst growth including vasopressin antagonists (tolvaptan: decrease in Kidney volume seen), somatostatin analogues, metformin, and transcription inhibitors.",
    "Autosomal recessive polycystic Kidney disease 1 in 20 000, chromosome 6. Presents ante/perinatally with renal cysts (salt and pepper appearance on USS), congenital hepatic fi brosisportal hypertension. Poor prognosis if neonatal respiratory distress. No specifi c therapy. (See OHCS p132. ) Renal phakomatoses Tuberous sclerosis complex: 1 in 6000, autosomal dominant. Two genes: TSC1 (chromosome 9) and TSC2 (chromosome 16). Multisystem disorder with hamartoma formation in skin, brain (epilepsy), eye, Heart, and lung (see OHCS p638). In Kidney: angiomyolipomata in 90% with risk of aneurysm and haemorrhage, cystic disease in 50%. Replacement of renal tissue leads to Kidney failure. mTORC1 inhibitors (eg sirolimus, everolimus) block pathological cell signalling and reduce tumour volume. Von HippelLindau syndrome: 1 in 36 000, autosomal dominant (p712). Mutation in VHL gene (chromosome 3) leads to uncontrolled activation of growth factors. Phenotype is a familial, multisystem cancer syndrome including renal cysts and clear cell renal carcinoma at mean age 40s, 70% risk by age 60 (VHL tumour-suppressor gene is inactiva ted in most sporadic renal cell cancers). Manage by screening for tumours. Possibility of future therapies which inhibit growth factor signalling. Alport syndrome 1 in 5000. 8085% X-linked. Due to mutations in the COL4A5 gene, which encodes the 5 chain of type IV collagen. Haematuria, proteinuria, and progressive renal insuffi - ciency. Average age of renal failure in men 3040yrs. Female carriers can exhibit the phenotype, renal failure in 30% by 60yrs. High-tone sensorineural hearing loss. Anterior lenticonus: bulging of lens seen on slit-lamp examination (see OHCS p638). Type IV collagen is the antigen in anti-GBM disease (p311) so there is a risk of anti-GBM disease following transplantation as the graft type IV collagen is recognized as foreign. Fabry disease 1 in 40 000120 000. X-linked. Lysosomal storage disorder due to a defi ciency of the enzyme -galactosidase-A. Causes proteinuria and progressive renal failure in most men and some female carriers. Lipid deposits are seen in Urine and on renal biopsy (zebra body). Treatment with IV enzyme replacement can stabilize Kidney function if proteinuria controlled to 1g/24h. __OOHHCCMM__1100ee. . iinnddbb 332200 0022//0055//22001177 1199: : 0077 321 enicidem laneR Cystinuria 1 in 17 000. Autosomal recessive defect prevents reabsorption of cystine and dibasic amino acids in proximal tubule. Leads to cystinuria and cystine stone formation. Treatment: diet, fl uid intake, and Urine alkalinization. Current drugs which increase cystine solubility have adverse side-eff ect profi les. Cystinosis 1 in 100 000200 000. Autosomal recessive. Lysosomal storage disorder with accumulation of cystine. In nephropathic forms causes proximal tubule dysfunction, Fanconi syndrome (p316), and progressive renal impairment. Also visual impairment, myopathy, hypothyroidism. Oral cysteamine intralysosomal cystine, and delays ESRF, but is poorly tolerated (GI symptoms, skin deposits, fever, seizures). Fig 7. 14 A polycystic Kidney (left) compared with a normal-sized Kidney (right). The progressive increase in size can lead to abdominal discomfort. There may be haemorrhage into a cyst causing haematuria, or infection. Courtesy of the polycystic kidney disease Foundation. __OOHHCCMM__1100ee. . iinnddbb 332211 0022//0055//22001177 1199: : 0077 8 Haematology Contents A sense of humourism 323 Anaemia 324 Iron-defi ciency anaemia 326 Anaemia of chronic disease 326 Sideroblastic anaemi a 326 The peripheral Blood fi lm 328 The diff erential white cell count 330 Macrocytic anaemia 332 B12 defi ciency and pernicious anaemia 334 An approach to haemolytic anaemia 336 Causes of haemolytic anaemia 338 Sickle-cell anaemia 340 Thalassaemia 342 Bleeding disorders 344 Coagulations pathways 345 An approach to bleeding 346 Blood transfusion and bood products 348 Fig 8.",
    "Such was the conviction of the healing brought about by bloodletting that haematomania reigned despite a suspicious degree of mortality. Indeed, it may have even killed inaugural ultrasound president George Washington in 1799: on developing laryngitis he was enthusiastically bled four times by his personal physician, and died 24 hours after symptom onset. Eventually, the credibility of this practice waned, and by 1860 it had virtually disappeared. However, venesection still plays an important role in the management of haemachromatosis (see p288) and polycythaemia rubra vera (p366). Fig 8. 2 A normal Blood fi lm, with a neutrophil, red cells, and platelets (arrows). Prof. potassium Lewandowski Dr H Jastrow. 1 Compare these personalities with those of the 2015 anthropomorphic Pixar fi lm Inside Out. __OOHHCCMM__1100ee. . iinnddbb 332233 0022//0055//22001177 1199: : 0077 324 ygolotameaH Anaemia Anaemia is defi ned as a Low haemoglobin (hemoglobin) concentration, and may be due either to a Low red cell mass or increased plasma volume (eg in pregnancy). A Low hemoglobin (at sea level) is 135g/L for men and 115g/L for women. Anaemia may be due to reduced production or increased loss of RBCS and has many causes. These will often be distinguishable by history, examination, and inspection of the Blood fi lm (fi g 8. 2, p323). Symptoms Due to the underlying cause or to the anaemia itself: Fatigue, dyspnoea, faintness, palpitations, headache, tinnitus, anorexiaand angina if there is pre-existing coronary artery disease. Signs May be absent even in severe anaemia. There may be pallor (eg of the conjunctivae, see fi g 8. 3, although this is not a reliable sign). In severe anaemia (hemoglobin 80g/L), there may be signs of a hyperdynamic circulation, eg tachycardia, fl ow murmurs (ejection-systolic loudest over apex), and cardiac enlargement; or retinal haemorrhages (rarely). Later, Heart failure may occur: here, rapid Blood transfusion can be fatal. Types of anaemia The fi rst step in diagnosis is to look at the mean cell volume (MCV). Normal MCV is 7696 femtolitres (1015 fL 1L). Low MCV (microcytic anaemia): 1 Iron-defi ciency anaemia (IDA), the most common cause: see p326. 2 Thalassaemia (suspect if the MCV is too Low for the hemoglobin level and the red cell count is raised, though defi nitive diagnosis needs DNA analysis): see p342. 3 Sideroblastic anaemia (very rare): p326. NB: there is iron accumulation in the last two conditions, and so tests will show increased serum iron and ferritin with a Low total iron-binding capacity (TIBC). Normal MCV (normocytic anaemia): 1 Acute Blood loss. 5 Hypothyroidism (or MCV). 2 Anaemia of chronic disease (or MCV). 6 Haemolysis (or MCV). 3 Bone marrow failure. 7 Pregnancy. 4 Renal failure. NB: if wcc or platelet in normocytic anaemia, suspect marrow failure: see p364. High MCV (macrocytic anaemia): 1 B12 or folate defi ciency. 5 Myelodysplastic syndromes. 2 Alcohol excessor Liver disease. 6 Marrow infi ltration. 3 Reticulocytosis (p328, eg with haemolysis). 7 Hypothyroidism. 4 Cytotoxics, eg hydroxycarbamide. 8 Antifolate drugs (eg phenytoin). Haemolytic anaemias: These do not fi t into the above-mentioned classifi cation as the anaemia may be normocytic or, if there are many young (hence larger) RBCS and reticulocytes, macrocytic (p332). Suspect if there is a reticulo cytosis (2% of RBCS; or reticu locyte count 100109/L), mild macroc ytosis, haptoglobin, bilirubin, LDH, or urobilinogen. These patients will often be mildly jaundiced (but note that haemolysis causes pre-hepatic jaundice so there will be no bilirubin in their Urine). Does the patient need a Blood transfusion? Probably not if hemoglobin 70g/L.",
    "Does the patient need a Blood transfusion? Probably not if hemoglobin 70g/L. Chronic anaemia in particular can be well-tolerated (though it is crucial to ascertain the cause), and in IDA iron supplements will raise the hemoglobin more safely and cost-eff ectively. In acute anaemia (eg haemorrhage with active peptic ulcer), transfusion for those with hemoglobin 70g/L may be indicated. Other factors to consider include comorbidities (particularly IHD) and whether the patient is symptomatic. In severe anaemia with Heart failure, transfusion is vital to restore hemoglobin to a safe level, eg 6080g/L, but this must be done with great care. Give it slowly with 10 4 0mg furosemide IV/PO with alternate units (dose depends on previous exposure to diuretics; do not mix with Blood). Check for signs of worsening overload: rising JVP and basal crackles: in this eventuality, stop and treat. __OOHHCCMM__1100ee. . iinnddbb 332244 0022//0055//22001177 1199: : 0077 325 ygolotameaH Fig 8. 3 Conjunctival pallor, the classic sign of anaemia, is a confusing term as the conjunctiva is translucent, trans mitting the colour of structures under it. The pallor refers to the vasculature on the inner surface of the lid which is lacking hemoglobin. It is this colour but it should be: Red cell distribution width (RCDW or RDW) In health or in unifactorial anaemia, all the red cells in a sample are about the same size, and the graph of their volume distribution forms a narrow peak. In mixed anaemias, however, this peak broadens, refl ecting an abnormally large RDWthis may be the fi rst clue to dual pathology. In coeliac disease, for example, poor absorption of iron (MCV) and folate (MCV) may occur simultaneously, resulting in a combination of microcytes and macrocytes in the circulation. The visual analogue of this is anisocytosis (p328) on a Blood fi lm. The laboratory measure is a RDW, where RDW the standard deviation of MCV divided by the mean MCV, multiplied by 100. Reference interval: 11. 514. 6%. If the MCV is High and the RDW is normal, the cause is likely to be alcohol, Liver disease, or a marrow problem (chemotherapy or aplastic anaemia). __OOHHCCMM__1100ee. . iinnddbb 332255 0022//0055//22001177 1199: : 0077 326 ygolotameaH Iron-defi ciency anaemia (IDA) This is common (seen in up to 14% of menstruating women). Causes Blood loss, eg menorrhagia or GI bleeding2 (upper p256; lower p629). Poor diet or poverty may cause IDA in babies or children (but rarely in adults). Malabsorption (eg coeliac disease) is a cause of refractory IDA. In the tropics, hookworm (GI Blood loss) is the most common cause. Signs Chronic IDA (signs now rare): koilonychia (fi g 8. 4 and p76), atrophic glossitis, angular cheilosis (fi g 8. 5), and, rarely, post-cricoid webs (PlummerVinson syndrome). Tests Blood fi lm: microcytic, hypochromic anaemia with anisocytosis and poikilocytosis (fi gs 8. 6, 8. 7). MCV, MCH, and MCHC. Confi rmed by ferritin (also serum iron with TIBC, but these are less reliable, see table 8. 1). NB: ferritin is an acute phase Protein and with infl ammation, eg infection, malignancy. Transferrin is also in IDA but is less aff ected by infl ammation. Check coeliac serology in all (p266): if negative then refer all males and females who are not menstruating for urgent gastroscopy and colonoscopy. Consider stool microscopy for ova if relevant travel history. Faecal occult Blood is not recommended as sensitivity is poor. IDA with no obvious source of bleeding mandates careful GI workup. 2 Treatment Treat the cause. Oral iron, eg ferrous sulfate 200mg/8h PO. SE: nausea, abdominal discomfort, diarrhoea or constipation, black stools.",
    "Oral iron, eg ferrous sulfate 200mg/8h PO. SE: nausea, abdominal discomfort, diarrhoea or constipation, black stools. hemoglobin should rise by 10g/L/ week, with a modest reticulocytosis (young red blood cell, p328). Continue for at least 3 months after hemoglobin normalizes to replenish stores. IV iron is only indicated if the oral route is impossible or ineff ective, eg functional iron defi ciency in chronic renal failure, where there is inadequate mobilization of iron stores in response to erythropoietin therapy. The usual reason that IDA fails to respond to iron replacement is that the patient has rejected the pillscheck compliance. Is the reason for the problem GI disturbance? Altering the dose of elemental iron with a diff erent preparation may help. Alternatively, there may be continued Blood loss, malabsorption, anaemia of chronic disease; or misdiagnosis, eg when thalassaemia is to blame. Anaemia of chronic disease (secondary anaemia) The commonest anaemia in hospital patients (and the 2nd commonest, after IDA, worldwide). It arises from three problems (in which the polypeptide, hepcidin, plays a key role): 1 Poor use of iron in erythropoiesis. 2 Cytok ine-induced shortening of red blood cell survival. 3 Production of and response to erythropoietin. Causes Many, eg chronic infection, vasculitis, rheumatoid, malignancy, renal failure. Tests Ferritin normal or in mild normocytic or microcytic anaemia (eg hemoglobin 80g/L; see table 8. 1). Check Blood fi lm, B12, folate, TSH, and tests for haemolysis (p336). Treatment Treating the underlying disease may help (eg in 60% of patients with RA), as may erythropoietin (SE: fl u-like symptoms, hypertension, mild rise in the platelet count and thromboembolism). Also eff ective in improving quality of life in malignant disease. IV iron can safely overcome the functional iron defi ciency. Hepcidin inhibitors and infl ammatory modulators show promise. Sideroblastic anaemia Microcytic anaemia does not always mean iron defi ciency! 20% of older people with an MCV 75fL are not iron defi cient. Think of sideroblastic anaemia whenever microcytic anaemia is not responding to iron. This condition is characterized by ineff ective erythropoiesis, leading to iron absorption, iron loading in marrow ± haemosiderosis (endocrine, Liver, and Heart damage due to iron deposition). Causes Congenital (rare, x-linked) or acquir ed, eg idiopathic as one of the myelodysplastic/myeloprolife rative diseases, can also follow chemotherapy, anti-TB drugs, irradiation, alcohol or lead excess. Tests Look for ferritin, a hypo chromic Blood fi lm, and disease-defi ning sideroblasts in the marrow (fi gs 8. 8, 8. 9; table 8. 1). Treatment Remove the cause. Pyridoxine ± repeated transfusions for severe anaemia. 2 In one study, 11% presenting to their GP with IDA had GI carcinoma. Plan both upper and lower GI investigation: there may be abnormalities on both. __OOHHCCMM__1100ee. . iinnddbb 332266 0022//0055//22001177 1199: : 0077 327 ygolotameaH Table 8. 1 Interpreting plasma iron studies Iron TIBC Ferritin Iron defi ciency Anaemia of chronic disease Chronic haemolysis Haemochromatosis (or ) Pregnancy Sideroblastic anaemia Fig 8. 4 Koilonychia: spoon-shaped nails. Fig 8. 5 Angular cheilosis (also known as stomatitis): ulceration at the side of the mouth. Also a feature of vitamin B12 and B2 (ribofl avin) defi ciency, and glucagonoma (p223). Courtesy of Dr Joseph Thompson: AskAnOrthodontist. com. Fig 8. 6 Microcytic hypochromic cells. Fig 8. 7 Poikilocytosis and anisocytosis. Courtesy of Prof. Krzysztof Lewandowski Courtesy of Prof. Christine Lawrence. Fig 8. 8 Ring sideroblasts in the marrow, with a Fig 8. 9 Two ringed sideroblasts showing perinuclear ring of iron granules, found in siderohow the distribution of perin uclear mitoblastic anaemia. chondrial ferritin can vary. The problem in Courtesy of Prof. Christine Lawrence.",
    "chondrial ferritin can vary. The problem in Courtesy of Prof. Christine Lawrence. congenital sideroblastic anaemia is disordered mitochondrial haem synthesis. Courtesy of Prof. Tangün and Dr Körogˇlu. __OOHHCCMM__1100ee. . iinnddbb 332277 0022//0055//22001177 1199: : 0077 328 ygolotameaH The peripheral Blood fi lm Many haematological (and other) diagnoses are made by careful examination of the peripheral Blood fi lm. It is also necessary for interpretation of the FBC indices. Features Include: Acanthocytes: (fi g 8. 10) Spicules on RBCS ( unstable red blood cell membrane lipid structure); causes: splenectomy, alcoholic Liver disease, abetalipoproteinaemia, spherocytosis. Anisocytosis: Variation in red blood cell size, eg megaloblastic anaemia, thalassaemia, IDA. Basophilic red blood cell stippling: (fi g 8. 11) Denatured RNA found in RBCS, indicating accelerated erythropoiesis or defective hemoglobin synthesis. Seen in lead poisoning, megaloblastic anaemia, myelodysplasia, Liver disease, haemoglobinopathy, eg thalassaemia. Blasts: Nucleated precursor cells. They should not normally appear in peripheral Blood but do in myelofi brosis, leukaemia, and malignant marrow infi ltration. Burr cells (echinocytes): red blood cell projections (less marked than in acanthocytes); fi g 8. 12. Cabot rings: Seen in: pernicious anaemia; lead poisoning; Bad infections (fi g 8. 13). 1 Dimorphic picture: Two populations of red cells. Seen after treatment of Fe, B12, or folate defi ciency, in mixed defi ciency (Fe with B12 or folate), post-transfusion, or with primary sideroblastic anaemia, where a clone of abnormal erythroblasts produce abnormal red cells, alongside normal red cell production. HowellJolly bodies: DNA nuclear remnants in RBCS, which are normally removed by the spleen (fi g 8. 14). Seen post-splenectomy and in hyposplenism (eg sickle-cell disease, coeliac disease, congenital, UC/Crohns, myeloproliferative disease, amyloid). Also in dyserythropoietic states: myelodysplasia, megaloblastic anaemia. Hypochromia: (p326. ) Less dense staining of RBCS due to hemoglobin synthesis, seen in IDA, thalassaemia, and sideroblastic anaemia (iron stores unusable, p366). Left shift: Immature neutrophils released from the marrow, eg in infection (fi g 8. 15). Leukoerythroblastic fi lm: Immature cells (myelocytes, promyelocytes, metamyelocytes, normoblasts) ± tear-drop RBCS from haemolysis or marrow infi ltration/infection (maligna ncy; TB; brucella; visceral leishmaniasis; parvovirus B19). Leukaemoid reaction: A marked leucocytosis (WCC 50109/L). Seen in severe illness, eg with infection or burns, and also in leukaemia. Pappenheimer bodies: (fi g 8. 16) Granules of siderocytes containing iron. Seen in lead poisoning, carcinomatosis, and post-splenectomy. Poikilocytosis: Variation in red blood cell shape, eg in IDA, myelofi brosis, thalassaemia. Polychromasia: RBCS of diff erent ages stain unevenly (young are bluer). This is a response to bleeding, haematinic replacement (ferrous sulfate, B12, folate), haemolysis, or marrow infi ltration. Reticulocyte count is raised. Reticulocytes: (Normal range: 0. 82%; or 85109/L. ) (fi g 8. 17) Young, larger RBCS (contain RNA) signifying active erythropoiesis. Increased in haemolysis, haemorrhage, and if B12, iron, or folate is given to marrow that lack these. Right shift: Hypermature white cells: hypersegmented polymorphs (5 lobes to nucleus) seen in megaloblastic anaemia, uraemia, and Liver disease. See p333, fi g 8. 25. Rouleaux formation: (fi g 8. 18) Red cells stack on each other (causing a raised ESR; p372). Seen with chronic infl ammation, paraproteinaemia, and myeloma. Schisto cytes: Fragmented RBCS sliced by fi brin bands, in intravascular haemolysis (p339, fi g 8. 31). Look for microangiopathic anaemia, eg DIC (p352), haemolytic uraemic syndrome, thrombotic thrombocytopenic purpura (TTP: p315), or pre-eclampsia. Spherocytes: Spherical cells found in hereditary spherocytosis and autoimmune haemolytic anaemia. See p338. Target cells: (Also known as Mexican hat cells, fi g 8. 14 and fi g 8. 41, p343. )",
    "Target cells: (Also known as Mexican hat cells, fi g 8. 14 and fi g 8. 41, p343. ) These are RBCS with central staining, a ring of pallor, and an outer rim of staining seen in Liver disease, hyposplenism, thalassaemiaand, in small numbers, in IDA. Tear-drop RBCS: Seen in extramedullary haematopoiesis; see leukoerythroblastic fi lm. 3 Cabot fi gure-of-eight rings may be micro tubules from mitotic spindles. It is easy to confuse them with malaria parasites, p416 (especially if stippling gives a chromatin dot artefact, as here). Richard Clarke Cabot (18681939) liked diagnostic challenges: he founded the notoriously hard but beautifully presented weekly clinicopathological exercises of the Massachusetts General Hospital which made the New England Journal of Medicine so famous. He also wisely recommended that: before you tell the truth to the patient, be sure you know the truth, and that the patient wants to hear it. __OOHHCCMM__1100ee. . iinnddbb 332288 0022//0055//22001177 1199: : 0077 329 ygolotameaH Fig 8. 10 Acanthocytosis. Fig 8. 11 Basophilic stippling. Dr N Medeiros. From the New England Journal of Medicine, Bain, B, Diagnosis from the Blood smear, 353(5), 498. Copyright 2005 Massachusetts Medical Society. Reprinted with permission from Massachusetts Medical Society. Fig 8. 12 Burr cells: the cause may be renal or Liver failure, or an European Dialysis and Transplant Association storage artefact. Prof. Christine Lawrence. Fig 8. 13 A Cabot ring. 3 Crookston Collection. Fig 8. 14 Film in hyposplenism: target cell (short arrow), acanthocyte (long arrow), and a HowellJolly body (arrow head). From the New England Journal of Medicine, Bain, B, Diagnosis from the Blood smear, 353(5), 498. Copyright 2005 Massachusetts Medical Society. Fig 8. 15 Left shift: presence of immature neuReprinted with permission from Massachusetts trophils in the Blood. See p328. Medical Society. Prof. Krzysztof Lewandowski. Fig 8. 16 Pappenheimer bodies. Fig 8. 17 Reticulocytes. RNA in RBCs; supravital Top image Prof. Christine Lawrence, staining (azure B; cresyl blue) is needed. bottom image Crookston Collection. Dr N Medeiros. Fig 8. 18 Rouleaux formation. Dr N Medeiros. __OOHHCCMM__1100ee. . iinnddbb 332299 0022//0055//22001177 1199: : 0077 330 ygolotameaH The diff erential white cell count Neutrophils (fi gs 8. 19, 8. 20) 27. 5 109/L (4075% of white Blood cells: but absolute values are more meaningful than percentages). Increased in (ie neutrophilia): Bacterial infections. Infl ammation, eg myocardial infarction, polyarteritis nodosa. Myeloproliferative disorders. Drugs (steroids). Disseminated malignancy. Stress, eg trauma, surgery, burns, haemorrhage, seizure. Decreased in (ie neutropeniasee p352): Viral infections. Drugs: post-chemotherapy, cytotoxic agents, carbimazole, sulfonamides. Severe sepsis. Neutrophil antibodies (SLE, haemolytic anaemia)destruction. Hypersplenism (p373), eg Feltys syndrome (p698). Bone marrow failureproduction (p364). Other neutrophil responses to infection: These include: vacuoles in the cytoplasm (the most specifi c sign of bacterial infection); Döhle bodies: inconspicuous grey-blue areas of cytoplasm (residual ribosomes). Up to 17% of neutrophils from females show a drumstick-shaped Barr body (arrow, fi g 8. 20d). It is the inactivated X chromosome. Lymphocytes (fi g 8. 21) 1. 54. 5 109/L (2045%). Increased in (ie lymphocytosis): Acute viral infections. Chronic infections, eg TB, brucellosis, hepatitis, syphilis. Leukaemias and lymphomas, especially chronic lymphocytic leukaemia (CLL). Large numbers of abnormal (atypical) lymphocytes are characteristically seen with EBV infection: these are T cells reacting against EBV-infected B cells. They have a large amount of clearish cytoplasm with a blue rim that fl ows around neighbouring RBCS. Other causes of atypical lymphocytes: see p405. Decreased in (ie lymphopenia): Steroid therapy; SLE; uraemia; Legionnaires disease; HIV infection; marrow infi ltration; post chemotherapy or radiotherapy. T-lymphocyte subset reference values: CD4 count: 5371571/mm3 (Low in HIV infection). CD8 count: 235753/mm3; CD4/CD8 ratio: 1. 23. 8.",
    "T-lymphocyte subset reference values: CD4 count: 5371571/mm3 (Low in HIV infection). CD8 count: 235753/mm3; CD4/CD8 ratio: 1. 23. 8. Eosinophils (fi g 8. 22) 0. 040. 4 109/L (16%). Increased in (ie eosinophilia): Drug reactions, eg with erythema multiforme, p562. Allergies: asthma, atopy. Parasitic infections (especially invasive helminths). Skin disease: especially pemphigus, eczema, psoriasis, dermatitis herpetiformis. Also seen in malignant disease (including lymphomas and eosinophilic leukaemia), PAN, adrenal insuffi ciency, irradiation, Löffl ers syndrome (p704), ChurgStrauss symdrome (p696) and during the convalescent phase of any infection. The hypereosinophilic syndrome (HES) occurs when eosinophila 1. 5 109/L is sustained for 6 weeks leading to end-organ damage (endomyocardial fi brosis and restrictive cardiomyopathy, skin lesions, thromboe mbolic disease, lung disease, neuropathy, and hepatosplenom egaly). The cause is often unknown, though if FIP1L1-PDFRA genotype, diag nose myeloprolife rative HES or eosinophilic leukaemia. : PO steroids ± mepoliz umab (anti-interleukin-5 monoclonal antibody). Imatinib is 1st choice for myoproliferative HES. Monocytes (fi g 8. 23) 0. 20. 8 109/L (210%). Increased in (ie monocytosis): the aftermath of chemoor radiotherapy, chronic infections (eg malaria, TB, brucellosis, protozoa), malignant disease (including M4 and M5 acute myeloid leukaemia (p356), and Hodgkins disease), myelodysplasia. Basophils (fi g 8. 24) 00. 1 109/L (01%). Increased in (ie basophilia): myeloproliferative disease, viral infections, IGE-mediated hypersensitivity reactions (eg urticaria, hypo thyroid ism), and infl ammatory disorders (eg UC, rheumatoid arthritis). __OOHHCCMM__1100ee. . iinnddbb 333300 0022//0055//22001177 1199: : 0077 331 ygolotameaH (a) (b) (c) (d) Fig 8. 19 Neutrophil. These ingest and kill bacFig 8. 20 Neutrophils: (a) toxic granulation teria, fungi, and damaged cells. seen in infection or pregnancy; (b) normal apCourtesy of Prof. Krzysztof Lewandowski. pearances; (c) left shift: immature forms are released with few lobes to their nuclei, seen in infection; (d) Barr body (arrow, see text). Courtesy of Prof. Tangün and Dr Köroˇglu. Fig 8. 21 Lymphocyte: divided into T B types, Fig 8. 22 Eosinophil: these mediate allergic rewhich have important roles in cell-med i ated imactions and defend against parasites. munity and antibody production. Courtesy of Prof. Krzysztof Lewandowski. Courtesy of Prof. Krzysztof Lewandowski. Fig 8. 23 Monocyte: precursors of tissue macFig 8. 24 Basophil. The cytoplasm is fi lled with rophages. dark-staining granules, containing histamine, Courtesy of Prof. Krzysztof Lewandowski. myeloperoxidase and other enzymes. On binding IgE, histamine is released from the basophil. Courtesy of Prof. Krzysztof Lewandowski. __OOHHCCMM__1100ee. . iinnddbb 333311 0022//0055//22001177 1199: : 0077 332 ygolotameaH Macrocytic anaemia Macrocytosis (MCV 96fL) is common, and may not always be accompanied by anaemia (eg in alcohol excess). Causes of macrocytosis (MCV 96fL) Megaloblastic: (fi g 8. 25) a megaloblast is a cell in which nuclear maturation is delayed compared with the cytoplasm. This occurs with B12 (p334) and folate defi ciency: both are required for DNA synthesis. Another cause is cytotoxic drugs. Non-megaloblastic: Alcohol excess, reticulocytosis (eg in haemolysis), Liver disease, hypothyroidism, pregnancy. Other haematological disease: Myelodysplasia (fi g 8. 26), myeloma, myeloproliferative disorders, aplastic anaemia. Tests B12 and folate defi ciency result in similar Blood fi lm and bone marrow biopsy appearances. Blood fi lm: Hypersegmented neutrophils (fi g 8. 25) in B12 and folate defi ciency. Target cells if Liver disease; see fi g 8. 14, p329 and fi g 8. 41, p343. Other tests: LFT (include GT), TFT, serum B12, and serum folate (or red cell folatea more reliable indicator of folate status, as serum folate only refl ects recent intake). Bone marrow biopsy is indicated if the cause is not revealed by the above tests. It is likely to show one of the following four states: 1 Megaloblastic marrow.",
    "It is likely to show one of the following four states: 1 Megaloblastic marrow. 2 Normoblastic marrow (eg in Liver disease, hypothyroidism). 3 Abnormal erythropoiesis (eg sideroblastic anaemia, p326, leukaemia, aplasia). 4 Increased erythropoiesis (eg haemolysis). Folate Found in green vegetables, nuts, yeast, and Liver; it is synthesized by gut bact eria. Body stores can last for 4 months. Maternal folate defi ciency causes fetal neural tube defects. It is absorbed by duodenum/proximal jejunum. Causes of defi ciency: Poor diet, eg poverty, alcoholics, elderly. Increased demand, eg pregnancy or cell turnover (seen in haemolysis, malignancy, infl ammatory disease, and renal Dialysis). Malabsorption, eg coeliac disease, tropical sprue. Alcohol. Drugs: anti-epileptics (phenytoin, valproate), methotrexate, trimethoprim. Treatment: Assess for an underlying cause, eg poor diet, malabsorption. Treat with folic acid 5mg/day PO for 4 months, never without B12 unless the patient is known to have a normal B12 level, as in Low B12 states it may precipitate, or worsen, subacute combined degeneration of the cord (p334). In pregnancy, prophy lactic doses of folate (400mcg/day) are given from conception until at least 12wks; this helps prevent spina bifi da, as well as anaemia. NB: in unwell patients (eg CCF) with megaloblastic anaemia, it may be necessary to treat before serum B12 and folate results are known. Do tests then treat with large doses of hydroxocobalamin, eg 1mg/48h IMsee BNF, with folic acid 5mg/24h PO. Blood transfusions are very rarely needed (see p324). __OOHHCCMM__1100ee. . iinnddbb 333322 0022//0055//22001177 1199: : 0077 333 ygolotameaH Fig 8. 25 Megaloblastic anaemia: peripheral Fig 8. 26 Oval macrocytes seen here in myelodBlood fi lm showing many macrocytes and one ysplastic syndromes. Note anisoand poikilocyhypersegmented neutrophil (normally there tosis with small fragmented cells (schistocytes). should be ≤5 segments). NB: B12 and folate defi ciencies also cause oval From the New England Journal of Medicine, Bain, B, macrocytes, but macrocytes caused by alcohol Diagnosis from the Blood smear, 353(5), 498. and Liver disease are usually round. Copyright 2005 Massachusetts Medical Society. Courtesy of Prof. Tangün and Dr Körogˇlu. Reprinted with permission from Massachusetts Medical Society. __OOHHCCMM__1100ee. . iinnddbb 333333 0022//0055//22001177 1199: : 0077 334 ygolotameaH B 12 defi ciency and pernicious anaemia Vitamin B12 defi ciency is common, occurring in up to 15% of older people. B12 helps synthesize thymidine, and hence DNA, so in defi ciency red blood cell production is slow. Untreated, it can lead to megaloblastic anaemia (p332) and irreversible CNS complications. Body stores of B12 are suffi cient for 4yrs. Causes of defi ciency Dietary (eg vegans: B12 is found in meat, fi social history, and dairy products, but not in plants). Malabs orption: during digestion, intrinsic factor (IF) in the stomach binds B12, enabling it to be absorbed in the terminal ileum. Malabsorption can therefore arise in the stomach due to lack of IF (pernicious anaemia, post gastrectomy) or the terminal ileum (ileal resection, Crohns disease, bacterial overgrowth, tropical sprue, tapeworms). Congenital metabolic errors. Features General: Symptoms of anaemia (p324), lemon tinge to skin due to combination of pallor (anaemia) and mild jaundice (due to haemolysis), glossitis (beefy-red sore tongue; fi g 8. 27), angular cheilosis (p326). Neuropsychiatric: Irritability, depression, psychosis, dementia. Neurological: Paraesthesiae, peripheral neuropathy. Also subacute combined degeneration of the spinal cord, a combination of peripheral sensory neuropathy with both upper and lower motor neuron signs due to B12. The patient may display the classical triad of: extensor plantars (UMN) absent knee jerks (LMN) absent ankle jerks (LMN). The onset is insidious (subacute) and signs are symmetrical.",
    "The onset is insidious (subacute) and signs are symmetrical. There is a combination of poste rior (dorsal) column loss, causing the sensory and LMN signs, and corticospinal tract loss, causing the motor and UMN signs (p446). The spinothalamic tracts are preserved so Pain and temperature sensation may remain intact even in severe cases. Joint-position and vibration sense are often aff ected fi rst leading to ataxia, followed by stiff ness and weakness if untreated. The neurological signs of B12 defi ciency can occur without anaemia. Pernicious anaemia (PA) This is an autoimmune condition in which atrophic gastritis leads to a lack of IF secretion from the parietal cells of the stomach. Dietary B12 therefore remains unbound and conseqeuently cannot be absorbed by the terminal ileum. Incidence: 1: 1000; : 1. 6: 1; usually 40yrs; higher incidence if Blood group A. Associations: Other autoimmune diseases (p553): thyroid disease (25%), vitiligo, Addisons disease, hypoparathyroidism. Carcinoma of stomach is 3-fold more common in pernicious anaemia, so have a Low threshold for upper GI endoscopy. Tests: hemoglobin. MCV. WCC and platelets if severe. Serum B12 4. Reticulocytes may be as production impaired. Hypersegmented neutrophils (p332). Megaloblasts in the marrow. Specifi c tests for PA: 1 Parietal cell antibodies: found in 90% with PA, but also in 310% without. 2 IF antibodies: specifi c for PA, but lower sensitivity. Treatment: Treat the cause if possible. If due to malabsorption, give hydroxocobalamin (B12) 1mg IM alternate days for 2wks (or, if CNS signs, until improvement stops), then 1mg IM every 3 months for life. If the cause is dietary, then oral B12 can be given after the initial IM course (50150mcg/daily, between meals). Improvement is indicated by a transient marked reticulocytosis (MCV), after 45 days. Practical hints: Beware of diagnosing PA in those under 40yrs old: look for GI malabsorption (small bowel biopsy, p266). Watch for hypokalaemia due to uptake into new haematopoietic cells. Transfusion is best avoided, but PA with High-output CCF may require transfusion, after doing tests for FBC, folate, B12, and marrow sampling. As haematopoiesis accelerates on treatment, additional iron may be needed. hemoglobin rises 10g/L per week; WCC and platelet count should normalize in 1wk. Prognosis: Supplementation usually improves peripheral neuropathy within the fi rst 36 months, but has little eff ect on cord signs. Patients do best if treated as soon as possible after the onset of symptoms: dont delay! 4 Serum B12 levels are normal in many patients with subclinical B12 defi ciency. Measuring homocysteine or methylmalonic acid ( if B12 Low) may be helpful, but these are non-standard tests. __OOHHCCMM__1100ee. . iinnddbb 333344 0022//0055//22001177 1199: : 0077 335 ygolotameaH Fig 8. 27 The big, beefy tongue of B12 defi ciency glossitis. Other causes of glossitis: iron (or Zn) defi ciency, pellagra, contact dermatitis/specifi c food intolerances, Crohns disease, drugs (minocycline, clarithromycin, some angiotensin-converting enzyme inhibitor), TB of the tongue. Glossitis may be the presenting feature of coeliac disease or alcoholism. __OOHHCCMM__1100ee. . iinnddbb 333355 0022//0055//22001177 1199: : 0077 336 ygolotameaH An approach to haemolytic anaemia Haemolysis is the premature breakdown of RBCS, before their normal lifespan of 120d. It occurs in the circulation (intravascular) or in the reticuloendothelial system, ie macrophages of Liver, spleen, and bone marrow (extravascular). In sickle-cell anaemia, lifespan may be as short as 5d. Haemolysis may be asymptomatic, but if the bone marrow does not compensate suffi ciently, a haemolytic anaemia results. An approach is fi rst to confi rm haemolysis and then fi nd the causetry to answer these four questions: 1 Is there increased red cell breakdown? Anaemia with normal or MCV.",
    "Anaemia with normal or MCV. Bilirubin: unconjugated, from haem breakdown (pre-hepatic jaundice). Urinary urobilinogen (no urinary conjugated bilirubin). Serum LDH, as it is released from red cells. 2 Is there increased red cell production? Reticulocytes, causing MCV (reticulocytes are large immature RBCS) and polychromasia. 3 Is the haemolysis mainly extraor intravascular? Extravascular haemolysis may lead to splenic hypertrophy and splenomegaly. Features of intravascular haemolysis are: Free plasma haemoglobin: released from RBCS. Methaemalbuminaemia: some free hemoglobin is broken down in the circulation to produce haem and globin; haem combines with albumin to make methaemalbumin. Plasma haptoglobin: mops up free plasma hemoglobin, then removed by the Liver. Haemoglobinuria: causes red-brown Urine, in absence of red Blood cells. Haemosiderinuria: occurs when haptoglobin-binding capacity is exceeded, causing free hemoglobin to be fi ltered by the renal glomeruli, with absorption of free hemoglobin via the renal tubules and storage in the tubular cells as haemosiderin. This is detected in the Urine as sloughed tubular cells by Prussian blue staining 1 week after onset (implying a chronic intravascular haemolysis). 4 Why is there haemolysis? Causes are on p338. History Family history, race, jaundice, dark Urine, drugs, previous anaemia, travel. Examination Jaundice, hepatosplenomegaly, gallstones (pigmented, due to bilirubin from haemolysis), leg ulcers (due to poor Blood fl ow). Tests FBC, reticulocytes, bilirubin, LDH, haptoglobin, urinary urobilinogen. Thick and thin fi lms for malaria screen if history of travel. The Blood fi lm may show polychromasia and macrocytosis due to reticulocytes, or point to the diagnosis: Hypochromic microcytic anaemia (thalassaemia). Sickle cells (sickle-cell anaemia). Schistocytes (fi g 8. 30, p339; microangiopathic haemolytic anaemia). Abnormal cells in haematological malignancy. Spherocytes (hereditary spherocytosis or autoimmune haemolytic anaemia). Elliptocytes (fi g 8. 36, p339; hereditary elliptocytosis). Heinz bodies, bite cells (fi g 8. 32, p339; glucose-6-phosphate dehydrogenase defi ciency). Further tests (if the cause is still not obvious) Osmotic fragility testing will confi rm the presence of membrane abnormalities which have been identifi ed on the fi lm. hemoglobin electrophoresis will detect haemoglobinopathies. The direct antiglobulin (Coombs) test (DAT, fi g 8. 28) identifi es red cells coated with antibody or complement, the presence of which indicates an immune cause. Enzyme assays are reserved for when other causes have been excluded. __OOHHCCMM__1100ee. . iinnddbb 333366 0022//0055//22001177 1199: : 0077 337 ygolotameaH Fig 8. 28 The direct Coombs test detects antibodies on RBCS. The indirect Coombs test is used in pre-natal testing and before Blood transfusion. It detects antibodies against RBCs that are free in serum: serum is incubated with RBCS of known antigenicity. If agglutination occurs, the indirect Coombs test is positive. With kind permission of Aria Rad. __OOHHCCMM__1100ee. . iinnddbb 333377 0022//0055//22001177 1199: : 0077 338 ygolotameaH Causes of haemolytic anaemia Acquired 1 Immune-mediated/direct antiglobulin test ve: (Coombs test, p337. ) Drug-induced: causing formation of red blood cell autoantibodies from binding to red blood cell membranes (eg penicillin) or production of immune complexes (eg quinine). Autoimmune haemolytic anaemia (AIHA; fi g 8. 29): mediated by autoantibodies causing mainly extravascular haemolysis and spherocytosis. Classify according to optimal binding temperature to RBCs: Warm AIHA: IgG-mediated, bind at body T° 37°C. : Steroids/immunosuppressants (± splenectomy). Cold AIHA: IgM-mediated, bind at T° (4°C), activating cell-surface complement. Causes a chronic anaemia made worse by cold, often with Raynauds or acrocyanosis. : keep warm. Chloram bucil may help. Causes: most are idiopathic; 2° causes of warm AIHA include lymphop roliferative disease (CLL, lymphoma), drugs, autoimmune disease, eg SLE. Cold AIHA may follow infection (mycoplasma; EBV). Paroxysmal cold haemoglobinuria: seen with viruses/syphilis.",
    "Cold AIHA may follow infection (mycoplasma; EBV). Paroxysmal cold haemoglobinuria: seen with viruses/syphilis. It is caused by DonathLandsteiner antibodies sticking to RBCS in the cold, causing self-limiting complement-mediated haemolysis on rewarming. Isoimmune: acute transfusion reaction (p349); haemolysis of the newborn. 2 Direct antiglobulin/Coombs Ωve AIHA: (2% of all AIHA. ) Autoimmune hepatitis; hepatitis B C; post fl u and other vaccinations; drugs (piperacillin, rituximab). 3 Microangiopathic haemolytic anaemia (MAHA): Mechanical damage to RBCS in circulation, causing intravascular haemolysis and schistocytes (fi gs 8. 30, 8. 31). Causes include haemolyticuraemic syndrome (HUS), TTP (p315), DIC, pre-eclampsia, and eclampsia. Prosthetic Heart valves can also cause mechanical damage. 4 Infection: Malaria (p416): red blood cell lysis and blackwater fever (haemoglobinuria). All infections can exacerbate haemolysis. 5 Paroxysmal nocturnal haemoglobinuria: Rare acquired stem cell disorder, with haemolysis (esp. at nighthaem oglobinuria, fi g 15. 8, p705), marrow failure thrombophilia. Tests: urinary haemosiderin ve; if suspect in Coombs -ve intravascular haemolysis, seek confi rmation by fl ow cytometry. : anti coagulation; monoclonal anticomplement antibodies (eg eculizumab); stem cell transplantation. Hereditary 1 Enzyme defects: Glucose-6-phosphate dehydrogenase (G6PD) defi ciency (X-linked): the chief red blood cell enzyme defect, aff ects 100 million (mainly ) in Mediterranean, Africa, Middle/Far East. Most are asymptomatic, but may get oxidative crises due to gluta thione production, precipitated by drugs (eg primaquine, sulfonamides, aspirin), exposure to Vicia faba (broad beans/favism), or illness. In attacks, there is rapid anaemia and jaundice. Film: biteand blister-cells (fi gs 8. 32, 8. 33). Tests: Enzyme assay (8wks after crisis as young RBCs may have enough enzyme so results normal). : Avoid precipitants (eg, henna, fi g 8. 34); transfuse if severe. Pyruvate kinase defi ciency (AUTOSOMAL RECESSIVE): ATP production causes red blood cell survival. Homozygotes have neonatal jaundice; later, haemolysis with splenomegaly ± jaundice. Tests: enzyme assay. : often not needed; splenectomy may help. 2 Membrane defects: All are Coombs Ωve; all need folate; splenectomy helps some. Hereditary spherocytosis (AUTOSOMAL DOMINANT): prevalence: 1: 3000. Less deformable spherical RBCS, so trapped in spleen extravascular haemolysis. Signs: Splenomegaly, jaundice. Tests: Mild if hemoglobin 110g/L and reticulocytes 6%; fi lm: fi g 8. 35. Bilirubin (gallstones). Hereditary elliptocytosis (AUTOSOMAL DOMINANT): fi lm: fi g 8. 36. Mostly asymptomatic (somewhat protects from malaria). 10% display a more severe phenotype (± death in utero). Hereditary ovalocytosis and stomatocytosis are rarer. Refer to a haematologist. 3 Haemoglobinopathy: Sickle-cell disease (p340). Thalassaemia (p342). __OOHHCCMM__1100ee. . iinnddbb 333388 0022//0055//22001177 1199: : 0077 339 ygolotameaH Fig 8. 29 Autoimmune haemolytic anaem ia: Fig 8. 30 Microangiopathic anaemia, eg from antibody-coated red cells underg oing phagocyDIC: num erous cell fragments (schisto cytes) are tosis by monocytes. present. Prof C Lawrence. From the New England Journal of Medicine, Bain, B, Diagnosis from the Blood smear, 353(5), 498. Copyright 2005 Massachusetts Medical Society. Reprinted with permission from Massachusetts Medical Society. Fig 8. 31 Fibrin strands, deposited in HUS and TTP (p315), slicing up RBCS (micro angiopathy). From the New England Journal of Medicine, Bain, B, Fig 8. 32 A bite-cell in G6PD, after removal of a Diagnosis from the Blood smear, 353(5), 498. Copyright Heinz body by the spleen; these are formed from 2005 Massachusetts Medical Society. Reprinted denatured hemoglobin during oxidative crises. with permission from Massachusetts Medical Society. From the New England Journal of Medicine, Bain, B, Diagnosis from the Blood smear, 353(5), 498. Copyright 2005 Massachusetts Medical Society. Reprinted with permission from Massachusetts Medical Society. BEWARE! Fig 8. 33 Blister-cells (arrows) in G6PD, following removal of Heinz bodies. Also contracted red cells (arrowheads).",
    "BEWARE! Fig 8. 33 Blister-cells (arrows) in G6PD, following removal of Heinz bodies. Also contracted red cells (arrowheads). From the New England Journal of Medicine, Bain, B, Diagnosis from the Blood smear, 353(5), 498. Copyright 2005 Massachusetts Medical Society. Reprinted with permission from Massachusetts Medical Society. Fig 8. 34 Avoid henna use in G6PD defi ciency! Catherine Cartwright-Jones (artist) and Roy Jones (photographer). Fig 8. 35 Hereditary spherocytosis. Osmotic fragility tests: RBCS show fragility in hypotonic solutions. Fig 8. 36 Hereditary elliptocytosis. From the New England Journal of Medicine, Bain, B, From the New England Journal of Medicine, Bain, B, Diagnosis from the Blood smear, 353(5), 498. Copyright Diagnosis from the Blood smear, 353(5), 498. Copyright 2005 Massachusetts Medical Society. Reprinted 2005 Massachusetts Medical Society. Reprinted with permission from Massachusetts Medical Society. with permission from Massachusetts Medical Society. __OOHHCCMM__1100ee. . iinnddbb 333399 0022//0055//22001177 1199: : 0077 340 ygolotameaH Sickle-cell anaemia Sickle-cell anaemia is an autosomal recessive disorder in which production of abnormal haemoglobin results in vaso-occlusive crises. It is most commonly seen in people of African origin, and arises from an amino acid substitution in the gene coding for the chain (Glu Val at position 6) which leads to production of HbS rather than HbA (HbA2 and HbF are still produced). Homozygotes (SS) have sickle-cell anaemia (HbSS), and heteroz ygotes (HbAS) have sickle-cell trait, which causes no disability (and protects from falciparum malaria). Heterozygotes may still, however, experience symptomatic sickling in hypoxia, eg in unpressurized aircraft or anaesthesia (so all those of African descent need a pre-op sickle-cell test). Pathogenesis HbS polymerizes when deoxygenated, causing RBCS to deform, producing sickle cells, which are fragile and haemolyse, and also block small vessels. Prevalence 1: 700 people of African descent. Tests Haemolysis is variable. hemoglobin 6090g/L, reticulocytes 1020%, bilirubin. Film: sickle cells and target cells (fi g 8. 37). Sickle solubility test: ve, but does not distinguish between HbSS and HbAS. hemoglobin electrophoresis: Confi rms the diagnosis and distinguishes SS, AS states, and other hemoglobin variants. Aim for diagnosis at birth (cord Blood) to aid prompt pneumococcal prophylaxis (vaccine, p167 ± penicillin V). Signs/symptoms Chronic haemolysis is usually well tolerated (except in crises; see BOX Managing sickle-cell crises). Vaso-occlusive painful crisis: Common, due to microvascular occlusion. Often atrial fibrillationfects the marrow, causing severe Pain, triggered by cold, dehydration, infection, or hypoxia. Hands and feet are aff ected if 3yrs old leading to dactylitis. Occlusion may cause mesenteric ischaemia, mimicking an acute abdomen. CNS infarction occurs in 10% of children, leading to stroke, seizures, or cognitive defects. Transc ranial Doppler ultrasonography indicates risk of impending stroke, and Blood transfusions can prevent this by reducing HbS. Also avascular necrosis (eg of femoral head), leg ulcers (fi g 8. 38) and Low-fl ow priapism (also seen in CML, may respond to hydration, -agonists, eg phenylephrine, or aspiration of Blood irrigation with saline; if for 12h prompt cavernosusspongiosum shunting can prevent later impotence). Aplastic crisis: This is due to parvovirus B19, with sudden reduction in marrow production, especially RBCs. Usually self-limiting 2wks; transfusion may be needed. Sequestration crisis: Mainly aff ects children as in adults the spleen becomes atrophic. There is pooling of Blood in the spleen ± Liver, with organomegaly, severe anaemia, and shock. Urgent transfusion is needed. Complications Splenic infarction occurs before 2yrs old, due to microvascular occlusion, leading to susceptibility to infection (40% of childhood sickle deaths are caused this way). Poor growth. Chronic renal failure. Gallstones. Retinal disease. Iron overload (see BOX A 7-year-old ). Lung damage: hypoxiafi brosispulmonary hypertension. Management of chronic disease Get help from a haematologist.",
    "Lung damage: hypoxiafi brosispulmonary hypertension. Management of chronic disease Get help from a haematologist. Hydroxycarbamide if frequent crises (production of fetal haemoglobin, HbF). Dose example: 20mg/kg/d if estimated glomerular filtration rate 60mL/min. Splenic infarction leads to hyposplenism and immunocompromise. Prophylaxis, in terms of antibiotics and immunization, should be given (p373). Febrile children risk septicaemia: repeated admission may be avoided by early rescue out-patient antibiotics, eg ceftriaxone (eg 2 doses, 50mg/kg IV on day 0 and 1). Consider admission if hemoglobin 50g/L, WCC 5 or 30 109/L, T° 40°C, severe Pain, dehydration, lung infi ltration. Seek expert advice. Bone marrow transplant can be curative but remains controversial. Prevention Genetic counselling; prenatal tests (OHCS pp1545). Parental education can help prevent 90% of deaths from sequestration crises. __OOHHCCMM__1100ee. . iinnddbb 334400 0022//0055//22001177 1199: : 0077 341 ygolotameaH Managing sickle-cell crises Give prompt, generous analgesia, eg IV opiates (see p574). Most sickle patients will have a personalized analgesia planask them! Seek expert help early. Crossmatch Blood, check FBC and reticulocyte count. Do a septic screen: Blood cultures, MSU ± CXR if T° or chest signs. Rehydrate with IVI and keep warm. Give O2 by mask if Pa O2 or O2 sats 95%. Consider starting antibiotics empirically if T° 38°, unwell, or chest signs. Measure PCV, reticulocytes, Liver, and spleen size twice daily. Give Blood transfusion if hemoglobin or reticulocytes fall sharply. This helps oxygenation, and is as Good as exchange transfusion. Match Blood for the Blood group antigens Rh(C, D, E) and Kell, to prevent alloantibody formation. Exchange transfusion is reserved for those who are rapidly worsening: it is a process where Blood is removed and donor Blood is given in stages. Indications: severe chest crisis, suspected CNS event, or multiorgan failurewhen the proportion of HbS should be reduced to 30%. Inform their haematologist of admission early. The acute chest syndrome: Entails pulmonary infi ltrates involving complete lung segments, causing Pain, fever, tachypnoea, wheeze, and cough. It is serious. Incidence: 0. 1 episodes/patient/yr. 13% in the landmark Vichinsky study needed ventilation, 11% had CNS symptoms, and 9% of those over 20 years old died. Prodromal painful crisis occur 2. 5 days before any abnormalities on CXR in 50% of patients. The chief causes of the infi ltrates are fat embolism from bone marrow or infection with Chlamydia, Mycoplasma, or viruses. : O2, analgesia, empirical antibiotics (cephalosporin macrolide) until culture results known. Bronchodilators (eg salbutamol, p182) have proved to be eff ective in those with wheezing or obstructive pulmonary function at presentation. Blood transfusion (exchange if severe). Take to ITU if Pa O2 cannot be kept above 9. 2kPa (70mmHg) when breathing air. Patient-controlled analgesia is a Good option if supportive measures and oral analgesia do not control Pain. Start with morphine 1mg/kg in 50mL 5% glucose (paediatric dose) and try a rate of 1mL/h, allowing the patient to deliver extra boluses of 1mL when needed. Check respiratory rate and GCS every ¼h O2 sats if chest/abdominal Pain. Liaise with the local Pain service. Fig 8. 37 Sickle-cell fi lm: there are sickle cells, Fig 8. 38 Leg ulcers in sickle-cell dis ease. target cells, and a nucleated red cell. Prof. C Lawrence. Prof. C Lawrence. A 7-year-old tells ultrasound what its like to have sickle-cell disease I have been hospitalized over 50 times for complications from this disease. To keep it controlled I started having monthly transfusions. After repeated transfusions my body began to get too much iron so I had to start getting infusions.",
    "After repeated transfusions my body began to get too much iron so I had to start getting infusions. I was taking the medication desferal5 which my mummy had to insert a needle in my belly hooked up to a pump which I had to carry on my back in my neat Spiderman backpack. I was hooked up to the machine for 10 hours a day 5 days a week but it was okay I still got to play! I suff ered from Pain crisis which makes my legs and back hurt like someone is hitting me with a hammer. You may notice that I may move slow or look tired when it is time for my Blood transfusion. That is because the transfusions are like a heartbeat for my body, without it I cant survive. When Im in Pain the only thing that helps is morphine I tell my mummy when shes crying I WILL BE OK! 5 This was necessary until a once-daily oral iron chelator came along: deferasirox. __OOHHCCMM__1100ee. . iinnddbb 334411 0022//0055//22001177 1199: : 0077 342 ygolotameaH Thalassaemia The thalassaemias are genetic diseases of unbalanced hemoglobin synthesis, with underproduction (or no production) of one globin chain (see table 8. 2 and BOX). Unmatched globins precipitate, damaging red blood cell membranes, causing their haemolysis while still in the marrow. They are common in areas from the Mediterranean to the Far East. The thalassaemias Usually caused by point mutations in -globin genes on chromosome 11, leading to chain production () or its absence (0). Various combinations of mutations are possible (eg 0/0, /, or /0). Tests: FBC, MCV, fi lm, iron, HbA2, HbF, hemoglobin electrophoresis. magnetic resonance imaging where myocardial siderosis suspected (from iron overload). thalassaemia minor or trait (eg /; heterozygous state): this is a carrier state, and is usually asymptomatic. Mild, well-tolerated anaemia (hemoglobin 90g/L) which may worsen in pregnancy. MCV 75fL, HbA2 3. 5%, slight HbF. Often confused with iron-defi ciency anaemia. thalassaemia intermedia: describes an intermediate state with moderate anaemia but not requiring transfusions. There may be splenomegaly. There are a variety of causes including mild homozygous thalassaemia mutations, eg /, or co-inheritance of thalassaemia trait with another haemoglobinopathy, eg HbC thalassaemia (one parent has the HbC trait, and the other has ). Sickle-cell thalassaemia produces a picture similar to sickle-cell anaemia. thalassaemia major: denotes signifi cant abnormalities in both -globin genes, and presents in the 1st year, with severe anaemia and failure to thrive. Extramedullary haematopoiesis (RBCS made outside the marrow) occurs in response to anaemia, causing characteristic head shape, eg skull bossing (fi gs 8. 39, 8. 40) and hepato spleno megaly (also due to haem olysis). There is osteopenia (may respond to zoledronic acid). Skull X-ray shows a hair on end sign due to marrow activity. Life-long Blood transfusions are needed, with resulting iron overload/deposition seen after 10yrs as endocrine failure (pituitary, thyroid, pancreasDiabetes mellitus), Liver disease, and cardiac toxicity. The fi lm shows very hypochromic, microcytic cells target cells nucleated RBCs. HbF, HbA2 variable, HbA absent. Treatment: Promote fi tness; healthy diet. Folate supplements help. Regular (24 weekly) life-long transfusions to keep hemoglobin 90g/L, to suppress the ineff ective extramedullary haematopoiesis and to allow normal growth. Iron overload is a big problem causing hypothyroidism, hypocalcaemia, and hypogonadism. Can be mitigated by iron-chelators (deferiprone PO desferrioxamine sc twice weekly. SE: Pain, deafness, cataracts, retinal damage, risk of Yersinia). Large doses of ascorbic acid can also help by urinary excretion of iron. Splenectomy if hypersplenism persists with increasing transfusion requirements (p373)this is best avoided until 5yrs old due to risk of infections.",
    "Coagulation disorders cause delayed bleeding into joints and muscle. 1 Vascular defects Congenital: OslerWeberRendu syndrome (p708), conne ctive tissue disease (eg EhlersDanlos syndrome, OHCS p642, pseudoxanthoma elasticum). Acquired: Senile purpura, infection (eg meningococcal, measles, dengue fever), steroids, scurvy (perifollicular haemorrhages), HenochSchönlein purpura (p702). 2 Platelet disorders Decreased marrow production: Aplastic anaemia (p364), megaloblastic anaemia, marrow infi ltration (eg leukaemia, myeloma), marrow suppression (cytotoxic drugs, radiotherapy). Excess destruction: Immune: immune thrombocytopenia (ITP, see BOX Immune thrombocytopenia), other autoimmune causes, eg SLE, CLL, drugs, eg heparin, viruses; Non-immune: DIC (p352), thrombotic thrombocytopenic purpura (TTP), or HUS (p315), sequestration (in hypersplenism). Poorly functioning platelets: Seen in myeloproliferative disease, NSAIDS, and urea. 3 Coagulation disorders Congenital: Haemophilia, von Willebrands disease (p712). Acquired: Anticoagulants, Liver disease, DIC (p352), vitamin potassium defi ciency. Haemophilia A Factor VIII defi ciency; inherited in an X-linked recessive pattern in 1: 10 000 male birthsusually due to a fl ip tip inversion in the factor VIII gene in the X chromosome. There is a High rate of new mutations (30% have no family history). Presentation depends on severity and is often early in life or after surgery/ traumawith bleeds into joints leading to crippling arthropathy, and into muscles causing haematomas (Hypertension can lead to nerve palsies and compartment syndrome). Diagnose by APTT and factor VIII assay. Management: Seek expert advice. Avoid NSAIDS and IM injections (fi g 8. 43). Minor bleeding: Hypertension and elevation of the part. Desmopressin (0. 3mcg/kg/12h IVI over 20min) raises factor VIII levels, and may be suffi cient. Major bleeds (eg haemarthrosis): factor VIII levels to 50% of normal, eg with recombinant factor VIII. Life-threatening bleeds (eg obstructing airway) need levels of 100%. Genetic counselling: OHCS p154. Haemophilia B (Christmas disease) Factor IX defi ciency (inherited, X-linked recessive); behaves clinically like haemophilia A. Treat with recombinant factor IX. Acquired haemophilia is a bleeding diathesis causing big mucosal bleeds in males and females caused by suddenly appearing autoantibodies that interfere with factor VIII. Tests: APPT; VIII autoantibody; factor VIII activity 50%. : Steroids. Liver disease Produces a complicated bleeding disorder with synthesis of clotting factors, absorption of vitamin potassium, and abnormalities of platelet function. Malabsorption Leads to less uptake of vitamin potassium (needed for synthesis of factors II, VII, IX, and X). Treat with IV vitamin potassium (10mg). In acute haemorrhage, use human prothrombin complex or FFP. __OOHHCCMM__1100ee. . iinnddbb 334444 0022//0055//22001177 1199: : 0077 345 ygolotameaH Fig 8. 43 Mild haemoph ilia after an IM inject ion. Give vacc ines etc SC! Fig 8. 42 Intrinsic and extrinsic pathways of coagulation (simplifi ed! ). Crookston collection 53. Fibrinolysis The fi brinolytic system works by generating plasmin, which causes fi brin dissolution. The process starts with the release of tissue plasminogen activator (t-PA) from endothelial cells, a process stimulated by fi brin formation. t-PA converts inactive plasminogen to plasmin which can then cleave fi brin, as well as several other factors. t-PA and plasminogen both bind fi brin thus localizing fi brinolysis to the area of the clot. Fibrinolytic agents activate this system and can be utilized in order to break down pathological thrombi, eg in: acute myocardial infarction, acute ischaemic stroke, DVT, physical examination, and central retinal venous or arterial thrombosis. In all cases the risk of adverse eff ects of thrombolysis (eg haemorrhage) must be outweighed by the potential benefi ts. Streptokinase, a streptococcal exotoxin that binds and activates plasminogen, was the fi rst licensed agent but risks anaphylaxis on repeat dosing. Alteplase is recombinant t-PA. Newer agents include tenecteplase and reteplase. Immune thrombocytopenia (ITP) ITP is caused by antiplatelet auto anti bodies.",
    "Management Depends on the degree of bleeding. If shocked, resuscitate (p790). If bleeding continues in the presence of a clotting disorder or a massive transfusion, discuss the need for FFP, cryoprecipitate, factor concentrates, or platelets with a haematologist. In ITP (p345), steroids ± IV immunoglobulin may be used. Especially in pregnancy (OHCS p88), consult an expert. Is there overdose with anticoagulants (p842)? In haemophiliac bleeds, consult early for coagulation factor replacement. Never give IM injections. __OOHHCCMM__1100ee. . iinnddbb 334466 0022//0055//22001177 1199: : 0077 347 ygolotameaH Table 8. 3 Clotting screen abnormalities in coagulopathies Disorder INR APTT Thrombin time Platelet count Notes Heparin DIC D-dimer, p346 Liver disease / / AST Platelet defect Vit potassium defi ciency Haemophilia see p344 von Willebrands see p712 Special tests may be available (factor assays: consult a haematologist). Towards a better assay for clotting function Bleeding time, a barbaric and unreliable test (the clue is in the name), is no longer used. Amongst the range of techniques to replicate the clotting process in vitro is thromboelastography (TEG). TEG permits rapid and more precise assays of clotting function under massive transfusion situations (eg major surgery, especially trauma). In particular, advances in this fi eld have been driven by recent military usage. Is this pre-op patient at risk of excessive bleeding? Take a bleeding history! The more structured this is the better. Enquire about factors which may indicate increased bleeding risk, such as: past history of excessive, prolonged, or unexplained bleeding comorbidities such as lupus or Liver disease on agents known to aff ect haemostasis. In such cases, or if bleeding would be disastrous, further tests may be indicated after discussion with a haematologist. __OOHHCCMM__1100ee. . iinnddbb 334477 0022//0055//22001177 1199: : 0077 348 ygolotameaH Blood transfusion and Blood products Blood should only be given if strictly necessary and there is no alternative. Outcomes may be worse after an inappropriate transfusion. Know and use local procedures to ensure that the right Blood gets to the right patient at the right time. Take Blood for crossmatching from only one patient at a time. Label immediately. This minimizes risk of wrong labelling of samples. When giving Blood, monitor TPR and blood pressure every ½h. Use a dedicated line where practicable (or dedicated lumen of multilumen line). Group-and-save (GS) requests Know your local guidelines for elective surgery. Having crossmatched Blood to hand may not be needed if a Blood sample is already in the lab, with group determined, without any atypical antibodies (ie GS). Products2 Whole Blood: The only option for the fi rst 250 years of transfusion history, but now rarely used. Red cells: (Packed to make haematocrit 70%. ) Use to correct anaemia or Blood loss. 1U hemoglobin by 1015g/L. In anaemia, transfuse until hemoglobin 80g/L. Platelets: (p364. ) Usually only needed if bleeding or count is 20 109/L. 1U should platelet count by 20 109/L. Failure to do so suggests refractory cause: discuss with haematologist. If surgery is planned, get advice if count is 100 109/L. Fresh frozen plasma (FFP): Use to correct clotting defects: eg DIC (p352); warfarin overdosage where vitamin potassium would be too slow; Liver disease; thrombotic thrombocytopenic purpura (p315). It is expensive and carries all the risks of Blood transfusion. Do not use as a simple volume expander. Human albumin solution is produced as 4. 5% or 20% Protein solution and is used to replace Protein. 20% albumin can be used temporarily in the hypoproteina emic patient (eg Liver disease; nephrosis) who is fl uid overloaded, without giving an excessive salt load. Also used as replacement in abdominal paracentesis (p765).",
    "Also used as replacement in abdominal paracentesis (p765). Others Cryoprecipitate (a source of fi brinogen); coag ulation concentrates (self-injected in haemophilia); immunoglobulins. Complications of transfusion Management of acute reactions: 2 see BOX Transfusion reactions and table 8. 4. Early (within 24h): Acute haemolytic reactions (eg ABO or Rh incompatibility); anaphylaxis; bacterial contamination; febrile reactions (eg from HLA antibodies); allergic reactions (itch, urticaria, mild fever); fl uid overload; transfusion-related acute lung injury (TRALI, ie ARDS due to antileucocyte antibodies in donor plasma). Delayed (after 24h): Infections (eg viruses: hepatitis B/C, HIV; bacteria; protozoa; prions); iron overload (treatment, p342); GVHD; post-transfusion purpurapotentially lethal fall in platelet count 57d post-transfusion requiring specialist treatment with IV immunoglobulin and platelet transfusions. Massive Blood transfusion This is defi ned as replacement of an individuals entire Blood volume (10U) within 24h. Complications: platelets; Ca2; clotting factors; potassium; hypothermia. Seek early and ongoing support from haematologist and Blood bank who should advise on products and monitoring. In acute haemorrhage, use crossmatched Blood if possible, but if not, use universal donor group O RhΩve Blood, changing to crossmatched Blood as soon as possible. Transfusing patients with Heart failure If hemoglobin 50g/L with Heart failure, transfusion with packed red cells is vital to restore hemoglobin to a safe level, eg 6080g/L, but must be done with care. Give each unit over 4h with furosemide (eg 40mg slow IV/PO; dont mix with Blood) with alternate units. Check for JVP and basal lung crackles; consider CVP line. Autologous transfusion There is a role for patients having their own Blood stored pre-op for later use. Erythropoietin (erythropoietin, p304) can increase the yield of autologous Blood in normal people. Intraoperative cell salvage with retransfusion is also being used more often, especially in cardiac, vascular, and emergency surgery, Cost-analysis shows that it may be worthwhile on an economic basis alone. __OOHHCCMM__1100ee. . iinnddbb 334488 0022//0055//22001177 1199: : 0077 349 ygolotameaH Transfusion reactions All UK Blood products are now leucocyte-depleted (white cells 5106/L) so as to reduce the incidence of complications such as alloimmunization to HLA class I antigens and febrile transfusion reactions. Table 8. 4 Management of transfusion reactions Acute haemolytic reaction STOP transfusion. Check identity and (eg ABO incompatibility) Agitati on, T° name on unit; tell haematologist; send (rapid onset), blood pressure, fl ultrasound hing, abdominal/ unit FBC, UE, clotting, cultures, Urine chest Pain, oozi ng venepuncture sites, DIC. (haemo globinuria) to lab. Keep IV line open with 0. 9% saline. Treat DIC (p352). Anaphylaxis STOP the transfusion. Maintain airway Bronchospasm, cyanosis, blood pressure, soft tissue and give oxygen. Contact anaesthetist. Edema. See p794. Bacterial contamination STOP the transfusion. Check identity T° (rapid onset), blood pressure, and rigors. against name on unit; tell haematologist and send unit FBC, UE, clotting, cultures Urine to lab. Start broad-spectrum antibiotics. TRALI (See p348) Dyspnoea, cough; CXR STOP the transfusion. Give 100% O2. white out. Treat as ARDS, p186. Donor should be removed from donor panel. Non-haemolytic febrile transf usion SLOW or STOP the transfusion. Give an reaction anti pyretic, eg paracetamol 1g. Monitor Shivering and fever usually ½1h after closely. If recurrent, use white blood cell fi lter. starting transfusion. Allergic reactions SLOW or STOP the transfusion; chlorphenUrticaria and itch. amine 10mg slow IV/IM. Monitor closely. Fluid overload SLOW or STOP the transfusion. Give oxygen Dyspnoea, hypoxia, tachycardia, JVP and and a diuretic, eg furosemide 40mg IV basal crepitations. initially. Consider CVP line.",
    "Give oxygen Dyspnoea, hypoxia, tachycardia, JVP and and a diuretic, eg furosemide 40mg IV basal crepitations. initially. Consider CVP line. Blood transfusion and Jehovahs Witnesses Adult human beings (with mental capacity see p568) have an absolute right to refuse any medical treatment, even if to do so seems illogical or could result in their death. To treat patients despite such a refusal would amount to battery under common law, or could even amount to a degrading act or torture, against which the European Convention on Human Rights gives absolute, inalienable protection. The biblical verse no soul of you shall Eat Blood (Leviticus 17: 12) is one of several that have been interpreted by some religious groups to extend to acceptance of Blood products in a medical context. Jehovahs Witnesses, for example, may refuse potentially vital Blood transfusions on such grounds. These views must be respected, but complex issues arise if the patient is a child, or an adult who may not be able to give or withhold consent in an informed way. In an immediately life-threatening situation where further delay may cause harm, treatment such as Blood products may be given in the childs best interest, but the team should always involve senior paediatricians and hospital ethicists where practical. If the requirement is less immediate, then the clinicians should seek further legal advice, which might involve approaching the Courts. __OOHHCCMM__1100ee. . iinnddbb 334499 0022//0055//22001177 1199: : 0077 350 ygolotameaH Anticoagulants Main indications Therapeutic: Venous thromboembolic disease: DVT and physical examination. Prophylactic: Prevention of DVT/physical examination in High-risk patients (p375), eg post-op. Prevention of stroke, eg in chronic atrial fibrillation or prosthetic Heart valves. Heparin 1 Low-molecular-weight heparin (LMWH): Eg dalteparin, enoxaparin, tinzaparin. The preferred option in the prevention and initial treatment of venous thromboembolism. Inactivates factor Xa (but not thrombin). t½ is 2to 4-fold longer than standard heparin, and response is more predictable: only needs to be given once or twice daily SC, and laboratory monitoring is usually not required. See BNF for doses. It accumulates in renal failure: decrease dose for prophylaxis, use UFH for therapeutic treatment 2 Unfractionated heparin (UFH): IV or SC. Binds antithrombin (an endogenous inhibitor of coagulation), increasing its ability to inhibit thrombin, factor Xa, and IXa. Rapid onset and has a short t½. Monitor and adjust dose with APTT (p346). SE for both: Bleeding (eg at operative site, gastrointestinal, intracranial), heparininduced thrombocytopenia (HIT), osteoporosis with long-term use. HIT and osteoporosis are less common with LMWH than UFH. Beware hyperkalaemia. CI: Bleeding disorders, platelets 60109/L, previous HIT, peptic ulcer, cerebral haemorrhage, severe hypertension, neurosurgery. Warfarin Used PO OD as long-term anticoagulation. The therapeutic range is narrow, varying with the condition being treated (see BOX Warfarin guidelines and target levels for INR)and eff ects are refl ected in the INR. Warfarin inhibits the reductase enzyme responsible for regenerating the active form of vitamin potassium, producing a state analogous to vitamin potassium defi ciency. CI: Peptic ulcer, bleeding disorders, severe hypertension, pregnancy (teratogenic, see OHCS p640). Use with caution in elderly and those with past GI bleeds. In the UK, warfarin tablets are 0. 5mg (white), 1mg (brown), 3mg (blue), or 5mg (pink). Interactions: p757. DOACS (Direct oral anticoagulants. ) Rivaroxaban, apixaban (factor Xa inhibitors) and dabigatran (a direct thrombin inhibitor) do not require regular monitoring and dose adjustment; just a quarterly assessment and annual Blood test. They off er an attractive alternative to warfarin (particularly where monitoring and maintaining a therapeutic INR is diffi cult). CI: severe renal/Liver impairment; active bleeding; Bloodsion at risk of bleeding; clotting factors. Interactions: heparin, clopidogrel.",
    "CI: severe renal/Liver impairment; active bleeding; Bloodsion at risk of bleeding; clotting factors. Interactions: heparin, clopidogrel. Others Fondaparinux is a pentasaccharide Xa inhibitor and is used in acute coronary syndrome or in place of LMWH for prophylaxis. Beginning therapeutic anticoagulation (Follow local guidelines, and see BNF. ) For treatment of venous thromboembolism, LMWH or UFH are typically used initially. When transitioning to warfarin, give heparin in combination (as early as day 1) and continue until INR is in target therapeutic range on 2 consecutive days (see BOX Warfarin dosage). Start warfarin at 510mg given at 18. 00 on days 1 and 2, then check INR on day 3 (it takes 4872h for anticoagulant eff ect to develop). Adjust subsequent doses according to the INR (see table 8. 5), which needs to be measured on alternate days until stable, then weekly or less often. When transitioning to a DOAC switch from heparin (ie do not coadminister DOAC and heparin). DOACS and warfarin may both be initiated as monotherapy in chronic atrial fibrillation (DOACS also in less extensive thromboembolism). Antidotes If UFH overdose: stop infusion. If there is bleeding, protamine sulphate counteracts UFH: discuss with a haematologist. Warfarin: see BOX Warfarin dosage and table 8. 6. DOACS: challenging and evolving area (including monoclonal anti-drug antibodies eg idarucizumab for dabigatran)discuss with haematologist. __OOHHCCMM__1100ee. . iinnddbb 335500 0022//0055//22001177 1199: : 0077 351 ygolotameaH Warfarin guidelines and target levels for INR Pulmonary embolism and DVT. Aim for INR of 23; 3. 5 if recurrent physical examination or DVT whilst anticoagulated. Atrial fi brillation: for stroke prevention (p130). Target INR 23. Prosthetic metallic Heart valves: for stroke prevention. Target INR 23 if aortic valve or 2. 53. 5 if mitral valve. Duration of anticoagulation in DVT/physical examination: First episodes of DVT or physical examination require at least 3 months of anticoagulation. Consider extending this to 6 months in patients with more extensive, life-threatening clot at presentation, for those with transient but persistent risk factors (eg prolonged immobility) or if evidence of persistent clot at 3 months. For those with recurrent unprovoked emboli or underlying thrombophilia (p374), consider bleeding risks against benefi ts of indefi nite treatment. Warfarin dosage and what to do when the INR is much too High Below is a rough guide to warfarin dosing for target INR of 23. Table 8. 5 Suggested dosing for day 3 of warfarin loading INR 2 2 2. 5 2. 9 3. 3 3. 6 4. 1 3rd dose 5mg 5mg 4mg 3mg 2mg 0. 5mg 0mg Maintenance ≥6mg 5. 5mg 4. 5mg 4mg 3. 5mg 3mg Miss a dose; give 12mg the next day; if INR 4. 5, miss 2 doses. Table 8. 6 When the INR is much too High (see also BNF) Withold 12 doses. Restart warfarin at a lower maintaINR 58, no bleed nence dose once INR 5. INR 58, minor bleed s S l t o o w p l y w ). a R rf e a s r t i a n r a t n w d a a r d fa m ri i n t f w or h e u n rg I e N n R t I 5 V. vitamin potassium (give INR 8, no bleed Stop warfarin and seek haematology advice. Stop warfarin and admit for urgent IV vitamin potassium. Check INR NR 8, minor bleed dailyrepeat vitamin potassium if INR too High after 24h. Restart warfarin at a lower dose when INR 5. Any major Stop warfarin.",
    "Restart warfarin at a lower dose when INR 5. Any major Stop warfarin. Give prothrombin complex concentrate 50 bleed (including units/kg (if unavailable, give FFP 15mL/kg 1L for a 70kg intracranial man) and 510mg vitamin potassium IV. Discuss with haematologist. haemorrhage) Minor bleeding includes epistaxis. Vitamin potassium may take several hours to work and can cause prolonged resistance when restarting warfarin, so should be avoided if possible when long-term anticoagulation is needed. Prothrombin complex concentrate contains a concentrate of factors II, VII, IX, and X and provides a more complete and rapid reversal of warfarin than FFP. __OOHHCCMM__1100ee. . iinnddbb 335511 0022//0055//22001177 1199: : 0077 352 ygolotameaH Leukaemia and the on-call junior doctor Leukaemia divides into four main types depending on the cell line involved (table 8. 7). Table 8. 7 Principal subtypes of leukaemia Lymphoid Myeloid Acute Acute lymphoblastic leukaemia (ALL) Acute myeloid leukaemia (AML) Chronic Chronic lymphocytic leukaemia (CLL) Chronic myeloid leukaemia (CML) These patients (esp. AML) fall ill suddenly and deteriorate fast, eg with: infection, ble eding (: platelets ± FFP), and hyperviscosity (p372). Take non-specifi c confusion/drowsiness or just I feel a bit ill today seriously: do Blood cultures, FBC, UE, LFT, Ca2, glucose, and clotting. Consider CNS bleedingcomputed tomography if in doubt. With any new patient, fi nd out the agreed aim of treatment: cure; prolonging disease-free survival; or palliation with minimal toxicity? Direct your eff orts accordingly; get help if lack of clarity here. Neutropenic regimen (For when neutrophil count ≤0. 5 109/L. )3 Close liaison with a microbiologist and haematologist is vital. Abide by infection control procedures! Use a risk-assessment tool (eg MASCC, see BOX). Full barrier nursing in a side room if possible. Hand-washing is vital. Avoid IM injections (danger of an infected haematoma). Look for infection (mouth, axillae, perineum, IVI site). Take swabs. Check: FBC, platelets, INR, UE, LFT, LDH, CRP. Take cultures (Blood 3peripherally ± Hickman line; Urine, sputum, stool if diarrhoea); CXR if clinically indicated. Wash perineum after defecation. Swab moist skin with chlorhexidine. Avoid unnecessary rectal examinations. Oral hygiene (eg hydrogen peroxide mouth washes/2h) and Candida prophylaxis are important (p246). Check vital signs 4-hrly. High-calorie diet; avoid foods with High risk of microbial contamination. Vases containing cut fl owers pose a Pseudomonas risk. Use of antibiotics in neutropenia Treat any known infection promptly. If T° 38°C or T° 37. 5°C on two occasions, 1h apart, or the patient is septic, start blind combination therapy according to local guidelineseg piperacillin tazobactamp386 ( vancomycin, p386, if Gram ve organisms suspected or isolated, eg Hickman line sepsis). Continue until afebrile for 72h or 5d course, and until neutrop hils 0. 5109/L. If fever persists despite antibiotics, think of CMV, fungi (eg Candida; Aspergillus, p408) and central line infection. Consider treatment for Pneumocystis (p400, eg co-trimoxazole, though beware as this can worsen neutropenia). Remember TB. Other dangers Tumour lysis syndrome: Results in potassium, urate, and acute kidney injury. See p529. Hyperviscosity: (p372). If WCC is 100 109/L white blood cell thrombi may form in brain, lung, and Heart (leukostasis). Avoid transfusing before lowering WCC, eg with hydroxycarbamide or leukaph eresis, as viscosity rises (risk of leukostasis). DIC: The release of procoagulants into the circulation causes widespread activation of coagulation, consuming clotting factors and platelets and causing risk of bleeding. Fibrin strands fi ll small vessels, haemolysing passing RBCs. Fibrinolysis is also activated. Causes: Malignancy, sepsis, trauma, obstetric events. Signs: (fi g 8. 44) Bruising, bleeding anywhere (eg venep uncture sites), renal failure. Tests: Platelets; patient; APTT; fi brinogen (correlates with severity); fi brin degradation products (D-dimers). Film: broken RBCS (schisto cytes).",
    "Chemotherapy: Complex multi-drug, multi-phase regimens that may take years: Remission induction: eg vincristine, prednisolone, L-asparaginase daunorubicin. Consolidation: High-medium-dose therapy in blocks over several weeks. CNS prophylaxis: intrathecal (or High-dose IV) methotrexate ± CNS irradiation. Maintenance: prolonged chemotherapy, eg mercaptopurine (daily), methotrexate (weekly), and vincristine prednisolone (monthly) for 2yrs. Relapse is common in Blood, CNS, or testis (examine these sites at follow-up). More details: OHCS p194. Matched related allogeneic marrow transplantations: Once in 1st remission is the best option in standard-risk younger adults. Haematological remission: Means no evidence of leukaemia in the Blood, a normal or recovering Blood count, and 5% blasts in a normal regenerating marrow. Prognosis Cure rates for children are 7090%; for adults only 40% (higher when imatinib/rituximab, p358, are used). Poor prognosis if: adult, male, Philadelphia chromosome (p358: BCRABL gene fusion due to translocation of chromosomes 9 and 22), presentation with CNS signs, hemoglobin, WCC 100109/L, or B-cell ALL. protein-creatinine ratio is used to detect minimal residual disease, undetectable by standard means. Prognosis in relapsed Ph-negative ALL is poor (but improvable by marrow transplant). Personalized treatment One size does not fi t all! Aim to tailor therapy to the exact gene defect, and according to individual metabolism. Monoclonal antibodies, gene-targeted retinoids, cytokines, vaccines, and T-cell infusions are relevant here. Biomarkers, eg thiopurine methyltransferase, can predict toxicity from thiopurines. 6 Eg t(12: 21) ETV6-RUNX1, t(1; 19) TCF3-PBX1, t(9; 22) BCR-ABL1, and rearrangement of MLL. __OOHHCCMM__1100ee. . iinnddbb 335544 0022//0055//22001177 1199: : 0077 355 ygolotameaH Fig 8. 45 Blood fi lm in ALL, L1 subtype. Small Fig 8. 46 Bone marrow in ALL, L1 subtype. blasts with scanty cytoplasm. Courtesy of Prof. Christine Lawrence. Courtesy of Prof. Christine Lawrence. Fig 8. 47 Blood fi lm in ALL, L2 subtype. Larger blast cells with greater morphological vari ation and more abundant cytoplasm. Fig 8. 48 ALL L3. Blasts with vacuolated basophilic cytoplasm. A and B: Blood fi lms. C: lymph Courtesy of Prof. Christine Lawrence. node. Courtesy of Prof. Tangün and Dr Köroˇglu. Fig 8. 49 Bilateral parotid infi ltration in ALL. (Enlarged salivary glands are also seen in mumps, HIV, bulimia, myxoedema, etc. , p594. ) __OOHHCCMM__1100ee. . iinnddbb 335555 0022//0055//22001177 1199: : 0077 356 ygolotameaH Acute myeloid leukaemia (AML) Neoplastic proliferation of blast cells derived from marrow myeloid elements. It progresses rapidly (death in 2 months if untreated; 20% 3yr survival after ). Incidence The commonest acute leukaemia of adults (1/10 000/yr; increases with age). AML can be a long-term complication of chemotherapy, eg for lymphoma. Also associated with myelodysplastic states (see BOX Myelodysplastic syndromes), radiation, and syndromes, eg Downs. Morphological classifi cation There is much heterogeneity (see BOX Heterogeneity in AML). Four types based on WHO histological classifi cation, cytogenetics, and molecular genetics: 1 AML with recurrent genetic abnormalities. 2 AML multilineage dysplasia (eg 2° to pre-existing myelodysplastic syndrome). 3 AML, therapy related (in those previously treated with cytotoxic drugs). 4 AML, other (not fi tting above-listed; further subclassifi ed as M0M7 by maturation). Signs and symptoms Marrow failure: Anaemia, infection, or bleeding. DIC occurs in acute promyelocytic leukaemia, a subtype of AML, where there is release of thromboplastin (p352). Infi ltration: Hepatomegaly, splenomegaly, gum hypertrophy (fi g 8. 50), skin involvement. CNS involvement at presentation is rare. Diagnosis WCC is often , but can be normal or even Low. Blast cells may be few in the peripheral Blood, so diagnosis depends on bone marrow biopsy, immunophenotyping, and molecular methods. On biopsy, AML is diff erentiated from ALL by Auer rods (fi gs 8. 51 8. 53).",
    "On biopsy, AML is diff erentiated from ALL by Auer rods (fi gs 8. 51 8. 53). Cytogenetic analysis (eg type of mutation) guides treatment recommendations and prognosis. Complications Predisposition to infection by both the disease and the treatment; may be bacterial, fungal, or viralprophylaxis is given for each during therapy. Be alert to septicaemia (p352): common organisms present oddly and rare organisms can infect commonly (particularly the fungi Candida and Aspergillus). Be aware that AML itself causes fever. Chemotherapy causes plasma urate levels (from tumour lysis)so give allopurinol with chemotherapy, and keep well hydrated with IV fl uids. Leukostasis (p352) may occur if WCC. Treatment Supportive care: As for ALL. Walking exercises can relieve Fatigue. Chemotherapy: Very intensive, resulting in long periods of marrow suppression with neutropenia platelets . The main drugs used include daunorubicin and cyt arabine, with 5 cycles given in 1-week blocks to get a remission (renal artery stenosis mutations occur in 20% of patients with AML and enhance sensitivity to cytarabine). Bone marrow transplant (BMT): Pluripotent haematopoietic stem cells are collected from the marrow. Allogeneic transplants from HLA-matched donors (held on international databases) are indicated in refractory or relapsing disease. The idea is to destroy leuka emic cells and the immune system by, eg cyclophosphamide total body irradiation, then repopulate the marrow with donor cells infused IV. Ciclosporin ± methotrexate are used to reduce the eff ect of the new marrow attacking the patients body (GVHD). Complications: GVHD (may help explain the curative eff ect of BMT); opportunistic infections; relapse of leukaemia; infertility. Prognosis: Lower relapse rates 60% long-term survivors, but signifi cant mortality of 10%. Autologous BMT (where stem cells are taken from the patient themselves) is used in intermediate prognosis disease, although some studies suggest better survival rates with intensive chemotherapy regimens. Autologous mobilized peripheral Blood stem cell transplantation may off er faster haemopoietic recovery and less morbidity. Supportive care, or lower-dose chemotherapy for disease control, may be more appropriate in elderly patients, where intensive therapies have poorer outcomes. __OOHHCCMM__1100ee. . iinnddbb 335566 0022//0055//22001177 1199: : 0077 357 ygolotameaH Fig 8. 50 Gum hypertrophy in AML. Courtesy of Prof. Christine Lawrence. Fig 8. 51 Auer rods (crystals of coalesced granules) found in AML myeloblast cells. Courtesy of Prof. Christine Lawrence. Fig 8. 52 AML with monoblasts and myelo blasts on the peripheral Blood fi lm. Fig 8. 53 Marrow in AML: multiple monoblasts. Courtesy of Prof. Christine Lawrence. Courtesy of Prof. Christine Lawrence. Myelodysplastic syndromes (MDS, myelodysplasia) These are a heterogeneous group of disorders that manifest as marrow failure with risk of life-threatening infection and bleeding (median survival varies from 6 months to 6 years according to disease type). Mostly primary, but can develop secondary to chemotherapy or radiotherapy. 30% transform to acute leukaemia. Tests: Pancytopenia (p364), with reticulocyte count. Marrow cellularity is usually increased due to ineff ective haematopoiesis. Ring sideroblasts may also be seen in the marrow (fi g 8. 9, p327). Treatment: Multiple transfusions of red cells or platelets as needed. Erythropoietin ± G-CSF (p352) may lower transfusion requirement. Allogeneic stem cell transplantation is one option (curative but often inappropriate owing to age-related comorbiditiesmost are 70yrs old). Low-intensity treatments that are not curative but may improve quality of life in symptomatic disease include thalidomide analogues (eg lenalidomide) or hypomethylating agents (eg azacitidine and decitabine). Heterogeneity in AML Consider four types of heterogeneity as we move through medical history: morphologic, immunophenotypic, cytogenetic, and molecular. Genomic technologies enable an ever more detailed molecular analysis of AML and this can be used to inform prognosis and guide risk stratifi cation.",
    "Epigenetic and other profi ling reveals more and more biomarkers, eg mutations in the genes encoding DNA (cytosine-5)- methyltransferase 3A (DNMT3A). __OOHHCCMM__1100ee. . iinnddbb 335577 0022//0055//22001177 1199: : 0077 358 ygolotameaH Chronic myeloid leukaemia (CML) CML is characterized by an uncontrolled clonal proliferation of myeloid cells (fi g 8. 54). It accounts for 15% of leukaemias. It is a myeloproliferative disorder (p366) having features in common with these diseases, eg splenomegaly. It occurs most often between 4060yrs, with a slight male predominance, and is rare in childhood. Philadelphia chromosome (Ph) Present in 80% of those with CML. It is a hybrid chromosome comprising reciprocal translocation between the long arm of chromosome 9 and the long arm of chromosome 22t(9; 22)forming a fusion gene BCR/ ABL on chromosome 22, which has tyrosine kinase activity. Those without Ph have a worse prognosis. Some patients have a masked translocationcytogenetics do not show the Ph, but the rearrangement is detectable by molecular techniques. Symptoms Mostly chronic and insidious: weight, tiredness, fever, sweats. There may be features of gout (due to purine breakdown), bleeding (platelet dysfunction), and abdominal discomfort (splenic enlargement). 30% are detected by chance. Signs Splenomegaly (75%)often massive. Hepatomegaly, anaemia, bruising (fi g 8. 55). Tests white blood cell (often 100109/L) with whole spectrum of myeloid cells, ie neutrophils, monocytes, basophils, eosinophils. hemoglobin or , platelets variable. Urate, B12. Bone marrow hypercellular. Cytogenetic analysis of Blood or bone marrow for Ph. Natural history Variable, median survival 56yrs. There are three phases: Chronic, lasting months or years of few, if any, symptoms. Accelerated phase, with increasing symptoms, spleen size, and diffi culty in controlling counts. Blast transformation, with features of acute leukaemia ± death. Treatment See BOX. d F i i ff g e r 8 e. 5 n 4 t st C a M g L e: s n o u f m d e iff r o e u re s n g ti r a a t n io u n lo. cytic cells at Fig 8. 55 Hepatosplenomegaly in CML. Courtesy of Prof. Christine Lawrence. Treating CML CML is the fi rst example of a cancer where knowledge of the genotype has led to a specifi cally targeted drugimatinib, a BCR-ABL tyrosine kinase inhibitor. This has transformed therapy over the last 10yrs. Side eff ects are usually mild: nausea, cramps, oedema, rash, headache, arthralgia. May cause myelosuppression. More potent 2nd-generation BCR-ABL inhibitors: dasatinib, nilotinib, bosutinib, and ponatinib. Dasatinib and nilotinib allow more patients to achieve deeper, more rapid responses associated with improved outcomes, and dasatinib has been used in imatinib-resistant blast crises (though NICE says that it is often not cost-eff ective). Hydroxycarbamide is also used. Those with lymphoblastic trans formation may benefi t from treatment as for ALL. Treatment of myeloblastic transformation with chemotherapy rarely achieves lasting remission, and allo geneic transplantation off ers the best hope. Stem cell transplantation. Allogeneic transplantation from an HLA-matched sibling or unrelated donor off ers the only cure, but carries signifi cant morbidity and mortality. Guidelines suggest that this approach should be only rarely used 1st line in young patients (where mortality rates are lower). Other patients should be offered a BCR-ABL inhibitor. Patients are then reviewed annually to decide whether to continue, to off er combination therapy or stem cell transplantation. __OOHHCCMM__1100ee. . iinnddbb 335588 0022//0055//22001177 1199: : 0077 359 ygolotameaH Chronic lymphocytic leukaemia (CLL) CLL is the commonest leukaemia (25%; incidence: 5/100 000/yr). : 2: 1. The hallmark is progressive accumulation of a malignant clone of functionally incompetent B cells. Mutations, trisomies, and deletions (eg del17p13) infl uence risk (table 8.",
    "Mutations, trisomies, and deletions (eg del17p13) infl uence risk (table 8. 8). Table 8. 8 Staging and survival in CLL Rai stage: 0 Lymphocytosis alone Median survival 13yrs I Lymphocytosis lymphadenopathy 8yrs II Lymphocytosis splenoor hepatomegaly 5yrs III Lymphocytosis anaemia (hemoglobin 110g/L) 2yrs IV Lymphocytosis platelets 100 109/L 1yr Symptoms Often none, presenting as a surprise fi nding on a routine FBC. Patients may be anaemic or infection-prone, or have weight, sweats, anorexia if severe. Signs Enlarged, rubbery, non-tender nodes (fi g 8. 56). Splenomegaly, hepatomegaly. Tests Lymphocytesmay be marked (fi g 8. 57). Later: autoimmune haemolysis (p338), marrow infi ltration: hemoglobin, neutrophils, platelets. Complications 1 Autoimmune haemolysis. 2 Infection due to hypogammaglobulinaemia (IgG), bacterial, viral especially herpes zoster. 3 Marrow failure. Treatment Consider drugs if symptomatic. Fludarabine rituximab ± cyclophosphamide is 1st line (there is synergism). Ibrutinib, chlorambucil, bendamustine, and ofatumumab all have a role. Steroids help autoimmune haemolysis. Radiotherapy helps lymphadenopathy and splenomegaly. Stem-cell transplantation may have a role in carefully selected patients. Supportive care: Transfusions, IV human immunoglobulin if recurrent infection. Natural history ⅓ never progress (or even regress), ⅓ progress slowly, and ⅓ progress actively. CD23 and 2 microglobulin correlate with bulk of disease and rates of progression. Death is often due to infection or transformation to aggressive lymphoma (Richters syndrome). Fig 8. 56 Bilateral cervical lymphadenopathy Fig 8. 57 CLL: many lymphocytes and a smear in CLL. cell: a fragile cell damaged in preparation. Courtesy of Prof. Christine Lawrence. __OOHHCCMM__1100ee. . iinnddbb 335599 0022//0055//22001177 1199: : 0077 360 ygolotameaH Hodgkins lymphoma (HL) Lymphomas are disorders caused by malignant proliferations of lymphocytes. These accumulate in the lymph nodes causing lymphadenopathy, but may also be found in physical examinationripheral Blood or infi ltrate organs. Lymphomas are histologically divided into Hodgkins and non-Hodgkins types. In Hodgkins lymphoma, 7 characteristic cells with mirror-image nuclei are found, called ReedSternberg cells (fi gs 8. 588. 60). Incidence Two peaks: young adults (HL is the commonest malignancy in 1524yr olds) and elderly. : 2: 1. Risk factors: An aff ected sibling; EBV (p405); SLE; post-transplantation. Symptoms Often presents with enlarged, non-tender, rubbery superfi cial lymph nodes (6070% cervical, fi g 8. 61, also axillary or inguinal). Node size may fl uctuate, and they can become matted. 25% have constitutional upset, eg fever, weight loss, night sweats, pruritus, and lethargy. There may be alcohol-induced lymph node Pain. Mediastinal lymph node involvement can cause mass eff ect, eg bronchial or SVC obstruction (p528), or direct extension, eg causing pleural eff usions. Signs Lymphadenopathy. Also, cachexia, anaemia, splenoor hepatomegaly. Tests Tissue diagnosis: Lymph node excision biopsy if possible. Image-guided needle biopsy, laparotomy, or mediastinoscopy may be needed. Bloods: FBC, fi lm, ESR, LFT, LDH, urate, Ca2. ESR or hemoglobin indicate a worse prognosis. LDH as it is released during cell turnover. Imaging: CXR, computed tomography/PET of thorax, abdo, and pelvis. Staging (Ann Arbor system. ) Infl uences treatment and prognosis. Done by imaging ± marrow biopsy if B symptoms, or stage IIIIV disease. I Confi ned to single lymph node region. II Involvement of two or more nodal areas on the same side of the diaphragm. III Involvement of nodes on both sides of the diaphragm. IV Spread beyond the lymph nodes, eg Liver or bone marrow. Each stage is either Ano systemic symptoms other than pruritus; or Bpresence of B symptoms: weight loss 10% in last 6 months, unexplained fever 38°C, or night sweats (needing change of clothes). B indicates worse disease. Localized extra-nodal extension does not advance the stage, but is indicated by subscripted E, eg I-AE.",
    "B indicates worse disease. Localized extra-nodal extension does not advance the stage, but is indicated by subscripted E, eg I-AE. Chemoradiotherapy Radiotherapy short courses of chemotherapy for stages I-A and II-A (eg with ≤3 areas involved). Longer courses of chemotherapy for II-A with 3 areas involved through to IV-B. ABVD: Adriamycin (doxorubicin), Bleomycin, Vinblastine, Dacarbazine cures 80% of patients. More intensive regimens are used if poor prognosis or advanced disease. 8 In relapsed disease: High-dose chemotherapy followed by autologous stem cell transplantation. Complications of treatment: See pp5247. Radiotherapy may risk of second malignanciessolid tumours (especially lung and breast, also melanoma, sarcoma, stomach and thyroid cancers), ischaemic Heart disease, hypothyroidism, and lung fi brosis due to the radiation fi eld. Chemotherapy SE include myelosuppression, nausea, alopecia, infection. AML (p356), non-Hodgkins lymphoma, and infertility may be due to both chemoand radiotherapysee p525. 5-year survival Depends on stage and grade (table 8. 9): 95% in I-A lymphocytepredomi nant disease; 40% with IV-B lymphocyte-depleted. Emergency presentations Infection; SVC obstructionJVP, sensation of fullness in the head, dyspnoea, blackouts, facial oedema (seek expert help; see p528). 7 Thomas Hodgkin (17981866); rediscovered by Samuel Wilks (18241911) who magnanimously gave the disease Hodgkins name. 8 Eg BEACOPP (bleomycin/etoposide/doxorubicin/cyclophosphamide/vincristine/procarbazine/prednisone). In IIB, III, or IV, BEACOPP gives better initial control, but 7yr event-free survival is similar: 78% vs 71%. __OOHHCCMM__1100ee. . iinnddbb 336600 0022//0055//22001177 1199: : 0077 361 ygolotameaH Table 8. 9 HL subtypes Classifi cation (% of cases) Prognosis Nodular sclerosing (70%) Good Mixed cellularity (2025%) Good Lymphocyte rich (5%) Good Lymphocyte depleted (1%) Poor NB: nodular lymphocyte predominant Hodgkins is recognized as a separate entity, behav ing as an indolent B-cell lymphoma. Higher incidence and worse prognosis if HIV ve. Fig 8. 58 A ReedSternberg cell with two Fig 8. 59 Another ReedSternberg cell. nuclei, characteristic of Hodgkins lymphoma. Courtesy of the Crookston collection. Courtesy of Prof. Christine Lawrence. Fig 8. 60 Mononuclear ReedSternberg cell Fig 8. 61 Cervical lymphadenopathy in Hodgin a lymph node. kins disease. Prof. Tangün and Dr Körogˇlu. Quality of life, lymphoma, and the role of expressive writing Being treated for Hodgkins lymphoma is arduous. Our job is often to give encouragementthe more this is personalized for our individual patient the better. One method is to encourage our patients to write about their experiences. In one study this gave clear-cut benefi ts in lymphoma patients. Participants report positive responses to writing, and half said that writing changed their thoughts about their illness in a positive way (this increased on subsequent follow-up). Textual analysis identifi es themes related to experiences of positive change, transformation, and self-affi rmation through refl ection. These techniques are akin to those used in post-traumatic stressand remind ultrasound that some of our treatments are as destabilizing to our patients as any shipwreck or earthquake. I can whine, I can complain, I can moan, and bitch, about all of the above, but I wont. The true feat International Society of Nephrologyt escaping death, rather, learning how to live. Sometimes narrating lymphoma experiences reveals bitterness, loss of control, and a feeling that life has been rendered void. Here our role is to receive these negatives and to try to keep the channels of communication open, as dialogue is the only validated means of fi lling these voids. The need to enhance support networks and bolster social ties may trump all our pharmacological imperatives. __OOHHCCMM__1100ee. . iinnddbb 336611 0022//0055//22001177 1199: : 0077 362 ygolotameaH Non-Hodgkins lymphoma This includes all lymphomas without ReedSternberg cells (p360)a diverse group. Most are derived from B-cell lines; diff use large B-cell lymphoma (DLBCL) is commonest.",
    "Most are derived from B-cell lines; diff use large B-cell lymphoma (DLBCL) is commonest. Not all centre on nodes (extranodal tissues generating lymphoma include mucosa-associated lymphoid tissue, eg gastric MALT, later in topic). Incidence has doubled since 1970 (to 2: 10 000). Causes Immunodefi ciencydrugs; HIV (usually High-grade lymphoma from EBV transformed cells, p405); HTLV-1, p405; H. pylori; toxins; congenital. Signs and symptoms Superfi cial lymphadenopathy (75% at presentation). Extranodal disease (50%) Gut (commonest): 1 Gastric MALT is caused by H. pylori, and may regress with its eradication (p252). Symptoms: as for gastric calcium (p619), with systemic features (see below). MALT usually involves the antrum, is multifocal, and metastasizes late. 2 Non-MALT gastric lymphomas (60%) are usually diff use large-cell B lymphomasHigh-grade and not responding well to H. pylori eradication. 3 Small-bowel lymphomas eg IPSID (immunoproliferative small intestine disease p370), or EATCL (enteropathy/coeliac-associated intra-epithelial T-cell lymphoma)presents with diarrhoea, Vomiting, abdominal Pain, and weight. Poor prognosis. Skin: (2nd commonestsee fi g 8. 62) Eg clonal T cells in mycosis fungoides (accounts for 50%p596). Oropharynx: Waldeyers ring lymphoma causes sore throat/obstructed breathing. Other possible sites: Bone, CNS, and lung. Systemic featuresfever, night sweats, weight loss (less common than in Hodgkins lymphoma, and indicates disseminated disease). Pancytopenia from marrow involvementanaemia, infection, bleeding (platelets). Tests Blood: FBC, UE, LFT. LDH worse prognosis, refl ecting cell turnover. Marrow and node biopsy for classifi cation (complex, based on the WHO system of Highor Low-grade). Staging: Ann Arbor system (p360)computed tomography ± PET of chest, abdomen, pelvis. Send cytology of any eff usion; LP for CSF cytology if CNS signs. Diagnosis/management is multidisciplinary, synthesizing details from clinical evaluation, histology, immunology, molecular genetics, and imaging. Generally: Low-grade lymphomas are indolent, often incurable and widely disseminated. Include: follicular lymphoma, marginal zone lymphoma/MALT, lymphocytic lymphoma (closely related to CLL and treated similarly), lymphoplasmacytoid lymphoma (produces IgM Waldenströms macroglobulinaemia, p370). See fi g 8. 63. High-grade lymphomas are more aggressive, but often curable. There is often rapidly enlarging lymphadenopathy with systemic symptoms. Include: Burkitts lymphoma (childhood disease with characteristic jaw lymphadenopathy; fi gs 8. 64, 8. 65), lymphoblastic lymphomas (like ALL), diff use large B-cell lymphoma. Treatment Huge range of options, depending on disease subtype. Low grade: If symptomless, none may be needed. Radiotherapy may be curative in localized disease. Chlorambucil is used in diff use disease. Remission may be maintained by using interferon alfa or rituximab (see later in paragraph). Bendamustine is eff ective both with rituximab and as a monotherapy in rituximab-refractory patients. High grade: (eg large B-cell lymphoma, DLBCL), R-CHOP regimen: Rituximab, Cyclophosphamide, Hydroxy daunorubicin, vincristine (Oncovin) and Prednisolone. Granulocyte colony-stimulating factors (G-CSFs) help neutropeniaeg fi lgrastim or lenograstim (at Low doses it may be cost-eff ective). Survival Histology is important. Prognosis is worse if, at presentation: Age 60yrs. Systemic symptoms. Bulky disease (abdominal mass 10cm). LDH. Disseminated disease. Typical 5yr survival for treated patients: 30% for High-grade and 50% for Low-grade lymphomas, but the picture is very variable. __OOHHCCMM__1100ee. . iinnddbb 336622 0022//0055//22001177 1199: : 0077 363 ygolotameaH (a) (b) Fig 8. 62 Cutaneous T-cell lymphoma, which has caused severe eryt hroderma (Sézary syndrome) in a Caucasian woman. Courtesy of Prof. Christine Lawrence. (c) (d) Fig 8. 63 (a) and (b): villous lymphocytes (splenic marginal zone lymphoma). (c): buttock cells with cleaved nuclei (follicular lymphoma). (d): Sézary cells with convoluted nuclei. Courtesy of Prof. Tangün Dr Körogˇlu. Fig 8. 64 Burkitts lymphoma, with characteristic jaw lymphadenopathy. Courtesy of Dr Tom D Thacher. Fig 8. 65 Burkitts lymphoma, with three basophilic vacuolated lymphoma cells.",
    "Courtesy of Dr Tom D Thacher. Fig 8. 65 Burkitts lymphoma, with three basophilic vacuolated lymphoma cells. From the New England Journal of Medicine, Bain, B, Diagnosis from the Blood smear, 353(5), 498. Copyright 2005 Massachusetts Medical Society. Reprinted with permission from Massachusetts Medical Society. The role of rituximab in untreated follicular lymphoma Rituximab kills CD20 ve cells by antibody-directed cytotoxicity ± apoptosis induction. It also sensitizes cells to CHOP. It is cost-eff ective when used with: cyclophosphamide, vincristine, and prednisolone (CVP) cyclophosphamide, doxorubicin, vincristine, and prednisolone (CHOP) cyclophosphamide, doxorubicin, etoposide, prednisolone, and interferon alfa (CHVPi) mitoxantrone, chlorambucil, and prednisolone (MCP) chlorambucil. It also has a role in maintaining remission, and in relapsed disease. __OOHHCCMM__1100ee. . iinnddbb 336633 0022//0055//22001177 1199: : 0077 364 ygolotameaH Pancytopenia and bone marrow failure Bone marrow is responsible for haematopoiesis. In adults, this normally takes place in the central skeleton (vertebrae, sternum, ribs, skull) and proximal long bones. In some anaemias (eg thalassaemia), increased demand induces haematopoiesis beyond the marrow (extramedullary haematopoiesis), in Liver and spleen, causing organomegaly. All Blood cells arise from an early pluripotent stem cell, which divides asymmetrically to produce another stem cell and a progenitor cell committed to a lineage (see fi g 8. 66). Committed progenitors further diff erentiate into myeloid or lymphocyte lineages, releasing their progeny into the Blood. Pancytopenia Reduction in all the major cell lines: red cells, white cells, and platelets. Causes are due to: 1 Marrow production: Aplastic anaemia (see BOX), infi ltration (eg acute leukaemia, myelodysplasia, myeloma, lymphoma, solid tumours, TB), megaloblastic anaemia, myelofi brosis (p366). 2 Peripheral destruction: Hypersplenism. Agranulocytosis Implies that granulocytes (WBCs with neutrophil, basophil, or eosin ophil granules) have stopped being made, leaving the patient at risk of fatal infections. Many drugs can be the culprit: eg carbimazole, procainamide, sulfonamides, gold, clozapine, dapsone. When starting drugs known to cause agranulocytosis, warn patients to report any fever. Neutropenia (wcc 0. 5109/L) may declare itself initially as a sore throat. Stop the drug, commence neutropenic regimen and consider G-CSF if indicated (p352). Marrow support Red cells survive for 120d, platelets for 8d, and neutrophils for 12d, so early problems are mainly from neutropenia and thrombocytopenia. 1 Red cell transfusion: Transfusing 1U should raise hemoglobin by 1015g/L (p348). Transfusion may drop the platelet count (you may need to give platelets before or after). 2 Platelets: Traumatic bleeds, purpura, and easy bruising occur if platelets 50109/L. Spontaneous bleeding may occur if platelets 20109/L, with intracranial haemo rrhage rarely. Platelets are stored at room temperature (22°C; not in the fridge). In marrow transplant or if severely immunosuppressed, platelets may need irradiation before use to prevent transfusion-associated GVHD. Platelets must be ABO compatible. They are not used in ITP (p345). Indications: Platelets 10109/L. Haemorrhage (eg DIC, p352). Before invasive procedures (eg biopsy, lumbar puncture) to increase count to 50109/L. 4U of platelets should raise the count to 40109/L in adults; check dose needed with lab. 3 Neutrophils: Use neutropenic regimen if the count 0. 5109/L (p352). Bone marrow biopsy Gives diagnostic information where there are abnormalities in the peripheral Blood; it is also an important staging test in the lymphoproliferative disorders. Ideally take an aspirate and trephine usually from the posterior iliac crest (aspirates can be taken from the anterior iliac crest or sternum). The aspirate provides a fi lm which is examined by microscope. The trephine is a core of bone which allows assessment of bone marrow cellularity, architecture, and the presence of infi ltrative disease (eg neoplasia). Coagulation disorders may need to be corrected pre-biopsy.",
    "Coagulation disorders may need to be corrected pre-biopsy. Apply Hypertension afterwards (lie on that side for 12h if platelets are Low). Aplastic anaemia This is a rare (5 cases per million/year) stem cell disorder in which bone marrow stops making cells, leading to pancytopenia. Presents with features of anaemia (hemoglobin), infection (WCC), or bleeding (platelets). Causes: Most cases are autoimmune, triggered by drugs, viruses (eg parvovirus, hepatitis), or irradiation. May also be inherited, eg Fanconi anaemia (p698). Tests: Bone marrow biopsy is diagnostic. Treatment: Mainly supportive in asymptomatic patients. Transfuse Blood products as required and initiate neutropenic regimen if count 0. 5109/L (p352). The treatment of choice in young patients with severe disease is allogeneic marrow transplantation from an HLA-matched sibling, which can be curative. Otherwise, immunosuppression with ciclosporin and antithymocyte globulin may be eff ective, although it is not curative in most. There is no clear role for G-CSF. __OOHHCCMM__1100ee. . iinnddbb 336644 0022//0055//22001177 1199: : 0077 365 ygolotameaH Fig 8. 66 Haematopoiesis and Sods law. When we contemplate a diagram like this (of seemingly galactic complexity) we, being doctors, think What can go wrong? With a sinking feeling we realize that every arc is an opportunity for multiple disasters. Perhaps, using the Hammer of Los (p322) and our own ingenuity we might occasionally complete these pathways without Sod intervening (Sods law states that if something can go wrong, it willhere Sods tubercular breath is seen blowing the red cell line off courseTB is a famous cause of leukoerythroblastic anaemia). When we realize that every day each of ultrasound makes 175 billion red cells, 70 billion granulocytes, and 175 billion platelets we sense that Sod is smiling to himself with especial relish. Anything can go wrong. Everything can go wrong. This latter we call aplastic anaemia. Agranulocytosis is when the Southerly arcs go wrong; thrombocytopenia when the West-pointing arcs go wrong. To the East we have the lymphocytes and their Band T-cell complexities. Anaemia lies in the North of this diagram. And as for bleedinghow could our predecessors bear to waste a single drop of this stuff on purpose? Our minds are reeling at 175 billion red cells per daybut this is just when the system is idling. When we bleed, throughput can rise by an order of magnitudeif Sod is turning a blind eye are there suffi cient haematinics (eg iron, B12, and folate) to allow maximum haemopoiesis? Figure Aria Rad. __OOHHCCMM__1100ee. . iinnddbb 336655 0022//0055//22001177 1199: : 0077 366 ygolotameaH The myeloproliferative disorders Caused by clonal proliferation of haematopoietic myeloid stem cells in the bone marrow. These cells retain the ability to diff erentiate into RBCS, WBCS, or platelets, causing an excess of one or more of these cell types (table 8. 10). Table 8. 10 Classifi cation of myeloproliferative disorders By proliferating cell type red blood cell Polycythaemia vera (PRV) white blood cell Chronic myeloid leukaemia (CML, p358) Platelets Essential thrombocythaemia Fibroblasts Myelofi brosis Polycythaemia Relative polycythaemia (plasma volume, normal red blood cell mass) may be acute (due to dehydration) or chronic (associated with obesity, hypertension, and a High alcohol and tobacco intake). Absolute polycythaemia (red blood cell mass) is classically measured by dilution of infused autologous radioactive chromium (51Cr) labelled RBCs. Causes are primary (polycythaemia vera) or secondary due to hypoxia (eg High altitudes, chronic lung disease, cyanotic congenital Heart disease, heavy smoking) or inappropriately erythropoietin secretion (eg in renal carcinoma, hepatocellular carcinoma). Polycythaemia vera The malignant proliferation of a clone derived from one pluripotent stem cell. A mutation in JAK2 (JAK2 V617F) is present in 95%.",
    "A mutation in JAK2 (JAK2 V617F) is present in 95%. The erythroid progenitor off spring are unusual in not needing erythropoietin to avoid apoptosis. There is excess proliferation of RBCs, WBCs, and platelets, leading to hyperviscosity and thrombosis. Commoner if 60yrs old. Presentation: May be asymptomatic and detected on FBC, or present with vague symptoms due to hyperviscosity (p372): headaches, dizziness, tinnitus, visual disturbance. Itching after a hot Rice, and erythromelalgia, a burning sensation in fi ngers and toes, are characteristic. Signs: facial plethora and splenomegaly (in 60%). Gout may occur due to urate from red blood cell turnover. Features of arterial (cardiac, cerebral, peri pheral) or venous (DVT, cerebral, hepatic) thrombosis may be present. Investigations: FBC: RCC, hemoglobin, hematocrit, PCV, often also white blood cell and platelets. B12. Marrow shows hypercellularity with erythroid hyperplasia. Cytogenetics as required to diff erentiate from CML. Serum erythropoietin. Raised red cell mass on 51Cr studies and splenomegaly, in the setting of a normal PaO2, is diagnostic. Treatment: Aim to keep hematocrit 0. 45 to risk of thrombosis. In younger patients at Low risk, this is done by venesection. If higher risk (age 60yrs, previous thrombosis), hydroxycarbamide (hydroxyurea) is used. -interferon is preferred in women of childbearing age. Aspirin 75mg daily is also given. Prognosis: Variable, many remain well for years. Thrombosis and haemorrhage (due to defective platelets) are the main complications. Transition to myelofi brosis occurs in 30% or acute leukaemia in 5%. Monitor FBC every 3 months. Essential thrombocythaemia (fi g 8. 67) A clonal proliferation of megakaryocytes leads to persistently platelets, often 1000 109/L, with abnormal function, causing bleeding or arterial and venous thrombosis, and microvascular occlusionheadache, atypical chest Pain, light-headedness, erythromelalgia. Exclude other causes of thrombocytosis (see BOX). Treatment: aspirin 75mg OD. Hydroxycarbamide in High-risk patients. Myelofi brosis There is hyperplasia of megakaryocytes which produce plateletderived growth factor, leading to intense marrow fi brosis and haematopoiesis in the spleen and Livermassive hepatosplenomegaly. Presentation: Hypermetabolic symptoms: night sweats, fever, weight loss; abdominal discomfort due to splenomegaly; bone marrow failure (hemoglobin, infections, bleeding). Film: Leuko erythroblastic cells (nucleated red cells, p328); characteristic teardrop RBCS (see fi g 8. 68). hemoglobin. Bone marrow trephine for diagnosis (fi g 8. 69). Treatment: Marrow support (see p364). Allogeneic stem cell transplant may be curative in young people but carries a High risk of mortality. Prognosis: Median survival 45 years. __OOHHCCMM__1100ee. . iinnddbb 336666 0022//0055//22001177 1199: : 0077 367 ygolotameaH Causes of thrombocytosis Platelets 450 109/L may be a reactive phenomenon, seen with many conditions including: Bleeding Malignancy Post-surgery Infection Trauma Iron defi ciency Chronic infl ammation, eg collagen disorders. Fig 8. 67 Essential thrombocythaemia: many Fig 8. 68 Teardrop cells, in myelofi brosis. platelets seen. Dr Nivaldo Medeiros. Prof. Christine Lawrence. Fig 8. 69 Marrow trephine in myelo fi brosis: the streaming eff ect is caused by intense fi - brosis. Other causes of marrow fi brosis: any myeloprolife rative disorder, lymphoma, secondary carcinoma, TB, leukaemia, and irradiation. Prof. Christine Lawrence. __OOHHCCMM__1100ee. . iinnddbb 336677 0022//0055//22001177 1199: : 0077 368 ygolotameaH Myeloma: the chief plasma cell dyscrasia (PCD) PCDS are due to an abnormal proliferation of a single clone of plasma or lymphoplasmacytic cells leading to secretion of immunoglobulin (Ig) or an Ig fragment, causing the dysfunction of many organs (esp Kidney). The Ig is seen as a monoclonal band, or paraprotein, on serum or Urine electrophoresis (see later in topic). Classifi cation Based on Ig productIgG in ⅔; IgA in ⅓; a very few are IgM or IgD. Other Ig levels are Low (immunoparesis, causing susceptibility to infection).",
    "Other Ig levels are Low (immunoparesis, causing susceptibility to infection). In ⅔, Urine contains Bence Jones proteins, which are free Ig light chains of kappa (κ) or lambda (λ) type, fi ltered by the Kidney. Incidence 5/100 000. Peak age: 70yrs. : 1: 1. Afro-Caribbeans: Caucasians 2: 1. Clinical features Osteolytic bone lesions cause backache, pathological fractures and vertebral collapse. Do serum electrophoresis on all 50 with new back Pain. Hypercalcaemia may be symptomatic (p676). Lesions are due to osteoclast activation, from signalling by myeloma cells. Anaemia, neutropenia, or thrombocytopenia may result from marrow infi ltration by plasma cells, leading to symptoms of anaemia, infection, and bleeding. Recurrent bacterial infections due to immunoparesis, and also because of neutropenia due to the disease and from chemotherapy. Renal impairment due to light chain deposition (p314 p370) is seen in up to 20% at diagnosis. The light chains have a toxic and infl ammatory eff ect on the proximal tubule cells, but the damage is mainly caused by precipitation of light chains in the distal loop of Henle. Deposits may rarely be AL-amyloid (causing nephrotic syndrome, see p370). Monoclonal immunoglobulins also disrupt glomeruli. Tests Bloods: FBC: normocytic normochromic anaemia. Film: rouleaux (p328). Persistently ESR (p372). Urea and Creatinine, Ca2 (in 40%). Alk phosphate usually unless healing fracture. Bone marrow biopsy: See fi gs 8. 708. 73. Screening test: Serum and/or Urine electrophoresis. 2-microglobulin (prognostic). Imaging: X-rays: lytic punched-out lesions, eg pepper-pot skull, vertebral collapse, fractures, or osteoporosis. computed tomography or magnetic resonance imaging may be useful to detect lesions not seen on XR. Diagnostic criteria: See BOX Myeloma diagnosis. Treatment Supportive: Analgesia for bone Pain (avoid NSAIDS due to risk of renal impairment). Give all patients a bisphosphonate (clod ronate, zolendronate, or pamidronate), as they reduce fracture rates and bone Pain. Local radiotherapy can help rapidly in focal disease. Orthopaedic procedures (vertebroplasty or kyphoplasty) may be helpful in vertebral collapse. Anaemia should be corrected with transfusion, and erythropoietin may be used. Renal failure: rehydrate, and ensure adequate fl uid intake of 3L/day to prevent further light chain-induced renal impairment. Dialysis may be needed in acute Kidney injury. Infections: Treat rapidly with broadspectrum antibiotics until culture results are known. Regular IV immunoglobulin infusions may be needed if recurrent. Chemotherapy: Induction therapy with, eg lenalidomide, bortezomib, and dexamethasone. In suitably fi t patients this may be followed by autologous stem-cell transplantation. In those unsuitable for transplantation, induction therapy is typically continued for 1218 months, or until serum paraprotein levels have plateaued. Treatment is then typically held until (inevitably) paraprotein levels start to rise again, at which point further chemotherapy or stem cell transplantation may be considered. NB: lenalidomide is a teratogenic immunomodulator which has multiple SE, notably neutropenia and thromboembolism: monitor for sepsis and consider aspirin or anticoagulation if risk , eg hyperviscosity or other comorbidities. Prognosis Worse if: 2 osteolytic lesions, 2 -microglobulin 5. 5mg/L, hemoglobin 11g/L; albumin 30g/L. Risk stratifi cation increasingly based upon detection of specifi c cytogenetic abnormalities associated with High risk of progression. Causes of death: infection, renal failure. __OOHHCCMM__1100ee. . iinnddbb 336688 0022//0055//22001177 1199: : 0077 369 ygolotameaH Myeloma diagnosis Causes of bone Pain/tenderness Have a High index of suspicion, eg in Trauma/fracture (steroids risk) bone Pain or back Pain which is not Myeloma and other primary maligimproving. Check Blood fi lm and elecnancy, eg plasmacytoma or sarcoma trophoresis. Diagnostic criteria: Secondaries (eg from breast, lung etc) 1 Monoclonal Protein band in serum Osteonecrosis, eg from microemboli or Urine electrophoresis. Osteomyelitis/periostitis (eg syphilis) 2 Plasma cells on marrow biopsy.",
    "Osteomyelitis/periostitis (eg syphilis) 2 Plasma cells on marrow biopsy. Hydatid cyst (bone is a rare site) 3 Evidence of end-organ damage Osteosclerosis, eg from hepatitis C from myeloma: Pagets disease of bone Hypercalcaemia. Sickle cell anaemia Renal insuffi ciency. Renal osteodystrophy Anaemia. CREST syndrome/Sjögrens syndrome 4 Bone lesions: a skeletal survey after Hyperparathyroidism. diagnosis detects bone disease: XTests: PSA, ESR, Ca2, LFT, electrophoresis. rays of chest; all of spine; skull; pelvis Treatment: Treat the cause; bisphosph- ± Tc-99m MIBI and PET (p739). onates NSAIDS may control symptoms. Complications of myeloma Hypercalcaemia (p676). This occurs with active disease, eg at presentation or r elapse. Rehydrate vigorously with IV saline 0. 9% 46L/d (careful fl uid balance). IV bisphosphonates, eg zolendronate or pamidronate, are useful for treating hypercalcaemia acutely. Spinal cord compression (p466). Occurs in 5% of those with myeloma. Urgent magnetic resonance imaging if suspected. Treatment is with dexamethasone 816mg/24h PO and local radiotherapy. Hyperviscosity (p372) causes reduced cognition, disturbed vision, and bleeding. It is treated with plasmapheresis to remove light chains. Acute renal injury is treated with rehydration. Urgent Dialysis may be needed. Fig 8. 70 Myeloma bone marrow: many plasma Fig 8. 71 Marrow section in myelo ma, stained cells with abnormal forms. with IGG kappa monoclonal antibody. Courtesy of Prof. Christine Lawrence. Courtesy of Prof. Christine Lawrence. (a) (b) Fig 8. 72 An IGG kappa paraprotein monoclonal Fig 8. 73 Plasma cells in myeloma. (a) marrow band (immunofi xation electrophoresis; a consmear, (b) peripheral smear. Note rouleaux fortrol sample has run on the left). mation of red cells (p328 p368). Courtesy of Prof. Christine Lawrence. Courtesy of Prof. Tangün Dr Körogˇlu. __OOHHCCMM__1100ee. . iinnddbb 336699 0022//0055//22001177 1199: : 0077 370 ygolotameaH Paraproteinaemia Paraproteinaemia denotes the presence in the circulation of immunoglobulins produced by a single clone of plasma cells. The para Protein is recognized as a monoclonal band (M band) on serum electrophoresis. 9 There are six major categories: 1 Multiple myeloma See p368. 2 Waldenströms macroglobulinaemia This is a lymphoplasmacytoid lymphoma producing a monoclonal IgM paraprotein. Hyperviscosity is common (p372), with CNS and ocular symptoms. Lymphadenopathy and splenomegaly are also seen. ESR, with IgM paraprotein on serum electrophoresis. : None if asymptomatic. Chlorambucil, fl udarabine, or combination chemotherapy may be used. Plasmapheresis9 for hyperviscosity (p372). 3 Primary amyloidosis See following topic. 4 Monoclonal gammopathy of uncertain signifi cance (MGUS) is common (3% 70yrs). There is a paraprotein in the serum but no myeloma, 1° amyloid, macroglobulinaemia, or lymphoma, with no bone lesions, no Bence Jones Protein, and a Low concentration of paraprotein, with 10% plasma cells in the marrow. Some develop myeloma or lymphoma. Refer to a haematologist (? for marrow biopsy). 5 Paraproteinaemia in lymphoma or leukaemia Eg seen in5 % of CLL. 6 Heavy chain disease Neoplastic cells produce free Ig heavy chains. chain disease is most important, causing malabsorption from infi ltration of bowel wall (immunoproliferative small intestine diseaseIPSID). It may progress to lymphoma. Amyloidosis This is a group of disorders characterized by extracellular deposits of a Protein in abnormal fi brillar form, resistant to degradation. The following are the systemic forms of amyloidosis. Amyloid deposition is also a feature of Alzheimers disease, type 2 Diabetes mellitus, and haemodialysis-related amyloidosis. AL amyloid (primary amyloidosis) Proliferation of plasma cell clone Amyloidogenic monoclonal immunoglobulins Fibrillar light chain Protein deposition Organ failure Death. Associations: myeloma (15%); Waldenströms, lymphoma. Organs involved: Kidneys: glomerular lesionsproteinuria and nephrotic syndrome. Heart: restrictive cardiomyopathy (looks sparkling on echo), arrhythmias, angina. Nerves: peripheral and autonomic neuropathy; carpal tunnel syndrome. Gut: macroglossia (big tongue), malabsorption/weight, perforation, haemorrhage, obstruction, and hepatomegaly.",
    "Nerves: peripheral and autonomic neuropathy; carpal tunnel syndrome. Gut: macroglossia (big tongue), malabsorption/weight, perforation, haemorrhage, obstruction, and hepatomegaly. Vascular: purpura, especially periorbitala characteristic feature (fi g 8. 74). : optimize nutrition; PO melphalan prednisolone extends survival. High-dose IV melphalan with autologous stem cell transplantation may be better. AA amyloid (secondary amyloidosis) Here amyloid is derived from serum amyloid A, an acute phase Protein, refl ecting chronic infl ammation in rheumatoid arthritis, UC/Crohns, familial Mediterranean fever, and chronic infectionsTB, bronchiectasis, osteomyelitis. It aff ects kidneys, Liver, and spleen (fi g 8. 75), and may present with proteinuria, nephrotic syndrome, or hepatosplenomegaly. Macroglossia is not seen; cardiac involvement is rare (ventricular hypertrophy and murmurs). : manage the underlying condition optimally. Familial amyloidosis (Autosomal dominant, eg from mutations in transthyretin, a transport Protein produced by the Liver. ) Usually causes a sensory or autonomic neuropathy ± renal or cardiac involvement. Liver transplant can cure. Diagnosis: Made with biopsy of aff ected tissue, and positive Congo Red staining with apple-green birefringence under polarized light microscopy. The rectum or subcutaneous fat are relatively non-invasive sites for biopsy and are ve in 80%. Prognosis: Median survival is 12 years. Patients with myeloma and amyloidosis have a shorter survival than those with myeloma alone. 9 Electrophoresis and plasmapheresis look as though they should share endings, but they do not: Greek phoros bearing (esis process), but aphairesis is Greek for removal. __OOHHCCMM__1100ee. . iinnddbb 337700 0022//0055//22001177 1199: : 0077 371 ygolotameaH Fig 8. 74 Periorbital purpura in amyloidosis. Prof. Christine Lawrence. Fig 8. 75 Areas of amyloid de position in Liver and spleen in amyloidosis (isotope scan). Reproduced from Warrell et al. , Oxford Textbook of Medicine, 2010, with permission from Oxford University Press. __OOHHCCMM__1100ee. . iinnddbb 337711 0022//0055//22001177 1199: : 0077 372 ygolotameaH Erythrocyte sedimentation rate (ESR) The ESR is a sensitive but non-specifi c indicator of the presence of disease. It measures how far RBCS fall through a column of anticoagulated Blood in 1h. If certain proteins cover red cells, these cause RBCS to stick to each other in columns (the same phenomenon as rouleaux, p328) so they fall faster. Causes of a raised ESR Any infl ammation (eg infection, rheumatoid arthritis, malignancy, myocardial infarction), anaemia, and macrocytosis. Caveats ESR with age. The Westergren method is a rough guide to calculate the upper limit of normal in older patients: : ESRage 2; : ESR(age 10) 2. Some conditions lower the ESR, eg polycythaemia (due to red cell concentration), microcytosis, and sickle-cell anaemia. Even a slightly raised ESR in these patients should prompt one to ask: What else is the matFig 8. 76 Hyperviscosity syndrome. ter? Management In those with a slightly raised ESR, the best plan is probably to wait a month and repeat the test. If the ESR is markedly raised (100mm/h), this can have a 90% predictive value for disease, so such patients should be thoroughly investigated, even in the presence of non-specifi c symptoms. Take a full history, examine carefully and consider these tests: FBC, plasma electrophoresis, UE, PSA, chest and abdominal imaging, ± biopsy of bone marrow or temporal artery. Plasma viscosity (PV) Normal range: 1. 501. 72mPa/s. In many labs, this has replaced the ESR, as it is less aff ected by anaemia and simpler to automate. PV is aff ected by the concentration of large plasma proteins and in the same conditions as the ESRboth PV and ESR in chronic infl ammation and are less aff ected by acute changes (unlike CRP, p686).",
    "Hyperviscosity syndrome Symptoms Lethargy; confusion; cognition; CNS disturbance; chest Pain; abdomi nal Pain (and sometimes spontaneous GI or GU bleeding); faints; visual disturbance (eg vision, amaurosis fugax, retinopathyeg engorged retinal veins, haemorrhages, exudates; and a blurred disc as seen in fi g 8. 76). The visual symptoms are like looking through a watery car windscreen. Causes of High Blood viscosity Very High red cell count (haematocrit 50, eg polycythaemia vera), white cell count (100109/L, eg leukaemia), or plasma componentsusually immunoglobulins, in myeloma or Waldenströms macroglobulinaemia (p370, as IgM is larger and so viscosity more than the same amount of IgG). Drugs: oral contraceptives, diuretics, IV IG, erythropoietin, chemotherapy, radio-contrast media. Treatment Urgent treatment is needed which depends on the cause. Venesection is done in polycythaemia. Leukapheresis in leukaemias to remove white cells. Plasmapheresis in myeloma and Waldenströms: Blood is withdrawn via a plasma exchange machine, the supernatant plasma from this is discarded, and the RBCS returned to the patient after being resuspended in a suitable medium. __OOHHCCMM__1100ee. . iinnddbb 337722 0022//0055//22001177 1199: : 0077 373 ygolotameaH The spleen and splenectomy The spleen plays a vital immunological role by acting as a reservoir for lymphocytes, and in dealing with bacteraemias. Causes of splenomegaly: (See also p604. ) Massive (enlarged to the RIF): CML, myelofi brosis, malaria (hyperreactive malarial splenomegaly), visceral leishmaniasis, tropical splenomegaly (idiopathic Africa, south-east Asia), and Gauchers syndrome. Moderate: Infection (eg EBV, endocarditis, TB, malaria, leishmaniasis, schistosomiasis). Portal hypertension (Liver cirrhosis). Haematological (haemolytic anaemia, leukaemia especially CML, lymphoma). Connective tissue disease (RA, SLE). Others: sarcoidosis, primary antibody defi ciency (OHCS p198), idiopathic. When is a mass in the left upper quadrant a spleen: (Main diff erential: enlarged left Kidney. ) The spleen: Is dull to percussion. Enlarges towards the RIF. Moves down on inspiration. You may feel a medial notch. You cant get above it (ie the top margin disappears under the ribs). Tests: Image the spleen with abdominal USS or computed tomography. Hunt for the cause of enlargement: look for lymphadenopathy and Liver disease, eg: FBC, ESR, LFT ± Liver, marrow, or lymph node biopsy. Complications: Symptoms of anaemia, infection, or bleeding can occur as a result of hypersplenism: cells become trapped in the spleens reticuloendothelial system causing pancytopenia. Splenectomy may be required if severe. Splenectomy: Main indications: splenic trauma, hypersplenism, autoimmune haemolysis: in ITP (p345), warm autoimmune haemolytic anaemia (p338), or congenital haemolytic anaemias. Mobilize early post-splenectomy as transient platelets predisposes to thrombi. A characteristic Blood fi lm is seen following splenectomy, with HowellJolly bodies, Pappenheimer bodies, and target cells (see p328). The main problem post-splenectomy is lifelong increased risk from infection. The spleen contains macrophages which fi lter and phagocytose bacteria. Post-splenectomy infection is caused most commonly by encapsulated organisms: Streptococcus pneumoniae, Haemophilus infl uenzae, and Neisseria meningitidis. Reduce this risk by giving: 1 Immunizations: Pneumococcal vaccine (p167), at least 2 weeks pre-op to ensure Good response, or as soon as possible after emergency splenectomy, eg after trauma. Re-immunize every 510yrs. Avoid in pregnancy. Haemophilus infl uenzae type b vaccine (Hib, see p391). Meningococcal vaccination course, including Men B, Men C, and Men ACWY. Annual infl uenza vaccine (p396). 2 Life-long prophylactic oral antibiotics: phenoxymethylpenicillin (penicillin V) or erythromycin if penicillin allergic. 3 Pendants, bracelets, or patient-held cards to alert medical staff. 4 Advice to seek urgent medical attention if any signs of infection: will require admission for broad-spectrum antibiotics if infection develops. 5 If travelling abroad, warn of risk of severe malaria and advise meticulous prophylaxis, with nets, repellent, and medication.",
    "5 If travelling abroad, warn of risk of severe malaria and advise meticulous prophylaxis, with nets, repellent, and medication. The advice given here also applies to hyposplenic patients, eg in sickle-cell anaemia or coeliac disease. __OOHHCCMM__1100ee. . iinnddbb 337733 0022//0055//22001177 1199: : 0077 374 ygolotameaH Thrombophilia Thrombophilia is an inherited or acquired coagulopathy that predisposes to thrombosis, usually venous: DVT or physical examination (venous thromboembolism: VTE). Special precautions are needed when there is an additional risk factor for thrombosis, eg surgery, pregnancy, or enforced rest (see BOX for other risk factors). Only 50% of patients with thrombosis and a ve family history have an identifi able thrombophilia on routine tests: others may have abnormalities that are as yet unidentifi ed. Inherited Activated Protein c (APC) resistance/factor V Leiden: Chief cause of inherited thrombophilia. Present in 5% of the population, although most will not develop thrombosis. Usually associated with a single point mutation in factor V (factor V Leiden), so that this clotting factor is not broken down by APC. Risk of DVT or physical examination is raised 5-fold if heterozygous for the mutation (50-fold if homozygous). Thrombotic risk is increased in pregnancy and those on oestrogens (OHCS p33, p257 p303). Prothrombin gene mutation: Causes High prothrombin levels and thrombosis due to down-regulation of fi brinolysis, by thrombin-activated fi brinolysis inhibitor. Protein C S defi ciency: These vitamin potassium-dependent factors act together to cleave and so neutralize factors V VIII. Heterozygotes defi cient for either Protein risk thrombosis. Skin necrosis also occurs (esp. if on warfarin). Homozygous defi - ciency for either Protein causes neonatal purpura fulminansfatal, if untreated. Antithrombin defi ciency: Antithrombin is a co-factor of heparin, and inhibits thrombin. Less common, aff ects 1: 500. Heterozygotes thrombotic risk is greater than Protein C or S defi ciency by 4-fold. Homozygosity is incompatible with life. Acquired Causes: Antiphospholipid syndrome (APL: p554)serum antiphospholipid antibodies (lupus anticoagulant ± anticardiolipin antibody) predispose to venous and arterial thrombosis, thrombocytopenia, and recurrent fetal loss. In most it is a primary disease, but it is also seen in SLE. Oral contraceptive pills/HRT (relative risk 24; related to both oestrogen and progesterone content/type). Any cause of thrombocytosis or polycythaemia may also cause thrombosis (p366). Which tests? Ask the lab. Do FBC, fi lm, clotting (patient, thrombin time, APTT, fi brinogen) ± APC resistance test, lupus anticoagulant and anticardiolipin antibodies, and assays for antithrombin and proteins C S defi ciency (± DNA analysis by protein-creatinine ratio for the factor V Leiden mutation if APC resistance test is ve, and for prothrombin gene mutation). These tests should ideally be done when the patient is well, not pregnant, and off anticoagulation for 1 month. Who? Test those with: arterial thrombosis or myocardial infarction at 50yrs old (eg for APL) unprovoked VTE (ie at 40yrs with no risk factors) VTE with oral contraceptives/ pregnancy unexplained recurrent VTE unusual site, eg mesenteric or portal vein thrombosis recurrent fetal loss (≥3) neonatal thrombosis. Who not? Those already on lifelong anticoagulation, 1st-degree relatives of people with a history of DVT/physical examination or thrombophilia except in special circumstances. There is often no benefi t to testing (ie no change to management), it is expensive and may cause signifi cant worry to patients: be sparing in requesting these tests. Treatment Anticoagulate acute thrombosis (p350). If recurrence occurs with no other risk factors, consider lifelong anticoagulation. Recurrence whilst on treatment should be treated by increasing treatment intensity (eg target INR to 34). In antithrombin defi ciency, High doses of heparin may be needed; liaise with a haematologist.",
    "In antithrombin defi ciency, High doses of heparin may be needed; liaise with a haematologist. In Protein C or S defi ciency, monitor treatment closely as skin necrosis may occur with warfarin. Prevention Lifelong anticoagulation is not needed in absence of VTE, but advise of risk with the oral contraceptive pill or HRT, and counsel as regards to the best form of contraception. Warn about other risk factors for VTE. Prophylaxis may be needed in pregnancy, eg in antiphospholipid syndrome (get expert help: aspirin and, sometimes, prophylactic heparin are used as warfarin is teratogenic, see OHCS p33). Prophylactic SC heparin may also be indicated in High-risk situations, eg presurgery. __OOHHCCMM__1100ee. . iinnddbb 337744 0022//0055//22001177 1199: : 0077 375 ygolotameaH Other risk factors for thrombosis Arterial: Venous: Smoking Surgery Hypertension Trauma Hyperlipidaemia Immobility Diabetes mellitus. Pregnancy, oral contraceptive pill, HRT Age Obesity Varicose veins Other conditions: Heart failure, malignancy, infl amma tory bowel disease, nephrotic syndrome, paroxys mal nocturnal haemoglobinuria (p338). For thrombophilia in pregnancy, see OHCS p32; for anticoagulant use in pregnancy and thromboprophylaxis, see OHCS p33. __OOHHCCMM__1100ee. . iinnddbb 337755 0022//0055//22001177 1199: : 0077 376 ygolotameaH Immunosuppressive drugs As well as being used in leukaemias and cancers, immunosuppression is required in organ and marrow transplants, and plays a role in the treatment of many diseases: rheumatoid arthritis, psoriasis, autoimmune hepatitis, asthma, SLE, vasculitis, and IBD, to name a few. Prednisolone Steroids can be life-saving, but bear in mind: Long-term steroids (3 weeks, or repeated courses) must not be stopped suddently. Risk of Addisonian crisis due to adrenal insuffi ciency, see p836. Plan a gradual taper over weeks (with the advice of an endocrinologist if needed). Certain conditions may be made worse by steroids, eg TB, hypertension, Chickenpox, osteoporosis, Diabetes: here careful monitoring is needed. Growth retardation may occur in young patients, and the elderly frequently get more SE from treatment. Interactions: effi cacy is reduced by anti-epileptics (see later in topic) and rifampicin. Caution in pregnancy (may cause fetal growth retardation). See BNF for use in breastfeeding. Side effects: Multiple and serious (see table 8. 11): minimize these by using the lowest dose possible for the shortest period of time. Prescribe calcium and vitamin D supplements to reduce risk of osteoporosis (p682) or consider bisphosphonates. Before starting long-term treatment, explain clearly the potential SE to patients and ensure they are aware of the following: Do not stop steroids suddenly (p836). Consult a doctor if unwell; steroid dose (eg if requiring antibiotics or surgery). Carry a steroid card stating dose taken, and the indication. Avoid over-the-counter drugs, eg NSAIDS: aspirin and ibuprofen (risk of DU). Exercise and smoking cessation help to prevent osteoporosis. Azathioprine SE: Diarrhoea, abdominal Pain, marrow suppression (anaemia, lymphopenia), nephritis, pancreatitis, transaminitis. Interactions: Mercaptopurine and azathioprine (which is metabolized to mercaptopurine) are metabolized by xanthine oxidase (XO). So toxicity results if full dose azathioprine co-administered with XO inhibitors (eg allopurinol). Monitoring: Local guidelines should be in place to guide; typically weekly FBC, UE, creatine, LFT during initation then 13-monthly once stable. Ciclosporin, tacrolimus Calcineurin inhibitors with important roles in reducing rejection in organ and marrow transplant. The main SE is dose-related nephrotoxicity: check Blood levels. Other SE: gum hyperplasia (ciclosporin), tremor, blood pressure (stop if ), oedema, paraesthesiae, confusion, seizures, hepatotoxicity, lymphoma, skin canceravoid sunbathing. Monitor UE and Creatinine every 2 weeks for the fi rst 3 months, then monthly if dose 2. 5mg/kg/d (every 2 months if less than this). Reduce the dose if creatinine rises by 30% on two measurements even if the Creatinine is still in normal range. Stop if the abnormality persists.",
    "When infection is organ specifi c, you may need to look elsewhere (table 9. 2). Table 9. 1 Infectious disease by pathogen (illustrative, not exhaustive) Bacteria Viruses Gram positive RNA viruses Staphylococci: Picornavirus (tiny RNA): Staph. aureus (coagulase ve) Rhinovirus Staph. epidermidis (coagulase Ωve) Poliovirus Streptococci: Calicivirus (cup), eg norwalk -haemolytic, eg Strep. pneumoniae Flavivirus (yellow): -haemolytic, eg Strep. pyogenes Dengue Zika Enterococci Yellow fever Clostridium species: Coronavirus (crown): URTI C. botulinum (botulism) Rhabdovirus (renal osteodystrophy), eg rabies C. perfringens(gas gangrene) Filovirus (thread), eg Ebola/Marburg C. tetani (tetanus) Paramyxovirus (near mucus), eg mumps C. diffi cile (diarrhoea) Gram negative DNA viruses Neisseria: Hepadnavirus (Liver DNA): hepatitis N. meningitidis (meningitis) Parvovirus (small): gastroenteritis N. gonorrheae (gonorrhea) Herpesvirus (creeping): Helicobacter pylori HSV Escherichia coli VZV Shigella species CMV Salmonella species EBV Campylobacter jejuni Fungi Klebsiella pneumoniae Candida Pseudomonas aeruginosa Pneumocystis jirovecii Haemophilus infl uenzae Cryptococcus Bordetella pertussis (whooping cough) Parasites Vibrio cholerae (cholera) Protozoa Yersinia pestis (plague) Entamoeba histolytica Mycobacteria Giardia lamblia M. tuberculosis Cryptosporidium species M. leprae Toxoplasma gondii Intracellular bacteria Plasmodium species (malaria) Chlamydia Leishmania species (leishmaniasis) Rickettsia (rickettsial disease) Trypanosoma species (trypanosomiasis) Coxiella burnetii Nematodes Spirochaetes Soil-transmitted helminths Borrelia burgdorferi (Lyme disease) Filarial disease Treponema (syphilis, yaws) Trematodes Leptospira (Weils disease) Schistosoma (schistosomiasis), fl ukes Cestodes Hydatid disease, tapeworm __OOHHCCMM__1100ee. . iinnddbb 338800 0022//0055//22001177 1199: : 0077 381 sesaesid suoitcefnI Table 9. 2 Infectious disease by organ system System Infection Page Respiratory Pneumonia pp16670 Empyemainfected pleural eff usion p170 Fungal infections of the lung p177 GI Peptic ulcer disease p252 Gastroenteritis pp42833 Colitis, proctitis, diverticulitis, appendicitis Viral hepatitis p278 Tropical Liver disease pp4345 Cholecystitis, cholangitis, gallbladder empyema p634 Peritonitis p606 GU and Lower urinary tract infection, cystitis, pyelonephritis pp2967 gynaecology Cervicitis, vulvovaginitis pp4123 Genital ulceration pp4123 Genital warts p406 Pelvic infl ammatory disease, endometritis OHCS p286 Cardiovascular Infective endocarditis pp1501 Myocarditis pp1524 Pericarditis p154 Nervous Meningitis, encephalitis, subdural empyema pp8224 system Infective neuropathy pp5045 Skin and soft Skin ulcers, gangrene pp6601 tissue Tropical skin disease pp4223 Surgical wound infection p571, p576 Bone and joint Osteomyelitis OHCS p696 Septic arthritis p544 ENT Pharyngitis, laryngitis, otitis media OHCS p564 Eye Tropical eye disease pp4389 The management of infectious disease includes prevention whenever possible. Tracing the source of disease and contacts are essential in the management of outbreaks. Notifi cation to your local health protection team (see notifi able-diseases-and-causative-organisms-how-to-report) is a statutory duty for the following conditions (only clinical suspicion is required, accuracy of diagnosis is secondary): Acute encephalitis HUS Rubella Acute infectious hepatitis Infectious dysentery SARS Acute meningitis Invasive group A strep Scarlet fever Acute poliomyelitis Legionnaires disease Small pox Anthrax Leprosy Tetanus Botulism Malaria Tuberculosis Brucellosis Measles Typhus Cholera Meningococcal sepsis Viral haemorrhagic fever Diphtheria Mumps Whooping cough Enteric fever Plague Yellow fever. Food poisoning Rabies Infectious disease resources The Hillis plot (fi g 9. 2, p379) tells ultrasound that ID chapters will always fail to be exhaustive. We therefore direct you to the following excellent resources: Public Health England, World Health Organization (WHO), Centers for Disease Control and Prevention, __OOHHCCMM__1100ee. . iinnddbb 338811 0022//0055//22001177 1199: : 0077 382 sesaesid suoitcefnI Bacterial infection: an overview Humans and bacteria are symbiotes, with each of ultrasound host to ten times as many bacterial cells as our own human cells. Our gut, skin, and mucosal linings are covered with bacteria. We rely on this for nutrition, functioning vitamin potassium, anti-infl ammatory eff ects, and immune system regulation.",
    "We rely on this for nutrition, functioning vitamin potassium, anti-infl ammatory eff ects, and immune system regulation. Bacterial disease results from a breach of the measures that limit bacteria to their normal roles: skin commensals moved into the bloodstream by a cannula, antibiotics altering the commensal microfl ora, immune system evasion or dysfunction allowing organisms to stray beyond their usual boundaries, toxin production. When treating infections we should therefore remember to look beyond the off ending organism and consider what factors may have aided pathogenesis: malnutrition, barrier breach by cancer/plastic, immunosuppression. See Sepsis, p792. Bacterial glossary Bacteria: Prokaryotic micro-organism without a membrane-bound nucleus. Classifi cation of bacteria: By microscopy and culture of infected samples. Informs antibiotic choice. Includes: Gram stain: a staining technique. Bacteria with thick, exposed peptidoglycan layers will stain Gram positive (purple/blue). Bacteria with a protected peptidoglycan layer will counterstain pink/red and are Gram negative (fi g 9. 3). Shape: cocci round; bacilli renal osteodystrophy-shaped; spiro chaete spiral. Aerobes/anaerobes: some bacteria cannot survive without oxygen (obligate aerobes), whilst others cannot grow in its presence (obligate anaerobes). Many more can survive in either environment (facultative anaerobes). Some types of infection are more likely to involve aerobic or anaerobic bacteria, eg GI infections are typi-Fig 9. 3 (a) Gram-positive versus cally anaerobic. (b) Gram-negative cell membranes. Bacteraemia: Bacteria circulating in the Reprinted by permission from Macmilbloodstream. lan Publishers Ltd: Nature Reviews Bacteriocidal: Kills bacteria both in and out Microbiology, Cabeen et al. , 3(8), 601610, of the replication cycle. copyright 2005. Bacteriostatic: Stops replication without killing existing bacteria. Capsulate bacteria: Bacteria with a thick outer capsule, eg Haemophilus infl uenzae, Neisseria meningitidis, and Streptococcus pneumoniae. These are destroyed in the spleen. Following splenectomy (or splenic infarction, eg sickle cell anaemia) there is an increased risk of infection by capsulate bacteria and prophylactic vaccination should be off ered (p407). Commensal: An organism that lives in/on a host without causing harm. Endotoxin: A lipopolysaccharide complex found on the outer membrane of Gramnegative bacteria. Can elicit an infl ammatory response. Activates complement via the alternative pathway. Enterotoxin: Exotoxin that targets the gut, eg Clostridium diffi cile toxin (p411). Exotoxin: Toxins secreted by bacteria acting at a site distant from bacterial growth. Production of an exotoxin can determine virulence, eg botulinum, tetanus, diphtheria, shiga toxins. Flagella: A tail-like appendage that moves to propel the bacterium, eg Helicobacter pylori. Nosocomial: Acquired in a hospital/healthcare setting (pp4101). Obligate intracellular: Bacteria that can only survive in host cells induce a cellmediated immune response and will not grow on standard culture media. ZiehlNeelsen stain: Mycolic acid in the cell wall of mycobacteria resists Gram staining but will appear red with acid-fast techniques ( acid-fast stain). __OOHHCCMM__1100ee. . iinnddbb 338822 0022//0055//22001177 1199: : 0077 383 sesaesid suoitcefnI Antibiotics: action and resistance The antibiotic revolution began in 1928 when a extraordinary series of fortuitous events (including a cancelled holiday and an unpredictable British summer) led to Alexander Flemings observation that a contaminating Penicillium colony caused lysis of staphylococci. Mass production and the golden age of antibiotics followed, with the introduction of a variety of drugs selectively toxic to bacterial, but not mammalian cells. This is achieved by: utilizing a target unique to bacteria, eg cell wall selectively targeting bacterial-specifi c components, eg enzymes, ribosomes preventing transport of the drug into human cells, eg metronidazole can only be transported into anaerobic bacteria. The mechanism of action of diff erent classes of antibiotic is shown in fi g 9. 4.",
    "The mechanism of action of diff erent classes of antibiotic is shown in fi g 9. 4. Folate synthesis Nucleic acid Sulfamethoxazole synthesis Cell wall synthesis Trimethoprim DNA synthesis βlactams Fluoroquinolones Penicillins Metronidazole Cephalosporins Carbapenems THF A RNA polymerase DHF A Rifamycins PABA Glycopeptides 50S 50S subunit Vancomycin 30S Macrolides Teicoplanin Clindamycin Linezolid Chloramphenicol Polymyxins 30S subunit Fusidic acid Colistin Aminoglycosides Tetracyclines Protein synthesis Fig 9. 4 Classes of antibiotics and their bacterial cell targets. This spectrum of available antibiotics revolutionized clinical practice and led to the declaration: It is time to close the book on infectious diseases, and declare the war against pestilence won (attributed in urban legend to Dr. William H Stewart, ultrasound Surgeon General, 19651969). Such confi dence failed to consider that the capacity for a prokaryotic micro-organism to develop resistance far outstrips the human capacity to develop new antibiotic drugs. Antibiotic resistance can be: Intrinsic: due to inherent structural or functional characteristics, eg vancomycin cannot cross the outer membrane of Gram-negative organisms. Acquired: bacteria have been evolving to resist antibacterial agents for billions of years through mutation and/or the transfer of resistance properties. This evolutionary phenomenon is accelerated by selection Hypertension from antibiotic use (including agriculture, aquaculture, and horticulture) which provides a competitive advantage for mutated, resistant strains. Resistance has emerged for all known antibiotics causing morbidity, mortality, and a huge cost burden worldwide. 1 Misadventure is evident. Quinolones are synthetic, resistance cannot be acquired in nature, and yet it is epidemic. Which brings ultrasound back to Alexander Fleming who, within 2 years of the massproduction of his miracle-mould, gave this sage warning in his Nobel lecture of 1945: Mr X has a sore throat. He buys some penicillin and gives himself, not enough to kill the streptococci, but enough to educate them to resist penicillin. He then infects his wife. Mrs X gets pneumonia and is treated with penicillin. As the streptococci are now resistant to penicillin the treatment fails. Mrs X dies. Who is primarily responsible for Mrs Xs death? Why Mr X, whose negligent use of penicillin changed the nature of the microbe. __OOHHCCMM__1100ee. . iinnddbb 338833 0022//0055//22001177 1199: : 0077 384 sesaesid suoitcefnI Antibiotics A guide to antibiotic prescribing Give antibiotics immediately in patients with a systemic infl ammatory response to infection. See Sepsis, p792. Start smart: 1 Do not prescribe2 antibiotics in the absence of clinical evidence of bacterial infection, or for a self-limiting condition. Take time to discuss: why an antibiotic is not the best option alternative options, eg symptomatic treatment, delayed prescribing the views and expectations of the patient safety-netting advice: what the patient should do if their condition deteriorates. 2 Take microbiological samples before prescribing, 1 especially for: hospital in-patients: review your prescription as soon as MCS result is available recurrent or persistent infection non-severe infection: consider if your prescription can wait for MCS results. 3 Follow local guidelines fi rst: best practice is informed by local epidemiology and sensitivities. 4 Consider benefi t and harm for each individual patient: Allergies: clarify the patients reactionthe true incidence of penicillin allergy in patients who report that they are allergic is 10%. In those with a confi rmed penicillin allergy, cross-reactivity with 3rd-generation cephalosporins and carbapenems is possible but rare (1%). Dose adjust for renal function and weight: use ideal body weight in extremes of body mass index (or ideal weight plus a % of excess weightsee local guidelines). Check for medication interactions. In pregnancy and lactation, see p17. 5 Prescribe the shortest eff ective course. Most antibiotics have Good oral availability.",
    "In pregnancy and lactation, see p17. 5 Prescribe the shortest eff ective course. Most antibiotics have Good oral availability. Use IV antibiotics only if in line with local or national (sepsis) guidelines. Then focus: Review the clinical diagnosis and continuing need for antibiotics at 48h for all inpatients and all patients prescribed IV antibiotics: Stop antibiotics if there is no evidence of infection. Switch from IV to oral whenever possible. Change to a narrower spectrum antibiotic whenever possible. Continue regular clinical review whilst antibiotics are prescribed. Antimicrobial stewardship In England between 2010 and 2014, antibiotic prescribing rose by 4% in general practice, 12% in hospitals, and 32% in other healthcare settings; E. coli resistance to ciprofl oxacin increased by 18%, to cephalosporins by 28%, and to gentamicin by 27%. 25 000 people in Europe die every year from antibiotic-resistant bacteria. Each year 500 000 develop drug-resistant TB. Cost is the only barrier to buying carbapenems over-the-counter in Egypt, India, and Pakistan. This will be a post-antibiotic European Renal Association. In terms of new replacement antibiotics, the pipeline is virtually dry, especially for Gram negative bacteria. The cupboard is nearly bare. Prospects for turning this situation around look dim. Dr M Chan, Director-General of WHO, March 2012. Antimicrobial stewardship2 is necessary in all healthcare settings: monitoring, evaluation, and feedback on antimicrobial prescribing, benchmarked against up-to-date local and national guidelines evaluation of High/Low levels of prescribing and prescribing outside of guidelines review of patient safety events: avoidable infection, drug reactions, complications of antibiotic therapy, eg MRSA (p388), C. diffi cile (p259, p411) education and decision support systems for all antibiotic prescribers antibiotic pack sizes that correspond to appropriate course lengths regular review of all antimicrobial policy, treatment, and prophylaxis guidelines. 1 Clinical diagnosis of Low-severity community-acquired pneumonia is an exception, see also UTI p296. __OOHHCCMM__1100ee. . iinnddbb 338844 0022//0055//22001177 1199: : 0077 385 sesaesid suoitcefnI Inhibitors of cell wall synthesis See fi g 9. 4. The bacterial cell wall is unique in nature and therefore acts as a selective target for antibiotics. Antibiotics which act on the cell wall include: -lactam antibiotics others: glycopeptides, polymyxins. -lactams: penicillins, cephalosporins, carbapenems, monobactam Contain a -lactam ring which inhibits the formation of peptidoglycan cross-links in the bacterial cell wall. Resistance occurs when the bacteria (eg staphylococci) produce a -lactamase enzyme. Penicillins: See table 9. 3. Include natural penicillins (penicillin G and V) and synthetic penicillins which are chemically modifi ed to extend their spectrum of activity, eg amoxicillin, piperacillin. In an attempt to overcome -lactamase resistance, penicillins have been combined with -lactamase inhibitors to create -lactam--lactamase inhibitor combinations eg co-amoxiclav (amoxicillinclavulanic acid), Tazocin (piperacillintazobactam). Staphylococcal resistance is conventionally defi ned by stability to meticillin, an acid-labile and IV-only equivalent of fl ucloxacillin (see MRSA p388). Cephalosporins: See table 9. 4. Contain a -lactam ring attached to a six-membered nuclear structure (fi ve in penicillin), which allows synthetic modifi cation at two sites (one in penicillin). This means that cephalosporins are the largest groups of available antibiotics. Classifi cation into generations is not standardized: as a rough rule, the higher the generation, the wider the spectrum. Carbapenems: See table 9. 5. Broadest spectrum of all -lactam antibiotics. Seek expert microbiology advice before use. Monobactam: Aztreonam is only active against Gram-negative species including Neisseria meningitidis, Haemophilus infl uenzae, Pseudomonas. Given IV/IM. Inhaled preparation for chronic pulmonary Pseudomonas (cystic fi brosis). Dose adjust for renal function. SEs: NV, GI bleed, rash, LFTS, plts, paraesthesia, seizures, bronchospasm. Non--lactam cell wall inhibitors See fi g 9. 4 and table 9. 6. Includes glycopeptides, eg vancomycin, teicoplanin, and polymyxins, eg colistin.",
    "4 and table 9. 6. Includes glycopeptides, eg vancomycin, teicoplanin, and polymyxins, eg colistin. Inhibitors of Protein synthesis See fi g 9. 4 and table 9. 7. Includes: aminoglycosides macrolides tetracyclines and derivatives of tetracycline others: clindamycin, linezolid, chloramphenicol, fusidic acid. Inhibitors of nucleic acid synthesis See fi g 9. 4 and table 9. 8. Includes: folate synthesis inhibitors: trimethoprim, co-trimoxazole fl uoroquinolones others: metronidazole, rifampicin. Nitrofurantoin is unique. Metabolites interfere with cell growth via ribosomes, DNA, RNA, and cell wall. Multiple sites of attack means resistance. Concentrates in the Urine (but not if glomerular filtration rate), used in uncomplicated UTI. SES: haemolysis, pulmonary fi brosis, hepatotoxicity. Antibiotics for TB, see pp3945. __OOHHCCMM__1100ee. . iinnddbb 338855 0022//0055//22001177 1199: : 0077 386 sesaesid suoitcefnI Antibiotics: summary tables Table 9. 3 Penicillins Antibiotic Indications Considerations Penicillin G Gram ve: streptococci (chest, Give IV, poor oral absorp- (benzylpenicillin, throat, endocarditis, cellulitis), tion. Dose adjust for glomerular filtration rate. penicillin) meningococcus, diphtheria, anSE: allergy, rash, NV, C. thrax, leptospirosis, Lyme disease. diffi cile, cholestasis. Penicillin V Prophylaxis: splenectomy/hypoOral bioavailability may (phenoxymethylpenicillin) splenism, rheumatic Heart disease. vary. Ampicillin/amoxicillin Amino acid side chain extends Ampicillin IV, amoxicillin penicillin spectrum to include PO. Dose adjust for glomerular filtration rate. enterobacteria (but activity SE: as per penicillin G, rash against Gram ve): URTI, sinusitis, with EBV. chest, otitis media, UTI, H. pylori. Amoxicillinclavulanic Used if resistance to narrowerDose adjust for glomerular filtration rate. acid (co-amoxiclav) spectrum antibiotics: chest, SE: as per amoxicillin. pyelonephritis, cellulitis, bone. Piperacillintazobactam Broad spectrum including Gram Tazobactam has ve, Gram Ωve, Pseudomonas: penetration of Blood neutropenic sepsis, hospitalbrain barrier. Dose adjust acquired/complicated infection. for glomerular filtration rate. SE: as per penicillin G. Myelosuppression with prolonged use (rare). Flucloxacillin -lactamase resistant, StaphyDose adjust for glomerular filtration rate. lococcus: skin, bone, post-viral SE: allergy, rash, NV, pneumonia. cholestasis. Table 9. 4 Cephalosporins Antibiotic Indications Considerations Cefalexin Gram ve infection: UTI, pneumonia. First-line use in (1st generation) UK due to risk of C. Cefuroxime Gram ve and Gram Ωve (Enterobacteriacediffi cile. (2nd generation) ae, H. infl uenzae): UTI, sinusitis, skin, wound. Caution: false ve urinary glucose and Cefotaxime Broad spectrum (not Pseudomonas, EnteroCoombs test. (3rd generation) coccus spp, Bacteroides). SE: allergy, rash, Ceftriaxone Meningococcus. Broad spectrum (not PseuNV, cholestasis. (3rd generation) domonas, Enterococcus spp, Bacteroides). Ceftriaxone can Ceftazidime Broad spectrum including Pseudomonas but precipitate in urinary (3rd generation) activity against Gram ve: empirical treattract and biliary tree ment of neutropenic sepsis. pseudolithiasis. Table 9. 5 Carbapenems Antibiotic Indications Considerations Imipenem Broad spectrum (Gram ve, Gram Dose adjust for glomerular filtration rate. Imipenem Meropenem Ωve, aerobes, anaerobes): hospitalgiven with cilastatin to renal Ertapenem acquired/ventilator-associated/ metabolism. complicated infection, neutropenic SE: NV, C. diffi cile, rash, eosinosepsis. philia, plts, LFTs, seizures. Table 9. 6 Lipopeptides and polymyxins Antibiotic Indication Considerations Lipopeptides Vancomycin Complicated Gram ve Dose IV to trough serum concentration. SEs: Teicoplanin including MRSA. Oral for C. nephrotoxic (monitor Creatinine, care with diffi cile (not absorbed). other nephrotoxics) ototoxic, plts. Polymyxins Colistin, Multi-resistant Gram Ωve. Nephrotoxicity in 50%. Inhaled colistin for polymyxin B ventilator-associated pneumonia. __OOHHCCMM__1100ee. . iinnddbb 338866 0022//0055//22001177 1199: : 0077 387 sesaesid suoitcefnI Table 9. 7 Inhibitors of Protein synthesis Antibiotic Indications Considerations Aminoglycosides Gentamicin Gram Ωve infection (activity SEs: nephrotoxic (monitor drug Tobramycin against most Gram ve and levels and serum Creatinine), anaerobes). Tobramycin has vestibular toxicity, ototoxicity. Amikacin activity against Pseudomonas. Amikacin has least resistance. Macrolides Azithromycin Gram ve cocci (not enterococci SEs ( with erythromycin): GI, Clarithromycin and staphylococci), syphilis, chlacholestasis, QT. Erythromycin mydia. Cytochrome P450 inhibition ( with azithromycin): warfarin, rhabdomyolysis with statins, calcineurin inhibitor levels.",
    "Erythromycin mydia. Cytochrome P450 inhibition ( with azithromycin): warfarin, rhabdomyolysis with statins, calcineurin inhibitor levels. Tetracyclines and derivatives Tetracycline Exacerbation COPD, chlamydia, CI: pregnancy, 8y (teeth/bones). Lyme disease, mycoplasma, rickSEs: NV, C. diffi cile, fatty Liver, Doxycycline ettsiae, brucella, anthrax, syphiidiopathic intracranial hypertenlis, MRSA, malaria prophylaxis. sion. Tigecycline Gram ve and Gram Ωve includDose adjust in Liver dysfunction. ing -lactam-resistant strains. SEs: NV, photosensitivity, LFTs. Other Clindamycin Gram ve cocci (not enterococci), risk C. diffi cile. MRSA, anaerobes. Linezolid Gram ve cocci, MRSA, VRE, MAOI: check interactions, myeloanaerobes, mycobacteria. suppression, optic neuropathy. Chloramphenicol Gram ve, Gram Ωve, anaerobes, Systemic use limited by myelomycoplasma, chlamydia, conjuncsuppression. tivitis (topical). Fusidic acid Staphylococci. SES: GI, LFTs. Table 9. 8 Inhibitors of nucleic acid synthesis Antibiotic Indications Considerations Folate synthesis inhibitors Trimethoprim Gram Ωve: UTI, prostatitis. Inhibits Creatinine secretion: serum Creatinine without glomerular filtration rate. Co-trimoxazole Pneumocystis jirovecii, GI Synergistic combination. Good (sulfamethoxainfection (eg Shigella, E. coli), oral absorption and tissue/ zole trimethoprotozoans (eg Cyclospora), CSF penetration. SEs: folate prim) listeria, nocardia, MRSA. defi ciency, potassium, rash, myelosuppression, haemolysis with G6PD defi ciency. Fluoroquinolones Ciprofl oxacin Broad including Pseudomonas: SEs: GI irritation, CNS eff ects ( Levofl oxacin UTI, prostatitis, atypical and seizure threshold, headache, hospital-acquired chest infection, drowsiness, mood change), physical examinationMoxifl oxacin infectious diarrhoea. ripheral neuropathy, tendinopathy (Achilles), QT, C. diffi cile. Others Metronidazole Anaerobic infection: intra-abGood oral absorption. Dose dominal, pelvic, oral, soft-tissue. adjust for Liver function. SEs: Bacterial vaginosis. C. diffi cile. Disulfi ram reaction with alcohol, inhibits warfarin metabolism. Rifamycins: Mycobacteria (TB, atypical SEs: hepatitis (monitor LFTs), GI, rifampicin, mycobacteria, leprosy), some CNS eff ects, myelosuppression, rifabutin, staphylococci, Legionella, meninred secretions (Urine, saliva, rifapentine gococcal prophylaxis. sweat, sputum, tears). __OOHHCCMM__1100ee. . iinnddbb 338877 0022//0055//22001177 1199: : 0077 388 sesaesid suoitcefnI Gram-positive bacteria Gram-positive cocci Staphylococci: Staphylococci are skin/nasal commensals in 80% of adults. They can also cause infectious disease. This produces a diagnostic challenge: are the detected organisms causing infection or a contaminating commensal? The answer may lie in the presence or absence of coagulase, an enzyme which coagulates plasma. Coagulase-negative staphylococci: eg Staphylococcus epidermidis are less virulent. Pathogenicity is likely only if there is underlying immune system dysfunction or foreign material (prosthetic valve/joint, IV line, peritoneal dialysis catheter, pacemaker). Staphylococcus aureus is coagulase positive. Presentation: 1 Toxin release causes disease distant from infection. Includes: scalded skin syndromebullae and desquamation due to epidermolytic toxins (no mucosal disease, skin loss compared to toxic epidermal necrolysis) preformed toxin in foodsudden DV (p428) toxic shockfever, confusion, rash, diarrhoea, blood pressure, acute kidney injury, multiorgan dysfunction. Tampon associated or occurs with (minor) local infection. 2 Local tissue destruction: impetigo, cellulitis, mastitis, septic arthritis, osteomyelitis, abscess, pneumonia, UTI. 3 Haematogenous spread: bacteraemia, endocarditis, metastatic seeding. Diagnosis: positive culture from relevant site of infection. Treatment: Sepsis, see p792. Drain infected foci, antibiotic (topical/oral/IV) based on illness severity and risk factors. Consider local epidemiology of resistance. If systemic treatment indicated, use -lactam whenever possible (may need to cover resistant strains until sensitivity available). Preformed toxin in food: supportive, antibiotics not usually indicated. Resistant Staphylococcus aureus: MRSA, VISA, VRSA Staph. aureus which produces -lactamase, or an altered enzyme responsible for cell wall formation, will be resistant to -lactam antibiotics (penicillins, cephalosporins, carbapenems, see p385). Resistance is usually defi ned by stability to meticillin, ie meticillin-resistant Staph. aureus (MRSA). Vancomycin resistance also exists and is classifi ed according to the amount of vancomycin needed to inhibit bacterial growth: vancomycin-intermediate Staph. aureus (VISA) and vancomycin-resistant Staph. aureus (VRSA). Resistant staphylococci cause morbidity and mortality compared to sensitive strains.",
    "aureus (VISA) and vancomycin-resistant Staph. aureus (VRSA). Resistant staphylococci cause morbidity and mortality compared to sensitive strains. Risk factors for colonization include: antibiotic exposure, hospital stay, surgery, nursing home residence. Treatment of infection (not colonization): vancomycin (for MRSA), teicoplanin. Oral agents with activity against MRSA include clindamycin, co-trimoxazole, doxycycline, linezolid. Prevention: surveillance, barrier precautions, hand-hygiene, decolonization (mupirocin 2%, chlorhexidine, tea tree oil), antimicrobial stewardship. See p384, pp41011. Streptococci: Classifi cation based on Lancefi eld group persists in terminology (fi g 9. 5). Includes: Streptococcus pyogenes (-haemolytic group A): colonizes throat, skin, anogenital tract. Range of infection: tonsillitis, pharyngitis, scarlet fever, impetigo, erysipelas, cellulitis, pneumonia, peripartum sepsis, necrotizing fasciitis. All canstreptococcal toxic shock sudden-onset blood pressure, multiorgan failure. Post-infectious complications rare: rheumatic fever (p142), glomerulonephritis (p310). Treatment: penicillin. Streptococcus agalactiae (-haemolytic group B): neonatal and peurperal infection, skin, soft tissue. Invasive disease (bacteraemia, endocarditis, osteomyelitis, septic arthritis, meningitis) usually has risk factors: diabetes mellitus, malignancy, chronic disease. Treatment: penicillin, macrolide, cephalosporin, chloramphenicol. Streptococcus milleri: if found in Blood culture look for an abscessmouth, Liver, lung, brain. Treatment: penicillin. Streptococcus pneumoniae: pneumonia (pp1668), otitis media, meningitis, septicaemia. Treatment: penicillin. Vaccination: childhood, hyposplenism, 65y (p407). Viridans streptococci: commonest cause of oral/dental origin endocarditis (p150). Streptococcus bovis: bacteraemiaendocarditis. Look for colon/Liver disease. __OOHHCCMM__1100ee. . iinnddbb 338888 0022//0055//22001177 1199: : 0077 389 sesaesid suoitcefnI Enterococci: Gut commensal. Resistance to cephalosporins and quinolones leads to nosocomial colonization and infection. Most common is Enterococcus faecalis: if found in Blood culture, assume endocarditis until proven otherwise. Treatment: intrinsic and acquired resistance including vancomycin-resistant enterococci (VRE). Seek expert help. Gram-positive bacilli Listeria: Caused by Listeria monocytogenes which lives in soil. Able to multiply at Low temperatures. Found in pâté, raw vegetables/salad, unpasteurized milk/cheese. Presentation: most asymptomatic, or mild fl u-like illness. In immunosuppressed (including elderly): gastroenteritis, local infection (abscess, osteomyelitis, septic arthritis, endocarditis, pneumonia), meningoencephalitis, life-threatening septicaemia. Listeria in pregnancy may cause mild disease in mother but transplacental infectionplacentitis, amnionitis, preterm delivery, neonatal sepsis, intrauterine death. Diagnosis: culture: Blood, placenta, amniotic fl uid, CSF. protein-creatinine ratio. Serology is nonspecifi c. Treatment: ampicillin plus gentamicin (synergistic action) for systemic disease. Also co-trimoxazole (CNS disease), macrolides, tetracycline, rifampicin, vancomycin, carbopenem. Resistant to cephalosporins which are often 1st-line empirical treatment for meningitis so remember additional antimicrobial cover if listeria is a possibility. Clostridia: Clostridium diffi cile, see p259, p411. Clostridium perfringens: Gastroenteritis, see p430. Gas gangrene due to exotoxin production (alpha toxin most common). Previously Clostridium welchii. Presentation: sudden, severe Pain due to myonecrosis, tissue crepitus, systemic shock. Most post surgery (GI, biliary), or following soft-tissue trauma/open fracture. If spontaneous, look for malignancy. Treatment: early recognition, surgical debridement, Protein synthesis inhibitors, eg clindamycin inhibit toxins penicillins. Hyperbaric O2 unproven in trials (fi g 9. 4, table 9. 7). Clostridium botulinum, see p436. Clostridium tetani, see p436. Diphtheria: Caused by Corynebacterium diphtheriae toxin. Preventable with vaccine. Presentation: tonsillar pseudomembrane with fever, painful dysphagia, cervical lymphadenopathy (see OHCS p158). Diagnosis: culture, toxin detection, protein-creatinine ratio. Treatment: antitoxin within 48h. Benzylp enicillin/erythromycin. Airway support. Actinomycosis: Due to Actinomyces israelii, a mucous membrane commensal. Presentation: subacute granulomatous/suppurative infection adjacent to mucous membrane. Diagnosis: culture. Sulphur granules in pus/tissue are pathognomonic. Treatment: antibiotics covering actinomycetes and concomitant microbes. Nocardia: Rare cause of disease. Presentation: tropical skin abscess, lung/brain abscess, disseminated infection if immunosuppressed. Treatment: usually co-trimoxazole. Anthrax: See p424. Fig 9. 5 Streptococci are grouped by haemolytic pattern (, , or non-haemolytic), by Lancefi eld antigen (AG), or by species. Rebecca Lancefi eld (18951981) is shown with her hand lens, typing streptococci with a variety of M Protein-specifi c antibodies.",
    "Rebecca Lancefi eld (18951981) is shown with her hand lens, typing streptococci with a variety of M Protein-specifi c antibodies. Her lab became known as the Scotland Yard of Streptococcal Mysteries after she found that the most grievous crimes of streptococci almost always involve M as a secret accomplice. Although she arrested M on many occasions, M outlived her, and still stalks our wards and clinics. Dr V Fischetti, Rockefeller University, NY. __OOHHCCMM__1100ee. . iinnddbb 338899 0022//0055//22001177 1199: : 0077 390 sesaesid suoitcefnI Gram-negative bacteria Gram-negative cocci Neisseria: Neisseria meningitidis (meningococcus) is an upper respiratory tract commensal in 10% (25% adolescents) adhering to non-ciliated epithelial cells in nasopharynx and tonsils. Person-to-person transmission via droplets or upper respiratory tract secretions. Most strains are harmless but induce immunity. Pathogenic, virulent strains are mostly encapsulated and have the potential to cause septicaemia and meningitis. Serogroups A, B, C, W and Y account for nearly all invasive forms. Group C following introduction of vaccination in UK. in serotype W in UK since 2009. Incubation 27d. Peak ages: 2yr, 18yr. Risk factors: complement system defects, hyposplenism, HIV. Presentation: 1 Meningitis (50% cases). Main proliferation of bacteria is in CSF. Insidious onset with malaise, nausea, headache, Vomiting. May be misdiagnosed as gastroenteritis, URTI, or childhood viral illness. Later meningism: headache, Vomiting, nuchal/ back rigidity, photophobia, altered consciousness. Complications in up to 20%: sensorineural hearing loss, impaired vestibular function, epilepsy, diff use brain injury. 2 Meningococcaemia. Symptoms/signs depends on amount of circulating bacteria. Mild disease presents with fever, macular rash (fi g 9. 6) but no signs of shock. High-grade meningococcaemia (30% cases) causes pyrexia and septic shock within 612h due to rapidly escalating endotoxin levels: circulatory failure, coagulopathy with skin haemorrhage (fi g 9. 7), thrombosis of extremities/adrenals, acute kidney injury, ARDS. Meningism may be absent. Complications: amputation, skin necrosis, pericarditis, arthritis, ocular infection, pneumonia (especially serotypes Y and W), permanent adrenal insuffi ciency. Fig 9. 7 Massive skin haemorrhage with fulmiFig 9. 6 Macular lesions on legs. nant meningococcal septicaemia. Reproduced from Warrell et al. Oxford Textbook Reproduced from Warrell et al. Oxford Textbook of Medicine, 2010, with permission from Oxford of Medicine, 2010, with permission from Oxford University Press. University Press. Diagnosis: Start treatment immediately if meningitis/meningococcal sepsis is a possible diagnosis. Do not wait for confi rmation: delay can be deadly. Intraand extracellular diplococci on microscopy of CSF/Blood/skin lesion. protein-creatinine ratio of CSF/Blood/ skin lesion. Treatment: urgent antibiotic treatment: benzylpenicillin, ceftriaxone (see pp8223). Cefotaxime, chloramphenicol, meropenem also bactericidal. Prevention: routine infant vaccination against capsular group C in UK. Capsular group B vaccine in UK infants since 2015: induces bacteriocidal antibodies, no population data, duration of protection unknown. Quadrivalent ACWY vaccine at age 14 and if High-risk travel. Additional B, C, ACWY doses if hyposplenism and complement defi ciency. Prophylaxis of contacts: ciprofl oxacin/ceftriaxone (single dose), or rifampicin 600mg BD for 48h. Neisseria gonorrhoea: see pp4123. Moraxella catarrhalis: Colonizes upper respiratory tract in children ( in adults). Resembles Neisseria commensal so may be overlooked. Presentation: pneumonia, exacerbation of COPD, up to 20% of acute otitis media, sinusitis. Bacteraemia is rare. Diagnosis: culture of sputum, ear eff usion, sinus aspirate, Blood. Hockey puck sign: colonies can be pushed along agar surface without disruption. Treatment: macrolide, cephalosporin. __OOHHCCMM__1100ee. . iinnddbb 339900 0022//0055//22001177 1199: : 0077 391 sesaesid suoitcefnI Gram-negative bacilli Enterobacteriaceae: Enterobacteriaceae family is large: 50 genera, 170 named species. In the clinical setting, 3 species make up 8095% of isolates: 1 Escherichia coli: part of normal colonic fl ora. Pathogenic forms can cause: Intestinal disease: Enterotoxigenic: a major cause of travellers diarrhoea (pp4289).",
    "Pathogenic forms can cause: Intestinal disease: Enterotoxigenic: a major cause of travellers diarrhoea (pp4289). Enterohaemorrhagic: diarrhoea, haemorrhagic colitis eg O157: H7 (p431). Enteropathogenic: infants in areas of poor sanitation. Enteroinvasive: dysentery-like syndrome. Enteroadherent: travellers diarrhoea, chronic diarrhoea in children/HIV. Extra-intestinal disease: usually patients own fl ora that is not pathogenic in the intestine but causes disease elsewhere: UTI (pp2967); neonatal meningitis; nosocomial infection: pneumonia, meningitis, sepsis. Treat according to sensitivity: trimethoprim, ampicillin, cephalosporin, ciprofl oxacin, aminoglycoside. 2 Klebsiella pneumoniae: colonizes skin, nasopharynx, GI tract, hospitalized patients. Associated with antibiotic exposure, in-dwelling catheters, immunosuppression. Causes pneumonia (necrotizing disease and sepsis if immunosuppressed). Also UTI, nasopharyngeal infl ammation. Treat according to sensitivity: aminoglycoside, cephalosporin, carbapenem, quinolone. 3 Proteus mirabilis: gut commensal. Causes UTI (pp2967). Stone formation due to urease production: breaks down urea to produce ammonia, struvite stones (infection stones) then form in the presence of magnesium, calcium, and phosphatephate (pp6389). Other Enterobacteriaceae include Salmonella, Shigella, Yersinia: see enteric fever (p415), gastroenteritis (pp42831), plague (p425). Resistance: widespread antibiotic use has led to the development of highly virulent, multiple resistant E. coli and Klebsiella species including: extended-spectrum -lactamase (ESBL) producing Enterobacteriaceae. Resistant to penicillins, cephalosporins, fl uoroquinolones, trimethoprim, tetracycline, with possible extension to other antibiotic groups carbapenem-resistant Enterobacteriaceae (CRE). Resistance requires antimicrobial stewardship (p384), surveillance, robust infection control, research into resistance risk and transmission (p383). Pseudomonas aeruginosa: Found in environment. Spread by contact/ingestion. Presentation: important cause of nosocomial infection. Infection if compromised tissue, eg wound, pneumonia with lung disease or ventilation, UTI with catheterization. Septicaemia if immunosuppressed. Treatment: options include ceftazidime/carbapenem, aminoglycoside, colistin. Combination may be needed. Impermeability of membrane and biofi lm colonization lead to antibiotic resistance. Multidrug-resistance. Seek expert help. Haemophilus infl uenzae: Divided into encapsulated, typeable forms (a-f); and unencapsulated, non-typeable forms. Upper respiratory tract carriage, transmitted by droplets. H. infl uenzae b (Hib) causes meningitis, epiglottitis, otitis media, pneumonia, cellulitis, septic arthritis, and bacteraemia. Fatal in 5%. Routine immunization in childhood and splenectomy/hyposplenism (p407). Non-typeable forms cause pneumonia and sinusitis. Treatment: amoxicillin, macrolide, cephalosporin, chloramphenicol, rifampicin. Whooping cough: Bordetella pertussis. Presentation: catarrhal phase 12wk, then paroxysmal coughing. Whoop is a breath through partially closed vocal cords, seen mainly in children. Cough is prolonged (100 day cough). Infants have complications/mortality. Diagnosis: protein-creatinine ratio nasal/throat swab. Culture sensitivity 1060%. Treatment: macrolides infectivity, but may not alter disease course. Routine childhood vaccination. Vaccination in pregnancy placental antibody transfer to protect neonate (p407). Other: Brucellosis (p424), cholera (p430), melioidosis (p414). __OOHHCCMM__1100ee. . iinnddbb 339911 0022//0055//22001177 1199: : 0077 392 sesaesid suoitcefnI Tuberculosis (TB): presentation Epidemiology 9. 6 million new cases/yr of which 37% are unreported/undiagnosed (fi g 9. 8). 3. 3% of new cases, and 20% of previously treated cases are drug resistant (p395). Co-infection with HIV in 12% of new cases. Leading cause of death worldwide, 1. 5 million deaths/yr. Eff ective diagnosis and treatment saved 43 million lives between 2000 and 2014. UK: 8000/yr, 12 per 100 000. 73% born outside UK, 70% in deprived areas, 30% with pulmonary disease wait 4 months from symptoms to treatment. Fig 9. 8 Estimated TB incidence rate worldwide. Reproduced with permission from World Health Organization, Global tuberculosis report 2016. World Health Organization 2016. Pathophysiology Caused by infection with Mycobacterium tuberculosis. Active infection occurs when containment by the immune system (T-cells/macrophages) is inadequate. It can arise from primary infection, or re-activation of previously latent disease. Transmission of TB is via inhalation of aerosol droplets containing bacterium. This means only pulmonary disease is communicable. Latent TB is infection without disease due to persistent immune system containment (ie granuloma formation prevents bacteria growth and spread).",
    "Latent TB is infection without disease due to persistent immune system containment (ie granuloma formation prevents bacteria growth and spread). Positive skin/Blood testing (p394) shows evidence of infection but the patient is asymptomatic and noninfectious (normal sputum/CXR). 2 billion persons worldwide (⅓ of worlds population) are estimated to have latent TB. Lifetime risk of reactivation is 510%. Risk factors for reactivation: new infection (2y), HIV, organ transplantation, immunosuppression (including corticosteroids), silicosis, illicit drug use, malnutrition, High-risk settings (homeless shelter, prison), Low socio-economic status, haemodialysis. Presentation TB, or not TBthat is the question. Maintain a High index of suspicion. TB can aff ect any organ in the body (table 9. 9). Table 9. 9 UK TB case reports by site of disease Site of disease Number of cases in UK (%) Pulmonary 4096 (52) Extra-thoracic lymph nodes 1874 (24) Intra-thoracic lymph nodes 916 (12) Pleural 673 (9) Gastrointestinal 432 (6) Spine 353 (5) Other bone 220 (3) Miliary 211 (3) Meningitis 172 (3) F 20 ro 14 m: R T e u p b o e r r t c, ul P o u s b is l i i c n t H h e e a U lt potassium h Genitourinary 145 (2) England. www. gov. uk/phe __OOHHCCMM__1100ee. . iinnddbb 339922 0022//0055//22001177 1199: : 0077 393 sesaesid suoitcefnI Clinical features of TB Systemic features: Low-grade fever, anorexia, weight loss, malaise, night sweats, clubbing (bronchiectasis), erythema nodosum (p562). Pulmonary TB: Cough (in 50%, 23 weeks, dry then productive), pleurisy, haemoptysis (uncommon, seen with bronchiectasis not always active disease), pleural eff usion. An aspergilloma/mycetoma (p177) may form in the cavities. Presentation varies and may be silent or atypical, especially with immunosuppression, eg HIV, post-transplantation. Tuberculous lymphadenitis: (Usually) painless enlargement of cervical or supraclavicular lymph nodes. Axillary and inguinal node involvement less common. Coexisting systemic symptoms in 4050%. Node is typically fi rm to touch and not acutely infl amed (cold abscess). Skin can adhere to the underlying mass with risk of rupture and sinus formation. Can occur with or without pulmonary disease. Investigate with fi ne-needle aspiration, AFB staining, and culture (p394). Gastrointestinal TB: Most disease is ileocaecal. Causes colicky abdominal Pain and Vomiting. Bowel obstruction can occur due to bowel wall thickening, stricture formation, or infl ammatory adhesions. Biopsy is required for diagnosis. calciumseation necrosis and an absence of transmural cracks/fi ssures distinguish from Crohns disease. Spinal TB: Local Pain and bony tenderness for weeksmonths. Slow, insidious progression. May not present until deformity or neurological symptoms. Look for bony destruction, vertebral collapse, and soft tissue abscess (see Potts vertebra p708). Miliary TB: Haematogenous dissemination leads to the formation of discrete foci (2mm) of granulomatous tissue throughout the lung (millet seed appearance). CXR: fi g 9. 9. Dissemination is throughout the body with meningeal involvement in 25%. Sputum may be negative for AFB as spread is haematogenous. Have a Low threshold for LP. Untreated mortality is assumed to be close to 100%. Do not delay treatment while test results are pending. CNS TB: Haematogenous spread leading to foci of infection in brain and Fig 9. 9 Miliary TB (nodular opacities). spinal cord. Foci can enlarge to form Dr Vijay Sadasivam, Radiologist, SKS Hosp, Salem, tuberculomas. Foci rupture leads to Tamil Nadu, India. meningitis. Risk with immune suppression, HIV, aged 3y. Headache, meningism, confusion, seizures, focal neurological defi cit, and systemic symptoms. Needs LP and examination of CSF (leucocytosis, raised Protein, CSF: plasma glucose 50%, AFB stain, protein-creatinine ratio and culture). Look for TB elsewhere (CXR, etc), test for HIV. computed tomography/ magnetic resonance imaging may show hydrocephalus, basal exudates.",
    "Look for TB elsewhere (CXR, etc), test for HIV. computed tomography/ magnetic resonance imaging may show hydrocephalus, basal exudates. Tuberculomas are ring-enhancing. All rapid diagnostic tests (p394) have sensitivity, so treat on suspicion. Genitourinary TB: Symptoms may be chronic, intermittent, or silent. Include dysuria, freque ncy, loin Pain, haematuria, sterile pyuria (see p296). Granuloma may cause fi brosis, strictures, infertility, and genital ulceration. Cardiac TB: Usually involves the pericardium: pericarditis, pericardial eff usion, and/or constrictive pericarditis (p154). Check chest imaging for other TB pathology, eg pulmonary disease, mediastinal lymph nodes. Pericardiectomy may be indicated for persistent constriction despite anti-tuberculous treatment. Myocardial involvement (arrhythmias, Heart failure, ventricular aneurysm, or outfl ow obstruction) is rare. Skin: Lupus vulgaris persistent, progressive, cutaneous TB: red-brown, applejelly nodules. Scrofuloderma: skin lesion extended from underlying infection eg lymph node, bone; causes ulceration and scarring. __OOHHCCMM__1100ee. . iinnddbb 339933 0022//0055//22001177 1199: : 0077 394 sesaesid suoitcefnI Tuberculosis (TB): diagnosis and treatment Diagnostic tests for TB Latent TB: Off er testing3 to close contacts of those with pulmonary or laryngeal TB, those with immune dysfunction, healthcare workers, and High-risk populations, eg prison, homeless, vulnerable migrants. Tuberculin skin testing (TST) Mantoux test. Intradermal injection of purifi ed Protein derivative (PPD) tuberculin. Size of skin induration is used to determine positivity depending on vaccination history and immune status (5mm if risk factors, 15mm if no risk factors). Interferon-gamma release assays (IGRAS) diagnose exposure to TB by measuring the release of interferon-gamma from T-cells reacting to TB antigen. Specifi city compared to TST if history of BCG vaccination. Neither test can diagnose or exclude active disease (falsely negative in 2025% of active disease): clinical evaluation is required. Immune-suppressed states reduce the sensitivity of both tests. Active pulmonary TB: CXR. Fibronodular/linear opacities in upper lobe (typical), middle or lower lobes (atypical), cavitation, calcifi cation, miliary disease (see fi g 9. 9), eff usion, lymphadenopathy. Sputum smear. Sputum can be spontaneously produced or induced (with nebulized saline and precautions to prevent transmission). Three specimens are needed including an early-morning sample. It is stained for the presence of acid-fast bacilli (AFB). All mycobacteria are acid-fast including M. tuberculosis. If AFB are seen, treatment should be commenced and the patient isolated (in hospital only if clinical indication, or public health reason for admission; or at home). Sputum culture. More sensitive than smear testing. Culture takes 13 weeks (liquid media) or 48 weeks (solid media). Can assess drug sensitivity. Nucleic acid amplifi cation test (NAAT). Direct detection of M. tuberculosis in sputum by DNA or RNA amplifi cation. Rapid diagnosis (8hrs). Can also detect drug resistance (see p395). Extra-pulmonary TB: Investigate for coexisting pulmonary disease. Obtain material from aspiration or biopsy (lymph node, pleura, bone, synovium, GI/GU tract) to enable AFB staining, histological examination (caseating granuloma) and/or culture. NAAT can be carried out on any sterile body fl uid, eg CSF, pericardial fl uid. Offer HIV test for all. Treatment Antibiotics used in the treatment3 of TB are detailed in table 9. 10. Table 9. 10 Antibiotics used in the treatment of TB Standard course for Antibiotic Notes active disease Rifampicin 2 months intensive Enzyme inducer: care with warfarin, calcineurin 4 months continuation inhibitors, oestrogens, phenytoin; body secretions coloured orange-red (includes contact lens staining); altered Liver function. Isoniazid 2 months intensive Inhibits formation of active pyridoxine (Vit B6) 4 months continuation which causes a peripheral neuropathy (risk with diabetes mellitus, chronic kidney disease, HIV, malnutrition) give with prophylactic pyridoxine; hepatitis. Pyrazinamide 2 months intensive Idiosyncratic hepatotoxicity, dose if estimated glomerular filtration rate30. Ethambutol 2 months intensive Colour blindness, visual acuity, optic neuritis.",
    "Ethambutol 2 months intensive Colour blindness, visual acuity, optic neuritis. Check visual acuity at start of treatment, monitor for symptoms. Monthly visual check if treatment 2 months. Monitor levels if estimated glomerular filtration rate30. __OOHHCCMM__1100ee. . iinnddbb 339944 0022//0055//22001177 1199: : 0077 395 sesaesid suoitcefnI Latent TB Balance the risk of development of active disease with the possible side-eff ects of treatment. Consider treatment in all at risk of active disease: HIV, transplantation, chemotherapy, biological agents eg anti-TNF (see p265), Diabetes, chronic kidney disease including dialysis, silicosis, bariatric surgery, and recent close contact with pulmonary/laryngeal TB. Off er HIV, hepatitis B and C testing prior to treatment. Treat with 3 months of isoniazid (with pyridoxine) and rifampicin OR 6 months of isoniazid (with pyridoxine). If concerns about hepatotoxicity then 3 months of isoniazid and rifampicin may be preferred. In severe Liver disease, seek specialist advice. If interactions with rifamycins are a concern (eg HIV, transplant) then 6 months of isoniazid may be preferred. Active TB All forms of active TB are statutorily notifi able in UK. This includes both clinical and culture diagnoses. Notifi cation is via your local public health protection team (www. gov. uk/health-protection-team). Treatment is given under the care of a specialist TB clinician/service according to table 9. 10. Exceptions include: active CNS disease (including spinal cord involvement): continuation phase of treatment is extended from 4 to 10 months CNS and pericardial disease: use adjunctive High-dose steroids (with weaning and withdrawal during the intensive treatment period) drug-resistant TB. Adherence is important for treatment to be eff ective and to prevent drug resistance. Directly observed therapy (DOT) should be considered if: previous treatment for TB, homelessness, drug/alcohol misuse, prison, psychiatric or cognitive disorder, multidrug resistant disease, patient request. Universal access to diagnosis and treatment of TB is part of social justice. WHO has developed an End TB strategy aiming to reduce TB deaths by 90% by 2030, and TB incidence by 90% by 2035 (www. who. int/tb/strategy/en). Drug-resistant TB NAAT (p394) for drug resistance should be requested for all patients with risk factors for drug-resistance: previous TB treatment, contact with drug-resistant disease, birth or residence in a country where ≥5% new cases are drug resistant (fi g 9. 10). Drug resistance may be: to any single agent in table 9. 10. multidrug-resistant TB (MDR-TB): resistant to rifampicin and isoniazid. extensively drug-resistant TB (XDR-TB): resistant to rifampicin, isoniazid, one injectable agent (capreomycin, kanamycin or amikacin) and one fl uoroquinolone. If rifampicin resistance is detected, treat with at least six agents to which the mycobacterium is likely to be sensitive. Test for resistance to 2nd-line drugs. Remember infection control measures. Seek expert advice for all drug-resistant cases. Fig 9. 10 Percentage of new TB cases with multi-drug resistant TB. Reproduced with permission from World Health Organization, Global tuberculosis report 2016. World Health Organization 2016. __OOHHCCMM__1100ee. . iinnddbb 339955 0022//0055//22001177 1199: : 0077 396 sesaesid suoitcefnI Infl uenza Infl uenza is common throughout the world, aff ecting 510% of adults, and 2030% of children each year. In most, it is a self-limiting illness. Complications can be lifethreatening in the elderly, pregnant women, and those with chronic disease. There are 4 million cases of severe infl uenza and 500 000 deaths worldwide/yr. Seasonal infl uenza Acute viral infection of lungs and airways. Rapid person-to-person spread by aerosolized droplets and contact. Infectivity from 1d prior, to 7d after symptoms. Includes three subtypes of virus: A, B, and C. Type A infl uenza is subdivided according to combinations of virus surface proteins eg A(H1N1), A(H3N2). Seasonal epidemics peak during the winter in temperate countries.",
    "Seasonal epidemics peak during the winter in temperate countries. Acquired immunity is specifi c to the virus subtype. Presentation: Incubation: 14d. Fever, dry cough, sore throat, coryzal symptoms, headache, malaise, myalgia, conjunctivitis, eye Pain ± photophobia. Complications include pneumonia, exacerbation of chronic lung disease, croup, otitis media, DV, myositis, encephalitis, Reye syndrome (encephalopathy fatty degenerative Liver failure). Diagnosis: Clinical: acute onset cough fever has positive predictive value 79%. Testing limited to outbreaks, and public health surveillance. Includes: viral protein-creatinine ratio, rapid antigen testing, viral culture of clinical samples (throat swab, nasal swab, nasopharyngeal washings, sputum). Treatment: Uncomplicated infl uenza symptomatic treatment eg paracetamol. Antivirals only if High risk: Chronic disease: lung, Heart, Kidney, Liver, CNS, diabetes mellitus Immunosuppression: immunodefi ciency, current or planned or within 6 months of immunosuppressive therapy, CD4 (200 in adults, 500 if child 5yr) Pregnancy 65yr body mass index40 6 months old. Complicated infl uenza includes lower respiratory tract infection, exacerbation of any underlying medical condition, all needing hospital admission. Give antiviral4 inhibitors of infl uenza neuraminidase: 1 Oseltamivir: P O or NG. Adult dose: 75mg BD. 5d course. 1st line in UK. 2 Zanamivir: inhaled (10mg BD, 5d course, confi rm technique), nebulized, or IV (respiratory disease aff ecting nebulizer delivery, ITU). Used if: oseltamivir resistance (eg A(H1N1)), poor clinical response to oseltamivir, concerns re GI absorption of oseltamivir. Retrospective observational data, and animal studies of oseltamivir and zanamivir show no evidence of harm in pregnancy. Supportive treatment for all. Extracorporeal membrane oxygenation (ECMO) has been used to support gas exchange in severe acute lung injury due to infl uenza. Prevention: Post-exposure prophylaxis: if High risk (see Treatment) AND not protected by vaccination: oseltamivir PO OD (inhaled zanamivir OD if oseltamivir resistance) for 10d. Annual vaccination in UK: all High risk (see Treatment), children2yrs, healthcare workers. See p407. Pandemic infl uenza Seasonal infl uenza is subject to antigenic drift: small genetic changes during replication which can be accounted for in the annual vaccine. Antigenic shift is a major change in infl uenza A resulting in new haemgglutinin (H) and neuraminidase proteins (N) for which there is no pre-existing immunity in the population. Any nonhuman infl uenza viruses which transfer to humans are novel. If they also have, or develop, capacity for rapid human-to-human transmission a pandemic results. Based on previous pandemics, up to 50% of the UK population may become infected leading to 20 000750 000 excess deaths. __OOHHCCMM__1100ee. . iinnddbb 339966 0022//0055//22001177 1199: : 0077 397 sesaesid suoitcefnI Sailing the choppy waters of pandemic infl uenza Pandemic infl uenza is the stormy sea of clinical medicine. Like sailors, we know there are deadly challenges to come, but we cannot predict their exact timing or nature. To prepare a boat for the tempestuous waters ahead, the mast is key; without it the sails are unsupported and progress will fl ounder. The mast of pandemic infl uenza is a tall, vertical spar which produces maximum drive through the swell, and allows sailors to climb up High to see what the horizon has in store. When preparing for pandemic infl uenza, we must make for ourselves a spar of principles and plans fi t for the storm ahead: Surveillance, planning, and communication: worldwide infl uenza virological surveillance has been conducted through the WHO for 50yr. It off ers a global alert mechanism for viruses with pandemic potential and defi nes methodologies for assessing antiviral susceptibility. Cooperation between international and national public health bodies is required for an understanding of clinical characteristics and disease spread.",
    "Where HIV prevalence is 2/1000 universal testing by GPs and medical admissions units should be considered. Any request for a HIV test should be met. With complications of immune system dysfunction: See pp4001. HIV testing The prognosis for patients with HIV in the UK is much better than for many other serious illness for which doctors routinely test. HIV testing6 should not be viewed diff erently. Any doctor can consent for a HIV test: explain the benefi ts of testing and detail how results will be given. Written consent is unnecessary. Arrange follow-up with a local HIV/GUM service within 2 weeks (preferably 48h) for patients testing positive for the fi rst time. ELISA for HIV antibody and antigen (p24): 4th-generation assays test for HIV antibody and p24 antigen. This reduces the window period (time of false-negative testing between infection and the production of measurable antigen/antibody) to average 10 days. Diagnosis in UK is confi rmed by a confi rmatory assay. Rapid point-of-care testing: Immunoassay kit which gives a rapid result from a fi nger-prick or mouth swab. Only CE-marked kits should be used. Needs serological confi rmation. Viral load: Quantifi cation of HIV RNA. Used to monitor response to ART. Not diagnostic due to possibility of a false-positive result care if used to test for symptomatic primary HIV in the window periodconfi rmation of seroconversion is still required. Nucleic acid testing/viral protein-creatinine ratio: Qualitative test for the presence of viral RNA. Used to test for vertical transmission in neonates as placental transfer of maternal antibodies can aff ect ELISA antibody testing up to 18 months of age. CD4 count: Cannot diagnose HIV. Used to monitor immune system function and disease progression in patients with HIV. 200 cells/microlitre is one of the defi ning criteria for AIDS. See www. aidsmap. com for available HIV testing and country-specifi c resources. Needle-stick injury Risk of HIV transmission from a single needle-stick exposure from a person with HIV not on ART is 1 in 300 (lower than risks of hepatitis B and C transmission). Prevent: Use safer sharps (incorporates a mechanism to minimize accidental injury). Do not recap unprotected medical sharps. When using sharps, ensure there is a disposal container nearby. Manage: Encourage the wound to bleed, ideally under running Water (do not suck). Wash with soap and running Water, do not scrub. Seek advice from occupational health/infection control (or AE outside of working hours) regarding source testing and post-exposure prophylaxis (p398). __OOHHCCMM__1100ee. . iinnddbb 339999 0022//0055//22001177 1199: : 0077 400 sesaesid suoitcefnI Complications of HIV infection Complications of HIV can be divided into: complications of immune dysfunction (opportunistic infection/malignancy) complicating comorbidity complications of treatment, ie adverse drug eff ects (see pp4023). The diff erential diagnosis for symptoms presenting in a person with HIV is given in table 9. 11. This is not exhaustive. Do not forget your usual diff erentials, the presentation may not relate to the patients HIV status. Opportunistic disease ART is part of the treatment regimen of all opportunistic infections (see pp4023). Pneumocystis jirovecii: (yee-row-vet-zee) Presentation: progressive SOB on exertion, malaise, dry cough. Haemoptysis and pleuritic Pain rare. Examination: respiratory rate, often normal breath sounds. Investigation: SpO 2 (compare rest and exertion). CXR: classically perihilar infi ltrates (fi g 9. 12), but may be normal. Induced sputum or BAL with staining or nucleic acid amplifi cation. Treatment: IV co-trimoxazole (convert to oral if favourable response). 21-day course. Steroids in moderatesevere disease (PO9. 3KPa/SpO92%). 2nd-line: clindamycin, pentaa 2 2 midine, atovaquone. Prophylaxis: co-trimoxazole if CD4 200 cells/microlitre. Candidiasis: Oral or oesophageal. Pain in the tongue, dysphagia, odynophagia. Diagnosed clinically or endoscopically.",
    "Prophylaxis: co-trimoxazole if CD4 200 cells/microlitre. Candidiasis: Oral or oesophageal. Pain in the tongue, dysphagia, odynophagia. Diagnosed clinically or endoscopically. Treated with systemic -azole, eg fl uconazole. Cryptococcus neoformans: Commonest systemic fungal infection in HIV (510% pre-ART). Presentation: meningitis: headache, fever, meningism variable. May be associated skin (molluscum-like papules) and lung disease. Investigation: LP with manometry. CSF stain (India ink), CSF/Blood cryptococcal antigen. Treatment: induction with liposomal amphotericin B (SE: renal tubular damage and acute kidney injury). Addition of fl ucytosine has shown benefi t in patients not on ART (SE: haematological toxicity). Maintenance treatment with fl uconazole. Normalize ICP with repeat LPs/shunt. Toxoplasma gondii: Toxoplasma abscesses are commonest cause of intracranial mass lesions when CD4 200 cells/microlitre. Presentation: focal neurological signs ± seizures. Headache and Vomiting if raised ICP. Investigation: ring-enhancing Bloodsions on magnetic resonance imaging ( lymphoma) with associated oedema. CSF protein-creatinine ratio for T. gondii is specifi c but only moderately sensitive. Blood serology is not diagnostic as most cases are a reactivation of previous infection. Treatment: consider in any brain mass lesion with CD4 200 cell/microlitre. Pyrimethamine, sulfadiazine, folinic acid. Cytomegalovirus (CMV): Severe primary or reactivated disease (see p405). Presentation: retinitis (blurred then loss of vision), encephalitis, GI disease (oesophagitis, colitis), hepatitis, bone marrow suppression, pneumonia. Diagnosis: serial CMV viral load, retinal lesions (p438), GI ulceration, owls eye inclusions on biopsy. Treatment: ganciclovir/valganciclovir. Side-eff ects: rash, diarrhoea, bone myelosuppression. Cryptosporidium: Common cause of chronic diarrhoea in HIV pre-ART. Presentation: acute or sub-acute non-bloody, watery diarrhoea. Also cholangitis, pancreatitis. Investigation: stool microscopy (multiple samples as oocyst excretion intermittent), protein-creatinine ratio, enzyme immunoassay, direct fl uorescent antibody. Treatment: supportive, ART. Kaposis sarcoma: Most common tumour in HIV and AIDS defi ning. Caused by ketoanalogueposi sarcoma herpes virus (human herpesvirus 8, p405). Presentation: cutaneous or mucosal lesions: patch, plaque, or nodular. Visceral disease less common. Investigation: histological confi rmation. Treatment: ART. Intralesional retinoids or vinblastine. Radiotherapy for cosmesis/Pain. Chemotherapy (ART) in advanced disease. Lymphoma: Increased risk of non-Hodgkins lymphoma in HIV. Includes: diff use large B-cell lymphoma, Burkitts lymphoma, primary CNS lymphoma. Presentation: dependent upon area of involvement. Includes lymphadenopathy, cytopenia, CNS symptoms. Treatment: combined ART and chemotherapy. Rituximab for non-CNS disease. Whole-brain radiotherapy for CNS disease if excess toxicity with chemotherapy. __OOHHCCMM__1100ee. . iinnddbb 440000 0022//0055//22001177 1199: : 0077 401 sesaesid suoitcefnI Fig 9. 12 Bilateral interstitial infi ltrates in P. jirovecii. Reproduced from Lim, Acute Respiratory Infections, 2012, with permission from Oxford University Press. Complicating comorbidity Cardiovascular disease: Increased risk of cardiovascular disease in HIV. Includes individuals where risk traditionally lower: younger age, normotensive, no diabetes mellitus, non-obese. Contributing factors: dyslipidaemia caused by ART, acceleration of pro-atherosclerotic infl ammatory processes by HIV. Management of CV risk factors although no outcome data to guide specifi c lipid and blood pressure targets in HIV. Bone disease: Increased risk of Low bone-mineral density and fragility fractures in HIV. Contributing factors: side eff ect of ART, increased prevalence of risk factors, eg poor nutrition, smoking, alcohol, Low vitamin D levels. Risk assess and consider bisphosphonate. TB: All patients with TB and HIV need ART (as soon as TB treatment tolerated and within 2 weeks if CD4 100 cells/microlitre). Seek expert advice and refer to local guidelines. Consider Truvada plus efavirenz as 1st line in UK (serum levels of integrase inhibitors are decreased by rifampicin). See ART, pp4023, TB, pp3945. Hepatitis B (HBV): Co-infection requires an ART regimen including antivirals with anti-HBV activity, eg tenofovir plus emtricitabine (not lamivudine or emtricitabine as a single agent due to potential for emergence of HBV resistance).",
    "Hepatitis C (HCV): Assess all with HIV for HCV treatment. Pegylated interferon effi - cacy is less with lower CD4 count. Aim for CD4 500 cells/microlitre with ART fi rst. Table 9. 11 Diff erential diagnoses in HIV Presentation Diff erential diagnosis Fever Intraoral abscess, sinusitis, pneumonia, TB, endocarditis, meningitis, encephalitis, pyomyositis, lymphoma, immune-reconstitution after commencement of ART, any non-HIV cause. Lymphadenopathy Persistent generalized lymphadenopathy (p399), TB, syphilis, histoplasmosis, cryptococcus, lymphoma, Kaposis sarcoma, local infection. Rash Drug reaction, herpes zoster, scabies, cutaneous cryptococcus or histoplasmosis, Kaposis sarcoma, seborrhoeic dermatitis. Cough/SOB Community-acquired pneumonia, Pneumocystis jirovecii, TB, bronchial compression (TB, lymphoma, Kaposis sarcoma), pulmonary Kaposis sarcoma (uncommon), cardiac failure (HIV cardiomyopathy, infective pericardial eff usion, HIV vasculopathy). Diarrhoea Salmonella, Shigella, Clostridium diffi cile, amoebiasis, Giardia, Cryptosporidia, CMV, HIV enteropathy is a diagnosis of exclusion. Abdominal Pain TB, CMV colitis, pancreatitis (CMV, TB or secondary to ART). Do not forget a pregnancy test. Dysphagia Candidiasis, HSV. Liver enzymes Viral hepatitis (A, B, C, CMV, HSV, EBV), drug-induced Liver injury (anti-TB or ART), HIV cholangiopathy, lymphoma, congestion due to cardiac disease (pericardial eff usion? ). acute kidney injury Pre-renal due to sepsis/dehydration, interstitial nephritis secondary to medication, HIV-associated nephropathy (proteinuria, chronic kidney disease). Headache/ Meningitis (bacterial, TB, cryptococcal, syphilis), empyema, spaceseizures/focal occupying lesion (toxoplasmosis, lymphoma, tuberculoma), adverse neurology drug reaction, HIV encephalopathy, progressive multifocal leukoencephalopathy (PML), stroke (HIV vasculopathy). See p517. Eye disease Herpes zoster, CMV retinitis. See pp4389. Peripheral ART, CMV, HIV neuropathy, nutritional defi ciency. neuropathy __OOHHCCMM__1100ee. . iinnddbb 440011 0022//0055//22001177 1199: : 0077 402 sesaesid suoitcefnI HIV: antiretroviral therapy (ART) Antiretroviral therapy (ART)7 is recommended for everyone with HIV, regardless of CD4 count. Strategic Timing of AntiRetroviral Treatment (START) study, 2015 4685 participants (215 sites, 35 countries) with HIV, CD4 500 cells/microlitre, no previous ART. Randomized to: immediate ART deferred ART until CD4 350 cells/microlitre or AIDS-defi ning illness. Study was terminated early when an independent interim analysis revealed benefi t to immediate initiation of ART, and recommended that patients on the deferred group start ART. Immediate initiation of ART reduced the risk of AIDS, serious non-AIDS events, or death by 57% (CI 3870%) at 3 years. Aims of ART To reduce the HIV viral load to a level undetectable by standard laboratory techniques leading to immunological recovery, reduced clinical progression, and reduced mortality. These aims should be met with the least possible side-eff ects. Mechanism of action (See fi g 9. 13. ) CCR5 antagonists inhibit the entry of the virus into the cell by blocking the CCR5 co-receptor. Nucleos(t)ide and non-nucleoside reverse transcriptase inhibitors (NRTIs, NNRTIs) inhibit reverse transcriptase and the conversion of viral RNA into DNA. Integrase strand transfer inhibitors (INSTIs) inhibit integrase and prevent HIV DNA integrating into the nucleus. Protease inhibitors (PIs) inhibit protease, an enzyme involved in the maturation of virus particles. Pharmacokinetic enhancers/boosters increase the eff ectiveness of antiretroviral drugs allowing lower doses eg cobicistat, ritonavir. Starting treatment Seek expert help. Infectious T T CCR5 antagonist virion Entry to cell Maturation PI HIV RNA NRTI Reverse Proteins NNRTI transcriptase HIV DNA INSTI Fig 9. 13 Mechanism of action of ART. T T T T T T T T T T T T T T T T T T T T T T T T T T T T T T T T 1 Counselling: HIV transmission and sexual health, benefi ts of therapy (not cure), adherence (life long), resistance, side-eff ects of treatment, necessary monitoring, disclosure to partner/family/friends, partner testing. 2 Screen for infections and malignancy (pp4001). Includes TB, hepatitis BC. Treat or off er prophylaxis with co-trimoxazole if CD4 200 cells/microlitre.",
    "Includes TB, hepatitis BC. Treat or off er prophylaxis with co-trimoxazole if CD4 200 cells/microlitre. For latent TB see p395. Aim to start ART within 2 weeks of initiation of antimicrobial treatment for opportunistic or serious infection (seek expert advice if drug interactions or intracerebral disease). 3 Baseline tests: CD4, viral load, FBC, LFT, electrolytes, Creatinine, pregnancy test, viral genotype for drug resistance. 4 Review usual medications for possible drug interactions. Advise the patient to check for drug interactions with any new medication. See www. hiv-druginteractions. org __OOHHCCMM__1100ee. . iinnddbb 440022 0022//0055//22001177 1199: : 0077 403 sesaesid suoitcefnI What to start Use local guidelines. Get expert help. For a treatment-naive patient consider two nucleoside reverse transcriptase inhibitors (NRTI backbone) plus one of: ritonavir-boosted protease inhibitor non-nucleoside reverse transcriptase inhibitor integrase inhibitor. 1st line drugs commonly used in the UK include: NRTI backbone: Tenofovir and emtricitabine (combination tabletTruvada), abacavir and lamivudine (combination tabletKivexa). Side-eff ects: GI disturbance, anorexia, pancreatitis, hepatic dysfunction (severe lactic acidosis with hepatomegaly and hepatic steatosis reported, caution with hepatitis B/C), bonemineral density. Avoid abacavir if High risk of cardiovascular disease. Avoid tenofovir if estimated glomerular filtration rate 30. Protease inhibitors: Atazanavir, darunavir. Side-eff ects: hyperglycaemia, insulin resistance (mainly 1st-generation drugs), dyslipidaemia, jaundice, and hepatitis. NNTRI: Rilpivirine (give with food, interaction with proton pump inhibitors), efavirenz (CNS toxicity, association with suicidality care in depression/anxiety, adverse lipid profi Blood). Other side-eff ects: rash, GI disturbance. Integrase inhibitor: Dolutegravir, elvitegravir, raltegravir. Side-eff ects: rash, GI disturbance, insomnia. Monitor: adherence (see BOX Adherence), adverse eff ects (LFTs, glucose), virological response (viral load). CD4 counts guide prophylaxis of opportunistic infection (values may not correlate with virological response, use viral load preferentially). Adherence Adherence to ART is associated with drug resistance, disease progression, and death. Adherence support should be integral to ART provision. Assess: Ask about adherence in a non-judgemental way. Do not blame. Explain the reasoning behind your questions. Is non-adherence due to practical problems or healthcare beliefs? Be ready to address both. What help would your patient like? Intervene: Normalize the situationdoubts and concerns about ART are common. Find time for discussion/information. Address concerns. Simplify the dosage regimen, off er a multicompartment medication system. Link the taking of medication to a regular daily activity. Discuss side-eff ects: what are the risks/benefi ts to changing dose or ART regimen? Resource-limited settings In many resource-limited settings, universal access to ART remains an objective yet to be achieved. 50% of those in need of treatment for HIV do not receive it. Interim prioritization of those with symptomatic HIV or CD4 count 350 cells/ microlitre may be appropriate as these patients are at High risk of mortality and have most short-term benefi t from ART. Equality in the treatment of HIV requires: Eff ective, acceptable, and reliable methods to reduce HIV transmission, including treatment as prevention. Rapid, accurate, and Low-cost diagnosis and monitoring. Standardization and simplifi cation of ART regimens. Evidence-based ART to prevent the use of sub-standard protocols which compromise treatment and lead to the emergence of drug-resistant strains. Reduced ART costs and/or eff ective allocation of resources. An HIV vaccine? Vaccines are the most eff ective way to prevent infectious disease. They can also be therapeutic, clearing a virus after infection. HIV vaccines to date have failed to induce an immune response suffi cient to confer protection. Research is ongoing into neutralizing HIV antibodies, peptides, genes, viral vectors, physiological boosters, and mechanisms to counter the mutational evolution of HIV. See www. hvtn. org __OOHHCCMM__1100ee. .",
    "See www. hvtn. org __OOHHCCMM__1100ee. . iinnddbb 440033 0022//0055//22001177 1199: : 0077 404 sesaesid suoitcefnI Herpes viruses Herpes simplex virus (HSV) (human herpesvirus 1 and 2) Includes HSV1 and HSV2. HSV1 infection in ⅔ of worlds population (3. 7 billion 50yrs), and HSV2 in 11% (400 million). Viruses multiply in epithelial cells of mucosal surface producing vesicles or ulcers. Lifelong latent infection when virus enters sensory neurons at infection site. Can then reactivate, replicate, and infect surrounding tissue. Disseminated infection if impaired T-cell immunity: pneumonitis, hepatitis, colitis. Presentation: Primary infection: subclinical or sensory nerve (tingling) prodrome, then vesicles, shallow ulcers. Systemic symptoms possible: fever, malaise, lymphadenopathy. Heals 812d. Reactivation: usually severe unless immunosuppressed. Anatomy of infection: Herpes labialis: cold sore lesion at lip border, predominantly HSV1. Genital herpes: predominantly HSV2 (see p412). Gingivostomatitis: fever, sore throat followed by tender oropharyngeal vesicles. Keratoconjunctivitis: corneal dendritic ulcers. Avoid steroids. See OHCS p416. Herpetic whitlow: painful vesicles on distal phalanx due to inoculation through a break in the skin. Herpes encephalitis: most common treatable viral encephalitis. Transfer of virus from peripheral site to brain via neuronal transmission. Prodrome: fever, malaise, headache, nausea. Then encephalopathy: general/focal signs of cerebral dysfunction including psychiatric symptoms, seizure, focal neurology (temporal involvement in 60%), memory loss. Predominantly HSV1 in immunocompetent patients. Secondary infection: eg HSV infection of eczematous skineczema herpeticum. Diagnosis: Clinical diagnosis. Confi rmation required in encephalitis, keratoconjunctivits, or immunosuppression: viral protein-creatinine ratio of CSF, swab, or vesicle scraping. Also culture, immunofl uorescence, serology. Treatment: Aciclovir: symptoms and viral shedding, will not prevent latent infection. Give empirical IV aciclovir as soon as HSV encephalitis is suspected, mortality 70% in untreated disease (see p824). Varicella zoster virus (VZV) (human herpesvirus 3) Primary infection transmitted by respiratory droplets. Incubation 1421d. Invades respiratory mucosa, replicates in lymph nodes. Disseminates via mononuclear cells to infect skin epithelial cells. Leads to virus containing vesicles Chicken pox. Virus then remains dormant in sensory nerve roots. Reactivation is dermatomal shingles. Presentation: Chicken pox: prodrome 12d: fever, malaise, headache, abdominal Pain. Then rash (fi g 9. 14): pruritic, erythematous maculesvesicles, crust in 48h. Infectious 12d pre-, to 5d post-rash development (lesions scabbed). Complications in immunosuppression: encephalitis (cerebellar ataxia), VZV pneumonia, transverse myelitis, pericarditis, purpura fulminans/DIC. Shingles: painful, hyperaesthetic area, then Fig 9. 14 Chicken pox (VZV). macularvesicular rash in dermatomal distri- D A Warrell. bution. Disseminated infection if immunosuppressed. Infectious until scabs appear. Chicken pox risk in non-immune contacts. Complications: post-herpetic neuralgia, Ramsay Hunt syndrome (p501). Diagnosis: Clinical diagnosis unless immunosuppressed: viral protein-creatinine ratio, culture, immunofl uorescence. Treatment: Oral aciclovir/valaciclovir for uncomplicated Chicken pox/shingles in adults, aim to give within 48h of rash. IV aciclovir if pregnant, immunosuppressed, severe/disseminated disease (including ocular). Prevention: Vaccination: not routine in children in UK, given at aged 70 to prevent shingles reactivation. VZV immunoglobulin if non-immune exposure in immunosuppression, pregnancy, neonates. __OOHHCCMM__1100ee. . iinnddbb 440044 0022//0055//22001177 1199: : 0077 405 sesaesid suoitcefnI Epstein-Barr virus (EBV) (human herpesvirus 4) Virus targets circulating B lymphocytes (lifelong latent infection) and squamous epithelial cells of oropharynx. Presentation: Usually asymptomatic infection in childhood. Infectious mononucleosis in 50% of primary infection in adults: sore throat, fever, anorexia, lymphadenopathy (esp. posterior triangle of neck), palatal petechiae, splenomegaly, hepatomegaly, jaundice. Malaise is prominent. Resolution of symptoms usually within 2 weeks. Chronic active infection and recurrence are rare. Oncogenicity: see BOX Oncogenic viruses. Diagnosis: Blood fi lm: lymphocytosis. Atypical lymphocytes (large, irregular nuclei) also occur in other viral infection (CMV, HIV, par vovirus, dengue), toxoplasmosis, typhus, leukaemia, lymphoma, drug reactions, lead poisoning.",
    "Heterophile antibody tests (eg Monospot, Paul-Bunnell) detect non-EBV heterophile antibodies which are present in 85% of infectious mononucleosis sera. False positive: pregnancy, autoimmune disease, lymphoma/leukaemia. Serology: IgM to EBV viral capsid antigen in acute infection. IgG if past infection. Reverse transcriptase viral protein-creatinine ratio. Treatment: Supportive. Seek expert help if severe disease/immunosuppression: observational data on the use of antivirals and steroids. Cytomegalovirus (CMV) (human herpesvirus 5) 50100% of adults are seropositive depending on socioeconomic and sexual risk. Latent infection: periodic, asymptomatic (but infectious) viral shedding in bodily fl uids including Blood transfusion, transplantation (CMVve donor to CMVΩve recipient). Presentation: Asymptomatic in most. Symptoms mimic infectious mononucleosis (see earlier in topic) or hepatitis. Severe disease in immunosuppressed (post-transplantation, HIV): oesophagitis, gastritis, colitis, retinitis (p438), pneumonitis, hepatitis. Infection in pregnancy is associated with congenital abnormality. Diagnosis: Primary infection in immunocompetent: IgM. Immunosuppressed: quantitative nucleic acid amplifi cation testing (QNAT) in Blood greater than a defi ned threshold, or rising titre. Invasive disease: tissue QNAT, histopathology. Treatment: Given in severe infection/immunosuppression. Ganciclovir, valganciclovir (oral bioavailability). Foscarnet and cidofovir: nephrotoxicity limit use. Preemptive treatment in transplant patients based on QNAT results. Risk/benefi t for antivirals/immunoglobulin in pregnancy remains unclear. Use CMVΩve, irradiated Blood for transfusion if immunosuppressed and at risk: transplant, HIV, leukaemia. Other herpes viruses Human herpesvirus 6 (HHV6): Roseola infantum, febrile illness without rash. Human herpesvirus 8 (HHV8): Oncogenic (see BOX Oncogenic viruses), Castlemans disease. Oncogenic viruses 12% of human cancers are caused by viruses, 80% of these occur in Lowand middle-income countries (table 9. 12). Common traits of oncoviruses: Virus is necessary but not suffi cient to cause cancer. Cancers appear in context of chronic infection, taking years-decades to appear. Immune system has variable role: cancers are associated with both immunosuppression and chronic infl ammation. Table 9. 12 Oncogenic viruses Virus Cancers EBV (HHV4) Burkitts lymphoma, Hodgkins lymphoma, B-cell lymphoma in immunosuppression, gastric cancer, nasopharyngeal cancer, posttransplantation lymphoproliferative disease (PTLD) HHV8 Kaposis sarcoma (p400) and primary eff usion lymphoma HPV Cancers of: cervix, anus, vulva, penis, head, neck, oropharynx (p406) Hepatitis B and C Hepatocellular carcinoma (p278) HTLV-1 Human T-lymphotropic virusadult T-cell leukaemia MCV Merkel cell polyomavirusMerkel cell carcinoma __OOHHCCMM__1100ee. . iinnddbb 440055 0022//0055//22001177 1199: : 0077 406 sesaesid suoitcefnI Other viruses Respiratory tract viruses Include rhinovirus, coronovirus, adenovirus, respiratory syncytial virus (RSV). Transmission by direct contact, infected fomites, airborne droplets. Presentation: Coryza, pharyngitis, croup, bronchiolitis, pneumonia. Diagnosis: Clinical. Viral culture, antigen detection, protein-creatinine ratio. Treatment: None in uncomplicated disease/immunocompetent. Limited evidence for specifi c treatments in High-risk complicated disease, immunosuppression: cidofovir for adenovirus; aerosolized ribavarin, immunoglobulin, monoclonal antibody in RSV. For infl uenza see pp3967. Human papilloma virus (HPV) 120 HPVs. Pathology: Skin warts, verrucas (HPV 1, 2). Treatment: none, topical salicylic acid, freezing. Anogenital warts (HPV 6, 11). Treatment: topical podophyllin, imiquimod; ablation. Cervical cancer (HPV 16, 18), other cancers (see p405). Vaccination in UK: only, age 1213, HPV 6, 11, 16, and 18 since 2012. Polyomavirus 100% exposure. Disease only with immunosuppression: BK virus causes renal transplant nephropathy; JC virus causes progressive multifocal leucoencephalopathy. Measles Transmitted by respiratory droplets. Incubation 1018d. Highly contagious: 95% population coverage needed for herd immunity. Presentation: Prodrome (24d): fever, conjunctivitis, coryza, diarrhoea, Koplik spots (white spots on red buccal mucosa, fi g 9. 15). Then generalized, maculopapular rash, classically face/necktrunklimbs (fi g 9. 16). Complications: Secondary infection: bacterial pneumonia, otitis media, ocular herpes simplex, oral/GI candidiasis. Acute demyelinating encephalitis: 1 in 1000, usuFig 9. 15 Koplik spots. ally within 2wk of rash. Seizures, fever, irritabilCourtesy of CDC. ity, headache, conscious level.",
    "15 Koplik spots. ally within 2wk of rash. Seizures, fever, irritabilCourtesy of CDC. ity, headache, conscious level. Subacute sclerosing panencephalitis: 510yr atrial fibrillationter infection, disturbances in intellect, personality, seizures, motor dysfunction, decerebration. No treatment available. Diagnosis: Clinical. IgM. Antigen in saliva/Urine. Treatment: Prevent with vaccination. Human immunoglobulin within 3d of exposure in nonimmune. Supportive. No benefi t shown for dexamethasone in encephalitis. Fig 9. 16 Measles rash. Mumps Reproduced from Gardiner et al. , Training in Paediatrics, 2008, with permisRespiratory droplet spread. Incubation 1421d. sion from Oxford University Press. Common cause of encephalitis pre-vaccination. Presentation: Can be subclinical. Prodrome: fever, myalgia, headache. Infection and tender Edema of salivary glands: parotid submandibular. Complications: meningoencephalitis, epididymo-orchitis if pubertal/post-pubertal infection (warm, swollen, tender testes 4d-6wk after parotitissubfertility in 10%, infertility rare), oophoritis, pancreatitis, deafness. Diagnosis: Clinical. If confi rmation needed eg meningitis/encephalitis: mumps specifi c IgM/IgA, protein-creatinine ratio. Treatment: Supportive. Rubella (German measles) Respiratory droplet spread. Presentation: Usually mild/subclinical. Prodrome: fever, conjunctivitis, rhinorrhoea. Rash: generalized, pink, maculopapular. Lymphadenopathy: occipital, cervical, post-auricular. Congenital infection: Up to 90% risk of fetal malformation in 1st trimester, sensorineural hearing loss/retinopathy in 2nd trimester. Off er IgM/IgG testing. Immunoglobulin may viraemia but will not prevent infection. Vaccinate PRE-pregnancy, live vaccines are contraindicated in pregnancy. __OOHHCCMM__1100ee. . iinnddbb 440066 0022//0055//22001177 1199: : 0077 407 sesaesid suoitcefnI Immunization Passive immunity uses pre-formed antibody to protect against infection. It offers immediate but short-lived protection. Natural passive immunity occurs in the placental transfer of maternal antibodies to the fetus; acquired passive immunity includes treatment with immunoglobulin eg hepatitis B, rabies, tetanus, varicellazoster. Active immunity follows exposure to an antigen, which generates an adaptive immune response. Natural active immunity occurs following infection. Acquired active immunity is provided by vaccination. Routine vaccinations in the UK are shown in table 9. 13. Additional vaccines are off ered to specifi c vulnerable groups (table 9. 14). Immunosuppression is a contraindication to live vaccines due to the risk of disseminated disease. Includes immunodefi ciency, immunosuppressive treatment, HIV. Inactivated vaccines can be given but the antibody response may be less: aim to give 2wks prior to immunosuppressive therapy when possible (or vaccinate whilst on treatment and considered repeat re-immunization when/if treatment complete). Table 9. 13 UK vaccination summary (live vaccine) Age (mmonths, yyears) Vaccination 2m 3m 4m 12m 2y 35y 12y 14y 65y 70y Diphtheria Tetanus Pertussis Poliomyelitis Haemophilus infl uenzae B (Hib) Pneumococcal Rotavirus Meningitis B Meningitis C Measles, mumps, rubella Infl uenza HPV 6, 11, 16, 18 Meningitis ACWY Varicella zoster Table 9. 14 Additional vaccination of specifi c groups in UK (live vaccine) Vaccination Off ered to BCG Infants/children where TB incidence 40/100 000 or parent/grandparent born in country where incidence 40/100 000, TB contacts. Hib Hyposplenism, complement disorders. Meningitis B, ACWY Hyposplenism, complement disorders. Infl uenza Hyposplenism, diabetes mellitus, chronic Heart disease, chronic respiratory disease, chronic kidney disease, chronic Liver disease, chronic neurological disease, immunosuppression, pregnancy. Pneumococcal Hyposplenism, cochlear implants, complement disorders, diabetes mellitus, chronic Heart disease, chronic respiratory disease, chronic kidney disease, chronic Liver disease, chronic neurological disease, immunosuppression. Hepatitis A, B Chronic Liver disease, haemophilia, chronic kidney disease (hepatitis B only). Pertussis Pregnancy 1632 weeks (neonatal protection). Travel Travel advice (food/Drink, insect repellent, malaria prophylaxis, condoms) is more important than vaccination. Check routine vaccinations are up to date. Vaccination depends upon area of travel and planned activities: BCG (live), rabies, yellow fever (live), hepatitis A/B, cholera, Japanese encephalitis, tick-borne encephalitis, typhoid. For up-to-date recommendations see tfortravel. nhs. uk/destinations. __OOHHCCMM__1100ee. . iinnddbb 440077 0022//0055//22001177 1199: : 0077 408 sesaesid suoitcefnI Fungi Worldwide in fungal infection with new pathogenicity, virulence, and new infective mechanisms.",
    "Incidence data limited by failures in recognition and diagnosis. Divided into superfi cial/cutaneous and systemic/invasive. Superfi cial/cutaneous mycoses Dermatophytosis: Dermatophyte fungi digest keratin. Cause infection of skin and keratinized structures, eg hair, nails. Presentation: Scale and pruritus. Skin lesion may be annular with central healing, eg ring worm, tinea corporis. Tinea pedis atrial fibrillationfects up to 15% of healthy population: skin erosions and blisters in toe web spaces, dry scale on soles. Fungal nail disease onychomycosis/tinea unguium: discolouration, nail thickening. Tinea capitis: scalp scaling, alopecia. Superfi cial candidiasis: Usually Candida albicans (fi g 9. 17), a commensal in mouth, vagina, and GI tract. Risk factors: immunosuppression, antibiotic treatment. Presentation: Oropharyngeal: white patches on erythematous background (plaque type); sore, infl amed areas (erythematous type). GU: soreness, white patches/discharge (fi g 9. 18). Skin: usually in folds/inFig 9. 17 Candida albicans. terdigital (fi g 9. 19). Courtesy of P-Y Guillaume. Malassezia: Commensals of greasy skin. Presentation: Pityriasis versicolor: scaly hypo/hyperpigmented rash with scaling (fi g 9. 20). Seborrhoeic dermatitis: scaling of face, scalp (dandruff ), anterior chest. Malassezia folliculitis: itchy, follicular rash on back and shoulders ( acne). Diagnosis: Clinical, microscopy of skin scrapings. Treatment: All superfi cial mycoses: topical -azole antifungal or terbinafi ne 14wk. Also topical nystatin and amphotericin in superfi cial candidiasis. Tinea capitis: griseofulvin, terbinafi ne, itraconazole. Nail infection requires systemic treatment (terbinafi ne, itraconazole) confi rm diagnosis, and caution re side-eff ects including hepatotoxicity. Systemic/invasive mycoses Invasive candidiasis: Typically occurs in immunocompr omised, comorbidity, or ITU settings. Genetic susceptibility likely contributes. Estimated 250 000/yr with 50 000 deaths. Candidaemia in 7/1000 ICU patients. Presentation: Risk factors for invasive fungal disease (see p409), febrile with no microbiological evidence of infection, new murmur, muscle tenderness, skin nodules. Diagnosis: (Repeated) Blood/ tissue culture. protein-creatinine ratio. Candida in respiratory secretions alone is insuffi cient. Treatment: Remove all possible catheters. Echinocandins (caspofungin, anidulafungin, micafungin), fl uconazole, amphotericin (liposomal for renal toxicity). Consider fl uconazole prophylaxis if risk factors for invasive disease (p403). Consider empirical treatment if persistent fever, unresponsive to other therapy (discuss with microbiologist, choice depends on local epidemiology, comorbidity). Cryptococcus: See HIV p400. Causes meningitis, pneumonia. Presentation: Usually immunosuppression, eg HIV, sarcoid, Hodgkins, haematological malignancy, post-transplant. History may be long, non-specifi c. Headache, confusion, ataxia, focal neurological signs, fever, cough, pleuritic Pain, SOB. Diagnosis: Indian ink CSF stain, culture Blood/CSF/BAL, antigen testing in Blood/CSF. Treatment: Amphotericin fl ucytosine, fl uconazole. Histoplasmosis: Worldwide distribution of Histoplasma, in soil contaminated with bird/bat faeces. Illness depends on host immunity, estimated 1%. Presentation: Flu-like symptoms, fever, malaise, cough, headache, myalgia, pneumonia, lung nodules/cavitation, pericarditis, mediastinal fi brosis/granuloma ( sarcoid, TB). Diagnosis: Serology, antigen testing. Treatment: Moderate-severe lung disease or any CNS involvement: amphotericin, itraconazole. Blastomycosis: Blastomyces in decomposing matter, mainly USA/Canada. Presentation: Fever, cough, night sweats, ARDS. risk of extra-pulmonary disease with immunosuppression: skin, bone, GU, CNS. Diagnosis: Culture, antigen detection (cross-reacts with histoplasmosis). Treatment: Amphotericin, itraconazole. See also: Fungi and the lung p177, Pneumocystis jirovecii p400. __OOHHCCMM__1100ee. . iinnddbb 440088 0022//0055//22001177 1199: : 0077 409 sesaesid suoitcefnI Invasive fungal infection Invasion: fungus in normally sterile tissues. Dissemination: infection of remote organs via haematogenous spread. Suspect an invasive fungal infection in: 1 Any patient with risk factors (see table 9. 15). 2 Any systemically unwell patient who fails to respond to antibiotic therapy. 3 Any persistently febrile patient with no microbiological evidence of infection. Table 9. 15 Risk factors associated with invasive fungal infection. Risk factor Includes Infection HIV, CMV, TB, colonization/inadequate treatment of superfi cial fungal disease, broad-spectrum antibiotics, prior fungal infection. Malignancy Neutropenia, mucositis, haematological malignancy.",
    "Malignancy Neutropenia, mucositis, haematological malignancy. Critical illness Mortality prediction score (eg APACHE), prolonged ITU admission, prolonged ventilation, severe trauma/pancreatitis. Catheter Central venous catheter, urinary catheter, Dialysis access, TPN. Transplantation Immunosuppressant medication, recent rejection, graft-versushost disease. Genetic Hereditary chronic granulomatous disease, abnormalities in tumour necrosis factor/interleukins/cytokines. Surgical Major surgery, GI perforation, anastomotic leak, length of transplant operation, delayed closure. Other comorbidity Any disease managed with immunosuppressive therapy, burns. Data source: Ramana KV et al. Invasive fungal infections. Am J Infectious Diseases and Microbiology 2013, 1(4); 6469. Investigations: Blood culture: three samples, diff erent sites, same sitting, aim total 4060mL Blood. Microscopyimmunohistochemistry/fl uorescence depending on site/risk. Other: antigen/antibody testing for general (eg mannan, galactomannan) and specifi c (eg cryptococcal) fungi; fungal metabolites; protein-creatinine ratio: for typing/confi rmation. Seek expert advice on empirical treatment, agent depends on local epidemiology. Facts of life for budding mycologists To the uninitiated, fungi are like bacteria, but their chitin cell walls and their knack of mitosis puts them in their own kingdom. They are larger than bacteria (eg 8μm across), and mostly reproduce by budding of germ tubes (fi g 9. 21), not by fi ssion. Yeasts occur as single cells or as clusters. Hyphae often occur in a mass of cells (called moulds). A hyphal cell with cross-walls is called a mycelium. Some yeasts are dimorphic: single cells at 37°C but forming structures called mycelia, containing fruiting bodies (hyphae), at room temperature. Fig 9. 18 Candida of the glans. Fig 9. 19 Web-space candida. Courtesy of P-Y Guillaume. Courtesy of A Huntley. Fig 9. 20 Pityriasis versicolor. Fig 9. 21 Germ tubes emerging from diReproduced from Lewis-Jones (ed), Paediatric mor ph ic Candida albicans blastospores. Dermatology 2010, with permission from Courtesy of P-Y Guillaume. Oxford University Press. __OOHHCCMM__1100ee. . iinnddbb 440099 0022//0055//22001177 1199: : 0077 410 sesaesid suoitcefnI Healthcare-associated (nosocomial) infection Healthcare-associated, or nosocomial, infections include diseases which occur: As a direct result of treatment or contact in a hospital or healthcare setting. As a result of healthcare delivered in the community. Outside a healthcare setting but are brought in by patients, staff, or visitors and transmitted to others. 725% of hospital admissions are complicated by a nosocomial infection resulting in morbidity, mortality, and cost. The causal microbe may be benign in normal circumstances, but is able to cause disease when the patient: 1 has been given broad-spectrum antibiotics (eg antibiotic-resistant organisms, Clostridium diffi cile colitis) 2 is unwell/immunosuppressed (opportunistic infection) 3 has compromised barriers (indwelling catheter/line, ventilation, surgery). Healthcare-associated infection Catheter-associated UTI: A catheter is inserted in 20% of hospitalized patients. UTI is the most common infection acquired as a result of healthcare, accounting for 19% of all healthcareassociated infection. 50% of UTIS are associated with a urethral catheter. Risk of infection is related to method of catheter insertion, duration of catheter, quality of catheter care, and patient susceptibility. To reduce risk, only catheterize if necessary: Is there obstruction? Do you need precise Urine output monitoring? Remove as soon as possible. See UTI pp2967. Infections associated with the use of intravascular access devices: Includes peripheral, central venous, and arterial catheters: tunnelled and nontunnelled. 60% of bloodstream infections are associated with intravascular devices. Risk is higher with central catheters. Infection can result from introduction of microbes during insertion, access (eg when giving IV antibiotics), or from microbes elsewhere in the body seeding to the foreign material. Organisms include Staphylococcus epidermidis (p388), Staphylococcus aureus (including meticillinresistant forms MRSA see p388), Candida species (p408), and enterococci (p389). Ensure that vascular access devices are used only when clinically indicated.",
    "Ensure that vascular access devices are used only when clinically indicated. Switch to oral treatment (fl uid, medication, nutrition) as soon as clinically appropriate. Treatment includes removal/exchange of the device whenever possible. Ventilator-associated pneumonia (VAP): VAP aff ects up to 20% of patients admitted to intensive care units. Occurs as the endotracheal tube interferes with protective upper airway refl exes and facilitates microaspiration. Risks with non-invasive ventilation. In critical illness, the oropharynx becomes contaminated with GramΩve bacteria due to antibiotic exposure, altered host defences, and changes in mucosal adherence. Access to the airway occurs via folds in the endotracheal cuff and the bacterial biofi lm is then propelled to the distal airways. Organisms include Pseudomonas aeruginosa (p391), Enterobacteriaceae (p391), and Staphylococcus aureus (p388). Clinical diagnosis has sensitivity and specifi city. Suspect if new/persistent infi ltrates on CXR plus two or more of: purulent sputum, leucocytosis (12109/L), leucopenia (4109/L), temperature 38. 3°C. Prevent by reducing colonization (mouthwash, silver-coated endotracheal tubes), nurse at 45° to aspiration risk, wean off ventilator as soon as possible. . Surgical site infection: Aff ects 5% of patients undergoing surgical procedures, contributes to ⅓ of postoperative deaths. Common organisms include Staphylococcus aureus (p388), Streptococcus pyogenes (p388), and Enterobacteriaceae when surgery involves entry to hollow viscera (p391). Prevention methods include hand hygiene, strict asepsis, MRSA screening and decolonization, hair removal, peri-operative normothermia, minimally disturbed Low adherence/transparent dressings. __OOHHCCMM__1100ee. . iinnddbb 441100 0022//0055//22001177 1199: : 0077 411 sesaesid suoitcefnI Clostridium diffi cile Gram-positive anaerobic bacillus and most common healthcare-associated pathogen. Part of colonic fl ora in 25% of healthy adults, and 2040% of hospitalized adults. Disease occurs when it converts to a vegetative (growth) state with production of enterotoxins A and B, causing colitis. Typically happens when inhibition by competing colonic fl ora is lost due to antibiotic exposure. Presentation: Watery diarrhoea, mildfulminant colitis (pseudomembranes on endoscopypseudomembranous colitis), ileus, toxic megacolon. Consider in all diarrhoea associated with antibiotic use, especially if marked neutrophilia. Diagnosis: Immunoassay for glutamate dehydrogenase (common antigen) detects all strains of C. diffi cile. Detection of toxin (toxin immunoassay, toxin gene nucleic acid amplifi cation) distinguishes infection from carriage. Management: SIGHT: Suspect, Isolate within 2h, Gloves and aprons, Hand wash with soap, Test immediately. Mild/moderate: metronidazole PO. Severe (WCC 15109/L or acute kidney injury or colitis or temperature 38. 5oC): vancomycin PO (injection preparation can be given orally and is cheaper than capsules) or fidaxomicin (cost). Non-responders: High-dose vancomycinIV metronidazole, fidaxomicin, IV immunoglubulin (no RCT data). Recurrence: (weaning) vancomycin, fi daxomicin, faecal transplantation. Management of healthcare-associated infection Identify: Screening (eg hospital admissions for MRSA) allows isolation and decolonization before harm. Be alert to new infections. Protect: Isolate multi-antibiotic-resistant microbes (eg MRSA), highly transmissible infections (eg norovirus), and High-risk groups including reverse barrier nursing (avoids transmission to, rather than from, patients, eg neutropenia). Patients with High-risk infections may need negative-Hypertension rooms (to prevent potentially infected air leaving the room), or in severe immunosuppression, positive-Hypertension rooms (to prevent potentially infected air entering the room). When many patients have the same nosocomial infection (eg norovirus) they may be barrier nursed together in dedicated bays. Treat: Refer to local guidelines, seek expert help. Initial antibiotic choice may diff er for healthcare-associated infection. Prevent: Modify risk factors, eg nutrition, post-operative incentive spirometry to reduce pneumonia risk. Use/convert to narrow-spectrum antibiotics whenever possible. Remove catheters, intravascular access devices, and wean off ventilators as soon as clinically appropriate. Take measures to person-to-person transmission: 1 Hand hygiene. Wash hands before and after each patient contact (fi g 9. 22). Alcohol-based gels are helpful but soap is needed to kill C. diffi cile spores.",
    "22). Alcohol-based gels are helpful but soap is needed to kill C. diffi cile spores. 2 Personal attire. In the UK there is a bare-below-the-elbows policy. Long hair should be tied back. In areas where infection risk is particularly High (theatre, ICU), staff change into scrubs on arrival. Fig 9. 22 Areas commonly missed when 3 Personal protective equipment (PPE). Used washing hands. for isolated patients and during proceContains public sector information licensed dures. Includes gloves, aprons, caps, resunder Open Government Licence v3. 0, www. piratory protection/mask according to risk, whatdotheyknow. com/request/21861/response/56086/ eg FFP3 respirators in aerosolized infection. attach/3/04072 Hand Hygiene 5 1. 1. pdf 4 Procedures. Strict aseptic techniques for any procedure which breaches the bodys defences including insertion/maintenance of invasive devices, IV infusions, wound care. 5 Environment. Should be clean and safe, with eff ective decontamination. System interventions: Up-to-date infection guidelines, audit, education, training. 8 __OOHHCCMM__1100ee. . iinnddbb 441111 0022//0055//22001177 1199: : 0077 412 sesaesid suoitcefnI Sexually transmitted infection (STI) STIS6 are common with increasing rates of diagnosis: 2 for Chlamydia trachomatis, N. gonorrhoeae, genital herpes, and syphilis since 2006. Prevalence highest in young adults (25yr) and MSM. For HIV see pp398403. For hepatitis B and C see p278. Taking a sexual history Symptoms: : urethral discharge, dysuria, genital skin problems, testicular Pain/ Edema, peri-anal or anal symptoms in MSM. : unusual vaginal discharge, vulval skin problems, abdominal Pain, dyspareunia, unusual vaginal bleeding (post-coital, intermenstrual, consider referral for urgent colposcopy). Exposure: Sexual contacts within last 3 months including sex of partner(s), type of contact (oral, vaginal, anal), contraceptive method (properly used? ), type and duration of relationship, symptoms in partner(s), risk factors for HIV/hepatitis in partner(s), whether partner(s) can be contacted. STI history in all. Ask men whether they have ever had sex with another man. Other: Last menstrual period, menstrual pattern, date of last cervical cytology (smear). Current contraceptive, diffi culties with use/supply. Current/recent antimicrobial therapy. HPV vaccine history. There may be disclosure of non-consensual sex, or intimate partner violence. Do not be afraid to ask for help: Everything you tell me today is confi dential unless you tell me something that worries me about your safety, at which point I may need to discuss this with another professional in order to keep you safe. Examination : retract foreskin, inspect urethral meatus for discharge, scrotal contents/tenderness/Edema (stand patient up). : vulval examination (lithotomy), speculum of vagina/cervix, bimanual examination for adnexal tenderness, abdomen/pelvis for masses. In all: genitoanal area, protoscopy if anal symptoms, inguinal lymph nodes, oral mucosa if orogenital sex. Use a chaperone and document their name. Urethritis/vaginal discharge See table 9. 16. Genital warts Caused by human papilloma virus (HPV). See p406. Genital ulcer(s) Genital herpes: HSV. Presentation: fl u-like prodrome, then vesicles/papules around genitals, anus, throat. These burst, forming painful shallow ulcers. Also urethral discharge, dysuria, urinary retention, proctitis. Diagnosis: protein-creatinine ratio. Treatment: analgesia, topical lidocaine. Antivirals within 5d: aciclovir, valaciclovir, famciclovir. Syphilis: Treponema pallidum. Presentation: 1 Primary: 90d after innoculation (median 3wk). Maculepapuletypically Painless ulcer (chancre). Central slough, defi ned rolled edge. Highly infectious. 2 Secondary: dissemination 410wks after chancre. Rash (maculopapular in 50 75%, on palms/soles in 1170%), mucous patches, condyloma lata (raised, pale plaques, often fl exural), fever, headache, myalgia, lymphadenopathy, hepatitis. 3 Tertiary: 2040yr after infection. Neurosyphilis: aseptic meningitis, focal neurological defi cits, seizures, psychiatric symptoms, Argyll Robertson pupil (p72), tabes dorsalis (arefl exia, extensor plantar refl ex, dorsal column defi cits, Charcot joints). Gummatous syphilis: destructive granulomata in skin, mucus membranes, bones, viscera. Cardiovascular: aortitis, aortic regurgitation/aneurysm. Diagnosis: protein-creatinine ratio.",
    "Gummatous syphilis: destructive granulomata in skin, mucus membranes, bones, viscera. Cardiovascular: aortitis, aortic regurgitation/aneurysm. Diagnosis: protein-creatinine ratio. Serology: non-specifi c (RPR, VDRL) sensitive in early infection then decline; specifi c (T. pallidum as antigen, eg TPHA, TPPA) reacts in early infection and persists. Treatment: parenteral benzylpenicillin (eg benzathine penicillin IM), duration depends on stage. Procaine benzylpenicillin boosted with probenicid in CSF disease. Lymphogranuloma venerum: Chlamydia trachomatis. Presentation: mostly MSM in UK. Painless papule/ulcerlymphadenopathy, fever, arthritis, pneumonitis. Direct transmission to rectal mucosa causes haemorrhagic proctitis: Pain, rectal bleeding/discharge, tenesmus. Diagnosis: protein-creatinine ratio. Treatment: doxycycline. Tropical infections: Chancroid (Haemophilus ducreyi), Donovanosis (Klebsiella granulomatis). Presentation: both cause genital ulceration, and lymphadenitis with spread of infection into overlying tissue (pseudobubo). Diagnosis: H. ducreyi protein-creatinine ratio, Donovan bodies in tissue. Treatment: azithromycin, ceftriaxone. __OOHHCCMM__1100ee. . iinnddbb 441122 0022//0055//22001177 1199: : 0077 413 Table 9. 16 Overview of urethritis and vaginal discharge STI Presentation Diagnosis Treatment Other Chlamydia Often asymptomatic: detected on Nucleic acid amplifi cation test (NAAT) on: Azithromycin 1g PO (single dose) Pharyngeal and rectal infection may be asymptrachomatis screening. : vulvovaginal swabcan be done by or tomatic. Complications: : dyspareunia, dysuria, post-coital/ patient. Endocervical swabs and Urine 100mg doxycycline BD for 7d. : pelvic infl ammatory disease, salpingitis, ininter-menstrual bleeding, vaginal samples less sensitive. Partner tracing, screening, treatment. fertility, ectopic pregnancy, reactive arthritis, discharge. : fi rst-pass Urine. Avoid sexual intercourse until treatperihepatitis (Fitz-HughCurtis syndrome). : dysuria, urethral discharge. Oral/anal swabs if oral/anal sex. ment complete. : epididymo-orchitis, reactive arthritis. Eye disease see p438. Neisseria Urethral/vaginal discharge, dysuria. Nucleic acid amplifi cation test (NAAT) on: Ceftriaxone 500mg IM azithromycin Antibiotic resistance. Complications: gonorrhoeae Asymptomatic: 50% , 10% , most : vaginal swab or endocervical swab. 1g PO. Complicated disease: add : pelvic infl ammatory disease: salpingitis, inpharyngeal/rectal infection. Urine samples less sensitive. doxycycline ± metronidazole. fertility, ectopic pregnancy. : fi rst-pass Urine. Partner tracing, screening, treatment. : epididymitis, prostatitis, increased HIV Culture (endocervical/urethral swab Avoid sexual intercourse until treattransmission, reactive arthritis; infective enprior to antibiotics) for sensitivity. ment complete. docarditis, disseminated gonococcal infection. NonUrethral discharge, dysuria, urethral Polymorphonuclear leucocytes on As for Chlamydia trachomatis. NGU refers to a pattern of infection rather gonococcal discomfort. Only assess symptomicroscopy of urethral swab. Needs 5d course of azithromycin if patient/ than a cause. The main causes are Chlamydia urethritis matic patients/visible discharge for testing for chlamydia and gonorrhoea. partner known to be positive for trachomatis (1150%) and Mycoplasma geni- (NGU) urethritis. Exclude UTI. Mycoplasma genitalium. talium (650%). Tricho- : vaginal discharge (70%), itch. NAAT, culture, microscopy (mobile trichMetronidazole (2g single dose or 57d Pregnancy: risk of preterm delivery, Low birth monas : asymptomatic (70%), discharge. omonads). course). Partner tracing, screening, weight. vaginalis treatment. Avoid sexual intercourse May enhance HIV transmission. until treatment complete. Bacterial Thin, white, fi shy-smelling vaginal Gram stain to examine vaginal fl ora Oral or PV metronidazole Elevated vaginal pH alters vaginal fl ora: vaginosis discharge. No itch or soreness. (predominance/absence of lactobacilli), or anaerobic bacteria. Not sexually transmitted Asymptomatic in 50%. clue cells, vaginal pH 4. 5. PV clindamycin. but associated with STI. Genital Genital itch, burning, cottage cheeseMicroscopy and culture for Candida -azoles: pessary, eg clotrimazole, cream Very common. No evidence for treatment of candidiasis like discharge, dyspareunia. (see p408). if vulval symptoms, oral fl uconazole if sexual partners. Risk: pregnant, antibiotic severe. therapy, diabetes mellitus, immunosuppressed. Infectious diseases __OOHHCCMM__1100ee. . iinnddbb 441133 0022//0055//22001177 1199: : 0077 414 sesaesid suoitcefnI Fever in the returning traveller Exclude malaria in all travellers from the tropics (p4169). Exclude HIV in all (p398). Most travellers have self-limiting illnesses that could have been acquired in UK.",
    "Exclude HIV in all (p398). Most travellers have self-limiting illnesses that could have been acquired in UK. Look for tropical infection9 but dont forget your usual diff erentials. History Detailed geography of travel (table 9. 17)9 including setting (rural/urban), time of onset of symptoms, duration of symptoms (table 9. 18). 9 Ask about activities and events: bites, diet, fresh-Water exposure (schistosomiasis, leptospirosis), dust exposure, sexual activity, game parks (tick typhus, anthrax, trypanosomiasis), farms, caves (histoplasmosis, rabies, Ebola), unwell contacts. Associated symptoms: Respiratory: S. pneumoniae, H. infl uenzae, legionella, infl uenza, viral respiratory disease (SARS, MERS), TB, HIV-associated disease, melioidosis. 2 Neurological: malaria, meningococcal meningitis, HIV, syphilis, Lyme disease, leptospirosis, brucellosis, tick-borne encephalitis, relapsing fever, trypanosomiasis. Table 9. 17 Diff erential diagnosis by geography Area of travel Common Occasional Rare but do not miss Sub-Saharan Malaria (pp4169) Schistosomiasis (p434) Other arbovirus (p420) Africa HIV (pp398403) Amoebiasis (p432) Trypanosomiasis (p423) Rickettsiae (p422) Brucellosis (p424) VHF (pp4267) Dengue (p420) Visceral leishmaniasis Enteric fever (p415) (p423) Meningococcus (p390) South-East Malaria (pp4169) Leptospirosis (p425) Hanta virus (p426) Asia Chikungunya (p420) Melioidosis2 Japanese encephalitis Dengue (p420) (p436) Enteric fever (p415) Rickettsiae (p422) Scrub typhus (p422) South and Malaria (pp4169) Chikungunya (p420) VHF (CCHF) (pp4267) Central Asia Dengue (p420) Visceral leishmaniasis Rickettsiae (p422) Enteric fever (p415) (p423) Japanese encephalitis (p436) Middle East Brucellosis (p424) Visceral leishmaniasis Mediterranean Q-fever (p424) (p423) North Africa Zika (p421) South America Malaria (pp4169) Brucellosis (p424) Trypansomiasis (p423) Caribbean Dengue (p420) Leptospirosis (p425) Hanta virus (p426) Enteric fever (p415) Zika (p421) Yellow fever (p420) Eastern Lyme disease (p422) Hanta virus (p426) Europe Tick-borne encephalitis Scandinavia Australia Dengue (p420) Melioidosis2 Q fever (p424) Rickettsiae (p422) North America Lyme disease (p422) Melioidosis2 Rickettsiae (p422) Table 9. 18 Diff erential diagnosis according to incubation time Incubation period Infections Short 10d Dengue, chikungunya, gastroenteritis, relapsing fever, rickettsiae Medium 1021d Malaria, HIV, brucellosis, enteric fever, leptospirosis, melioidosis, Q-fever, coccidioidomycosis, VHF, Chagas disease, trypanosomiasis Long 21d Malaria, HIV, TB, viral hepatitis, brucellosis, schistosomiasis, amoebic Liver abscess, trypanosomiasis, visceral leishmaniasis Chronic fever 14d TB, HIV plus opportunistic infection, pyogenic deep seated abscess, infective endocarditis, brucellosis, enteric fever, fungal infection, schistosomiasis, visceral leishmaniasis, physical examination 2 Burkholderia pseudomallei in tropical Water/soil. Causes pneumonia, pleural eff usions, pulmonary abscess. Systemic abscess if haematogenous spread: Liver, spleen, skin, muscle. Treat with co-amoxiclav, doxycycline, co-trimoxazole. In severe disease: ceftazidime, meropenem. __OOHHCCMM__1100ee. . iinnddbb 441144 0022//0055//22001177 1199: : 0077 415 sesaesid suoitcefnI Examination Rash: Maculopapular: dengue, chikungunya, EBV, HIV seroconversion, VHF. Purpuric: dengue, meningococcal infection, plague, DIC, VHF. Ulcer: trypanosomiasis, Yesinia pestis, tick typhus, anthrax, tropical ulcer. Jaundice: Viral hepatitis, severe falciparum malaria, enteric fever, leptospirosis, relapsing fever, typhus, VHF, bartonellosis Hepatosplenomegaly: Viral hepatitis, HIV, enteric fever, brucellosis, leptospirosis, rickettsial infection, relapsing fever, schistosomiasis, amoebic Liver abscess, trypanosomiasis, visceral leishmaniasis. Investigation Directed by travel history and examination. In undiff erentiated fever: Malaria fi lm/rapid diagnostic testing (p417). HIV test (p399). FBC: lymphopenia in viral infection including HIV; eosinophilia in parasitic/fungal eg soil-transmitted helminths, fi liariasis, schistosomiasis, hydatid disease; platelets in malaria, dengue, HIV, typhoid, severe sepsis. Blood culture 2: prior to antibiotics. LFT. Consider: save serum, specifi c serology, or European Dialysis and Transplant Association sample for protein-creatinine ratio. Support Local infectious diseases team (including on-call). Disease notifi cation: www. gov. uk/health-protection-team. Public Health England imported fever service 0844 778 8990. National Travel Health Network and Centre (NaTHNaC)/TravelHealthPro www. travelhealthpro. org. uk (0845 602 6712). Hospital for Tropical Diseases 0203 456 7890. Travel fever diagnostic website: www. fevertravel. ch Enteric fever: typhoid and paratyphoid 20 million cases and 200 000 deaths per year worldwide, 500/yr in UK mostly imported from India, Pakistan, and Bangladesh.",
    "Caused by related, Gram-negative strains of typhoidal Salmonella spp: Typhoid (7590%): Salmonella typhi. Paratyphoid (1025%, less severe): Salmonella paratyphi serotype ABC. The bacteria invade the intestinal mucosa. Dissemination occurs without a primary diarrhoeal response. This distinguishes typhoidal from non-typhoidal serovars of Salmonella which cause DV (p428). Transmission is faecaloral from contaminated Water/food. Incubation 630d (most 1020d). 10 000 organisms are required to cause illness. Can be asymptomatic (but shed organism). Symptoms: Fatigue, headache, anorexia. Marked fever, stepwise (rising through each day with progressive peaks) in 20%. Abdominal Pain, relative bradycardia (Fagets sign), cough, constipation. Rose spots in 25% (salmon-coloured, 14cm, blanching, due to bacterial emboli to dermis). Diarrhoea (pea-soup) and hepatosplenomegaly in 2nd week. Progressive toxicity and complicated disease in up to 10%: intestinal haemorrhage/perforation, myocarditis, hepatitis, pneumonia, DIC, CNS involvement (delirium, meningism, encephalitis, cerebellar signs, fi ts, coma), eye complications (corneal ulcer, uveitis, neuritis, thrombosis). Diagnosis: Isolation of S. typhi from: Blood (take multiple cultures of 1015mL in fi rst 10d to sensitivity), bone marrow, intestinal secretions, or stool (sensitivity after 1st week). Serology has sensitivity and specifi city, not suffi cient as sole diagnostic tool (Widal test is Ωve in 30% of culture-proven cases). LFT. protein-creatinine ratio (not routine). Treatment: Azithromycin ± IV ceftriaxone. 70% imported from Asia are resistant to fl uoroquinolones. Fever takes median 57d to respond due to intracellular niche of organism. Antipyretics, fl uid management, nutrition. CNS disease: dexamethasone 3mg/kg IV then 1mg/kg/6h for 8 doses (limited data). Vaccine: Ty21a (oral, live, CI: immunosuppression, pregnancy) or Vi (IM, capsular vaccine). 5080% eff ective for 3yr. Limited/no protection against paratyphoid. __OOHHCCMM__1100ee. . iinnddbb 441155 0022//0055//22001177 1199: : 0077 416 sesaesid suoitcefnI Malaria: diagnosis Epidemiology 3. 2 billion people at risk in 95 countries half the worlds population (fi g 9. 23). 214 million/cases per year with 438 000 deaths. Sub-Saharan Africa: 88% of malaria cases, 90% of deaths (most age 5yr). Most common tropical disease imported into UK, 2000 cases/yr. 20% fever in travellers from Africa presenting to UK hospitals is due to malaria. Plasmodium falciparum is the most prevalent parasite in Africa and responsible for most malaria deaths worldwide (75% of malaria presenting in UK). Plasmodium vivax is the dominant parasite outside of sub-Saharan Africa. Preventable and treatable: incidence by 37% and deaths by 60% since 2000. Malaria parasites Malaria parasites belong to the genus Plasmodium. 100 species exist of which 5 cause human disease (see table 9. 19). Transmission occurs through the bite of an infected Anopheles mosquito. Only female mosquitoes transmit Plasmodium as only females require a Blood meal for egg development. Transmission in the absence of a mosquito is rare: vertical (congenital transfer from mother to child), transfusion, organ transplantation, needle-sharing. Fig 9. 23 Countries with malaria transmission. Reproduced with permission from World Health Organization, World malaria report 2015. World Health Organization 2015. Table 9. 19 Malaria species in humans Average incubaPersistent Species Distribution tion (range) Liver stage P. falciparum 12 days No Africa, India, South East Asia, Indonesia, (fi g 9. 24) (6 days6 months) Oceania, Central America, Middle East P. vivax 14 days Yes South Asia, South and Central America, (fi g 9. 25) (daysyears) Africa, Middle East P. malariae 30 days No Africa, South and Central America, (fi g 9. 26) (28 daysyears) South East Asia P. ovale 1116 days (years) Yes Africa P. knowlesi 912 days No South East Asia Reproduced from Detels et al. , Oxford Textbook of Global Public Health, 2015, with permission from Oxford University Press. Fig 9. 24 P. falciparum Fig 9. 25 P. vivax ring partly Fig 9.",
    "Fig 9. 24 P. falciparum Fig 9. 25 P. vivax ring partly Fig 9. 26 P. malariae ring and sau sage-like game to cytes hidden by Schuff ners dots. band forms from 2 specimens. in red blood cell. S Upton, Kansas Univ. Stained and exam fi e in ld e d b y in J t M h L e. S Upton, Kansas Univ. __OOHHCCMM__1100ee. . iinnddbb 441166 0022//0055//22001177 1199: : 0077 417 sesaesid suoitcefnI The life cycle of malaria is dePlasmodium pendent on both humans and sporozoites mosquitoes (fi g 9. 27). Sporozoites are transferred to a human host when an infected mosquito 1st vector Next human bites. These travel via the BloodInitial host stream to the Liver where matuhuman ration occurs to form schizonts host Liver containing 30 000 merozoite infection off spring. If a dormant stage Blood exists (vivax, ovale, see table infection 9. 19), and is inadequately treated, merozoites can be released from the Liver weeks, months, In utero 2nd vector or years later causing recurrent transmission disease. The rupture of schizonts Fig 9. 27 Malaria lifecycle. releases merozoites which enter RBCs (what a fantastic niche! ). In the red blood cell, merozoites form larger trophozoites and erthrocytic schizonts (poor prognostic indicator if seen on Blood fi lm). The rupture of erthrocytic schizonts produces the clinical manifestations of malaria. Clinical features Consider in anyone with a fever who has previously visited a malarial area (fi g 9. 23), regardless of prophylaxis. Presentation: P. falciparum has a minimum incubation of 6 days and most commonly occurs within 3 months of return from an endemic area. Take a careful travel history: country, area of travel, date of return. Do not forget to ask about stopovers. Symptoms are non-specifi c: fever, headache, malaise, myalgia, diarrhoea, cough. Fever patterns are described but only occur if rupture of infected RBCs is synchronized: alternate day for P. falciparum, P. vivax, P. ovale (tertian); every 3rd day for P. malariae (quartan). Most patients have no specifi c fever pattern. Examination: Fever, otherwise unremarkable. If diagnosis is delayed or severe disease then may present with jaundice, confusion, seizures. Diagnosis Immediate Blood testing is mandatory in UK: Microscopy of thick and thin Blood smear. Sensitive and specifi c in experienced hands. Rapid diagnostic test (RDT) detection of parasite antigen. Used for initial screen if expert microscopy is unavailable, eg out-of-hours. Used in addition to (not instead of) Blood fi lm. Results should be available within 4h. If malaria is suspected but Blood fi lm is negative: repeat at 1224h and after further 24h. Malaria is unlikely if three expert serial Blood fi lms are negative. dengue, typhoid, hepatitis, meningitis/encephalitis, HIV, viral haemorrhagic fever. Care in pregnancy: thick fi lms can be negative despite parasites in the placenta. Seek expert help. If P. falciparum (or P. knowlesi) estimated % parasitized red cells should be given: 2% chance of severe disease (indication for parenteral treatment see pp4189). 10% severe disease. Other: FBC (anaemia, thrombocytopenia), Creatinine and Urine output (acute kidney injury), clotting (DIC), glucose (hypoglycaemia), ABG/lactate (acidosis), urinalysis (haemoglobinuria). Malaria is notifi able to public health: www. gov. uk/health-protection-team Errors to avoid Failure to consider diagnosis Delay in Blood fi lm/RDT Inadequate travel history No serial Blood fi lm if fi rst test negative Belief prophylaxis prevents all malaria Inadequate treatment (pp4189) Belief presents with a fever pattern Inappropriate treatment (pp4189) Non-specifi c symptoms not recognized Failure to anticipate/treat complications. Reproduced from Beeching et al. , Returned travellers. In: Principles and Practice of Travel Medicine, 2013, John Wiley and Sons. Copyright 2013 by Blackwell Publishing Ltd. __OOHHCCMM__1100ee.",
    "In: Principles and Practice of Travel Medicine, 2013, John Wiley and Sons. Copyright 2013 by Blackwell Publishing Ltd. __OOHHCCMM__1100ee. . iinnddbb 441177 0022//0055//22001177 1199: : 0077 418 sesaesid suoitcefnI Malaria: treatment Falciparum malaria Risk of deterioration admit to hospital. Treatment10 depends upon whether the disease is uncomplicated, or severe. Features of severe disease are: Impaired consciousness/seizures (consider LP) hemoglobin 80g/L acute kidney injury (oliguria 0. 4mL/kg/h, Creatinine265μmol/L) Spontaneous bleeding/DIC Shock (blood pressure 90/60) Algid malaria Acidosis (pH 7. 3) Hypoglycaemia (2. 2mmol/L) Haemoglobinuria Pulmonary oedema/ARDS Parasitaemia 10%. Remember other poor prognostic indicators: peripheral Blood schizonts (see p417), elevated serum lactate, age. Uncomplicated falciparum malaria: Artemisinin combination therapies (ACT) achieve rapid clearance of parasites by combined action at diff erent stages of the parasite cycle (p417): 1 Artemether-lumefantrine: 4 tablets at 0, 4, 8, 24, 36, 48, and 60h. 1st line in UK (including pregnant 13wks), take with High-fat food to absorption. 2 Dihydroartemisinin (DHA)-piperaquine: 4 tablets OD for 3d (if weight 60kg). Take 3h before and after food to prevent excessive peak levels. Possible QTC avoid in arrhythmia. Options if ACT not available: Atovaquone-proguanil: 4 tablets OD for 3 days. Parasite clearance 66% after 3d, GI side-eff ects in 25%. Oral quinine sulphate 600mg TDS for 57d plus doxycycline 200mg OD (or clindamycin 450mg TDS if pregnant) for 7d. Parasite monitoring required. Can cause cinchonism: nausea, deafness, ringing in ears. Resistance to ACT is emerging in Asia. Failure rates with antifolate drugs mean Fansidar is no longer used. Chloroquine is not used in the treatment of falciparum malaria. Severe P. falciparum malaria Give urgent parenteral treatment. Artesunate is treatment of choice. Meta-analysis shows reduction in mortality of 39% (CI: 2550%) compared to quinine, preventing 94 deaths for every 1000 adults treated. 11 IV artesunate is stocked by many infectious disease units in the UK. It can be obtained from tropical disease centres in London (020 3456 7890) and Liverpool (0151 706 2000). Artesunate regimen (adult): 2. 4mg/kg IV at 0h, 12h, 24h and then daily for up to 5d. Converted to a full course of ACT (see uncomplicated falciparum earlier in topic) when able to tolerate oral medication. Side-eff ects: delayed haemolysis 721d post-treatment (usually self-limiting)check hemoglobin 14d post treatment. If artesunate is not available immediately, treatment should be started with quinine. It is safe to overlap/combine with artensuate when it is available. Quinine regimen (adult): Loading dose 20mg/kg over 4h. Then 10mg/kg every 8h for next 48h or until patient can swallow (dose every 12h if patient has renal failure or hepatic dysfunction or if IV needed 48h). Convert to 600mg PO TDS to total quinine course 57d. Give with 7d oral doxycycline (clarithromycin in children/ pregnant). Side-eff ects: cinchonism (see earlier in topic), hyperinsulinaemia. Manage in a High dependency setting. Capillary permeability so vulnerable to pulmonary oedema if over-fi lled. Lactate levels may refl ect intravascular obstruction rather than circulating hypovolaemia. Monitor: Blood glucose every 4h (2h if quinine infusion), hemoglobin, clotting, electrolytes, Creatinine. Daily parasite counts are suffi cient NB: will fl uctuate with the life cycle of the parasite (see p417) and an increase in fi rst 36h of treatment may not indicate treatment failure. Given the rapid action of artesunate, exchange transfusion is no longer considered to off er any additional benefi t. Pregnancy: Little evidence on use/safety of artesunate. On balance of risk (pregnancy loss, pulmonary oedema, maternal mortality), artesunate should be given. __OOHHCCMM__1100ee. . iinnddbb 441188 0022//0055//22001177 1199: : 0077 419 sesaesid suoitcefnI Non-falciparum malaria P. vivax, P. ovale, P. malariae, P. knowlesi: If mixed infection with falciparum, treat as falciparum.",
    "If severe/complicated non-falciparum disease, treat as severe falciparum. If uncomplicated disease, treat with ACT as uncomplicated falciparum. Chloroquine can be used for non-falciparum disease. Dosing in adult: 620mg base at 0h, 310mg base at 68h, 310mg base on day 2 and 3. But: do not use if P. falciparum cannot be excluded be aware that ACT may work more quickly on both fever and parasite count chloroquine resistance exists in P. vivax (Papua New Guinea, Indonesia). In addition to other treatment, P. vivax and P. ovale require eradication of Liver hypnozoites with primaquine: P. vivax: adult 30mg (0. 5mg/kg) daily for 14d. P. ovale: adult 15mg (0. 25mg/kg) daily for 14d. Risk of haemolysis with primaquine in G6PD defi ciency so screen prior to use. Seek expert advice for dosing/monitoring patients with G6PD defi ciency, and in pregnancy. Malaria prevention Vector control for all people at risk of malaria. Includes: Source reduction by destruction of mosquito breeding sites (ie standing Water). Long-lasting insecticidal nets. These should be provided free of charge and with equity of access. Nets last for 3y, a lifespan of 5y could save 3. 8bn. Insecticidal resistance is an increasing concern, should dual agents be used? Indoor residual spraying, eff ective for 36 months when 80% of houses included. Sterile male mosquito release. Estimated to initially require 20 males/human to be protected 64 billion sterile mosquitoes worldwide. Genetic modifi cation to develop mosquitoes that are not susceptible to malaria (and other) parasites. Requires modifi cation that does not fertility or will not disperse in vector population. Requires acceptability, infrastructure, and money. Chemoprophylaxis is the use of antimalarial drugs to prevent clinical disease. In High-transmission areas it is recommended for pregnant women (given at antenatal visits) and infants (given with routine vaccination). Travellers from the UK to malaria areas should be given: 1 Bite prevention advice: insect repellents with 2050% DEET (for all 2 months old including pregnant and breast-feeding). Apply after sunscreen with SPF 30 as DEET may sunscreen effi cacy. 2 Chemoprophylaxis (table 9. 20) according to area of travel. See www. fi tfortravel. nhs. uk/destinations. aspx Table 9. 20 Prophylactic regimen against malaria in adults (refer to BNF) Area Regimen Notes No drug Chloroquine 310mg base/week 1wk before and 4wks after travel. resistance OR proguanil 200mg OD Chloroquine: GI disturbance, headLittle Chloroquine 310mg base/week ache. CI epilepsy. chloroquine PLUS proguanil 200mg OD Proguanil: diarrhoea, antifolate (care resistance if possibility of pregnancy). ChloroquineMefl oquine 250mg/week 23wks prior and 4wks after. Neuresistant OR ropsychiatric SE, dizziness. P. falciparum Doxyxcycline 100mg OD OR 12d prior, 4wks after, SE: hepatic impairment, teratogenic. Atovaquone-proguanil combi12d prior, 1wk after, expert advice nation with HIV ART. Malaria eradication is the permanent reduction of the incidence of malaria meaning that intervention is no longer required. It is dependent upon the social, demographic, and economic status of a country, the available healthcare system, and investment. It requires diagnosis and treatment to achieve parasitologic (as opposed to clinical) cure in order to eliminate asymptomatic transmission. __OOHHCCMM__1100ee. . iinnddbb 441199 0022//0055//22001177 1199: : 0077 420 sesaesid suoitcefnI Mosquito-borne disease Mosquito-borne diseases12 are transmitted by the bite of a mosquito infected with a virus, bacteria, or parasite. The mosquito acts as the disease vector. Mosquitoes are arthropods (see table 9. 21). Mosquito-borne diseases can therefore also be described as vector-borne or arthropod-borne disease. When a virus is transmitted by an arthropod it is termed an arbovirus (ARthropod-BOrne VIRUS). Malaria See pp4169. Dengue Most important arbovirus in humans. Dengue viruses (Flaviviruses DENV 14) are transmitted by day-biting Aedes mosquito. 120 countries (fi g 9. 28).",
    "Dengue viruses (Flaviviruses DENV 14) are transmitted by day-biting Aedes mosquito. 120 countries (fi g 9. 28). Symptoms in 100 million/yr. UK: 500 imported cases/yr. Fig 9. 28 Countries at risk of dengue (dotted line 10°C isotherm). Reproduced from Johnson et al. , Oxford Handbook of Expedition and Wilderness Medicine, 2016, with permission from Oxford University Press. Presentation: Incubation 314d. Fever (up to 40°C), NV, headache, retro-orbital Pain, myalgia, arthralgia, ve tourniquet test (infl ate blood pressure cuff to midway between systolic and diastolic for 5 min≥10 petechiae/inch2). Warning signs/critical phase may occur 37d into illness and needs hospital admission: abdominal Pain, persistent Vomiting, fl uid accumulation, mucosal bleeding, hepatomegaly, haematocrit platelet. Severe disease: shock (includes postural blood pressure drop 20mmHg), respiratory distress, severe bleeding, organ involvement (transaminases 1000, GCS, other organ failure). Diagnosis: protein-creatinine ratio for virus/ELISA antigen3 during viraemia (1st 5d of fever). Serology (IgM, IgG) after 5d. Also platelet, WCC, transaminitis. (: Chikungunya, Zika. ) Treatment: Supportive: prompt but careful fl uid balance due to potential for plasma leak. IV crystalloid, to maintain eff ective circulation, only in severe disease. 20mL/kg over 1530min if hypotensive shock. Monitor clinically and via haematocrit. Reduce IV fl uid as soon as stable. Beware: plasma leak maintains haemocrit unless bleeding. Consider transfusion if haematocrit without clinical improvement. Avoid NSAIDs. Chikungunya Arbovirus (Alphavirus) transmitted by Aedes mosquito. Widespread: Asia, Africa, Europe, and Americas. Name derives from Kimakonde language meaning to become contorted due to arthralgia. Blood-borne and vertical transmission possible, but rare. Presentation: Incubation 112d. Fever. Polyarthralgia: bilateral, symmetrical, can be severe, persistent. Headache, myalgia, NV, maculopapular rash. Diagnosis: 3 Viral culture/protein-creatinine ratio (1st 8d), serology. Treatment: Supportive. Analgesia. Yellow fever Arbovirus (Flavivirus) spread by Aedes mosquitoes in Africa, South America. Presentation: Incubation 36d. Viraemia 3d with fever, headache, myalgia, anorexia, NV, relative bradycardia (: enteric fever p415). 15% have remission followed by severe symptoms 48h later: epigastric Pain, jaundice, acute kidney injury, cardiac instability, bleeding. Mortality 5%-30%. Diagnosis: Clinical and travel history. Virus/protein-creatinine ratio in 1st 3d. 3 Serology: cross reacts with other fl aviviruses, IgM can persist after vaccination. Treatment: Supportive. Live vaccine, eff ective for life (certifi cate for 10yr). West Nile and Japanese encephalitis, see Neurological disease pp4367. 3 In UK testing done via Rare and Imported Pathogens Laboratory (RIPL): www. gov. uk/government/collections/rare-and-imported-pathogens-laboratory-ripl __OOHHCCMM__1100ee. . iinnddbb 442200 0022//0055//22001177 1199: : 0077 421 sesaesid suoitcefnI Zika virus Arbovirius (Flavivirus) transmitted by Aedes mosquito. First identifi ed in Zika forest, Uganda, 1947. Human cases rare until outbreak in Pacifi c Islands (20072013), and Brazil (2015). Estimated 1. 5 million cases in Brazil by 2016. Zika detected in sperm and Blood products so transmission not limited to vector. Up-to-date geographic and clinical data available at: www. ecdc. europa. eu Presentation: Subclinical in 80%. Mild illness in 20%: fever, conjunctivitis, myalgia, rash. Severe acute illness and GuillianBarré are rare. Zika and birth defects: Geographical and temporal relationship between infection and microcephaly. Zika detected in amniotic fl uid is evidence of placental transfer. Specifi c fetal syndrome: microcephaly, intracranial calcifi cation, eye pathology, redundant scalp skin. Small, uncontrolled studies show fetal abnormalities in up to 30% of pregnant women infected with Zika. 13 Absolute and relative risks unknown (2016). Diagnosis: protein-creatinine ratio of viral DNA in Blood/body fl uid. Treatment: Vector control, avoid non-essential travel in pregnancy, condoms to prevent sexual transmission. Vaccine trials ongoing (2016). Lymphatic fi lariasis (elephantiasis) 40 million aff ected and disfi gured. 1 billion at risk (80% in sub-Saharan Africa). Filarial parasites (nematodes) transmitted via mosquitoes which bite infected hosts and ingest microfi laria.",
    "Filarial parasites (nematodes) transmitted via mosquitoes which bite infected hosts and ingest microfi laria. These mature in the mosquito with infective larvae transferring to new hosts during feeding. Adult worms form nests in lymphatic vessels causing damage and lymphoedema. Transmission prevented by an annual dose of two drugs5. 63 billion treatments delivered by WHO since Fig 9. 29 Blood smear of 2000. 12 Types of fi larial worm: Wuchereria bancrofti (fi g 9. 29) 90% of disease. W. bancrofti (2908. 5μm). Courtesy of Prof. S. Upton, Brugia malaya 10%. Kansas University. Brugia timori possible cause of disease. Presentation: Asymptomatic infection ± subclinical lymphatic damage. Acute episodes of local infl ammation: Pain, fever. Chronic damage: lymphoedema (fi g 9. 30), hydrocele, chylocele, scrotal/penile Edema. chronic kidney disease: proteinuria, haematuria. Immune hyperr eactivity tropical pulmonary eosinophilia (cough, wheeze, fi brosis, eosinophil counts, IgE). Diagnosis: Microfi lariae in Blood smear (fi g 9. 29), antifi larial IgG, visualization of worms on USS/tissue sample. Treatment: Lymphoedema care. Prevention in High-risk populations: albendazole plus either diethylcarbamazine (DEC) or ivermecFig 9. 30 Lymphoedema. Reproduced with permistin. DEC is contraindicated in onchocerciasis (p439), care with sion from World Health circulating Loa Loa (p439) due to risk of encephalopathy and Organization. World renal failure. Household salt can be fortifi ed with DEC. Health Organization. fi lariasis/disease/en/ The global advance of vector-borne disease? Since 1990, fi ve species of Aedes mosquito have become established in Europe. The adaptation of mosquitoes to a temperate environment, combined with future climate forecasts has led to models14 that predict the UK will be suitable for: Plasmodium falciparum transmission by 20302080 Plasmodium vivax transmission by 2030 Chikungunya transmission in London by 2041 Dengue transmission after 2100. Of course, modelling is not simple. Socioeconomic development, urbanization, land-use change, migration, and globalization all come into play. Surveillance of mosquitoes at sea-ports, airports, and used-tyre companies remains uninteresting to date. But consider a time when a visit to South-East England off ers an opportunity to explore the historical gems of our wonderful capital, and simultaneously becomes a pertinent question in your diagnostic sieve __OOHHCCMM__1100ee. . iinnddbb 442211 0022//0055//22001177 1199: : 0077 422 sesaesid suoitcefnI Vector-borne disease Vector borne diseases are infections transmitted by the bite of infected arthropod species including mosquitoes, ticks, fl ies, and bugs (table 9. 21). Table 9. 21 Vector-borne disease Vector/arthropod Disease Page Mosquito Anopheles Malaria 4169 Aedes Dengue, Chikungunya, yellow fever, Zika 4201 Culex Lymphatic fi lariasis, Japanese encephalitis, West Nile 421, 4367 Ticks Lyme disease, rickettsial disease, relapsing fever, tick4223, borne encephalitis, Crimean-Congo haemorrhagic fever 4267 Bugs/Flies Leishmaniasis, trypanosomiasis, onchocerciasis, loiasis 423, 439 Snails Schistosomiasis 434 Lyme disease (Lyme borreliosis) Tick-borne multisystem disease caused by the spirochaete Borrelia burgdorferi (or related Borrelia spp). All cases limited to northern hemisphere (mainly Europe and ultrasound). 20003000 cases/ yr in UK. Risk of infection from tick bite is 312% in Europe. Presentation: ≤75% remember the tick bite. Peak infection with 4872h of attachment. Disease stages: Early localized (330d after bite): erythema migrans (fi g 9. 31), Fig 9. 31 Erythema Pain/pruritus, lymphadenopathy, ± constitutional symptoms: migrans: distinct adfever, malaise, headache. ⅓ do not see a rash. vancing edge. Early disseminated (wksmonths): borrelial lymphocytoma Reproduced from bluish-red plaque/nodule: check earlobes, nipples, genitals. Lewis-Jones, PaediNeuroborreliosis: lymphocytic meningitis, ataxia, amnesia, atric Dermatology facial/cranial nerve palsies, neurop athy (severe Pain, worse 2010, with permission at night), encephalomyelitis. Carditis: acute onset 2nd/3rdfrom Oxford University degree Heart-block, myocarditis. Press. Late disseminated (monthsyr): acrodermatitis chronic atrophicans focal infl ammation then atrophic skin; Lyme arthritis. Diagnosis: Clinical: erythema migrans with known exposure or evidence of infection.",
    "Diagnosis: Clinical: erythema migrans with known exposure or evidence of infection. Borrelia culture (sensitivity: 4070% for erythema migrans, 20% for CSF), protein-creatinine ratio. 4 Twotier serology due to false-positive reaction with other spirochaete infection: enzyme immunoassay/immunofl uorescence immunoblot. Sensitivity due to slow seroconversion: IgM 12wks (and may persist), IgG 46wks and background positivity 315%. Treatment: Erythema migrans: doxycycline 100mg BD PO for 1021d (CI 8y, pregnant). Alternatives: amoxicillin, phenoxymethylpenicillin, azithromycin. Neuroborreliosis: ceftriaxone or IV benzylpenicillin or doxycycline for 1030d. Arthritis/carditis: doxycyline or amoxicillin or ceftriaxone for 1430d. 15 Prevention: Keep limbs covered; use insect repellent (DEET); inspect skin and remove ticks (use tweezers, hold close to head/mouth). Rickettsial disease Rickettsiae are obligate, intracellular coccobacillary forms lying between bacteria and viruses. Mammals and arthropods are natural hosts. Risk with rural activities eg camping, hiking, hunting. Divided into: Spotted fevers: eg Rocky Mountain spotted fever (Americas); rickettsialpox ( Chicken-pox). Typhus: scrub typhus in Asia-Pacifi c regions; endemic (fl ea-borne) typhus in tropical areas; epidemic (louse-borne) typhus in homeless populations, eg refugees. Other emerging illnesses: eg ehrlichia, anaplasma. Presentation: Incubation 12wks. Fever, headache, malaise, rash (maculopapular, vesicular or petechial), NV, myalgia. Check for local lymphadenopathy and an eschar at the site of the bite (scrub typhus). Wide variation in severity depending on aetiology. Fulminant, life-threatening infection possible with Rocky Mountain spotted fever, louse-borne typhus, scrub typhus. Diagnosis: Clinical: fever rash travel to an endemic area. Serology, culture/protein-creatinine ratio of Blood/skin biopsy. Treatment: Antibiotics in severe cases: doxycycline, azithromycin, chloramphenicol. 4 Specialist diagnostic service and advice in UK via Rare and Imported Pathogens Laboratory (RIPL): www. gov. uk/government/collections/rare-and-imported-pathogens-laboratory-ripl __OOHHCCMM__1100ee. . iinnddbb 442222 0022//0055//22001177 1199: : 0077 423 sesaesid suoitcefnI Leishmaniasis Caused by protozoan parasites of Leishmania12 species, transmitted by infected female phlebotomine sandfl ies. 556 million at risk. Risk factors: poverty, malnutrition, displacement, deforestation, dam building/irrigation. Presentation: Cutaneous, most common form, ulceration (fi g 9. 56, p440). Fig 9. 32 Mucocutane- Mucocutaneous (fi g 9. 32): leads to tissue destruction of ous leishmaniasis. nose, mouth, throat. 90% occurs in Bolivia, Brazil, Peru. Reproduced with permis- Visceral leishmaniasis (VL, kala-azar, black sickness) (fi g sion from World Health 9. 33): fever, weight loss, hepatosplenomegaly, anaemia. Organization. World 95% mortality without treatment. Endemic in Indian subHealth Organization. http: // continent, East Africa. 90% of new cases occur in Banglawww. who. int/leishmaniasis/mudesh, Brazil, Ethiopia, India, South Sudan, Sudan. 300 000 cocutaneous_leishmaniasis/en/ cases/yr, 20 000 deaths/yr. Post kala-azar is a complication of Leishmania donovani a hypopigmented macular/nodular rash ( leprosy), 6 months1yr after apparent cure, can heal but is a reservoir for parasites and maintains transmission. Diagnosis: Clinical. Microscopy of tissue samples (skin, bone marrow) for parasite. Antibody detection in VL (indirect fl uorescence, ELISA, western blot, direct agglutination test, or immunochromatographic test) is limited due to: 1 Ab levels detectable for years after cure, cannot distinguish VL relapse/active infection. 2 Tests are ve in many with no history of VL. 3 Serology may be Ωve if HIV ve. Treatment: Liposomal amphoterin (single Fig 9. 33 Visceral leishmaniasis. dose), oral miltefosine, pentavalent antimonials (resistance in India). The WHO Kala-azar Elimination Programme (including Reproduced with permission from World Health donated liposomal amphotericin) has achieved a 75% reduction Organization. World in new cases of VL. Health Organization. http: // Human African trypanosomiasis (HAT, sleeping sickness) www. who. int/leishmaniasis/ Infection with Trypanosoma protozoan parasites16, transvisceral_leishmaniasis/en/ mitted by the tsetse fl y in sub-Saharan Africa. Divided into: Rhodesiense HAT, incubation 21d, High fever, GI disturbance, lymphadenopathy, headache. Chancre at bite site in 84%, maculopapular rash. Progresses to myopericarditis, arrhythmias, and neurological symptoms.",
    "Chancre at bite site in 84%, maculopapular rash. Progresses to myopericarditis, arrhythmias, and neurological symptoms. Gambiense HAT, chronic disease in African population, presents years after infection (can present with acute febrile illness in travellers). Low-grade fever. Sleep disorder: reversal of sleepwake cycle, uncontrollable sleep episodes. Weakness, abnormal gait, psychiatric symptoms. Diagnosis: hemoglobin, platelet, acute kidney injury, LFTs, polyclonal IgM. Microscopy of parasite (Blood, lymph node, chancre, CSF). Serology and protein-creatinine ratio if available. Treatment: According to disease type and stage. Available from WHO. Includes suramin, melarsoprol, pentamidine, nifurtimox-efl ornithine. Seek specialist adviceside-eff ects from all. Chagas disease (American trypanosomiasis) Life-threatening illness due to protozoan Trypanosoma cruzi transmitted by triatomine bugs. Endemic in Latin America: 67 million infected. Presentation: Acute phase (2 months): skin lesion (chagoma), fever, headache, myalgia, lymphadenopathy, unilateral conjunct ivitis, periorbital oedema (Rom añas sign), myocard itis, meningo encephalitis. Chronic phase (yrs): cardiac: dilated cardiomyopathy; GI: mega -oesophagus (dysphagia, aspiration), mega-colon (abdominal distension, constipa tion); CNS symptoms. Diagnosis: Acute: trypomastigotes in Blood, CSF, node aspirate. Chronic: serology (Chagas IgG ELISA). Treatment: Benznidazole, nifurtimox. eff ective in chronic disease. Relapsing fever Caused by spirochaete Borrelia recurrentis (louse-borne, sub-Saharan Africa, refugee camps) or other Borrelia (tick-borne, world-wide). Presentation: Intermittent fever crisis due to antigenic variation (3d fever, then afebrile 7d), headache, myalgia, blood pressure. Diagnosis: Spirochaetes on Blood smear, false ve serology for Lyme disease. Treatment: Doxycyline/macrolides (single dose if louse-borne). Neuroborreliosis treatment if CNS disease (p422). JarischHerxheimer reaction due to endotoxins (? TNF) can mimic fever crisis: observe 1st 4h treatment, use cooling/antipyretics. __OOHHCCMM__1100ee. . iinnddbb 442233 0022//0055//22001177 1199: : 0077 424 sesaesid suoitcefnI Zoonoses Anthrax (Bacillus anthracis) Gram-positive, aerobic bacillus found in soil worldwide. Humans exposed via infected livestock or animal products, eg hide, wool, tusks. Infection via inhalation, ingestion, contamination of broken skin (includes IV drug use). Bacteria secrete exotoxins: oedema toxin and lethal toxin. Presentation: Cutaneous (95%): itchy papulevesiclenecrotic eschar. Oedema may be striking. Regional lymphadenopathy, malaise. Inhalation: fever, cough, myalgia, SOB, pleural eff usion (haemorrhagic mediastinitis), stridor, death. GI (rare): fever, abdominal Pain, ascites, mucosal ulcers, GI perforation. Diagnosis: Vesicular fl uid culture (care, do not disseminate), Blood culture, antibody ELISA, protein-creatinine ratio. (NB: not pneumonic so sputum cultures are Ωve). Treatment: Quinolone/doxycycline. Two agents if systemic disease, eg ciprofl oxacinclindamycin or linezolid (then narrow according to sensitivity). Consider anti-anthrax monoclonal antibody/immunoglobulin as adjunct in inhalational disease. Bartonella B. henselae (cat-scratch disease): from infected cat fl eas. Low-grade fever, regional lymphadenopathy. Encephalitis rare. Skin lesions mimic Kaposis sarcoma. B. quintana (trench fever): from human body louse. Fever, headache, bone Pain. B. bacilliformis (bartonellosis): from infected sandfl ies in Andes mountains. Oroya fever fever, headache, myalgia, haemolysis. Later nodularvascular skin lesions. Diagnosis: Clinical, Blood culture (fastiduous needs prolonged culture), serology. Treatment: Cat-scratch disease often self-limiting. Azithromycin, aminoglycoside. Brucellosis Most common zoonosis worldwide: 500 000 cases/yr. Gram Ωve infection of cattle, swine, goats, sheep, dogs. Human infection via ingestion of infected meat/unpasteurized milk/cheese; or through inhalational/mucosal contact with animal body fl uids (eg farmers, slaughterhouse workers, meat packers, hunters). Risk in countries without animal health programmes. Presentation: Acute (1 month), sub-acute (16 months), or chronic (6 months). Non-specifi c: fever, anorexia, sweats, weight loss, malaise ( TB). Localized infection: septic arthritis, spondylitis, meningitis, endocarditis, orchitis, abscess. Diagnosis: Culture with prolonged incubation due to slow doubling time. 17 Serology (four assays performed by Public Health England Brucella Reference Unit 0151 529 4900). Treatment: Doxycycline, rifampicin, aminoglycoside, ceftriaxone, co-trimoxazole. Needs prolonged course as intracellular with slow doubling time. Relapse usually due to inadequate dose/duration/adherence.",
    "Needs prolonged course as intracellular with slow doubling time. Relapse usually due to inadequate dose/duration/adherence. Coxiella burnetii (Q fever) Q fever is derived from the label query fever attributed to an unexplained disease in Australian abattoir workers. C. burnetii is now recognized as the pathogenic agent. Sheep, goats, cattle are main sources of infection (also cats, dogs, rabbits, ducks, ticks). Occurs worldwide. Spores can survive in soil, animal products, and Water for monthsyr. Transmitted by contact, inhalation of dust, or consumption of raw milk products. Presentation: Incubation 330d. 50% asymptomatic. Non-specifi c symptoms: fever (13wks), nausea, Fatigue, headache. Pneumonia in 12%: typical or atypical, may have rapid progression. Also splenomegaly, granulomatous hepatitis, aseptic meningitis, encephalitis, osteomyelitis. Endocarditis is the most common form of chronic disease. Diagnosis: Coxiella cannot be cultured using routine lab methods. 17 protein-creatinine ratio is rapid. Serology can take 26wks to become positive and detects variation in lipopolysaccharide (LPS) coat. Phase II LPS appears before phase I LPS acute infection IgM/IgG to phase II LPS, chronic infection IgG to phase I LPS. Serology on paired sera 24wks apart provides best diagnostic evidence. Treatment: Doxycycline. Also rifampicin, chloramphenicol, fl uoroquinolone, macrolide. Hydroxychloroquine alkalinizes the phagosomes in which the bacteria resides and may bactericidal eff ect. __OOHHCCMM__1100ee. . iinnddbb 442244 0022//0055//22001177 1199: : 0077 425 sesaesid suoitcefnI Leptospirosis (Weils disease) Pathogenic leptospire spirochaetes belonging to the subgroup Leptospira interrogans. 250 pathogenic serovars. Chronic renal infection of carrier animals: rodent, cattle, pigs. Spread by Water/soil/food contaminated by infected animal Urine. Presentation: Incubation 7d (230d). 1st (acute/septicaemic) phase: fever, non-specifi c fl u-like symptoms. Mild/subclinical in 90%. Followed by recovery or 2nd (immune/ leptospiruric) phase: conjunctival suff usion, myalgia (CK), jaundice, meningitis, uveitis, acute kidney injury, pulmonary haemorrhage, ARDS, myo/pericarditis. (Weils disease described in 1886: fever, jaundice splenomegaly, renal failure, CNS symptoms. Term now applied to all severe disease. ) Diagnosis: In UK18 via National Leptospirosis Service ( gov. uk/guidance/leptospira-reference-unit-services). Culture (Blood/CSF) ve during 1st phase. Serology. protein-creatinine ratio. Treatment: Doxycycline, penicillin. Confl icting evidence of benefi t for steroids in severe disease. Yersinia pestis (plague) Gram Ωve, obligate intracellular pathogen transmitted by small animals and their fl eas by bite, direct contact, inhalation or ingestion (rare). 300 cases/yr worldwide. Presentation: Incubation: 37d. Flu-like symptoms, then one of three disease forms: 1 Bubonic: most common form. Yersinia pestis enters at bite and travels via lymphatics. Infl amed, painful lymph node is termed bubo and can suppurate. 2 Septic aemic: direct spread without bubo, or advanced stage after bubo. 3 Pneumonic: lung disease. Most virulent, least common. Usually from advanced bubonic form but can then transmit via droplets to other humans without fl eas/animals. Diagnosis: Culture bubo fl uid, Blood, sputum. Rapid antigen testing available. Treatment: Reduces mortality from 60% to 15%: streptomycin, tetracycline. 12 Toxoplasmosis Fig 9. 34 Oocysts in cat faeces can stay in the soil for months, where rats Eat them. The rats get infected, and, under the direction of Toxoplasma in the amygdala, the rats lose their fear of cats, and so get eaten in turn. So the parasite ensure success by facilitating a jump from intermediate to defi nitive host. How does the parasite overwhelm the innate fear of cats? By causing a sexual attraction to normally aversive cat odour through limbic activity. From Fernando Monroy: www2. nau. edu/fpm/research/res. html Caused by protozoan Toxoplasma gondii. Found worldwide. Life cycle (fi g 9. 34). Infection is lifelong (⅓ of population). HIV may cause reactivation (p400). Presentation: Asymptomatic in 90%. Self-limiting cervical lymphadenopathy, Lowgrade fever if normal immune system.",
    "HIV may cause reactivation (p400). Presentation: Asymptomatic in 90%. Self-limiting cervical lymphadenopathy, Lowgrade fever if normal immune system. Disseminated disease if immunosuppressed: cerebral abscess, encephalitis, choroidoretinitis, myocarditis, myositis, pneumonitis, hepatitis. Congenital infection: pregnancy loss, neurocognitive defi cit, retinal damage. Diagnosis: In UK via Toxoplasma Reference Laboratory (0179 228 5058). Serology: IgGprevious exposure (High avidity IgG suggests infection 35 months ago, used in pregnancy); IgMacute infection, false ve or chronic infection with persistent IgM; IgA in cord serumcongenital infection. protein-creatinine ratio: Blood/CSF/Urine/amniotic fl uid/aqueous/vitreous humour. Treatment: If eye disease, immunosuppressed or neonate: pyrimethamine sulfadiazine folinic acid. Corticosteroids for eye infl ammation. Spiramycin reduces vertical transmission. Prophylaxis: co-trimoxazole (see HIV, p400). Echinococcosis (hydatid disease) p435. Rabies p437. Hanta virus p426. __OOHHCCMM__1100ee. . iinnddbb 442255 0022//0055//22001177 1199: : 0077 426 sesaesid suoitcefnI Viral haemorrhagic fever (VHF) Viral haemorrhagic fever (VHF) is a term used for severe, multi-organ disease in which the endothelium is damaged, and homeostasis is impaired. Haemorrhage complicates the disease course and can be life-threatening. VHF classifi cation by viral subtype is shown in table 9. 22. Table 9. 22 VHF classifi cation (heart failurehaemorrhagic fever) Virus family Disease (virus subtype) Details Filovirus Ebola See Ebola, this page Marburg See Marburg, p427 Arenavirus Lassa fever (Lassa) See Lassa, p427 Argentinian heart failure (Junin) South American VHF are rare causes of infecBolivian heart failure (Chapare, tion in travellers. Incubation 216d. Resemble Machupo) Lassa fever. Severe disease with bleeding in Brazilian heart failure (Sabia) ⅓. Supportive treatment. Live vaccine available for Junin virus. Venezualan heart failure (Guanarito) Bunyavirus Crimean-Congo heart failure See CCHF, p427 Hanta Rodent host. Incubation 2d-8wk. Causes: 1 heart failure with renal syndrome: fever, headache, GI symptoms, and acute kidney injury. 2 Hanta virus pulmonary syndrome: bilateral interstitial pulmonary infi ltrates, mortality 3040%. Supportive treatment. Rift valley fever Endemic in Africa. 80% asymptomatic or self-limiting febrile illness. 2% CNS involvement/haemorrhagic. Flavivirus Dengue see p420 Yellow fever see p420 The Advisory Committee on Dangerous Pathogens (ACDP) classifi es a pathogen as Group 4 (highest) when it causes severe human disease, with High risk of spread, and no eff ective prophylaxis or treatment. Ebola, 19 Marburg, Lassa, and Crimean-Congo haemorrhagic fever (CCHF) are all Hazard Group 4 haemorrhagic fever viruses. They are largely confi ned to Africa (fi g 9. 35), with Fig 9. 35 VHF risk in Africa. the exception of CCHF which ocReproduced with permission from Viral haemorrhagic curs in Africa, the Middle East, fevers: origins, reservoirs, transmission and guidelines, Crown Eastern Europe, and Asia. copyright 2016. Contains public sector information licensed Ebola under the Open Government Licence v3. 0. Incubation 221d (usually 312d). Evidence for fruit bats as reservoir. Outbreaks with mortality. Largest epidemic (201416) due to Ebola virus (EBOV, formally Zaire ebolavirus): 28 646 cases and 11 323 deaths in Guinea, Liberia, and Sierra Leone. Cytokine activationendothelial damage, oedema, coagulopathy, tissue necrosis, multi-organ failure. Transmission from index case via mucous membranes, or contact with body fl uids (including burial contact), viral shedding in semen. Presentation: Undifferentiated (03d). Fever (38°C axillary), myalgia, weakness, anorexia, headache, sore throat. May not look unwell. GI (410d). Epigastric/abdominal Pain, Liver tenderness, NV, hiccups, diarrhoea, hypovolaemia. Late organ stage (10d). Haemorrhagic: petechiae, ecchymoses, mucosal haemorrhage, GI bleeding, haemoptysis. Neurological: extreme weakness, confusion, agitation, bradypsychia, coma. Other: hypoglycaemia, electrolyte abnormalities, secondary infection, shock, DIC, multi-organ failure, death. __OOHHCCMM__1100ee. . iinnddbb 442266 0022//0055//22001177 1199: : 0077 427 sesaesid suoitcefnI Post-infection: arthralgia, hepatitis, orchitis, transverse myelitis, meningitis, uveitis, vision/hearing impairment, social isolation, psychological eff ects. Diagnosis: PPE (see BOX Equipment) if High possibility (see Risk assessment). WCC, platelet, ASTALT.",
    "Diagnosis: PPE (see BOX Equipment) if High possibility (see Risk assessment). WCC, platelet, ASTALT. IgM (day 3), IgG (day 7), reverse transcriptase protein-creatinine ratio on Blood/Urine/saliva/ throat swab. Exclude malaria. Treatment: Supportive: fl uid resuscitation, correct electrolytes/coagulation/gluEquipment cose, treat secondary infection, nutrition. Ribavirin not Double gloves eff ective. Trace contacts, support family. Experimental: Fluid-repellent gown anti-RNA agents, immunotherapy with Blood/plasma Full-length plastic apron from survivors, monoclonal antibodies (ZMapp), Head cover (surgical cap) Ebola vaccine (rVSV-ZEBOV, Ebola ça suffit! trial). Ethics: Fluid-repellent footwear Randomization versus compassionate use: is it ethi- Full face shield cal to withhold even potentially benefi cial therapy to Full-repellent respirator a control group with a life-threatening condition? Is Meticulous removal. observational data gained through the compassionate use of experimental therapy suffi cient to guide clinical decisions? Where should resources be directed to improve outcome: drug development or basic healthcare provision, eg would the capacity to check potassium improve mortality? Marburg, Lassa, and CCHF Diff erentiating features are given in table 9. 23. Table 9. 23 Diff erentiation between VHF VHF Clinical features Marburg Incubation typically 59d. Clinically identical disease course to Ebola. Ebola/ Marburg suggested by Liver tenderness. Lassa 80% mild/asymptomatic. Haemorrhage in 20%. Variable mortality in different epidemics 2580%. Exudative pharyngitis. Convalescent hearing loss. Observational data shows response to ribavarin if given in fi rst 6d. CCHF Tick-borne. Sudden onset prodrome. Haemorrhagic stage common, develops rapidly, but usually short-lived 23d. Ribavarin used in treatment (evidence). Risk assessment for VHF in UK Assess for possible transmission and fever. Transmission: 1 Travel to endemic area (rural for Lassa fever; caves/primates/antelopes/bats for Ebola/Marburg; tick/animal slaughter for CCHF). 2 Travel to known outbreak ( 3 Contact with infected specimen. Fever: 37. 5°C in the past 24h. If possible transmission and fever consider High possibility (High probability), isolate, PPE (see BOX Equipment). Inform local infectious disease team and contact the Imported Fever Service (0844 778 8990) for VHF investigation. Bruising, bleeding, and uncontrolled DV also warrant isolation and discussion if relevant contact history. Ebola and sacrifi ce This page is dedicated to Dr Sam Brisbane, director of the emergency department in Monrovia, Liberia. Caring, light-hearted, intense, profane. In 2013, he expressed his greatest worry: an epidemic of VHF. A well-founded fear which would ultimately prove prophetic, in a hospital with a shortage of personnel, rationing of gloves, and limited soap. Universal precautions? Unaff ordable, and not even close. He was also a coff ee farmer. But not for him a deserved retirement to his plantation, surrounded by photographs of 8 children, 6 adopted children, and grandchildren to match. Unprotected, despite a lucky fedora and a gallows sense of humour, he contracted Ebola in 2014 at the age of 74 whilst manning the front line of the worlds deadliest VHF epidemic to date. During his illness he told his doctors, When we fi nd ourselves in the middle of the sea and there are rough waves, we should not give up. We should fi ght on to the end. A truly sagacious man whose life and doctoring transcends Western perspectives. We can never replicate your courage, because we will never know your fear. It is fi ttingly, the stuff of legend. __OOHHCCMM__1100ee. . iinnddbb 442277 0022//0055//22001177 1199: : 0077 428 sesaesid suoitcefnI Gastroenteritis: an overview Gastroenteritis diarrhoea (± Vomiting) due to enteric infection with viruses, bacteria, or parasites.",
    "Diarrhoea can be defi ned as: acute diarrhoea: ≥3 episodes partially formed or watery stool/day for 14d dysentery: infectious gastroenteritis with bloody diarrhoea persistent diarrhoea: acutely starting diarrhoea lasting 14d travellers diarrhoea: starting during, or shortly after, foreign travel food poisoning: disease (infection or toxin) caused by consumption of food/Water. Food poisoning is notifi able in the UK (www. gov. uk/health-protection-team). Gastroenteritis can be classifi ed according to infectious aetiology (table 9. 24) or predominant clinical presentation (table 9. 25, also see p259). Table 9. 24 Gastroenteritis by infectious aetiology Infection Organism Incubation Notes Page Virus Norovirus 1d Important cause of epidemic gastroenteritis. 430 5060% 600 0001million cases/yr in UK. Rotavirus 13d Aff ects nearly all children by age 5y. Routine, 430 childhood (live) vaccine in UK. Astrovirus 45d Often less severe than norovirus. Adenovirus 310d Enteric adenovirus. Mainly children. Sapovirus 13d Children. Not common in food-borne disease. CMV 312wks Usually asymptomatic. If immunosuppression: 400, colitis, hepatitis, retinitis, pneumonia. 405 Bacteria Salmonella 1272h Under-cooked eggs, poultry, meat. 431 3040% (non-typhoidal) Campylo25d Under-cooked meat, cross-contamination, un-431 bacter pasteurized milk, Water. E. coli 110d Bloody diarrhoea if Shiga-toxin producing 391, (usually 34d) E. coli (STEC) eg 0157. Can cause HUS. Under-429, cooked beef, unpasteurized milk most common. 431 Shigella 12d S. sonnei most common. Deadly epidemics 431 with S. dysenteriae in Low-income countries. Staphylococ30min6h Unpasteurized milk/cheese, uncooked food. 388 cus aureus Multiplication leads to toxin production. Clostridium 624h Raw meat. Inadequately reheated food. 430 perfringens Clostridium Antibiotic-associated diarrhoea. Spore-form-411 diffi cile ing therefore persists: wash your hands. Listeria 370d Cold meat, soft cheese, refrigerated pâté. 389 Diarrhoea, fever, myalgia. Severity in immunosuppression and pregnancy (bacteraemia, fetal loss). Vibrio chol2h5d Human and aquatic reservoirs. Epidemics due 430 erae to inadequate environmental management. Yersinia en47d Main source is undercooked pork. Most infec-431 terocolitica tion in young children. Bacillus cereus30min15h Leftover food, Rice. Emetic or diarrhoeal toxins. Parasites Giardia 13wks Intestinal parasite. Cyst transfer via infected 432 2% faeces, eg contaminated Water. Malabsorption. Crypto112d Transfer via infected faeces. Symptoms and 400, sporidium severity with immunosuppression, eg HIV. 432 Entamoeba 24wks (can Asymptomatic carrier, intestinal disease and/432 histolytica be years) or extra-intestinal disease (Liver, skin, lung, brain). Cyclospora 1wk Transfer via infected faeces. May have relaps-433 cayetanensis ing course. Trichinella 12d Enteral at 12d. Parenteral at 28wks: larval 433 migration, facial Edema, myocarditis, encephalitis. Trichuriasis 3months Whipworm. Dysentery with heavy infection. 433 Intestinal 4dmonths Eg Fasciolopsis buski. fl ukes __OOHHCCMM__1100ee. . iinnddbb 442288 0022//0055//22001177 1199: : 0077 429 sesaesid suoitcefnI Table 9. 25 Gastroenteritis by clinical presentation Diarrhoea without Blood (enteritis) Diarrhoea with Blood (dysentery) Norovirus Shigellosis (bacillary dysentery) Rotavirus Enterohaemorrhagic E. coli Astrovirus Campylobacter enterocolitis Enteric adenovirus Salmonella enterocolitis Enterotoxigenic E. coli Clostridium diffi cile Enteropathogenic E. coli Yersinia enterocolitis Toxin-producing Staph. aureus Entamoebic histolytica (amoebic dysentery) Cholera Trichuriasis (whipworm) Clostridium perfringens CMV Giardia Cryptosporidium Cyclospora cayetanensis Milder disease may present as diarrhoea without Blood. Travellers diarrhoea Diarrhoea aff ects 2060% of travellers. 20, 21 High-risk areas: South Asia, Central and South America, Africa. Major cause enterotoxigenic E. coli. Prevention: Boil Water, cook thoroughly, peel fruit and vegetables. Avoid ice, salads, shellfi social history. Drink with a straw. Hand washing with soap may risk. Presentation: Most diarrhoea is during fi rst week of travel. Symptoms are often unreliable indicators of aetiology but the following may be indicative: Enterotoxigenic E. coli: watery diarrhoea preceded by cramps and nausea. Giardia lamblia: upper GI symptoms, eg bloating, belching. Campylobacter jejuni and Shigella: colitic symptoms, urgency, cramps. Duration of diarrhoea: most 1wk, 10%1wk, 5% 2wks, 1%30d. Treatment: Oral rehydration. Clear fl uid or oral rehydration salts.",
    "Duration of diarrhoea: most 1wk, 10%1wk, 5% 2wks, 1%30d. Treatment: Oral rehydration. Clear fl uid or oral rehydration salts. Home-made oral rehydration recipe: 6 level teaspoons of Glucose half level teaspoon salt in 1L clean, drinking Water. Antimotility agents, eg loperamide, bismuth subsalicylates. Avoid if severe Pain or bloody diarrhoea as may indicate invasive colitis. Antibiotics: usually not indicated. Considered if rapid cessation of diarrhoea needed and/or limited access to sanitation/healthcare. Reduce diarrhoea from 3 to 1. 5 days. Choice depends on allergy, comorbidity, concomitant medication, and destination of travel: ciprofl oxacin 500mg BD for 3d (care quinolone resistance, eg SE Asia), rifaximin 200mg TDS for 3d, azithromycin 1g single dose or 500mg OD for 3d. Prophylaxis: Not recommended as severe disease and long-term sequelae rare, risk of C. diffi cile. Consider in immunosuppressed (transplant, HIV, chemotherapy), GI pathology (IBD, ileostomy, short-bowel), risk with dehydration (sickle cell, chronic kidney disease). Care with interactions with usual medications. Ciprofl oxacin 500mg OD (80100% protection). Norfl oxacin 400mg OD (7595% protection). Rifaximin 200mg every 1224h (7277% protection). Bismuth subsalicylate 2 tablets QDS (6265% protection, 1st line in ultrasound). Persistent diarrhoea: Investigate if 14d or dysentery: FBC, UE, LFT, infl ammatory markers, stool microscopy for ova/cysts/parasites (historically 3 samples but may not actually improve diagnostic yield, time intensive), molecular testing for (pre-defi ned) microbes. of persistent diarrhoea Giardia (most common diagnosis, send protein-creatinine ratio), Entamoeba histolytica, Shigella. Post-infectious irritable bowel syndrome is a diagnosis of exclusion (in up to 30%). Do not forget: malaria, HIV. __OOHHCCMM__1100ee. . iinnddbb 442299 0022//0055//22001177 1199: : 0077 430 sesaesid suoitcefnI Gastroenteritis: specifi c infections Diarrhoea without Blood Norovirus: Single-stranded RNA virus. Highly infectious. Transmission by contact with infected people, environment, food (10%). Most common cause of infectious GI disease, 600 000 cases in England/yr. Presentation: 1248h after exposure, lasting 2472h: acute-onset Vomiting, watery diarrhoea, cramps, nausea. Virus shed in stool even if asymptomatic. Numerous genotypes and unknown longevity of immunity repeat infection occurs. Diagnosis: clinical, stool sample reverse transcriptase protein-creatinine ratio. Treatment: supportive, anti-motility agents, usually self-limiting. Rotavirus: Double-stranded RNA virus. Wheel-like appearance on EM rota. Commonest cause of gastroenteritis in children (50%). Most infected by 5y. Presentation: incubation 2d. Watery diarrhoea and Vomiting for 38d, fever, abdominal Pain. Diagnosis: clinical, antigen in stool. Treatment: supportive. Routine vaccination in UK (p407). Virus shed in stool post vaccine careful hygiene if immunosuppressed and changing nappies. Live vaccine delay vaccination if in utero biological agents with active transfer across placenta (eg infl iximab, adalimumab). Enterotoxigenic E. coli: Gram Ωve anaerobe. Disease due to heat-stable or heatlabile toxin which stimulates sodium, chlorideand Water effl ux into gut lumen. 20% of all infective diarrhoea, 80% of travellers diarrhoea. Presentation: incubation 13d. Watery diarrhoea, cramps. Lasts 34d. Diagnosis: clinical, identifi cation of toxin from stool culture. Treatment: supportive. See Travellers diarrhoea p429. Clostridium perfringens (type A): Gram ve, anaerobe. Produces enterotoxin. Spores survive cooking and germinate during unrefrigerated storage. 230 outbreaks/yr in UK. Presentation: sudden-onset diarrhoea, cramps, usually lasts 24h. Diagnosis: stool toxin, quantifi cation of faecal bacteria. Treatment: supportive. -toxin of C. perfringens type C can cause a necrotizing enteritis with fulminant disease, Pain, bloody diarrhoea, septic shock. -toxin is sensitive to trypsin proteolysis so risk with trypsin inhibition by sweet potatoes, ascaris infection occurs in New Guinea (pigbel), central/south America, south-east Asia, China. Cholera: Vibrio cholerae is a Gram Ωve, aerobic, comma-shaped fl agellated motile vibrati ng/swarming renal osteodystrophy. Found in faecally contaminated Water. Serovars O1 and O139 cause disease. 190 000 cases in 2014 (fi g 9. 36). Last indigenous case in UK in 1893. Presentation: incubation 2h5d.",
    "190 000 cases in 2014 (fi g 9. 36). Last indigenous case in UK in 1893. Presentation: incubation 2h5d. 75% asymptomatic but shed bacteria. Profuse (1L/h) diarrhoea (Rice-Water stool), Vomiting, dehydration, metabolic acidosis, circulatory collapse, death. Diagnosis: Clinical: death due to dehydration from watery diarrhoea age 5y, or any watery diarrhoea age 5y during known epidemic. Identifi cation of serovars 01 or 0139 in stool. Rapid dipstick testing available but culture confi rmation recommended. Treatment: oral rehydration salts (WHO/UNICEF ORS sachet) will treat12 up to 80%. Needs safe Water. Adults may need 1L/heart rate initially: off er 100mL/5 min. NG if Vomiting. IV fl uids if severely dehydrated: Ringers lactate or 0. 9% saline plus ORS (beware potassium) up to 200mL/kg in fi rst 24h. Antibiotics in severe dehydration to diarrhoea: doxycycline (single dose 300mg) or tetracycline (3d course) guided by local susceptibility (azithromycin in children/pregnancy). Zinc shortens illness in child ren (1020mg/24h). Prevention: cholera loves fi lth: clean Water (and clean politics) abolishes it. Oral cholera vaccines (5694% effi cacy in adults) dependent on logistics, cost, production capacity. Antibiotic prophylaxis breeds resistance. Fig 9. 36 Cholera: areas reporting outbreaks 20102014. Reproduced with permission from World Health Organization, Countries reporting cholera, 20102015. World Health Organization 2016. http: // www. who. int/gho/epidemic_diseases/cholera/epidemics/en/ __OOHHCCMM__1100ee. . iinnddbb 443300 0022//0055//22001177 1199: : 0077 431 sesaesid suoitcefnI On the mode of communication of cholera In 1854, at 40 Broad St, London, a child became ill with diarrhoea, dying on 2 September. Her mother rinsed her soiled nappies into the house drains where faulty brickwork allowed mixing with the Water supply of the Broad St pump (fi g 9. 37). From this confl uence sprung the discipline of Public Health. The ensuing deaths from cholera clustered around the Broad St pump, as detailed by the local doctor, Dr John Snow. He used his now famous Voronoi diagram showing the deaths within a line of nearest pump to motiva te the parish vestry: In consequence of what I said, the handle of the pump was removed the following day, so inauguFig 9. 37 Deaths Dispensary, rating the control of cholera. These events illustrate George Pinwell, 1866. a number of truths: Granger, NYC / Topfoto 1 Knowledge of the microscopic cause of disease is not required for public health measures to succeed (Vibrio cholerae was identifi ed by Robert Kock in 1883). 2 Even the most parochial are capable of life-saving action when assisted by a doctor in command of the facts. 3 Infl uential friends help. Snow remained largely unknown until the 1930s when On the Mode of Communication of Cholera was republished by Wade Hampton Frost, fi rst professor of epidemiology at John Hopkins School. 4 Randomization (Broad St pump versus an alternative Water supply) is king. Diarrhoea with Blood (dysentery) Shigella (sonnei, fl exneri, dysenteriae, boydii): Gram Ωve anaerobe. Presentation: watery or bloody diarrhoea, Pain, tenesmus, fever 12d after exposure. Lasts 57d. in MSM. Complications: bacteraemia, reactive arthritis (2% of fl exneri), HUS (Shigatoxin-producing dysenteriae, p315). Diagnosis: stool culture. protein-creatinine ratio/enzyme immunoassay. Treatment: supportive. Nutrition: green bananas (short-chain fatty acids in colon), zinc if age 6y, vitamin A. Antibiotics if systemically unwell, immunosuppressed. Guided by local sensitivities (ciprofl oxacin, azithromycin). Avoid antidiarrhoeal agents: risk of toxic dilatation. Enterohaemorrhagic/Shiga-toxin producing E. coli (STEC), eg O157: H7: Gram Ωve anaerobe. Produces veratoxins which are Shiga-like due to similarity with Shigella dysenteriae. Presentation: incubation 38d. Diarrhoea, haemorrhagic colitis. HUS in up to 10% (p315). Diagnosis: stool culture. protein-creatinine ratio/enzyme immunoassay for Shiga-toxin. Treatment: Supportive. Do not give antibiotics: risk of HUS. Campylobacter: Gram Ωve, spiral-shaped renal osteodystrophy.",
    "protein-creatinine ratio/enzyme immunoassay for Shiga-toxin. Treatment: Supportive. Do not give antibiotics: risk of HUS. Campylobacter: Gram Ωve, spiral-shaped renal osteodystrophy. Presentation: incubation 110d (usually 25d). Bloody diarrhoea, Pain, fever, headache. Complications: bacteraemia, hepatitis, pancreatitis, miscarriage, reactive arthritis, GuillainBarré. Diagnosis: stool culture. protein-creatinine ratio/enzyme immunoassay. Treatment: supportive. Antibiotics only in invasive cases, refer to local sensitivities (macrolide, doxycycline, quinolone). Salmonella enterocolitis (non-typhoidal): Gram Ωve, anaerobic, motile bacilli. Presentation: diarrhoea, cramps, fever, usually within 1236h of exposure. Invasive infection (10%) can cause bacteraemia/sepsis, meningitis, osteomyelitis, septic arthritis. Diagnosis: stool culture. protein-creatinine ratio. Treatment: supportive. Meta-analysis shows no evidence of benefi t for antibiotics in healthy people. Consider in severe/extra-intestinal disease according to local sensitivities (quinolone, macrolide). Yersinia enterocolitica: Gram Ωve renal osteodystrophy. Presentation: incubation 47d. Diarrhoea, fever, Pain (may mimic appendicitis), Vomiting. May last 13wk. Also erythema nodosum, reactive arthritis (1 month after diarrhoea). Diagnosis: stool culture, agglutination titres. Treatment: antibiotics in severe disease depending on local sensitivities (aminoglycosides, co-trimoxazole, quinolone). See also: Staph. aureus pre-formed toxin (p388), GI parasites (pp4323), Clostridium diffi cile (p411). __OOHHCCMM__1100ee. . iinnddbb 443311 0022//0055//22001177 1199: : 0077 432 sesaesid suoitcefnI Gastrointestinal parasites Giardiasis Giardia lamblia (fi g 9. 38) is a fl agellate protozoan. Faecaloral spread from infected drinking Water/food/fomites. Presentation: Asymptomatic in the majority. Incubation 13wks. Diarrhoea, fl atulence, bloating, Pain, malabsorption. Duration of symptoms typically 26wks. Most common diagnosis if persistent travellers diarrhoea (p429). Diagnosis: Stool microscopy for cysts and troph ozoites. Intermittent shedding so multiple samples (3) may sensitivity. Faecal immunoassay. protein-creatinine ratio for diagnosis/subtype. Duodenal fl uid aspirate analysis. Treatment: Hygiene to prevent transmission. Metronidazole (treatment failure in up to 20%), tinidazole (single dose), albendazole ( side-eff ects, simultaneous treatment Fig 9. 38 Giardia: the of other parasites). Lactose-intolerance develops in 2040%. No only dip lo monadid to treatment for asymptomatic disease in endemic areas due to liketrouble ultrasound. lihood of re-infection. Cryptosporidium Apicomplexan protozoan (fi g 9. 39). Ingestion of oocytes in infected Water. Asymptomatic or self-limiting diarrhoea in immunocompetent hosts. Chronic/severe diarrhoea with immunosuppression: HIV (p400), transplantation, hypogammaglobulinaemia, immunosuppressive therapy. Fig 9. 39 Cryptosporidium immuno fl uo rescence. Amoebiasis Prof. S Upton; Kansas Univ. Protozoan Entamoeba histolytica (fi g 9. 40) 10% worlds population, mortality 100 000/yr. Faecaloral spread. B. oil Water to destroy cysts. Presentation: Asymptomatic passage of cysts in 90% (luminal amoebiasis). Intestinal amoebiasis: dysentery (often insidious onset/relapsing), Pain, colitis, appendicitis, toxic megacolon. Amoeboma infl ammatory abdominal mass, usually caecal/RIF ± obstruction. Extra-intestinal (invasive) disease. Amoebic Liver abscess in 1%. Single mass containing anchovy-sauce pus. High swinging fever, RUQ Pain/tenderness. LFT normal or (cholestatic). 50% have no history of amoebic dysentery. Also peritonitis (rupture of colonic abscess), pleuropulmonary abscess, cutaneous/genital lesions. Fig 9. 40 The lifecycle of Entamoeba histolytica is in two stages: cysts and trophozoites. Cysts (1015μm across) typically contain four nuclei (upper right image). During excystation in the gut lumen, nuclear division is followed by cytoplasmic division, giving rise to eight trophozoites. Tropho zoites (1050μm across) contain one nucleus with a central karyosome (lower right image). Trophozoites inhabit the caecum and colon. Re-encystation of the trophozoites occurs in the colon, and excretion of cysts in faeces perpetuates the lifecycle. Left hand image from Hutson C et al. , Molecular-based diagnosis of Entamoeba histolytica infection, Expert Reviews in Molecular Medicine, 1(9): 111, 1999, reproduced with permission from Cambridge University Press. Upper and lower right images courtesy of Prof. S Upton, Kansas University. __OOHHCCMM__1100ee. . iinnddbb 443322 0022//0055//22001177 1199: : 0088 433 sesaesid suoitcefnI Diagnosis: Microscopy of stool (cysts and trophozoites, fi g 9. 40), aspirate or biopsy sample.",
    "40), aspirate or biopsy sample. Enzyme immunoassay: antigen detection as adjunct to microscopy, antibody detection in extra-intestinal disease. protein-creatinine ratio can distinguish E. histolytica from morphologically identical but non-invasive E. dispar. Treatment: Metronidazole/tinidazole for amoebic dysentery and invasive disease. Diloxanide furoate: luminal agent, 10d course to destroy gut cysts, given in asymptomatic gut carriers and symptomatic disease, in addition to other treatment. Abscess may require (image-guided) drainage. Cyclospora Coccidean protozoan Cyclospora cayetanensis. 50 imported cases/yr in UK. Presentation: Flu-like prodrome, watery diarrhoea, weight loss, marked Fatigue, Low-grade fever in 25%. Self-limiting after 79wks in immunocompetent. Diagnosis: Autofl uorescent oocytes in stool (appear blue-green under UV fl uorescence fi g 9. 41), protein-creatinine ratio. Treatment: Co-trimoxazole. Fig 9. 41 Cyclospora Nematodes (soil-transmitted helminths and Trichinella) oocysts fl uorescence. Roundworm: Ascaris lumbricoides 1 billion aff ected, Credit: CDC DPDx. Trichinella spiralis (contaminated meat source). Whipworm: Trichuris trichiura, 600800 million aff ected. Hookworm: Necator americanus, Ancylostoma duodenale 700 million atrial fibrillationfected. Threadworm: eg Strongyloides stercoralis, 30100 million aff ected. One of most common infections worldFig 9. 42 Larva currens: a serpinginous maculowide, aff ects poor and deprived (fi g 9. 42). papular rash pathognomonic of chronic strongyParasites live in intestines, producing loidiasis. Oedema, an urticarial appearance, and 1000s egg/day in faeces. Humans infected speed of migration (5cm/heart rate) distinguish this from cutaneous larva migrans which is caused by aniby eggs (ascariasis, trichinosis) or larvae mal (dog/cat) hookworm. (Ancylostoma) in contaminated food; or Reproduced from Johnson et al. , Oxford Handbook via direct penetration of the skin (hookof Expedition and Wilderness Medicine, 2016, with worm, Strongyloides). Presentation: permission from Oxford University Press. Diarrhoea, abdominal Pain, Blood/Protein loss, impaired growth/cognitive development. Pruritus/urticaria if migration involves skin (Strongyloides fi g 9. 42). Lung invasion (ascariasis, hookworm, Strongyloides) can lead to a Loeffl er-like syndrome: cough, SOB, wheeze, haemoptysis, consolidation, eosinophilia. Other tissue invasion (trichinosis): myalgia, conjunctivitis, photophobia, meningitis, encephalitis, neuropathy. Diagnosis: Clinical, eggs in stool sample (fi g 9. 43). Eosinophilia. Strongyloides Fig 9. 43 Ascaris eggs (45 serology/protein-creatinine ratio. Treatment: table 9. 26. 40μm) worm (20cm). Courtesy of Prof. S Upton; Table 9. 26 Anthelmintic drugs Kansas University. Drug Mechanism Indication Mebendazole Irreversible block of glucose/nutrient uptake Roundworm, whipworm, hookworm Albendazole ATP, immobilization and death of worm Ascariasis, hookworm, (strongyloides) Ivermectin chloridepermeability, hyperpolarization, paralysis Strongyloides, ascariasis Pyrantel Depolarizing neuromuscular blockade causing Single dose in threadworm, roundpamoate spastic paralysis of worm worm, hookworm Piperazine Flaccid paralysis of worm, expel live worm (Ascariasis), pregnancy Taeniasis (tapeworm) Includes Taenia solium (pork, 28m, 50 000 eggs/worm), Taenia saginata (beef, 412m, 100 000 eggs/worm), Taenia asiatica (Asian, 48m, millions of eggs). Presentation: No or mild GI symptoms, tapeworm segments (proglottids) through anus/in faeces. Diagnosis: Eggs/proglottids in faeces. Treatment: Praziquantel, niclosamide. See also toxoplasmosis (p425), schistosomiasis (p434), cysticercosis (p437). __OOHHCCMM__1100ee. . iinnddbb 443333 0022//0055//22001177 1199: : 0088 434 sesaesid suoitcefnI Schistosomiasis and Liver disease Schistosomiasis (bilharzia) Fig 9. 44 Schistosomiasis life cycle. Reproduced from: Coltart C, CJM Whitty. Schistosomiasis in non-endemic countries. Clin Med 2015; 15: 679. www. clinmed. rcpjournal. org/content/15/1/67. full. pdfhtml. Copyright 2015 Royal College of Physicians. Reproduced with permission. Caused by Blood-fl ukes (trematode worms) of the genus Schistosoma (table 9. 27). 258 million people in 78 countries required treatment in 2014. The life cycle is shown in fi g 9. 44. Disease develops after contact with contaminated freshwater (swimming, washing). Symptoms are due to an immune complex response to the migrating parasite (Katayama syndrome), or deposition of parasite eggs in body tissues. Presentation: 50% asymptomatic or non-specifi c symptoms. Clinical syndromes: Larval penetration: pruritic papular rash (swimmers itch).",
    "Presentation: 50% asymptomatic or non-specifi c symptoms. Clinical syndromes: Larval penetration: pruritic papular rash (swimmers itch). Migration of schistosomules: Katayama syndrome 28wks after exposure: fever, urticaria, diarrhoea, cough, wheeze, hepatos plenomegaly, eosinophilia. Host response to egg deposition: Intestinal disease: Pain, diarrhoea, Blood in stool, (granulomatous) hepatomegaly, splenomegaly. Heavy chronic infection can cause bowel perforation, hyperplasia, polyposis, Liver fi brosis, portal hypertensionvarices. Urogenital disease: haematuria, dysuria, ureteric fi brosishydronephrosis, chronic kidney disease, bladder fi brosis/cancer, genital lesions, vaginal bleeding, dyspareunia, vulval nodules, haemospermia, prostatitis. Lung disease: pulmonary hypertension and cor pulmonale. CNS disease: rare, acute lower limb paraplegia, transverse (travellers) myelitis. Diagnosis: Ova in Urine (S. haematobium) or faeces (all other species) is specifi c, but sensitivity 50% if light infection. Serology for egg antigen becomes ve once mature fl ukes lay eggs will be Ωve in Katayama fever. Bowel/bladder histology. Chronic S. haematobium: bladder calcifi cation on AXR, renal obstruction, hydronephrosis ± thick bladder wall on USS. Treatment: two doses of praziquantel 20mg/ kg PO separated by 4h. Steroids for Katayama fever. If eosinophils 3months after treatment look for other helminths (ve serology can persist for years). Table 9. 27 Parasite species and geographical distribution Disease form Species Geography Intestinal S. mansoni Africa, Middle East, Caribbean, Brazil, Venezuela, Suriname S. japonica China, Indonesia, Philippines Other S. mekongi: Cambodia, Laos; S. guineensis/ intercalatum: rainforests of central Africa Urogenital S. haematobium Africa, Middle East, France __OOHHCCMM__1100ee. . iinnddbb 443344 0022//0055//22001177 1199: : 0088 435 sesaesid suoitcefnI Echinococcosis (hydatid disease) Zoonotic disease caused by tapeworms of the genus Echinococcus. Clinically important disease forms in humans are: Cystic echinococcosis (hydatid disease, hydatosis): E. granulosus. Found worldwide. Usual host is dog. Also goats, swine, horses, cattle, camels, yaks. Alveolar echinococcosis: E. multilocularis. Found in northern hemisphere. Usual hosts are foxes and rodents. Human ingest parasite eggs via food/Water contaminated by animal faeces, or by handing animals which are infected with the tapeworm. Disease is due to the development of cyst-like larvae in viscera, usually Liver/lungs. Presentation: Slow growing cysts may be asymptomatic for many years. Symptoms and signs depends on location: Liver: abdominal Pain, nausea, hepatomegaly, obstructive jaundice, cholangitis, PUO. Lung: : dyspnoea, chest Pain, cough, haemoptysis. CNS: space-occupying signs. Bone: an interesting osteolytic cause of knee Pain, cord compression. Silent disease in breast, Kidney, adrenals, bladder, Heart, psoas. Diagnosis: USS/computed tomography/magnetic resonance imaging: avascular fl uid-fi lled cysts ± calcifi cation ( benign cyst, TB, mycoses, abscess, neoplasm). Serology. Positive echinococcal antigen. Treatment: Get help (including surgical). Depends on cyst type, location, size, and complications. Prolonged treatment (months/years) with albendazole. PAIR: Puncture, Aspirate, Inject (hypertonic saline/chemicals), Reaspirate. Beware spillage of cyst contents: praziquantel can be given peri-operatively. Fasciola hepatica (common Liver fl uke) Parasitic infection. 2 million infected worldwide. Highest rates of infection in Bolivia and Peru. Infective larvae develop in aquatic snail hosts. Humans infected via contaminated Water, waterplants eg watercress, or by eating the undercooked Liver of another host animal eg sheep, goat. Disease caused by migration of parasite to bile ducts. Presentation: Acute phase with migration from intestine through Liver (24 months): abdominal Pain, nausea, fever, urticarial rash, eosinophilia. Chronic phase with egg production in the bile ducts: cholecystitis, cholangitis, pancreatitis, cirrhosis. Diagnosis: Serology in acute and chronic phase. Ova in stool/bile aspirate only in chronic phase. Treatment: Triclabendazole as a single dose. Treat all suspected cases in endemic areas. Other Liver fl ukes: opisthorchiasis and clonorchiasis Opisthorchis and clonorchis are Liver fl ukes acquired by eating contaminated fi social history, mainly in south-east Asia. Adult worms lodge in the small bile ducts and gallbladder.",
    "Adult worms lodge in the small bile ducts and gallbladder. Presentation: Abdominal Pain, GI disturbance, cholecystitis, cholangitis, cholangiocarcinoma. Diagnosis: Ova in stool. Treatment: Praziquantel. Tropical Liver disease An overview of the diff erential diagnosis of tropical/imported Liver disease is shown in table 9. 28. Table 9. 28 Tropical Liver disease by presentation22 Presentation Diff erential diagnosis Jaundice/hepatitis Viral hepatitis, brucellosis, dengue, enteric fever, HIV, leptospirosis, malaria, rickettsial infection, sepsis, TB, viral haemorrhagic fever, yellow fever Hepatomegaly Amoebic/pyogenic Liver abscess, echinococcosis, Liver fl uke, carcinoma Massive hepatomegaly Visceral leishmaniasis, tropical lymphoma, late-stage schistosomiasis Fibrosis/cirrhosis Chronic hepatitis, schistosomiasis, alcohol, non-alcoholic fatty Liver disease Consider Liver toxicity: ackee fruit (Jamaica), afl atoxins (peanuts, corn, tropical countries without monitoring/regulation), death cap mushroom, iron, bush tea, methanol, copper, paraquat, pyrrolizidine alkaloids (herbal remedies). __OOHHCCMM__1100ee. . iinnddbb 443355 0022//0055//22001177 1199: : 0088 436 sesaesid suoitcefnI Neurological disease Botulism Neuroparalytic infection caused by neurotoxin from anaerobic, spore-forming Clostridium botulinum (rarely C. butyricum, C. barattii). Food-borne due to toxin production in food (botulus is Latin for sausage), or wound botulism due to spore germination in wound (includes IV drug use). Toxin blocks release of acetylc holine at neuromuscular junction causing fl accid paralysis. Presentation: Incubation up to 8d (usually 1236h). Afebrile, descending, fl accid paralysis: diplopia, ptosis, dysarthria, dysphagia, progressive paralysis of limbs, respiratory failure. Autonomic signs: dry mouth, fi xed/dilated pupils, urinary/cardiac/GI dysfunction. No sensory signs. Diagnosis: Clinical: do not delay treatment. Take samples (serum, faeces, wound swab) for later confi rmation by culture/protein-creatinine ratio. In UK contact GI Bacteria Reference Unit (020 8327 7887). Treatment: Get help. Admit to ITU. Botulinum antitoxin (from Public Health England, Colindale 020 8200 4400), benzylpenicillin, metronidazole. Tetanus Caused by anaerobic Clostridium tetani spores universally present in soil. Enters body via a breach in skin. Produces a neurotoxin (tetanospasmin) which disseminates via Blood/ lymphatics and interferes with neurotransmitter release causing unopposed muscle contraction and spasm (tetanus to stretch). 6 cases/yr Fig 9. 45 Spasm causing opisthotonus (arching of in England and Wales (2015). Materbody with neck hyperextension). tetanus, rabies, nal and neonatal tetanus important cerebral malaria, neurosyphilis, acute cerebral injury, cause of preventable mortality in catatonia. Lowmiddle income countries. Pres- Centers for Disease Control and Prevention. entation: Site of entry may be trivial/unnoticed. Incubation 321d. Prodrome: fever, malaise, headache. Trismus (lockjaw, Greek trismos grinding). Risus sardonicus a grin-like posture of hypertonic facial muscles. Opisthotonus (fi g 9. 45). Muscular spasms induced by movement, injections, noise, then spontaneous. Dysphagia. Autonomic dysfunction: arrhyt hmias ± fl uctuating blood pressure. Respiratory arrest. Diagnosis: Clinical. Detection of tetanus toxin/isolation of C. tetani. Treatment: Get help on ITU: level of supportive care predicts outcome. Tetanus immunoglobulin (TIG) IM (or equine antitetanus serum if not available). Take Blood for detection of tetanus-toxin and anti-tetanus antibodies fi rst. Wound debridement, metronidazole. Management of spasm: diazepam/lorazepam/midazolam (may need High doses IV), IV magnesium sulphate, baclofen (intra-thecal administration needed for penetration of Blood brain barrier only with ICU ventilatory support), dantrolene, botulinum toxin-A. 23 Vaccination: Routine in UK (p407). Prophylaxis following injury: TIG if heavy contamination. If vaccination history unknown/incomplete: TIG plus dose of vaccine in a different site. Precautionary travel booster if 10y since last dose. Poliomyelitis A highly infectious picornavirus, transmitted via faecooral route or contaminated food/Water. Replicates in intestine. Invades nervous system with destruction of anterior horn cells/brain stemirreversible paralysis. Incidence by 99% since formation of Global Polio Eradication Initiative in 1988. 74 cases in 2015. Remains endemic in Afghanistan and Pakistan (2016). 12 Presentation: Incubation 710d. Flu-like prodrome in 25%. Pre-paralytic stage: fever, heart rate, headache, Vomiting, neck stiff ness, tremor, limb Pain.",
    "Flu-like prodrome in 25%. Pre-paralytic stage: fever, heart rate, headache, Vomiting, neck stiff ness, tremor, limb Pain. 1 in 200 progress to paralytic stage: LMN/bulbar signs ± respiratory failure. No sensory signs. Post-polio syndrome in 40% of survivors (up to 40y later): new progressive muscle weakness, myalgia, Fatigue. Diagnosis: Viral culture of stool (most sensitive, 2 samples 24h apart), pharyngeal swabs, Blood, CSF. protein-creatinine ratio can diff erentiate wild-type from vaccine. Paired serology. Treatment: None. Vaccination: Salk (inactivated, IM) or Sabin (live, oral). In previously endemic areas 200 million volunteers have vaccinated 3 billion children, preventing 1. 5 million deaths in the last 20y. __OOHHCCMM__1100ee. . iinnddbb 443366 0022//0055//22001177 1199: : 0088 437 sesaesid suoitcefnI Rabies Rhabdovirus transmitted through saliva or CNS tissue, usually from the bite of an infected mammal, eg bat (in UK), dog (95% of transmissions to humans), cat, fox. Disease is fatal once symptoms appear. Worldwide distribution. 50 000 deaths/yr, most in Africa/Asia. Presentation: Incubation 990d. Prodrome: headache, malaise, odd behaviour, agitation, fever, paraesthesia at bite/wound site. Progresses to one of two disease forms: Furious rabies: hyperactivity and terror (hydrophobia, aerophobia) Paralytic rabies: fl accid paralysis in the bitten limbcomadeath. Diagnosis: Clinical: potential exposure signs of myelitis/encephalitis (non-progressive disease and disease 3wk are negative indicators). Viral protein-creatinine ratio (saliva, brain, nerve tissue) or CSF antibodies may off er later (post-mortem) confi rmation. Treatment: If bitten, or lick to broken skin, wash (15min) with soap and seek urgent help. Post-exposure prophylaxis: vaccination ± rabies immunoglobulin. Experimental treatments: ribavirin, interferon alfa, ketamine. Preventable and elimination feasible with pre-exposure vaccination of all at risk. Vaccination of dogs can human cases. Japanese encephalitis virus Flavivirus spread by mosquitoes. Endemic transmission (3 billion at risk) and common cause of viral encephalitis in Asia and west Pacifi c. Severe disease is rare (1 in 250) but leads to neurological or psychiatric sequelae in up to 50%, mortality up to 30%. Presentation: Incubation 515d. Most asymptomatic, or mild fever and headache only. Severe disease: High fever, headache, meningism, altered mental status, coma, seizures, spastic paralysis, death. Diagnosis: Clinical in endemic area. Serum/ CSF serology, protein-creatinine ratio. 7 Treatment: Supportive. Vaccination. West Nile virus Mosquito-borne fl avivirus with transmission in Europe, Middle East, Africa, Asia, Australia, and Americas. Presentation: Incubation 214d. Asymptomatic in 80%. West Nile fever in 20%: fever, headache, NV, lymphadenopathy. Neuroinvasive in 1%: encephalitis, meningitis, fl accid paralysis, mortality 10%. Diagnosis: Serum/ CSF IgM, viral protein-creatinine ratio. Treatment: Supportive. Vaccine awaited (2016). Neurocysticercosis Most common helminthic disease of the CNS and most frequent cause of preventable epilepsy (50% of epilepsy in endemic areas, fi g 9. 46). Caused by pork tapeworm Taenia solium. Consumption of infected pork leads to intestinal infection (taeniasis) and the shedding of T. solium eggs in stool. Invasive disease occurs when the shed eggs are ingested via faecooral transmission. Neurocysticercosis is due to larval cysts infecting the CNS. Presentation: Determined by site and number of lesions (cysticerci) within the brain/spinal cord. Epilepsy in 70%. Focal neurology in 20%: motor/sensory loss, language disturbance, involuntary movements. Also headache, visual loss, meningitis, hydrocephalus, cognitive impairment. Diagnosis: computed tomography/magnetic resonance imaging imaging plus serology. Treatment: Seizure control (evidence on drug choice, length of treatment or prophylaxis). Neurosurgical advice if Fig 9. 46 Endemicity (red) and suspected endemicity (orange) hydrocephalus/ICP. Albenof Taenia solium 2015. dazole for non-calcifi ed Reproduced with permission from WHO, Endemicity of Taenia solium, lesions (better penetration 2015. World Health Organization 2016. of CNS than praziquantel). factsheets/Endemicity_Taenia_Solium_20151000x706. jpg? ua1 Beware infl ammatory response provoked by treatment consider dexamethasone.",
    "World Health Organization 2016. of CNS than praziquantel). factsheets/Endemicity_Taenia_Solium_20151000x706. jpg? ua1 Beware infl ammatory response provoked by treatment consider dexamethasone. 7 Specialist diagnostic service and advice in UK via Rare and Imported Pathogens Laboratory (RIPL): www. gov. uk/government/collections/rare-and-imported-pathogens-laboratory-ripl __OOHHCCMM__1100ee. . iinnddbb 443377 0022//0055//22001177 1199: : 0088 438 sesaesid suoitcefnI Eye disease Conjunctivitis Common in tropical areas. Vision is normal. Diff erentiation between common infectious causes is outlined in table 9. 29. Table 9. 29 Common causes of conjunctivitis Cause Secretions Features Treatment Bacterial Purulent Red and swollen Topical antibiotics for 5d Viral Watery ± Corneal lesion Symptomatic Trachoma Mucopurulent Follicles and papillae on lid Azithromycin PO or topical (chlamydial) tetracycline Reproduced from Brent et al. , Oxford Handbook of Tropical Medicine, 2014, with permission from Oxford University Press. Trachoma Leading infectious cause of blindness worldwide: visual impairment/blindness in 1. 9 million, 200 million at risk. Prevalence in endemic areas 6090% (Africa, Central and South America, Asia, Middle East). Caused by Chlamydia trachomatis. Human-tohuman transmission with contact, or via fl ies which land on noses/eyes. Presentation: Active infection causes purulent discharge and follicular infl ammation of the eyelid (fi g 9. 47a)scarring (fig 9. 47b)eyelids turn inwards (entropion) and irritate the cornea (trichiasis) (fig 9. 47c) leading to visual loss. Treatment: WHO public health strategy SAFE: surgery to treat blinding disease (trichiasis), antibiotics (azithromycin) to clear infection (mass administration in endemic areas through International Trachoma Initiative), facial cleanliness, environmental improvement with access to Water and sanitation. 12 (a) (b) (c) Fig 9. 47 (a) Follicular trachoma. (b) Scarring. (c) Trichiasis. Reproduced from Warrell et al. , Oxford Textbook of Medicine, 2010, with permission from Oxford University Press. Immunosuppression and the eye Herpes zoster ophthalmicus: Due to reactivation of latent varicella zoster virus (p404) in the ophthalmic branch of the trigeminal nerve. Risk of reactivation and ocular complications in immunosuppression: HIV, post-transplantation. Presentation: vesiculomacular skin rash and dysaesthesia in ophthalmic division of the trigeminal nerve (fi g 9. 48). Hutchinsons sign lesion at tip/side of nose indicates involvement of nasociliary branch of V1 and chance of eye involvement. Complications: corneal Fig 9. 48 Herpes zoster ophthalmicus. opacifi cation, uveitis, ocular nerve palsy, eyelid de- membranous nephropathy Oxman, University of California. formity, optic neuritis, post-herpetic neuralgia. Can be sight-threatening recognition and urgent treatment are required. Diagnosis: clinical. Antibody staining/protein-creatinine ratio of skin scrapings. Treatment: oral famciclovir/valacyclovir or systemic aciclovir reduce complications if given within 72h of symptoms. Analgesia. If retinitis IV cidofovir ± intravitreal ganciclovir or foscarnet. CMV retinitis: Reactivation of CMV infection (p405). Presentation: fl oaters due to infl ammatory cells in vitreous, fl ashing Fig 9. 49 CMV retinitis (mozzarella pizza fundus). lights, scotomata, eye Pain, visual loss. Peripheral lesions Prof Trobe. __OOHHCCMM__1100ee. . iinnddbb 443388 0022//0055//22001177 1199: : 0088 439 sesaesid suoitcefnI may be asymptomatic. Routine examination for those at risk (CD4100 cells/microlitre). Diagnosis: clinical. Fundoscopy: granular white dots, haemorrhage (fi g 9. 49). Can progress to an arcuate/triangular zone of infection, or can be linear following vessels/nerve fi bres. Treatment: systemic valganciclovir (oral, IV). Also ganciclovir, foscarnet, cidofovir. ART if underlying HIV (see p402). Ocular toxoplasmosis: Causes posterior uveitis. Presentation: blurred vision/ fl oaters. Diagnosis: clinical. Fundoscopy (fi g 9. 50): focus Fig 9. 50 Retinal toxoplasof choroiditis, chorioretinal scar from previous infection, mosis. Prof Trobe. overlying vitreal haze due to infl ammatory response. Multiple/bilateral/extensive lesions if immunosuppression. Serology. Ocular fl uid protein-creatinine ratio. Treatment: atovaquone (toxicity), sulfadiazine, and pyrimethamine. Filarial infection Onchocerciasis (river blindness) Caused by fi larial worm, Onchocerca volvulus. Transmitted by the bite of infected black fl ies which breed in fast-fl owing rivers and streams.",
    "visible (fi g 9. 55). Itch can lead to secondary bacterial Reproduced from Burge et al. , Oxford infection. Diagnosis: Clinical. Skin scraping for mite/ Handbook of Medical Dermatology, eggs/faeces. Treatment: Topical permethrin 5% or 2016, with permission from Oxford malathion 0. 5%. Ivermectin given for fi lariasis (p421) University Press. may eff ectively treat concurrent scabies. Cutaneous leishmaniasis Most common form of leishmaniasis. Estimated 0. 71. 3 million new cases/yr: Americas, Mediterranean basin, north Africa, Middle East, central Asia. Presentation: Lesions develop at the bite site, beg i nning as an itchy papule; crusts fall off to leave a Painless ulcer with a well-defi ned, raised border and a crusted base Chicleros ulcer (fi g 9. 56). Diagnosis: Skin biopsy protein-creatinine ratio. Treatment: Most heal in 215 months with scarring (disfi guring if extensive). New World disease (South America) needs treating due Fig 9. 56 Cutaneous leishmaniasis with cento risk of mucocutaneous disease: pentavatral crusting. lent antimony, eg meglumine antimoniate, Reproduced from Lewis-Jones, Paediatric DerSodium stibogluconate. (See p423. ) matology, 2010, with permission from Oxford University Press. __OOHHCCMM__1100ee. . iinnddbb 444400 0022//0055//22001177 1199: : 0088 441 sesaesid suoitcefnI Myiasis Infection with fl y larvae/maggot. Can aff ect living and necrotic tissue. In south and central America the human botfl y lays its eggs on mosquitoes which deposit them when they bite. In sub-Sahran Africa the tumbu fl y lays its eggs on clothing which then transfer to skin. Presentation: Painful Edema. May have sensation of movement within the lesion. May open to reveal larval breathing tubes (fi g 9. 57). Diagnosis: Clinical. Identifi cation of larvae in lesion. Treatment: Petroleum or pork fat cause asphyxiation of the magFig 9. 57 Myiasis. got causing it to protrude further out of the skin enaReproduced under Creative Commons bling removal with tweezers. Care: backward-facing CC0 1. 0 Universal Public Domain from spines in American disease may prevent complete removal unless done surgically. Ensure tetanus vacFile: Miasis_human. jpg cination is up to date. Tungiasis Infection of the skin by the sand/jigger fl ea Tunga penetrans. Acquired (usually walking barefoot) in sandy soil, rainforests, and Banana plantations in south and central America, sub-Saharan Africa, Asia, Caribbean. Presentation: Painful, itchy papule on the feet. May be visible extrusion of eggs. Black crusting when fl ea dies. Diagnosis: Clinical. Treatment: None, self-limiting. Leprosy (Hansens disease) Caused by slow-growing, acid-fast Mycobacterium leprae which aff ects skin, nerves, and mucous membranes. Incubation 520y. Transmitted via droplets from nose/mouth during close and frequent contact. Classifi ed as: Multibacillary (lepromatous): immune response, bacilli, ve smear. Paucibacillary (tuberculoid): immune response, granulomata with bacilli, smears may be Ωve. Free treatment through WHO since 1995: prevalence by 99% to 176 000 in 2014 (5. 2 million in 1985). 12 Presentation: Hypopigmented skin lesions (fi g 9. 58, less well demarcated than vitiligo), sensory loss, thickened nerves, nodules, plaques, nasal congestion, epistaxis, muscle weakness, paralysis, neuropathic ulcers. Eye involvement: chronic iritis, scleritis, episcleritis, corneal sensation (V nerve palsy), blinking and lagophthalmos (VII nerve palsy), trauma from eyelashes (trichiasis). Diagnosis: Clinical, ve skin smear, skin biopsy. Serology unreliable. Treatment: WHO multidrug therapy: Multibacillary: Rifampicin 600mg/month, Fig 9. 58 Leprosy: hypopigmented macdapsone 100mg OD, clofazimine 300mg/month ules. Courtesy of Prof. Jayakar Thoma. and 50mg OD. Duration: 1yr. Paucibacillary: rifampicin 600mg/month, dapsone 100mg OD. Duration: 6 months. If single lesion: rifampicin 600mgofl oxacin 400mgminocycline 100mg (single dose). Yaws Chronic granulomatous disease caused byTreponema pertenue. Found in humid/rainforest areas in Africa, Asia, Latin American, Pacifi c. Associated with socioeconomic conditions. Transmission via direct contact. Presentation: Primary disease papilloma. If untreated will ulcerate (fi g 9. 59).",
    "Transmission via direct contact. Presentation: Primary disease papilloma. If untreated will ulcerate (fi g 9. 59). Secondary disease: yellow skin Bloodsions, dactylitis. cvs and CNS complications do not occur. Diagnosis: Serology is indistinguish able from syphilis Fig 9. 59 Ulceropapilloma- (Treponema pallidum). Dual-path platform (DPP) assay tous yaws. can distinguish between current and past infection. protein-creatinine ratio. Courtesy of Dr B Hudson, Treatment: Single-dose azithromycin PO. Sydney, Australia. __OOHHCCMM__1100ee. . iinnddbb 444411 0022//0055//22001177 1199: : 0088 442 sesaesid suoitcefnI Pyrexia of unknown origin (PUO) This chapter gives guidance on hundreds of pyrexia-causing infections; but what should you do if your patient has a fever that you cannot explain? Pyrexia of unknown origin (PUO)24 has a diff erential of 200 diseases. 1530% of these patients will eventually be given an infective diagnosis (depending on your corner of the globe). 20% will remain undiagnosed, but in most of these the fever will resolve within 4wks. Diagnostic criteria Pyrexia 3wks with no identifi ed cause after evaluation in hospital for 3d or ≥3 out-patient visits. Fever may also be undiagnosed in specifi c subgroups despite appropriate evaluation for 3d, including negative cultures at ≥ 2 days: Nosocomial PUO: Patient hospitalized for 48h with no infection at admission. Immunodefi cient PUO: Pyrexia in patient with 500 neutrophils/microlitre. HIV PUO: Pyrexia in HIV infection lasting 3d as an in-patient or 4wks as an outpatient. History Most PUO are due to common diseases with atypical presentation. Consider all details as potentially relevant. Include: travel (p414), diet, animal contact, changes in medication, recreational drug use, obstetric/sexual history, family history (table 9. 30). Examination Confi rm fever. Pattern of fever is rarely helpful (contrary to the textbooks, most malaria has no specifi c pattern). Do not forget: mouth, genitals, skin, thyroid, lymphatic system, eyes including retina, temporal arteries (table 9. 30). Investigation Extent of investigation depends on immune status and how well the patient is. Blood tests: FBC, UE, LFT, CRP, ESR, electrophoresis, LDH, CK, ANA, ANCA, rheumatoid factor, HIV test, malaria smear, interferon-gamma release assay for TB (p394). Microscopy and culture: Blood 3, Urine, sputum (including AFB), stool, CSF. Imaging: CXR, abdominal/pelvic USS, venous Doppler. Consider: computed tomography(PA), magnetic resonance imaging, echo (TOE). Fluorodeoxyglucose-PET (FDG-PET) highlights areas of glucose uptake including tumour and infl ammation. It may aid/direct diagnosis in up to 50% of PUO. Other: Hepatitis serology, CMV, EBV, autoimmune screen, cryoglobulins, toxoplasmosis, brucellosis, Coxiella, lymph node biopsy, endoscopy, temporal artery biopsy. Table 9. 30 PUO diff erential according to history and examination fi ndings History Diff erential Animal contact Brucellosis, toxoplasmosis, Bartonella, leptospirosis, Q fever, psittacosis Cough TB, physical examination, Q fever, enteric fever, sarcoidosis, legionnaires disease Nasal symptoms Sinusitis, GPA, relapsing fever, psittacosis Confusion TB, Cryptococcus, sarcoid, carcinomatosis, brucellosis, enteric fever Arthralgia SLE, infective endocarditis, Lyme disease, brucellosis, TB, IBD Weight loss Malignancy, vasculitis, TB, HIV, IBD, thyrotoxicosis Family history Familial Mediterranean fever Drug history Drug-induced fever (710d after new drug) Examination Diff erential Conjunctivitis Leptospirosis, relapsing fever, spotted fever, trichinosis Uveitis TB, sarcoid, adult Stills disease, SLE, Behçets disease Mouth Dental abscess, Behçets disease, CMV, IBD Lymphadenopathy Lymphoma, TB, EBV, CMV, HIV, toxoplasmosis, brucellosis, Bartonella Rash HIV, EBV, SLE, vasculitis, Stills disease, endocarditis Hepatomegaly TB, EBV, malignancy, malaria, enteric fever, granulomatous hepatitis, Q fever, visceral leishmaniasis Splenomegaly Leukaemia, lymphoma, TB, brucellosis, infective endocarditis, CMV, EBV, rheumatoid arthritis, sarcoid, enteric fever, relapsing fever Renal Chronic pyelonephritis, perinephric abscess, renal tumour Epididymo-orchitis TB, lymphoma, EBV, brucellosis, leptospirosis __OOHHCCMM__1100ee. .",
    ". iinnddbb 444422 0022//0055//22001177 1199: : 0088 443 sesaesid suoitcefnI Eliciting the weird and the wonderful Listen to your patient You have two cultures to master: the host and the pathogen. Prolonged immersion in both may be needed. Ask Do not expect to fi nd apposite questions such as these in any other textbook: 1 Have you delivered any septic babies in the last year? Impress and cure your obstetrician friends who tell you that Im so depressed about not being able to shake off this fl u, and who have forgotten about transfer of brucellosis from baby to obstetrician. 2 Are your carp well at present? Mycobacte rium marinum skin infection. 3 Could that be a Hyalomma tick bite from when you rode your ostrich in last weeks race? Crimean-Congo haemorrhagic fever. 4 Who has been licking your face recently? Pasteurella multocida. 5 Has your dog been on holiday this year? Monkeypox from prairie dogs. 6 Has your pet hedgehog lost weight? Salmonella. 7 Did you develop your headache after you adopted your pet magpie? Zoonotic transmission of Cryptococcus neoformans causing meningitis. 8 Did you have a stray pig living under your house when the monsoon started? Pigs standing Water mosquitoes Japanese encephalitis. 9 Did you sample the local frog paella? Angiostrongyliasis causing eosinophilic meningitis. 10 Did your goat miscarry last year? Coxiella burnetii. 11 Did your depressed pig develop a purple snout? Erysipelothrix rhusiopathiae endocarditis via swine erysipelas. 12 Can I see your pet lobster: he may be the cause of your Bad hand? Lobstermans hand, an erysipeloid infection from Erysipelothrix. Pet lobsters have a grand pedigree. Gérard de Nerval used to take his pet lobster for walks, on a blue silk lead, beside the Seine (fi g 9. 60). A lobster, he said, is, serious-minded and quiet, doesnt scratch or bark like a dog, and knows all of the secrets of the deep. His lobsters mission was to combat the Philistinism chaining ultrasound all to mediocrity. Ask also, Where have you been? Though you will not be Fig 9. 60 Is your pet lobster absolved of thought, even when the answer is, Southwell? (Gérard de Nerval). end. It may be a question of amnesic stopovers. Or perhaps your patient is an airport baggage-handler, bitten by a hitch-hiking mosquito. And even when there has been no travel to the tropics, global warming is ensuring that the tropics are travelling to ultrasound. To the fi rst writers of medical books, Paradise was just beyond the Far East, and the world was a disc surrounded by oceans of blue Water. But the world moves on, tarnished, tawdry, and trashed; and Paradise appears to be evolving with ever more serpents in the garden, beguiling ultrasound with ambiguous answers to our great questions. Dont give up If the culture is negative, tests may need repeating. Perhaps the organism is fastidious in its nutritional requirement or requires a longer incubation? Even if culture is achieved, it may be that the organism grown is fl ora not pathogen. If culture fails, look for antibodies or antigen. protein-creatinine ratio is increasingly used for identifi cation, but it is far from infallible; beware of inhibitors, contamination, and a primer that is not as unique as your patient. Remember Sherlock: My mind, he said, rebels at stagnation. Give me problems, give me work, give me the most abstruse cryptogram or the most intricate analysis, and I am in my own proper atmosphere. I can dispense then with artifi cial stimulants. But I abhor the dull routine of existence. I crave for mental exaltation.",
    "But I abhor the dull routine of existence. I crave for mental exaltation. That is why I have chosen my own particular profession, - or rather created it, for I am the only one in the world. The Sign of the Four, Arthur Conan Doyle, 1890. No, Sherlock, you are not; you have the infectious disease physicians for company. __OOHHCCMM__1100ee. . iinnddbb 444433 0022//0055//22001177 1199: : 0088 10 Neurology Contents Neurology at the bedside: Where is the lesion? 446 Drugs and the nervous system 448 Cerebral Blood supply 450 Testing peripheral nerves 452 Dermatomes and peripheral nerves 454 Some common presentations: Headache 456 Migraine 458 Blackouts 460 Vertigo dizziness 462 Hearing loss tinnitus 464 Acute bilateral leg weakness 466 Abnormal involuntary movements (dyskinesia) 468 Diseases and conditions: Stroke: Clinical features and acute management 470 Investigation and prevention 472 Re-enablement after stroke 474 Transient ischaemic attack (TIA) 476 Subarachnoid haemorrhage (SAH) 478 Intracranial venous thrombosis (IVT) 480 s F u ig b - 1 4 0 m. 1 in S u i t r e R m og il e e r o B n a 6 n n M is a t y e r 1 C 9 B 5 E 4 r a a t n t t h h e e a fi g r e s t o e f v 2 e 5 r. Subdural haematoma 482 At that time he was a medical student at Oxford Extradural (epidural) University, and graduated the following year. He haematoma 482 went on to become a prominent academic neuDelirium (acute confusional rologist, conducting research into the autonomic state) 484 nervous system, which he regarded as his greatDementia 486 est achievement. Autonomic activity and running Alzheimers disease (AD) 488 are, of course, intimately linked, as Bannister Epilepsy: diagnosis 490 refl ected in a more poetic manner than the usual Epilepsy: management 492 fi ght or fl ight cliché: As a child I ran barefoot Parkinsonism 494 along damp, fresh sand by the seashore. The air Multiple sclerosis (MS) 496 there had a special quality. The sound of breakSpace-occupying lesions (SOL) 498 ers shut out all others, and I was startled, almost Idiopathic intracranial frightened, by the tremendous excitement a few hypertension 498 steps could create. It was an intense moment of discovery of a source of power and beauty that Bells palsy 500 one previously hardly dreamt existed. In 2014, Mononeuropathies 502 Bannister spoke publicly of his sense of irony at Polyneuropathies 504 being diagnosed with Parkinsons disease. Autonomic neuropathy 505 Bettmann / Bettmann collection / Getty Images. Motor neuron disease (MND) 506 Bulbar palsy 507 Cervical spondylosis 508 Myopathy 510 Myasthenia gravis (magnesium) 512 LambertEaton myasthenic syndrome (LEMS) 512 Neurofi bromatosis 514 Syringomyelia 516 Retroviruses and neurology 517 __OOHHCCMM__1100ee. . iinnddbb 444444 0022//0055//22001177 1199: : 0088 445 ygolorueN I think, therefore I am It is the brain, more than any other organ, that marks Homo sapiens apart from other animals. Our ability to be self-aware, to think, and to reason has formed the basis of scientifi c inquiry and philosophical speculation for millennia, as we attempt to rationalize and defi ne this cognitive capability. What is the mind? Less tangible than other aspects of our being, throughout time humans have looked to explanations from philosophy, folklore, religion, and now science. The concept of the sense of self and being that defi nes ultrasound awhether it be called the ego, nous, or the soulremains intriguing yet elusive to explain.",
    "Fig 10. 9 Feet and hands. __OOHHCCMM__1100ee. . iinnddbb 445555 0022//0055//22001177 1199: : 0088 456 ygolorueN Headache Every day, thousands of people visit the doctor complaining of headache. Tension headaches are the most common, but beware the disabling and treatable (migraine, cluster headache), and the sinister (space-occupying lesions, meningitis, subarachnoid haemorrhage). A Good history is the key. Ask about: Onset Rapid onset headaches are concerning; the key diagnosis to rule out here is subarachnoid haemorrhage (SAH, p478), sudden-onset, worst ever headache, often occipital, stiff neck, focal signs, consciousness. Other diff erentials include: Meningitis (p822): fever, photophobia, stiff neck, purpuric rash, coma. May be associated with neck stiff ness ( meningeal irritation). Do an LP, start antibiotics. Encephalitis (p824): fever, odd behaviour, fi ts, or reduced consciousness. Do an urgent computed tomography head and LP to look for signs of infection. Post-coital headache. Subacute/gradual onset headaches: Venous sinus thrombosis (p480): subacute headache, papilloedema. Sinusitis: dull, constant ache over frontal or maxillary sinuses, with tenderness ± postnasal drip. Pain is worse on bending over. Ethmoid or sphenoid sinus Pain is felt deep in the midline at the root of the nose. Common with coryza (p406). The Pain lasts 12 wks. computed tomography can confi rm diagnosis but is rarely needed. Tropical illness: eg malaria: travel history, fl u-like illness (p416); typhus (p415). Intracranial hypotension: CSF leakage, eg iatrogenic after LP or epidural anaesthesia. Suspect if headaches worse on standing; . treat with epidural Blood patch over leak, if conservative management with IV fl uids and caff eine fails. Character Tight band? Think tension headache (the usual cause of bilateral, nonpulsatile headache ± scalp muscle tenderness). Throbbing/pulsatile/lateralizing? Think migraine (p458). Frequency Headaches that recur tend to be benign: Migraine: p458. Cluster headache: (see BOX Cluster headache) Trigeminal neuralgia: (see BOX Trigeminal neuralgia) Recurrent (Moll arets) meningitis: suspect if fever/meningism with each headache. Send CSF for herpes simplex protein-creatinine ratio (HSV2). Is there access to subarachnoid spaces via a skull fracture, or a recurring cause of aseptic meningitis (SLE, eg abducens nerve palsy, Behçets, sarcoid)? Duration Chronic, progressive headaches can indicate ICP. Typically worse on waking, lying, bending forward, or coughing. Also: Vomiting, papilloedema, seizures, false localizing signs, or odd behaviour. Do imaging to exclude a spaceoccupying lesion, and consider idiopathic intracranial hypertension. LP is contraindicated until after imaging. Associated features Eye Pain ± reduced vision: Think acute glaucoma. Typically elderly, long-sighted people. Constant Pain develops rapidly around one eye, radiating to the forehead with markedly reduced vision, visual haloes, and a red, congested eye (p561). Seek expert help at once. If delay in treatment of 1h is likely, give eye drops (eg 0. 5% timolol maleate ± 2% pilocarpine) and acetazolamide 500mg PO. Jaw claudication tender with thickened, pulseless temporal arteries: Giant cell arteritis: (p556) Subacute-onset headache with ESR 40mm/h. Exclude in all 50yrs old with a headache that has lasted a few weeks: prompt diagnosis and steroids avoid blindness. Precipitating causes Head trauma: Commonly causes localized Pain but can be more generalized. It lasts 2wks; often resistant to analgesia. Do computed tomography to exclude subdural or extradural haemorrhage if drowsiness ± lucid interval, or focal signs (p482). Also ask about: Analgesia, sex, food (eg chocolate, cheese, coff ee). Red fl ags See p780. Drug history Exclude medication overuse (analgesic rebound) headache: Culprits are mixed analgesics (paracetamol codeine/opiates), ergotamine, and triptans. This is a common reason for episodic headache becoming chronic daily headache. Analgesia must be withdrawnaspirin or naproxen may mollify the rebound headache. A preventive may help once off other drugs (eg tricyclics, valproate, g abapentin; p504).",
    "A preventive may help once off other drugs (eg tricyclics, valproate, g abapentin; p504). Limit use of over-the-counter analgesia (no more than 6d per month). Social history Ask about stress or recent life events; may not explain the pathology, but will help you appreciate the context in which symptoms are experienced. __OOHHCCMM__1100ee. . iinnddbb 445566 0022//0055//22001177 1199: : 0088 457 ygolorueN Cluster headache Cluster headache may be the most disabling of the primary headache disorders. The cause (unknown : ≥5: 1; onset at any age; comm oner in smokers). Symptoms Rapid-onset of excruciating Pain around one eye that may become watery and bloodshot with lid Edema, lacrimation, facial fl ushing, rhinorrhoea, miosis ± ptosis (20% of attacks). Pain is strictly unilateral and almost always atrial fibrillationfects the same side. It lasts 15180min, occurs once or twice a day, and is often nocturnal. Clusters last 412wks and are followed by Pain-free periods of months or even 12yrs before the next cluster. Sometimes it is chronic, not episodic. Treatment Acute attack: Keep calm carry oxygen: give 100% O2 for 15min via non-rebreathable mask (not if COPD); sumatriptan SC 6mg at onset (or zolmitriptan nasal spray 5mg). Preventives Avoid triggers: Eg alcohol. Medication: Consider: corticosteroids (short term only; many SE); verapamil 360mg, lithium 900mg (monitor carefully). Trigeminal neuralgia Symptoms: Paroxysms of intense, stabbing Pain, lasting seconds, in the trigeminal nerve distribution. It is unilateral, typically aff ecting mandibular or maxillary div isions. The face screws up with Pain (hence tic douloureux). Triggers: Washing aff ect ed area, shaving, eating, talking, dental prostheses. Typical patient: 50yrs old; in Asians : 2: 1. Secondary causes: Compress ion of the trigeminal root by anomalous or aneurysmal intracranial vessels or a tumour, chronic meningeal infl am mation, MS, zoster, skull base malformation (eg Chiari). magnetic resonance imaging: Is necessary to exclude secondary causes (14% of cases). : Carba mazepine (start at 100mg/12h PO; max 400mg/6h; lamotrigine; phenytoin 200400mg/24h PO; or gabapentin (p504). If drugs fail, surgery may be necessary. This may be directed at the peripheral nerve, the trigeminal ganglion, or the nerve root. Microvascular decompression: Anomalous vessels are separated from the trigem inal root. Stereotactic gamma knife surgery can work, but length of Pain relief and the time to treatment response are limiting factors. Facial Pain : p65. __OOHHCCMM__1100ee. . iinnddbb 445577 0022//0055//22001177 1199: : 0088 458 ygolorueN Migraine 15% of ultrasound suff er from migraines, (: 3: 1); the economic costs extend to billions/yr. Symptoms Classically: Visual or other aura (see below) lasting 1530min followed within 1h by unilateral, throbbing headache. Or: Isolated aura with no headache; Epi sodic severe headaches without aura, often premenstrual, usually unilateral, with nausea, Vomiting ± photophobia/phono phobia (common migraine). There may be allodyniaall stimuli produce Pain: I cant brush my hair, wear earrings or glasses, or shave, its so painf ul. Prodrome: Precedes headache by hours/days: yawning, cravings, mood/sleep change. Aura: Visual: chaotic distorting, melting and jumbling of lines, dots, or zigzags, scotomata or hemianopia; Somatosensory: paraesthesiae spreading from fi ngers to face; Motor: dysarthria and ataxia (basilar migraine), ophthalmoplegia, or hemiparesis; Speech: (8% of auras) dysphasia or paraphasia. Partial triggers Seen in 50%: CHOCOLATE or: chocolate, hangovers, orgasms, cheese/caff eine, oral contraceptives, lie-ins, alcohol, travel, or exercise. Associations Obesity, family history. Diagnosis Clinical, based on the history. Diagnostic criteria if no aura: ≥5 headaches lasting 472h nausea/Vomiting (or photo/phonophobia) any 2 of: Unilateral Pulsating Impairs (or worsened by) routine activity. Diff erentials Cluster or tension headache, cervical spondylosis, blood pressure, intracranial pathology, sinusitis/otitis media, dental caries. TIAS may mimic migraine aura.",
    "Triptans also inhibit release of substance P and pro-infl ammatory neuropeptides, blocking transmission from the trigeminal nerve and implicating trigeminal nerve dysfunction. The bigger picture Vincent Van Gogh suffered from sick headaches, widely believed to have been migraines. Could his swirling, cascading starry night (fi g 10. 10) be a visual aura? Just as with the fragile mental health of Van Gogh, migraine often co-exists with other chronic conditionsand the combined negative impact on physical and mental health is immense. Dont treat each disease in isolation. Rather, Fig 10. 10 The Starry Night Vincent Van Gogh 1889 attempt to restore a Good World History Archive/Ann Ronan Collection / Age relationship with the self Fotostock and the recovery of the purpose of life through dialogue. This is the hardest but the most rewarding task, and may save some ears. __OOHHCCMM__1100ee. . iinnddbb 445599 0022//0055//22001177 1199: : 0088 460 ygolorueN Blackouts Causes of collapse ± loss of consciousness (LOC) are many; take a careful history (BOX). Vasovagal (neurocardiogenic) syncope Occurs due to refl ex bradycardia ± physical examinationripheral vasodilation provoked by emotion, Pain, or standing too long (it cannot occur when lying down). Onset is over seconds (not instantaneous), and is often preceded by pre-syncopal symptoms, eg nausea, pallor, sweating, and narrowing of visual fi elds. Brief clonic jerking of the limbs may occur due to cerebral hypoperfusion, but there is no tonic/clonic sequence. Urinary incontinence is uncommon, and there is no tongue-biting. Unconsciousness usually lasts for 2min and recovery is rapid. Situation syncope Symptoms as for vasovagal syncope but with a clear precipitant: cough syncope occurs after a paroxysm of coughing; effort syncope is brought on by exercise; there is usually a cardiac cause, eg aortic stenosis, HCM; micturition syncope happens during or after urination: mostly men, at night. Carotid sinus syncope Hypersensitive baroreceptors cause excessive refl ex bradycardia ± vasodilation on minimal stimulation (eg head-turning, shaving). Epilepsy (p490) Features suggestive of this diagnosis include: attacks when asleep or lying down; aura; identifi able triggers (eg TV); altered breathing; cyanosis; typical tonicclonic movements; incontinence of Urine; tongue-biting; prolonged post-ictal drowsiness, confusion, amnesia, and transient focal paralysis (Todds palsy). StokesAdams attacks Transient arrhythmias (eg bradycardia due to complete Heart block) cause cardiac output and LOC. The patient falls to the ground (often with no warning except palpitations; injuries are common), and is pale, with a slow or absent pulse. Recovery is in seconds: the patient fl ushes, the pulse speeds up, and consciousness is regained. As with vasovagal syncope, anoxic clonic jerks may occur in prolonged LOC. Attacks may happen several times a day and in any posture. Other causes Hypoglycaemia: (p214) Tremor, hunger, and perspiration herald lightheadedness or LOC; rare in non-diabetics. Orthostatic hypotension: Unsteadiness or LOC on standing from lying in those with inadequate vasomotor refl exes: the elderly; autonomic neuropathy (p505); antihypertensive medication; overdiuresis; multisystem atrophy (MSA; p494). Anxiety: Hyperventilation, tremor, sweating, tachycardia, paraesthesiae, light-headedness, and no LOC suggest a panic attack. Drop attacks: Sudden fall to the ground without LOC. Mostly benign and due to leg weakness but may also be caused by hydrocephalus, cataplexy, or narcolepsy. Factitious blackouts: Pseudoseizures, Münchausens (p706). Examination Cardiovascular, neurological. Measure blood pressure lying and standing. Investigation All with recurrent syncope (or falls) need cardiac assessmenturgently if associated with palpitations, arrhythmias, 3rd-degree AV block, or prolonged QT interval (p711). ECG ± 24h ECG (arrhythmia, long QT, eg RomanoWard, p96); UE, FBC, Mg2, Ca2, glucose; tilt-table test; 3 EEG, sleep EEG; echocardiogram; computed tomography/magnetic resonance imaging brain; ABG if practical (PaCO2 in attacks suggests hyperventilation as the cause).",
    "No deafness or tinnitus. Causes: virus; vascular lesion. Severe vertigo subsides in days, complete recovery takes 34wks. : reassure. Sedate. Ménières disease: Increased Hypertension in the endolymphatic system of the inner ear causes recurrent attacks of vertigo lasting 20min, fl uctuating (or permanent) sensorineural hearing loss, and tinnitus (with a sense of aural fullness ± falling to one side). : bed rest and reassurance in acute attacks. An antihistamine (eg cinnarizine) is useful if prolonged, or buccal prochlorperazine if severe, for up to 7d. Ototoxicity: Amino glycosides, loop diuretics, or cisplatin can cause deafness ± vertigo. Acoustic neuroma: (fi gs 10. 12, 10. 13) Doubly misnamed: it is a Schwannoma (not neuroma) arising from the vestibular (not auditory) nerve. They account for 80% of cerebellopontine angle tumours and often present with unilateral hearing loss, with vertigo occurring later. Growth rate is slow (usually 12 mm/year) and can be predicted by serial MRIs. With progression, ipsilateral Vth, VIth, IXth, and Xth nerves may be aff ected (also ipsilateral cerebellar signs). Signs of ICP occur late, indicating a large tumour. Commoner in and neurofi bromatosis (esp. NF2, p514). Traumatic damage: If trauma aff ects the petrous temporal bone or the cerebellopontine angle then the auditory nerve may be damaged, causing vertigo, deafness, and/or tinnitus. Herpes zoster: Herpetic eruption of the external auditory meatus; facial palsy ± deafness, tinnitus, and vertigo (Ramsay Hunt syndrome, see p501). Others: Vertiginous epilepsy; MS; stroke/TIA; migraine; motion sickness; alcohol intoxication. __OOHHCCMM__1100ee. . iinnddbb 446622 0022//0055//22001177 1199: : 0088 463 ygolorueN Acoustic Vestibular neuroma Facial nerve nerve Cochlear nerve Fig 10. 12 An acoustic neuroma (vestibular schwannoma) growing dangerously near the facial nerve. (a) (b) Fig 10. 13 Large vestibular schwannoma: axial T2W (a) and contrast-enhanced coronal magnetic resonance imaging (b). Reproduced from Manji et al. , Oxford Handbook of Neurology, 2007, with permission from Oxford University Press. __OOHHCCMM__1100ee. . iinnddbb 446633 0022//0055//22001177 1199: : 0088 464 ygolorueN Hearing loss Whisper test A simple but eff ective crude assessment of hearing: whisper numbers in one ear while blocking the other. Ask your patient to repeat the number. Make sure that failure is not from misunderstanding. Tuning fork tests Rinne: Hold a vibrating tuning fork (512Hz or 256Hz) on the mastoid to test bone conduction (BC). When the sound is no longer audible move it in front of the ear with the prongs perpendicular to the auditory canal to test air conduction (before meals). If there is no conductive defi cit (ie in normal hearing or sensorineural hearing loss), before meals is better than BC and the patient will be able to hear the note again. This is a Rinne positive result. If BC is better than before meals (Rinne negative), this indicates conductive deafness 20dB. A false-negative may occur in severe sensorineural hearing loss (SNHL) as the contralateral cochlea picks up the sound by bone conduction. Weber: With the vibrating tuning fork on the vertex or forehead, ask the patient which ear the sound is louder in. Sound localizes to the aff ected ear with conductive loss (10dB loss), to the contralateral ear in SNHL, and to the midline if both ears are normal (or if bilateral SNHL). Conductive deafness Causes: Wax (remove, eg by syringing with warm Water atrial fibrillationter softening with olive oil drops), otosclerosis, otitis media, or glue ear (OHCS p546). Chronic sensorineural deafness Often due to accumulated environmental noise toxicity, presbyacusis, or inherited disorders. Presbyacusis: Loss of acuity for Highfrequency sounds starts before 30yrs old. We do not usually notice it until hearing of speech is aff ected.",
    "This is an emergency; it suggests cord compression so get urgent help (see next paragraph). Are there any signs of infection (eg tender spine, T°, WCC, ESR, CRP: extradural abscess)? Cord compression (See also p528. ) Symptoms: Bilateral leg weakness (arm weaknessoften less severesuggests a cervical cord lesion, see p508) a sensory level ± preceding back Pain (see p542). Bladder (and anal) sphincter involvement is late and manifests as hesitancy, frequency, and, later, as painless retention. Signs: Look for a motor, refl ex, and sensory level, with normal fi ndings above the level of the lesion, LMN signs at the level (especially in cervical lesions), and UMN signs below the level (but remember tone and refl exes are usually reduced in acute cord compression; OHCS p756). Causes: Secondary malignancy (breast, lung, prostate, thyroid, Kidney) in the spine is commonest. Rarer: infection (epidural abscess), cervical disc prolapse, haematoma (warfarin), intrinsic cord tumour, atlantoaxial subluxation, myeloma. : Transverse myelitis, MS, carcinomatous meningitis, cord vasculitis (PAN, syphilis), spinal artery thrombosis or aneurysm, trauma, GuillainBarré syndrome (p702). Investigations: Do not delay imaging at any cost. Spinal x-rays are unreliable; magnetic resonance imaging is the defi nitive modality. Biopsy or surgical exploration may be needed to identify the nature of any mass. Do a CXR (primary lung malignancy, lung secondaries, TB). Bloods: FBC, ESR, B12, syphilis serology, UE, LFT, PSA, serum electrophoresis. Treatment: Give urgent dexamethasone in malignancy (p528) while considering more specifi c therapy, eg radiotherapy or chemotherapy ± decompressive laminectomy; which is most appropriate depends on tumour type, quality of life, and likely prognosis. Epidural abscesses must be surgically decompressed and antibiotics given. Cauda equina and conus medullaris lesions The big diff erence between these lesions and those High up in the cord is that leg weakness is fl accid and arefl exic, not spastic and hyperrefl exic. Causes: As above, plus congenital lumbar disc disease and lumbosacral nerve lesions. Signs: Conus medullaris lesions feature mixed UMN/ LMN signs, leg weakness, early urinary retention and constipation, back Pain, sacral sensory disturbance and erectile dysfunction. Cauda equina lesions feature back Pain and radicular Pain down the legs; asymmetrical, atrophic, arefl exic paralysis of the legs; sensory loss in a root distribution; and sphincter tone; do PR. Other patterns of leg weakness Unilateral foot drop: diabetes mellitus, common peroneal nerve palsy, stroke, prolapsed disc, MS. Weak legs with no sensory loss: MND, polio, para sagittal meningioma (an exception to the rule that weak legs mean cord or distal lesion). Chronic spastic paraparesis: MS, cord primary malignancy/metastasis, MND, syringomyelia, subacute combined degeneration of the cord (p334), hereditary spastic paraparesis, taboparesis (tertiary syphilis, see p412), histiocytosis X, parasites (eg schistosomiasis). Chronic fl accid paraparesis: Peripheral neuro pathy, myopathy. Absent knee jerks and extensor plantars: (Ie combined LMN or UMN signs. ) Combined cervical and lumbar disc disease, conus medullaris lesions, MND, myeloradiculitis, Friedreichs ataxia, subacute combined degeneration of the cord, taboparesis. 4 4 Tertiary syphilis (p412): in tabes dorsalis the aff erent pathways from muscle spindles are lost, with reduced tone and tendon refl exes (without weakness). Later, additional involvement of the pyramidal tracts causes taboparesisa spastic paraparesis with the peculiar combination of extensor plantars (from the taboparesis) and absent tendon reflexes (from the tabes dorsalis). __OOHHCCMM__1100ee. . iinnddbb 446666 0022//0055//22001177 1199: : 0088 467 ygolorueN Gait disorders Spastic: Stiff, circumduction of legs ± scuffi ng of the toe of the shoes: UMN lesions. Extrapyramidal: Flexed posture, shuffl ing feet, slow to start, postural instability, eg Parkinsons disease.",
    "Extrapyramidal: Flexed posture, shuffl ing feet, slow to start, postural instability, eg Parkinsons disease. Apraxic: Pathognomonic gluing-to-the-fl oor on attempting walking or a widebased unsteady gait with a tendency to fall, like a novice on an ice-rink. Seen in normal Hypertension hydroc ephalus and multi-infarct states. Ataxic: Wide-based; falls; cannot walk heel-to-toe. Caused by cerebellar lesions (eg MS, posterior fossa tumours, alcohol, phenytoin toxicity); proprioceptive sensory loss (eg sensory neuropathy, B12). Often worse in the dark or with eyes closed. Myopathic: Waddling gait, cannot climb steps or stand from sitting due to hip girdle weakness. Psychogenic: Suspect if there is a bizarre gait not conforming to any pattern of organic gait disturbance and without any signs when examined on the couch. Tests Spinal X-rays; magnetic resonance imaging; FBC; ESR; syphilis serology; serum B12; UE; LFT; PSA; serum electrophoresis; CXR; LP; EMG; muscle ± sural nerve biopsy. Non-neurological considerations in paralysed patients Avoid Hypertension sores by turning and review weight-bearing areas often. Use appropriate Hypertension-relieving mattresses/cushions. Prevent thrombosis in paralysed limbs by frequent passive movement, Hypertension stockings, and LMWH (p350). Bladder care is vital; catheterization is only one option (do not control incontinence by decreasing fl uid intake). Bowel evacuation may be manual or aided by suppositories; increasing dietary fi bre intake may help. Exercise of unaff ected or partially paralysed limbs is important to avoid unnecessary loss of function. __OOHHCCMM__1100ee. . iinnddbb 446677 0022//0055//22001177 1199: : 0088 468 ygolorueN Abnormal involuntary movements (dyskinesia) These are characterized by impairment of the planning, control, or execution of movement. They can have multiple manifestations: Tremor Note frequency, amplitude, and exacerbating factors (stress; Fatigue). Rest tremor: Abolished on voluntary movement. Cause: parkinsonism (p494). Intention tremor: Irregular, large-amplitude, worse at the end of purposeful acts, eg fi nger-pointing or using a remote control. Cause: cerebellar damage (eg MS, stroke). Postural tremor: Absent at rest, present on maintained posture (arms out stretched) and may persist (but is not worse) on movement. Causes: benign essential tremor (autosomal dominant; improves with alcohol), thyrotoxicosis, anxiety, -agonists. Re-emergent tremor: Postural tremor developing after a delay of 10s. Causes: Parkinsons disease (dont mistake for essential tremor). Chorea Non-rhythmic, jerky, purposeless movements fl itting from one place to anothereg facial grimacing, raising the shoulders, fl exing/extending the fi ngers. Causes: Huntingtons disease, Syden hams chorea (rare complication of group A streptococcal infection). Worsened by levodopa. Hemiballismus Large-amplitude, fl inging hemichorea (aff ects proximal muscles) contralateral to a vascular lesion of the subthalamic nucleus (often elderly diabetics). Recovers spontaneously over months. Athetosis Slow, sinuous, confl uent, purposeless movements (especially digits, hands, face, tongue), often diffi cult to distinguish from chorea. Causes: Commonest is cerebral palsy (OHCS p214). Most other athetoid patterns may now be better classed as dystonias. Pseudoathetosis: Caused by severe proprioceptive loss. Tics Brief, repeated, stereotyped movements which patients may suppress for a while. Tics are common in children (and usually resolve). In Tourettes syndrome (p700), motor and vocal tics occur. Consider psychological support, clonazepam or clonidine if tics are severe (haloperidol may help but risks tardive dyskinesia). Myoclonus Sudden involuntary focal or general jerks arising from cord, brainstem, or cerebral cortex, seen in metabolic problems, neurodegenerative disease (eg lysosomal storage enzyme defects), CJD (p696), and myoclonic epilepsies (infantile spasms). Benign essential myoclonus: Childhood onset with frequent generalized myoclonus, without progression. Often autosomal dominant. It may respond to valproate, clonazepam, or piracetam. Asterixis (metabolic fl ap): Jerking (12 jerks/sec) of outstretched hands, worse with wrists extended, from loss of extensor toneie incoordination between fl exors and extensors (negative myoclonus).",
    "Causes: Liver or Kidney failure, sodium, CO2, gabapentin, thalamic stroke (consider if unilateral). Tardive syndromes Delayed onset yet potentially irreversible symptoms occuring after chronic exposure to dopamine antagonists (eg antipsychotics, antiemetics). Classifi cation: Tardive dyskinesia: orobuccolingual, truncal, or choreiform movements, eg vacuous chewing and grimacing movements. Tardive dystonia: sustained, stereotyped muscle spasms of a twisting or turning character, eg retrocollis and back arching/opisthotonic posturing. Tardive akathisia: sense of restlessness or unease ± repetitive, purposeless movements (stereotypies, eg pacing). Tardive myoclonus. Tardive tourettism (p700). Tardive tremor. Treating tardive dyskinesia: Gradually withdraw neuroleptics and wait 36 months. Tetrabenazine may help. Quetiapine, olanzapine, and clozapine are examples of atypical antipsychotics that are less likely to cause tardive syndromes. __OOHHCCMM__1100ee. . iinnddbb 446688 0022//0055//22001177 1199: : 0088 469 ygolorueN Dystonia Dystonia describes prolonged muscle contractions causing abnormal posture or repetitive movements. Idiopathic generalized dystonia: Childhood-onset dystonia often starting in one leg with ipsilateral progression over 510yrs. Autosomal dominant inheritance is common (DYT1 deletion). Exclude Wilsons disease and dopa-responsive dystonia (needs an L-dopa trial). Anticholinergics and muscle relaxants may help. Deep brain stimulation for refractory, disabling symptoms. Focal dystonias: Confi ned to one part of the body, eg spasmodic torticollis (head pulled to one side), blepharospasm (involuntary contraction of orbicularis oculi, OHCS p417), writers cramp. Focal dystonias in adults are typically idiopathic, and rarely generalize. They are worsened by stress. Patients may develop a geste antagoniste to try to resist the dystonic posturing (eg a touch of the fi nger to the jaw in spasmodic torticollis). Injection of botulinum toxin into the overactive muscles is usually eff ective. Acute dystonia: (fi g 10. 14) May occur on starting many drugs, including neuroleptics and some anti-emetics (eg metoclopramide, cyclizine). There is torticollis (head pulled back), trismus (oromandibular spasm), and/or oculogyric crisis (eyes drawn up). You may mistake this for tetanus or meningitis, but such reacti ons rapidly disappear after a dose of an antic holinergic, see p843. Fig 10. 14 Oromandibular/oculogyric crisis in acute dystonia. Reprinted from Mayo Clinic Proceedings, 78(9), Ritter et al. , Ondansetron-induced multifocal encephalopathy, 11502, 2003, with permission from Elsevier. St Vituss dance Throughout the middle ages, Europe was plagued by epidemics of dancing mania, in which affl icted individuals were described to have danced wildly, displaying strange contortions and convulsions until they collapsed from exhaustion. If the affl icted touched a relic of St Vitus they were miraculously cured: observing this, Paracelsus, 16th-century Swiss-German physician and philosopher, described the phenomenon of chorea Sancti Viti (St Vituss dance). There may have been an infectious component, although mass hysteria induced by religious cults that swept across medieval Europe seems a more likely cause. Chorea was subsequently used as a general term for large-amplitude involuntary movements before being further refi ned by physicians such as Sydenham (though he did not connect his eponymous chorea seen in rheumatic fever with an infectious trigger) and Charcot. Nowaways, a more frequent cause of involuntary movements with behavioural disturbance is NMDA-receptor antibody encephalitis, the impact of which was documented in Susannah Cahalans excellent 2012 autobiography Brain on Fire: My Month of Madness. __OOHHCCMM__1100ee. . iinnddbb 446699 0022//0055//22001177 1199: : 0088 470 ygolorueN Stroke: clinical features and acute management Infarction or bleeding into the brain manifests with sudden-onset focal CNS signs. Someone in the UK has a stroke every 3. 5 minutes; 1 in 4 of those will die within a year and half of survivors will have a permanent disability. Causes Small vessel occlusion/cerebral microangiopathy or thrombosis in situ. Cardiac emboli (atrial fibrillation; endocarditis; myocardial infarctionsee BOX Cardiac causes of stroke, p473). Atherothromboembolism (eg from carotids).",
    "Cardiac emboli (atrial fibrillation; endocarditis; myocardial infarctionsee BOX Cardiac causes of stroke, p473). Atherothromboembolism (eg from carotids). CNS bleeds (blood pressure, trauma, aneurysm rupture, anticoagulation, thrombolysis). Other causes: Consider in younger patients: sudden blood pressure drop by ≥40mmHg (most likely to aff ect the boundary zone between vascular beds), carotid artery dissection (spontaneous, or from neck trauma or fi bromuscular dysplasia), vasculitis, subarachnoid haemorrhage (p478), venous sinus thrombosis (p480), anti phosphate pho lipid syndrome, thrombophilia (p374), Fabry disease (p698), CADASIL. 5 Diff erentials Head injury, hypo/hyperglycaemia, subdural haemorrhage, intracranial tumours, hemiplegic migraine, post-ictal (Todds palsy), CNS lymphoma, Wernickes encephalopathy, hepatic encephalopathy, encephalitis, toxoplasmosis, cerebral abscesses, mycotic aneurysm, drug overdose (if comatose). Modifi able risk factors blood pressure, smoking, diabetes mellitus, Heart disease (valvular, ischaemic, atrial fibrillation), peripheral vascular disease, PCV, carotid bruit, combined OCP, lipids, alcohol use, clotting (eg plasma fi brinogen, antithrombin III, p374), homocysteine, syphilis. Signs Worst at onset. Pointers to bleeding (unreliable! ): meningism, severe headache, coma. Pointers to ischaemia: carotid bruit, atrial fibrillation, past TIA, IHD. Cerebral infarcts: (50%. ) Depending on site there may be contralateral sensory loss or hemiplegia initially fl accid (fl oppy limb, falls like a dead weight when lifted), becoming spastic (UMN); dysphasia; homonymous hemianopia; visuo-spatial defi cit. Brainstem infarcts: (25%. ) Varied; include quadriplegia, disturbances of gaze and vision, lockedin syndrome (aware, but unable to respond). Lacunar infarcts: (25%). Basal ganglia, internal capsule, thalamus, and pons. ) Five syndromes: ataxic hemiparesis, pure motor, pure sensory, sensorimotor, and dysarthria/clumsy hand. Cognition/consciousness are intact except in thalamic strokes. Acute management Protect the airway: This avoids hypoxia/aspiration. Maintain homeostasis: Blood glucose: keep between 411 millimoles per liter. Blood Hypertension: only treat if there is a hypertensive emergency (eg encephalopathy or aortic dissection) or thrombolysis is considered (ideally aim for 185/110) as treating even very High BPS may impair cerebral perfusion. Screen swallow: Nil by mouth until this is done (but keep hydrated). computed tomography/magnetic resonance imaging within 1h: Essential if: thrombolysis considered, High risk of haemorrhage (GCS, signs of ICP, severe headache, meningism, progressive symptoms, bleeding tendency or antic oagulated), or unusual presentation (eg fl uctuating consciousness, fever). Otherwise imaging less urgent (aim 24h). Diff usion-weighted magnetic resonance imaging is most sensitive for an acute infarct, but computed tomography helps rule out primary haemorrhage (fi g 10. 15). Antiplatelet agents: Once haemorrhagic stroke is excluded, give aspirin 300mg (continue for 2 weeks, then switch to long-term antithrombotic treatment, p472). Thrombolysis: Consider this as soon as haemorrhage has been excluded, provided the onset of symptoms was ≤4. 5h ago. 2 The benefi ts of thrombolysis outweigh the risks within this window, though best results are within 90min. Alteplase is the agent of choice and must be given by trained staff, ideally within an expert acute stroke team. Always do computed tomography 24h post-lysis to identify bleeds. 6 CI to thrombolysis: Major infarct or haemorrhage on computed tomography. Mild/non-disabling defi cit. Recent surgery, trauma, or artery or vein puncture at uncompressible site. Previous CNS bleed. AVM/aneurysm. Severe Liver disease, varices, or portal hypertension. Seizures at presentation. Blood glucose (3 or 22). Stroke or serious head injury in last 3 months. GI or urinary tract haemorrhage in the last 21 days. Known clotting disorder. Anticoagulants or INR 1. 7. Platelets 100 109/L. History of intracranial neoplasm. Rapidly improving symptoms. blood pressure 180/105. Thrombectomy: Intra-arterial mechanical thrombectomy provides additional benefi t for those with large artery occlusion in the proximal anterior circulation. Admit to an acute stroke unit: multidisciplinary care improves outcomes (p474). __OOHHCCMM__1100ee. . iinnddbb 447700 0022//0055//22001177 1199: : 0088 471 ygolorueN Fig 10.",
    "__OOHHCCMM__1100ee. . iinnddbb 447700 0022//0055//22001177 1199: : 0088 471 ygolorueN Fig 10. 15 The T2-weighted (p746) image on the left shows oedema in the right occipital lobe. Differentials: infarct (right PCA), infl ammation, or tumour. The diff usion-weighted image on the right shows limited diff usion in the region, indicating this is an infarct. Prof Peter Scally. Act FAST Several public health measures have aimed to increase awareness of stroke and the seriousness of the condition: the relabelling of stroke as a brain attack, and via the graphic mass media FAST campaign Facial asymmetry, Arm/leg weakness, Speech diffi culty, Time to call 999. The publicity surrounding this acronym has increased recognition of the symptoms of stroke and emphasized the urgency of seeking medical help; following the introduction of the campaign in 2011 the NHS in England saw a 24% rise in stroke-related 999 calls. 5 Cerebral Autosomal Dominant Arteriopathy with Subcortical Infarcts Leucoencephalopathy: the main genetic cause of stroke (there is also an autosomal recessive form). 6 If ve, register at SITS, www. sitsinternational. org __OOHHCCMM__1100ee. . iinnddbb 447711 0022//0055//22001177 1199: : 0088 472 ygolorueN Stroke: investigation and prevention Primary prevention (Ie before any stroke. ) Control risk factors (p470): look for and treat hypertension, diabetes mellitus, lipids (p690), cardiac disease (see BOX Cardiac causes of stroke) and help quit smoking (see p93). Exercise helps (HDL, glucose tolerance). Use lifelong anticoagulation in atrial fibrillation (see BOX Cardiac causes of stroke) and prosthetic Heart valves. For prevention post-TIA see p476. Secondary prevention (Ie preventing further strokes. ) Control risk factors (as Primary prevention mentioned above): there is a considerable advantage from lowering Blood Hypertension and cholesterol (even if not particularly raised). Antiplatelet agents after stroke: (See BOX Antiplatelets. ) If no primary haemorrhage on computed tomography, give 2 weeks of aspirin 300mg, then switch to long-term clopidogrel monotherapy. If this is CI or not tolerated then give Low dose aspirin plus slow-release dipyridamole. Anticoagulation after stroke from atrial fibrillation: See BOX Cardiac causes of stroke. Tests (See p470 for imaging. ) Investigate promptly to identify risk factors for further strokes, but consider whether results will aff ect management. Look for: Hypertension. Look for retinopathy (p560), nephropathy, or cardiomegaly on CXR. Cardiac source of emboli. (See BOX Cardiac causes of stroke. ) 24h ECG to look for atrial fibrillation (p130). CXR may show an enlarged left atrium. Echocardiogram may reveal mural thrombus due to atrial fibrillation or a hypokinetic segment of cardiac muscle post-myocardial infarction. It may also show valvular lesions in infective endocarditis or rheumatic Heart disease. Transo esophageal echo is more sensitive than transthoracic. Carotid artery stenosis. Do carotid Doppler ultrasound ± computed tomography/magnetic resonance imaging angiography. Benefi ts and risks of revascularization should be individualized by an expert but generally most with ≥ 70% stenosis and life expectancy ≥ 5yrs will benefi t while some (especially ) will benefi t with 5069% stenosis7 (see p476). Carotid endarterectomy is the procedure of choice; endovascular carotid artery angioplasty with stenting is an alternative for those unfi t for surgery and achieves similar long-term outcomes but has higher peri-procedure stroke and mortality rates. Hypoglycaemia, hyperglycaemia, dyslipidaemia, and hyperhomocysteinaemia. Vasculitis. ESR, ANCA (p556). VDRL to look for active, untreated syphilis (p412). Prothrombotic states, eg thrombophilia (p374), antiphospholipid syndrome (p554). Hyperviscosity, eg polycythaemia (p366), sickle-cell disease (p340). Thrombocytopenia and other bleeding disorders. Genetic tests. CADASIL (p470); Fabry disease (p698). Prognosis Overall mortality: 60 000/yr; UK 20% at 1 month, then 10%/yr. Full recovery: ≤ 40%. Drows i ness poor prognosis. Avoid Hypertension ulcers (fi g 10. 16).",
    "Full recovery: ≤ 40%. Drows i ness poor prognosis. Avoid Hypertension ulcers (fi g 10. 16). 7 Interventions for 5069% stenoses can be justifi able; individualize risk and check local guidelines. In particular, check which criteria used to estimate degree of stenosis since NASCET (North American Symptomatic Carotid Endarterectomy Trial) criteria tend to include some more severe lesions in 5069% range as compared to the ECST (European Carotid Surgery Trialists Collaborative Group) criteria. __OOHHCCMM__1100ee. . iinnddbb 447722 0022//0055//22001177 1199: : 0088 473 ygolorueN Cardiac causes of stroke Cardioembolic causes are the source of stroke in 30% of patients, and may be hinted at if there are bilateral infarcts on imaging. Non-valvular atrial fi brillation: (p130) Associated with an overall risk of stroke of 4. 5%/yr, and ischaemic strokes in atrial fibrillation carry a worse prognosis. CHA2DS2VASC score (p131) can be used to calculate risk of stroke in patients with atrial fibrillation. Off er anticoagulation in patients with a score of 2 or above. Take bleeding risk into account: calculate the risk of major bleeding using the HAS-BLED score. Caution and regular review of oral anticoagulants are required if the HAS-BLED score 3. Do not off er stroke prevention therapy in patients with atrial fibrillation if 65y and CHA2DS2VASC score is 0 for men or 1 for women. Anticoagulation (see p350) can be commenced 2wks after a stroke (or from 710d if clinically and radiologically small). Off er a direct oral anticoagulant (DOAC) or warfarin (p350), following a discussion of risks and benefi ts. Other cardiac sources of emboli: Cardioversion. Prosthetic valves. Acute myocardial infarct with large left ventricular wall motion abnormalities on echocardiography. Patent foramen ovale/septal defects. Cardiac surgery. Infective endocarditis (gives rise to septic emboli; 20% of those with endocarditis present with CNS signs). Antiplatelets: mechanism of action Aspirin: Inhibits COX-1, suppressing prostaglandin and thromboxane synthesis. Clopidogrel: A thienopyridine that inhibits platelet aggregation by modifying platelet ADP receptors, preventing further strokes and MIS. Dipyridamole: CAMP and thromboxane A2. (a) (b) (c) (d) Fig 10. 16 Categorization of Hypertension ulcers. (a) Stage 1: non-blanchable redness of intact skin, typically over a bony prominence. (b) Stage 2: partial thickness loss of dermis presenting as a shalLow open ulcer with a red/pink wound bed, without slough. May also present as an intact or open/ ruptured sero-sanguinous blister. (c) Stage 3: full thickness skin loss with visible subcutaneous fat. Bone, tendon, or muscle are not exposed. (d) Stage 4: full thickness tissue loss wth exposed bone, tendon, or muscle. Images (a) to (d) reproduced from Gosney et al. , Oxford Desk Reference: Geriatric Medicine, 2012, with permission from Oxford University Press. __OOHHCCMM__1100ee. . iinnddbb 447733 0022//0055//22001177 1199: : 0088 474 ygolorueN Re-enablement after stroke Coordinated multidisciplinary care on a specialized stroke unit is essential, and leads to better patient outcomes. Rehabilitation must be started early post-stroke in order to maximize improvement and prevent complications related to immobility such as Hypertension sores, aspiration pneumonia, constipation, and contractures. Ongoing input after discharge consolidates inpatient gains and helps align the individual with their previous capability. It also helps with depressionboth in the patient and their carer. Setting achievable goals and acknowledging the patients own agenda is key. Imperatives for re-enablement Watch the patient swallow a small volume of Water; if signs of aspiration (a cough or voice change) make nil by mouth until formal assessment by a speech therapist. Use IV fl uids, then semi-solids (eg jelly; avoid soups and crumbly food). Avoid early NG tube feeds; these may be needed to safeguard nutrition in those with swallowing problems that persist beyond the fi rst 23d.",
    "If swallowing fails to recover, consider benefi ts of enteral feeding tube placement (p759). Speech therapists skilled in assessing swallowing diffi culties are invaluable here. Avoid further injury: minimize falls risk and take care when lifting the patient not to damage their shoulders. Ensure Good bladder and bowel care through frequent toileting. Avoid early catheterization which may prevent return to continence. Position to minimize spasticity (occurs in 40%). Get prompt physiotherapy. Splints and botulinum toxin injections are helpful for focal spasticity. Monitor progress: eg measure time taken to sit up and transfer to chair. Monitor mood: in pseudo-emotionalism/emotional lability (sobbing unprovoked by sorrow, from failure of cortical inhibition of the limbic system), tricyclics or fl uoxetine may help. Engage the patient in their own recovery by making physiotherapy fun. Swimming (a hemiplegic arm may be supported on a special fl oat), music, and video games are all enjoyable and recovery through promoting cerebral reorganization. Constraint of the Good arm may be helpful. Involve the carer/spouse with all aspects of care-giving. Good rehab saves lives. Tests Asking to point to a named part of the body tests perceptual function. Copying matchstick patterns tests spatial ability. Dressing or copying a clock face tests for apraxia (p86). Picking out and naming easy objects from a pile tests for agnosia (acuity OK, but cannot mime use; guesses are way-out, semantically, and phonetically). Screen for depression (Low mood; inability to feel pleasure or to concentrate). End-of-life decisions See p13. __OOHHCCMM__1100ee. . iinnddbb 447744 0022//0055//22001177 1199: : 0088 475 ygolorueN Assessing dependence in daily life Handicap entails inability to carry out social functions. A disadvantage for a given individual, resulting from an impairment or disability, that limits or prevents the fulfi lment of a role. Two people with the same impairment (eg paralysed arm) may have diff erent disabilities (table 10. 5, eg one may be able to dress but the other cannot). Disabilities are likely to determine quality of future life. Treatment is often best aimed at reducing disability, not curing disease. For example, Velcro fasteners in place of buttons may enable a person to dress. Table 10. 5 Barthels index of activities of daily living Bowels 0 Incontinent (or needs to be given enemas) 1 Occasional accidents (once a week) 2 Continent Bladder 0 Incontinent, or catheter inserted but unable to manage it 1 Occasional accidents (up to once per 24h) 2 Continent (for more than 7 days) Grooming 0 Needs help with personal care: face, hair, teeth, shaving 1 Independent (implements provided) Toilet use 0 Dependent 1 Needs some help but can do some things alone 2 Independent (on and off, wiping, dressing) Feeding 0 Unable 1 Needs help in cutting, spreading butter, etc. 2 Independent (food provided within reach) Transfer 0 Unable to get from bed to commode: the vital transfer to prevent the need for 24-hour nursing care 1 Major help needed (physical, 12 people), can sit 2 Minor help needed (verbal or physical) 3 Independent Mobility 0 Immobile 1 Wheelchair-independent, including corners, etc. 2 Walks with help of one person (verbal or physical) 3 Independent Dressing 0 Dependent 1 Needs help but can do about half unaided 2 Independent (including buttons, zips, laces, etc. ) Stairs 0 Unable 1 Needs help (verbal, physical, carrying aid) 2 Independent up and down Rice/shower 0 Dependent 1 Independent (must get in and out unaided and wash self) Mahoney FI, Barthel DW: Functional evaluation: the Barthel Index. Maryland State Medical Journal. 1965; 14: 6165.",
    "Maryland State Medical Journal. 1965; 14: 6165. Barthels paradox The more we contemplate Barthels eulogy of independence, the more we see it as a mirage refl ecting a greater truth about human aff airs: there is no such thing as independenceonly interdependenceand in fostering this interdependence lies our true vocation: No man is an Island, intire of it selfe; every man is a peece of the Continent, a part of the maine; if a Clod bee washed away by the Sea, Europe is the lesse, as well as if a promontorie were, as well as if a Mannor of thy friends or of thine owne were. Any mans death diminishes me, because I am involved in mankinde; And therefore never send to know for whom the bell tolls: It tolls for thee. John Donne 15721631; Meditation XVII. __OOHHCCMM__1100ee. . iinnddbb 447755 0022//0055//22001177 1199: : 0088 476 ygolorueN Transient ischaemic attack (TIA) This is an ischaemic (usually embolic) neurological event with symptoms lasting 24h (often much shorter). Without intervention, more than 1 in 12 patients will go on to have a stroke within a week, so prompt management is imperative. Signs Specifi c to the arterial territory involved (p450). Amaurosis fugax occurs when the retinal artery is occluded, causing unilateral progressive vision loss like a curtain descending. Global events (eg syncope, dizziness) are not typical of TIAs. Attacks may be single or many; multiple highly stereotyped attacks (crescendo TIAs) suggest a critical intra cranial stenosis (commonly the superior division of the MCA). Causes (See p470. ) Atherothromboembolism from the carotid is the chief cause: listen for bruits (though not a sensitive test). Cardioembolism: mural thrombus post-myocardial infarction or in atrial fibrillation, valve disease, prosthetic valve (p473). Hyperviscosity: eg polycythaemia, sickle-cell anaemia, myeloma. Vasculitis is a rare, non-embolic cause of TIA symptoms (eg cranial arteritis, PAN, SLE, syphilis, etc. ). Diff erentials Hypoglycaemia, migraine aura (p458), focal epilepsy (symptoms spread over seconds and often include twitching and jerking), hyperventilation, retinal bleeds. Rare mimics of TIA: Malignant hypertension, MS (paroxysmal dysarthria), intra cranial tumours, peripheral neuropathy, phaeochromocytoma, somatization. Tests FBC, ESR, UEs, glucose, lipids, CXR, ECG, carotid Doppler ± angiography, computed tomography or diff usion-weighted magnetic resonance imaging, echoc ardio gram. Treatment Control cardiov ascular risk factors: Optimize: blood pressure (cautiously lower; aim for 140/85mmHg, p140); hyperlipidaemia (p690); diabetes mellitus (p206); help to stop smoking (p93). Antiplatelet drugs: As with stroke, give aspirin 300mg OD for 2wks, then switch to clopidogrel 75mg OD. If this is contraindicated or not tolerated, give aspirin 75mg OD combined with slow-release dipyridamole. Anticoagulation indications: Cardiac source of emboli (see p473). Carotid endarterectomy: Perform within 2wks of fi rst presentation if 7099% stenosis8 and operative risk is acceptable (higher risk in: , 75y, systolic blood pressure, contralateral artery occl uded; ipsilateral carotid syphon/external carotid stenosed). Do not stop aspirin preoperatively. Surgery is preferred to endovascular carotid artery angioplasty with stenting in those fi t enough to tolerate due to higher peri-procedure stroke and mortality rates with stenting. Driving Prohibited for at least 1 month, see p158. Prognosis Long-term risks of stroke or cardiovascular events following TIAs are dependent on underlying vascular risk factors: calculate using the ABCD2 score (see BOX and table 10. 6). 8 Interventions for 5069% stenoses can be justifi able; individualize risk and check local guidelines. In particular, check which criteria used to estimate degree of stenosis since NASCET (North American Symptomatic Carotid Endarterectomy Trial) criteria tend to include some more severe lesions in 5069% range as compared to the ECST (European Carotid Surgery Trialists Collaborative Group) criteria. __OOHHCCMM__1100ee. .",
    "Surgery: endovascular coiling vs surgical clipping (requiring craniotomy): the decision depends on the accessibility and size of the aneurysm, though coiling is preferred where possible (fewer complications, better outcomes). Do catheter or computed tomography angiography to identify single vs multiple aneurysms before intervening. Newer techniques such as balloon remodelling and fl ow diversion can be helpful in anatomically challenging aneurysms. Complications Rebleeding is the commonest cause of death, and occurs in 20%, often in the 1st few days. Cerebral ischaemia due to vasospasm may cause a permanent CNS defi cit, and is the commonest cause of morbidity. If this happens, surgery is not helpful at the time but may be so later. Hydrocephalus, due to blockage of arachnoid granulations, requires a ventricular or lumbar drain. Hyponatraemia is common but should not be managed with fl uid restriction. Seek expert help. __OOHHCCMM__1100ee. . iinnddbb 447788 0022//0055//22001177 1199: : 0088 479 ygolorueN Table 10. 7 Mortality in subarachnoid haemorrhage Grade Signs Mortality: % I None 0 II Neck stiff ness and cranial nerve palsies 11 III Drowsiness 37 IV Drowsy with hemiplegia 71 V Prolonged coma 100 Most mortality occurs in 1st month. 90% of survivors of the 1st month, survive 1 year. Unruptured aneurysms: the time-bomb in my head Bear in mind the old adage: if it aint broke, dont fi x itusually, risks of preventive intervention outweigh any benefi ts, except perhaps in young patients (more years at risk, and surgery is twice as hazardous if 45yrs old) who have aneurysms 7mm in diameter, especially if located at the junction of the internal carotid and the posterior communicating cerebral artery, or at the rostral basilar artery bifurcation, and especially if there is uncontrolled hypertension or a past history of bleeds. Data from the 2003 International Study of Unruptured Intracranial Aneurysms (ISUIA) show that relative risk of rupture for an aneurysm 712mm across is 3. 3 compared with aneurysms 7mm across; if the diameter is 12mm, the relative risk is 17. Fig 10. 17 computed tomography images can be manipulated to Fig 10. 18 Blood from a ruptured aneury sm ocshow only High-density structures such as cupies the interhemispheric fi ssure (top arrow), bones and arteries containing contrast. Here is a crescentic intracerebral area presumably near a middle cerebral artery aneurysm. the aneurysm (2nd arrow), the basal cisterns, We thank Prof. Peter Scally for these computed tomography images and the lateral ventricles (temporal horns), and the the commentaries on them. 4th ventricle (bottom arrow). We thank Prof. Peter Scally for these computed tomography images and the commentaries on them. __OOHHCCMM__1100ee. . iinnddbb 447799 0022//0055//22001177 1199: : 0088 480 ygolorueN Intracranial venous thrombosis (IVT) Thrombosis of the cerebral sinuses or veins causes cerebral infarction, though much less commonly than arterial disease. Seizures are common and focal; they can complicate diagnosis and post-ictal drowsiness may impair GCS assessment. Although 80% will make a Good functional recovery, death is mainly due to transtentorial herniation from mass eff ect or oedema. 9 Dural venous sinus thrombosis Most commonly sagittal sinus thrombosis (fi gs 10. 19, 10. 20; 47% of all IVT) or transverse sinus thrombosis (35%). Sagittal sinus thrombosis often coexists if other sinuses are thrombosed. Symptom onset is gradual (over days or weeks). Features are dependent on the sinus aff ected: Sagittal sinus: Heada che, Vomiting, seizures, vision, papilloedema. Transverse sinus: Headache ± mastoid Pain, focal CNS signs, seizures, papilloedema. Sigmoid sinus: Cerebellar signs, lower cranial nerve palsies. Inferior petrosal sinus: Vth and VIth cranial nerve palsies, with temporal and retro-orbital Pain (Gradenigos syndrome, . suggesting otitis media is the cause).",
    "We thank Prof. Peter Scally for these computed tomography images and commentary. Fig 10. 23 The Blood (High attenu ation, fusiform or biconvex collection) on the right side is limited anteriorly by the coronal suture and posteriorly by the lambdoid suture. This is therefore an extradural haem at oma. The Low-attenuation CSF density collection on the left is causing scalloping of the overlying bone. It is in the typical location of an arachnoid cyst; an incidental fi nding of a congenital abnorm ality. We thank Prof. Peter Scally for these computed tomography images and commentary. __OOHHCCMM__1100ee. . iinnddbb 448833 0022//0055//22001177 1199: : 0088 484 ygolorueN Delirium (acute confusional state) Delirium10 aff ects up to 50% of inpatients 65y, and is associated with a longer admission, more complications, and higher mortality. Look for an underlying cause in any acute fl uctuating, baffl ing behaviour change; it may be an early indication of treatable pathology (eg UTI). Clinical features Globally impaired cognition, perception, and consciousness which develops over hours/days, characterized by a marked memory defi cit, disordered or disorientated thinking, and reversal of the sleepwake cycle. Some patients experience tactile or visual hallucinations. Delirium can be: hyperactive, with restlessness, mood lability, agitation, or aggression hypoactive in which the patient becomes slow and withdrawn or mixed. Hypoactive and mixed delirium are much harder to recognize: it is crucial to compare current behaviour to the patients baseline (see BOX). Risk factors 65y, dementia/previous cognitive impairment, hip fracture, acute illness, psychological agitation (eg Pain). Causes Surgery/post-GA. Systemic infection: pneumonia, UTI, malaria, wounds, IV lines. Intracranial infection or head injury. Drugs/drug withdrawal: opiates, levodopa, sedatives, recreational. Alcohol withdrawal (25d post-admission; LFTS, MCV; history of alcohol abuse). Metabolic: uraemia, Liver failure, sodium or glucose, hemoglobin, malnutrition (beriberi, p268). Hypoxia: respiratory or cardiac failure. Vascular: stroke, myocardial infarction. Nutritional: thiamine, nicotinic acid, or B12 defi ciency. Diff erentials Dementia (see BOX), anxiety, epilepsy: non-convulsive status epilepticus is an underdiagnosed cause of impaired cognition and odd behaviour: consider an EEG. Primary mental illness (eg schizophrenia) can also mimic delirium, but this is rare on the wards (especially if no past history). Tests Look for the cause (eg UTI, pneumonia, myocardial infarction): do FBC, UE, LFT, Blood glucose, ABG, septic screen (Urine dipstick, CXR, Blood cultures); also consider ECG, malaria fi lms, LP, EEG, computed tomography. Management As well as identifying and treating the underlying cause, aim to: 3 Reorientate the patient: explain where they are and who you are at each encounter. Hunt down hearing aids/glasses. Visible clocks/calendars may help. Encourage visits from friends and family. Monitor fl uid balance and encourage oral intake. Be vigilant for constipation. Mobilize and encourage physical activity. Practise sleep hygeine: restrict daytime napping, minimize night-time disturbance. Avoid or remove catheters, IV cannulae, monitoring leads and other devices (they increase infection risk and may get pulled out). Watch out for infection and physical discomfort/distress. Review medication and discontinue any unnecessary agents. Only use sedation if the patient is a risk to their own/other patients safety (never use physical restraints). Consider haloperidol 0. 52mg, or chlorpromazine 50100mg, PO if they will take it, IM if not (p15). Wait 20min to judge eff ectfurther doses can be given if needed. NB: avoid chlorp romazine in the elderly and in alcohol withdrawal (p280); avoid antipsychotics in those with Parkinsons disease or Lewy body dementia. Be aware that delirium may persist beyond the duration of the original illness by several weeks in the elderly. Do not assume this must be dementiaprovide support and reassess 12 months later.",
    "Patients display executive impairment; behavioural/personality change; disinhibition; hyperorality, stereotyped behaviour, and emotional unconcern. Episodic memory and spatial orientation are preserved until later stages. Picks disease refers to the few fronto-temporal dementia patients who have Pick inclusion bodies on histology (spherical clusters of tau-laden neurons). Other causes Alcohol/drug abuse; repeated head trauma; pellagra (p268), Whipples disease (p716); Huntingtons (p702); CJD (p696); Parkinsons (p494); HIV; cryptococcosis (p408); familial autosomal dominant Alzheimers; CADASIL (p470). Management Refer suspected or diagnosed dementia to integrated memory services for further assessment and management. Medication: (p489). Avoid drugs that impair cognition (eg neuroleptics, sedatives, tricyclics). Non-pharmacological interventions: Non-cognitive symptoms (eg agitation) may respond to measures such as aromatherapy, multisensory stimulation, massage, music, and animal-assisted therapy. Other considerations Depression: Common. Try an SSRI (eg citalopram 1020mg OD) or, if severe, mirtazapine (1545mg at night if estimated glomerular filtration rate 40). Cognitive behavioural therapy can help with social withdrawal and catastrophic thinking. Capacity: Can the patient make decisions regarding medical or fi nancial aff airs? Wherever possible, allow them to. Suggest making an advanced directive or appointing a Lasting Power of Attorney in the early stages of the disease. 11 Dilated ventr icles without enlarged sulci. Signs: gait apraxia, incontinence, de m entia; CSF shunts help. __OOHHCCMM__1100ee. . iinnddbb 448866 0022//0055//22001177 1199: : 0088 487 ygolorueN Who will care for the carers? Our ageing population and improvements in medicine mean that we not only have an increasing number of people with dementia in the UK, but that those people are living longer with the disease in more advanced stages. Their needs become more complex and they become increasingly dependent. Currently, informal (mostly family) carers of people with dementia save the UK 11 billion a year. Yet this is not an easy task: most dementia suff erers display behavioural or psychological symptoms, which can be particularly distressing for the carer. Carer stress is inevitable and causes morbidity and mortality. Ameliorate this with: A care coordinator (via Social Services or the local Old Age Community Mental Healthcare Team); vital to coordinate the various teams and services available: Laundry services for soiled linen Attendance allowance Car badge giving priority parking Respite care in hospital Help from occupational therapist, district Council tax rebate (forms nurses, and community psychiatric nurses from local council offi ce). Day services can be invaluable for stimulating patients and providing regular, much-needed breaks for carers. Moral support Support groups, telephone helplines, and charities can all ease the burden, eg UK Alzheimers Disease Society. Combatting challenging behaviour: First rule out Pain, infection, and depression. Then consider trazodone (50300mg at night) or lorazepam (0. 51mg/1224h PO). Haloperidol (0. 54mg) can be useful in the short term. __OOHHCCMM__1100ee. . iinnddbb 448877 0022//0055//22001177 1199: : 0088 488 ygolorueN Alzheimers disease (AD) This leading cause of dementia is the big neuropsychiatric disorder of our times, dominating the care of the elderly and the lives of their families who give up work, friends, and ways of life to support relatives through the long fi nal years as they exit into their worlds of preoccupied emptiness. Suspect AD in adults 40yrs with persistent, 12 progressive, and global cognitive impairment: visuo-spatial skill, memory, verbal abilities, and executive function (planning) are all aff ected, unlike other dementias which may aff ect certain domains but not others (identify which with neuropsychometric tests). There is also anosognosiaa lack of insight into the problems engendered by the disease, eg missed appointments, misunderstood conversations or plots of fi lms, and mishandling of money.",
    "Later there may be irritability; mood disturbance (depression or euphoria); behavioural change (eg aggression, wandering, disinhibition); psychosis (hallucinations or delusions); agnosia (may not recognize self in the mirror). There is no standard natural history. Cognitive impairment is progressive, but non-cognitive symptoms may come and go over months. Eventually many patients become sedentary, taking little interest in anything. Cause Environmental and genetic factors both play a role. Accumulation of -amyloid peptide, a degradation product of amyloid precursor Protein, results in progressive neuronal damage, neurofi br illary tangles, numbers of amyloid plaques, and loss of the neurotransmitter acetylcholine (fi g 10. 24). Neuronal loss is selective the hippocampus, amygdala, temporal neocortex, and subcortical nuclei are most vulnerable. Vascular eff ects are also important95% of AD patients show evidence of vascular dementia. Risk factors 1st-degree relative with AD; Downs syndrome (in which AD is inevitable, often 40yrs); homozygosity for apolipoprotein E (ApoE) E4 allele (see BOX Genetics and the future); PICALM, CL1 CLU variants; vascular risk factors (blood pressure, diabetes, dyslipidaemia, homocysteine, atrial fibrillation); physical/cognitive activity; depression; loneliness (risk 2; simply living alone is not a risk factor); smoking. Management See p486 for a general approach to management in dementia. Refer to a specialist memory service. Acetylcholinesterase inhibitors (see BOX Pharmacological treatment). blood pressure control (in Heart failure there is a 2x risk of AD; extra risk halves with blood pressure control). Prevention in the context of ADs time-course: Changes in CSF -amyloid are seen 25yrs before onset of unequivocal symptoms (USy) and its deposition is detected 15yrs before USy. CSF tau Protein and brain atrophy are also detected 15yrs before USy. Cerebral hypometabolism and impaired episodic memory occur 10yrs before USy. Global cognitive impairment occurs 5yrs before USy. Prevention will probably be most eff ective before any of this startsthough there is currently insuffi cient evidence to recommend any specifi c interventions (BOX Genetics and the future). Ultimately, there is no simple relationship between brain structure, neurofi brillary tangles, and function. Prognosis Mean survival 7yrs from USy. 12 Enduring doesnt mean unfl uctuating: cognition comes and goes, allowing poetic insights, as in Iris Murdochs poignant self-diagnosis: I am sailing into the dark. __OOHHCCMM__1100ee. . iinnddbb 448888 0022//0055//22001177 1199: : 0088 489 ygolorueN Pharmacological treatment of cognitive decline There is overlap between Lewy body dementia, AD, and Parkinsons disease (peritoneal dialysis), complicating treatment decisions: L-dopa (p495) can precipitate delusions, and antipsychotic drugs worsen peritoneal dialysis. Rivastigmine may help all three. Acetylcholinesterase (AChE) inhibitors: Donepezil, rivastigmine, and galantamine are all mod estly eff ective in treating AD and are recommended by NICE. 6 There is also some evidence for their effi cacy in the dementia of Parkinsons disease, and rivastigmine may improve behavioural symptoms in Lewy body dementiathough none should be used in mild disease and they should be discontinued if there is no worthwile eff ect on symptoms. Doses: Donepezil: initially 5mg PO, eg doubled after 1 month. Riva stigm ine: 1. 5mg/12h initially, to 36mg/12h. Patches are also available. Galantamine: initially 4mg/12h, to 812mg/12h PO. The cholinergic eff ects of acetylcholinesterase inhibitors may exacerbate peptic ulcer disease and Heart block. Ask about symptoms and do an ECG fi rst. Antiglutamatergic treatment: Memantine (an NMDA antagonist, p449) is reasonably eff ective in late-stage AD, and is recommended in patients with severe disease or those with moderate disease in which AChE inhibitors are not tolerated/CI. Dose: 5mg/24h initially, by 5mg/d weekly to 10mg/12h. SE: hallucinations, confusion, hypertonia, hypersexuality. Antipsychotics: Consider in severe, non-cognitive symptoms only (eg psychosis or extreme agitation). Possible increased risk of stroke/TIA so discuss risks and assess cerebrovascular risk factors.",
    "Possible increased risk of stroke/TIA so discuss risks and assess cerebrovascular risk factors. Avoid in mild-to-moderate: Lewy body dementia (risk of neuroleptic sensitivity reactions), AD, and vascular dementia. Vitamin supplementation: Trials of dietary and vitamin supplements have been mixed and disappointing. Perhaps the best evidence exists for vitamin E (2000IU OD) which may confer a modest benefi t in delaying functional progression in mild to moderate AD, but with no eff ect on cognitive performance. Genetics and the future Possession of the APOE4 allele on chromosome 19 is the leading genetic cause of AD; homozygosity increases risk of developing the disease 12x. Yet while identifying this risk could enable a person to make lifestyle changes, there is little else to be done but anticipate ones impending cognitive decline (just one of the dilemmas raised by genetic testing). While the proteins that make up the plaques and neurofi - brillary tangles seen in AD were identifi ed in the early 1980s, progress has since been slow. So much so that in 2013, world leaders pledged to have a drug that would halt dementia within the next 10 years. Now a second-generation tau aggregation inhibitor called LMTX just might do the job, having shown success in phase III clinical trials in patients with mild/moderate AD, with clinical improvement and a slowing of atrophy on magnetic resonance imaging. Perhaps in the imminent future, identifying those at greater risk of developing AD through genetic testing will have a role. Fig 10. 24 Normal neuron (left) and one exhibiting senile plaques and neurofi brillary tangles (right). The corresponding changes on functional neuroimaging are also shown. __OOHHCCMM__1100ee. . iinnddbb 448899 0022//0055//22001177 1199: : 0088 490 ygolorueN Epilepsy: diagnosis Epilepsy is a recurrent tendency to spontaneous, intermittent, abnormal elec trical activity in part of the brain, manifesting as seizures. Convulsions are the motor signs of elect rical discharges. Elements of a seizure Some patients may experience a preceding prodrome lasting hours or days in which there may be a change in mood or behaviour. An aura implies a focal seizure, often, but not necessarily, from the temporal lobe. It may be a strange feeling in the gut, an experience such as déjà vu or strange smells or fl ashing lights. Post-ictally there may be headache, confusion, and myalgia; or temporary weakness after a focal seizure in the motor cortex (Todds palsy, p712), or dysphasia following a focal seizure in the temporal lobe. Causes ⅔ are idiopathic. Structural: Cortical scarring (eg head injury years before onset), developmental (eg dysembryoplastic neuroepithelial tumour or cortical dysgenesis), space-occupying lesion, stroke, hippocampal sclerosis (eg after a febrile convulsion), vascular malformations. Others: Tuberous sclerosis, sarcoidosis, SLE, PAN, antibodies to voltage-gated Potassium channels. Diagnosis Can be diffi cult due to the heterogenous nature of the disease (there are 40 diff erent types of epilepsy). NICE estimate 530% of people with epilepsy have been wrongly diagnosed. All patients with a seizure must be referred for specialist assessment and investigation in 2 wks. Take a thorough history: Including a detailed description from a witness. Ask specifi cally about tongue-biting and a slow recovery. If this is a fi rst seizure, enquire about past funny turns/odd behaviour. Déjà vu and odd episodic feelings of fear may well be relevant. Are there any triggers (eg alcohol, stress, fl ickering lights/TV)? Triggered attacks tend to recur. Establish the type of seizure: See BOX Seizure classifi cation. 7 NB: if a seizure begins with focal features, it is a partial seizure, however rapidly it then generalizes. Dont forget non-epileptic attack disorder ( pseudo seizurespsychogenic): this is not uncommon.",
    "Dont forget non-epileptic attack disorder ( pseudo seizurespsychogenic): this is not uncommon. (Suspect if seizures have a gradual onset, prolonged duration, and abrupt termination and are accompanied by closed eyes ± resistance to eye opening, rapid breathing, fl uctuating motor activity, and episodes of motionless unresponsiveness. CNS exam, computed tomography, magnetic resonance imaging, and EEG are normal. It may coexist with true epilepsy. ) Rule out provoking causes: Most people would have a seizure given suffi cient provocation (eg refl ex anoxic seizures in faints) but would not be classed as epileptic: only 310% of provoked seizures recur; generally when the provocation is irreversible. Causes: trauma; stroke; haemorrhage; ICP; alcohol or benzodiazepine withdrawal; metabolic disturbance (hypoxia, sodium, Ca2, glucose, uraemia, Liver disease); infection (eg meningitis, encephalitis); T°; drugs (tricyclics, cocaine). Unprovoked seizures have a recur rence rate of 3050%. Investigations Look for provoking causes. Consider an EEG: it cannot exclude epilepsy and can be falsely ve, so dont do one if simple syncope is the likely diagnosis. Only do emergency EEGS if non-convulsive status is the problem. Other tests: magnetic resonance imaging (structural lesions); drug levels (if on anti-epileptics: is the patient compliant? ); drugs screen; LP (eg if infection suspected). Counselling After any fi t, advise about dangers, eg swimming, driving, heights until the diagnosis is known; then give individualized counselling on employment, sport, insurance, and conception (OHCS p28). The patient must contact DVLA and avoid driving until seizure-free for 1yr (p159). __OOHHCCMM__1100ee. . iinnddbb 449900 0022//0055//22001177 1199: : 0088 491 ygolorueN Seizure classifi cation Focal seizures Originating within networks linked to one hemisphere and often seen with underlying structural disease. Various subclasses include: Without impairment of consciousness: (Previously described as simple. ) Awareness is unimpaired, with focal motor, sensory (olfactory, visual, etc. ), autonomic, or psychic symptoms. No post-ictal symptoms. With impairment of consciousness: (Previously described as complex. )Awareness is impairedeither at seizure onset or following a simple partial aura. Most commonly arise from the temporal lobe, in which post-ictal confusion is a feature. Evolving to a bilateral, convulsive seizure: (Previously described as secondary generalized. ) In ⅔ of patients with partial seizures, the electrical disturbance, which start s focally, spreads widely, causing a generalized seizure, which is typically convulsive. Generalized seizures Originating at some point within, and rapidly engaging bilaterally distributed networks leading to simultaneous onset of widespread electrical discharge with no localizing features referable to a single hemisphere. Important subtypes include: Absence seizures: Brief (≤10s) pauses, eg suddenly stops talking in mid-sentence, then carries on where left off. Presents in childhood. Tonicclonic seizures: Loss of consciousness. Limbs stiff en (tonic), then jerk (clonic). May have one without the other. Post-ictal confusion and drowsiness. Myoclonic seizures: Sudden jerk of a limb, face, or trunk. The patient may be thrown suddenly to the ground, or have a violently disobedient limb: one patient described it as my fl ying-saucer epilepsy, as crockery which happened to be in the hand would take off. Atonic (akinetic) seizures: Sudden loss of muscle tone causing a fall, no LOC. Infantile spasms: (OHCS p206) Commonly associated with tuberous sclerosis. NB: the classifi cation of epileptic syndromes is separate to the classifi cation of seizures, and is based on seizure type, age of onset, EEG fi ndings, and other features such as family history. Localizing features of focal seizures Temporal lobe Automatismscomplex motor phenomena with impaired awareness, varying from primitive oral (lip smacking, chewing, swallowing) or manual movements (fumbling, fi ddling, grabbing), to complex actions. Dysphasia. Déjà vu (when everything seems strangely familiar), or jamais vu (everything seems strangely unfamiliar).",
    "Use in women of childbearing potential with caution and only after counselling. __OOHHCCMM__1100ee. . iinnddbb 449922 0022//0055//22001177 1199: : 0088 493 ygolorueN Anti-epileptic drugs (AEDS): typical adult doses and side-eff ects Carbamazepine: (As slow-release. ) Initially 100mg/12h, increase by 200mg/d every 2wks up to max 1000mg/12h. SE: leucopenia, diplopia, blurred vision, impaired balance, drowsin ess, mild generalized erythematous rash, SIADH (rare; see p673). Lamotrigine: As monotherapy, initially 25mg/d, by 50mg/d every 2wks up to 100mg/12h (max 250mg/12h). Halve monotherapy dose if on valproate; double if on carbamazepine or pheny toin (max 350mg/12h). SE: maculopapular rashoccurs in 10% (but 1/1000 develop Stevens-Johnson syndrome or toxic epidermal necrolysis) typically in 1st 8wks, especially if on valproate; warn patients to see a doctor at once if rash or fl u symptoms develop; Other SES: diplopia, blurred vision, photosensitivity, tremor, agita tion, Vomiting, aplastic anaemia. Levetiracetam: Initially 250mg/24h, increase by 250mg/12h every 2wks up to max 1. 5g/12h (if estimated glomerular filtration rate 80). SE: psychiatric side-eff ects are common, eg depression, agitation. Other SES: DV, dyspepsia, drowsiness, diplopia, Blood dyscrasias. Sodium valproate: Initially 300mg/12h, increase by 100mg/12h every 3d up to max 30mg/kg (or 2. 5g) daily. SE: teratogenic. Nausea is very common (take with food). Other SES: Liver failure (watch LFT especially during 1st 6 months), pancreatitis, hair loss (grows back curly), oedema, ataxia, tremor, thrombocytopenia, encephalopathy (hyperammonaemia). Phenytoin: No longer 1st line due to toxicity (nystagmus, diplopia, tremor, dysarthria, ataxia) and SE: intellect, depression, coarse facial features, acne, gum hyper trophy, polyneuropathy, Blood dyscra sias. Blood levels required for dosage. Carbamazepine, phenytoin, and barbiturates are Liver enzyme inducing. Epilepsy and pregnancy Epilepsy carries a 5% risk of fetal abnormalities, so Good seizure control prior to conception and during pregnancy is vital. Yet some anti-epileptics are teratogenic: the patient must be given accurate information and counselling about contraception, conception, pregnancy, and breastfeeding in order to make informed decisions. In particular: Advise women of child-bearing age to take folic acid 5mg/d. Strictly avoid Sodium valproate and polytherapy prior to conception and during pregnancy (lamotrigine is preferred but transition needs to be planned). Advise that most AEDS except carbamazepine and valproate are present in breast milk. Lamotrigine is not thought to be harmful to infants. Discuss contraceptive methods, bearing in mind that: enzyme-inducing AEDS make progesterone-only contraception unreliable, and oestrogen-containing contraceptives lower lamotrigine levelsan increased dose may be needed to achieve seizure control. __OOHHCCMM__1100ee. . iinnddbb 449933 0022//0055//22001177 1199: : 0088 494 ygolorueN Parkinsonism This is the extrapyramidal triad of: 1 Tremor. Worse at rest; often pill-rolling of thumb over fi ngers (see p468). 2 Hypertonia. Rigidity tremor gives cogwheel rigidity, felt by the examiner during rapid pronation/supination. 3 Bradykinesia. Slow to initiate movement; actions slow and decrease in amplitude with repetition, eg blink rate, micrographia. Gait is festinant (shuffl ing, pitched forward, fi g 10. 25) with armswing and freezing at obstacles or doors (due to poor simultaneous motor and cognitive function). Expressionless face. Causes Fig 10. 25 Marche à petit pas. Parkinsons disease (peritoneal dialysis): Loss of dopaminergic neurons in the substantia nigra, associated with Lewy bodies in the basal ganglia, brainstem, and cortex. Most cases are sporadic, though multiple genetic loci have been identifi ed in familial cases. Mean age at onset is 60yrs. Prevalence: with age: 3. 5% at 8589yrs. Clinical features: The parkinsonian triad, plus non-motor symptoms such as: autonomic dysfunction (postural hypotension, constipation, urinary frequency/urgency, dribbling of saliva), sleep disturbance, and reduced sense of smell. Neuropsychiatric complications, such as depression, dementia, and psychosis, are common and debilitating.",
    "Neuropsychiatric complications, such as depression, dementia, and psychosis, are common and debilitating. Diagnosis: Is clinical and based on the core features of bradykinesia with resting tremor and/or hypertonia; cerebellar disease and frontotemporal dementia should be excluded; a clinical response to dopaminergic therapy is supportive. Signs are invariably worse on one sideif symmetrical look for other causes. If an alternative cause is suspected then consider magnetic resonance imaging to rule out structural pathology. Functional neuroimaging (DaTscan, PET) is playing an emerging role. Treatment: Focuses on symptom control and does not slow disease progression (see BOX). Non-pharmacological options include deep brain stimulation (DBS, may help those who are partly dopamine-responsive) and surgical ablation of overactive basal ganglia circuits (eg subthalamic nuclei). Parkinsons plus syndromes Pro gressive supranuclear palsy: (PSP, SteeleRichardsonOlszewski syndrome. ) Early postural instability, vertical gaze palsy ± falls; rigidity of trunk limbs; symmetrical onset; speech and swallowing problems; little tremor. Multiple system atrophy: (MSA; ShyDrager. ) Early autonomic features, eg impotence/incontinence, postural blood pressure; cerebellar pyr amidal signs; rigidity tremor. Cortico-basal degeneration: (CBD. ) Akinetic rigidity involving one limb; cortical sensory loss (eg astereognosis); apraxia (even autonomous interfering activity by aff ected limbthe alien limb phenomenon). Lewy body dementia: See p486. Secondary causes Vascular parkinsonism: (2. 55% of parkinsonism, also called lower limb parkinsonism). Eg diabetic/hypertensive patient with postural instability and falls (rather than tremor, bradykinesia, and festination). Other secondary causes: Drugs (neuroleptics, metoclopramide, prochlorp European Renal Association zine), toxins (manganese), Wilsons disease (p285), trauma (dementia pugilistica), encephalitis, neurosyphilis. Management Requires input of a a multidisc iplinary team (GP, neurologist, nurse specialist, social worker, carers, physioand occupational therapist) to boost quality of life. Assess disability and cognition objectively and regu larly, and monitor mood depression is common. Involve palliative care services early on. Postural exercises and weight lifting may help. Dont forget the carers (p487): off er respite care. __OOHHCCMM__1100ee. . iinnddbb 449944 0022//0055//22001177 1199: : 0088 495 ygolorueN Pharmacological therapy in Parkinsons disease A key decision is when to start supplementation of dopaminergic signalling with levodopa. Effi cacy of this therapy reduces with time, requiring larger and more frequent dosing, with worsening SEs and response fl uctuations (such as unpredictable freezing and pronounced end-of-dose reduced response: 50% at 6yrs). Starting late may therefore be wise, eg when 70yrs or when peritoneal dialysis seriously interferes with life: discuss pros and cons with the patient. Do not withdraw medication suddenlyrisks acute akinesia and neuroleptic malignant syndrome. Be aware of situations where malabsorption could also have this eff ect (eg abdominal surgery, gastroenteritis). Levodopa: Dopamine precursor, given combined with a dopa-decarboxylase inhibitor in co-beneldopa or co-careldopa. SES: dyskinesia, painful dystonia. Non-motor SES: psychosis; visual hallucinations, nausea and Vomiting (give domperidone). Modifi ed-release preparations should only be used in late disease. Dopamine agonists (DAS): Ropinirole and pramipexole monotherapy can delay starting levodopa in early stages of peritoneal dialysis, and allow lower doses of levodopa as peritoneal dialysis progresses. Rotigotine transdermal patches are available as monoor additive. SES: drowsiness, nausea, hallucinations, compulsive behaviour (gambling, hypersexuality, p449). Ergot-derived DA-agonists (b romocriptine, pergolide, cabergoline) can cause fi brotic reactions, and are not favoured. Amantadine (weak DA) is used for drug-induced dyskinesias in late peritoneal dialysis. Apomorphine: Potent DA agonist used with continuous SC infusion to even out endof-dose eff ects, or as a rescue-pen for sudden off freezing. SE: injection-site ulcers. Anticholinergics: (Eg benzhexol, orphenadrine. ) Cause confusion in the elderly and have multiple SESlimit to younger patients (but not 1st line). MAO-B inhibitors: (Eg rasagiline, selegiline. ) An alternative to dopamine agonists in early peritoneal dialysis. SEs include postural hypotension and atrial fi brillation.",
    "An alternative to dopamine agonists in early peritoneal dialysis. SEs include postural hypotension and atrial fi brillation. COMT inhibitors: (Eg entacapone, tolcapone. ) May help motor complications in late disease. Lessen the off time in those with end-of-dose wearing off. Tolcapone has better effi cacy, but may cause severe hepatic complications and requires close monitoring of LFT. __OOHHCCMM__1100ee. . iinnddbb 449955 0022//0055//22001177 1199: : 0088 496 ygolorueN Multiple sclerosis (MS) Infl ammatory plaques of demyelination in the CNS disseminated in space and time; ie occuring at multiple sites, with ≥30d in between attacks. Demyelination heals poorly, eventually causing axonal loss; 80% of patients develop progressive disability. The exact cause of the disease remains unknown; it is most likely a combination of genetic and environmental factors. There is 30% concordance in identical twins, and unusual geographical distribution, with increasing incidence with latitude in some parts of the world (NB: adult migrants take their risk with them; children before mealsquire the risk of where they settle)leading to hypotheses of the roles of vitamin D and infection. Mean age of onset is 30yrs. : ≥3: 1. Presentation Usually monosymptomatic: 20% present with unilateral optic neuritis (Pain on eye movement and rapid central vision). Corticospinal tract and bladder involvement are also common, and symptoms may worsen with heat (eg hot Rice or exercise). Other symptoms/signs see table 10. 8. Diagnosis This is clinical, made by a consultant neurologist using established criteria (eg McDonald, see table 10. 9) and after alternative diagnoses have been excluded. Early diagnosis and treatment reduce relapse rates and disability so refer to neurology as soon as MS is suspected. Tests Depending on presenting symptoms, some patients may need extra supporting information to make a diagnosis (as per the McDonald criteria). magnetic resonance imaging: Sensitive but not sp e cifi c for plaque detection. It may also exclude other causes, eg cord compression. CSF: Oligoclonal bands of IgG on electrophoresis that are not present in serum suggest CNS infl am mation. Delayed visual, auditory, and somatosensory evoked potentials. Progression Most patients follow a relapsing-remitting course, with initial recovery in between relapses. With time, remission becomes incomplete, so disability accumulates (secondary progression). 10% of patients display steadily progressive disability in the absence of relapses (primary progressive MS), while a minority of patients experience no progressive disablement at all. Poor prognostic signs: Older ; motor signs at onset; many early relapses; many magnetic resonance imaging lesions; axonal loss. Pregnancy: Does not alter the rate of progression: relapses may reduce during pregnancy and increase 36 months afterwards, but return to their previous rate thereafter. Management As with all neurological conditions, requires the coordinated care of a multidis ciplinary team and full involvement of the patient in all decisions. 8 Lifestyle advice: Regular exercise, stopping smoking and avoiding stress may help. Disease-modifying drugs: Dimethyl fumarate is an option for mild/moderate relapsing-remitting MS. The monoclonal antibodies alemtuzumab (acts against T cells) and natalizumab (acts against VLA-4 receptors that allow immune cells to cross the Bloodbrain barrier) are also approved for relapsing-remitting disease. Interferon beta and glatiramer are not recommended by NICE on the balance of clinical and cost-eff ectiveness. Azathioprine is not recommended due to its SE profi Blood. Treating relapses: Methylprednisolone, eg 0. 51g/24h IV/PO for 35d shortens acute relapses; use sparingly ( twice/yr; steroid SE, p377). It doesnt alter overall prognosis. Symptom control: Spasticity: off er baclofen or gabapentin. Tizanidine or dantrolene are 2nd line; if these fail consider benzodiazepines. Tremor: botulinum toxin type A injections improve arm tremor and functioning. Urgency/frequency: if postmicturition residual Urine 100mL, teach intermittent self-catheterization; if 100mL, try tolterodine.",
    "Urgency/frequency: if postmicturition residual Urine 100mL, teach intermittent self-catheterization; if 100mL, try tolterodine. Fatigue: amantadine, CBT, and exercise may help. __OOHHCCMM__1100ee. . iinnddbb 449966 0022//0055//22001177 1199: : 0088 497 ygolorueN Table 10. 8 Clinical features of MS Sensory: Dysaesthesia GI: Swallowing disorders; constipation. Pins and needles Eye: Diplopia; hemianopia; optic neuritis; visual Vibration sense phe nomena (eg on exercise); bilateral intern uclear Trigeminal neuralgia ophthalmoplegia (p73); pupil defects. Motor: Spastic weakness Cerebellum: Trunk and limb ataxia; intention Myelitis trem or; scanning (ie monotonous) speech; falls. Sexual/GU: Erectile dysfunction Cognitive/visuospatial decline: A big cause Anorgasmia; Urine of un employment, accidents, amnesia, mood, ret ention; inconti- executive functioning. nence NB T°, malaise, nausea, Vomiting, positional vertigo, seizures, aphasia, meningism, bilateral optic neuritis, CSF leucocytosis and CSF Protein are rare in MS, and may suggest non-MS recurrent demyelinating disease, eg vasculitis or sarcoidosis. Diagnostic criteria for MS Table 10. 9 McDonald criteria for diagnosing MS (2010) Clinical presentation Additional evidence needed for diagnosis ≥2 attacks (relapses) with ≥2 None objective clinical lesions ≥2 attacks with 1 objective clinical magnetic resonance imaging: spatially disseminated lesions, or ve CSF lesion and ≥2 magnetic resonance imaging lesions, or 2nd attack at a new site 1 attack with ≥2 objective clinical Dissemination in time: new lesion on repeat magnetic resonance imaging lesions after 3 months or 2nd attack 1 attack with 1 objective clinical Dissemination in space: magnetic resonance imaging or ve CSF if ≥2 magnetic resonance imaging lesion (monosymptomatic preslesions consistent with MS and dissemination in entation) time (by magnetic resonance imaging or a 2nd clinical attack) Insidious neurological progression ve CSF and dissemination in space on magnetic resonance imaging/VEP suggestive of primary progresor continued progression for ≥1yr sive MS A careful history may reveal past episodes, eg brief unexplained visual loss, and detailed examination may show more than 1 lesion. Attacks must last 1h, with 30d between attacks. Six MS eponyms Devics syndrome: (Neuromyelitis optica, NMO. ) MS variant with transverse myelitis, (loss of motor, sensory, autonomic, refl ex, and sphincter function below the level of a lesion), optic atrophy, and anti-aquaporin 4 antibodies (p698). Lhermittes sign: Neck fl exion causes electric shocks in trunk/limbs. (Also ve in cervical spondylosis, cord tumours and B12. ) Uhthoffs phenomenon: Worsening of symptoms with heat, eg in Rice. Charles Bonnet syndrome: (Rare. ) Acuity/temporary blindness ± complex visual hallucinations of faces, as well as animals, plants, and trees. Pulfrich effect: Unequal eye latencies, causing disorie ntation in traffi c as straight trajectories seem curved and distances are misjudged on looking sideways. Argyll Roberts on pupil: See p72. __OOHHCCMM__1100ee. . iinnddbb 449977 0022//0055//22001177 1199: : 0088 498 ygolorueN Space-occupying lesions (SOL) Signs ICP: (See p830. ) Headache worse on waking, lying down, bending forward, or with coughing (p456); Vomiting; papilloedema (only in 50% of tumours); GCS. Seizures: Seen in ≤50%. Exclude SOL in all adult-onset seizures, especially if focal, or with a localizing aura or post-ictal weakness (Todds palsy, p712). Evolving focal neurology: See BOX for localizing signs. ICP causes false localizing signs: VIth nerve palsy is commonest (p70) due to its long intracranial course. Subtle personality change: Irritability, lack of application to tasks, lack of initiative, socially inappropriate behaviour. Causes Tumour (primary or metastatic, later in topic), aneurysm, abscess (25% multiple); chronic subdural haematoma, granuloma (p197, eg tuberculoma), cyst (eg cysticercosis). Tumours: 30% are metastatic (eg breast, lung, melanoma). Primaries: astrocytoma, glioblastoma multiforme, oligo dendro glioma, ependymoma. Also meningioma, primary CNS lymphoma (eg as non-infectious manifestation of HIV), and cerebellar haemangiob lastoma.",
    "Also meningioma, primary CNS lymphoma (eg as non-infectious manifestation of HIV), and cerebellar haemangiob lastoma. Diff erentials Stroke, head injury, venous sinus thrombosis, vasculitis, MS, encephalitis, post-ictal, metabolic, or idiopathic intracranial hypertension. Tests computed tomography ± magnetic resonance imaging (Good for posterior fossa masses). Consider biopsy. Avoid LP before imaging (risks coning, ie cerebellar tonsils herniate through the foramen magnum). Tumour management Benign: Remove if possible but some may be inaccessible. Malignant: Excision of gliomas is hard as resection margins are rarely clear, but surgery does give a tissue diagnosis, it debulks pre-radiotherapy, and makes a cavity for inserting carmustine wafers (delivers local chemotherapy). If a tumour is inaccessible but causing hydrocephalus, a ventriculo-peritoneal shunt can help. Chemo-radiotherapy is used post-op for gliomas or metastases, and as sole therapy if surgery is impossible. Oligodendroglioma with 1p/19q deletions is especially sensitive. In glioblastoma, temozolomide (alkylating agent) survival. Seizure prophylaxis (eg phenyt oin) is important, but often fails. Treat headache (eg codeine 60mg/4h PO). Cerebral oedema: Dexamethasone 4mg/8h PO; mannitol if ICP acutely (p831). Plan meticulous palliative treatment (p534). Prognosis Poor but improving (50% survival at 5yrs) for CNS primaries; 40% 20yr survival for cerebellar haemangiob lastoma; benign tumours are curable by excision. Third-ventricle colloid cysts These congenital cysts declare themselves in adult life with amnesia, headache(often positional), obtundation(blunted consciousness), incontinence, dim vision, bilateral paraesthesiae, weak legs, and drop attacks. : Excision or ventriculo-peritoneal shunting. Idiopathic intracranial hypertension Think of this in those presenting as if with a mass (headache, ICP, and papilloedema)when none is found. Most commonly seen in obese females in 3rd decade, who present with narrowed visual fi elds, blurred vision ± diplopia, VIth nerve palsy, and an enlarged blind spot, if papilloedema is present (it usually is). Consciousness and cognition are preserved. Associations Endocrine abnormalities (Cushings syndrome, hypoparathyroidism, TSH), SLE, chronic kidney disease, IDA, PRV, drugs (tetracycline, steroids, nitrofurantoin, and oral contraceptives). Management Weight loss, acetazolamide or topiramate, loop diuretics, and prednisolone (start at 40mg/24h PO; more SE than diuretics). Consider optic nerve sheath fenestration or lumbarperitoneal shunt if drugs fail and visual loss worsens. Prognosis Often self-limiting. Permanent signifi cant visual loss in 10%. __OOHHCCMM__1100ee. . iinnddbb 449988 0022//0055//22001177 1199: : 0088 499 ygolorueN Localizing features Temporal lobe: Dysphasia (p86). Contralateral homonymous hemia nopia (or upper quadrantanopia if only Meyers loop aff ected). Amnesia. Many odd or seemingly inexplicable phenomena, p491. Frontal lobe: Hemiparesis. Personality change (indecent, indolent, indiscreet, facetious, tendency to pun). Release phenomena such as the grasp refl ex (fi ngers drawn across palm are grasped), signifi cant only if unilateral. Brocas dysphasia (p86), or more subtle diffi culty with initiating and planning speech with intact repetition and no anomiabut loss of coherence. Unilateral anosmia (loss of smell). Perseveration (unable to switch from one line of thinking to another). Executive dysfunction (unable to plan tasks). Verbal fl uency. Parietal lobe: Hemisensory loss. 2-point discrimination. Astereognosis (unable to recognize an object by touch alone). Sensory inattention. Dysphasia (p86). Gerstmanns syndrome (p700). Occipital lobe: Contralateral visual fi eld defects. Palinopsia (persisting images once the stimulus has left the fi eld of view). Polyopia (seeing multiple images). Cerebellum: Remember DANISH: dysdiadochokinesis (impaired rapidly alternating movements, p67) and dysmetria (past-pointing); ataxia (limb/truncalbut if truncal ataxia is worse on eye closure, blame the dorsal columns); nystagmus; intention tremor; slurred speech (dysarthria); hypotonia. Cerebellopontine angle: (Eg acoustic neuroma/vestibular Schwannoma; p462. ) Ipsi lateral deafness, nystagmus, corneal refl ex, facial weakness (rare), ipsilateral cerebellar signs (above), papilloedema, VIth nerve palsy (p70). Midbrain: (Eg pineal tumours or midbrain infarction. )",
    "Phrenic nerve C35 C3, 4, 5 keeps the diaphragm alive: lesions cause orthopnoea with a raised hemidiaphragm on CXR. Causes: Lung cancer, TB, paraneopla stic syndromes, myeloma, thymoma, cervical spondylosis/trauma, thoracic surgery, infections (HZV, HIV, Lyme disease), muscular dystrophy. Lateral cutaneous nerve of the thigh L2L3 Meralgia paraesthetica is anterolateral burning thigh Pain from entrapment under the inguinal ligament. Sciatic nerve L4S3 Damaged by pelvic tumours or fractures to pelvis or femur. Lesions aff ect the hamstrings and all muscles below the knee (foot drop), with loss of sensation below the knee laterally. Common peroneal nerve L4S1 Originates from sciatic nerve just above knee. Often damaged as it winds round the fi bular head (trauma, sitting cross-legged). Signs: Foot drop, weak ankle dorsifl exion/eversion, sensory loss over dorsal foot. Tibial nerve L4S3 Originates from sciatic nerve just above knee. Lesions lead to an inability to stand on tiptoe (plantarfl exion), invert the foot, or fl ex the toes, with sensory loss over the sole. Mononeuritis multiplex Describes the involvement of two or more peripheral nerves. Causes tend to be systemic: diabetes mellitus, connective tissue disorders (rheumatoid, SLE), vasculitis (granulomatosis with polyangiitis formerly Wegeners granulomatosis, PAN), and more rarely sarcoidosis, amy loid, leprosy. Electrom yography (EMG) helps defi ne the anatomic site of lesions. __OOHHCCMM__1100ee. . iinnddbb 550022 0022//0055//22001177 1199: : 0088 503 ygolorueN Carpal tunnel syndrome: the commonest mononeuropathy The median nerve and nine tendons compete for space within the wrist. Compression is common, especially in women who have narrower wrists but similar-sized tendons to men. Clinical features: Aching Pain in the hand and arm (especially at night), and paraesthesiae in thumb, index, and middle fi ngers: relieved by dangling the hand over the edge of the bed and shaking it (remember wake and shake). There may be sensory loss and weakness of abductor pollicis brevis ± wasting of the thenar eminence. Light touch, 2-point discrimination, and sweating may be impaired. Causes: Anything causing Edema or compression of the tunnel: myxoedema; prolonged fl exion (eg in a Colles splint); acromegaly; myeloma; local tumours (lipomas, ganglia); rheumatoid arthritis; amyloidosis; pregnancy; sarcoidosis. Tests: Neurophysiology helps by confi rming the lesions site and severity (and likelihood of improvement after surgery). Maximal wrist fl exion for 1 min (Phalens test) may elicit symptoms, and tapping over the nerve at the wrist can induce tingling (Tinels test) but both are rather non-specifi c. Treatment: Splinting, local steroid injection ± decompr ession surgery. NB: There is also tarsal tunnel syndrome: unilateral burning sole Pain following tibial nerve compression. Managing ulnar mononeuropathies from entrapments The ulnar nerve asks for trouble in at least fi ve places at the elbow, starting proximally at the arcade of Struthers (a musculofascial band 8cm proximal to the medial epicondyle), and ending distally where it exits the fl exor carpi ulnaris muscle in the forearm. Most often, compression occurs at the epicondylar groove or at the point where the nerve passes between the two heads of fl exor carpi ulnaris (true cubital tunnel syndrome). Trauma can easily damage the nerve against its bony confi nes (the medial condyle of the humerusthe funny bone). Normally, stretch and compression forces on the ulnar nerve at the elbow are moderated by its ability to glide in its groove. When normal excursion is restricted, irritation ensues. This may cause a vicious cycle of perineural scarring, consequent loss of excursion, and progressive symptomswithout antecedent trauma. Compressive ulnar neuropathies at the wrist (Guyons canalbetween the pisiform and hamate bones) are less common, but they can also result in disability.",
    "Treatment centres on rest and avoiding Hypertension on the nerve, but if symptoms conti nue, night-time soft elbow splinting (to prevent fl exion 60°) is warranted. A splint for the hand may help prevent permanent clawing of the fi ngers. For chronic neuropathy associated with weakness, or if splinting fails, a variety of surgical procedures have been tried. For moderately severe neuropathies, decompressions in situ may help, but often fail. Medial epicondylectomies are eff ective in 50% (but many will recur). Subcutaneous nerve re-routing (transposition) may be tried. __OOHHCCMM__1100ee. . iinnddbb 550033 0022//0055//22001177 1199: : 0088 504 ygolorueN Polyneuropathies Motor and/or sensory disorder of multiple periphe ral or cranial nerves: usually symmetrical, widespread, and often worse distally (glove and stocking distribution). They can be classifi ed by: chronicity, function (sensory, motor, autonomic, mixed), or pathology (demyelination, axonal degeneration, or both). For example, Guillain Barré syndrome (p702) is an acute, predominantly motor, demyelinating neurop athy, whereas chronic alcohol abuse leads to a chronic, initially sensory then mixed, axonal neuropathy. Diagnosis The history is vital: be clear about the time course, the precise nature of the symptoms, and any preceding or associated events (eg DV before GuillainBarré syndrome; weight in cancer; arthralgia from a connective tissue disease). Ask about travel, alcohol and drug use, sexual infections, and family history. If there is palpable nerve thickening think of leprosy or CharcotMarieTooth. Examine other systems for clues to the cause, eg alcoholic Liver disease. Tests FBC, ESR, glucose, UE, LFT, TSH, B12, electrophoresis, ANA, ANCA, CXR, urinalysis, consider LP ± specifi c genetic tests for inherited neuropathies, lead level, antiganglioside antibodies. Nerve conduction studies distinguish demyelinating from axonal causes. Sensory neuropathy: (Eg diabetes mellitus, chronic kidney disease, leprosy. ) Numbness; pins and needles, paraesthesiae; aff ects glove and stocking distribution. Diffi culty handling small objects such as buttons. Signs of trauma (eg fi nger burns) or joint deformation may indicate sensory loss. Diabetic and alcoholic neuropathies are typically painful. Motor neuropathy: (Eg GuillainBarré syndrome, lead poisoning, CharcotMarie Tooth syndrome. ) Often progressive (may be rapid); weak or clumsy hands; diffi - culty in walking (falls, stumbling); diffi culty in breathing (vital capacity). Signs: LMN lesion: wasting and weakness most marked in the distal muscles of hands and feet (foot or wrist drop). Refl exes are reduced or absent. Cranial nerves: Swallowing/speaking diffi culty; diplopia. Autonomic system: See BOX. Management Treat the cause (table 10. 10). Involve physio and OT. Foot care and shoe choice are important in sensory neuropathies to minimize trauma. Splinting joints helps prevent contractures in prolonged paralysis. In GuillainBarré and chronic infl ammatory demyelinating polyradiculoneuropathy (CIDP: autoimmune demyelination of peripheral nerves), IV immunoglobulin helps. For vasculitic causes, steroids/immuno suppressants may help. Treat neuropathic Pain with amitriptyline, duloxetine, gabapentin or pregabalin. __OOHHCCMM__1100ee. . iinnddbb 550044 0022//0055//22001177 1199: : 0088 505 ygolorueN Table 10. 10 Causes of polyneuropathy Metabolic Vasculitides Malignancy Infl ammatory Diabetes mellitus Polyarteritis Paraneoplastic GuillainBarré Renal failure nodosa syndromes syndrome Hypothyroidism Rheumatoid Polycythaemia rubra Sarcoidosis; CIDP Hypoglycaemia arthritis vera Mito chondrial disorders GPA Infections Nutritional Inherited Drugs Leprosy Vit B1 syndromes Vincristine HIV Vit B12/folate CharcotMarieTooth Cisplatin Syphilis Vit B6 Refsums syndrome Isoniazid Lyme disease Vit E Porphyria Nitrofurantoin Leucodystrophy Phenytoin Metronidazole Others Paraproteinaemias, amyloidosis, lead, arsenic Chronic infl ammatory demyelinating polyradiculoneuropathy (CIDP): autoimmune demyelination of peripheral nerves (distal onset of weakness/sensory loss in limbs nerve enlargement CSF Protein). Autonomic neuropathy Sympathetic and parasympathetic neuropathies may be isolated or part of a generalized sensorimotor peripheral neuropathy.",
    "Autonomic neuropathy Sympathetic and parasympathetic neuropathies may be isolated or part of a generalized sensorimotor peripheral neuropathy. Causes diabetes mellitus, amyloidosis, GuillainBarré and Sjögrens syndromes, HIV, leprosy, SLE, toxic, genetic (eg porphyria), or paraneoplastic, eg paraneoplastic e ncephalomyelo neuropathies and LambertEaton myasthenic syndrome (LEMS, p512). Signs Sympathetic: Postural hypotension, sweating, ejaculatory failure, Horners syndrome (p702). Parasympathetic: Constipation, nocturnal dia rrhoea, Urine retention, erectile dysf unction, HolmesAdie pupil (p72). Autonomic function tests blood pressure: Postural drop of 20/10mmHg is abnormal. ECG: A variation of 10bpm with respiration is abnormal (check R-R interval). Cystometry: Bladder Hypertension studies. Pupils: Instil 0. 1% adrenaline (dilates if post-ganglionic sympathetic denervation, not if normal); 2. 5% cocaine (dilates if normal; not if sympathetic denervation); 2. 5% methacholine (constricts if parasympathetic lesion)rarely used. Paraneoplastic antibodies: Anti-HU, anti-YO, anti-RI, anti-amphiphysin, antiCV2, anti-MA2. Other Ab: Antiganglionic acetylcholine receptor antibody presence shows that the cause may be autoimmune autonomic ganglionopathy. Primary autonomic failure Occurs alone (autoimmune autonomic ganglionopathy), as part of multisystem atrophy (MSA, p494), or with Parkinsons disease, typically in a middle-aged/elderly man. Onset: insidious; symptoms as listed previously. __OOHHCCMM__1100ee. . iinnddbb 550055 0022//0055//22001177 1199: : 0088 506 ygolorueN Motor neuron disease (MND) MND is a cluster of neurodegenerative diseases aff ecting 6/100 000 (: 3: 2), characterized by selective loss of neurons in motor cortex, cranial nerve nuclei, and anterior horn cells. Upper and lower motor neurons can be aff ected but there is no sensory loss or sphincter disturbance, thus distinguishing MND from MS and polyneuropathies. MND never aff ects eye movements, distinguishing it from myasthenia (p512). There are four clinical patterns: 1 ALS/amyotrophic lateral sclerosis. (Archetypal MND; up to 80%. ) Loss of motor neurons in motor cortex and the anterior horn of the cord, so combined UMN LMN signs (p446). Worse prognosis if: bulbar onset, age; FVC. 2 Progressive bulbar palsy. (1020%. ) Only aff ects cranial nerves IXXII. See BOX Bulbar and corticobulbar (pseudobulbar) palsy. 3 Progressive muscular atrophy. (10%. ) Anterior horn cell lesion, so LMN signs only. Aff ects distal muscle groups before proximal. Better prognosis than ALS. 4 Primary lateral sclerosis. (Rare. ) Loss of Betz cells in motor cortex: mainly UMN signs, marked spastic leg weakness and pseudobulbar palsy. No cognitive decline. Presentation Think of MND in those 40yrs (median UK age at onset is 60) with stumbling spastic gait, foot-drop ± proximal myopathy, weak grip (door-handles dont turn) and shoulder abduction (hair-washing is hard), or aspiration pneumonia. Look for UMN signs: spasticity, brisk refl exes, plantars; and LMN signs: wasting, fasciculation of tongue, abdomen, back, thigh. Is speech or swallowing aff ected (bulbar signs)? Fasciculation is not enough to diagnose an LMN lesion: look for weakness too. Frontotemporal dementia occurs in 25% (see BOX Dignity and Dignitas). Diagnostic criteria (See BOX Revised El Escorial diagnostic criteria for ALS). There is no diagnostic test. Brain/cord magnetic resonance imaging helps exclude structural causes, LP helps exclude infl ammatory ones, and neurophysiology can detect subclinical denervation and help exclude mimicking motor neuropathies. 14 Prognosis Poor, 3yrs post onset in half of patients. Management Adopt a multidisciplinary approach: neurologist, palliative nurse, hosp ice, physio, OT, speech therapist, dietician, social servicesall orchestrated by the GP. Riluzole, an inhibitor of glutamate release and NMDA receptor antagonist, is the only medication shown to improve survival. Mulitple other drugs that have shown promise in animal models have failed to prove benefi t in clinical trials, including neurotrophic factors, anti-apoptotic agents, antioxidants, and immunomodulatory drugs. For supportive/symptomatic treatment: Excess saliva: Advise on positioning, oral care, and suctioning.",
    "For supportive/symptomatic treatment: Excess saliva: Advise on positioning, oral care, and suctioning. Try an antimuscarinic (eg propantheline) or glycopyrronium bromide (can be given SC). Botulinum toxin A may help. Dysphagia: Blend food. Gastrostomy is an optiondiscuss early on. Spasticity: Exercise, orthotics. See MS for drugs (p496). Communication diffi culty: Provide augmentative and alternative communication equipment. End-of-life care: Involve palliative care team from diagnosis (p532). Consider opioids to relieve breathlessness and discuss non-invasive ventilation (see BOX Dignity and Dignitas). 14 If no UMN signs and distal arm muscles are aff ected in the distribution of individual nerves, suspect multifocal motor neuropathy with conduction block (diagnose on nerve conduction studies; : IV Ig). Gyn aeco mastia, atrophic testes ± infertility suggests Kennedy syndrome (bulbospinal muscular atrophy). __OOHHCCMM__1100ee. . iinnddbb 550066 0022//0055//22001177 1199: : 0088 507 ygolorueN Bulbar and corticobulbar (pseudobulbar) palsy Bulbar palsy denotes diseases of the nuclei of cranial nerves IXXII in the medulla. Signs: An LMN lesion of the tongue and muscles of talking and swallowing: fl accid, fasciculating tongue (like a sack of worms); jaw jerk is normal or absent, speech is quiet, hoarse, or nasal. Causes: MND, GuillainBarré, polio, myasthenia gravis, syringo bulbia (p516), brainstem tumours, central pontine myelinolysis (p672). Corticobulbar palsy UMN lesion of muscles of swallowing and talking due to bilateral lesions above the mid-pons, eg corticobulbar tracts (MS, MND, stroke, central pontine myelinolysis). It is commoner than bulbar palsy. Signs: Slow tongue movements, with slow deliberate speech; jaw jerk; pharyngeal and palatal refl exes; pseudobulbar aff ect (PBA)weeping unprovoked by sorrow or mood-incongruent giggling (emotional incontinence without mood change is also seen in MS, Wilsons, and Parkinsons disease, dementia, nitrous oxide use, and head injury). In some countries, dextromethorphan quinidine is licensed for PBA. Revised El Escorial diagnostic criteria for ALS Defi nite Lower upper motor neuron signs in 3 regions. Probable Lower upper motor neuron signs in 2 regions. Probable with lab support Lower upper motor neuron signs in 1 region, or upper motor neuron signs in ≥1 region EMG shows acute denervation in ≥2 limbs. Possible Lower upper motor neuron signs in 1 region. Suspected Upper or lower motor neuron signs onlyin 1 or more regions. Dignity and Dignitas ALS is closely linked with frontotemporal dementia (FTD, p486) by increasing clinical, genetic, and molecular evidence (nucleotide repeat expansions in gene C9orf72 have been described in familial and sporadic ALS and in FTD). However, patients with MND often have no cognitive impairment in the early stages of the disease, and witness their inorexable physical decline with terrifi ed awareness. For this reason it is imperative to plan for the future early: discuss their wishes for end-of-life care and in the eventuality of respiratory decline before it is too late for wishes to be communicated. These discussions are crucial but not binding: the patient can change their mind at any point, and also refuse any life-prolonging treatment, knowing the consequence is death. However, in most countries, including the UK, we cannot traverse that line that lies between management of a supported death following withdrawal of life-prolonging (or death-prolonging) interventions, and acting with the intention of causing death. Court battles ensue, with requests for assisted suicide that may frustrate and challenge ethicists, physicians, politicians, and the judiciary, but above all, patients and their families. Faced with such confl icting passions, perhaps our role is to be clear that we stand beside our patients, come what may. __OOHHCCMM__1100ee. .",
    "ring fi nger. Worrying symptoms: Night Pain, weight, fever. Passive head turning may exacerbate C6 radicular Pain but not carpal tunnel syndrome (Spurlings manoeuvre ). Fig 10. 27 A T2-weighted magnetic resonance imaging ( Fig 10. 28 Cervical vertebra. 1 Dorsal root ganglion; CSF looks bright). The cord is com2 Dorsal root; 3 Dura mater; 4 Subarachnoid space; 5 Pia pressed between osteop hytes mater; 6 Grey matter; 7 Spinal nerve; 8 Ventral ramus; anter iorly and the ligamentum fl a9 Vertebral artery in the transverse foramen; 10 White vum posteriorly. matter; 11 Ventral spinal nerve. Prof P Scally. Fig 10. 29 Laminectomy. Fig 10. 30 Laminoplasty (screws and plates). __OOHHCCMM__1100ee. . iinnddbb 550099 0022//0055//22001177 1199: : 0088 510 ygolorueN Myopathy Primary disorder of muscle with gradual-onset symmetrical weakness; it may be confused clinically with neuropathy. In favour of myopathy: Gradual onset of symmetric proximal weaknessdiffi culty combing hair and climbing stairs (NB: weakness is also distal in myotonic dystrophy). Specifi c muscle groups aff ected (ie selective weakness on fi rst presentation). Preserved tendon refl exes. No paraesthesiae or bladder problems. No fasciculation (suggests anterior horn cell or root disease). Rapid onset suggests a toxic, drug, or metabolic myopathy (or a neuropathy). Excess fatigability (weakness with exercise) suggests myasthenia (p512). Spontaneous Pain at rest and local tenderness occurs in infl ammatory myopathies. Pain on exercise suggests ischaemia or metabolic myopathy (eg McArdles disease). Oddly fi rm muscles (due to infi ltrati ons with fat or connective tissue) suggest pseudohyper trop hic muscular dystrophi es (eg Duchennes). Tests ESR, CK, AST, and LDH may be raised. Do EMG and tests relevant to systemic causes (eg TSH, p216). Muscle biopsy and genetic testing may help reach a diagnosis. Muscular dystrophies A group of genetic diseases (see table 10. 12) with progressive degeneration and weakness of specifi c muscle groups. The primary abnormality may be in the muscle membrane. There may be unusually fi rm muscles due to infi ltrati on by fat or connective tissue, and marked variation in size of individual muscle fi bres on histology. Duchennes muscular dystrophy: The commonest (3/1000 male live births). Presents at 4yrs old with clumsy walking, then diffi - culty in standing, and respiratory failure. Pseudohypertrophy is seen, especially in the calves. Serum creatine kinase 40-fold. There is no specifi c treatment. Some survive beyond 20yrs. Home ventilation improves prognosis. Genetic counselling is vital. Beckers muscular dystrophy: (0. 3/1000 births. ) Presents similarly to Duchennes but with milder symptoms, at a later age, and with a better prognosis. Facioscapulohumeral muscular dystrop hy: (FSHD, LandouzyDejerine. ) Almost as common as Duchennes. Onset is 1214yrs old, with inability to puff out the cheeks and diffi culty raising the arms above the head. Signs: weakness of face (ironed out expression), shoulders, and upper arms (often asymmetric with deltoids spared), foot-drop, scapular winging (fi g 10. 31), scoliosis, anterior axillary folds, and horizontal clavicles. 20% need a wheelchair by 40yrs. Myotonic disorders Cause tonic muscle spasm (myotonia), and demonstrate long chains of central nuclei within muscle fi bres on histology. The commonest is myotonic dystrophy which is, in fact, clinically and genetically heterogeneous, with two major forms (DM1 and DM2see table 10. 12), both showing abnormal trinucleotide repeat expansions in regulatory (non-coding) genetic regions. DM1 is the commoner, more severe, and typically presents between 2040 yrs old with distal weakness (hand/foot drop), weak sternomastoids, and myotonia. Facial weakness and muscle wasting give a long, haggard appearance. Also: cataracts, male frontal baldness, Diabetes, testis/ovary atrophy, cardiomyopathy, and cognition.",
    "Also: cataracts, male frontal baldness, Diabetes, testis/ovary atrophy, cardiomyopathy, and cognition. Most DM1 patients die in late middle age of respiratory or cardiac complications. Mexiletine may help with disabling myotonia. Genetic counselling is important. Infl ammatory myopathies There may be spontaneous muscle Pain at rest and local tenderness on palpation. Inclusion body myositis is the chief example if aged 50yrs. Weakness starts with quadriceps, fi nger fl exors, or pharyngeal muscles. Ventral extremity muscle groups are more aff ected than dorsal or girdle groups. Response to therapy is poor and patients typically progress over a decade to require assistance with activites of daily living. Histology shows ringed vacuoles intranuclear inclusions. Polymyositis and dermatomyositis, see p552. Metabolic myopathies Eg McArdles disease (glycogen storage disorder). Presents with muscle Pain and weakness after exercise. Acquired myopathies of late onset Often part of systemic diseaseeg hyperthyroidism, malignancy, Cushings, hypoand hypercalcaemia. Drug causes Alcohol; statins; steroids; chloroquine; zidovudine; vincristine; cocaine. __OOHHCCMM__1100ee. . iinnddbb 551100 0022//0055//22001177 1199: : 0088 511 ygolorueN Fig 10. 31 Winging of both scapulae in facioscapulohumeral muscular dystrophy, due to weakness of thoracoscapular muscles. Reproduced from Donaghy, Brains Diseases of the Nervous System, 12th edition, with permission from Oxford University Press. Table 10. 12 Genetics of some commoner congenital myopathies Condition Inheritance Chr Gene Pathogenesis Duchennes X-linked X Dystrophin (staPartial deletions or duplications in muscular recessive bilizes muscle dystrophin render non-functional dystrophy fi bres) Beckers X-linked X Dystrophin Partial deletions or duplications in muscular recessive dystrophin render hypo-functional dystrophy FSHD Autosomal 4 DUX4 (transcripPartial deletion of D4Z4 repeating type 1 dominant tional activator) unit releases normal repression of DUX4 expression FSHD Autosomal 4 DUX4 (transcripHypomethylation of D4Z4 releases type 2 dominant tional activator) normal repression of DUX4 expression diabetes mellitus Autosomal 19 DMPK (serineExpansion of short repetitive type 1 dominant threonine sequences of nucleotides; in both kinase) forms this expanded sequence is diabetes mellitus Autosomal 3 ZNF9 (transcriptranscribed into RNA which then type 2 dominant tional regulator) misfolds and sequesters other RNA binding proteins __OOHHCCMM__1100ee. . iinnddbb 551111 0022//0055//22001177 1199: : 0088 512 ygolorueN Myasthenia gravis (magnesium) magnesium is an autoimmune disease mediated by antibodies to nicotinic acetylcholine receptors (AChR) on the post-synaptic side of the neuromuscular junction (fi g 10. 32). Both B and T cells are implicated. Presentation Slowly increasing or relapsing muscular Fatigue. Muscle groups atrial fibrillationfected, in order: extra ocular; bulbar (swallowing, chewi ng); face; neck; limb girdle; trunk. Signs: Ptosis, diplopia, myasthenic snarl on smiling, peek sign of orbicularis fatigability (eyelids begin to separate after manual opposition to sustained closure). On counting to 50, the voice fades (dysphonia is a rare presentation). Tendon refl exes are normal. Symptoms exacerbated by: Pregnancy, potassium, infection, over-treatment, change of climate, emotion, exercise, gentamicin, opiates, tetracycline, quinine, -blockers. Diff erentials Polymyositis/other myopathies (p510); SLE; Takayasus arteritis (fatigability of the extremities); botulism (see BOX). Associations Include autoimmune disease (especially rheumatoid arthritis and SLE). If 50yrs, it is commoner in and associated with thymic hyperplasia; 50, it is commoner in men, and associated with thymic atrophy or thymic tumour. Tests Antibodies: Anti-AChR antibodies in 90% (70% in magnesium variant confi ned to ocular muscles). If anti-AChR Ωve look for MuSK antibodies (muscle-specifi c tyrosine kinase; especially in ). EMG: Decremental muscle response to repetitive nerve stimulation ± single-fi bre jitter. Imaging: computed tomography to exclude thymoma (68% 5yr survival). Other: Ptosis improves by 2mm after ice application to the eyelid for 2mina neat, non-invasive test (but not diagnostic). The Tensilon (edrophonium) test may not give clear answers and has dangers, so is rarely used.",
    "The Tensilon (edrophonium) test may not give clear answers and has dangers, so is rarely used. Treatment Symptom control: Anticholinesterase, eg pyridostigmine (60120mg PO up to 6daily; max 1. 2g/d). Cholinergic SE: salivation, lacrimation, sweats, vomiting, miosis. Other SE: diarrhoea, colic (controllable with propant he line 15mg/8h). Immunosuppression: Treat relapses with prednisolonestart at 5mg on alternate days, by 5mg/wk up to 1mg/kg on each treatment day. Dose on remission (may take months). Give osteo porosis prophylaxis. SE: weakness (hence Low starting dose). Azathioprine, ciclosporin, and mycophenolate mofetil may also be used. Thymectomy: Has benefi cial eff ects, even in patients without a thymoma: consider especially in younger patients with onset 5yrs previously and poor response to medical therapy. A recent randomized controlled trial shows improved symptom scores sustained over 3yrs, with reduced need for immunosuppression. Surgery also prevents local invasion if thymoma is present. Myasthenic crisis Life-threatening weakness of respiratory muscles during a relapse. Can be diffi cult to diff erentiate from cholinergic crisis (ie overtreatment but this is rare, and usually only occurs in doses of pyridostigmine 960mg/d). Monitor forced vital capacity. Ventilatory support may be needed. Treat with plasmapheresis (removes AChR antibodies from the circulation) or IVIg and identify and treat the trigger for the relapse (eg infection, medications). LambertEaton myasthenic syndrome (LEMS) LEMS can be paraneoplastic (50% are associated with malignancies, in particular small-cell lung cancer) or autoimmune. Unlike magnesium, antibodies are to voltage-gated Ca2 channels on pre-synaptic memb rane (see fi g 10. 33; anti-P/Q type VGCC antibodies are ve in 8595%). Clinical features Gait diffi culty before eye signs. Autonomic involvement (dry mouth, constipation, impotence). Hyporefl exia and weakness, which improve after exercise. Dip lo pia and respiratory muscle involvement are rare. EMG shows similar changes to magnesium except amplitude increases greatly post-exercise. Treatment Pyridostigmine, 3, 4-diaminopyridine or IVIg (get specialist help). Do regular CXR/High-resolution computed tomography as symptoms may precede the cancer by 4yrs. __OOHHCCMM__1100ee. . iinnddbb 551122 0022//0055//22001177 1199: : 0088 513 ygolorueN How synapses workthe neuromuscular junction 1 Before transmission can occur, neurotransmitter must be packed into synaptic vesicles. At the neuromuscular junction (NMJ) this is acetylcholine (ACh). Each vesicle contains 8000 ACh molecules. 2 When an action potential arrives at the pre-synaptic terminal, depolarization opens voltage-gated Ca2 channels (VGCCS). In LambertEaton syndrome, antiP/Q type VGCC antibodies disrupt this stage of synaptic transmission. 15 3 Infl ux of Ca2 through the VGCCs triggers fusion of synaptic vesicles with the pre-synaptic membrane (a process that botulinum toxin interferes with), and neurotransmitter is released from the vesicles into the synaptic cleft. 4 Transmitter molecules cross the synaptic cleft by diff usion and bind to receptors on the post-synaptic membrane, causing depolarization of the postsynaptic membrane (the end-plate potential). This change in the post-synaptic membrane triggers muscle contraction at the NMJ, or onward transmission of the action potential in neurons. In myasthenia gravis, antibodies block the post-synaptic ACh receptors, preventing the end-plate potential from becoming large enough to trigger muscle contractionand muscle weakness ensues. 5 Transmitter action is terminated by enzyme-induced degradation of transmitter (eg acetylcholinesterase), uptake into the pre-synaptic terminal or glial cells, or by diff usion away from synapse. Anticholinesterase treatments for myasthenia gravis, such as pyridostigmine, reduce the rate of degradation of ACh, increasing the chance that it will trigger an end-plate potential. Fig 10. 32 Myasthenia gravis features post-synaptic Fig 10. 33 LambertEaton syndrome feaAChR antibodies. Tendon refl exes are normal betures pre-synaptic Ca2-channel antibodies. cause the synapses do not have time to become Depressed tendon refl exes are common, fatigued with such a brief muscle contraction.",
    "because less transmitter is released, but reOcular palsies are common (its not exactly clear fl exes may after maximum voluntary conwhy). traction due to a build of transmitter in the synaptic cleft (post-tetanic potentiation). 15 Disruption of pre-synaptic transmission aff ects release of ACh in autonomic nervous system as well as at neuromuscular junction, explaining the prominence of dysautonomia in LEMS unlike in magnesium. __OOHHCCMM__1100ee. . iinnddbb 551133 0022//0055//22001177 1199: : 0088 514 ygolorueN Neurofi bromatosis Type 1 neurofi bromatosis (NF1, von Recklinghausens disease) Autosomal dominant inheritance (gene locus 17q11. 2). Expression of NF1 is variable, even within a family. Prevalence: 1 in 2500, : 1: 1; no racial predilection. Signs: Café-au-lait spots: fl at, coff ee-coloured patches of skin seen in 1st year of life (clearest in UV light), increasing in size and number with age. Adults have ≥6, 15mm across. They do not predispose to skin cancer. Freckling: typically in skinfolds (axillae, groin, neck base, and submammary area), and usually present by age 10. Dermal neurofi bromas: small, violaceous nodules, gelatinous in texture, which appear at puberty, and may become papillomatous. They are not painful but may itch. Numbers increase with age. Nodular neurofi bromas arise from nerve trunks. Firm and clearly demarcated, they can give rise to paraesthesiae if pressed. Lisch nodules (fi g 10. 34) are tiny harmless regular brown/transl ucent mounds (hamartomas) on the iris (use a slit lamp) 2mm in diameter. They Fig 10. 34 Multiple brown Lisch m de a v c e r l o o c p e b p y h a 6 ly y. rs old in 90%. Also short stature and nodul es on the iris. Jon Miles. Complications: Occur in 30%. Mild learning disabil ity is comm on. Local effects of neurofi bromas: nerve root compression (weakness, Pain, paraesthesiae); GIbleeds, obstruction; bonecystic lesions, scoliosis, pseudarth rosis. blood pressure from renal artery stenosis or phaeochromo cytoma. Plexiform neurofi bromas (large, subcutaneous swellings). Malignancy (5% patients with NF1): optic glioma, sarcomatous change in a neurofi broma. Epilepsy risk (slight). Rare association: carcinoid syndrome (p271). Management: Multidisciplinary team with geneticist, neuro logist, surgeon, and physiotherapist, orchestrated by a GP. Yearly cutaneous survey and measurement of blood pressure. Dermal neurofi bromas are unsightly, and catch on clothing; if troublesome, excise, but removing all lesions is unrealistic. Genetic counselling is vital (OHCS p154). Type 2 neurofi bromatosis (NF2) Autosomal dominant inheritance, though 50% are de novo, with mosaicism in some (NF2 gene locus is 22q11). Rarer than NF1 with a prevalence of only 1 in 35 000. Signs: Café-au-lait spots are fewer than in NF1. Bilateral vestibular Schwannomas ( acoustic neuromas; p462) are characteristic, becoming symptomatic by 20yrs old when sensorineural hearing loss is the 1st sign. There may be tinnitus and vertigo. The rate of tumour growth is unpredictable and variable. The tumours are benign but cause problems by pressing on local structures and by ICP. They may be absent in mosaic NF2. Juvenile posterior subcapsular lenticular opacity (a form of cataract) occurs before other manifest ations and can be useful in screening those at risk. Complications: Tender Schwannomas of cranial and peripheral nerves, and spinal nerve roots. Meningiomas (45% in NF2, often multiple). Glial tumours are less common. Consider NF2 in any young person presenting with one of these tumours in isolation. Management: Hearing tests yearly from puberty in aff ected families, with magnetic resonance imaging brain if abnormality is detected. A normal magnetic resonance imaging in the late teens is helpful in assessing risk to any off spring.",
    "11, p213). Syringo bulbia (Brains tem involvement. ) Nyst agmus, tongue atrophy, dysphagia, pharyngeal/palatal weak ness, Vth nerve sensory loss. magnetic resonance imaging imaging How big is the syrinx? Any base-of-brain (Chiari) malformation? Surgery Dont wait for gross deterioration to occur. Decompression at the foramen magnum may be tried in Chiari malformati ons to promote free fl ow of CSF, and so prevent syrinx dilatation. Surgery may reduce Pain and progression. Fig 10. 35 The anterolateral system. __OOHHCCMM__1100ee. . iinnddbb 551166 0022//0055//22001177 1199: : 0088 517 ygolorueN Retroviruses and neurology HIV and AIDS (p398. ) Can have multiple neurological manifestations: these conditions are part of the diff erential diagnosis of meningitis, intrac ranial mass lesions, dementia, encephalomyelitis, cord problems, and peripheral neuropathies. Acute infection: May be associated with transient aseptic meningoencephalitis (typically self-limiting), myelo pathy, and neuropathy. Opportunistic infections: Arise during Low CD4 counts, which allow unusual or atypical organisms to infect the nervous system: Toxoplasma gondii (p400) is the main CNS pathogen in AIDS, causing cerebral abscesses which present with focal signs, eg seizures, hemiparesis. computed tomography/magnetic resonance imaging shows ring-shaped contrast-enhancing lesions. Treat with pyrimethamine (folinic acid) sulfadiazine or clindamycin for 6 months. Continue secondary prophylaxis until CD4 count 200. Pneumocys tis prophylaxis also protects against toxoplasmosis. Cryptococcus neof orm ans (fi g 10. 36) causes a chronic meningitis with fever and headache (neck stiff ness may be absent). Cognition alters slowly, seizures and coma may follow. Treat with amphotericin followed by fl uconazole. Cytomegalovirus (CMV) can cause encephalopathy. Progressive multifocal leukoencephalopathy (PML) is caused by the JC virus. There is progressive white matter infl ammation. Mortality even with antiretroviral therapy is around 50% at 1yr. Syphilis and TB may also cause meningitis. Tumours: Aff ecting the CNS include primary cerebral lymphoma (associated with EBV) and B-cell lymphoma. CSF JC virus protein-creatinine ratio is useful in distinguishing PML from lymphoma. Neuropathies: Common in HIV, and may be a result of the disease itself or antiretroviral therapy. Up to 30% of patients have a peripheral neuropathy, which is Painful and predominantly sensory. Other clinical pictures include polyradiculopathy, mononeuritis multiplex, and proximal myopathy. Chronic HIV-associated neurocognitive disorder (HAND): While antiretroviral therapy (ART) has decreased the incidence of CNS complications in HIV/AIDS, people are living longer with the disease, and chronic complications such as HIV-associated dementia are increasing. This occurs in 715%, late in the disease, and usually when the CD4 count is 200. Progressive behavioural changes are seen along with subcortical features: memory loss, poor attention, and bradykinesia. Various encephalopathies may also contribute to this, eg PML. Human T-cell lymphotrophic virus (HTLV-1) Is another retrovirus with neurological manifestations, though much more rarely than HIV (0. 5%). It causes: Tropical spastic paraplegia, a slowly progressing myelopathy, typically aff ecting the thoracic area. There may be paraesthesiae, sensory loss, and disorders of micturition. Demyelinating polyneuropathy and ataxia may also occur. (a) (b) Fig 10. 36 Cryptococcosis: (a) Chronic meningitis involving the basal leptomeningitis with multiple small intraparenchymal cysts seen in the cerebral cortex. (b) Under the microscope we see these cysts as dilatation of the perivascular space to form cavities fi lled with colonies of cryptococci, which appear as round basophilic structures. Reproduced from Gray et al. , Escourelle and Poiriers Manual of Basic Neuropathology, 2013, by permission of Oxford University Press, USA. __OOHHCCMM__1100ee. .",
    ", Escourelle and Poiriers Manual of Basic Neuropathology, 2013, by permission of Oxford University Press, USA. __OOHHCCMM__1100ee. . iinnddbb 551177 0022//0055//22001177 1199: : 0088 11 Oncology and palliative care Contents Looking after people with cancer 519 The genetics of cancer 520 Cancer diagnosis 522 Cancer treatment: medicine and surgery 524 Cancer treatment: radiotherapy 526 Interventional oncology 527 Oncology emergencies 528 Paraneoplastic syndromes 529 Tumour markers 530 Palliative care: Principles and Pain 532 Other symptoms 534 Care in the last days of life 536 Fig 11. 1 How not to break Bad news. The third day of admission brings me some examples of doctors communication skills being the worst I could possibly imagine under the most painful of circumstancesIm laid in a hospital bed sobbing and scared, about at the most vulnerable a patient could bea young gynaecology SHO I have never met enters my roomI can tell he has pulled the short straw He nervously sits down next to me and out of the blue, after a cursory introduction tells me, Your magnetic resonance imaging shows evidence of spread. I am quite astounded at the lack of quality communication given the circumstances. The Other Side, by Kate Granger MBE, FRCP, 19812016. Kate Granger, a medical registrar then consultant geriatrician, was diagnosed with a desmoplastic small round cell tumour at the age of 29. This is a cancer that medical science has no answer to. But Kate had her own answer. She turned her terminal diagnosis on its head and began a dialogue on death and dying, off ering her experience as an inspirational lesson in compassion and care. Before you are a patient, before you have cancer, but most importantly, before you are a doctor, you are simply a human being. And if your humanity is lost or forgotten, then you cannot care, even if medical science is able to provide an answer. hellomynameis. org. uk; hellomynameis Image and text reproduced courtesy of the family of Dr Kate Granger, MBE. We thank Professor Max Watson, our Specialist Reader, for his contribution to this chapter. __OOHHCCMM__1100ee. . iinnddbb 551188 0022//0055//22001177 1199: : 0088 519 erac evitaillap dna ygolocnO Looking after people with cancer Cancer will aff ect 50% of people born after 1960 and 25% of all deaths in the UK are from cancer. 1 While many may not appreciate the poor prognosis attached to diagnoses such as Liver failure or Heart failure, cancer has a widespread association with suff ering and death. Yet cancer is not a homogenous disease but a group of conditions with prognoses ranging from very Good (98% 10yr survival for testicular cancer) to extremely poor (21% 1yr survival for pancreatic cancer). 1 Communication2 is the fi rst step on a cancer pathway and underpins whatever that diagnosis may subsequently entail for the individual. A range of overwhelming feelings can surface upon receiving a cancer diagnosis: shock, numbness, denial, panic, anger, resignation (I knew all along). Preconceptions, possibly derived vicariously from friends and family, may be deeply embedded leading to despair or inappropriate optimism. Without an understanding of your patients starting point, you may fail to be eff ective in your guidance and support. Tips for the discussion of a cancer diagnosis 1 Set the environment up carefully. Choose a quiet place where you will not be disturbed. Make sure family or friends are present according to your patients wishes. Anticipate likely questions and be sure of your facts. 2 Find out what the patient already knows and believes (often a great deal). What are you worried about today?",
    "Colonoscopic surveillance (at least biennial) from 2575yrs. Familial adenomatous polyposis: Due to mutations in the APC tumour suppressor gene (5q) (fi g 11. 2). 1% of colorectal cancer. Causes multiple colorectal adenomas (100 in classical disease) which undergo malignant transformation. Gene penetrance approaches 100% by 50yrs. Surveillance sigmoidoscopy from 12yrs, with prophylactic surgery usually 25yrs guided by polyp number, size, and dysplasia. PeutzJeghers syndrome: 1 in 25 000280 000. Hamartomatous polpys. 1020% risk of colorectal cancer, 5060% risk of GI cancer, 60% risk of breast cancer. Due to germline mutations in STK11, a tumour suppressor gene (19p14). Surveillance in all (see p708). Prostate cancer 510% (50% disease 55yrs) estimated to be due to inherited factors. Genes include BRCA1, BRCA2, mismatch repair, and HOXB13 which interacts with androgen receptor. Age and race contribute. See p530 for screening. Other familial cancer syndromes Von HippelLindau (p320, p712), Carney complex (p223), MEN (p223), neurofi bromatosis (p514). __OOHHCCMM__1100ee. . iinnddbb 552211 0022//0055//22001177 1199: : 0088 522 erac evitaillap dna ygolocnO Cancer diagnosis A variety of clinical signs and symptoms should alert you to the possible presence of malignancy. The following list is based on clinical features with a 3% positive predictive value for cancer. 6 It is by no means exhaustive and does not negate the value of clinical judgement. Urgent within 2 weeks. Lung Admit if: symptomatic superior vena caval obstruction (p528), stridor. Urgent referral if: 40yrs with unexplained haemoptysis, CXR suggestive of cancer. Urgent CXR if 40yrs and: persistent/recurrent chest infection fi nger clubbing supraclavicular/cervical lymphadenopathy thrombocytosis two of: cough, Fatigue, SOB, chest Pain, weight loss, appetite, smoker, asbestos. Upper GI Urgent endoscopy if: dysphagia, or 55yrs with weight loss and upper abdominal Pain/refl ux/dyspepsia. Urgent referral if: 40yrs plus jaundice, or upper abdominal mass. Urgent computed tomography of the pancreas if 60yrs plus weight loss plus any of: diarrhoea, back Pain, abdominal Pain, nausea, constipation, new-onset Diabetes. Non-urgent endoscopy if: 55yrs and one of: treatment-resistant dyspepsia, upper abdominal Pain plus Low hemoglobin, plts, or NV plus upper GI symptoms/weight loss haematemesis. Lower GI PR examination and FBC in all. Urgent referral if: positive faecal occult Blood, 40yrs with abdominal Pain plus weight loss, 50yrs with unexplained rectal bleeding, 60yrs with iron-defi cient anaemia or change in bowel habit. Consider urgent referral if: rectal/abdominal mass, anal ulceration, 50yrs with rectal bleeding plus lower GI symptoms or weight loss or iron-defi ciency anaemia. Faecal occult Blood testing if: 50yrs plus abdominal Pain or weight loss, 60yrs with change in bowel habit or iron-defi ciency anaemia, 60yrs and anaemia. Gynaecological Urgent referral if: ascites, pelvic mass (fi broid excluded), 55yrs with post-menopausal bleeding. Breast Urgent referral if: 30yrs with unexplained breast lump, 50yrs with symptoms or change to one nipple. Consider urgent referral if: skin changes, 30yrs with axillary lump. Urology Urgent referral if: irregular prostate on PR, abnormal age-specifi c PSA (see p530) 40yrs with unexplained visible haematuria, 60yrs with unexplained nonvisible haematuria plus dysuria or WCC non-painful enlargement or change in shape/texture of testicle. Central nervous system Urgent magnetic resonance imaging in progressive, sub-acute loss of central neurological function. Unexplained weight loss, appetite, and DVT can be non-specifi c signs of cancer. Assess for any additional risk factors, symptoms, signs, and refer accordingly. See also haematology (p352); thyroid (p600); skin (p596). __OOHHCCMM__1100ee. . iinnddbb 552222 0022//0055//22001177 1199: : 0088 523 erac evitaillap dna ygolocnO Cancer and the multidisciplinary team The care of all patients diagnosed with cancer is formally reviewed by a multidisciplinary team (MDT). The aim of the MDT is to coordinate High-quality diagnosis, treatment, and care.",
    "Chemotherapy is the only systemic treatment for cancer (surgery and radiotherapy are local treatments). This is important as most cancers are considered to be systemic either due to metastases, or the potential to metastasize in the future. Chemotherapy should be prescribed and given only under expert guidance by people trained in its use. Includes: Single-agent: Rarely curative as genetically resistant cells are selected out. Combination chemotherapy: A combination of drugs with diff erent mechanisms of action and diff erent side-eff ect profi les reduces the likelihood of resistance and toxicity. The drugs used should have: cytotoxic activity for that tumour, preferentially able to induce remission diff erent mechanisms of action, ideally additive or synergistic eff ects non-overlapping toxicity to maximize benefi t of full therapeutic doses diff erent mechanisms of resistance. Adjuvant: After other initial treatment to reduce the risk of relapse, eg following surgical removal of, eg breast, bowel cancer. Neoadjuvant: Used to shrink tumours prior to surgical or radiological treatment. May allow later treatment to be more conservative. Palliative: No curative aim, off ers symptom relief, may prolong survival. Classes of cytotoxic drugs Alkylating agents: Anti-proliferative drugs that bind via alkyl groups to DNA leading to apoptotic cell death, eg cyclophosphamide, chlorambucil, busulfan. Angiogenesis inhibitors: Eg bevacizumab, afl ibercept, sunitinib. Antimetabolites: Interfere with cell metabolism including DNA and Protein synthesis, eg methotrexate, 5-fl uorouracil. Antioestrogens: Aromatoase inhibitors (eg letrozole, anastrozole), oestrogen receptor antagonists (eg tamoxifen, raloxifene) used in breast cancer treatment. Antitumour antibiotics: Interrupt DNA function, eg dactinomycin, doxorubicin, mitomycin, bleomycin. Monoclonal antibodies: Antibodies to a specifi c tumour antigen can slow tumour growth by enhancing host immunity, or be conjugated with chemotherapy/radioactive isotopes to allow targeted treatment. Expect more of these in future. Topoisomerase inhibitors: Interrupt regulation of DNA winding, eg etoposide. Vinca alkaloids and taxanes: Spindle poisons which target mechanisms of cell division, eg vincristine, vinblastine, docetaxel. Side-eff ects Due to cytotoxic eff ects on non-cancer cells. Greatest eff ect seen on dividing cells, ie gut, hair, bone marrow, gametes (see BOX Fertility and cancer, p525). Vomiting: Prophylaxis given with most cytotoxic regimens (see p251). Alopecia: May profoundly impact quality of life. Consider cold-cap, wig services. Neutropenia: Most commonly seen 714d after chemotherapy. Neutropenic sepsis is life-threatening and needs urgent assessment and empirical treatment (p352). Extravasation of chemotherapy Extravasation8 inadvertent infi ltration of a drug into subcutaneous/subdermal tissue. Presentation: Tingling, burning, Pain, redness, Edema, no fl ashback/resistance from cannula. Management: Stop and disconnect infusion. Aspirate any residual drug before cannula removed. Follow local policies (ask for the extravasation kit). Follow any drug-specifi c recommendations. For DNA-binding drugs (anthracyclines, alkylating agents, antitumour antibiotics), use a dry cold compress to vasoconstrict and drug spread. For non-DNA-binding drugs (vinca alkaloids, taxanes, platin salts), use a dry warm compress to vasodilate and drug distribution. __OOHHCCMM__1100ee. . iinnddbb 552244 0022//0055//22001177 1199: : 0088 525 erac evitaillap dna ygolocnO Surgery Prevention: Risk-reducing surgery, eg thyroidectomy in MEN (p223), colectomy in FAP (p521). Screening: Endoscopy, colposcopy. Diagnosis and staging: Fine needle aspiration, core needle biopsy, vacuumassisted biopsy, excisional/incisional biopsy, sentinel lymph node biopsy, endoscopy, diagnostic/staging laparoscopy, laparascopic ultrasound. Treatment: Resection of solid tumour (may be combined with chemo/radiotherapy). Reconstruction: Eg following treatment for breast, head and neck cancers. Palliation: Bypass, stoma, stenting, pathological fractures. Clinical trials Advantages: Possibility of more eff ective treatment than currently available, close monitoring with direct access to a research team, reassurance from increased number of clinical encounters, gain from altruism. Disadvantages: Possibility of receiving therapy that is no better or worse than standard therapy, unknown toxicity from new agents, time-consuming, anxiety from increased number of clinical encounters.",
    "Nausea and Vomiting: Occur when stomach, Liver, or brain treated. Try metoclopramide 10mg/8h PO (dopamine antagonist), domperidone 10mg/8h PO (blocks the central chemoreceptor trigger zone), or ondansetron 48mg/8h PO/IV (serotonin 5HT3 antagonist) (see p251). Diarrhoea: Usually after abdominal or pelvic treatments. Maintain Good hydration. Avoid High-fi bre agents. Try loperamide 2mg PO after loose stools (max 16mg/24h). Dysphagia: Following thoracic treatments. Speech and language input, nutrition. Cystitis: After pelvic treatments. Drink plenty of fl uid. Late reactions Months-years after treatment. CNS/PNS: Somnolence: 46wks after brain radiotherapy. Consider steroid dose. Spinal cord myelopathy: progressive weakness. magnetic resonance imaging to exclude cord compr ession. Brachial plexopathy: numb, weak, or painful arm after axillary radio therapy. Lung: Pneumonitis can occur 612wks after thoracic treatment causing dry cough ± dyspnoea. Bronchodilators and tapered steroids may help. GI: Xerostomia reduced saliva. Dental care and nutrition important. Treat with Water, saliva substitutes, salivary stimulants. Benign strictures of oesophagus or bowel. Treat with dilatation. Seek a specialist surgical opinion regarding fi stulae. Radiation proctitis may be a problem after prostate irradiation. GU: Urinary frequency: small fi brosed bladder after pelvic treatment. Vaginal stenosis, dyspareunia, erectile dysfunction can occur after pelvic radiotherapy. fertility: due to pelvic radiotherapy (see p525). Endocrine: Panhypopituitarism following radical treatment involving pituitary fossa. Check hormone profi Blood in children: growth hormone replacement may be required. Hypothyroidism in 50% after neck treatment: check TFTs annually. Secondary cancers: Risk (24 per 10 000 person-years) is usually insignifi cant compared to recurrence/death from primary lesion. More important for younger patients after curative treatment. Women 35yrs receiving radiotherapy for Hodgkins lymphoma should be off ered breast screening from 8yrs after treatment. Cancer survival means numbers living with poor health or disability after treatment (625 000 in UK). Remember the emotional and physical impact of cancer extends beyond the prescribed course of radiotherapy/chemotherapy. __OOHHCCMM__1100ee. . iinnddbb 552266 0022//0055//22001177 1199: : 0088 527 erac evitaillap dna ygolocnO Methods of delivering radiotherapy Conventional external beam radiotherapy (EBRT): Is the most common form of treatment. Delivers beams of ionizing radiation to the patient from an external linear accelerator. Stereotactic radiotherapy is a highly accurate form of EBRT used to target small lesions with great precisionmost frequently in treating intracranial tumours. It is often referred to by the manufacturers name, eg Gamma Knife, Truebeam. Brachytherapy involves a radiation source being placed within or close to a tumour, allowing a High local radiation dose. Implants may be placed within a cavity (eg uterus, post-surgical space) or within tissue (eg prostate, breast). Radioisotope therapy uses tumour-seeking radionuclides to target specifi c tissues. For example, 131I (radioiodine) to ablate remaining thyroid tissue after thyroidectomy for thyroid cancer. Interventional oncology Interventional oncology (IO) refers to interventional radiology procedures used in the treatment or palliation of patients with cancer. IO can be divided into diseasemodifying and symptomatic procedures. Disease-modifying IO: Intended to modify cancer progression and/or to improve prognosis. Includes: Image-guided ablation, eg radiofrequency ablation, cryoablation, irreversible electroporation. Embolization, eg transarterial embolization, chemoembolization, selective internal radiation therapy. Image-guided brachytherapy. Isolated perfusion chemotherapy: uses occlusion techniques to protect normal tissue from High doses of chemotherapy. Symptomatic IO: Provides relief from cancer-related symptoms, but does not modify the underlying disease process. The techniques (table 11. 2) can off er signifi cantly improved quality of life, reduce admissions, and increase time spent outside of hospital. Table 11.",
    "Calcitonin produces a more rapid (2h) but short-term eff ect and tolerance can develop. Long-term treatment is by cont rol of t he underlying malignancy. 1 Pemberton described this useful sign of venous obstruction due to a goitre in 1946. __OOHHCCMM__1100ee. . iinnddbb 552288 0022//0055//22001177 1199: : 0088 529 erac evitaillap dna ygolocnO Brain metastases Aff ect up to 40% of patients with cancer. Most commonly: lung, breast, colorectal, melanoma. Poor prognosis: median survival 12 months; better prognosis with single lesion, breast cancer (see also p830). Signs and symptoms: Headache (50%, often worse in the morning, when coughing or bending), focal neurological signs (30%), ataxia (21%), fi ts (18%), nausea, Vomiting, papilloedema. Management: Urgent computed tomography/magnetic resonance imaging depending on underlying diagnosis, disease stage, and performance status. Dexamethasone 16mg/24h to reduce cerebral oedema. Stereotactic radiotherapy (see p527). Discuss with neurosurgery, especially if large lesion or associated hydrocephalus. Tumour lysis syndrome Chemotherapy for rapidly proliferating tumours (leukaemia, lymphoma, myeloma) leads to cell death and urate, potassium, phosphate, calcium. Risk of arrhythmia and renal failure (see p314). Management: Prevent with hydration and uricolytics, eg rasburicase, allopurinol. Paraneoplastic syndromes Paraneoplastic syndromes13 (table 11. 3) consist of symptoms attributable to a malignancy mediated by hormones, cytokines, or the cross-reaction of tumour antibodies. They do not correlate with stage/prognosis and may pre-date other cancer symptoms. Table 11. 3 Examples of paraneoplastic syndromes Paraneoplastic Comment Malignancies See syndrome Hypercalcaemia Parathyroid hormone-related Lung, oesophagus, p528 Protein secreted by tumour skin, cervix, breast, Kidney SIADH Excessive antidiuretic hormone Lung, pancreas, lymp673 (ADH) secretion causing sodium phomas, prostate Cushings Tumour secretes ACTH or chronic renal failure, Lung, pancreas, p224 syndrome causing adrenal to produce High thymus, carcinoid levels of corticosteroid Neuropathy Antibody-mediated neuronal Lung, breast, myp504 degeneration: peripheral, autoeloma, Hodgkins, GI nomic, cerebellar LambertEaton Antibody to voltage-gated Mostly lung. Also GI, p512 myasthenic ion channel on pre-synaptic breast, thymus syndrome membrane causes weakness (proximal leg most common) Dermatomyositis Infl ammation of the muscles /- Lung, breast, p552 polymyositis heliotrope rash ovary, GI Acanthosis Velvety, hyperpigmented skin GI p562 nigricans (usually fl exural) Pemphigus Blisters to skin/mucous memLymphoma, thymus, branes Kaposis sarcoma Hypertrophic Periosteal bone formation, arthriLung osteoarthropathy tis, and fi nger clubbing Trousseaus sign Trousseau (fi g 11. 5) was probably the fi rst to discover a paraneoplastic syndrome. He noticed that many patients with migratory thrombophlebitis (Trousseaus sign) developed gastric cancer. Unfortunately, he developed migratory thrombophlebitis himself and correctly predicted his own death from GI malignancy. Fig 11. 5 Armand Trousseau 18011867. Wellcome Library, London. Armand Trousseau. Lithograph by JBA Lafosse, 1866, after P Petit. __OOHHCCMM__1100ee. . iinnddbb 552299 0022//0055//22001177 1199: : 0088 530 erac evitaillap dna ygolocnO Tumour markers Tumour markers14 are specifi c molecules (usually glycoproteins) that may be found in higher concentrations in the serum, tissue, or Urine in patients with certain cancers. Tumour markers in diagnosis Tumour markers are insuffi ciently sensitive or specifi c to be diagnostic in isolation. Many tumour markers are in several cancers and benign conditions (table 11. 4). Measuring ≥1 tumour marker is unlikely to aid diagnosis unless suspecting a germ cell tumour. Do not make opportunistic requests for panels of tumour markers in patients with non-specifi c symptoms: they are not helpful and lead to potentially unnecessary investigation. This includes testing PSA in women and calcium 125 in men. In carefully selected patients, in whom cancer is suspected, highly raised levels of a tumour marker may be helpful: -fetoprotein (FP) and human chorionic gonadotrophin (hCG) in testicular/ germ cell tumours. calcium 125 in combination with USS and menopausal status. FPin those at High risk of hepatocellular carcinoma.",
    "calcium 125 in combination with USS and menopausal status. FPin those at High risk of hepatocellular carcinoma. PSA 100ng/mL usually indicates metastatic prostate cancer. Tumour markers in monitoring The main value of tumour markers is in monitoring patients known to have cancer. This includes the course of the disease, the eff ectiveness of treatment, and the detection of cancer recurrence. The following markers may be useful: FP and hCG in testicular/germ cell tumours. CEA in colorectal cancer. calcium 125 in ovarian cancer. A cautious interpretation of PSA within the limits of its specifi city and sensitivity. Screening for cancer The UK has several well-established cancer screening programmes. Women are invited for mammography every 3yrs (5070yrs) and off ered cervical smear tests every 35yrs (2564yrs). Men and women aged 6074yrs are off ered faecal occult Blood testing every 2yrs. Screening tests aim to pick out those who need further investigation to rule out or diagnose a cancer, in the hope that earlier diagnosis and treatment result in better outcomes. All screening tests come with risk: anxiety, harm/discomfort from the test, cost, false positives resulting in further invasive tests, false negatives conferring inappropriate reassurance when symptoms arise. When considering screening an asymptomatic population the potential risks and benefi ts need to be weighed carefully and the Wilson criteria (see p23) should be satisfi ed. Should PSA be used to screen for prostate cancer? Most men with prostate cancer will have a High prostate-specifi c antigen (PSA). The higher the PSA, the more likely cancer is. However, PSA is non-specifi c and also raised in benign prostatic disease, body mass index 25, recent ejaculation, recent rectal examination, prostatitis, and UTI. 76% of patients with a raised PSA do not have cancer. Following screening tests (see PROMIS study, 2017, for use of multi-parametric magnetic resonance imaging), prostate biopsy is required for diagnosis. This has an inherent risk of complications including bleeding, infection, and urinary retention. 1% will require hospital admission. The risks of PSA testing and subsequent biopsy need to be counterbalanced by benefi ts from screening. 15 1 in 800 men avoid death from prostate cancer as a result of PSA screening. But screening picks up many cancers that will never become fatal. This overdiagnosis is thought to occur in 40% of positive screens with signifi cant risks from treatment including urinary incontinence, erectile dysfunction, and IHD. This balance of risk versus benefi t means that population screening for prostate cancer using PSA is not recommended. Despite this, any patient 50yrs (or 45yrs if High risk) can request PSA testing in primary care. Interpret any PSA result in conjunction with digital rectal examination and other risk factors. __OOHHCCMM__1100ee. . iinnddbb 553300 0022//0055//22001177 1199: : 0088 531 Table 11. 4 Summary of tumour markers Tumour marker Relevant cancer Use Other associated cancers Associated benign conditions Alpha-fetoprotein Germ cell/testicular Diagnosis, monitoring treatColorectal; gastric; hepatobiliary; lung Cirrhosis; pregnancy; neural tube defects (FP) ment, detecting recurrence Hepatocellular Calcitonin Medullary thyroid Diagnosis, monitoring treatNone known C-cell hyperplasia ment, detecting recurrence Cancer antigen Ovarian Monitoring ovarian cancer.",
    "Breast; cervical; endometrial; hepatocellular; Liver disease; cystic fi brosis; pancreatitis; urinary reten- (calcium)125 Prognosis after chemotherapy lung; non-Hodgkins lymphoma; pancreatic; tion; Diabetes; Heart failure; pregnancy; SLE; sarcoid; RA; medullary thyroid carcinoma; peritoneal; diverticulitis; IBS; endometriosis; fi broids uterine CA199 Pancreatic Monitoring pancreatic cancer Colorectal; gastric; hepatocellular; Acute cholangitis; cholestasis; pancreatitis; Diabetes; oesophageal; ovarian IBS; jaundice CA153 Breast Monitoring breast cancer Hepatocellular; pancreatic Cirrhosis; benign breast disease; in normal health Carcinoembryonic Colorectal Monitoring adenocarcinomas Breast; gastric; lung; mesothelioma; Smoking; chronic Liver disease; chronic Kidney disease; antigen (CEA) oesophageal; pancreatic diverticulitis; jaundice Human chorionic Germ cell/testicular, Diagnosis, prognosis, monitorLung Pregnancy gonadotrophin (hCG) gestational trophoblastic ing of germ cell tumours Paraproteins Myeloma Diagnosis, monitoring treatNone known None known ment, detecting recurrence Thyroglobulin Thyroid Monitoring treatment, None known None known (follicular/papillary) detecting recurrence Source data from Serum tumour markers: how to order and interpret them, Sturgeon C M, Lai L C, Duff y M J, 2012, BMJ Publishing Ltd. Oncology and palliative care __OOHHCCMM__1100ee. . iinnddbb 553311 0022//0055//22001177 1199: : 0088 532 erac evitaillap dna ygolocnO Palliative care: principles and Pain You matter because you are you and you matter to the last moment of your life. We will do all we can to help you, not only to die peacefully, but to live until you die. Dame Cicely Saunders (19182005), founder of the modern hospice. Palliative care is the active, holistic care of patients with advanced progressive illness. It combines management of Pain and other symptoms, with the provision of psychological, social, and spiritual support. Palliative care is not just for the end of life and it is not just for patients with cancer. Palliative care should run in parallel with other medical treatments. Good symptom control is important in any disease for improving quality of life and may even prolong survival. 16 Take time to fi nd out exactly what is troubling your patient using a problem-based approach. Consider: physical psychological spiritual social. Remember, each person comes with a set of emotions, preconceptions, and a family already attached. Most hospitals now have a dedicated palliative care team for help and advice (including out of hours). Use their expertise. Assessment of Pain Pain is one of the most feared sequelae of a terminal diagnosis and yet it is not inevitable. However, Pain is a complex phenomenon. While the aim of management is for the patient to be Pain free, this may not be achievable in all cases so do not promise this. Do not assume a cause: detailed history and examination are needed to understand aetiology, which will guide subsequent treatment, eg Pain from nerve infi ltration or local Hypertension may respond better to agents other than opioids. History and examination are essential for all patients, including those at the end of life. Evaluate severity, nature, functional defi cit, and psychological state as all of these contribute to the symptom burden. Management of Pain Aim to modify the underlying pathology where possible, eg radiotherapy, chemotherapy, surgery. Use analgesia to relieve background Pain and provide additional as needed doses for breakthrough Pain. Eff ective analgesia is possible in the majority of patients by combining fi ve principles: 1 By the mouthgive orally whenever possible. 2 By the clockgive at fi xed intervals to off er continuous relief. 3 By the ladderfollowing the WHO stepwise approach (see fi g 13. 5, p575). 4 For the individualthere are no standard doses for opioids, needs vary. 5 Attention to detailcommunicate, set times carefully, warn of side-eff ects. The WHO analgesic ladder Increase and decrease the analgesia required according to the steps on the ladder17 (fi g 13.",
    "The WHO analgesic ladder Increase and decrease the analgesia required according to the steps on the ladder17 (fi g 13. 5, p575): 1 Non-opioid, eg paracetamol. 2 Opioid for mild to moderate Pain, eg codeine. 3 Opioid for moderate to severe Pain, eg morphine, diamorphine, oxycodone. Persisting/increasing Pain and side-eff ects inform the decision to step up and step down. Take one step at a time to achieve Pain relief without toxicity (except in new, severe Pain when step 2 may be omitted). Paracetamol (PO/PR/IV) at step 1 may have an opiate-sparing eff ect, and should be continued at steps 2 and 3. Stop step 2 opioids if moving to step 3. Use laxatives and anti-emetics with strong opioids. Adjuvants which can be added at all steps include: NSAIDS, amitriptyline, pregabalin, corticosteroids, nerve block, transcutaneous electrical nerve stimulation (TENS), radiotherapy. __OOHHCCMM__1100ee. . iinnddbb 553322 0022//0055//22001177 1199: : 0088 533 erac evitaillap dna ygolocnO Opioids The amount of opioid required to relieve Pain varies and should be titrated on an individual basis. Oral morphine is 1st-line. If the oral route is unavailable, use morphine or diamorphine SC (see table 11. 5, and tables 11. 6, 11. 7, p536). Explanation and regular review are important. Prescribe anti-emetics and laxatives for all patients. Start Low, go slow: For an opioid-naïve patient with moderate to severe Pain, consider oral morphine 5mg every 4 hours plus 5mg as needed (maximum hourly). Consider a lower starting dose if elderly, body mass index, or renal impairment. If Pain is not controlled, dose by 3050% every 24h. Convert to modifi ed release: When Pain is controlled, calculate the total daily dose including as needed and divide into two 12h doses of a modifi ed-release preparation (eg MST Continus 12h). Transdermal preparations are available: seek expert help for dose, check adhesion, and rotate site. Use a as needed dose for breakthrough Pain: 1/10th1/6th of the total daily dose as an immediate-release preparation, eg Oramorph or Sevredol. Side-effects: Drowsiness, nausea/Vomiting (usually after 5 days), constipation, dry mouth. If diffi culty tolerating morphine, or Pain plus toxicity, consider an opioid switch (eg oxycodone) and dose by 2530%. Toxicity: Sedation, respiratory depression, visual hallucinations, myoclonic jerks, delirium. Be alert: recognizing toxicity early usually means naloxone is avoided. Monitor pulse oximetry, give oxygen if required. Consider : intracranial bleed, renal failure. Opioids and sedating drugs. Consider hydration. Seek expert help if remains opioid-toxic or in Pain. Naloxone is only indicated for life-threatening respiratory depression (see p842). In patients on regular opiates it can precipitate a Pain crisis and potentially fatal acute withdrawal. 18 Renal failure: Patients with renal impairment (estimated glomerular filtration rate 30) are at risk of toxicity due to accumulation of renally excreted opioids and metabolites. Monitor closely. Fentanyl, alfentanil, and buprenorphine have predominantly hepatic metabolism seek expert advice. Concerns: Patients may shrink from using opioids. Misconceptions are common: they are addictive, for the dying, if they use morphine now it will not work when they really need it. Respiratory depression is very rare when opioids are correctly titrated but opioids often get blamed when a patient deteriorates. Reassure patients that opioids are effective and safe when used appropriately. Morphine-resistant Pain: Seek expert help. Consider methadone, ketamine, and adjuvants such as NSAIDS, steroids, muscle relaxants, anxiolytics, nerve blocks. If neuropathic Pain is suspected, try amitriptyline, pregabalin, or topical lidocaine. Consider the eff ect of psychological and spiritual well-being on Pain (see p535). Rapid analgesia: Most as needed medication takes time to have an eff ect.",
    "Rapid analgesia: Most as needed medication takes time to have an eff ect. If this is a problem, seek expert help regarding rapid-release preparations (eg sublingual, intranasal, or buccal fentanyl). Try to pre-empt times of High Pain (eg dressing changes) and give analgesia in advance. Table 11. 5 Opioid dose equivalents: conversions are not exact, potency can vary. If in doubt, use a dose below your estimate. Practice is variable: always defer to local guidelines fi rst. Relative potency 4h dose (magnesium) 24h dose (magnesium) Morphine PO 1 5 30 Morphine SC 2 2. 5 15 Diamorphine SC 3 1. 52 10 Oxycodone PO 2 2. 5 15 Oxycodone SC 4 1. 25 7. 5 Alfentanil SC 30 Too short-acting 1 Codeine PO 0. 1 60 (6h dose) 240 Tramadol PO 0. 1 100 (6h dose) 400 Fentanyl patch 25mcg/h approximates to 60mg/24h oral morphine __OOHHCCMM__1100ee. . iinnddbb 553333 0022//0055//22001177 1199: : 0088 534 erac evitaillap dna ygolocnO Palliative care: other symptoms Non-Pain symptoms19 include: Nausea and Vomiting Causes: Chemotherapy, constipation, hypercalcaemia, oral candidiasis, GI obstruction, drugs, severe Pain, infection, renal failure. Management: Treat reversible causes, eg laxatives for constipation, analgesia for Pain, hypercalcaemia (see p528), fl uconazole for oral candidiasis. Anti-emetic choice should be based on the likely mechanism of nausea. Consider the site of anti-emetic action, especially when using a combination of drugs. Oral absorption may be poor so consider alternative routes (SC/IV/PR). Options include the following: Cyclizine 50mg/8h: antihistamine, anticholinergic, central action so Good for intracranial disorders. Metoclopramide 1020mg/8h: blocks central chemoreceptor trigger zone, peripheral prokinetic eff ects so Good in gastroparesis, monitor for extra-pyramidal side-eff ects. Domperidone 1020mg/8h PO: peripheral antidopaminergic so no dystonic eff ects. Haloperidol 1. 5mg PO initially 12 times daily: dopamine antagonist, eff ective in drugor metabolically induced nausea, use lower doses IV/SC as twice as potent. Ondansetron 48mg/8h: serotonin antagonist, Good for chemo/radiotherapy-related nausea, may cause constipation. Levomepromazine 6. 25mg, initially 12 times daily: broad spectrum, but can sedate, may be very eff ective if fear/anxiety are contributing to symptoms. Antisecretory drugs, such as hyoscine butylbromide or octreotide may be required for patients with Vomiting and bowel obstruction: seek expert advice. Constipation Causes: Very common side-eff ect of opioids. Better to prevent than treat so prescribe laxatives for all patients starting opioids. Also hypercalcaemia (see p528), dehydration, drugs, or intra-abdominal disease. Treatment: Treat reversible causes. Good fl uid intake. Ensure privacy and access to toilet. Medication options include the following: Stimulant (eg senna 24 tablets or bisacodyl 510mg) at night ± a softener (eg Sodium docusate 100mg BD). Osmotic laxative (eg macrogol). Rectal treatments: bisacodyl/glycerol suppositories, phosphate enema. Breathlessness Causes: Look for reversible causes including infection, eff usion, anaemia, arrhythmia, thromboembolism. If stridor or signs of superior vena cava syndrome, treat urgently (see p528). Treatment: Treat reversible causes as appropriate. Consider thoracocentesis ± pleurodesis for a pleural eff usion. Recurrent pleural eff usions may warrant a radiologically placed permanent drain (see p527). If the patient remains distressed, consider a trial of Low-dose opioids. These reduce respiratory drive and the sensation of breathlessness. If opioid-naive, start with 2. 5mg of an immediate-release morphine every 4h. If already taking an opioid, use the appropriate breakthrough dose (see p533). Benzodiazepines may help if associated anxiety, eg lorazepam 500mcg SL every 46h. Oral problems Causes: Poor oral hygiene, radiation, drugs (anticholinergics, chemotherapy, diuretics), infection (candidiasis, herpes simplex). Treatment: Oral candidiasis: topical miconazole, oral fl uconazole 50mg OD but check for interactions (eg warfarin). Nystatin is often ineff ective and may exacerbate nausea. Herpes simplex: oral gan/aciclovir.",
    "Nystatin is often ineff ective and may exacerbate nausea. Herpes simplex: oral gan/aciclovir. Good mouth care maintains comfort and the ability to communicate. Maintain fl uid intake with frequent, small drinks. Simple measures are often eff ective: Glucose-free chewing gum, normal saline mouthwashes, soft toothbrush. Products containing alcohol may sting. Salivary stimulants (rather than substitutes) can be helpful for dry mouth, eg pilocarpine eye drops 4%, 3 drops in the fl oor of mouth QDS. Severe mucositis may need admission and systemic opioids. __OOHHCCMM__1100ee. . iinnddbb 553344 0022//0055//22001177 1199: : 0088 535 erac evitaillap dna ygolocnO Insomnia Causes: Terminally ill patients may experience physical and emotional exhaustion. Often multifactorial. Poor sleep can increase symptom burden. Treatment: Simple steps may make a big diff erence: appropriate room temperature, darkness, and quiet during the night (request a side room for in-patients). Give prescribed glucocorticoids in the morning. Avoid waking patients for late medications and routine observations. Discuss and address psychosocial issues. In some cases zopiclone or benzodiazepines may be used to help patients rest and re-establish normal sleepwake cycles (may exacerbate delirium). Pruritus Causes: Systemic disease (renal failure, hepatitis, polycythaemia), cancer-related (cholestasis, lymphoma, leukaemia, hepatoma, myeloma, paraneoplastic), primaryskin disease, drug reaction (opioids, SSRI, chemotherapy). Treatment: Underlying causes where possible: cholestasis (biliary stenting, colestyramine, sertraline, rifampicin), opioid-induced (antihistamine, opioid switch), paraneoplastic (paroxetine). Topical emollients regularly and as a soap substitute. Avoid topical antihistamines due to risk of contact dermatitis. Venepuncture Repeated venepuncture with the risk of painful extravasation and phlebitis may be avoided by use of a central catheter (eg Hickman tunnelled line or PICC). Problems: infection, blockage (fl ush with 0. 9% saline or dilute heparin every week), axillary thrombosis, and line slippage. Agitation See Care in the last days of life, p536. Respiratory tract secretions See Care in the last days of life, p536. Spiritual Pain The spiritual aspects of an illness concerns the human experiences of sickness (or dis-ease) and the search for meaning within it. Peter W Speck Spirituality is a means of experiencing life. It relates to the way in which people understand and live their lives. It is comprised of elements including meaning, purpose, and something greater than self. It is distinct from faith, which is a religious experience, that may or may not be part of spirituality. Spiritual pain20, 21 or suff ering is common when people are facing death. It can include feelings of hopelessness, guilt, isolation, meaninglessness, and confusion. Consider: the past: painful memories, guilt the present: isolation, anger the future: fear, hopelessness. Reminiscence helps address the past, provides context, and off ers recognition of the patient as an individual. Anger should be acknowledged. Fear of the imagined future may not change, but is potentially reduced through discussion. The nature of hope may need to be modifi ed. If hope for a cure is inappropriate, it should not be the main or only hope. Realistic hopes include discharge from hospital, seeing family members happy, being remembered. Making a will, handing over responsibilities, and dealing with unfi nished business facilitate control and may allow a sense of completion. Remember the whole person: history, coping mechanisms, state of well-being. Elements such as these will alter how disease aff ects the patient and how the patient responds to disease. Companionship is essential in spiritual support. At times a doctor needs to modify their role to simply accompany the dying patient. This is manageable within established professional boundaries and therapeutic.",
    "Listen. Answer questions. Off er palliative care. Palliative care is never futile. A wish to die is associated with a need for information, reassurance, and competence in symptom control. Provide these, or fi nd someone who can. __OOHHCCMM__1100ee. . iinnddbb 553377 0022//0055//22001177 1199: : 0088 12 Rheumatology Contents The rheumatological history 539 Assessing the locomotor system 540 Rheumatological investigations 541 Back Pain 542 Osteoarthritis (OA) 544 Septic arthritis 544 Rheumatoid arthritis (RA) 546 Crystal arthropathies: Gout 548 CPPD arthropathy 548 Spondyloarthritides: Ankylosing spondylitis (AS) 550 Enteropathic, psoriatic and reactive arthritis 550 Autoimmune connective tissue diseases: Systemic sclerosis 552 Mixed connective tissue disease 552 Relapsing polychondritis 552 Fig 12. 1 When William Pitt the Elder, British Polymyositis dermatomyositis 552 statesman, was struck by yet another attack Systemic lupus erythematosus (SLE) 554 of gout he was absent from Parliament in 1773 when its members were persuaded to Vasculitides: levy a substantial tax on tea imports to the Giant cell arteritis 556 American colonies. The resulting Tea Act of Polyarteritis nodosa 556 1773 was born. Colonists boarded ships of Microscopic polyangiitis 556 the East India Company in Boston Harbour Polymyalgia rheumatica 557 and crates of tea were thrown overboard. In Fibromyalgia 558 response, the British government sent troops to occupy Boston to control the colonists. The Systemic disease with: armed response to these occupying forces Ocular manifestations 560 led to the American War of Independence. Dermatological manifestations 562 Thirteen colonies from the United Kingdom Rheumatological emergencies: became independent. And so it is told that Acute SLE 554 gout had a part to play in the beginning of the Acute systemic vasculitis 314 556 American Revolution! Acute cord compression 466 543 GCA 556 Methotrexate-induced pneumonitis 547 Neutropenic sepsis 352 Scleroderma: pulmonary hypertensive or renal crisis 315 552 Septic arthritis 544 A rapidly advancing speciality Rheumatology originates from the Greek word rheuma meaning that which fl ows as a river or stream. The British Society of Rheumatology defi nes rheumatology as a multidisciplinary branch of medicine that deals with the investigation, diagnosis and management of patients with arthritis and other musculoskeletal conditionsincorporating over 200 disorders aff ecting joints, bones, muscles and soft tissues, including infl ammatory arthritis and other systemic autoimmune disorders, vasculitis, soft tissue conditions, spinal Pain and metabolic bone disease. Rheumatological diseases aff ect over 10 million UK adults and 12 000 children. Recent advances owe largely to new discoveries about the immunology of these disorders and the discovery of biologic DMARDS. We thank Professor Kevin Davies, our Specialist Reader, for his contribution to this chapter. We also thank Dr Susie Higgins for her contribution to this chapter. __OOHHCCMM__1100ee. . iinnddbb 553388 0022//0055//22001177 1199: : 0088 539 ygolotamuehR The rheumatological history In the assessment of an arthritic presentation, pay particular attention to the distribution of joint involvement (including spine) and the presence of symmetry. Also look for disruption of joint anatomy, limitation of movement (by Pain or contracture), joint eff usions and peri-articular involvement (see p540 for a fuller assessment). Ask about, and examine for, extra-articular features: skin and nail (see p76) involvement (include scalp, hairline, umbilicus, genitalia, and natal cleftpsoriasis can easily be missed); eye signs (see p560); lungs (eg fi brosis) (see p198); kidneys (see p314); Heart; GI (eg mouth ulcers, diarrhoea); GU (eg urethritis, genital ulcers); and CNS. Three screening questions for musculoskeletal disease 1 Are you free of any Pain or stiff ness in your joints, muscles, or back? 2 Can you dress yourself without too much diffi culty? 3 Can you manage walking up and down stairs?",
    "2 Can you dress yourself without too much diffi culty? 3 Can you manage walking up and down stairs? If yes to all three, serious infl ammatory muscle/joint disease is unlikely. Presenting symptoms: Related diseases: Pattern of involved joints. Crohns/UC (in ank yl osing spondylitis), Symmetry (or not). preceding infections, psoriasis. Current and past drugs: Morning stiff ness 30min (eg RA). Pain, Edema, loss of function, NSAIDS, DMARDS (p547). Biological agents (eg TNF inhibitors). erythema, warmth. Family history: Extra-articular features: Arthritis, psoriasis, autoimmune disease. Rashes, photosensitivity (eg SLE). Social history: Raynauds (SLE; systemic sclerosis; Age. polymyositis and dermatomyositis). Occupation. Dry eyes or mouth (Sjögrens). Sexual history. Red eyes, iritis (eg AS). Ethnicity (eg SLE is commoner in African- Diarrhoea/urethritis (reactive arthriCaribbeans and Asians). tis). Ability to function (eg dressing, groom- Nodules or nodes (eg RA; TB; gout). ing, writing, walking). Mouth/genital ulcers (eg Behçets, Domestic situation, social support, home SLE). adaptations. Weight loss (eg malignancy, any sys- Smoking (may worsen RA). temic infl ammatory disease). IBD. Arthritides The pattern of joint involvement can provide clues to the underlying cause (table 12. 1). Table 12. 1 Patterns of presentation of arthritis Monoarthritis Oligoarthritis (≤5 joints) Polyarthritis (5 joints involved) Septic arthritis Crystal arthritis Symmetrical Asymmetrical Crystal arthritis Psoriatic arthritis Rheumatoid Reactive (gout, CPPD) arthritis arthritis Osteoarthritis Reactive arthritis, eg Yersinia, Osteoarthritis Psoriatic Salmonella, Campylobacter arthritis Trauma Ankylosing spondylitis Viruses (eg (haemarthrosis) hepatitis A, B, C; mumps) Osteoarthritis Systemic conditions (can be either) Connective tissue disease (eg SLE and relapsing polychondritis), sarcoidosis, malignancy (eg leukaemia), endocarditis, haemochromatosis, sickle-cell anaemia, familial Mediterranean fever, Behçets. Exclude septic arthritis in any acutely infl amed joint, as it can destroy a joint in under 24h (p544). Infl ammation may be less overt if immunocompromised (eg from the many immunosuppressive drugs used in rheumatological conditions) or if there is underlying joint disease. Joint aspiration (p541) is the key investigation, and if you are unable to do it, fi nd someone who can. __OOHHCCMM__1100ee. . iinnddbb 553399 0022//0055//22001177 1199: : 0088 540 ygolotamuehR Assessing the locomotor system This aims to screen for rheumatological conditions primarily aff ecting mobility (as a consequence of underlying joint disease). It is based on the GALS locomotor screen (Gait, Arms, Legs, Spine). 1 Essence Look, feel, and move (active and passive). If a joint looks normal to you, feels normal to the patient, and has full range of movement, it usua lly is normal. Make sure the patient is comfortable, and obtain their consent before examination. The GALS screening examination should be done in light underwear. Spine: Observe from behind: is muscle bulk normal (buttocks, shoulders)? Is the spine straight? Are paraspinal muscles symmetrical? Any swellings/deformities? Observe from the side: is cervical and lumbar lordosis normal? Any kyphosis? Touch your toes, please: is lumbar spine fl exion normal, eg Schobers test? 1 Observe from in front: Tilt your head (without moving the shoulders)tests lateral neck fl exion. Palpate for typical fi bromyalgia tender points (see p558). Arms: Try putting your hands behind your headtests functional shoulder movement. Arms out straighttests elbow extension and forearm supination/pronation. Examine the hands: any deformity (fi g 12. 2), wasting, or swellings? Squeeze across 2nd5th metacarpophalangeal joints. Pain may denote joint or tendon synovitis. Put your index fi nger on your thumbtests pincer grip. Assess dexterity, eg fastening a button or picking up a coin. Legs: Observe legs: normal quadriceps bulk? Any Edema or deformity? With patient lying supine: any leg length discrepancy? Internally/externally rotate each hip in fl exion. Passively fl ex knee and hip to the full extent. Is movement limited? Any crepitus?",
    "Passively fl ex knee and hip to the full extent. Is movement limited? Any crepitus? Find any knee effusion using the patella tap test. If there is fl uid, consider aspirating and testing for crystals or infection. With patient standing: observe feet: any deformity? Are arches High or fl at? Any callosities? These may indicate an abnormal gait of some chronicity. Squeeze across metatarsophalangeal joints: see as for arms. Also: although not in the GALS system, palpate the heel and Achilles tendon to identify plantar fasciitis and Achilles tendonitis often associated with seronegative rheumatological conditions. Examine the patients shoes for signs of uneven wear. Gait: Observe walking: is the gait smooth? Good arm swing? Stride length OK? Normal heel strike and toe off? Can they turn quickly? Range of joint movement Is noted in degrees, with anatomical position being the neutral positioneg elbow fl exion 0°150° normally, but with fi xed fl exion and limited movement, range may be reduced to 30°90°. A valgus deformity deviates laterally (away from the mid-line, fi g 12. 3); a varus deformity points towards the mid-line. Fig 12. 2 Swan-neck deformity. Reproduced from Watts et al. , Oxford Textbook of Rheumatology, 2013, with permission from Oxford University Press. Fig 12. 3 Bilateral hallux valgus. Reproduced from British Medical Journal, Hallux valgus, R Choa, R Sharp, potassium R Mahtani, 2010, with permission from BMJ Publishing Group Ltd. 1 Schobers test: make a mark on the lumbar spine at the level of the posterior iliac spine. Measure out a line from 5cm below to 10cm above the mark. Ask to bend forward as far as they can. If the line does not lengthen by at least 5cm in fl exion, there is reduced lumbar fl exion, eg in ankylosing spondylitis. __OOHHCCMM__1100ee. . iinnddbb 554400 0022//0055//22001177 1199: : 0088 541 ygolotamuehR Some important rheumatological investigations Joint aspiration: The most important investigation in any monoarthritic presentation (table 12. 2, see also OHCS p706). Send synovial fl uid for urgent white cell count, Gram stain, polarized light microscopy (for crystals, p548), and culture. The risk of inducing septic arthritis, using sterile precautions, is 1: 10 000. 2 Look for Blood, 3 pus, and crystals (gout or CPPD crystal arthropathy; p548). Do not attempt joint aspiration through infl amed and potentially infected skin (eg through a psoriatic plaque or overlying cellulitis). Table 12. 2 Synovial fl uid in health and disease Appearance Viscosity white blood cell/mm3 Neutrophils Normal Clear, colourless 200 None Osteoarthritis Clear, straw 1000 50% Haemorrhagic Bloody, Varies 10 000 50% xanthochromic Acutely infl amed RA Turbid, yellow 100050 000 Varies Crystal Turbid, yellow 500050 000 80% Septic Turbid, yellow 10 000100 000 90% Eg trauma, tumour, or haemophilia. Blood tests: FBC, ESR, urate, UE, CRP. Blood culture for septic arthritis. Consider rheumatoid factor, anti-CCP, ANA, other auto antibodies (p553), and HLA B27 (p551) as guided by presentation. Consider causes of reactive arthritis (p551), eg viral serology, Urine chlamydia protein-creatinine ratio, hepatitis and HIV serology if risk factors are present. Radiology: Look for erosions, calcifi cation, widening or loss of joint space, changes in underlying bone of aff ected joints (eg periarticular osteopenia, sclerotic areas, osteophytes). Characteristic X-ray features for various arthritides are shown in fi gs 12. 412. 6. Irregularity of the sacroiliac joints is seen in spondyloarthritis. Ultrasound and magnetic resonance imaging are more sensitive in identifying eff usions, synovitis, enthesitis and infection than plain radiographsdiscuss further investigations with a radiologist. Do a CXR for RA, vasculitis, TB, and sarcoid. Loss of joint space Osteophytes Subarticular sclerosis Fig 12. 4 X-ray features of Subchondral cysts osteoarthritis.",
    "Loss of joint space Osteophytes Subarticular sclerosis Fig 12. 4 X-ray features of Subchondral cysts osteoarthritis. Courtesy of Dr DC Howlett. Fig 12. 5 X-ray features of rheumatoid arthritis (MCPJ). Courtesy of Dr DC Howlett. Fig 12. 6 X-ray features of gout (1st MTPJ). Courtesy of Dr DC Howlett. __OOHHCCMM__1100ee. . iinnddbb 554411 0022//0055//22001177 1199: : 0088 542 ygolotamuehR Back Pain Back Pain is very common, and often self-limiting, but be alert to sinister causes, ie malignancy, infection, or infl ammatory causes. Red fl ags for sinister causes of back Pain Aged 20yrs or 55yrs old Thoracic back Pain Acute onset in elderly people Morning stiff ness Constant or progressive Pain Bilateral or alternating leg Pain Nocturnal Pain Neurological disturbance (incl. sciatica) Worse Pain on being supine Sphincter disturbance Fever, night sweats, weight loss Current or recent infection History of malignancy Immunosuppression, eg steroids/HIV Abdominal mass Leg claudication or exercise-related leg weakness/numbness (spinal stenosis). Examination 1 With the patient standing, gauge the extent and smoothness of lumbar forward/ lateral fl exion and extension (see p540). 2 Test for sacroiliitis: palpate posteriorly down the length of the spine, including over spinous processes, paraspinal muscles, and the sacroiliac joints; examining for tenderness. 3 Neurological defi cits (see BOX): test lower limb sensation, power, and deep tendon and plantar refl exes. Digital rectal examination for perianal tone and sensation. 4 Examine for nerve root Pain (table 12. 3): this is distributed in relevant dermatomes, and is worsened by coughing or bending forward. Straight leg test (L4, L5, S1): positive if raising the leg with the knee extended causes Pain below the knee, which increases on foot dorsifl exion (Lasègues sign). It suggests irritation to the sciatic nerve. The main cause is lumbar disc prolapse. Also femoral stretch test (L2L4): Pain in front of thigh on lifting the hip into extension with the patient lying face downwards and the knee fl exed. 5 Signs of generalized diseaseeg malignancy. Examine other systems (eg abdomen) as Pain may be referred. Causes Age determines the most likely causes: 1530yrs: Prolapsed disc, trauma, fractures, ankylosing spondylitis (AS; p550), spondylolisthesis (a forward shift of one vertebra over another, which is congenital or due to trauma), pregnancy. 3050yrs: Degenerative spinal disease, prolapsed disc, malignancy (primary or secondary from lung, breast, prostate, thyroid, or Kidney calcium). 50yrs: Degenerative, osteoporotic vertebral collapse, Pagets (see p685), malignancy, myeloma (see p368), spinal stenosis. Rarer: Cauda equina tumours, psoas abscess, spinal infection (eg discitis, usually staphylococcal but also Proteus, E. coli, S. typhi, and TBthere are often no systemic signs). Investigations Arrange relevant tests if you suspect a specifi c cause, or if red fl ag symptoms: FBC, ESR, and CRP (myeloma, infection, tumour), UE, ALP (Pagets), serum/Urine electrophoresis (myeloma), PSA. X-raysimaging may not always be necessary but can exclude bony abnormalities and fractures. Correlation between radiographic abnormalities and clinical features can be poor. magnetic resonance imaging is the image of choice and can detect disc prolapse, cord compression (fi g 12. 7), cancer, infection, or infl ammation (eg sacroiliitis). Management Urgent neurosurgical referral if any neurological defi cit (see BOX). Keep the diagnosis under review. For non-specifi c back Pain, focus on education and self-management. Advise patients to continue normal activites and be before mealstive. Regular paracetamol ± NSAIDS ± codeine. Consider Low-dose amitriptyline/duloxetine if these fail (not SSRIS for Pain). Off er physiotherapy, acupuncture, or an exercise programme if not improving. 4 Address psychosocial issues, which may predispose to developing chronic Pain and disability (see p559). Referral to Pain clinic or surgical options for patients with intractable symptoms. __OOHHCCMM__1100ee. .",
    "Referral to Pain clinic or surgical options for patients with intractable symptoms. __OOHHCCMM__1100ee. . iinnddbb 554422 0022//0055//22001177 1199: : 0088 543 ygolotamuehR Neurosurgical emergencies Acute cauda equina compression Alternating or bilateral root Pain in legs, saddle anaesthesia (perianal), loss of anal tone on PR, bladder ± bowel incontinence. Acute cord compression Bilateral Pain, LMN signs (p446) at level of compression, UMN and sensory loss below, sphincter disturbance. Immediate urgent treatment prevents irreversible loss, eg laminectomy for disc protrusions, radiotherapy for tumours, decompression for abscesses. Causes (same for both): bony metastasis (look for missing pedicle on X-ray), large disc protrusion, myeloma, cord or paraspinal tumour, TB (p392), abscess. Table 12. 3 Nerve root lesions Nerve root Pain Weakness Refl ex aff ected L2 Across upper thigh Hip fl exion and adduction Nil L3 Across lower thigh Hip adduction, knee extension Knee jerk L4 Across knee to Knee extension, foot inversion Knee jerk medial malleolus and dorsifl exion L5 Lateral shin to Hip extension and abduction Great toe jerk dorsum of foot and Knee fl exion great toe Foot and great toe dorsifl exion S1 Posterior calf to Knee fl exion Ankle jerk lateral foot and Foot and toe plantar fl exion little toe Foot eversion Fig 12. 7 Sagittal T2-weighted magnetic resonance imaging of the lumbar spine showing a herniated L5S1 disc. Courtesy of Norwich Radiology Department. __OOHHCCMM__1100ee. . iinnddbb 554433 0022//0055//22001177 1199: : 0088 544 ygolotamuehR Osteoarthritis (OA) Osteoarthritis is the most common joint condition worldwide, with a clinically significant impact on 10% of persons aged 60 years. 5 It is usually primary (generalized), but may be secondary to joint disease or other conditions (eg haemochromatosis, obesity, occupational). Signs and symptoms Localized disease (often knee or hip): Pain and crepitus on movement, with background ache at rest. Worse with prolonged activity. Joints may gel (brief stiff ness after rest, usually 1015 minutes or so). Joints may feel unstable, with a perceived lack of power due to Pain. Generalized disease: Nodal OA (typically DIP, PIP, CMC joints, and knees in post-menopausal females). There may be joint tenderness, derangement and bony Edema (Heberdens at DIP and Bouchards at PIP), reduced range of movement and mild synovitis. Assess eff ect of symptoms on occupation, family duties, hobbies, and lifestyle expectations. Tests Plain radiographs show: Loss of joint space, Osteophytes, Subarticular sclerosis and Subchondral cysts (fi g 12. 4 p541). CRP may be slightly elevated. 6 Management Core treatments: Exercise to improve local muscle strength and general aerobic fi tness (irrespective of age, severity, or comorbidity). Weight loss if overweight. 7 Analgesia: Regular paracetamol ± topical NSAIDS. If ineff ective use codeine or short-term oral nonsteroidal anti-inflammatory drug (proton pump inhibitor)see BOX. Topical capsaicin (derived from chillies) may help. Intra-articular steroid injections temporarily relieve Pain in severe sym ptoms. Intra-articular hyaluronic acid injections (viscosupplementation) are not NICE approved8 Glucosamine and chondroitin products are not recommended, although patients may try them if they wish (can be bought over the counter). Nonpharmacological: Use a multidisciplinary approach, including physiotherapists and occupational therapists. Try heat or cold packs at the site of Pain, walking aids, stretching/manipulation or TENS. Surgery: Joint replacement (hips, or knees) is the best way to deal with severe OA that has a substantial impact on quality of life. Septic arthritis Consider septic arthritis in any acutely infl amed joint, as it can destroy a joint in under 24h and has a mortaility rate up to 11%. Infl ammation may be less overt if immunocompromised (eg from medication) or if there is underlying joint disease. The knee is aff ected in 50% cases.",
    "The knee is aff ected in 50% cases. Risk factors Pre-existing joint disease (especially rheumatoid arthritis); Diabetes mellitus, immunosuppression, chronic renal failure, recent joint surgery, prosthetic joints (where infection is particularly diffi cult to treat), IV drug abuse, age 80yrs. 9 Investigations Urgent joint aspiration for synovial fl uid microscopy and culture is the key investigation (p541), as plain radiographs and CRP may be normal. The main diff erential diagnoses are the crystal arthropathies (p548). Blood cultures are essential (prior to antibiotics). Ask yourself How did the organism get there? Is there immuno suppression, or another focus of infection, eg from indwelling IV lines, infected skin, or pneumonia (present in up to 50% of those with pneumococcal arthritis)? 10 Treatment If in doubt start empirical IV antibiotics (after aspiration) until sensitivities are known. Common causative organisms are Staph. aureus, streptococci, Neisseria gonococcus, and Gram Ωve bacilli. Follow local guidelines for antibiotic choice and contact microbiology for advice for all complex cases/immunosuppressed patients (eg HIV). Consider fl ucloxacillin 2g QDS IV (clindamycin if penicillin allergic); Vancomycin IV plus 2ndor 3rd-generation cephalosporin, eg cefuroxime if MRSA risk; 2ndor 3rd-generation cephalosporin if Gram Ωve organisms suspected. 11 For suspected gonococcus or meningococcus, consider ceftriaxone. Antibiotics are required for a prolonged period, conventionally 2 weeks IV, then if patient improving 24 weeks PO. 12 Consider orthopaedic review for arthrocentesis, washout, and debridement; always urgently refer patients with prosthetic joint involvement. __OOHHCCMM__1100ee. . iinnddbb 554444 0022//0055//22001177 1199: : 0088 545 ygolotamuehR Prescribing NSAIDS: benefi t vs risk profi ling Around 60% of patients will respond to any nonsteroidal anti-inflammatory drug, but there is considerable variation in response and toleranceif one International Society of Nephrologyt eff ective, try another. Mainly act as analgesics rather than modifying the disease process per se. NSAIDs caused 2000 UK deaths in 2011. 13 Individualized risk: benefi t analysis for each patient (including indication, dose, proposed duration of use, and comorbidity) is crucial and needs careful and experienced thought. Follow local recommendations and national guidelines where available. nonsteroidal anti-inflammatory drug side effects: The main serious side eff ects are GI bleeding (and ulcers and perforation), cardiovascular events (myocardial infarction and stroke), and renal injury. The risks are dose related, starting with the fi rst dose, so always aim to use the lowest possible dose for the shortest period of time. Risks increase considerably with age, polypharmacy, history of peptic ulcers, and renal impairment. GI side effects: NICE recommends co-prescription of proton pump inhibitor for any patient aged 45 years, and those with other risk factors for GI bleeding. Drug interactions can increase bleeding risksavoid concomitant prescribing of anticoagulants, antiplatelet agents, SSRI, spironolactone, steroids, and bisphosphonates. Coxibs are slightly lower risk than non-selective NSAIDs. Cardiovascular side effects: NSAIDSall are associated with a small increased risk of myocardial infarction and stroke (independent of cardiovascular risk factor or duration of use). 14 Risks are higher in those with concomitant IHD risk factors, eg Diabetes and hypertension. Coxibs and diclofenac are higher risk, and are contraindicated if prior history of myocardial infarction, peripheral vascular disease, stroke, or Heart failure. Naproxen has the lowest cardiovascular risk. Low-dose celecoxib may be considered for patients on Low-dose aspirin (if nonsteroidal anti-inflammatory drug is required) as it does not interact with it. 15 Renal risks: Higher for patients already on diuretics, ACE, or angiotensin receptor blocker. Risks are also increased in the elderly, those with hypertension and type 2 diabetes mellitus. Overall, naproxen (1000mg/day) or ibuprofen (1200mg/day) plus proton pump inhibitor may be the safest options. Alternatives to NSAIDs: Paracetamol, topical NSAIDs, opioids.",
    "Alternatives to NSAIDs: Paracetamol, topical NSAIDs, opioids. Strengthening exercises may be more benefi cial than mild oral analgesics. Counselling patients: Make sure patients understand about the drugs they are taking: bleeding is more common in those who know less about their drugs. 16 Only to take NSAIDs when they need them. Stop NSAIDs and seek urgent medical review if they develop abdominal Pain or any symptoms of GI bleeding (eg report black stools ± faints immediately). Do not mix prescription NSAIDs with over-the-counter formulations: mixing NSAIDS can increase risks 20-fold. Smoking and alcohol increase risk profi Blood of NSAIDs. __OOHHCCMM__1100ee. . iinnddbb 554455 0022//0055//22001177 1199: : 0088 546 ygolotamuehR Rheumatoid arthritis (RA) RA is a chronic systemic infl ammatory disease, characterized by a symmetrical, deforming, peripheral polyarthritis. It increases the risk of cardiovascular disease by 23 fold. Epidemiology Prevalence is 1% ( in smokers). : 2: 1. Peak onset: 5th 6th decade. HLA DR4/DR1 linked (associated with severity). Presentation Typically: Symmetrical swollen, painful, and stiff small joints of hands and feet, worse in the morning. This can fl uctuate and larger joints may become involved. Less common presentations: Sudden onset, widespread arthritis. Recurring mono/polyarthritis of various joints (palindromic RA). 2 Persistent monoarthritis (knee, shoulder, or hip). Systemic illness with extra-articular symptoms, eg fa tigue, fever, weight loss, pericarditis, and pleurisy, but initially few joint problems (commoner in ). Polymyalgic onsetvague limb girdle aches. Recurrent soft tissue problems (eg frozen shoulder, carpal tunnel syndrome, de Quervains tenosynovitis). Signs Early: (Infl ammation, no joint damage. ) Swollen MCP, PIP, wrist, or MTP joints (often symmetrical). Look for tenosynovitis or bursitis. Later: (Joint damage, deformity. ) Ulnar deviation and subluxation of the wrist and fi ngers. Boutonnière and swan-neck deformities of fi ngers (fi g 12. 2 on p540) or Z-deformity of thumbs occur. Hand extensor tendons may rupture. Foot changes are similar. Larger joints can be involved. Atlanto-axial joint subluxation may threaten the spinal cord (rare). Extra-articular manifestations Aff ect 40% of RA patients. Nodules: Elbows, lungs, cardiac, CNS, lymphadenopathy, vasculitis. Lungs: Pleural disease, interstitial fi brosis, bronchiolitis obliterans, organizing pneumonia. Cardiac: IHD, pericarditis, pericardial eff usion; carpal tunnel syndrome; peripheral neuropathy; splenomegaly (seen in 5%; only 1% have Feltys syndrome: RA splenomegaly neutropenia, see p698). Eye: Episcleritis, scleritis, scleromalacia, keratoconjunctivitis sicca (p560); osteoporosis; amyloidosis is rare (p370). 17, 18 Investigations Rheumatoid factor (RhF) is positive in 70% (p553). High titres associated with severe disease, erosions, and extra-articular disease. Anticyclic citrullinated peptide antibodies (anti-CCP) are highly specifi c (98%) for RA with a reasonable sensitivity (7080%); they may also predict disease progression. 19 Anaemia of chronic disease, platelets, ESR, CRP. X-rays show soft tissue swelling, juxta-articular osteopenia and joint space. Later there may be bony erosions, subluxation, or complete carpal destruction (see fi g 12. 5 on p541). Ultrasound and magnetic resonance imaging can identify synovitis more accurately, and have greater sensitivity in detecting bone erosions than conventional X-rays. 20 Diagnostic criteria See table 12. 4. Management Refer early to a rheumatologist (before irreversible destruction). Disease activity is measured using the DAS28. 3 Treatment should be escalated until satisfactory control is achieved: treat to target. Early use of DMARDS and biological agents improves long-term outcomes (see BOX Infl uencing biological events in RA). Steroids rapidly reduce symptoms and infl ammation. Avoid starting unless appropriately experienced. Useful for acute exacerbations, eg IM depot methylprednisolone 80120mg. Intra-articular steroids have a rapid but short-term eff ect (OHCS pp7069). Oral steroids (eg prednisolone 7. 5mg/d) may control diffi cult symptoms, but side eff ects preclude routine long-term use.",
    "Oral steroids (eg prednisolone 7. 5mg/d) may control diffi cult symptoms, but side eff ects preclude routine long-term use. NSAIDS (see p545) are Good for symptom relief, but have no eff ect on disease progression. Paracetamol and weak opiates are rarely eff ective. Off er specialist physioand occupational therapy, eg for aids and splints. Surgery may relieve Pain, improve function, and prevent deformity. There is risk of cardiovascular and cerebrovascular disease, as atherosclerosis is accelerated in RA. 21 Manage risk factors (p93). Smoking also symptoms of RA. 2 In rheumatological palindromes, arthritis lasting hours or days runs to and fro, visiting and revisiting three or more sites, typically knees, wrists, and MCP joints. It may presage RA, SLE, Whipples, or Behçets disease. Remissions are (initially) complete, leaving no radiological mark. 3 28-joint Disease Activity Scoreassesses tenderness and Edema at 28 joints (MCPS, PIPS, wrists, elbows, shoulders, knees), ESR/CRP, and patients self-reported symptom severity. __OOHHCCMM__1100ee. . iinnddbb 554466 0022//0055//22001177 1199: : 0088 547 ygolotamuehR Table 12. 4 Criteria for diagnosing RA22 When to suspect RA? Those with ≥1 swollen joint and a suggestive clinical history, which is not better explained by another disease. Scores ≥6 are diagnostic. A Joint involvement (Edema or tenderness ± imaging evidence) 1 large joint 0 210 large joints 1 13 small joints 2 410 small joints 3 10 joints (at least 1 small joint) 5 B Serology (at least 1 test result needed) Negative RF and negative anti-CCP 0 Low ve RF or Low ve anti-CCP 2 High ve RF or High ve anti-CCP 3 C Acute phase reactants (at least 1 test result needed) Normal CRP and normal ESR 0 Abnormal CRP or abnormal ESR 1 D Duration of symptoms: 6 weeks 0 ≥6 weeks 1 MCPJ, PIPJ, 2nd5th MTPJ, wrists, and thumb IPJ; with or without involvement of large joints. Quality of life Depression, disability, and Pain are important quality of life predictors. Be mindful of the impact of disease on relationships, work, and hobbies and acknowledge and explore this with your patients. Patients may wish to investigate complementary therapies and may fi nd benefi t from support groups. Infl uencing biological events in RA The chief biological event is infl ammation. Over-produced cytokines and cellular processes erode cartilage and bone, and produce the systemic eff ects seen in RA. Disease-modifying antirheumatic drugs (DMARDS) are 1st line and should ideally be started within 3 months of persistent symptoms. They can take 612 weeks for symptomatic benefi t. Best results are often achieved with a combination of methotrexate, sulfasalazine, and hydroxychloroquine. 23 Lefl unomide is another option. Immunosuppression is a potentially fatal SE of treatment (especially in combination with methotrexate) which can result in pancytopenia, susceptibility to infection (including atypical organisms), and neutropenic sepsis (p352). Regular FBC, LFT monitoring. 24 Other SE Methotrexatepneumonitis (pre treatment CXR), oral ulcers, hepatotoxicity, teratogenic. Sulfasalazinerash, sperm count, oral ulcers, GI upset. Lefl unomideteratogenicity ( and ), oral ulcers, blood pressure, hepatotoxicity. Hydroxychloroquinecan cause retinopathy; pre treatment and annual eye screen required. Biological agents and NICE guidance Initiated by specialists, for patients with active disease despite adequate trial of at least 2 DMARDS. Pre treatment screening for TB, hepatitis B/C, HIV essential. 1 TNF inhibitors: Eg infl iximab (p265), etanercept, adalimumab, are approved by NICE as 1st-line agents. Where methotrexate is contraindicated, can be used as monotherapy. Clinical response can be striking, with improved function and health outcomes, although response may be inadequate/unsustained. 25 2 B-cell depletion: Eg rituximab, used in combination with methotrexate and approved by NICE for severe active RA where DMARDS and a TNF blocker have failed.",
    "26 3 IL-1 and IL-6 inhibition: Eg tocilizumab (IL-6 receptor blocker), approved by NICE in combination with methotrexate where TNF blocker has failed (or is contraindicated). 27 Monitor for hypercholesterolaemia. 4 Inhibition of T-cell co-stimulation: Eg abataceptlicensed for active RA where patients have not responded to DMARDS or TNF blocker. 28 Side eff ects of biological agents Serious infection, reactivation of TB ( screen and consider prophylaxis) and hepatitis B; worsening Heart failure; hypersensitivity; injection-site reactions and Blood disorders. ANA and reversible SLE-type illness may evolve. Data suggests there is no increased risk of solid organ tumours but skin cancers may be more common. 29 TNF inhibitors do not appear to be associated with a further increase in the already elevated lymphoma occurrence in RA. 30 __OOHHCCMM__1100ee. . iinnddbb 554477 0022//0055//22001177 1199: : 0088 548 ygolotamuehR Crystal arthropathies: gout Gout31 typically presents with an acute monoarthropathy with severe joint infl ammation (fi g 12. 8). 50% occur at the metatarsophalangeal joint of the big toe (fi g 12. 12) (podagra). Other common joints are the ankle, foot, small joints of the hand, wrist, elbow, or knee. It can be polyarticular. It is caused by deposition of monoSodium urate crystals in and near joints. Attacks may be precipitated by trauma, surgery, starvation, infection, or diuretics. It is associated with raised plasma urate. In the long term, urate deposits ( tophi, eg in pinna, tendons, joints; see fi g 12. 9) and renal disease (stones, interstitial nephritis) may occur. Prevalence: 1%. : 4: 1. Diff erential diagnoses Exclude septic arthritis in any acute monoarthropathy (p544). Then consider reactive arthritis, haemarthrosis, CPPD (see following topic) and palindromic RA (p546). Risk factors Reduced urate excretion: Elderly, men, post-menopausal females, impaired renal function, hypertension, metabolic syndrome, diuretics, antihypertensives, aspirin. Excess urate production: Dietary (alcohol, sweeteners, red meat, seafood), genetic disorders, myeloand lymphoproliferative disorders, psoriasis, tumour-lysis syndrome, drugs (eg alcohol, warfarin, cytotoxics). Associations: Cardiovascular disease, hypertension, Diabetes mellitus, and chronic renal failure (see p680). 31 Gout is an independent risk factor for mortality from cardiovascular and renal disease. Screen for and treat chronic kidney disease, hypertension, dyslipidaemia, Diabetes. Investigations Polarized light microscopy of synovial fl uid shows negatively birefringent urate crystals (fi g 12. 10). Serum urate (SUA) is usually raised but may be normal. 32 Radiographs show only soft-tissue Edema in the early stages. Later, welldefi ned punched out erosions are seen in juxta-articular bone (see fi g 12. 6 on p541). There is no sclerotic reaction, and joint spaces are preserved until late. Treatment of acute gout High-dose nonsteroidal anti-inflammatory drug (see BOX, p545) or if CI use colchicine (500mcg BD) which is eff ective but slower to work (BNF states max 6mg per course although rheumatologists will often use more). 33 NB: in renal impairment, NSAIDS and colchicine are problematic. Steroids (oral, IM, or intra-articular) may also be used. 34 Rest and elevate joint. Ice packs and bed cages can be eff ective. Prevention Lose weight, avoid prolonged fasts, alcohol excess, purine-rich meats, and Low-dose aspirin. Prophylaxis: Start if 1 attack in 12 months, tophi, or renal stones. The aim is to attacks and prevent damage caused by crystal deposition. Use allopurinol and titrate from 100mg/24h, increasing every 4 weeks until plasma urate 0. 3mmol/L (max 300mg/8h). SE: rash, fever, WCC. Allopurinol may trigger an attack so wait 3 weeks after an acute episode, and cover with regular nonsteroidal anti-inflammatory drug (for up to 6 weeks) or colchicine (0. 5mg/12h PO for up to 6 months). Avoid stopping allopurinol in acute attacks once established.",
    "5mg/12h PO for up to 6 months). Avoid stopping allopurinol in acute attacks once established. Febuxostat (80mg/24h) is an alternative if allopurinol is CI or not tolerated. It uric acid by inhibiting xanthine oxidase (SE: LFTS) and is more eff ective at reducing serum urate than allopurinol (number of acute attacks the same). 35 Uricosuric drugs urate excretion. Calcium pyrophosphate deposition (CPPD) Acute CPPD crystal arthritis Acute monoarthropathy usually of larger joints in elderly. Usually spontaneous but can be provoked by illness, surgery, or trauma. Chronic CPPD Infl ammatory RA-like (symmetrical) polyarthritis and synovitis. Osteoarthritis with CPPD chronic polyarticular osteoarthritis with superimposed acute CPP attacks. Risk factors Old age, hyperparathyroidism (see p222), haemochromatosis (see p288), hypophosphataemia (see p679). Tests Polarized light microscopy of synovial fl uid shows weakly positively birefringent crystals (fi g 12. 11). It is associated with soft tissue calcium deposition on x-ray. Management Acute attacks: cool packs, rest, aspiration, and intra-articular steroids. NSAIDS (proton pump inhibitor) ± colchicine 0. 51. 0mg/24h (used with caution) may prevent acute attacks. Methotrexate and hydroxychloroquine may be considered for chronic CPP infl ammatory arthritis. 36 __OOHHCCMM__1100ee. . iinnddbb 554488 0022//0055//22001177 1199: : 0088 549 ygolotamuehR Fig 12. 8 Acute monoarthritis in gout. Fig 12. 9 Ulcerated tophi in gout. Fig 12. 10 Needle-shaped monosodium urate Fig 12. 11 Rhomboid-shaped calcium pyrophoscrystals found in gout, displaying Negative phate dihydrate crystals in Pseudogout, s how ing birefringence under polarized light. Positive birefringence in polarized light. Reproduced from Warrell et al. , Oxford Textbook Image courtesy of Prof. Eliseo Pascual, of Medicine, 2010, with permission from Oxford Sección de Reumatología, University Press. Hospital General Universitario de Alicante. Fig 12. 12 Dont underestimate the s everity of Pain caused by goutas illustrated by satirical artist and gout s uff erer James Gillray (17561815). Lordprice collection / Alamy Stock Photo. __OOHHCCMM__1100ee. . iinnddbb 554499 0022//0055//22001177 1199: : 0088 550 ygolotamuehR Spondyloarthritides The spondyloarthropathies (SpA) are a group of related chronic infl ammatory conditions. They tend to, although not always, aff ect the axial skeleton with shared clinical features: 1 Seronegativity ( rheumatoid factor Ωve). 2 HLA B27 associationsee BOX. 3 Axial arthritis: pathology in spine (spondylo-) and sacroiliac joints. 4 Asymmetrical large-joint oligoarthritis (ie 5 joints) or monoarthritis. 5 Enthesitis: infl ammation of the site of insertion of tendon or ligament into bone, eg plantar fasci itis, Achilles tendonitis, costochondritis. 6 Dactylitis: infl ammation of an entire digit (sausage digit), due to soft tissue oedema, and tenosynovial and joint infl ammation. 7 Extra-articular manifestations: eg iritis (anterior uveitis), psoriaform rashes (psoriatic arthritis), oral ulcers, aortic valve incompetence, infl ammatory bowel disease. NB: BehÇets syndrome (p694) can also present with uveitis, skin lesions, and a rthritis and is not always associated with gross oral or genital ulcerations. 1 Ankylosing spondylitis (AS) A chronic infl ammatory disease of the spine and sacroiliac joints, of unknown aetiology (likely strong genetic/environmental interplay). Prevalence: 0. 251%. Men present earlier: : 6: 1 at 16yrs old, and 2: 1 at 30yrs old. 90% are HLA B27 ve (see BOX). Symptoms and signs: The typical patient is a man 30yrs old with gradual onset of Low back Pain, worse during the night with spinal morning stiff ness relieved by exercise. Pain radiates from sacroiliac joints to hips/buttocks, and usually improves towards the end of the day. There is progressive loss of spinal movement (all directions) hence thoracic expansion. See pp5402 for tests of spine fl exion and sacroiliitis. The disease course is variable; a few progress to kyphosis, neck hyperextension (question-mark posture; fi g 12. 13), and spino-cranial ankylosis.",
    "13), and spino-cranial ankylosis. Other features include enthesitis (see BOX), especially Achilles tendonitis, plantar fasciitis, at the tibial and ischial tuberosities, and at the iliac crests. Anterior mechanical chest Pain due to costochondritis and Fatigue may feature. Acute iritis occurs in ⅓ of patients and may lead to blindness if untreated (but may also have occurred many years before, so enquire directly). AS is also associated with osteoporosis (up to 60%), aortic valve incompetence (3%), and pulmonary apical fi brosis. Tests: Diagnosis is clinical, supported by imaging. 4 magnetic resonance imaging allows detection of active infl ammation (bone marrow oedema) as well as destructive changes such as erosions, sclerosis, and ankylosis. X-rays can show SI joint space narrowing or widening, sclerosis, erosions, and ankylosis/fusion. Vertebral syndesmophytes are characteristic (often T11L1 initially): bony proliferations due to enthesitis between ligaments and vertebrae. These fuse with the vertebral body above, causing ankylosis. In later stages, calcifi cation of ligaments with ankylosis lead to a bamboo spine appearance. Also: FBC (normocytic anaemia), ESR, CRP, HLA B27 ve (ve in 9095% of cases but only 5% of patients HLA B27 ve have AS). Management: Exercise, not rest, for backache, including intense exercise regimens to maintain posture and mobilityideally with a specialist physiotherapist. NSAIDS usually relieve symptoms within 48h, and may slow radiographic progression. 37 TNF BLOCKERS (eg etanercept, adalimumab) are indicated in severe before mealstive AS. 38 Local steroid injections provide temporary relief. Surgery includes hip replacement to improve Pain and mobility if the hips are involved, and rarely spinal osteotomy. There is risk of osteoporotic spinal fractures (consider bisphosphonates). Prognosis: There is not always a clear relationship between the activity of arthritis and severity of underlying infl ammation (as for all the spondyloarthritides). Prognosis is worse if ESR 30; onset 16yrs; early hip involvement or poor response to NSAIDS. 39 2 Enteric arthropathy Associations: Infl ammatory bowel disease, GI bypass, coeliac and Whipples disease (p716). Arthropathy often improves with the treatment of bowel symptoms (beware NSAIDS). Use DMARDS for resistant cases. 4 Sacroiliitis on imaging plus ≥1 SpA feature or HLA B27 positive plus ≥2 SpA features. __OOHHCCMM__1100ee. . iinnddbb 555500 0022//0055//22001177 1199: : 0088 551 ygolotamuehR 3 Psoriatic arthritis (OHCS p594. ) Occurs in 1040% with psoriasis and can present before skin changes. Patterns are: symmetrical polyarthritis (like RA) DIP joints asymmetrical oligoarthritis spinal (similar to AS) psoriatic arthritis mutilans (rare, 3%, severe deformity). Radiology: Erosive changes, with pencil-in-cup deformity in severe cases. Associated with nail changes in 80%, synovitis (dactylitis), acneiform rashes and palmo-plantar pustulosis. Management: NSAIDS, sulfasalazine, methotrexate. Anti-TNF agents are also eff ective. 4 Reactive arthritis A condition in which arthritis and other clinical manifestations occur as an autoimmune response to infection elsewhere in the body typically GI or GU, although the preceding infection may have resolved or be asymptomatic by the time the arthritis presents. Other clinical features: Iritis, keratoderma blenorrhagica (brown, raised plaques on soles and palms), circinate balanitis (painless penile ulceration secondary to Chlamydia), mouth ulcers, and enthesitis. Patients may present with a triad of urethritis, arthritis, and conjunctivitis (Reiters syndrome). Tests: ESR CRP. Culture stool if diarrhoea. Infectious serology. Sexual health review. X-ray may show enthesitis with periosteal reaction. Management: There is no specifi c cure. Splint aff ected joints acutely; treat with NSAIDS or local steroid injections. Consider sulfasalazine or methotrexate if symptoms 6 months. Treating the original infection may make little diff erence to the arthritis. HLA-B27 disease associations The HLA system plays a key role in immunity and self-recognition.",
    "HLA-B27 disease associations The HLA system plays a key role in immunity and self-recognition. More than one hundred HLA B27 disease associations have been made40, yet the actual role of HLA B27 in triggering an infl ammatory response is not fully understood. 5% of the UK population are HLA B27 positivemost do not have any disease. The chance of an HLA B27 positive person developing spondyloarthritis or eye disease is 1 in 4. Common associations include: Ankylosing spondylitis: 85-95% of all those with AS are HLA B27 positive. Acute anterior uveitis: 5060% are HLA B27 positive. Reactive arthritis: 6085% are HLA B27 positive. Enteric arthropathy: 5060% are HLA B27 positive. Psoriatic arthritis: 6070% are HLA B27 positive. Fig 12. 13 Progression of disease and eff ect on posture in severe ankylosing spondylitis. Reproduced from American Journal of Medicine 1976: 60; 27985 with permission from Elsevier. __OOHHCCMM__1100ee. . iinnddbb 555511 0022//0055//22001177 1199: : 0088 552 ygolotamuehR Autoimmune connective tissue diseases Included under this heading are SLE (p554), systemic sclerosis, Sjögrens syndrome (p710), idiopathic infl ammatory myopathies (myositissee following topic), mixed connective tissue disease, relapsing polychondritis, and undiff erentiated connective tissue disease and overlap syndromes. They overlap with each other, aff ect many organ systems, and often require immunosuppressive therapies (p376). Consider as a diff erential in unwell patients with multi-organ involvement, especially if no infection. Systemic sclerosis Features scleroderma (skin fi brosis), internal organ fi brosis, and microvascular abnormalities. Severe cases have a 4050% mortality at 5 years. 90% are ANA positive and 3040% have anticentromere antibodies (see BOX). Skin disease is limited or diff use. Limited involves the face, hands, and feet (formally CREST syndrome). It is associated with anticentromere antibodies in 7080%. Pulmonary hypertension is often present subclinically, and can become rapidly life-threatening, so should be looked for (: sildenafi l, bosentan). Diffuse can involve the whole body. Antitopoisomerase-1 (SCL-70) antibodies in 40% and anti-RNA polymerase in 20%. Prognosis is often poor. Control blood pressure meticulously. Perform annual echocardiogram and spirometry. Both limited and diff use have the potential for organ fi brosis: lung, cardiac, GI, and renal (p314) but this occurs later in limited sub-set. Management: Currently no cure. Immunosuppressive regimens, including IV cyclophos phamide, are used for organ involvement or progressive skin disease. Trials of antifi brotic tyrosine kinase inhibitors are ongoing. 41 Monitor blood pressure and renal function. Regular angiotensin-converting enzyme inhibitor or A2RBS risk of renal crisis (p314). Raynauds phenomenon: (see p708). Mixed connective tissue disease Combines features of systemic sclerosis, SLE, and polymyositis and the presence of High titres of anti-U1-RNP antibodies. Relapsing polychondritis Rare condition with recurrent episodes of cartilage infl ammation and destruction. Aff ects pinna (fl oppy ears), nasal septum, larynx (stridor), tracheobronchial tree (infections), and joints. Associations: Aortic valve disease, polyarthritis, and vasculitis. 30% have underlying rheumatic or autoimmune disease. Diagnosis is clinical. : Steroids, DMARDS or CPAP/tracheostomy for airway involvement. Polymyositis and dermatomyositis Rare conditions characterized by insidious onset of progressive symmetrical proximal muscle weakness and autoimmune-mediated striated muscle infl ammation (myositis), associated with myalgia ± arthralgia. Muscle weakness may also cause dysphagia, dysphonia (ie poor phonation, not dysphasia), or respiratory weakness. The myositis (esp. in dermatomyositis) may be a paraneoplastic phenomenon, commonly from lung, pancreatic, ovarian, or bowel malignancy. Screen for cancers. Dermatomyositis Myositis plus skin signs: Macular rash (shawl sign is ve if over back and shoulders). Lilac-purple (heliotrope) rash on eyelids often with oedema (fi g 12. 26, p563). Nailfold erythema (dilated capillary loops). Gottrons papules: roughened red papules over the knuckles, also seen on elbows and knees (pathognomonic if CK muscle weakness).",
    "Gottrons papules: roughened red papules over the knuckles, also seen on elbows and knees (pathognomonic if CK muscle weakness). Malignancy in 30% cases. Extra-muscular signs In both conditions include fever, arthralgia, Raynauds, interstitial lung fi brosis and myocardial involvement (myocarditis, arrhythmias). Tests Muscle enzymes (ALT, AST, LDH, CK, aldolase) in plasma; EMG shows characteristic fi brillation potentials; muscle biopsy confi rms diagnosis (and excludes mimicking conditions). magnetic resonance imaging shows muscle oedema in acute myositis. Autoantibody associations: (see BOX) anti-Mi2, anti-Jo1associated with acute onset and interstitial lung fi brosis that should be treated aggressively. Diff erential diagnoses Carcinomatous myopathy, inclusion-body myositis, muscular dystrophy, PMR, endocrine/metabolic myopathy (eg steroids), rhabdomyolysis, infection (eg HIV), drugs (penicillamine, colchicine, statins, or chloroquine). Management Start prednisolone. Immunosuppressives (p376) and cytotoxics are used early in resistant c ases. Hydroxychloroquine/topical tacrolimus for skin disease. __OOHHCCMM__1100ee. . iinnddbb 555522 0022//0055//22001177 1199: : 0088 553 ygolotamuehR Plasma autoantibodies (Abs): disease associations Always interpret in the context of clinical fi ndings: Diff erent antibodies have diff erent disease asssociations. Rheumatological: Rheumatoid factor (RhF) positive in: Sjögrens syndrome ≤100% Mixed connective tissue disease 50% Feltys syndrome ≤100% SLE ≤40% RA 70% Systemic sclerosis 30% Infection (SBE/IE; hepatitis) ≤50% Normal 210% Anticyclic citrullinated peptide Ab (anti-CCP): 5 rheumatoid arthritis (96% specifi city) Antinuclear antibody (ANA) positive by immunofl uorescence in: SLE 95% Systemic sclerosis 96% Autoimmune hepatitis 75% RA 30% Sjögrens syndrome 68% Normal 02% ANA titres are expressed according to dilutions at which antibodies can be detected, ie 1: 160 means antibodies can still be detected after the serum has been diluted 160 times. Titres of 1: 40 or 1: 80 may not be signifi cant. The pattern of staining may indicate the disease (although these are not specifi c): Homogeneous SLE Nucleolar Systemic sclerosis Speckled Mixed computed tomography disease Centromere Limited systemic sclerosis Anti-double-stranded DNA (dsDNA): SLE (60% sensitivity, but highly specifi c). Antihistone Ab: drug-induced SLE (100%). Antiphospholipid Ab (eg anti-cardiolipin Ab): antiphospholipid syndrome, SLE. Anticentromere Ab: limited systemic sclerosis. Anti-extractable nuclear antigen (ENA) antibodies (usually with ve ANA): Anti-Ro (SSA) SLE, Sjögrens syndrome, systemic sclerosis. Associated with congenital Heart block. Anti-La (SSB) Sjögrens syndrome, SLE (15%). Anti-Sm SLE (2030%). Anti-RNP SLE, mixed connective tissue disease. Anti Jo-1; Anti-myocardial infarction-2 Polymyositis, dermatomyositis. Anti-Scl70 Diff use systemic sclerosis. Gastrointestinal: (For Liver autoantibodies, see p284. ) Antimitochondrial Ab (AMA): primary biliary cholangitis (95%), autoimmune hepatitis (30%), idiopathic cirrhosis (2530%). Anti-smooth muscle Ab (SMA): autoimmune hepatitis (70%), primary biliary cholangitis (50%), idiopathic cirrhosis (2530%). Gastric parietal cell Ab: pernicious anaemia (90%), atrophic gastritis (40%), normal (10%). Intrinsic factor Ab: pernicious anaemia (50%). -gliadin Ab, antitissue transglutaminase, anti-endomysial Ab: coeliac disease. Endocrine: Thyroid peroxidase Ab: Hashimotos thyroiditis (87%), Graves (50%). Islet cell Ab (ICA), glutamic acid decarboxylase (GAD) Ab: type 1 Diabetes mellitus (75%). Renal: Glomerular basement membrane Ab (anti-GBM): Goodpastures disease (100%). Antineutrophil cytoplasmic Ab (ANCA): Cytoplasmic (cANCA), specifi c for serine proteinase-3 (PR3 ve). Granulom atosis with polyangiitis(Wegeners) (90%); also microscopic polyangiitis(30%), Coconutyarteritis nodosa (11%). Perinuclear (pANCA), specifi c for myeloperoxidase (MPO ve). Microscopic polyangiitis (45%), ChurgStrauss, pulmonary-renal vasculitides (Goodpastures). Unlike immune-complex vasculitis, in ANCA-associated vasculitis no compl ement consumption or immune complex deposition occurs (ie pauci-immune vasculitis). 42 ANCA may also be ve in UC/Crohns, sclerosing cholangitis, auto immune hepatitis, Feltys, RA, SLE, or drugs (eg antithyroid, allopurinol, ciprofl oxacin). Neurological: Acetylcholine receptor Ab: myasthenia gravis (90%)(see p512). Anti-voltage-gated potassium -channel Ab: limbic encephalitis. Anti-voltage-gated calcium 2-channel Ab: LambertEaton syndrome (see p512). Anti-aquaporin 4: neuromyelitis optica (Devics disease, p698). 5 Most centres now use anti-CCP antibodies for the initial workup of suspected RA. __OOHHCCMM__1100ee. .",
    "5 Most centres now use anti-CCP antibodies for the initial workup of suspected RA. __OOHHCCMM__1100ee. . iinnddbb 555533 0022//0055//22001177 1199: : 0088 554 ygolotamuehR Systemic lupus erythematosus (SLE) SLE is a multisystemic autoimmune disease. Autoantibodies are made against a variety of autoantigens (eg ANA) which form immune complexes. Inadequate clearance of immune complexes results in a host of immune responses which cause tissue infl ammation and damage. Environmental triggers play a part (eg EBV p405). 43 Prevalence 0. 2%. : 9: 1, typically women of child-bearing age. Commoner in African-Caribbeans, Asians, and if HLA B8, DR2, or DR3 ve. 10% of patients have a 1stor 2nd-degree relative with SLE. Clinical features See BOX. Remitting and relapsing illness of variable presentation and course. Features often non-specifi c (malaise, Fatigue, myalgia, and fever) or organ-specifi c and caused by active infl ammation or damage. Other features include lymphadenopathy, weight loss, alopecia, nail-fold infarcts, non-infective endocarditis (LibmanSacks syndrome), Raynauds (30%; see p708), stroke, and retinal exudates. Immunology 95% are ANA ve. A High anti-double-stranded DNA (dsDNA) antibody titre is highly specifi c, but only ve in 60% of cases. ENA (p553) may be ve in 2030% (anti-Ro, anti-La, anti-Sm, anti-RNP); 40% are RhF ve; antiphospholipid antibodies (anticardiolipin or lupus anticoagulant) may also be ve. SLE may be associated with other autoimmune conditions: Sjögrens (1520%), autoimmune thyroid disease (510%). Diagnosis See BOX. Monitoring activity Three best tests: 1 Anti-dsDNA antibody titres. 2 Complement: C3, C4 (denotes consumption of complement, hence C3 and C4, and C3d and C4d, their degradation products). 3 ESR. Also: blood pressure, Urine for casts or protein (lupus nephritis, below), FBC, UE, LFTs, CRP (usually normal) think of SLE whenever someone has a multisystem disorder and ESR but CRP normal. If CRP, think instead of infection, serositis, or arthritis. Skin or renal biopsies may be diagnostic. Drug-induced lupus Causes (80 drugs) include isoniazid, hydralazine (if 50mg/24h in slow acetylators), procainamide, quinidine, chlorpromazine, minocycline, phenytoin, anti-TNF agents. It is associated with antihistone antibodies in 95% of cases. Skin and lung signs prevail (renal and CNS are rarely aff ected). The disease remits if the drug is stopped. Sulfonamides or the oral contraceptive pill may worsen idiopathic SLE. Management Refer: complex cases should involve specialist SLE/nephritis clinics. General measures: High-factor sunblock. Hydroxychloroquine, unless contraindicated, reduces disease activity and improves survival. Screen for co-morbidities and medication toxicity. For skin fl ares, fi rst trial topical steroids. Maintenance: NSAIDs (unless renal disease) and hydroxychloroquine for joint and skin symptoms. Azathioprine, methotrexate, and mycophenolate as steroid-sparing agents. Belimumab (monoclonal antibody) used as an add-on therapy for autoantibody positive disease where disease activity is High. 44 (See BOX. ) Mild fl ares: (No serious organ damage. ) Hydroxychloroquine or Low-dose steroids. Moderate fl ares: (Organ involvement. ) May require DMARDs or mycophenolate. Severe fl ares: If lifeor organ-threatening, eg haemolytic anaemia, nephritis, severe pericarditis or CNS disease; urgent High-dose steroids, mycophenolate, rituximab, cyclophosphamide. MDT working vital for neuropsychiatric lupus (psychometric testing, lumbar puncture may be indicated). Lupus nephritis: (p314. ) May require more intensive immunosuppression with steroids and cyclophosphamide or mycophenolate. blood pressure control vital (e. g. angiotensin-converting enzyme inhibitor). Renal replacement therapy (p306) may be needed if disease progresses; nephritis recurs in 50% post-transplant, but is a rare cause of graft failure. 45 Prognosis: 80% survival at 15 years. 43 There is an increased long-term risk of cardiovascular disease and osteoporosis. Antiphospholipid syndrome Can be associated with SLE (2030%). Often occurs as a primary disease. Antiphospholipid antibodies (anticardiolipin lupus anticoagulant, anti- 2 glycoprotein 1) cause CLOTS: Coagulation defect (arterial/venous), Livedo reticularis (p557), Obstetric (recurrent miscarriage), Thrombocytopenia.",
    "Thrombotic tendency aff ects cerebral, renal, and other vessels. diagnosis: Persistent antiphosphlolipid antibodies with clinical features. : Anticoagulation; seek advice in pregnancy. 46 __OOHHCCMM__1100ee. . iinnddbb 555544 0022//0055//22001177 1199: : 0088 555 ygolotamuehR Systemic Lupus International Collaborating Clinics Classifi cation A favourite diff erential diagnosis, SLE mimics other illnesses, with wide variation in symptoms that may come and go unpredictably. Diagnose SLE47 in an appropriate clinical setting if ≥4 criteria (at least 1 clinical and 1 laboratory) or biopsy-proven lupus nephritis with positive ANA or anti-DNA. Clinical criteria 1 Acute cutaneous lupus: Malar rash/butterfl y. Fixed erythema, fl at or raised, over the malar eminences, tending to spare the nasolabial folds (fi g 12. 14). Occurs in up to 50%. Bullous lupus, toxic epidermal necrolysis variant of SLE, maculopapular lupus rash, photosensitive lupus rash, or subacute cutaneous lupus (non-indurated psoriasiform and/or annular polycyclic lesions that resolve without scarring). 2 Chronic cutaneous lupus: Discoid rash, erythematous raised patches with adherent keratotic scale s and follicular plugging ± atrophic scarring (fi g 12. 15). Think of it as a three-stage rash aff ecting ears, cheeks, scalp, forehead, and chest: erythemapigmented hyperkeratotic oedematous papulesatrophic depressed lesions. 3 Non scarring alopecia: (In the absence of other causes. ) 4 Oral/nasal ulcers: (In the absence of other causes. ) 5 Synovitis: (Involving two or more joints or two or more tender joints with 30 minutes of morning stiff ness. ) 6 Serositis: a) Lung (pleurisy for 1 day, or pleural eff usions, or pleural rub; b) pericardial Pain for 1 day, or pericardial eff usion, or pericardial rub, or pericarditis on ECG. 7 Urinanalysis: Presence of proteinuria (0. 5g/d ) or red cell casts. 8 Neurological features: Seizures; psychosis; mononeuritis multiplex; myelitis; peripheral or cranial neuropathy; cerebritis/acute confusional state in absence of other causes. 9 Haemolytic anaemia. 10 Leucopenia: (WCC 4. ) At least once, or lymphopenia (lymphocytes 1) at least once. 11 Thrombocytopenia: (Platelets 100. ) At least once. Laboratory criteria 1 ve ANA (ve in 95%). 2 Anti-dsDNA. 3 Anti-Smith antibodies present. 4 Antiphospholipid Abs present. 5 Low complement (C3, C4, or C50). 6 ve Direct Coombs test. Adapted from Derivation and validation of the Systemic Lupus International Collaborating Clinics classifi cation criteria for systemic lupus erythematosus. Petri M et al. , Arthritis and Rheumatism, vol 64, issue 8 (2012) 26772686. Fig 12. 14 Malar rash, with sparing of the nasolabial folds. Courtesy of David F. Fiorentino, MD, PhD; by kind permission of Skin Aging. Fig 12. 15 Discoid rash. Courtesy of Amy McMichael, MD; by kind permission of Skin Aging. __OOHHCCMM__1100ee. . iinnddbb 555555 0022//0055//22001177 1199: : 0088 556 ygolotamuehR Vasculitis The vasculitides are infl ammatory disorders of Blood vessels; commonly classifi ed using the modifi ed Chapel Hill criteria. 48 They can aff ect any organ, and presentation depends on the organs involved. It may be a primary condition or secondary to other diseases, eg SLE, RA, hepatitis B C, HIV. Categorized by size of Blood vessels aff ected. Large Giant cell arteritis, Takayasus arteritis (see p712). Medium Polyarteritis nodosa, Kawasaki disease (OHCS p646). Small ANCA-associated: microscopic polyangiitis; granulomatosis with polyangiitis (Wegeners granulomatosis); and eosinophilic granulomatosis with polyangiitis (Churg Strauss syndrome; 4060% are ANCA positive). Immune complex vasculitis: Goodpastures disease; cryoglobulinaemic vasculitis; IgA vasculitis (Henoch-Schonlein purpura). Variable vessel vasculitis Behçets (p694) and Cogans syndrome. Symptoms Diff erent vasculitides preferentially aff ect diff erent organs, causing different patterns of symptoms (see BOX Features of vasculitis), Often only overwhelming Fatigue with ESR/CRP. Consider vasculitis in any unidentifi ed multisystem disorder.",
    "Consider vasculitis in any unidentifi ed multisystem disorder. If presentation does not fi t clinically or serologically into a specifi c category consider malignancy-associated vasculitis. A severe vasculitis fl are is a medical emergency. If suspected, seek urgent help, as organ damage may occur rapidly (eg critical renal failure 24h). Tests ESR/CRP. ANCA may be ve. Creatinine if renal failure. Urine: proteinuria, haematuria, casts on microscopy. Angiography ± biopsy may be diagnostic. Management Large-vessel: steroids in most cases, may add steroid-sparing agents later. Medium/small: immunosuppression (steroids, ± another agent, eg cyclophosphamide if severe, or methotrexate/azathioprine depending on features). Giant cell arteritis (GCA) temporal arteritis Common in the elderlyconsider Takayasus if under 55yrs (p712). Associated with PMR in 50%. Symptoms: Headache, temporal artery and scalp tenderness (eg when combing hair), tongue/jaw claudication, amaurosis fugax, or sudden unliateral blindness. Extracranial symptoms: malaise, dyspnoea, weight loss, morning stiff ness, and unequal or weak pulses. 49 The risk is irreversible bilateral visual loss, which can occur suddenly if not treatedask an ophthalmologist. Tests: ESR CRP are , platelets, ALP, hemoglobin. Temporal artery biopsy within 14 days of starting steroids, or FDG-PET. Skip lesions occur, so dont be put off by a negative biopsy (up to 10%). Management: Start prednisolone 60mg/d PO immediately or IV methylprednisolone if evolving visual loss or history of amaurosis fugax. 50 Prognosis: Typically a 2-year course, then complete remission. Reduce prednisolone once symptoms have resolved and ESR; dose if symptoms recur. Main cause of death and morbidity in GCA is long-term steroid treatment so balance risks! Give proton pump inhibitor, bisphosphonate, calcium with colecalciferol, and consider aspirin. 6; 51 Polyarteritis nodosa (PAN) PAN is a necrotizing vasculitis that causes aneurysms and thrombosis in medium-sized arteries, leading to infarction in aff ected organs with severe systemic symptoms. : 2: 1. It may be associated with hepatitis B, and is rare in the UK. Symptoms: See BOX. Systemic features, skin (rash, punched out ulcers, nodules), renal (main cause of death, renal artery narrowing, glomerular ischaemia, insuffi ciency, hypertension), cardiac, GI, GU, neuro involvement. Usually spares lungs. Coronary aneurysms occur in Kawasaki disease (OHCS p646). Tests: Often WCC, mild eosino philia (in 30%), anaemia, ESR, CRP, ANCA Ωve. Renal or mesenteric angiography (see fi g 12. 16), or renal biopsy can be diagnostic. Treatment: Control blood pressure and refer. Steroids for mild cases and steroid-sparing agents if more severe. Hepatitis B should be treated (p278) after initial treatment with steroids. 52 Microscopic polyangiitis A necrotizing vasculitis aff ecting smalland mediumsized vessels. Symptoms: Rapidly progressive glomerulonephritis usually features; pulmonary haemorrhage occurs in up to 30%; other features are rare. Tests: pANCA (MPO) ve (p553). Treatment: Steroids plus eg methotrexate. For maintenance: methotrexate, rituximab, or azathioprine. Hypocomplementaemic urticarial vasculitis A lupus-like illness with urticaria and antibodies to complement (C1q). 6 Low-dose aspirin has been shown to decrease the rate of visual loss and cerebrovascular accidents in GCA but there are also confl icting reports regarding its effi cacy at preventing ischaemic events in GCA. __OOHHCCMM__1100ee. . iinnddbb 555566 0022//0055//22001177 1199: : 0088 557 ygolotamuehR Features of vasculitis The presentation of vasculitis will depend on the organs aff ected: Systemic: Fever, malaise, weight loss, arthralgia, myalgia. Skin: Purpura, ulcers, livedo reticularis (fi g 12. 17), nailbed infarcts, digital gangrene. Eyes: Episcleritis, scleritis, visual loss. ENT: Epistaxis, nasal crusting, stridor, deafness. Pulmonary: Haemoptysis and dyspnoea (due to pulmonary haemorrhage). Cardiac: Angina or myocardial infarction (due to coronary arteritis), Heart failure, and pericarditis. GI: Pain or perforation (infarcted viscus), malabsorption (chronic ischaemia). Renal: Hypertension, haematuria, proteinuria, casts, and renal failure (renal cortical infarcts; glomerulonephritis in ANCA ve vasculitis).",
    "Renal: Hypertension, haematuria, proteinuria, casts, and renal failure (renal cortical infarcts; glomerulonephritis in ANCA ve vasculitis). Neurological: Stroke, fi ts, chorea, psycho sis, confusion, impaired cognition, altered mood. Arteritis of the vasa nervorum (arterial supply to peripheral nerves) may cause mononeuritis multiplex or a sensorimotor polyneuropathy. 53 GU: Orchitistesticular Pain or tenderness. Polymyalgia rheumatica (PMR) PMR is not a true vasculitis and its pathogenesis is unknown. PMR and GCA share the same demographic characteristics and, although separate conditions, the two frequently occur together. Features: Age 50yrs; subacute onset (2 weeks) of bilateral aching, tenderness, and morning stiff ness in shoulders, hips, and proximal limb muscles ± Fatigue, fever, weight, anorexia, and depression. There may be associated mild poly arthritis, tenosynovitis, and carpal tunnel syndrome (10%). Weakness is not a feature. Investigations: CRP, ESR typically 40 (but may be normal); AlkP is in 30%. Note Creatinine kinase levels are normal (helping to distinguish from myositis/myopathies). Differential diagnoses: Recent-onset RA, polymyositis, hypothyroidism, primary muscle disease, occult malignancy or infection, osteoarthritis (especially cervical spondylosis, shoulder OA), neck lesions, bilateral subacromial impingement (OHCS p666), spinal stenosis (OHCS p676). Management: Prednisolone 15mg/d PO. Expect a dramatic response within 1 week and consider an alternative diagnosis if not. dose slowly, eg by 1mg/month (according to symptoms/ESR). Investigate apparent fl ares during withdrawal attributable to another condition? Most need steroids for ≥2yrs, so give bone protection. Addition of methotrexate may be considered, under specialist supervision, for patients at risk of relapse/prolonged therapy. NSAIDS are not eff ective. Inform patients to seek urgent review if symptoms of GCA develop. Fig 12. 17 Livedo reticularis: pinkblue Fig 12. 16 Renal angiogram showing mottling caused by capillary dilatamultiple aneurysms in PAN. tion and stasis in skin venules. Causes: Courtesy of Dr William Herring. physio l ogical, cold, or vasculitis. __OOHHCCMM__1100ee. . iinnddbb 555577 0022//0055//22001177 1199: : 0088 558 ygolotamuehR Fibromyalgia and chronic Fatigue syndrome Fibromyalgia and chronic Fatigue syndrome are part of a diff use group of overlapping syndromes, sharing similar demographic and clinical characteristics, in which chronic symptoms of Fatigue and widespread Pain feature prominently. Their existence as discrete entities is controversial, especially in the absence of clear pathology, and some fi nd such dysfunctional diagnoses frustrating. However, a correct diagnosis enables the doctor to give appropriate counselling and advise appropriate therapies, and allows the patient to begin to accept and deal with their symptoms. Fibromyalgia Fibromyalgia comprises up to 10% of new referrals to the rheumatology clinic. 54 Prevalence: 0. 54%. : 6: 1 but varies depending on which diagnostic criteria are used. Risk factors: BOX Risk factors. Female sex, middle age, Low household income, divorced, Low educational status. Associations: Other somatic syndromes such as chronic Fatigue syndrome, irritable bowel syndrome (p266), and chronic headaches syndromes (see OHCS p502). Also found in 25% of patients with RA, AS, and SLE. Features: Diagnosis depends on Pain that is chronic (3 months) and widespread (involves left and right sides, above and below the waist, and the axial skeleton). Profound Fatigue is almost universal with complaint of unrefreshing sleep and signifi cant Fatigue and Pain with small increases in physical exertion. Additional features: morning stiff ness (8090%), paraesthesiae (without underlying cause), headaches (migraine and tension), poor concentration, Low mood, and sleep disturbance (70%). Widespread and severe tender points. Investigations: All normal. Diagnosis is clinical. Over-investigation can consolidate illness behaviour; but exclude other causes of Pain and/or Fatigue (eg RA, PMR see p557, vasculitis see p556, hypothyroidism see p220, myeloma see p368).",
    "Management: Multidisciplinary with optimal results coming from full engagement of the patient who should be encouraged to remain as active as they feel able, and ideally to continue to participate in the workforce. New symptoms should be fully reviewed to exclude an alternative diagnosis. Patients should be advised that there is no one specifi c treatment that is guaranteed to work, but any of the following may help: graded exercise programmes, including both aerobic and strength-based training. Pacing of activity is vital to avoid over-exertion and consequent Pain and Fatigue. Long-term graded exercise programmes improve functional capacity. 55, 56 Relaxation, rehabilitation and physiotherapy may also help. Cognitive-behavioural therapy (CBT) aims to help patients develop coping strategies and set achievable goals. 57 Pharmacotherapy: Low-dose amitriptyline (eg 1020mg at night) has been shown to help relieve Pain and improve sleep. Pregabalin (150300mg/12h PO) can be used if amitriptyline is ineff ective. Duloxetine or an SSRI can be used for fi bromyalgia with comorbid anxiety and depression. Steroids or NSAIDS are not recommended because there is no infl ammation (if it does respond, reconsider your diagnosis! ). Chronic Fatigue syndrome (AKA myalgic encephalomyelitis) Chronic Fatigue syndrome58 is defi ned as persistent disabling Fatigue lasting 6 months, aff ecting mental and physical function, present 50% of the time, plus ≥4 of: myalgia (80%), polyarthralgia, memory, unrefreshing sleep, Fatigue after exertion 24h, persistent sore throat, tender cervical/axillary lymph nodes. Management principles are similar to fi bromyalgia and include graded exercise and CBT. No pharmacological agents have yet been proved eff ective for chronic Fatigue syndrome (see also OHCS p502). __OOHHCCMM__1100ee. . iinnddbb 555588 0022//0055//22001177 1199: : 0088 559 ygolotamuehR Risk factors: yellow fl ags Psychosocial risk factors for developing persisting chronic Pain and long-term disability have been termed yellow fl ags: 59 Belief that Pain and activity are harmful. Sickness behaviours such as extended rest. Social withdrawal. Emotional problems such as Low mood, anxiety, or stress. Problems or dissatisfaction at work. Problems with claims for compensation or time off work. Overprotective family or lack of support. Inappropriate expectations of treatment, eg Low active participation in treatment. An existential approach to diffi cult symptoms The manner in which management is discussed is almost as important as the management itself, which should focus on education of the patient and their family and on developing coping strategies. Such a diagnosis may be a relief or a disappointment to the patient. Explain that fi bromyalgia is a relapsing and remitting condition, with no easy cures, and that they will continue to have Good and Bad days. Reassure them that there is no serious underlying pathology, that their joints are not being damaged, and that no further tests are necessary, but be sympathetic to the fact that they may have been seeking a physical cause for their symptoms. We all at some stage come across a patient with diffi cult symptoms and an exasperating lack of pathology to explain them. Investigations are all normal, and medications do not seem to work. It is tempting to dismiss such patients as malingerers, but often this conclusion comes from the clinician approaching the problem from the wrong angle. The patient has symptoms that are real and disabling to them, and that will not improve without help.",
    "The patient has symptoms that are real and disabling to them, and that will not improve without help. Perhaps a more pragmatic approach is to take advice from the Danish philosopher Kierkegaard who wrote to a friend in 1835, What I really lack is to be clear in my mind what I am to do, not what I am to know The thing is to understand myself to fi nd a truth which is true for me. Listen to the patient and accept their story. Then help them to focus on what they can do to improve their situation, and to move away from dwelling on fi nding a physical answer to their symptoms. Pathogenesis of fi bromyalgia The current hypothesis is that fi bromyalgia is caused by aberrant peripheral and central Pain processing. Two key features of the condition are allodynia (Pain in response to a non-painful stimulus) and hyperaesthesia (exaggerated perception of Pain in response to a mildly painful stimulus), examined for by palpation of tender points. Research is beginning to suggest that certain antidepressants can relieve Pain and other symptoms, and especially those that have both serotonergic and noradrenergic activity (tricyclics and venlafaxine). Those acting on serotonergic receptors only are less eff ective. There is also some evidence to support the use of alternative therapies such as acupuncture and spa therapies, which have been postulated to act through similar spinal Pain-modulatory pathways. 60 Thus far, trials have involved relatively small numbers of patients or short time periods, and lack the power to draw strong conclusions. However, it is interesting to note that the CSF of patients with fi bromyalgia appears to have increased levels of substance P, while levels of noradrenaline and serotonin metabolites are decreased. All three are neurotransmitters involved in descending Pain-modulatory pathways in the spinal cord. 61, 62 Evidence from PET imaging suggests that patients with fi bromyalgia may have an abnormal central dopamine response to Pain. 63 The critical question is: is this cause or eff ect? __OOHHCCMM__1100ee. . iinnddbb 555599 0022//0055//22001177 1199: : 0088 560 ygolotamuehR Systemic conditions causing eye signs The eye is host to many diseases: the more you look, the more youll see, and the more youll enjoy, not least because the eye is as beautiful as its signs are legion. Behçets (p694. ) Systemic infl ammatory disorder, HLA B27 association. Causes a uveitis amongst other systemic manifestations. Cause unknown. Granulomatous disorders Syphilis, TB, sarcoidosis, leprosy, brucellosis, and toxoplasmosis may infl ame either the front chamber (anterior uveitis/iritis) or back chamber (posterior uveitis/choroiditis). Refer to an ophthalmologist. Systemic infl ammatory diseases May manifest as iritis in ankylosing spondylitis and reactive arthritis; uveitis in Behçets; conjunctivitis in reactive arthritis; scleritis or episcleritis in RA, vasculitis, and SLE. Scleritis in RA and granulomatosis with polyangiitis (Wegeners) may damage the eye. Refer urgently if eye Pain. GCA causes optic nerve ischaemia presenting as sudden blindness. Keratoconjunctivitis sicca A reduction in tear formation, tested by the Schirmer fi lter paper test (5mm in 5min). It causes a gritty feeling in the eyes, and a dry mouth (xerostomia from saliva production). It is found on its own (Sjögrens syndrome), or with other diseases, eg SLE, RA, sarcoidosis. : Artifi cial tears/saliva. Hypertensive retinopathy blood pressure damages retinal vessels. Hardened arteries are shiny (silver wiring; fi g 12. 18) and nip veins where they cross (AV nipping; fi g 12. 19). Narrowed arterioles may become blocked, causing localized retinal infarction, seen as cotton-wool spots. Leaks from these in severe hypertension manifest as hard exudates or macular oedema. Papilloedema (fi g 12.",
    "Leaks from these in severe hypertension manifest as hard exudates or macular oedema. Papilloedema (fi g 12. 20) or fl ame haemorrhages suggest accelerated hypertension (p138) requiring urgent treatment. Vascular occlusion Emboli passing through the retinal vasculature may cause retinal artery occlusion (global or segmental retinal pallor) or amaurosis fugax (p476). Roth spots (small retinal infarcts occur in infective endocarditis. In dermatomyositis, there is orbital oedema with retinopathy showing cotton-wool spots (micro-infarcts). Retinal vein occlusion is caused by blood pressure, age, or hyperviscosity (p372). Suspect in any acute fall in acuity. If it is the central vein, the fundus is like a stormy sunset (those angry red clouds are haemorrhages). In branch vein occlusion, changes are confi ned to a wedge of retina. Get expert help. Haematological disorders Retinal haemorrhages occur in leukaemia; commashaped conjunctival haemorrhages and retinal new vessel formation may occur in sickle-cell disease. Optic atrophy is seen in pernicious anaemia (and also MS). Metabolic disease Diabetes mellitus: p210. Hyperthyroid exophthalmos: p219. Lens opacities are seen in hypoparathyroidism. Conjunctival and corneal calcifi cation can occur in hypercalcaemia. In gout, conjunctival urate deposits may cause sore eyes. Systemic infections Septicaemia may seed to the vitreous causing endophtha lmitis. Syphilis can cause iritis ( pigmented retinopathy if congenital). Systemic fungal infections may aff ect the eye, eg in the immunocompromised or in IV drug users, requiring intra-vitreal antibiotics. AIDS and HIV CMV retinitis (pizza-pie fundusa mixture of cotton-wool spots, infi ltrates, and haemorrhages, p438) may be asymptomatic but can cause sudden visual loss. If present, it implies AIDS (CD4 count 100 106/L; p398). Cotton-wool spots on their own indicate HIV retinopathy and may occur in early disease. Kaposis sarcoma may aff ect the lids (non-tender purple nodule) or conjunctiva (red fl eshy mass). Fig 12. 18 Silver wiring. Fig 12. 19 AV nipping. Fig 12. 20 Papilloedema. Prof Jonathan Trobe. Prof Jonathan Trobe. Prof Jonathan Trobe. __OOHHCCMM__1100ee. . iinnddbb 556600 0022//0055//22001177 1199: : 0088 561 Table 12. 5 Diff erential diagnosis of a red eye Anterior Intraocular Conjunctiva Iris Pupil Cornea Treatment Appearance chamber Hypertension Acute glaucoma Both ciliary and conjunctival vessels injected. Injected Dilated, Steamy, Very shalVery High Refer. Entire eye is red. fi xed, hazy Low IV acetazolamide See OHCS p430. oval pilocarpine drops (miotic); peripheral iridotomy. Anterior uveitis Redness most marked around cornea, which Injected Small, Normal Turgid Normal Refer. (iritis) doesnt blanch on Hypertension. Usually unilateral. irregular due Steroid eye drops Causes: AS, RA, Reiters sarcoidosis, herpes to adhesions (eg 0. 5% prednisosimplex, herpes zoster, and Behçets disease. between the lone) mydriatic NB: a similar scleral appearance but without anterior lens (eg cyclopentolate papillary or anterior chamber involvement and the pupil 0. 5%). may be scleritis (eg RA, SLE, vasculitis). margin Conjunctivitis Often bilateral. Normal Normal Normal Normal Normal Most do not require Conjunctival vessels injected, greatest toward treatment. fornices, but blanching on Hypertension. Consider chloramMobile over sclera. phenicol ointment Purulent discharge. or drops. Subconjunctival Bright red sclera with white rim around Normal Normal Normal Normal Normal Looks alarming but haemorrhage limbus. Causes: blood pressure; leptospirosis; bleeding resolves spontanedisorders; trauma; snake venom; haemorously. Check blood pressure rhagic fevers. if elderly; refer if traumatic; on warfarin? Images courtesy of Prof. Jonathan Trobe. Rheumatology __OOHHCCMM__1100ee. . iinnddbb 556611 0022//0055//22001177 1199: : 0088 562 ygolotamuehR Skin manifestations of systemic diseases Erythema nodosum (fi g 12. 21) Painful, blue-red, raised lesions on shins (± thighs/ arms). Causes: sarcoidosis, drugs (sulfonamides, contraceptive pill, dapsone), streptococcal infection. Less common: IBD, BCG vaccination, leptospirosis, Mycobacterium (TB, leprosy), Yersinia, or various viruses and fungi. Cause unknown in 3050%. Erythema multiforme (See OHCS p588. )",
    "Cause unknown in 3050%. Erythema multiforme (See OHCS p588. ) (fi g 12. 22) Target lesions: symmetrical ± central blister, on palms/soles, limbs, and elsewhere. StevensJohnson syndrome (p710): a rare, s evere variant with fever and mucosal involvement (mouth, genital, and eye ulcers), associated with a hypersensitivity reaction to drugs (NSAIDS, sulfonamides, anticonvulsants, allopurinol), or infections (herpes, Mycoplasma, orf). Also seen in collagen disorders. 50% of cases are idiopathic. Get expert help in severe disease. Erythema migrans (fi g 12. 23) Presents as a small papule at the site of a tick bite which develops into a spreading large erythematous ring, with central fading. It lasts from 48h to 3 months and there may be multiple lesions in disseminated disease. Cause: the rash is pathognomonic of Lyme disease and occurs in 80% of cases (p422). Erythema marginatum Pink coalescent rings on trunk which come and go. It is seen in rheumatic fever (or rarely other causes, eg drugs). See fi g 3. 42, p143. Pyoderma gangrenosum (fi g 12. 24) Recurring nodulo-pustular ulcers, 10cm wide, with tender red/blue overhanging necrotic edge, purulent surface, and healing with cribriform scars on leg, abdomen, or face. Associations: IBD, autoimmune hepatitis, granulomatosis with polyangiitis (Wegeners), myeloma, neoplasia. . Treatment: get help. Oral steroids ± ciclosporin should be 1st-line therapy. 64 Vitiligo (fi g 12. 25) Vitellus is Latin for spotted calf: typically white patches ± hyperpigmented borders. Sunlight makes them itch. Associations: autoimmune disorders; premature ovarian failure. Treat by camoufl age cosmetics and sunscreens (± steroid creams ± dermabrasion). UK Vitiligo Society: 0800 018 2631. Specifi c diseases and their skin manifestations Crohns Perianal/vulval/oral ulcers; erythema nodosum; pyoderma gangrenosum. Dermatomyositis Gottrons papules (rough red papules on the knuckles/extensor surfaces); shawl sign; heliotrope rash on eyelids (fi g 12. 26). It may be associated with lung, bowel, ovarian, or pancreatic malignancy (p552). Diabetes mellitus Ulcers, necrobiosis lipoidica (shiny yellowish area on shin ± telangiectasia; fi g 12. 27), granuloma annulare (OHCS p586), acanthosis nigricans (pigmented, rough thickening of axillary, neck, or groin skin with warty lesions; fi g 12. 28). Coeliac disease Dermatitis herpetiformis: Itchy blisters, in groups on knees, elbows, and scalp. The itch (which can drive patients to suicide) responds to dapsone 25200mg/24h PO within 48hand this may be used as a diagnostic test. The maintenance dose may be as little as 50mg/wk. A gluten-free diet should be adhered to, but in 30% dapsone will need to be continued. SE (dose-related): haemolysis (CI: anaemia, G6PD-defi ciency), hepatitis, agranulocytosis (monitor FBC and LFTS). There is an risk of small bowel lymphoma with coeliac disease and dermatitis herpetiformisso surveillance is needed. Hyperthyroidism Pretibial myxoedema: Red oedematous swellings above lateral malleoli, progressing to thickened oedema of legs and feet, thyroid acropachy clubbing subperiosteal new bone in phalanges. Other endocrinopathies: p203. Liver disease Palmar erythema; spider naevi; gynaecomastia; decrease in pubic hair; jaundice; bruising; scratch marks. Malabsorption Dry pigmented skin, easy bruising, hair loss, leuconychia. Neoplasia Acanthosis nigricans: (See Diabetes mellitus and fi g 12. 28. ) Associated with gastric cancer. Dermatomyositis: see earlier in topic. Thrombophlebitis migrans: Successive crops of tender nodules aff ecting Blood vessels throughout the body, associated with pancreatic cancer (especially body and tail). Acquired ichthyosis: Dry scaly skin associated with lymphoma. Skin metastases: Especially melanoma, and colonic, lung, breast, laryngeal/oral, or ovarian malignancy. __OOHHCCMM__1100ee. . iinnddbb 556622 0022//0055//22001177 1199: : 0088 563 ygolotamuehR Fig 12. 21 Erythema nodosum. Fig 12. 25 Vitiligo. Compare with fi g 9. 58, p441. Fig 12. 26 Heliotrope rash. Fig 12. 22 Erythema multiforme. Courtesy of Nick Taylor, East Sussex Hospitals Trust. Fig 12. 27 Necrobiosis lipoidica.",
    "-pexy Anchoring of a structure to keep it in position. -plasty Surgical refashioning in order to regain function/cosmesis. -scopy Procedure with instrumentation for looking into the body. -stomy An artifi cial union between a conduit and the outside or another conduit. -tomy Cutting something open to the outside world. -tripsy Fragmentation of an object. angioTube or vessel lithStone appendicAppendix mastBreast choleRelating to gall/bile mesoMesentery colpVagina nephrKidney cystBladder orchidTesticle -dochDucts oophorOvary enterSmall bowel phrenDiaphragm escharDead tissue, eg from burn pyloroPyloric sphincter gastrStomach pyelRenal pelvis hepatLiver proctAnal canal hysterUterus salpingFallopian tube laparAbdomen splenSpleen abscess A cavity containing pus. Remember: if there is pus about, let it out. colic Intermittent Pain from over-contraction/obstruction of a hollow viscus. cyst Fluid-fi lled cavity lined by epi/endothelium. fi stula An abnormal connection between two epithelial surfaces. Fistulae often close spontaneously, but will not in the presence of malignant tissue, distal obstruction, foreign bodies, chronic infl ammation, and the formation of a muco-cutaneous junction (eg stoma). hernia The protrusion of a viscus/part of a viscus through a defect of the wall of its containing cavity into an abnormal position. ileus Used in this book as a term for adynamic bowel. sinus A blind-ending tract, typically lined by epithelial or granulation tissue, which opens to an epithelial surface. stent An artifi cial tube placed in a biological tube to keep it open. stoma (p582) An artifi cial union between conduits or a conduit and the outside. ulcer (p660) Interruption in the continuity of an epi/endothelial surface. volvulus (p611) Twisting of a structure around itself. Common GI sites include the sigmoid colon and caecum, and more rarely the stomach. epiUpon panWhole periAround endInside paraAlongside subBeneath megaEnlarged perGoing through transAcross __OOHHCCMM__1100ee. . iinnddbb 556655 0022//0055//22001177 1199: : 0088 566 yregruS Pre-operative care Aims To provide diagnostic and prognostic information. Ensures the patient understands the nature, aims, and expected outcome of surgery. To allay anxiety and Pain: Ensure that the right patient gets the right surgery. Have the symptoms and signs changed? If so, inform the surgeon. Assess/balance risks of anaesthesia, and maximize fi tness. Comorbidities? Drugs? Smoker? Optimizing oxygenation before major surgery improves outcome. Obtain informed consent (p568). Check proposed anaesthesia/analgesia with anaesthetist. Family history May be relevant, eg in malignant hyperpyrexia (p572); dystrophia myotonica (p510); porphyria; cholinesterase problems; sickle-cell disease. Drugs Any drug/plaster/antiseptic allergies? Inform the anaesthetist about all drugs even if over-the-counter. Steroids: see p590; Diabetes: see p588. Antibiotics: Tetracycline and neomycin may neuromuscular blockade. Anticoagulants: Tell the surgeon. Avoid epidural, spinal, and regional blocks. Aspirin should probably be continued unless there is a major risk of bleeding. Discuss stopping clopidogrel therapy with the cardiologists/neurologists. See p590. Anticonvulsants: Give as usual pre-op. Post-op, give drugs IV (or by NGT) until able to take orally. Valproate: give usual dose IV. Phenytoin: give IV slowly (50mg/min, on cardiac monitor). IM phenytoin absorption is unreliable. -blockers: Continue up to and including the day of surgery as this precludes a labile cardiovascular response. Contraceptive pill: See BNF. Stop 4wks before major/leg surgery; ensure alternative contraception is used. Restart 2wks after surgery, provided patient is mobile. Digoxin: Continue up to and including morning of surgery. Check for toxicity (ECG; plasma level); do plasma potassium and Ca2 (suxamethonium can potassium and lead to ventricular arrhythmias in the fully digitalized). Diuretics: Beware hypokalaemia, dehydration. Do UE (and bicarbonate). Eye-dr o ps: -blockers get systemically absorbed. HRT: As with contraceptive pill there may be an increased risk of DVT/physical examination. Levodopa: Possible arrhythmias when patient under GA. Lithium: Get expert help; may potentiate neuromuscular blockade and cause arrhythmias. See OHCS p349.",
    "See OHCS p349. MAOIS: Get expert help as interactions may cause hypotensive/hypertensive crises. Thyroid medication: see p600. Tricyclics: These enhance adrenaline (epinephrine) and arrhythmias. Preparation Starve patient; NBM ≥2h pre-op for clear fl uids and ≥6h for solids. 1 Is any bowel or skin preparation needed, or prophylactic antibiotics (p570)? Start DVT prophylaxis as indicated, eg graduated compression stockings (CI in physical examinationripheral arterial disease); LMWH (p350): eg moderate risk, 20mg 2h pre-op then 20mg/24h; High risk (eg orthopaedic surgery), 40mg 12h pre-op then 40mg/24h; or heparin 5000U SC 2h pre-op, then every 812h SC for 7d or until ambulant. Ensure necessary premedications (p572), regular medications, analgesia, antiemetics, antibiotics are all prescribed as appropriate. Confi rm NBM. Book any pre-, intra-, or post-operative x-rays or frozen sections. Book post-operative physiotherapy. If needed, site IV cannula, catheterize (p762), and/or insert a Ryles tube (p759). Meta-analyses have shown no benefi t to patients from mechanical bowel cleansing before colonic surgerythis is no longer considered Good practice. There is also no evidence for the use of enemas prior to rectal surgery. __OOHHCCMM__1100ee. . iinnddbb 556666 0022//0055//22001177 1199: : 0088 567 yregruS Pre-operative history, examination, and tests It is the anaesthetists responsibility to assess suitability for anaesthesia. The ward doctor assists with a Good history and examination, should anticipate necessary tests, and can also reassure and inform the patient. The surgical team should consent the patient. The World Health Organization Surgical Safety Checklist should be completed for every patient undergoing a surgical procedure, ensuring pre-operative preparation, intra-operative monitoring, and post-operative review. History Assess past history of: MI1, Diabetes, asthma, hypertension, rheumatic fever, epilepsy, jaundice. Existing illnesses, drugs, and allergies? Be alert to chronic lung disease, blood pressure, arrhyt hmias, and murmurs. Assess any specifi c risks, eg is the patient pregnant? Is the neck/jaw immobile and teeth stable (intubation risk)? Has there been previous anaesthesia? Were there any complications (eg nausea, DVT)? Examination Assess cardiorespiratory system, exercise tolerance. Is the neck unstable (eg arthritis complicating intubation)? Is DVT/physical examination prophy laxis needed (p578)? For unilateral surgery, mark the correct arm/leg/Kidney (surgeon). Tests Be guided by the history and examination and local/NICE protocols. UE, FBC, and fi nger-prick Blood glucose in most patients. If hemoglobin 100g/L tell anaesthetist. Investigate/treat as appropriate. UE are particularly important if the patient is starved, diabetic, on diuretics, a burns patient, has hepatic or renal disease, has an ileus, or is parenterally fed. Crossmatch: Blood type is identifi ed and units are allocated to the patient. Group and save (GS): Blood type is identifi ed and held, pending crossmatch (if required). Contact your lab to discuss requirementsthis decreases wastage and allows increased effi ciency of Blood stocks. Specifi c Blood tests: LFT in jaundice, malignancy, or alcohol abuse. Amylase in acute abdominal Pain. Blood glucose if diabetic (p588). Drug levels as appropriate (eg digoxin, lithium). Clotting studies in Liver or renal disease, DIC (p352), massive Blood loss, or if on valproate, warfarin, or heparin. HIV, HBsAg in High-risk patients, after counselling. Sickle test in those from Africa, West Indies, or Mediterraneanand if origins are in malarial areas (including most of India). Thyroid function tests in those with thyroid disease. CXR if known cardiorespiratory disease, pathology, or symptoms or 65yrs old. Remember to check the fi lm prior to surgery. ECG if 55yrs old or poor exercise tolerance, or history of myocardial ischaemia, hypertension, rheumatic fever, or other Heart disease. Echocardiogram may be performed if there is a suspicion of poor LV function. Pulmonary function tests in known pulmonary disease/obesity.",
    "Echocardiogram may be performed if there is a suspicion of poor LV function. Pulmonary function tests in known pulmonary disease/obesity. Lateral cervical spine X-ray (fl exion and extension views) if history of rheumatoid arthritis/ankylosing spondylitis/Downs syndrome, to warn of diffi cult intubations. MRSA screen: Screen and decolonize nasal carriers according to local policy (eg nasal mupirocin ointment). Colonization is not a cont ra indication to surgery. Place patients last on the list to minimize transmission to others and cover with appropriate antibiotic prophylaxis, eg vancomycin or teicoplanin. Consider and document major Blood-borne virus risk (HIV/HBV/HCV) according to local policies. American Society of Anesthesiologists (ASA) classifi cation Class I Normally healthy patient. Class II Mild systemic disease. Class III Severe systemic disease that limits activity but is not incapacitating. Class IV Incapacitating systemic disease which poses a constant threat to life. Class V Moribund: not expected to survive 24h even with operation. You will see a space for an ASA number on most anaesthetic charts. It is a health. index at the time of surgery. The suffi x E is used in emergencies, eg ASA 2E. 1 If within the last 6 months, the perioperative risk of re-infarction (up to 40%) makes most elective surgery too risky. ECHO, and stress testing ( exercise ECG or MUGA scan, p741) should be done. __OOHHCCMM__1100ee. . iinnddbb 556677 0022//0055//22001177 1199: : 0088 568 yregruS Consent In which of the following situations would you seek informed written consent from a patient? 1 Feeling for a pulse. 2 Taking Blood. 3 Inserting a central line. 4 Removing a section of small bowel during a laparotomy for division of adhesions. 5 Orchidectomy after a failed operation for testicular torsion. English law states that any intervention or treatment needs consentie all of the aboveyet, for diff erent reasons. In fact, written consent itself is not required by law, but it does constitute Good medical practice in the best interests of the patient and practitioner. Sometimes actions and words can imply valid consent, eg by simply entering into conversation or holding out an arm. If the consequences are not clear and the patient has capacity to give consent, you should seek informed written consent as a record of your conversation. For consent to be valid It can be given any time before the intervention/treatment is initiated. Earlier is better as this will give the patient time to think about the risks, benefi ts, and alternativeshe or she may even bring forward questions on issues that you had not considered relevant. Think of consent as an ongoing process throughout the patients time with you, not just the moment of signing the form. The proposed treatment or test must be clearly understood by the patient, taking into account the benefi ts, risks (including complication rates if known), additional procedures, alternative courses of action, and their consequences. It must be given voluntarily. This can be diffi cult to evaluateeg when live organ donation is being consideredsee BOX Special circumstances for consent for other diffi cult situations. The doctor providing treatment or undertaking the test needs to ensure that the patient has given valid consent. The act of seeking consent is ultimately the responsibility of the doctor looking after the patient, though the task may be delegated to another health professional, as long as they are suitably trained and qualifi ed. Capacity relates to the ability to 1 understand, 2 retain, and 3 weigh up relevant information and 4 communicate the decision.",
    "Alfred, Lord Tennyson from The Charge of the Light Brigade, 1854. The rights of a patient are something of an antithesis to this military macabre of Tennyson, and it is our responsibility to respect the legal and ethical rights of those we treat. We do this not only for the sake of the individual, but also for the sake of an enduring trust between the patient and doctor, remembering that it is the patients right to refuse treatment (if a fully competent adult) even when this may result in the death of the patient, or even the death of an unborn child, whatever the stage of pregnancy. The only exceptions apply to treatment of mental health disorders (see eg in England and Wales the Mental Health Act 2007). 2 If in any doubt, turn to: your senior/consultant; your employing organization; your legal defence organization; your national medical association; your local research ethics committee. __OOHHCCMM__1100ee. . iinnddbb 556699 0022//0055//22001177 1199: : 0088 570 yregruS Prophylactic antibiotics in surgery Prophylactic antibiotics are given to counter the risk of wound infection (see table 13. 1), which occurs in 20% of elective GI surgery (up to 60% in emergency surgery). Antibiotics are also given if infection elsewhere, although unlikely, would have severe consequences (eg when prostheses are involved). A single dose given before surgery has been shown to be just as Good as more prolonged regimens in biliary and colorectal surgery. Additional doses may be given if High-risk/prolonged procedures, or if major Blood loss. Wound infections are not necessarily trivial since sepsis may lead to haemorrhage, wound dehiscence, and initiate a fatal chain of events, so take measures to minimize the risk of wound infection: Time administration correctly (eg IV prophylaxis should be given 30min prior to surgery to maximize skin concentration; metronidazole PR is given 2h before). Use antibiotics which will kill anaerobes and coliforms. Consider use of peri-operative supplemental oxygen. This is a practical method of reducing the incidence of surgical wound infections. Practise strictly sterile surgical technique. (Ask for a hand with scrubbing up if you are not suretheatre staff will be more than pleased to help! ) Antibiotic regimens Adhere to local guidelines. BNF examples include: Appendicectomy; colorectal resections and open biliary surgery: A single dose of IV piperacillin/tazobactam 4. 5g/8h or gentamicin 1. 5mg/kg metronidazole 500mg or co-amoxiclav 1. 2g alone. Oesophageal or gastric surgery: 1 dose of IV gentamicin or piperacillin/tazobactam or co-amoxiclav (doses as for appendicectomy). Vascular surgery: 1 dose of IV piperacillin/tazobactam or fl ucloxacillin 12g gentamicin. Add metronidazole if risk of anaerobes (eg amputations, gangrene, or Diabetes). MRSA: For High-risk patients add teicoplanin or vancomycin to the above-listed regimens. Table 13. 1 Classifi cation of surgical procedures and wound infection risk Category Description Infection risk Clean Incising uninfected skin without opening a viscus 2% Clean-contaminated Intra-operative breach of a viscus (but not colon) 810% Contaminated Breach of a viscus spillage or opening of colon 1220% Dirty The site is already contaminated with pus or 25% faeces, or from exogenous contagion, eg trauma Data from MRCS Core Modules: Essential Revision Notes, S. Andrews, Pastest. __OOHHCCMM__1100ee. . iinnddbb 557700 0022//0055//22001177 1199: : 0088 571 yregruS Sutures Sutures are central to the art of surgery. No single suture fi ts the bill for every occasion, and so suture selection (including size) depends on the job in hand (see tables 13. 2, 13. 3). In their broadest sense they are absorbable or non-absorbable, synthetic or natural, and their structure may be divided into monofi lament, twisted, or braided.",
    "The aim is to dampen Pain signals before they arrive. In children or anxious adults, local anaesthetic cream may be used on a few sites before inserting an IVI (the anaesthetist may prefer to site the cannula themselves! ). Anti-emetics: Post-operative nausea and Vomiting is experienced by 25% of all patients. 5HT3 antagonists (eg ondansetron 4mg IV/IM) are the most eff ective agents; others, eg metoclopramide 10mg/8h IV/IM/PO, are also usedsee p251. Antacids: Ranitidine 50mg IV or omeprazole 40mg PO/IV if aspiration risk. Antisialogues: Glycopyrronium (200400mcg in adults, 48mcg/kg in children; given IV/IM 3060min before induction) is sometimes used to decrease secretions that may cause respiratory obstruction in smaller airways. Antibiotics: See p570. Side-eff ects of anaesthetic agents Hyoscine, atropine: Anticholinergic, tachycardia, urinary retention, glaucoma, sedation (especially in the elderly). Opioids: Respiratory depression, cough refl ex, nausea and Vomiting, constipation. Thiopental: (Induction agent. ) Laryngospasm. Propofol: (Induction agent. ) Respiratory/cardiac depression, Pain on injection. Volatile agents, eg isofl urane: Nausea and Vomiting, cardiac depression, respiratory depression, vasodilation, hepatotoxicity (see BNF). The complications of anaesthesia are due to loss of: Pain sensation: Urinary retention, Hypertension necrosis, local nerve injuries (eg radial nerve palsy from arm hanging over the table edge). Consciousness: Cannot communicate wrong leg/Kidney. NB: in some patients (eg 0. 15%) retained consciousness is the problem. Awareness under GA sounds like a contradiction of terms, but remember that anaesthesia is a process rather than an event. Such awareness can lead to ill-defi ned, delayed neuroses and post-traumatic stress disorder (OHCS p353). Muscle power: Corneal abrasion ( tape the eyes closed), no respiration, no cough (leads to pneumonia and atelectasispartial lung collapse causing shunting ± impaired gas exchange: it starts minutes after induction, and may be related to the use of 100% O2, supine position, surgery, age, and to loss of power). Local/regional anaesthesia If unfi t/unwilling to undergo general anaesthesia, local nerve blocks (eg brachial plexus) or spinal blocks (contraindication: anticoagulation, local infection) using long-acting local anaesthetics such as bupivacaine may be indicated. See table 13. 4 for doses and toxicity eff ects. Drugs complicating anaesthesia Inform anaesthetist. See p566 for lists of specifi c drugs, and actions to take. Malignant hyperpyrexia This is a rare complication, precipitated by any volatile agent, eg halothane, or suxamethonium. It exhibits autosomal dominant inheritance. There is a rapid rise in temperature (1°C every 30min); masseter spasm may be an early sign. Complications include hypoxaemia, hypercarbia, hyperkalaemia, metabolic acidosis, and arrhythmias. Get expert help immediately. Prompt treatment with dantrolene3 (skeletal muscle relaxant), active cooling and ITU care can reduce mortality signifi cantly. 3 Give 1mg/kg every 5min IVup to 10mg/kg in total (OHCS p628). __OOHHCCMM__1100ee. . iinnddbb 557722 0022//0055//22001177 1199: : 0088 573 yregruS Principles and practical conduct of anaesthesia Hypnosis Analgesia Muscle relaxation Fig 13. 4 Principles of anaesthesia. The conduct of anaesthesia (fi g 13. 4) typically involves: Induction: Either intravenous (eg propofol 1. 52. 5mg/kg IV at a rate of 2040mg every 10s; thiopental is an alternative) or, if airway obstruction or diffi cult IV before mealscess, gaseous (eg sevofl urane or nitrous oxide, mixed in O2). Airway control: Either using a facemask, an oropharyngeal (Guedel) airway or by intubation. The latter usually requires muscle relaxation with a depolarizing/ non-depolarizing neuromuscular blocker (OHCS p622). Maintenance of anaesthesia: Either a volatile agent added to NO/O mixture, 2 2 or High-dose opiates with mechanical ventilation, or IV infusion anaesthesia (eg propofol 412mg/kg/h IVI). Recovery: Change inspired gases to 100% oxygen only, then discontinue any anaesthetic infusions and reverse muscle paralysis.",
    "Recovery: Change inspired gases to 100% oxygen only, then discontinue any anaesthetic infusions and reverse muscle paralysis. Extubate once spontaneously breathing, place patient in recovery position, and give oxygen by facemask. For further details, see the Anaesthesia chapter in OHCS (p612). Local anaesthetic toxicity and maximum doses Anaesthetists are masters of the drug dose by weight! It is important to remember the maximum doses for local anaesthetics, not least because we use them so frequently, but because the eff ects of overdose can be lethal. Handy to remember (though it can be worked out with a pen, paper, and SI units) is that a 1% concentration is equivalent to 10mg/mL. Local anaesthetics are also basic, and so do not work well in acidic environments, eg abscesses. Table 13. 4 Example of maximum doses for local anaesthetic Lidocaine concn Approx. allowable Approx. allowable volume % concn (magnesium/mL) volume (mL/kg) for 70kg adult (mL) 0. 25% 2. 5 1. 12 ≤80 0. 5% 5 0. 56 ≤40 1% 10 0. 28 ≤20 2% 20 0. 14 ≤10 Local anaesthetic toxicity starts with peri-oral tingling and paraesthesiae, progressing to drowsiness, seizures, coma, and cardiorespiratory arrest. If suspected (the patient feels funny and develops early signs) then stop administration immediately and commence ABC resuscitation as required. Treatment is with lipid emulsion. Find out where this is stored in your hospital. __OOHHCCMM__1100ee. . iinnddbb 557733 0022//0055//22001177 1199: : 0088 574 yregruS The control of Pain Humans are the most exquisite devices ever made for experiencing Pain: the rich er our inner lives, the greater the varieties of Pain there are for ultrasound to feel, and the more resources we have for dealing with Pain. If we can connect with patients in ner lives we may make a real diff erence. Never forget how painful Pain is, nor how fear magnifi es Pain. Try not to let these sensations, so often interposed between your patient and recovery, be invisible to you as he or she bravely puts up with them. Approach to management (fi g 13. 5 and p532. ) Review and chart each Pain carefully and individually. Identify and treat the underlying pathology wherever possible. Give regular doses rather than on an as-required basis. Choose the best route: PO, PR, IM, epidural, SC, inhalation, or IV. Explanation and reassurance contribute greatly to analgesia. Allow the patient to be in charge. This promotes wellbeing, and does not lead to overuse. Patient-controlled continuous IV morphine delivery systems are useful. Liaise with the Acute Pain Service, if possible. Non-narcotic (simple) analgesia Paracetamol 0. 51. 0g/4h PO (up to 4g daily; 15mg/ kg/4h IV over 15min in children 50kg; up to 60mg/kg/d). Caution in Liver impairment. NSAIDS, eg ibuprofen 400mg/8h PO (see BNFC for dosing in children) are Good for musculoskeletal Pain and renal or biliary colic. CI: peptic ulcer, clotting disorders, anticoagulants. Cautions: asthma, renal or hepatic impairment, Heart failure, IHD, pregnancy, and the elderly. Aspirin is contraindicated in children due to the risk of Reyes syndrome (OHCS p652). Opioid drugs for severe Pain Morphine (eg 1015mg/24h IV/IM) or diamor phine (510mg/24h PO, SC, or slow IV, but you may need much more) are best. NB: these are controlled drugs. For palliative care, see p532. Alternative delivery routes include transdermal (once baseline requirements are established) or sublingual. Side-effects of opioids: These include nausea (so give with an anti-emetic, p251), respiratory depression, constipation, cough suppression, urinary retention, blood pressure, and sedation (do not use in hepatic failure or head injury). Dependency is rarely a problem.",
    "Dependency is rarely a problem. Naloxone (eg 100200mcg IV, followed by 100mcg increments, eg every 2min until responsive) may be needed to reverse the eff ects of excess opioids (p842). Epidural analgesia Opioids and anaesthetics are given into the epidural space by infusion or as boluses. Ask the advice of the Pain Service. SES are thought to be less, as the drug is more localized: watch for respiratory depression and local anaestheticinduced autonomic blockade (blood pressure). Adjuvant treatments Eg radiotherapy for bone cancer Pain; anticonvulsants, antidepressants, gabapentin or steroids for neuropathic Pain, antispasmodics, eg hyoscine butylbromide4 (Buscopan 1020mg/8h PO/IM/IV) for intestinal or renal tract colic. If brief Pain relief is needed (eg for changing dressings or exploring wounds), try inhaled nitrous oxide (with 50% O2as Entonox) with an on-demand valve. Transcutaneous electrical nerve stimulation (TENS), local heat, local or regional anaesthesia, and neurosurgical procedures (eg excision of neuroma) may be tried but can prove disappointing. Treat conditions that exacerbate Pain (eg constipation, depression, anxiety). 4 Not to be confused with hyoscine hydrobromide; used for drying secretions and in motion sickness. __OOHHCCMM__1100ee. . iinnddbb 557744 0022//0055//22001177 1199: : 0088 575 yregruS WHOs Pain relief ladder Freedom from Pain Opioid for moderate 3 to severe Pain, / non-opioid / adjuvant Pain persisting or increasing 2 O / p i o n i o d n f - o o r p m io i i l d d to moderate Pain, / adjuvant 1 Pain persisting or increasing Non-opioid, / adjuvant Fig 13. 5 World Health Organization Pain ladder. __OOHHCCMM__1100ee. . iinnddbb 557755 0022//0055//22001177 1199: : 0088 576 yregruS General post-operative complications Pyrexia Mild pyrexia in the 1st 48h is often from atelectasis (needs prompt physio, not antibiotics), tissue damage/necrosis, or even from Blood transf usions, but still have a Low threshold for infection screen. Consider evidence for peritonism, chest, urinary, wound, or cannula site infections, as well as possible endocarditis, meningism, or DVT (also causes °T). Send Blood for FBC, UE, CRP, and cultures (±LFT). Dipstick the Urine. Consider MSU, CXR, and abdominal ultrasound/computed tomography depending on clinical fi ndings. Confusion may manifest as agitation, disorientation, and attempts to leave hospital, especially at night. Gently reassure the patient in well-lit surroundings. See p484 for a full work-up. Common causes are: hypoxia (pneumonia, atelectasis, LVF, physical examination) infection (see earlier) drugs (opiates, sedatives, and many others) alcohol withdrawal (p280) urinary retention Liver/renal failure. myocardial infarction or stroke Occasionally, sedation is necessary to examine the patient; consider lorazepam 1mg PO/IM (antidote: fl umazenil) or haloperidol 0. 52mg IM. Reassure relatives that postop confusion is common (seen in up to 40%) and reversible. Dyspnoea or hypoxia Any previous lung disease? Sit patient up and give O2, m onitor peripheral O2 sats by pulse oximetry (p162). Examine for evidence of: pneum onia, pulmonary collapse, or aspiration LVF (myocardial infarction; fl uid overload) pulmonary embolism (p190) pneumothorax (p190; due to CVP line, intercostal block, or mechanical ventilation). Tests: FBC; ABG; CXR; ECG. Manage according to fi ndings. blood pressure If severe, tilt bed head-down and give O2. Check pulse and blood pressure yourself; compare it with pre-op values. Post-op blood pressure is often from hypovolaemia resulting from inadequate fl uid input, so check fl uid chart and replace losses. Monitor Urine output (may need catheterization). A CVP line can help monitor fl uid resuscitation (normal is 05cmH2O relative to sternal angle). Hypovolaemia may also be caused by haemorrhage so review wounds, drains, and abdomen. If unstable, return to theatre for haemostasis. Beware cardiogenic and neurogenic causes and look for evidence of myocardial infarction or physical examination.",
    "Beware cardiogenic and neurogenic causes and look for evidence of myocardial infarction or physical examination. Consider sepsis and anaphylaxis. Management: p790. blood pressure may be from Pain, urinary retention, idiopathic hypertension (eg missed medication), or inotropic drugs. Oral cardiac medications (including antihypertensives) should be continued throughout the perioperative period even if NBM. Treat the cause, consider increasing the regular medication, or if not absorbing orally try 50mg labetalol IV over 1min (see p140). Urine output (oliguria) Aim for output of 30mL/h in adults (or 0. 5mL/kg/h). Anuria may refl ect a blocked or malsited catheter (see p763) rather than acute kidney injury. Flush or replace catheter. Oliguria is usually due to too little replacement of lost fl uid. Treat by increasing fl uid input. Acute Kidney injury may follow shock, drugs, transfusion, pancreatitis, or trauma (see p300 for classifi cation and management of acute kidney injury). Review fl uid chart and examine for signs of volume depletion. Urinary retention is also common, so examine for a palpable bladder. Establish normovolaemia (a CVP line may help); you may need 1L/h IVI for 23h. A fl uid challenge of 250500mL over 30min may also help. Catheterize bladder (for accurate monitoring)see p762; check UE. If intrinsic renal failure is suspected, stop nephrotoxic drugs (eg NSAIDS, angiotensin-converting enzyme inhibitor) and refer to a nephrologist early. Nausea/vomitingAny mechanical obstruction, ileus, or emetic drugs (opiates, dig - oxin, anaesthetics)? Consider AXR, NGT, and an anti-emetic (not metoclopramide because of its prokinetic property). See p251 for choice of anti-emetics. sodium Pre-op level? Excess IV fl uids may exacerbate the situation. Correct slowly (p672). SIADH (p673) can be precipitated by Pain, nausea, opioids, and chest infection. __OOHHCCMM__1100ee. . iinnddbb 557766 0022//0055//22001177 1199: : 0088 577 yregruS Post-operative bleeding Primary haemorrhage: Continuous bleeding, starting during surgery. Replace Blood loss. If severe, return to theatre for adequate haemostasis. Treat shock vigorously (p790804). Reactive haemorrhage: Haemostasis appears secure until blood pressure rises and bleeding starts. Replace Blood and re-explore wound. Secondary haemorrhage (caused by infection) occurs 12wks post-op. Talking about post-op complications When asked to give your thoughts on the complications of an operationmaybe with an examiner or a patienta Good starting point is to divide them up accordingly (and for each of the following stratify as immediate, early, and late): From the anaesthetic: (p572. ) Eg respiratory depression from induction agents. From surgery in general: (p576. ) Eg wound infection, haemorrhage, neurovascular damage, DVT/physical examination. From the specifi c procedure: Eg saphenous nerve damage in stripping of the long varicose vein. Tailor the discussion towards the individual who, eg if an arteriopath, may have a signifi cant risk of cardiac ischaemia during hypotensive episodes while under the anaesthetic. For some other post-op complications, see: Pain (p574) DVT (p578) Pulmonary embolus (p190; massive, p818) Wound dehiscence (p580) Complications in post-gastric surgery (p622) Other complications of specifi c operations (p580). __OOHHCCMM__1100ee. . iinnddbb 557777 0022//0055//22001177 1199: : 0088 578 yregruS Deep vein thrombosis (DVT) DVTS occur in 2550% of surgical patients, and many non-surgical patients. All hospital inpatients should be assessed for DVT/physical examination risk and off ered prophylaxis if appropriate. 65% of below-knee DVTs are asymptomatic; these rarely embolize to the lung. Risk factors Age, pregnancy, synthetic oestrogen, trauma, surgery (especially pelvic/orthopaedic), past DVT, cancer, obesity, immobility, thrombophilia (p374). Signs Calf warmth/tenderness/Edema/erythema. Mild fever. Pitting oedema. Cellulitis; ruptured Bakers cyst. Both may coexist with a DVT. Tests Calculate Wells score (see table 13. 5) before ordering D-dimer. D-dimer is sensitive but not specifi c for DVT (also in infection, pregnancy, malignancy, and post-op). Wells score: ≤1 point DVT unlikely: Perform D-dimer.",
    "Wells score: ≤1 point DVT unlikely: Perform D-dimer. If negative, DVT excluded. If positive, proceed to USS (if USS negative, DVT excluded; if positive, treat as DVT). ≥2 points DVT likely: Do D-dimer and USS. If both negative, DVT excluded. If USS positive, treat as DVT. If D-dimer positive and USS negative, repeat USS in 1 week. Do thrombophilia tests (p374) before commencing anticoagulant therapy if there are no predisposing factors, in recurrent DVT, or if DVT in unusual site. Look for underlying malignancy: Urine dip; FBC, LFT, Ca2; CXR ± computed tomography abdomen/pelvis (and mammography in ) if 40yrs. Prevention Stop the oral contraceptive pill 4wks pre-op. Mobilize early. LMWH eg enoxaparin 20mg/24h SC, to 40mg for High-risk patients (p375) (caution if estimated glomerular filtration rate less than 30mL/min/1. 73m2). Graduated compression stockings (thromboembolic deterrent (TED) stockings; CI: ischaemia) and intermittent pneumatic compression devices risk of DVT by 70% in surgical patients. Fondaparinux (a factor Xa inhibitor) risk of DVT over LMWH in eg major orthopaedic surgery without risk of bleeding. Treatment LMWH (eg enoxaparin 1. 5mg/kg/24h SC) or fondaparinux. LMWH is superior to unfractionated heparin (used in renal failure or if risk of bleeding; dose guided by APTT, p350). Cancer patients should receive LMWH for 6 months (then review). In others, start warfarin simultaneously with LMWH (warfarin is prothrombotic for the fi rst 48h). Stop heparin when INR is 23; treat for 3 months in most (longer in some casessee p351). Direct oral anticoagulants (DOACS p190), eg dabigatan, apixaban, rivoraxaban, are newer alternatives licensed for the treatment of DVT with benefi ts relating to simpler dosing and monitoring and bleeding risk. Inferior vena caval fi lters may be used in active bleeding, or when anticoagulants fail, to minimize risk of physical examination. Post-phlebitic change (Pain, Edema, and skin changes) can be seen in 1030% graduated compression stockings may help. Pretest clinical probability scoring for DVT: the Wells score In patients with symptoms in both legs, the more symptomatic leg is used. Table 13. 5 Wells score Clinical features Score Active cancer (treatment within last 6 months or palliative) 1 point Paralysis, paresis, or recent plaster immobilization of leg 1 point Recently bedridden for 3d or majory surgery in last 12wks 1 point Local tenderness along distribution of deep venous system 1 point Entire leg swollen 1 point Calf Edema 3cm compared with asymptomatic leg (measured 1 point 10cm below tibial tuberosity) Pitting oedema (greater in the symptomatic leg) 1 point Collateral superfi cial veins (non-varicose) 1 point Previously documented DVT 1 point Alternative diagnosis at least as likely as DVT Ω2 points Reprinted from the Lancet, 350, Wells PS et al. , Value of assessment of pretest probability of deep-vein thrombosis in clinical management, 17958, Copyright 1997, with permission from Elsevier. __OOHHCCMM__1100ee. . iinnddbb 557788 0022//0055//22001177 1199: : 0088 579 yregruS Swollen legs Bilateral oedema implies systemic disease with venous Hypertension (eg right Heart failure) or intravascular oncotic Hypertension (any cause of albumin, so test the Urine for Protein). It is dependent (distributed by gravity), which is why legs are aff ected early, but severe oedema extends above the legs. In the bed-bound, fl uid moves to the new dependent area, causing a sacral peripheral arterial disease. The exception is the local increase in venous Hypertension occurring in IVC obstruction: the Edema neither extends above the legs nor redistributes. Causes: Right Heart failure (p134). Albumin (p686, eg renal or Liver failure). Venous insuffi ciency: acute, eg prolonged sitting, or chronic, with haemosiderin-pigmented, itchy, eczematous skin ± ulcers. Vaso dilators, eg nifedipine, amlodipine. Pelvic mass (p57, p604).",
    "Vaso dilators, eg nifedipine, amlodipine. Pelvic mass (p57, p604). Pregnancyif blood pressure proteinuria, diagnose pre-eclampsia (OHCS p48): fi nd an obstetrician urgently. In all the above, both legs need not be aff ected to the same extent. Unilateral oedema Pain ± redness implies DVT or infl ammation, eg cellulitis or insect bites (any blisters? ). Bone or muscle may be to blame, eg tumours; necrotizing fasciitis (p660); trauma (check for sensation, pulses, and severe Pain esp. on passive movement: a compartment syndrome with ischaemic necrosis needs prompt fasciotomy). Impaired mobility suggests trauma, arthritis, or a Bakers cyst (p694). Non-pitting oedema is oedema you cannot indent: see p35. Nine questions to ask 1 Is itb oth legs? 2 Is she pregnant? 3 Is she mobile? 4 Any trauma? 5 Any pitting (p35)? 6 Past diseases/on drugs? 7 Any Pain? 8 Any skin changes? 9 Any oedema elsewhere? Tests Look for proteinuria (hypoalbuminaemia nephrotic syndrome). CCF? Treatment of leg oedema Treat the cause. Diuretics for all is not an answer. Elevating legs for dependent oedema (ankles higher than hipsdo not just use footstools); raise the foot of the bed. Graduated support stockings may help (CI: ischaemia). Travel and DVT Long-distance travel appears to be a risk factor for the development of venous thromboembolism (VTE). Data suggests this is not confi ned to air travel, increases with the duration of travel, and results in clinical thrombosis more often in travellers with pre-existing risk factors. Dehydration, immobilization, decreased oxygen tension, and prolonged sitting have all been suggested as contributory factors. The risk of developing a DVT from a long-distance fl ight has been estimated at 1 in 10 000 to 1 in 40 000 for the general population. The incidence of DVT in High-risk groups has been shown to be 46% for fl ights 10h. Travellers with ≥1 risk factor should consider compression stockings. For High-risk individuals consider a single dose of prophylactic LMWH for fl ights 6h. There is risk of physical examination associated with long-distance air travel. Compression stockings may risk of DVT. There is no evidence to support the use of prophylactic aspirin. Risk reduction measures: leg exercises, increased Water intake, and refraining from alcohol or caff eine during the journey. __OOHHCCMM__1100ee. . iinnddbb 557799 0022//0055//22001177 1199: : 0088 580 yregruS Specifi c post-operative complications Laparotomy Wound may break down from a few days to a few weeks post-op (incidence 3. 5%). Particular risk in the elderly, malnourished (eg cancer, IBD), if infection, uraemia, or haematoma is present, or in repeat laparotomies. Warning sign is a pink serous discharge. Always assume the defect involves the whole of the wound. Wound dehiscence may lead to a burst abdomen with eviscera tion of bowel (mortality 1530%). If you are on the ward when this happens, call your senior, put the viscera back into the abdomen, place a sterile dressing over the wound, and give IV antibiotics (eg piperacillin/tazobactam; see local guidelines). Allay anxiety, give parenteral Pain control, set up an IVI, and return patient to theatre. Incisional hernia is a common late problem (20%), repairable by mesh insertion (if necessary). Biliary surgery Early: Iatrogenic bile duct injury, cholangitis, bile leakage, bleeding into the biliary tree (haemobiliamay lead to melaena or haematemesis); pancreatitis. Retained stones may be removed by ERCP (p742); if this is not available a T-tube left in the bile duct at the time of closure allows free drainage to the exterior; unrelieved distal obstruction of the bile duct may result in fi stula formation and chronic leakage of bile. If jaundiced, maintain a Good Urine output, monitor coagulation, and consider antibiotics.",
    "If jaundiced, maintain a Good Urine output, monitor coagulation, and consider antibiotics. Late: Bile duct stricture; post-cholecystectomy syndrome (symptoms arising from alterations in bile fl ow due to loss of the reservoir function of the gallbladder). Thyroid surgery Early: Recurrent (± superior) laryngeal nerve palsy (hoarseness) can occur permanently in 0. 5% and transiently in 1. 5%warn the patient that their voice will be different for a few days post-op because of intubation and local oedema (NB: pre-operative fi breoptic laryngoscopy should be performed to exclude pre-existing vocal cord dysfunction); thyroid storm (symptoms of severe hypert hyroidismsee p834); tracheal obstruction due to haematoma in the wound: relieve by immediate removal of stitches or clips using the cutter/remover that should remain at the beside; may require urgent surgery; hypoparathyroidism (p222); check plasma Ca2 daily; transient drops in serum concentration are common, permanent in 2. 5%. Late: Hypothyroidism; recurrent hyperthyroidism. Mastectomy Arm lymphoedema in up to 20% of those undergoing axillary node sampling or dissection. The risk of lymphoedema increases with the level of axillary dissection: risk is lower with level 1 dissection (remains inferior to pec. minor) compared to level 3 dissection (goes superior to pec. minor, rarely done); skin necrosis. Arterial surgery Bleeding; thrombosis; embolism; graft infection; myocardial infarction; AV fi stula formation. Complications of aortic surgery: Gut ischaemia; renal failure; respiratory distress; trauma to ureters or anterior spinal artery (leading to paraplegia); ischaemic events from distal emboli from dislodged thrombus; aorto-enteric fi stula. Colonic surgery Early: Sepsis; ileus; fi stulae; anastomotic leak (11% for radical rectal surgery); haemorrhage; trauma to ureters or spleen. Late: Adhesional obstruction (BOX). Small bowel surgery Short gut syndrome (best defi ned functionally, as malabsorption due to insuffi cient residual small bowel; adults with 150cm at risk). Diarrhoea and malabsorption (particularly of fats) lead to a number of metabolic abnormalities including defi ciency in vitamins A, D, E, potassium, and B12, hyper oxaluria (causing renal stones), and bile salt depletion (causing gallstones). The management of short bowel syndrome is complex, aiming to correct metabolic abnormalities, optimize residual bowel function, and support nutrition (using parenteral route if necessary). Tracheostomy Mediastinitis; surgical emphysema. Later: stenosis. Splenectomy (p373. ) Acute gastric dilatation (a serious consequence of not using a NGT, or to check that the one in place is working); thrombocytosis; sepsis. Lifetime sepsis risk is partly preventable with pre-op vaccinesie Haemophilus type B, meningococcal, and pneumococcal(p407 p167)and prophylactic penicillin. Genitourinary surgery Septicaemia (from instrumentation in the presence of infected Urine)consider a stat dose of gentamicin; urinomarupture of a ureter or renal pelvis leading to a mass of extravasated Urine. Gastrectomy See p622. Prostatectomy p642. Haemorrhoidectomy p632. __OOHHCCMM__1100ee. . iinnddbb 558800 0022//0055//22001177 1199: : 0088 581 yregruS Adhesionslegacy of the laparotomy, bane of the surgeon When re-operating on the abdomen, the struggle against adhesions tests the farthest and darkest boundaries of patience of the abdominal surgeon and the assistant. The skill and persistence required to gently and atraumatically tease apart these fi brous bands that restrict access and vision makes any progression, no matter how slight, cause for subdued celebration. Perseverance is the name of this game. Surgical division of adhesions is known as adhesiolysis. Any surgical procedure that breaches the abdominal or pelvic cavities can predispose to the formation of adhesions, which are found in up to 90% of those with previous abdominal surgery; this is why we do not rush to operate on small bowel obstruction: the operation predisposes to yet more adhesions.",
    "Transanal endoscopic microsurgery: Allows excision of small tumours within the rectum with preservation of sphincter function. Urostomies are fashioned after total cystectomy, bringing Urine from the ureters to the abdominal wall via an ileal conduit that is usually incontinent. Formation of a catheterizable valvular mechanism may retain continence. Advances in urological surgery have seen an increase in continence-saving procedures such as orthotopic neobladder reconstruction, with Good long-term continence rates. When choosing a stoma site, avoid: Bony prominences (eg anterior superior iliac spine, costal margins). The umbilicus. Old wounds/scarsthere may be adhesions beneath. Skin folds and creases. The waistline. The site should be assessed pre-operatively by the stoma nurse, with the patient both lying and standing. __OOHHCCMM__1100ee. . iinnddbb 558822 0022//0055//22001177 1199: : 0088 583 yregruS Complications of stomas Liaise early with the stoma nurse, starting pre-operatively. Early: Haemorrhage at stoma site. Stoma ischaemiacolour progresses from dusky grey to black. High output (can lead to potassium)consider loperamide ± codeine to thicken output. Obstruction secondary to adhesions (see p581). Stoma retraction. Delayed: Obstruction (failure at operation to close lateral space around stoma). Dermatitis around stoma site (worse with ileostomy). Stoma prolapse. Stomal intussusception. Stenosis. Parastomal hernia (risk increases with time). NB: prophylactic mesh insertion at the time of stoma formation reduces this risk. Fistulae. Psychological problems. Psychological aspects of stoma care The physical and psychological aspects of stoma care must not be undervalued. Be alert to any vicious cycle in which a skin reaction leads to leakage and precipitates a fear of going out, or a fear of eating. This in turn may lead to poor nutrition and further skin reactions, resulting in further leakage and depression. These cycles can be circumvented by the stoma nurse, who is the expert in fi tting secure, odourless devices and providing patients with a wealth of physical and psychological support, both pre and post operative (explaining what is going to happen, what the stoma will be like, and troubleshooting post-op problems). Early referral prevents problems. Without input from the stoma nurse, a patient may reject their colostomy, never attend to it, and develop deep-seated psychological and psychiatric problems. Fig 13. 7 An ileostomy sits proud, has prominent mucosal folds, and is often right-sided. Fig 13. 6 A loop colostomy with double-barrelled stoma and supporting ostomy renal osteodystrophy. Fig 13. 8 A colostomy sits fl ush with the skin and is typically sited in the left iliac fossa. __OOHHCCMM__1100ee. . iinnddbb 558833 0022//0055//22001177 1199: : 0088 584 yregruS Nutritional support in hospital Over 25% of hospital inpatients may be malnourished. Hospitals can become so focused on curing disease that they ignore the foundations of Good healthmalnourished patients recover more slowly and experience more complications. See table 13. 6. Why are so many hospital patients malnourished? 1 Increased nutritional requirements (eg sepsis, burns, surgery). 2 Increased nutritional losses (eg malabsorption, output from stoma). 3 Decreased intake (eg dysphagia, nausea, sedation, coma). 4 Eff ect of treatment (eg nausea, diarrhoea). 5 Enforced starvation (eg prolonged periods nil by mouth). 6 Missing meals (eg due to investigationsminimize meal time disruption). 7 Diffi culty with feeding(eg lost dentures; no one available to assist). 8 Unappetizing food. Identifying at-risk patients Assess nutrition state (using eg Malnutrition Universal Screening Tool3) and weight on admission; reassess weekly thereafter. Involve dieticians early in those at risk. History: Recent weight (20%, accounting for fl uid balance); recent reduced intake; diet change (eg recent change in consistency of food); nausea, Vomiting, Pain, diarrhoea which might have led to reduced intake. Examination: State of hydration (p666): dehydration can go hand-in-hand with malnutrition, and overhydration can mask malnutrition.",
    "Examination: State of hydration (p666): dehydration can go hand-in-hand with malnutrition, and overhydration can mask malnutrition. Evidence of malnutrition: skin hanging off muscles (eg over biceps); no fat between fold of skin; hair rough and wiry; Hypertension sores; sores at corner of mouth. Calculate body mass index (p244); body mass index 18. 5kg/m2 suggests malnouri shment. Anthropomorphic indices, eg mid-arm circumference, skin fold measures, and grip strength are also used. Investigations: Generally unhelpful. Low albumin suggestive, but is aff ected by many things other than nutrition. Albumin can be helpful in monitoring recovery. Enteral nutrition (Ie nutrition given into gastrointestinal tract. ) If at all possible, give nutrition by mouth. An all-fl uid diet can meet requirements (but get advice from dietician). If danger of choking or aspiration (eg after stroke), consider semi-solid diet. Early post-op enteral nutrition has been shown to benefi t patients (eg after GI surgery) and may reduce complications. Tube feeding: Liquid nutrition via a tube: Nasogastric typically placed without guidance (p759); nasojejunal tubes require endoscopic placement (used if gastric outlet obstruction, delayed gastric emptying, post-gastrectomy, or pancreatitis). Alternatively, gastric or jejunal tubes may be inserted radiologically or surgically (ie gastrostomy/jejunostomy). Use for nutritionally complete, commercially prepared feeds. Close liaison with a dietician is essential. Polymeric feeds consist of undigested proteins, starches, and long-chain fatty acids (eg Nutrison standard, Osmolite). Normally contain 1kCal/mL and 46g Protein per 100mL. Typical requirements met with 2L/24h. Elemental feeds consist of individual amino acids, oligoand monosaccharides needing minimal digestion. Feed is typically initiated at a slow, continuous rate (nausea and Vomiting less problematic) but patients may build up to shorter, bolus feeds, freeing them from pumps between. Guidelines for success Use fi ne-bore (9Fr) nasogastric feeding tube when possible. Check position of nasogastric tube (pH testing) b efore starting feeding (p759); the positioning of a nasojejunal tube can be checked on abdominal X-ray. Build up feeds gradually to avoid diarrhoea and distension. Weigh at least weekly. Check Blood glucose and plasma electrolytes (monitor for refeeding syndrome if previously malnourishedp587). Treat underlying conditions vigorously, eg sepsis may impede ve nitrogen balance. __OOHHCCMM__1100ee. . iinnddbb 558844 0022//0055//22001177 1199: : 0088 585 yregruS Nil by mouth (NBM) before theatre If in doubt about what is acceptable oral intake prior to induction for general anaesthesia (eg for GI surgery), it is best to liaise with the anaesthetist concerned. However, guidelines have been published by many colleges and societies to outline what is safe in the perioperative period: For adult elective surgery in healthy patients without GI comorbidity: Water or clear fl uids (eg black tea/coff ee) are allowed up to 2h beforehand. All other intake up to 6h beforehand. In emergency surgery, ≥6h NBM prior to theatre is bestbut poor scheduling of an emergency list is not an excuse for starving patients for days. Table 13. 6 Daily energy and nutritional requirements Substance Requirement (/kg/d) Notes Energy 2040kCal Normal adult requirements will be 20002500kCal/d; even catabolic patients rarely require 2500kCal/d. 84168kJ Multiply kCal by a factor of 4. 2. Nitrogen 0. 20. 4g 6. 25g of enteral Protein gives 1g of nitrogen. Considering nitrogen balance is important because although catabolism is inevitable, replenishment is vital. Protein 0. 5g Contains 5kCal/g. Fat 3g Contains 10kCal/g. Carbohydrate 2g Contains 4kCal/g. Water 2530mL 500mL/d for each °C of pyrexia. sodium/potassium/chloride 1. 0mmol each Electrolytes need to be considered, even if not on IVI. __OOHHCCMM__1100ee. . iinnddbb 558855 0022//0055//22001177 1199: : 0088 586 yregruS Parenteral (intravenous) nutrition Do not undertake parenteral feeding lightly: it has risks. Specialist advice is vital.",
    "Specialist advice is vital. It should only be considered if the patient is likely to become malnourished without itthis normally means that the gastrointestinal tract is not functioning (eg bowel obstruction), and is unlikely to function for at least 7d. Parenteral feeding may supplement other forms of nutrition (eg in short bowel syndrome or active Crohns disease, when nutrition cannot be suffi ciently absorbed in the gut) or it can be used alone (total parenteral nutritionTPN). Even if there is GI disease, studies show that enteral nutrition is safer, cheaper, and at least as effi cacious as parenteral nutrition in the perioperative period. 5 Administration Nutrition must be given via a dedicated central venous line (or peripherally inserted central catheterPICC line) or via a dedicated lumen of a multilumen catheter (see fi gs 13. 9 and 13. 10). Requirements There are many diff erent regimens for parenteral feeding. Most provide 2000kCal and 1014g nitrogen in 23L; this usually meets a patients daily requirements (see table 13. 6, p585). 50% of calories are provided by fat and 50% by carbohydrate. Regimens comprise vitamins, minerals, trace elements, and electrolytes; these will normally be included by the pharmacist. Complications Sepsis: (eg Staphylococcus epidermidis and Staphylococcus aureus; Candida; Pseudomonas; infective endocarditis. ) Look for spiking pyrexia and examine wound at tube insertion point. Stop PN, take line and peripheral cultures and give antibiotics via the line. If central venous line-related sepsis is suspected, the safest course of action is always to remove the line. Do not attempt to salvage a line when Staph. aureus or Candida infection has been identifi ed. Thrombosis: Central vein thrombosis may occur, resulting in pulmonary embolus or superior vena caval obstruction (p528). Metabolic imbalance: Electrolyte abnormalitiessee BOX Refeeding syndrome; deranged plasma glucose; hyperlipidaemia; defi ciency syndromes (table 6. 9, p268); acid-base disturbance (eg hypercapnia from excessive CO2 production). Mechanical: Pneumothorax; embolism of IV line tip. Guidelines for success Liaise closely with line insertion team, nutrition team, and pharmacist. Meticulous sterility. Do not use central venous lines for uses other than nutrition. Remove the line if you suspect infection. Culture its tip. Review fl uid balance at least twice daily, and requirements for energy and electrolytes daily. Check weight, fl uid balance, and Urine glucose daily during establishment of parenteral nutrition. Check plasma glucose, Creatinine and electrolytes (including calcium and phosphate), and FBC daily until stable. Check LFT and lipid clearance three times a week until stable. Check zinc and magnesium weekly. Do not rush. Achieve the maintenance regimen in small steps. Treat underlying conditions vigorouslyeg sepsis may impede ve nitrogen balance. 5 Enteral feeding promotes integrity of the gut mucosal barrier, thus preventing bacterial and endotoxin translocation across the gut wall, which can lead to multiple organ dysfunction and perpetuation of a systemic infl ammatory responseeven when the gut is not the primary source of pathology. __OOHHCCMM__1100ee. . iinnddbb 558866 0022//0055//22001177 1199: : 0088 587 yregruS Refeeding syndrome This is a life-threatening metabolic complication of refeeding via any route after a prolonged period of starvation. At-risk patients include those initiating artifi cial feeding (enteral or parenteral) after prolonged starvation, or with malignancy, anorexia nervosa, or alcoholism. As the body turns to fat and Protein metabolism in the starved state, there is a drop in the level of circulating insulin (because of the paucity of dietary carbohydrates). The catabolic state also depletes intracellular stores of phosphate, although serum levels may remain normal (0. 851. 45mmol/L).",
    "The catabolic state also depletes intracellular stores of phosphate, although serum levels may remain normal (0. 851. 45mmol/L). When refeeding begins, the level of insulin rises in response to the carbohydrate load, and one of the consequences is to increase cellular uptake of phosphate. A hypophosphataemic state (0. 50mmol/L) normally develops within 4d and is mostly responsible for the features of refeeding syndrome, which include: rhabdomyolysis; red and white cell dysfunction; respiratory insuffi ciency; arrhythmias; cardiogenic shock; seizures; sudden death. Prevention Give High-dose Pabrinex during re-feeding window. Identify at-risk patients, assess and monitor closely during refeeding (glucose, lipids, Sodium, potassium, phosphate, calcium, magnesium, and zinc). Close involvement of a nutritionist is required. Treatment is of the complicating features and includes parenteral phosphate administration (eg 18mmol/d) in addition to oral supplementation. The venous system at the thoracic outlet When trying to judge the position of a central venous line tip on CXR (see fi g 13. 10) it helps to know the anatomical landmarks of the venous system (fi g 13. 9). The subclavian veins join the internal jugular veins behind the sternoclavicular joints to form the brachiocephalic veins. These come together behind the right 1st sternocostal joint to form the superior vena cava (SVC), which runs from this point to the right 3rd sternocostal joint. The right atrium starts here. Fig 13. 9 Neck veins. Fig 13. 10 Right arm PICC (peripherally inserted central catheter) still with a wire in the lumen. This is a radiograph at the time of insertion to determine if placement is correct. The tip lies in the SVCie Good positioning for TPN or long-term antibiotic therapy. The tip of a Hickman line, for cytotoxic administration, is better in the right atrium, to avoid possible irritation of the SVC and consequent thrombosis or stenosis. NB: this image was acquired in the angiography room, where radio-opaque material appears black (it is easier to see contrast media against a white background). A similar eff ect may be achieved by digitally inverting a standard X-ray. Image courtesy of Prof. Peter Scally. __OOHHCCMM__1100ee. . iinnddbb 558877 0022//0055//22001177 1199: : 0088 588 yregruS Diabetic patients undergoing surgery Over 10% of surgical patients will have Diabetes. This group face a greater risk of postoperative infection and cardiac complications. Tight glycaemic control is therefore essential and improves outcome. Aim to achieve an hemoglobin hemoglobin A1c of 69mmol/mol prior to elective surgery. Patients are often well informed about their Diabetesinvolve them fully in managing their diabetic care. Check your hospitals policy for managing diabetic patients who will be NBM before surgery. A general guide follows. Insulin-treated Diabetes mellitus Try to place the patient fi rst on the list in order to minimize the fasting period. Give all usual insulin the night before surgery. Long-acting (basal) insulin is usually continued at normal times (eg glargine; detemir), even when patients are on a variable rate intravenous insulin infusion (VRIII) previously known as a sliding scale (see BOX). If on AM list, ensure no subcutaneous rapid-acting (bolus) or mixed insulin is given on the morning of surgery. If PM list, give the normal morning bolus insulin, or half the mixed insulin dose. If eating and drinking post-operatively, resume the usual insulin with evening meal. If AM list (or early PM) and eating a late lunch, give half the morning insulin dose with this meal. If not eating until evening, a VRIII may be needed if the capillary glucose readings are High. Omit all rapid-acting and mixed insulin while the patient is on a VRIII.",
    "Omit all rapid-acting and mixed insulin while the patient is on a VRIII. It not eating or drinking post-op, start a VRIII 2 hrs prior to surgery. Aim for serum glucose levels of 610mmol/L and check fi nger-prick glucose every 2 hrs. When ready to Eat, give normal dose of rapid acting or mixed insulin with the 1st meal and stop the VRIII 3060min later. IV fl uid is required while the patient is on a VRIII: see BOX. A glucosePotassiuminsulin (GKI) infusion can be used as an alternative to a VRIII, although it is no longer used as standard in the UK. Tablet-treated Diabetes mellitus If Diabetes is poorly controlled (eg fasting glucose 10mmol/L), treat as for patients on insulin (see earlier in topic). Give usual medications the night before surgery, except long-acting sulfonylureas (eg glibenclamide) which can cause prolonged hypoglycaemia when fasting and may need to be substituted 23 days pre-operatively. Discuss with the Diabetes team. If eating and drinking post-operatively: on AM list, omit morning medication and take any missed drugs with lunch, after surgery. If PM list, take normal medications with breakfast, omit midday doses, and take any missed drugs with a late lunch. The dose of these may need reducing, depending on dietary intake. If not eating or drinking post-op, start a VRIII 2 hours prior to surgery. Once eating and drinking, oral hypoglycaemics can be restarted. Some patients may need a phase of subcutaneous insulin following major surgeryrefer to the Diabetes team if serum glucose levels are persistently raised. Metformin and iodine IV contrast: Metformin can be continued after IV contrast in patients with normal serum Creatinine and/or estimated glomerular filtration rate 60mL/min. To minimize the risk of nephrotoxicity, if serum Creatinine is raised or estimated glomerular filtration rate 60mL/min, stop metformin for 48h after contrast and check renal function has returned to baseline before restarting. Diet-controlled Diabetes There are usually no problems; patients should be treated as if not diabetic (and do not need to be fi rst on the list). Check capillary Blood glucose peri-operatively. Avoid 5% glucose IVI as this increases Blood glucose levels. Peri-operative morbidity and mortality Diabetes mellitus is classed as an intermediate risk factor for increased peri-operative cardiovascular risk by the American Heart Association, so screen for the presence of asymptomatic cardiac and renal disease (p567) and be aware of possible silent myocardial ischaemia. Long-term post-op survival has been found to be poorer for patients with Diabetes; however, peri-operative cardiovascular morbidity and mortality were only increased in the presence of congestive Heart failure and haemodialysisie not Diabetes alone. __OOHHCCMM__1100ee. . iinnddbb 558888 0022//0055//22001177 1199: : 0088 589 yregruS How to write up a variable rate intravenous insulin infusion (VRIII) Variable rate intravenous insulin infusion (VRIII) is more accurate a term than the previously used sliding scale. Prescribe 50 units of short-acting insulin in 50mL of 0. 9% saline to infuse at the rate shown in table 13. 7 (according to Blood glucose levels). NB: this is a guide onlyinfusions may vary between institutions and no one infusion rate is suitable for all patients. Table 13. 7 Guide to VRIII according to Blood glucose levels Capillary Blood glucose (millimoles per liter) IV soluble insulin (rate of infusion) 4. 0 0. 5 units/h (0. 0 if long-acting insulin continued) 4. 17. 0 1 unit/h 7. 19. 0 2 units/h 9. 111. 0 3 units/h 11. 114. 0 4 units/h 14. 117. 0 5 units/h 17.",
    "19. 0 2 units/h 9. 111. 0 3 units/h 11. 114. 0 4 units/h 14. 117. 0 5 units/h 17. 120 6 units/h 20 6 units/h; request urgent diabetic review Fluids should be prescribed to run with the VRIII (through the same cannula via a non-return valve). Ideally use 0. 45% Sodium chloride with 5% glucose and either 0. 15% Potassium chloride (KCl) (20mmol/L) or 0. 3% KCl (40mmol/L). This provides a constant supply of substrate, but it is not widely available. Alternatively, use 10% glucose KCl. This has a lower risk of hypoglycaemia and hyponatraemia than 5% glucose. If capillary glucose 15mmol/L when starting the VRIII use 0. 9% saline until 15mmol/L, then use 10% glucose. Fluid should infuse at 83125mL/h (ie 1L over 812 hours). Omit Potassium if there is renal impairment or hyperkalaemia and slow the rate of infusion in Heart failure. __OOHHCCMM__1100ee. . iinnddbb 558899 0022//0055//22001177 1199: : 0088 590 yregruS Jaundiced patients undergoing surgery Avoid operating in patients with obstructive jaundiceΩconsider prior ERCP to relieve. There is risk of bleeding, peri-operative infection, and renal failure. Coagulopathy Vitamin potassium in obstruction (requires bile in order to be absorbed. If no history of chronic Liver disease, give parenteral vitamin potassium (consider even if clotting is normal). FFP may be required in Liver disease or active bleeding. Sepsis Risk due to bacterial translocation bacterial colonization of biliary tree neutrophil function. If cholangitis present, give antibiotics. Antibiotic prophylaxis for ERCP not recommended unless biliary decompression fails, or there is a history of biliary disorders; Liver transplantation; presence of a pancreatic pseudocyst; or neutropenia, in which case give oral ciprofl oxacin or IV gentamicin (check local policy). Renal failure Risk post-op due to intestinal absorption of endotoxin (normally limited by the detergent eff ect of bile). This causes renal vasoconstriction and acute tubular necrosis (see p298). The use of lactulose or bile salts pre-op may help. Ensure adequate IV fl uids preand post-operatively to maintain Good Urine output. Monitor Urine output every 2h. Consider central line, inotropes, and furosemide if output poor despite adequate hydration. Measure and correct UE daily. Surgery in those on anticoagulants Inform the surgeon and anaesthetist. Risks and benefi ts must be individualized. Warfarin Minor surgery can be undertaken without stopping (if INR 3. 5 it may be safe to proceed). In major surgery, stop for 35d pre-op. Vitamin potassium ± FFP or Beriplex may be needed for emergency reversal of INR. One elective option is conversion to heparin (stop 6h prior to surgery, and monitor APTT perioperatively). When re-warfarinizing, give LMWH until INR is therapeutic, as warfarin is initially prothrombotic. DOACS Decision to stop will be based upon the patients risk of having a thromboembolic event and bleeding risk associated with the procedure. 4 Where procedure has no clinically important bleeding risk it can be performed just before the next DOAC dose/1824h after last dose and dosing restarted 6h post-op. Low bleeding risk procedure, omit DOAC 24h pre-op. High bleeding risk procedure, omit DOAC 48h pre-op. If renal function impaired, may require longer periods of omission pre-op. Antiplatelets Decision to stop is complex and best discussed with the treating team (eg cardiologist or neurologist). Premature discontinuation of clopidogrel in patients with drug-eluting stents can lead to stent thrombosis. The bleeding eff ects of aspirin are reversed 5d after stoppingcheck local policy to see if cessation required. Surgery in those on steroids Patients on steroids may not be able to mount an appropriate adrenal response to meet the stress of surgery due to suppression of the hypothalamicpituitaryadrenal (HPA) axis.",
    ": Extirpation by vascular surgeon. Posterior triangle (Behind sternocleidomastoid, in front of trapezius, above clavicle. ) Cervical ribs may intrude into this area. These are enlarged costal elements from C7 vertebra. The majority are asymptomatic but can cause Raynauds syndrome by compressing subclavian artery and neurological symptoms (eg wasting of 1st dorsal interosseous) from Hypertension on lower trunk of the brachial plexus. Pharyngeal pouches can protrude into the posterior triangle on swallowing (usually left-sided). Cystic hygromas (usually infants) arise from jugular lymph sac. These macrocystic lymphatic malformations transilluminate brightly. Treat by surgery or hypertonic saline sclerosant injection. Recurrence can be troublesome. Pancoasts tumour (see p708). Subclavian artery aneurysm will be pulsatile. __OOHHCCMM__1100ee. . iinnddbb 559988 0022//0055//22001177 1199: : 0088 599 yregruS External carotid Parotid gland artery Parotid nodes Sternomastoid Mylohyoid Hypoglossal nerve Tonsillar node Submandibular nodes Occipital nodes Scalenus medius Ant. and Post. digastric Internal jugular vein Submandibular gland Omohyoid Scalenus anterior Hyoid bone Sternohyoid Vagus nerve Sternothyroid Common carotid Subclavian artery artery Subclavian vein Sternomastoid Fig 13. 19 Important structures in the head and neck. Salivary gland pathology There are three pairs of major salivary glands: parotid, submandibular, and sublingual (there are many minor glands). History: Lumps; Edema related to food; Pain. Examination: Note external Edema; look for secretions; bimanual palpation for stones. Examine VIIth nerve and regional lymph nodes. Cytology: Do FNA. Acute Edema Think of mumps and HIV. Recurrent unilateral Pain and Edema is likely to be from a stone. 80% are submandibular. The classical story is of Pain and Edema on eatingwith a red, tender, swollen, but uninfected gland. The stone may be seen on plain X-ray or by sialography (fi g 13. 20). Distal stones are removed via the mouth but deeper stones may require excision of the gland. Chronic bilateral symptoms may coexist with dry eyes and mouth and autoimmune disease, eg hypothyroidism, Mikuliczs or Sjögrens syndrome (p706 p710)also bulimia or alcohol excess. Fixed Edema may be from a tumour/ALL (fi g 8. 49, Fig 13. 20 Normal sialogram of the subp355), sarc oid, amyloid, granulomatosis with mandibular gland. Whartons (submanpolyangiitis, or be idiopathic. dibular) duct opens into the mouth near Salivary gland tumours (table 13. 9) 80% are the frenulum of the tongue. in the parotid, 80% of these are pleomorphic adenomas, 80% of these are in the superfi cial lobe. Defl ection of the ear outwards is a classic sign. Remove any salivary gland Edema for assessment if present for 1 month. VIIth nerve palsy means malignancy. Table 13. 9 Types of salivary gland tumours Benign or malignant Malignant Malignant Cystadenolymphoma Mucoepidermoid Squamous or adeno calcium Pleomorphic adenoma Acinic cell Adenoid cystic calcium Pleomorphic adenomas often present in middle age and grow slowly. Remove by superfi cial parotidectomy. Adenolymphomas (Warthins tumour): usually older men; soft; treat by enucleation. Carcinomas: rapid growth; hard fi xed mass; Pain; facial palsy. Treatment: surgery radiotherapy. __OOHHCCMM__1100ee. . iinnddbb 559999 0022//0055//22001177 1199: : 0088 600 yregruS Lumps in the thyroid If the thyroid (fi g 13. 21) is enlarged (goitre), ask yourself: 1 Is the thyroid diff usely enlarged or nodular? 2 Is the patient euthyroid, thyrotoxic (p218), or hypothyroid (p220)? Diff use goitre: Causes: Endemic (iodine defi ciency); congenital; secondary to goitrogens (substances that iodine uptake); acute thyroiditis (de Quervains); physiological (pregnancy/puberty); autoimmune (Graves disease; Hashimotos thyroiditis). Nodular goitre: Multinodular goitre (MNG): The most common goitre in the UK. 50% who present with a single nodule actually have MNG. Patients are usually euthyroid, but may become hyperthyroid (toxic). MNG may be retroor substernal. Hypothyroidism and malignancy within MNG are rare.",
    "MNG may be retroor substernal. Hypothyroidism and malignancy within MNG are rare. Plummers disease is hyperthyroidism with a single toxic nodule (uncommon). Fibrotic goitre: Eg Reidels thyroiditis. Solitary thyroid nodule: typically cyst, adenoma, discrete nodule in MNG or malignant (10%). Investigations Check TSH and USS (solid, cystic, complex or part of a group of lumps). If abnormal consider: T4, autoantibodies (p216, eg if Hashimotos /Graves, suspected). CXR with thoracic inlet view (tracheal goitres and metastases? ). Radionuclide scans (fi g 13. 22) may show malignant lesions as hypofunctioning or cold, whereas a hyperfuncti oning hot lesion suggests adenoma. FNA (fi ne-needle aspiration) and cytologyΩwill characterize lesion. A FNA fi nding of a follicular neoplasm can be challenging (1530% malignant)Ωdiscuss with cytopathologist and perform molecular diagnostics where available; if any doubt, refer for surgery. What should you do if High-resolution ultrasound shows impalpable nodules? Such thyroid nodules can usually be observed provided they are: 1cm across (which accounts for most; ultrasound can detect lumps 2mm; such incidentalomas occur in 46% of routine autopsies) and are asymptomatic. There is no past history of thyroid cancer or neck irradiation. No family history of medullary cancer (if present, do USS-guided FNA). Thyroid cancer 1 Papillary: (60%. ) Often in younger patients. Spread: lymph nodes and lung (jugulodigastric node metastasis is the so-called lateral aberrant thyroid). : total thyroidectomy to remove non-obvious tumour ± node excision ± radioiodine (131I) to ablate residual cells. Give levothyroxine to suppress TSH. Prognosis: better if young and . 2 Follicular: (≤25%. ) Occurs in middle-age and spreads early via Blood (bone, lungs). Well-diff erentiated. : total thyroidectomy T4 suppression radioiodine ablation. 3 Medullary: (5%. ) Sporadic (80%) or part of MEN syndrome (p223). May produce calcitonin which can be used as a tumour marker. They do not concentrate iodine. Perform a phaeochromocytoma screen pre-op. : thyroidectomy node clearance. External beam radiot herapy may prevent regional recurrence. 4 Lymphoma: (5%. ) : 3: 1. May present with stridor or dysphagia. Do full staging pre-treatment (chemoradiotherapy). Assess histology for mucosa-associated lymphoid tissue (MALT) origin (associated with a Good prognosis). 5 Anaplastic: Rare. : 3: 1. Elderly, poor response to any treatment. In the absence of unresectable disease, excision radiotherapy may be tried. Thyroid surgery Plays a signifi cant role in the management of thyroid disease. Operations include partial lobectomy or lobectomy (for isolated nodules); and thyroidectomy (for cancers, MNG, or Graves). Indications: Hypertension symptoms, relapse hyperthyroidism after 1 failed course of drug treatment, carcinoma, cosmetic reasons, symptomatic patients planning pregnancy. Pre-operative management: Render euthyroid pre-op with antithyroid drugs (eg carbimazole up to 20mg/12h PO or p ropylthiouracil 200mg/12h PO but stop 10d prior to surgery as these increase vascularity). Propranolol up to 80mg/8h PO can be used to control tachycardia or tremor associated with hyperthyroidism (continue for 5d post-op). Check vocal cords by indirect laryngoscopy preand post-op (risk of recurrent laryngeal nerve injury). Check serum Ca2 (and parathyroid hormone if abnormal). Complications: see p580. __OOHHCCMM__1100ee. . iinnddbb 660000 0022//0055//22001177 1199: : 0088 601 yregruS Fig 13. 21 The anatomy of the region of the thyroid gland. The important structures that must be considered when operating on the thyroid gland include: Recurrent laryngeal nerve Superior laryngeal nerve Parathyroid glands Trachea Common carotid artery Internal jugular vein (not depictedsee fi g 13. 23). Fig 13. 22 Radionuclide study of the thyroid Fig 13. 23 Transverse ultrasound of the left lobe showing changes consistent with Graves disof the thyroid showing a small Low-refl ectivity ease (see also hot and cold nodules (p216) and cyst within higher-refl ectivity thyroid tissue. nuclear medicine, p738).",
    "nuclear medicine, p738). There is increased upNote the proximity to the gland of the common take of the radionuclide trace diff usely throughcarotid artery and internal jugular vein (the latout both lobes of the gland. ter compressed slightly by Hypertension from the Image courtesy of Norwich Radiology Department. probe), both seen beneath the body of sternocleidomastoid muscle. Image courtesy of Norwich Radiology Department. __OOHHCCMM__1100ee. . iinnddbb 660011 0022//0055//22001177 1199: : 0088 602 yregruS Breast carcinoma Epidemiology Aff ects 1 in 8 ; nearly 60 000 new cases per year in UK (incidence increasing). Rare in men (1% of all breast cancers). Risk factors Risk is related to family history, age, and uninterr upted oestrogen exposure, hence: nulliparity; 1st pregnancy 30yrs old, early menarche; late menopause; HRT; obesity; BRCA genes (p521); not breastfeeding; past breast cancer (metachronous rate 2%, synchronous rate 1%). Pathology Non-invasive ductal carcinoma in situ (DCIS) is premalignant and seen as microcalcifi cation on mammography (unifocal or widespread). Non-invasive lobular CIS is rarer and tends to be multifocal. Invasive ductal carcinoma is most common (70%) whereas invasive lobular carcinoma accounts for 1015% of breast cancers. Medullary cancers (5%) tend to aff ect younger patients while colloid/mucoid (2%) tend to aff ect the elderly. Others: papillary, tubular, adenoid-cystic and Pagets (p708). 6070% of breast cancers are oestrogen receptor ve, conveying better prognosis. 30% over-express HER2 (growth factor receptor gene) associated with aggressive disease and poorer prognosis. Investigations (See p82 for history and examination. ) All lumps should undergo triple assessment: Clinical examination histology/cytology mammography/ultrasound; see fi g 13. 24. Staging: Stage 1: Confi ned to breast, mobile. Stage 2: Growth confi ned to breast, mobile, lymph nodes in ipsilateral axilla. Stage 3: Tumour fi xed to muscle (but not chest wall), ipsilateral lymph nodes matted and may be fi xed, skin involvement larger than tumour. Stage 4: Complete fi xation of tumour to chest wall, distant metastases. Also TNM staging: (p523) T12cm, T2, 25cm, T3 5cm, T4, fi xity to chest wall or peau dorange; N1, mobile ipsilateral nodes; N2, fi xed nodes; M1, distant metastases. Treating local disease (Stage 12. )7 Surgery: Removal of tumour by wide local excision (WLE) or mastectomy ± breast reconstruction axillary node sampling/ surgical clearance or sentinel node biopsy (BOX Sentinel node biopsy). Radiotherapy: Recommended for all patients with invasive cancer after WLE. Risk of recurrence decreases from 30% to 10% at 10yrs and increases overall survival. Axillary radiotherapy used if lymph node ve on sampling and surgical clearance not performed (risk of lymphoedema and brachial plexopathy). SE: pneumonitis, pericarditis, and rib fractures. Chemotherapy: Adjuvant chemotherapy improves survival and reduces recurrence in most groups of women (consider in all except excellent prognosis patients), eg epirubicin CMF (cyclophosphamide methotrexate 5-FU). Neoadjuvant chemotherapy has shown no diff erence in survival but may facilitate breast-conserving surgery. Endocrine agents: Aim to oestr ogen activity and are used in oestrogen receptor (ER) or progesterone receptor (PR) ve disease. The ER blocker tamoxifen is widely used, eg 20mg/d PO for 5yrs post-op (may rarely cause uterine cancer so warn to report vaginal bleeding). Aromatase inhibitors (eg anastrozole) targeting peripheral oestrogen synthesis are also used (may be better tolerated). They are only used if post-menopausal. If pre-menopausal and an ERve tumour, ovarian ablation (via surgery or radiotherapy) or GnRH anal ogues (eg goserelin) recurrence and survival. Support: Breastcare nurses Reconstruction options: Eg tissue expanders/implants/nipple tattoos, latissimus dorsi fl ap, TRAM (transverse rectus abdominis myocutaneous) fl ap. Treating distant disease (Stage 34. )8 Long-term survival is possible and median survival is 2yrs.",
    "Treating distant disease (Stage 34. )8 Long-term survival is possible and median survival is 2yrs. Staging investigations should include CXR, bone scan, Liver USS, computed tomography/ magnetic resonance imaging or PET-computed tomography (p739), LFTS and Ca2. Radiotherapy (p526) to painful bony lesions (bisphosphonates, p677, may Pain and fracture risk). Tamoxifen is often used in ERve; if relapse after initial success, consider chemotherapy. Trastuzumab should be given for HER2 ve tumours, in combination with chemotherapy. CNS surgery for solitary (or easily accessible) metastases may be possible; if notradiotherapy. Get specialist help for arm lymphoedema (try decongestive methods fi rst). Preventing deaths Promote awareness. Screening: 2-view mammography every 3yrs for women aged 4773 in UK has breast cancer deaths by 30% in women 50yrs. __OOHHCCMM__1100ee. . iinnddbb 660022 0022//0055//22001177 1199: : 0088 603 yregruS Breast lump Triple assessment 1 Clinical examination 2 Radiology: ultrasound for 35yrs; mammography and ultrasound for 35yrs old 3 Histology/cytology (FNA or core biopsy: ultrasound-guided core biopsy is best for new lumps) Cystic lump Solid lump aspirate core biopsy Residual Clear fl uid Malignant Clear fl uid mass discard fl uid plan discard fl uid core biopsy and reassure and reassure Reassurance can be more emphatic if there is no family Bloody fl uid history and biopsy shows a non-proliferative lesion. cytology Fig 13. 24 Triple assessment and investigation of a breast lump. ultrasound is more accurate at detecting invasive breast cancer, though mammography remains most accurate at detecting ductal carcinoma in situ (DCIS). magnetic resonance imaging is used in the assessment of multif ocal/bilateral disease and patients with cosmetic implants who are identifi ed as High risk. Sentinel node biopsy Decreases needless axillary clearances in lymph node Ωve patients. Patent blue dye and/or radiocolloid injected into periareolar area or tumour. A gamma probe/visual inspection is used to identify the sentinel node. The sentinel node is biopsied and sent for histology ± immunohisto chemistry; further clearance only if sentinel node ve. Sentinel node identifi ed in 90%. False Ωve rates 5% for experienced surgeons. Prognostic factors in breast cancer Tumour size, grade, lymph node status, ER/PR status, presence of vascular invasion all help assess prognosis. Nottingham Prognostic Index (NPI) is widely used to predict survival and risk of relapse, and to help select appropriate adjuvant systemic therapy. NPI 0. 2 tumour size (cm) histological grade nodal status6 If treated with surgery alone, 10yr survival rates are: NPI 2. 4: 95%; NPI 2. 43. 4: 85%; NPI 3. 44. 4: 70%; NPI 4. 45. 4: 50%; NPI 5. 4: 20%. Benign breast disease Fibroadenoma: Usually presents 30yrs but can occur up to menopause. Benign overgrowth of collagenous mesenchyme of one breast lobule. Firm, smooth, mobile lump, the breast mouse. Painless. May be multiple. ⅓ regress, ⅓ stay the same, ⅓ get bigger. : observation and reassurance, but if in doubt refer for USS (usually conclusive) ± FNA. Surgical excision if large. Breast cysts: Common 35yrs, esp. perimenopausal. Benign, fl uid-fi lled rounded lump. Not fi xed to surrounding tissue. Occasionally painful. : diagnosis confi rmed on aspiration (perform only if trained). Infective mastitis/breast abscesses: Infection of mammary duct often associated with lactation (usually Staph. aureus). Abscess presents as painful, hot Edema of breast segment. : antibiotics. Open incision or percutaneous drainage if abscess. Duct ectasia: Typically around menopause. Ducts become blocked and secretions stagnate. Present with nipple discharge (green/brown/bloody) ± nipple retraction ± lump. Refer for confi rmation of diagnosis. Usually no needed. Advise to stop smoking. Fat necrosis: Fibrosis and calcifi cation after injury to breast tissue. Scarring results in a fi rm lump. Refer for triple assessment.",
    "Not only was this feat performed in the age before anaesthesia and antisepsis, but it was also performed on a table in the front room of McDowells Kentucky home, at that time on the frontier of the West in the United States. His account of the operation makes fascinating reading. While the strength of his diagnostic convictions combined with his speed and skill at operating is to be admired (the operation took 25 minutes), there is an even more laudable part played in this story. The patient, Mrs Jane Todd-Crawford, was fully willing to be involved with what can only be described as experimental surgery in the face of uncertainty. She defi ed Pain simply by reciting psalms and hymns, and was back at home within 4 weeks with no complications, ultimately living another 33 years. We would be well served in remembering the exceptional commitment of Mrs Todd-Crawford. In the rush and hurry of our daily tasks perhaps it is all to easy to forget that the undertaking of surgery today may be no less fear-provoking for patients than it was 200 years ago. __OOHHCCMM__1100ee. . iinnddbb 660055 0022//0055//22001177 1199: : 0088 606 yregruS The acute abdomen Someone who becomes acutely ill and in whom symptoms and signs are chiefl y related to the abdomen has an acute abdomen. Prompt laparotomy is sometimes essential: repeated examination is the key to making the decision. Clinical syndromes that usually require laparotomy 1 Rupture of an organ (Spleen, aorta, ectopic pregnancy. ) Shock is a leading sign see table 13. 10 for assessment of Blood loss. Abdominal Edema may be seen. Any history of trauma: blunt trauma spleen; penetrating trauma Liver? Delayed rupture of the spleen may occur weeks after trauma. Peritonism may be mild. 2 Peritonitis (Perforation of peptic ulcer/duodenal ulcer, diverticulum, appendix, bowel, or gallbladder. ) Signs: prostration, shock, lying still, ve cough test (p62), tenderness (± rebound/percussion Pain, p62), board-like abdominal rigidity, guarding, and no bowel sounds. Erect CXR may show gas under the diaphragm (fi g 13. 26). NB: acute pancreatitis (p636) causes these signs, but does not require a laparotomy so dont be caught out and always check serum amylase. Syndromes that may not require a laparotomy Local peritonitis: Eg diverticulitis, cholecystitis, salpingitis, and appendicitis(the latter will need surgery). If abscess formation is suspected (Edema, swinging fever, and WCC) do ultrasound or computed tomography. Drainage can be percutaneous (ultrasound or computed tomography-guided), or by laparotomy. Peritoneal infl ammation can cause localized ileus with a sentinel loop of intraluminal gas visible on plain AXR (p729). Colic is a regularly waxing and waning Pain, caused by muscular spasm in a hollow viscus, eg gut, ureter, salpinx, uterus, bile duct, or gallbladder (in the latter, Pain is often dull and constant). Colic, unlike peritonitis, causes restlessness and the patient may well be pacing around when you go to review! Obstruction of the bowel See p610. Tests UE; FBC; amylase; LFT; CRP; lactate (is there mesenteric ischaemia? ); urinalysis. Urine and serum hCG is vital to exclude ectopic pregnancy. Erect CXR (fi g 13. 26), AXR may show Riglers sign (p728). Laparoscopy may avert open surgery. computed tomography can be helpful provided it is readily available and causes no delay (pp7323); ultrasound may identify perforati on or free fl uid (appropriate performer training is important). Pre-op Dont rush to theatre. Anaesthesia compounds shock, so resuscitate properly fi rst (p790) unless Blood being lost faster than can be replaced, eg ruptured ectopic pregnancy, (OHCS p262), aneurysm leak (p654), trauma.",
    "Plan Bed rest, keep NBM; assess volume status (BOX) and treat shock (p790); crossmatch/group and save; analgesia (p574); arrange imaging; consider need for IVI, Blood cultures, and antibiotics (eg piperacillin/tazobactam 4. 5g/8h IV); ECG. The medical acute abdomen Irritable bowel syndrome (p266) is the chief cause, so always ask about episodes of Pain associated with loose stools, relieved by defecation, bloating, and urgency (but not Bloodthis may be UC). Other causes: Myocardial infarction Pneumonia (p166) Sickle-cell crisis (p341) Gastroenteritis or UTI Thyroid storm (p834) Phaeochromocytoma (p837) Diabetes mellitus/DKA (p206) Zoster (p404) Malaria (p416) Bornholm disease Tuberculosis (p393) Typhoid fever (p415) Pneumococcal peritonitis Porphyria (p692) Cholera (p430) HenochSchönlein (p702) Narcotic addiction Yersinia enterocolitica (p431) Tabes dorsalis (p412) PAN (p556) Lead colic Hidden diagnoses Mesenteric ischaemia (p620), acute pancreatitis (p636), and leaking AAA (p654) are the Unterseeboote of the acute abdomenunsuspected, undetectable unless carefully looked for, and underestimatedly deadly. They may have non-specifi c symptoms and signs that are surprisingly mild, so always think of them when assessing the acute abdomen and hopefully you will spot them! Finally: always exclude pregnancy (± ectopic? ) in females. __OOHHCCMM__1100ee. . iinnddbb 660066 0022//0055//22001177 1199: : 0088 607 yregruS Fig 13. 25 Causes of abdominal Pain. Assessing hypovolaemia from Blood loss Treat suspected shock rather than wait for blood pressure to fall. The most likely cause of shock in a surgical patient is hypovolaemia. Check Urine output, GCS, and capillary refi ll (creatinine) as measures of renal, brain, and skin perfusion. When there is any Blood loss, assess the status of the following: Table 13. 10 Estimating Blood loss based on patients initial presentation Parameter Class I Class II Class III Class IV Blood loss 750mL 7501500mL 15002000mL 2000mL 15% 1530% 3040% 40% Pulse 100bpm 100bpm 120bpm 140bpm blood pressure Pulse Hypertension or Respirations 1420/min 2030/min 3040/min 35/min Urine output 30mL/h 2030mL/h 515mL/h Negligible Mental state Slightly anxious Anxious Confused Lethargic Fluid to give Crystalloid Crystalloid Crystalloid Blood Assumes a body mass of 70kg. An adaptation of Estimated Blood loss based on initial presentation table from the 9th edition of the Advanced Trauma Life Support Manual. Adapted with permission from the American College of Surgeons. Fig 13. 26 Erect CXR showing air beneath the right hemidiaphragm, indicating presence of a pneumo peritoneum. Causes: Bowel perforation (visible only in 75%) (fi g 13. 25). Gas-forming infection, eg C. perfringens. Iatrogenic, eg laparoscopic surgery (detectable on CXR up to 10d post-op). Per vaginam (eg sexual activity). Interposition of bowel between Liver and diaphragm (Chilaiditi signnot true free air). Image courtesy of Mr P. Paraskeva. __OOHHCCMM__1100ee. . iinnddbb 660077 0022//0055//22001177 1199: : 0088 608 yregruS Acute appendicitis Incidence Most common surgical emergency (lifetime incidence 6%). Can occur at any age, though highest incidence is between 1020yrs. 8 It is rare before age 2 because the appendix is cone shaped with a larger lumen. Pathogenesis Gut organisms invade the appendix wall after lumen obstruction by lymphoid hyperplasia, faecolith, or fi larial worms. This leads to oedema, ischaemic necrosis, and perforation. Presentation Classically periumbilical Pain that moves to the RIF. Associated signs may include tachycardia, fever, peritonism with guarding and rebound or percussion tenderness in RIF. Pain on right during PR examination suggests an infl ammed, Lowlying pelvic appendix. Anorexia is an important feature; Vomiting is rarely prominentPain normally precedes Vomiting in the surgical abdomen. Constipation is usual, though diarrhoea may occur. Additional signs: Rovsings sign (Pain in RIF than LIF when the LIF is pressed). Psoas sign (Pain on extending hip if retrocaecal appendix).",
    "These principles also help ultrasound understand patterns of referred Pain. In pneumonia, the T9 dermatome is shared by the lung and the abdomen. Also, irritation of the underside of the diaphragm (sensory innervation is from above through the phrenic nerve, C35) by an infl amed gallbladder or a subphrenic abscess refers Pain to the right shoulder: dermatomes C35. Ectopic (do a pregnancy Cholecystitis Crohns disease test! ) Diverticulitis Perforated ulcer UTI (test Urine! ) Salpingitis/PID Food poisoning Mesenteric adenitis Dysmenorrhoea Meckels diverticulum Cystitis. Fig 13. 27 Appendicectomy. Reproduced from McLatchie et al. , Operative Surgery, 2006, with permission from Oxford University Press. __OOHHCCMM__1100ee. . iinnddbb 660099 0022//0055//22001177 1199: : 0088 610 yregruS Obstruction of the bowel Cardinal features of intestinal obstruction Vomiting, 9 nausea and anorexia. Colic occurs early ( in long-standing obstruction). Constipation may be absolute (ie no faeces or fl atus passed) in distal obstruction; less pronounced if obstruction is High. Abdominal distension as the obstruction progresses with active, tinkling bowel sounds. The key decisions 1 Is it obstruction of the small or large bowel? In small bowel obstruction, Vomiting occurs early, distension is less, and Pain is higher in the abdomen; in large bowel obstruction, Pain is more constant. The AXR plays a key role (fi g 13. 28 p728). 2 Is there an ileus or mechanical obstruction? Ileus is functional obstruction from bowel motility (see BOX Paralytic ileus or pseudo-obstruction? p728). Bowel sounds are absent; Pain tends to be less. 3 Is the obstructed bowel simple/closed loop/strangulated? Simple: one obstructing point and no vascular compromise. Closed loop: obstruction at two points (eg sigmoid volvulus) forming a loop of grossly distended bowel at risk of perforation. Strangulated: Blood supply is compromised and the patient is iller than you would expect. There is sharper, more constant, and localized Pain. Peritonism is the cardinal sign. There may be fever WCC with other signs of mesenteric ischaemia (p620). Causes See table 13. 12. Table 13. 12 Causes of bowel obstruction Causes: small bowel Causes: large bowel Rarer causes Adhesions (p581) Colon calcium (p616) Crohns stricture Hernias (p612) Constipation (p260) Gallstone ileus (p634) Diverticular stricture Intussusception Volvulus TB (developing world) Sigmoid (see BOX Sigmoid Foreign body volvulus) Caecal Management General principles: Cause, site, speed of onset, and completeness of obstruction determine defi nitive therapy: strangulation and large bowel obstruction require surgery; ileus and incomplete small bowel obstruction can be managed conservatively, at least initially. Immediate action: Drip and suckNGT and IV fl uids to rehydrate and correct electrolyte imbalance (p668). Being NBM does not give adequate rest for the bowel because it can produce up to 9L of fl uid/d. Also: analgesia, Blood tests (inc. amylase, FBC, UE), AXR, erect CXR, catheterize to monitor fl uid status. Further imaging: computed tomography to establish the cause of obstruction (may show dilated, fl uidfi lled bowel and a transition zone at the site of obstructionfi gs 13. 29, 13. 30). Oral Gastrografi n prior to computed tomography can help identify level of obstruction and may have mild therapeutic action against mechanical obstruction. Consider investigating the cause of large bowel obstruction by colonoscopy but beware risk of perforation. Surgery: Strangulation needs emergency surgery. Closed loop obstruction may be managed with surgery or endoscopic decompression attempted. Endoscopic stenting may be used for obstructing large bowel malignancies either in palliation or as a bridge to surgery in acute obstruction (p616). Small bowel obstruction secondary to adhesions should rarely lead to surgerysee BOX, p581. 9 Fermentation of the intestinal contents in established obstruction causes faeculent vomiti ng.",
    "The spermatic cord: Vas deferens, obliterated processus vaginalis, and lymphatics. Arteries to the vas, cremaster, and testis. The pampiniform plexus and the venous equivalent of the above. The genital branch of the genitofemoral nerve and sympathetic nerves. The ilioinguinal nerve, which enters the inguinal canal via the anterior wall and runs anteriorly to the cord. NB: in the female the round ligament of the uterus is in place of the male structures. A hydrocele of the canal of Nuck is the female equivalent of a hydrocele of the cord. __OOHHCCMM__1100ee. . iinnddbb 661155 0022//0055//22001177 1199: : 0088 616 yregruS Colorectal carcinoma This is the 3rd most common cancer and 2nd most common cause of UK cancer deaths (16 000 deaths/yr). Usually adenocarcinoma. 86% of presentations are in those 60yrs old. Lifetime UK incidence: 1: 15; 1: 19. Predisposing factors Neoplastic polyps (see BOX p520); IBD (UC and Crohns); genetic predisposition (8%), eg FAP and HNPCC (see p521); diet (Low-fi bre; red and processed meat); alcohol; smoking; previous cancer. Prevention: While routine chemoprevention is not currently recommended due to gastrointestinal SES, aspirin ≥75mg/d reduces incidence and mortality. Presentation depends on site: Left-sided: Bleeding/mucus PR; altered bowel habit or obstruction (25%); tenesmus; mass PR (60%). Right: Weight; hemoglobin; abdominal Pain; obstruction less likely. Either: Abdominal mass; perforation; haemorrhage; fi stula. See p522 for a guide to urgent referral criteria. See fi g 13. 34 for distribution. Tests FBC (microcytic anaemia); faecal occult Blood (FOB, see BOX); sigmoidoscopy or colonoscopy (fi gs 6. 7 6. 8, p249), which can be done virtually by computed tomography (fi g 16. 31, p743); LFT; Liver magnetic resonance imaging/ultrasound. CEA (p531) may be used to monitor disease and eff ectiveness of treatment. If family history of FAP, refer for DNA test once 15yrs old. Spread Local, lymphatic, by Blood (Liver, lung, bone) or transcoelomic. The TNM system (Tumour, Node, Metastases see table 13. 13 and p523) is used to stage disease and is preferred to the older Dukes classifi cation (Dukes A: limited to muscularis mucosae; Dukes B: extension through muscularis mucosae; Dukes C: involvement of regional lymph nodes). Surgery aims to cure and may survival times by up to 50%. In elective surgery, anastomosis is typically achieved at the 1st operation. Laparoscopic surgery has revolutionized surgery for colon cancer. It is as safe as open surgery and there is no diff erence in overall survival or disease recurrence. Right hemicolectomy for caecal, ascending, or proximal transverse colon tumours. Left hemicolectomy for tumours in distal transverse or descending colon. Sigmoid colectomy for sigmoid tumours. Anterior resection for Low sigmoid or High rectal tumours. Abdomino-perineal (AP) resection for tumours Low in the rectum (8cm from anus): permanent colostomy and removal of rectum and anus. Hartmanns procedure in emergency bowel obstruction, perforation, or palliation (p582). Transanal endoscopic microsurgery allows local excision through a wide proctoscope for localized rectal disease. Endoscopic stenting should be considered for palliation in malignant obstruction and as a bridge to surgery in acute obstruction. Stenting need for colostomy, has less complications than emergency surgery, shortens intensive care and total hospital stays, and prevents unnecessary opera tions. Surgery with Liver resection may be curative if single-lobe hepatic metastases and no extrahepatic spread. Radiotherapy is mostly used in palliation for colonic cancer. It is occasionally used pre-op in rectal cancer to allow resection. Post-op radiotherapy is only used in patients with rectal tumours at High risk of local recurrence. Chemotherapy Adjuvant chemotherapy for stage 3 disease has been shown to reduce disease recurrence by 30% and mortality by 25%.",
    "Chemotherapy Adjuvant chemotherapy for stage 3 disease has been shown to reduce disease recurrence by 30% and mortality by 25%. Benefi ts for stage 2 disease are more marginal and warrant an individualized approach. The FOLFOX regimen has become standard (fl uorouracil, folinic acid and oxaliplatin). Chemotherapy is also used in palliation of metastatic disease. Biological therapies: Bevacizumab (antiVEGF antibody) improves survival when added to combination therapy in advanced disease. Cetuximab and panitumumab (anti-estimated glomerular filtration rate agents) improve response rate and survival in KRAS wild-type metastatic colorectal cancer. Prognosis Survival is dependent on age and stage; for stage 1 disease, 5yr survival is 75% but this drops to just 5% with diagnosis at stage 4, hence the imperative for eff ective screening (BOX). __OOHHCCMM__1100ee. . iinnddbb 661166 0022//0055//22001177 1199: : 0088 617 yregruS Right side Left side Splenic flexure 2% Hepatic flexure 3% Ascending colon 7% Transverse colon 5% Descending colon 3% Caecum 14% Sigmoid colon 20% Appendix 1% Rectum 27% Anus 2% Other and unspecified 9% Fig 13. 34 Distribution of colorectal carcinomas. These are averages: black females tend to have more proximal neoplasms. White men tend to have more distal neoplasms. TNM staging in colorectal cancer Table 13. 13 Colorectal cancer: TNM staging transplant Primary tumour cannot be assessed Nx Nodes cannot be assessed Tis Carcinoma in situ N0 No node spread T1 Invading submucosa N1 Metastases in 13 regional nodes T2 Invading muscularis propria N2 Metastases in 3 regional nodes T3 Invading subserosa and beyond (not M0 No distant spread other organs) T4 Invasion of adjacent structures M1 Distant metastasis Reproduced with permission from Edge, SB et al. (Eds. ), AJCC Cancer Staging Manual, 7th Edition. New York: Springer; 2010. TNM status used to defi ne overall stage. This is complex with several important subtypes, but in essence, stage 1 disease is T1 or T2/N0/M0; stage 2 is T3 or T4/N0/M0; stage 3 is characterized by N1 or N2 but still M0; stage 4 is M1. Polyps, the challenges of screening, and the NHS Polyps are growths that appear above the mucosa and can be infl ammatory, hamartomatous, or neoplastic. Left in situ, polyps carry a risk of malignant transformation that will relate to size and histology (tubular or villous adenomas, esp. if 2cm). Patients with polyps may have no symptoms and thus a colonoscopy is required to detect and remove. Colonscopy allows the opportunity to detect colorectal cancer at an earlier stage when treatment may be more eff ective. However, population-based colonoscopic screening is costly and some studies have suggested that the test does not impact on deaths from right-sided cancers which are rarer and harder to detect (fi g 13. 34). Therefore, the NHS has introduced a one-off screening fl exible sigmoidoscopy off ered to all people in their 55th year. Trial results have shown the incidence of colorectal cancer in the intervention (screening) group is reduced by 33% and mortality from colorectal cancer is reduced by 43%. Number needed to screen to prevent one diagnosis (191); or death (489). In parallel, the NHS Bowel Cancer Screening Programme (introduced in 2006) offers colonoscopy to all men and women aged 6075 who test positive for faecal occult Blood (FOB) using a home testing kit performed every 2 years. This FOBstratifi cation targets screening to those in the highest risk groups, permitting detection of more advanced adenomas and early stage cancers. The relative risk of death from colorectal cancer in patients undergoing screening is reduced by 16%.",
    "The relative risk of death from colorectal cancer in patients undergoing screening is reduced by 16%. A 11% increase in incidence rates since 2006 for people aged 6069 is almost certainly due to earlier detection through the screening programme. __OOHHCCMM__1100ee. . iinnddbb 661177 0022//0055//22001177 1199: : 0088 618 yregruS Carcinoma of the oesophagus Incidence Australia 5/100 000/yr; UK 9; Iran 100. Risk factors: Diet, alcohol excess, smoking, achalasia, refl ux oesophagitis ± Barretts oesophagus (p695); obesity, hot drinks, nitrosamine exposure, PlummerVinson syndrome (p250). : 5: 1. Site 20% occur in the upper part, 50% in the middle, and 30% in the lower part. They may be squamous cell (proximal) or adenocarcinomas (distal; incidence rising). Presentation Dysphagia; weight; retrosternal chest Pain. Signs from the upper third of the oesophagus: Hoarseness; cough (may be paroxysmal if aspiration pneumonia). : See Dysphagia, p250. Tests Oesophagoscopy with biopsy is the investigation of choice ± EUS, computed tomography/magnetic resonance imaging for staging (fi g 13. 35), or laparoscopy if signifi cant infra-diaphragmatic component. Staging: See table 13. 14. Treatment Survival rates are poor with or without treatment. If localized T1/T2 disease, radical curative oesophagectomy may be tried. Pre-op chemotherapy (cisplatin fl uorouracil) for localized disease may improve survival, but causes some morbidity. If surgery is not indicated, then chemor adiotherapy may be better than radiotherapy alone. Palliation in advanced disease aims to restore swallowing with chemo/radiotherapy, stenting, and laser use. TNM staging in oesophageal cancer Spread of oesophageal cancer is direct, by submucosal infi ltration and local spreador to nodes, or, later, via the Blood. Table 13. 14 Oesophageal cancer: TNM staging Tis Carcinoma in situ Nx Nodes cannot be assessed T1 Invading lamina propria/submucosa N0 No node spread T2 Invading muscularis propria N1N3 Regional node metastases T3 Invading adventitia M0 No distant spread T4 Invasion of adjacent structures M1 Distant metastasis Reproduced with permission from Edge, SB et al. (Eds. ), AJCC Cancer Staging Manual, 7th Edition. New York: Springer; 2010. Fig 13. 35 Axial computed tomography of the chest after IV contrast medium showing concentric thickening of the oesophagus (arrow); the diagnosis here is oesophageal carcinoma. Loss of the fatty plane around the oesophagus suggests local invasion. Anterior to the oesophagus is the trachea and next to it is the arch of the aorta. Image courtesy of Dr Stephen Golding. __OOHHCCMM__1100ee. . iinnddbb 661188 0022//0055//22001177 1199: : 0088 619 yregruS Carcinoma of the stomach Incidence of adenocarcinoma at the gastro-oesophageal junction is increasing in the West, though incidence of distal and gastric body carcinoma has fallen sharply. It remains a tumour notable for its gloomy prognosis and non-specifi c presentation. Incidence 23/100 000/yr in the UK, but there are unexplained wide geographical variations; it is espe cially common in Japan, as well as Eastern Europe, China, and South America. : 2: 1. Risk factors: Pernicious anaemia, Blood group A, H. pylori (p252), atrophic gastritis, adenomatous polyps, lower social class, smoking, diet (High nitrate, High salt, pickling, Low vitamin C), nitrosamine exposure. Pathology A range of clinical and histological classifi cations are in use. Of note, early gastric carcinoma (confi ned to mucosa and submucosa) carries a better prognosis with endoscopic resection often possible. Presentation Symptoms: Often non-specifi c. Dyspepsia (p59; age ≥55yrs with treatment-refractory symptoms demands investigation), weight, Vomiting, dysphagia, anaemia. Signs suggesting incurable disease: epigastric mass, hepatomegaly; jaundice, ascites (p604); large left supraclavicular (Virchows) node (Troisiers sign); acanthosis nigricans (p562). Most patients in the West present with locally advanced (inoperable) or metastatic disease. Spread is local, lymphatic, Blood-borne, and transcoelomic, eg to ovaries (Krukenberg tumour). Tests Gastroscopy multiple ulcer edge biopsies.",
    "Spread is local, lymphatic, Blood-borne, and transcoelomic, eg to ovaries (Krukenberg tumour). Tests Gastroscopy multiple ulcer edge biopsies. Aim to biopsy all gastric ulcers as even malignant ulcers may appear to heal on drug treatment. Endoscopic ultrasound (EUS) can evaluate depth of invasion; computed tomography/magnetic resonance imaging helps staging. Staging laparoscopy is recommended for locally advanced tumours. Cytology of peritoneal washings can help identify peritoneal metastases. Treatment See p622 for a description of surgical resections. Early gastric cancers may be resectable endoscopically (endoscopic mucosal resection). Partial gastrectomy may suffi ce for more advanced distal tumours. If proximal, total gast rectomy may be needed. Combination chemotherapy (eg epirubicin, cisplatin and fl uorouracil) appears to increase survival in advanced disease. If given perioperatively in operable disease it improves survival compared to surgery alone. Surgical palliation is often needed for obstruction, Pain, or haemorrhage. In locally advanced and metastatic disease, chemotherapy increases quality of life and survival. Targeted therapies are likely to have an increasing role, eg trastuzumab for HER-2-positive tumours. 5yr survival 10% overall, but nearly 20% for patients undergoing radical surgery. The prognosis is much better for early gastric carcinoma. Bile duct and gallbladder cancers All are rare, have an overall poor prognosis, and are diffi cult to diagnose. They before mealscount for 3% of all GI cancers worldwide, but there is geographical variation ( in north-east Thailand, Japan, Korea, and Eastern Europe). Most are adenocarcinomas. Primary sclerosing cholangitis (p282) is the commonest predisposing factor in the West. Presentation: Varies according to location and may include obstructive jaundice, pruritus, abdominal Pain, weight loss, and anorexia. Investigations: ultrasound, computed tomography, and ERCP. magnetic resonance imaging has a role for determining extent of invasion in bile duct cancers. Treatment: Bile duct cancer: surgical resection is the only potentially curative treatment yet 80% present with inoperable disease. Palliation includes biliary stenting and chemotherapy. Gallbladder cancer: again, radical surgery is the only chance of cure. Patients with a calcified (porcelain) gallbladder have an increased risk of cancerprophylactic surgery should be considered. Palliative treatment of inoperable disease includes biliary stenting and chemotherapy. __OOHHCCMM__1100ee. . iinnddbb 661199 0022//0055//22001177 1199: : 0088 620 yregruS Bowel ischaemia There are three main types of bowel ischaemia: atrial fibrillation with abdominal Pain should always prompt thoughts of mesenteric ischaemia. 1 Acute mesenteric ischaemia almost always involves the small bowel and may follow superior mesenteric artery (SMA; fi g 13. 36) thrombosis (35%) or embolism (35%), mesenteric vein thrombosis (5%; younger patients with hypercoagulable statestends to aff ect smaller lengths of bowel), or non-occlusive disease (20%; occurs in Low-fl ow states and usually refl ects poor cardiac output, though there may be other factors such as recent cardiac surgery or renal failure). Other causes include trauma, vasculitis (p556), radiotherapy, or strangulation (volvulus or hernia, p612). Presentation is a classical clinical triad: acute severe abdominal Pain; no/minimal abdominal signs; rapid hypovolaemiashock. Pain tends to be constant, central, or around the RIF. The degree of illness is often far out of proportion with clinical signs. Tests: There may be hemoglobin (due to plasma loss), WCC, modestly raised plasma amylase, and a persistent metabolic acidosis (High lactate). Early on, the abdominal x-ray shows a gasless abdomen. computed tomography/MR may show evidence of ischaemia with computed tomography/MR angiography or formal arteriography if doubt remains. Often the diganosis is made on fi nding a nasty, necrotic bowel at laparotomy. Treatment: The main life-threatening complications secondary to acute mesenteric ischaemia are 1 septic peritonitis and 2 progression of a systemic infl ammatory response syndrome (SIRS) to multi-organ failure, mediated by bacterial translocation across the dying gut wall.",
    "Physical complications of gastrectomy Abdominal fullness: Feeling of early satiety (± discomfort and distension) improving with time. Advise to take small, frequent meals. Afferent loop syndrome: Post-gastrectomy (eg Billroth II), the aff erent loop may fi ll with bile after a meal, causing upper abdominal Pain and bilious vomiting. This is diffi cult to treatbut often improves with time. Diarrhoea: May be disabling after vagotomy. Codeine phosphate may help. Gastric tumour: A rare complication of any surgery which acid production. Amylase: If with abdominal Pain, this may indicate aff erent loop obstruction after Billroth II surgery and requires emergency surgery. Metabolic complications Dumping syndrome: Fainting and sweating after eating due to food of High osmotic potential being dumped in the jejunum, causing oligaemia from rapid fl uid shifts. Late dumping is due to rebound hypoglycaemia and occurs 13h after meals. Both tend to improve with time but may be helped by eating less Glucose, and more guar gum and pectin (slows glucose absorption). Acarbose may also help to reduce the early hyperglycaemic stimulus to insulin secretion. Weight loss: Often due to poor calorie intake. Bacterial overgrowth ± malabsorption (blind loop syndrome) may occur. Anaemia: Usually from lack of iron, hypochlorhydria, and stomach resection. B12 levels are frequently Low but megaloblastic anaemia is rare. Osteomalacia: There may be pseudofractures which look like metastases. __OOHHCCMM__1100ee. . iinnddbb 662222 0022//0055//22001177 1199: : 0088 623 yregruS Oesophagus Stomach Bile duct Duodenum Bile Gastrojejunostomy (stomach joined to jejunum) Jejunum Fig 13. 37 Billroth II. Fig 13. 38 The Roux-en-Y reconstruction. Theodor Billroth Theodor Billroth was a surgeon of German-Austrian origin, whose name lives on as a set of operations on the stomach. He was a pioneer of abdominal surgery and the use of aseptic techniques, performing the fi rst Billroth I procedure in 1881 for the resection of a pyloric gastric carcinoma. Among the many of his remarkable achievements is included the fi rst laryngectomy. He was also a talented musician (a close friend of Brahms) and a dedicated educator with something of a realists view of the world: The pleasure of a physician is little, the gratitude of patients is rare, and even rarer is material reward, but these things will never deter the student who feels the call within him. Theodor Billroth (182994). __OOHHCCMM__1100ee. . iinnddbb 662233 0022//0055//22001177 1199: : 0088 624 yregruS Fundoplication for gastro-oesophageal refl ux Laparoscopic fundoplication is the surgical procedure of choice when symptoms of GORD are refractory to medical therapy and there is severe refl ux (confi rmed by pHmonitoring)see p254. Symptoms may be complicated by a hiatus hernia, which is repaired during the procedure. Surgery The defect in the diaphragm is repaired by tightening the crura. Refl ux is prevented by wrapping the gastric fundus around the lower oesophageal sphinctersee fi g 13. 39. There are various types of procedure, eg Nissen (360° wrap), Toupet (270° posterior wrap), Watson (anterior hemifundoplication). Laparoscopic surgery is at least as eff ective at controlling refl ux as open surgery but with a lower mortality and morbidity. Wound infections and respiratory complications are also more common in open surgery, though the incidence of dysphagia is similar for the two proceduresbut see p592. Complications Dysphagia (if the wrap is too tight), gas-bloat syndrome (inability to belch/vomit), and new-onset diarrhoea. Diaphragm Surgical instrument Oesophagus Oesophagus Oesophagus The gastric fundus Lower is wrapped around oesophageal the lower sphincter oesophageal Tightened sphincter hiatus Stomach Stomach Lower oesophageal sphincter Fig 13. 39 Laparoscopic Nissen fundoplication. Oesophageal rupture Causes Iatrogenic, eg endoscopy/biopsy/dilatation (accounts for 8590% of perforations). Trauma, eg penetrating injury/ingestion of foreign body.",
    "Oesophageal rupture Causes Iatrogenic, eg endoscopy/biopsy/dilatation (accounts for 8590% of perforations). Trauma, eg penetrating injury/ingestion of foreign body. Carcinoma Boerhaave syndromerupture due to violent Vomiting. Corrosive ingestion. Clinical features Odynophagia, tachypnoea, dyspnoea, fever, shock, surgical emphysema (a crackling sensation felt on palpating the skin over the chest or neck caused by air tracking from the lungs. : Pneumothorax). Iatrogenic perforations are less prone to mediastinitis and sepsis and may be managed conservatively with NG tube, proton pump inhibitor, and antibiotics. Others require resuscitation, proton pump inhibitor, antibiotics, antifungals, and surgery (debridement of mediastinum and placement of T-tube for drainage and formation of a controlled oesophago-cutaneous fi stula). __OOHHCCMM__1100ee. . iinnddbb 662244 0022//0055//22001177 1199: : 0088 625 yregruS __OOHHCCMM__1100ee. . iinnddbb 662255 0022//0055//22001177 1199: : 0088 626 yregruS Surgical management of obesity Severe obesity is increasing in prevalence worldwide and is associated with type 2 Diabetes mellitus (type 2 diabetes mellitus); hypertension; ischaemic Heart disease; sleep apnoea; osteoarthritis; and depression. Bariatric surgery has become very successful at weight reduction, symptom improvement, and improving quality of life. Surgery increases life expectancy by around 3 years (but may not prolong survival in High-risk men). Indications: According to NICE guidelines, 9 weight-loss surgery in adults should be considered if all the following criteria are met: 1 body mass index ≥40 (or ≥35 with signifi cant comorbidities that could improve with weight). 2 Failure of non-surgical management to achieve and maintain clinically benefi cial weight loss for 6 months. 3 Fitness for surgery and anaesthesia. 4 Intensive management in tier 3 service (provides guidance on diet, physical before mealstivity, and psychosocial concerns, as well as lifelong medical monitoring). 5 The patient must be well informed and motivated. If body mass index ≥50, or in newly diagnosed type 2 diabetes mellitus with body mass index ≥30, surgery is recommended as fi rst-line treatment. Comparison with medical therapy Surgery is more eff ective in achieving weight loss than non-surgical management and weight loss is more likely to be maintained in the longer term. Adverse events are more common following surgery, and vary from one procedure to another. Procedures There are two main mechanisms causing weight loss: 1 Restriction of calorie intake by reducing stomach capacity. 2 Malabsorption of nutrients by reducing the length of functional small bowel. NB: This also aff ects the levels of circulating gut peptides (eg PYY and GLP-1), which are thought to play a role in the mechanism of satiety and weight loss. Choose surgical intervention jointly with patient: Laparoscopic adjustable gastric banding (LAGB): This restrictive technique creates a pre-stomach pouch by placing a silicone band around the top of the stomach, which serves as a new smaller stomach. The band can be adjusted by addition or removal of saline through a subcutaneous port (see fi g 13. 40). LAGB is associated with improvements in comorbidities and quality of life. Weight loss is slower and less than with gastric bypass but there is lower mortality and fewer complications. Relatively noninvasive and band removal possible. Complications: pouch enlargement, band slip, band erosion, and port infection/breakage. Sleeve gastrectomy: (fi g 13. 41) Involves division of the stomach vertically, reducing it in size by about 75%. The pyloric valve at the bottom of the stomach is left intact so function and digestion are unaltered. The procedure is not reversible and may be a fi rst stage for progression to Roux-en-Y gastric bypass or duodenal switch in very obese patients where a single-stage procedure would be technically diffi cult or unsafe. Roux-en-Y gastric bypass: (fi g 13. 42) Laparoscopic or open.",
    "Roux-en-Y gastric bypass: (fi g 13. 42) Laparoscopic or open. A portion of the jejunum is attached to a small stomach pouch to allow food to bypass the distal stomach, duodenum, and proximal jejunum. It can be performed laparoscopically and works by both restriction and malabsorption. Mean excess weight loss at 5 years is 62. 8%. Current evidence demonstrates greater weight loss, greater resolution of comorbidities, and lower reoperation rates compared to LAGB. Complications: myocardial infarctioncronutrient defi ciency (requires vitamin supplementation and lifelong follow-up/ Blood tests), dumping syndrome, wound infection, hernias, malabsorption, diarrhoea, and a mortality of 0. 5% (at experienced centres). __OOHHCCMM__1100ee. . iinnddbb 662266 0022//0055//22001177 1199: : 0088 627 yregruS Oesophagus Pouch Adjustable band Duodenum Subcutaneous access port Fig 13. 40 Adjustable gastric band. Gastric sleeve Pylorus Excised stomach Fig 13. 41 Vertical sleeve gastrectomy. Fig 13. 42 Gastric bypass. __OOHHCCMM__1100ee. . iinnddbb 662277 0022//0055//22001177 1199: : 0088 628 yregruS Diverticular disease A GI diverticulum is an outpouching of the gut wall, usually at sites of entry of perforating arteries. Diverticulosis means that diverticula are present, and diverticular disease implies they are symptomatic. Diverticulitis refers to infl ammation of a diverticulum. Diverticula can be aquired or congenital and may occur elsewhere, but the most important are acquired colonic diverticula, to which this page refers. Pathology Most within sigmoid colon with 95% of complications at this site, but right-sided and massive single diverticula can occur. High intraluminal pressures (due, perhaps, to lack of dietary fi bre) force the mucosa to herniate through the muscle layers of the gut at weak points adjacent to penetrating vessels. 30% of Westerners have diverticulosis by age 60. The majority are asymptomatic. Diagnosis Diverticula are a common incidental fi nding at colonoscopy (fi g 6. 11, p249). computed tomography abdomen is best to confi rm acute diverticulitis and can identify extent of disease and any complications (eg colovesical fi stulae). Colonoscopy risk perforation in acute setting. AXR may identify obstruction or free air (perforation). Diverticular disease Altered bowel habit ± left-sided colic relieved by defecation; nausea and fl atulence. High-fi bre diets do not help symptoms; try antispasmodics, eg mebeverine 135mg/8h PO. Surgical resection occasionally resorted to. Diverticulitis features above pyrexia, WCC, CRP/ESR, a tender colon ± localized or generalized peritonism. Mild attacks can be treated at home with bowel rest (fl uids only) ± antibiotics. If fl uids and Pain not tolerated, admit for analgesia, NBM, IV fl uids and IV antibiotics. Most attacks settle but complications include abscess formation (neces sitating percutaneous computed tomography-guided drainage), or perforation. Beware diverticulitis in immunocompromised patients (eg on steroids) who often have few symptoms and may present late. Surgery The need for surgery is refl ected by the degree of infective complications: Stage 1 Pericolic or mesenteric abscess Surgery rarely needed Stage 2 Walled off or pelvic abscess May resolve without surgery Stage 3 Generalized purulent peritonitis Surgery required Stage 4 Generalized faecal peritonitis Surgery required Indications for elective surgery include stenosis, fi stulae, or recurrent bleeding. Complications Perforation: There is ileus, peritonitis ± shock. Mortality: 40%. Manage as for an acute abdomen. At laparotomy a Hartmanns procedure may be performed (p582). Primary anastomosis is possible in selected patients. Emergency laparoscopic management is an emerging alternative. Haemorrhage is usually sudden and painless. It is a common cause of big rectal bleeds (p629). Embolization (at angiography) or colonic resection only necessary if ongoing massive bleeding and colonoscopic haemostasis has been unsuccessful. Fistulae: Enterocolic, colovaginal, or colovesical (pneumaturia ± intractable UTIS). Treatment is surgical, eg colonic resection.",
    "Fistulae: Enterocolic, colovaginal, or colovesical (pneumaturia ± intractable UTIS). Treatment is surgical, eg colonic resection. Abscesses, eg with swinging fever, leucocytosis, and localizing signs, eg boggy rectal mass (pelvic abscessdrain rectally). If no localizing signs, remember the aphorism: pus somewhere, pus nowhere pus under the diaphragm. A subphrenic abscess is a horrible way to die, so do an urgent ultrasound. Antibiotics ± ultrasound/computed tomography-guided drainage may be needed. Post-infective strictures may form in the sigmoid colon. __OOHHCCMM__1100ee. . iinnddbb 662288 0022//0055//22001177 1199: : 0088 629 yregruS Rectal bleedingan acute management plan Causes Diverticulitis, colorectal cancer, haemorrhoids, IBD, perianal disease, angiodyplasia (submucosal arteriovenous malformations, typically elderly). Rarities: trauma, ischaemia colitis, radiation proctitis, aorto-enteric fi stula. An acute mana gement plan for this common surgical event: ABC resuscitation, if necessary. History and examination. Blood tests: FBC, UE, LFT, clotting, amyl ase (always thinking of pancreatitis), CRP, group and saveawait hemoglobin result before crossmatching unless unstable and bleeding. Imaging: May only need plain AXR, but if there are signs of perforation (eg sepsis, peritonism) or if there is cardiorespiratory comorbidity, then request an erect CXR. Fluid management: Insert 2 cannulae (≥18G) into the antecubital fossae. Insert a urinary catheter if there is a suspicion of haemodynamic comprom isethere is no absolute indication, but remember that you are weighing up the risks and benefi ts. Give crystalloid as replacement and maintenance IVI. Blood transfusion only if signifi cant Blood loss (table 13. 10, p607). Clotting: Withold ± reverse anticoagulation and antiplatelet agents (p351). Antibiotics may occasionally be required if there is evidence of sepsis or perforation, eg piperacillin/tazobactam 4. 5g/8h IV. Keep bedbound: The patient may feel the need to get out of bed to pass stool, but this could be another large bleed, resulting in collapse if they try to walk. Dont allow them to mobilize and inform the nursing staff of this. Start a stool chart to monitor volume and frequency of motions. Send a sample for MCS (x3 if known to have compromising comorbidity such as IBD). Diet: Keep on clear fl uids so that they can have something, yet the colon will be as clear as possible if colonoscopy required. Interventions if bleeding not settling with conservative management: Angiography may allow localization of bleeding (eg sigmoid diverticulum or right sided angiodysplasia) as well as therapeutic embolization; computed tomography angiography is a non-invasive alternative (without interventional options); colonoscopy may permit endoscopic haemostasis. Surgery: The main indication for this is unremitting, massive bleeding that is not controlled by other means. __OOHHCCMM__1100ee. . iinnddbb 662299 0022//0055//22001177 1199: : 0088 630 yregruS Perianal problems Pruritus ani Itch occurs if the anus is moist/soiled; fi ssures, incontinence, poor hygiene, tight pants, threadworm, fi stula, dermatoses, lichen sclerosis, anxiety, contact dermatitis (perfumed goods). Cause is often unknown. : Avoid scratching, perianal hygiene, avoid foods which loosen stools. Soothing ointment, mild topical corticosteroid if perinanal infl ammation (max 2wks), oral antihistamine for noctural itch. Fissure-in-ano Painful tear in the squamous lining of the lower anal canaloften, if chronic, with a sentinel pile or mucosal tag at the external aspect. 90% are posterior (anterior ones follow parturition). . Causes: Most are due to hard faeces. Spasm may constrict the inferior rectal artery, causing ischaemia, making healing diffi cult and perpetuating the problem. Rare causes (multiple ± lateral): syphilis; herpes; trauma; Crohns; anal cancer; psoriasis. Groin nodes suggest a complicating factor (eg immunosuppression/HIV). : 5% lidocaine ointment GTN ointment (0. 20. 4%) or topical diltiazem (2%); dietary fi bre, fl uids, stool softener, and hygiene advice.",
    "20. 4%) or topical diltiazem (2%); dietary fi bre, fl uids, stool softener, and hygiene advice. Botulinum toxin injection (2nd line) and topical diltiazem (2%) are at least as eff ective as GTN with fewer side-eff ects. If conservative measures fail, surgical options include lateral partial internal sphincterotomy. Fistula-in-ano A track communicates between the skin and anal canal/rectum. Blockage of deep intramuscular gland ducts is thought to predispose to the formation of abscesses, which discharge to form the fi stula. Goodsalls rule determines the path of the fi stula track: if anterior, the track is in a straight line (radial); if posterior, the internal opening is always at the 6 oclock position, taking a tortuous course. Causes: perianal sepsis, abscesses (see later in topic), Crohns disease, TB, diverticular disease, rectal carcinoma, immunocompromise. Tests: magnetic resonance imaging; endoanal ultrasound scan. : Fistulot omy excision. High fi stulae (involving continence muscles of anus) require seton suture tightened over time to maintain continence; Low fi stulae are laid open to heal by secondary intentiondivision of sphincters poses no risk to continence. Anorectal abscesses Usually caused by gut organisms (rarely staphs or TB). : 1: 8. Perianal (45%), ischiorectal (≤30%), intersphincteric (20%), supralevator (5%) (fi g 13. 43). : Incise drain under GA. Associations: diabetes mellitus, Crohns, malignancy, fi stulae. Perianal haematoma (AKA thrombosed external pilesee p633). Strictly, it is actually a clotted venous saccule. It appears as a 24mm dark blueberry under the skin at the anal margin. It may be evacuated under LA or left to resolve spontaneously. Pilonidal sinus Obstruction of natal cleft hair follicles 6cm above the anus. Ingrowing of hair excites a foreign body reaction and may cause secondary tracks to open laterally ± abscesses, with foul-smelling discharge. (Barbers get these between fi ngers. ) : 10: 1. Obese Caucasians and those from Asia, the Middle East, and Mediterranean at risk. : Excision of the sinus tract ± primary closure. Consider preop antibiotics. Complex tracks can be laid open and packed individually, or skin fl aps can be used to cover the defect. Off er hygiene and hair removal advice. Rectal prolapse The mucosa (partial/type 1), or all layers (complete/type 2more common), may protrude through the anus. Incontinence in 75%. It is due to a lax sphincter, prolonged straining, and related to chronic neurological and psychological disorders. : Abdominal approach: fi x rectum to sacrum (rectopexy) ± mesh insertion ± rectosigmoidectomy. Laparoscopic rectoplexy is as eff ective as open repair. Perineal approach: Delormes procedure (resect close to dentate line and suture mucosal boundaries), anal encirclement with a Thiersch wire. Perianal warts Condylomata acuminata (viral warts) are treated with podophyllotoxin or imiquimod or cryotherapy/surgical excision. Giant condylomata acuminata of Buschke Loewenstein may evolve into verrucous cancers (Low-grade, non-metastasizing). Condylomata lata secondary to syphilis is treated with penicillin. Proctalgia fugax Idiopathic, intense, brief, stabbing/crampy rectal Pain, often worse at night. The mainstay of treatment is reassurance. Inhaled salbutamol or topical GTN (0. 20. 4%) or topical diltiazem (2%) may help. Anal ulcers Consider Crohns, anal cancer, lymphogranuloma venerum, TB, syphilis. Skin tags Seldom cause trouble but are easily excised. __OOHHCCMM__1100ee. . iinnddbb 663300 0022//0055//22001177 1199: : 0088 631 yregruS Anal cancer Incidence: 1233 new cases of anal cancer in the UK (2013). Risk factors: Anorec eptive intercourse; HPV (HPV 16 associated with worse prognosis); HIV. Histology: Squamous cell (85%); rarely basaloid, melanoma, or adenocarcinoma. Anal margin tumours are usually well-diff erentiated, keratinizing lesions with a Good prognosis. Anal calciumnal tumours arise above dentate line, are poorly diff erentiated and non-keratinizing with a poorer prognosis.",
    "Anal calciumnal tumours arise above dentate line, are poorly diff erentiated and non-keratinizing with a poorer prognosis. Spread: Tumours above the dentate line spread to pelvic lymph nodes; those below spread to the inguinal nodes. Presentation: Bleeding, Pain, bowel habit change, pruritus ani, masses, stricture. : Perianal warts; leucoplakia; lichen sclerosis; Bowens disease; Crohns disease. Treatment: Chemoirradiation (radiotherapy fl uorouracil mitomycin/cisplatin) is usually prefer red to anor ectal excision colostomy; 75% retain normal anal function. Fig 13. 43 Anatomy of the anal canal. Perianal abscesses present as tender, infl amed, localized swellings at the anal verge. Ischiorectal abscess es are also tender but cause a diff use, indurated Edema in the ischioanal fossa area. You will fi nd your patient waiting anxiously for you, pac ing about, or on the edge of their chair: avoiding all Hypertension is imperative. NB: above the dentate line visceral nerve innervation (hence no Pain sensation); below somatic innervation (very sensitive to Pain). __OOHHCCMM__1100ee. . iinnddbb 663311 0022//0055//22001177 1199: : 0088 632 yregruS Haemorrhoids (piles) Defi nition Haemorrhoids (running Blood in Greek) are disrupted and dilated anal cushions. The anus is lined mainly by discontinuous masses of spongy vascular tissuethe anal cushions, which contribute to anal closure. Viewed from the lithotomy position, the three anal cushions are at 3, 7, and 11 oclock (where the three major arteries that feed the vascular plexuses enter the anal canal). They are attached by smooth muscle and elastic tissue, but are prone to displacement and disruption, either singly or together. The eff ects of gravity (standing), increased anal tone (? stress), and the eff ects of straining at stool may make them become both bulky and loose, and so to protrude to form piles (Latin pila, meaning a ball). They are vulnerable to trauma (eg from hard stools) and bleed readily from the capillaries (bright red Blood) of the underlying lamina propria. NB: piles are not varicose veins. As there are no sensory fi bres above the dentate line (squamomucosal junction), piles are not painful unless they thrombose when they protrude and are gripped by the anal sphincter, blocking venous return. See fi g 13. 44. Diff erential diagnosis Perianal haematoma; anal fi ssure; abscess; tumour; proctalgia fugax. Never ascribe rectal bleeding to piles without examination or investigation. Causes Constipation with prolonged straining is a key factor. In many the bowel habit may be normal. Congestion from a pelvic tumour, pregnancy, CCF, or portal hypertension are important in only a minority of cases. Elicit red fl ags in history. Pathogenesis There is a vicious circle: vascular cushions protrude through a tight anus, become more congested, and hypertrophy to protrude again more readily. These protrusions may then strangulate. See table 13. 15 for classifi cation. Symptoms Bright red rectal bleeding, often coating stools, on the tissue, or dripping into the pan after defecation. There may be mucous discharge and pruritus ani. Severe anaemia may occur. Symptoms such as weight loss, tenesmus, and change in bowel habit should prompt thoughts of other pathology. In all rectal bleeding do: An abdominal examination to rule out other diseases. PR exam: prolapsing piles are obvious. Internal haemorrhoids are not palpable. Colonoscopy/fl exible sigmoidoscopy to exclude proximal pathology if 50 years old. Treatment 1 Medical: (1st-degree. ) Fluid and fibre is key ± topical analgesics stool softener (bulk forming). Topical steroids for short periods only. 2 Non-operative: (2nd 3rd degree, or 1st degree if medical therapy failed. ) Rubber band ligation. Cheap, but needs skill. Banding produces an ulcer to anchor the mucosa (SE: bleeding, infection; Pain). It has the lowest recurrence rate. Sclerosants.",
    "Banding produces an ulcer to anchor the mucosa (SE: bleeding, infection; Pain). It has the lowest recurrence rate. Sclerosants. (1stor 2nd-degree. ) 2mL of 5% phenol in oil is injected into the pile above the dentate line, inducing fi brotic reaction. Recurrence higher (SE: impotence; prostatitis). Infra-red coagulation. Applied to localized areas of piles, it works by coagulating vessels and tethering mucosa to subcutaneous tissue. It is as successful as banding and may be less painful. Bipolar diathermy and direct current electrotherapy. Causes coagulation and fi brosis after local application of heat. Success rates are similar to those of infrared coagulation, and complication rates are Low. 3 Surgery: Excisional haemor rhoid ectomy is the most eff ective treatment (excision of piles ± ligation of vascular pedicles, as day-case surgery, needing 2wks off work). Scalpel, electrocautery, or laser may be used. Stapled haemorrhoidopexy (procedure for prolapsing haemorrhoids) may result in less Pain, a shorter hospital stay, and quicker return to normal activity than conventional surgery. It is used when there is a large internal component, but has a higher recurrence and prolapse rate than excisional. Surgical complications include constipation; infection; stricture; bleeding. Prolapsed, thrombosed piles Analgesia, ice packs, and stool softeners. Pain usually resolves in 23wks. Some advocate early surgery. __OOHHCCMM__1100ee. . iinnddbb 663322 0022//0055//22001177 1199: : 0088 633 yregruS Table 13. 15 Classifi cation of haemorrhoids 1st degree Remain in the rectum 2nd degree Prolapse through the anus on defecation but spontaneously reduce 3rd degree As for 2nd-degree but require digital reduction 4th degree Remain persistently prolapsed Fig 13. 44 Internal and external haemorrhoids. __OOHHCCMM__1100ee. . iinnddbb 663333 0022//0055//22001177 1199: : 0088 634 yregruS Gallstones Bile contains cholesterol, bile pigments (from broken down hemoglobin), and phospholipids. If the concentrations vary, diff erent stones may form. Pigment stones: Small, friable, and irregular. Causes: haemolysis. Cholesterol stones: Large, often solitary. Causes: , age, obesity (Admirands triangle: risk of stone if lecithin, bile salts, cholesterol). Mixed stones: Faceted (calcium salts, pigment, and cholesterol). Gallstone prevalence: 8% of those over 40yrs. 90% remain asymptomatic. Risk factors for stones becoming symptomatic: smoking; parity. Biliary colic Gallstones are symptomatic with cystic duct obstruction or if passed into the common bile duct (CBD10). RUQ Pain (radiates back) ± jaundice. : Analgesia (see p636), rehydrate, NBM. Elective laparoscopic cholecystectomy (see BOX Early or delayed cholecystectomy? ). Do urinalysis, CXR, and ECG. Acute cholecystitis follows stone or sludge impaction in the neck of the gallbladder (GB10), which may cause continuous epigastric or RUQ Pain (referred to the right shouldersee p609), Vomiting, fever, local peritonism, or a GB mass. The main difference from biliary colic is the infl ammatory component (local peritonism, fever, WCC; see table 13. 16). If the stone moves to the CBD, obstructive jaundice and cholangitis may occursee BOX Complications of gallstones. Murphys sign: lay 2 fi ngers over the RUQ; ask patient to breathe in. This causes Pain arrest of inspiration as an infl amed GB impinges on your fi ngers. It is only ve if the same test in the LUQ does not cause Pain. A phlegmon (RUQ mass of infl amed adherent omentum and bowel) may be palpable. Tests: WCC, ultrasounda thick-walled, shrunken GB (also seen in chronic disease), peri cholecystic fl uid, stones, CBD (dilated if 6mm). Plain AXR only shows 10% of gallstones; it may identify a porcelain GB (associated risk of cancer). Treatment: NBM, Pain relief, IVI, and antibiotics, eg co-amoxiclav 625mg/8h IV. Laparoscopic cholecystectomy is the treatment of choice for all patients fi t for GA. Open surgery is required if there is GB perforation.",
    "If elderly or High risk/unsuita ble for surgery, consi der percutaneous cholecystostomy; cholecystectomy can still be done later. Cholecystostomy is also the preferred treatment for acalculous cholecystitis. Chronic cholecystitis Chronic infl ammation ± colic. Flatulent dyspepsia: vague abdom inal discomfort, distension, nausea, fl atulence, and fat intolerance (fat stimulates cholecystokinin release and GB contraction). ultrasound to image stones and assess CBD diameter. MRCP (p742) is used to fi nd CBD stones. : Cholec ystectomy. If ultrasound shows a dilated CBD with stones, ERCP (p742) sphincterotomy before surgery. If symptoms persist post-surgery consider hiatus hernia/IBS/peptic ulcer/chronic pancreatitis/tumour. Other presentations Obstructive jaundice with CBD stones: (See p272. ) If LFT worsening, ERCP with sphincterotomy ± biliary trawl, then cholecystectomy may be needed, or open surgery with CBD exploration. If CBD stones are suspected pre-operatively, they should be identifi ed by MRCP (p742). Cholangitis: (Bile duct infection. ) Causing RUQ Pain, jaundice, and rigors (Charcots triad, BOX Complications of gallstones). Treat with, eg piperacillin/tazobactam 4. 5g/8h IV. Gallstone ileus: A stone erodes through the GB into the duodenum; it may then obstruct the terminal ileum. AXR shows: air in CBD ( pneumobilia), small bowel fl uid levels, and a stone. Duodenal obstruction is rarer (Bouverets syndrome). Pancreatitis: See p636. Mucocoele/empyema: Obstructed GB fi lls with mucus (secreted by GB wall)/pus. Silent stones: Do elective surgery on those with sickle cell, immunosuppression, (debatably Diabetes) as well as all calcifi ed/porcelain GBS. Mirizzis syndrome: A stone in the GB presses on the bile duct causing jaundice. Gallbladder necrosis: Rare because of dual Blood supply (hepatic artery via cystic artery, and from small branches of the hepatic artery in the GB fossa). Other: Causes of cholecystitis and biliary symptoms other than gallstones are rare. Consider infection (typhoid, cryptosporidiosis, and brucellosis); cholecystokinin release; parenteral nutrition; anatomical abnormality; polyarteritis nodosa (p556). 10 Common abbreviations used in this section: CBD, common bile duct; GB, gallbladder. __OOHHCCMM__1100ee. . iinnddbb 663344 0022//0055//22001177 1199: : 0088 635 yregruS Complications of gallstones In the gallbladder cystic duct: In the bile ducts: Biliary colic Obstructive jaundice Acute and chronic cholecystitis Cholangitis Mucocoele Pancreatitis. Empyema In the gut: Carcinoma Gallstone ileus. Mirizzis syndrome. Table 13. 16 Biliary colic, cholecystitis, or cholangitis? RUQ Pain Fever / WCC Jaundice Biliary colic X X Acute cholecystitis X Cholangitis Early or delayed cholecystectomy? For acute cholecystitis Laparoscopic cholecystectomy for acute cholecystitis has traditionally been performed 612wks after the acute episode due to anticipated increased mortality and conversion to open procedure. Early laparoscopic cholecystectomy, within 7d of symptom onset, is now the treatment of choice. Early surgery reduces the duration of hospital admission compared with delayed surgery, but does not reduce mortality or complications. Up to one-quarter of people scheduled for delayed surgery may require urgent operations because of recurrent or worsening symptoms. 10 For biliary colic Patients with biliary colic due to gallstones waiting for an elective laparoscopic cholecystectomy may develop signifi cant complications, such as acute pancreatitis (p636) during the waiting period. One High-bias trial found early laparoscopic cholecystectomy (within 24h of an acute episode) decreased potential complications that may develop during the wait for elective surgery. __OOHHCCMM__1100ee. . iinnddbb 663355 0022//0055//22001177 1199: : 0088 636 yregruS Acute pancreatitis This unpredictable disease (mortality 12%) is characterized by self-perpetuating pancreatic enzyme-mediated autodigestion; oedema and fl uid shifts cause hypovolaemia, as extracellular fl uid is trapped in the gut, peritoneum, and retroperitoneum (worsened by Vomiting). Although pancreatitis is mild in 80% of cases; 20% develop severe complicated and life-threatening disease: progression may be rapid from mild oedema to necrotizing pancreatitis.",
    "50% of cases that advance to necrosis are further complicated by infection. Causes The one mnemonic we can all agree on: GET SMASHED. Gallstones (35%), Ethanol (35%), Trauma (1. 5%), Steroids, Mumps, Autoimmune (PAN), Scorpion venom, Hyperlipidaemia, hypothermia, hypercalcaemia, ERCP (5%) and emboli, Drugs. Also pregnancy and neoplasia or no cause found (1030%). Symptoms Gradual or sudden severe epigastric or central abdominal Pain (radiates to back, sitting forward may relieve); Vomiting prominent. Signs May be subtle in serious disease. heart rate, fever, jaundice, shock, ileus, rigid abdomen ± local/general tenderness, periumbilical bruising (Cullens sign) or fl anks (Grey Turners sign) from Blood vessel autodigestion and retroperitoneal haemorrhage. Tests Raised serum amylase (1000U/mL or around 3-fold upper limit of normal). The degree of elevation is not related to severity of disease. Amylase may be normal even in severe pancreatitis (levels starts to fall within 2448h). It is excreted renally so renal failure will levels. Cholecystitis, mesenteric infarction, and GI perforation can cause lesser rises. Serum lipase is more sensitive and specifi c for pancreati tis (especially when related to alcohol), and rises earlier and falls later. ABG to monitor oxy genation and acidbase status. AXR: No psoas shadow (retroperitoneal fl uid), sentinel loop of proximal jejunum from ileus (solitary air-fi lled dilatation). Erect CXR helps exclude other causes (eg perforation). computed tomography is the standard choice of imaging to assess severity and for complications. ultrasound (if gallstones AST). ERCP if LFTS worsen. CRP 150mg/L at 36h after admission is a predictor of severe pancreatitis. Management Severity assessment is essential (see BOX and table 13. 17). Nil by mouth, consider NJ feeding (decrease pancreatic stimulation). Set up IVI and give lots of crystalloid, to counter third-space sequestration, unt il vital signs are satisfactory and Urine fl ow stays at 30mL/h. Insert a urinary catheter and consider CVP monitoring. Analgesia: pethidine 75100mg/4h IM, or morphine (may cause Oddis sphincter to contract more, but it is a better analgesic and not contraindicated). Hourly pulse, blood pressure, and Urine output; daily FBC, UE, Ca2, glucose, amylase, ABG. If worsening: ITU, O2 if PaO2. In suspected abscess formation or pancreatic necrosis (on computed tomography), consider parenteral nutrition ± laparotomy debridement (necrosectomy). Antibiotics may help in severe disease. ERCP gallstone removal may be needed if there is progressive jaundice. Repeat imaging (usually computed tomography) is performed in order to monitor progress. Any acute abdomen (p606), myocardial infarct. Early complications Shock, ARDS (p186), renal failure (give lots of fl uid! ), DIC, sepsis, Ca2, glucose (transient; 5% need insulin). Late complications (1wk. ) Pancreatic necrosis and pseudocyst(fl uid in lesser sac, fi g 13. 45), with fever, a mass ± persistent amylase/LFT; may resolve or need drainage. Abscesses need draining. Bleeding from elastase eroding a major vessel (eg splenic artery); embolization may be life-saving. Thrombosis may occur in the splenic/gastrod uodenal arteries, or colic branches of the SMA, causing bowel necrosis. Fistulae normally close spontaneously. If purely pancreatic they do not irritate the skin. Some patients suff er recurrent oedematous pancreatitis so often that near-total pancreate ctomy is contemplated. It can all be a miserable course. __OOHHCCMM__1100ee. . iinnddbb 663366 0022//0055//22001177 1199: : 0088 637 yregruS Modifi ed Glasgow criteria for predicting severity of pancreatitis Three or more positive factors detected within 48h of onset suggest severe pancreatitis, and should prompt transfer to ITU/HDU. Mnemonic: PANCREAS. Table 13.",
    "Mnemonic: PANCREAS. Table 13. 17 PaO2 8kPa Age 55yrs Neutrophilia white blood cell 15 x 109/L Calcium 2mmol/L Renal function Urea 16mmol/L Enzymes LDH 600iu/L; AST 200iu/L Albumin 32g/L (serum) Glucose Blood glucose 10mmol/L Republished with permission of Royal College of Surgeons of England, from Annals of the Royal College of Surgeons of England, Moore E M, 82, 1617, 2002. Permission conveyed through Copyright Clearance Center, Inc. These criteria have been validated for pancreatitis caused by gallstones and alcohol; Ransons criteria are valid for alcohol-induced pancreatitis, and can only be fully applied after 48h, which does have its disadvantages. Other criteria for assessing severity include the Acute Physiology and Chronic Health Examination (APACHE)-II, and the Bedside Index for Severity in Acute Pancreatitis (BISAP). Fig 13. 45 Axial computed tomography of the abdomen (with IV and PO contrast media) showing a pancreatic pseudocyst occupying the lesser sac of the abdomen posterior to the stomach. It is called a pseudocyst because it is not a true cyst, rather a collection of fl uid in the lesser sac (ie not lined by epi/endothelium). It develops at ≥6wks. The cyst fl uid is of Low attenuation compared with the stomach contents because it has not been enhanced by the contrast media. Image courtesy of Dr Stephen Golding. __OOHHCCMM__1100ee. . iinnddbb 663377 0022//0055//22001177 1199: : 0088 638 yregruS Urinary tract calculi (nephrolithiasis) Renal stones (calculi) consist of crystal aggregates. Stones form in collecting ducts and may be deposited anywhere from the renal pelvis to the urethra, though classically at: 1 Pelviureteric junction 2 Pelvic brim 3 Vesicoureteric junction. Prevalence Common: lifetime incidence up to 15%. Peak age: 2040yr. : 3: 1. Types Calcium oxalate (75%). Magnesium ammonium phosphate (struvite/triple phosphate; 15%). Also: urate (5%), hydroxyapatite (5%), brushite, cystine (1%), mixed. Presentation Asymptomatic or: 1 Pain: Excruciating spasms of renal colic loin to groin (or genitals/inner thigh), with nausea/Vomiting. Often cannot lie still (diff erentiates from perit onitis). Obstruction of Kidney: felt in the loin, between rib 12 and lateral edge of lumbar muscles(like intercostal nerve irritation Pain; the latter is not colicky, and is worsened by specifi c movements/Hypertension on a trigger spot). Obstruction of mid-ureter: may mimic appendicitis/diverticulitis. Obstruction of lower ureter: may lead to symptoms of bladder irritability and Pain in scrotum, penile tip, or labia majora. Obstruction in bladder or urethra: causes pelvic Pain, dysuria, strangury (desire but inability to void) ± interrupted fl ow. 2 Infection: Can coexist (risk if voiding impaired), eg UTI; pyelo nephritis (fever, rigors, loin Pain, nausea, Vomiting); pyonephrosis (infected hydronephrosis) 3 Haematuria. 4 Proteinuria. 5 Sterile pyuria. 6 Anuria. Examination Usually no tenderness on palpation. May be renal angle tenderness especially to percussion if there is retroperitoneal infl ammation. Tests FBC, UE, Ca2, phosphate 3Ω, glucose, bicarbonate, urate. Urine dipstick: Usually ve for Blood (90%). MSU: MCS. Further tests for cause: Urine pH; 24h Urine for: calcium, oxalate, urate, citrate, Sodium, Creatinine; stone biochemistry (sieve Urine send stone). Imaging: Non-contrast computed tomography is investigation of choice for imaging stones (99% visible) helps exclude diff erential causes of an acute abdomen. A ruptured abdominal aortic aneurysm may present similarly. 80% of stones are visible on kidney, ureter, bladder XR (kidneys ureters bladder). Look along ureters for calcifi cation over the transverse processes of the vertebral bodies. ultrasound an alternative for hydronephrosis or hydroureter. Initially: Analgesia, eg diclofenac 75mg IV/IM, or 100mg PR. (If CI: opioids) IV fl uids if unable to tolerate PO; antibiotics (eg piperacillin/tazobactam 4. 5g/8h IV, or gentamicin) if infection. Stones 5mm in lower ureter: 9095% pass spontaneously. Fluid intake.",
    "5g/8h IV, or gentamicin) if infection. Stones 5mm in lower ureter: 9095% pass spontaneously. Fluid intake. Stones 5mm/Pain not resolving: Medical expulsive therapy: start at presentation; nifedipine 10mg/8h PO or -blockers (tams ulosin 0. 4mg/d) promote expulsion and reduce analgesia requirements. Most pass within 48h (80% after 30d). If not, try extracorporeal shockwave lithotripsy (ESWL) (if 1cm), or ureteroscopy using a basket. ESWL: ultrasound waves shatter stone. SE: renal injury, may also cause blood pressure and diabetes mellitus. Percutaneous nephrolithotomy (PCNL): keyhole surgery to remove stones, when large, multiple, or complex. Open surgery is rare. Indications for urgent intervention (delay kills glomeruli): Presence of infection and obstructiona percutaneous nephr ostomy or ureteric stent may be needed to relieve obstruction (p640); urosepsis; intractable Pain or Vomiting; impending acute kidney injury; obstruction in a solitary Kidney; bilateral obstructing stones. Prevention General: Drink plenty. Normal dietary Ca2 intake (Low Ca2 diets increase oxalate excretion). Specifi cally: Calcium stones: in hypercalciuria, a thiazide diuretic is used to Ca2 excretion. Oxalate: oxalate intake; pyridoxine may be used (p295). Struvite (phosphate mineral): treat infection promptly. Urate: allopurinol (100300mg/24h PO). Urine alkalinization may also help, as urate is more soluble at pH6 (eg with Potassium citrate or Sodium bicarbonate). Cystine: vigorous hydration to keep Urine output 3L/d and urinary alkalinization (as above-mentioned). Penicillamine is used to chelate cystine, given with pyridoxine to prevent vitamin B6 defi ciency. __OOHHCCMM__1100ee. . iinnddbb 663388 0022//0055//22001177 1199: : 0088 639 yregruS Questions to address when confronted by a stone What is its composition? (See table 13. 18. ) Table 13. 18 Types, causes, and X-ray appearance of renal stones Type Causative factors Appearance on X-ray Calcium oxalate (fi g 13. 46) Metabolic or idiopathic Spiky, radio-opaque Calcium phosphate Metabolic or idiopathic Smooth, may be large, radioopaque Magnesium ammonium UTI (proteus causes alLarge, horny, staghorn, radiophosphate (fi g 13. 47) kaline Urine and calcium opaque precipitation and ammonium salt formation) Urate (p680) Hyperuricaemia Smooth, brown, radiolucent Cystine (fi g 13. 48) Renal tubular defect Yellow, crystalline, semi-opaque Why has he or she got this stone now? Diet: chocolate, tea, rhubarb, strawberries, nuts, and spinach all oxalate levels. Season: variations in calcium and oxalate levels are thought to be mediated by vitamin D synthesis via sunlight on skin. Work: can he/she Drink freely at work? Is there dehydration? Medications: precipitating drugs include: diuretics, antacids, acetazolamide, corticosteroids, theophylline, aspirin, allopurinol, vitamin C and D, indinavir. Are there any predisposing factors? For example: Recurrent UTIS (in magnesium ammonium phosphate calculi). Metabolic abnormalities: Hypercalciuria/hypercalcaemia (p676): hyperparathyroidism, neoplasia, sarc oido sis, hyperthyroidism, Addisons, Cushings, lithium, vitamin D excess. Hyperuricosuria/plasma urate: on its own, or with gout. Hyperoxaluria. Cystinuria (p321). Renal tubular acidosis (pp3167). Urinary tract abnormalities: eg pelviureteric junction obstruction, hydronephrosis (renal pelvis or calyces), calyceal diverticulum, horseshoe Kidney, ureterocele, vesicoureteric refl ux, ureteral stricture, medullary sponge Kidney. 11 Foreign bodies: eg stents, catheters. Is there a family history? Risk of stones 3-fold. Specifi c diseases include X-linked nephrolithiasis and Dents disease (proteinuria, hypercalciuria, and nephrocalcinosis). Is there infection above the stone? Eg fever, loin tender, pyuria? This needs urgent intervention. Fig 13. 46 Calcium oxalate Fig 13. 47 Struvite stone. Fig 13. 48 Cystine stone. monohydrate. Image courtesy of Dr Glen Austin. Image courtesy of Dr Glen Austin. Image courtesy of Dr Glen Austin. 11 Medullary sponge Kidney is a typically asymptomatic developmental anomaly of the Kidney mostly seen in adult females, where there is dilatation of the collecting ducts, which if severe leads to a sponge-like appearance of the renal medulla.",
    "Complications/associations: UTIs, nephrolithiasis, haematuria and hypercalciuria, hyperparathyroidism (if present, look for genetic markers of MEN type 2A, see p223). __OOHHCCMM__1100ee. . iinnddbb 663399 0022//0055//22001177 1199: : 0088 640 yregruS Urinary tract obstruction Urinary tract obstruction is common and should be considered in any patient with impaired renal function. Damage can be permanent if the obstruction is not treated promptly. Obstruction may occur anywhere from the renal calyces to the urethral meatus, and may be partial or complete, unilateral or bilateral. Obstructing lesions are luminal (stones, Blood clot, sloughed papilla, tumour: renal, ureteric, or bladder), mural (eg congenital or acquired stricture, neuromuscular dysfunction, schistosomiasis), or extra-mural (abdom inal or pelvic mass/tumour, retroperitoneal fi brosis, or iatrogeniceg post surgery). Unilateral obstruction may be clinically silent (normal Urine output and UE) if the other Kidney is functioning. Bilateral obstruction or obstruction with infection requires urgent treatment. See p641. Clinical features Acute upper tract obstruction: Loin Pain radiating to the groin. There may be superimposed infection ± loin tenderness, or an enlarged Kidney. Chronic upper tract obstruction: Flank Pain, renal failure, superimposed infection. Polyuria may occur due to impaired urinary concentration. Acute lower tract obstruction: Acute urinary retention typically presents with severe suprapubic Pain ± acute confusion (elderly); often acute on chronic (hence preceded by chronic symptoms, see next bullet point). Clinically: distended, palpable bladder containing 600mL, dull to percussion. Causes include prostatic obstruction (usual cause in older ), urethral strictures, anticholinergics, Blood clots eg from bladder lesion (clot retention), alcohol, constipation, post-op (Pain/infl ammation/ anaesthetics), infection (p296), neurological (cauda equina syndrome, see p466). Chronic lower tract obstruction: Symptoms: urinary frequency, hesitancy, poor stream, terminal dribbling, overfl ow incontinence. Signs: distended, palpable bladder (capacity may be 1. 5L) ± large prostate on PR. Complications: UTI, urinary retention, renal failure (eg bilateral obstructive uropathysee BOX Obstructive uropathy). Causes include prostatic enlargement (common); pelvic malignancy; rectal surgery; diabetes mellitus; CNS disease, eg transverse myelitis/MS; zoster (S2S4). Tests Blood: UE, Creatinine, FBC, and prostate-specifi c antigen (PSA, p530). 12 Urine: Dipstick and MCS. Ultrasound (p744) is the imaging modality of choice for investigating upper tract obstruction: If there is hydronephrosis or hydroureter (distension of the renal pelvis and calyces or ureter), arrange a computed tomography scan. This will determine the level of obstuction. NB: in 5% of cases of obstruction, no distension is seen on ultrasound. Radionuclide imaging enables functional assessment of the kidneys. Treatment Upper tract obstruction: Nephrostomy or ureteric stent. NB: stents may cause signifi cant discomfort and patients should be warned of this and other risks (see BOX Problems of ureteric stenting). -blockers help reduce stent-related Pain (ureteric spasm). Pyeloplasty, to widen the PUJ, may be performed for idiopathic PUJ obstruction. Lower tract obstruction: Insert a urethral or suprapubic catheter (p762) to relieve acute retention. In chronic obstruction only catheterize patient if there is Pain, urinary infection, or renal impairment; intermittent self-catheterization is sometimes required (p763). If in clot retention the patient will require a 3-way catheter and bladder washout. If 1L residual check UE and monitor for post-obstructive diuresis (see BOX Obstructive uropathy). Monitor weight, fl uid balance, and UE closely. Treat the underlying cause if possible, eg if prostatic obstruction, start an -blocker (see p642). After 23 days, trial without catheter (TWOC, p763) may work (especially if 75yrs old and 1L drained or retention was triggered by a passing event, eg GA). 12 Do venepuncture for PSA before PR, as PR can total PSA by 1ng/mL (free PSA by 10%). Its diffi cult to know if acute retention raises PSA, but relieving obstruction does cause it to drop. __OOHHCCMM__1100ee. .",
    "Its diffi cult to know if acute retention raises PSA, but relieving obstruction does cause it to drop. __OOHHCCMM__1100ee. . iinnddbb 664400 0022//0055//22001177 1199: : 0088 641 yregruS Problems of ureteric stenting (depend on site) Common: Rare: Stent-related Pain Obstruction Trigonal irritation Kinking Haematuria Ureteric rupture Fever Stent misplacement Infection Stent migration (especially if made of silicone) Tissue infl ammation Tissue hyperplasia Encrustation Forgotton stents. Biofi lm formation. Obstructive uropathy In chronic urinary retention, an episode of acute retention may go unnoticed for days and, because of their background symptoms, may only present when overfl ow incontinence becomes a nuisancePain is not necessarily a feature. After diagnosing acute on chr onic retent ion and placing a catheter, the bladder residual can be as much as 1. 5L of Urine. Dont be surprised to be called by the biochemistry lab to be told that the serum Creatinine is 1000μmol/L! The Good news is that renal fun ction usually returns to baseline after a few days (there may be mild background impairment). Ask for an urgent renal ultrasound (fi g 13. 49) Fig 13. 49 Ultrasound of an obstr ucted Kidney and con sider the following in the show ing hydro nephrosis. Note dilatation of renal acute plan to ensure a safe course: pelvis and ureter, and clubbed calyces. Hyperkalaemia See p301. Image courtesy of Norwich Radiology Department. Metabolic acidosis On ABG there is likely to be a respiratory compensated metabolic acidosis. Concerns should prompt discussion with a renal specialist (a Good idea anyway), in case haemoDialysis is required (p306). Post-obstructive diuresis In the acute phase after relief of the obstruction, the kidneys produce a lot of Urineas much as a litre in the fi rst hour. It is vital to provide resuscitation fl uids and then match input with output. Fluid depletion rather than overload is the danger here. Sodiumand bicarbonatelosing nephropathy As the Kidney undergoes diuresis, sodium and bicarbonate are lost in the Urine in large quantities. Replace in for out (as mentioned above) with isotonic 1. 26% Sodium bicarbonate solutionthis should be available from ITU. Some advocate using 0. 9% saline, though the chloride load may exacerbate acidosis. Withhold any nephrotoxic drugs. Infection Treat infection, bearing in mind that the WCC and CRP may be part of the stress response. Send a sample of Urine for MCS. __OOHHCCMM__1100ee. . iinnddbb 664411 0022//0055//22001177 1199: : 0088 642 yregruS Benign prostatic hyperplasia Benign prostatic hyperplasia (BPH) is common (24% if aged 4064; 40% if older). Pathology: Benign nodular or diff use proliferation of musculofi brous and glandular layers of the prostate. Inner (transitional) zone enlarges in contrast to peripheral layer expansion seen in prostate carcinoma. Features: Lower urinary tract symptoms (LUTS) nocturia, frequency, urgency, post-micturition dribbling, poor stream/fl ow, hesitancy, overfl ow incontinence, haematuria, bladder stones, UTI. Management: Assess severity of symptoms and impact on life. PR exam. Tests: MSU; UE; ultrasound (large residual volume, hydronephrosisfi g 13. 49), PSA (prior to PR exam; see also BOX Advice to asymptomatic men, p645), transrectal ultrasound ± biopsy. Then consider: Lifestyle: Avoid caff eine, alcohol (to urgency/nocturia). Relax when voiding. Void twice in a row to aid emptying. Control urgency by pract ising distraction methods (eg breathing exercises). Train the bladder by holding on to time between voiding. Drugs are useful in mild disease, and while awaiting surgery. -blockers are 1st line (eg tamsulosin 400mcg/d PO; also alfuzosin, doxazosin, terazosin). Smooth muscle tone (prostate and bladder). SE: drowsiness; depression; dizziness; blood pressure; dry mouth; ejaculatory failure; extra-pyramidal signs; nasal congestion; weight.",
    "SE: drowsiness; depression; dizziness; blood pressure; dry mouth; ejaculatory failure; extra-pyramidal signs; nasal congestion; weight. 5-reductase inhibitors: can be added, or used alone, eg fi nasteride 5mg/d PO (conversion of testosterone to the more potent androgen dihydrotestosterone). Excreted in semen, so use condoms; females should avoid handling. SE: impotence; libido. prostate size over 36mths and long-term retention risk. Surgery: Transurethral resection of prostate (TURP) ≤14% become impotent (see BOX). Crossmatch 2U. Beware bleeding, clot retention, and post TURP syndrome: absorption of washout causing CNS CVS disturbance. 12% need redoing within 8yrs. Transurethral incision of the prostate (TUIP) involves less destruction than TURP, and less risk to sexual function, gives similar benefi t. Relieves Hypertension on the urethra. Maybe best surgical option for those with small glands 30g. Retropubic prostatectomy is an open operation (if prostate very large). Transurethral laser-induced prostatectomy (TULIP) may be as Good as TURP. Robotic prostatectomy is gaining popularity as a less traumatic and minimally invasive treatment option. Advice for patients concerning transurethral prostatectomy (TURP) Pre-op consent issues may centre on risks of the procedure, eg: Haematuria/haemorrhage Infection; prostatitis Haematospermia Erectile dysfunction 10% Hypothermia Incontinence ≤10% Urethral trauma/stricture Clot retention near strictures Post TURP syndrome (T°; sodium) Retrograde ejaculation (common). Postoperative advice Avoid driving for 2wks after the operation. Avoid sex for 2wks after surgery. Then get back to normal. The amount ejaculated may be reduced (as it fl ows backwards into the bladderharmless, but may cloud the Urine). It means you may be infertile. Erections may be a problem after TURP, but do not expect this: in some men, erections improve. Rarely, orgasmic sensations are reduced. Expect to pass Blood in the Urine for the fi rst 2wks. A small amount of Blood colours the Urine bright red. Do not be alarmed. At fi rst you may need to urinate more frequently than before. Do not be despondent. In 6wks things should be much betterbut the operation cannot be guaranteed to work (8% fail, and lasting incontinence is a problem in 6%; 12% may need repeat TURPS within 8yrs, compared with 1. 8% of men undergoing open prostatectomy). If feverish, or if urination hurts, take a sample of Urine to your doctor. __OOHHCCMM__1100ee. . iinnddbb 664422 0022//0055//22001177 1199: : 0088 643 yregruS Retroperitoneal fi brosis Causes Idiopathic retroperitoneal fi brosis (RPF), infl ammatory aneurysms of the abdominal aorta, and perianeurysmal RPF. With idiopathic RPF there is an associated infl ammatory response resulting in fi brinoid necrosis of the vasa vasorum, aff ecting the aorta and small and medium retroperitoneal vessels. The ureters get embedded in dense, fi brous tissue resulting in progressive bilateral ureteric obstruction. Secondary causes of RPF include malignancy, typically lymphoma. Associations Drugs (eg -blockers, bromocriptine, methysergide, methyldopa), autoimmune disease (eg thyroiditis, SLE, ANCAve vasculitis), smoking, asbestos. Typical patient Middle-aged with vague loin, back, or abdominal Pain, blood pressure. Tests Blood: Urea and Creatinine; ESR; CRP; anaemia. Ultrasound: Dilated ureters (hydronephrosis). computed tomography/magnetic resonance imaging: Periaortic mass (fi g 13. 50). Biopsy under imaging guidance is used to rule out malignancy. Treatment Retrograde stent placement to relieve obstruction (removed after 12 months) ± ureterolysis (dissection of the ureters from the retroperitoneal tissue). Immunosuppression (in idiopathic RPF) with Low-dose steroids has Good long-term results. Fig 13. 50 computed tomography scan of retroperitoneal fi brosis (RPF), with subsequent obstruction and dilatation of the ureters (thick arrows). Reproduced from Davison et al. , Oxford Textbook of Nephrology, 2005, with permission from Oxford University Press. __OOHHCCMM__1100ee. . iinnddbb 664433 0022//0055//22001177 1199: : 0088 644 yregruS Urinary tract malignancies Renal cell carcinoma (RCC) arises from proximal renal tubular epithelium.",
    "Epidemiology: Accounts for 90% of renal cancers; mean age 55yrs. : 2: 1. 15% of haemodialysis patients develop RCC. Features: 50% found incidentally. Haematuria, loin Pain, abdominal mass, anorexia, malaise, weight loss, PUOoften in isolation. Rarely, invasion of left renal vein compresses left testicular vein causing a varicocele. Spread may be direct (renal vein), via lymph, or haemat ogenous (bone, Liver, lung). 25% have metastases at presentation. Tests: blood pressure: from renin secretion. Blood: FBC (polycythaemia from erythropoietin secretion); ESR; UE, ALP (bony mets? ). Urine: RBCS; cytology. Imaging: ultrasound (p744); computed tomography/magnetic resonance imaging; CXR (cannon ball metastases). : Radical nephrectomy (nephron-sparing surgery is as Good for T1 tumours preserves renal function). Cryotherapy and radiofrequency ablation is an option for patients unfi t or unwilling to undergo surgery. RCC is generally radio- chemoresistant. In those with unresectable or metastatic disease, options include: High-dose IL-2 and other T-cell activation therapies; anti-angiogenesis agents (eg pazopanib, sunitinib, axitinib, or bevacizumab); mTOR inhibitors, eg temsir olimus. The Mayo prognostic risk score (SSIGN) was developed to predict survival and uses information on tumour stage, size, grade, and necrosis. Prognosis: 10yr survival ranges from 96. 5% (scores 01) to 19. 2% (scores ≥ 10). Transitional cell carcinoma (TCC) may arise in the bladder (50%), ureter, or renal pelvis. Epidemiology: Age 40yrs; : 4: 1. Risk factors: p646. Presentation: Painless haematuria; frequency; urgency; dysuria; urinary tract obstruction. Diagnosis: Urine cytology; IVU; cystoscopy biopsy; computed tomography/magnetic resonance imaging. : See Bladder tumours, p646. Prognosis: Varies with clinical stage/histological grade: 1080% 5yr survival. Wilms tumour (nephroblastoma) is a childhood tumour of primitive renal tubules and mesenchymal cells. Prevalence: 1: 100 000the chief abdominal malignancy in children. It presents with an abdominal mass and haematuria. : OHCS p133. Prostate cancer The commonest male malignancy. Incidence: with age: 80% in men 80yrs (autopsy studies). Associations: ve family history (x23 risk, p521), testost erone. Most are adenocarcinomas arising in peripheral prostate. Spread may be local (seminal vesicles, bladder, rectum) via lymph, or haemat ogenously (sclerotic bony lesions). Symptoms: Asymptomatic or nocturia, hesitancy, poor stream, terminal dribbling, or obstruction. Weight ± bone Pain suggests mets. DRE exam of prostate: may show hard, irregular prostate. Diagnosis: PSA (normal in 30% of small cancers); transrectal ultrasound biopsy; bone scan; computed tomography/magnetic resonance imaging. Staging: magnetic resonance imaging. Treatment: Disease confi ned to prostate: options depend on prognosis (see BOX Prognostic factors), patient preference, and comorbidities. Radical prostatectomy if 70yrs gives excellent disease-free survival (laparoscopic surgery is as Good). The role of adjuvant hormonal therapy is being explored. Radical radiotherapy (± neoadjuvant adjuvant hormonal therapy) is an alternative curative option that compares favourably with surgery (no RCTS). It may be delivered as external beam or brachytherapy. Hormone therapy alone temporarily delays tumour progression but refractory disease eventually develops. Consider in elderly, unfi t patients with High-risk disease. Active surveillanceparticularly if 70yrs and Low-risk. Metastatic disease: Hormonal drugs may give benefi t for 12yrs. LHRH agonists, eg 12-weekly goserelin (10. 8mg SC) fi rst stimulate, then inhibit pituitary gonadotrophin. NB: risks tumour fl are when fi rst usedstart anti-androgen, eg cyproterone acetate, in susceptible patients. The LHRH antagonist degarelix is also used in advanced disease. Symptomatic : Analgesia; treat hypercalca emia; radiotherapy for bone mets/spinal cord compression. Prognosis: 10% die in 6 months, 10% live 10yrs. Screening: DRE of prostate; transrectal ultrasound; PSA (see BOX Advice to asymptomatic men). Penile cancer Epidemiology: Rare in UK, more common in Far East and Africa, very rare in circumcised. Related to chronic irritation, viruses, smegma.",
    "Related to chronic irritation, viruses, smegma. Presentation: Chronic fungating ulcer, bloody/purulent discharge, 50% spread to lymph at presentation : Radiotherapy irridium wires if early; amputation lymph node dissection if late. __OOHHCCMM__1100ee. . iinnddbb 664444 0022//0055//22001177 1199: : 0088 645 yregruS Advice to asymptomatic men asking for a PSA Blood test Many men over 50 consider a PSA test to detect prostatic cancer. Is this wise? The test is not very accurate, and we cannot say that those having the test will live longereven if they turn out to have prostate cancer. Most men with prostate cancer die from an unrelated cause. If the test is falsely positive, you may needlessly have more tests, eg prostate sampling via the back passage (causes bleeding and infection in 15% of men). Only one in three of those with a High PSA level will have cancer. You may be worried needlessly if later tests put you in the clear. If a cancer is found, theres no way to tell for sure if it will impinge on health. You might end up having a Bad eff ect from treatment that wasnt needed. There is much uncertainty on treating those who do turn out to have prostate cancer: options are radical surgery to remove the prostate (risks erectile dysfunction and incontinence), radiotherapy, or hormones. Screening via PSA has shown confl icting results. Some RCTS have shown no difference in the rate of death from prostate cancer, others have found reduced mortality, eg 1 death prevented per 1055 men invited for screening (if 37 cancers detected). Ultimately, you must decide for yourself what you want. Prognostic factors in prostate cancer A number of prognostic factors help determine if watchful waiting or agg ressive therapy should be advised: Pre-treatment PSA level. Tumour stage (as measured by the TNM system; p523). Tumour gradeGleason score. Gleason grading is from 1 to 5, with 5 being the highest grade, and carrying the poorest prognosis. Gleason grades are decided by analysing histology from two separate areas of tumour specimen, and adding them to get the total Gleason score for the tumour, from 2 to 10. Scores 810 suggest an aggressive tumour; 57: intermediate; 24: indolent. Benign diseases of the penis Balanitis Acute infl ammation of the foreskin and glans. Associated with strep and staph infections. More common in diabetics. Often seen in young children with tight foreskins : Antibiotics, circumcision, hygiene advice. Phimosis The foreskin occludes the meatus. In young boys this causes recurrent balanitis and ballooning, but time ( trials of gentle retraction) may obviate the need for circumcision. In adulthood presents with painful intercourse, infection, ulceration, and is associated with balanitis xerotica obliterans. Paraphimosis Occurs when a tight foreskin is retracted and becomes irreplaceable, preventing venous return leading to oedema and even ischaemia of the glans. Can occur if the foreskin is not replaced after catheterization. : Ask patient to squeeze glans. Try applying a 50% glucose-soaked swab (oedema may follow osmotic gradient). Ice packs and lidocaine gel may also help. May require aspiration/dorsal slit/circumcision. Prostatitis May be acute or chronic. Usually those 35yrs. Acute prostatitis is caused mostly by S. faecalis and E. coli, also Chlamydia (and previously TB). Features: UTIs, retention, Pain, haematospermia, swollen/boggy prostate on DRE. : Analgesia; levofl oxacin 500mg/24h PO for 28d. Chronic prostatitis may be bacterial or non-bacterial. Symptoms as for acute prostatitis, but present for 3 months. Non-bacterial chronic prostatitis does not respond to antibiotics. Anti-infl ammatory drugs, blockers, and prostatic massage all have a place. __OOHHCCMM__1100ee. .",
    "Anti-infl ammatory drugs, blockers, and prostatic massage all have a place. __OOHHCCMM__1100ee. . iinnddbb 664455 0022//0055//22001177 1199: : 0088 646 yregruS Bladder tumours 90% are transitional cell carcinomas (TCCS) in the UK. Adenocarcin omas and squamous cell carcinomas are rare in the West (the latter may follow schistosomiasis). UK incidence 1: 6000/yr. : 5: 2. Histology is important for prognosis: Grade 1 diff erentiated; Grade 2intermediate; Grade 3poorly diff ere ntiated. 80% are confi ned to bladder mucosa, and only 20% penetrate muscle (increasing mortality to 50% at 5yrs). Presentation Painless haematuria; recurrent UTIs; voiding irritability. Associations Smoking; aromatic amines (rubber industry); chronic cystitis; schistosomiasis (risk of squamous cell carcinoma); pelvic irradiation. Tests Cystoscopy with biopsy is diagnostic. Urine: microscopy/cytology (cancers may cause sterile pyuria). computed tomography urogram is both diagnostic and provides staging. Bimanual EUA helps assess spread. magnetic resonance imaging or lymphangiography may show involved pelvic nodes. Staging See table 13. 19. Treating TCC of the bladder Tis/Ta/T1: (80% of all patients) Diathermy via transurethral cystoscopy/transurethral resection of bladder tumour (TURBT). Consider a regimen of intravesical BCG (which stimulates a non-specifi c immune response) for multiple small tumours or High-grade tumours. Alternative chemotherapeutic agents include mitomycin, epirubicin and gemcitabine. 5yr survival 95%. T23: Radical cystectomy is the gold standard. Radiotherapy gives worse 5yr survival rates than surgery, but preserves the bladder. Salvage cystectomy can be performed if radiotherapy fails, but yields worse results than primary surgery. Post-op chemotherapy (eg M-VAC: methotrexate, vinblastine, doxorubicin, and cisplatin) is toxic but eff ective. Neoadjuvant chemotherapy with M-VAC or GC (gemcitabine and cisplatin) has improved survival compared to cystectomy or radiotherapy alone. Methods to preserve the bladder with transurethral resection or partial cyst ectomy systemic chemot herapy have been tried, but long-term results are disappointing. If the bladder neck is not involved, orthotopic reconstru ction rather than forming a urostoma is an option (both using 40cm of the patients ileum), but adequate tumour clearance must not be compromised. The patient should have all these options explained by a urologist and an oncologist. T4: Usually palliative chemo/radiotherapy. Chronic catheterization and urinary diversions may help to relieve Pain. Follow-up History, examination, and regular cystoscopy: High-risk tumours: Every 3 months for 2yrs, then every 6 months. Low-risk tumours: First follow-up cystoscopy after 9 months, then yearly. Tumour spread Local to pelvic structures; lymphatic to iliac and para-aortic nodes; haematogenous to Liver and lungs. Survival This depends on age at surgery. For example, the 3yr survival after cystectomy for T2 and T3 tumours is 60% if 6575yrs old, falling to 40% if 7582yrs old (operative mortality is 4%). With unilateral pelvic node involvement, only 6% of patients survive 5yrs. The 3yr survival with bilateral or para-aortic node involvement is nil. Complications Cystectomy can result in sexual and urinary malfunction. Massive bladder haemorrhage may complicate treatment or be a feature of disease treated palliatively. Determining the cause of bleeding is key. Consider alum solution bladder irrigation (if no renal failure) as 1st-line treatment for intractable haematuria in advanced malignancy: it is an inpatient procedure. __OOHHCCMM__1100ee. . iinnddbb 664466 0022//0055//22001177 1199: : 0088 647 yregruS Table 13. 19 TNM staging of bladder cancer (See also p523) Tis Carcinoma in situ Ta Tumour confi ned to epithelium T1 Tumour in submucosa or lamina propria T2 Invades muscle T3 Extends into perivesical fat T4 Invades adjacent organs N0 No LN involved N1N3 Progressive LN involvement M0 No metastases M1 Distant metastasis Reproduced with permission from Edge, SB et al. (Eds. ), AJCC Cancer Staging Manual, 7th Edition. New York: Springer; 2010. Is asymptomatic non-visible haematuria signifi cant?",
    "(Eds. ), AJCC Cancer Staging Manual, 7th Edition. New York: Springer; 2010. Is asymptomatic non-visible haematuria signifi cant? Dipstick tests are often done routinely for patients on admission. If non-visible (previously microscopic) haematuria is found, but the patient has no related symptoms, what does this mean? Before rushing into a barrage of investigations, consider: One study found that incidence of urogenital disease (eg bladder cancer) was no higher in those with asymptomatic microhaematuria than in those without. Asymptomatic non-visible haematuria is the sole presenting feature in only 4% of bladder cancers, and there is no evidence that these are less advanced than malignancies presenting with macroscopic haematuria. When monitoring those with treated bladder cancer for recurrence, non-visiblehaematuria tests have a sensitivity of only 31% in those with superfi cial bladder malignancy, in whom detection would be most useful. Although 80% of those with fl ank Pain due to a renal stone have microscopic haematuria, so do 50% of those with fl ank Pain but no stone. The conclusion is not that Urine dipstick testing is useless, but that results should not be interpreted in isolation. Unexplained non-visible haematuria in those 50yrs should be referred under the 2-week rule. Smokers and those with ve family history for urothelial cancer may also be investigated diff erently from those with no risk factors. It is worth considering, that in a young, fi t athlete, the diagnosis is more likely to be exercise-induced haematuria. Wise doctors work collaboratively with their patients. Shall we let sleeping dogs lie? is a reasonable question for some patients. __OOHHCCMM__1100ee. . iinnddbb 664477 0022//0055//22001177 1199: : 0088 648 yregruS Urinary incontinence Think twice before inserting a urinary catheter. Carry out rectal examination to exclude faecal impaction. Is the bladder palpable after voiding (retention with overfl ow)? Is there neurological comorbidity: eg MS; Parkinsons disease; stroke; spinal trauma? Incontinence in men Enlargement of the prostate is the major cause of incontinence: urge incontinence (see later in topic) or dribbling may result from partial retention of Urine. TURP (p642) other pelvic surgery may weaken the bladder sphincter and cause incontinence. Troublesome incontinence needs specialist assessment. Incontinence in women Often under-reported with delays before seeking help. Functional incontinence: Ie when physiological factors are relatively unimportant. The patient is caught short and too slow in fi nding the toilet because of (for example) immobility, or unfamiliar surroundings. Stress incontinence: Leakage from an incompetent sphincter, eg when intraabdominal Hypertension rises (eg coughing, laughing). Increasing age and obesity are risk factors. The key to diagnosis is the loss of small (but often frequent) amounts of Urine when coughing etc. Examine for pelvic fl oor weakness/prolapse/pelvic masses. Look for cough leak on standing and with full bladder. Stress incontinence is common in pregnancy and following birth. It occurs to some degree in 50% of post-menopausal women. In elderly women, pelvic fl oor weakness, eg with uterine prolapse or urethrocele (OHCS p290), is a very common association. Urge incontinence/overactive bladder syndrome: The urge to urinate is quickly followed by uncon t rollable and sometimes complete emptying of the bladder as the detrusor muscle contracts. Urgency/leaking is precipitated by: arriving home (latchkey incontinence, a conditioned refl ex); cold; the sound of running Water; caffeine; and obesity. : urodynamic studies. Cause: detrusor overactivity (see table 13. 20), eg from central inhibitory pathway malfunction or sensitization of peripheral aff erent terminals in the bladder; or a bladder muscle problem. Check for organic brain damage (eg stroke; Parkinsons; dementia). Other causes: urinary infection; Diabetes; diuretics; atrophic vaginitis; urethritis. In both sexes incontinence may result from confusion or sedation.",
    "Other causes: urinary infection; Diabetes; diuretics; atrophic vaginitis; urethritis. In both sexes incontinence may result from confusion or sedation. Occasionally it may be purposeful (eg preventing admission to an old peoples home) or due to anger. Management Eff ective treatment can have a huge impact on quality of life. Check for: UTI; diabetes mellitus; diuretic use; faecal impaction; palpable bladder; glomerular filtration rate. Stress incontinence: Pelvic fl oor exercises are 1st line (8 contractions 3/d for 3 months). Intravaginal electrical stimulation may also be eff ective, but is not acceptable to many women. A ring pessary may help uterine prolapse, eg while awaiting surgical repair. Surgical options (eg tension-free vaginal tape) aim to stabilize the mid-urethra. Urethral bulking also available. Medical options: duloxetine 40mg/12h PO (50% have ≥50% in incontinence episodes). SE nausea. Urge incontinence: The patient (or carer) should complete an incontinence chart for 3d to defi ne the pattern of incontinence. Examine for spinal cord and CNS signs (including cognitive test, p64); and for vaginitis (if postmenopausal). Vaginitis can be treated with topical oestrogen therapy for a limited period. Bladder training (may include pelvic fl oor exercises) and weight loss are important. Drugs may help reduce night-time incontinence (see BOX) but can be disappointing. Consider aids, eg absorbent peripheral arterial disease. If consider a condom catheter. Do urodynamic assessment (cystometry Urine fl ow rate measurement) before any surgical intervention to exclude detrusor overactivity or sphincter dyssynergia. __OOHHCCMM__1100ee. . iinnddbb 664488 0022//0055//22001177 1199: : 0088 649 yregruS Table 13. 20 Managing detrusor overactivity in urge incontinence Agents for detrusor overactivity Notes Antimuscarinics: eg tolterodine SR Improves frequency urgency. Alternatives: 4mg/24h; SE: dry mouth, eyes/skin, solifena cin 5mg/24h (max 10mg); oxyb utynin, drowsiness, constipation, tachycardia, but more SE unless transdermal route or modiabdominal Pain, urinary retention, fi ed release used; trospium or feso t erodine sinusitis, oedema, weight, glaucoma (prefers M3 receptors). Avoid in myasthenia, precipitation. Up to 4mg/12h may be and if glaucoma or UC are uncontrolled. needed (unlicensed). Topical oestrogens Post-menopausal urgency, frequency nocturia may occasionally be improved by raising the bladders sensory threshold. Systemic therapy worsens incontinence. 3 adrenergic agonist: mirabegron Consider if antimuscarinics are contrain50mg/24h; SE tachycardia; CI: severe hypertension; dicated or clinically ineff ective, or if SE Caution if renal/hepatic impairment. unacceptable. Intravesical botulinum toxin (Botox) Consider if above medications ineff ective. Percutaneous posterior tibial nerve Consider if drug treatment ineff ective and stimulation (PTNS). (A typical treatment Botox not wanted. PTNS delivers neuromoduconsists of 12 weekly 30 min sessions. ) lation to the S2S4 junction of the sacral nerve plexus. Neuromodulation via transcutaneous Sacral nerve stimulation inhibits the refl ex electrical stimulation behaviour of involuntary detrusor contractions. Modulation of aff erent input from Gabapentin (unlicensed). bladder Hypnosis, psychotherapy, bladder (These all require Good motivation. ) training Surgery (eg clam ileocystoplasty) Reserved for troublesome or intractable symptoms. The bladder is bisected, opened like a clam, and 25cm of ileum is sewn in. NB: desmopressin nasal spray 20mcg nocte reduces Urine production and nocturia in overactive bladder. Unsuitable if elderly (SE: fl uid retention, Heart failure, sodium). Mind over bladder: Void when you DONT have urge; DONT go to the bathroom when you do have urge. Gradually extend the time between voiding. Schedule your trips to toilet. Stretch your bladder to normal capacity. When urge comes, calm down and make it go using mind over bladder tricks. Not all male urinary symptoms are prostate-related! Detrusor overactivity Men get this as well as women. Hypertension-fl ow studies help diagnose this (as does detrusor thickness ≥2. 9mm on ultrasound).",
    "Hypertension-fl ow studies help diagnose this (as does detrusor thickness ≥2. 9mm on ultrasound). Primary bladder neck obstruction A condition in which the bladder neck does not open properly during voiding. Studies in men and women with voiding dysfunction show that it is common. The cause may be muscular or neurological dysfunction or fi brosis. Diagnosis: Video-urodynamics, with simultaneous Hypertension-fl ow measurement, and visualization of the bladder neck during voiding. Treatment: Watchful waiting; -blockers (p642); surgery. Urethral stricture This may follow trauma or infection (eg gonorrhoea)and frequently leads to voiding symptoms, UTI, or retention. Malignancy is a rare cause. Imaging: Retrograde urethrogram or antegrade cystourethrogram if the patient has an existing suprapubic catheter. Internal urethrotomy involves incising the stricture transurethrally using endoscopic equipmentto release scar tissue. Stents incorporate themselves into the wall of the urethra and keep the lumen open. They work best for short strictures in the bulbar urethra (anterior urethral anatomy, from proximal to distal: prostatic urethraposterior or membranous urethrabulbar urethrapenile or pendulous urethrafossa navicularismeatus). __OOHHCCMM__1100ee. . iinnddbb 664499 0022//0055//22001177 1199: : 0088 650 yregruS Lumps in the groin and scrotum Testicular lump cancer until proved otherwise. Acute, tender enlargement of testis torsion (p652) until proved otherwise. Diagnosing scrotal masses (fi g 13. 51) 1 Can you get above it? 2 Is it separate from the testis? 3 Cystic or solid? Cannot get above: inguinoscrotal hernia (p614) or hydrocele extending proximally. Separate and cystic: epididymal cyst. Separate and solid: epididymitis/varicocele. Testicular and cystic: hydrocele. Testicular and solidtumour, haem atocele, granuloma (p196), orchitis, gumma (p412). ultrasound may help. Epididymal cysts Usually develop in adulthood and contain clear or milky (spermatocele) fl uid. They lie above and behind the testis. Remove if symptomatic. Hydroceles (Fluid within the tunica vaginalis. ) Primary (associated with a patent processus vaginalis, which typically resolves during the 1st year of life) or seconda ry to testis tumour/trauma/infection. Primary hydro celes are more common, larger, and usually in younger men. Can resolve spontaneously. : Aspira tion (may need repeating) or surgery: plicating the tunica vaginalis (Lords repair)/inverting the sac (Jaboulays repair). Is the testis normal after aspiration? If any doubt, do ultrasound. Epididymo-orchitis Causes: Chlamydia(eg if35yrs); E. coli; mumps; N. gonorrhoeae; TB. Features: Sudden-onset tender Edema, dysuria, sweats/fever. Take 1st catch Urine sample; look for urethral discharge. Consider STI screen. Warn of possible infertility and symptoms worsening before improving. : If 35yrs; doxycycline 100mg/12h (covers chlamydia; treat sexual partn ers). If gonorrhoea suspected add ceftriaxone 500mg IM stat. If 35yrs (mostly non-STI), associated UTI is common so try ciprofl oxacin 500mg/12h or ofl oxacin 200mg/12h. Antibiotics should be used for 24wks. Also: analgesia, scrotal support, drainage of any abscess. Varicocele Dilated veins of pampiniform plexus. Left side more commonly aff ected. Often visible as distended scrotal Blood vessels that feel like a bag of worms. Patient may complain of dull ache. Associated with subfertility, but repair (via surgery or embolization) seems to have little eff ect on subsequent pregnancy rates. Haematocele Blood in tunica vaginalis, follows trauma, may need drainage/excision. Testicular tumours The commonest malignancy in aged 1544; 10% occur in undescended testes, even after orchidopexy. A contralateral tumour is found in 5%. Types: Seminoma, 55% (3065yrs); non-seminomatous germ cell tumour, 33% (NSGCT; previously teratoma; 2030yrs); mixed germ cell tumour, 12%; lymphoma. Signs: Typically painless testis lump, found after trauma/infection ± haemospermia, secondary hydrocele, Pain, dyspnoea (lung mets), abdominal mass (enlarged nodes), or eff ects of secreted hormones. 25% of seminomas 50% of NSGCTS present with metastases. Risk factors: Undescended testis; infant hernia; infertility. Staging: 1 No evidence of metastasis.",
    "Risk factors: Undescended testis; infant hernia; infertility. Staging: 1 No evidence of metastasis. 2 Infradiaphragmatic node involvement (spread via the para-aortic nodes not inguinal nodes). 3 Supra diaphragmatic node involvement. 4 Lung involvement (haematogenous). Tests: (Allow staging. ) CXR, computed tomography, excision biopsy. -FP (eg 3IU/mL)13 and -hCG are useful tumour markers and help monitor treatment (p531); check before during . : Radical orchidectomy (inguinal incision; occlude the spermatic cord before mobilization to risk of intra-operative spread). Options are constantly updated (surgery, radiotherapy, chemotherapy). Seminomas are exquisitely radiosensitive. Stage 1 seminomas: orchidectomy radiotherapy cures 95%. Do close followup to detect relapse. Cure of NSGCT, even if metasta ses are present, is achieved by 3 cycles of bleomycin etoposide cisplatin. 5yr survival 90% in all groups. Encourage regular self-examination (prevents late presentation). 13 FP is not in pure seminoma; may also be in: hepatitis, cirrhosis, Liver cancer, open neural tube defect. __OOHHCCMM__1100ee. . iinnddbb 665500 0022//0055//22001177 1199: : 0088 651 yregruS Diagnosing groin lumps: lateral to medial thinking Psoas abscessmay present with back Pain, limp, and swinging pyrexia. Neuroma of the femoral nerve. Femoral artery aneurysm. Saphena varixlike a hernia, it has a cough impulse. Lymph node. Femoral hernia. Inguinal hernia. Hydrocele or varicocele. Also consider an undescended testis (cryptorchidism). Fig 13. 51 Diagnosis of scrotal masses. (transilluminates: position of pen torch shown in image). __OOHHCCMM__1100ee. . iinnddbb 665511 0022//0055//22001177 1199: : 0088 652 yregruS Torsion of the testis The aim is to recognize this condition before the cardinal signs and symptoms are fully manifest, as prompt surgery saves testes. If surgery is performed in 6h the salvage rate is 90100%; if 24h it is 010%. If in any doubt, surgery is required. If suspected refer immediately to urology. Symptoms: Sudden onset of Pain in one testis, which makes walking uncomfortable. Pain in the abdomen, nausea, and Vomiting are common. Signs: Infl ammation of one testisit is very tender, hot, and swollen. The testis may lie High and transversely. Torsion may occur at any age but is most common at 1130yrs. With intermittent torsion the Pain may have passed on presentation, but if it was severe, and the lie is horizontal, prophylactic fi xing may be wise. : The main one is epididymo-orchitis (p650) but with this the patient tends to be older, there may be symptoms of urinary infection, and more gradual onset of Pain. Also consider tumour, trauma, and an acute hydrocele. NB: torsion of testicular or epididymal appendage (the hydatid of Morgagnia remnant of the Müllerian duct)usually occurs between 712yrs, and causes less Pain. Its tiny blue nodule may be discernible under the scrotum. It is thought to be due to the surge in gonadotrophins which signal the onset of puberty. Idiopathic scrotal oedema is a benign condition usually between ages 2 and 10yrs, and is diff erentiated from torsion by the absence of Pain and tenderness. Tests: Doppler ultrasound may demonstrate lack of Blood fl ow to testis. Only perform if diagnosis equivocaldo not delay surgical exploration. Treatment: Ask consent for possible orchidectomy bilateral fi xation (orchidopexy)see p568. At surgery expose and untwist the testis. If its colour looks Good, return it to the scrotum and fi x both testes to the scrotum. Undescended testes Incidence About 3% of boys are born with at least one undescended testis (30% of premature boys) but this drops to 1% after the fi rst year of life. Unilateral is four times more common than bilateral. (If bilateral then should have genetic testing. ) Cryptorchidism: Complete absence of the testis from the scrotum (anorchism is absence of both testes).",
    "Cryptorchidism: Complete absence of the testis from the scrotum (anorchism is absence of both testes). Retractile testis: The genitalia are normally developed but there is an excessive cremasteric refl ex. The testis is often found at the external inguinal ring. : reassurance (examining while in a warm Rice, for example, may help to distinguish from maldescended/ectopic testes). Maldescended testis: May be found anywhere along the normal path of descent from abdomen to groin. Ectopic testis: Most commonly found in the superior inguinal pouch (anterior to the external oblique aponeurosis) but may also be abdominal, perineal, penile, and in the femoral triangle. Complications of maldescended and ectopic testis Infertility; 40 increased risk of testicular cancer (risk remains after surgery but in cryptorchidism may be if orchidopexy performed before aged 10), increased risk of testicular trauma, increased risk of testicular torsion. Also associated with hernias (due to patent processus vaginalis in 90%, p613) and other urinary tract anomalies. Treatment of maldescended and ectopic testis restores (potential for) spermatogenesis; the increased risk of malignancy remains but becomes easier to diagnose. Surgery: Orchidopexy, usually dartos pouch procedure, is performed in infancy: testis and cord are mobilized following a groin incision, any processus vaginalis or hernial sac is removed and the testis is brought through a hole made in the dartos muscle into the resultant subcutaneous pouch where the muscle prevents retraction. Hormonal: Hormonal therapy, most commonly human chorionic gonadotrophin (hCG), is sometimes attempted if an undescended testis is in the inguinal canal. __OOHHCCMM__1100ee. . iinnddbb 665522 0022//0055//22001177 1199: : 0088 653 yregruS __OOHHCCMM__1100ee. . iinnddbb 665533 0022//0055//22001177 1199: : 0088 654 yregruS Aneurysms of arteries An artery with a dilatation 50% of its original diameter has an aneurysm; remember this is an ongoing process. True aneurysms are abnor mal dilatations that involve all layers of the arterial wall. False aneurysms (pseudoaneurysms) involve a collection of Blood in the outer layer only (adventitia) whichcommunicates with the lumen (eg after trauma). Ane ury sms may be fusiform (eg most AAAS) or sac-like (eg Berry aneurysms; fi g 10. 17 p479). Causes Atheroma, trauma, infection (eg mycotic aneurysm in endocarditis; tertiary syphilisespecially thoracic aneurysms), connective tissue disorders (eg Marfans, EhlersDanlos), infl ammatory (eg Takayasus aortitis, p712). Common sites Aorta (infrarenal most common), iliac, femoral, and popliteal arteries. Complications Rupture; thrombosis; embolism; fi stulae; Hypertension on other structures. Screening All at age 65yr are invited for screening in UK, decreases mortality from ruptured AAA. Ruptured abdominal aortic aneurysm (AAA) Death rates/year from ruptured AAAS rise with age: 125 per million in those aged 5559; 2728 per million if over 85yrs. Symptoms signs: Intermittent or continuous abdominal Pain (radiates to back, iliac fossae, or groins; dont dismiss this as renal colic), collapse, an expansile abdominal mass (it expands and contracts, unlike swellings that are purely pulsatile, eg nodes overlying arteries), and shock. If in doubt, assume a ruptured aneurysm. Unruptured AAA Defi nition: 3cm across. Prevalence: 3% of those 50yrs. : 3: 1. Less common in diabetics. Cause: Degeneration of elastic lamellae and smooth muscle loss. There is a genetic component. Symptoms: Often none, they may cause abdominal/back Pain, often discovered incidentally on abdominal examination (see BOX). Monitoring: RCTS have failed to demonstrate benefi t from early endovascular repair (EVAR, see later in paragraph) of aneurysms 5. 5cm (where rupture rates are Low). Risk of rupture below this size is 1%/yr, compared to 25%/yr for aneurysms 6cm across. 75% of aneurysms under monitoring will eventually need repair. Rupture is more likely if: blood pressure Smoker Positive family history. Modify risk factors if possible at diagnosis.",
    "Rupture is more likely if: blood pressure Smoker Positive family history. Modify risk factors if possible at diagnosis. Elective surgery: Reserve for aneurysms ≥5. 5cm or expanding at 1cm/yr, or symptomatic aneurysms. Operative mortality: 5%; complications include spinal or visceral ischaemia and distal emboli from dislodged thrombus debris. Studies show that age 80yrs should not, in itself, preclude surgery. Stenting (EVAR): Major surgery can be avoided by inserting an endovascular stent via the femoral artery. EVAR has less early mortality but higher graft complications, eg failure of stent-graft to totally exclude Blood fl ow to the aneurysmendoleak. See fi g 13. 52. Emergency management of a ruptured abdominal aneurysm Mortalitytreated: 41% and improving; untreated: 100%. Summon a vascular surgeon and an experienced anaesthetist; warn theatre. Do an ECG, and take Blood for amylase, hemoglobin, crossmatch (1040U may eventually be needed). Catheterize the bladder. Gain IV access with 2 large-bore cannulae. Treat shock with O RhΩve Blood (if not cross matched), but keep systolic blood pressure ≤100mmHg to avoid rupturing a contained leak (NB: raised blood pressure is common early on). Take the patient straight to theatre. Dont waste time on X-rays: fatal delay may result, though computed tomography can help in a stable patient with an uncertain diagnosis. Give prophylactic antibiotics, eg co-amoxiclav 625mg IV. Surgery involves clamping the aorta above the leak, and inserting a Dacron graft (eg tube graft or, if signifi cant iliac aneurysm also, a trouser graft with each leg attached to an iliac artery). __OOHHCCMM__1100ee. . iinnddbb 665544 0022//0055//22001177 1199: : 0088 655 yregruS Thoracic aortic dissection Blood splits the aortic media with sudden tearing chest Pain (± radiation to back). As the dissection extends, branches of the aorta occlude sequentially leading to hemiplegia (carotid artery), unequal arm pulses and blood pressure, or acute limb ischaemia, para plegia (anterior spinal artery), and anuria (renal arteries). Aortic valve incompetence, inferior myocardial infarction, and cardiac arrest may develop if dissection moves proximally. Type A (70%) dissections involve the ascending aorta, irrespective of site of the tear, while if the ascending aorta is not involved it is called type B (30%). All patients with type A thoracic dissection should be considered for surgery: get urgent cardiothoracic advice. Defi nitive treatment for type B is less clear and may be managed medically, with surgery reserved for distal dissections that are leaking, ruptured, or compromising vital organs. Management: Crossmatch 10U Blood. ECG CXR (expanded mediast inum is rare). computed tomography or transoesophageal echocardiography (TOE). Take to ITU; hypotensives: keep systolic at 100110mmHg: labetalol (p140) or esmolol (t½ is ultra-short) by IVI is helpful here (calcium-channel blockers may be used if -blockers contraindicated). Acute operative mortality: 25%. Fig 13. 52 Stenting: not an open or closed case this is a digital subtraction angiogram showing correct positioning of an endovascular stent at the end of the procedure. Although less invasive than open repair, some are unsuited to this method, owing to the anatomy of their aneurysm. Lifelong monitoring is needed: stents may leak and the aneurysm progress (the risk can be reduced by coiling the internal iliac arteries, as shown). Image courtesy of Norwich Radiology Dept. __OOHHCCMM__1100ee. . iinnddbb 665555 0022//0055//22001177 1199: : 0088 656 yregruS Peripheral arterial disease (peripheral arterial disease) Occurs due to atherosclerosis causing stenosis of arteries (fi g 13. 53) via a multifactorial process involving modifi able and non-modifi able risk factors. 65% have coexisting clinically relevant cerebral or coronary artery disease. Cardiovascular risk factors should be identifi ed and treated aggressively. The chief feature of peripheral arterial disease is intermittent claudication ( to limp). Prevalence 10%.",
    "The chief feature of peripheral arterial disease is intermittent claudication ( to limp). Prevalence 10%. Symptoms Cramping Pain in the calf, thigh, or buttock after walking for a given distance (the claudication distance) and relieved by rest (calf claudication suggests femoral disease while buttock claudication suggests iliac disease). Ulceration, gangrene (p660), and foot Pain at resteg burning Pain at night relieved by hanging legs over side of bedare the cardinal features of critical ischaemia. Buttock claudication ± impotence imply Leriches syndrome (p704). Young, heavy smokers are at risk from Buergers disease (thromboangiitis obliterans, p696). Fontaine classifi cation for peripheral arterial disease: 1 Asymptomatic. 2 Intermittent claudication. 3 Ischaemic rest Pain. 4 Ulceration/gangrene (critical ischaemia). Signs Absent femoral, popliteal, or foot pulses; cold, white leg(s); atrophic skin; punched out ulcers (often painful); postural/dependent colour change; Buergers angle (angle that leg goes pale when raised off the couch) of 20° and capillary fi lling time 15s are found in severe ischaemia. Tests Exclude diabetes mellitus, arteritis (ESR/CRP). FBC (anaemia, polycythaemia); UE (renal disease); lipids (dyslipidaemia); ECG (cardiac ischaemia). Do thrombophilia screen and serum homocysteine if 50 years. Anklebrachial Hypertension index (ABPI): Normal 11. 2; peripheral arterial disease 0. 50. 9; critical limb ischaemia 0. 5 or ankle systolic Hypertension 50mmHg. Beware falsely High results from incompressible calcifi ed vessels in severe atherosclerosis, eg diabetes mellitus. Imaging Colour duplex ultrasound 1st line. If considering intervention MR/computed tomography angiography (fi g 13. 54) for extent and location of stenoses and quality of distal vessels (run-off ). 1 Risk factor modifi cation: Quit smoking (vital). Treat hypertension and High cholesterol. Prescribe an antiplatelet agent (unless contraindicated), to prevent progression and to reduce cardiovascular risk. Clopidogrel is recommended as 1st-line. 2 Management of claudication: Supervised exercise programmes reduce symptoms by improving collateral Blood fl ow (2h per wk for 3 months). Encourage patients to excercise to the point of maximal Pain. Vasoactive drugs, eg naftidrofuryl oxalate, off er modest benefi t and are recommended only in those who do not wish to undergo revascularization and if exercise fails to improve symptoms. If conservative measures have failed and peripheral arterial disease is severely aff ecting a patients lifestyle or becoming limb-threatening, intervention is required. Percutaneous transluminal angioplasty (PTA) is used for disease limited to a single arterial segment (a balloon is infl ated in the narrowed segment). 5-year patency is 79% (iliac) and 55% (femoral). Stents can be used to maintain artery patency. Surgical reconstruction: If atheromatous disease is extensive but distal run-off is Good (ie distal arteries fi lled by collateral vessels), consider arterial reconstruction with a bypass graft (fi g 13. 54). Procedures include femoralpopliteal bypass, femoralfemoral crossover, and aortobifemoral bypass grafts. Autologous vein grafts are superior to prosthetic grafts (eg Dacron or PTFE) when the knee joint is crossed. Amputation 3% of patients with intermittent claudication require major amputation within 5 years ( in Diabetes, p212). Amputation may relieve intractable Pain and death from sepsis and gangrene. A decision to amputate must be made by the patient, usually against a background of failed alternative strategies. The knee should be preserved where possible as it improves mobility and rehabilitation potential (this must be balanced with the need to ensure wound healing). Rehabilitation should be started early with a view to limb fi tting. Gabapentin (regimen on p504) can be used to treat the gruelling complication of phantom limb Pain. Future therapies: Early-phase clinical trials have demonstrated the safety and benefi t of gene therapy (eg hepatocyte growth factor) in critical limb ischaemia. __OOHHCCMM__1100ee. .",
    "__OOHHCCMM__1100ee. . iinnddbb 665566 0022//0055//22001177 1199: : 0088 657 yregruS (a) (b) Fig 13. 53 Leg arteries. Fig 13. 54 computed tomography an gi ogram showing (a) normal lower limb vasculature and (b) heavily diseased arteries with previous left femoral anterior tibial bypass. Reproduced from Diagnosis and management of peripheral arterial disease, BMJ, Peach et al. , 345: e5208, 2012, with permission from BMJ Publishing Group Ltd. Acute limb ischaemia Surgical emergency requiring revascularization within 46h to save the limb. May be due to thrombosis in situ (40%), emboli (38%), graft/angioplasty occlusion (15%), or trauma. Thrombosis more likely in known vasculopaths; emboli are sudden, eg in those without previous vessel disease; they can aff ect multiple sites, and there may be a bruit. Mortality: 22%. Amputation rate: 16%. Symptoms and signs: The 6 PS of acute ischaemia: pale, pulseless, painful, paralysed, paraesthetic, and perishingly cold. Onset of fi xed mottling implies irreversibility. Emboli commonly arise from the Heart (atrial fibrillation; mural thrombus) or aneurysms. In patients with known peripheral arterial disease, sudden deterioration of symptoms with deep duskiness of the limb may indicate acute arterial occlusion. This appearance is due to extensive preexisting collaterals and must not be misdiagnosed as gout/cellulitis. Management: This is an emergency and may require urgent open surgery or angioplasty. If diagnosis is in doubt, do urgent arteriography. If the occlusion is embolic, the options are surgical embolectomy (Fogarty catheter) or local thrombolysis, eg tissue plasminogen activator (t-PA, p345), balancing the risks of surgery with the haemorrhagic complications of thrombolysis. Anticoagulate with heparin after either procedure and look for the source of emboli. Be aware of possible post-op reperfusion injury and subsequent compartment syndrome. __OOHHCCMM__1100ee. . iinnddbb 665577 0022//0055//22001177 1199: : 0088 658 yregruS Varicose veins (VVS) Long, tortuous, dilated veins of the superfi cial venous system (see fi g 13. 55). Pathology Blood from superfi cial veins of the leg passes into deep veins via perforator veins (perforate deep fascia) and at the saphenofemoral and saphenopopliteal junctions. Valves prevent Blood from passing from deep to superfi cial veins. If they become incompetent there is venous hypertension and dilata tion of the superfi cial veins occurs. Risk factors: Prolonged standing, obesity, pregnancy, family history, and contraceptive pill. Causes: Primary mechanical factors (in 95%); secondary to obstruction (eg DVT, fetus, pelvic tumour), arteriovenous malformations, overactive muscle pumps (eg cyclists); rarely congenital valve absence. Symptoms My legs are ugly. Pain, cramps, tingling, heaviness, and restless legs. But studies show these symptoms are only slightly commoner in those with VVS. Signs Oedema; eczema; ulcers; haemosiderin; haemorrhage; phlebitis; atrophie blanche (white scarring at the site of a previous, healed ulcer); lipodermatosclerosis (skin hardness from subcutaneous fi brosis caused by chronic infl ammation and fat necrosis). On their own VVS dont cause DVTS (except possibly proximally spreading thrombophlebitis of the long saphe nous vein). Examination See p78. Treatment NICE guidelines11 suggest that the criteria for specialist referral of patients with VVS should be: bleeding, Pain, ulceration, superfi cial thrombophlebitis, or a severe impact on quality of life (ie not for cosmetic reasons alone). Treat any underlying cause. Educationavoid prolonged standing and elevate leg(s) whenever possible; support stockings (compliance is a problem); lose weight; regular walks (calf muscle action aids venous return). Endovascular treatment (less Pain and earlier return to activity than surgery. ) Radiofrequency ablation (VNUS Closure)a catheter is inserted into the vein and heated to 120°C destroying the endothelium and closing the vein. Results are as Good as conventional surgery at 3 months. Endovenous laser ablation (EVLA) is similar but uses a laser.",
    "Results are as Good as conventional surgery at 3 months. Endovenous laser ablation (EVLA) is similar but uses a laser. Outcomes are similar to surgical repair after 2yrs (in terms of quality of life and recurrence). Injection sclerotherapyeither liquid or foam can be used. Liquid sclerosant is indicated for varicosities below the knee if there is no gross saphenofemoral incompetence. It is injected at multiple sites and the vein compressed for a few weeks to avoid thrombosis (intravascular granulation tissue obliterates the lumen). Alternatively foam sclerosant is injected under ultrasound guidance at a single site and spreads rapidly throughout the veins, damaging the endothelium. Ultrasound monitoring prevents inadvertent spread of foam into the femoral vein. It achieves 80% complete occlusion but is not more eff ective than liquid sclerotherapy or surgery. Surgerythere are several choices, depending on vein anatomy and surgical preference, eg saphenofemoral ligation (Trendelenburg procedure); multiple avulsions; stripping from groin to upper calf (stripping to the ankle is not needed, and may damage the saphenous nerve). Post-op: bandage legs tightly and elevate for 24h. Surgery is more eff ective than sclerotherapy in the long term. Before surgery and after venous mapping, ensure that all varicosities are indelibly marked to either side (to avoid tattooing if the incision is made through inked skin). Saphena varix Dilatation in the saphenous vein at its confl uence with the femoral vein (the SFJ). It transmits a cough impulse and may be mistaken for an inguinal or femoral hernia, but on closer inspection it may have a bluish tinge. __OOHHCCMM__1100ee. . iinnddbb 665588 0022//0055//22001177 1199: : 0088 659 yregruS Fig 13. 55 The superfi cial veins of the leg. When do varicose veins become an illness? Perhaps when they hurt? Or is this too simple? Certain illnesses are desirable: they provide a compensation for a functional disorder (Albert Camus); this is known to be common with VVS. Perhaps many opt for surgery as a displacement activity to confronting deeper problems. We adopt the sickness role when we want sympathy. Somatization is hard to manage; here is one approach to consider: Give time; dont dismiss these patients as just the worried well. Explore factors perpetuating illness behaviour (misinformation, social stressors). Agree a plan that makes sense to the patients holistic view of themself. Treat any underlying depression (drugs and cognitive therapy, OHCS p344). __OOHHCCMM__1100ee. . iinnddbb 665599 0022//0055//22001177 1199: : 0088 660 yregruS Gangrene and necrotizing fasciitis Defi nitions Gangrene is death of tissue from poor vascular supply and is a sign of critical ischaemia (see p656). Tissues are black and may slough. Dry gangrene is necrosis in the absence of infection. Note a line of demarcation between living and dead tissue. 14 : restoration of Blood supply ± amputation. Wet gangrene is tissue death and infection (associated with discharge) occurring together (p213, fi g 5. 10). : analgesia; broad-spectrum IV antibiotics; surgical debridement ± amputation. Gas gangrene is a subset of necrotizing myositis caused by spore-forming clostridial species. There is rapid onset of myonecrosis, muscle Edema, gas production, sepsis, and severe Pain. Risk factors include Diabetes, trauma, and malignancy. : remove all dead tissue (eg amputation). Give benzylpenicillin ± clindamycin. Hyperbaric O2 can improve survival and the number of debridements. Necrotizing fasciitis is a rapidly progressive infection of the deep fascia causing necrosis of subcutaneous tissue. Prompt recognition (diffi cult in the early stages) and aggressive treatment is required. In any atypical cellulitis, get early surgical help. There is intense Pain over aff ected skin and underlying muscle. Group A -haemolytic streptococci is a major cause, although infection is often polymicrobial.",
    "Group A -haemolytic streptococci is a major cause, although infection is often polymicrobial. Fourniers gangrene is necrotizing fasciitis localized to the scrotum and perineum. : Radical debridement ± amputation; IV antibiotics, eg benzylpenicillin and clindamycin. Skin ulcers Ulcers are abnormal breaks in an epithelial surface. Leg ulcers aff ect 2% in developed countries. Causes May be multiple. For leg ulcers, venous disease accounts for 70%, mixed arterial and venous disease for 15%, and arterial disease alone for 2%. Other contributory factors include neuropathy (eg in diabetes mellitus), lymphoedema, vasculitis, malignancy (p596), infection (eg TB, syphilis), trauma (eg Hypertension sores: see fi g 10. 16, p473), pyoderma gangrenosum, drugs (eg nicorandil, hydroxyurea). History Ask about number, Pain, trauma. Explore comorbiditieseg VVS, peripheral arterial disease, Diabetes, vasculitis. Length of history? Is the patient taking steroids? Are self-induced ulcers, dermatitis artefacta, a possibility? Has a biopsy been taken? Examination Note features such as site, number, surface area, depth, edge, base, discharge, lymphadeno pathy, sensation, and healing (see BOX). If in the legs, note features of venous insuffi ciency or arterial disease and, if possible, apply a blood pressure cuff to perform anklebrachial Hypertension index (ABPI). Tests Skin and ulcer biopsy may be necessaryeg to assess for vasculitis (will need immunohistopathology) or malignant change in an established ulcer (Marjolins ulcer SCC presenting in chronic wound). If ulceration is the fi rst sign of a suspected systemic disorder then further screening tests will be required. Management Managing ulcers is often diffi cult and expensive. Treat the cause(s) and focus on prevention. Optimize nutrition. Are there adverse risk factors (drug addiction, or risk factors for arteriopathy, eg smoking)? Get expert nursing care. Consider referral to specialist community nurse or leg ulcer/tissue viability clinic: Charing-Cross 4-layer compression bandaging is better than standard bandages (use only if arterial pulses OK: ABPI (p656) should be 0. 8). Honey dressings can improve healing in mildmoderate burns, but as an adjuvant to compression bandaging for leg ulcers they do not signifi cantly improve healing rate. Negative Hypertension wound therapy (eg VAC) helps heal diabetic ulcers. Surgery, larval therapy, and hydrogels are used to debride sloughy necrotic tissue (avoid hydrogels in diabetic ulcers due to risk of wet gangrene). Routine use of antibiotics does not improve healing. Only use if there is infection (not colonization). 14 The fi rst sign of his approaching end was when one of my old aunts, while undressing him, removed a toe with one of his old socks. Graham Greene, A Sort of Life, 1971, Simon Schuster. __OOHHCCMM__1100ee. . iinnddbb 666600 0022//0055//22001177 1199: : 0088 661 yregruS Features of skin ulceration to note on examination Site Above the medial malleolus (gaiter area) is the favourite place for venous ulcers (fi g 13. 56; mostly related to superfi cial venous disease, but may refl ect venous hypertension via damage to the valves of the deep venous system, eg 2° to DVT). Venous hypertension leads to the development of superfi cial varicosities and skin changes (lipodermatosclerosis induration, pigmentation, and infl ammation of the skin). Minimal trauma to the leg leads to ulceration which often takes many months to heal. Ulcers on the sacrum, greater trochanter, or heel suggest Hypertension sores (OHCS p604), particularly if the patient is bed-bound with suboptimal nutrition. Temperature The ulcer and surrounding tissues are cold in an ischaemic ulcer. If the skin is warm and well perfused then local factors are more likely. Surface area Draw a map of the area to quantify and time any healing (a wound 4wks old is a chronic ulcer as distinguished from an acute wound).",
    "Shape Oval, circular (cigarette burns), serpiginous (Klebsiella granulomatis, p412); unusual morphology can be secondary to mycobacterial infection, eg cutaneous tuberculosis or scrofuloderma (tuberculosis colliquativa cutis, where an infected lymph node ulcerates through to the skin). Edge Shelved/sloping healing; punched-out ischaemic or syphilis; rolled/everted malignant; undermined TB. Base Any muscle, bone, or tendon destruction (malignancy; Hypertension sores; ischaemia)? There may be a grey-yellow slough, beneath which is a pale pink base. Slough is a mixture of fi brin, cell breakdown products, serous exudate, leucocytes, and bacteriait need not imply infection, and can be part of the normal wound healing process. Granulation tissue is a deep pink gel-like matrix contained within a fi brous collagen network and is evidence of a healing wound. Depth If not uncomfortable for the patient (eg in neuropathic ulceration), a probe can be used to gauge how deep the ulceration extends. Discharge Culture before starting any antibiotics (which usually dont work). A watery discharge is said to favour TB; bleeding can malignancy. Associated lymphadenopathy Suggests infection or malignancy. Sensation Decreased sensation around the ulcer implies neuropathy. Position in phases of extension/healing Healing is heralded by granulation, scar formation, and epithelialization. Infl amed margins extension. Fig 13. 56 Venous ulcer in the gaiter area in an obese woman. Reproduced from Burge et al. , Oxford Handbook of Medical Dermatology, 2016, with permission from Oxford University Press. __OOHHCCMM__1100ee. . iinnddbb 666611 0022//0055//22001177 1199: : 0088 14 Clinical chemistry Contents On being normal in the society of numbers 662 The essence of laboratory medicine 663 Biochemistry: some major disease patterns 664 Lab results: act NOW 665 Fluid balance and IV fl uid therapy 666 Electrolyte physiology and the Kidney 668 Acidbase balance 670 Hyperand hyponatraemia 672 Syndrome of inappropriate ADH secretion (SIADH) 673 Hyperand hypokalaemia 674 Calcium and phosphate physiology 676 Hypercalcaemia 676 Hypocalcaemia 678 Fig 14. 1 Rosalyn Yalow (19212011). Trained Phosphate, magnesium, zinc, in nuclear physics, and made Good use of this and selenium 679 when she developed the radioimmunoassay Urate and the Kidney 680 technique to allow trace amounts of peptides Metabolic bone diseases to be measured in serum using antibodies. This Osteoporosis 682 revolutionized laboratory medicine, making Osteomalacia 684 reliable assays for hormones widely available, Pagets disease of bone 685 and underpinned the development of endocriPlasma proteins 686 nology. It was also employed to screen Blood Urinary proteins 686 against a range of pathogens, and the techPlasma enzymes 688 nique is still commonly used today. She was awarded the Nobel prize for her work in 1977, Hyperlipidaemia 690 and commented to a group of children that: The porphyrias 692 Initially, new ideas are rejectedLater they become dogma, if youre right. And if youre really lucky you can publish your rejections as part of your Nobel presentation. On being normal in the society of numbers Laboratory medicine reduces our patients to a few easy-to-handle numbers: this is the disciplines great attractionand its greatest danger. The normal range (reference interval) is usually that which includes 95% of a given population (given a normal distribution, see p750). If variation is randomly distributed, 2. 5% of our results will be too High, and 2. 5% too Low on an average day, when dealing with apparently normal people. This statistical defi nition of normality is the simplest. Other defi nitions may be normativeie stating what an upper or lower limit should be. The upper end of the reference interval for plasma cholesterol may be given as 6mmol/L because this is what biochemists state to be the desired maximum.",
    "40% of people in some populations will have a plasma cholesterol greater than 6mmol/L and thus may be at increased risk. The WHO defi nition of anaemia in pregnancy is an hemoglobin of 110g/L, which makes 20% of mothers anaemic. This lax criterion has the presumed benefi t of triggering actions that result in fewer deaths from haemorrhage. So do not just ask What is the normal range? also enquire about who set the range, for what population, and for what reason. We thank Dr Petra Sulentic, our Specialist Reader, for her contribution to this chapter. __OOHHCCMM__1100ee. . iinnddbb 666622 0022//0055//22001177 1199: : 0088 663 yrtsimehc lacinilC The essence of laboratory medicine General principles Laboratory testing may contribute to four aspects of medicine: diagnosis (eg TSH in hypothyrodism) prognosis (eg clotting in Liver failure) monitoring disease activity or progression (eg Creatinine in chronic Kidney disease) screening (eg phenylketonuria in newborn babies). Only do a test if the result will infl uence management. Make sure you look at the result. Always interpret laboratory results in the context of the patients clinical picture. If a result does not fi t with the clinical picture, trust clinical judgement and repeat the test. Could it be an artefact? The normal range for a test (reference interval) is usually defi ned as the interval, symmetrical about the mean, containing 95% of results in a given population (p751). The more tests you run, the greater the probability of an abnormal result of no signifi cance (see p751). Laboratory staff like to have contact with you. They are an excellent source of help and information for both requests and results. Involve the patient. Dont forget to explain to them where the test fi ts into their overall management plan. Getting the best out of the laba laboratory decalogue 1 Interest someone from the laboratory in your patients problem. 2 Fill in the request form fully. 3 Give clinical details, not your preferred diagnosis. 4 Ensure that the lab knows who to contact. 5 Label specimens as well as the request form. 6 Follow the hospital labelling routine for crossmatching. 7 Find out when analysers run, especially batched assays. 8 Talk with the lab before requesting an unusual test. 9 Be thoughtful: at1 6: 30h the routine results are being sorted. 10 Plot results graphically: abnormalities show sooner. Artefacts and pitfalls in laboratory tests Do not take Blood samples from an arm that has IV fl uid running into it. Repeat any unexpected and inconsistent result before acting on it. For clotting time do not sample from a heparinized IV catheter. Serum potassium is overestimated if the sample is old or haemolysed (this occurs if venepuncture is diffi cult). If using Vacutainers, fi ll plain tubes fi rstotherwise, anticoagulant contam ination from previous tubes can cause errors. Total calcium results are aff ected by albumin concentration (p676). INR may be overestimated if citrate bottles are underfi lled. Drugs may cause analytic errors (eg prednisolone cross-reacts with cortisol). Be suspicious if results are unexpected. Food may aff ect result, eg bananas raise urinary HIAA (p271).",
    "Be suspicious if results are unexpected. Food may aff ect result, eg bananas raise urinary HIAA (p271). Ford Madox Ford 1915 The Good Soldier Normal values can have hidden historical, social, and political desideratajust like the normal values novelists ascribe to their characters: Conventions and traditions I suppose work blindly but surely for the preservation of the normal type; for the extinction of proud, resolute and unusual individuals Society must go on, I suppose, and society can only exist if the normal, if the virtuous, and the slightly-deceitful fl ourish, and if the passionate, the headstrong, and the tootruthful are condemned to suicide and to madness. Yes, society must go on; it must breed, like rabbits. That is what we are here for But, at any rate, there is always Leonora to cheer you up; I dont want to sadden you. Her husband is quite an economical person of so normal a fi gure that he can get quite a large proportion of his clothes ready-made. That is the great desideratum of life. Oxford Worlds Classics, pp18192 __OOHHCCMM__1100ee. . iinnddbb 666633 0022//0055//22001177 1199: : 0088 664 yrtsimehc lacinilC Biochemistrysome major disease patterns Dehydration Urea (disproportionate relative to smaller in Creatinine), 1 albumin (also useful to plot change in a patients con dition), haematocrit (PCV); also Urine volume and skin turgor. Abnormal Kidney function There are two major biochemical pictures (table 14. 1): Low glomerular filtration rate: Usually oliguric. Causes: early acute oliguric renal failure (p298), chronic Kidney disease (p302). In chronic Kidney disease also hemoglobin, parathyroid hormone, and renal bone disease. Tubular dysfunction: Results from damage to tubules. Diagnosis is made by testing renal concentrating ability (p241). May be polyuric with urinary glucose, amino acids, proteins (lysozyme, 2-microglobulin), or phosphate. Causes: recovery from acute Kidney injury, hypercalcaemia, hyperurica emia, myeloma, pyelonephritis, hypokalaemia, Wilsons disease, galactosaemia, and heavy metal poisoning. Table 14. 1 Biochemical profi Blood in abnormal Kidney function Low glomerular filtration rate Tubular dysfunction Urea Creatinine Normal potassium urate H bicarbonate Ω phosphate 3Ω Ca2 Normal Thiazide and loop diuretics sodium, potassium, bicarbonate Ω, urea. Bone disease See table 14. 2 for typical biochemical patterns. Table 14. 2 Serum biomarkers in common diseases of bone Ca2 PO 4 3Ω ALP Osteoporosis (p682) Normal Normal Normal Osteomalacia (p684) Pagets Normal Normal Myeloma , normal Normal Bone metastases , normal 1° Hyperparathyroidism , normal Normal, Hypoparathyroidism Normal Renal failure (Low glomerular filtration rate) Normal, Hepatocellular disease Bilirubin, AST, ALP slightly, albumin. Also clotting times. For details of the diff erences between AST and ALT, see p291. Cholestasis Bilirubin, GT, ALP, AST. Excess alcohol intake Evidence of hepatocellular disease. Early evidence if GT, MCV, and ethanol in Blood before lunch. Myocardial infarction Troponin, CK, AST, LDH (p118). Addisons disease potassium, sodium, urea. Cushings syndrome May show potassium, bicarbonate Ω, sodium. Conns syndrome May show potassium, bicarbonate Ω. sodium normal or . (Also hypertension. ) Diabetes mellitus Glucose, (bicarbonate Ω if acidotic). Diabetes insipidus sodium, plasma osmolality, Urine osmolality. (Both hypercalcaemia and hypokalaemia may cause nephrogenic Diabetes insipidus. ) Inappropriate ADH secretion (SIADH) (See p673. ) sodium with urea and Creatinine, plasma osmolality. Urine osmolality (plasma osmolality), Urine sodium (20mmol/L). Some immunodefi ciency states Normal serum albumin but Low total Protein (because immunoglobulins are missing. Also makes crossmatching diffi cult because expected haemagglutinins are absent; OHCS p198). 1 Dehydration aff ects urea more than Creatinine because in dehydration a greater proportion of fi ltered urea is reabsorbed by the Kidney. Creatinine is hardly reabsorbed at all. __OOHHCCMM__1100ee. .",
    "Creatinine is hardly reabsorbed at all. __OOHHCCMM__1100ee. . iinnddbb 666644 0022//0055//22001177 1199: : 0088 665 yrtsimehc lacinilC Laboratory results: when to take action NOW On receiving a dangerous result, fi rst check the name and date. Go to the bedside. If the patient is conscious, turn off any IVI (until fl uid is checked: a mistake may have been made) and ask the patient how he or she is. Any fi ts, faints, collapses, or unexpected symptoms? Be sceptical of an unexpectedly, wildly abnormal result with a well patient. Compare with previous values. Could the specimens have got muddled up; whose is it? Is there an artefact? Was the sample taken from the drip arm? Is a Low calcium due to a Low albumin (p676)? Perhaps the lab is using a new analyser with a faulty wash cycle? When in doubt, seek help and repeat the test. The following values are somewhat arbitrary and must be taken as a guide only. Many results less extreme than those listed will be just as dangerous if the patient is old, immunosuppressed, or has some other pathology such as pneumonia. Plasma biochemistry: The main risks when plasma electrolytes are dangerously abnormal (table 14. 3) are of cardiac arrhythmias and CNS events such as seizures. Table 14. 3 Dangerous levels of the common serum elecrolytes Electrolyte Lower limit Upper limit Relevant pages sodium 120mmol/L 155mmol/L p672 potassium 2. 5mmol/L 6. 5mmol/L p674, p301 Corrected Ca2 2. 0mmol/L 3. 5mmol/L p676, p678 Glucose 2. 0mmol/L 20mmol/L p832, p834 Blood gases: PaO2 8. 0kPa Severe hypoxia. Give O2. See p188. pH 7. 1 Dangerous acidosis. See p670 to determine the cause. Haematology results: hemoglobin 70g/L with Low mean cell volume (75fL) or history of bleeding. This patient may need urgent transfusion (no spare capacity)ask about symptoms, co-morbidities, and baseline hemoglobin. Check haematinics before transfusion. See p324. Platelets 40109/L. May need a platelet transfusion; call a haematologist. Plasmodium falciparum seen on Blood fi lm. Start antimalarials now. See p418. ESR 30mm/h headache. Could there be giant cell arteritis? See p556. CSF results: Never delay treatment when bacterial meningitis is suspected. 1 neutrophil/mm3. Is there meningitis: usually 1000 neutrophils? See p822. Positive Gram stain. Talk to a microbiologist; urgent blind therapy. See p822. Confl icting, equivocal, or inexplicable results: Get prompt help. __OOHHCCMM__1100ee. . iinnddbb 666655 0022//0055//22001177 1199: : 0088 666 yrtsimehc lacinilC Fluid balance and IV fl uid therapy Fluid requirement Roughly 22. 5L in a normal person (70kg) over 24h. Normal daily losses are through Urine (1500mL), stool (200mL), and insensible losses (800mL). This requirement is normally met through food (1000mL) and Drink (1500mL). Intravenous fl uids Given if suffi cient fl uids cannot be given orally. About 22. 5L of fl uid containing roughly 70mmol sodium and 70mmol potassium per 24h are required. 1 Thus, a Good regimen is 22. 5L of 0. 18% glucose with Sodium chloride with 2030mmol of potassium per litre of fl uid. Alternative routes are via a central venous line or subcutaneously. However, remember that all cannulae carry a risk of MRSA infection: femoral jugular subclavian peripheral, so always resume oral fl uid intake as soon as possible. In a sick patient, dont forget to include additional sources of fl uid loss when calculating daily fl uid requirements, such as drains, fevers, or diarrhoea (see BOX Special cases). Daily weighing helps to monitor overall fl uid balance, as will fl uid balance charts. Examine patients regularly to assess fl uid balance (see BOX Assessing fl uid balance).",
    "Examine patients regularly to assess fl uid balance (see BOX Assessing fl uid balance). Fluid compartments and types of IV fl uid For a 70kg man, total bodily fl uid is 42L (60% body weight). Of this, ⅔ is intracellular (28L) and ⅓ is extracellular (14L). Of the extracellular compartment, ⅓ is intravascular, ie Blood (5L). Diff erent types of IV fl uid will equilibrate with the diff erent fl uid compartments depending on the osmotic content of the given fl uid. 5% glucose: (Dextrose. ) Isotonic, but contains only a small amount of glucose (50g/L) and so provides little energy (10% daily energy per litre). The Liver rapidly metabolizes all the glucose leaving only Water, which rapidly equilibrates throughout all fl uid compartments. It is, therefore, useless for fl uid resuscitation (only 1/9 will remain in the intravascular space), but suitable for maintaining hydration. Excess 5% glucose IV may lead to Water overload and hyponatraemia (p672). 0. 9% saline: (Normal saline. ) Has about the same sodium content as plasma (150mmol/L) and is isotonic with plasma. 0. 9% saline will equilibrate rapidly throughout the extracellular compartment only, and takes longer to reach the intracellular compartment than 5% glucose. It is, therefore, appropriate for fl uid resuscitation, as it will remain predominantly in the extracellular space (and thus ⅓ of the given volume in the intravascular space), as well as for maintaining hydration. Hypertonic and hypotonic saline solutions are also available, but are for specialist use only. Colloids: (eg Gelofusine. ) Have a High osmotic content similar to that of plasma and therefore remain in the intravascular space for longer than other fl uids, making them appropriate for fl uid resuscitation, but not for general hydration. Colloids are expensive, and may cause anaphylactic reactions. In reality, eff ective fl uid resuscitation will use a combination of colloid and 0. 9% saline. Hypertonic glucose (10% or 50%): May be used in the treatment of hypoglycaemia. It is irritant to veins, so care in its use is needed. Infusion sites should be inspected regularly, and fl ushed with 0. 9% saline after use. Glucose with Sodium chloride: (One-fi fth normal saline. ) Isotonic, containing 0. 18% saline (30mmol/L of sodium) and 4% glucose (222mmol/L). It has roughly the quantity of sodium required for normal fl uid maintenance, when given 10-hourly in adults, but is now most commonly used in a paediatric setting. Hartmanns solution: Contains sodium 131mmol, ClΩ 111mmol, lactate 29mmol, potassium 5mmol, bicarbonate Ω 29mmol, and Ca2 2mmol per litre of fl uid. It is an alternative to 0. 9% saline, and some consider it more physiological. __OOHHCCMM__1100ee. . iinnddbb 666666 0022//0055//22001177 1199: : 0088 667 yrtsimehc lacinilC Assessing fl uid balance Underfi lled: Overfi lled: Tachycardia JVP (p43) Postural drop in blood pressure (Low blood pressure is a late Pitting oedema of the sacrum, ankles, or sign of hypovolaemia) even legs and abdomen capillary refi ll time Tachypnoea Urine output Bibasal crepitations Cool peripheries Pulmonary oedema on CXR (fi g 16. 3, p723). Dry mucous membranes See also p134 for signs of Heart failure. skin turgor Sunken eyes. The JVP is a substitute marker of central venous Hypertension, and when assessing fl uid balance is diffi cult, a CVP line may help to guide fl uid management. Special cases Acute Blood loss: Resuscitate with colloid or 0. 9% saline via large-bore cannulae until Blood is available. Children: Use glucose with Sodium chloride for fl uid maintenance: 100mL/kg for the fi rst 10kg, 50mL/kg for the next 10kg, and 20mL/kg thereafterall per 24h.",
    "Elderly: May be more prone to fl uid overload, so use IV fl uids with care (smaller fl uid bolus). GI losses: (Diarrhoea, Vomiting, NG tubes, etc. ) Replace lost potassium as well as lost fl uid volume. Heart failure: Use IV fl uids with care to avoid fl uid overload (p134). Liver failure: Patients often have a raised total body Sodium, so use salt-poor albumin or Blood for resuscitation, and avoid 0. 9% saline for maintenance. Acute pancreatitis: Aggressive fl uid resuscitation is required due to large amounts of sequestered third-space fl uid (p636). Poor Urine output: Aim for 1 mL/kg/h; the minimum is 0. 5mL/kg/h. Give a fl uid challenge, eg 500mL 0. 9% saline over 1h (or half this volume in Heart failure or the elderly), and recheck the Urine output. If not catheterized, exclude retention; if catheterized, ensure the catheter is not blocked! Post-operative: Check the operation notes for intraoperative losses, and ensure you chart and replace added losses from drains, etc. Shock: Resuscitate with colloid or 0. 9% saline via large-bore cannulae. Identify the type of shock (p790). Transpiration losses: (Fever, burns. ) Beware the large amounts of fl uid that can be lost unseen through transpiration. Severe burns in particular may require aggressive fl uid resuscitation (p846). Potassium in IV fl uids Potassium ions can be given with 5% glucose or 0. 9% saline, usually 20mmol/L or 40mmol/L. potassium may be retained in renal failure, so beware giving too much IV. Gastrointestinal fl uids are rich in potassium, so increased fl uid loss from the gut (eg diarrhoea, Vomiting, High-output stoma, intestinal fi stula) will need increased potassium replacement. The maximum concentration of potassium that is safe to infuse via a peripheral line is 40mmol/L, at a maximum rate of 20mmol/h in a cardiac monitored patient. Fluidrestricted patients may require higher concentrations or rates in life-threatening hypokalaemia. Faster rates risk cardiac dysrhythmias and asystole, and higher concentrations thrombophlebitis, depending on the size of the vein, so give concentrated solutions 40mmol/L via a central venous catheter, and use ECG monitoring for rates 10mmol/h. For symptoms and signs of hyperand hypokalaemia see p674. __OOHHCCMM__1100ee. . iinnddbb 666677 0022//0055//22001177 1199: : 0088 668 yrtsimehc lacinilC Electrolyte physiology and the Kidney The Kidney Controls the homeostasis of a number of serum electrolytes (including sodium, potassium, Ca2, and phosphate 3Ω), helps to maintain acidbase balance, and is responsible for the excretion of many substances. It also makes erythropoietin and renin, and hydroxylates 25-hydroxyvitamin D to 1, 25-di hydroxy vitamin D (see p676 for Ca2 and phosphate 3Ω physiology). All of these functions can be aff ected in chronic Kidney disease (p302), but it is the biochemical eff ects of Kidney failure that are used to monitor disease progression. The reninangiotensinaldosterone system Plasma is fi ltered by the glomeruli, and sodium, potassium, H, and Water are reabsorbed from this fi ltrate under the control of the reninangiotensinaldosterone system. Renin is released from the juxtaglomerular apparatus (fi g 7. 13, p316) in response to Low renal fl ow and raised sympathetic tone, and catalyses the conversion of angiotensinogen (a peptide made by the Liver) to angiotensin I. This is then converted by angiotensin-converting enzyme (ACE), which is located throughout the vascular tree, to angiotensin II.",
    "This is then converted by angiotensin-converting enzyme (ACE), which is located throughout the vascular tree, to angiotensin II. The latter has several important actions including eff erent renal arteriolar constriction (thus perfusion Hypertension), peripheral vaso constriction, and stimulation of the adrenal cortex to produce aldosterone, which activates the sodium/potassium pump in the distal renal tubule leading to reabsorption of sodium and Water from the Urine, in exchange for potassium and H. Glucose spills over into the Urine when the plasma concentration renal threshold for reabsorption (10mmol/L, but this varies between people, and is in pregnancy). Control of Sodium Control is through the action of aldosterone on the distal convoluted tubule (DCT) and collecting duct to increase sodium reabsorption from the Urine. The natriuretic peptides ANP, BNP, and CNP (p137) contribute to sodium homeostasis by reducing sodium reabsorption from the DCT and inhibiting renin. A High glomerular filtration rate (see later in this topic) results in increased sodium loss, and High renal tubular fl ow and haemodilution decrease sodium reabsorption in the proximal tubule. Control of Potassium Most potassium is intracellular, and thus serum potassium levels are a poor refl ection of total body Potassium. The concentrations of potassium and H in extracellular fl uid tend to vary together. This is because these ions compete with each other in the exchange with sodium that occurs across most cell membranes and in the distal convoluted tubule of the Kidney, where sodium is reabsorbed from the Urine. Thus, if the H concentration is High, less potassium will be excreted into the Urine. Similarly, potassium will compete with H for exchange across cell membranes and extracellular potassium will accumulate. Insulin and catecholamines both stimulate potassium uptake into cells by stimulating the sodium/potassium pump. Serum osmolality A laboratory measurement of the number of osmoles per kilogram of solvent. It is approximated by serum osmolarity (the number of osmoles per litre of solution) using the equation 2(sodium potassium) Urea Glucose, since these are the predominant serum electrolytes. Normal serum osmolarity is 280300mmol/L, which will always be a little less than the laboratory-measured osmolalitythe osmolar gap. However, if the osmolar gap is greater than 10mmol/L, this indicates the presence of additional solutes: consider Diabetes mellitus or High Blood ethanol, methanol, mannitol, or ethylene glycol. Control of Water Control is mainly via serum sodium concentration, since Water intake and loss are regulated to hold the extracellular concentration of sodium constant. Raised plasma osmolality (eg dehydration or glucose in Diabetes mellitus) causes thirst through the hypothalamic thirst centre and the release of antidiuretic hormone (ADH) from the posterior pituitary. ADH increases the passive Water reabsorption from the renal collecting duct by opening Water channels to allow Water to fl ow from the hypotonic luminal fl uid into the hypertonic renal interstitium. Low plasma osmolality inhibits ADH secretion, thus reducing renal Water reabsorption. Glomerular fi ltration rate (glomerular filtration rate) Defi ned as the volume of fl uid fi ltered by the glomeruli per minute (units milliliters per minute), and is one of the primary measures of disease progression in chronic Kidney disease. It can be estimated in a number of diff erent ways (see BOX). __OOHHCCMM__1100ee. . iinnddbb 666688 0022//0055//22001177 1199: : 0088 669 yrtsimehc lacinilC Estimating glomerular filtration rate Calculating glomerular filtration rate is useful because it is a more sensitive indication of the degree of renal impairment than serum Creatinine. Subjects with Low muscle mass (eg the elderly, women) can have a normal serum Creatinine, despite a signifi cant reduction in glomerular filtration rate.",
    "This can be important when prescribing nephrotoxic drugs, or drugs that are renally excreted, which may therefore accumulate to toxic levels in the serum. A number of methods for estimating glomerular filtration rate exist, all relying on a calculation of the clearance of a substance that is renally fi ltered and then not reabsorbed in the renal tubule. For example, the rate of clearance of Creatinine can be used as a marker for the rate of fi ltration of fl uid and solutes in the glomerulus because it is only slightly reabsorbed from the renal tubule. The more of the fi ltered substance that is reabsorbed, however, the less accurate the estimate of glomerular filtration rate. MDRD (Modifi cation of Diet in Renal Disease Study Group): This provides an estimate of glomerular filtration rate from four simple parameters: serum Creatinine, age, gender, and race (black/non-black). It is one of the best validated for monitoring patients with established moderately severe renal impairment, 2 and most labs now routinely report estimated glomerular filtration rate (estimated glomerular filtration rate) using the MDRD equation on all UE reports: estimated glomerular filtration rate 32 788 serum creatinineΩ1. 154 ageΩ0. 203 1. 212 if black 0. 742 if female However, a number of caveats exist, so that it is best used in monitoring declining renal function rather than labelling elderly patients with mild renal impairment: It is not validated for mild renal impairment, and therefore its use for screening general populations is questionable. Inter-individual variations (and thus confi dence intervals) are wide, although for each individual variations are small so that a decline in estimated glomerular filtration rate over a number of serum samples is always signifi cant. Single results may be aff ected by variations in serum Creatinine, such as after a Protein-rich meal. CockcroftGault equation: This provides an estimate of Creatinine clearance. It is an improvement on the MDRD equation because it also takes into account the patients weight. However, 10% of Creatinine is actively excreted in the tubules, and therefore Creatinine clearance overestimates true glomerular filtration rate and underestimates renal impairment. Moreover, the equation assumes ideal body weight and is thus unreliable in the obese or oedematous. Also unreliable in unstable renal function. (140 Ω age) weight (kg) 0. 85 if female 1. 212 if black Creatinine clearance 0. 813 serum Creatinine (μmol/L) Creatinine clearance can also be calculated by measuring the excreted Creatinine in a 24h Urine collection and comparing it with the serum Creatinine concentration. However, the accuracy of collection is vital but often poor, making this an unreliable and inconvenient method. glomerular filtration rate can also be measured by injection of a radioisotope followed by sequential Blood sampling (51Cr-European Dialysis and Transplant Association) or by an isotope scan (eg diethylenetriamine pentaacetic acid scan 99Tc, p190). These methods allow a more accurate estimate of glomerular filtration rate than Creatinine clearance, since smaller proportions of these substances are reabsorbed in the tubules. They also have the advantage of being able to provide split renal function. Inulin clearance: The gold standard for calculating glomerular filtration rate, because 100% of fi ltered inulin (not insulin) is retained in the luminal fl uid and therefore refl ects exactly the rate of fi ltration of Water and solutes in the glomerulus. However, measuring inulin clearance again requires Urine collection over several hours, and also a constant IV infusion of inulin, and is therefore inconvenient to perform. __OOHHCCMM__1100ee. . iinnddbb 666699 0022//0055//22001177 1199: : 0088 670 yrtsimehc lacinilC Acidbase balance Arterial Blood pH is closely regulated in health to 7. 40 ± 0.",
    "40 ± 0. 05 by various mechanisms including bicarbonate, other plasma buff ers such as deoxygenated haemoglobin, and the Kidney. Acidbase disorders needlessly confuse many people, but if a few simple rules are applied, then interpretation and diagnosis are easy. The key principle is that primary changes in bicarbonate Ω are metabolic and in CO2 respiratory. See fi g 14. 2. A simple method 1 Look at the pH, is there an acidosis or alkalosis? pH 7. 35 is an acidosis; pH 7. 45 is an alkalosis. 2 Is the CO abnormal? (Normal range 4. 76. 0kPa. ) 2 If so, is the change in keeping with the pH? CO2 is an acidic gasis CO2 raised with an acidosis, lowered with an alkalosis? If so, it is in keeping with the pH and thus caused by a respiratory problem. If there is no change, or an opposite one, then the change is compensatory. 3 Is the HCOΩ abnormal? (Normal concentration 2228mmol/L. ) 3 If so, is the change in keeping with the pH? bicarbonate Ω is alkalineis bicarbonate Ω raised with an alkalosis, lowered with an acidosis? If so, the problem is a metabolic one. 4 Is the PO abnormal? Interpret in the context of the FiO. a 2 2 An example Your patients Blood gas shows: pH 7. 05, CO2 2. 0kPa, bicarbonate Ω 8. 0mmol/L. There is an acidosis. The CO2 is Low, and thus it is a compensatory change. The bicarbonate Ω is Low and is thus the primary change, ie a metabolic acidosis. The anion gap Estimates unmeasured plasma anions (fi xed or organic acids such as phosphate, ketones, and lactatehard to measure directly). It is calculated as the diff erence between plasma cations (sodium and potassium) and anions (ClΩ and bicarbonate Ω). Normal range: 1018mmol/L. It is helpful in determining the cause of a metabolic acidosis. Metabolic acidosis pH, bicarbonate Ω Causes of metabolic acidosis and an increased anion gap: Due to increased production, or reduced excretion, of fi xed/organic acids. bicarbonate Ω falls and unmeasured anions associated with the acids accumulate. Lactic acid (shock, infection, tissue ischaemia). Urate (renal failure). Ketones (Diabetes mellitus, alcohol). Drugs/toxins (salicylates, biguanides, ethylene glycol, methanol). Causes of metabolic acidosis and a normal anion gap: Due to loss of bicarbonate or ingestion of H ions (ClΩ is retained). Renal tubular acidosis. Diarrhoea. Drugs (acetazolamide). Addisons disease. Pancreatic fi stula. Ammonium chloride ingestion. Metabolic alkalosis pH, bicarbonate Ω Vomiting. potassium depletion (diuretics). Burns. Ingestion of base. Respiratory acidosis pH, CO2 Type 2 respiratory failure due to any lung, neuromuscular, or physical cause (p188). Most commonly chronic obstructive pulmonary disease (COPD). Look at the PaO2. It will probably be Low. Is oxygen therapy required? Use controlled O2 (Venturi connector) if COPD is the underlying cause, as too much oxygen may make matters worse (p189). Beware exhaustion in asthma, pneumonia, and pulmonary oedema, which can present with this picture when close to respiratory arrest. A normal or High PaCO2 is worrying. These patients require urgent ITU review for ventilatory support. __OOHHCCMM__1100ee. . iinnddbb 667700 0022//0055//22001177 1199: : 0088 671 yrtsimehc lacinilC Respiratory alkalosis pH, CO2 A result of hyperventilation of any cause. CNS causes: Stroke; subarachnoid bleed; meningitis. Others: Mild/moderate asthma; anxiety; altitude; T°; pregnancy; pulmonary emboli (refl ex hyperventilation); drugs, eg salicylates. Terminology To aid understanding, we have used the terms acidosis and alkalosis, where a purist would sometimes have used acidaemia and alkalaemia. Technically acidaemia is the state of having a Low Blood pH, whereas acidosis refers to the processes which generate H, leading to the acidaemia. Fig 14.",
    "Fig 14. 2 The shaded area represents normality. This method is very powerful. The result represented by point , for example, indicates that the acidosis is in part respiratory and in part metabolic. Seek a cause for each. __OOHHCCMM__1100ee. . iinnddbb 667711 0022//0055//22001177 1199: : 0088 672 yrtsimehc lacinilC Hy pernatraemia Signs and symptoms Lethargy, thirst, weakness, irritability, confusion, coma, and fi ts, along with signs of dehydration (p666). Laboratory features: sodium, PCV, albumin, urea. Causes Usually due to Water loss in excess of sodium loss: Fluid loss without Water replacement (eg diarrhoea, vomit, burns). Diabetes insipidus (p240). Suspect if large Urine volume. This may follow head injury, or CNS surgery, especially pituitary. Osmotic diuresis (for diabetic coma, see p832). Primary aldosteronism: rarely severe, suspect if blood pressure, potassium, alkalosis (bicarbonate Ω). Iatrogenic: incorrect IV fl uid replacement (excessive saline). Management Give Water orally if possible. If not, give glucose 5% IV slowly (1L/6h) guided by Urine output and plasma sodium. Use 0. 9% saline IV if hypovolaemic, since this causes less marked fl uid shifts and is hypotonic in a hypertonic patient. Avoid hypertonic solutions. Hy ponatraemia Plasma sodium concentration depends on the amount of both sodium and Water in the plasma. Hyponatraemia therefore does not necessarily imply sodium depletion. Assessing fl uid status is the key to diagnosis (see fi g 14. 3). Signs and symptoms Look for anorexia, nausea, and malaise initially, followed by headache, irritability, confusion, weakness, GCS, and seizures, depending on the severity and rate of change in serum sodium. Cardiac failure or oedema may help to indicate the cause. Hyponatraemia also increases the risk of falls in the elderly. 3 Causes See fi g 14. 3. Artefactual causes include: Blood sample was from a drip arm High serum lipid/Protein content causing serum volume, with sodium concentration but normal plasma osmolality if hyperglycaemic (20mmol/L) add 4. 3mmol/L to plasma sodium for every 10mmol/L rise in glucose above normal. Iatrogenic hyponatraemia If 5% glucose is infused continuously without adding 0. 9% saline, the glucose is quickly used, rendering the fl uid hypotonic and causing hyponatraemia, esp. in those on thiazide diuretics, women (esp. pre-menopausal), and those undergoing physiological stress (eg post-operative, septic). In some patients, only marginally Low plasma sodium levels cause serious eff ects (eg 128mmol/L)dont attribute odd CNS signs to non-existent strokes/TIAS if sodium. Management Correct the underlying cause; never base treatment on sodium concentration alone. The presence of symptoms, the chronicity of the hyponatraemia, and state of hydration are all important. Replace sodium and Water at the same rate they were lost. Asymptomatic chronic hyponatraemia, fl uid restriction is often suffi cient if asymptomatic, although demeclocycline (ADH antagonist) may be required. If hypervolaemic (cirrhosis, CCF), treat the underlying disorder fi rst. Acute or symptomatic hyponatraemia, or if dehydrated, cautious rehydration with 0. 9% saline may be given, but do not correct changes rapidly as central pontine myelinolysis2 may result. Maximum rise in serum sodium 15mmol/L per day if chronic, or 1mmol/L per hour if acute. Consider using furosemide when not hypovolaemic to avoid fl uid overload. Vasopressor receptor antagonists (vaptans, eg tolvaptan) promote Water excretion without loss of electrolytes, and appear to be eff ective in treating hypervolaemic and euvolaemic hyponatraemia but are expensive. 4 In emergency: (Seizures, coma) seek expert help. Consider hypertonic saline (eg 1. 8% saline) at 70mmol sodium/h ± furosemide. Aim for a gradual increase in plasma sodium to 125mmol/L. Beware Heart failure and central pontine myelinolysis. 2 2 Central pontine myelinolysis: irreversible and often fatal pontine demyelination seen in malnourished alcoholics or rapid correction of sodium.",
    "2 2 Central pontine myelinolysis: irreversible and often fatal pontine demyelination seen in malnourished alcoholics or rapid correction of sodium. There is subacute onset of lethargy, confusion, pseudobulbar palsy, paraor quadriparesis, locked-in syndrome, or coma. __OOHHCCMM__1100ee. . iinnddbb 667722 0022//0055//22001177 1199: : 0088 673 yrtsimehc lacinilC Hyponatraemia Is the patient dehydrated? Yes No Is urinary sodium Is the patient 20mmol/L? oedematous? Yes No Yes No sodium and H2O are sodium and H2O Nephrotic synIs the Urine lost via kidneys: are lost other drome osmolality Addisons dis. than via the Cardiac failure 100mmol/kg? Renal failure, kidneys: Liver cirrhosis eg diuretic Diarrhoea (hyponatraemia phase of renal Vomiting may precede failure; Fistulae oedema) nephro- Burns Renal failure calc inosis or Rectal villous med ullary adeno ma cystic disease Small bowel Diuretic obstruction Yes No excess Trauma Osmolar Cystic fi brosis SIADH Water di uresis Heat expo- (see BOX) overload Severe hypo- (glu cose; sure thy roidism urea) Glucocorticoid insuffi ciency Fig 14. 3 Hyponatraemia. Syndrome of inappropriate ADH secretion (SIADH) An important, but over-diagnosed, cause of hyponatraemia. The diagnosis requires concentrated Urine (sodium 20mmol/L and osmolality 100mosmol/kg) in the presence of hypon atraemia (plasma sodium 125mmol/L) and Low plasma osmolality ( 260mosmol/kg), in the absence of hypovolaemia, oedema, or diuretics. Causes: Malignancy: lung small-cell, pancreas, prostate, thymus, or lymphoma. CNS disorders: meningoencephalitis, abscess, stroke, subarachnoid or subdural haemorrhage, head injury, neurosurgery, GuillainBarré, vasculitis, or SLE. Chest disease: TB, pneumonia, abscess, aspergillosis, small-cell lung cancer. Endocrine disease: hypothyroidism (not true SIADH, but perhaps due to excess ADH release from carotid sinus baroreceptors triggered by cardiac output). Drugs: opiates, psychotropics, SSRIs, cytotoxics. Other: acute intermittent porphyria, trauma, major abdominal or thoracic surgery, symptomatic HIV. Treatment: Treat the cause and restrict fl uid. Consider salt ± loop diuretic if severe. Demeclocycline is used rarely. Vasopressin receptor antagonists (vaptans, p672) are an emerging class of drug used in SIADH and other types of hyponatraemia. __OOHHCCMM__1100ee. . iinnddbb 667733 0022//0055//22001177 1199: : 0088 674 yrtsimehc lacinilC Hyperkalaemia A plasma Potassium 6. 5mmol/L is a potential emergency and needs urgent assessment (see p301). The worry is of myocardial hyperexcitability leading to ventricular fi brillation and cardiac arrest. First assess the patientdo they look unwell, is there an obvious cause? If not, could it be an artefactual result? Concerning signs and symptoms Include a fast irregular pulse, chest Pain, weakness, palpitations, and light-headedness. ECG: (see fi g 14. 4) tall tented T waves, small P waves, a wide QRS complex (eventually becoming sinusoidal), and ventricular fi brillation. Artefactual results: If the patient is well, and has none of the above-mentioned fi ndings, repeat the test urgently as it may be artefactual, caused by: haemolysis (diffi cult vene puncture; patient clenched fi st) contamination with Potassium European Dialysis and Transplant Association anticoagulant in FBC bottles (do FBCS after UES) thrombocythaemia (potassium leaks out of platelets during clotting) delayed analysis (potassium leaks out of RBCS; a particular problem in a primary care setting due to long transit times to the lab). 5 Causes Oliguric renal failure. Addisons disease (see p226). potassium-sparing diuretics. Massive Blood transfusion. Rhabdomyolysis (p319). Burns. Metabolic acidosis (diabetes mellitus). Drugs, eg angiotensin-converting enzyme inhibitor, suxamethonium. Excess potassium therapy. Artefactual result (see earlier Artefactual results). Treatment in non-urgent cases Treat the underlying cause; review medications. Polystyrene sulfonate resin (eg Calcium Resonium 15g/8h PO) binds potassium in the gut, preventing absorption and bringing potassium levels down over a few days. If Vomiting prevents PO administration, give a 30g enema, followed at 9h by colonic irrigation. Emergency treatment If there is evidence of myocardial hyperexcitability, or potassium is 6.",
    "Emergency treatment If there is evidence of myocardial hyperexcitability, or potassium is 6. 5mmol/L, get senior assistance, and treat as an emergency (see p301). Hypokalaemia If potassium 2. 5mmol/L, urgent treatment is required. Note that hypokalaemia exacerbates digoxin toxicity. Signs and symptoms Muscle weakness, hypotonia, hyporefl exia, cramps, tetany, palpitations, light-headedness (arrhythmias), constipation. ECG Small or inverted T waves, prominent U waves (after T wave), a long PR interval, and depressed ST segments. Causes Diuretics. Cushings syndrome/steroids/ACTH. Vomiting and diarrhoea. Conns syndrome. Pyloric stenosis. Alkalosis. Rectal villous adenoma. Purgative and liquorice abuse. Intestinal fi stula. Renal tubular failure (p316 p664). If on diuretics, bicarbonate Ω is the best indication that hypokalaemia is likely to have been long-standing. Mg2 may be Low, and hypokalaemia is often diffi cult to correct until Mg2 levels are normalized. Suspect Conns syndrome if hypertensive, hypokalaemic alkalosis in someone not taking diuretics (p228). In hypokalaemic periodic paralysis, intermittent weakness lasting up to 72h appears to be caused by potassium shifting from extrato intracellular fl uid. See OHCS p652. Treatment If mild: (2. 5mmol/L, no symptoms. ) Give oral potassium supplement (≥80mmol/24h, eg Sando-potassium 2 tabs/8h). Review potassium after 3 days. If taking a thiazide diuretic, and potassium 3. 0 consider repeating and/or potassium-sparing diuretic. If severe: (2. 5mmol/L, and/or dangerous symptoms. ) Give IV Potassium cautiously, not more than 20mmol/h, and not more concentrated than 40mmol/L. Do not give potassium if oliguric. Never give potassium as a fast stat bolus dose. __OOHHCCMM__1100ee. . iinnddbb 667744 0022//0055//22001177 1199: : 0088 675 Fig 14. 4 Hyperkalaemianote the fl attening of the P waves, prominent T waves, and widening of the QRS complex. Clinical chemistry __OOHHCCMM__1100ee. . iinnddbb 667755 0022//0055//22001177 1199: : 0088 676 yrtsimehc lacinilC Calcium and phosphate physiology Calcium and phosphate homeostasis is maintained through: Parathyroid hormone (parathyroid hormone): Overall eff ect is Ca2 phosphate 3Ω. Secretion by four parathyroid glands is triggered by serum ionized Ca2; controlled by Ωve feedback loop. Actions are: osteoclast activity releasing Ca2 and phosphate 3Ω from bones Ca2 phosphate 3Ω reabsorption in the Kidney renal production of 1, 25-dihydroxy-vitamin D3. Vitamin D and calcitriol: vitamin D is hydroxylated fi rst in the Liver to 25-hydroxy-vitamin D, and again in the Kidney to 1, 25-dihydroxy-vitamin D (calcitriol), the biologically active form, and 24, 25-hydroxy-vitamin D (inactive). Calcitriol production is stimulated by Ca2, phosphate 3Ω, and parathyroid hormone. Actions are: Ca2 and phosphate 3Ω absorption from the gut inhibition of parathyroid hormone release enhanced bone turnover Ca2 and phosphate 3Ω reabsorption in the Kidney. Cholecalciferol (vit D3from animal sources) and ergocalciferol (vit D2from vegetables) are biologically identical in their activity. Disordered regulation of calcitriol underlies familial normocalca emic hypercalciuria, which is a major cause of calcium oxalate renal stone formation (p638). Calcitonin: Made in C-cells of the thyroid, this causes Ca2 and phosphate 3Ω, but its physiological role is unclear. It can be used as a marker of recurrence or metastasis in medullary carcinoma of the thyroid. Magnesium: Mg2 prevents parathyroid hormone release, and may cause hypocalcaemia. Plasma binding: Labs usually measure total plasma Ca2. 40% is bound to albumin, and the rest is free ionized Ca2 which is the physiologically important amount (often available on Blood gas analyser). Therefore, correct total Ca2 for albumin as follows: add 0. 1mmol/L to Ca2 level for every 4g/L that albumin is below 40g/L, and a similar subtraction for raised albumin. However, many other factors aff ect binding (eg other proteins in myeloma, cirrhosis, individual variation) so be cautious in your interpretation.",
    "If in doubt over a High Ca2, take Blood specimens uncuff ed (remove tourniquet after needle in vein, but before taking Blood sample), and with the patient fasted. Hypercalcaemia Signs and symptoms Bones, stones, groans, and psychic moans. Abdominal Pain; Vomiting; constipation; polyuria; polydipsia; depression; anorexia; weight loss; tiredness; weakness; hypertension, confusion; pyrexia; renal stones; renal failure; ectopic calcifi cation (eg corneasee BOX); cardiac arrest. ECG: QT interval. Causes (See fi g 14. 5. ) Most commonly malignancy (eg from bone metastases, myeloma, PTHrP) or primary hyperparathyroidism. Others include sarcoidosis, vitamin D intoxication, thyrotoxicosis, lithium, tertiary hyperparathyroidism, milk-alkali syndrome, and familial benign hypocalciuric hypercalcaemia (rare; defect in calcium-sensing receptor). HIV can cause both Ca2 (perhaps from parathyroid hormone-related bone remodelling). 6 Investigations The main distinction is malignancy vs 1° hyperparathyroidism. Pointers to malignancy are albumin, ClΩ, alkal osis, potassium, phosphate 3Ω, ALP. parathyroid hormone indicates hyperparathyroidism. Also FBC, Protein electrophoresis, CXR, isotope bone scan, 24h urinary Ca2 excretion (for familial hypocalciuric hypercalcaemia). Causes of metastatic (ectopic) calcifi cation PARATTHORMONE Parathormone (parathyroid hormone) (p222) and other causes of Ca2, eg sarcoidosis; Amyloidosis; Renal failure (relates to phosphate 3Ω); Addisons disease (adrenal calcifi cation); TB nodes; Toxoplasmosis (CNS); Histoplasmosis (eg in lung); Overdose of vitamin D; Raynauds-associated diseases (eg SLE; systemic sclerosis p552; dermatomyositis); Muscle primaries/leiomyosarcomas); Ossifying metastases (Osteosarcoma) or Ovarian mets (to peritoneum); Nephrocalcinosis; Endocrine tumours (eg gastrinoma). __OOHHCCMM__1100ee. . iinnddbb 667766 0022//0055//22001177 1199: : 0088 677 yrtsimehc lacinilC Hypercalcaemia1 Albumin raised Albumin normal or Low Urea raised: Urea normal: Phosphate Phosphate Dehydration Cuff ed or or specimen Urea normal: 1° or 3° hyperparathyroidism ALP (eg from bone ALP normal: turnover): Myeloma (plasma Bone Protein) metastases2 Vitamin D excess Sarcoidosis Sarcoidosis Thyrotoxicosis With bicarbonate Ω, Lithium milk-alkali syndrome3 Fig 14. 5 Hypercalcaemia. 1 This diagram is only a guide: use in conjunction with the clinical picture. 2 Most common primary: breast, Kidney, lung, thyroid, prostate, ovary, colon. 3 Ingesting too much calcium and alkali (eg in milk) can cause hypercalcaemia with metastatic calcifi calciumtion and renal failure. Thyrotoxicosis causes alkalaemia because of hyperventilation. 7 Treating acute hypercalcaemia Diagnose and treat the underlying cause. If Ca2 3. 5mmol/L and symptomatic: 1 Correct dehydration: If dehydrated give IV 0. 9% saline. 2 Bisphosphonates: These prevent bone resorption by inhibiting osteoclast before mealstivity. A single dose of pamidronate lowers Ca2 over 23d; maximum eff ect is at 1wk. Infuse slowly, eg 30mg in 300mL 0. 9% saline over 3h via a largish vein. Max dose 90mg (see table 14. 4). Zoledronic acid is signifi cantly more eff ective in reducing serum Ca2 than previously used bisphosphonates. 8 Usually, a single dose of 4mg IV (diluted to 100mL, over 15min) will normalize plasma Ca2 within a week. SE, fl u symptoms, phosphate 3Ω, bone Pain, myalgia, nausea, Vomiting, headache, lymphocytopenia, Mg2, Ca2, seizures. 3 Further management: Chemotherapy may help in malignancy. Steroids are used in sarcoidosis, eg prednisolone 4060mg/d. Salmon calcitonin acts similarly to bisphosphonates, and has a quicker onset of action, but is now rarely used. NB: the use of furosemide is contentious, as supporting RCT evidence is scant. 9, 10 It helps to promote renal excretion of Ca2, but can exacerbate hypercalcaemia by worsening dehydration. Thus it should only be used once fully rehydrated, and with concomitant IV fl uids (eg 0. 9% saline 1L/46h). Avoid thiazides. Table 14. 4 Disodium pamidronate doses Calcium (millimoles per liter; corrected) Single-dose pamidronate (magnesium) 3 1530 33. 5 3060 3. 54 6090 4 90 __OOHHCCMM__1100ee. . iinnddbb 667777 0022//0055//22001177 1199: : 0088 678 yrtsimehc lacinilC Hypocalcaemia Apparent hypocalcaemia may be an artefact of hypoalbuminaemia (p676).",
    ". iinnddbb 667777 0022//0055//22001177 1199: : 0088 678 yrtsimehc lacinilC Hypocalcaemia Apparent hypocalcaemia may be an artefact of hypoalbuminaemia (p676). Signs and symptoms See BOX. 11 Mild: cramps, perioral numbness/paraesthesiae. Severe: carpopedal spasm (especially if brachial artery compressed, Trousseaus sign; see fi g 14. 6), laryngos pasm, seizures. Neuromuscular excitability may also be demonstrated by tapping over parotid (facial nerve) causing facial muscles to twitch (Chvosteks sign; see fi g 14. 7). Cataract if chronic hypocalcaemia. ECG: Long QT interval. Causes With phosphate 3Ω With or phosphate 3Ω Chronic Kidney disease (p302). Vitamin D defi ciency. Hypoparathyroidism (incl thyroid Osteomalacia (ALP). or parathyroid surgery, p222). Acute pancreatitis. Pseudohypoparathyroidism (p222). Over-hydration. Acute rhabdomyolysis. Respiratory alkalosis (total Ca2 Hypomagnesaemia. is normal, but ionized Ca2 due to pH symptomatic). Treatment Mild symptoms: Give calcium 5mmol/6h PO, with daily plasma Ca2 levels. In chronic Kidney disease: See p302. May require alfacalcidol, eg 0. 51mcg/24h PO. Severe symptoms: Give 10mL of 10% calcium gluconate (2. 25mmol) IV over 30min, and repeat as necessary. If due to respiratory alkalosis, correct the alkalosis. Features of hypocalcaemia SPASMODIC Spasms (carpopedal spasms Trous seaus sign) Perioral paraesthesiae Anxious, irritable, irrational Seizures Muscle tone in smooth musclehence colic, wheeze, and dysphagia Orientation impaired (time, place, and person) and confusion Dermatitis (eg atopic/exfoliative) Im petigo herpetiformis (Ca2 and pus t ules in pregnancyrare and serious) Chvosteks sign; choreoathetosis; cataract; cardiom yopathy (long QT interval on ECG). Fig 14. 6 Trousseaus sign: on infl ating the cuff, Fig 14. 7 Chvosteks sign: the corner of the the wrist and fi ngers fl ex and draw together mouth twitches when the facial nerve is tapped (carpopedal spasm). over the parotid. __OOHHCCMM__1100ee. . iinnddbb 667788 0022//0055//22001177 1199: : 0088 679 yrtsimehc lacinilC Phosphate Hypophosphataemia Common and of little signifi cance unless severe (0. 4mmol/L). Causes: Vitamin D defi ciency, alcohol withdrawal, refeeding syndrome (p587), inadequate oral intake, severe diabetic ketoacidosis, renal tubular dysfunction and 1° hyperparathyroidism. Signs and symptoms: Muscle weakness or rhabdomyolysis, red cell, white cell and platelet dysfunction, and cardiac arrest or arrhythmias. Treatment: Oral or parenteral phosphate supplementation, eg Phosphate Polyfusor IVI (100mmol phosphate 3Ω in 500mL). Never give IV phosphate to a patient who is hypercalcaemic or oliguric. Hyperphosphataemia Most commonly due to chronic Kidney disease, when it is treated with phosphate binders, eg sevelamer 800mg/8h PO during meals. Also catabolic states such as tumour lysis syndrome (p529). Magnesium Magnesium is distributed 65% in bone and 35% in cells; plasma concentration tends to follow that of Ca2 and potassium. Hypomagnesaemia Causes paraesthesiae, ataxia, seizures, tetany, arrhythmias. Digitalis toxicity may be exacerbated. Causes: Diuretics, severe diarrhoea, ketoacidosis, alcohol abuse, total parenteral nutrition (monitor weekly), Ca2, potassium, and phosphate 3Ω. Treatment: If needed, give magnesium salts, PO or IV (eg 8mmol MgSO4 IV over 3min to 2h, depending on severity, with frequent Mg2 levels). Hypermagnesaemia Rarely requires treatment unless severe (7. 5mmol/L). Causes: Renal failure or iatrogenic (eg excessive antacids). Signs: If severe: neuromuscular depression, blood pressure, pulse, hypor efl exia, CNS respiratory depression, coma. Zinc Zinc defi ciency This may occur in parenteral nutrition or, rarely, from a poor diet (too few cereals and dairy products; anorexia nervosa; alcoholism). Rarely it is due to a genetic defect. Symptoms: Alopecia, dermatitis (look for red, crusted skin Bloodsions especially around nostrils and corners of mouth), night blindness, diarrhoea. Diagnosis: Therapeutic trial of zinc (plasma levels are unreliable as they may be Low, eg in infection or trauma, without defi ciency). Selenium An essential element present in cereals, nuts, and meat.",
    "Selenium An essential element present in cereals, nuts, and meat. Low soil levels in some parts of Europe and China cause defi ciency states. Required for the antioxidant glutathione peroxidase, which harmful free radicals. Selenium is also antithrombogenic, and is required for sperm motility proteins. Defi ciency may increase risk of neoplasia and atheroma, and may lead to a cardiomyopathy or arthritis. Serum levels are a poor guide. Toxic symptoms may also be found with over-energetic replacement. __OOHHCCMM__1100ee. . iinnddbb 667799 0022//0055//22001177 1199: : 0088 680 yrtsimehc lacinilC Urate and the Kidney Causes of hyperuricaemia High levels of urate in the Blood (hyperuricaemia) may result from increased turnover (15%) or reduced excretion of urate (85%). Either may be drug induced. Drugs: Cytotoxics, thiazides, loop diuretics, pyrazinamide. Increased cell turnover: Lymphoma, leukaemia, psoriasis, haemolysis, muscle death (rhabdomyolysis, p319; tumour lysis syndrome, p529). Reduced excretion: Primary gout (p548), chronic Kidney disease, lead nephropathy, hyperparathyroidism, pre-eclampsia (OHCS p48). Other: Hyperuricaemia may be associated with hypertension and hyperlipidaemia. Urate may be raised in disorders of purine synthesis such as the LeschNyhan syndrome (OHCS p648). Hyperuricaemia and renal failure Severe renal failure from any cause may be associated with hyperuricaemia, and rarely this may give rise to gout. Sometimes the relationship of cause and eff ect is reversed so that it is the hyperuricaemia that causes the renal failure. This can occur following cytotoxic treatment (tumour lysis syndrome, p529), and in muscle necrosis. How urate causes renal failure: Urate is poorly soluble in Water, so over-excretion can lead to crystal precipitation. Renal failure occurs most commonly because urate precipitates in the renal tubules. This may occur at plasma levels ≥1. 19mmol/L. In some instances, ureteric obstruction from urate crystals may occur. This responds to retrograde ureteric catheterization and lavage. Prevention of renal failure: Before starting chemotherapy, ensure Good hydration and initiate allopurinol (xanthine oxidase inhibitor) or rasburicase (recombinant urate oxidase), which prevent a sharp rise in urate following chemotherapy (see p528). There is a remote risk of inducing xanthine nephropathy. Treatment of hyperuricaemic acute Kidney injury: Exclude bilateral ureteric obstruction, then give prompt rehydration ± loop diuretic to wash uric acid crystals out of the renal tubules, and correct electrolyte abnormalities. Once oliguria is established, haemodialysis is required (in preference to peritoneal Dialysis). There is no evidence for either preventing (see previous paragraph) or treating hyperuricaemic renal failure. Gout See p548. Urate renal stones Urate stones (fi g 14. 8) comprise 510% of all renal stones and are radiolucent. Incidence: 510% in temperate climates (double if confi rmed gout), 12 but up to 40% in hot, arid climates. : 4: 1. But most urate stone formers have no detectable abnormalities in urate metabolism. Risk factors: Acidic or strongly concentrated Urine; urinary excretion of urate; chronic diarrhoea; distal small bowel disease or resection (regional enteritis); ileostomy; obesity; Diabetes mellitus; chemotherapy for myeloproliferative disorders; inadequate caloric or fl uid intake. Treatment: Hydration to increase Urine volume (aim 2L/d). Unlike most other renal calculi, existing uric acid stones can often be dissolved with either systemic Fig 14. 8 Urate stone. or topical alkalinizing agents. Potassium citrate or Dr G. Austin. Potassium bicarbonate at a dose titrated to alkalinize the Urine to a pH of 67 dissolves some urate stones. If hyperuricosuria, consider dietary management ± allopurinol (xanthine oxidase inhibitor). __OOHHCCMM__1100ee. . iinnddbb 668800 0022//0055//22001177 1199: : 0088 681 yrtsimehc lacinilC __OOHHCCMM__1100ee. . iinnddbb 668811 0022//0055//22001177 1199: : 0088 682 yrtsimehc lacinilC Metabolic bone diseases: osteoporosis Osteoporosis implies reduced bone mass. It may be 1° (age-related) or 2° to another condition or drugs.",
    "It may be 1° (age-related) or 2° to another condition or drugs. If trabecular bone is aff ected, crush fractures of vertebrae are common (hence the littleness of little old ladies and their dowagers hump); if cortical bone is aff ected, long bone fractures are more likely, eg femoral neck: the big cause of death and orthopaedic expense (80% hip fractures in the UK occur in women 50yrs). Prevalence (In those 50yrs): 6%, 18%. Women lose trabeculae with age, but in men, although there is reduced bone formation, numbers of trabeculae are stable and their lifetime risk of fracture is less. Risk factors Age-independent risk factors for 1° osteoporosis: parental history, alcohol 4 units daily, rheumatoid arthritis, body mass index 19, prolonged immobility, and untreated menopause. See BOX Osteoporosis risk factors for other risk factors, including for 2° osteoporosis. Investigations X-ray (Low sensitivity/specifi city, often with hindsight after a fracture). Bone densitometry (DEXAsee BOX DEXA bone densitometry; table 14. 5). Bloods: Ca2, phosphate 3Ω, and ALP normal. Consider specifi c investigations for 2° causes if suggestive history. Biopsy is unreliable and unnecessary with non-invasive techniques available. Management Loss of bone mineral density may not be entirely irreversible. Age, number of risk factors, and bone mineral density (DEXA scan; see BOX DEXA bone densitometry) guide the pharmacological approach (eg FRAX, which is a WHO risk assessment tool for estimating 10-yr risk of osteoporotic fracture in untreated patients; see www. shef. before meals. uk/frax), 13, 14 although DEXA is not necessary if age 75yrs. Lifestyle measures should apply to all (including those at risk but not yet osteoporotic). Lifestyle measures: Quit smoking and reduce alcohol consumption. Weight-bearing exercise may increase bone mineral density. 15 Balance exercises such as tai chi reduce risk of falls. Calcium and vitamin D-rich diet (use supplements if diet is insuffi cientsee Pharmacological measures later in this topic). Home-based fall-prevention programme, with visual assessment and a home visit. NB: hip-protectors are unreliable for preventing fractures. 16 Pharmacological measures: Bisphosphonates: alendronic acid is 1st line (10mg/d or 70mg/wk; not if estimated glomerular filtration rate 35). Use also for prevention in long-term steroid use. If intolerant, try etidronate or risedronate. Tell patient to swallow pills with plenty of Water while remaining upright for 30min and wait 30min before eating or other drugs. (SE: photosensitivity; GI upset; oesophageal ulcersstop if dysphagia or abdo Pain; rarely, jaw osteonecrosis). Calcium and vitamin D: rarely used alone for prophylaxis, as questionable effi cacy and some evidence of a small CV risk. Off er if evidence of defi ciency, eg calcium 1g/d vitamin D 800U/d. Target serum 25-hydroxy-vitamin D level ≥75nmol/L. Strontium ranelate: due to an increased risk of cardiac problems it should only be used in those with severe intolerance of other agents and without cardiovascular disease. Hormone replacement therapy (HRT) can prevent (not treat) osteoporosis in postmenopausal women. Relative risk of breast cancer is 1. 4 if used 10yrs; CV risk. Raloxifene is a selective oestrogen receptor modulator (SERM) that acts similarly to HRT, but with breast cancer risk. Teriparatide (recombinant parathyroid hormone) is useful in those who suff er further fractures despite treatment with other agents. There is a potential risk of renal malignancy. Calcitonin may reduce Pain after a vertebral fracture. Testosterone may help in hypo gonadal men by promoting trabecular connectivity. Denosumab, a monoclonal Ab to RANK ligand, given SC twice yearly reabsorption. __OOHHCCMM__1100ee. . iinnddbb 668822 0022//0055//22001177 1199: : 0088 683 yrtsimehc lacinilC DEXA bone densitometry: WHO osteoporosis criteria It is better to scan the hip than the lumbar spine.",
    "Bone mineral density (g/cm2) is compared with that of a young healthy adult. The T-score is the number of standard deviations (SD, p751) the bone mineral density (BMD) is from the youthful average. Each decrease of 1 SD in BMD 2. 6-fold in risk of hip fracture. Table 14. 5 Interpreting DEXA bone scan results T-score 0 BMD is better than the reference. 0 to Ω1 BMD is in the top 84%: no evidence of osteoporosis. Ω1 to Ω2. 5 Osteopenia. Risk of later osteoporotic fracture. Off er lifestyle advice. Ω2. 5 or worse Osteoporosis. Off er lifestyle advice and treatment (p682). Repeat DEXA in 2yrs. Some indications for DEXA: NICE suggests DEXA if previous Low-trauma fracture, or for women ≥ 65yrs with one or more risk factors for osteoporosis, or younger if two or more. The benefi ts of universal screening for osteoporosis remain unproven, but some authorities recommend this for men and women over 70and earlier if risk factors are present. 17 DEXA is not needed pre-treatment for women over 75yrs if previous Low-trauma fracture, or ≥ 2 present of rheumatoid arthritis, alcohol excess, or positive family history. Prior to giving long-term predniso lone (eg 3 months at 5mg/d). Steroids cause osteoporosis by promoting osteoclast bone resorption, muscle mass, and Ca2 absorption from the gut. Men or women with osteopenia if Low-trauma, non-vertebral fracture. Bone and bone-remodelling disorders (eg parathyroid disorders, myeloma, HIV, esp. if on protease inhibitors). Osteoporosis risk factors: SHATTERED Steroid use of 5mg/d of prednisolone. Hyperthyroidism, hyperparathyroidism, hypercalciuria. Alcohol and tobacco use . Thin (body mass index 18. 5). Testosterone (eg antia ndrogen calcium prostate ). Early menopause. Renal or Liver failure. Erosive/infl ammatory bone disease (eg myeloma or rheumatoid arthritis). Dietary Ca2/malab sorption; Diabetes mellitus type 1. __OOHHCCMM__1100ee. . iinnddbb 668833 0022//0055//22001177 1199: : 0088 684 yrtsimehc lacinilC Metabolic bone diseases: osteomalacia In osteomalacia, there is a normal amount of bone but its mineral content is Low (there is excess uncalcifi ed osteoid and cartilage). This is the reverse of osteoporosis in which mineralization is unchanged, but there is overall bone loss. Rickets is the result if this process occurs during the period of bone growth; osteomalacia is the result if it occurs after fusion of the epiphyses. Signs and symptoms Rickets: Growth retardation, hypotonia, apathy in infants. Once walking: knockkneed, bow-legged, and deformities of the metaphysealepiphyseal junction (eg the rachitic rosary). Features of Ca2often mild (p678). Children with rickets are ill. Osteomalacia: Bone Pain and tenderness; fractures (esp. femoral neck); proximal myopathy (waddling gait), due to phosphate 3Ω and vitamin D defi ciency per se. Causes Vitamin D defi ciency: Due to malabsorption (p266), poor diet, or lack of sunlight. Renal osteodystrophy: Renal failure leads to 1, 25-dihydroxy-cholecalciferol defi ciency 1, 25(OH)2-vitamin D defi ciency. See also renal bone disease (p312). Drug-induced: Anticonvulsants may induce Liver enzymes, leading to an increased breakdown of 25-hydroxy-vitamin D. Vitamin D resistance: A number of mainly inherited conditions in which the osteomalacia responds to High doses of vitamin D (see Treatment later in this topic). Liver disease: Due to reduced hydroxylation of vitamin D to 25-hydroxy-cholecalciferol and malabsorption of vitamin D, eg in cirrhosis (p276). Tumour-induced osteomalacia: (Oncogenic hypophosphataemia. ) Mediated by raised tumour production of phosphato nin fi broblast growth factor 23 (FGF-23) which causes hyperphosphaturia. serum phosphate 3Ω often causes myalgia and weakness. 18 Investigations Plasma: Mildly Ca2 (but may be severe); phosphate 3Ω; ALP; parathyroid hormone High; 25(OH)-vitamin D, except in vitamin D resistance. In renal failure, 1, 25(OH)2-vitamin D (p312). Biopsy: Bone biopsy shows incomplete mineralization. Muscle biopsy (if proximal myopathy) is normal.",
    "In renal failure, 1, 25(OH)2-vitamin D (p312). Biopsy: Bone biopsy shows incomplete mineralization. Muscle biopsy (if proximal myopathy) is normal. X-ray: In osteomalacia, there is a loss of cortical bone; also, apparent partial fractures without displacement may be seen especially on the lateral border of the scapula, inferior femoral neck, and medial femoral shaft (Loosers zones; see fi g 14. 9). Cupped, ragged metaphyseal surfaces are seen in rickets (fi g 14. 10). Treatment In dietary insuffi ciency, give vitamin D, eg as one calcium D3 forte tablet/12h PO. In malabsorption or hepatic disease, give vitamin D2 (ergocalciferol), up to 40 000U (1mg) daily, or parenteral calcitriol, eg 7. 5mg monthly. If due to renal disease or vitamin D resistance, give alfacalcidol (1-hydroxyvitamin D3) 250ng1mcg daily, or calcitriol (1, 25-dihydroxy-vitamin D3) 250ng1mcg daily, and adjust dose according to plasma Ca2. Alfacalcidol and calcitriol can cause dangerous hypercalcaemia. Monitor plasma Ca2, initially weekly, and if nausea/Vomiting. Vitamin D-resistant rickets Exists in two forms. Type I has Low renal 1-hydroxylase activity, and type II has end-organ resistance to 1, 25-dihydroxy-vitamin D3, due to a point mutation in the receptor. Both are treated with large doses of calcitriol. X-linked hypophosphataemic rickets Dominantly inheriteddue to a defect in renal phosphate handling (due to mutations in the PEX or PHEX genes which encode an endopeptidase). Rickets develops in early childhood and is associated with poor growth. Plasma phosphate 3Ω is Low, ALP is High, and there is phosphaturia. Treatm ent is with High doses of oral phosphate, and calcitriol. __OOHHCCMM__1100ee. . iinnddbb 668844 0022//0055//22001177 1199: : 0088 685 yrtsimehc lacinilC Metabolic bone diseases: Pagets disease of bone Also called osteitis deformans, there is increased bone turnover associated with increased numbers of osteoblasts and osteoclasts with resultant remodelling, bone enlargement, deformity, and weakness. Rare in the under-40s. Incidence rises with age (3% over 55yrs old). Commoner in temperate climates, and in Anglo-Saxons. Clinical features Asymptomatic in 70%. Deep, boring Pain, and bony deformity and enlargementtypically of the pelvis, lumbar spine, skull, femur, and tibia (classically a bowed sabre tibia; fi g 14. 11). Complications include pathological fractures, osteoa rthritis, Ca2, nerve compression due to bone overgrowth (eg deafness, root compression), High-output CCF (if 40% of skeleton involved), and osteosarcoma (1% of those aff ected for 10yrssuspect if sudden onset or worsening of bone Pain). 19 Radiology X-ray Localized enlargement of bone. Patchy cortical thickening with sclerosis, osteolysis, and deformity (eg osteoporosis circumscripta of the skull). atrial fibrillationfi nity for axial skeleton, long bones, and skull. Bone scan may reveal hot spots. Blood chemistry Ca2 and phosphate 3Ω normal; ALP markedly raised. Treatment If analgesia fails, alendronic acid may be tried to reduce Pain and/or deformity. It is more eff ective than etidronate or calcitonin, and as eff ective as IV pamidronate. Follow expert advice. Fig 14. 10 Rickets. Typical ragged metaphyseal surfaces are seen in the knee and ankle joints of a child with rickets, with bowing of the long bones. Image courtesy of Dr Ian Maddison. Fig 14. 9 Osteomalacia. Cortical bone lucency and Loosers zones are seen in both forearms of a patient with osteomalacia. Image courtesy of Dr Ian Maddison. Fig 14. 11 Pagets disease. The sabre tibia seen in Pagets disease, with multiple sclerotic lesions. Image courtesy of Dr Ian Maddison. __OOHHCCMM__1100ee. . iinnddbb 668855 0022//0055//22001177 1199: : 0088 686 yrtsimehc lacinilC Plasma proteins The plasma contains a number of proteins including albumin, immunoglobulins, 1antitrypsin, 2-macroglobulin, caeruloplasmin, transferrin, Low-density lipoprotein (LDL), fi brinogen, complement, and factor VIII. The most abundant is albumin (see fi g 14. 12).",
    "The most abundant is albumin (see fi g 14. 12). Albumin Synthesized in the Liver; t½ 20d. It binds bilirubin, free fatty acids, Ca2, and some drugs. Low albumin: Results in oedema, and is caused by: synthesis: Liver disease, acute phase response (due to vascular permeabilityeg sepsis, trauma, surgery), malabsorption, malnutrition, malignancy loss: nephrotic syndrome, Protein-losing enteropathy, burns haemodilution: late pregnancy, artefact (eg from drip arm). Also posture (5g/L if upright) and genetic variations. High albumin: Causes are dehydration; artefact (eg stasis). Immunoglobulins (Antibodies) are synthesized by B cells. Five isoforms Ig A, D, E, G, M exist in humans, and IgG is the most abundant circulating form. Specifi c monoclonal band in paraproteinaemia (see p370). Diffusely raised in chronic infections, TB, bronchiectasis, Liver cirrhosis, sarcoidosis, SLE, RA, Crohns disease, 1° biliary cirrhosis, hepatitis, and parasitaemia. Low in nephrotic syndrome, malabsorption, malnutrition, and immune defi ciency states (eg severe illness, renal failure, Diabetes mellitus, malignancy, or congenital). Acute phase response The body responds to a variety of insults with, among other things, the synthesis, by the Liver, of a number of proteins (normally present in serum in small quantities)eg 1-antitrypsin, fi brinogen, complement, haptoglobin, and CRP. A concomitant reduction in albumin level, is characteristic of conditions such as infection, malignancy (especially 2-fraction), trauma, surgery, and infl ammatory disease. CRP So called because it binds to a polysaccharide (fraction C) in the cell wall of pneumococci. Levels help monitor infl ammation/infection (normal 8mg/L). Like the ESR, it is raised in many infl ammatory conditions, but changes more rapidly. It increases in hours and begins to fall within 23d of recovery; thus it can be used to follow disease activity (eg Crohns disease) or the response to therapy (eg antibiotics). CRP values in mild infl ammation 1050mg/L; active bacterial infection 50200mg/L; severe infection or trauma 200mg/L; see table 14. 6. Urinary proteins Urinary Protein loss 150mg/d is pathological (p294). Albuminuria Usually caused by renal disease (p294). Microalbuminuria: Urinary Protein loss between 30 and 300mg/d (so not visible on normal dipstick) and may be seen with Diabetes mellitus, blood pressure, SLE, and glomerulonephritis (see p314 for role in diabetes mellitus). Can also be quantifi ed by measuring the urinary albumin: Creatinine ratio (A: creatinine), usually a fi rst-in-the-morning spot Urine sample. A level 30mg/mmol indicates albuminuria, and microalbuminuria is defi ned as 2. 5mg/mmol in men and 3. 5 in women. This is a useful screening test in diabetics, and subjects with reduced estimated glomerular filtration rate. Note some labs measure total urinary Protein not albumina P: creatinine of 50, is equivalent to an A: creatinine of 30. 20 Bence Jones Protein Consists of light chains excreted in excess by some patients with myeloma (p368). They are not detected by dipsticks and may occur with normal serum electrophoresis. Haemoglobinuria Caused by intravascular haemolysis (p336). Myoglobinuria Caused by rhabdomyolysis (p319). __OOHHCCMM__1100ee. . iinnddbb 668866 0022//0055//22001177 1199: : 0088 687 yrtsimehc lacinilC Table 14. 6 C-reactive Protein (CRP) Marked elevation Normal-to-slight elevation Bacterial infection Viral infection Abscess Steroids/oestrogens Crohns disease Ulcerative colitis Connective tissue diseases (except SLE) SLE Neoplasia Morbid obesity Trauma Atherosclerosis Necrosis (eg myocardial infarction) Fig 14. 12 A normal electrophoretic scan. __OOHHCCMM__1100ee. . iinnddbb 668877 0022//0055//22001177 1199: : 0088 688 yrtsimehc lacinilC Plasma enzymes Reference intervals vary between laboratories. See p752 for a guide to normal values. Raised levels of specifi c enzymes can be a useful indicator of a disease. However, remember that most can be raised for other reasons too. Levels may be raised due to cellular damage, cell turnover, cellular proliferation (malignancy), enzyme induction, and clearance.",
    "Levels may be raised due to cellular damage, cell turnover, cellular proliferation (malignancy), enzyme induction, and clearance. The major causes of raised enzymes: Alkaline phosphatase (Several distinguishable isoforms exist, eg Liver and bone. ) Liver disease (suggests cholestasis; also cirrhosis, abscess, hepatitis, or malignancy). Bone disease (isoenzyme distinguishable, refl ects osteoblast activity) especially Pagets, growing children, healing fractures, bone metastases, osteomalacia, osteomyelitis, chronic Kidney disease, and hyperparathyroidism. Congestive cardiac failure (moderately raised). Pregnancy (placenta makes its own isoenzyme). Alanine and aspartate aminotransferase (ALT and AST) Liver disease (suggests hepatocyte damage). AST also in myocardial infarction, skeletal muscle damage (especially crush injuries), and haemolysis. -Amylase Acute pancreatitis (smaller rise in chronic pancreatitis as less tissue remaining). Also: severe uraemia, diabetic ketoacidosis, severe gastroenteritis, and peptic ulcer. Creatine kinase (CK) A raised CK does not necessarily mean an myocardial infarction. Myocardial infarction (p118; isoenzyme CK-MB. Diagnostic if CK-MB 6% of total CK, or CK-MB mass 99 percentile of normal). CK returns to baseline within 48h (unlike troponin, which remains raised for 10 days), useful for detecting re-infarction. Muscle damage (rhabdomyolysis, p319; prolonged running; haematoma; seizures; IM injection; defi brillation; bowel ischaemia; myxoedema; dermatomyositis, p552) and drugs (eg statins). Gamma-glutamyl transferase (GGT, GT) Liver disease (particularly alcohol-induced damage, cholestasis, drugs). Lactate dehydrogenase (LDH) Myocardial infarction (p118). Liver disease (suggests hepatocyte damage). Haemolysis (esp. sickle cell crisis), pulmonary embolism, and tumour necrosis. Troponin Subtypes troponin T and troponin I are used clinically. Cardiac damage or strain (myocardial infarctionp118, pericarditis, myocarditis, physical examination, sepsis, CPR). Chronic Kidney disease (troponin T only; elevation less marked; aetiology unknown). __OOHHCCMM__1100ee. . iinnddbb 668888 0022//0055//22001177 1199: : 0088 689 yrtsimehc lacinilC Enzyme inducers and inhibitors Hepatic drug metabolism is mainly by conjugation or oxidation. The oxidative pathways are catalysed by the family of cytochrome P450 isoenzymes, the most important of which is the CYP 3A4 isoenzyme. The cytochrome P450 pathway may be either induced or inhibited by a range of commonly used drugs and foods (table 14. 7). This can lead to important interactions or side-eff ects. For example, phenytoin reduces the eff ectiveness of the contraceptive pill due to more rapid oestrogen metabolism, and ciprofl oxacin retards the metabolism of methylxanthines (aminophylline) which leads to higher plasma levels and potentially more side-eff ects. The BNF contains a list of the major interactions between drugs. Table 14. 7 Common inhibitors and inducers of cytochrome P450 isoenzymes Enzyme inducers Enzyme inhibitors Phenytoin SSRIS Amiodarone Rifampicin Ciprofl oxacin Diltiazem Carbamazepine Isoniazid Verapamil Alcohol Macrolides Omeprazole St Johns wort HIV protease inhibitors Grapefruit juice Barbiturates Imidazole and triazole antifungal agents __OOHHCCMM__1100ee. . iinnddbb 668899 0022//0055//22001177 1199: : 0088 690 yrtsimehc lacinilC Hyperlipidaemia Lipids travel in Blood packaged with proteins as lipoproteins. There are four classes: chylomicrons and VLDL (mainly triglyceride), LDL (mainly cholesterol), and HDL (mainly phospho lipid) (for abbreviations see footnote3). The evidence that cholesterol is a major risk factor for cardiovascular disease (cardiovascular disease) is undisputed (4S STUDY, 21 WOSCOPS, 22 CARE STUDY, 23 Heart PROTECTION STUDY 24) and indeed it may even be the green light that allows other risk factors to act. 25 Half the UK population have a serum cholesterol putting them at signifi cant risk of cardiovascular disease. HDL appears to correlate inversely with cardiovascular disease. Who to screen for hyperlipidaemia NB: full screening requires a fasting lipid profi Blood. Those at risk of hyperlipidaemia: Family history of hyperlipidaemia. Corneal arcus 50yrs old. Xanthomata or xanthelasmata (fi g 14. 13). Those at risk of cardiovascular disease: Known cardiovascular disease. Family history of cardiovascular disease 60yrs old. diabetes mellitus or impaired glucose tolerance. Hypertension. Smoker.",
    "Family history of cardiovascular disease 60yrs old. diabetes mellitus or impaired glucose tolerance. Hypertension. Smoker. body mass index. Low socioeconomic or Indian Asian background. Types of hyperlipidaemia Common primary hyperlipidaemia: Accounts for 70% of hyperlipidaemia. LDL only. Familial primary hyperlipidaemias: Multiple phenotypes exist (see table 14. 8). Risk of cardiovascular disease, although evidence suggests protection from cardiovascular disease is achieved with lower doses of statin than for common primary hyperlipidaemia. 26 Refer to specialist. Secondary hyperlipidaemia: Causes include: Cushings syndrome, hypothyroidism, nephrotic syndrome, or cholestasis. LDL. Treat the cause fi rst. Mixed hyperlipidaemia: Results in in both LDL and triglycerides. Caused by type 2 Diabetes mellitus, metabolic syndrome, alcohol abuse, and chronic renal failure. Management Identify familial or 2° hyperlipidaemias, as may diff er. Give lifestyle advice; aim for body mass index of 2025; encourage a Mediterranean-style dietfruit, vegetables, fi social history, unsaturated fats; and red meat; exercise. Top priority are those with known cardiovascular disease (there is no need to calculate their risk: ipso facto they already have High risk). Second priority is primary prevention in patients with chronic Kidney disease or type-1 Diabetes, and those with a 10-yr risk of cardiovascular disease 10%, irrespective of baseline lipid levels. 1st-line therapy: Atorvastatin 20mg PO at night, for primary prevention, and 80mg for secondary prevention and primary prevention in those with Kidney disease. 27 Simvastatin 40mg, is an alternative. cholesterol synthesis in the Liver by inhibiting HMGCOA reductase. CI: porphyria, cholestasis, pregnancy. SE: myalgia ± myositis (stop if CK ≥10-fold; if any myalgia, check CK; risk is 1 per 100 000 treatment-years), 28 abdominal Pain, and LFTS (stop if AST 100U/L). Cytochrome P450 inhibitors (p689) serum concentrations (200mL of grapefruit juice simvastatin concentration by 300%, and atorvastatin 80%, but pravastatin is almost unchanged). Current guidelines suggest a target plasma cholesterol reduction of ≥40 % in those with cardiovascular disease. 2nd-line therapy: Ezetimibea cholesterol absorption inhibitor, may be used in statin intolerance or combination with statins to achive target reduction. 3rd-line therapy: Alirocumaba monoclonal antibody against PCSK9 (acts to reduce hepatocyte LDL receptor expression). Very eff ective in reducing LDL, 29 but expensive and needs to be given by injection every 2 weeks. Others: fi brates, eg bezafi brate (useful in mixed hyperlipidaemias); anion exchange resins, eg colestyramine; nicotinic acid (HDL; LDL; SE: severe fl ushes; aspirin 300mg ½h pre-dose helps this). Hypertriglyceridaemia: Responds best to fi brates, nicotinic acid, or fi social history oil. Xanthomata These yellow lipid deposits may be: eruptive (itchy nodules in crops in hypertriglyceridaemia); tuberous (plaques on elbows and knees); or planaralso called palmar (orange streaks in palmar creases), diagnostic of remnant hyperlipidaemia; or in tendons (p38), eyelids (xanthelasma, see fi g 14. 13), or cornea (arcus, p39). 3 Abbreviations: (V)LDL (very) Low-density lipoprotein; IDL intermediate-density lipoprotein; HDL High-density lipoprotein; chol cholesterol; trig trigylcerides. __OOHHCCMM__1100ee. . iinnddbb 669900 0022//0055//22001177 1199: : 0088 691 yrtsimehc lacinilC Primary hyperlipidaemias Table 14. 8 Classifi cation of primary hyperlipidaemias Familial hyperchylomicronaeChol 6. 5 Eruptive xanthomata; mia (lipoprotein lipase defi - Trig 1030 lipaemia retinalis; ciency or apoCII defi ciency)I hepatosplenomegaly Chylomicrons Familial hypercholesterolChol 7. 516 LDL Tendon xanthoma; aemiaII Trig 2. 3 corneal arcus; (LDL receptor defects) xanthelasma Familial defective Chol 7. 516 LDL Tendon xanthoma; apolipoprotein B-100IIa Trig 2. 3 arcus; xanthelasma Common hypercholesterolChol 6. 59 LDL The commonest 1° aemiaIIa Trig 2. 3 lipidaemia; may have xanthelasma or arcus Familial combined hyperChol 6. 510 LDL VLDL Next commonest 1° lipidlipidaemiaIIb, IV, OR V Trig 2.",
    "510 LDL VLDL Next commonest 1° lipidlipidaemiaIIb, IV, OR V Trig 2. 312 HDL aemia; xanthelasma; arcus Dysbetalipoproteinaemia Chol 914 IDL Palmar striae; tubero- (remnant particle disease)III Trig 914 HDL LDL eruptive xanthoma Familial hypertriglyceridaeChol 6. 512 VLDL miaIV Trig 3. 06. 0 Type V hyperlipoproteina emia Trig 1030; Eruptive xanthomata; chylomicrons lipaemia retinalis; found hepatosplenomegaly Blue superscript numbers WHO phenotype; chol/trig levels given in millimoles per liter. Primary HDL abnormalities: Hyperalphalipoproteinaemia: HDL, chol 2. Hypoalphalipoproteinaemia (Tangier disease): HDL, chol 0. 92. Primary LDL abnormalities: Abetalipoproteinaemia (ABL): trig 0. 3, chol 1. 3, missing LDL, VLDL, and chylomicrons. Autosomal recessive disorder of fat malabsorption causing vitamin A E defi ciency, with retinitis pigmentosa, sensory neuropathy, ataxia, pes cavus, and acanthocytosis. Hypobetalipoproteinaemia: chol 1. 5, LDL, HDL. Autosomal codominant disorder of apolipoprotein B metabolism. longevity in heterozygotes. Homozygotes present with a similar clinical picture to ABL. Fig 14. 13 Xanthelasma. Xanthos is Greek for yellow, and elasma means plate. Xanthelasmata are lipid-laden yellow plaques, typically a few millimetres wide. They congregate around the lids, or just below the eyes, and signify hyperlipidaemia. __OOHHCCMM__1100ee. . iinnddbb 669911 0022//0055//22001177 1199: : 0088 692 yrtsimehc lacinilC The porphyrias The porphyrias are a heterogenous group of rare diseases caused by various errors of haem biosynthesis (produced when iron is chelated into protoporphyrin IX), which may be genetic or acquired. Depending on the stage in haem biosynthesis that is faulty, there is accumulation of either porphyrinogens, which are unstable and oxidize to porphyrins, or their precursors, porphobilinogen and -aminolaevulinic acid. Porphyrin precursors are neurotoxic, while porphyrins themselves induce photosensitivity and the formation of toxic free radicals. Alcohol, lead, and iron defi ciency cause abnormal porphyrin metabolism. Genetic counselling (OHCS p154) should be off ered to all patients and their families. Acute porphyrias Occur when the accumulation of porphyrinogen precursors predominates, and are characterized by acute neurovisceral crises, though some forms have additional photosensitive cutaneous manifestations. Acute intermittent porphyria: (The Madness of King George. ) A Low-penetrant autosomal dominant condition (porphobilinogen deaminase gene); 28% have no family history (de novo mutations). 10% of those with the defective gene have neurovisceral symptoms. Attacks are intermittent, more common in women and those aged 1840, and may be precipitated by drugs. Urine porphobilinogens are raised during attacks (the Urine may go deep red on standing) and also, in 50%, between attacks. Faecal porphyrin levels are normal. There is never cutaneous photosensitivity. It is the commonest form of porphyriaprevalence in UK: 12/100 000. Variegate porphyria and hereditary coproporphyria: Autosomal dominant, characterized by photosensitive blistering skin lesions and/or acute attacks. The former is prevalent in Afrikaners in South Africa. Porphobilinogen is High only during an attack, and other metabolites may be detected in faeces. Triggers of an acute attack: Include infection, starvation (including pre-operative nil-by-mouth), reproductive hormones (pregnancy, premenstrual), smoking, anaesthesia, and cytochrome P450 enzyme inducers (alcohol, and other drugssee BOX). Features of an acute attack: Gastrointestinal: abdominal Pain, Vomiting, constipation. Neuropsychiatric: peripheral neuropathy (weakness, hypotonia, Pain, numbness), seizures (often associated with severe sodium), psychosis (or other odd behaviour). 4 Cardiovascular: hypertension, tachycardia, shock (due to sympathetic overactivity). Other: fever, sodium, potassium, proteinuria, urinary porphobilinogens, discoloured Urine. Rare but serious complications include bulbar and respiratory paralysis. Beware the acute abdomen in acute intermittent porphyria: colic, Vomiting, fever, and WCCso mimicking an acute surgical abdomen. Anaesthesia could be disastrous. Treatment of an acute attack: Remove precipitants (review medications; treat intercurrent illness/infection). IV fl uids to correct electrolyte imbalance. High carbohydrate intake (eg Hycal) by NG tube, or IV if necessary. IV haematin is 1st-line (inhibits production of porphyrinogen precursors).",
    "IV haematin is 1st-line (inhibits production of porphyrinogen precursors). Nausea controlled with prochlorperazine 12. 5mg IM. Sedate if necessary with chlorpromazine 50100mg PO/IM. Pain control with opiate or opioid analgesia (avoid oxycodone). Seizures can be controlled with diazepam (although this will prolong the attack). Treat tachycardia and hypertension with a -blocker. Non-acute porphyrias Porphyria cutanea tarda (PCT), erythropoietic protoporphyria, and congenital erythro poietic porphyria are characterized by cutaneous photosensitivity alone, as there is no overproduction of porphyrinogen precursors, only porphyrins. PCT presents in adults with blistering skin lesions ± facial hypertrichosis and hyperpigmentation. Total plasma porphyrins and LFTS are . Screen for associated disorders: hep C, HIV, iron overload, hepatocellular calcium. : phlebotomy, iron chelators, chloroquine, sunscreens. __OOHHCCMM__1100ee. . iinnddbb 669922 0022//0055//22001177 1199: : 0088 693 yrtsimehc lacinilC Drugs to avoid in acute intermittent porphyria There are many, many drugs that may precipitate an acute attack ± quadriplegia, and this is by no means an exhaustive list (see BNF/Oxford Textbook of Medicine). For an up-to-date list of drugs considered safe in acute porphyria see www. wmic. wales. nhs. uk/porphyria-safe-list-may-2016/ Diclofenac Alcohol Oral contraceptive pill HRT Tricyclic antidepressants Benzodiazepines Anaesthetic agents (barbiturates, halothane) Antibiotics (cephalosporins, sulfonamides, macrolides, tetracyclines, rifampicin, trimethoprim, chloramphenicol, metronidazole) Metoclopramide ACE-inhibitors Ca2-channel blockers Statins Anticonvulsants Furosemide Sulfonylureas Lidocaine Gold salts Antihistamines Amphetamines. 4 Be sure I looked at her eyes Happy and proud; at last I knew Porphyria worshipped me; surprise Made my Heart swell, and still it grew While I debated what to do. That moment she was mine, mine, fair, Perfectly pure and Good: I found A thing to do, and all her hair In one long yellow string I wound Three times her little throat around, And strangled her From Porphyrias Lover by Robert Browning. __OOHHCCMM__1100ee. . iinnddbb 669933 0022//0055//22001177 1199: : 0088 15 Eponymous syndromes Fig 15. 1 No scientifi c discovery is named atrial fibrillationter its original discoverer, asserts Professor Stephen Stigler in Stiglers Law of Eponymy , and in doing so, names the sociologist RK Merton as its discovererdeliberately making Stiglers law exemplify itself. Is the same true in medicine? At least six others described Alzheimers disease before Alois Alzheimer in 1906, and Tetralogy of Fallot (named after Étienne-Louis Fallot in 1888) was fi rst described in 1672 by Niels Stenson. Not all medical eponyms obey Stiglers law. Forty years after it was fi rst described, the French neurologist Jean-Marie Charcot (himself associated with at least 15 medical eponyms) attributed the name Parkinsons Disease to the illness outlined in James Parkinsons 1817 essay The Shaking Palsy . Monochromatic doctors may try to abolish eponyms by regimenting them to histologically driven disease titles. But classifi cations vary as facts emerge, and as a result the renaming of non-eponyms becomes essential. Eponyms, however, carry on forever, because they imply nothing about causes. Alice in Wonderland syndrome Altered perception in size and shape of body parts or objects ± an impaired sense of passing timeas experienced by Alice in Lewis Carrolls novel. Seen in epilepsy, migraine, and cerebral lesions. 1, 2Alice Pleasance Liddell, 18651934 ArnoldChiari malformation Malformed cerebellar tonsils and medulla herniate through the foramen magnum. This may cause infantile hydrocephalus with mental retardation, optic atrophy, ocular palsies, and spastic paresis of the limbs. Spina bifi da, syringomyelia (p516), or focal cerebellar and brainstem signs may occur (p499). There may be bony abnormalities of the base of the skull. Often presents in early adulthood. magnetic resonance imaging aids diagnosis.",
    "Often presents in early adulthood. magnetic resonance imaging aids diagnosis. Julius Arnold, 18351915 (German pathologist); Hans Chiari, 18511916 (Austrian pathologist) Bakers cyst Fluid from a knee eff usion escapes to form a popliteal cyst (often swollen and painful) in a sub-gastrocnemius bursa. 3 Usually secondary to degeneration. : DVT (exclude if calf Edema); sarcoma. Imaging: USS; M RI. : None if asymptomatic. NSAIDS/ice if painful. Spontaneous resolution may take 1020 months. Arthroscopy cystectomy may be needed. William M Baker, 18381896 (British surgeon) Bazins disease (Erythema induratum. ) Localized areas of fat necrosis that produce painful, fi rm nodules ± ulceration and an indura ted rash, characteristically on adolescent girls calves. It is associated with TB. Nodular vasculitis is a variant unrelated to TB. 4 Pierre-Antoine-Ernest Bazin, 18071878 (French dermatologist) Behçets disease A systemic infl ammatory disorder of unknown cause, associated with HLA-B5. It is most common along the old Silk Road, from the Mediterranean to China. Features: Recurrent oral and genital ulceration, uveitis, skin lesions (eg erythema nodosum, papulopustular lesions); arthritis (non-erosive large joint oligoarthropathy); thrombophlebitis; vasculitis; myo/pericarditis; CNS involvement (pyramidal signs); and colitis. Diagnosis: Mainly clinical. Pathergy test: needle prick leads to papule formation within 48hrs. : Colchicine for orogenital ulceration; steroids, azathioprine/cyclophosphamide for systemic disease. Infl iximab has a role in ocular disease unresponsive to topical steroids. 5 Hulusi Behçet, 18891948 (Turkish dermatologist) Bergers disease (IgA nephropathy, p311. ) Ranges from invisible haematuria to rapidly progressive glomerulonephritis. Biopsy shows mesangial IgA deposition. Usually indolent disease, but progression to end-stage renal failure occurs. : angiotensin-converting enzyme inhibitor/angiotensin receptor blocker if blood pressure or proteinuria. Immunosuppression considered for progressive disease. 6 Jean Berger, 19302011 (French nephrologist) Bickerstaff s brainstem encephalitis Ophthalmoplegia, ataxia, arefl exia, and extensor plantars ± tetra plegia ± coma, and a reversible brain death picture (but there is no structural damage). magnetic resonance imaging: hyperintense brainstem signals. GQ1b antibodies ve. 7 Plasmapheresis may help. Edwin R Bickerstaff, 19202008 (British physician) We thank Dr Simon Eyre, our Specialist Reader, for his contribution to this chapter. __OOHHCCMM__1100ee. . iinnddbb 669944 0022//0055//22001177 1199: : 0088 695 semordnys suomynopE Barretts oesophagus Barretts oesophagus is metaplasia of the normal stratifi ed squamous epithelium of the distal oesophagus to a columnar epithelium, as a result of chronic GORD (p254). Estimates of prevalence vary widely, but in patients with a history of symptomatic GORD, rates of 8% have been reported. Importantly, screening studies in asymptomatic individuals have reported rates of 6%. General population-based screening is not recommended, although screening endoscopy may be considered in individuals with chronic GORD symptoms and multiple risk factors (50 years old, obesity, , white race, family history of Barretts or oesophageal adenocarcinoma). Diagnosis: Biopsy of endoscopically visible columnarization allows histological corroboration. The length should be recorded (using the Prague classifi cation). Management: Focus on detecting and preventing the most signifi cant associated morbidity: oesophageal adenocarcinoma. The risk of progression is Low (0. 10. 4% per patient per year, much lower than previously suggested). Risk factors for malignant transformation include age, , long segment of oesophagus involved, and evidence of dysplasia. Endoscopic surveillence for dysplasia is controversial and the evidence base is lacking. Current guidelines suggest that patients without dysplasia and in whom the length of involved oesophagus is 3cm should be considered for discharge from surveillance programmes, depending on the precise histology. 8 For those with more extensive disease, endoscopic assessment every 23 years is appropriate. If High-grade dysplasia or intramural carcinoma is detected, endoscopic resection or mucosal radiofrequency abl ation (RFA) is recommended.",
    "If High-grade dysplasia or intramural carcinoma is detected, endoscopic resection or mucosal radiofrequency abl ation (RFA) is recommended. If Low-grade dysplasia is detected, it should be confi rmed by repeat examination after 6 months and by an independent pathologist, prior to RFA. 9 Norman Rupert Barrett, 19031979 (British surgeon) Brugada syndrome Note right bundle branch block and the unusual morphology of the raised ST segments in V1V3 (fi g 15. 2; there are three ECG variants of this pattern). This predominently autosomal dominant condition causing faulty Sodium channels predis poses to fatal arrhythmias (eg vent ricular fi br illation), typically in young males (eg triggered by a fever). 10 It is preventable by implanting a defi br il lator. Consider primary electrical cardiac disease in all with unexplained syncope. Programm ed electrical stimula tion may be needed. Relatives of those with sudden unex pl ained death may undergo unmaski ng of arrhythmias by IV ajmaline testsbut some results are false ve. Use judgement in subjecting those with ST abnormalities but no symptoms to electrophysiolo gical tests, right ventricular myocardial biopsy, and magnetic resonance imaging. Mutations in the SCN5A gene (encodes the cardiac voltagegated Na1. 5 channel) are found in 1520%. v Other mutations have also been described. 11 Pedro Josep Brugada, described 1992 (Spanish cardiologists). Fig 15. 2 Note right bundle branch block and ST morph ology in leads V13. Courtesy of Dr Shayashi. __OOHHCCMM__1100ee. . iinnddbb 669955 0022//0055//22001177 1199: : 0088 696 semordnys suomynopE Brown-Séquard syndrome A lesion in one half of the spinal cord (due to hemisection or unilateral cord lesion) causes: Ipsilateral UMN weakness below the lesion (severed corticospinal tract, causing spastic paraparesis, brisk refl exes, extensor plantars). Ipsilateral loss of proprioception and vibration (dorsal column severed). Contral ateral loss of Pain and temperature sensation (severed spinothalamic tract which has crossed over; fi g 10. 35 p516). Causes: Bullet, stab, tumour, disc hernia, myelitis, 12 septic emboli. Imaging: magnetic resonance imaging. Charles-Édouard Brown-Séquard, 18171894 (Mauritian neurologist) BuddChiari syndrome Hepatic vein obstruction by thrombosis or tumour causes congestive ischaemia and hepatocyte damage. Abdominal Pain, hepatomegaly, ascites, and ALT occur. Portal hyperte nsion occurs in chronic forms. Causes: Include hypercoag ulable states (combined OCP, pregnancy, malignancy, paroxysmal nocturnal haemoglobin uria, polycythaemia, thrombophilia), TB, Liver, renal, or adrenal tumour. Tests: USS Dopplers, computed tomography, or magnetic resonance imaging. Angioplasty or a transjugular intrahepatic porto systemic shunt (TIPSS) may be needed. Anticoagulate (lifelong) unless there are varices. Consider Liver transplant in fulminant hepatic necrosis or cirrhosis. 13 George Budd, 18081882 (British physician); Hans Chiari, 18511916 (Austrian pathologist) Buergers disease (Thromboangiitis obliterans. ) Non-atherosclerotic smokingrelated infl ammation and thrombosis of veins and middle-sized arteries causing thrombophlebitis and ischaemia (ulcers, gangrene). Cause: Unknown. Stopping smoking is vital. Most patients are men aged 2045yrs (see BOX Poisoning your boss). Leo Buerger, 18791943 (ultrasound physician) Caplans syndrome Multiple lung nodules in coal workers with RA, caused by an infl ammatory reaction to anthracite (also associated with silica or asbestos exposure). CXR: bilateral perip heral nodules (0. 55cm). : TB. Anthony Caplan, 19071976 (British physician) CharcotMarieTooth syndrome (Peroneal muscular atrophy. ) This inherited neuropathy starts in puberty with weak legs and foot drop variable loss of sensation and refl exes. The peroneal muscles atrophy, leading to an inverted champagne bottle appearance. Atrophy of hand and arm muscles also occurs. The most common form, CMT1A (PMP22 myelin gene mutation on chr. 17), has AD inheritance. Quality of life is Good; total incapacity rare. Hand Pain/paraesthesiae may respond to nerve release.",
    "17), has AD inheritance. Quality of life is Good; total incapacity rare. Hand Pain/paraesthesiae may respond to nerve release. Jean-Marie Charcot, 18251893; Pierre Marie, 18531940 (French neurologists); Howard H Tooth, 18561926 (British physician) ChurgStrauss syndrome (Eosinophilic granulomatosis with polyangiitis. ) A triad of adult-onset asthma, eosinophilia, and vasculitis (± vasospasm ± myocardial infarction ± DVT), aff ecting lungs, nerves, Heart, and skin. A septic-shock picture/systemic infl ammatory response syndrome may occur (with glomerulon eph ritis/renal failure, esp. if ANCA ve). : Steroids; biological agents if refractory disease, eg rituximab. 14 Jacob Churg, 19102005; Lotte Strauss, 19131985 (ultrasound pathologists) CreutzfeldtJakob disease (CJD) The cause is a prion (PrPSc), a misfolded form of a normal Protein (PrPc), that can transform other proteins into prion proteins (hence its infectivity). PrPSc leads to spongiform changes (tiny cavities ± tubulovesicular structures) in the brain. 15 Most cases are sporadic (incidence: 13/million/yr). Variant CJD (vCJD; 225 cases worldwide)16 is transmitted via con tamin ated CNS tissue aff ected by bovine spongiform encephalopathy (BSE) (see BOX Signs that may distinguish variant CJD). Inherited forms: (eg GerstmannSträusslerScheinker syndrome, P102L mutation in PRNP gene with ataxia ± self-mutilation), the normal Protein is too unstable, readily trans forming to PrPSc. Iatrogenic causes: Cont aminated surgical instruments, corneal transplants, growth hormone from human pituitaries, and Blood (vCJD only). 17 Prion Protein resists sterilization. Signs: Progressive dementia, focal CNS signs, myoclonus (present in 95%), 18 depression, eye signs (diplopia, supranuclear palsies, complex visual disturbances, homonymous fi eld defects, hallucinations, cortical blindn ess). 19 Tests: Tonsil/olfactory mucosa biopsy; 20 CSF gel electrophoresis; magnetic resonance imaging. Treatment: None proven. Death occurs in 6 months in sporadic CJD (a little slower in variant CJD). Prevention: Regulations to spread of BSE and transmission to humans iatrogenic transmission. Hans G Creutzfeldt, 18851964 (German pathologist); Alfons M Jakob 18841931 (German neurologist) CriglerNajjar syndrome Two rare syndromes of inherited unconjugated hyperbilirubinaemia presenting in the 1st days of life with jaundice ± CNS signs. Cause: Mutation in UGT enzyme activity causing absent (type 1) or impaired (type 2; mild) ability to excrete bilirubin. : T1: phototherapy and plasmapheresis to control jaundice; Liver transplant before irreversible kernicterus (OHCS p115) develops. 21 T2: usually no needed. John F Crigler 19192002; Victor A Najjar b1914 (ultrasound paediatricians) __OOHHCCMM__1100ee. . iinnddbb 669966 0022//0055//22001177 1199: : 0088 697 semordnys suomynopE Signs that may distinguish variant CJD from sporadic CJD (SCJD) An earlier age at presentation (median 29yrs vs 60yrs in sporadic CJD). Longer survival and later dementia (median 14 months vs 4 for sporadic CJD). Psychiatric features are an early sign (anxiety, withdrawal, apathy, agitation, a permanent look of fear in the eyes, depression, personality change, insomnia). Hallucinations and delusions may occurbefore akinetic mutism. Painful sensory symptoms are commoner (eg foot Pain hyperaesthesia). More normal EEG (sporadic CJD has a characteristic spike and wave pattern). Mean CSF tau-pT181/tau Protein ratio is 10-fold higher in VCJD than in SCJD. 22 Homozygosity for methionine at codon 129 of the PRP gene is typical. Fame and infamy in the search for lost youth After his neurological experiments, Brown-Séquard, the most visionary of all neuroanatomists and the grandfather of HRT, proclaimed he had found the secret of perpetual youth after injecting himself with a concoction of testicular Blood, semen, and testicular extracts from dogs and guinea pigs. In the 1880s, over 12 000 doctors were queuing up to use his special extracts on patients, which he gave away free, provided results were reported back to him. 314 out of 405 cases of spinal syphilis improved, and his own urinary fl ow rate rose by 25%.",
    "Symptoms: Recurrent fever and chest Pain ± pleural or pericardial rub (from serositis). Cardiac tamponade may occur, so avoid anticoagulants. : Aspirin, NSAIDS, or steroids. William Dressler, 18901969 (ultrasound cardiologist) DubinJohnson syndrome There is defective hepatocyte excretion of conjugated bilirubin. Typically presents in late teens with intermittent jaundice ± hepatosplenomegaly (autosomal recessive). Tests: Bilirubin; ALT and AST are normal; bilirubinuria on dipstick; ratio of urinary coproporphyrin I to III. Liver biopsy: diagnostic pigment granules. 32 : Usually none needed. Isadore N Dubin, 19131981; Frank B Johnson, b1919 (ultrasound pathologists) Dupuytrens contracture (fi g 15. 3) Progressive shortening and thickening of the palmar fascia causing fi nger contracture and loss of extension (often 5th fi nger). Prevalence: 10% of 65yrs ( if ve family history). Associations: Smoking, alcohol use, heavy manual labour, trauma, diabetes mellitus, phenytoin, HIV. Peyronies may coexist (p708). It is thought to be caused by local hypoxia. : Collagenase injections. 33 Surgery may be needed. Baron Guillaume Dupuytren, 17771835 (French surgeon, famed also for treating Napoleons haemorrhoids) Ekboms syndrome (Restless legs. ) Criteria: 1 Compelling desire to move legs. 2Worse at night. 3 Relieved by movement. 4 Unpleasant leg sensations (eg shootings or tinglings) worse at rest. Mechanism: Endogenous opioid system fault causes altered central processing of Pain. Prevalence: 13%. : 2: 1. Associations: Iron defi ciency, uraemia, pregnancy, diabetes mellitus, polyneuropa thy, RA, COPD. Exclude: Cramps, positional discomfort, and local leg pathology. : Dopamine agonists are commonly used; also, anticonvulsants, opioids, and benzodiazepines. 34 Karl Axel Ekbom, 19071977 (Swedish neurologist) Fabry disease X-linked lysosomal storage disorder caused by abnormalities in the GLA gene, leading to a defi ciency in -galactosidase A. There is accumulation of glycosphingolipids in skin (angiokeratoma classically in a swimming trunk distribution), eyes (corneal verticillata), Heart (hypertrophy, mitral valve prolapse, dilated aortic root, arrhythmias, angina), kidneys (renal failure, p320), CNS (stroke) and nerves (neuropathy/acro paraesthesia). Prior to enzyme replacement, premature death in the 6th decade was due to CV and renal disease. : Enzyme replacement therapy with or human agalsidase. 35 Johannes Fabry, 18601930 (German dermatologist) Fanconi anaemia Autosomal recessive, defective stem cell repair chromosomal fragility leads to aplastic anaemia, risk of AML and breast calcium (BRCA2), skin pigmentation, absent radii, short stature, microcephaly, syndactyly, deafness, IQ, hypopituitarism, and crypto rchidism. : Stem-cell transplant. Guido Fanconi, 18921979 (Swiss paediatrician) Feltys syndrome A triad of rheumatoid arthritis WCC splenomegaly (±hypersplenism, causing anaemia and platelets), recurrent infections, skin ulcers, and lymphadenopathy. 95% are Rh factor ve. Splenectomy may raise the wcc. : DMARDS (p547) ± rituximab if refractory. 36 Augustus Roi Felty, 18951964 (ultrasound physician) Fitz-HughC urtis syndrome Liver capsule infl ammation causing RUQ Pain due to transabdominal spread of chlamydial or gonococcal infection, often with PID ± violinstring adhesions. : Antibiotics for PID ( treat sexual partners) ± laparoscopic division of adhesions. Thomas Fitz-Hugh, 18941963 (ultrasound physician); Arthur H Curtis, 18811955 (ultrasound gynaecologist) Foster Kennedy syndrome Optic atrophy of one eye due to optic nerve compression (most commonly from an olfactory groove meningioma), with papilloedema of the other eye secondary to ICP. There is also central scotoma and anosmia. Robert Foster Kennedy, 18841952 (British neurologist) Friedreichs ataxia Expansions of the trinucleotide repeat GAA in the frataxin gene (recessive) causes degeneration of many nerve tracts: spinocerebellar tracts degenerate causing cerebellar ataxia, dysarthria, nystagmus, and dysdiado chokinesis. Loss of corticospinal tracts occurs (weakness and extensor plantar response) with peripheral __OOHHCCMM__1100ee. . iinnddbb 669988 0022//0055//22001177 1199: : 0088 699 semordnys suomynopE Devics syndrome and multiple sclerosis Table 15.",
    ". iinnddbb 669988 0022//0055//22001177 1199: : 0088 699 semordnys suomynopE Devics syndrome and multiple sclerosis Table 15. 1 Distinguishing Devics syndrome from multiple sclerosis Devics syndrome Multiple sclerosis Course Monophasic or relapsing Relapsing usually; see p496 Attack severity Usually severe Often mild Respiratory failure 30%, from cervical myelitis Rare magnetic resonance imaging head Usually normal Many periventricular whitematter lesions magnetic resonance imaging cord lesions Longitudinal, central Multiple, small, peripheral CSF oligoclonal bands Absent Present Permanent disability Unusual, and attack-related In late progressive disease Other autoimmunities In ≤50% (eg Sjögrens) Uncommon Diagnostic criteria for Devics Optic neuritis, myelitis, and ≥2 out of 3 of: magnetic resonance imaging evidence of a continuous cord lesion for ≥3 segments. Brain magnetic resonance imaging at onset nondiagnostic for MS. NMO-IgG (anti-AQP4) serum or CSF positivity (poorer prognosis). NB: CNS involvement beyond the optic nerves and cord is compatible with NMO. Fig 15. 3 Dupuytrens contracture of the 5th fi nger. Note scar from previous surgery to the index fi nger. __OOHHCCMM__1100ee. . iinnddbb 669999 0022//0055//22001177 1199: : 0088 700 semordnys suomynopE nerve damage, so tendon refl exes are paradoxically depressed (diff erential diagnosis p446). There is also dorsal column degeneration, with loss of positional and vibration sense. Pes cavus and scoliosis occur. Cardiomyopathy may cause CCF. Typical age at death: 50yrs. : There is no cure. Treat CCF, arrhythmias, and diabetes mellitus. Nikolaus Friedreich, 18251882 (German neurologist) Froins syndrome CSF Protein xanthochromia with normal cell counta sign of blockage in spinal CSF fl ow (eg from a spinal tumour). Georges Froin, 18741932 (French physician) Gardners syndrome A dominant variant of familial adenomatous polyposis, caused by mutations in the APC gene (5q21). There are multiple colon polyps (which inevitably become malignant; p520), 37 benign bone osteomas, epidermal cysts, dermoid tumours, fi bromas, and neurofi bromas. Fundoscopy reveals black spots (congenital hypertrophy of retinal pigment epithelium); this helps pre-symptomatic detection. Presentation: Can present from 270yrs with colonic (eg bloody diarrhoea) or extracolonic symptoms. Prophylactic surgery (eg proctocolectomy) is the only curative treatment. Endoscopic polypectomy with long-term celecoxib therapy has been used to postpone prophylactic colectomy. 38 Eldon J Gardner, 19091989 (ultrasound physician) Gélineaus syndrome (Narcolepsy. ) The patient, usually a young man, succumbs to irresistible attacks of inappropriate sleep ± vivid hypnogogic hallucinations, cataplexy (sudden hypotonia), and sleep paralysis (paralysis of speech and movement, while fully alert, at sleep onset or on waking). Hypothesis: Mutations lead to loss of hypothalamic hypocretin-containing neurons, via autoimmune des truction. 39 95% are ve for HLA DR2. : Stimulants (eg methylphenidate) may cause dependence ± psychosis. Modafi nil may be better. SE: anxiety, aggression, dry mouth, euphoria, insomnia, blood pressure, dyskinesia, ALP. Jean-Baptiste-Édouard Gélineau, 18281906 (French physician) Gerstmanns syndrome A constellation of symptoms suggesting a dominant parietal lesion: fi nger agnosia (inability to identify fi ngers), agraphia (inability to write), acalculia (inability to calculate), and leftright disorientation. Josef Gerstmann, 18871969 (Austrian neurologist) Gilberts syndrome A common cause of unconjugated hyperbilirubinaemia due to UGT-1 activity (the enzyme that conjugates bilirubin with glucuronic acid). Prevalence: 12%; 515% have a family history of jaundice. It may go unnoticed for many years and usually presents in adolescence with intermittent jaundice occuring during illness, exercise or fasting. Diagnosis: Mild bilirubin; normal FBC and reticulocytes (ie no haemolysis). It is a benign condition. Nicolas Augustin Gilbert, 18581927 (French physician) Gilles de la Tourette syndrome Tonic, clonic, dystonic, or phonic tics: jerks, blinks, sniff s, nods, spitting, stuttering, irrep ressible explosive obscene verbal ejaculations (coprolalia, in 20%) or gestures (coprophilia, 6%), 40 grunts, squeaks, burps, twirlings, and nipping others ± tantrums.",
    "There may be glomerulonephritis (p310), arthritis, and abdominal Pain (± intussusception), which may mimic an acute abdomen. : Mostly supportive. Eduard H Henoch, 18201910 (German paediatrician); Johann L Schönlein, 17931864 (German physician) Horners syndrome A triad of 1 miosis (pupil constriction, fi g 15. 4) 2 partial ptosis (drooping upper eyelid) apparent enophthalmos (sunken eye) 3 anhidrosis (ipsilateral loss of sweating). Due to interruption of the faces sympathetic supply, eg at the brainstem (demyelination, vascular disease), cord (syringom yelia), thoracic outlet (Pancoasts tumour, p708), or on the sympathetics trip on the internal carotid artery into the skull (fi g 15. 6), and orbit. Johann Friedrich Horner, 18311886 (Swiss ophthalmologist) Huntingtons disease Incurable, progressive, autosomal dominant, neurodegenerative disorder presenting in middle age, often with prodromal phase of mild symptoms (irritability, depression, incoordination). Progresses to chorea, dementia ± fi ts death (within 15yrs of diagnosis). Pathology: Atrophy and neuronal loss of striatum and cortex. Genetic basis: Expansion of CAG repeat on Chr. 4. : (p87. ) No treatment prevents progression. Counselling for patient and family. 46 George Huntington, 18501916 (ultrasound physician) Jervell and Lange-Nielsen syndrome Congenital, bilateral, autosomal recessive, sensorineural deafness, and long QT interval (p96, hence syncope, VT, torsades, ± sudden death50% by age 15 if untreated). KCNQ1 or KCNE1 gene mutation causes potassium channelopathy. : -blocker, pacemaker, ICD, cochlear implants. 47 Anton Jervell, 19011987; Fred Lange-Nielsen, 19191989 (Norwegian physicians) Kaposis sarcoma (KS) A spindle-cell tumour derived from capillary endotheli al cells, caused by human herpes virus 8 (Kaposis sarcoma-associated herpes virus KSHV). It presents as purple papules (½1cm) or plaques on skin (fi g 15. 7) and mucosa (look in mouth, but any organ). It metastasizes to nodes. There are four types: 1 Classic, a rare disease of the elderly. 2 Endemic, a disease of children documented prior to HIV. 3 Iatrogenic KS due to immunosuppression, eg organ transplant recipients. 4 AIDS-associated KS. Usually presents with Low CD4 count and can indicate failure of HAART (p402). However ⅓ presents in HIV with near normal CD4 counts and an undetectable viral load. Initiation of HAART with rapid immune system constitution can precipitate KS. Lung KS may present in HI V ve men and women as dyspnoea and haemoptysis. Bowel KS may cause nausea, abdominal Pain. Rare sites: CNS, larynx, eye, glands, Heart, breast, wounds, or biopsy sites. : Biopsy. : Optimize HAART, local radiotherapy, surgical excision, intralesional therapy (vincristine, bleomycin), topical retinoids, interferon alfa, interleukin-12. Current research includes thalidomide, VEGF monoclonal antibodies, and sirolimus. Moricz Kaposi, 18371902 (Hungarian dermatologist) __OOHHCCMM__1100ee. . iinnddbb 770022 0022//0055//22001177 1199: : 0088 703 semordnys suomynopE GuillainBarré polyneuritis Table 15. 2 Diagnostic criteria Features required for Features supporting diagnosis Progressive weakness of 1 limb Progression over days, up to 4wks Arefl exia Near symmetry of sytoms Features making diagnosis doubtful Sensory symptoms/signs only mild Sensory level CN involvement (eg bilateral facial weakness) Marked, persistent asymmetry of Recovery starts 2wks after the period of weakness progression has fi nished Severe bowel and bladder dysfunction Autonomic dysfunction CSF WCC 50 Absence of fever at onset CSF Protein with CSF WCC 10106/L Typical electrophysiological tests Variants of GuillainBarré syndrome include: Chronic infl ammatory demyelinating polyradiculopathy (CIDP): Characteri zed by a slower onset and recovery. Miller Fisher syndrome: Comprises of ophthalmoplegia, ataxia, and arefl exia. Associated with anti-GQ1b antibodies in the serum. Fig 15. 4 Right Horners: everything reduces: pupil, eye, sweating, etc. Fig 15. 5 HenochSchönlein vasculitis. Fig 15. 7 Kaposis sarcoma. Reproduced from Oxford Handbook of Medical Fig 15. 6 Pathways in Horners syndrome. Dermatology, 2010, with permission from Oxford University Press. __OOHHCCMM__1100ee. .",
    "6 Pathways in Horners syndrome. Dermatology, 2010, with permission from Oxford University Press. __OOHHCCMM__1100ee. . iinnddbb 770033 0022//0055//22001177 1199: : 0088 704 semordnys suomynopE KlippelTrénaunay syndrome A triad of port wine stain, varicose veins, and limb hypertrophy, due to vascular malformation. Usually sporadic (although AD inheritance has been reported). 48 Maurice Klippel, 18581942; Paul Trénaunay, 18751938 (French physicians) Korsakoff s syndrome Hypothalamic damage cerebral atrophy due to thiamine (vitamin B1) defi ciency (eg in alcoholics). May accompany Wernickes encephalopathy. There is ability to acquire new memories, confabulation (invented memory, owing to retrograde amnesia), lack of insight apathy. : See Wernickes, p714; patients rarely recover. Sergei Sergeievich Korsakoff, 18531900 (Russian neuropsychiatrist) Langerhans cell histiocytosis (Histiocytosis X. ) A group of single- (73%, eg bone) or multisystem (27%) disorders, with infi ltrating granulomas containing dendritic (Langerhans) cells. : 1. 5: 1; at-risk organs are Liver, lung, spleen, marrow. Pulmonary disease presents with pneumothorax or pulmonary hypertension. CXR/computed tomography: nodules and cysts honeycombing in upper and middle zones. : Biopsy (skin, lung). : Local excision, steroids, vinblastine ± etoposide if severe. 49 OHCS p644. Paul Langerhans, 18471888 (German pathologist) Leriches syndrome Absent femoral pulse, claudication/wasting of the buttock, a pale cold leg, and erectile dysfunction from aorto-iliac occlusive dise ase, eg a saddle embolus at the aortic bifurcation. Surgery may help. René Leriche, 18791955 (French surgeon) Löffl ers eosinophilic endocarditis Restrictive cardiomyopathy eosinophilia (eg 120 109/L). It may be an early stage of tropical endomyocardial fi brosis (and overlaps with hypereosinophilic syndrome, p330) but is distinct from eosinophilic leuk aemia. Signs: Heart failure (75%) ± mitral regurgitation (49%) ± Heart block. : Suppress the eosin ophilia (prednisolone ± hydroxycarbamide), and then treat with anti-Heart failure medication. Wilhelm Löffl er, 18871972 (Swiss physician) Löffl ers syndrome (Pulmonary eosinophilia. ) An allergic infi ltration of the lungs by eosinophils. Allergens include: Ascaris lumbricoides, Trichinella spiralis, Fasciola hep atica, Strongyloides, Ankylostoma, Toxocara, Clonorchis sinensis, sulfonamides, hydralazine, and nitrofurantoin. Often symptomless with incidental CXR (diff use fan-shaped shadows), or cough, fever, eosinophilia (in 20%) larval migrans (p433). : Eradicate cause. Steroids (if idiopathic). Wilhelm Löffl er, 18871972 (Swiss physician) LownGanongLevine syndrome A pre-excitation syndrome, similar to WolfParkinsonWhite (WPW, p133), characterized by a short PR interval (0. 12sec), a normal QRS complex (as opposed to the -waves of WPW), and risk of supraventricular tachycardia (but not atrial fibrillation/fl utter). The cause is not completely understood, but may be due to paranodal fi bres that bypass all or part of the atrioventricular node. The patient may complain of intermittent palpitations. 50 Bernard Lown, b1921 (ultrasound cardiologist); William F Ganong, 19242007 (ultrasound physiologist); Samuel A Levine, 18911966 (ultrasound cardiologist) McArdles glycogen storage disease (type V) Absence of muscle phosphorylase enzyme with resulting inability to convert glycogen into glucose (eg R50X mutation of PYGM gene; autosomal recessive). Fatigue crises of cramps ± hyperthermia. Rhabdomyolysis/myoglobinuria follow exercise. Tests: CK. Muscle biopsy is diagnostic (necrosis and atrophy). : Mod erate aerobic exercise helps (by utilizing alternative fuel substrates). 51 Avoid heavy exertion and statins. Sucrose pre-exercise improves performance, as does a carbohydrate-rich diet. Low-dose creatine and ramipril (only if D/D ACE phenotype) may be of minimal benefi t. 52 Brian McArdle, 19112002 (British paediatrician) MalloryWeiss tear Persistent Vomiting/retching causes haematemesis via an oesophageal mucosal tear. George potassium Mallory, 19001986 (ultrasound pathologist); Soma Weiss, 18981942 (ultrasound physician) MarchiafavaBignami syndrome Corpus callosum demyelination and necrosis, most often secondary to chronic alcoholism. Type A is characterized by coma, stupor, and pyramidal tract features involving the entire corpus callosum. In type B, symptoms are mild and the corpus callosum is partially aff ected.",
    "There may be gastric acid secretion, causing GI Pain occult bleeding. : Radionucleotide scan; laparotomy. J ohann Friedrich Meckel, 17811833 (German anatomist) Meigs syndrome A triad of 1 benign ovarian tumour (fi broma) 2 pleural eff usion (RL) 3 ascites. It resolves on tumour resection. Joe Vincent Meigs, 18921963 (ultrasound gynaecologist) Ménétriers disease Giant gastric mucosal folds up to 4cm High, in the fundus, with atrophy of the glands mucosal thickness hypoc hlorhydria Protein-losing gastropathy (hence hypoalbuminaemia ± oedema). Causes: CMV, strep, H. pylori. There may be epigastric Pain, Vomiting, ± weight. It is pre-malignant. : Treat H. pylori or CMV if present; give High-dose proton pump inhibitor; if this fails, consider epidermal growth factor blockade with cetuximab or gastrectomy (eg if intractable symptoms or malignant change). Epidermal growth factor receptor blockade with cetuximab is 1stline treatment. 55 Surgery if intractable symptoms or malignant change. Pierre Eugène Ménétrier, 18591935 (French pathologist) MeyerBetz syndrome (Paroxysmal myoglobinuria. ) Rare idiopathic condition causing necrosis of exercising muscles. There is muscle Pain, weakness, and discoloured Urine: pinkbrown (as myoglobin is excreted). Acute Kidney injury can result from myoglobinuria (p319). DIC is associated. Tests: WCC, LFT, LDH, CPK, Urine myoglobin. Diagnosis: Muscle biopsy, CPK, and serum myoglobin. Exertion should be avoided. Friedrich Meyer-Betz, described 1910 (German physician) Mikuliczs syndrome Benign persistent Edema of lacrimal and parotid (or submandibular) glands due to lymphocytic infi ltration. Exclude other causes (sarcoidosis, TB, viral infection, lymphoproliferative disorders). It is thought to be an IgG4-related plasmacytic systemic disease. 56 Johann Freiherr von Mikulicz-Radecki, 18501905 (PolishAustrian surgeon) Milroy disease 1° congenital lymphoedema. Mutations in the VEGFR3 gene (dominant) cause lymphatic malfunction with lower leg Edema from birth (fi g 15. 10). : Lymphoscintigraphy; genetic testing. : Compression hosiery/bandages. Encourage exercise. Good skin hygiene. Treat cellulitis actively. William Forsyth Milroy, 18551942 (ultrasound physician) Münchausens syndrome Vivid liars, who are addicted to institutions, fl it from hosp ital to hospital, feigning illness, eg hoping for a laparotomy or mastectomy, or they complain of awful bleeding, odd eye movements, curious fi ts, sexual assaults, throat closings, false asthma, or Heart attacks. Münchausen-by-proxy entails injury to a dependent person by a carer (eg mother) to gain medical attention. Karl Friedrich Hieronymus, Freiherr von Münchausen, 17201797 (German aristocrat). Described by RAJ Asher in 195157 Ogilvies syndrome (Acute colonic pseudo-obstruction. ) Colonic obstruction in the absence of a mechanical cause, associated with recent severe illness or surgery. : Correct UE. Colonoscopy allows decompr ession, and excludes mechanical causes. Neostigmine is also eff ective, suggesting parasympathetic suppression is to blame. 58 Surgery is rarely needed (eg if perforation). William Heneage Ogilvie, 18871971 (British surgeon) __OOHHCCMM__1100ee. . iinnddbb 770066 0022//0055//22001177 1199: : 0088 707 semordnys suomynopE Fig 15. 9 Lens dislocation in Marfans syndrome: here the lens is dislocated superiorly and medially. Courtesy of Prof Jonathan Trobe. Fig 15. 10 Milroy disease. Lymphoedema may be primary, as in Milroy or Meige disease, and is a feature in both Turner and Noonan syndromes. More commonly it is secondary to other conditions, eg cancer (after surgery, lymph node dissection, radiotherapy, or from direct tumour eff ect), cellulitis, varicose veins, or immobility/dependency. Filariasis (p421) is a common cause in tropical regions. Who was Baron Münchausen? Baron Karl Münchausen was an 18thcentury German aristocrat and fabulist, whose tall tales became fi rst a popular book, then a byword for circular logic, and fi nally a medical syndrome of selfdelusion. He is famous for riding cannonballs, travelling to the moon, and pulling himself out of a swamp by his own hair.",
    "In emergencies (weve all had that sinking feeling), this method may save your life, for example in your fi nal exams (fi g 15. 11): Examiner: What is ITP? You: ITP is idiopathic thrombocytopenic purpura. (you have scored 50% already). Fig 15. 11 Münchausen during his fi nals. Examiner: And what is idiopathic thrombocytopenic purpura? You: Its when a cryptogenic cause of a Low platelet count leads to purpura. You have deployed your skills with logical brilliance, without adding a single insight. For this Münchausen circularity you may be awarded 100%unless your examiner is a philosopher, when the right answer would be What is ITP? I dont knowand nor do youbut dont try this too often. You see, you must never forget that medicine is marvellously scientifi c, and no one is popular who dares cast doubt on this article of faith. __OOHHCCMM__1100ee. . iinnddbb 770077 0022//0055//22001177 1199: : 0088 708 semordnys suomynopE Ortners cardiovocal syndrome Recurrent laryngeal nerve palsy from a large left atrium (eg from mitral stenosis) or aortic dissection. Norbert Ortner, 18651935 (Austrian physician) OslerWeberRendu syndrome (Hereditary telangiectasia. ) Autosomal dominant telangiec tasia of skin mucous membranes (causing epistaxis and GI bleeds), see fi g 15. 12. Associated with pulmonary, hepatic, and cerebral arteriovenous malformations. William Osler, 18491919 (Canadian); Frederick Weber, 18631962 (British); Henri Rendu, 18441902 (French)physicians Pagets disease of the breast (PDB) Intra-epidermal spread of an intraduct cancer, which can look just like eczema. Any red, scaly lesion at the nipple (see fi g 15. 13) must suggest PDB: do a biopsy. : Breast-conserving surgery radiotherapy. Sentinel node biopsy should be performed. Sir James Paget, 18141899 (British surgeon) Pancoasts syndrome Apical lung calcium invades the sympathetic plexus in the neck (ipsi lateral Horners, p702) ± brachial plexus (arm Pain ± weakness) ± recurrent laryngeal nerve (hoarse voice/bovine cough). Henry Pancoast, 18751939 (ultrasound radiologist) Parinauds syndrome (Dorsal midbrain syndrome. ) Upward gaze palsy pseudoArgyll Robertson pupils (p72) ± bilateral papilloedema. Causes: Pineal or midbrain tumours; upper brainstem stroke; MS. Henry Parinaud, 18441905 (French neuro-ophthalmologist) PeutzJeghers syndrome Dominant germline mutations of tumour suppressor gene STK11 (in 6694%) cause mucocutaneous dark freckles on lips (fi g 15. 14), oral mucosa, palms and soles, multiple GI polyps (hamartomas), causing obstruction, intussusception, or bleeds. There is a 15-fold risk of developing GI cancer perform colonoscopy (from age 18yrs) and OGD (from age 25yrs) every 3yrs. NB: hamartomas are excessive focal overgrowths of normal cells in an organ composed of the same cell type. Johannes LA Peutz, 18861957 (Dutch physician); Harold J Jeghers, 19041990 (ultrasound physician) Peyronies disease (Penile angulation. ) Pathogenesis: A poorly understood connective tissue disorder most commonly attributed to repetitive microvascular trauma during sexual intercourse, resulting in penile curvature and painful erec t ile dysfunction (in 50%; p230). Preval ence: 39%. Typical age: 40yrs. Associations: Dupuytrens (p698); atheroma; radical prosta tectomy. : Haemangioma. Tests: Ultrasound/magnetic resonance imaging. : Oral Potassium para-aminobenzoate (Potaba), intralesional verapamil, clostridial collagenase, or interferon 2B; topical verapamil 15% gel; iontophoresis with verapamil and dexamethasone. All have various success. 59 Surgery: (If disease stable for 3 months) tunica plication ± penile prostheses. Manage associated depression (seen in 48%). Penile rehabilitation can help (p230). 60 Francois Gigot de la Peyronie, 16781747 (French surgeon) Potts syndrome (Spinal TB. ) Rare in the West, this is usually from an extra-spinal source, eg lungs. Features: Backache, and stiff ness of all back movements. Fever, night sweats, and weight loss occur. Progressive bone destruction leads to vertebral collapse and gibbus (sharply angled spinal curvature). Abscess formation may lead to cord compression, causing paraplegia, and bowel/bladder dysfunction (p466). Xrays: (fi g 15.",
    "Fig 15. 13 Pagets disease of the breast. Fig 15. 12 Telangiectasia in OslerWeberRendu syndrome. Fig 15. 15 TB of axis: soft tiswi R t R h o e p p p e e r r r o, m d C u i l s i c n s U e i i o d n c n a i f v r l f e o r S r o m s potassium m i i t l C l y s O o, P x x 2 r f 0 a e o 0 n s r 5 s d d. , F t s i y i o g n n d, 1 ro 5 s R. m e 1 e e 4 p e n r. o P d i e n u r c io P e r d e a u f l r t o z p m ig J C e m g o e x h n e a t r n a s d - s r b a e u n o t e u r a n o n d p s t a h w e r a r e y i r o l y l r i f n n o g d g r e e w a fe a d l c r is d t p s i l. n a a c T i t r e h h s e e t i r s v e s t e h u r i e e s - Roper, Clinical Skills, 2005, tebra, below the axis peg. with permission from Oxford Courtesy of Dr Ian Maddison, University Press. myweb. lsbu. before meals. uk. Conditions in which Raynauds phenomenon may be exhibited Connective tissue disorders: Syste mic sclerosis, SLE, rheumatoid arthr itis, dermatomyositis/polymyositis. Occupational: Using vibrating tools. Obstructive: Thoracic outlet obstruction, Buergers disease, atheroma. Blood: Thrombocytosis, cold aggl utinin disease, polycyth aemia rubra vera (p366), monoc lonal gammopathies. Drugs: -blockers. Fig 15. 16 Raynauds phenomenon in SLE. Others: Hypothyroidism. Courtesy of the Crookston Collection. 4 Patient information on Raynauds is available from www. raynauds. org. uk. 5 Since Prinzmetal angina is not a demand-induced symptom, but a supply (vasospastic) abnormality, exercise tolerance tests dont help. The most sensitive and specifi c test is IV ergonovine; 50mcg at 5min intervals in a specialist lab until a ve result or 400mcg is given. When positive, the symptoms and ST should be present. Nitroglycerin rapidly reverses the eff ects of ergonovine if refractory spasm occurs. 62 __OOHHCCMM__1100ee. . iinnddbb 770099 0022//0055//22001177 1199: : 0088 710 semordnys suomynopE Refsum disease Phytanic acid accumulates in tissues and serum, due to PHYH or PEX7 gene mutation (recessive). This leads to anosmia (a universal fi nding) and early-onset retinitis pigmentosa, with variable combinations of neuropathy, deafness, ataxia, ichthyosis, and cardiomyopathy. Tests: Plasma phytanic acid. : Restrict foods containing phytanic acid (animal fats, dairy products, green leafy vegetables); plasmapheresis is used for severe symptoms. 63 Sigvald Bernhard Refsum, 19071991 (Norwegian physician) RomanoWard syndrome A dominant mutation in a potassium channel subunit causes long QT syndrome ± episodic VT, VF, torsades, ± sudden death. (Jervell and Lange-Nielsen syn is similar, p702. ) Cesarino Romano, 19242008 (Italian paediatrician); Owen C Ward, b1923 (Irish paediatrician) Rotor syndrome A rare, benign, autosomal recessive disorder. Primary non-haemolytic conjugated hyperbilirubinaemia, with almost normal hepatic histology (no pigmentation, in contrast to DJS, p698). Typically presents in childhood with mild jaundice. Cholescintigraphy reveals an absent Liver.",
    "Typically presents in childhood with mild jaundice. Cholescintigraphy reveals an absent Liver. Arturo Belleza Rotor, 19071988 (Filipino physician) Sister Mary Joseph nodule An umbilical metastatic nodule from an intra-abdominal malignancy (fi g 15. 17). Sister Mary Joseph Dempsey, 18561939 (ultrasound catholic nun Dr William Mayos surgical assistant) Sjögrens syndrome A chronic infl ammatory autoimmune disorder, which may be primary (: 9: 1, onset 4th5th decade) or secondary, associated with connective tissue disease (eg RA, SLE, systemic sclerosis). There is lymphocytic infi ltration and fi brosis of exocrine glands, especially lacrimal and salivary glands. Features: Tear production (dry eyes, keratoconjunctivitis sicca), salivation (xerostomiadry mouth, caries), parotid Edema. Other glands are aff ected causing vaginal dryness, dyspareunia, dry cough, and dysphagia. Systemic signs include polyarthritis/arthralgia, Raynauds, lymphadenopathy, vasculitis, lung, Liver, and Kidney involvement, physical examinationripheral neuropathy, myositis, and Fatigue. It is associated with other autoimmune diseases (eg thyroid disease, autoimmune hepatitis, PBC) and an risk of non-Hodgkins B-cell lymphoma. Tests: Schirmers test measures conjunctival dryness (5mm in 5min is ve). Rose Bengal staining may show keratitis (use a slit-lamp). Anti-Ro (SSA; in 40%) anti-La (SSB; in 26%) antibodies may be present (in pregnancy, these cross the placenta and cause fetal congenital Heart block in 5%). ANA is usually ve (74%); rheumatoid factor is ve in 38%. There may be hypergammaglob ulinaemia. Biopsy shows focal lymphocytic aggregation. : Treat sicca symptoms: eg hypro mellose (artifi cial tears), frequent drinks, Glucose-free pastilles/gum. NSAIDS and hydroxychloroquine are used for arthralgia. Immunosuppressants may be indicated in severe systemic disease. 64 Henrik Conrad Samuel Sjögren, 18991986 (Swedish ophthalmologist) StevensJohnson syndrome A severe form of erythema multiforme (p562), and a variant of toxic epidermal necrolysis. It is caused by a hypersensitivity reaction, usually to drugs (eg salicylates, sulfonamides, penicillin, barbiturates, carbamazepine, phenytoin), but is also seen with infections or cancer. There is ulceration of the skin and mucosal surfaces (see fi g 15. 18). Typical target lesions develop, often on the palms or soles with blistering in the centre. There may be a prodromal phase with fever, malaise, arthralgia, myalgia ± Vomiting and diarrhoea. : Mild disease is usually self-limitingremove any precipitant and give supportive care (eg calamine lotion for the skin). Steroid use is controversialtrials have been variable, so ask a dermatologist and ophthalmologist. IV immunoglobulin has shown benefi t. Plasmapheresis and immunosuppressive agents may have a role. 65 Prognosis: Mortality 5%. May be severe for the fi rst 10d before resolving over 30d. Damage to the eyes may persist and blindness can result. Albert M Stevens 18841945; Frank C Johnson, 18941934 (ultrasound paediatricians) SturgeWeber syndrome (SWS) Essential features: 1 Facial cutaneous capillary malformation (port wine stain; PWS) in the ophthalmic dermatome (V1 ± V2/V3). 2 Clinical signs or radiologic evidence of a leptomeningeal vascular malformation. 75% of patients with unilateral involvement develop seizures by age 1yr (95% if bilateral)due (in part) to the increased metabolic demand of a developing brain in the setting of vascular compromise. Early management of seizures is critical to minimize brain injury. Some patients have severe cognitive and neurologic defi cits beyond simple seizure activity. Screen early for glaucoma (50%). EEG and magnetic resonance imaging help establish early diagnosis and treatment in patients at risk for SWS. Treat the PWS early with pulsed dye laser. William A Sturge, 18501919; Frederick P Weber, 18631962 (British physicians) __OOHHCCMM__1100ee. . iinnddbb 771100 0022//0055//22001177 1199: : 0088 711 semordnys suomynopE Causes of a long QT interval Many conditions and drugs (check BNF) cause a long QT interval. Brugada syndrome (p695) is similar, predisposing to sudden cardiac death. Congenital: RomanoWard syndrome (autosomal dominant).",
    "Brugada syndrome (p695) is similar, predisposing to sudden cardiac death. Congenital: RomanoWard syndrome (autosomal dominant). Jervell and LangeNielsen syndrome (autosomal recessive) with associated deafness (p702). Cardiac: Myocardial infarction or ischaemia; mitral valve prolapse. HIV: May be a direct eff ect of the virus or from protease inhibitors. Metabolic: potassium; Mg2; Ca2; starvation; hypothyroidism; hypothermia. Toxic: Organophosphates. Anti-arrhythmic drugs: Quinidine; amiodarone; procainamide; sotalol. Antimicrobials: Erythromycin; levofl oxacin; pentamidine; halofantrine. Antihistamines: Terfenadine; astemizole. Motility drugs: Domperidone. Psychoactive drugs: Haloperidol; risperidone; tricyclics; SSRIs. Connective tissue diseases: Anti-Ro/SSA antibodies (p552). Herbalism: Ask about Chinese folk remedies (may contain unknown amounts of arsenic). Cocaine, quinine, and artemisinins (and other antimalarials) are examples of herbalism-derived products that can prolong the QT interval. Fig 15. 17 Sister Mary Joseph nodule. Reproduced from Postgraduate Medical Journal, Sister Joseph nodule, J E Clague, 78(917), 174, 2002 with permission from BMJ Publishing Group Ltd. Fig 15. 18 StevensJohnson syndrome. Reproduced from Emberger et al, StevensJohnson syndrome associated with anti-malarial prophylaxis. Clinical Infectious Diseases (2003) 37: 1, with permission from Oxford University Press. __OOHHCCMM__1100ee. . iinnddbb 771111 0022//0055//22001177 1199: : 0088 712 semordnys suomynopE Takayasus arteritis (Aortic arch syndrome; pulseless disease. ) Rare outside of Japan, this systemic vasculitis aff ects the aorta and its major branches. Granulomatous infl ammation causes stenosis, thrombosis, and aneurysms. It often aff ects women aged 2040yrs. Symptoms depend on the arteries involved. The aortic arch is often aff ected, with cerebral, ophthalmological, and upper limb symptoms, eg dizziness, visual changes, weak arm pulses. Systemic features are commoneg fever, weight loss, and malaise. blood pressure is often a feature, due to renal artery stenosis. Complications include aortic valve regurgitation, aortic aneurysm and dissection; ischaemic stroke (blood pressure and thrombus); and ischaemic Heart disease. Diagnosis: ESR and CRP; magnetic resonance imaging/PET allows earlier diagnosis than standard angiography. : Prednisolone (1mg/kg/d PO). Methotrexate or cyclophosphamide have been used in resistant cases. blood pressure control is essential to risk of stroke. Angioplasty ± stenting, or bypass surgery is performed for critical stenosis. Prognosis: 95% survival at 15 years. Mikito Takayasu, 18601938 (Japanese ophthalmologist) Tietzes syndrome (Idiopathic costochondritis. ) Localized Pain/tenderness at the costosternal junction, enhanced by motion, coughing, or sneezing. The 2nd rib is most often aff ected. The diagnostic key is localized tenderness which is marked (fl inches on prodding). Treatment: Simple analgesia, eg NSAIDS. Its importance is that it is a benign cause of what at fi rst seems to be alarming, eg cardiac Pain. In lengthy illness, local steroid injections may be used. Alexander Tietze, 18641927 (German surgeon) Todds palsy Transient neurological defi cit (paresis) after a seizure. There may be face, arm, or leg weakness, aphasia, or gaze palsy, lasting from 30min36h. The aetiology is unclear. Robert Bentley Todd, 18091860 (Irish-born physician) Vincents angina (Necrotizing ulcerative gingivitis. ) Mouth infection with ulcerative gingivitis from Borrelia vincentii (a spirochaete) fusiform bacilli, often aff ecting young smokers with poor oral hygiene. Try amoxicillin 500mg/8h and metronidazole 400mg/8h PO, chlorhex idine mouthwash. Jean Hyacinthe Vincent, 18621950 (French physician) Von HippelLindau syndrome A dominant germline mutation of a tumour suppressor gene. It predisposes to bilateral renal cysts and clear cell renal carcinoma (p320), retinal cerebellar haemangioblastoma, and phaeochromocytoma. See fi gs 15. 19, 15. 20. It may present with visual impairment or cerebellar signs (eg unilateral ataxia). Eugen von Hippel, 18671939 (German ophthalmologist); Arvid Lindau, 18921958 (Swedish pathologist) Von Willebrands disease (VWD) Von Willebrands factor (vWF) has three roles in clotting: 1 To bring platelets into contact with exposed subendothelium. 2 To make platelets bind to each other.",
    "It has a predilection for the upper respiratory tract, lungs, and kidneys. Features: Upper airways disease is common, with nasal obstruction, ulcers, epistaxis, or destruction of the nasal septum causing a characteristic saddle-nose deformity. 6 Sinusitis is often a feature. Renal disease causes rapidly progressive glome rulo nephritis with crescent formation, proteinuria, or haematuria. Pulmonary involvement may cause cough, haemoptysis (severe if pulmonary haemorrhage), or pleuritis. There may also be skin purpura or nodules, peripheral neuropathy, mononeuritis multiplex, arthritis/arthralgia, or ocular involvement, eg keratitis, conjunctivitis, scleritis, episcleritis, uveitis. Tests: CANCA directed against PR3 is most specifi c and raised in the majority of patients (p553). Some patients express PANCA specifi c for MPO. ESR/CRP. Urinalysis should be performed to look for proteinuria or haematuria. If these are present, consider a renal biopsy. CXR may show nodules ± fl uff y infi ltrates of pulmonary haemorrhage. computed tomography may reveal diff use alveolar haemorrhage. Atypical cells from cytology of sputum/BAL can be confused with bronchial carcinoma. 66 Treatment: Depends on the extent of disease. Severe disease (eg biopsy-proven renal disease) should be treated with corticosteroids and cyclophosphamide (or rituximab) to induce remission. Azathioprine and methotrexate are usually used as maintenance. Indications for plasma exchange include patients presenting with severe renal disease (eg Creatinine 500μmol/L) and those with pulmonary haemorrhage. Co-trimoxazole should be given as prophylaxis against Pneumocystis jirovecii and staphylococcal colonization. Friedrich Wegener, 19071990 (German pathologist) Wernickes encephalopathy Thiamine (vitamin B1) defi ciency with a classical triad of 1 confusion 2 ataxia and 3 ophthalmoplegia (nystagmus, lateral rectus, or conjugate gaze palsies). There is inadequate dietary intake, GI absorption, and impaired utilization of thiamine resulting in focal areas of brain damage, including periaqueductal punctate haemorrhages (mechanism unclear). Always consider this diagnosis in alcoholics: it may also present with memory disturbance, hypotension, hypothermia, or reduced consciousness. 67 Recognized causes: Chronic alcoholism, eating disorders, malnutrition, prolonged Vomiting, eg with chemotherapy, GI malignancy, or hyperemesis gravidarum. Diagnosis: Primarily clinical. Red cell transketolase activity is decreased (rarely done). Treatment: Urgent replacement to prevent irreversible Korsakoff s syndrome (p704). Give thiamine (Pabrinex), 2 pairs of Highpotency ampoules IV/IM/8h over 30min for 2d, then 1 pair OD for a further 5d. Oral supplementation (100mg OD) should continue until no longer at risk ( give other B vitamins). Anaphylaxis is rare. If there is coexisting hypoglycaemia (often the case in this group of patients), make sure thiamine is given before glucose, as Wernickes can be precipitated by glucose administration to a thiamine-defi cient patient. Prognosis: Untreated, death occurs in 20%, and Korsakoff s psychosis occurs in 85%a quarter of whom will require long-term institutional care. Karl Wernicke, 18481905 (German neurologist) __OOHHCCMM__1100ee. . iinnddbb 771144 0022//0055//22001177 1199: : 0088 715 semordnys suomynopE Fig 15. 22 Meningococcal sepsis with purpura. 6 Common causes of a saddle-nose deformity are trauma and iatrogenic (eg post-rhinoplasty). Rarer causes (popular with some fi nals examiners): GPA, relapsing polychondritis, syphilis, and leprosy. __OOHHCCMM__1100ee. . iinnddbb 771155 0022//0055//22001177 1199: : 0088 716 semordnys suomynopE Whipples disease A rare disease68 featuring GI malabsorption which usually occurs in middle-aged white males, most commonly in Europe. It is fatal if untreated and is caused by Tropheryma whippelii, which, combined with defective cell-mediated immunity, produces a systemic disease. Features: Often starts insidiously with arthralgia (chronic, migratory, seronegative arthropathy aff ecting mainly peripheral joints). GI symptoms commonly include colicky abdominal Pain, weight loss, steatorrhea/ diarrhoea, which leads to malabsorption (p266). Systemic symptoms such as chronic cough, fever, sweats, lymphadenopathy, and skin hyperpigmentation also occur. Cardiac involvement may lead to endocarditis, which is typically Blood culture negative.",
    "Cardiac involvement may lead to endocarditis, which is typically Blood culture negative. CNS features include a reversible dementia, ophthalmoplegia, and facial myoclonus (if all together, they are highly suggestive)also hypothalamic syndrome (hyperphagia, polydipsia, insomnia). NB: CNS involvement may occur without GI involvement. Tests: Diagnosis requires a High level of clinical suspicion. Jejunal biopsy shows stunted villi. There is deposition of macrophages in the lamina propria-containing granules which stain positive for periodic acidSchiff (PAS). Similar cells may be found in atrial fibrillationfected samples, eg CSF, cardiac valve tissue, lymph nodes, synovial fl uid. The bacteria may be seen within macrophages on electron microscopy. protein-creatinine ratio of bacterial RNA can be performed on serum or tissue. magnetic resonance imaging may demonstrate CNS involvement. : Should include antibiotics which cross the Bloodbrain barrier. Current recommendations: IV ceftriaxone (or penicillinstreptomycin) for 2wks then oral co-trimoxazole for 1 year. Shorter courses risk relapse. A rapid improvement in symptoms usually occurs. George Hoyt Whipple, 18781976 (ultrasound pathologist) Zellweger syndrome (Cerebrohepatorenal syndrome. ) A rare recessive disorder characterized by absent peroxisomes (intracellular organelles required for many cellular activities including lipid metabolism). The syndrome has a similar molecular basis to infantile Refsums syndrome, and although more severe, exhibits comparable biochemical abnormalities (p710). Clinical features include craniofacial abnormalities, severe hypotonia and mental retardation, glaucoma, cataracts, hepatomegaly, and renal cysts. A number of causative PEX gene mutations have been identifi ed. Life expectancy is usually a few months only. Hans Zellweger, 19091990 (ultrasound paediatrician) ZollingerEllison syndrome This is the association of peptic ulcers with a gastrinsecreting adenoma (gastrinoma). Gastrin excites excessive gastric acid production, which may produce multiple ulcers in the duodenum and stomach. The adenoma is usually found in the pancreas, although it may arise in the stomach or duodenum. Most cases are sporadic; 20% are associated with multiple endocrine neoplasia, type 1 (MEN1, p223). 60% are malignant; metastases are found in local lymph nodes and the Liver. Symptoms: Include abdominal Pain and dyspepsia, from the ulcer(s), and chronic diarrhoea due to inactivation of pancreatic enzymes (also causes steatorrhoea) and damage to intestinal mucosa. Incidence: 0. 1% of patients with peptic ulcer disease. Suspect in those with multiple peptic ulcers, ulcers distal to the duodenum, or a family history of peptic ulcers (or of islet cell, pituitary, or parathyroid adenomas). Tests: (fi g 15. 23) Fasting serum gastrin level (1000pg/mL). Measure three fasting levels on diff erent days. Hypoc hlorhydria (reduced acid production, eg in chronic atrophic gastritis) should be excluded as this also causes a raised gastrin level: gastric pH should be 2. The secretin stimulation test is useful in suspected cases with only mildly raised gastrin levels (1001000pg/mL). The adenoma is often small and diffi cult to image; a combination of somatostatin receptor scintigraphy, endoscopic ultrasound, and computed tomography is used to localize and stage the adenoma. OGD evaluates gastric/duodenal ulceration. : High-dose proton pump inhibitors, eg omeprazole: start with 60mg/d and adjust according to response. Measuring intragastric pH helps determine the best dose (aim to keep pH at 27). All gastrinomas have malignant potentialand surgery is better sooner than later (with lymph node clearance generally recommended if 2cm in size). Surgery may be avoided in MEN1, as adenomas are often multiple, and metastatic disease is rare. If well-diff erentiated (G1 and G2) somatostatin analogues may be 1st-line and chemotherapy with streptozotocin (if available) doxorubicin/5-FU is 2nd-line. In G3, etoposide cisplatin is possible. 69 Selective embolization may be done for hepatic metastases. Prognosis: 5yr survival: 80% if single resectable lesion, 20% with hepatic metastases. Screen all patients for MEN1.",
    "6 40 3 months computed tomography head 1. 4 90 7. 5 months computed tomography chest 6. 6 440 3 years computed tomography abdo/pelvis 6. 7 450 3 years Radionuclide studies Lung ventilation 0. 4 30 9 weeks Lung perfusion 1 70 6 months Bone 3 200 1. 4 years PET head 7 460 3. 2 years PET-computed tomography 18 1200 8. 1 years Reproduced from iRefer Making the Best Use of Clinical Radiology, 7th edition, Royal College of Radiologists, 2012. Justifying exposure to ionizing radiation The very nature of ionizing radiation that gives ultrasound vision into the human body also gives it lethal properties. In considering the decision to expose patients to radiation, the clinical benefi ts should outweigh the risks of genetic mutation and cancer induction. These risks can be hard to quantify (and estimates vary wildlyextrapolation of eff ects from doses associated with nuclear explosions are likely unreliable) but even with strict guidelines we still have a tendency to over-exposure in medical practice. Perhaps the best advice is to be certain of the importance of every dose of radiation that you sanction, and mindful of the comparative doses involved (see table 16. 1). The responsibility lies with ultrasound not to rely too heavily on radiology. Dont request examinations to comfort patients (or appease their consultants), to replace images already acquired elsewhere (or lost) simply to avoid medico-legal issues, or when the result will not aff ect management. To give an idea of relative doses, a computed tomography of the abdomen and pelvis gives a typical eff ective dose of 500 times as much radiation as a CXR. This important factor also tells ultrasound about the preference of ultrasound over computed tomography when investigating abdominal and pelvic complaints such as acute appendicitis, especially given the youthful demographics of this diagnosis. Unwitting exposure of the unborn fetus to radiation is inexcusable at any stage of gestationunless the mothers life is in immediate dangerand it is the responsibility of the referring clinician, as well as the radiographer and the radiologist, to ensure that this is avoided. __OOHHCCMM__1100ee. . iinnddbb 771199 0022//0055//22001177 1199: : 0088 720 ygoloidaR The art of the request One of the most nerve-wracking moments that you can encounter as a recently qualifi ed doctor is having to request an investigation from a seasoned consultant radiologist. What information do you need to give? How much? Who do you ask? Put yourself on the other side: what does the radiologist need to know to decide who needs what imaging and when? Keep the following in mind when requesting (never ordering! ) an investigation: Patient details Get the patients name right! Include hospital number and date of birth on all requests. Clinical details Think of your clinical question, what answer are you hoping radiology will provide? It can: Confi rm a suspected diagnosis. Exclude something important (though remember that exclusion is never 100%). Defi ne the extent of a disease. Monitor the progress of a disease. Dont forget to mention pertinent facts that may change the way the investigation is carried out: an agitated or confused patient may need sedation prior to an magnetic resonance imaging of their head. A computed tomography scan on a patient with an acutely raised Creatinine may need to be done without contrast medium. Insertion of a drain on a patient with deranged clotting may need to wait while this is corrected. Include recent Creatinine, hemoglobin, and clotting on the form if appropriate. Dont forget to mention anticoagulants, eg warfarin, LMWH, and aspirin for intervention requests.",
    "Inspiration: There should be 5 to 7 ribs visible anteriorly (or 10 posteriorly). Hyperinfl ation can be abnormal, eg COPD. Poor inspiration can mimic cardiomegaly, as the Heart is usually pulled down (hence elongated) with inspiration, and crowding of vessels at the lung bases can mimic consolidation or collapse. This is common in patients who are acutely unwell, particularly those in Pain or unconscious. Take care in interpreting these images. Exposure: An under-exposed image will be too white and an over-exposed image will be too black. Both cause a loss of defi nition and quality although some compensation can be made with standard viewing software. Position: The entire lung margin should be visible. Trachea Normally central or just to the right. Deviated by collapse (towards the Bloodsion), expansion (away from the lesion), or patient rotation. Mediastinum May be: Widened by mediastinal fat; retrosternal thyroid; aortic aneurysm/unfolding; lymph node enlargement (sarcoidosis, lymphoma, metastases, TB); tumour (thymoma, teratoma); cysts (bronchogenic, pericardial); paravertebral mass (TB). Shifted towards a collapsed lung or away from processes that add volume (eg a large mass or a tension pneumothorax). There are three bulges normally visible on the left border of the mediastinum that help identify pathology if abnormal. From superior to inferior they are: 1 Aortic knuckle. 2 Pulmonary outfl ow tract. 3 Left ventricle. Hila The left hilum is higher than the right or at the same level (not lower); they should be the same size and density. The hila may be: Pulled up or down by fi brosis or collapse. Enlarged by: pulmonary arterial hypertension; bronchogenic calcium; lymph nodes. Sarcoidosis, TB, and lymphoma can give bilateral hilar lymphadenopathy. Calcifi ed due to: sarcoid, past TB; silicosis; histoplasmosis (p408). Heart Normally less than half of the width of the thorax (cardiothoracic ratio 0. 5). ⅓ should lie to the right of the vertebral column, ⅔ to the left. It may appear elongated if the chest is hyperinfl ated (COPD); or enlarged if the image is AP or if there is LV failure (fi g 16. 3), or a pericardial eff usion. Are there calcifi ed valves? Diaphragm The right side is often slightly higher (due to the Liver). Causes of raised hemidiaphragm: Trouble above the diaphragmlung volume loss or infl ammation. Trouble with the diaphragmstroke; phrenic nerve palsy (causes, p504; any mediastinal mass? ). Trouble below the diaphragmhepatomegaly; subphrenic abscess. NB: subpulmonic eff usion (eff usions having a similar contour to the diaphragm without a characteristic meniscus) and diaphragm rupture give apparent elevation. NB: bilateral palsies (polio, muscular dystrophy) cause hypoxia. __OOHHCCMM__1100ee. . iinnddbb 772222 0022//0055//22001177 1199: : 0088 723 ygoloidaR Fig 16. 2 Lower lobe collapse (right lung). The right Heart border is obscured. Volume loss in the right lower zone results in a hyper-expanded right upper lobe that is more radiolucent than the left upper lobe. Courtesy of Dr Edmund Godfrey. Fig 16. 3 Bats wing, peri-hilar pulmonary oedema indicating Heart failure and fl uid overload. Courtesy of Dr Edmund Godfrey. __OOHHCCMM__1100ee. . iinnddbb 772233 0022//0055//22001177 1199: : 0088 724 ygoloidaR Chest X-raypart 2: the lungs The apex of the lower lobe rises up to the 4th rib posteriorly, so it is diffi cult to ascribe the true location of a lobe on a PA image without additional information from a lateral view. It may therefore be better to use the term zone rather than lobe when localizing a lesion. Opacifi cation Lung opacities are described as nodular, reticular (network of fi ne lines, interstitial), or alveolar (fl uff y). A single nodule may be called a space-occupying lesion (SOL).",
    "A single nodule may be called a space-occupying lesion (SOL). Nodules: (If 3cm across, the term pulmonary mass is used instead. ) Neoplasia: metastases (often missed if small), lung cancer, hamartoma, adenoma. Infections: varicella pneumonia, septic emboli, abscess (eg as an SOL), hydatid. Granulomas: miliary TB, sarcoidosis (see GPA, p714), histoplasmosis. Pneumoconioses (except asbestosis), Caplans syndrome (p696). Reticular opacifi cation: Lung parenchymal changes. Acute interstitial oedema. Infection: acute (viral, bacterial), chronic (TB, histoplasmosis). Fibrosis: usual interstitial pneumonia (UIP), non-specifi c interstitial pneumonia (NSIP), drugs (eg methotrexate, bleomycin, crack cocaine), connective tissue disorders (rheumatoid arthritisp546, GPAp714, SLE, PAN, systemic sclerosisp552, sarcoidosis), industrial lung diseases (silicosis, asbestosis). Malignancy (lymphangitis carcinomatosa). Alveolar opacifi cation: Airspace opacifi cation, can be due to any material fi lling the alveoli: Puspneumonia. Bloodhaemorrhage, DIC (p352). WaterHeart, renal, or Liver failure (p302, p274), ARDS (p186), smoke inhalation (p847), drugs (heroin), O 2 toxicity, near drowning (OHCS p768). Cellslymphoma, adenocarcinoma. Proteinalveolar proteinosis, ARDS, fat emboli (7d post fracture). Ring opacities: Either airways seen end-on (bronchitis; bronchiectasis) or cavitating lesions, eg abscess (bacterial, fungal, amoebic), tumour, or pulmonary infarct (wedge-shaped with a pleural base). Linear opacities: Septal lines (Kerley B lines, ie interlobular lymphatics seen with fl uid, tumour, or dusts); atelectasis; pleural plaques (asbestos exposure). White-out of whole hemithorax: (fi g 16. 4) Pneumonia, large pleural eff usion, ARDS, post-pneumonectomy. Gas outside the lungs Check for a pneumothorax (hard to spot if apical or in a supine image, can you see vascular markings right out to the periphery? ), surgical emphysema (trauma, iatrogenic), and gas under the diaphragm (surgery, perforated viscus, trauma). Pneumomediastinum: Air tracks along mediastinum, into the neck. Due to rupture of alveolar wall (eg asthma or pulmonary barotrauma) or bronchial or oesophageal trauma (can be iatrogenic, eg from endoscope). Pneumopericardium: Rare (usually iatrogenic). Bones Check the clavicles for fracture, ribs for fractures and lesions (eg metastases), vertebral column for degenerative disease, collapse, or destruction, and shoulders for dislocation, fracture, and arthritis. An apparently normal CXR? Check for tracheal compression, absent breast shadow (mastectomy), double left Heart border (left lower lobe collapse, fi g 16. 5), fl uid level behind the Heart (hiatus hernia, achalasia), and paravertebral abscess (TB). __OOHHCCMM__1100ee. . iinnddbb 772244 0022//0055//22001177 1199: : 0088 725 ygoloidaR Fig 16. 4 Opacifi cation of the left hemithorax from consolidation. Courtesy of Dr Edmund Godfrey. Fig 16. 5 Large right-sided pneumothorax; note the trachea remains central, suggesting this is a simple pneumothorax, not a tension pneumothorax. Courtesy of Dr Edmund Godfrey. __OOHHCCMM__1100ee. . iinnddbb 772255 0022//0055//22001177 1199: : 0088 726 ygoloidaR Chest X-raypart 3 Confi rming the position of various tubes, lines, and leads on a CXR can be a daunting task, as incorrect positioning can have deadly consequences: an NG tube which is misplaced can cause aspiration pneumonia, or a poorly positioned central venous catheter can lead to fatal arrhythmias. However, this can be a straightforward task if you recall some basic anatomy (fi gs 16. 6, 16. 7; table 16. 2). If you are unsure, always ask a senior. Table 16.",
    "6, 16. 7; table 16. 2). If you are unsure, always ask a senior. Table 16. 2 Radiological confi rmation of device placement Line/tube/lead Correct position for tip(s) central venous catheter (p774) In the SVC or brachiocephalic vein PICC In the SVC or brachiocephalic vein Tunnelled line, eg Hickman At the junction of the SVC and right atrium Endotracheal 37 cm above the carina (in adult) Nasogastric (p759) 10cm beyond the gastro-oesophageal junction Chest drain (p766) In the pleural space tracking either up (for pneumothorax) or down (for eff usion) Cardiac pacemaker/tempoAtrial leadin the right appendage rary pacing wire (p776) Ventricular leadin the apex of the right ventricle Normal anatomy The SVC begins at the right 1st anterior intercostal space. The right atrium lies at the level of the 3rd intercostal space. The carina should be visible at the level of T5T7 thoracic vertebrae. The right atrial appendage sits at the level of the 3rd intercostal space. Common bleeps from nursing staff 1 Central line not aspirating: Is the tip in the right place (see earlier in topic) or has it gone up into the internal jugular, too far in (sitting against the tricuspid valve, does the patient have an arrhythmia? ) or not far enough in (sitting against a venous valve)? Is the tip kinked, suggesting it may be in a side vessel or against the vessel wall? If the line looks appropriately positioned, consider fl ushing gently, could the line be blocked? 2 Patient not ventilating well: Is the ET tube down the right main bronchus (causes left lung collapse, or rarely right pneumothorax)? Retract tube to correct position (see earlier in topic). Is the ET tube blocked? Most have a secondary port allowing ventilation even if the main hole is blocked, get anaesthetic assistance! 3 Chest drain not bubbling/swinging: Is it correctly positioned (see earlier in topic)if not in the pleural space, it cannot drain the air/fl uid. Common problems include sitting in the soft tissue of the chest wall, or sitting above the eff usion, below the pneumothorax, or in the oblique fi ssure. Is it blocked? If draining an eff usion and correctly positioned, consider gently fl ushing with 10mL of sterile saline, then aspirating. If not successful, obtain senior advice. Has the eff usion/pneumothorax resolved? Pneumothoraces can rapidly resolve with a correctly positioned drain. 4 Unable to aspirate from NG tube: Is NG tube not far enough in/coiled in oesophagus? Tip is radio-opaque and should be visible below the diaphragm, if it is coiled it may lie in the pharynx or anywhere along the mediastinum. Is NG tube passing down the trachea and into the bronchus? The oesophagus is (generally speaking) a straight vertical line, if the tube veers off to left or right before it goes below the diaphragm, assume it is in the bronchus and replace it. __OOHHCCMM__1100ee. . iinnddbb 772266 0022//0055//22001177 1199: : 0088 727 ygoloidaR Fig 16. 6 Image from ICU showing ET tube, central venous catheter, and NG tube in situ with ECG leads placed across the chest. Image courtesy of Dr Elen Thomson, Leeds Teaching Hospitals. Fig 16. 7 Knowing where lines and tubes should be placed is an essential skill. An ET tube (orange) should sit 37cm above the carina; this one is slightly High. The tip of the central venous catheter (red, here a right internal jugular line) should lie in the SVC, as seen here, or just in the right atrium. The tip of the NG tube (green) must be seen below the diaphragm to ensure it is placed in the oesophagus, not the trachea.",
    "Other soft tissues Look for size/position of: Liver, spleen, and bladder. A big Liver will push bowel to the left side of the abdomen. An enlarged spleen displaces bowel and stomach bubble to the right. A big bladder elevates these. Medical devices Double-J and biliary stents, nephrostomy and gastrostomy tubes, intrauterine devices, laparoscopic clips, and peritoneal Dialysis catheters can be seen. Bones and joints Plain AXR is not ideal, but there may be important abnormalities. In the lumbar spine, look for scoliosis and degeneration (osteophytes, joint space narrowing) as well as bone metastases or sacroiliitis. 1 Dont get confused by other calcifi cationseg phleboliths: harmless calcifi cations found in the perivesical veins (rounded with a radiolucent centre). __OOHHCCMM__1100ee. . iinnddbb 772288 0022//0055//22001177 1199: : 0088 729 ygoloidaR Fig 16. 8 Multiple dilated air-fi lled loops of large and small bowel. This pattern is seen in ileus. Courtesy of Norwich Radiology Department. Fig 16. 9 Abdominal image showing toxic megacolon associated with ulcerative colitis, note colon wall thickening and loss of mucosal folds. Courtesy of Dr Edmund Godfrey. __OOHHCCMM__1100ee. . iinnddbb 772299 0022//0055//22001177 1199: : 0088 730 ygoloidaR Computed tomography (computed tomography) Can give whole-body images in under one breath (thanks to continuous, helical data acquisition). Within a single slice (eg 0. 5 or 5mm thick), computed tomography records the attenuation (loss of energy from, eg absorption or refl ection) of diff erent tissues to ionizing radiation and calculates a mean value for a given volume of tissue (a voxel). This value is represented in greyscale as a single point, called a pixel, in the fi nal 2D image (or 3D reconstructionfi g 16. 13). The greyscale of the pixel is measured on the Hounsfi eld scale (see fi g 16. 10) relative to the attenuation of Water, 0 Hounsfi eld units (HU), and air, Ω1000HU. The human eye and display systems have a limited greyscale range, so diff erent settings (levels and windows) are used to focus on diff erences in attenuation in ranges typical for tissues of diff erent density, eg bone or lung (fi g 16. 11). CTS are responsible for up to 40% of iatrogenic radiation in High-use settings, which could account for 1% of all cancers: always balance benefi ts of computed tomography vs other modalities with less or no radiation (ultrasound; magnetic resonance imaging), particularly in the young or in those with chronic disease likely to undergo multiple imaging investigations. Discuss with a radiologistthere are several technical aspects of imaging that can limit radiation dose whilst still providing clinically useful information. Imaging of choice for Staging and monitoring most malignant disease. Intracranial pathology, eg stroke, trauma, ICP, and space-occupying lesions. Trauma. Pre-operative assessment of complex masses. Assessment of acute abdomen (fi gs 16. 15, 16. 16). NB ultrasound increasingly used (p736). Following abdominal surgery. Contrast medium (p748) Enhance anatomical detail by use of a Highor Low (Water)-attenuating medium to fi ll the lumen of a structure. Give IV to image vascular anatomy (fi g 16. 12) and vascular structures (including highly perfused tumours). Images acquired at diff erent times (phases) after injection will show the agent in arterial or venous structures or during washout (clearing). Perfusion computed tomography maps cerebral Blood fl ow by acquiring serial images after contrast administration then combines these into a colour-coded image of perfusion times (fi g 16. 14). Ensure IV cannulae secure and suffi cient gauge to allow for rapid injection of agent as bolus extravasation of contrast can cause signifi cant tissue damage. Give PO eg 112h before imaging bowel. Give PR for examining distal colonic lumen.",
    "Give PO eg 112h before imaging bowel. Give PR for examining distal colonic lumen. Contrast-enhanced CTS may include a pre-contrast series. Unenhanced imaging alone reduces radiation exposure and may be adequate for images of the brain, spine, lung, and musculoskeletal system or necessary in those with renal failure (contrast is nephrotoxic). Streak artefact Remember that the computed tomography slice image is a matrix representation of the attenuation produced by rotating around the patient. High-attenuation items such as metal fi llings, clips, and prostheses (and even bone) can cause interference. computed tomography combined with PET (See p739. ) Combines the anatomical detail of computed tomography with the metabolic information of PET, to aid assessment of, eg neoplastic lesions. Radiation doses are much higher than computed tomography alone. __OOHHCCMM__1100ee. . iinnddbb 773300 0022//0055//22001177 1199: : 0088 731 ygoloidaR Fig 16. 10 The Hounsfi eld scale. Courtesy of Dr T Turmezei. Fig 16. 11 Axial High-resolution computed tomography chest on a lung window algorithm; note solitary lesion in the right lung (in this case, from GPA). Courtesy of Norwich Radiology Dept. Fig 16. 12 Axial computed tomography of the abdomen after IV contrast (arterial phase). The tortuous splenic artery is enhanced (arrow)so is the aorta, but not the inferior vena cava (compare to Water in the stomach). Courtesy of Norwich Radiology Dept. Fig 16. 13 Surface rendered 3D computed tomography reconstruction of the pelvis. The posterior aspect of the right acetabulum is fractured. The right femur has been digitally removed for better viewing. Courtesy of Norwich Radiology Dept. Fig 16. 14 Cerebral perfusion computed tomography showing ischaemia around the Sylvian fi ssure (arrow). Courtesy of Dr C Cousens. __OOHHCCMM__1100ee. . iinnddbb 773311 0022//0055//22001177 1199: : 0088 732 ygoloidaR computed tomography images of two patients with acute abdominal Pain Fig 16. 15 The history was of central abdominal Pain with a non-peritonitic abdomen. The computed tomography shows a leaking AAA. Under fl uoroscopic screening, this can be repaired using stents, inserted via femoral arterial puncture and deployed in the aneurysm (p654). This kind of endovascular aneurysm repair (EVAR) is commonly used in the treatment of leaking AAA as well as elective repair of intact but enlarging aneurysms. The changing roles of surgeons and computed tomography in the acutely unwell In the days when general surgeons did their rounds towards the end of an on-call day, there would be wards of patients with undiagnosed abdominal Pain having drip-and-suck regimens (IVI and NGT) while awaiting improvement or a change in their clinical condition that revealed the need for surgery. On opening up, the surgeon would try to deal with whatever pathology was found. With increased subspecialization and accurate emergency imaging (computed tomography and ultrasound), patients are now matched to a team best equipped to deal with their condition. In this context, drip-and-suck is on the ebb, giving way to imaging, early intervention, rapid discharge, or onward referral. With increasing pressures to safeguard surgical beds for elective cases and on junior surgeons to polish their surgical logbooks in decreased training hours, can come attempts to defl ect away from surgical teams the care of patients in whom imaging or clinical circumstances suggest no current requirement for an operation. But is this always appropriate? Do we expect on-call surgeons to be practitioners of medicine, assessing and managing patients with surgical pathology, even if a trip to the operating theatre is not currently called for, or simply technicians restricted to cutting? __OOHHCCMM__1100ee. . iinnddbb 773322 0022//0055//22001177 1199: : 0088 733 ygoloidaR Fig 16. 16 Triple-phase computed tomography abdomen, cropped to show the pancreas.",
    "iinnddbb 773322 0022//0055//22001177 1199: : 0088 733 ygoloidaR Fig 16. 16 Triple-phase computed tomography abdomen, cropped to show the pancreas. Top panelunenhanced image, middle panelarterial phase of contrast medium to look for pseudocysts and parenchymal enhancement, bottom panelportal venous phase to look at veins. The history here was also central abdominal Pain with a non-peritonitic abdomen. The computed tomography shows an enlarged pancreatic head with fat stranding around the duodenopancreatic groove (groove pancreatitis), and two small areas of fl uid attenuation posteriorly, likely to be pseudocysts. Top panel courtesy of Dr Edmund Godfrey. __OOHHCCMM__1100ee. . iinnddbb 773333 0022//0055//22001177 1199: : 0088 734 ygoloidaR Magnetic resonance imaging (magnetic resonance imaging) 1 A large proportion of the human body is fat or Water (80%). 2 Fat and Water contain a large number of hydrogen nuclei (unpaired protons). 3 The spin of a positively charged hydrogen nucleus gives it magnetic polarity. Thus Placing the human body in a magnetic fi eld aligns its hydrogen nuclei either with (parallel) or against (anti-parallel) the fi eld. A radiofrequency (RF) pulse at the resonant frequency fl ips a few nuclei away from their original alignment by an angle depending on the amount of energy they absorb. When the RF pulse stops, the nuclei fl ip back (or relax) into their original alignment, emitting the energy (called an echo) that was absorbed from the RF pulse. Measuring and plotting the energy of the returning signal according to location (provided the nuclei havent moved) gives a picture of fat, tissue, and Water as distributed throughout the body. The hydrogen nuclei in fl owing Blood move after receiving the RF pulses. The echo is not detected, and so the vessel lumen appears black (fl ow void). Rather than radiodensity or attenuation, the correct descriptive terminology for the greyscale seen in magnetic resonance imaging is signal intensity: High signal appears white and Low signal black (see table 16. 4). Weighting is a quality of magnetic resonance imaging that is dependent on the time between the RF pulses (repetition time, TR) and the time between an RF pulse and the echo (echo time, TE). MR images are most commonly T1-weighted (Good for visualizing anatomy) or T2-weighted (Good for visualizing disease) but can also be a mixture of both, called proton density (peritoneal dialysis) weighting. FLAIR sequences produce heavily T2-weighted images. A Good way to determine the weighting of an MR image is to look for Watereg in the aqueous humour of the eye, CSF, or synovial fl uid (see table 16. 4; fi g 16. 17). Table 16. 4 magnetic resonance imaging sequence characteristics T1-weighted T2-weighted TR Short (1000ms) Long (2000ms) TE Short (30ms) Long (80ms) Low Water Bone signal Flowing hemoglobin Flowing hemoglobin Fresh hemoglobin DeoxyHb Haemosiderin Haemosiderin Melanin High Bone marrow Water signal Fat Cholesterol Cholesterol Fresh hemoglobin Gadolinium (p762) MetHb MetHb Fig 16. 17 T1-weighted magnetic resonance imaging of the hips. Normal Advantages magnetic resonance imagings great bonus is that it adult bone marrow is High signal due to fat; note also Low signal from Urine in the bladder. does not involve ionizing radiation. It has Courtesy of Norwich Radiology Department no known long-term adverse eff ects. It is excellent for imaging soft tissues (Waterand hence proton-dense) and is preferred over computed tomography for musculoskeletal disorders and for many intracranial, head, and neck pathologies (fi gs 16. 1816. 20). Multiplanar acquisition of images can provide multiple views and 3D reconstruction from one scan. MR angiography is also excellent for reconstructing vascular anatomy.",
    "Normal perfusion excludes physical examination but ventilation component requires a normal CXR for comparison (fi gs 16. 25, 16. 26). Due to the large number of indeterminate scans VQ is considered inferior to CTPA for the investigation of physical examination except in pregnancy (see p192). Fig 16. 25 Ventilation scintigram. Fig 16. 26 Perfusion scintigram Fig 16. 27 Bone Courtesy of Norwich Radiology showing mismatches with fi g 16. 25. scintigram showing Department. Courtesy of Norwich Radiology metastases. Department. Courtesy of Norwich Radiology Department. Bone scintigraphy 99mTc-labelled bisphosphonates are readily taken up by bone, and concentrate in areas of pathology, eg tumours, fractures. It is much more sensitive in identifying metastases than X-ray, where lesions may not appear until 50% of bone matrix has been destroyed (fi g 16. 27). Thyroid disease TcO is used for diff erentiating Graves, toxic multinodular goitre, 4 and subacute thyroiditis (fi g 13. 22, p601) as well as identifying ectopic tissue, functioning nodules, and residual/recurrent thyroid tissue after surgery. 15% of cold (non-functioning) nodules are malignant. Hot nodules are often toxic adenomas. Phaeochromocytoma Iodine-123 (123I) meta-iodobenzylguanidine (MIBG) is taken up by sympathetic tissues, and indicates functioning, ectopic, and metastatic adrenal medullary (other neural crest) tumours. 131I-MIBG is also used for treatment. Hyperparathyroidism 99mTc-methoxyisobutyl isonitrile (MIBI) scans can detect parathyroid adenomas. Haemorrhage Red cells are removed from the patient and labelled with 99mTc, then reinjected to allow identifi cation of a bleeding point. Used in both acute (after endoscopy and computed tomography) and chronic GI bleeding, red cell scans are more sensitive than computed tomography angiography and useful in intermittent bleeding, although localization can be challenging. __OOHHCCMM__1100ee. . iinnddbb 773388 0022//0055//22001177 1199: : 0088 739 ygoloidaR Renal function Chromium-51 (51Cr) European Dialysis and Transplant Association or diethylenetriamine pentaacetic acid scan (99mTc, p669) is used to assess glomerular filtration rate. 99mTcmercapto-acetyltriglycine (mercaptoacetyltriglycine scan) technique assesses relative (leftright) renal function and renal transit time (eg in renovascular disease). 99mTc-dimercaptosuccinic acid (DMSA) scanning (fi g 16. 28) is the gold standard for evaluation of renal scarring that occurs, eg in refl ux nephropathy. Positron emission tomography (PET) One of the key investigations in malignancy, but also has a wide range of other uses. If the tracer Fig 16. 28 DMS showing relative renal chosen is 18F-fl uorodeoxyglucose (FDG), a short function of each Kidney. half-life glucose analogue, it becomes concenCourtesy of Norwich Radiology Department. trated in metabolically active tissues. FDG decays rapidly to produce a positron that, after travelling a few millimetres through tissue, annihilates with an electron to produce a pair of High-energy photons (gamma rays), which PET detects. Normal High uptake of FDG occurs in brain, Liver, Kidney, bladder, larynx, and lymphoid tissue of pharynx and must be considered when assessing images. Neoplasms have High uptake of FDG with hotspots suggesting primary disease or metastases. Since infl ammatory lesions will also show High uptake, there is a risk of false-positive results (eg sarcoid, TB); diagnosis must be confi rmed with histology of suspicious lesions. PET allows staging of many solid organ malignancies (lung, melanoma, oesophageal) as well as lymphomas, and is particularly useful for planning of radiotherapy and surgery for both primary disease and metastases. PET can also be used to image occult sources of infection. PET can be combined with computed tomography or magnetic resonance imaging to provide High-quality images combining anatomy with physiology. A range of alternative tracers are now entering clinical use with radiotracers conjugated to other tissue-specifi c substrates (eg 11C-labelled metomidate to detect tumors of adrenocortical origin, somatostatin tracers in neuroendocrine tumours, and amyloid tracers in Alzheimers disease).",
    "Single photon emission computed tomography (SPECT) Similar to PET but rather than using positron emission, it uses a radioisotope-labelled molecule as per conventional nuclear imaging, but with two gamma cameras for detection. The images produced are of lower resolution than PET but the isotopes used are longer lived and more easily available. Examples include myocardial perfusion scanning (p741). __OOHHCCMM__1100ee. . iinnddbb 773399 0022//0055//22001177 1199: : 0088 740 ygoloidaR Cardiovascular imaging computed tomography Cardiac computed tomography: Modern computed tomography scanners can acquire images with suffi cient speed and resolution to image coronary arteries and exclude signifi cant disease with a negative predictive value of 9799%. It can also visualize CABG patency, provide coronary artery Ca2 scoring (a risk factor for coronary artery disease, p117), demonstrate cardiac anatomy including congenital anomalies, and estimate ventricular function. Vascular computed tomography: Has become routine in emergency assessment of suspected dissections, ruptured aneurysms, and arterial and venous thromboses (fi g 16. 29). computed tomography angiography has overtaken invasive angiography in the assessment of many Fig 16. 29 computed tomography angiogram showing type A (ascendconditions such as stable angina ing) aortic dissection with haemopericardium. and renal artery stenosis. Courtesy of Dr C Cousins. Catheter angiography Wherever intervention may be required, contrast studies such as angiography provide both image clarity and the possibility of proceeding to intervention, eg angioplasty or stenting of vessels, endovascular repair of aneurysms, clipping/coiling of aneurysms (see p746). Remember that these have a High burden of both radiation and contrast medium, so check renal function before requesting. Complications include those of arterial puncture (bleeding, infection, thrombosis, dissection, pseudoaneurysm formation) plus cholesterol emboli, thromboemboli, and vasospasm. magnetic resonance imaging Cardiac magnetic resonance imaging using ECG-gating to acquire the imaging data and relate it to the position in the cardiac cycle (best when the patient is in sinus rhythm) can reduce movement artefact and lead to excellent resolution images for functional assessment. This, coupled with a lack of radiation, makes it ideal for the assessment of a wide range of structural and functional Heart diseases. Flow velocities can be measured and, because the fl ow is proportional to the Hypertension diff erences, degrees of stenosis and regurgitation across Heart valves can be calculated. Myocardial infarction, perfusion, and viability can also be imaged with the use of IV gadolinium contrast (p748). Vascular magnetic resonance imaging is used to limit radiation exposure where multiple investigations may be required over a long time period, eg follow-up of intracranial aneurysm coiling, aortic root size in a young patient with Marfans syndrome (p706), or Takayasus arteritis (p712). Ultrasound Non-invasive, relatively Low cost, and with no radiation, ultrasound is excellent for assessing the Heart and vasculature particularly in acute settings where the test can be performed at the bedside. Cardiac ultrasound (echocardiography) evaluates myocardial and valvular anatomy and function (p110). The use of exercise or pharmacological agents for stress echocardiography can permit more detailed functional assessment. Vascular ultrasound Doppler ultrasonography is widely used for detection of thrombotic disease (eg DVT p578, portal vein thrombosis p276) and carotid atherosclerosis (p472). Multiple gated acquisition (MUGA) scanning is a non-invasive way to measure left ventricle ejection fraction. After injection of 99mTc-labelled RBCS, a dynamic image of the left ventricle is obtained for a few hundred heartbeats by gamma camera. Since estimates of LVEF show less inter-operator variation than with echocardiograpy, uses include the detailed serial assessment of LVEF in patients undergoing cardiotoxic chemotherapy (eg anthracyclines, trastuzumab). __OOHHCCMM__1100ee. . iinnddbb 774400 0022//0055//22001177 1199: : 0088 741 ygoloidaR Myocardial perfusion imaging A non-invasive method of assessing regional myocardial Blood fl ow and the cellular integrity of myocytes.",
    "The technique uses radionuclide tracers which cross the myocyte membrane and are trapped intracellularly. Thallium-201 (201Tl), a potassium analogue, is distributed via regional myocardial Blood fl ow and requires cellular integrity for uptake. Newer technetium-99 (99Tc)-based agents are similar to 201Tl but have improved imaging characteristics, and can be used to assess myocardial perfusion and LV performance in the same study (fi g 16. 30). Myocardial territories supplied by unobstructed coronary vessels have normal perfusion whereas regions supplied by stenosed coronary vessels have poorer relative perfusion, a diff erence that is accentuated by exercise. For this reason, exercise tests are used in conjunction with radionuclide imaging to identify areas at risk of ischaemia/infarction. Exercise scans are compared with resting views: reversible (ischaemia) or fi xed defects (infarct) can be seen and the coronary artery involved reliably predicted. Drugs (eg adenosine, dobutamine, and dipyridamole) can also be used to induce perfusion diff erences between normal and underperfused tissues. Myocardial perfusion imaging adds information in patients presenting with acute myocardial infarction (to determine the amount of myocardium salvaged by thrombolysis) and in diagnosing acute chest Pain in those without classical ECG changes (to defi ne the presence of signifi cant perfusion defects). Fig 16. 30 99Tc perfusion study showing perfusion defect in the left ventricle anterior and lateral walls at stress which is partially reversible (diff erence between stress and rest images). This study is Good for small vessel disease such as in Diabetes; computed tomography and coronary angiography do not show small vessel disease well. Courtesy of Dr C Cousins. __OOHHCCMM__1100ee. . iinnddbb 774411 0022//0055//22001177 1199: : 0088 742 ygoloidaR Gastrointestinal imaging Ultrasound Widely used for imaging all intra-abdominal organs, including an emerging role in small bowel imaging (though overlying bowel gas can cast acoustic shadows). ultrasound is the 1st-line imaging choice for abnormal LFTS, jaundice, hepatomegaly, renal dysfunction, and abdominal masses. Ensure the patient is nil by mouth for 4 hours beforehand (aids gallbladder fi lling). Pelvic ultrasound needs a full bladder (consider clamping the catheter if appropriate). ultrasound may also guide diagnostic biopsy and therapeutic aspiration of cysts or collections. computed tomography plays an important role in the investigation of acute abdominal Pain (see pp7303). It is unparalleled in the detection of free gas and intra-abdominal collections, and allows Good visualization of the colon and retroperitoneal areas. Oral or IV contrast medium enhances defi nition (p730). The big disadvantage is the radiation dose. computed tomography colonography (CTC; fi g 16. 31) uses rectal air or CO 2 insuffl ation, usually coupled with an oral stool tagging agent to visualize the colonic mucosa in those unfi t for endoscopic evaluation or in whom endoscopic evaluation has failed (eg in a stenosing tumour, where it can be used to assess the proximal colon and allow assessment of Liver and nodal metastases at the same time). A negative test can be regarded as defi nitive but if polyps or masses are seen then patients will usually require a colonoscopy. Wireless capsule endoscopy: See p248. Magnetic resonance imaging (magnetic resonance imaging) This gives excellent soft tissue imaging, giving it an important role in imaging the Liver, biliary system, pancreas, and pancreatic duct (MRCPmagnetic resonance cholangiopancreatography; fi g 16. 32). As well as assessing potential malignant disease, MRCP is the imaging modality of choice for detection of common bile duct stones that can be missed on ultrasound.",
    "magnetic resonance imaging performed after fl uid loading of the small bowel (fl uid delivered orallymagnetic resonance imaging enterography; fl uid delivered via nasoduodenal tubemagnetic resonance imaging enteroclysis) permits assessment of small bowel infl ammation (eg Crohns) and lesions that can be challenging to reach with conventional endoscopy. Endoscopic retrograde cholangiopancreatography (ERCP; fi g 16. 33) Indications: No longer routinely used for diagnosis, it still has a signifi cant therapeutic role: sphincterotomy for common bile duct stones; stenting of benign or malignant strictures and obtaining brushings to diagnose the nature of a stricture. Method: A catheter is advanced from a side-viewing duodenoscope via the ampulla into the common bile duct. Contrast medium is injected and images taken to show lesions in the biliary tree and pancreatic ducts. Complications: Pancreatitis; bleeding; cholangitis; perforation. Mortality 0. 2% overall; 0. 4% if performing stone removal. Endoscopic ultrasound (EUS; see p736. ) Commonly used in diagnosis of upper GI abnormalities, and is excellent for diagnosis of oesophageal, gastric, and pancreatic cancers. It allows staging by assessing depth of invasion, as well as histological diagnosis by biopsy of lesions. Contrast studies (fi g 16. 34) These can help in dysphagia (p250) and assessing integrity of anastomoses post-op. Real-time fl uoroscopic imaging studies assess swallowing function. Barium gives better contrast but iodine-based Water-soluble contrast medium is used if there is a concern of perforation. Contrast enemas are increasingly obsolete and now used to exclude a leak following a Low anterior resection, for proctograms, and not much else. __OOHHCCMM__1100ee. . iinnddbb 774422 0022//0055//22001177 1199: : 0088 743 ygoloidaR Fig 16. 31 Axial computed tomography colonogram: mural thickening (? ascending colon tumour). Courtesy of Norwich Radiology Department. Fig 16. 32 MRCP of the biliary system showing: left hepatic duct (yellow arrow); multiple gallstones in the gallbladder (black arrow); common bile duct (white arrow); pancreatic duct (red arrow); duodenum (green arrow). Courtesy of Norwich Radiology Department. Fig 16. 33 The ERCP shows a dilated common bile duct. The multiple fi lling defects are calculi within and obstructing the duct. Courtesy of Norwich Radiology Department. Fig 16. 34 Barium swallow: note corkscrew appearance of the oesophagus found in some motility disorders. Courtesy of Norwich Radiology Department. __OOHHCCMM__1100ee. . iinnddbb 774433 0022//0055//22001177 1199: : 0088 744 ygoloidaR Genitourinary imaging Ultrasound Imaging modality of choice for genitourinary problems. Can be used to assess: Kidneys: Renal sizesmall in chronic Kidney disease, large in renal masses, cysts, hypertrophy if other Kidney missing, polycystic Kidney disease (fi g 16. 35), and rarities (eg amyloidosis, p370). Hydronephrosis, which may indicate ureteric obstruction or refl ux (fi g 13. 49, p641). Perinephric collections (trauma, post-biopsy). Renal perfusion (assessment of renovascular disease: Doppler ultrasound of renal arteries). Transplanted kidneys (collections, obstruction, perfusion). Lower urinary tract: Bladder volume: useful in assessment of the need to catheterize (see p640) or for assessment of adequacy of bladder emptying (post-micturition residual volume). Prostate: transrectal ultrasound enables ultrasound-guided biopsy of focal lesions. NB: prostate size does not correlate with symptoms. Other: Ovarian cysts, size, infections (pyosalpinx), uterine fi broids and other masses. Testicular masses, hydrocele, varicocele. Advantages: Fast; cheap; independent of renal function; no IV contrast or radiation risk. Disadvantages: Intraluminal masses (transitional cell calcium) in the upper tracts may not be seen; not a functional study; only suggests obstruction if there is dilatation of the collecting system (95% of obstructed kidneys) and so can miss obstruction from, eg retroperitoneal fi brosis. computed tomography (fi g 16. 36) First choice in renal colic.",
    "computed tomography (fi g 16. 36) First choice in renal colic. Performed without intravenous contrast so safe in renal impairment; such unenhanced images miss 2% of stones, but can show other pathologies. With IV contrast, computed tomography can delineate masses (cystic or solid, contrast enhancement, calcifi cation, local/distant extension, renal vein involvement); assess renal trauma (presence of two kidneys; haemorrhage; devascularization; laceration; Urine leak); and show retroperitoneal lesions. computed tomography has all but replaced intravenous urography and the radiation dose is similar. Plain abdominal X-ray Can be used to look at the kidneys, the paths of the ureters, and bladder. However, in practice it is only useful for monitoring known renal calculi. Contrast studies Retrograde pyelography/ureterograms are Good at showing pelvi-calyceal, ureteric anatomy, and transitional cell carcinomas (TCCS). Contrast medium is injected via a ureteric catheter. With the advent of cystoscopy, allowing immediate intervention, these are rarely done in isolation. However, contrast medium is routinely used in cystoscopic placement of retrograde stents for obstruction. Percutaneous nephrostomy. Used in obstruction to decompress the renal pelvis, which is punctured under local anaesthetic with imaging guidance. Images are obtained following contrast injection (antegrade pyelogram). A nephrostomy tube is then placed to allow decompression, sometimes followed by an antegrade stent if there is no easily treatable cause of obstruction. Renal arteriography (fi g 16. 37) Therapeutic indications: angioplasty; stenting; embolization (bleeding tumour, trauma, AV malformation). Magnetic resonance imaging (magnetic resonance imaging) Soft tissue resolution can help clarify equivocal computed tomography fi ndings. Magnetic resonance angiography (MRA) helps image renal artery anatomy/stenosis (fi g 16. 38) and is also used in the assessment of potential live donors for Kidney transplant, as well as to monitor patients following embolization of tumours, arteriovenous malformations, and aneurysms. Radionuclide imaging See p738. __OOHHCCMM__1100ee. . iinnddbb 774444 0022//0055//22001177 1199: : 0088 745 ygoloidaR Fig 16. 35 Ultrasound of the Kidney showing multiple simple cysts. Fig 16. 36 3D reconstruction of computed tomography urogram showing normal appearances of both kidneys, ureters, and bladder. Courtesy of Dr Edmund Godfrey. Fig 16. 37 Renal artery digital subtraction angiogram (DSA; DSA is the fi nal arbiter of renal artery stenosis). It is possible to tell that this is a DSA as no other structure has any defi nition or contrast in the image. There is, however, some interference from overlying bowel gas, which is not an uncommon problem. GI tract peristalsis can be diminished during the examination by using IV buscopan. Fig 16. 38 Coronal 3D MRA of the kidneys showing two renal arteries supplying the left Kidney. This is important information pre-transplant. Anomalous renal arteries are common and, like the normal renal arteries, are end arteries, hence the consequence of infarction if tied at surgery. __OOHHCCMM__1100ee. . iinnddbb 774455 0022//0055//22001177 1199: : 0088 746 ygoloidaR Neuroimaging computed tomography (fi g 16. 39) Imaging modality of choice for patients presenting with acute neurological symptoms suggestive of a stroke. It is better than magnetic resonance imaging at showing acute haemorrhage and fractures, and is much easier to do in ill or anaesthetized patients, and so is Good in emergencies. The attenuation of biological soft tissues is in a narrow range from about 80 for Blood and muscle, to 0 for CSF, and down to Ω100 for fat (Hounsfi eld units, p730). IV contrast medium initially gives an angiographic eff ect, whitening the vessels. Later, if there is a defect in the Bloodbrain barrier (eg tumours or infection), contrast medium will opacify a lesions margins, giving enhancing white areas. Some CNS areas, eg pituitary gland, choroid plexus, have no Bloodbrain barrier and enhance normally.",
    "Some CNS areas, eg pituitary gland, choroid plexus, have no Bloodbrain barrier and enhance normally. Fresh Blood is of higher attenuation (ie whiter) than brain tissue. In old haematomas, hemoglobin breaks down and loses attenuation, so a subacute subdural haematoma at 2wks may be of the same attenuation as adjacent brain. A chronic subdural haematoma will be of relatively Low attenuation. computed tomography is often used in acute stroke to exclude haemorrhage (eg pre-antiplatelets) and with perfusion scanning (fi g 16. 14) to aid management decisions regarding thrombolysis. The actual area of infarction/ischaemia may not show up for a day or so, and will be Low-attenuation cytotoxic oedema (aff ecting both white and grey matter look for loss of grey matter defi nition). Tumours and abscesses appear similar, eg a ring-enhancing mass, surrounding vasogenic oedema, and mass eff ect. Vasogenic oedema (from leaky capillaries) is extracellular and spreads through the white matter (grey matter spared). Mass effect causes compression of the sulci and ipsilateral ventricles, and may also cause herniation (subfalcine, transtentorial, or tonsillar). See p483 (and also fi g 16. 40). Another indication for computed tomography is acute, severe headache, eg suggestive of subarachnoid haemorrhage (p478). An unenhanced computed tomography may show fresh Blood, hydrocephalus or ICP, any of which could make LP unsafe. computed tomography angiography gives excellent mapping of the cerebral circulation (fi g 16. 41), and can be done directly after unenhanced computed tomography, looking for an aneurysm if the unenhanced computed tomography shows subarachnoid haemorrhage. magnetic resonance imaging (magnetic resonance imaging in stroke: fi g 10. 19, p481) The chief image sequences are: T1-weighted images: Give Good anatomical detail to which the T2 image can be compared. Fat is brightest (signal intensity); other tissues are darker to varying degrees. Flowing Blood is Low signal. Gadolinium contrast (p748) usually results in an increase in signal intensity. See table 16. 4. T2-weighted images: These provide the best detection of most lesions as they usually contain some oedema or fl uid and therefore appear white (eg fi g 16. 20, p735). Fat and fl uid appear brightest. Flowing Blood is again Low signal. Magnetic resonance angiography maps carotid, vertebrobasilar, and cerebral arterial circulations (and sinuses, veins). Functional magnetic resonance imaging can image local Blood fl ow. Catheter angiography (fi g 16. 42) Less commonly used since the advent of MRA and computed tomography angiography and perfusion techniques, though it has the advantage of allowing immediate therapyeg coil embolization of saccular aneurysms. Radionuclide imaging (p738) PET is mostly used as a research tool in dementia, but perfusion scintigraphy scan be used in the assessment of Alzheimers disease, other dementias, and localizing epileptogenic foci. SPECT to visualize uptake of 123IFP-CIT (DaTSCAN) can be used to assess reduced striatal dopaminergic transport in Parkinsons disease. __OOHHCCMM__1100ee. . iinnddbb 774466 0022//0055//22001177 1199: : 0088 747 ygoloidaR Fig 16. 39 Unenhanced axial computed tomography head: note the old infarct in the left middle cerebral artery territory. Courtesy of Norwich Radiology Department. Fig 16. 40 T1-weighted magnetic resonance imaging of the brain showing a haemangioblastoma in a patient with Von HippelLindau syndrome (p712). Note enhancement with contrast medium. Courtesy of Dr Edmund Godfrey. Fig 16. 41 A 3D reconstruction of a computed tomography angiogram of the paired internal carotid arteries (yellow arrows) and their branches (anterior cerebral arteriesgreen arrows, middle cerebral arteriesred arrows), seen from the front and slightly to the right. There is an aneurysm of the right middle cerebral artery (). Courtesy of Norwich Radiology Department. Fig 16. 42 Digital subtraction angiogram (DSA).",
    "Courtesy of Norwich Radiology Department. Fig 16. 42 Digital subtraction angiogram (DSA). The right internal carotid artery (yelLow arrow), anterior cerebral artery (green arrow), and middle cerebral artery (red arrow) are shown. Courtesy of Norwich Radiology Department. __OOHHCCMM__1100ee. . iinnddbb 774477 0022//0055//22001177 1199: : 0088 748 ygoloidaR Contrast media in imaging The use of a contrast medium can alter the electron density of two previously similar tissues, thus allowing them to be distinguished. Contrast medium is usually administered by the following routes: PO: Bariumor iodine-based agents for, eg swallow or enhancing visualization of bowel lumen on computed tomography. Inhaled: Technetium or xenon used in ventilation scintigraphy. IV: (Most widespread clinical application. ) Iodine or gadolinium. PR: Air or CO 2 can be introduced to the colon for computed tomography colonography, iodinated contrast medium is used for Water-soluble enemas. Iodine-based contrast agents Iodine is used because of its relatively High electron density and Good physiological tolerance. When used with computed tomography, the examination is said to be contrast enhancedlook for c amongst the scan details. Exercise caution in: renal or cardiac impairment; myeloma; Diabetes; sickle cell disease; elderly; infants; the acutely unwell. Avoid iodine-based agents in active hyperthyroidism. Have renal function to hand in these patients (see p315). Minor reactions include nausea, Vomiting, and a sensation of warmth. More severe reactions include urticaria, bronchospasm, angioedema, and Low blood pressure (1: 250); theoretical risk of death for 1: 150 000. Metformin should be withheld for 48h after IV contrast administration because of the risk of lactic acidosis. Barium sulfate Used in examination of the GI tract. Water-insoluble particles of 0. 61. 4μm diameter are mixed with large organic molecules such as pectin and gum to promote Good fl ow, mucosal adherence, and High density in thin layers. Complications: Chemical pneumonitis or peritonitis. Never administer if you suspect perforated viscus. Water-soluble, non-ionic, iodine-based contrast agents Used instead of barium where there is a risk of peritoneal contamination (eg fi stula, megacolon, ulceration, diverticulitis, bowel anastomosis, acute intestinal haemorrhage). Gastrograffi n should not be used. Contains iodine so establish allergy history and thyroid status. Air In computed tomography colonography, air (or CO 2 ) is insuffl ated as a negative contrast medium after barium administration to enhance mucosal defi nition. Water can also be used PO and PR to outline the lumen of the gut. Gadolinium A lanthanide series element with paramagnetic qualities that is administered intravenously (as gadolinium-diethylenetriamine pentaacetic acid scan) to enhance the contrast of certain structures in magnetic resonance imaging. It works by reducing the time to relaxation (TR) of hydrogen nuclei in its proximity and appears as High signal on T1-weighted scans. It does not cross the Bloodbrain barrier so is useful in enhancing isointense extra-axial tumours such as meningiomas. It can also highlight areas where the Bloodbrain barrier has broken down secondary to infl ammatory or neoplastic processes. It is renally excreted: check estimated glomerular filtration rate: if signifi cantly reduced, gadolinium is contraindicated, as up to 30% may develop progressive nephrogenic systemic fi brosis/ nephrogenic fi brosing dermopathy which causes generalized fi brosis which impairs movement and breathingand which may be fatal. Aberrations in calciumphosphate metabolism and erythropoietin treatment seem to increase risk. Other adverse reactions include headache, nausea, and local irritation at the site of injection, with idiosyncratic reaction reported in less than 1%. __OOHHCCMM__1100ee. . iinnddbb 774488 0022//0055//22001177 1199: : 0088 749 ygoloidaR Imaging the acutely unwell patient Asking yourself Does this investigation need to be done right now? will often yield the answer No!",
    "will often yield the answer No! , yet there are a few occasions when early imaging can provide vital diagnostic information and infl uence the prognosis for a patient: Acute cauda equina syndrome (p466): magnetic resonance imaging lumbar spine. Suspected thoracic aorta dissection (p655): computed tomography thorax IV contrast, magnetic resonance imaging or transoesophageal echo (TOE). The mediastinum is rarely widened on CXR. Suspected leaking abdominal aortic aneurysm (p654): computed tomography aorta. Acute Kidney injury (p298): ultrasound of renal tract to exclude obstruction. Acute pulmonary oedema: portable CXR: dont delay to get an ideal fi lm. Acute abdomen with signs of peritonism: erect CXR to fi nd intraperitoneal free gas (fi g 13. 26, p607; GI perforation). Remember: post-op there will be detectable gas (air/CO2 ) in the abdomen for 10 days. computed tomography if suspicion of intra-abdominal source for sepsis or pathology requiring prompt surgery (eg appendicitis). ultrasound for ectopic pregnancy. Any patient with post-traumatic midline cervical spine tendernessnot just for the emergency department! Collar and backboard immobilization followed by a computed tomography. All the vertebrae down to the top of T1 must be visualized and cleared before it is safe to take the collar off. Sudden-onset focal neurology, worst-ever headache, deteriorating GCS: computed tomography head, then LP if no evidence of ICP. Remember that imagingor re-imaging for a poor quality fi lmshould never delay the defi nitive treatment of an emergency condition, eg: Tension pneumothorax (p814 and fi g 16. 43): decompression not CXR. Intra-abdominal haemorrhage or viscus rupture (p606): laparotomy. High clinical suspicion of torsion of testis (p652): surgery not Doppler ultrasound. Prior to the advent of interventional radiology, a collapsed, shocked patient with an acute abdomen would have skipped computed tomography and gone straight for a laparotomy. However, you should bear in mind that ruptured aneurysms are increasingly being managed by endovascular repair under fl uoroscopic guidance (p654) so this is one area where rapid imaging may be preferable to immediate intervention. Fig 16. 43 This is a great educational image from ICU. The inexperienced doctor could be distracted by the poor quality image, missing the lung bases: technicians do their best under diffi cult conditions. To ask for a new CXR here would be a mistake note the large right-sided tension pneumothorax needing immediate decompression! Lungs: The right lung fi eld is too black compared to the left, the right hemidiaphragm is depressed, and the right lung is seen collapsed against the mediastinum. Mediastinum: Left-shifted, obstructing venous returnso cardiac output, and a threat to life. Is it being pushed or pulled? Check hila, bones, and soft tissues. Since the right lung is collapsed and mediastinum shifted to left this suggests right tension pneumothorax. Needle thoracocentesis decompression and a chest drain are needed now. Courtesy of Dr Edmund Godfrey. __OOHHCCMM__1100ee. . iinnddbb 774499 0022//0055//22001177 1199: : 0088 17 Reference intervals, etc. Contents Statistics in medicine 751 Biochemistry reference intervals 752 Haematology reference intervals 754 Drug therapeutic ranges in plasma 756 Some important drug interactions 757 Fig 17. 1 Carl Friedrich Gauss (17771855) was a German astronomer and mathematician who made many contributions to science, not least of which was establishing the normal (Gaussian) distribution (see p751). After his death, Gausss brain was examined by anatomist Rudolph Wagner, to test the popular theory that intellectual ability correlated with physical properties of the brain such as weight and surface markings. While his brain was noted to display an unusually intricate pattern of sulci, lack of similarly patterned sulci among the brains of other intellectuals cast doubts on the theory.",
    "Further lack of evidence to support Wagners hypothesis came when Gauss brain was weighed: it would perhaps have amused Gauss to learn that the weight of his brain, whilst slightly above average, lay very much within the central region of a Gaussian distribution. After some rather sloppy housekeeping, Gauss brain was stored in a mislabelled pot at the University in Göttingen, accidentally switched with that of his contemporary, the physician Conrad Fuchs. Over 150 years later, some careful searching of the archives and a magnetic resonance imaging scanner revealed the switch. __OOHHCCMM__1100ee. . iinnddbb 775500 0022//0055//22001177 1199: : 0088 751. cte, slavretni ecnerefeR Statistics in medicine The normal (Gaussian) distribution curve. This bell-shaped graph (fi g 17. 2) is the theoretical basis of reference intervals, and explains lab errorwhy some tests repeated at close intervals may reveal slightly diff erent values. hemoglobin for example, has a lab error of 5g/L. This emphasizes the importance of the clinical picture in decision-making, rather than treating the numbers alone: dont subject anaemic patients to Blood transfusions unless they have a clinical need. See p324. Range is the lowest and highest value of all observations in the set being studied. Arithmetic mean is the sum of all observations by the number of observations. Median is the middle value (eg 9 data points are higher and 9 are lower). If their distribution is Normal, then the median coincides with the mean. Standard deviation (SD) is the square root of the variance (the average of the square of the distance of each data point from the mean). When the distribution of the observations is Normal, 95% of observations are located in the interval mean ± 1. 96 SD. This is the basis of the reference interval. Standard error of the mean gives an estimate of the reliability of the mean of a sample representing the mean of the population from which the sample was taken, and is the SD of the sample by the square root of the number of observations in the sample. Thus the larger the sample size, the smaller the standard error of the meanthe basis of ensuring that clinical trial evidence is based upon enough observations to be confi dent that diff erences seen between groups do not occur by chance alone. Fig 17. 2 Normal (Gaussian) distribution curve. Reproduced from Bhopal, Concepts of Epidemiology, 2008, with permission from Oxford University Press. __OOHHCCMM__1100ee. . iinnddbb 775511 0022//0055//22001177 1199: : 0088 752. cte, slavretni ecnerefeR Biochemistry reference intervals See p662 for the philosophy of the normal range; see OHCS p220 for children. Drugs (and other substances) may interfere with any chemical method; as these effects may be method dependent, it is diffi cult for the clinician to be aware of all the possibilities. If in doubt, discuss with the lab. Table 17. 1 Reference interval Your Substance Specimen (labs vary, so a guide only) hospital Adrenocorticotrophic hormone P 80ng/L Alanine aminotransferase (ALT) P 535U/L Albumin1 P 3550g/L Aldosterone2 P 100500pmol/L Alkaline phosphatase1 P 30130U/L (adults) -amylase P 0180IU/dL -fetoprotein S 10kU/L Angiotensin II2 P 535pmol/L Antidiuretic hormone (ADH) P 0. 94. 6pmol/L Aspartate transaminase P 535U/L Bicarbonate1 P 2430mmol/L Bilirubin P 317μmol/L BNP (see p137) P 50ng/L C-reactive Protein P 10mg/L Calcitonin P 0. 1mcg/L Calcium (ionized) P 1. 01. 25mmol/L Calcium1 (total) P 2. 122. 60mmol/L See p676 to correct for albumin Chloride P 95105mmol/L Cholesterol3 (see p690) P 5. 0mmol/L VLDL (see p690) P 0. 1280. 645mmol/L LDL P 2. 0mmol/L HDL P 0. 91.",
    "0mmol/L VLDL (see p690) P 0. 1280. 645mmol/L LDL P 2. 0mmol/L HDL P 0. 91. 93mmol/L Cortisol P AM 450700nmol/L Midnight 80280nmol/L Creatine kinase (CK) P 25195U/L 25170U/L Creatinine1 (proportional to lean P 70100μmol/L body mass) Ferritin P 12200mcg/L Folate S 2. 1mcg/L Follicle-stimulating hormone (FSH) P/S 28U/L in (luteal); 25U/L in menopause Gamma-glutamyl transpeptidase P 1151U/L 733U/L Glucose (fasting) P 3. 55. 5mmol/L Growth hormone P 20mu/L hemoglobin hemoglobin A1c glycosylated hemoglobin (DCCT) B 46%. 7% Good diabetes mellitus control hemoglobin hemoglobin A1c IFCC (more specifi c than DCCT)B 2042mmol/mol; 53 Good diabetes mellitus control Iron S 1431μmol/L 1130μmol/L Lactate P Venous 0. 62. 4mmol/L ABG Arterial 0. 61. 8mmol/L Lactate dehydrogenase (LDH) P 70250U/L Lead B 1. 8mmol/L Luteinizing hormone (LH) P 316U/L (luteal) (premenopausal) Magnesium P 0. 751. 05mmol/L O smolality P 278305mosmol/kg __OOHHCCMM__1100ee. . iinnddbb 775522 0022//0055//22001177 1199: : 0088 753. cte, slavretni ecnerefeR Parathyroid hormone (parathyroid hormone) P 0. 88. 5pmol/L Potassium P 3. 55. 3mmol/L Prolactin P 450U/L 600U/L Prostate-specifi c antigen (PSA) P 04mcg/mL, age specifi c, see p530 Protein (total) P 6080g/L Red cell folate B 0. 361. 44μmol/L (160640mcg/L) Renin2 (erect/recumbent) P 2. 84. 5/ 1. 12. 7pmol/mL/h Sodium1 P 135145mmol/L Thyroid-binding globulin (TBG) P 717mg/L Thyroid-stimulating hormone (TSH) P 0. 54. 2mU/L widens with age, p216 assays vary; 45 is a grey area Thyroxine (T4) P 70140nmol/L Thyroxine (free) P 922pmol/L Total iron-binding capacity S 5475μmol/L Triglycerides (fasting) P 0. 502. 3mmol/L Triiodothyronine (T3) P 1. 23. 0nmol/L Troponin T (see p119) P 0. 1mcg/L Urate1 P 210480μmol/L 150390μmol/L Urea1 P 2. 56. 7mmol/L Vitamin B12 S 0. 130. 68nmol/L (150ng/L) Vitamin D S 50nmol/L (total) Pplasma (eg citrate bottle); Sserum (clotted; no anticoagulant); Bwhole Blood (European Dialysis and Transplant Association bottle); ABGarterial Blood gas). 1 See OHCS p9 for reference intervals in pregnancy. 2 The sample requires special handling: contact the laboratory. 3 Desired upper limit of cholesterol would be 6mmol/L. In some populations, 7. 8mmol/L is the top end of the distribution. Table 17. 2 Arterial Blood gases reference intervals pH: 7. 357. 45 PaCO2: 4. 76. 0kPa PaO2: 10. 6kPa Base excess: ±2mmol/L Note: 7. 6mmHg 1kPa (atmospheric Hypertension 100kPa) Table 17. 3 Urine reference intervals Reference interval Your hospital Cortisol (free) 280nmol/24h Hydroxyindole acetic acid 1673μmol/24h Hydroxymethylmandelic acid 1648μmol/24h Metanephrines 0. 030. 69μmol/mmol Creatinine (or 5. 5μmol/day) Osmolality 3501000mosmol/kg 17-oxogenic steroids 2830μmol/24h 2166μmol/24h 17-oxosteroids (neutral) 1776μmol/24h 1459μmol/24h Phosphate (inorganic) 1550mmol/24h Potassium 14120mmol/24h Protein 150mg/24h Protein Creatinine ratio 3mg/mmol Sodium 100250mmol/24h Interpret based upon plasma values. __OOHHCCMM__1100ee. . iinnddbb 775533 0022//0055//22001177 1199: : 0088 754. cte, slavretni ecnerefeR Haematolog y reference intervals Table 17. 4 (For B12, folate, Fe, and TIBC, see pp7523. ) Measurement Reference interval Your hospital White cell count (WCC) 4. 011. 0 109/L Red cell count 4. 56. 5 1012/L 3. 95. 6 1012/L Haemoglobin 130180g/L 115160g/L Packed red cell volume (PCV) 0. 40. 54L/L or haematocrit 0. 370. 47L/L Mean cell volume (MCV) 7696fL Mean cell haemoglobin (MCH) 2732pg Mean cell haemoglobin 300360g/L concentration (MCHC) Red cell distribution width 11. 614. 6% (p325) (RCDW, RDW) Neutrophils 2. 07. 5 109/L 4075% WCC Lymphocytes 1. 04. 5 109/L 2045% WCC Eosinophils 0. 040. 44 109/L 16% WCC Basophils 0. 00. 10 109/L 01% WCC Monocytes 0. 20. 8 109/L 210% WCC Platelet count 150400 109/L Reticulocyte count 0. 82. 0%1 25100 109/L Erythrocyte sedimentation rate Depends on age (p372) Prothrombin time (citrated bottle) 1014s (factors I, II, VII, X) Activated partial thrombo3545s plastin time (VIII, IX, XI, XII) Therapeutic ranges for INR: see p351.",
    "1 Only use percentages as reference interval if red cell count is normal; otherwise, use the absolute value. __OOHHCCMM__1100ee. . iinnddbb 775544 0022//0055//22001177 1199: : 0088 755. cte, slavretni ecnerefeR __OOHHCCMM__1100ee. . iinnddbb 775555 0022//0055//22001177 1199: : 0088 756. cte, slavretni ecnerefeR Drug ther apeutic ranges in plasma Ranges should only be used as a guide to treatment. A drug in an apparently too Low concentration may still be clinically useful, while some patients require (and tolerate) levels in the toxic range. The time since the last dose should be specifi ed on the request form. Amikacin. 1 Peak (1h post IV dose): 2030mg/L. Trough: 10mg/L. Carbamazepine. 1 Optimal concentration: 2050μmol/L (412mg/L). Digoxin1 (612h post dose) 12. 6nmol/L (0. 82mcg/L). 1. 3nmol/L may be toxic if there is hypokalaemia. Signs of toxicityCVS: arrhythmias, Heart block. CNS: confusion, insomnia, agitation, seeing too much yellow (xanthopsia), delirium. GI: nausea. Gentamicin1, 2 (p387) and tobramycin. 1, 2 The potential for otoand nephrotoxicity is High if aminoglycosides are used inappropriately, so only prescribe for short therapeutic courses and follow local expert advice/guidelines. CI in severe renal or Liver failure, ascites, burns, High cardiac output states (eg anaemia, Pagets disease), children, and pregnancy. Signs of toxicity: tinnitus, deafness, nystag mus, vertigo, renal failure. Once-daily dosing with dose adjustment is prefered as this has fewer SES and better bactericidal activity (eg gentamicin 5mg/kg/d or tobramycin 4mg/ kg/d; check with pharmacist in obese patients or when using tobramycin in cystic fi brosis). An exception to this dosing is endocarditis: split dosing (eg gentamicin 1mg/kg/8h or 12-hourly in renal failure) increases the synergistic bactericidal eff ect of other agents. Trough (just before dose) levels and renal function should initially be monitored daily (can be twice weekly in stable patients with normal renal function)aim for trough: 1mg/L for both gentamicin and tobramycin. If the trough level is out of range, withold the next dose until level 1mg/L (recheck after 1224h). Lithium2 (12h post dose). Guidelines vary: 0. 40. 8mmol/L is reasonable. Early signs of toxicity (Li 1. 5mmol/L): tremor. Intermediate: lethargy. Late: (Li 2mmol/L) spasms, coma, fi ts, arrhythmias, renal failure (haemodialysis may be needed). See OHCS p349. Phenytoin. 1, 2 Trough: 4080μmol/L (1020mg/L). Beware if albumin, as the assay is for bound phenytoin, while it is free pheny toin that is pharmacologically important. Signs of toxicity: ataxia, diplopia, nystagmus, sedation, dysarthria. Theophylline 1020mg/mL (55110μmol/L). (See p810. ) Take sample 46h after starting an infusion (which should be stopped for 15min just before the specimen is taken). Signs of toxicity: arrhythmias, anxiety, tremor, convulsions. Vancomycin. 1, 2 Renally excreted; dosing guided by age and renal function but typically 500mg1g/12h. Check trough levels prior to 3rd dose, aiming for: 510 magnesium/L (1015mg/L in SBE/IE and less-sensitive MRSA infections). If levels too Low check drug being given then cautiously increase dose; if levels High then confi rm timing of dose/ levels, omit next dose, recheck levels, and consider decreasing dose or frequency. 1 Trough levels should be taken just before the next dose. If values abnormally High, check that sample was indeed a trough level and not taken post-dose. 2 Drugs for which routine monitoring is indicated. __OOHHCCMM__1100ee. . iinnddbb 775566 0022//0055//22001177 1199: : 0088 757. cte, slavretni ecnerefeR Some important drug interactions See BNF. See p689 for a list of cytochrome P450 inducers and inhibitors. Note: eff ect of drug increased; eff ect decreased. Drugs Adenosine: by: aminophylline. by: dipyridamole. Aminoglycosides: by: loop diuretics. Antidiabetic drugs: (All) by: alcohol, -blockers, bezafi brate, monoamine oxidase inhibi tors. by: contraceptive steroids, corticosteroids, diazoxide, diuretics, (possibly also lithium). Metformin by: cimetidine.",
    "by: contraceptive steroids, corticosteroids, diazoxide, diuretics, (possibly also lithium). Metformin by: cimetidine. With alcohol: lactic acidosis risk. Sulfonylureas by: azapropazone, chloramphenicol, bezafi brate, co-trimoxazole, miconazole, sulfi npyrazone. by: rifampicin (nifedipine occasionally). Antiretroviral agents (HIV): See p402. Angiotensin-converting enzyme (ACE) inhibitors: by: NSAIDS, oestrogens. Antihistamines: Avoid anything that concentrations and risk of arrhythmias, eg anti-arrhythmics, antifungals, antip sychotics, -blockers, diuretics, halofantrine, macrolide antibiotics (erythromycin, azithromycin, etc), protease inhibitors (p402), SSRIs (p448), tricyclics. Azathioprine: by: allopurinol. -blockers: Avoid verapamil. by: NSAIDS. Lipophilic -blockers (eg propranolol) are metabolized by the Liver, and concentrations are by cimetidine. This does not happen with hydrophilic -blockers (eg atenolol). Carbamazepine: by: erythromycin, isoniazid, verapamil. Ciclosporin: by: erythromycin, grapefruit juice, nifedipine. by: phenytoin. Cimetidine: the eff ect of: amitriptyline, lidocaine, metronidazole, pethidine, phenytoin, propranolol, quinine, theophylline, warfarin. Contraceptive steroids: by: antibiotics, barbiturates, carbamazepine, phenytoin, rifampicin. Digoxin: by: amiodarone, carbenoxolone and diuretics (due to potassium), quinine, verapamil. Diuretics: by: NSAIDSparticularly indometacin. Ergotamine: by: erythromycin (ergotism may occur). Fluconazole: Avoid concurrent astemizole. Lithium: by: thiazide diuretics. Methotrexate: by: aspirin, NSAIDS. Many antibiotics (check BNF). Phenytoin: by: chloramphenicol, cimetidine, disulfi ram, isoniazid, sulfonamides. by: carbamazepine. Potassium-sparing diuretics with ACE-inhibitors: Hyperkalaemia. Theophyllines: by: cimetidine, ciprofl oxacin, erythromycin, contraceptive steroids, propranolol. by: barbiturates, carbamazepine, phenytoin, rifampicin. See p810. Valproate: by: carbamazepine, phenobarbital, phenytoin. Warfarin and nicoumalone: (Nicoumaloneacenocoumarol) by: alcohol, allopurinol, amiodaro ne, aspirin, chloramphenicol, cimetidine, ciprofl oxacin, co-trimoxazole, danazol, dipyridamole, disulfi ram, erythromycin (and broad-spectrum antibiotics), gemfi brozil, glucagon, ketoconazole, metronidazole, miconazole, sodiumlidixic acid, neomycin, NSAIDS, phenytoin, quinidine, simvastatin (but not pravastatin), sulfi npyrazone, sulfonamides, tetracyclines, levothyroxine. Warfarin and nicoumalone: by: aminoglutethimide, barbiturates, carbamaz epine, contraceptive steroids, dichloralphenazone, griseofulvin, rifampicin, phenytoin, vitamin potassium. Zidovudine (AZT): by: paracetamol (marrow toxicity). IVI solutions to avoid Glucose: Avoid furosemide, ampicillin, hydralazine, insulin, melphalan, phenytoin, and quinine. 0. 9% saline: Avoid amphotericin, lidocaine, nitroprusside. __OOHHCCMM__1100ee. . iinnddbb 775577 0022//0055//22001177 1199: : 0088 18 Practical procedures Contents Nasogastric tubes 759 Placing IV cannulae 760 Cut down on to a vein 761 Catheterizing bladders 762 Draining ascites 764 Diagnostic aspiration of a pleural eff usion 765 Abdominal paracentesis 765 Inserting a chest drain 766 Relieving a tension pneumothorax 767 Aspiration of a pneumothorax 767 Lumbar puncture (LP) 768 Cardioversion/defi brillation 770 Arterial Blood gas sampling 771 Emergency airway management 772 Central venous cannulation 774 Internal jugular catheterization 775 Inserting a temporary cardiac Fig 18. 1 NHS clean your hands campaign poster. pacemaker 776 Contains public sector information licensed under Open Government Licence v3. 0. request/21861/response/56086/attach/3/04072%20Hand%20 Hygiene%205%201. 1. pdf Hungarian obstetrician Ignaz Semmelweis demonstrated the benefi ts of handwashing in the 1840s: he observed that maternal mortality was nearly three times as High on a doctor-run maternity ward compared to a midwife-run ward. The explanation remained elusive until Semmelweis friend Jakob Kolletschka died after receiving an accidental scalpel cut from a student during a post-mortem demonstration. Semmelweis recognized in Kolletschkas death many of the features of the dying mothers. The explanation: the maternity ward doctors day started with post-mortem examinations, from which they would procede to perform vaginal examinations on the living without washing their hands. Noticing this, Semmelweis introduced the practice of washing hands with chloride of lime and cut death rates to that of the midwives patients. Despite the evidence he amassed, Semmelweiss theory was rejected by his contemporaries, a rejection which undoubtedly contributed to his psychiatric distress, eventual commitment to an asylum, and ultimate death from the blows of his guards. It would take another 20 years and countless deaths before Lister published his landmark work on the use of carbolic acid in surgery. Take a minute to wash your hands thoroughly before undertaking any procedure.",
    "Tape securely to the nose. Confi rming position This is vital prior to commencing any treatment through the tube. Misplaced nasogastric tubes have led to a number of preventable deaths, and feeding via a misplaced tube is considered an NHS Never Event (a serious, largely preventable patient safety incident that should never occur if the available preventative measures have been implemented). Use pH paper to test that you are in the stomach: aspirated gastric contents are acid (pH ≤5. 5) although antacids or PPIS may increase the pH. Small tubes can be diffi cult to aspirate, try withdrawing or advancing a few cm or turning the patient on the left side to help dip the tube in gastric contents. Aspirates should be 0. 5mL and tested directly on unhandled pH paper. Allow 10s for colour change to occur. If the pH is 5. 5 and the NGT is needed for drug or feed administration then the position must be checked radiologically. Request a CXR/abdo X-ray (tell the radiologist why you need it). Look for the radio-opaque line/tip (this can be hard to see, look below the diaphragm, but if in doubt, ask for help from the radiologist). The whoosh test is NOT an accepted method of testing for tube position. Either spigot the tube, or allow to drain into a dependent catheter bag secured to clothing (zinc oxide tape around tube to form a fl ap, safety pin through fl ap). Do not pass a tube nasally if there is any suspicion of a facial fracture. Get senior help if the patient has recently had upper GI surgeryit is not Good practice to push the tube through a fresh anastomosis. Complications Pain, or, rarely: Loss of electrolytes Oesophagitis Tracheal or duodenal intubation Necrosis: retroor nasopharyngeal Stomach perforation. Weaning When planning removal of an NGT in situ for decompression or relief of obstruction, it is wise to wean it so that the patient manages well without it. Drainage should be 750mL/24 hours for successful weaning. First it should be on free drainage with, eg, 4hrly aspirations. Then spigot with 4hrly aspirations. Then spigot only. If this is tolerated along with oral intake then it is probably safe to remove the tube; if not, then take a step backwards. __OOHHCCMM__1100ee. . iinnddbb 775599 0022//0055//22001177 1199: : 0099 760 serudecorp lacitcarP Placing IV cannulae Much of what we do is not evidence based; however, in more recent years, particularly in intensive care units, the rise of hospital-acquired infections and multidrug-resistant organisms has prompted a review of standard practice and a series of evidence-based interventions put together as a care bundle to reduce hospital-acquired infections. The technique for placing a cannula is best shown at the bedside by an expert, but following these simple rules will signifi cantly reduce the risk of infection from the cannula. Preparation is key, remember the following before you start 1 Equipment: Set up a tray with cleaning swabs, gauze, cannulae (swallow your pride and take at least three of diff erent sizes, see table 18. 1), dressings, 0. 9% saline, 10mL syringe, needle-free adaptor (eg octopus with bionector), Blood tubes if required, portable sharps bin needlestick injuries do happen. 2 Patient: Have them lying down, explain procedure, obtain verbal consent, place tourniquet around arm, rest the arm below the Heart to aid venous fi lling. 3 Site: Look for the best veinit should be palpable; some of the best veins are not easily visible, some of the most visible collapse on insertion. Tapping gently helps. Never cannulate: AV fi stulae arms, limbs with lymphoedema.",
    "For some, this is one of the challenges and thrills in medicine. There may be no one else available to help when there is an absolute and urgent indication for IV drugs/fl uids/Bloodand all of the previously discussed measures have been tried, and have failed. Think of lonesome night shifts, over-run emergency departments, a disaster scene, war, or medicine in the fi eld. The following measures are not recommended for non-life-threatening scenarios: Dont worry. Have a Good look again. Feet (avoid in diabetics)? Inside of the forearm? Upper arm? Have you really exhausted all of your options for help from a colleague? Maybe the anaesthetist or ICU registrar is approachablethey do have remarkable skills. Is the patient familiar with his/her own veins (eg previous IV drug abuser)? If there is only a small amount of IV medication required and a small, short vein, you may be able to gain access with a carefully placed butterfl y needle that is taped down. Some drugs cannot be passed this way (eg amiodarone, potassium). The external jugular vein may become prominent when the patient is head down (Trendelenburg) by 510° (not in situations of fl uid overload, LVF, ICP). Only attempt cannulation of this vein if you are not going to jeopardize future central line insertion, and if you can clearly determine the surrounding anatomy. In an arrest situation, the 2015 Advanced Life Support Guidelines recommend the intraosseous route in both adults and children if venous access is not possible; access devices should be available within resuscitation settings (eg emergency department). Only do the following if you have had the appropriate training/experience: In children, consider cannulating a scalp vein. Central venous catheterization (p775). This may be just as hard in a profoundly hypovolaemic arrest patient, and a Good knowledge of local anatomy and of the procedure (± ultrasound guidance) will be invaluable. If you dont have an intraosseous access device, a cut down to the long saphenous vein may be attempted, in extremis, even if you have no prior experience (at this site you wont kill by being ham-fi sted). Make a transverse incision 12cm anterior and superior to the medial malleolus. Free vein with forceps. Cannulate it under direct vision. Here, fi rst do no harm is trumped by nothing ventured, nothing gained. Hopefully, it shouldnt ever have to come to these measures, but one day 1 Poiseuilles law is a neat piece of physiology and worth rememberingit is applicable in some form to almost every system in the body. Note that it is a 4th-power law: a small change in the radius makes a huge diff erence to fl ow. __OOHHCCMM__1100ee. . iinnddbb 776611 0022//0055//22001177 1199: : 0099 762 serudecorp lacitcarP Catheterizing bladders Urinary tract infections are the second commonest health care-associated infection, and urinary catheters are frequently to blame. Think, does the patient really need a catheter? If so, use the smallest you can and take out as soon as possible. Size (in French gauge): 12small; 16large; 20very large (eg 3-way). Material Coated latex catheters are soft and a Good short-term option but unsuitable in true latex allergy. Silastic (silicone) catheters may be used long term, but cost more. Silver alloy coating reduces infections. Shape Foley is typical (fi g 18. 2); coudé (elbow) catheters have an angled tip to ease around prostates but are more risky; 3-way catheters are used in clot or debris retention and have an extra lumen for irrigation fl uid, attached to the irrigation set via an extra port on the distal end (fi g 18. 3). Get urology advice before starting irrigation.",
    "3). Get urology advice before starting irrigation. Condom catheters are often preferred by patients (less discomfort) even though they may leak and fall off. Catheter problems Infection: 5% develop bacteraemia (most will have bacterial colonization, antibiotics may not be required unless systemically unwelldiscuss with microbiology). A stat dose of, eg gentamicin 80mg is sometimes given preinsertion despite a lack of evidence for benefi t. Check your local policy. Bladder spasm: May be painfultry reducing the Water in the balloon or an anticholinergic drug, eg oxybutynin. Per urethram Aseptic technique required. Indications Relieve urinary retention. Monitor Urine output in critically ill patients. Collect uncontaminated Urine for diagnosis. It is contraindicated in urethral injury (eg pelvic fracture) and acute prostatitis. Explain the procedure, and obtain verbal consent. Prepare a catheterization trolley: gloves, catheter, lidocaine jelly, cleaning solution, drape, Kidney dish, gauze swabs, drainage bag, 10mL Water and syringe, specimen container. Lie the patient supine: women with knees fl exed and hips abducted with heels together. Use a gloved hand to clean urethral meatus in a pubis-to-anus direction, holding the labia apart with the other hand. With uncircumcised men, retract the foreskin to clean the glans; use a gloved hand to hold the penis still. The hand used to hold the penis or labia should not touch the catheter. Place a sterile drape with a hole in the middle to help you maintain asepsis. Remember: left hand dirty, right hand clean. Put sterile lidocaine 12% gel on the catheter tip and ≤10mL into the urethra (≤5mL if ). In men, lift and gently stretch the penis upwards to eliminate any urethral folds that may lead to false passage formation. Use steady gentle Hypertension to advance the catheter, rotating slightly can help it slide in. Never force the catheter. Tilting the penis up towards the umbilicus while inserting may help negotiate the prostate. Insert to the hilt; wait until Urine emerges before infl ating the balloon. Remember to check the balloons capacity before infl ation (written on the outer end). Collect a sterile specimen and attach a drainage bag. Pull the catheter back so that the balloon comes to rest at the bladder neck. If you are having trouble getting past the prostate, try: more lubrication, a gentle twisting motion; a larger catheter; or call the urologists, who may use a guidewire. Remember to reposition the foreskin in uncircumcised men after the catheter is inserted to prevent oedema of the glans and paraphimos. Documentation: In the notes be sure to document the indication for catheterization, size of catheter, whether insertion was diffi cult or straightforward, any complications, residual volume and colour of Urine. It is Good practice to document that the foreskin has been replaced. Sign with your name, date, and designation. Suprapubic catheterization: Sterile technique required Absolutely contraindicated unless there is a large bladder palpable or visible on ultrasound, because of the risk of bowel perforation. Be wary, particularly if there is a history of abdominal or pelvic surgery. Suprapubic catheter insertion is High risk and you should be trained before attempting it, speak to the urologists fi rst. __OOHHCCMM__1100ee. . iinnddbb 776622 0022//0055//22001177 1199: : 0099 763 serudecorp lacitcarP Self-catheterization This is a Good, safe way of managing chronic retention from a neuropathic bladder (eg in multiple sclerosis, diabetic neuropathy, spinal tumour, or trauma). Never consider a patient in diffi culties from a big residual volume to be too old, young, or disabled to learn. 5-yr-old children can learn the technique, and can have their lives transformedso motivation may be excellent.",
    "5-yr-old children can learn the technique, and can have their lives transformedso motivation may be excellent. There may be fewer UTIs as there is no residual Urineand less refl ux obstructive uropathy. Assessing suitability entails testing sacral dermatomes: a numb bum implies sensation of a full bladder; higher sensory loss may mean catheterization will be painless. Get help from your continence adviser who will be in a position to teach the patient or carer that catheterizations must be gentle (the catheter is of a much smaller calibre), particularly if sensation is lacking, and must number 4/d (always keep your catheter with you; dont wait for an urge before catheterizing). See fi g 18. 4. Fig 18. 2 A size 14F latex Foley Fig 18. 3 The external end of Fig 18. 4 A size 10F catheter catheter with the balloon infa size 20F 3-way catheter. The for self-catheterization. They l ated via the topmost port of lowest port is for the bladder are usually smaller than the outer end (green). irrigation fl uid and the upperindwell ing catheters, eg 10F Dr Tom Turmezei (not to scale). most port (yellow) is for balcomp ared to 14F. Note that this loon infl ation. catheter also has no balloon. Dr Tom Turmezei (not to scale). Dr Tom Turmezei (not to scale). The catheter is not draining You will be asked to check catheters that are not draining. Check the fl uid chart and the patient: Previously Good output, now anuric: Blocked catheter until proven otherwise. Was the Urine clear previously or bloodstained? Consider fl ushing the catheter: with aseptic technique fl ush and withdraw 20mL of sterile 0. 9% saline with a bladder syringe. This may get the fl ow going again. A 3-way catheter may be needed if there is clot or debris retention. If it blocks again, replace it. Repeated fl ushes lead to infection. Slow decline in Urine output over several hours: In a dehydrated/post-op patient a fl uid challenge of 500mL STAT (250mL if cardiac comorbidity) may help, come back and check the response in 30min. Check all other parameters (eg pulse, blood pressure, CVP) and increase rate of background IV fl uids if appropriate. Acute Kidney injury (p298): if Urine output has tailed off and now stopped, the cause is often renal hypoperfusion (ie pre-renal failure), but consider other factors, eg nephrotoxic drugs. Catheter is bypassing: A condom catheter may be more appropriate. Catheter has dislodged into the proximal (prostatic) urethra: Possible even if the balloon is fully infl ated. Consider this if a fl ush enters but cannot be withdrawn. If the patient still needs a catheter then replace it, consider a larger size. The catheter has perforated the lower urinary tract on insertion and is not lying in the bladder or urethra: If suspected, call the urologists immediately. Remember: Urine output should be 400mL in 24h or 0. 5mL/kg/h (see p576). Trial without catheter (TWOC) When it is time to remove a catheter, the possibility of urinary retention must be considered. Remove the catheter fi rst thing one morning. If retention does occur, insert a long-term catheter (eg silicone), consider an -blocker (p642), and arrange urology TWOC clinic follow-up. __OOHHCCMM__1100ee. . iinnddbb 776633 0022//0055//22001177 1199: : 0099 764 serudecorp lacitcarP Draining ascites For patients with refractory or recurrent ascites that is symptomatic, it is possible to drain the ascites using a long pig-tail catheter. Paracentesis in such patients even in the presence of spontaneous bacterial peritonitis may be safe. Learn at the bedside from an expert.",
    "Learn at the bedside from an expert. Contraindications (these are relative, not absolute) End-stage cirrhosis; coagulopathy; hyponatraemia (126mmol/L); sepsis. The main complication of the procedure is severe hypovolaemia secondary to reaccumulation of the ascites, so intravascular replenishment with a plasma expander is required. For smaller volumes, eg less than 5L, 500mL of 5% human albumin or Gelofusine would be suffi cient. For volumes over 5L, reasonable replacement would be 100mL 20% human albumin IV for each 13 litres of ascites drained (check your local policy). You may need to call the haematology lab to request this in advance. Procedure Requires sterile technique. Ensure you have Good IV accesseg 18G cannula in the antecubital fossa. Explain the procedure including the risks of infection, bleeding, hyponatraemia, renal impairment, and damage to surrounding structures (such as Liver, spleen, and bowel), and obtain consent from the patient. Serious complications occur in less than 1 in 1000 patients. Ask the patient to empty their bladder. Examine the abdomen carefully, evaluating the ascites and checking for organomegaly. Mark where you are going to enter. If in doubt, ask the radiology department to ultrasound the abdomen and mark a spot for drainage. Approach from the left side unless previous local surgery/stoma prevents thiscall a senior for support and advice if this is the case. Prepare a tray with 2% chlorhexidine solution, sterile drapes, 1% lidocaine, syringes, needles, sample bottles, and your drain. Clean the abdomen thoroughly and place sterile drapes, ensure you maintain sterile technique throughout. Infi ltrate the local anaesthetic. Perform an ascitic tap (see p765) fi rst so that you know you are in the correct place: remove 20mL fl uid for MCS. Away from the patient, carefully thread the catheter over the (large and long) needle using the guide so that the pig-tail has been straightened out. Remove the guide. With the left hand hold the needle 2. 5cm (1 inch) from the tipthis will stop it from advancing too far (and from performing an aortic biopsy). With the right hand, hold the other end. Gently insert the needle perpendicular to the skin at the site of the ascitic tap up to your hold with your left handascites should now drain easily. If necessary, advance the needle and catheter a short distance until Good fl ow is achieved. Advance the catheter over the needle with your left hand, keeping the needle in exactly the same place with your right hand. Do not re-advance the needle because it will go through the curled pig-tail and do not withdraw it because you wont be able to thread in the catheter. When fully inserted, remove the needle, connect the catheter to a drainage bag (keep it below the level of the abdomen), and tape it down securely to the skin. The patient should stay in bed as the ascites drains. Document clearly in the notes the indication for the procedure, that consent was obtained, clotting and UES checked pre-procedure, how much lidocaine was required, how much fl uid was removed for investigations, and whether there were any complications to the procedure. Replenish intravascular volume with human albumin (see Contraindications earlier in topic). Ask the nursing staff to remove the catheter after 6h or after a pre-determined volume has been drained (up to 20L can come off in 6h) and document this clearly in the medical notes. Drains are removed after 46h to prevent infection. Check UES after the procedure and re-examine the patient. __OOHHCCMM__1100ee. .",
    "Fig 18. 16 Methods of providing oxygen. __OOHHCCMM__1100ee. . iinnddbb 777733 0022//0055//22001177 1199: : 0099 774 serudecorp lacitcarP Central venous cannulation Central venous cannulae may be inserted to measure central venous Hypertension (CVP), to administer certain drugs (eg amiodarone, chemotherapy), or for intravenous before mealscess (fl uid, parenteral nutrition). In an emergency, the procedure can be done using the landmark method (see p775), though NICE recommends that all routine internal jugular catheters should be placed with ultrasound guidance. Even if the line is not placed under direct ultrasound visualization, a look to check vessel size, position in relation to artery, and patency (no thrombus or stenosis) is extremely useful. For contraindications, see table 18. 2. Table 18. 2 Contraindications to central venous cannulation Absolute Relative Infection at insertion site Coagulopathy Ipsilateral carotid endarterectomy Newly inserted cardiac pacemaker leads Thrombus within the vein Venous stenosis Ipsilateral abnormal anatomy Sites of insertion These include the internal jugular vein (see p775 and p43), subclavian vein, and the femoral vein. The choice depends largely on operator experience, but evidence suggests that the femoral approach is associated with a higher rate of line infection and thrombosis. Overall, the internal jugular approach (with ultrasound guidance) is most commonly used and risks fewer complications than the subclavian. If possible, get written consent (p568). Check clotting and platelets. The technique for internal jugular (routine) and femoral (emergency) are given here. Complications (20%. ) Insertion is not without hazard, so decide whether the patient requires a line fi rst, and then ask for help if you are inexperienced. Bleeding; arterial puncture/cannulation; AV fi stula formation; air embolism; pneumothorax; haemothorax; chylothorax (lymph); phrenic nerve palsy (the right phrenic nerve passes over the brachiocephalic artery, posterior to the subclavian veinhiccups may be a sign of injury); phlebitis; thrombus formation on tip or in vein (if High risk for thromboembolism, eg malignancy, consider anticoagulation, eg LMWH); bacterial colonization; cellulitis; sepsis (can be reduced by adherence to a strict aseptic technique; if taking Blood cultures in a febrile patient with a central venous line, remember to take samples from the central line and from a peripheral vein). Peripherally inserted central cannulas (PICC lines) These are a Good alternative to central lines, as they can stay in situ for up to 6 months, and provide access for Blood sampling, fl uids, antibiotics (allowing home IV therapy). They are placed using a Seldinger technique, puncturing the brachial or basilic vein then threading the line into the subclavian or superior vena cava. Because of the insertion site there is a much lower risk of pneumoor haemothorax, but they are tricky to insert in an emergency. Removing central lines Should be done carefully with aseptic technique. Position the patient slightly head down, remove dressings, clean and drape the area, remove sutures. Ask the patient to inhale and hold their breath, then breathe out smoothly while you are pulling the line out. This helps to prevent air emboli. Ask the patient to rehearse this sequence with you to ensure they have understood their role. Apply Hypertension for 5 minutes (longer if coagulopathic). __OOHHCCMM__1100ee. . iinnddbb 777744 0022//0055//22001177 1199: : 0099 775 serudecorp lacitcarP Internal jugular catheterization Internal jugular Should be the approach of choice in a non-emergency situation. Ideally the right side as it off ers a direct route to the Heart and there is less chance of misplacement of the line compared to the left. The subclavian approach is trickier and best taught by an expert.",
    "The technique is similar to internal jugular, except the insertion point is just medial to the femoral artery at the groin crease. Subclavian vein Should be taught by an expert and should ideally be carried out under ultrasound guidance. Some physicians prefer this approach, but even in experienced hands there is a risk of complications compared to ultrasound-guided internal jugular lines. __OOHHCCMM__1100ee. . iinnddbb 777755 0022//0055//22001177 1199: : 0099 776 serudecorp lacitcarP Inserting a temporary cardiac pacemaker Often it is wiser to liaise with a specialist pacing centre to arrange prompt, defi nitive pacing than to try temporary transvenous pacing, which often has complications (see later in topic) and therefore may delay a defi nitive procedure. Possible indications in the acute phase of myocardial infarction Complete AV block: With inferior myocardial infarction (right coronary artery occlusion) pacing may only be needed if symptomatic; spontaneous recovery may occur. With anterior myocardial infarction (representing massive septal infarction). Second-degree block: Wenckebach (p99; implies decremental AV node conduction; may respond to atropine in an inferior myocardial infarction; pace if anterior myocardial infarction). Mobitz type 2 block is usually associated with distal fascicular disease and carries High risk of complete Heart block, so pace in both types of myocardial infarction. First-degree block: Observe carefully: 40% develop higher degrees of block. Bundle branch block: Pace prophylactically if evidence of trifascicular disease (p100) or non-adjacent bifascicular disease. Sino-atrial disease serious symptoms: Pace unless responds to atropine. Other indications where temporary pacing may be needed Pre-op: if surgery is required in patients with type 2 or complete Heart block (whether or not myocardial infarction has occurred); do 24h ECG; liaise with the anaesthetist. Drug poisoning, eg with -blockers, digoxin, or verapamil. Symptomatic bradycardia, uncontrolled by atropine or isoprenaline. Suppression of drug-resistant VT and SVT (overdrive pacing; do on ICU). Asystolic cardiac arrest with P-wave activity (ventricular standstill). During or after cardiac surgeryeg around the AV node or bundle of His. Technique for temporary transvenous pacing Learn from an expert. Preparation: Monitor ECG; have a defi brillator to hand, ensure the patient has physical examinationripheral access; check that a radiographer with screening equipment is present. If you are screening, wear a protective lead apron. Insertion: Using an aseptic technique, place the introducer into the (ideally right) internal jugular vein (p775) or subclavian. If this is diffi cult, access to the right atrium can be achieved via the femoral vein. Pass the pacing wire through the introducer into the right atrium, ideally under radiological screening. It will either pass easily through the tricuspid valve or loop within the atrium. If the latter occurs, it is usually possible to fl ip the wire across the valve with a combined twisting and withdrawing movement (fi g 18. 19). Advance the wire slightly. At this stage the wire may try to exit the ventricle through the pulmonary outfl ow tract. A further withdrawing and rotation of the wire will aim the tip at the apex of the right ventricle. Advance slightly again to place the wire in contact with the endocardium. Remove any slack to risk of subsequent displacement. Checking the threshold: Connect the wire to the pacing box and set the demand rate slightly higher than the patients own Heart rate and the output to 3V. A paced rhythm should be seen. Find the pacing threshold by slowly reducing the voltage until the pacemaker fails to stimulate the tissue (pacing spikes are no longer followed by paced beats). The threshold should be less than 1V, but a slightly higher value may be acceptable if it is stableeg after a large infarction.",
    "Watch the team at an arrest, the best leaders are the ones who have learned to stand back, assess the whole situation, and take enough time to see where the critical intervention is needed. There is no substitute for experience, nobody becomes a consultant overnight, but watch the best clinicians at work and you will learn both practical and life skills. Most important in an emergency situation is communication. Wherever you can, involve the relatives and the whole team in discussions, but remember that at the Heart of this is a patient. What do they want? Never be afraid to ask the patient directly, they may hold very strong views. However, it is up to ultrasound as physicians to be honest with them about their prognosisdo not off er a treatment you know is not in the best interests of the patient, and this includes resuscitation. When faced with death, many patients are afraidour role is to try to relieve that fear, whether by intervening to delay death, or by easing their passing. But we cannot ever prevent death, we simply delay it. As Shakespeare has Julius Caesar say: Of all the wonders that I have yet heard, it seems to me most strange that men should fear, seeing that death, a necessary end, will come when it will come. ABCDE preliminary assessment (primary survey) Airway Protect cervical spine, if injury possible. Assessment: any signs of obstruction? Ascertain patency. Management: establish a patent airway. Breathing Assessment: determine respiratory rate, check bilateral chest movement, percuss, and auscultate. Management: if no respiratory eff ort, treat as arrest (see p894, fi g A3), intubate and ventilate. If breathing compromised, give Highconcentration O2, manage according to fi ndings, eg relieve tension pneumothorax. Circulation Assessment: check pulse and blood pressure; check if peripherally shut down; check capillary refi ll; look for evidence of haemorrhage. Management: if shocked, treat as on p790. If no cardiac output, treat as arrest (see p894, fi g A3). Disability Assess level of consciousness with AVPU score (alert? responds to voice? to Pain? unresponsive? ); check pupils: size, equality, reactions. Glasgow Coma Scale, if time allows. Exposure Undress patient, but cover to avoid hypothermia. Quick history from relatives assists diagnosis: Events surrounding onset of illness, evidence of overdose/suicide attempt, any suggestion of trauma? Past medical history, especially Diabetes, asthma, COPD, alcohol, opiate or street drug abuse, epilepsy or recent head injury, recent travel. Medication, current drugs. Allergies. Once ventilation and circulation are adequate, proceed to carry out history, examination, investigations, and management in the usual way. __OOHHCCMM__1100ee. . iinnddbb 777799 0022//0055//22001177 1199: : 0099 780 seicnegremE Headache: diff erential diagnosis The vast majority of headaches are benign, but when taking a history do not forget to ask about the following1 (early diagnosis can save lives): Worrying features or red fl ags First and worst headachesubarachnoid haemorrhage (p478). Thunderclap headachesubarachnoid haemorrhage (p478: p480 for other causes). Unilateral headache and eye Paincluster headache, acute glaucoma (p456). Unilateral headache and ipsilateral symptomsmigraine, tumour, vascular (p458). Cough-initiated headacheICP/venous thrombosis (p480). Worse in the morning or bending forwardICP/venous thrombosis (p480). Persisting headache ± scalp tenderness in over-50sgiant cell arteritis (p556). Headache with fever or neck stiff nessmeningitis (p822). Change in the pattern of usual headaches (p456). Decreased level of consciousness (p456). Two other vital questions: Where have you been? (Malaria, p416). Might you be pregnant? (Pre-eclampsia; especially if proteinuria and blood pressure, p458. )",
    "(Malaria, p416). Might you be pregnant? (Pre-eclampsia; especially if proteinuria and blood pressure, p458. ) Always examine a patient presenting with a severe headache; if nothing about history or examination is concerning, both you and the patient will be reassured, but subtle abnormalities are important not to miss. No signs on examination Tension headache (p456). Migraine (p458). Cluster headache (p457). Post-traumatic (p456). Drugs (nitrates, calcium-channel antagonists) (p114). Carbon monoxide poisoning or anoxia. (p842) Subarachnoid haemorrhage (p478). Signs of meningism? Meningitis (may not have fever or rashp822). Subarachnoid haemorrhage (p478examination may be normal). Decreased conscious level or localizing signs? Stroke (p470). Encephalitis/meningitis (p822). Cerebral abscess (p824). Subarachnoid haemorrhage (pp4789, fi gs 10. 17, 10. 18). Venous sinus occlusion (p480focal neurological defi cits). Tumour (p498). Subdural haematoma (p482). TB meningitis (p393). Papilloedema? Tumour (p498). Venous sinus occlusion (p480focal neurological defi cits). Malignant (accelerated phase) hypertension (p138). Idiopathic intracranial hypertension (p498). Any CNS infection, if prolonged (eg 2wks)eg TB meningitis (p393). Others Giant cell arteritis (p556ESR and tender scalp over temporal arteries). Acute glaucoma (p456painful red eyeget pressures checked urgently). Vertebral artery dissection (p470neck Pain and cerebellar/medullary signs). Cervical spondylosis (p508). Sinusitis. Pagets disease (p685ALP). Altitude sickness (OHCS p770). __OOHHCCMM__1100ee. . iinnddbb 778800 0022//0055//22001177 1199: : 0099 seicnegremE 781 __OOHHCCMM__1100ee. . iinnddbb 778811 0022//0055//22001177 1199: : 0099 782 seicnegremE Breathlessness: emergency presentations There may not be time to ask or the patient may not be able to give you a history in acute breathlessness, this in itself can be a helpful sign (inability to complete sentences in one breath severe breathlessness, inability to speak/impaired conscious level life-threatening). Collateral history of known respiratory disease, anaphylaxis, or other history can be extremely helpful but do not delay. Assess the patient for the following: Wheezing? Asthma (p810). COPD (p812). Heart failure (p800). Anaphylaxis (p794). Stridor? (Upper airway obstruction. ) Foreign body or tumour. Acute epiglottitis (younger patients). Anaphylaxis (p794). Trauma, eg laryngeal fracture. Crepitations? Heart failure (p800). Pneumonia (p816). Bronchiectasis (p172). Fibrosis (p198). Chest clear? Pulmonary embolism (p818). Hyperventilation. Metabolic acidosis, eg diabetic ketoacidosis (p832). Anaemia (p324). Drugs, eg salicylates. Shock (may cause air hunger, p790). Pneumocystis jirovecii pneumonia (p400). CNS causes. Others Pneumothorax (p814Pain, increased resonance, tracheal deviation if tension pneumothorax). Pleural eff usion (p192stony dullness). Key investigations Baseline observationsO2 sats, pulse, temperature, peak fl ow. ABG if saturations 94% or concern about acidosis/drugs/sepsis. ECG (signs of physical examination, LVH, myocardial infarction? ). CXR. Baseline bloods: glucose, FBC, UE, consider drug screen. __OOHHCCMM__1100ee. . iinnddbb 778822 0022//0055//22001177 1199: : 0099 seicnegremE 783 __OOHHCCMM__1100ee. . iinnddbb 778833 0022//0055//22001177 1199: : 0099 784 seicnegremE Chest Pain: diff erential diagnosis First exclude any potentially life-threatening causes, by virtue of history, brief examination, and limited investigations. Then consider other potential causes. For the full assessment of cardiac Pain, see pp94, 118. Life-threatening Acute myocardial infarction (pp7969). Angina/acute coronary syndrome (pp7969). Aortic dissection (p655). Tension pneumothorax (p814). Pulmonary embolism (p818). Oesophageal rupture (p820). Others Pneumonia (p816). Chest wall Pain: Muscular. Rib fractures. Bony metastases. Costochondritis. Gastro-oesophageal refl ux (p254). Pleurisy (p166). Empyema (p170). Pericarditis (p154). Oesophageal spasm (p250). Herpes zoster (p404). Cervical spondylosis (p508). Intra-abdominal: Cholecystitis (p634). Peptic ulceration (p252). Pancreatitis (p270). Sickle-cell crisis (p340). Before discharging patients with undiagnosed chest Pain, be sure in your own mind that the Pain is not cardiac (this Pain is usually dull, may radiate to jaw, arm, or epigastrium, and is usually associated with exertion). Carry out key investigations and discuss options with a colleague, and the patient. Safety-net, telling the patient to return or seek advice if they develop worrying features (specify these) or the Pain does not settle. Key investigations CXR.",
    "__OOHHCCMM__1100ee. . iinnddbb 778888 0022//0055//22001177 1199: : 0099 seicnegremE The neurological examination in coma 789 This is aimed at locating the pathology in one of two places. Altered level of consciousness implies either: 1 A diff use, bilateral, cortical dysfunction (usually producing loss of awareness with normal arousal), or 2 Damage to the ascending reticular activating system (ARAS) located throughout the brainstem from the medulla to the thalami (usually producing loss of arousal with unassessable awareness). The brainstem can be aff ected directly (eg pontine haemorrhage) or indirectly (eg compression from transtentorial or cerebellar herniation secondary to a mass or oedema). Systematic examination: Level of consciousness; describe using objective words/AVPU. Respiratory pattern (p53)Cheyne-Stokes (brainstem lesions or compression) hyperventilation (acidosis, hypoxia, or, rarely, neurogenic), ataxic or apneustic (breath-holding) breathing (brainstem damage with grave prognosis). Eyesalmost all patients with ARAS pathology will have eye fi ndings: 1 Visual fi eldsin light coma, test fi elds with visual threat. No blink in one fi eld suggests hemianopia and contralateral hemisphere lesion. 2 Pupilsnormal direct and consensual refl exes present intact midbrain. Midposition (35mm) non-reactive ± irregular midbrain lesion. Unilateral dilated and unreactive (fi xed) 3rd nerve compression. Small, reactive pontine lesion (pin-point pontine pupils) or drugs. Horners syndrome (p702, fi g 15. 4) ipsilateral lateral medulla or hypothalamus lesion, may precede uncal herniation. Beware patients with false eyes or who use eye drops for glaucoma. 3 Extraocular movements (EOMS)observe resting position and spontaneous movement; then test the vestibulo-ocular refl ex (VOR) with either the dollshead manoeuvre (normal if the eyes keep looking at the same point in space when the head is quickly moved laterally or vertically) or ice Water calorics (normal if eyes deviate towards the cold ear with nystagmus to the other side). If present, the VOR exonerates most of the brainstem from the VIIth nerve nucleus (medulla) to the IIIrd (midbrain). Dont move the head unless the cervical spine is cleared. 4 Fundipapilloedema, subhyaloid haemorrhage, hypertensive retinopathy, signs of other disease (eg diabetic retinopathy). Examine for CNS asymmetry (tone, spontaneous movements, refl exes). One way to test for hemiplegia in coma is to raise both arms together and compare how they fall under gravity. If one descends fast, like a lead weight, but the other descends more gracefully, you have found a valuable focal sign of cortical dysfunction. The same applies to the legs. Reproduced from Assessment of coma and impaired consciousness: a practical scale, Graham Teasdale and Bryan Jennett, The Lancet, Vol 304, No. 7872, 8184 (1974), Elsevier. __OOHHCCMM__1100ee. . iinnddbb 778899 0022//0055//22001177 1199: : 0099 790 seicnegremE Shock Circulatory failure resulting in inadequate organ perfusion. Often defi ned by blood pressure systolic 90mmHgor mean arterial Hypertension (MAP) 65mmHgwith evidence of tissue hypoperfusion, eg mottled skin, Urine output (UO) of 0. 5mL/kg/h, serum lactate 2mmol/L. Signs: GCS/agitation, pallor, cool peripheries, tachycardia, slow capillary refi ll, tachypnoea, oliguria. MAP cardiac output (CO) systemic vascular resistance (SVR). CO stroke volume Heart rate. shock can result from inadequate CO or a loss of SVR, or both. Inadequate cardiac output Hypovolaemia: Bleeding: trauma, ruptured aortic aneurysm, GI bleed. Fluid loss: Vomiting, burns, third-space losses, eg pancreatitis, heat exhaustion. Pump failure: Cardiogenic shock, eg ACS, arrhythmias, aortic dissection, acute valve failure. Secondary causes, eg physical examination, tension pneumothorax, cardiac tamponade. Peripheral circulatory failure (loss of SVR) Sepsis: (p792) Infection with any organism can cause acute vasodilation from infl ammatory cytokines. Gram ves can produce endotoxin, causing sudden and severe shock but without signs of infection (fever, WCC). Classically patients with sepsis are warm vasodilated, but may be cold shut down.",
    "Early warning scores (p892, fi g A1) help identify inpatients who are becoming septic. Have a Low threshold for assessing for sepsis if: the patient has communication diffi culties: limited English; limited verbal communication; cognitive impairment the patient is immunosuppressed, on chemotherapy, or an IV drug user the patient recently had surgery or is pregnant/recently gave birth the patient has indwelling lines/other foreign material. Assessing risk in sepsis Table 19. 3 Risk criteria in sepsis Moderateto High-risk criteria High-risk criteria Reports of altered mental state or acute Objective evidence of altered mental deterioration in functional status state Respiratory rate (respiratory rate) 2124 respiratory rate24; new requirement for FiO2 40% to keep sats 92% (88% in COPD) Systolic Blood Hypertension (SBP) 91100mmHg SBP 90 or 40mmHg less than baseline Heart rate 91130bpm or new arrhythmia Heart rate 130bpm Urine output: nil for 1218h; 0. 51. 0mL/kg/h Urine output: nil for 18h; 0. 5mL/kg/h if if catheterized catheterized Local signs of infection, incl. redness, swellMottled, ashen, or cyanotic skin. Noning, or discharge around wound blanching rash (p822) Rigors, or temperature 36°C Impaired immunity (illness or drugs) Recent surgery/trauma/invasive procedure When there is a suspicion of sepsis, the criteria in table 19. 3 are used to assess the patients risk of death or serious illness from sepsis as follows: High risk: At least one High-risk criterion OR at least two moderateto High-risk criteria with acute kidney injury or LACTATE 2. Moderate to High risk: At least one moderateto High-risk criterion. Low risk: No moderateor High-risk criteria. Acute management in sepsis Early recognition and treatment is key. See fi g 19. 3. 2 Antibiotics: These should be broad spectrum and start within 1h. Consider covering for non-bacterial microbes, eg give aciclovir if HSV encephalitis is suspected. Fluids: Give within 1h if High risk with SBP 90, acute kidney injury, or lactate 2 (consider if 2). Give 500mL boluses of crystalloids with 130154mmol/L Sodium (eg 0. 9% saline) over 15mins. Caution in Heart failure. If no improvement after two boluses, speak with a senior. Oxygen: Give oxygen as required for target saturations. These will be 9498% (or 8892% if the patient is at risk of CO2 retention, eg in severe COPD). Critical care review: Speak with critical care early if intensive care support (eg inotropes, ventilation, haemofi ltration, intensive monitoring) may be required. Surgical involvement: Eg emergency wound debridement. Manage acute complications: Shock (p790), acute kidney injury (p298), DIC (p352), ARDS (p186), arrhythmias (may spontaneously resolve when sepsis improves). __OOHHCCMM__1100ee. . iinnddbb 779922 0022//0055//22001177 1199: : 0099 seicnegremE 793 Acute management of sepsis in adults Recognize the need to assess for sepsis Consider possibility of sepsis in any patient with signs or symptoms that are suggestive of infection (eg productive cough or off ensive oozing wound) Consider non-specifi c signs (patient/carer concern; altered mental state; feeling generally unwell), particularly when there is reason to have Low threshold for sepsis assessment (see BOX) Gather information History: Full medical history: take time to clarify the time course of symptoms and any travel history Examination: General: capillary refi ll time, mottled/ashen skin, conscious level Localize source of infection: dont forget to assess wounds/ulcers which may be hidden by dressings Bedside tests: Blood gas for lactate, observations incl. heart rate, blood pressure, respiratory rate, sats, temperature; ECG; Urine dip and Urine output monitoring Assess risk (see BOX) High risk Moderate to High risk Low risk Request immediate Clinician review within 1h.",
    "Morphine: 510mg IV (repeat after 5min if necessary). Give anti-emetic with the 1st dose of morphine: metoclopramide 10mg IV (1st line), or cyclizine 50mg IV (2nd line). GTN: routine use now not recommended in the acute setting unless patient is hypertensive or in acute LVF. Useful as anti-anginal in chronic/stable patients. Oxygen is recommended if patients have SaO2 95%, are breathless or in acute LVF. Restore coronary perfusion in those presenting 12h after symptom onset (see BOX). Anticoagulation: An injectable anticoagulant must be used in primary PCI. Bivalirudin is preferred, if not available use enoxaparin ± a GP IIb/IIIa blocker. ß-blockers provide additional benefi t when started early, eg bisoprolol 2. 5mg PO OD. Ensure no evidence of cardiogenic shock, Heart failure, asthma/COPD, or Heart block. Right ventricular infarction Confi rm by demonstrating ST elevation in rV3/4 and/ or echo. NB: rV4 means that V4 is placed in the right 5th intercostal space in the midclavicular line. Treat hypotension and oliguria with fl uids (avoid nitrates and diuretics). Monitor blood pressure carefully, and assess early signs of pulmonary oedema. Intensive monitoring and inotropes may be useful in some patients. Reperfusion therapy Early coronary reperfusion saves lives; decisions must be taken quickly so seek senior advice early. Look for typical clinical symptoms of myocardial infarction plus ECG criteria: ST elevation 1mm in ≥2 adjacent limb leads or 2mm in ≥2 adjacent chest leads. LBBB (unless known to have LBBB previously). Posterior changes: deep ST depression and tall R waves in leads V1 to V3. Therapy may be percutaneous intervention (PCIwith angiographic identifi cation of the culprit blockage(s) and revascularization via deployment of an expandable metal stent) or thrombolysis (with systemically administered clot-dissolving enzymes): Primary PCI: Should be off ered to all patients presenting within 12h of symptom onset with a STEMI who either are at or can be transferred to a primary PCI centre within 120min of fi rst medical contact. If this is not possible, patients should receive thrombolysis and be transferred to a primary PCI centre after the infusion for either rescue PCI (if residual ST elevation) or angiography (if successful). Use beyond 12h if evidence of ongoing ischaemia or in stable patients presenting after 1224h may be appropriateseek specialist advice. Thrombolysis: Benefi t reduces steadily from onset of Pain, target time is 30min from admission; use 12h from symptom onset requires specialist advice. Do not thrombolyse ST depression alone, T-wave inversion alone, or normal ECG. Thrombolysis is best achieved with tissue plasminogen activators (eg tenecteplase as a single IV bolus). CI: Previous intracranial haemorrhage. Ischaemic stroke 6months. Cerebral malignancy or AVM. Recent major trauma/surgery/ head injury (3wks). GI bleeding (1 month). Known bleeding disorder. Aortic dissection. Non-compressible punctures 24h, eg Liver biopsy, lumbar puncture. Relative CI: TIA 6 months. Anticoagulant therapy. Pregnancy/1wk post partum. Refractory hypertension (180mmHg/110mmHg). Advanced Liver disease. Infective endocarditis. Active peptic ulcer. Prolonged/traumatic resuscitation. Patients with STEMI who do not receive reperfusion (eg presenting 12h after symptom onset) should be treated with fondaparinux, or enoxaparin/unfractionated heparin if not available. __OOHHCCMM__1100ee. . iinnddbb 779966 0022//0055//22001177 1199: : 0099 seicnegremE Management of an acute STEMI 797 Attach ECG monitor and record a 12-lead ECG IV access. Bloods for FBC, UE, glucose, lipids, troponin (p119, fi g 3. 22) Brief assessment: History of cardiovascular disease; risk factors for IHD Examination: pulse, blood pressure (both arms), JVP, murmurs, signs of CCF, upper limb pulses, scars from previous cardiac surgery, CXR if will not delay Contraindications to PCI or fi brinolysis?",
    "Aspirin: 300mg (unless already given by GP/paramedics) Ticagrelor: 180mg (or alternative antiplateletsee Aspirin in text) Morphine: 510mg IV anti-emetic, eg metoclopramide 10mg IV STEMI on ECG and PCI available within 120min? Yes No Primary PCI Fibrinolysis Transfer to primary PCI centre for either rescue PCI if fi brinolysis unsuccessful or for angiography For further management see p120 Fig 19. 5 Management of an acute STEMI. __OOHHCCMM__1100ee. . iinnddbb 779977 0022//0055//22001177 1199: : 0099 798 seicnegremE Acute coronary syndromewithout ST-elevation First stabilize with medical therapy; early risk stratifi cation will identify those in need of further treatment and prompt angiography (involve cardiologists). 4 Assessment Brief history: (See p36. ) Previous angina, relief with rest/nitrates, history of cardiovascular disease, risk factors for IHD. Examination: (See p38. ) Pulse, blood pressure, JVP, cardiac murmurs, signs of Heart failure, physical examinationripheral pulses, scars from previous cardiac surgery. Investigations ECG: ST depression; fl at or inverted T-waves; or normal; FBC, UE, troponin, glucose, random cholesterol; CXR. Management See fi g 19. 6 for acute management, but p796 if ST elevation. The aim of therapy is to control Pain then initiate anti-ischaemic and antiplatelet therapy. Oral antiplatelet therapy: Aspirin 300mg PO, followed by 75mg OD. For those with confi rmed ACS give a second antiplatelet agent, eg clopidogrel (300mg PO then 75mg OD PO). Ticagrelor (180mg then 90mg/12h PO) is a prefered alternative, particularly in higher risk groups5 (eg ≥60yrs age previous stroke, TIA, myocardial infarction, or CABG known coronary artery stenosis ≥50% in ≥2 vessels or carotid stenosis ≥50% diabetes mellitus peripheral arterial disease chronic Kidney disease). Prasugrel (60mg then 10mg/d PO) is an alternative to clopidogrel for those undergoing PCI. In practice, if the history is typical but ECG changes are non-diagnostic and troponin results are awaited, treatment with eg clopridogrel is often given on clinical suspicion; if troponin testing then confi rms ACS, it is still appropriate to give either ticagrelor or prasugrel to those patients in whom it is indicated, even if clopidogrel has already been given. Anticoagulation: Ideally fondaparinux (factor Xa inhibitor) 2. 5mg OD; if not available, use Low-molecular-weight heparin (LMWH, eg enoxaparin 1mg/kg/12h) or unfractionated heparin (aim APTT 5070s) until discharge. ß-blockers: In higher-risk patients with no contraindications (consider diltiazem as alternative). Do not use -blockers with verapamilcan precipitate asystole. Nitrates (PO or IV): For recurrent chest Pain. angiotensin-converting enzyme inhibitor: Should be given to all patients unless there are CI (monitor renal function). Lipid management: Start early, eg atorvastatin 80mg OD (see p120). Prognosis Overall risk of death 12%, but 15% for refractory angina despite medical therapy. Risk stratifi cation can help predict those most at risk and allow intervention to be targeted at those individuals: calculate using GRACE score. 2 The following are associated with an increased risk: History of unstable angina. ST depression or widespread T-wave inversion. Raised troponin (except patients with ST elevation myocardial infarction). Age 70 years. General comorbidity, previous myocardial infarction, poor LV function or diabetes mellitus. High-risk patients should be considered for inpatient coronary angiography. Symptomatic lesions may be addressed by coronary stenting or CABG (see p123). Further measures Wean off glyceryl trinitrate (GTN) infusion when stabilized on oral drugs. Continue fondaparinux (or LMWH or heparin) until discharge. Observe on cardiac monitor or telemetry in case of dysrhythmia. Check serial ECGS, and troponin 12h after Pain. Address modifi able risk factors: smoking, hypertension, hyperlipidaemia, Diabetes. Gentle mobilization. Ensure patient on dual antiplatelet therapy, -blocker, ACE inhibitor, and statin. If symptoms recur, refer to cardiologist for urgent angiography PCI or CABG. 2 GRACE Global Registry of Acute Coronary Events.",
    "If symptoms recur, refer to cardiologist for urgent angiography PCI or CABG. 2 GRACE Global Registry of Acute Coronary Events. Risk is scored based on age, Heart rate, blood pressure, renal function, Killip class of Heart failure, and other events, eg raised troponin. Very complicated to calculate so recommendation by European Society of Cardiology is to use an online calculator, eg __OOHHCCMM__1100ee. . iinnddbb 779988 0022//0055//22001177 1199: : 0099 seicnegremE Acute management of cardiac chest Pain 799 Monitor closely; record ECG while in Pain If SaO2 90% or breathless, Low-fl ow O2 Analgesia: Eg morphine 510mg IV metoclopramide 10mg IV Nitrates: GTN spray or sublingual tablets as required Aspirin: 300mg PO. Consider need for second antiplatelet agent (see Oral antiplatelet therapy in text) Measure troponin and clinical parameters to risk assess, eg GRACE score2 Invasive strategy (High-risk patient): Conservative strategy (Low-risk patient): Rise in troponin OR: No recurrence of chest Pain Dynamic ST or Twave changes No signs of Heart failure Secondary criteriaDiabetes, chronic kidney disease, Normal ECG LVEF 40%, early angina post myocardial infarction, ve baseline (± repeat) troponin recent PCI, prior CABG, intermediMay be discharged (check troponin ate to High-risk GRACE score interval required with your laboratory and retest after delay if necessary). Arrange further outpatient investigation, eg stress test. Fondaparinux: 2. 5mg OD SC or LMWH 1mg/kg/12h SC Second antiplatelet agent (see text), eg ticagrelor 180mg PO (or clopidogrel 300mg PO in lower risk, or prasugrel 60mg OD if proceeding to PCI) IV nitrate if Pain continues (eg GTN 50mg in 50mL 0. 9% saline at 210mL/h) titrate to Pain, and maintain systolic blood pressure 100mmHg Oral -blocker, eg bisoprolol 2. 5mg OD CI: cardiogenic shock, Heart failure, asthma/COPD or Heart block; consider rate-limiting calcium antagonist (eg verapamil 80120mg/8h PO, or diltiazem 60120mg/8h PO) Prompt cardiologist review for angiography 1 Urgent (120min after presentation) if ongoing angina and evolving ST changes, signs of cardiogenic shock or life-threatening arrhythmias 2 Early (24h) if GRACE score 140 and High-risk patient 3 Within7 2h if lower-risk patient Fig 19. 6 Acute management of chest Pain and ACS without ST-segment elevation. __OOHHCCMM__1100ee. . iinnddbb 779999 0022//0055//22001177 1199: : 0099 800 seicnegremE Severe pulmonary oedema Causes Cardiovascular, usually left ventricular failure (post-myocardial infarction or ischaemic Heart disease). Also valvular Heart disease, arrhythmias, and malignant hypertension. ARDS (p186) from any cause, eg trauma, malaria, drugs. Look for predisposing factors, eg trauma, post-op, sepsis. Is aspirin overdose or glue-sniffi ng/drug abuse likely? Ask friends/relatives. Fluid overload. Neurogenic, eg head injury. Diff erential diagnosis Asthma/COPD, pneumonia, and pulmonary oedema are often hard to distinguish, especially in the elderly, where they may coexist. If the patient is extremely unwell and you are not sure, consider treating all three (eg with salbutamol nebulizer, furosemide IV, diamorphine, amoxicillinp386). Symptoms Dyspnoea, orthopnoea (eg paroxysmal), pink frothy sputum. NB: note drugs recently given and other illnesses (recent myocardial infarction/COPD or pneumonia). Signs Distressed, pale, sweaty, pulse, tachypnoea, pink frothy sputum, pulsus alternans, JVP, fi ne lung crackles, triple/gallop rhythm (p44), wheeze (cardiac asthma). Usually sitting up and leaning forward. Quickly examine for possible causes. Investigations CXR (p135, pp7224): cardiomegaly, signs of pulmonary oedema: look for shadowing (usually bilateral), small eff usions at costophrenic angles, fl uid in the lung fi ssures, and Kerley B lines (septal linear opacities). ECG: signs of myocardial infarction, dysrhythmias. UE, troponin, ABG. Consider echo. BNP (p137) may be helpful if diagnosis in question (High negative predictive value). Management See fi g 19. 7. Begin treatment before investigations. Monitoring progress: blood pressure; pulse; cyanosis; respiratory rate; JVP; Urine output; ABG.",
    "7. Begin treatment before investigations. Monitoring progress: blood pressure; pulse; cyanosis; respiratory rate; JVP; Urine output; ABG. Observe on cardiac monitor or telemetry in case of dysrhythmia. Once stable and improving: Daily weights, aim reduction of 0. 5kg/day, check obs at least QDS. Repeat CXR. Change to oral furosemide or bumetanide. If on large doses of loop diuretic, consider the addition of a thiazide (eg bendrofl umethiazide or metolazone 2. 55mg daily PO). angiotensin-converting enzyme inhibitor if LVEF 40%. If angiotensin-converting enzyme inhibitor contraindicated, consider hydralazine and nitrate (may also be more eff ective in African-Caribbeans). Also consider -blocker and spironolactone (if LVEF 35%). Is the patient suitable for biventricular pacing or cardiac transplantation? Optimize management of atrial fibrillation if present (p130); consider anticoagulation. __OOHHCCMM__1100ee. . iinnddbb 880000 0022//0055//22001177 1199: : 0099 seicnegremE Management of acute Heart failure 801 Sit the patient upright High-fl ow oxygen if SpO2 IV access and monitor ECG Treat any arrhythmias, eg atrial fibrillation (pp12431) Investigations whilst continuing treatment See p800 Diamorphine 1. 255mg IV slowly Caution in Liver failure and COPD Furosemide 4080mg IV slowly Larger doses required in renal failure GTN spray 2 puff s SL or 2 0. 3mg tablets SL Dont give if systolic blood pressure 90mmHg Necessary investigations, examination, and history If systolic blood pressure ≥100mmHg, start a nitrate infusion, eg isosorbide dinitrate 210mg/h IVI; keep systolic blood pressure ≥90mmHg If the patient is worsening: Further dose of furosemide 4080mg Consider CPAPimproves ventilation by recruiting more alveoli, driving fl uid out of alveolar spaces and into vasculature (get help before initiating! ) Increase nitrate infusion if able to do so without dropping systolic blood pressure 100mmHg Consider alternative diagnoses, eg hypertensive Heart failure, aortic dissection, pulmonary embolism, pneumonia If systolic blood pressure 100mmHg, treat as cardiogenic shock (p802) and refer to ICU Avoid supplemental oxygen if not hypoxaemic since may cause vasoconstriction and reduce cardiac output. If known COPD, hypoxaemia still needs correcting; give High-fl ow oxygen but monitor closely for CO2 retention (check serial ABG if needed) and reduce fl ow as soon as possible. Fig 19. 7 Management of Heart failure. __OOHHCCMM__1100ee. . iinnddbb 880011 0022//0055//22001177 1199: : 0099 802 seicnegremE Cardiogenic shock This has a High mortality and is very diffi cult to treat. Ask a senior physicians help both in formulating an exact diagnosis and in guiding treatment. Cardiogenic shock is a state of inadequate tissue perfusion primarily due to cardiac dysfunction. It may occur suddenly, or after progressively worsening Heart failure. Causes Myocardial infarction (pp7969). Arrhythmias (pp12431). Pulmonary embolus (p818). Tension pneumothorax (p814). Cardiac tamponade (p154 and later in topic). Myocarditis; myocardial depression (drugs, hypoxia, acidosis, sepsis) (p152). Valve destruction (endocarditisp150). Aortic dissection (p655). Management See fi g 19. 8. If the cause is myocardial infarction prompt reperfusion therapy is vital (see p796). Manage in Coronary Care Unit, or ICU. Investigation and treatment may need to be done concurrently. Investigations: ECG, UE, troponin, ABG, CXR, echocardiogram. If indicated, computed tomography thorax (speak with radiologists, this can be protocolled for both aortic dissection and physical examination). Monitor: CVP, blood pressure, ABG, ECG, Urine output. Keep on cardiac monitor/telemetry. Record a 12-lead ECG every hour until the diagnosis is made. Consider a CVP line and an arterial line to monitor Hypertension, if these are in situ consider measuring cardiac output and volume status. 3 Catheterize for accurate Urine output. Cardiac tamponade Pericardial fl uid collects intrapericardial Hypertension rises Heart cannot fi ll pumping stops. Causes: Trauma, lung/breast cancer, pericarditis, myocardial infarct, bacteria, eg TB. Rarely: urea, radiation, myxoedema, dissecting aorta, SLE.",
    "Causes: Trauma, lung/breast cancer, pericarditis, myocardial infarct, bacteria, eg TB. Rarely: urea, radiation, myxoedema, dissecting aorta, SLE. Also coronary artery dissection (secondary to PCI) and/or ruptured ventricle. Signs: blood pressure, JVP, and muffl ed Heart sounds (Becks triad); JVP on inspiration (Kussmauls sign); pulsus paradoxus (pulse fades on inspiration). Echocardiography may be diagnostic. CXR: globular Heart; left Heart border convex or straight; right cardiophrenic angle 90°. ECG: electrical alternans (p154). Management: This can be very diffi cult. Everything is against you: time, physiology, and your own confi dence, as the patient may be too ill to give a history, and signs may be equivocalbut bitter experience has taught ultrasound not to equivocate for long. Request the presence of your senior at the bedside (do not make do with telephone advice). With luck, prompt pericardiocentesis (p773) brings swift relief. While awaiting this, give O2, monitor ECG, and set up IVI. Take Blood for group save. NB: there may be a role for cardiothoracic surgery (eg CABG, ventricular repair, or pericardial window) as a defi nitive solution to some causes. 3 Eg Pulse contour cardiac output (PICCO) or lithium dilution cardiac output (LIDCO). Both use injection (PICCO cold Water, LIDCO lithium) to estimate fi lling Hypertension, extravascular Water (ie pulmonary oedema) and cardiac output. The time from injection via a central vein to detection via an arterial line, plus dilution, gives estimates of cardiac output and volume status and can guide fl uid and inotrope therapy. __OOHHCCMM__1100ee. . iinnddbb 880022 0022//0055//22001177 1199: : 0099 seicnegremE Management of cardiogenic shock 803 Oxygen Titrate to maintain arterial saturations of 9498% (8892% if COPD) Diamorphine 1. 255mg IV for Pain and anxiety Investigations and close monitoring (see p802) Correct arrhythmias (pp12431), UE abnormalities, or acidbase disturbance Optimize fi lling Hypertension with clinical assessment of pulse, blood pressure, JVP/ CVP (if in ICU consider using PICCO, LIDCO, transoesophageal doppler or SwanGantz catheter to estimate cardiac output and fl uid balance) Underfi lled? Well/over-fi lled? Give a plasma expander Inotropic support, eg dobutamine 100mL every 15min IV 2. 510mcg/kg/min IVI. Aim MAP Aim MAP 70mmHg, CVP 810mmHg 70mmHg Look for and treat any reversible cause: myocardial infarction or physical examinationconsider thrombolysis; surgery for: acute VSD, mitral, or aortic incompetence Fig 19. 8 Management of cardiogenic shock. MAP mean arterial Hypertension. __OOHHCCMM__1100ee. . iinnddbb 880033 0022//0055//22001177 1199: : 0099 804 seicnegremE Broad complex tachycardia ECG shows rate of 100bpm and QRS complexes 120ms (3 small squares on ECGS done at the standard UK rate of 25mm/s). Identify the underlying rhythm and treat accordingly. 6 Diff erential diagnosis (See p128. ) Ventricular tachycardia (VT) including torsade de pointes. Single ventricular ectopics should not cause confusion; if 3 together at a rate 100, this is VT. SVT (p806) with aberrant conduction, eg atrial fibrillation or atrial fl utter, with bundle branch block. Pre-excited tachycardias, eg atrial fibrillation, atrial fl utter, or AV re-entry tachycardia, with underlying WPW (p133). Identifying the underlying rhythm (See p128. ) If in doubt, treat as VT. Management See fi g 19. 9. 6 Connect patient to a cardiac monitor and have a defi brillator to hand. Monitor O2 sats and if 90% give supplemental oxygen. Correct electrolyte abnormalities, esp potassium and Mg2. Check for adverse signs. Low cardiac output (clammy, consciousness, blood pressure 90); oliguria; angina; pulmonary oedema. Obtain 12-lead ECG (request CXR) and obtain IV access. If haemodynamically unstable VT: Synchronized DC shock (see p894, fi g A3). Correct any hypokalaemia and hypomagnesaemia: up to 60mmol KCl at 30mmol/h, and 4mL 50% magnesium sulfate over 30min both via central line.",
    "Follow with amiodarone 300mg IV over 1020min (peripherally only in emergency). For refractory cases consider procainamide or sotalol. If haemodynamically stable VT: Correct hypokalaemia and hypomagnesaemia: as above. Amiodarone 300mg IV over 2060min (avoid if long QT) via central line. If this fails, use synchronized DC shock. After correction of VT: Establish the cause (via the history and tests described above). Maintenance anti-arrhythmic therapy may be required. If VT occurs after myocardial infarction, give IV amiodarone infusion for 1224h; if 24h after myocardial infarction, also start oral anti-arrhythmic: sotalol (if Good LV function) or amiodarone (if poor LV function). Prevention of recurrent VT: surgical isolation of the arrhythmogenic area or an implantable cardioverter defi brillator (ICD) may help. Ventricular fi brillation: (ECG p129, fi g 3. 29) Use non-synchronized DC shock (there is no R wave to trigger defi brillation, p770): see p894, fi g A3. If SVT with aberrant conduction: Manage as SVT with eg adenosine (see p806). Ventricular extrasystoles (ectopics): These are the commonest post-myocardial infarction arrhythmia but they are also seen in healthy people (often 10/h). Patients with frequent ectopics post-myocardial infarction have a worse prognosis, but there is no evidence that antidysrhythmic drugs improve outcome, indeed they may increase mortality. Torsade de pointes: A form of VT, with a constantly varying axis, often in the setting of long QT syndromes (ECG p129, fi g 3. 31). Causes (p711): congenital or from drugs (eg some antidysrhythmics, tricyclics, antimalarials, antipsychotics). Torsade in the setting of congenital long-QT syndromes can be treated with High doses of -blockers. In acquired long-QT syndromes (p711), stop all predisposing drugs, correct hypokalaemia, and give magnesium sulfate (2g IV over 10min). Alternatives include: overdrive pacing (pace at a faster rate, then slow reduce) or isoprenaline IVI to increase Heart rate. __OOHHCCMM__1100ee. . iinnddbb 880044 0022//0055//22001177 1199: : 0099 seicnegremE Management of broad complex tachycardia 805 No Use arrest protocol Pulse? Yes Give O2 if SaO290%, get IV access 12-lead ECG Adverse signs? Shock (blood pressure 90mmHg, pulse 100) Chest Pain/ischaemia on ECG No Heart failure Yes Syncope Correct electrolyte problems: Get expert help (esp. Low potassium, Mg2, Ca2) Sedation Assess rhythm If regular: If VT or uncertain rhythm, give amiodarone Up to 3 synchronized DC 300mg IV over ≥20min. Then 900mg over shocks: 120150J for the fi rst, 24h, all via central line then 150360J subsequently If known history of SVT and BBB treat as for narrow complex tachycardia with eg Check and correct potassium, Mg2, Ca2 adenosine (p806) If irregular: Seek expert help; diagnosis is usually one of: Amiodarone 300mg IV over atrial fibrillation (p130) with bundle branch block ≥20min; consider repeat shock; Pre-excited atrial fibrillation: consider amiodarone then 900mg/24h IVI via central line Polymorphic VT, eg torsade de pointes; see above; give Mg2 2g IVI Further cardioversion if needed If no success or becomes unstable: For refractory cases seek Sedation expert help and consider: Procainamide Overdrive pacing Synchronized DC shock: 150200J 150360J x 2 (biphasic) Check your defi brillator: energies given are for a typical biphasic defi brillator (preferred); if a monophasic shock used, higher energies will be required. Fig 19. 9 Management of broad complex tachycardia. __OOHHCCMM__1100ee. . iinnddbb 880055 0022//0055//22001177 1199: : 0099 806 seicnegremE Narrow complex tachycardia ECG shows rate of 100bpm and QRS complex duration of 120ms (3 small squares on ECGs done at the standard UK rate of 25mm/s). Diff erential diagnosis (See p126. ) Sinus tachycardia: Normal P wave followed by normal QRSnot an arrhythmia! Do not attempt to cardiovert; if necessary (ie not a physiological response to fever/ hypovolaemia) rate control with -blockers.",
    "Shock Chest Pain/ischaemia on ECG No Heart failure Yes Syncope Is the rhythm regular? Get expert help Yes No Probable atrial fibrillation Sedation See BOX Start continuous ECG trace. Perform vagal Up to 3 synchronized DC shocks: manoeuvres (caution if possible digoxin 70120J for the fi rst (120150J for toxicity, acute ischaemia or carotid bruit) atrial fibrillation), then 120360J subsequently If vagal manoeuvres fail, give adenosine Check and correct potassium, Mg2, Ca2 6mg bolus IV, then 12mg, and further 12mg if necessary (verapamil 2. 55mg over 2min is an alternative if adenosine contraindiAmiodarone 300mg IV over cated or does not succeed) ≥20min; consider repeat shock; then 900mg/24h IVI via central line Sinus rhythm achieved? Yes No Probable paroxysPossible atrial fl utter mal re-entrant SVT Seek expert help Assess ECG for eg WPW Control rate with, eg If recurrent consider -blocker referral for electrophysiology/prophylaxis Check your defi brillator: energies given are for a typical biphasic defi brillator (preferred); if a monophasic shock used, higher energies will be required. Fig 19. 10 Management of narrow complex tachycardia (supraventricular tachycardia). Irregular narrow complex tachycardia Treat as atrial fibrillationby far the most likely diagnosis. Control rate with: -blocker: eg metoprolol 110mg IV, give small increments to slow rate rate-limiting Ca2-channel blocker eg verapamil 510mg IV digoxin is an alternative in Heart failure (load with eg 500mcg PO then 500mcg PO after 8h and further 250mcg PO after 8h) amiodarine (may also control rhythmsee last bullet point in this box). Consider anticoagulation with warfarin or NOAC to risk of stroke. If onset defi nitely 48h, or if eff ectively anticoagulated for 3wk, consider cardioversion with synchronized DC cardioversion under sedation (see p770). Chemical cardioversion may be achieved with fl ecanide 300mg PO (only if defi nitely no structural Heart damage) or amiodarone, 300mg IVI over 2060min, then 900mg over 24h. __OOHHCCMM__1100ee. . iinnddbb 880077 0022//0055//22001177 1199: : 0099 880088 sseeiiccnneeggrreemmEE Bradycardia Bradycardia is defi ned as a Heart rate 60bpm. This may be normal and asymptomatic in very fi t, young individuals whose High stroke volumes will maintain adequate cardiac output at Low Heart rates. Symptoms Often asymptomatic. Fatigue, nausea, dizziness. The presence of syncophysical examination, chest Pain, or breathlessness is concerning and suggests the presence of adverse signs; sudden cardiac death can occur. Rhythm The immediate management tends to relate more to cause and adverse signs than to the underlying rhythm, which may be sinus bradycardia Heart block (see p98) atrial fibrillation with a slow ventricular response atrial fl utter with a High-degree block junctional bradycardia. Causes Physiological: Heart rates as Low as 40bpm at rest and 30bpm in sleep can be before mealscepted in asymptomatic trained athletes. Cardiac: Degenerative changes causing fi brosis of conduction pathways (risk in elderly patients; may have previous ECGs showing bundle branch block or 1stor 2nddegree Heart block). Post-myocardial infarctionparticularly after an inferior myocardial infarction (the right coronary artery supplies the sinoatrial node and atrioventricular node in most people). Sick sinus syndrome (p125). Iatrogenicablation, surgery. Aortic valve disease, eg infective endocarditis (p150; do daily ECGs looking for Heart block). Myocarditis, cardiomyopathy, amyloid, sarcoid, SLE. Non-cardiac origin: Vasovagalvery common (p460). Endocrinehypothyroidism, adrenal insuffi ciency. Metabolichyperkalaemia, hypoxia. Otherhypothermia, ICP (Cushings triad: bradycardia, hypertension, and irregular breathing: urgent senior input needed). Drug-induced: -blockers, amiodarone, verapamil, diltiazem, digoxin. Management Follow a logical approach, 6 see fi g 19. 11. 6 Think ahead. If you may need an anaesthetist to sedate the patient for transcutaneous pacing, or a cardiologist for transvenous pacing, call them now. Perform a 12-lead ECG, check electrolytes (including potassium, Ca2, Mg2), do digoxin levels. Connect patient to cardiac monitor/telemetry.",
    "Perform a 12-lead ECG, check electrolytes (including potassium, Ca2, Mg2), do digoxin levels. Connect patient to cardiac monitor/telemetry. Address the cause: correct metabolic defects; if the patient has adverse signs or is deteriorating, give antidotes to medicines likely to have caused the bradycardia (eg glucagon if -blocker overdose). If the patient has adverse signs or risk of asystole, give atropine (not to be given if patient has a transplanted Heart). If atropine is insuffi cient and adverse signs persist, transcutaneous pacing should be considered (p777). If this cannot be initiated immediately (eg waiting for an anaesthetist), consider other medications such as isoprenaline infusion. Remember electrical capture with transcutaneous pacing does not guarantee mechanical capture. Once pacing is established, check the patients pulse. It is possible to have two patients sat next to each other with identical bradycardic ECG tracings, one of whom is peri-arrest, the other is sat comfortably and cannot understand your concern. The clinical state is more important than the numbers on the screen. __OOHHCCMM__1100ee. . iinnddbb 880088 0022//0055//22001177 1199: : 0099 seicnegremE 809 seicnegremE Management of bradycardia 809 Give O2 if hypoxic; manual blood pressure; ECG; IV access Identify reversible causes (eg electrolyte abnormalities) Adverse signs? Shock Syncope Yes Heart failure No Myocardial ischaemia Give atropine 500mcg IV Risk of asystole? Recent asystole Yes Mobitz II AV block (p98) Satisfactory Complete Heart block with response? broad QRS Yes Ventricular pause 3s No No Interim measures: Repeat atropine 500mcg IV every 35mins (max 3mg) Transcutaneous pacingp777 Isoprenaline 5mcg/min IVI Adrenaline 210mcg/min IVI Continue observation Alternatives: aminophylline, dopamine, glucagon (if bradycardia caused by -blocker or calcium channel blocker) Seek expert help and arrange transvenous pacing Fig 19. 11 Management of bradycardia. __OOHHCCMM__1100ee. . iinnddbb 880099 0022//0055//22001177 1199: : 0099 810 seicnegremE Acute severe asthma The severity of an attack is easily underestimated. An atmosphere of calm helps. Presentation Acute breathlessness and wheeze. History (See p48. ) Ask about usual and recent treatment; previous acute episodes and their severity and best peak expiratory fl ow rate (PEF). Have they been admitted to ICU? Diff erential diagnosis Acute infective exacerbation of COPD, pulmonary oedema, upper respiratory tract obstruction, pulmonary embolus, anaphylaxis. Investigations PEFbut may be too ill; ABG if saturations 92% or life-threatening features; CXR (if suspicion of pneumothorax, infection or life-threatening attack); FBC; UE. Assessing the severity of an acute asthma attack Severe attack: Unable to complete sentences in one breath. Respiratory rate ≥ 25/min. Pulse rate ≥110 beats/min. PEF 3350% of predicted or best. Life-threatening attack: PEF 33% of predicted or best. Silent chest, cyanosis, feeble respiratory eff ort. Arrhythmia or hypotension. Exhaustion, confusion, or coma. Arterial Blood gases: Normal/High PaCO2 4. 6kPa. PaO2 8kPa, or SaO2 92%. Management Rapid treatment and reassessment is key, 7 see fi g 19. 12. Salbutamol 5mg nebulized with oxygen and give prednisolone 30mg PO. If PEF remains 75%, repeat salbutamol; add ipratropium. Monitor oxygen saturation, Heart rate, and respiratory rate. Admit all with severe features not responding to initial treatment or with lifethreatening features. NB: the routine use of antibiotics is not recommended in exacerbations of asthma. Discharge Patients with PEF 75% within 1h of initial treatment can be discharged if no other reason to admit. Otherwise, before discharge patients must have: been stable on discharge medication for 24h had inhaler technique checked peak fl ow rate 75% predicted or best with diurnal variability 25% steroid (inhaled and oral) and bronchodilator therapy their own PEF meter and have written management plan GP appointment within 2d respiratory clinic appointment within 4wks. Drugs used in acute asthma Salbutamol (2-agonist). SE: tachycardia, arrhythmias, tremor, potassium.",
    "Drugs used in acute asthma Salbutamol (2-agonist). SE: tachycardia, arrhythmias, tremor, potassium. Hydrocortisone and prednisolone (steroid; reduces infl ammation). Aminophylline is used much less frequently and is not routinely recommended in current BTS guidelines, but may be initiated by respiratory team or ICU. It inhibits phosphodiesterase; cAMP. SE: pulse, arrhythmias, nausea, seizures. The amount of IVI aminophylline may need altering according to the individual patient: always check the BNF. Monitor ECG. Aim for plasma concentration of 1020mcg/mL (55110μmol/L). Serious toxi city (blood pressure arrhythmias, cardiac arrest) can occur at concentrations ≥25mcg/mL. Measure plasma potassium: theophyllines may cause potassium. Dont load patients already on oral preparations. Stick with one brand (bioavailability varies). __OOHHCCMM__1100ee. . iinnddbb 881100 0022//0055//22001177 1199: : 0099 seicnegremE Management of acute asthma 811 Assess severity of attack: PEF, ability to speak, respiratory rate, pulse rate, O2 sats Warn ICU if severe or life-threatening attack Immediate treatment: Supplemental O2 to maintain sats 9498% Salbutamol 5mg (or terbutaline 10mg) nebulized with O2 If severe/life-threatening add in ipratropium 0. 5mg/6h to nebulizers Hydrocortisone 100mg IV or prednisolone 4050mg PO Reassess every 15min: If PEF 75% repeat salbutamol nebulizers every 1530min, or 10mg/h continuously. Add ipratropium if not already given Monitor ECG; watch for arrhythmias Consider single dose of magnesium sulfate (MgSO4) 1. 22g IV over 20min in those with severe/life-threatening features without Good initial response to therapy If not improving: If improving within 1530min: Refer to ICU for consideration of Continue nebulized salbutamol ventilatory support and intensifi - every 46h ( ipratropium if cation of medical therapy, eg amistarted in previous step) nophylline, IV salbutamol if any of Prednisolone 4050mg PO OD the following signs are present: for 57 days Deteriorating PEF Monitor peak fl ow and O2 Persistent/worsening hypoxia sats, aim 9498% with sup- Hypercapnia plemental if needed ABG showing Low pH or High H If PEF 75% 1h after initial Exhaustion, feeble respiration treatment, consider discharge Drowsiness, confusion, altered with outpatient follow-up conscious level Respiratory arrest Fig 19. 12 Management of acute asthma. __OOHHCCMM__1100ee. . iinnddbb 881111 0022//0055//22001177 1199: : 0099 812 seicnegremE Acute exacerbations of COPD A common medical emergency especially in winter. May be triggered by viral or bacterial infections. Presentation Increasing cough, breathlessness, or wheeze. Decreased exercise capacity. History (See p48. ) Ask about usual/recent treatments (especially home oxygen), smoking status, and exercise capacity (may infl uence a decision to ventilate the patient). Diff erential diagnosis Asthma, pulmonary oedema, upper respiratory tract obstruction, pulmonary embolus, anaphylaxis. Investigations ABG (p771). CXR to exclude pneumothorax and infection. FBC; UE; CRP. Theophylline level if patient on therapy at home. ECG. Send sputum for culture if purulent. Blood cultures if pyrexial. Management Ensure oxygenation then treat the reversible, 8 see fi g 19. 13. Look for a cause, eg infection, pneumothorax. Prior to discharge, liaise with GP regarding steroid reduction, domiciliary oxygen (p184), smoking cessation, and pneumococcal and fl u vaccinations (p166). Treatment of stable COPD and more advanced disease: See pp1845. Consider the ceiling of care: What is in the best interests of the patient? Invasive ventilation for exacerbations of COPD may not be appropriate: it can be diffi cult to wean patients off ventilatory support, and brings with it the risk of ventilator-associated pneumonias and pneumothoraces from ruptured bullae. If possible, speak to the patient early, before deterioration, try to ascertain their wishes. Patients who have previously been ventilated may not wish to repeat the experience. Consider comorbidities, FEV1, functional status, whether the patient requires home oxygen, and whether the patient has previously been admitted to ICU (and if so, whether they were easily weaned from invasive ventilation).",
    "Involve the patient, the family, your seniors, and ICU early in making a decision. Oxygen therapy The greatest danger is hypoxia, which probably accounts for more deaths than hypercapnia. Dont leave patients severely hypoxic. However, in some patients, who rely on their hypoxic drive to breathe, too much oxygen may lead to a reduced respiratory rate and hypercapnia, with a consequent fall in conscious level. Always prescribe O2 as if it were a drug. Care is always required with O2, especially if there is evidence of CO2 retention. Start with 2428% O2 in such patients. Whenever you initiate or change oxygen therapy, do consider an ABG within 1h. Monitor the patient carefully. Aim to raise the PaO2 above 8. 0kPa with a rise in PaCO2 1. 5kPa. In patients without evidence of retention at baseline use 2840% O2, but still monitor and repeat ABG. __OOHHCCMM__1100ee. . iinnddbb 881122 0022//0055//22001177 1199: : 0099 seicnegremE Management of acute COPD 813 Nebulized bronchodilators: Salbutamol 5mg/4h and ipratropium 500mcg/6h Investigate: CXR, ABG Controlled oxygen therapy if SaO2 88% or PaO2 7 kPa: Start at 2428%, aim sats 8892% Adjust according to ABG, aim PaO2 8. 0kPa with a rise in PaCO2 1. 5kPa Steroids: IV hydrocortisone 200mg and oral prednisolone 30mg OD (continue for 714d) Antibiotics: Use if evidence of infection, eg amoxicillin 500mg/8h PO, alternatively clarithromycin or doxycycline (p387) Physiotherapy to aid sputum expectoration If no response to nebulizers and steroids: Consider IV aminophylline If no response: 1 Consider non-invasive positive Hypertension ventilation (NIPPV) if respiratory rate 30 or pH 7. 35, or PaCO2 rising despite best medical treatment. OR: 2 Consider a respiratory stimulant drug, eg doxapram1. 54mg/ min IV in patients who are not suitable for mechanical ventilation. SE: agitation, confusion, tachycardia, nausea. It is a short-term measure, used only if NIV is not available Consider intubation and ventilation if pH 7. 26 and PaCO2 is rising despite non-invasive ventilation only where appropriate (see Consider the ceiling of care in text) Load with 250mg over 20min, then infuse at a rate of 500mcg/kg/h (300mcg/kg/h if elderly), where kg is ideal body weight. Do not give a loading dose to patients on maintenance methylxanthines (theophyllines/ aminophylline; see p811). Check plasma levels if given for 24h. ECG monitoring is required. This may alone serve as a rescue therapy, be an intermittent step before ventilation, or be considered as a ceiling of therapy for those deemed not suitable for mechanical ventilation. Fig 19. 13 Management of acute COPD. __OOHHCCMM__1100ee. . iinnddbb 881133 0022//0055//22001177 1199: : 0099 814 seicnegremE Pneumothorax Causes Spontaneous: (Especially in young thin men) due to rupture of a subpleural bulla. Chronic lung disease: Asthma; COPD; cystic fi brosis; lung fi brosis; sarcoidosis. Infection: TB; pneumonia; lung abscess. Traumatic: Including iatrogenic (CVP line insertion, pleural aspiration or biopsy, percutaneous Liver biopsy, positive Hypertension ventilation). Carcinoma. Connective tissue disorders: Marfans syndrome, EhlersDanlos syndrome. Clinical features Symptoms: Can be asymptomatic (especially in fi t young people with small pneumothoraces) or sudden onset of dyspnoea and/or pleuritic chest Pain. Patients with asthma or COPD may present with a sudden deterioration. Mechanically ventilated patients can suddenly develop hypoxia or an increase in ventilation pressures. Signs: Reduced expansion, hyper-resonance to percussion, and diminished breath sounds on the aff ected side. With a tension pneumothorax, the trachea will be deviated away from the aff ected side and the patient will be very unwell. Tests A CXR should not be performed if a tension pneumothorax is suspected, as it will delay immediate necessary treatment.",
    "Management Ensure oxygenation then identify and treat reversible pathology, 10 see fi g 19. 15. Investigations: Assess severitythis will guide both investigation and treatment. CXR (X-ray images, fi g 16. 4 on p725). Oxygen saturation and ABG if SaO2 92% or severe pneumonia. FBC, UE, LFT, CRP. Blood cultures (if CURB-65 ≥2). Sputum cultures (if CURB-65 ≥3 or if CURB-65 2 and not had antibiotics yet). Urine pneumococcal antigen (if CURB-65 ≥2); Legionella antigen (if CURB-65 ≥3 or if clinical suspicion). Consider need for viral throat swabs and mycoplasma protein-creatinine ratio/serology. Pleural fl uid may be aspirated for culture (if CURB-65 ≥2). Consider bronchoscopy and bronchoalveolar lavage if the patient is immunocompromised or on ICU. Severity: Calculate the core adverse features CURB-65 score: Confusion (abbreviated mental test ≤8). Urea 7mmol/L. Respiratory rate ≥30/min. blood pressure 90/60mmHg. Age ≥65. Score: 01: home treatment if possible; ≥2: hospital therapy; ≥3: indicates severe pneumonia and should consider ICU referral. Other features increasing the risk of death are: coexisting disease; bilateral/multilobar involvement; PaO2 8kPa or SaO2 92%. Treatment: See antibiotic guidance (table 4. 2 on p167). Most patients who require IV antibiotics can safely be switched to PO therapy by day 3. Complications (Of infection or treatment. ) Pleural eff usion, empyema, lung abscess, respiratory failure, septicaemia, pericarditis, myocarditis, cholestatic jaundice, acute Kidney injury. __OOHHCCMM__1100ee. . iinnddbb 881166 0022//0055//22001177 1199: : 0099 seicnegremE Management of pneumonia 817 Assess using ABC: Treat hypoxia (sats 88%) with oxygen, start at 2428% if history COPD/hypercapnia Treat hypotension/shock from infection: see p790 Assess for dehydration (common if acutely unwell and fever), consider IV fl uid support Investigations: See p816 Antibiotics: See p167 Analgesia for pleuritic chest Pain, eg paracetamol 1g/6h or nonsteroidal anti-inflammatory drug No improvement? If hypoxic despite oxygen, consider CPAP to recruit lung parenchyma and improve oxygenation. But if patient is hypercapnic, they will require non-invasive or invasive (ie intubation) ventilation Discuss with ICU early if patient has rising PaCO2 or remains hypoxic despite best medical therapy Fig 19. 15 Management of pneumonia. __OOHHCCMM__1100ee. . iinnddbb 881177 0022//0055//22001177 1199: : 0099 818 seicnegremE Pulmonary embolism (physical examination) Always suspect pulmonary embolism (physical examination) in sudden collapse 12wks after surgery. Mechanism Venous thrombi, usually from DVT, pass into the pulmonary circulation and block Blood fl ow to lungs. The source is often occult. Risk factors Malignancy; myeloproliferative disorder; antiphospholipid syndrome. Surgeryespecially pelvic and lower limb (much lower if prophylaxis used). Immobility; active infl ammation (eg infection, IBD). Pregnancy; combined OCP; HRT. Previous thromboembolism and inherited thrombophilia, see p374. Signs and symptoms Acute dyspnoea, pleuritic chest Pain, haemoptysis, and syncope. Hypotension, tachycardia, gallop rhythm, JVP, loud P2, right ventricular heave, pleural rub, tachypnoea, cyanosis, atrial fibrillation. With thromboprophylaxis, physical examination following surgery is far less common, but physical examination may occur after any period of immobility, or with no predisposing factors. Breathlessness may be the only sign. Multiple small emboli may present less dramatically with pleuritic Pain, haemoptysis, and gradually increasing breathlessness. Look for a source of emboliespecially DVT (is a leg swollen? ). Investigations Risk stratify based upon clinical features (use 2-level Wells score for physical examinationp191). A Ωve D-dimer in a Low-probability patient eff ective excludes physical examination. 11 UE, FBC, baseline clotting. ECG: commonly normal or sinus tachycardia; right ventricular strain pattern V1V3 (p98), right axis deviation, RBBB, atrial fibrillation, may be deep S waves in I, Q waves in III, inverted T waves in III (SI QIII TIII). CXR: often normal; decreased vascular markings, small pleural eff usion. Wedgeshaped area of infarction. Atelectasis. ABG: hyperventilation poor gas exchange: PaO2, PaCO2, pH.",
    "Wedgeshaped area of infarction. Atelectasis. ABG: hyperventilation poor gas exchange: PaO2, PaCO2, pH. Serum D-dimer: Low specifi city ( if thrombosis, infl ammation, post-op, infection, malignancy) check only in patients with Low pre-test probability (p191). computed tomography pulmonary angiography (CTPA) is sensitive and specifi c and is the test of choice for High-risk patients or Low-risk patients with a ve D-dimer. If unavailable, a ventilationperfusion (V/Q) scan can aid diagnosis but frequently produces equivocal results Management See fi g 19. 16 for immediate management. 11 If Good story and signs, make the diagnosis. Start treatment (fi g 19. 16) before defi nitive investigations: most physical examination deaths occur within 1h. Commence LMWH or fondaparinux. If there is haemodynamic instability, consider thromolysis. Long-term anticoagulation: either DOAC (p350switch directly from LMWH) or warfarin (continue LMWH until INR 2). Is there an underlying cause, eg thrombophilia (p374), SLE, or polycythaemia? Consider malignancy (take a careful history and perform a full physical examination; check CXR, FBC, LFT, Ca2; urinalysis; consider computed tomography abdomen/pelvis and mammogram). If obvious remedial cause, 3 months of anticoagulation (p351) may be enough; otherwise, continue for ≥36 months (long term if recurrent emboli, or underlying malignancy). Prevention See p190. __OOHHCCMM__1100ee. . iinnddbb 881188 0022//0055//22001177 1199: : 0099 seicnegremE Management of large pulmonary embolism 819 Oxygen if hypoxic, 1015L/min Morphine 510mg IV with anti-emetic if the patient is in Pain or very distressed IV access and start LMWH/fondaparinux If blood pressure give 500mL IV fl uid bolus Get ICU input Haemodynamically unstable? No Yes If persistent blood pressure consider vasopressors, Consider thrombolysis eg dobutamine 2. 510mcg/kg/min IV or (eg alteplase 10mg IV bolus noradrenaline; aim for systolic blood pressure 90mmHg then IVI 90mg/2h) Initiate long-term anticoagulation Fig 19. 16 Management of large pulmonary embolism. __OOHHCCMM__1100ee. . iinnddbb 881199 0022//0055//22001177 1199: : 0099 820 seicnegremE Acute upper gastrointestinal bleeding Causes Peptic ulcer disease (PUD) 3550%. Gastroduodenal erosions 815%. Oesophagitis 515%. MalloryWeiss tear 15%. Varices 510%. Other: upper GI malignancy, vascular malformations. Consider also facial trauma, nose bleed, or haemoptysis as causes of swallowed Blood. Signs and symptoms (See pp5663. ) Haematemesis, or melaena, dizziness (especially postural), fainting, abdominal Pain, dysphagia? Hypotension (in young may be postural only), tachyc ardia (not if on -blocker), JVP, Urine output, cool and clammy, signs of chronic Liver disease (p276), eg telangiectasia, purpura, jaundice. NB: ask about previous GI problems, drug use, alcohol. Management Focus on circulation, 12 see fi g 19. 17. Risk stratify based upon, eg Rockall score (see table 6. 6, p257). Is the patient shocked? Peripherally cool/clammy; capillary refi ll time 2s; Urine output 0. 5mL/kg/h. GCS or encephalopathy (p275). Tachycardic (pulse 100bpm). Systolic blood pressure 100mmHg; postural drop 20mmHg. If shocked: See fi g 19. 17 for management. If haemodynamically stable: Insert two large-bore (1416G) IV cannulae and take Blood for FBC, UE, LFT, clotting, and group save. Give IV fl uids (p821) to restore intravascular volume; avoid saline if cirrhotic/ varices; consider a CVP line to monitor and guide fl uid replacement. Organize a CXR, ECG, and check ABG. Consider a urinary catheter and monitor hourly Urine output. Transfuse if signifi cant hemoglobin drop (70g/L). Correct clotting abnormalities (vitamin potassium (p274), FFP, platelets). If suspicion of varices (eg known history of Liver disease or alcohol excess) then give terlipressin IV (12mg/6h for ≤3d) and initiate broad-spectrum IV antibiotics (eg piperacillin/tazobactam IV 4. 5g/8h). Monitor pulse, blood pressure, and CVP (keep 5cmH20) at least hourly until stable. Arrange an urgent endoscopy (p248). If endoscopic control fails, surgery or emergency mesenteric angiography/embolization may be needed.",
    "Arrange an urgent endoscopy (p248). If endoscopic control fails, surgery or emergency mesenteric angiography/embolization may be needed. For uncontrolled oesophageal variceal bleeding, a SengstakenBlakemore tube may compress the varices, but should only be placed by someone with experience. Acute drug therapy: There is no role for routine administration of proton pump inhibitor pre-endoscopy (provided endoscopy can be arranged in a timely manner). In patients undergoing successful endoscopic haemostasis, give proton pump inhibitor (eg omeprazole 40mg/12h IV/PO). Treat if positive for H. pylori (p253). Rebleeds Serious event: 40% of patients who rebleed will die. If at risk maintain a High index of suspicion. If a rebleed occurs, check vital signs every 15min and call senior cover for repeat endoscopy and/or surgical intervention. Signs of a rebleed: Rising pulse rate. Falling JVP ± decreasing hourly Urine output. Haematemesis or fresh melaena (NB: it is normal to pass decreasing amounts of melaena for 24h post-haemostasis, as Blood makes its way through the GI tract). Fall in blood pressure (a late and sinister fi nding) and decreased conscious level. __OOHHCCMM__1100ee. . iinnddbb 882200 0022//0055//22001177 1199: : 0099 seicnegremE Immediate management if shocked 821 Protect airway and keep NBM Insert two large-bore cannulae (1416G) Urgent bloods: FBC, UE, LFT, glucose, clotting screen, crossmatch 46 units Rapid IV crystalloid infusion up to 1L If signs of grade III or IV shock (p790) give Blood Group specifi c or O Rhve until crossmatch done Otherwise continue IV fl uids to maintain blood pressure and transfuse if eg hemoglobin 7 Correct clotting abnormalities Vitamin potassium, FFP, platelet concentrate If risk of varices (eg known Liver disease or alcohol excess), give terlipressin IV 12mg/6h and broad-spectrum IV antibiotics Consider referral to ICU or HDU, and consider CVP line to guide fl uid replacement. Aim for 5cmH2O CVP may mislead if there is ascites or CCF Catheterize and monitor Urine output. Aim for 30mL/h Monitor vital signs every 15min until stable, then hourly Notify surgeons of all severe bleeds Urgent endoscopy for diagnosis ± control of bleeding at the earliest possible point after adequate resuscitation Fig 19. 17 Immediate management of suspected upper GI bleed with shock. __OOHHCCMM__1100ee. . iinnddbb 882211 0022//0055//22001177 1199: : 0099 822 seicnegremE Meningitis Primary care Prompt actions save lives. If suspect meningitis arrange urgent transfer to secondary care. If a non-blanching rash is present, give benzylpenicillin 1. 2g IM/IV before admitting. Organisms Meningococcus or pneumococcus. Less commonly Haemophi lus infl uenzae; Listeria monocytogenes. HSV, VZV, enteroviruses. CMV, cryptococcus (p400), or TB (p393) if immunocompromised, eg HIV ve, organ transplant, malignancy. Diff erential Malaria, encephalitis, septicaemia, subarachnoid, dengue, tetanus. Features Early: Headache, fever, leg pains, cold hands and feet, abnormal skin colour. Later: Meningism: neck stiff ness, photophobia, Kernigs sign (Pain resistance on passive knee extension with hip fully fl exed). GCS, coma. Seizures (20%) ± focal CNS signs (20%) ± Fig 19. 18 Glass test for petechiae. opisthotonus (p436, fi g 9. 46). Courtesy of Meningitis Research Foundation. Petechial rash (non-blanchingfi g 19. 18; may only be 1 or 2 spots, or none). Shock: prolonged capillary refi ll time; DIC; blood pressure. Signs of disease causing meningitis: Zoster; cold sore/genital vesicles (HSV); HIV signs (lymph ad en opathy, dermatitis, candidiasis, uveitis); bleeding ± red eye (leptospirosis); parotid Edema (mumps); sore throat ± jaundice ± nodes (glandular fever, p405); splenectomy scar ( immunodefi cient). Management See fi g 19. 19; investigations and treatment proceed in parallel. 13 If ICP, summon help immediately and inform ICU. Initiate early antibiotics. Take Blood cultures fi rst.",
    "13 If ICP, summon help immediately and inform ICU. Initiate early antibiotics. Take Blood cultures fi rst. Then perform LP prior to antibiotics only in patients where no evidence of shock, petechial rash or ICP and where able to obtain LP within 1h (table 19. 4). Consult local policies and seek advice. Empirical options include ceftriaxone 2g/12h IV; add eg amoxicillin 2g/4h IV if 60yrs age or immunocompromised. If suspect viral encephalitis see p824. If features of menigism give dexamethasone 10mg/6h IV Other investigations, UE, FBC (white blood cell immunocompromise: get help), LFT, glucose, coagulation. Throat swabs (1 for bacteria, 1 for virology). CXR. Consider HIV, TB tests. Prophylaxis (discuss with public health/ID): Household contacts in droplet range. Those who have kissed the patients mouth. Give ciprofl oxacin (500mg PO, 1 dose; child 512yrs: 250mg; child 5yrs: 30mg/kg to max 125mg). Lumbar puncture in meningitis Table 19. 4 CSF analysis in meningitis CSF in meningitis Bacterial Tuberculous (p393) Viral (aseptic) Appearance Often turbid Often fi brin web Usually clear Predominant cell Polymorphs Mononuclear Mononuclear Cell count/mm3 Eg 901000 or more 101000 501000 Glucose ½ plasma ½ plasma ½ plasma Protein (g/L) 1. 5 15 1 Bacteria In smear culture Often none in smear None seen or cultured Predominant cell type may also be lymphocytes in TB, listerial, and cryptococcal meningitis. Perform LP (p768) without waiting for computed tomography (not if GCS ≤12 or focal neurology). Wait for clotting screen only if suspect coagulopathy. Record opening Hypertension718cm CSF normal but in meningitis. Send CSF for MCS, Protein, lactate, glucose, virology/protein-creatinine ratio. Normal values: ≤5 lymphocytes/mm3 with no neutrophils is normal. Protein: 0. 15 0. 45g/L. CSF glucose: 2. 84. 2mmol/L. __OOHHCCMM__1100ee. . iinnddbb 882222 0022//0055//22001177 1199: : 0099 seicnegremE Management of suspected bacterial meningitis and 823 meningococcal sepsis ABCs: IVI fl uid resus. Check and correct Blood glucose Meningitic: (eg neck stiff ness; Septicaemic: eg shock (prolonged capillary photophobia) without shock refi ll time; cold hands feet; blood pressure), evolving rash Take Blood cultures Get ICU help: Take Blood cultures IV antibiotics (see text) Signs of ICP/shift of brain (papil- Airway support /pre-emptive intubation loedema, uncontrolled seizures, focal Fluid resuscitation/ionotropes/vasoneurology, GCS ≤12) pressors (aim for: MAP 70mmHg; Urine output 30mL/h) Delay LP until stable Yes No Get ICU help: Get senior help: IV antibiotics (see text) Perform LP ≤1h Dexamethasone 10mg IV IV antibiotics (see text) Airway support pre-LP, if LP delayed 1h Fluid resuscitation Dexamethasone 10mg IV Delay LP until stable Nurse at 30° Careful monitoring Subsequent therapy: Discuss antibiotic therapy with microbiology and adjust based on organism and local sensitivities. Maintain normovolaemia with IVI if needed. Isolate for 1st 24h. Inform Public Health, p381. Fig 19. 19 Management of suspected bacterial meningitis and meningococcal sepsis in immunocompetent adults. __OOHHCCMM__1100ee. . iinnddbb 882233 0022//0055//22001177 1199: : 0099 824 seicnegremE Encephalitis Suspect encephalitis whenever odd behaviour, consciousness, focal neurology or seizure is preceded by an infectious prodrome (T°, rash, lymphadenopathy, cold sores, conjunctivitis, meningeal signs). It is often wise to treat (see below) before the exact cause is knownusually viral, and often never identifi ed. Without the infectious prodrome consider encephalopathy: hypoglycaemia, hepatic encephalopathy, diabetic ketoacidosis, drugs, hypoxic brain injury, uraemia, SLE, Wernickes (give vit B1 if in doubt p714). Signs and symptoms Bizarre encephalopathic behaviour or confusion. GCS or coma. Fever. Headache. Focal neurological signs. Seizures. History of travel or animal bite. Causes Viral: HSV-1 2, arboviruses, CMV, EBV, VZV (varicella-zoster virus), HIV (seroconversion), measles, mumps, rabies, Japanese B encephalitis, West Nile virus, tick-borne encephalitis. Non-viral: Any bacterial meningitis, TB, malaria, listeria, Lyme disease, legionella, leptospirosis, aspergillosis, cryptococcus, schistosomiasis, typhus.",
    "Non-viral: Any bacterial meningitis, TB, malaria, listeria, Lyme disease, legionella, leptospirosis, aspergillosis, cryptococcus, schistosomiasis, typhus. Investigations Bloods: Blood cultures; serum for viral protein-creatinine ratio (also throat swab and MSU); toxoplasma IgM titre; malaria fi lm. Contrast-enhanced computed tomography: Focal bilateral temporal lobe involvement is suggestive of HSV encephalitis. Meningeal enhancement suggests meningoencephalitis. Do before LP. magnetic resonance imaging is alternative if allergic to contrast. LP: Typically moderately CSF Protein and lymphocytes, and glucose (p822). Send CSF for viral protein-creatinine ratio including HSV. EEG: Urgent EEG showing diff use abnormalities may help confi rm a diagnosis of encephalitis, but does not indicate a cause. Management Mortality in untreated viral encephalitis is 70%. Aim to start aciclovir within 30min of the patient arriving (10mg/kg/8h IV over 1h) for 14d as empirical treatment for HSV (21d if immunosuppressed). Specifi c therapies also exist for CMV and toxoplasmosis (p425). Supportive therapy, in High-dependency unit or ICU environment if necessary. Symptomatic treatment: eg phenytoin for seizures (p826). Cerebral abscess Suspect this in any patient with ICP, especially if there is fever or WCC. It may follow ear, sinus, dental, or periodontal infection; skull fracture; congenital Heart disease; endocarditis; bronchiectasis. It may also occur in the absence of systemic signs of infl ammation. Signs Seizures, fever, localizing signs, or signs of ICP. Coma. Signs of sepsis elsewhere (eg teeth, ears, lungs, endocarditis). Investigations computed tomography/magnetic resonance imaging p746 (eg ring-enhancing lesion); WCC, ESR; biopsy. Treatment Urgent neurosurgical referral; treat ICP (p830). If frontal sinuses or teeth are the source, the likely organism will be Strep. milleri (microaerophilic), or oropharyngeal anaerobes. In ear abscesses, B. fragilis or other anaerobes are most common. Bacterial abscesses are often peripheral; toxoplasma lesions (p425) are deeper (eg basal ganglia). NB: ask yourself: is the patient immunocompromised? Discuss with infectious diseases/microbiology. __OOHHCCMM__1100ee. . iinnddbb 882244 0022//0055//22001177 1199: : 0099 seicnegremE 825 __OOHHCCMM__1100ee. . iinnddbb 882255 0022//0055//22001177 1199: : 0099 826 seicnegremE Status epilepticus This means seizures lasting for 30min, or repeated seizures without intervening consciousness. Mortality and the risk of permanent brain damage increase with the length of attack. Aim to terminate seizures lasting more than a few minutes as soon as possible (20min). Status usually occurs in patients with known epilepsy. If it is the 1st presentation, the chance of a structural brain lesion is High (50%). Diagnosis of tonicclonic status is usually clear. Non-convulsive status (eg absence status or continuous partial seizures with preservation of consciousness) may be more diffi cult: look for subtle eye or lid movement. For other signs, see pp484, 4903. An EEG can be very helpful. Could the patient be pregnant (any pelvic mass)? If so, eclampsia (OHCS p48) is the likely diagnosis, check the Urine and blood pressure: call a senior obstetricianimmediate delivery may be needed. Investigations Bedside glucose, the following tests can be done once has started: lab glucose, ABG, UE, Ca2, FBC, ECG. Consider anticonvulsant levels, toxicology screen, LP, culture Blood and Urine, EEG, computed tomography, carbon monoxide level. Pulse oximetry, cardiac monitor. Management See fi g 19. 20. Basic life supportand these agents: 14 1 Lorazepam: 0. 1mg/kg (usually 4mg) as a slow bolus into a large vein. If no response after 1020min give a second dose. Beware respiratory arrest during the last part of the injection. Have full resuscitation facilities to hand for all IV benzodiazepine use. The rectal route is an alternative for diazepam if IV access is diffi cult.",
    "The rectal route is an alternative for diazepam if IV access is diffi cult. Buccal midazolam is an easier to use oral alternative where no IV access (eg in a community setting); dose for those 10yrs old and older 10mg; if 15yrs 5mg, if 510yrs 7. 5mg; squirt half the volume between the lower gum and the cheek on each side. While waiting for this to work, prepare other drugs. If fi ts continue 2 Phenytoin infusion: 1518mg/kg IVI (roughly 1g if 60kg, and 1. 5g if 80kg; max 2g), at a maximum rate of 50mg/min (dont put diazepam in same line: they dont mix). Beware blood pressure and do not use if bradycardic or Heart block. Requires blood pressure and ECG monitoring. 100mg/68h is a maintenance dose (check levels). If fi ts continue 3 SeekI CU help: Paralysis and anaesthesia with eg propofol is required. Close monitoring, especially respiratory function, is vital. Consider whether this could be pseudoseizures (p490), particularly if there are odd features (pelvic thrusts; resisting attempts to open lids and your attempts to do passive movements; arms and legs fl ailing around). 4 Dexamethasone: 10mg IV if vasculitis/cerebral oedema (tumour) possible. As soon as seizures are controlled, start oral drugs (p492). Ask what the cause was, eg hypoglycaemia, pregnancy, alcohol, drugs, CNS lesion or infection, hypertensive encephalopathy, inadequate anticonvulsant dose/compliance (p490). __OOHHCCMM__1100ee. . iinnddbb 882266 0022//0055//22001177 1199: : 0099 seicnegremE Management of convulsive status epilepticus 827 Open and secure the airway (adjuncts as necessary) Remove false teeth if poorly fi tting Oxygen, 100% suction (as required) IV access and take Blood: UE, LFT, FBC, glucose, Ca2 Toxicology screen if indicated Anticonvulsant levels IV bolusto stop seizures: eg lorazepam 4mg Give 2nd dose of lorazepam if no response after 1020min Thiamine 250mg IV over 30min if alcoholism or malnourishment suspected Glucose 50mL 50% IV, unless glucose known to be normal Treat acidosis if severe (contact ICU) Correct hypotension with fl uids IV infusion: If seizures continue, start phenytoin, 1518mg/kg IVI, at a rate of 50mg/min. Monitor ECG and blood pressure. 100mg/68h is a maintenance dose (check levels) General anaesthesia: Continuing seizures after 6090mins of above therapies require expert help with paralysis (eg propofol infusion) and ventilation with continuous EEG monitoring in ICU. NB: never spend longer than 20min on someone with status epilepticus without having help at the bedside from an anaesthetist Fig 19. 20 Management of status epilepticus. __OOHHCCMM__1100ee. . iinnddbb 882277 0022//0055//22001177 1199: : 0099 828 seicnegremE Head injury If the pupils are unequal, diagnose rising intracranial Hypertension (ICP), eg from extradural haemorrhage, and summon urgent neurosurgical help (p482). Retinal vein pulsation at fundoscopy helps exclude ICP. Initial management See fi g 19. 21. Write full notes. Record times. Stabilization of airway, breathing, and circulation (ABC) remains the 1st priority. If GCS ≤8 then seek urgent anaesthetic and ICU help to protect airway. 15 Involve neurosurgeons early, especially if GCS, or if ICP suspected. Examine the CNS. Chart pulse, blood pressure, T°, respirations pupils every 15min. Assess anterograde amnesia (loss from the time of injury, ie post-traumatic) and retrograde amnesia (for events prior to injury)extent of retrograde loss correlates with severity of injury, and never occurs without anterograde amnesia. Nurse semi-prone if no spinal injury; meticulous care to airway and bladder. Perform a computed tomography head 1h if: GCS 13 on initial assessment, or GCS 15 at 2h following injury. Focal neurological defi cit. Suspected open or depressed skull fracture, or signs of basal skull fracture: periobital ecchymoses (panda eyes/racoon sign), postauricular ecchymosis (Battles sign), CSF leak through nose/ears, haemotympanum. Post-traumatic seizure.",
    "54kPa): This causes cerebral vasoconstriction and reduces ICP almost immediately. Maintain PaO2 12kPa Osmotic agents (eg mannitol) can be useful but may lead to rebound ICP after prolonged use (1224h): Give 20% solution 0. 250. 5g/kg IV over 1020min (eg 5mL/kg). Eff ect is seen after 20min and lasts for 26h. Follow serum osmolalityaim for about 300mosmol/kg but dont exceed 310 Corticosteroids are not effective in reducing ICP except for oedema surrounding tumours: Eg dexamethasone 10mg IV and follow with 4mg/6h IV/PO Consider other measures, eg sedation, anti-epileptics, therapeutic hypothermia Restrict fl uid to 1. 5L/d Monitor the patient closely; consider monitoring ICP Aim to make a diagnosis Treat cause or exacerbating factors, eg hyperglycaemia, hyponatraemia Defi nitive treatment if possible Fig 19. 22 Immediate management plan for raised intracranial Hypertension. __OOHHCCMM__1100ee. . iinnddbb 883311 0022//0055//22001177 1199: : 0099 832 seicnegremE Diabetic ketoacidosis (DKA) Mechanism Normally the body metabolizes carbohydrates, leading to effi cient energy production. Ketoacidosis is an alternative metabolic pathway used in starvation states; it is far less effi cient, and produces acetone as a byproduct (hence the fruity breath of patients in ketosis). In acute diabetic ketoacidosis, there is excessive glucose, but because of a lack of insulin, this cannot be taken up into cells to be metabolized, so pushing the body into a starvation-like state where ketoacidosis is the only mechanism of energy production. The combination of severe acidosis and hyperglycaemia can be deadly, so early recognition and treatment is important. Typical picture Gradual drowsiness, Vomiting, and dehydration in type 1 diabetic (very rarely type 2). Do glucose in all those with unexplained Vomiting, abdo Pain, polyuria, polydipsia, lethargy, anorexia, ketotic breath, dehydration, coma, or deep breathing (sighing Kussmaul hyperventilation). Triggers: Infection, eg UTI; surgery; myocardial infarction; pancreatitis; chemotherapy; antipsychotics; wrong insulin dose/non-compliance. Diagnosis 1 Acidaemia (venous Blood pH 7. 3 or bicarbonate Ω 15. 0mmol/L). 2 Hyperglycaemia (Blood glucose 11. 0mmol/L) or known diabetes mellitus. 3 Ketonaemia (≥3. 0mmol/L) or signifi cant ketonuria (more than 2 on dipstick). Tests: ECG, CXR. Urine: Dipstick and MSU. Blood: Capillary and lab glucose, ketones, pH (use venous Blood; ABG only if GCS or hypoxia), UE, bicarbonate Ω, osmolality, FBC, Blood culture. Severe DKA If one or more of the following features is present on admission, consider transfer to HDU/ICU for monitoring and central venous access. Get senior help! Blood ketones 6mmol/L. O2 sats 92% on air (assuming no res- Venous bicarbonate 5mmol/L. piratory disease). Venous/arterial pH 7. 0. Systolic blood pressure 90mmHg. potassium 3. 5mmol/L on admission. Pulse 100 or 60 bpm. GCS 12. Anion gap above 16 (p670). Management Replace volume then correct metabolic defects, 16 see fi g 19. 23. Pitfalls in diabetic ketoacidosis Plasma glucose is usually High, but not always, especially if insulin continued. High WCC may be seen in the absence of infection. Infection. Often there is no fever. Do MSU, Blood cultures, and CXR. Start broadspectrum antibiotics (eg co-amoxiclav, p386) early if infection is suspected. Creatinine. Some assays for Creatinine cross-react with ketone bodies, so plasma Creatinine may not refl ect true renal function. Hyponatraemia is common, due to osmolar compensation for the hyperglycaemia. or sodium indicates severe Water loss. As treatment commences sodium rises as Water enters cells. sodium is also Low due to an artefact; corrected plasma sodium sodium 2. 4(glucose Ω5. 5)/5. 5. Ketonuria does not equate with ketoacidosis. Anyone may have up to ketonuria after an overnight fast. Not all ketones are due to Diabetesconsider alcohol if glucose normal. Always check venous Blood ketones. Recurrent ketoacidosis.",
    "Not all ketones are due to Diabetesconsider alcohol if glucose normal. Always check venous Blood ketones. Recurrent ketoacidosis. Blood glucose may return to normal long before ketones are removed from the Blood, and premature termination of insulin infusion may lead to lack of clearance and return to DKA. This may be avoided by maintaining a constant rate of insulin infusion (with co-infusion of glucose 10% to maintain plasma glucose at 610mmol/L) until Blood ketones 0. 6mmol/L and pH 7. 3. Acidosis but without gross elevation of glucose may occur, but consider overdose (eg aspirin) and lactic acidosis (in elderly diabetics). Serum amylase is often raised (up to 10) and non-specifi c abdominal Pain is common, even in the absence of pancreatitis. Complications Cerebral oedema (get help if sudden CNS decline), aspiration pneumonia, hypokalaemia, hypom agnesaemia, hypophosphataemia, thromboembolism. Prevention Talk to the patient: evaluate compliance and educate about triggers. __OOHHCCMM__1100ee. . iinnddbb 883322 0022//0055//22001177 1199: : 0099 seicnegremE Management plan for diabetic ketoacidosis 833 ABC approach, 2 large-bore cannulae: Start fl uid: 1L 0. 9% saline over 1h (if systolic blood pressure 90mmHg then give 500mL bolus over 15mins and reassessif systolic blood pressure still 90mmHg then seek senior review and give further 500mL bolus; if blood pressure remains 90mmHg then involve ICU) Tests: Venous Blood gas for pH, bicarbonate; bedside and lab glucose and ketones; UES, FBC, CRP; CXR, ECG Insulin: Add 50 units human soluble insulin to 50mL 0. 9% saline. Infuse continuously at 0. 1 unit/kg/h. Continue patients regular long-acting insulin at usual doses and times; consider initiating long-acting insulin in newly diagnosed type 1 diabetes mellitus. Aim for a fall in Blood ketones of 0. 5mmol/L/h, or a rise in venous bicarbonate of 3mmol/L/h with a fall in glucose of 3mmol/L/h. If not achieving this, increase insulin infusion by 1 unit/h until target rates achieved Check capillary Blood glucose and ketones hourly Check VBG (pH, bicarbonate Ω, potassium) at 2h, 4h, 8h, 12h, and 24h (or more frequent) Continue fl uids and assess need for potassium (see below) Consider catheter if not passed Urine by 1h, aim for Urine output 0. 5mL/kg/h. Consider NG tube if Vomiting or drowsy Start all patients on LMWH Avoid hypoglycaemia! When glucose 14mmol/L start 10% glucose at 125mL/h to run alongside saline and prevent hypoglycaemia Continue fi xed-rate insulin until ketones 0. 6mmol/L, venous pH 7. 3, and venous bicarb 15mmol/L. Do not rely on urinary ketones to indicate resolutionthey stay positive after DKA resolved Find and treat infection/cause for DKA Fig 19. 23 Management plan for diabetic ketoacidosis. Fluid replacement 0. 9% saline is the replacement fl uid of choice. Typical fl uid defi cit is 100mL/kg, so for an average 70kg man 7 litres. Give eg 1L in 1h (faster if systolic blood pressure 90mmHg) then: 1L over 2h, 1L over 2h, 1L over 4h, 1L over 4 h, 1L over 8h. This regimen may not be appropriate for all: reassess frequently, especially if young, elderly, pregnant, or comorbidities. Bicarbonate may increase risk of cerebral oedema and is not recommended. Potassium replacement Typical defi cit 35mmol/kg, plasma potassium falls with treatment as potassium enters cells. Dont add potassium to the 1st bag. Thereafter add potassium according to most recent VBG result (table 19. 5). Table 19. 5 Potassium replacement in DKA Serum potassium (millimoles per liter) Amount of KCl to add per litre of IV fl uid 5. 5 Nil 3. 55. 5 40mmol 3. 5 Seek help from HDU/ICU for higher doses __OOHHCCMM__1100ee. .",
    "5 Nil 3. 55. 5 40mmol 3. 5 Seek help from HDU/ICU for higher doses __OOHHCCMM__1100ee. . iinnddbb 883333 0022//0055//22001177 1199: : 0099 834 seicnegremE Other diabetic emergencies Hypoglycaemia Usually rapid onset; may be accompanied by odd behaviour (eg aggression), sweating, pulse, seizures. Management: If conscious, orientated, and able to swallow, give 1520g of quick-acting carbohydrate snack (eg 200mL orange juice) and recheck Blood glucose after 1015mins (repeat snack up to 3 times). If conscious but uncooperative, squirt glucose gel between teeth and gums. In unconscious patients, or those not responding to these measures, start glucose IVI (eg 10% at 200mL/h if conscious; 10% at 200mL/15mins if unconscious), or give glucagon 1mg IV/IM (will not work in malnourished patients). Expect prompt recovery. Once Blood glucose 4. 0mmol/L and patient has recovered, give long-acting carbohydrate (eg slice of toast). Hyperglycaemic hyperosmolar state (HHS) Seen in unwell patients with type 2 diabetes mellitus. 17 The history is longer (eg 1wk), with marked dehydration and glucose 30mmol/L. There is no switch to ketone metabolism, so ketonaemia stays 3mmol/L and pH 7. 3. Osmolality is typically 320mosmol/kg: Occlusive events are a danger (focal CNS signs, chorea, DIC, leg ischaemia/rhabdomyolysis)give LMWH prophylaxis to all unless contraindication (p350). Rehydrate slowly with 0. 9% saline IVI over 48h, typical defi cits are 110220mL/ kg, ie 815L for a 70kg adult. Replace potassium when Urine starts to fl ow (see DKA BOX, p833). Only use insulin if Blood glucose not falling by 5mmol/L/h with rehydration or if ketonaemiastart slowly 0. 05u/kg/h. Keep Blood glucose at least 1015mmol/L for fi rst 24 hours to avoid cerebral oedema. Look for the cause, eg myocardial infarction, drugs, sepsis, or bowel infarct. Lactic acidosis A rare but serious complication of diabetes mellitus with metformin use or septicaemia. Blood lactate: 5mmol/L. Seek expert help. Treat sepsis vigorously, maintain Blood Hypertension and hence tissue perfusion. Stop metformin. Thyroid emergencies Myxoedema coma The ultimate hypothyroid state before death. Signs and symptoms: Looks hypothyroid (p220, p221, fi g 5. 16); often 65yrs; hypothermia; hyporefl exia; glucose; bradycardia; coma; seizures. May have had radioiodine, thyroidectomy, or pituitary surgery (signs of hypopituitarism, p232). Psychosis (myxoEdema madness) may precede coma. Precipitants: infection, myocardial infarction, stroke, or trauma. Examination: Goitre; cyanosis; blood pressure (cardiogenic); Heart failure; signs of precipitants. Treatment: Preferably on ICU. Blood for: T3, T4, TSH, FBC, UE (often sodium), cultures, cortisol, glucose. ABG for PaO2. High-fl ow O2 if cyanosed. Ventilation may be needed. Correct any hypoglycaemia. Give T3 (liothyronine) 520mcg/12h IV slowly. Be cautious: you may precipitate manifestations of ischaemic Heart disease. Alternative regimens involve levothyroxine. Give hydrocortisone 100mg/8h IVvital if pituitary hypothyroidism is suspected (ie no goitre, no previous radioiodine, and no previous thyroid surgery). If infection suspected, give antibiotic, eg co-amoxiclav 1. 2g/8h IV. Caution with fl uid, rehydrate as needed but watch for cardiac dysfunction; blood pressure may not respond to fl uid and inotropes may be needed. Active warming (blankets, fl uids) may be needed for hypothermia. Beware complications (hypoglycaemia, pancreatitis, arrhythmias). See p848. Further : T3 520mcg/412h IV until sustained improvement (23d) then levothyroxine 50mcg/24h PO. Hydrocortisone IV fl uids as needed (hyponatraemia is dilutional). Hyperthyroid crisis (thyrotoxic storm) Signs and symptoms: : 4: 1. Severe hyper thyroidi sm (see p218): T°, agitation, confusion, coma, tachycardia, atrial fibrillation, DV, goitre, thyroid bruit, acute abdomen (exclude surgical causes), Heart failure. Precipitants: Recent thyroid surgery or radioiodine; infection; myocardial infarction; trauma. Diagnosis: Do not wait for test results if urgent treatment is needed. Do TSH, free T4, and free T3. Confi rm with technetium uptake if possible. Treatment: See fi g 19. 24.",
    "Do TSH, free T4, and free T3. Confi rm with technetium uptake if possible. Treatment: See fi g 19. 24. Seek endocrinology advice and aim to: 1 Counteract peripheral eff ects of thyroid hormones. 2 Inhibit thyroid hormone synthesis. 3 Treat systemic complications. If you are not making headway in 24h, thyroidectomy may be an option. __OOHHCCMM__1100ee. . iinnddbb 883344 0022//0055//22001177 1199: : 0099 seicnegremE Management plan for thyrotoxic storm 835 IV access, fl uids if dehydrated. NG tube if Vomiting Take Blood for: T3, T4, TSH, cultures (if infection suspected) Sedate if necessary (eg chlorpromazine 50mg PO/IM). Monitor blood pressure If no contraindication, and cardiac output OK, give propranolol 60mg/4 6h PO; max IV dose: 1mg over 10min; may need repeating every few hours. In asthma/poor cardiac output, propranolol has caused cardiac arrest in thyr oid storm, so ultra-short-acting -blockers have a role, eg IV esmolol. Consider diltiazem if -blockers contraindicated. Get help High-dose digoxin may be needed to slow the Heart, but ensure adequately -blocked, give with cardiac monitoring Antithyroid drugs: carbimazole 1525mg/6h PO (or via NGT); after 4h give Lugols solution (aqueous iodine oral solution) 0. 3mL/8h PO well diluted in Water for 710d to block thyroid Hydrocortisone 100mg/6h IV or dexamethasone 2mg/6h PO to prevent peripheral conversion T4 to T3 Treat suspected infection, eg with co-amoxiclav 1. 2g/8h IV Adjust IV fl uids as necessary; cool with tepid sponging ± paracetamol Continuing treatment: After 5d reduce carbimazole to 15mg/8h PO. After 10d stop propranolol and iodine. Adjust carbimazole (p218) Fig 19. 24 Management plan for thyrotoxic storm. __OOHHCCMM__1100ee. . iinnddbb 883355 0022//0055//22001177 1199: : 0099 836 seicnegremE Addisonian crisis Signs and symptoms Patients may present in shock (heart rate; vasoconstriction; postural hypotension; oliguria; weak; confused; comatose)often (but not always) in a patient with known Addisons (eg when oral steroid has not been increased to cover stress such as pneumonia), or someone on long-term steroids who has forgotten their tablets. Remember bilateral adrenal haemorrhage (eg meningococcaemia) as a cause. An alternative presentation is with hypoglycaemia. Precipitating factors Infection, trauma, surgery, missed medication. Management If suspected, treat before biochemical results. Bloods for cortisol and ACTH (this needs to go straight to laboratory, call ahead! ), UEScan have potassium (check ECG and give calcium gluconate if needed, see p301) and sodium (salt depletion, should resolve with rehydration and steroids). Hydrocortisone 100mg IV stat. IV fl uid bolus eg 500mL 0. 9% saline to support blood pressure, repeated as necessary. Monitor Blood glucose: the danger is hypoglycaemia. Blood, Urine, sputum for culture, then antibiotics if concern about infection. Continuing treatment Glucose IV may be needed if hypoglycaemic. Give IV fl uids as guided by clinical state and to correct UE imbalance. Continue hydrocortisone, eg 100mg/8h IV or IM. Change to oral steroids after 72h if patients condition Good. Fludrocortisone may well be needed if the cause is adrenal disease: ask an expert. Search for (and vigorously treat) the underlying cause. Get endocrinological help. Hypopituitary coma Think of decompensated chronic hypophyseal failure whenever hypothermia, refractory hypotension ± septic signs without fever occur with short stat ure or loss of axillary/pubic hair ± gonadal atrophy. Waiting for lab confi rmation may be fatal. It usually develops gradually in a person with known hypopituitarism. If rapid onset due to pituitary infarction (eg postpartum, Sheehans, p232), subarachnoid haemorrhage is often misdiagnosed as symptoms include headache and meningism. Presentation Headache; ophthalmoplegia; consciousness; hypotension; hypothermia; hypoglycaemia; signs of hypopituitarism (p232). Tests Cortisol; T4; TSH; ACTH; glucose. Pituitary fossa computed tomography/magnetic resonance imaging. Treatment Hydrocortisone, eg 100mg IV/6h.",
    "Tests Cortisol; T4; TSH; ACTH; glucose. Pituitary fossa computed tomography/magnetic resonance imaging. Treatment Hydrocortisone, eg 100mg IV/6h. Only after hydrocortisone begun: liothyronine (L-tri-iodothyronine Sodium), eg 10mcg/12h PO or by slow IV: 520mcg/12h (4-hourly may be needed). Prompt surgery is needed if the cause is pituitary apoplexy (p234). __OOHHCCMM__1100ee. . iinnddbb 883366 0022//0055//22001177 1199: : 0099 seicnegremE Phaeochromocytoma emergencies 837 Patients with phaeochromocytoma may have had undiagnosed symptoms for some time, but stress, abdominal palpation, parturition, general anaesthetic, or contrast media used in imaging can cause acute hypertensive crises. Signs and symptoms Pallor, pulsating headache, hypertension, feels about to die, pyrexial. ECG: signs of LVF, ST segment, VT, and cardiogenic shock. Treatment Get help. Take to ICU. Principle is combined - and -adrenoreceptor blockade, but must be started fi rst, as unopposed -blockade can worsen hypertension. Start with short-acting, IV -blocker, eg phentolamine 25mg IV. Repeat to maintain safe blood pressure. When blood pressure controlled, give long-acting -blocker, eg phenoxybenzamine 10mg/24h PO (increase by 10mg/d as needed, up to 30mg/12h PO); SE: postural hypotension; dizziness; tachycardia; nasal congestion; miosis; idiosyncratic marked blood pressure drop after 1st dose. The idea is to the dose until blood pressure is controlled and there is no signifi cant postural hypotension. Alternative 1-selective blockers, eg doxazosin, are preferred in some centres, particularly if surgery is not an option, eg metastatic tumour. A 1-blocker may also be given at this stage to control any tachycardia or myocardial ischaemia/dysrhythmias (p114). Surgery is usually done electively after 46wks to allow full -blockade and volume expansion. When admitted for surgery the phenoxybenzamine dose is increased until signifi cant postural hypotension occurs. __OOHHCCMM__1100ee. . iinnddbb 883377 0022//0055//22001177 1199: : 0099 838 seicnegremE Acute poisoninggeneral measures Diagnosis Mainly from the history. The patient may not tell the truth about what has been taken. If there are any tablets with the patient, use MIMS Colour Index, EMIMS images, BNF descriptions, or the computerized system TICTAC (ask pharmacy) to identify tablets and plan specifi c treatment. TOXBASE The best resource for managing acute poisoning: www. toxbase. orgcheck with your Emergency Department about log-in details for your hospital. Clues May become apparent from examination: Fast or irregular pulse: Salbutamol, antimuscarinics, tricyclics, quinine, or phenothiazine poisoning. Respiratory depression: Opiate (p842) or benzodiazepine (p842) toxicity. Hypothermia: Phenothiazines (p843), barbiturates. Hyperthermia: Amphetamines, MAOIS, cocaine, or ecstasy (p843). Coma: Benzodiazepines, alcohol, opiates, tricyclics, or barbiturates. Seizures: Recreational drugs, hypoglycaemic agents, tricyclics, phenothia zines, or theophyllines. Constricted pupils: Opiates (p842) or insecticides (organophosphates, p843). Dilated pupils: Amphetamines, cocaine, quinine, or tricyclics. Hyperglycaemia: Organophosphates, theophyllines, or MAOIS. Hypoglycaemia: (p834) Insulin, oral hypoglycaemics, alcohol, or salicylates. Renal impairment: Salicylate (p844), paracetamol (p844), or ethylene glycol. Metabolic acidosis: Alcohol, ethylene glycol, methanol, paracetamol, or carbon monoxide poisoning (p842). Osmolality: Alcohols (ethyl or methyl); ethylene glycol. See p668. Management See fi g 19. 25. Take Blood as appropriate (p840). Always check paracetamol and salicylate levels. Empty stomach if appropriate (p840). Consider specifi c antidote (p842) or oral activated charcoal (p840). If you are not familiar with the poison get more information. Toxbase (www. toxbase. org) should be your fi rst thought. If no information here or in doubt how best to act, phone the Poisons Information Service: in the UK phone 0844 892 0111. Continuing care Measure temperature, pulse, blood pressure, and Blood glucose regularly. Keep on cardiac monitor. If unconscious, nurse semi-prone, turn regularly. Catherize if the bladder is distended, or acute Kidney injury (p298) is suspected, or forced diuresis undertaken. Consider ICU, eg if respiration. Psychiatric assessment Be sympathetic despite the hour! Interview relatives and friends if possible.",
    "Consider ICU, eg if respiration. Psychiatric assessment Be sympathetic despite the hour! Interview relatives and friends if possible. Aim to establish: Intentions at time. Was this a suicide attempt, if so was the act planned? What precautions against being found? Did the patient seek help afterwards? Does the patient think the method was dangerous? Was there a fi nal act (eg suicide note)? Present intentions. Do they still feel suicidal? Do they wish it had worked? What problems led to the act: do they still exist? Is there a psychiatric disorder (depression, alcoholism, personality disorder, schizophrenia, dementia)? What are the patients resources (friends, family, work, personality)? The assessment of suicide risk: The following chance of future suicide: original intention was to die; present intention is to die; presence of psychiatric disorder; poor resources; previous suicide attempts; socially isolated; unemployed; male; 50yrs old. See OHCS p358. There is risk of death in the fi rst year following initial presentation. Referral to psychiatrist: This depends partly on local resources. Refer all with presence of psychiatric disorder or High suicide risk. Consider discussing all presentations with deliberate self-poisoning. Mental Capacity Act or the Mental Health Act: (In England and Wales) may provide for the detention of the patient against his or her will: see OHCS p406. __OOHHCCMM__1100ee. . iinnddbb 883388 0022//0055//22001177 1199: : 0099 seicnegremE Emergency care in acute poisoning 839 ABC, clear airway Consider ventilation (if the respiratory rate is 8/min, or PaO2 8kPa, when breathing 60% O2, or the airway is at risk, eg GCS ≤ 8) Treat shock (p790) If unconscious, nurse semi-prone Further management Assess the patient History from patient, friends, or family is vital Features from the examination may help (see p838) Investigations: Glucose, UE, FBC, LFT, INR, ABG, ECG, paracetamol, and salicylate levels Urine/serum toxicology, specifi c assays as appropriate Monitor: T°, pulse, and respiratory rate, blood pressure, O2 saturations, Urine output ± ECG Treatment: Supportive measures: may need catheterization Absorption: consider gastric lavage ± activated charcoal (see p840) Specifi c measures: See p840; for antidotes, see p842 Consider naloxone if conscious level and pin-point pupils Consider Pabrinex and glucose if drowsy/confused Fig 19. 25 Emergency care in acute poisoning. __OOHHCCMM__1100ee. . iinnddbb 883399 0022//0055//22001177 1199: : 0099 840 seicnegremE Acute poisoningspecifi c points Plasma toxicology For all unconscious patients, paracetamol and aspirin levels and Blood glucose are required. The necessity of other assays depends on the drug taken and the index of suspicion. Be guided by the Poisons Information Service. More common assays include: digoxin; methanol; lithium; iron; theophylline. Toxicological screening of Urine, especially for recreational drugs, may be of use in some cases (although not always, see BOX). GI decontamination Recommended for many drugs. The treatment of choice is now activated charcoal rather than gastric lavage. If in doubt, consult Toxbase or Poisons Information Service. Activated charcoal Reduces the absorption of many drugs from the gut when given as a single dose of 50g with Water, eg salicylates, paracetamol. It is given in repeated doses (50g/4h) to increase elimination of some drugs from the Blood, eg carbamazepine, dapsone, theophyllines, quinine, phenobarbital, and paraquat. Lower doses are used in children. Do not use with petroleum products, corrosives, alcohols, clofenotane, malathion, or metal salts (eg iron, lithium). Gastric lavage Rarely used. Lavage after 3060min may make matters worse. Do not empty stomach if petroleum products or corrosives such as acids, alkalis, bleach, descalers have been ingested (exception: paraquat), or if the patient is unconscious or unable to protect their airway (unless intubated). Never induce Vomiting.",
    "Never induce Vomiting. Gastric emptying and lavage NB: we do not recommend gastric lavage is attempted unless specifi cally suggested by Toxbase or Poisons Information Service. If comatose, or no gag refl ex, ask for an anaesthetist to protect airway with cuff ed endotracheal tube. If conscious, get verbal consent. Monitor O2 by pulse oximetry. See p162. Have suction apparatus to hand and working. Position the patient in left lateral position. Raise the foot of the bed by 20cm. Pass a lubricated tube (14mm external diameter) via the mouth, asking the patient to swallow. Confi rm position in stomach (see p759). Siphon the gastric contents. Check pH with litmus paper. Perform gastric lavage using 300600mL tepid Water at a time. Massage the left hypochondrium then siphon fl uid. Repeat until no tablets in siphoned fl uid. Leave activated charcoal (50g in 200mL Water) in the stomach unless alcohol, iron, Li, or ethylene glycol ingested. When pulling out tube, occlude its end (prevents aspiration of fl uid remaining in the tube). Haemodialysis This may be needed for poisoning from ethylene glycol, lithium, methanol, phenobarbital, salicylates, and Sodium valproate. Help on the web Healthcare providers in the UK can register for free toxological advice at www. toxbase. org or call 0344 892 0111 for Poisons Information Service. __OOHHCCMM__1100ee. . iinnddbb 884400 0022//0055//22001177 1199: : 0099 seicnegremE Legal highs 841 Increasingly, designer drugs, with chemical properties similar to illegal drugs (but yet suffi ciently distinct to fall outside current legislation), are leading to acute poisoning and complications requiring admission. These drugs pose a diffi cult problem for the admitting physician, as the precise chemistry and mechanisms of action of both the active compound as well as any impurities are often unclear. Although many are legal, they can be as deadly as many well-known recreational drugs, leading to death or life-threatening complications such as rhabdomyolysis. Be aware that these drugs are out there, and ask specifi cally about legal highs when taking a history, as there are often no screening tools for these drugs. __OOHHCCMM__1100ee. . iinnddbb 884411 0022//0055//22001177 1199: : 0099 842 seicnegremE Some specifi c poisons and their antidotes Benzodiazepines Flumazenil (for respiratory arrest) 200mcg over 15s; then 100mcg at 60s intervals if needed. Usual dose range: 300600mcg IV over 36min (up to 1mg; 2mg if on ICU). May provoke fi ts. Use only after expert advice. -blockers Severe bradycardia or hypotension. Try atropine up to 3mg IV. Give glucagon 210mg IV bolus 5% glucose if atropine fails then infusion of 50mcg/ kg/h. Also consider including phosphodiesterase inhibitor infusions (eg enoximone 520mcg/kg/min). If unresponsive, consider pacing. Cyanide This fast-killing poison has affi nity for Fe3, and inhibits the cytochrome system, aerobic respiration (therefore patients are acidotic with raised lactate). Depending on degree of poisoning presentation can be: Mild: Dizziness, anxiety, tachycardia, nausea, drowsiness/confusion. Moderate: Vomiting, reduced consciousness, convulsions, cyanosis. Severe: Deep coma, fi xed unreactive pupils, cardiorespiratory failure, arrhythmias, pulmonary oedema. Treatment: 100% O2, GI deconta mination. If mild, supportive care is usually suffi cient. If moderate/severe then specifi c treatment to bind cyanide is required. Give Sodium nitrite/Sodium thiosulfate, or dicobalt edetate 300mg IV over 1min, then 50mL 50% glucose IV (repeat once if no response after a minute); or hydroxocobalamin (Cyanokit) 5g over 15min repeated once if required. Get expert help. See p847. Carbon monoxide Despite hypoxaemia skin is pink (or pale), not blue, as carboxyhaemoglobin (COHb) displaces O2 from hemoglobin binding sites. For the same reasons SpO2 from a pulse oximeter may be normal.",
    "For the same reasons SpO2 from a pulse oximeter may be normal. Check ABG in a co-oximeter (ie ensure it measures haemoglobin, SaO2, Meth-hemoglobin and COHb) which will show Low SaO2 and High COHb (normal 5%). Symptoms: Headache, Vomiting, pulse, tachypnoea, and, if COHb 50%, fi ts, coma, and cardiac arrest. Treatment: Remove the source. Give 100% O2 until COHb 10%. Metabolic acidosis usually responds to correction of hypoxia. If severe, anticipate cerebral oedema and give mannitol IVI (p831). Confi rm diagnosis with an ABG quickly as levels may soon return to normal. Monitor ECG. If COHb 20%, patient has neurological or psychological features, or cardiovascular impairment, fails to respond to treatment, or is pregnant, consider hyperbaric O2: discuss with the poisons service. Digoxin Symptoms: Cognition, yellow-green visual halos, arrhythmias, nausea, and anorexia. If serious arrhythmias are present, correct hypokalaemia, and inactivate with digoxin-specifi c antibody fragments (DigiFab). If load or level is unknown, give 20 vials (800mg)adult or child 20kg. Heavy metals Enlist expert help. Iron Desferrioxamine 15mg/kg/h IVI; max 80mg/kg/d. NB: gastric lavage if iron ingestion in last hour; consider whole-bowel irrigation. Oral anticoagulants See p351. If major bleed, give vitamin potassium 5mg slow IV and prothrombin complex concentrate 50U/kg IV (or if unavailable, fresh frozen plasma 15mL/kg IVI). For abnormal INR with no (or minimal) bleeding, see BNF. If it is vital that anticoagulation continues, enlist expert help. Discuss with haematology. NB: coagulation defects may be delayed for 23d following ingestion. Opiates (Many analgesics contain opiates. ) Give naloxone, eg 0. 42mg IV; repeat every 2min until breathing is adequate (it has a short t½, so it may need to be given often or IM; max 10mg). Naloxone may precipitate features of opiate withdrawal diarrhoea and cramps, which will normally respond to diphenoxylate and atropine (eg co-phenotrope). Sedate as needed (see p15). High-dose opiate misusers may need methadone (eg 1030mg/24h PO) to combat withdrawal. Refer for help (OHCS p374). __OOHHCCMM__1100ee. . iinnddbb 884422 0022//0055//22001177 1199: : 0099 seicnegremE Phenothiazine poisoning (Eg chlorpromazine. ) No specifi c antidote. Dystonia 843 (torticollis, retrocollis, glossopharyngeal dystonia, opisthotonus): try procyclidine, eg 510mg IM or IV. Treat shock by raising the legs (± plasma expander IVI, or inotropes if desperate). Restore body temperature. Monitor ECG. Use lorazepam IV for prolonged fi ts in the usual way (p826). Neuroleptic malignant syndrome consists of: hyperthermia, rigidity, extrapyramidal signs, autonomic dysfunction (labile blood pressure, heart rate, sweating, urinary incontinence), mutism, confusion, coma, WCC, CK; it may be treated with cooling. Dantrolene 12. 5mg/kg IV (p572) (max 10mg/kg/day) can help, bromocriptine and amantadine are alternatives. Carbon tetrachloride poisoning This solvent, used in many industrial processes, causes Vomiting, abdominal Pain, diarrhoea, seizures, coma, renal failure, and tender hepatomegaly with jaundice and Liver failure. IV acetylcysteine may improve prognosis. Seek expert help. Organophosphate insecticides Inactivate cholinesterasethe resulting increase in acetylcholine causes the SLUD response: salivation, lacrimation, urination, and diarrhoea. Also look for sweating, small pupils, muscle fasciculation, coma, respiratory distress, and bradycardia. Treatment: Wear gloves; remove soiled clothes. Wash skin. Take Blood (FBC and serum cholinesterase activity). Give atropine IV 2mg every 10min till full atropinization (skin dry, pulse 70, pupils dilated). Up to 3d treatment may be needed. Also give pralidoxime 30mg/kg IVI over 20min, then 8mg/kg/h, max 12g in 24h. Even if fi ts are not occurring, diazepam 510mg IV slowly seems to help. Paraquat poisoning (Found in weed-killers. ) This causes DV, painful oral ulcers, alveolitis, and renal failure. Diagnose by Urine test. Give activated charcoal at once (100g followed by a laxative, then 50g/34h). Get expert help. Avoid O2 early on (promotes lung damage).",
    "Get expert help. Avoid O2 early on (promotes lung damage). Ecstasy poisoning Ecstasy is a semi-synthetic, hallucinogenic substance (MDMA, 3, 4-methylenedioxymethamphetamine). Its eff ects range from nausea, muscle Pain, blurred vision, amnesia, fever, confusion, and ataxia to tachyarrhythmias, hyperthermia, hyper/hypotension, Water intoxication, DIC, potassium, acute Kidney injury (acute kidney injury), hepatocellular and muscle necrosis, cardiovascular collapse, and ARDS. There is no antidote and treatment is supportive. Management depends on clinical and lab fi ndings, but may include: Administration of activated charcoal and monitoring of blood pressure, ECG, and temperature for at least 12h (rapid cooling may be needed). Monitor Urine output and UE (acute kidney injury pp2989), LFT, CK, FBC, and coagulation (DIC p352). Metabolic acidosis may benefi t from treatment with bicarbonate. Anxiety: lorazepam 1-2mg IV as a slow bolus into a large vein. Repeat doses may be administered until agitation is controlled (see p826). Narrow complex tachycardias (p806) in adults: consider metoprolol 5mg IV. Hypertension can be treated with nifedipine 510mg PO or phentolamine 25mg IV. Treat hypotension conventionally (p790). Hyperthermia: attempt to cool, if rectal T° 39°C consider dantrolene 1mg/kg IV (may need repeating: discuss with your senior and a poisons unit). Hyperthermia with ecstasy is akin to serotonin syndrome, and propranolol, muscle relaxation, and ventilation may be needed. Snakes (adders) Anaphylaxis: p794. Signs of envenoming: blood pressure (vasodilation, viper cardiotoxicity); DV; Edema spreading proximally within 4h of bite; bleeding gums or venepuncture sites; anaphylaxis; ptosis; trismus; rhabdomyolysis; pulmonary oedema. Tests: WCC; abnormal clotting; platelets; UE; Urine red blood cell; CK; PaO2, ECG. Management: Avoid active movement of aff ected limb (so use splints/slings). Avoid incisions and tourniquets. Get help from local/national poisons service. Is antivenom indicated (IgG from venom-immunized sheep)? eg 10mL IV over 15min (adults and children) of European Viper Antiserum (from Monviato) for adder bites (see BNF); 20mL if severe envenoming have adrenaline to handp794. Monitor ECG. For non-UK endemic snakes, see BNF. __OOHHCCMM__1100ee. . iinnddbb 884433 0022//0055//22001177 1199: : 0099 844 seicnegremE Paracetamol poisoning 12g (24 tablets) or 150mg/kg in adults may be fatal. If the patient weighs 110kg, calculate ingested dose using a body weight of 110kg to avoid underestimating toxicity. If the patient is malnourished then 75mg/kg can kill. Signs and symptoms None initially, or Vomiting ± RUQ Pain. Later: jaundice and encephalopathy from Liver damage (the main danger) ± acute Kidney injury (acute kidney injury). Management General measures: See p838. GI decontamination is recommended in those presenting 4h after overdose: give activated charcoal 1g/kg (max 50g). Glucose, UE, LFT, INR, ABG, FBC, bicarbonate Ω; Blood paracetamol level at 4h post-ingestion. If 1012h since overdose, not Vomiting, and plasma paracetamol is above the line on the graph (see fi g 19. 26), start acetylcysteine. If 824h and suspicion of large overdose (7. 5g) err on the side of caution and start acetylcysteine, stopping it if level below treatment line and INR/ALT normal. If ingestion time is unknown, or it is staggered, or presentation is 15h from ingestion, treatment may still help. Get advice. Acetylcysteine is given by IVI: 150mg/kg in 5% glucose over 1560min; then 50mg/ kg in 500mL of 5% glucose over 4h; then 100mg/kg/16h in 1L of 5% glucose. Rash is a common SE: treat with chlorphenamine observe; do not stop unless anaphylatoid reaction with shock, Vomiting, and wheeze (occur 10%). An alternative (if acetylcysteine unavailable) is methionine 2. 5g/4h PO for 16h (total: 10g), but absorption is unreliable if Vomiting. Ongoing management Next day do INR, UE, LFT. If INR rising, continue acetylcysteine until 1. 4. If continued deterioration, discuss with the Liver team.",
    "If INR rising, continue acetylcysteine until 1. 4. If continued deterioration, discuss with the Liver team. Dont hesitate to get help. Consider referral to specialist Liver unit guided by eg Kings College criteria (BOX, p275). Salicylate poisoning Aspirin is a weak acid with poor Water solubility. It is present in many over-thecounter preparations. Uncoupling of oxidative phosphorylation leads to anaerobic metabolism and the production of lactate and heat. Eff ects are dose related and potentially fatal: 150mg/kg: mild toxicity. 250mg/kg: moderate 500mg/kg: severe toxicity. Levels over 700mg/L are potentially fatal. Signs and symptoms Unlike paracetamol, there are many early features: Vomiting, dehydration, hyperventilation, tinnitus, vertigo, sweating. Rarely GCS, seizures, blood pressure and Heart block, pulmonary oedema, hyperthermia. Patients present initially with respiratory alkalosis due to a direct stimulation of the central respiratory centres and then develop a metabolic acidosis. Hyperor hypoglycaemia may occur. Management General: (pp8389. ) Correct dehydration. Keep patient on ECG monitor. Give activated charcoal to all presenting 1hconsider even if delayed presentation, slow-release formations, or bezoar formation (can delay absorption): at least one dose of 1g/kg (max 50g). Consider repeat doses (two further doses of 50g, 4h apart). 1 Bloods. Paracetamol and salicylate level, glucose, UE, LFT, INR, ABG, bicarbonate Ω, FBC. Salicylate level may need to be repeated after 2h, due to continuing absorption if a potentially toxic dose has been taken. Monitor Blood glucose 12hrly, beware hypoglycaemia, if severe poisoning, monitor salicylate levels, serum pH, and UE. 2 Urine. Check pH, consider catheterization to monitor output and pH. 3 Correct acidosis. If plasma salicylate level 500mg/L (3. 6mmol/L) or severe metabolic acidosis, consider alkalinization of the Urine, eg with 1. 5L 1. 26% sodium bicarbonate IV over 3h. Aim for Urine pH 7. 58. NB: monitor serum potassium as hypokalaemia may occur, and should be treated (caution if acute kidney injury). 4 Dialysis may well be needed if salicylate level 700mg/L, and if acute kidney injury or Heart failure, pulmonary or cerebral oedema, confusion or seizures, severe acidosis despite best medical therapy, or persistently plasma salicylate. Contact nephrology early. Discuss any serious cases with the local toxicological service or national poisons information service. __OOHHCCMM__1100ee. . iinnddbb 884444 0022//0055//22001177 1199: : 0099 seicnegremE 845 120 Fig 19. 26 Plasma concentration of paracetamol vs time, see p844 for interpretation. The graph may mislead if HIV ve (hepatic glutathione), or if long-acting paracetamol has been taken, or if pre-existing Liver disease or induction of Liver enzymes has occurred. Reproduced from Drug Safety Update September 2012, vol 6, issue 2: A1 Crown Copyright 2013. )ertil/gm( noitartnecnoc lomatecarap-amsalP Time (hours) Plasma-paracetamol concentration (m mol/litre) 0. 8 110 Treatment line 0. 7 100 90 0. 6 80 0. 5 70 60 0. 4 50 0. 3 40 30 0. 2 20 0. 1 10 0 0 0 2 4 6 8 10 12 14 16 18 20 22 24 __OOHHCCMM__1100ee. . iinnddbb 884455 0022//0055//22001177 1199: : 0099 846 seicnegremE Burns Assessment Burn size is important to assess as it infl uences the size of the infl ammatory response (vasodilation, increased vascular permeability) and thus fl uid shift from the intravascular volume. Use Lund and Browder charts (see fi g 19. 27) or the rule of nines (arm: 9%; front of trunk 18%; head and neck 9%; leg 18%; back of trunk 18%; perineum 1%). Ignore erythema. Burn depth determines healing time/scarring; assessing this can be hard, even for the experienced. The big distinction is whether the burn is partial thickness (painful, red, and blistered) or full thickness (insensate/ painless; grey-white). NB: burns can evolve, particularly over the fi rst 48h.",
    "Initially laryngospasm leads to hypoxia and straining (leading to petechiae), then hypoxic cord relaxation leads to true inhalation injury. Free radicals, cyanide compounds, and carbon monoxide (CO) accompany thermal injury. Cyanide (p842) compounds (generated, eg from burning plastics) stop oxidative phosphorylation, causing dizziness, headaches, and seizures. Tachycardia dyspnoea soon give way to bradyc ardia apnoea. CO is generated later in the fi re as oxygen is depleted. NB: COHb levels do not correlate well with the severity of poisoning and partly refl ect smoking status and urban life. Use nomograms to extrapolate peak levels. 100% O2 is given to elute both cyanide and CO. Involve ICU/anaesthetists early if any signs of airway obstruction or respiratory failure: early intubation and ventilation may be useful. Enlist expert help in cyanide poisoningsee p842. Fig 19. 27 Lund and Browder charts. Acknowledgement We thank Professor Tor Chiu for help in preparing this topic. __OOHHCCMM__1100ee. . iinnddbb 884477 0022//0055//22001177 1199: : 0099 848 seicnegremE Hypothermia Have a High index of suspicion and a Low-reading thermometer. Most patients are elderly and do not complain of, or feel, coldso they have not tried to warm up. In the young, hypothermia is usually from cold exposure (eg near-drowning), or is secondary to impaired consciousness (eg following excess alcohol or drug overdose). Defi nition Hypothermia implies a core (rectal) temperature 35°C. Causes In the elderly, hypothermia is often caused by a combination of factors: Impaired homeostatic mechanisms: usually age-related. Low room temperature: poverty, poor housing. Impaired thermoregulation: pneumonia, myocardial infarction, Heart failure. Reduced metabolism: immobility, hypothyroidism, Diabetes mellitus. Autonomic neuropathy (p505); eg Diabetes mellitus, Parkinsons. Excess heat loss: psoriasis and any other widespread dermatological diseases (ie TEN/ erythrodermic eczema). Cold awareness: dementia, confusion. Increased exposure to cold: falls, especially at night when cold. Drugs: major tranquillizers, antidepressants, diuretics, alcohol. The patient If the patient is shivering then the hypothermia is mild, if they are not shivering despite temperature 35°C then the hypothermia is severe. Symptoms and signs include confusion, agitation, GCS, coma, bradycardia, hypotension and arrhythmias (atrial fibrillation, VT, VF), especially if temperature 30°C. There are many stories of people returning to life when warmed despite absence of vital signs, see BOX. It is essential to rewarm (see Treatment later in topic) and re-examine. Diagnosis Check oral or axillary T°. If ordinary thermometer shows 36. 5°C, use a Low-reading one PR. Is the rectal temperature 35°C? Infra-red ear thermometers can accurately refl ect core temperature. Tests Urgent UE, plasma glucose, and amylase. Thyroid function tests; FBC; Blood cultures. Consider Blood gases. The ECG may show J-waves (fi g 19. 28). Treatment Use ABCDE approach (p779)but dont expose to cold. All patients should receive warm, humidifi ed O2; ventilate if comatose or respiratory insuffi ciency. Remove wet clothing, slowly rewarm, aiming for rise of ½°C/h (check temperature, blood pressure, heart rate, and respiratory rate every 30min) using blankets or active external warming (hot air duvets). If T° rising too quickly stop and allow to cool slightly. Rapid rewarming causes peripheral vasodilation and shock. A falling blood pressure can be a sign of too rapid warming. Warm IVI. Cardiac monitor is essential (atrial fibrillation, VF, and VT can occur at any time during rewarming or on stimulation). Consider antibiotics for the prevention of pneumonia (p166). Give these routinely in patients over 65yrs with T° 32°C. Consider urinary catheter (to monitor renal function). NB: in sudden hypothermia from immersion or profound hypothermia with cardiovascular instability/cardiac arrest, the temperature needs to be raised rapidly. Options include warmed fl uid lavage (intravesical, nasogastric, intrapleural, intraperitoneal) and intravascular warming (cardiopulmonary bypass, Dialysis).",
    "Options include warmed fl uid lavage (intravesical, nasogastric, intrapleural, intraperitoneal) and intravascular warming (cardiopulmonary bypass, Dialysis). In the event of cardiac arrest, defi brillation is usually unsuccessful if T° 30°C (consider amiodarone, bretylium). Resuscitation must continue until core T° 33°C (OHCS p786). Complications Arrhythmias (if there is a cardiac arrest continue resuscitating until T° 33°C, as cold brains are less damaged by hypoxia); pneumonia; pancreatitis; acute kidney injury; DIC. Prognosis: Depends on age and degree of hypothermia. If age 70yrs and T° 32°C then mortality 50%. Before hospital discharge Anticipate problems. Will it happen again? What is their network of support? Review medication (could you stop tranquillizers)? How is progress to be monitored? Liaise with GP/social worker. __OOHHCCMM__1100ee. . iinnddbb 884488 0022//0055//22001177 1199: : 0099 seicnegremE 849 Fig 19. 28 J-wave in hypothermia. Courtesy of Dr R Luke and Dr E McLachlan. I did not die but nothing of life remained Remember that death is a process not an event, and that in hypothermia, all processes are suspended: metabolism may slow to as much as 10% of baseline, drastically diminishing the oxygen requirements of all tissues. Perhaps this is what Dante had in mind for the last round of the 9th circle of Hell, in which those betraying their benefactors are encased in ice (canto XXXIV) Comio divenni allor gelato e fi ocoIo non mori e non rimasi vivoHow frozen I then became: I did not die but nothing of life remained. Human records: 13 month old Canadian Erica Nordby came to life 2 hours atrial fibrillationter her Heart stopped (core T°: 16°C). Anna Bågenholm, a Swedish trainee orthopaedic surgeon, became trapped under freezing Water covered by a layer of ice for 80 minutes following a skiing accident, suff ering a cardiac arrest (core T°: 13. 7°C). After resuscitation and 20 days in intensive care, she regained consciousness, suff ering no permanent brain damage. She is now a radiologist. Do not declare anybody dead until they are warm and dead. __OOHHCCMM__1100ee. . iinnddbb 884499 0022//0055//22001177 1199: : 0099 850 seicnegremE Major disasters Planning All hospitals have a detailed Major Incident Plan, but additionally the tasks of key personnel can be distributed on individual Action Cards. At the scene Call the police to notify them of the Major Incident and ask them to take command. They will set up a central command centre to assess and manage the incident, depending on casualty numbers they will inform multiple hospitals of the need to prepare for the imminent arrival of casualties. Safety: Paramountyour own and others. Be visible (luminous monogrammed jacket) and wear protective clothing where appropriate (safety helmet; waterproofs; boots; respirator in chemical environment). Triage: See OHCS p800. There are several commercial systems available to label patients so emergency personnel can see at a glance the scale of the incident. The key is to divide patients by the urgency of care/transfer to hospital: 1 Emergency (labelR ED will die in a few minutes if no treatment) 2 Urgent (labelY ELLOW will die in 2h if no treatment) 3 Non-urgent (labelG REEN walking wounded/those who are stable and can wait) 4 Deceased (labelB LUE/WHITE). Communications: Essential; each emergency service will dispatch a control vehicle and will have a designated incident offi cer for liaison. Support medical staff from hospital report to the medical incident offi cer (MIO)he or she is usually the fi rst doctor on the scene. Their job is to assess then communicate to the receiving hospital the number severity of casualties, to organize resupply of equipment and to replace fatigued staff.",
    "The MIO must resist temptation to treat casualties as this compromises their role. Equipment: Must be portable and include: intubation and cricothyrotomy set; intravenous fl uids (colloid); bandages and dressings; chest drain (fl utter valve); amputation kit (when used, ideally 2 doctors should concur); drugsanalgesic: morphine; anaesthetic: ketamine 2mg/kg IV over 60s (0. 5mg/kg is a powerful analgesic without respiratory depression); limb splints (may be infl atable); defi brillator/monitor ± pulse oximeter. Evacuation: Remember that with immediate treatment on scene, the priority for evacuation may be reduced (eg a tension pneumothoraxREDonce relieved can wait for evacuation and becomes YELLOW), but those who may suff er by delay at the scene must go fi rst. Send any severed limbs to the same hospital as the patient, ideally chilledbut not frozen. At the hospital A major incident is declared. The fi rst receiving hospital will take most of the casualties; the support hospital(s) will cope with overfl ow and may provide mobile teams so that staff are not depleted from the fi rst hospital. A control room is established and the medical coordinator ensures staff have been summoned and informed of their roles, nominates a triage offi cer, and supervises the best use of inpatient beds and ICU/theatre resources. __OOHHCCMM__1100ee. . iinnddbb 885500 0022//0055//22001177 1199: : 0099 seicnegremE Blast injuries 851 These may be caused by domestic (eg gas explosion) or industrial (eg mining) accidents, or by terrorist bombs. Death may occur without any obvious external injury. Injury occurs in a number of ways: 1 Blast wave: A transient (milliseconds) wave of overpressure expands rapidly producing cellular disruption, shearing forces along tissue planes (submuco sal/ subserosal haemorrhage) and re-expansion of compressed trapped gasbowel perforation, fatal air embolism. 2 Blast wind: This can totally disrupt a body or cause avulsive amputations. Bodies can be thrown and sustain injuries on landing. 3 Missiles: Penetration or laceration from missiles are by far the commonest injuries. Missiles arise from the bomb or are secondary, eg glass. 4 Flash burns: These are usually superfi cial and occur on exposed skin. 5 Crush injuries: Beware sudden death or acute Kidney injury from rhabdomyolysis after release. 6 Contamination: There is increasing concern about the use of biological or radioactive material in terrorist bombs. Even domestic or industrial blasts can scatter chemicals widely and cause both superfi cial and penetrating contamination. Consider the location and mechanism of the blast, and seek advice. 7 Psychological injury: Eg post-traumatic stress disorder (OHCS p353). Treatment: Approach the same as any major trauma (OHCS p778). Rest and observe any suspected of exposure to signifi cant blast but without other injury. Gun-shot injury: see OHCS p789. Major blast injuries, whatever the cause, should be reported to the police for investigation. __OOHHCCMM__1100ee. . iinnddbb 885511 0022//0055//22001177 1199: : 0099 20 References Contents Chapter 1 Thinking about medicine 852 Chapter 2 History and examination 853 Chapter 3 Cardiovascular medicine 853 Chapter 4 Chest medicine 856 Chapter 5 Endocrinology 858 Chapter 6 Gastroenterology 858 Chapter 7 Renal medicine 859 Chapter 8 Haematology 859 Chapter 9 Infectious diseases 859 Chapter 10 Neurology 860 Chapter 11 Oncology and palliative care 860 Chapter 12 Rheumatology 861 Chapter 13 Surgery 863 Chapter 14 Clinical chemistry 864 Chapter 15 Eponymous syndromes 864 Chapter 16 Radiology 867 Chapter 17 Reference intervals 867 Chapter 18 Practical procedures 867 Chapter 19 Emergencies 867 Chapter 1: Thinking about medicine 1 Davis potassium, Stremikis potassium, Squires D, et al. Mirror, mirror on the wall: How the performance of the ultrasound healthcare system compares internationally. New York: The Commonwealth Fund, 2014. 2 Appleby J.",
    "Abbreviations: F indexes a notable fi gure or image; dis disease; syn syndrome. A Acute continued African appendicitis 608 eye worm 439 AA amyloid 370 asthma 810, 811F trypanosomiasis 423 Abbreviated Mental Test chest syn 341 Ageing 16 Score 64 cholecystitis 634, 635 Agitation 537 ABCD2 score 477 colonic pseudo-obstruction Agranulocytosis 364 ABCDE preliminary assessment 706 AIDS 517, 560 779 confusional state 484 Air travel, DVT 579 Abdomen coronary syn 11821, 7969 Airway 772 acute 606 demyelinating encephalitis Akinetic seizures 491, 492 areas 565 406 AL amyloid 370 auscultation 61, 63 dystonia 469 Alanine aminotransferase (ALT) burst 580 exacerbations of COPD 291, 688 distension 57, 604 812, 813F Albumin 686 examination 40, 601, 623 glaucoma 456, 561 Albumin: Creatinine ratio hernias 612, 613F, 614 Heart failure 134, 136 294, 686 mass 604 infl ammatory demyelinating Albuminuria 686 Pain 30, 57, 607F, 609, 732F, polyneuropathy (GBS) 447, Alcohol 733F 702, 703 alcoholism 280 palpation 61, 62 intermittent porphyria biochemistry 664 percussion 61, 63 692, 693 CNS 705 X-ray 728, 729F, 744 Kidney injury 298301 hepatitis 280, 281 Abdominal aortic aneurysm labyrinthitis 462 Liver dis 280, 291 732F limb ischaemia 657 screening 281 ruptured 654 lung injury 186, 187F withdrawal 280 Abetalipoproteinaemia 691 lymphoblastic leukaemia Aldosterone 668 Abscess 565 354, 355F Alfentanil 533 anorectal 630 mesenteric ischaemia 620 Alice in Wonderland syn 694 appendix 608 myeloid leukaemia 3567 Alkaline phosphatase 291, 688 breast 603 myocarditis 152 Alkalosis 6701 cerebral 824 pancreatitis 6367, 667 Allergic bronchopulmonary cutaneous 594 pericarditis 154, 155F aspergillosis 177 lung 170, 171F phase response 686 Allergies 8, 26 Absence seizures 491, 492 porphyrias 692 Allocation of resources 3 Absolute risk diff erence 20 prostatitis 645 Allodynia 559 Acanthocytosis 328, 329F pyelonephritis 296 amylase 688 Acan 5 t 6 h 2 o, s 5 is 6 3 n F igricans 529, res 1 p 8 i 6 r, a 1 t 8 o 7 r F y distress syn A 1 l - p a h n a t - it fe ry to p p si r n o t d e e i fi n c 5 i 3 e 1 ncy 290 Accelerated phase tubulointerstitial nephritis -gliadin antibody 553 hypertension 138 318 thalassaemia 342, 343F Accommodation 72 Adder bites 843 Alport syn 320 ACE inhibitors 114 Addisonian crisis 836 Alveolar opacifi cation 724 drug interactions 757 Addisons dis 203, 2267, 664 Alzheimers dis 488, 489 Acenocoumarol 757 Adenocarcinoma, colon 249F Amanita phalloides 273F Acetylcholine 449 Adenoma Amaurosis fugax 476, 560 receptor antibody 553 adrenal 224 American Society of Acetylcholinesterase inhibitors bronchial 174 Anesthesiologists (ASA) 489 Liver 286 classifi cation 567 Achalasia 250 pleomorphic 599 American trypanosomiasis Acidbase balance 6701 toxic 218 423 Acid-fast stain 382 Adenosine, drug interactions Amfebutamone 93 Acidaemia 671 757 Amikacin 387 Acidosis 300, 6701 Adenovirus 428 therapeutic range 756 lactic 834 Adhesions/adhesiolysis 581 Amino acids 449 metabolic 670 Adjuvant analgesia 574 Aminoglycosides 387 respiratory 670 Admirands triangle 634 drug interactions 757 Acoustic neuroma 462, 463F, 514 ADP receptor antagonists 114 nephrotoxicity 319 Acromegaly 149, 203, 2389 Adrenal Aminophylline 810 Actinic keratoses 596 adenoma 224 Aminotransferases Actinomycosis 389 carcinoma 224 ALT 291, 688 Activated cortex 224 AST 291, 688 charcoal 840 insuffi ciency 2267 Amiodarone 115, 220 partial thromboplastin nodular hyperplasia 224 Amoebiasis 4323 time 346 vein sampling 229 Amoxicillin 386 Protein C resistance 374 Adrenaline 449 clavulanic acid 386 Active immunity 407 Adult congenital Heart dis Ampicillin 386 Acuity 70 1567 Amputation 656 driving 159 Advanced life support 761, 894 Amyloidosis 149, 315, 370, 371F Acute Aerobes 382 Amyotrophic lateral sclerosis abdomen 606 Aff erent loop syn 622 506, 507 __OOHHCCMM__1100ee. .",
    ". iinnddbb 886688 0022//0055//22001177 1199: : 0099 Amyotrophy 212 Anorectal abscess 630 Anti-voltage-gated Anacrotic pulse 42 Anterior Ca2-channel antibody 553 869 Anaemia 34, 324 cerebral artery 450 potassium-channel antibody 553 aplastic 364 uveitis 561 Anuria 81, 293 Blood transfusion 324 Anterolateral system 516 Anus chronic dis (secondary) 326 Anthrax 424 cancer 631 Fanconi 698 Anti-anginals 116 examination 63 haemolytic 324, 3369 Anti-aquaporin 4 antibody ulcer 630 iron-defi ciency 326 553 Anxiety 460 macrocytic 324, 332, 333F Antibiotics Aorta megaloblastic 332, 333F infective endocarditis 151 abdominal aneurysm 654, microangiopathic 338, 339F mechanisms of action 732F microcytic 324 383, 385 coarctation 156 normocytic 324 neutropenia 352 palpation 61, 62 pernicious 334 pneumonia 167 thoracic dissection 655 sickle cell 3401 prescribing guide 384 Aortic sideroblastic 326, 327F prophylactic in surgery 570 arch syn 712 Anaerobes 382 resistance 383 bicuspid valve 156 Anaesthesia 5723 stewardship 384 calcifi cation 147F Anal summary tables 3867 coarctation 156 canal 631F TB 160F, 394 regurgitation 47, 146 cancer 631 Antibodies 686; see also root surgery 148 examination 63 Autoantibodies sclerosis 146 ulcer 630 Anticentromere antibody 553 stenosis 146 Analgesia/analgesics Anticholinergics 495 Apex beat 39, 40 nephropathy 311 Anticoagulants 114, 3501 Aphasia 86, 87 Pain relief 532, 574, 575F antidotes 350 Aphthous ulcer 246, 247F patient-controlled 341 atrial fi brillation 131 Aplastic anaemia 364 rebound headache 456 poisoning 842 ApoCII defi ciency 691 Anaphylactic shock 794, 795F surgery 590 Apology 5 ANCA-associated vasculitis Anticyclic citrullinated peptide Apomorphine 495 314, 556 antibody 553 Appendicectomy 609F Aneurysm Antidiabetics 208 Appendicitis 608 arterial 654 drug interactions 757 Appendix Berry 478 Anti-double stranded DNA abscess 608 false 654 antibody 553 mass 608 leaking abdominal aortic Antidromic conduction 127 Apraxic gait 467 732F Anti-emetics 251 Arbovirus 420 left ventricular 122 Anti-endomysial antibody 553 ARDS 186, 187F ruptured abdominal aortic Antiepileptic drugs 492, 493 Argentinian heart failure 426 654 Anti-extractable nuclear Argyll Robertson pupil 72 subclavian artery 598 antigen antibody 553 Aristolochic acid nephropathy unruptured intracranial 479 Anti-glomerular basement 319 Angina pectoris 116 membrane dis 311 Aristotle 445 decubitus 116 Antihelminths 433 Arithmetic mean 751 driving 158 Antihistamines, drug Arm 50, 60, 667 stable 116 interactions 757 GALS screen 540 unstable (crescendo) 116, 118 Antihistone antibody 553 ArnoldChiari malformation variant (Prinzmetals) 116, Anti-Jo-1 553 694 117, 708, 709 Anti-La 553 Arrhythmias 12431 Angiodysplasia 249F Anti-myocardial infarction-2 553 congenital 133 Angiography Antimicrobial stewardship 384 driving 158 catheter 740, 746, 747 Antimitochondrial antibody Arrhythmogenic computed tomography 657F, 746, 747F 553 right ventricular MR 744, 745F, 746 Antineutrophil cytoplasmic cardiomyopathy 133 Angioplasty 656 antibody 553 Art and medicine driving 158 Antinuclear antibody 553 Gillray 549F Angiotensin I/II 668 Anti-parkinson drugs 495 Michelangelo 233F Angiotensinogen 668 Antiphospholipid Picasso 5 Angular stomatitis (cheilosis) antibody 553 Rubens 237F 246, 327F syn 374, 554 van Gogh 459 Anion gap 670 Antiplatelets 114, 473, 590 Arterial Blood gases Anisocoria 72 Antiretroviral therapy (ART) dangerous results 665 Anisocytosis 327F, 328 4023 interpretation 189 Ankle drug interactions 757 reference intervals 753 brachial Hypertension index Anti-RNP 553 taking samples 162, 771 656 Anti-Ro 553 when to consider 188 movements 69 Anti-Scl70 553 Arteries refl exes 68 Anti-Sm 553 aneurysms 654 Ankylosing spondylitis 149, Anti-smooth muscle antibody cerebral 450 550, 551F 553 leg 656 Ann Arbor system 360 Antithrombin defi ciency 374 peripheral dis 6567 Anocutaneous refl ex 63 Anti-tissue transglutaminase surgery 580 Anogenital warts 406 antibody 553 __OOHHCCMM__1100ee. .",
    "244 Athetosis 87, 468 Gram-negative 3901 Billroth 622, 623F Atonic seizures 491, 492 Gram-positive 3889 Biochemistry 664 Atrial fi brillation 122, 130, 806 infection, overview 382 reference intervals 7523 anticoagulation 131 overgrowth 267 Biological agents 265, 547 ECG 98, 131F vaginosis 413 Biopsy INR 351 Bacteriocidal 382 bone marrow 364 pneumonia 170 Bacteriostatic 382 duodenal 248 pre-excited 131 Bacteriuria 296 Liver 248 stroke 473 Bad news 518F, 519 lung 164 Atrial fl utter 122, 127, 131, 806 Bagassosis 198 renal 310 Atrial natriuretic peptide 137 Bakers cyst 694 sentinel node 603 Atrial septal defect 156 Balanitis 645 Bird-fanciers lung 198 Atrial tachyarrhythmia 806 Balkan endemic nephropathy Bisferiens pulse 42 Atrial tachycardia 806 319 Bite-cell 339F Atrioventricular Bannister, R. 444F Bitôts spots 268 nodal re-entry tachycardia Bariatric surgery 626, 627F Black sickness 423 127 Barium contrast 742, 743F, 748 Blackouts 36, 4601 node 115 Barrel chest 55 Bladder re-entry tachycardia 127 Barretts oesophagus 254, 695 catheterization 297, 7623 Atrophie blanche 658 Barthels index 475 neck obstruction 649 Atrophy Bartonella 424 obstructive/irritative multiple system 494 Barts hydrops 342 symptoms 81 optic 71, 560 Bartters syn 228, 317 overactive 648 peroneal muscular 696 Basal cell carcinoma 596, 597F overdistension 81 progressive muscular 506 Basophilia 330 percussion 61 Attributable risk 20 Basophilic stippling 328, 329F tumours 6467 Auer rods 357F Basophils 330, 331F Blast injuries 851 Auscultation Bats wing 723F Blastomycosis 408 abdomen 61, 63 Bazins dis 694 Blasts 328 chest 51, 52 Beaus lines 76, 525 Bleeding Heart 40 Beckers muscular dystrophy approach to 346 peripheral vascular system 510, 511 disorders 344 78, 79 Becks triad 154 history 347 praecordium 39 Bedside manner 67 post-operative 577 thyroid 84, 85 Beefy tongue 335F rectal 629 Austin Flint murmur 46, 146 Beethoven, L. Van 465 upper GI 57, 2567, 820, 821F __OOHHCCMM__1100ee. .",
    ". iinnddbb 887700 0022//0055//22001177 1199: : 0099 Blepharospasm 469 Breast continued Calcium continued Blindness 71 cancer 521, 522, 6023 defi ciency 268 871 Blister-cells 339F cyst 603 oxalate crystals 295 Blood fi lm 323F, 328, 329F examination 83 pyrophosphate deposition Blood-letting 323 feeding 17 548 Blood loss history 82 stones 638, 639 estimation 607 lump 82, 603F Campylobacter 428, 429, 431 fl uids 667 nipple discharge 82 Canal Blood Hypertension 38, 40 Pagets dis 708, 709F anal 631F Diabetes 211 Pain 82 femoral 613F sphygmomanometer 139 triple assessment of lumps Guyons 503 unusual measurement 41 603F inguinal 615 Blood products 3489 Breathing Cancer/carcinoma Blood transfusion 3489 bronchial 52 adrenal 224 anaemia 324 CheyneStokes 53 anal 631 Bloody tap 768 patterns 53 antigen (calcium) 531 Blue bloaters 184 sounds 52 basal cell 596, 597F Blue lanulae 62 Breathlessness bile duct 619 BODE index 184 emergencies 782 biliary tree 286 BODEX 10 palliative care 534 bladder 6467 Body Brisbane, S. 427 breast 521, 522, 6023 habitus 32 Broad complex tachycardia bronchial 1746, 522 mass index 245 128, 129F, 804, 805F cervical 406 temperature 32 Broad St pump 431 chemotherapy 524 Boil 594 Brocas dysphasia 86 clinical trials 525 Bolivian heart failure 426 Broken Heart syn 145 CNS 522 Bone Bronchial colorectal 521, 61617 biomarkers 664 adenoma 174 diagnosis 519, 522 DEXA 683 breathing 52 emergencies 5289 metabolic dis 6825 cancer 1746, 522 fertility 525 Pain/tenderness 369 Bronchiectasis 172 gallbladder 619 scintigraphy 738 Bronchitis, chronic 184 genetics 5201 Bone marrow Bronchoalveolar lavage 164 gynaecological 522 biopsy 364 Bronchoscopy 164 hereditary 521 failure 364 BrownSéquard syn 696, 697 imaging 523 transplant 356 Brucellosis 424 interventional oncology 527 Boone, N. 307, 309F Brugada syn 133, 695 Liver 2867 Bordatella pertussis 391 Brugia lower GI 522 Bornholm dis 82 malaya 421 lung 1746, 522 Borrelia 422, 423 timori 421 multidisciplinary team 523 Boston Tea Party 538F Bruits 61 oesophageal 250, 618 Botulism 436 Bubonic plague 425 ovarian 521 Bouchards nodes 77, 544 BuddChiari syn 696 palliative care 5327 Bounding pulse 42 Buergers pancreas 270 Bouverets syn 634 angle 78 penile 644 Bowel dis 696, 697 prostate 521, 644, 645 gas patterns 728, 729F sign 78 radiotherapy 5267 obstruction 610, 611F test 79 renal cell 644 radiological assessment 728 Buffl er, P. 18 screening 530 sounds 61 Bulbar palsy 86, 506, 507 secondary skin 596 Bowens dis 596 Bundle branch block 100, 101F, skin 596, 597 Brachial 102F, 122, 127 skin manifestations 562 plexus 502 Bupropion 93 squamous cell 596, 597F pulse 38 Burkitts lymphoma 362, 363F staging 523 Brachytherapy 527 Burnout 11 stomach 619, 622 Bradford Hill criteria 18 Burns 8467 surgery 525 Bradyarrhythmias 122 Burr cells 328, 329F testes 650, 651F Bradycardia 124, 808, 809F Burst abdomen 580 therapeutic targeting 520F sinus 98, 122 C thyroid 600 Bradykinesia 494 tongue 246 Brain 13C breath test 253 transitional cell 644, 646 Blood supply 450, 451F C-reactive Protein 686, 687 tumour markers 530, 531 metastases 529 C3 glomerulonephritis 313 upper GI 522 natriuretic peptide 137 Cabot ring 328, 329F urology 522, 644 Brainstem Cachexia 35 viruses 405 death 12 Café-au-lait spots 514, 515 Candida albicans 408F, 409F infarcts 470 Calabar swellings 439 Candidiasis 246, 247F, 400, 408, lesions 447 Calcifi cation 409F, 413 Branchial cyst 598 aortic 147F Candour 5 Brazilian heart failure 426 metastatic (ectopic) 676 Cannula BRCA1/2 521 Calcitonin 531, 676 central venous 774 Breast Calcitriol 676 IV 7601 abscess 603 Calcium 676 nasal 189 benign dis 603 antagonists 114 PICC 774 __OOHHCCMM__1100ee. .",
    ". iinnddbb 887722 0022//0055//22001177 1199: : 0099 Cimetidine 757 Communication 67, 519, Corticospinal tract 447 Cingulate herniation 830 537, 779 Corynebacterium diphtheriae 873 Ciprofl oxacin 387 Community-acquired 389 Circle of Willis 450, 451F pneumonia 166, 167 Costochondritis 712 Cirrhosis 2767 Comparison measures 20 Co-trimoxazole 387 Clarithromycin 387 Compassion 3 Cough 48 Claudication 36, 656 Complete Heart block 98, test 62 Clerking 25 99F, 122 Couplet 128 Clindamycin 387 Compliance 9 Courvoisiers law 272 Clinical trials 525 Computed tomography, see computed tomography Coxiella burnetii 424 Clonorchiasis 435 COMT inhibitors 495 Crabtrees bludgeon 4 Clonus 68 Concordance 9 Crack dancing 87 Closed questions 7 Conduction aphasia 86 Crackles 52 Clostridium Conductive deafness 464 Cramp 65 botulinum 436 Condylomata Cranial nerves 703 diffi cile 259, 411, 428 acuminata 630 Craniopharyngioma 234 perfringens 389, 428, 430 lata 630 Creatine kinase 688 tetani 436 Confi dence intervals 20 Creatinine clearance 669 Clotting screen 347 Confounding 18 Crepitations 52 Cloudy Urine 81 Confusion 576 Crescendo (unstable) angina Clubbing 40, 77, 151F Congenital 116, 118 Cluster headache 457 cardiac arrhythmias 133 CreutzfeldtJakob dis 696, 697 CNS erythropoietic porphyria 692 Cricothyroidotomy 772 alcohol eff ects 705 Heart dis 1567 CriglerNajjar syn 696 cancer 522 insensitivity to Pain 8 Crimean-Congo heart failure 426, 427 TB 393 Congestive Heart failure 134 Critical ischaemia 656 CO2 670 Conjugated Crocodile tears 500 Coagulation 345F hyperbilirubinaemia 272 Crohns dis 2645, 562 disorders 344 Conjunctiva Cryoglobulinaemic vasculitis Coal workers pneumoconiosis haemorrhage 560 556 201 pallor 325F Cryptococcus 408 Co-amoxiclav 386 Conjunctivitis 438, 560, 561 Cryptococcus neoformans Coarctation of the aorta 156 Conns syn 228, 229, 664 400, 517 Cocci 382 Consent 5689 Cryptorchidism 652 Gram-negative 390 Constipation 2601, 534 Cryptosporidium 400, 428, 432 Gram-positive 388 Constrictive pericarditis 43, 154 Crystal CockcroftGault equation 669 Constructional dyspraxia 86 arthropathies 548, 549F Codeine 533 Contraceptive steroids, drug Urine 295 Coeliac dis 266, 562 interactions 757 Crystalloids 300 Cogans syn 556 Contrast studies CSF Cognitive genitourinary 744 dangerous results 665 decline 489 GI 742, 743F meningitis 822 state 64 media 730, 748 normal 768 Cohort studies 18 Conus medullaris 466 computed tomography 730, 731F Cold autoimmune haemolytic Convergence 72 AAA 732F anaemia 338 Convulsions 490 acute abdominal Pain 732F, Colic 565, 606 Coombs test 337F 733F biliary 634, 635 Coordination 67, 69 angiography 657F, 746, 747F Colistin 386 Cope sign 608 bowel obstruction 611F Colitis Coping 11 cardiac 108, 109F, 740 ischaemic 620 Copper 268 colonography 742, 743F ulcerative 2623 Cor pulmonale 1945 contrast medium 730 Collapsing pulse 42 Cord extradural haematoma Colloids 300, 666 compression 466, 508, 509F, 483F Colon 528, 543 GI 742, 743F adenocarcinoma 249F localizing lesions 447 head 746, 747F arterial supply 621F subacute combined headache 746 ischaemia 620 degeneration 334 hiatus hernia 255F polyps 249F, 617 Corneal arcus 39F, 41 middle cerebral artery surgery 580 Coronary aneurysm 479F Colonoscopy 248, 249 artery anatomy 113F neuroimaging 746, 747F Colorectal cancer 521, 61617 artery bypass graft (CABG) oesophageal cancer 618F Colostomy 582, 583F 38F, 116, 123 pancreatic pseudocyst 637F Colour-fl ow echocardiography spasm 709 PET and 523, 730 110 Coronaviruses 169 retroperitoneal fi brosis 643F Coma 7869 Corrigans SPECT 739 hypopituitary 836 secret door 11 streak artefact 730 myxoedema 220, 834 sign 38, 47, 146 stroke 746 Commensal 382 Cortical subdural haematoma 483F Common lesions 447 urogram 744, 745F hypercholesterolaemia 691 vein thrombosis 480 vascular 740 peroneal nerve 452, 502 Cortico-basal degeneration Cubital tunnel syn 503 primary hyperlipidaemia 690 494 Cullens sign 636 Corticobulbar palsy 507 Cushing, H. 6, 697 __OOHHCCMM__1100ee. .",
    ". iinnddbb 887733 0022//0055//22001177 1199: : 0099 Cushings Detrusor Disease-modifying drugs 874 dis 224 overactivity 649 antirheumatics 547 syn 149, 203, 2245, 529, 664 weakness/myopathy 81 MS 496 Cutaneous Device placement confi rmation Disseminated intravascular abscess 594 726, 727F coagulation (DIC) 353, 354F larva migrans 433F Devics syn 497, 698, 699 Distal renal tubular acidosis leishmaniasis 423, 440 Devils grip 82 317 mycoses 408 DEXA 683 Distributive justice 3 TB 393 Dexamethasone suppression Diuretics 114, 316, 317, 664, 757 Cyanide poisoning 842 test 225 drug interactions 757 Cyanosis 34, 38F, 50F Dextrose 666 Diverticular dis 628 Cyclophosphamide 376 drug interactions 757 Diverticulitis 628 Cyclospora cayetanensis saline 666 Diverticulosis 249F, 628 428, 433 Diabetes insipidus 240, 664 Dizziness 36, 64, 462 Cyst 565 Diabetes mellitus 20613 Dizziness-plus syn 450 Bakers 694 biochemistry 664 Dolls head manoeuvre 789 branchial 598 Blood Hypertension control 211 Dopamine 449 breast 603 complications 210 agonists 495 dermoid 594, 595F diagnosis 207 Doppler echocardiography 110 epidermal 594, 595F emergencies 834 Dorsal midbrain syn 708 epididymal 320, 650 foot care 212, 213 Downs syn 149 pilar 594 glucose monitoring 207 Doxycycline 387 sebaceous 594 insulin 208 DPP4 inhibitors 208 third-ventricle colloid 498 ketoacidosis 215, 8323 Drains thyroglossal 598 nephropathy 210, 314 ascites 764 Cystic neuropathy 21213 chest 7667 fi brosis 173 oral hypoglycaemics 208 surgical 571 hygroma 598 pregnancy 213 Dressing dyspraxia 86 Cystine retinopathy 210, 211F Dresslers syn 122, 698 crystals 295 skin 562 Drip and suck 732 stones 638, 639 surgery 213, 588 Driving 120, 1589 Cystinosis 321 treatment 2089 Drop attacks 460 Cystinuria 321 type 1 206, 207, 211 Drug-induced conditions Cystitis 296 type 2 206, 207, 208F, 211 cramp 65 Cytochrome P450 689 Diagnosis 4 haemolytic anaemia 338 Cytomegalovirus (CMV) 400, Diagnostic taps 765 hepatitis 291 405, 428, 4389, 517 Dialysis 292F, 3067 insomnia 29 Cytoplasmic ANCA 553 Diamorphine 533, 574 jaundice 273 Cytotoxic drugs 524 Diaphragm 722 lupus 554 D Diarrhoea 258, 259F, 428 myopathy 510 travellers 428, 429 nephropathy 318 D-dimers 346 with Blood 429, 431 osteomalacia 684 Da Vinci robot 564F without Blood 429, 430 porphyria 693 Day case surgery 592 Diastolic sweating 29 De Mussets sign 47, 146 blood pressure 40 Drug-resistant TB 395 De Quervains thyroiditis 218 failure 134 Drugs Deafness 464 Diet allergy 8 Death 1213 gluten-free 266 anticipatory at end-of-life Decision-making 7 healthy 244 536 Decubitus angina 116 hospital inpatients 584 cardiovascular 11415 Deep vein thrombosis 351, Diff erential white cell count cytochrome P450 689 578, 579 330 cytotoxic 524 Defi brillation 770 Diff use oesophageal spasm 250 history 26 Degeneration Digital subtraction angiogram interactions 8, 757 cord 334 745F, 747F nervous system 4489 cortico-basal 494 Dignitas 507 pregnancy 17 hepatolenticular 285 Digoxin 115 pre-operative 566 Dehydration 664 drug interactions 757 prescribing, see Prescribing Déjà vu 491 ECG 98, 115F reactions 8 Delirium 484, 485 poisoning 842 side-eff ect 8 tremens 280 therapeutic range 756 therapeutic ranges 756 Dementia 159, 485, 4867, 507 Dihydropyridines 114 toxicity 8 Dengue 420 Dilated cardiomyopathy 152 Dry gangrene 660 Depression 15 Dimorphic Blood fi lm 328 DubinJohnson syn 698 Dermal neurofi bromas 514 Diphtheria 389 Duchennes muscular Dermatitis Dipstick urinalysis 294 dystrophy 510, 511 herpetiformis 562 Direct Duct ectasia 603 seborrheic 408 antiglobulin test 337F Ductal carcinoma in situ 602 Dermatomes 4545 Coombs test 337F Duke criteria 151 Dermatomyositis 529, 552, 562 oral anticoagulants 114, 191, Dumping syn 622 Dermatophytosis 408 350, 590 Duodenal Dermoid cyst 594, 595F Disaster planning 850 biopsy 248 Descartes, R. 445 Disc herniation 543F ulcer 252, 253F Duplex ultrasound 736 __OOHHCCMM__1100ee. .",
    ". iinnddbb 887755 0022//0055//22001177 1199: : 0099 Escherichia coli 391, 428, 429 Factious blackouts 460 Fibromyalgia continued 876 enterohaemorrhagic/ShigaFactor V Leiden 374 progressive massive 201 toxin producing 431 Faecal incontinence 58 progressive nephrogenic enterotoxigenic 430 Faints 36, 64 systemic 748 ESR 372 Falciparum malaria 416, retroperitonal 643 Essential thrombocythaemia 417, 418 Field defects 71 366, 367F Fallots tetralogy 157 Filarial infection 439 Estimated glomerular fi ltration Falls 16, 28 Finger clubbing 40, 77, 151F rate (estimated glomerular filtration rate) 293, 669 False Fingerprick glucose 207 Ethics 14 aneurysms 654 Fissure-in-ano 630 Evidence-based medicine 22 negative 20 Fistula 565 Examination positive 20 in-ano 630 abdomen 40, 601, 623 Familial Fits 64 anus 63 adenomatous polyposis 521 Fitz-HughCurtis syn 698 breast 83 amyloidosis 370 Flaccid paraparesis 466 cardiovascular system 3840 cancers 521 Flagella 382 chest 63 combined hyperlipidaemia Flatulence 58 coma 789 691 Fleming, A. 383 cranial nerves 703 defective apolipoprotein Flight of ideas 89 GI system 623 B-100 691 Flow musculoskeletal 747 hypercholesterolaemia 691 rate 761 neurological system 669 hyperchylomicronaemia 691 volume loop 164, 165F older person 16 hypertriglyceridaemia 691 Flucloxacillin 386 peripheral vascular system primary hyperlipidaemia Fluconazole 757 789 690, 691 Fluids physical 32 Family balance 300, 666, 667 pre-operative 567 history 26 drug interactions 757 rectum 63 trees 27 end of life 537 respiratory system 503 Fanconi overload 300 routine, method and anaemia 698 resuscitation 300 order 90 syn 316 status 32 thyroid 845 Farinelli 202F therapy 666, 667 Exenatide 209 Farmers lung 198 Fluoride Exercise ECG 125 Fasciola hepatica 435 defi ciency 268 Exertional dyspnoea 30 FAST campaign 471 teeth 247F Exomphalos 612 Fasting hypoglycaemia 214 Fluoroquinolones 387 Exotoxin 382 Fat necrosis 603 Fluticasone 183 Experimental studies 18 Fatigue 29 Flying, DVT 579 Extensor plantar refl ex 68, 466 Fauré, G. 465 Focal External beam radiotherapy Feet atrial tachycardia 127 527 diabetic 212, 213 dystonia 469 Extradural haematoma 482, drop 466 segmental 483F Feltys syn 698 glomerulosclerosis 313 Extrapyrimidal Femoral seizures 491, 492 gait 467 canal 613F Folate 322 speech 86 catheterization 775 inhibitors of synthesis 387 Extravasation 524 hernia 612 Folic acid 244, 268 Extrinsic allergic alveolitis 198 nerve 452 Follicular lymphoma 363 Exudates 192 stretch test 542 Fondaparinux 350 Eye Fentanyl patch 533 Fontaine classifi cation 656 ankylosing spondylitis 550 Fertility 525 Fontan procedure 157 coma 789 Fever 29 Food poisoning 428 cranial nerve lesions 723 enteric 415 Foot Diabetes 210, 211F Lassa 426 diabetic 212, 213 hypertension 139, 560 Oroya 424 drop 466 hyperviscosity syn 372F Q 424 Fordyce glands 246 infections 4389 relapsing 423 Foster Kennedy syn 698 movements 70 returning travellers 41415 Framing 7 neurofi bromatosis 514F rheumatic 142 Freckling 514 ptosis 73 Rift Valley 426 Fresh frozen plasma 348 red 561 Rocky Mountain spotted 422 Friedreichs ataxia 149, 698, 700 systemic conditions 560 spotted 422 Froins syn 700 thyroid dis 84, 85, 219 trench 424 Froments sign 75 xerophthalmia 268 viral haemorrhagic 4267 Frontal lobe F yellow 420 lesions 499 Fibreoptic bronchoscopy 164 seizures 491 Fabry dis 320, 698 Fibrinolysis 345 Fronto-temporal dementia Face 32, 39, 40, 50, 52, 60, 62 Fibroadenoma, breast 603 486, 507 masks 189 Fibroma 594 Fulminant hepatic failure 274 Pain 65 Fibromyalgia 558, 559 Functional incontinence 648 Facial nerve 501F Fibrosis Fundoplication 624 lesions 70, 500 cystic 173 Fungi 177, 4089 Facioscapulohumeral muscular idiopathic pulmonary 200F Funnel chest 55 dystrophy 510, 511 lung 54F Funny turns 64 __OOHHCCMM__1100ee. . iinnddbb 887766 0022//0055//22001177 1199: : 0099 Furuncle 594 Genetics Gram-positive bacteria 3889 Fusidic acid 387 Alzheimers dis 489 Gram stain 382 877 Fusion beat 129F, 133 cancer 5201 Granger, potassium.",
    "6, 518 G family trees 27 Granular cast 295 Genital Granulation tissue 661 Gadolinium 748 candidiasis 413 Granulomatosis with Gag refl ex 70 herpes 404, 412 polyangiitis 556, 714 Gait ulcers 412 Granulomatous disorders disorders 467 Genitourinary diff erential diagnosis 197 dyspraxia 86 history 801 eye signs 560 GALS screen 540 imaging 744, 745F Graves dis 218, 219, 601F neurological examination 68 surgery 580 Grey Turner sign 636 Galactorrhoea 237F symptoms 30 Groin lumps 650, 651 Gallbladder TB 393 Group-and-save 348 cancer 619 Gentamicin 387 Guanarito virus 426 necrosis 634 therapeutic range 756 GuillainBarré syn 447, 702, 703 Gallop rhythms 44 Geographic tongue 246 Gummatous syphilis 412 Gallstone 6345 German measles 406 Guyons canal 503 ileus 634 GerstmannSträussler Gynaecological cancer 522 GALS screen 540 Scheinker syn 696 Gynaecomastia 230 Gambling 21 Gerstmanns syn 700 H Gamma-glutamyltransferase Giant cell arteritis 456, 556 291, 688 Giant condylomata acuminata Haemangioma, Liver 286, 737F Ganglia 594, 595F of Bushke Loewenstein Haematemesis 30, 256 Gangrene 213F, 660 630 Haematocele 650 dry 660 Giardiasis (Giardia) 428, Haematology gas 389, 660 429, 432 dangerous results 665 wet 660 Gilberts syn 700 pregnancy 17 Gangrenous ischaemic colitis Gilles de la Tourette syn 700 reference intervals 754 620 Gillick competence 569 Haematoma Gardners syn 700 Gingivitis 246, 712 epidural 482, 483F Gas Gingivostomatitis 404 extradural 482, 483F gangrene 389, 660 Gitelman syn 317 perianal 630 outside lumen 724 Glasgow Blatchford score 257 subdural 482, 483F outside lungs 724 Glasgow Coma Scale (GCS) 788 Haematopoiesis 365F patterns in bowel 728, 729F Glass tests 822F Haematuria 81, 294 transfer coeffi cient 164 Glaucoma 456, 561 non-visible 293, 647 Gastrectomy 622 Gliptins 208 visible 293 Gastric Glitazone 208 Haemochromatosis 149, 2889 bypass 626, 627F Global Initiative for COPD Haemodialysis 306, 840 carcinoma 619, 622 (GOLD) 184 Haemofi ltration 306 emptying and lavage 840 Glomerular basement Haemoglobin 343 lavage 840 membrane antibody 553 Haemoglobinuria 336, 686 lymphomas 62 Glomerular fi ltration rate (glomerular filtration rate) paroxysmal cold 338 MALT 362 293, 668, 669 paroxysmal nocturnal 338, parietal cell antibody 553 Glomerulonephritis 31013 704, 705 surgery 622 Glomerulosclerosis, focal Haemolysis 336 ulcer 252 segmental 313 Haemolytic Gastrinoma 716, 717F Glossitis 246, 335F anaemia 324, 3369 Gastritis 252 Glucagon-like peptide uraemic syn 315 Gastroenteritis 42831 analogues 209 Haemophilias 344 Gastrointestinal Glucose Haemophilus infl uenzae 391 cancer diagnosis 522 5% 666 Haemopneumothorax 192 decontamination 840 drug interactions 757 Haemoptysis 48, 49 endoscopy 248, 249 hypertonic 666 Haemorrhage examination 623 monitoring 207 conjunctival 560 fl uid replacement 667 saline 666 nuclear medicine 738 history 567 Glucose-6-phosphate primary 577 imaging 742, 743F dehydrogenase defi ciency reactive 577 malabsorption 266, 267 338, 339F retinal 560 symptoms 30, 589 Glutamic acid decarboxylase secondary 577 TB 393 antibody 553 shock 790 upper bleeding 57, 2567, Gluten-free diet 266 splinter 76, 150, 151F 820, 821F Glycated haemoglobin 207 subarachnoid 456, 4789 Gastro-oesophageal Glycogen storage dis 510, 704 subconjunctival 561 refl ux dis 254, 624 Goitre 218, 219, 600 Haemorrhoids 6323 varices 257 GOLD 184 Haemosiderinuria 336 Gastroschisis 612 Goodpastures dis 311, 556, 700 Haemothorax 192 Gauss, C. F. 750F Goodsalls rule 630 Halitosis 59 Gaussian distribution 751 Gottrons papules 76, 552, 562 Hallux valgus 540F Gawande, A. 6 Gout 538F, 541F, 548, 549F Hamartoma, lung 174 Gélineaus syn 700, 701 Gouty trophi 74F Hand 38, 40, 41, 50, 52, 60, 62, Gene therapy 173 Graham Steell murmur 46 747, 84, 85, 540 Generalized seizures 491, 492 Gram-negative bacteria 3901 hygiene 411, 758F __OOHHCCMM__1100ee. .",
    ". iinnddbb 887777 0022//0055//22001177 1199: : 0099 Handicap 475 Hepatitis continued History continued 878 Handover 10 ischaemic 291 genitourinary 801 Hansens dis 441 viral 2789, 291 neurological 645 Hanta virus 426 Hepatocellular older person 16 Hartmanns solution 666 carcinoma 286 pre-operative 567 HAS-BLED 131 dysfunction 272, 291, 664 presenting complaint 26 Hashimotos thyroiditis 220 Hepatolenticular degeneration respiratory 489 hemoglobin hemoglobin A1c 207 285 rheumatology 539 bicarbonate 670 Hepatomegaly 63, 604 HIV 398401 Head injury 456, 828, 829F Hepatorenal syn 275 antiretrovirals 4023 Headache 64, 4567 Hepcidin 289 diff erential diagnosis 401 cluster 457 Herbal remedies 319 eye signs 560 computed tomography 746 Hereditary Heart dis 149, 401 diff erential diagnosis 780 cancers 521 neurocognitive disorders 517 medication overuse 456 coproporphyria 692 neurology 517 post-lumbar puncture 769 elliptocytosis 338, 339F opportunistic dis 400, 517 tension 456 haemochromatosis 2889 post-exposure prophylaxis Health-care associated non-polyposis colorectal 398 infections 41011 cancer 521 pre-exposure prophylaxis Healthy ovalocytosis 338 398 ageing 16 spherocytosis 338, 339F testing 399 eating 244 stomatocytosis 338 HLA-B27 551 Hearing telangiectasia 708, 709F Hoarseness 48 loss 464 Hernia 565 Hodgkins lymphoma 3601 testing 70, 464 abdominal 612, 613F, 614 Holiday Heart syn 126 Heart epigastric 612 HolmesAdies pupil 72 auscultation 40 femoral 612 HoltOram syn 149 block 98, 99F, 122 hiatus 255 Holter monitors 125 chest X-ray 108, 109F, 722 incisional 580, 612 Holts law 26 murmurs 467 indirect inguinal 612, 651F Homocystinuria 706 muscle dis 1523 inguinal 612, 614, 651F Homografts 148 normal conduction 127F irreducible 614 Hookworm 433 rate calculation from Littres 612 Hormones 204 ECG 97 lumbar 612 parathyroid 222, 676 sounds 44 Maydls 612 thyroid-stimulating 216 Heart failure 1347, 801F obturator 612 Horners syn 50F, 702, 703F acute 134, 136 paraoesophageal 255 Hospital-acquired pneumonia Blood transfusion 348 paraumbilical 612 166, 167 chronic 134, 136 Richters 612 Hot potato voice 86 congestive 134 rolling 255 Hounsfi eld scale 730, 731F fl uids 667 sciatic 612 HowellJolly bodies 328, 329F High-output 134 sliding 255, 612 5-height 449 intractable 136 Spigelian 612 Human Low-output 134 umbilical 612 albumin solution 348 New York classifi cation 135 Herniation syn 830 chorionic gonadotrophin 531 with preserved ejection Herpes herpes viruses 4045 fraction 134 encephalitis 404 immunodefi ciency virus, Heat exhaustion 790 genital 404, 412 see HIV Heaves 39, 40 labialis 404 papilloma virus 406 Heavy chain dis 370 simplex virus 404 T-cell lymphotrophic Heavy metal poisoning 842 sine herpete 501 virus 517 Heberdens nodes 77, 544 viruses 4045 Humours 323 Heelshin test 69 whitlow 404 Huntingtons dis 702 Helicobacter pylori 252, 253 zoster 462 Hutchinson Heliotrope rash 552, 562, 563F zoster ophthalmicus 438 pupil 72 Helminths 433 Heuristics 4 sign 438 Hemianopia 71 Hiatus hernia 255 Hyaline cast 295 Hemiballismus 87, 468 Hickams dictum 4 Hydatid dis 435 HenochSchönlein purpura 311, Hidradenitis suppurativa 594 Hydration, see Fluids 556, 702, 703F Hierarchy of evidence 22 Hydroceles 650, 651F Heparin 350 High-output Heart failure 134 5-hydroxytryptamine 449 Hepatic Higher mental function 867 Hyperaesthesia 559 encephalopathy 275 Hila 722 Hyperaldosteronism 228, 229 fl ap/asterixis 62 Hillis plot 379 Hyperalphalipoproteinaemia Hepatitis Hip movements 69 691 A 278 Hippocratic oath 1 Hyperandrogenism 203 alcoholic 280, 281 Hirsutism 230 Hyperbilirubinaemia 272 autoimmune 284, 291 Histamine 449 Hypercalcaemia 98, 528, 529, B 278, 279, 401 Histiocytosis X 704 676, 677 B vaccine 287 Histoplasmosis 408 Hypercholesterolaemia 691 C 278, 279, 401 History 26 Hypereosinophilic syn 330 D 278 breast 82 Hyperglycaemic hyperosmolar drug-induced 291 cardiovascular 367 state 834 E 278 gastrointestinal 567 Hyperhidrosis 29 __OOHHCCMM__1100ee. .",
    ". iinnddbb 887788 0022//0055//22001177 1199: : 0099 Hyperkalaemia 98, 301, 674, Ichthyosis 562 Infectious 675F Idiopathic dis overview 3801 879 Hyperlipidaemia 41, 6901 costochondritis 712 malabsorption 266 Hypermagnesaemia 679 facial nerve palsy 500 mononucleosis 405 Hypernatraemia 672 generalized dystonia 469 Infective endocarditis 1501 Hyperparathyroidism 222, 738 intracranial hypertension Inferior gluteal nerve 452 Hyperphosphataemia 498 Infl ammatory myopathies 510 302, 679 pulmonary fi brosis 200 Infl uenza 3967 Hyperpigmentation 32, 34 scrotal oedema 652 Inguinal Hyperplasia IgA canal 615 adrenal 224 nephropathy 311, 694 hernia 612, 614, 651F prostate 642 vasculitis 556 Inhalers 183 Hyperprolactinaemia 236 Ileal pouch-anal anastomosis Injection sclerotherapy 658 Hypertension 93, 13841 582 INR 351 driving 158 Ileostomy 582, 583F Insecticide poisoning 843 idiopathic intracranial 498 Ileus 565, 729F Insomnia 29, 535 malignant 138, 140, 141F paralytic 611 Insulin portal 257 Imaging therapy 208 pulmonary 105F acutely unwell patient 749 tolerance test 232 retinopathy 139, 560 cancer 523 variable rate intravenous white-coat 138 cardiac 108, 7401 infusion 589 Hyperthyroid crisis 834, 835F contrast media 319, 730, 748 Insulinoma 215 Hyperthyroidism 31, 216, 562 genitourinary 744, 745F Intention tremor 65, 468 subclinical 221 GI 742, 743F Interdependence 475 Hypertonia 494 neuroimaging 746, 747F Interferon-gamma release Hypertonic glucose 666 Imbalance 36 assay 394 Hypertrophic Imipenem 386 Internal cardiomyopathy 109F, Immune capsule 447 110, 152 complex vasculitis 556 carotid arteries 450 osteoarthropathy 529 thrombocytopenia 345 jugular catheterization 775 Hyperuricaemia 680 Immunity, active/passive 407 International normalized ratio Hyperventilation (syn) 53 Immunization (INR) 351 Hyperviscosity (syn) 352, 372 hepatitis B 287 Internuclear ophthalmoplegia Hypervolaemia 300 immunosuppression 407 73F Hypnotics 29 pneumococcal 167 Interstitial lung dis 198 Hypoalphalipoproteinaemia schedule 407 Interventional oncology 527 691 splenectomy 373 Intestinal Hypobetalipoproetinaemia Immunoglobulins 686 angina 620 691 Immunosuppression fl ukes 428 Hypocalcaemia 98, 678 biochemistry 664 obstruction 610 Hypochromia 328 drugs 377 Intracardiac electrophysiology Hypocomplementaemic eye 438 112 urticarial vasculitis 556 pneumonia 166, 167, 400 Intracranial Hypoglycaemia 214, 460, 834 renal transplantation 308 hypotension 456 Hypoglycaemic vaccination 407 Hypertension, raised 830, 831F hyperinsulinaemia 214 Impaired fasting glucose 206 venous thrombosis 480, 481F Hypogonadism 231 Impaired glucose tolerance Intractable Heart failure 136 Hypokalaemia 98, 674 206 Intravascular access device Hypokalaemic periodic Implanted cardioverter/ infections 410 paralysis 674 defi brillator 125, 158 Intravenous cannulae 7601 Hypomagnesaemia 679 Impotence 230 sizes and colour 761 Hyponatraemia 672, 673F Incidence Intravenous fl uids 666, 667 Hypoparathyroidism 203, 222 proportion 18 drug interactions 757 Hypophosphataemia 679, 684 rate 18 Intrinsic factor antibody 553 Hypopituitarism 203, 232 Incisional hernia 580, 612 Inulin clearance 669 Hypopituitary coma 836 Incisions 565 Invasive aspergillosis 177 Hypotension 170 Inclusion body myositis 510 Inverse care law 3 intracranial 456 Incontinence Involuntary movements orthostatic 460 faecal 58 64, 468 postural 40, 41 urinary 6489 Iodide 268 Hypothalamicpituitary axis Indigestion 59 Iodine contrast agents 748 204F Indirect Ionizing radiation Hypothermia 8489 antiglobulin test 337F dose 719 Hypothyroidism 31, 149, 203, Coombs test 337F nephritis 319 216, 220, 221F, 216 inguinal hernia 612, 651F risks and benefi ts 719 subclinical 221 Industrial dust dis 201 Iritis 550, 560, 561 Hypovolaemia 300 Infantile spasms 491 Iron shock 790 Infarcts defi ciency 268 Hypoxia, post-operative 576 brainstem 470 defi ciency anaemia 326 I cerebral 470 metabolism 289 lacunar 470 plasma 327 Iatrogenic hyponatraemia 672 myocardial 473 poisoning 842 IBD-unclassifi ed 263 nailfold 76 Irritable bowel syn 266, 267 Ice Water calorics 789 right ventricle 122, 796 Irritative bladder symptoms 81 __OOHHCCMM__1100ee. .",
    ". iinnddbb 887799 0022//0055//22001177 1199: : 0099 Ischaemia Kidney continued Left upper quadrant 880 colitis 620 obstructed 641F mass 604 colonic 620 palpation 61, 62 Pain 57 critical 656 polycystic dis 320, 321F Left ventricle Heart dis 37, 93, 117 toxins 318 aneurysm 122 hepatitis 291 transplantation 3089 assist device 137 limb 657 ultrasound 737F, 744, 745F echocardiography 110 mesenteric 620 urate 680 failure 134, 135F papillopathy 71 Kings College Hospital criteria, hypertrophy 100 Isotope scan, thyroid 216, 217F Liver failure 275 Leg Itch 28 Klebsiella pneumoniae arteries 656 IV cannulae 7601 168, 391 GALS screen 540 sizes and colour 761 Klinefelters syn 149, 231 superfi cial veins 658F IV fl uids 666, 667 KlippelTrénaunay syn 704 swollen 579 drug interactions 757 Knee varicose veins 658, 659 Ivabradine 115 fl exion and extension 69 venous ulcers 660, 661 Ivacaftor 173 refl exes 68, 466 weakness 466 J Knights move 89 see also Lower limb Koilonychia 62, 76, 327F Legal highs 841 J wave 96 Kopliks spots 406F Legionella pneumophila 168 Jamais vu 491 Korsakoff s syn 704 Leishmaniasis 423, 440 James, L. S. 778F Kuru 697 Leprosy 441, 596 Janeway lesions 38, 40, 150, Kussmaul Leptospirosis 425 151F respiration 53 Leriches syn 704 Japanese encephalitis virus sign 43, 154 Leuconychia 62, 74F, 276 437 Kyphosis 55 Leucoplakia 246, 247F, 596 Jaundice 2723 L Leukaemia 352 drug-induced 273 acute lymphoblastic 354, obstructive 634 Laboratory medicine 355F pneumonia 170 dangerous results 665 acute myeloid 3567 surgery 590 principles 663 antibiotics 352 Jehovahs Witnesses 349 Labyrinthitis 462 chronic lymphocytic 359 Jendrassik manoeuvre 67 Lactate dehydrogenase 688 chronic myeloid 358 Jervell and LangeNielsen Lactic acidosis 834 Leukaemoid reaction 328 syn 702 Lacunar infarcts 470 Leukoerythroblastic fi lm 328 Joint LambertEaton myasthenic Levetiracetam 493 aspiration 541 syn 512, 513, 529 Levodopa 495 Charcot 213F Laminectomy 509F Levofl oxacin 387 hand 75 Laminoplasty 509F Lewy body dementia 486 position sense 69 Lamotrigine 493 Lhermittes sign 497 range of movement 540 Lancefi eld group 388, 389F Liberskis imperative 697 Jugular venous Hypertension (JVP) LandouzyDejerine syn 510 Libertarian paternalism 7 38, 43, 300 Langerhans cell histiocytosis Life 379 Junctional tachycardia 127, 806 704 Light Junin virus 426 Laparoscopic adjustable refl ex 72 Justice 14 gastric band 626, 627F touch 67 Juvenile posterior subcapsular Laparotomy Lights criteria 193 lenticular opacity 514 clinical syn requiring 606 Linezolid 387 potassium fi rst successful 605 Lipodermatosclerosis 661 post-operative Lipoma 594 Kala-azar 423 complications 580 Lipopeptides 386 Kallmans syn 231 Large bowel Lipoprotein lipase defi ciency Kaposis sarcoma 400, 702, 703F gas patterns 728 691 Katayama syn 434 obstruction 610, 611F Liraglutide 209 Kawasaki dis 149, 556 Large vessel vasculitis 556 Lisch nodules 514 KayserFleischer rings 62, 285 Laryngocele 598 Listeria 389, 428 Kidney Disease: Improving Global Outcomes staging 298 Lasègues sign 542 Literature and medicine Keloids 594, 595F Laser ablation 658 Bennett 487 Kelvin, Lord 20 Lassa fever 426 Blake 322 Keratoconjunctivitis 404 Late malignant ventricular Brian 297 sicca 560 arrhythmias 122 Browning 693 Keratoses 596 Lateral Dante 849 Ketoacidosis, diabetic 215, aberrant thyroid 600 Donne 475 8323 cutaneous nerve of thigh Ford 663 Kidney 502 Hughes 37 acute injury 298301 medullary syn 450 James 261, 379 ballottement 61F Laxatives 260 Kipling 778F biochemistry 664 LDL receptor defects 691 Lifton 1 chronic dis 3025 Leeuwenhoeks microscope Plato 5 electrolytes 668 378F Shakespeare 779 inherited dis 3201 Left bundle branch block Steinbeck 269 medullary sponge 639 100, 101F Tennyson 569 MRA 744, 745F Left iliac fossa Pain 57 Twain 592 nuclear medicine 739 Left shift 328, 329F Wright 145 __OOHHCCMM__1100ee. .",
    ". iinnddbb 888800 0022//0055//22001177 1199: : 0099 Lithium Lumps continued Malabsorption 266, 267, drug interactions 757 neck 598 344, 562 881 therapeutic range 756 scrotum 650, 651F Malaria 41619 Littres hernia 612 skin 594, 595F Malassezia 408 Livedo reticularis 557F subcutaneous 595 Maldescended testes 652 Liver thyroid 600 Malignant adenoma 286 Lund and Browder chart 847 hyperparathyroidism 222 alcoholic dis 280, 291 Lung hyperpyrexia 572 biopsy 248 abscess 170, 171F hypertension 138, 140, 141F bleeding disorders 344 acute injury 186, 187F melanomas 596, 597 cholestasis predominant anatomy 161F mesothelioma 174 injury 291 biopsy 164 MalloryWeiss tear 704 cirrhosis 2767 cancer 1746, 522 Malnourished hospital patients failure 2745, 667 chest X-ray 724, 725F 584 fatty infi ltration 280, 291 consolidation 54F Malt workers lung 198 fl uke 435 examination 40 Mantoux test 394 function tests 291 extensive collapse 54F MAO-B inhibitors 495 haemangioma 286, 737F fi brosis 54F Marburg 426, 427 hepatocellular predominant function tests 164 MarchiafavaBignami syn 704 injury 291 fungal infection 177 MarchiafavaMicheli syn metastases 286 interstitial dis 198 704, 705 non-alcoholic fatty Liver nodules 175, 724 Marcus Gunn sign 72 dis 285 opacifi cation 724, 725F Marfans syn 149, 706, 707F palpation 61, 62 tumours 1746 MASCC score 353 percussion 61 volumes 165F Mass skin manifestation of dis 562 Lupus abdomen 604 transplantation 276, 277 nephritis 314, 554 appendix 608 tropical dis 435 vulgaris 393 pelvic 604 tumours 2867 Lyme dis 422 scrotum 650, 651F ultrasound 737F Lymph node thyroid isthmus 598 Local anaesthesia 572, 573 causes of enlargement 594 see also Lumps Locked-in syn 450 cervical 60F, 62 Massive Blood transfusion 348 Locomotor assessment 540 supraclavicular 60F Mastectomy 580 Löffl ers Lymphadenopathy 35 Mastitis 603 eosinophilic endocarditis 704 Lymphatic fi lariasis 421 Maydls hernia 612 syn 704 Lymphocytes 330, 331F MDMA 843 Loiasis 439 Lymphogranuloma venerum MDRD equation 669 Loin Pain 57, 293 412 Mean arterial Hypertension 790 London, O. 7 Lymphoma Mean cell volume 324 Long QT 133, 711 Burkitts 362, 363F Measles 406 Long-term oxygen therapy 184 follicular 363 Mechanical valves 148 Longitudinal studies 18 gastric 362 Meckels diverticulum 706 Loop HIV 400 Medial medullary syn 712 colostomy 582, 583F Hodgkins 3601 Median 751 diuretics 114, 317, 664 non-Hodgkins 3623 Median nerve 453, 502 ileostomy 582 skin 362, 363F Mediastinoscopy 164 recorders 125 small-bowel 362 Mediastinotomy 164 Loosers zones 684, 685F thyroid 600 Mediastinum 722 Lopez, T. 14 Waldeyers ring 362 Medical Low-molecular-weight heparin Lymphopenia 330 care 23 350 Lynch syn 521 history 26 Low-output Heart failure 134 mathematics 201 Low-voltage QRS complex 100 M Medicalization 23 Lower GI cancer 522 McArdles dis 510, 704 Medication overuse headache Lower limb McDonald criteria for MS 497 456 acute bilateral leg weakness McDowell, E. 605 Medium vessel vasculitis 556 466 Machupo virus 426 Medulla 713F neurological examination Macrocytic anaemia 324, Medullary sponge Kidney 639 689 332, 333F Mees lines 76 parkinsonism 494 Macroglossia 246 Megaloblastic anaemia 332, peripheral artery dis 6567 Macrolides 387 333F peripheral nerve tests 453 Maddrey Discrimination Meigs syn 706 see also Leg Factor 281 Melaena 30, 256 Lower motor neuron 446 Magnesium 268, 676, 679 Melanomas 596, 597 LownGanongLevine syn 704 Magnesium ammonium Memantine 489 Lucid interval 482 phosphate stones 638, 639 Membranoproliferative Lumacaftor 173 Magnetic resonance glomerulonephritis 313 Lumbar angiography 744, 745F, 746 Membranous nephropathy 313 hernia 612 cholangiopancreatography MEN syn 223 puncture 7689, 822 742, 743F Ménétriers dis 706 Lumps imaging, see magnetic resonance imaging Ménières dis 462 breast 82, 603F venogram 481F Meningitis 390, 456, 822, 823F groin 650, 651 Major disasters 850 Meningococcus 390, 390F, 715F intradermal 595 Mental Capacity Act 15 __OOHHCCMM__1100ee. .",
    ". iinnddbb 888811 0022//0055//22001177 1199: : 0099 Mental health Mononeuropathies 5023 Myocardial infarction 882 of doctors 15 Moraxella catarrhalis 390 continued driving 159 Morphine 533, 574 driving 120, 158 on wards 15 Mosquito-borne dis 4201, 422 ECG 98, 103F, 104F, 118, Mental Health Act 15 Motor 119F, 121F Mental state examination neuron dis 506 enzyme changes 119F 15, 88 neuropathy 504 NSTEMI 118, 120, 798, 799F Meralgia paraesthetica 502 Mouth lesions 2467, 534 STEMI 118, 120, 796, 797F Meropenem 386 Movement disorders 87 Myocardial perfusion imaging MERS 169 Moxifl oxacin 387 741 Mesenteric ischaemia 620 MRA 744, 745F, 746 Myocarditis 152, 153, 170 Mesothelioma 174 MRC muscle weakness grading Myoclonic seizures 491, 492 Metabolic 446 Myoclonus 468 abnormalities ECG 98 MRCP 742, 743F Myoglobinuria 686 acidosis 300, 670 magnetic resonance imaging 734, 735F paroxysmal 706 alkalosis 670 cardiac 108, 109F, 740 Myopathic gait 467 bone dis 6825 cord compression 509F Myopathy 510, 511 fl ap 468 disc herniation 543F Myotonic myopathies 510 enteroclysis 742 disorders 510 syn 206 enterography 742 dystrophy 149, 510, 511 Metastases genitourinary 744, 745F Myxoedema, see brain 529 GI 742 Hypothyroidism Liver 286 head 746, 747F Myxoedema coma 220, 834 Metastatic calcifi cation 676 intracranial venous N Metformin 208 thrombosis 481F drug interactions 757 lumbar spine 769F Nailfold Methaemalbuminaemia 336 pituitary tumours 235F erythema 552 Methicillin-resistant T1-/T2-weighted 734 infarcts 76 Staphylococcus aureus vascular 740 Nails 74, 76 (MRSA) 388, 567 MRSA 388, 567 fungal dis 408 Methotrexate 376 Mucocoele 634 Terrys 76, 276 drug interactions 757 Mucocutaneous leishmaniasis Naloxone 574 Metronidazole 387 423 Narcolepsy 700, 701 Mexican hat cells 328, 343F Muehrckes lines 62, 76 Narrow complex tachycardia MeyerBetz syn 607 MUGA scan 740 126, 8067 Microalbuminuria 294, 686 Mullers sign 47 Nasal cannulae 189 Microangiopathic anaemia Multifocal atrial tachycardia Nasogastric tubes 759 338, 339F 126, 806 National Health Service 2 Microcytic anaemia 324 Multiple Natriuretic peptides 137 Microscopic polyangiitis 556 endocrine neoplasia 223 Nausea and Vomiting 250 Microstomia 246, 247F gated acquisition scan 740 palliative care 534 Mid-diastolic murmur 46 sclerosis 4967, 699 post-operative 576 Mid-systolic click 44 system atrophy 494 Necator americanus 433 Midbrain lesions 499 Mumps 406 Neck 38, 50, 52, 60 Middle cerebral artery 450 Münchausens syn 706, 707 important structures 599F aneurysm 479F Murmurs 467 lumps 598 Middle East respiratory syn Murphys sign 634 veins 587F (MERS) 169 Muscle weakness 64 Necrobiosis lipoidica 562, 563F Migraine 4589 grading 446 Necrosis Mikuliczs syn 706 Muscular dystrophies 510, 511 fat 603 Miliary TB 393 Musculoskeletal gallbladder 634 Miller, C. J. 15 hand examination 747 pancreas 636 Milroy dis 706, 707F screening 539 Necrotizing Mineral defi ciencies 268 symptoms 31 fasciitis 660 Minimal change dis 313 Mushroom workers lung 198 ulcerative gingivitis 712 Minimally invasive surgery 592 Mutations 520 Needle Mirizzis syn 272, 634 Myalgic encephalomyelitis 558 cricothyroidotomy 772 Mistakes 5 Myasthenia gravis 512, 513 pericardiocentesis 773 Mitral Myasthenic crisis 512 stick injury 399 regurgitation 122, 144 Mycetoma 177 Negative stenosis 144 Mycobacterium predictive value 20 valve prolapse 144 leprae 441 symptoms 89 Mixed connective tissue tuberculosis 392 Neisseria dis 552 Mycoplasma pneumoniae 168 gonorrhoea 413 Mixed hyperlipidaemia 690 Mycosis fungoides 596 meningitidis 390, 822 Mobitz type I/II block 98, Myelodysplasia 357 Nelsons syn 76, 224 99F, 122 Myelodysplastic syn 357 Nematodes 433 Mollarets meningitis 456 Myelofi brosis 366, 367F Neologism 89 Monobactam 385 Myeloma 314, 3689 Nephritic glomerulonephritis Monoclonal gammopathy of Myeloproliferative disorders 366 310, 311 uncertain signifi cance 370 Myiasis 441 Nephritis Monocytes 330, 331F Myocardial infarction 118 lupus 314, 554 Mononeuritis multiplex biochemistry 664 radiation 319 212, 502 complications 122 tubulointerstitial 318 __OOHHCCMM__1100ee. .",
    ". iinnddbb 888822 0022//0055//22001177 1199: : 0099 Nephroblastoma 644 Nipple discharge 82 Obstruction continued Nephrogenic fi brosing Nissen fundoplication 624 jaundice 634 883 dermopathy 748 Nitrofurantoin 385 Kidney 641F Nephrolithiasis 6389 Nocardia 389 sleep apnoea 194 Nephropathy Nocturia 81 urinary tract 6401 analgesic 319 Nodule Obturator aristolochic acid 319 Lisch 514 hernia 612 Balkan endemic 319 lung 175F, 724 nerve 452 diabetic 210, 314 neurofi bromas 514 Occams razor 4 IgA 311, 694 rheumatoid 594, 595F Occipital lobe membranous 313 Sister Mary Joseph 710, lesions 499 radiocontrast 319 711F seizures 491 sickle cell 315 subcutaneous 142 Odds ratio 20 tubulointerstitial 318 Nominal dysphasia 86 Oedema 35, 40 urate 319 Non-alcoholic fatty Liver non-pitting 35 Nephrotic dis 285 periorbital 35 glomerulonephritis 310, 313 Non-dihydropyridines 114 pitting 35, 39F syn 293, 312 Non-gonococcal urethritis 413 post-operative leg 579 Nephrotoxins 318 Non-Hodgkins lymphoma pulmonary 800 Nerve root 3623 scrotal 652 impingement 509 Non-malefi cence 14 Oesophagus lesions 543 Non-MALT gastric lymphoma Barretts 254, 695 Nesidioblastosis 215 362 cancer 250, 618 Neuralgia Non-pitting oedema 35 rupture 624 post-herpetic 65 Non-polyposis colorectal spasm 250 trigeminal 457 cancer 521 stricture 250 Neuritis, optic 71 Non-rebreathing mask 189 Off -legs 28 Neuroborreliosis 422 Non small cell lung cancer Ogilvies syn 611, 706 Neurocardiogenic syncope 460 174, 176 Older people 16, 667 Neurocysticercosis 437 Non-ST elevation myocardial infarction (NSTEMI) Oliguria 81, 293, 576 Neurofi brillary tangles 489F 118, 120, 798 799F On call 10 Neurofi bromatosis 51415 Non-steroidal antiOnchocerciasis 439 Neurogenic hyperventilation 53 infl ammatory drugs Oncogenes 520 Neuroimaging 746, 747F (NSAIDS) 545, 574 Oncogenic Neuroleptic malignant syn 843 Non-sustained ventricular hypophosphataemia 684 Neurological system tachycardia 122 viruses 405 drugs and 4489 Non-visible haematuria Onycholysis 76 examination 669 293, 647 Opacifi cation 724, 725F history 645 Noonans syn 149 Open questions 7 infections 4367 Noradrenaline 449 Opening snap 44 lesion localization 4467 Norepinephrine 449 Ophthalmoscopy 70 symptoms 31 Normal Opiate poisoning 842 Neuroma, acoustic 462, distribution curve 751 Opioids 533, 574 463F, 514 range 662, 7524 Opisthorchiasis 435 Neuromuscular junction 513 saline 666, 757 Opportunistic dis 400, 517 Neuromyelitis optica 497, Normocytic anaemia 324 Optic 698, 699 Norovirus 428, 430 atrophy 71, 560 Neuropathy Nosocomial infections 382, neuritis 71 autonomic 212, 505 41011 Oral diabetic 21213 NSAIDS 545, 574 hairy leucoplakia 246 HIV 517 NSTEMI 118, 120, 798, 799F hypoglycaemics 208 motor 504 Nuclear medicine 108, 7389 lesions 2467, 534 paraneoplastic 529 Nudge 7 Orchitis 651F peripheral 447 Number needed to treat 21 Organ sensory 504 Nutrition donation 13 Neuropeptides 449 disorders 268 rupture 606 Neurosis 89 enteral 584 Organophosphate poisoning Neurosurgical emergencies healthy eating 244 843 543 parenteral 586 Orion constellation 2F Neurosyphilis 412 requirements 585 Oroya fever 424 Neurotransmitters 448, 449 supplements 244 Orthodromic conduction 127 Neutropenia support 584 Orthopnoea 49 antibiotics 352 Nystagmus 70 Orthostatic hypotension 460 causes 330 O Ortners cardiovocal syn 708 pneumonia 166, 167 Oseltamivir 396, 397 sepsis 528 Oat cell lung cancer 174, 176 Osler, W. 6, 24F Neutrophilia 330 Obesity 34 OslerWeberRendu syn 708, Neutrophils 330, 331F surgery for 626, 627F 709F NICE 3 Obligate intracellular bacteria Oslers nodes 38, 40, 150 Nicotinamide defi ciency 268 382 Osmotic diuretics 316 Nicotine gum/patches 93 Obstruction Osteitis Nicoumalone 757 bladder neck 649 deformans 685 Nil by mouth 585 bladder symptoms 81 fi brosa cystica 222 Nintedanib 200 bowel 610, 611F Osteoarthritis 75F, 541F, 544 __OOHHCCMM__1100ee. .",
    ". iinnddbb 888833 0022//0055//22001177 1199: : 0099 Osteomalacia 684, 685F Palsy Penis 884 Osteoporosis 6823 Bells 500 angulation 708 Ostium primum defect 156 bulbar 86, 506, 507 benign dis 645 Ostium secundum defect 156 corticobulbar 507 cancer 644 Ototoxicity 462 pseudobulbar 86, 507 Peptic ulcer dis 2523 Ovalocytosis 338 supranuclear 494 Percussion Ovary Todds 712 abdomen 61, 63 cancer 521 Pancoasts syn 708 ascites 61 polycystic 230 Pancreas bladder 61 Overactive bladder syn 648 carcinoma 270 chest 51, 52 Oxycodone 533 necrosis 636 Liver 61 Oxygen therapy pseudocyst 636, 637F spleen 61 acute exacerbations of Pancreatitis 270, 6367, 667 thyroid 84, 85 COPD 812 Pancytopenia 364 Percutaneous long-term for COPD 184 Pandemic infl uenza 396, 397 coronary intervention respiratory failure 189 Panhypopituitarism 232 116, 796 P Pansystolic murmur 46 nephrostomy 744 Papilloedema 71, 560F transluminal angioplasty 656 p-value 20 Pappenheimer bodies 328, 329F Perianal P wave 96 Paracetamol haematoma 630 Pacemaker 1323 dose 574 problems 630 continuous ECG monitoring KCHC for Liver failure 275 warts 630 125 poisoning 844, 845F Pericardial driving 158 Paraesthesiae 65 dis 154 ECG 107F, 132, 133F Paralysed patients 467 eff usion 110, 154 letter codes 132 Paralytic ileus 611 friction rub 46 permanent 132 Paraneoplastic syn 529 knock 44 syn 133 Paraoesophageal hernia 255 Pericardiocentesis 773 tachycardia 133 Paraphimosis 645 Pericarditis 122, 154, 155F, 170 temporary 132, 7767 Paraproteinaemia 370 constrictive 43, 154 terminology 133 Paraproteins 531 Perinuclear ANCA 553 transcutaneous 777 Paraquat poisoning 843 Period prevalence 18 Pack-years 26 Parasitic gastroenteritis 428 Periorbital Pagets dis Parathyroid hormone 222, 676 oedema 35 bone 685 Paratyphoid 415 purpura 371F breast 708, 709F Paraumbilical hernia 612 Peripheral Pain 8 Parenteral nutrition 586 arterial dis 6567 abdomen 30, 57, 607F, 609, Parietal lobe Blood fi lm 323F, 328, 329F 732F, 733F lesions 499 cyanosis 34, 38F back 542 seizures 491 inserted central cannulas bone 369 Parinauds syn 708 774 breast 82 Parkinsonism 494 nerve tests 4523 chest 36, 48, 94, 95, 784 Parkinsons nerves 4545 congenital insensitivity to 8 dis 494, 495 neuropathies 447 control 532, 574, 575F plus syn 494 pulses 79 epigastric 57 Parkland formula 846 stigmata 32 face 65 Paronychia 76 vascular system left iliac fossa 57 Paroxysmal examination 789 left upper quadrant 57 cold haemoglobinuria 338 Peritoneal Dialysis 306 loin 57, 293 myoglobinuria 706 Peritonitis pelvic 57 nocturnal dyspnoea 30, 49 laparotomy 606 pleuritic 94 nocturnal haemoglobinuria spontaneous bacterial 276 referred 609 338, 704, 705 Pernicious anaemia 334 right iliac fossa 57 ParsonageTurner syn 502 Peroneal muscular atrophy 696 right upper quadrant 57 Parvus et tardus 146 PET 739 spiritual 535 Passive immunity 407 PET-computed tomography 523, 730 Palliative care 136, 5327 Past medical history 26 Petechial rash 822 radiotherapy 526 Patient-centred questions 7 PeutzJeghers syn 521, 708, Pallor 32, 34 Patient-controlled analgesia 709F Palmar erythema 62, 76 341 Peyronies dis 708 Palpation PaulMikulicz colostomy 582 pH 670 abdomen 61, 62 PDE5 inhibitors 230, 231 Phaeochromocytoma 228, 229, aorta 61, 62 Peak expiratory fl ow 162, 181F 738, 837 axilla 83 Peak fl ow charts 181F Phalens test 74, 503 breast 83 Pectus Pharyngeal pouch 598 chest 52 carinatum 55 Phenothiazine poisoning 843 kidneys 61, 62 excavatum 55 Phenoxymethylpenicillin 386 Liver 61, 62 Pellagra 268 Phenytoin peripheral vascular system Pelvic drug interactions 757 78, 79 mass 604 epilepsy 493 praecordium 39 Pain 57 therapeutic range 756 spleen 61, 62 Pemphigus 529 Philadelphia chromosome 358 thyroid 84, 85 Penicillins 385, 386 Phimosis 645 Palpitations 36, 37, 94 allergy 384 Phlegmon 634 __OOHHCCMM__1100ee. .",
    ". iinnddbb 888844 0022//0055//22001177 1199: : 0099 Phosphate 268, 676, 679 Pneumonia continued Potts syn 708, 709F Phosphodiesterase inhibitors complications 170 Power 66, 69 885 230, 231 emergencies 816, 817F PR interval 96 Phrenic nerve 502 empirical treatment 167 Praecordium 39, 40 Physical hospital-acquired 166, 167 Prednisolone 376 examination 32; see also immunocompromised Pre-excited atrial fi brillation 131 Examination 166, 167 Pre-exposure prophylaxis 398 signs 28 specifi c 168 Pregnancy 17 Physician-assisted suicide 537 ventilator-associated 410 acromegaly 238 PICC lines 774 Pneumonic plague 425 Diabetes 213 Picks dis 486 Pneumoperitoneum 607F drug prescribing 17 Pigeon chest 55 Pneumothorax 190 epilepsy 493 Pigeon-fanciers lung 198 aspiration 767 hypothyroidism 220 Pilar cyst 594 chest X-ray 724, 725F, 749F migraine 458 Piles 6323 click 52 physiological changes 17 Pill-rolling 65 emergencies 814, 815F radiology 17 Pilonidal sinus 630 spontaneous 54F sepsis 17 Pin prick test 67 tension 54F, 190, 767, 814 urinary tract infection 297 Pink puff ers 184 POEMS syn 220 Premature ventricular Piperacillin tazobactam 386 Poikilocytosis 327F, 328 contractions 122 Pirferidrone 200 Point prevalence 18 Pre-operative care 5667 Pitted nails 76 Poiseuilles law 761 Presbyacusis 464 Pitting oedema 35, 39F Poisoning 83845 Prescribing 8 Pituitary Poliomyelitis 436 antibiotics 384 apoplexy 234 Polyarteritis nodosa 149, chronic Kidney dis 305 tumours 234, 235F 556, 557F Liver failure 275 Pityriasis versicolor 408, 409F Polychromasia 328 NSAIDS 545 Pizza-pie fundus 438F, 560 Polycystic older people 16 Placebo eff ect 9 Kidney dis 320, 321F porphyria 693 Plague 425 ovarian syn 230 pregnancy 17 Plain X-ray Polycythaemia 366 Presenting complaint 26 abdomen 728, 729F, 744 vera 366 Hypertension ulcers 473F bowel obstruction 611F Polymeric feed 584 Pretibial myxoedema 218, 562 chest, see Chest X-ray Polymyalgia rheumatica 557 Prevalence 18 fi rst 718F Polymyositis 529, 552 Primary gout 541F Polymyxin B 386 atrophic hypothyroidism 220 osteoarthritis 541F Polymyxins 386 autonomic failure 505 osteomalacia 685F Polyneuropathies 504, 505 biliary cholangitis 282 Pagets dis 685F acute infl ammatory bladder neck obstruction 649 rheumatoid arthritis 541F demyelinating (GBS) 447, hyperlipidaemias 690, 691 rickets 685F 702, 703 lateral sclerosis 506 Plantar refl exes 68, 466 sensory 212 PCI 796 Plasma Polyomavirus 406 sclerosing cholangitis 282, biochemistry 665 Polyps 249F, 617 283F calcium 676 Polyuria 81, 293 survey 779 cell dyscrasias 369 Porphyria cutanea tarda 692 Prinzmetals angina 116, 117, enzymes 688, 689 Porphyrias 6923 708, 709 fresh frozen 348 Portal hypertension 257 Proctalgia fugax 630 iron 327 Positive Progressive proteins 686 predictive value 20 bulbar palsy 506 toxicology 840 symptoms 89 massive fi brosis 201 viscosity 373 Positron emission tomography multifocal Plasmodium spp. 41619 (PET) 739 leukoencephalopathy 517 Platelet PET-computed tomography 523, 730 muscular atrophy 506 disorders 344 Post-exposure prophylaxis 398 nephrogenic systemic transfusion 348, 364 Post-herpetic neuralgia 65 fi brosis 748 Plato 5 Post kala-azar 423 supranuclear palsy 494 Pleomorphic adenomas 599 Post-lumbar puncture Prolactinoma 236 Pleural eff usion 54F, 170, 192 headache 769 Prolapse aspiration 765 Post-operative complications mitral valve 144 Pleural fl uid analysis 193 5767, 580 rectal 630 Pleural rub 52 Post-prandial hypoglycaemia Pronator drift 67 Pleuritic Pain 94 214 Proprioception 67 Pneumaturia 81 Post-streptococcal Proptosis 85 Pneumococcal glomerulonephritis 311 Prostate pneumonia 168 Posterior cerebral artery 450 benign hyperplasia 642 vaccine 167 Postural cancer 521, 644, 645 Pneumocystis hypotension 40, 41 -specifi c antigen 530, 645 jirovecii 168, 400, 401F tremor 65, 468 Prostatitis 296, 645 pneumonia 168 Potassium Prosthetic valves 148 Pneumomediastinum 724 IV fl uids 667 INR 351 Pneumonia 16671 Kidney 300, 668 murmurs 47 aspiration 166, 167 -sparing diuretics 114, sounds 44 community-acquired 166, 167 317, 757 Protein C defi ciency 374 __OOHHCCMM__1100ee. .",
    ". iinnddbb 888855 0022//0055//22001177 1199: : 0099 Protein: Creatinine ratio 294 Purpura Reablement 474 886 Protein S defi ciency 374 HenochSchönlein 311, 556, Reactive Proteins 702, 703F arthritis 551 plasma 686 meningococcal sepsis 715F haemorrhage 577 urinary 686 periorbital 371F Rectal Proteinuria 293, 294 thrombotic bleeding 629 Proteus mirabilis 391 thrombocytopenic 315 examination 63 Prothrombin Pyelonephritis 296 prolapse 630 gene mutation 374 Pyoderma gangrenosum Recurrent meningitis 456 time 346 562, 563F Red cell Proximal renal tubular acidosis Pyrexia cast 295 316 of unknown origin 4423 distribution width 325 Pruritus 28, 535 post-operative 576 transfusion 348, 364 ani 630 Pyridoxine 268 Red eye 561 Pseudoaneurysm 654 Pyruvate kinase defi ciency 338 Red fl ags 542, 780 Pseudoathetosis 87, 468 Q ReedSternberg cell 361F Pseudobulbar Re-emergent tremor 468 eff ect 507 Q Re-enablement 474 palsy 86, 507 Q fever 424 Refeeding syn 587 Pseudo-Cushings 225 QALY 3 Reference intervals 662, 7524 Pseudocyst, pancreas 636, QRISK2 score 93 Referral 10, 33 637F QRS complex 96, 100 Referred Pain 609 Pseudofusion beat 133 QT interval 96 Refl exes Pseudogout 549F long 133, 711 ankle 68 Pseudohypoparathyroidism Questions 7 anocutaneous 63 203, 222, 223F Quinckes sign 38, 40, 47, 146 gag 70 Pseudomonas R knee 68, 466 aeruginosa 391 lower limb 68 pneumonia 168 Rabies 436 plantar 68, 466 Pseudo-obstruction 611 Radial pupils 72, 789 Pseudopseudofusion beat nerve 453, 502 upper limb 67 133 pulse 38, 42 Refsum dis 710 PseudopseudohypoRadiation Refusing treatment 402, parathyroidism 222 dose 719 403, 569 Psittacosis 168 nephritis 319 Regional anaesthesia 572 Psoas sign 608 risks 719 Regular tachycardias 127 Psoriatic arthritis 551 Radiculopathy 508 Regurgitation Psychiatry 15, 88, 89 Radiocontrast nephropathy 319 aortic 47, 146 Psychogenic gait 467 Radio-femoral delay 40 GI 59 Psychosis 89 Radiofrequency ablation 658 mitral 122, 144 Ptosis 73 Radioiodine 218 pulmonary 148 Pulfrich eff ect 497 Radioisotope therapy 527 tricuspid 148 Pulmonary Radiology Reiters syn 551 embolism 98, 190, 191, 351, acutely unwell patients 749 Relapsing 818, 819F cancer 523, 526, 527 fever 423 eosinophilia 704 chest 164 polychondritis 552 hypertension 105F eff ective doses 719 Relative aff erent pupillary oedema 800 Heart 108 defect 72 regurgitation 148 interpreting images 721 Relative risk 20 renal syn 700 pregnancy 17 Remnant particle dis 691 stenosis 148 presenting images 721 Renal TB 393, 384 requests 720 arteriography 744, 745F Pulse risks and benefi ts 719 biopsy 310 anacrotic 42 Radionuclide imaging 746 cell carcinoma 644 bisferiens 42 Radio-radial delay 40 dis presentation 293 bounding 42 Radiotherapy 5267 failure 680 brachial 38 Raised intracranial Hypertension manifestations of systemic carotid 38 830, 831F dis 31415 collapsing 42 Ramsay Hunt syn 501 nuclear medicine 739 oximetry 162 Randomized controlled osteodystrophy 684 peripheral 79 trials 19 phakomatoses 320 Hypertension 38, 40 Range 751 replacement therapy 301, radial 38, 42 joint movement 540 305, 3069 radio-femoral delay 40 Ranula 246 stones 6389, 680 radio-radial delay 40 Rash transplantation 3089 rate and rhythm 42 heliotrope 552, 562, 563F tubular acidosis 316, 317 waterhammer 42 meningitis 822 tubules 31617 waveforms 42F returning travellers 415 urate 680 Pulseless dis 712 SLE 555F Reninangiotensinaldosterone Pulsus Rationing 3 system 668 alternans 42 Raynauds Reperfusion therapy 796 paradoxus 42 dis 708 Residual volume 164 Pupils 70, 72, 789 phenomenon 708, 709 Resilience 11 Purines 449 syn 708 Resource rationing 3 __OOHHCCMM__1100ee. .",
    ". iinnddbb 888866 0022//0055//22001177 1199: : 0099 Respiratory Röntgen, W. 718F Scrub typhus 422 acidosis 670 Root compression 508 Scurvy 268 887 alkalosis 671 Rotavirus 428, 430 Seasonal infl uenza 396 distress 53 Roths spots 150, 560 Sebaceous cyst 594 examination 503 Rotor syn 710 Seborrheic dermatitis 408 failure 170, 1889 Rouleaux formation 328, 329F Secretions 537 history 489 Roundworm 433 Seizures 490, 491, 492 important presentations 54 Roux-en-Y Selenium 268, 679 segments 53F bypass 626, 627F Self-catheterization 763 viruses 406 reconstruction 622, 623F Semmelweis, I. 758 Resting tremor 65, 468 Rovsings sign 608 Sensations 64, 67, 69 Restless legs 698 Rubella 406 Sensitivity 20 Restrictive cardiomyopathy 152 Rubeosis iridis 210 Sensorineural deafness 464 Reticular opacifi cation 724 Rule of nines 846 Sensory Reticulocytes 328, 329F Rupture defi cits 446, 447 Retina AAA 654 neuropathy 504 artery occlusion 560 Berry aneurysm 478 Sentinel node biopsy 603 diabetic 210, 211F oesophagus 624 Sepsis 17, 792, 793F haemorrhage 560 organ 606 meningococcal 390, 715F hypertensive 139, 560 S neutropenic 528 hyperviscosity 372F Septic vein occlusion 560 Sabia virus 426 arthritis 544 Retractile testis 652 Sabre tibia 685F shock 792 Retrograde pyelography 744 Sacroiliitis 542 Septicaemia 170 Retroperitoneal fi brosis 643 Safe triangle 767 Septicaemic plague 425 Retroviruses 517 St Vitus dance 142, 469 Serotonin 449 Reye syn 396 Salbutamol 183 Serum Rhabdomyolysis 319 Salicylate poisoning 844 osmolality 668 Rheumatic fever 142 Saline (0. 9%) 666, 757 thyroglobulin 216 Rheumatoid Salivary gland 599 Severe acute respiratory syn arthritis 149, 541F, 5467 Salmeterol 183 (SARS) 169 factor 553 Salmonella Sexually transmitted infection nodules 594, 595F non-typhoidal 428, 431 41213 Rheumatology paratyphi 415 Sézary syn 363F, 596 defi nition 538 Saphena varix 658 SGLT1 208 history 539 Sapovirus 428 Shared decision-making 7 investigations 541 Sarcoidosis 149, 196 Shawl sign 552 Rhonchi 52 Sarcoptes scabiei 440 Shiga-toxin producing E. coli Ribofl avin 268 SARS 169 431 Richters hernia 612 Saunders, C. 532 Shigella 428, 429, 431 Rickets 684, 685F SBAR 10 Shingles 404 Rickettsial dis 422 Scabies 440 Shock 790 Rifabutin 387 Scalded skin syn 388 anaphylactic 794, 795F Rifampicin 387 Scapula winging 511F Blood Hypertension 40, 790 Rifamycins 387 Schistocytes 328 cardiogenic 802, 803F Rifapentine 387 Schistosomiasis 434 classes 791 Rift Valley fever 426 Schopenhauer, A. 6 fl uid therapy 667 Right bundle branch block Schwannomatosis 514 haemorrhagic 790 100, 102F Sciatic hypovolaemic 790 Right Heart hernia 612 septic 792 dynamics 110 nerve 452, 502 toxic 388 valve dis 148 Scleritis 560 Short gut syn 580 Right iliac fossa Scleroderma renal crisis 315 ShyDrager syn 494 mass 604 Sclerosis Sick Pain 57 amyotrophic lateral 506, 507 euthyroidism 216 Right shift 328 aortic 146 sinus syn 125 Right upper quadrant Pain 57 hand 75F Sickle cell Right ventricle multiple 4967, 699 anaemia 3401 failure 122, 134 primary lateral 506 crisis 341 hypertrophy 100 systemic 149, 552 nephropathy 315 infarction 122, 796 Sclerotherapy 658 Sideroblastic anaemia 326, Rigid bronchoscopy 164 Scoliosis 55 327F Rigors 29 Scratch test 62 Sigmoid volvulus 611 Rinne test 464 Screening Sigmoidoscopy 248 Rituximab 363 alcohol use 281 Signs 345 River blindness 439 cancer 530 Silent Rockall score 257 medicalization 23 chest 52 Rocky Mountain spotted MRSA 567 stones 634 fever 422 musculoskeletal dis 539 Silicosis 201 Rolling hiatus hernia 255 thyroid function 217 Silver wiring 560F Romañas sign 423 Scribner shunt 307 Single photon emission RomanoWard syn 710 Scrotum computed tomography Rombergs test 68 idiopathic oedema 652 (SPECT) 739 Rome consensus 261 lumps 650, 651F __OOHHCCMM__1100ee. .",
    ". iinnddbb 888877 0022//0055//22001177 1199: : 0099 Sinus 565 Sphygmomanometer 139 Stigler, S. 694 888 bradycardia 98, 122 Spider naevi 60F, 277F StokesAdams attacks 460 pilonidal 630 Spigelian hernia 612 Stoma 60F, 565, 5823 rhythm 96 Spinal cord Stomach cancer 619, 622 tachycardia 98, 122, 127, 806 compression 466, 508, 509F, Stomatocytosis 338 Sinusitis 456 528, 543 Stones Sister Mary Joseph nodule localizing lesions 447 renal 6389, 680 710, 711F subacute combined silent 634 Situation syncope 460 degeneration 334 submandibular 598 Sjögrens syn 710 Spine Straight leg test 542 Skin cervical injury 447, 828 Strangury 80 colour 32, 34 GALS screen 540 Streptococcus hand 74, 76 TB 393, 708, 709F agalactiae 388 hypercorticolism 225F Spiritual Pain 535 bovis 388 important diagnoses 597 Spirochete 382 milleri 388 lumps 594, 595F Spirometry 162, 163F pneumoniae 388 lymphoma 362, 363F Spleen pyogenes 388 malignant tumours 596 diff erentiating from Stress pre-malignant tumours 596 enlarged Kidney 63 echocardiography 110 systemic dis 562, 563F palpation 61, 62 incontinence 648 tags 630 percussion 61 Stridor 48 TB 393 Splenectomy 373, 580 Stroke 159, 4705, 746 tropical disease 4401 Splenomegaly 63, 373, 604 Strongyloides stercoralis 433 ulcers 6601 Splinter haemorrhages 76, Struvite stones 638, 639F warts 406 150, 151F SturgeWeber syn 710 Sleep hygiene 29 Spondyloarthritides 5501 Subacute Sleeping sickness 423 Spontaneous combined degeneration of Sleeve gastrectomy 626, 627F bacterial peritonitis 276 spinal cord 334 Sliding hernia 255, 612 pneumothorax 54F sclerosing panencephalitis Slough 661 Spotted fevers 422 406 Small bowel Sputum 53, 162 Subarachnoid haemorrhage gas patterns 728 Squamous cell cancer 596, 456, 4789 lymphoma 362 597F Subclavian mucosa 267 SSRIS 57 artery aneurysm 598 obstruction 610, 611F ST depression 98 steal syn 450 surgery 580 ST elevation 98 vein catheterization 775 Small cell lung cancer 174, 176 ST elevation myocardial infarction (STEMI) 118, 120, Subclinical thyroid dis 221 Small vessel vasculitis 314, 556 796, 797F Subconjunctival haemorrhage Smell 70 ST segment 96 561 Smoke inhalation 847 Stable angina 116 Subcutaneous Smoking Staging cancer 523; see also lumps 595 cessation 93 TNM staging nodules 142 pack-years 26 Standard deviation 751 Subdural haematoma 482, 483F Snake bites 843 Standard error of the mean 751 Subfalcian herniation 830 Snow, J. 431 Staphylococcal pneumonia 168 Submandibular stone 598 Social history 26 Staphylococci 388 Sudden unexpected death in SOCRATES questions 26 Staphylococcus aureus epilepsy 492 Sods law 21, 365F 388, 428 Glucose workers lung 198 Sodium 668 resistant 388 Suicide, assisted 507, 537 Sodium channel blockers 115 Statins 115 Sulfamethoxazole Sodium valproate Statistics 201, 751 trimethoprim 387 dose and side-eff ects 493 Status epilepticus 826, 827F Sulfonylureas 208 drug interactions 757 Steatorrhoea 59 drug interactions 757 Soil-transmitted helminths 433 SteeleRichardsonOlszewski Superior Solar keratoses 596 syn 494 alternating hemiplegia 714 Sontag, S. 23 Stem cell transplantation 358 gluteal nerve 452 Space-occupying lesions STEMI 118, 120, 796, 797F vena cava syn 528 498, 499 Stenosis Supraclavicular lymph nodes Spasm aortic 146 60F coronary 709 carotid artery 472 Suprapubic catheterization 762 infantile 491 mitral 144 Supraventricular tachycardia oesophagus 250 pulmonary 148 806 Spasmodic torticollis 469 tricuspid 148 with aberrancy 128 Spastic Stent 565 Surgery gait 467 endovascular 655F anaesthesia 5723 paraparesis 466 ureteric 641 antibiotic prophylaxis 570 Specifi city 20 Stereotactic radiotherapy 527 anticoagulated patients 590 Speck, P. W. 535 Sternal notch 50F bariatric 626, 627F SPECT 739 Steroids cancer therapy 525 Speech 64, 867 advice and warnings 227, 376 cardiac 148 Spermatocele 651F side eff ects 376, 377 day case 592 Spherocytes 328 surgery 590 Diabetes 213, 588 Spherocytosis 338, 339F StevensJohnson syn 493, 562, Dialysis 307 Sphincter dysfunction 58 710, 711F drains 571 __OOHHCCMM__1100ee. .",
    ". iinnddbb 888888 0022//0055//22001177 1199: : 0099 Surgery continued Taenia solium 437 Thrombotic thrombocytopenic DVT risk 578 Taeniasis 433 purpura 315 889 gastric 622 Takayasus arteritis 556, 712 Thrush 246, 247F incisions 565 Takotsubo cardiomyopathy 145 Thyroglobulin 216, 531 infection at surgical site 410 Tap test 78 Thyroglossal cyst 598 jaundice 590 Tapeworm 433, 437 Thyroid language 565 Tar stains 50F acropachy 218, 562 minimally invasive 592 Tardive anatomy 601F nil by mouth 585 dyskinesia 468 autoantibodies 216 post-operative syn 468 cancer 600 complications 5767, 580 Target cells 328, 343F ectopic tissue 218 pre-operative care 5667 Taussig, H. 92F emergencies 834 steroid cover 590 TB, see Tuberculosis examination 845 sutures 571 Teardrop cell 328, 367F eye dis 84, 85, 219 thyroid 580, 600 Teeth 246, 247F function tests 21617 wound infection risk 570 Teicoplanin 386 goitre 218, 219, 600 Surgical cricothyroidotomy 772 Telangiectasia 246, 708, 709F isthmus mass 598 Sustained ventricular Telemetry 125 lateral aberrant 600 tachycardia 122 Temperature 32 lumps 600 Sutures 571 Temporal (giant cell) arteritis lymphoma 600 Swallow test 84, 85 456, 556 nuclear medicine 738 Swan-neck deformity 540F Temporal lobe peroxidase antibody 553 Sweats 29 lesions 499 -stimulating hormone 216 Sydenhams chorea 142, 469 seizures 491 subclinical dis 221 Symptoms 289 Temporary pacing 132, 7767 surgery 580, 600 Synacthen test 226 Tenesmus 30, 59 symptoms 31, 221 Syncope 94, 158, 460 Tension Thyroidectomy 218 Syndrome of inappropriate headache 456 Thyroiditis ADH secretion 241, 529, pneumothorax 54F, 190, De Quervains 218 664, 673 767, 814 Hashimotos 220 Syndrome X 206 Terminal dribbling 81 Thyrotoxic storm 834, 835F Synovial fl uid 541 Terrys nails 76, 276 Thyrotoxicosis 149, 203, 218 Syphilis 149, 412, 596 Tersons syn 478 Thyrotropin 216 Syringe drivers 536 Testes Tibial nerve 452, 502 Syringobulbia 516 ectopic 652 Tic paradox 700 Syringomyelia 516 maldescended 652 Tick-borne dis 422 Systemic retractile 652 Tics 468 enquiry 26, 301 torsion 652 Tietzes syn 82, 94, 712 lupus erythematosus 149, tumours 650, 651F Tigecycline 387 314, 5545 undescended 652 Tinea sclerosis 149, 552 Tetanus 436 capitis 408 sensory polyneuropathy 212 Tetracyclines 387 pedis 408 Systolic Tetralogy of Fallot 157 Tinels test 74, 503 blood pressure 40 Thalassaemia 149, 3423 Tinnitus 464 failure 134 Thenar wasting 74 Tiotropium bromide 183 T Theophylline Tissue Doppler imaging 110 drug interactions 757 TNM staging 523 T inversion 98 therapeutic range 756 bladder cancer 647 T score 683 Therapeutic ranges 756 colorectal cancer 617 T wave 96 Thiamine 268 lung cancer 176 T1-/T2-weighted imaging 734 Thiazide (-like) diuretics 114, oesophageal cancer 618 Tachy brady syn 125 317, 664 Tobacco, see Smoking Tachyarrhythmias 122 Third-ventricle colloid cyst 498 Tobramycin 387 atrial 806 Thoracic therapeutic range 756 Tachycardia aortic dissection 655 Todd-Crawford, J.",
    ". iinnddbb 888899 0022//0055//22001177 1199: : 0099 Toxins Trypanosomiasis 423 Ultrasound continued 890 Kidney 318 TSH receptor antibody 216 endoscopic 742 vertigo 462 Tube genitourinary 744, 745F Toxoplasmosis 400, 425, feeding 584 GI 742 439, 517 inserting nasogastric 759 Kidney 737F, 744, 745F TP53 521 Tuberculin skin test 394 Kidney obstruction 641F Trachea 722 Tuberculosis 3925 Liver 737F Tracheostomy 580 antibiotic therapy 160F, 394 urinary tract 744 Trachoma 438 cardiac 393 vascular 740 Training 758 CNS 393 Umbilical hernia 612 Tramadol 533 colliquativa cutis 661 Uncal herniation 830 Transcatheter aortic valve cutaneous 393 Unconjugated implants 147F diagnostic tests 394 hyperbilirubinaemia 272 Transcutaneous cardiac drug-resistant 395 Undescended testes 652 pacing 777 genitourinary 393 Unfractionated heparin 350 Transfusion reactions 349 GI 393 Unstable (crescendo) angina Transient ischaemic attack 159, HIV 401 116, 118 476, 477 latent 392 Upper GI Transitional cell carcinoma lymphadenitis 393 bleeding 57, 2567, 820, 821F 644, 646 miliary 393 cancer 522 Transoesophageal pulmonary 393, 394 endoscopy 248, 249 echocardiography 108, 110 spinal 393, 708, 709F Upper limb Transplantation urinary tract 297 neurological examination bone marrow 356 Tuberous sclerosis complex 320 667 cardiac 148 Tubular disorders 31617 peripheral nerve tests 453 Liver 276, 277 Tubulointerstitial nephropathy Upper motor neuron 446 organ donation 13 318 Uralgia 80 renal 3089 Tumour; see also Cancer Urate 680 stem cell 358 bladder 6467 nephropathy 319 Transthoracic carcinoid 271 stones 638, 639, 680 echocardiography 108, carotid body 598 Ureteric stent 641 110, 111F HIV 517 Ureterograms 744 Transudates 192 Liver 2867 Urethral Transurethral incision of lung 1746 caruncle 80 prostate (TUIP) 642 lysis syn 319, 352, 529 stricture 649 Transurethral resection of malignant connective Urethritis, non-gonococcal 413 prostate (TURP) 642 tissue 594 Urge incontinence 648 Traubes sign 47, 146 malignant skin 596 Uric acid crystals 295 Travel markers 530, 531 Urinary diarrhoea 428, 429 osteomalacia 684 calculi 6389, 680 DVT 579 pituitary 234, 235F catheterization 297, 7623 fever in returning travellers pre-malignant skin 596 changes 81 41415 salivary gland 599 frequency 80 malaria prophylaxis 419 space-occupying lesions incontinence 6489 vaccinations 407 498, 499 infection 2967, 410 Tremor 64, 65, 468, 494 suppressor genes 520 malignancies 522, 644 Trench fever 424 testicular 650, 651F obstruction 6401 Trendelenburgs test 78 Wilms 644 plain X-ray 728 Treponema Tungiasis 441 proteins 293, 294, 686 pallidum 412 Tuning fork tests 464 symptoms 293 pertenue 441 Turners syn 149 TB 297 Trial without catheter 763 Type V hyperlipoproteinaemia ultrasound 744 Trichinella 428, 433 691 Urine Trichomonas vaginalis 413 Typhoid 415 albuminuria 686 Trichuriasis 428, 433 Typhus 422 bacteriuria 296 Tricuspid U casts 295 regurgitation 148 cloudy 81 stenosis 148 Uhthoff s phenomenon 497 crystals 295 Trifascicular block 100 Ulcer 565 dipstick 294 Trigeminal neuralgia 457 anal 630 fl uids for poor output 300, 667 Trigeminy 128 aphthous 246, 247F haematuria 81, 293, 294, 647 Trimethoprim 387 Chicleros 440 haemoglobinuria 336, 686 Triple phosphate stones 638 duodenal 252, 253F haemosiderinuria 336 Triple rhythms 44 foot 212 microalbuminuria 294, 686 Triplet 128 gastric 252 microscopy 295 Troisiers sign 619 genital 412 myoglobinuria 686 Tropical Hypertension 473F oliguria 81, 293, 576 Liver dis 435 skin 6601 pneumaturia 81 spastic paraplegia 517 venous 660, 661 post-operative 576 STIs 412 Ulcerative colitis 2623 proteins 686 Troponin 119, 688 Ulnar nerve 453, 502, 503 proteinuria 293, 294 Trousseaus sign 529, 678F Ultrasound 736, 737F reference intervals 753 True negative 20 cardiac (echo) 108, 110, 111F, Urostomy 582 True positive 20 153F, 740 ultrasound, see Ultrasound __OOHHCCMM__1100ee. .",
    ". iinnddbb 889911 0022//0055//22001177 1199: : 0099 892 Early warning score Early warning scores are scoring systems based on physiological parameters. The magnitude of the given score refl ects how far the parameter varies from normal. The collated score from diff erent parameters is used in: the assesssment of acute illness the detection of a clinical deterioration the initiation of a timely and competent clinical response. A standardized National Early Warning Score (NEWS) is recommended for use across the NHS. 1 The components of the NEWS are detailed in fi g A1. An appropriate clinical response to the aggregate score from fi g A1 is outlined in fi g A2. Fig A1 National Early Warning Score for adult patients. RCP 2012. 1 Royal College of Physicians. National Early Warning Scores (NEWS): standardising the assessment of acute illness severity in the NHS. London: RCP, 2012. __OOHHCCMM__1100ee. . iinnddbb 889922 0022//0055//22001177 1199: : 0099 NEWSSCORE FREQUENCYOF CLINICALRESPONSE 893 MONITORING 0 Minimum12hourly ContinueroutineNEWSmonitoringwith everysetofobservations Informregisterednursewhomustassess Total: Minimum4-6hourly thepatient; 1-4 Registerednursetodecideifincreased frequencyofmonitoringand/or escalationofclinicalcareisrequired; Total: Registerednursetourgentlyinform themedicalteamcaringforthepatient; 5ormore Increasedfrequency toaminimum Urgentassessmentbyaclinician of1hourly withcorecompetenciestoassessacutely or illpatients; 3inone Clinicalcareinanenvironmentwith monitoringfacilities; parameter Registerednursetoimmediatelyinform Total: themedicalteamcaringforthepatient thisshouldbeatleastatSpecialist 7 Registrarlevel; Continuousmonitoringof ormore vitalsigns Emergencyassessmentbyaclinical teamwithcriticalcarecompetencies, whichalsoincludesapractitioner/swith advancedairwayskills; ConsidertransferofClinicalcaretoa level2or3carefacility, i. e. higher dependencyorITU; Fig A2 Clinical response to NEWS triggers. RCP 2012. Early warning scores are tools to aid assessment. They do not replace clinical judgement: use yours and respect the clinical opinion of others. Refer to local early warning scores where available. __OOHHCCMM__1100ee. . iinnddbb 889933 0022//0055//22001177 1199: : 0099 894 Cardiac arrest: advanced life support algorithm 2015 Fig A3 Cardiac arrest: advanced life support algorithm 2015. Reproduced with the kind permission of the Resuscitation Council (UK), 20146. __OOHHCCMM__1100ee. . iinnddbb 889944 0022//0055//22001177 1199: : 0099 Cardiorespiratory arrest Ensure the safety of the patient and yourself. Confi rm diagnosis: a patient who is unresponsive and not breathing properly is in cardiac arrest (a manual pulse check is inaccurate and not recommended). Basic life support Shout for help. Ask someone to call the arrest team and bring the defi brillator. Note the time. ABC: Airway: Head tilt (if no spine injury) and chin lift/jaw thrust. Breathing: Look, listen, and feel for breathing for no more than 10 seconds. If there is any doubt whether breathing is normal, proceed to chest compressions. Chest compressions: Place the heel of one hand on the centre of the chest (lower half of the stenum). Place your second hand on top and interlock fi ngers. Use straight arms. Give compressions at a rate of 100120/min. Aim to compress the sternum 56cm. After 30 compressions give 2 rescue breaths. Do not interrupt compressions 10s. Continue with a ratio of 30: 2 until defi brillator is available. Advanced life support See algorithm fi g A3. Continue chest compressions while adhesive defi brillation/monitoring pads are put in place. Plan all actions before pausing chest compressions. Stop chest compression for 5s to assess rhythm. Determine whether the rhythm is shockable (VF/pulseless VT) or non-shockable (asystole, pulseless electrical activity). Shockable rhythm: VF/pulseless VT A single person performs uninterrupted chest compressions while everyone else prepares for defi brillation: stand clear, move oxygen delivery device 1m away. Select the appropriate energy on the defi brillator (150J or manufacturers guidelines). When defi brillator is charged and safety check complete, the rescuer performing chest compressions stands clear and the shock is delivered. CPR is resumed immediately (30: 2). Reassess pulse/rhythm only after 2 minutes of CPR. Repeat if shockable rhythm remains. Give drugs after 3 shocks (see Drugs, this topic). Non-shockable rhythm: asystole/pulseless electrical activity (PEA) Continue CPR 30: 2.",
    "Give drugs after 3 shocks (see Drugs, this topic). Non-shockable rhythm: asystole/pulseless electrical activity (PEA) Continue CPR 30: 2. Obtain IV access and secure airway. Once airway secure switch to continuous compressions and ventilation. Give adrenaline 1mg IV. Check rhythm every 2 minutes. Consider reversible causes (4HS and 4TS: hypoxia, hypovolaemia, hyper/hypokalaemia/other metabolic derangement, hypothermia, thrombosis, tension pneumothorax, tamponade, toxins). Drugs Give adrenaline 1mg IV every 35 mins for both shockable (from 3rd shock) and nonshockable rhythms. In practice this means at every other rhythm check or shock. 1 In shockable rhythms give amiodarone 300mg IV after 3 defi brillation attempts. Consider a further 150mg IV after 5 shocks. Lidocaine is an alternative. Discontinuing resuscitation Needs clinical judgement: what is the likelihood of achieving a successful return of spontaneous circulation? If there is a shockable rhythm or a reversible cause then attempts are usually continued. It is reasonable to discontinue if asystole 20mins without a reversible cause. Ask for the opinion of others in the resuscitation team. Resuscitation decisions Consider, discuss, and record CPR decisions: at the request of a patient with capacity as part of end-of-life care (p12, p536) in deteriorating, severe illness. Your patient should be involved in decisions about CPR (unless it would cause physical or psychological harm). Explain your clinical decision to them, including futility. Do not make judgements about the quality of life of others based on your own perception. 1 Meta-analysis fails to show that adrenaline increases survival to hospital discharge ( gov/pubmed/24193240). RCT results are awaited (Paramedic 2: The Adrenaline Trial ISRCTN 73485024). __OOHHCCMM__1100ee. . iinnddbb ee 0022//0055//22001177 1199: : 0099 Useful doses for the new doctor These pages outline the typical adult doses of drugs that a foundation doctor will be called upon to prescribe. Refer to local guidelines fi rst. If in any doubt, consult a drug formulary (eg British National Formulary www. bnf. org) especially if estimated glomerular filtration rate or weight 50kg. Always check allergies before prescribing. Drug Dose and frequency Notes Analgesics Paracetamol 1g/6h PO/PR/IV, max. 4g/24h Avoid if hepatic impairment. Ibuprofen 400mg/8h PO, max SE: gastritis; bronchospasm; 2. 4g/24h acute kidney injury; fl uid retention; hypersensDiclofenac 50mg/8h PO/PR itivity. Sodium CI: peptic ulcer; nonsteroidal anti-inflammatory drug-induced asthma; coag ulopathy; advanced chronic kidney disease; Heart failure. Codeine 3060mg/4h PO/IM, max Chronic Pain, eg malignancy, phosphate 240mg/24h may require higher doses (see Dihydroco30mg/46h PO, or p536). Reduce dose if estimated glomerular filtration rate. deine tartrate 50mg/46h IM/SC Care in head injury, as may hinder neurological assessment. Morphine 510mg/4h PO/IM SE: NV; constipation; drowsiOxycodone 2. 55mg/4h PO ness; hypotension; respiratory Tramadol 50100mg/4h PO/IM/IV depression, dependence. CI: respiratory depression. Antibiotics (refer to local guidelines) Phenoxymeth500mg/6h PO (max 4g/24h) SE: rash; hypersensitivity and ylpenicillin anaphylaxis; diarrhoea. Benzylpenicillin 0. 61. 2g/6h IV/IM CI: history of allergy. Flucloxacillin 250500mg/6h PO/IM 1g/6h IV Erythromycin 250500mg/6h PO IV only if oral treatment Clarithromycin 250500mg/6h PO not possible. Beware of Azithromycin 500mg/24h PO cytochrome P450 interactions (not azithromycin). SE: NV; diarrhoea; cholestasis; QT prolongation; pancreatitis Doxycycline 200mg/24h PO as a single dose SE: hypersensitivity; hepatotoxthen 100mg/24h icity; may exacerbate myasthenia gravis and SLE. CI: pregnancy; age 12y. Metronidazole 400mg/8h PO, or IV only if oral treatment not 500mg/8h IV, or possible. 1g/8h PR Gentamicin 5mg/kg/24h IV adjusted to Adjust dose for renal function. serum concentration SE: nephrotoxicity (correct volume depletion); electrolyte disturbance; ototoxicity. Trimethoprim 200mg/12h PO CI: 1st trimester (folate antagonist). Anti-emetics Cyclizine 50mg/8h PO/IM/IV SE: drowsiness. Metoclop10mg/8h PO/IM/IV SE: extrapyramidal SE, esperamide cially in young adults. Ondansetron 48mg/812h PO/IV SE: constipation; headache CI: long QT syndrome. __OOHHCCMM__1100ee. .",
    "Ondansetron 48mg/812h PO/IV SE: constipation; headache CI: long QT syndrome. __OOHHCCMM__1100ee. . iinnddbb ff 0022//0055//22001177 1199: : 0099 Drug Dose and frequency Notes Acute asthma/COPD Salbutamol 5mg via nebulizer as required Oxygen-driven nebulizer in according to clinical response asthma, air-driven in COPD with appropriate concentration of oxygen provided in addition. SE: tachycardia; hypokalaemia. Ipratropium 500mcg/46h via nebulizer SE: GI disturbance, cough. bromide Prednisolone 3050mg/24h (refer to local Oral steroids are as eff ective guidelines). as IV. Specify course length. SE: diabetes mellitus; peptic ulceration; psychosis; blood pressure; fl uid retention. Antihistamines Chlorphena4mg/46h PO SE: drowsiness; urinary retenmine In anaphylaxis: 10mg IM tion; dry mouth; blurred vision; Cetirizine 10mg/24h PO GI disturbance. Loratidine 10mg/24h PO Gastric acid-reducing drugs Ranitidine 150mg/12h PO or 50mg/8h IV SE: diarrhoea; dizziness; cholestasis. Omeprazole 2040mg/24h PO or 40mg/24h IV SE: GI disturbance; hyperLansoprazole 1530mg/24h PO sensitivity. Pantoprazole 2040mg/24h PO or 40mg/24h IV May mask symptoms of gastric cancer. Heparins (refer to local guidelines) Unfractionated DVT prophylaxis: Dose needs correcting for heparin 5000U/812h SC renal function and pregnancy Enoxaparin DVT prophylaxis: (see local guidelines). 2040mg/24h SC SE: bleeding; thromDVT/physical examination treatment: bocytopenia (watch for by 1. 5mg/kg/24h SC 30% or thrombosis 510 days into treatment); hyperkalaeTinzaparin DVT prophylaxis: mia; osteop orosis after pro3500U/24h SC DVT/physical examination treatment: longed use (risk with LMWH). 175U/kg per 24h SC CI: heparin-induced thrombocytopenia; bleeding disorders; Dalteparin DVT prophylaxis: epidural anaesthesia, recent 25005000U/24h SC cerebral bleed; recent trauma DVT/physical examination treatment: or surgery; active bleeding. 200U/kg/d SC Tranquillizers for non-psychotic behavioural disturbance Lorazepam 12mg PO/IM De-escalation techniques fi rst. Medication only to risk of harm to self/others. Risk of medication in frail, elderly, comorbid conditions. Wait 60 min for response. Seek expert help if needs repeat dose. SE: respiratory depression; drowsiness; ataxia; confusion; GI disturbance; urinary retention. CI: respiratory disease See also: prescribing in palliative care (pp532537), laxatives (p260), inhalers (p183), digoxin (p115), insulin (p589), fl uid (p666), oxygen prescribing (p189), naloxone (p842). __OOHHCCMM__1100ee. . iinnddbb gg 0022//0055//22001177 1199: : 0099"
  ],
  "metadatas": [
    {
      "source": "8205Oxford Handbook of Clinical Medicine 10th 2017 Edition_SamanSarKo - Copy.pdf",
      "chunk_id": 0,
      "content_type": "dietary",
      "content_type_confidence": 4,
      "word_count": 588,
      "entity_count": 7,
      "has_ckd": false,
      "has_gfr": true,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "acute kidney injury,glomerular filtration rate,creatinine,urea,sodium,potassium,calcium",
      "year": "2025",
      "organization": "Unknown",
      "section": "Index to emergency topics Dont go so fast:"
    },
    {
      "source": "8205Oxford Handbook of Clinical Medicine 10th 2017 Edition_SamanSarKo - Copy.pdf",
      "chunk_id": 1,
      "content_type": "recommendation",
      "content_type_confidence": 2,
      "word_count": 520,
      "entity_count": 2,
      "has_ckd": false,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "potassium,exercise",
      "year": "2025",
      "organization": "Unknown"
    },
    {
      "source": "8205Oxford Handbook of Clinical Medicine 10th 2017 Edition_SamanSarKo - Copy.pdf",
      "chunk_id": 3,
      "content_type": "recommendation",
      "content_type_confidence": 1,
      "word_count": 591,
      "entity_count": 4,
      "has_ckd": false,
      "has_gfr": true,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": true,
      "medical_entities": "glomerular filtration rate,creatinine,magnesium,dialysis",
      "year": "2025",
      "organization": "Unknown"
    },
    {
      "source": "8205Oxford Handbook of Clinical Medicine 10th 2017 Edition_SamanSarKo - Copy.pdf",
      "chunk_id": 4,
      "content_type": "treatment",
      "content_type_confidence": 2,
      "word_count": 511,
      "entity_count": 10,
      "has_ckd": true,
      "has_gfr": true,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": true,
      "medical_entities": "chronic kidney disease,acute kidney injury,glomerular filtration rate,calcium,phosphate,hemoglobin,hematocrit,insulin,dialysis,peritoneal dialysis",
      "year": "2025",
      "organization": "Unknown"
    },
    {
      "source": "8205Oxford Handbook of Clinical Medicine 10th 2017 Edition_SamanSarKo - Copy.pdf",
      "chunk_id": 5,
      "content_type": "evidence",
      "content_type_confidence": 2,
      "word_count": 591,
      "entity_count": 5,
      "has_ckd": true,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "chronic kidney disease,potassium,magnesium,parathyroid hormone,insulin",
      "year": "2025",
      "organization": "Unknown"
    },
    {
      "source": "8205Oxford Handbook of Clinical Medicine 10th 2017 Edition_SamanSarKo - Copy.pdf",
      "chunk_id": 6,
      "content_type": "dietary",
      "content_type_confidence": 3,
      "word_count": 532,
      "entity_count": 6,
      "has_ckd": false,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "creatinine,sodium,magnesium,iron,nutrition,insulin",
      "year": "2025",
      "organization": "Unknown"
    },
    {
      "source": "8205Oxford Handbook of Clinical Medicine 10th 2017 Edition_SamanSarKo - Copy.pdf",
      "chunk_id": 10,
      "content_type": "definition",
      "content_type_confidence": 2,
      "word_count": 576,
      "entity_count": 1,
      "has_ckd": false,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "quality of life",
      "year": "2025",
      "organization": "Unknown"
    },
    {
      "source": "8205Oxford Handbook of Clinical Medicine 10th 2017 Edition_SamanSarKo - Copy.pdf",
      "chunk_id": 15,
      "content_type": "treatment",
      "content_type_confidence": 5,
      "word_count": 590,
      "entity_count": 2,
      "has_ckd": false,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "antihypertensive,neuropathy",
      "year": "2025",
      "organization": "Unknown",
      "section": "Consider the following when prescribing any medication:"
    },
    {
      "source": "8205Oxford Handbook of Clinical Medicine 10th 2017 Edition_SamanSarKo - Copy.pdf",
      "chunk_id": 17,
      "content_type": "recommendation",
      "content_type_confidence": 3,
      "word_count": 589,
      "entity_count": 2,
      "has_ckd": false,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "diet,exercise",
      "year": "2025",
      "organization": "Unknown"
    },
    {
      "source": "8205Oxford Handbook of Clinical Medicine 10th 2017 Edition_SamanSarKo - Copy.pdf",
      "chunk_id": 19,
      "content_type": "reference",
      "content_type_confidence": 2,
      "word_count": 594,
      "entity_count": 3,
      "has_ckd": false,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": true,
      "medical_entities": "dialysis,exercise,quality of life",
      "year": "2025",
      "organization": "Unknown"
    },
    {
      "source": "8205Oxford Handbook of Clinical Medicine 10th 2017 Edition_SamanSarKo - Copy.pdf",
      "chunk_id": 20,
      "content_type": "treatment",
      "content_type_confidence": 5,
      "word_count": 600,
      "entity_count": 2,
      "has_ckd": false,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "exercise,physical activity",
      "year": "2025",
      "organization": "Unknown"
    },
    {
      "source": "8205Oxford Handbook of Clinical Medicine 10th 2017 Edition_SamanSarKo - Copy.pdf",
      "chunk_id": 21,
      "content_type": "monitoring",
      "content_type_confidence": 5,
      "word_count": 597,
      "entity_count": 2,
      "has_ckd": false,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "nutrition,screening",
      "year": "2025",
      "organization": "Unknown"
    },
    {
      "source": "8205Oxford Handbook of Clinical Medicine 10th 2017 Edition_SamanSarKo - Copy.pdf",
      "chunk_id": 22,
      "content_type": "treatment",
      "content_type_confidence": 4,
      "word_count": 587,
      "entity_count": 4,
      "has_ckd": false,
      "has_gfr": true,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "glomerular filtration rate,creatinine,bicarbonate,hemoglobin",
      "year": "2025",
      "organization": "Unknown"
    },
    {
      "source": "8205Oxford Handbook of Clinical Medicine 10th 2017 Edition_SamanSarKo - Copy.pdf",
      "chunk_id": 25,
      "content_type": "monitoring",
      "content_type_confidence": 2,
      "word_count": 599,
      "entity_count": 5,
      "has_ckd": true,
      "has_gfr": true,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "chronic kidney disease,glomerular filtration rate,kidney failure,screening,monitoring",
      "year": "2025",
      "organization": "Unknown"
    },
    {
      "source": "8205Oxford Handbook of Clinical Medicine 10th 2017 Edition_SamanSarKo - Copy.pdf",
      "chunk_id": 26,
      "content_type": "monitoring",
      "content_type_confidence": 2,
      "word_count": 600,
      "entity_count": 1,
      "has_ckd": false,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "screening",
      "year": "2025",
      "organization": "Unknown"
    },
    {
      "source": "8205Oxford Handbook of Clinical Medicine 10th 2017 Edition_SamanSarKo - Copy.pdf",
      "chunk_id": 28,
      "content_type": "definition",
      "content_type_confidence": 1,
      "word_count": 594,
      "entity_count": 3,
      "has_ckd": false,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "exercise,quality of life,screening",
      "year": "2025",
      "organization": "Unknown"
    },
    {
      "source": "8205Oxford Handbook of Clinical Medicine 10th 2017 Edition_SamanSarKo - Copy.pdf",
      "chunk_id": 29,
      "content_type": "recommendation",
      "content_type_confidence": 1,
      "word_count": 596,
      "entity_count": 2,
      "has_ckd": false,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "pruritus,screening",
      "year": "2025",
      "organization": "Unknown"
    },
    {
      "source": "8205Oxford Handbook of Clinical Medicine 10th 2017 Edition_SamanSarKo - Copy.pdf",
      "chunk_id": 30,
      "content_type": "treatment",
      "content_type_confidence": 5,
      "word_count": 600,
      "entity_count": 8,
      "has_ckd": true,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "chronic kidney disease,vitamin D,iron,ferritin,pruritus,fatigue,neuropathy,follow up",
      "year": "2025",
      "organization": "Unknown"
    },
    {
      "source": "8205Oxford Handbook of Clinical Medicine 10th 2017 Edition_SamanSarKo - Copy.pdf",
      "chunk_id": 31,
      "content_type": "reference",
      "content_type_confidence": 2,
      "word_count": 593,
      "entity_count": 5,
      "has_ckd": false,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "chloride,ferritin,fatigue,exercise,monitoring",
      "year": "2025",
      "organization": "Unknown",
      "section": "At the bedside:"
    },
    {
      "source": "8205Oxford Handbook of Clinical Medicine 10th 2017 Edition_SamanSarKo - Copy.pdf",
      "chunk_id": 32,
      "content_type": "treatment",
      "content_type_confidence": 2,
      "word_count": 585,
      "entity_count": 3,
      "has_ckd": false,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "iron,insulin,edema",
      "year": "2025",
      "organization": "Unknown"
    },
    {
      "source": "8205Oxford Handbook of Clinical Medicine 10th 2017 Edition_SamanSarKo - Copy.pdf",
      "chunk_id": 33,
      "content_type": "treatment",
      "content_type_confidence": 4,
      "word_count": 597,
      "entity_count": 4,
      "has_ckd": false,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "creatinine,potassium,hemoglobin,insulin",
      "year": "2025",
      "organization": "Unknown",
      "section": "Pallor:"
    },
    {
      "source": "8205Oxford Handbook of Clinical Medicine 10th 2017 Edition_SamanSarKo - Copy.pdf",
      "chunk_id": 34,
      "content_type": "treatment",
      "content_type_confidence": 3,
      "word_count": 586,
      "entity_count": 5,
      "has_ckd": true,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "chronic kidney disease,urea,hemoglobin,iron,catheter",
      "year": "2025",
      "organization": "Unknown"
    },
    {
      "source": "8205Oxford Handbook of Clinical Medicine 10th 2017 Edition_SamanSarKo - Copy.pdf",
      "chunk_id": 35,
      "content_type": "dietary",
      "content_type_confidence": 5,
      "word_count": 598,
      "entity_count": 4,
      "has_ckd": true,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "chronic kidney disease,malnutrition,heart failure,exercise",
      "year": "2025",
      "organization": "Unknown",
      "section": "Viral:"
    },
    {
      "source": "8205Oxford Handbook of Clinical Medicine 10th 2017 Edition_SamanSarKo - Copy.pdf",
      "chunk_id": 36,
      "content_type": "definition",
      "content_type_confidence": 2,
      "word_count": 583,
      "entity_count": 2,
      "has_ckd": false,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "edema,exercise",
      "year": "2025",
      "organization": "Unknown"
    },
    {
      "source": "8205Oxford Handbook of Clinical Medicine 10th 2017 Edition_SamanSarKo - Copy.pdf",
      "chunk_id": 38,
      "content_type": "evidence",
      "content_type_confidence": 1,
      "word_count": 591,
      "entity_count": 1,
      "has_ckd": false,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "heart failure",
      "year": "2025",
      "organization": "Unknown"
    },
    {
      "source": "8205Oxford Handbook of Clinical Medicine 10th 2017 Edition_SamanSarKo - Copy.pdf",
      "chunk_id": 39,
      "content_type": "treatment",
      "content_type_confidence": 5,
      "word_count": 581,
      "entity_count": 5,
      "has_ckd": false,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "sodium,diuretics,neuropathy,exercise,monitoring",
      "year": "2025",
      "organization": "Unknown"
    },
    {
      "source": "8205Oxford Handbook of Clinical Medicine 10th 2017 Edition_SamanSarKo - Copy.pdf",
      "chunk_id": 40,
      "content_type": "recommendation",
      "content_type_confidence": 2,
      "word_count": 572,
      "entity_count": 1,
      "has_ckd": false,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "calcium",
      "year": "2025",
      "organization": "Unknown"
    },
    {
      "source": "8205Oxford Handbook of Clinical Medicine 10th 2017 Edition_SamanSarKo - Copy.pdf",
      "chunk_id": 41,
      "content_type": "recommendation",
      "content_type_confidence": 1,
      "word_count": 596,
      "entity_count": 2,
      "has_ckd": false,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "heart failure,fluid overload",
      "year": "2025",
      "organization": "Unknown"
    },
    {
      "source": "8205Oxford Handbook of Clinical Medicine 10th 2017 Edition_SamanSarKo - Copy.pdf",
      "chunk_id": 44,
      "content_type": "treatment",
      "content_type_confidence": 2,
      "word_count": 593,
      "entity_count": 1,
      "has_ckd": false,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "ACE inhibitors",
      "year": "2025",
      "organization": "Unknown",
      "section": "Prosthetic mitral valves:"
    },
    {
      "source": "8205Oxford Handbook of Clinical Medicine 10th 2017 Edition_SamanSarKo - Copy.pdf",
      "chunk_id": 45,
      "content_type": "reference",
      "content_type_confidence": 1,
      "word_count": 599,
      "entity_count": 3,
      "has_ckd": false,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "calcium,acidosis,metabolic acidosis",
      "year": "2025",
      "organization": "Unknown"
    },
    {
      "source": "8205Oxford Handbook of Clinical Medicine 10th 2017 Edition_SamanSarKo - Copy.pdf",
      "chunk_id": 47,
      "content_type": "treatment",
      "content_type_confidence": 2,
      "word_count": 596,
      "entity_count": 3,
      "has_ckd": false,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "calcium,acidosis,metabolic acidosis",
      "year": "2025",
      "organization": "Unknown"
    },
    {
      "source": "8205Oxford Handbook of Clinical Medicine 10th 2017 Edition_SamanSarKo - Copy.pdf",
      "chunk_id": 48,
      "content_type": "recommendation",
      "content_type_confidence": 1,
      "word_count": 600,
      "entity_count": 1,
      "has_ckd": false,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "exercise",
      "year": "2025",
      "organization": "Unknown",
      "section": "CheyneStokes breathing:"
    },
    {
      "source": "8205Oxford Handbook of Clinical Medicine 10th 2017 Edition_SamanSarKo - Copy.pdf",
      "chunk_id": 49,
      "content_type": "dietary",
      "content_type_confidence": 2,
      "word_count": 587,
      "entity_count": 3,
      "has_ckd": false,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "acute kidney injury,pruritus,neuropathy",
      "year": "2025",
      "organization": "Unknown"
    },
    {
      "source": "8205Oxford Handbook of Clinical Medicine 10th 2017 Edition_SamanSarKo - Copy.pdf",
      "chunk_id": 51,
      "content_type": "definition",
      "content_type_confidence": 2,
      "word_count": 590,
      "entity_count": 2,
      "has_ckd": false,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "calcium,phosphate",
      "year": "2025",
      "organization": "Unknown"
    },
    {
      "source": "8205Oxford Handbook of Clinical Medicine 10th 2017 Edition_SamanSarKo - Copy.pdf",
      "chunk_id": 52,
      "content_type": "dietary",
      "content_type_confidence": 3,
      "word_count": 590,
      "entity_count": 2,
      "has_ckd": true,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "chronic kidney disease,catheter",
      "year": "2025",
      "organization": "Unknown"
    },
    {
      "source": "8205Oxford Handbook of Clinical Medicine 10th 2017 Edition_SamanSarKo - Copy.pdf",
      "chunk_id": 54,
      "content_type": "recommendation",
      "content_type_confidence": 1,
      "word_count": 599,
      "entity_count": 3,
      "has_ckd": false,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "renal failure,iron,neuropathy",
      "year": "2025",
      "organization": "Unknown"
    },
    {
      "source": "8205Oxford Handbook of Clinical Medicine 10th 2017 Edition_SamanSarKo - Copy.pdf",
      "chunk_id": 56,
      "content_type": "treatment",
      "content_type_confidence": 4,
      "word_count": 599,
      "entity_count": 7,
      "has_ckd": true,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": true,
      "medical_entities": "chronic kidney disease,potassium,diuretics,dialysis,neuropathy,exercise,screening",
      "year": "2025",
      "organization": "Unknown"
    },
    {
      "source": "8205Oxford Handbook of Clinical Medicine 10th 2017 Edition_SamanSarKo - Copy.pdf",
      "chunk_id": 58,
      "content_type": "recommendation",
      "content_type_confidence": 1,
      "word_count": 587,
      "entity_count": 1,
      "has_ckd": false,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "edema",
      "year": "2025",
      "organization": "Unknown"
    },
    {
      "source": "8205Oxford Handbook of Clinical Medicine 10th 2017 Edition_SamanSarKo - Copy.pdf",
      "chunk_id": 59,
      "content_type": "recommendation",
      "content_type_confidence": 1,
      "word_count": 596,
      "entity_count": 1,
      "has_ckd": false,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "edema",
      "year": "2025",
      "organization": "Unknown",
      "section": "IV:"
    },
    {
      "source": "8205Oxford Handbook of Clinical Medicine 10th 2017 Edition_SamanSarKo - Copy.pdf",
      "chunk_id": 61,
      "content_type": "recommendation",
      "content_type_confidence": 2,
      "word_count": 588,
      "entity_count": 1,
      "has_ckd": false,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "retinopathy",
      "year": "2025",
      "organization": "Unknown"
    },
    {
      "source": "8205Oxford Handbook of Clinical Medicine 10th 2017 Edition_SamanSarKo - Copy.pdf",
      "chunk_id": 62,
      "content_type": "treatment",
      "content_type_confidence": 2,
      "word_count": 588,
      "entity_count": 4,
      "has_ckd": true,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "chronic kidney disease,iron,malnutrition,neuropathy",
      "year": "2025",
      "organization": "Unknown"
    },
    {
      "source": "8205Oxford Handbook of Clinical Medicine 10th 2017 Edition_SamanSarKo - Copy.pdf",
      "chunk_id": 65,
      "content_type": "treatment",
      "content_type_confidence": 3,
      "word_count": 597,
      "entity_count": 5,
      "has_ckd": false,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "acute kidney injury,phosphate,diuretics,catheter,neuropathy",
      "year": "2025",
      "organization": "Unknown",
      "section": "Causes:"
    },
    {
      "source": "8205Oxford Handbook of Clinical Medicine 10th 2017 Edition_SamanSarKo - Copy.pdf",
      "chunk_id": 68,
      "content_type": "recommendation",
      "content_type_confidence": 2,
      "word_count": 556,
      "entity_count": 1,
      "has_ckd": false,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "edema",
      "year": "2025",
      "organization": "Unknown"
    },
    {
      "source": "8205Oxford Handbook of Clinical Medicine 10th 2017 Edition_SamanSarKo - Copy.pdf",
      "chunk_id": 71,
      "content_type": "monitoring",
      "content_type_confidence": 4,
      "word_count": 592,
      "entity_count": 1,
      "has_ckd": false,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "screening",
      "year": "2025",
      "organization": "Unknown",
      "section": "Gait:"
    },
    {
      "source": "8205Oxford Handbook of Clinical Medicine 10th 2017 Edition_SamanSarKo - Copy.pdf",
      "chunk_id": 73,
      "content_type": "evidence",
      "content_type_confidence": 2,
      "word_count": 580,
      "entity_count": 1,
      "has_ckd": false,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "monitoring",
      "year": "2025",
      "organization": "Unknown"
    },
    {
      "source": "8205Oxford Handbook of Clinical Medicine 10th 2017 Edition_SamanSarKo - Copy.pdf",
      "chunk_id": 74,
      "content_type": "recommendation",
      "content_type_confidence": 1,
      "word_count": 599,
      "entity_count": 1,
      "has_ckd": false,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "exercise",
      "year": "2025",
      "organization": "Unknown"
    },
    {
      "source": "8205Oxford Handbook of Clinical Medicine 10th 2017 Edition_SamanSarKo - Copy.pdf",
      "chunk_id": 75,
      "content_type": "dietary",
      "content_type_confidence": 3,
      "word_count": 598,
      "entity_count": 2,
      "has_ckd": false,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "statins,exercise",
      "year": "2025",
      "organization": "Unknown"
    },
    {
      "source": "8205Oxford Handbook of Clinical Medicine 10th 2017 Edition_SamanSarKo - Copy.pdf",
      "chunk_id": 76,
      "content_type": "monitoring",
      "content_type_confidence": 2,
      "word_count": 589,
      "entity_count": 3,
      "has_ckd": false,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "edema,heart failure,exercise",
      "year": "2025",
      "organization": "Unknown"
    },
    {
      "source": "8205Oxford Handbook of Clinical Medicine 10th 2017 Edition_SamanSarKo - Copy.pdf",
      "chunk_id": 77,
      "content_type": "definition",
      "content_type_confidence": 2,
      "word_count": 599,
      "entity_count": 1,
      "has_ckd": false,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "fistula",
      "year": "2025",
      "organization": "Unknown"
    },
    {
      "source": "8205Oxford Handbook of Clinical Medicine 10th 2017 Edition_SamanSarKo - Copy.pdf",
      "chunk_id": 78,
      "content_type": "recommendation",
      "content_type_confidence": 1,
      "word_count": 591,
      "entity_count": 2,
      "has_ckd": false,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "potassium,fistula",
      "year": "2025",
      "organization": "Unknown",
      "section": "P wave:"
    },
    {
      "source": "8205Oxford Handbook of Clinical Medicine 10th 2017 Edition_SamanSarKo - Copy.pdf",
      "chunk_id": 79,
      "content_type": "treatment",
      "content_type_confidence": 2,
      "word_count": 590,
      "entity_count": 4,
      "has_ckd": false,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "calcium,hemoglobin,fistula,heart failure",
      "year": "2025",
      "organization": "Unknown"
    },
    {
      "source": "8205Oxford Handbook of Clinical Medicine 10th 2017 Edition_SamanSarKo - Copy.pdf",
      "chunk_id": 80,
      "content_type": "recommendation",
      "content_type_confidence": 2,
      "word_count": 600,
      "entity_count": 1,
      "has_ckd": false,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "fistula",
      "year": "2025",
      "organization": "Unknown"
    },
    {
      "source": "8205Oxford Handbook of Clinical Medicine 10th 2017 Edition_SamanSarKo - Copy.pdf",
      "chunk_id": 81,
      "content_type": "definition",
      "content_type_confidence": 1,
      "word_count": 581,
      "entity_count": 1,
      "has_ckd": false,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "hemoglobin",
      "year": "2025",
      "organization": "Unknown"
    },
    {
      "source": "8205Oxford Handbook of Clinical Medicine 10th 2017 Edition_SamanSarKo - Copy.pdf",
      "chunk_id": 82,
      "content_type": "reference",
      "content_type_confidence": 2,
      "word_count": 599,
      "entity_count": 2,
      "has_ckd": false,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "renal failure,fistula",
      "year": "2025",
      "organization": "Unknown"
    },
    {
      "source": "8205Oxford Handbook of Clinical Medicine 10th 2017 Edition_SamanSarKo - Copy.pdf",
      "chunk_id": 83,
      "content_type": "treatment",
      "content_type_confidence": 2,
      "word_count": 600,
      "entity_count": 2,
      "has_ckd": false,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "heart failure,exercise",
      "year": "2025",
      "organization": "Unknown"
    },
    {
      "source": "8205Oxford Handbook of Clinical Medicine 10th 2017 Edition_SamanSarKo - Copy.pdf",
      "chunk_id": 84,
      "content_type": "evidence",
      "content_type_confidence": 1,
      "word_count": 594,
      "entity_count": 2,
      "has_ckd": false,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "heart failure,exercise",
      "year": "2025",
      "organization": "Unknown"
    },
    {
      "source": "8205Oxford Handbook of Clinical Medicine 10th 2017 Edition_SamanSarKo - Copy.pdf",
      "chunk_id": 85,
      "content_type": "monitoring",
      "content_type_confidence": 3,
      "word_count": 593,
      "entity_count": 2,
      "has_ckd": false,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "catheter,edema",
      "year": "2025",
      "organization": "Unknown"
    },
    {
      "source": "8205Oxford Handbook of Clinical Medicine 10th 2017 Edition_SamanSarKo - Copy.pdf",
      "chunk_id": 86,
      "content_type": "treatment",
      "content_type_confidence": 4,
      "word_count": 593,
      "entity_count": 10,
      "has_ckd": false,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "acute kidney injury,renal function,creatinine,sodium,potassium,calcium,ACE inhibitors,diuretics,loop diuretics,thiazides",
      "year": "2025",
      "organization": "Unknown"
    },
    {
      "source": "8205Oxford Handbook of Clinical Medicine 10th 2017 Edition_SamanSarKo - Copy.pdf",
      "chunk_id": 87,
      "content_type": "treatment",
      "content_type_confidence": 4,
      "word_count": 597,
      "entity_count": 6,
      "has_ckd": false,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "sodium,potassium,calcium,statins,heart failure,neuropathy",
      "year": "2025",
      "organization": "Unknown"
    },
    {
      "source": "8205Oxford Handbook of Clinical Medicine 10th 2017 Edition_SamanSarKo - Copy.pdf",
      "chunk_id": 88,
      "content_type": "treatment",
      "content_type_confidence": 5,
      "word_count": 597,
      "entity_count": 8,
      "has_ckd": false,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "sodium,potassium,calcium,hemoglobin,ACE inhibitors,cardiovascular disease,heart failure,exercise",
      "year": "2025",
      "organization": "Unknown"
    },
    {
      "source": "8205Oxford Handbook of Clinical Medicine 10th 2017 Edition_SamanSarKo - Copy.pdf",
      "chunk_id": 89,
      "content_type": "recommendation",
      "content_type_confidence": 3,
      "word_count": 592,
      "entity_count": 3,
      "has_ckd": false,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "calcium,magnesium,exercise",
      "year": "2025",
      "organization": "Unknown"
    },
    {
      "source": "8205Oxford Handbook of Clinical Medicine 10th 2017 Edition_SamanSarKo - Copy.pdf",
      "chunk_id": 90,
      "content_type": "treatment",
      "content_type_confidence": 2,
      "word_count": 597,
      "entity_count": 1,
      "has_ckd": false,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "heart failure",
      "year": "2025",
      "organization": "Unknown"
    },
    {
      "source": "8205Oxford Handbook of Clinical Medicine 10th 2017 Edition_SamanSarKo - Copy.pdf",
      "chunk_id": 91,
      "content_type": "recommendation",
      "content_type_confidence": 3,
      "word_count": 599,
      "entity_count": 7,
      "has_ckd": false,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "renal function,renal failure,diet,cardiovascular disease,heart failure,exercise,monitoring",
      "year": "2025",
      "organization": "Unknown"
    },
    {
      "source": "8205Oxford Handbook of Clinical Medicine 10th 2017 Edition_SamanSarKo - Copy.pdf",
      "chunk_id": 92,
      "content_type": "evidence",
      "content_type_confidence": 3,
      "word_count": 593,
      "entity_count": 5,
      "has_ckd": false,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "potassium,calcium,diuretics,acidosis,exercise",
      "year": "2025",
      "organization": "Unknown"
    },
    {
      "source": "8205Oxford Handbook of Clinical Medicine 10th 2017 Edition_SamanSarKo - Copy.pdf",
      "chunk_id": 93,
      "content_type": "evidence",
      "content_type_confidence": 3,
      "word_count": 597,
      "entity_count": 3,
      "has_ckd": false,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "diuretics,exercise,monitoring",
      "year": "2025",
      "organization": "Unknown"
    },
    {
      "source": "8205Oxford Handbook of Clinical Medicine 10th 2017 Edition_SamanSarKo - Copy.pdf",
      "chunk_id": 94,
      "content_type": "reference",
      "content_type_confidence": 2,
      "word_count": 570,
      "entity_count": 5,
      "has_ckd": false,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "potassium,acidosis,metabolic acidosis,exercise,monitoring",
      "year": "2025",
      "organization": "Unknown"
    },
    {
      "source": "8205Oxford Handbook of Clinical Medicine 10th 2017 Edition_SamanSarKo - Copy.pdf",
      "chunk_id": 95,
      "content_type": "reference",
      "content_type_confidence": 3,
      "word_count": 570,
      "entity_count": 1,
      "has_ckd": false,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "exercise",
      "year": "2025",
      "organization": "Unknown"
    },
    {
      "source": "8205Oxford Handbook of Clinical Medicine 10th 2017 Edition_SamanSarKo - Copy.pdf",
      "chunk_id": 96,
      "content_type": "treatment",
      "content_type_confidence": 3,
      "word_count": 588,
      "entity_count": 1,
      "has_ckd": false,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "neuropathy",
      "year": "2025",
      "organization": "Unknown"
    },
    {
      "source": "8205Oxford Handbook of Clinical Medicine 10th 2017 Edition_SamanSarKo - Copy.pdf",
      "chunk_id": 97,
      "content_type": "evidence",
      "content_type_confidence": 2,
      "word_count": 594,
      "entity_count": 1,
      "has_ckd": false,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "urea",
      "year": "2025",
      "organization": "Unknown"
    },
    {
      "source": "8205Oxford Handbook of Clinical Medicine 10th 2017 Edition_SamanSarKo - Copy.pdf",
      "chunk_id": 98,
      "content_type": "recommendation",
      "content_type_confidence": 2,
      "word_count": 592,
      "entity_count": 2,
      "has_ckd": false,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "potassium,heart failure",
      "year": "2025",
      "organization": "Unknown"
    },
    {
      "source": "8205Oxford Handbook of Clinical Medicine 10th 2017 Edition_SamanSarKo - Copy.pdf",
      "chunk_id": 100,
      "content_type": "treatment",
      "content_type_confidence": 3,
      "word_count": 599,
      "entity_count": 2,
      "has_ckd": false,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "renal function,heart failure",
      "year": "2025",
      "organization": "Unknown"
    },
    {
      "source": "8205Oxford Handbook of Clinical Medicine 10th 2017 Edition_SamanSarKo - Copy.pdf",
      "chunk_id": 101,
      "content_type": "treatment",
      "content_type_confidence": 3,
      "word_count": 590,
      "entity_count": 3,
      "has_ckd": false,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "sodium,heart failure,exercise",
      "year": "2025",
      "organization": "Unknown"
    },
    {
      "source": "8205Oxford Handbook of Clinical Medicine 10th 2017 Edition_SamanSarKo - Copy.pdf",
      "chunk_id": 102,
      "content_type": "evidence",
      "content_type_confidence": 3,
      "word_count": 594,
      "entity_count": 5,
      "has_ckd": false,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "renal failure,fatigue,heart failure,exercise,screening",
      "year": "2025",
      "organization": "Unknown"
    },
    {
      "source": "8205Oxford Handbook of Clinical Medicine 10th 2017 Edition_SamanSarKo - Copy.pdf",
      "chunk_id": 103,
      "content_type": "treatment",
      "content_type_confidence": 4,
      "word_count": 586,
      "entity_count": 6,
      "has_ckd": true,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "chronic kidney disease,potassium,nutrition,diuretics,loop diuretics,heart failure",
      "year": "2025",
      "organization": "Unknown"
    },
    {
      "source": "8205Oxford Handbook of Clinical Medicine 10th 2017 Edition_SamanSarKo - Copy.pdf",
      "chunk_id": 104,
      "content_type": "dietary",
      "content_type_confidence": 4,
      "word_count": 578,
      "entity_count": 5,
      "has_ckd": false,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "sodium,potassium,nutrition,ARBs,heart failure",
      "year": "2025",
      "organization": "Unknown"
    },
    {
      "source": "8205Oxford Handbook of Clinical Medicine 10th 2017 Edition_SamanSarKo - Copy.pdf",
      "chunk_id": 105,
      "content_type": "evidence",
      "content_type_confidence": 2,
      "word_count": 600,
      "entity_count": 7,
      "has_ckd": false,
      "has_gfr": true,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "acute kidney injury,glomerular filtration rate,sodium,cardiovascular disease,heart failure,screening,monitoring",
      "year": "2025",
      "organization": "Unknown"
    },
    {
      "source": "8205Oxford Handbook of Clinical Medicine 10th 2017 Edition_SamanSarKo - Copy.pdf",
      "chunk_id": 106,
      "content_type": "dietary",
      "content_type_confidence": 2,
      "word_count": 600,
      "entity_count": 6,
      "has_ckd": false,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "renal failure,proteinuria,potassium,antihypertensive,retinopathy,monitoring",
      "year": "2025",
      "organization": "Unknown"
    },
    {
      "source": "8205Oxford Handbook of Clinical Medicine 10th 2017 Edition_SamanSarKo - Copy.pdf",
      "chunk_id": 107,
      "content_type": "treatment",
      "content_type_confidence": 5,
      "word_count": 595,
      "entity_count": 10,
      "has_ckd": false,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "renal failure,proteinuria,sodium,potassium,diet,thiazides,pruritus,fatigue,cardiovascular disease,heart failure",
      "year": "2025",
      "organization": "Unknown"
    },
    {
      "source": "8205Oxford Handbook of Clinical Medicine 10th 2017 Edition_SamanSarKo - Copy.pdf",
      "chunk_id": 108,
      "content_type": "treatment",
      "content_type_confidence": 2,
      "word_count": 600,
      "entity_count": 5,
      "has_ckd": false,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "sodium,acidosis,metabolic acidosis,heart failure,monitoring",
      "year": "2025",
      "organization": "Unknown",
      "section": "Encephalopathy:"
    },
    {
      "source": "8205Oxford Handbook of Clinical Medicine 10th 2017 Edition_SamanSarKo - Copy.pdf",
      "chunk_id": 109,
      "content_type": "evidence",
      "content_type_confidence": 1,
      "word_count": 594,
      "entity_count": 2,
      "has_ckd": false,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "diuretics,fatigue",
      "year": "2025",
      "organization": "Unknown"
    },
    {
      "source": "8205Oxford Handbook of Clinical Medicine 10th 2017 Edition_SamanSarKo - Copy.pdf",
      "chunk_id": 110,
      "content_type": "evidence",
      "content_type_confidence": 2,
      "word_count": 590,
      "entity_count": 3,
      "has_ckd": false,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "diuretics,statins,heart failure",
      "year": "2025",
      "organization": "Unknown",
      "section": "Indications for cardiac catheterization:"
    },
    {
      "source": "8205Oxford Handbook of Clinical Medicine 10th 2017 Edition_SamanSarKo - Copy.pdf",
      "chunk_id": 111,
      "content_type": "recommendation",
      "content_type_confidence": 1,
      "word_count": 581,
      "entity_count": 1,
      "has_ckd": false,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "catheter",
      "year": "2025",
      "organization": "Unknown"
    },
    {
      "source": "8205Oxford Handbook of Clinical Medicine 10th 2017 Edition_SamanSarKo - Copy.pdf",
      "chunk_id": 112,
      "content_type": "treatment",
      "content_type_confidence": 3,
      "word_count": 595,
      "entity_count": 4,
      "has_ckd": false,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "calcium,diuretics,fatigue,cardiovascular disease",
      "year": "2025",
      "organization": "Unknown"
    },
    {
      "source": "8205Oxford Handbook of Clinical Medicine 10th 2017 Edition_SamanSarKo - Copy.pdf",
      "chunk_id": 113,
      "content_type": "treatment",
      "content_type_confidence": 2,
      "word_count": 587,
      "entity_count": 1,
      "has_ckd": false,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "quality of life",
      "year": "2025",
      "organization": "Unknown"
    },
    {
      "source": "8205Oxford Handbook of Clinical Medicine 10th 2017 Edition_SamanSarKo - Copy.pdf",
      "chunk_id": 114,
      "content_type": "treatment",
      "content_type_confidence": 3,
      "word_count": 597,
      "entity_count": 3,
      "has_ckd": false,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "acute kidney injury,renal failure,heart failure",
      "year": "2025",
      "organization": "Unknown"
    },
    {
      "source": "8205Oxford Handbook of Clinical Medicine 10th 2017 Edition_SamanSarKo - Copy.pdf",
      "chunk_id": 115,
      "content_type": "treatment",
      "content_type_confidence": 3,
      "word_count": 569,
      "entity_count": 2,
      "has_ckd": false,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "heart failure,exercise",
      "year": "2025",
      "organization": "Unknown"
    },
    {
      "source": "8205Oxford Handbook of Clinical Medicine 10th 2017 Edition_SamanSarKo - Copy.pdf",
      "chunk_id": 116,
      "content_type": "treatment",
      "content_type_confidence": 3,
      "word_count": 591,
      "entity_count": 5,
      "has_ckd": false,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "sodium,diuretics,transplant rejection,fatigue,exercise",
      "year": "2025",
      "organization": "Unknown",
      "section": "Associations:"
    },
    {
      "source": "8205Oxford Handbook of Clinical Medicine 10th 2017 Edition_SamanSarKo - Copy.pdf",
      "chunk_id": 117,
      "content_type": "treatment",
      "content_type_confidence": 3,
      "word_count": 587,
      "entity_count": 1,
      "has_ckd": false,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "heart failure",
      "year": "2025",
      "organization": "Unknown"
    },
    {
      "source": "8205Oxford Handbook of Clinical Medicine 10th 2017 Edition_SamanSarKo - Copy.pdf",
      "chunk_id": 118,
      "content_type": "evidence",
      "content_type_confidence": 2,
      "word_count": 591,
      "entity_count": 2,
      "has_ckd": false,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "heart failure,exercise",
      "year": "2025",
      "organization": "Unknown"
    },
    {
      "source": "8205Oxford Handbook of Clinical Medicine 10th 2017 Edition_SamanSarKo - Copy.pdf",
      "chunk_id": 119,
      "content_type": "treatment",
      "content_type_confidence": 2,
      "word_count": 600,
      "entity_count": 2,
      "has_ckd": false,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "catheter,heart failure",
      "year": "2025",
      "organization": "Unknown"
    },
    {
      "source": "8205Oxford Handbook of Clinical Medicine 10th 2017 Edition_SamanSarKo - Copy.pdf",
      "chunk_id": 123,
      "content_type": "monitoring",
      "content_type_confidence": 3,
      "word_count": 589,
      "entity_count": 2,
      "has_ckd": false,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "creatinine,monitoring",
      "year": "2025",
      "organization": "Unknown"
    },
    {
      "source": "8205Oxford Handbook of Clinical Medicine 10th 2017 Edition_SamanSarKo - Copy.pdf",
      "chunk_id": 124,
      "content_type": "treatment",
      "content_type_confidence": 3,
      "word_count": 550,
      "entity_count": 2,
      "has_ckd": false,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "creatinine,urea",
      "year": "2025",
      "organization": "Unknown"
    },
    {
      "source": "8205Oxford Handbook of Clinical Medicine 10th 2017 Edition_SamanSarKo - Copy.pdf",
      "chunk_id": 125,
      "content_type": "treatment",
      "content_type_confidence": 3,
      "word_count": 600,
      "entity_count": 5,
      "has_ckd": false,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "renal failure,nephritis,creatinine,diet,heart failure",
      "year": "2025",
      "organization": "Unknown"
    },
    {
      "source": "8205Oxford Handbook of Clinical Medicine 10th 2017 Edition_SamanSarKo - Copy.pdf",
      "chunk_id": 127,
      "content_type": "treatment",
      "content_type_confidence": 4,
      "word_count": 593,
      "entity_count": 2,
      "has_ckd": false,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "catheter,acidosis",
      "year": "2025",
      "organization": "Unknown"
    },
    {
      "source": "8205Oxford Handbook of Clinical Medicine 10th 2017 Edition_SamanSarKo - Copy.pdf",
      "chunk_id": 128,
      "content_type": "treatment",
      "content_type_confidence": 4,
      "word_count": 592,
      "entity_count": 4,
      "has_ckd": false,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "sodium,chloride,catheter,screening",
      "year": "2025",
      "organization": "Unknown"
    },
    {
      "source": "8205Oxford Handbook of Clinical Medicine 10th 2017 Edition_SamanSarKo - Copy.pdf",
      "chunk_id": 129,
      "content_type": "dietary",
      "content_type_confidence": 3,
      "word_count": 600,
      "entity_count": 6,
      "has_ckd": false,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "potassium,calcium,iron,diuretics,neuropathy,screening",
      "year": "2025",
      "organization": "Unknown"
    },
    {
      "source": "8205Oxford Handbook of Clinical Medicine 10th 2017 Edition_SamanSarKo - Copy.pdf",
      "chunk_id": 130,
      "content_type": "evidence",
      "content_type_confidence": 3,
      "word_count": 592,
      "entity_count": 2,
      "has_ckd": false,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "parathyroid hormone,neuropathy",
      "year": "2025",
      "organization": "Unknown",
      "section": "Nonmetastatic neurological:"
    },
    {
      "source": "8205Oxford Handbook of Clinical Medicine 10th 2017 Edition_SamanSarKo - Copy.pdf",
      "chunk_id": 131,
      "content_type": "definition",
      "content_type_confidence": 2,
      "word_count": 583,
      "entity_count": 3,
      "has_ckd": false,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "edema,exercise,monitoring",
      "year": "2025",
      "organization": "Unknown"
    },
    {
      "source": "8205Oxford Handbook of Clinical Medicine 10th 2017 Edition_SamanSarKo - Copy.pdf",
      "chunk_id": 132,
      "content_type": "treatment",
      "content_type_confidence": 3,
      "word_count": 597,
      "entity_count": 2,
      "has_ckd": false,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "exercise,guideline",
      "year": "2025",
      "organization": "Unknown"
    },
    {
      "source": "8205Oxford Handbook of Clinical Medicine 10th 2017 Edition_SamanSarKo - Copy.pdf",
      "chunk_id": 133,
      "content_type": "recommendation",
      "content_type_confidence": 3,
      "word_count": 599,
      "entity_count": 2,
      "has_ckd": false,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "potassium,monitoring",
      "year": "2025",
      "organization": "Unknown"
    },
    {
      "source": "8205Oxford Handbook of Clinical Medicine 10th 2017 Edition_SamanSarKo - Copy.pdf",
      "chunk_id": 134,
      "content_type": "treatment",
      "content_type_confidence": 3,
      "word_count": 595,
      "entity_count": 4,
      "has_ckd": false,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "diet,supplements,smoking cessation,exercise",
      "year": "2025",
      "organization": "Unknown"
    },
    {
      "source": "8205Oxford Handbook of Clinical Medicine 10th 2017 Edition_SamanSarKo - Copy.pdf",
      "chunk_id": 135,
      "content_type": "recommendation",
      "content_type_confidence": 3,
      "word_count": 586,
      "entity_count": 2,
      "has_ckd": false,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "diuretics,exercise",
      "year": "2025",
      "organization": "Unknown"
    },
    {
      "source": "8205Oxford Handbook of Clinical Medicine 10th 2017 Edition_SamanSarKo - Copy.pdf",
      "chunk_id": 136,
      "content_type": "dietary",
      "content_type_confidence": 2,
      "word_count": 595,
      "entity_count": 4,
      "has_ckd": false,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "renal failure,catheter,heart failure,monitoring",
      "year": "2025",
      "organization": "Unknown",
      "section": "Causes Pulmonary:"
    },
    {
      "source": "8205Oxford Handbook of Clinical Medicine 10th 2017 Edition_SamanSarKo - Copy.pdf",
      "chunk_id": 137,
      "content_type": "recommendation",
      "content_type_confidence": 2,
      "word_count": 600,
      "entity_count": 2,
      "has_ckd": false,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "acidosis,metabolic acidosis",
      "year": "2025",
      "organization": "Unknown"
    },
    {
      "source": "8205Oxford Handbook of Clinical Medicine 10th 2017 Edition_SamanSarKo - Copy.pdf",
      "chunk_id": 138,
      "content_type": "treatment",
      "content_type_confidence": 4,
      "word_count": 586,
      "entity_count": 5,
      "has_ckd": false,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "sodium,potassium,acidosis,metabolic acidosis,heart failure",
      "year": "2025",
      "organization": "Unknown"
    },
    {
      "source": "8205Oxford Handbook of Clinical Medicine 10th 2017 Edition_SamanSarKo - Copy.pdf",
      "chunk_id": 139,
      "content_type": "reference",
      "content_type_confidence": 2,
      "word_count": 588,
      "entity_count": 2,
      "has_ckd": false,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "calcium,monitoring",
      "year": "2025",
      "organization": "Unknown"
    },
    {
      "source": "8205Oxford Handbook of Clinical Medicine 10th 2017 Edition_SamanSarKo - Copy.pdf",
      "chunk_id": 140,
      "content_type": "dietary",
      "content_type_confidence": 2,
      "word_count": 581,
      "entity_count": 1,
      "has_ckd": false,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "monitoring",
      "year": "2025",
      "organization": "Unknown"
    },
    {
      "source": "8205Oxford Handbook of Clinical Medicine 10th 2017 Edition_SamanSarKo - Copy.pdf",
      "chunk_id": 141,
      "content_type": "dietary",
      "content_type_confidence": 3,
      "word_count": 595,
      "entity_count": 6,
      "has_ckd": false,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "potassium,hemoglobin,supplements,diuretics,fatigue,heart failure",
      "year": "2025",
      "organization": "Unknown"
    },
    {
      "source": "8205Oxford Handbook of Clinical Medicine 10th 2017 Edition_SamanSarKo - Copy.pdf",
      "chunk_id": 142,
      "content_type": "dietary",
      "content_type_confidence": 3,
      "word_count": 585,
      "entity_count": 9,
      "has_ckd": false,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "potassium,supplements,heart failure,neuropathy,exercise,stage 1,stage 2,stage 3,stage 4",
      "year": "2025",
      "organization": "Unknown"
    },
    {
      "source": "8205Oxford Handbook of Clinical Medicine 10th 2017 Edition_SamanSarKo - Copy.pdf",
      "chunk_id": 143,
      "content_type": "treatment",
      "content_type_confidence": 2,
      "word_count": 598,
      "entity_count": 1,
      "has_ckd": false,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "acidosis",
      "year": "2025",
      "organization": "Unknown"
    },
    {
      "source": "8205Oxford Handbook of Clinical Medicine 10th 2017 Edition_SamanSarKo - Copy.pdf",
      "chunk_id": 144,
      "content_type": "recommendation",
      "content_type_confidence": 3,
      "word_count": 590,
      "entity_count": 1,
      "has_ckd": false,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "heart failure",
      "year": "2025",
      "organization": "Unknown"
    },
    {
      "source": "8205Oxford Handbook of Clinical Medicine 10th 2017 Edition_SamanSarKo - Copy.pdf",
      "chunk_id": 145,
      "content_type": "evidence",
      "content_type_confidence": 2,
      "word_count": 592,
      "entity_count": 2,
      "has_ckd": false,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "parathyroid hormone,neuropathy",
      "year": "2025",
      "organization": "Unknown"
    },
    {
      "source": "8205Oxford Handbook of Clinical Medicine 10th 2017 Edition_SamanSarKo - Copy.pdf",
      "chunk_id": 146,
      "content_type": "dietary",
      "content_type_confidence": 3,
      "word_count": 585,
      "entity_count": 2,
      "has_ckd": false,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "diet,exercise",
      "year": "2025",
      "organization": "Unknown"
    },
    {
      "source": "8205Oxford Handbook of Clinical Medicine 10th 2017 Edition_SamanSarKo - Copy.pdf",
      "chunk_id": 147,
      "content_type": "treatment",
      "content_type_confidence": 2,
      "word_count": 596,
      "entity_count": 5,
      "has_ckd": false,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "nephropathy,insulin,neuropathy,retinopathy,exercise",
      "year": "2025",
      "organization": "Unknown"
    },
    {
      "source": "8205Oxford Handbook of Clinical Medicine 10th 2017 Edition_SamanSarKo - Copy.pdf",
      "chunk_id": 148,
      "content_type": "treatment",
      "content_type_confidence": 4,
      "word_count": 585,
      "entity_count": 4,
      "has_ckd": false,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "hemoglobin,diet,insulin,exercise",
      "year": "2025",
      "organization": "Unknown"
    },
    {
      "source": "8205Oxford Handbook of Clinical Medicine 10th 2017 Edition_SamanSarKo - Copy.pdf",
      "chunk_id": 149,
      "content_type": "dietary",
      "content_type_confidence": 6,
      "word_count": 581,
      "entity_count": 9,
      "has_ckd": false,
      "has_gfr": true,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "glomerular filtration rate,renal function,proteinuria,hemoglobin,diet,insulin,acidosis,exercise,monitoring",
      "year": "2025",
      "organization": "Unknown"
    },
    {
      "source": "8205Oxford Handbook of Clinical Medicine 10th 2017 Edition_SamanSarKo - Copy.pdf",
      "chunk_id": 150,
      "content_type": "dietary",
      "content_type_confidence": 6,
      "word_count": 588,
      "entity_count": 5,
      "has_ckd": false,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "hemoglobin,diet,insulin,cardiovascular disease,exercise",
      "year": "2025",
      "organization": "Unknown",
      "section": "Sulfonylurea:"
    },
    {
      "source": "8205Oxford Handbook of Clinical Medicine 10th 2017 Edition_SamanSarKo - Copy.pdf",
      "chunk_id": 151,
      "content_type": "recommendation",
      "content_type_confidence": 4,
      "word_count": 599,
      "entity_count": 9,
      "has_ckd": false,
      "has_gfr": true,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "glomerular filtration rate,nephropathy,creatinine,hemoglobin,insulin,retinopathy,smoking cessation,blood pressure control,screening",
      "year": "2025",
      "organization": "Unknown"
    },
    {
      "source": "8205Oxford Handbook of Clinical Medicine 10th 2017 Edition_SamanSarKo - Copy.pdf",
      "chunk_id": 152,
      "content_type": "treatment",
      "content_type_confidence": 3,
      "word_count": 593,
      "entity_count": 9,
      "has_ckd": false,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "albuminuria,calcium,diet,edema,cardiovascular disease,neuropathy,retinopathy,quality of life,monitoring",
      "year": "2025",
      "organization": "Unknown",
      "section": "Cataracts:"
    },
    {
      "source": "8205Oxford Handbook of Clinical Medicine 10th 2017 Edition_SamanSarKo - Copy.pdf",
      "chunk_id": 153,
      "content_type": "dietary",
      "content_type_confidence": 2,
      "word_count": 595,
      "entity_count": 6,
      "has_ckd": false,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "phosphate,insulin,edema,fatigue,neuropathy,quality of life",
      "year": "2025",
      "organization": "Unknown"
    },
    {
      "source": "8205Oxford Handbook of Clinical Medicine 10th 2017 Edition_SamanSarKo - Copy.pdf",
      "chunk_id": 154,
      "content_type": "dietary",
      "content_type_confidence": 3,
      "word_count": 593,
      "entity_count": 3,
      "has_ckd": false,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "nephropathy,insulin,retinopathy",
      "year": "2025",
      "organization": "Unknown"
    },
    {
      "source": "8205Oxford Handbook of Clinical Medicine 10th 2017 Edition_SamanSarKo - Copy.pdf",
      "chunk_id": 155,
      "content_type": "treatment",
      "content_type_confidence": 4,
      "word_count": 594,
      "entity_count": 5,
      "has_ckd": false,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "calcium,diet,insulin,exercise,screening",
      "year": "2025",
      "organization": "Unknown"
    },
    {
      "source": "8205Oxford Handbook of Clinical Medicine 10th 2017 Edition_SamanSarKo - Copy.pdf",
      "chunk_id": 156,
      "content_type": "treatment",
      "content_type_confidence": 3,
      "word_count": 579,
      "entity_count": 2,
      "has_ckd": false,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "malnutrition,monitoring",
      "year": "2025",
      "organization": "Unknown"
    },
    {
      "source": "8205Oxford Handbook of Clinical Medicine 10th 2017 Edition_SamanSarKo - Copy.pdf",
      "chunk_id": 157,
      "content_type": "dietary",
      "content_type_confidence": 2,
      "word_count": 595,
      "entity_count": 1,
      "has_ckd": false,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "edema",
      "year": "2025",
      "organization": "Unknown"
    },
    {
      "source": "8205Oxford Handbook of Clinical Medicine 10th 2017 Edition_SamanSarKo - Copy.pdf",
      "chunk_id": 158,
      "content_type": "treatment",
      "content_type_confidence": 5,
      "word_count": 590,
      "entity_count": 2,
      "has_ckd": false,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "edema,heart failure",
      "year": "2025",
      "organization": "Unknown"
    },
    {
      "source": "8205Oxford Handbook of Clinical Medicine 10th 2017 Edition_SamanSarKo - Copy.pdf",
      "chunk_id": 159,
      "content_type": "dietary",
      "content_type_confidence": 3,
      "word_count": 596,
      "entity_count": 3,
      "has_ckd": false,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "sodium,potassium,neuropathy",
      "year": "2025",
      "organization": "Unknown"
    },
    {
      "source": "8205Oxford Handbook of Clinical Medicine 10th 2017 Edition_SamanSarKo - Copy.pdf",
      "chunk_id": 161,
      "content_type": "monitoring",
      "content_type_confidence": 3,
      "word_count": 591,
      "entity_count": 8,
      "has_ckd": false,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "renal function,renal failure,phosphate,parathyroid hormone,vitamin D,phosphate binders,thiazides,bone disease",
      "year": "2025",
      "organization": "Unknown"
    },
    {
      "source": "8205Oxford Handbook of Clinical Medicine 10th 2017 Edition_SamanSarKo - Copy.pdf",
      "chunk_id": 162,
      "content_type": "dietary",
      "content_type_confidence": 4,
      "word_count": 579,
      "entity_count": 7,
      "has_ckd": false,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "sodium,potassium,phosphate,magnesium,parathyroid hormone,calcitriol,supplements",
      "year": "2025",
      "organization": "Unknown"
    },
    {
      "source": "8205Oxford Handbook of Clinical Medicine 10th 2017 Edition_SamanSarKo - Copy.pdf",
      "chunk_id": 163,
      "content_type": "treatment",
      "content_type_confidence": 5,
      "word_count": 595,
      "entity_count": 2,
      "has_ckd": false,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "renal failure,follow up",
      "year": "2025",
      "organization": "Unknown"
    },
    {
      "source": "8205Oxford Handbook of Clinical Medicine 10th 2017 Edition_SamanSarKo - Copy.pdf",
      "chunk_id": 164,
      "content_type": "reference",
      "content_type_confidence": 2,
      "word_count": 596,
      "entity_count": 1,
      "has_ckd": false,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "potassium",
      "year": "2025",
      "organization": "Unknown"
    },
    {
      "source": "8205Oxford Handbook of Clinical Medicine 10th 2017 Edition_SamanSarKo - Copy.pdf",
      "chunk_id": 165,
      "content_type": "dietary",
      "content_type_confidence": 3,
      "word_count": 592,
      "entity_count": 3,
      "has_ckd": false,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "sodium,potassium,exercise",
      "year": "2025",
      "organization": "Unknown"
    },
    {
      "source": "8205Oxford Handbook of Clinical Medicine 10th 2017 Edition_SamanSarKo - Copy.pdf",
      "chunk_id": 166,
      "content_type": "dietary",
      "content_type_confidence": 3,
      "word_count": 587,
      "entity_count": 5,
      "has_ckd": false,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "sodium,potassium,chloride,diuretics,screening",
      "year": "2025",
      "organization": "Unknown"
    },
    {
      "source": "8205Oxford Handbook of Clinical Medicine 10th 2017 Edition_SamanSarKo - Copy.pdf",
      "chunk_id": 167,
      "content_type": "treatment",
      "content_type_confidence": 3,
      "word_count": 579,
      "entity_count": 6,
      "has_ckd": false,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "potassium,antihypertensive,edema,heart failure,exercise,screening",
      "year": "2025",
      "organization": "Unknown"
    },
    {
      "source": "8205Oxford Handbook of Clinical Medicine 10th 2017 Edition_SamanSarKo - Copy.pdf",
      "chunk_id": 168,
      "content_type": "treatment",
      "content_type_confidence": 7,
      "word_count": 574,
      "entity_count": 4,
      "has_ckd": false,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "diuretics,insulin,antihypertensive,neuropathy",
      "year": "2025",
      "organization": "Unknown"
    },
    {
      "source": "8205Oxford Handbook of Clinical Medicine 10th 2017 Edition_SamanSarKo - Copy.pdf",
      "chunk_id": 170,
      "content_type": "treatment",
      "content_type_confidence": 2,
      "word_count": 587,
      "entity_count": 3,
      "has_ckd": false,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "acute kidney injury,exercise,monitoring",
      "year": "2025",
      "organization": "Unknown"
    },
    {
      "source": "8205Oxford Handbook of Clinical Medicine 10th 2017 Edition_SamanSarKo - Copy.pdf",
      "chunk_id": 171,
      "content_type": "monitoring",
      "content_type_confidence": 3,
      "word_count": 590,
      "entity_count": 1,
      "has_ckd": false,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "screening",
      "year": "2025",
      "organization": "Unknown"
    },
    {
      "source": "8205Oxford Handbook of Clinical Medicine 10th 2017 Edition_SamanSarKo - Copy.pdf",
      "chunk_id": 172,
      "content_type": "treatment",
      "content_type_confidence": 3,
      "word_count": 600,
      "entity_count": 1,
      "has_ckd": false,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "renal failure",
      "year": "2025",
      "organization": "Unknown"
    },
    {
      "source": "8205Oxford Handbook of Clinical Medicine 10th 2017 Edition_SamanSarKo - Copy.pdf",
      "chunk_id": 173,
      "content_type": "recommendation",
      "content_type_confidence": 2,
      "word_count": 599,
      "entity_count": 2,
      "has_ckd": false,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "phosphate,insulin",
      "year": "2025",
      "organization": "Unknown"
    },
    {
      "source": "8205Oxford Handbook of Clinical Medicine 10th 2017 Edition_SamanSarKo - Copy.pdf",
      "chunk_id": 175,
      "content_type": "treatment",
      "content_type_confidence": 4,
      "word_count": 598,
      "entity_count": 5,
      "has_ckd": false,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "urea,sodium,potassium,calcium,diuretics",
      "year": "2025",
      "organization": "Unknown"
    },
    {
      "source": "8205Oxford Handbook of Clinical Medicine 10th 2017 Edition_SamanSarKo - Copy.pdf",
      "chunk_id": 176,
      "content_type": "dietary",
      "content_type_confidence": 5,
      "word_count": 545,
      "entity_count": 3,
      "has_ckd": false,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "sodium,stage 1,stage 2",
      "year": "2025",
      "organization": "Unknown"
    },
    {
      "source": "8205Oxford Handbook of Clinical Medicine 10th 2017 Edition_SamanSarKo - Copy.pdf",
      "chunk_id": 178,
      "content_type": "dietary",
      "content_type_confidence": 8,
      "word_count": 564,
      "entity_count": 4,
      "has_ckd": false,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "renal failure,vitamin D,diet,supplements",
      "year": "2025",
      "organization": "Unknown"
    },
    {
      "source": "8205Oxford Handbook of Clinical Medicine 10th 2017 Edition_SamanSarKo - Copy.pdf",
      "chunk_id": 179,
      "content_type": "dietary",
      "content_type_confidence": 3,
      "word_count": 594,
      "entity_count": 2,
      "has_ckd": false,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "diet,exercise",
      "year": "2025",
      "organization": "Unknown"
    },
    {
      "source": "8205Oxford Handbook of Clinical Medicine 10th 2017 Edition_SamanSarKo - Copy.pdf",
      "chunk_id": 180,
      "content_type": "treatment",
      "content_type_confidence": 4,
      "word_count": 595,
      "entity_count": 2,
      "has_ckd": false,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "iron,diuretics",
      "year": "2025",
      "organization": "Unknown",
      "section": "Risk factors:"
    },
    {
      "source": "8205Oxford Handbook of Clinical Medicine 10th 2017 Edition_SamanSarKo - Copy.pdf",
      "chunk_id": 181,
      "content_type": "monitoring",
      "content_type_confidence": 3,
      "word_count": 597,
      "entity_count": 3,
      "has_ckd": false,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "phosphate,iron,diet",
      "year": "2025",
      "organization": "Unknown",
      "section": "2. Pre"
    },
    {
      "source": "8205Oxford Handbook of Clinical Medicine 10th 2017 Edition_SamanSarKo - Copy.pdf",
      "chunk_id": 183,
      "content_type": "treatment",
      "content_type_confidence": 4,
      "word_count": 600,
      "entity_count": 3,
      "has_ckd": false,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "potassium,calcium,bicarbonate",
      "year": "2025",
      "organization": "Unknown",
      "section": "Treatment:"
    },
    {
      "source": "8205Oxford Handbook of Clinical Medicine 10th 2017 Edition_SamanSarKo - Copy.pdf",
      "chunk_id": 184,
      "content_type": "treatment",
      "content_type_confidence": 4,
      "word_count": 591,
      "entity_count": 2,
      "has_ckd": false,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "bicarbonate,iron",
      "year": "2025",
      "organization": "Unknown"
    },
    {
      "source": "8205Oxford Handbook of Clinical Medicine 10th 2017 Edition_SamanSarKo - Copy.pdf",
      "chunk_id": 185,
      "content_type": "treatment",
      "content_type_confidence": 3,
      "word_count": 593,
      "entity_count": 2,
      "has_ckd": false,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "urea,iron",
      "year": "2025",
      "organization": "Unknown",
      "section": "Surgery:"
    },
    {
      "source": "8205Oxford Handbook of Clinical Medicine 10th 2017 Edition_SamanSarKo - Copy.pdf",
      "chunk_id": 186,
      "content_type": "dietary",
      "content_type_confidence": 4,
      "word_count": 566,
      "entity_count": 4,
      "has_ckd": false,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "potassium,magnesium,smoking cessation,monitoring",
      "year": "2025",
      "organization": "Unknown"
    },
    {
      "source": "8205Oxford Handbook of Clinical Medicine 10th 2017 Edition_SamanSarKo - Copy.pdf",
      "chunk_id": 187,
      "content_type": "reference",
      "content_type_confidence": 2,
      "word_count": 546,
      "entity_count": 6,
      "has_ckd": false,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "creatinine,urea,potassium,hemoglobin,catheter,cardiovascular disease",
      "year": "2025",
      "organization": "Unknown"
    },
    {
      "source": "8205Oxford Handbook of Clinical Medicine 10th 2017 Edition_SamanSarKo - Copy.pdf",
      "chunk_id": 188,
      "content_type": "definition",
      "content_type_confidence": 1,
      "word_count": 592,
      "entity_count": 5,
      "has_ckd": false,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "renal failure,urea,hemoglobin,diet,heart failure",
      "year": "2025",
      "organization": "Unknown"
    },
    {
      "source": "8205Oxford Handbook of Clinical Medicine 10th 2017 Edition_SamanSarKo - Copy.pdf",
      "chunk_id": 189,
      "content_type": "dietary",
      "content_type_confidence": 3,
      "word_count": 587,
      "entity_count": 6,
      "has_ckd": false,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "creatinine,potassium,calcium,phosphate,acidosis,neuropathy",
      "year": "2025",
      "organization": "Unknown"
    },
    {
      "source": "8205Oxford Handbook of Clinical Medicine 10th 2017 Edition_SamanSarKo - Copy.pdf",
      "chunk_id": 190,
      "content_type": "dietary",
      "content_type_confidence": 2,
      "word_count": 586,
      "entity_count": 6,
      "has_ckd": false,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "creatinine,calcium,iron,diet,exercise,screening",
      "year": "2025",
      "organization": "Unknown"
    },
    {
      "source": "8205Oxford Handbook of Clinical Medicine 10th 2017 Edition_SamanSarKo - Copy.pdf",
      "chunk_id": 191,
      "content_type": "dietary",
      "content_type_confidence": 5,
      "word_count": 553,
      "entity_count": 10,
      "has_ckd": false,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "sodium,calcium,phosphate,magnesium,chloride,iron,diet,diuretics,neuropathy,exercise",
      "year": "2025",
      "organization": "Unknown",
      "section": "Bulking agents:"
    },
    {
      "source": "8205Oxford Handbook of Clinical Medicine 10th 2017 Edition_SamanSarKo - Copy.pdf",
      "chunk_id": 193,
      "content_type": "treatment",
      "content_type_confidence": 3,
      "word_count": 599,
      "entity_count": 3,
      "has_ckd": false,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "nephritis,potassium,hemoglobin",
      "year": "2025",
      "organization": "Unknown",
      "section": "Tests Blood:"
    },
    {
      "source": "8205Oxford Handbook of Clinical Medicine 10th 2017 Edition_SamanSarKo - Copy.pdf",
      "chunk_id": 194,
      "content_type": "definition",
      "content_type_confidence": 2,
      "word_count": 590,
      "entity_count": 4,
      "has_ckd": false,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "ferritin,nutrition,malnutrition,fatigue",
      "year": "2025",
      "organization": "Unknown"
    },
    {
      "source": "8205Oxford Handbook of Clinical Medicine 10th 2017 Edition_SamanSarKo - Copy.pdf",
      "chunk_id": 195,
      "content_type": "treatment",
      "content_type_confidence": 3,
      "word_count": 598,
      "entity_count": 3,
      "has_ckd": false,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "hemoglobin,nutrition,diet",
      "year": "2025",
      "organization": "Unknown",
      "section": "Assess severity:"
    },
    {
      "source": "8205Oxford Handbook of Clinical Medicine 10th 2017 Edition_SamanSarKo - Copy.pdf",
      "chunk_id": 196,
      "content_type": "dietary",
      "content_type_confidence": 4,
      "word_count": 598,
      "entity_count": 9,
      "has_ckd": false,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "potassium,hemoglobin,vitamin D,iron,ferritin,diet,bone disease,fatigue,neuropathy",
      "year": "2025",
      "organization": "Unknown"
    },
    {
      "source": "8205Oxford Handbook of Clinical Medicine 10th 2017 Edition_SamanSarKo - Copy.pdf",
      "chunk_id": 197,
      "content_type": "treatment",
      "content_type_confidence": 3,
      "word_count": 577,
      "entity_count": 5,
      "has_ckd": false,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "calcium,diet,fatigue,neuropathy,physical activity",
      "year": "2025",
      "organization": "Unknown",
      "section": "Other features:"
    },
    {
      "source": "8205Oxford Handbook of Clinical Medicine 10th 2017 Edition_SamanSarKo - Copy.pdf",
      "chunk_id": 198,
      "content_type": "dietary",
      "content_type_confidence": 4,
      "word_count": 593,
      "entity_count": 7,
      "has_ckd": false,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "calcium,phosphate,magnesium,iron,diet,heart failure,neuropathy",
      "year": "2025",
      "organization": "Unknown",
      "section": "Causes:"
    },
    {
      "source": "8205Oxford Handbook of Clinical Medicine 10th 2017 Edition_SamanSarKo - Copy.pdf",
      "chunk_id": 199,
      "content_type": "dietary",
      "content_type_confidence": 3,
      "word_count": 598,
      "entity_count": 2,
      "has_ckd": false,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "diet,insulin",
      "year": "2025",
      "organization": "Unknown"
    },
    {
      "source": "8205Oxford Handbook of Clinical Medicine 10th 2017 Edition_SamanSarKo - Copy.pdf",
      "chunk_id": 200,
      "content_type": "treatment",
      "content_type_confidence": 4,
      "word_count": 596,
      "entity_count": 3,
      "has_ckd": false,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "calcium,diet,insulin",
      "year": "2025",
      "organization": "Unknown",
      "section": "Signs:"
    },
    {
      "source": "8205Oxford Handbook of Clinical Medicine 10th 2017 Edition_SamanSarKo - Copy.pdf",
      "chunk_id": 201,
      "content_type": "treatment",
      "content_type_confidence": 3,
      "word_count": 596,
      "entity_count": 3,
      "has_ckd": false,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "pruritus,heart failure,screening",
      "year": "2025",
      "organization": "Unknown"
    },
    {
      "source": "8205Oxford Handbook of Clinical Medicine 10th 2017 Edition_SamanSarKo - Copy.pdf",
      "chunk_id": 202,
      "content_type": "treatment",
      "content_type_confidence": 3,
      "word_count": 584,
      "entity_count": 2,
      "has_ckd": false,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "sodium,statins",
      "year": "2025",
      "organization": "Unknown",
      "section": "Liver biopsy:"
    },
    {
      "source": "8205Oxford Handbook of Clinical Medicine 10th 2017 Edition_SamanSarKo - Copy.pdf",
      "chunk_id": 203,
      "content_type": "dietary",
      "content_type_confidence": 4,
      "word_count": 587,
      "entity_count": 10,
      "has_ckd": false,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "renal function,renal failure,creatinine,urea,potassium,ferritin,nutrition,diet,supplements,diuretics",
      "year": "2025",
      "organization": "Unknown",
      "section": "Toxins:"
    },
    {
      "source": "8205Oxford Handbook of Clinical Medicine 10th 2017 Edition_SamanSarKo - Copy.pdf",
      "chunk_id": 204,
      "content_type": "recommendation",
      "content_type_confidence": 1,
      "word_count": 581,
      "entity_count": 6,
      "has_ckd": false,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": true,
      "medical_entities": "renal function,renal failure,creatinine,iron,ferritin,dialysis",
      "year": "2025",
      "organization": "Unknown"
    },
    {
      "source": "8205Oxford Handbook of Clinical Medicine 10th 2017 Edition_SamanSarKo - Copy.pdf",
      "chunk_id": 205,
      "content_type": "dietary",
      "content_type_confidence": 7,
      "word_count": 600,
      "entity_count": 7,
      "has_ckd": false,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "renal failure,nephropathy,sodium,nutrition,diet,fluid restriction,pruritus",
      "year": "2025",
      "organization": "Unknown",
      "section": "Ascitic tap:"
    },
    {
      "source": "8205Oxford Handbook of Clinical Medicine 10th 2017 Edition_SamanSarKo - Copy.pdf",
      "chunk_id": 206,
      "content_type": "definition",
      "content_type_confidence": 2,
      "word_count": 594,
      "entity_count": 5,
      "has_ckd": false,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "renal failure,nephropathy,creatinine,sodium,monitoring",
      "year": "2025",
      "organization": "Unknown"
    },
    {
      "source": "8205Oxford Handbook of Clinical Medicine 10th 2017 Edition_SamanSarKo - Copy.pdf",
      "chunk_id": 207,
      "content_type": "recommendation",
      "content_type_confidence": 3,
      "word_count": 592,
      "entity_count": 1,
      "has_ckd": false,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "creatinine",
      "year": "2025",
      "organization": "Unknown"
    },
    {
      "source": "8205Oxford Handbook of Clinical Medicine 10th 2017 Edition_SamanSarKo - Copy.pdf",
      "chunk_id": 208,
      "content_type": "recommendation",
      "content_type_confidence": 3,
      "word_count": 593,
      "entity_count": 2,
      "has_ckd": false,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "creatinine,neuropathy",
      "year": "2025",
      "organization": "Unknown"
    },
    {
      "source": "8205Oxford Handbook of Clinical Medicine 10th 2017 Edition_SamanSarKo - Copy.pdf",
      "chunk_id": 209,
      "content_type": "dietary",
      "content_type_confidence": 7,
      "word_count": 589,
      "entity_count": 8,
      "has_ckd": false,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "creatinine,urea,sodium,potassium,nutrition,catheter,screening,monitoring",
      "year": "2025",
      "organization": "Unknown"
    },
    {
      "source": "8205Oxford Handbook of Clinical Medicine 10th 2017 Edition_SamanSarKo - Copy.pdf",
      "chunk_id": 210,
      "content_type": "treatment",
      "content_type_confidence": 4,
      "word_count": 576,
      "entity_count": 6,
      "has_ckd": false,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "potassium,phosphate,diuretics,pruritus,fatigue,monitoring",
      "year": "2025",
      "organization": "Unknown"
    },
    {
      "source": "8205Oxford Handbook of Clinical Medicine 10th 2017 Edition_SamanSarKo - Copy.pdf",
      "chunk_id": 213,
      "content_type": "dietary",
      "content_type_confidence": 4,
      "word_count": 591,
      "entity_count": 3,
      "has_ckd": false,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "hemoglobin,diet,fatigue",
      "year": "2025",
      "organization": "Unknown",
      "section": "Also:"
    },
    {
      "source": "8205Oxford Handbook of Clinical Medicine 10th 2017 Edition_SamanSarKo - Copy.pdf",
      "chunk_id": 214,
      "content_type": "treatment",
      "content_type_confidence": 2,
      "word_count": 577,
      "entity_count": 2,
      "has_ckd": false,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "quality of life,screening",
      "year": "2025",
      "organization": "Unknown"
    },
    {
      "source": "8205Oxford Handbook of Clinical Medicine 10th 2017 Edition_SamanSarKo - Copy.pdf",
      "chunk_id": 215,
      "content_type": "monitoring",
      "content_type_confidence": 3,
      "word_count": 597,
      "entity_count": 6,
      "has_ckd": false,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "hemoglobin,iron,ferritin,transferrin saturation,diet,screening",
      "year": "2025",
      "organization": "Unknown"
    },
    {
      "source": "8205Oxford Handbook of Clinical Medicine 10th 2017 Edition_SamanSarKo - Copy.pdf",
      "chunk_id": 216,
      "content_type": "dietary",
      "content_type_confidence": 3,
      "word_count": 578,
      "entity_count": 4,
      "has_ckd": false,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "iron,transferrin saturation,erythropoietin,screening",
      "year": "2025",
      "organization": "Unknown"
    },
    {
      "source": "8205Oxford Handbook of Clinical Medicine 10th 2017 Edition_SamanSarKo - Copy.pdf",
      "chunk_id": 218,
      "content_type": "treatment",
      "content_type_confidence": 3,
      "word_count": 579,
      "entity_count": 10,
      "has_ckd": true,
      "has_gfr": true,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "chronic kidney disease,acute kidney injury,glomerular filtration rate,renal function,nephropathy,proteinuria,creatinine,urea,magnesium,serum creatinine",
      "year": "2025",
      "organization": "Unknown"
    },
    {
      "source": "8205Oxford Handbook of Clinical Medicine 10th 2017 Edition_SamanSarKo - Copy.pdf",
      "chunk_id": 219,
      "content_type": "dietary",
      "content_type_confidence": 3,
      "word_count": 596,
      "entity_count": 10,
      "has_ckd": true,
      "has_gfr": true,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "chronic kidney disease,acute kidney injury,glomerular filtration rate,renal function,proteinuria,creatinine,sodium,potassium,magnesium,catheter",
      "year": "2025",
      "organization": "Unknown"
    },
    {
      "source": "8205Oxford Handbook of Clinical Medicine 10th 2017 Edition_SamanSarKo - Copy.pdf",
      "chunk_id": 220,
      "content_type": "recommendation",
      "content_type_confidence": 3,
      "word_count": 596,
      "entity_count": 10,
      "has_ckd": true,
      "has_gfr": true,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "chronic kidney disease,glomerular filtration rate,nephropathy,nephritis,albuminuria,proteinuria,creatinine,calcium,uric acid,diet",
      "year": "2025",
      "organization": "Unknown"
    },
    {
      "source": "8205Oxford Handbook of Clinical Medicine 10th 2017 Edition_SamanSarKo - Copy.pdf",
      "chunk_id": 221,
      "content_type": "reference",
      "content_type_confidence": 2,
      "word_count": 597,
      "entity_count": 3,
      "has_ckd": false,
      "has_gfr": true,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "glomerular filtration rate,nephritis,catheter",
      "year": "2025",
      "organization": "Unknown"
    },
    {
      "source": "8205Oxford Handbook of Clinical Medicine 10th 2017 Edition_SamanSarKo - Copy.pdf",
      "chunk_id": 222,
      "content_type": "recommendation",
      "content_type_confidence": 3,
      "word_count": 599,
      "entity_count": 7,
      "has_ckd": false,
      "has_gfr": true,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "acute kidney injury,glomerular filtration rate,renal function,nephritis,creatinine,serum creatinine,catheter",
      "year": "2025",
      "organization": "Unknown"
    },
    {
      "source": "8205Oxford Handbook of Clinical Medicine 10th 2017 Edition_SamanSarKo - Copy.pdf",
      "chunk_id": 223,
      "content_type": "treatment",
      "content_type_confidence": 7,
      "word_count": 585,
      "entity_count": 10,
      "has_ckd": true,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": true,
      "medical_entities": "chronic kidney disease,acute kidney injury,proteinuria,creatinine,potassium,serum creatinine,diuretics,dialysis,catheter,acidosis",
      "year": "2025",
      "organization": "Unknown"
    },
    {
      "source": "8205Oxford Handbook of Clinical Medicine 10th 2017 Edition_SamanSarKo - Copy.pdf",
      "chunk_id": 224,
      "content_type": "dietary",
      "content_type_confidence": 6,
      "word_count": 594,
      "entity_count": 10,
      "has_ckd": false,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "acute kidney injury,creatinine,sodium,potassium,chloride,bicarbonate,hemoglobin,fluid restriction,diuretics,sodium bicarbonate",
      "year": "2025",
      "organization": "Unknown"
    },
    {
      "source": "8205Oxford Handbook of Clinical Medicine 10th 2017 Edition_SamanSarKo - Copy.pdf",
      "chunk_id": 225,
      "content_type": "treatment",
      "content_type_confidence": 5,
      "word_count": 553,
      "entity_count": 10,
      "has_ckd": true,
      "has_gfr": true,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "chronic kidney disease,acute kidney injury,glomerular filtration rate,albuminuria,sodium,potassium,calcium,chloride,bicarbonate,nutrition",
      "year": "2025",
      "organization": "Unknown"
    },
    {
      "source": "8205Oxford Handbook of Clinical Medicine 10th 2017 Edition_SamanSarKo - Copy.pdf",
      "chunk_id": 226,
      "content_type": "treatment",
      "content_type_confidence": 4,
      "word_count": 591,
      "entity_count": 10,
      "has_ckd": true,
      "has_gfr": true,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "chronic kidney disease,acute kidney injury,glomerular filtration rate,renal function,nephropathy,albuminuria,proteinuria,creatinine,phosphate,hemoglobin",
      "year": "2025",
      "organization": "Unknown",
      "section": "Examination Periphery:"
    },
    {
      "source": "8205Oxford Handbook of Clinical Medicine 10th 2017 Edition_SamanSarKo - Copy.pdf",
      "chunk_id": 227,
      "content_type": "dietary",
      "content_type_confidence": 6,
      "word_count": 566,
      "entity_count": 10,
      "has_ckd": true,
      "has_gfr": true,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "chronic kidney disease,glomerular filtration rate,renal function,creatinine,sodium,potassium,calcium,phosphate,chloride,bicarbonate",
      "year": "2025",
      "organization": "Unknown",
      "section": "Treatment to slow renal disease progression blood pressure:"
    },
    {
      "source": "8205Oxford Handbook of Clinical Medicine 10th 2017 Edition_SamanSarKo - Copy.pdf",
      "chunk_id": 228,
      "content_type": "dietary",
      "content_type_confidence": 6,
      "word_count": 588,
      "entity_count": 10,
      "has_ckd": true,
      "has_gfr": true,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "chronic kidney disease,glomerular filtration rate,renal function,renal failure,kidney failure,creatinine,cystatin C,potassium,phosphate,diet",
      "year": "2025",
      "organization": "Unknown",
      "section": "Diet:"
    },
    {
      "source": "8205Oxford Handbook of Clinical Medicine 10th 2017 Edition_SamanSarKo - Copy.pdf",
      "chunk_id": 229,
      "content_type": "dietary",
      "content_type_confidence": 5,
      "word_count": 597,
      "entity_count": 10,
      "has_ckd": false,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": true,
      "medical_entities": "renal function,potassium,calcium,phosphate,malnutrition,insulin,dialysis,hemodialysis,peritoneal dialysis,catheter",
      "year": "2025",
      "organization": "Unknown"
    },
    {
      "source": "8205Oxford Handbook of Clinical Medicine 10th 2017 Edition_SamanSarKo - Copy.pdf",
      "chunk_id": 230,
      "content_type": "treatment",
      "content_type_confidence": 2,
      "word_count": 597,
      "entity_count": 7,
      "has_ckd": false,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": true,
      "medical_entities": "kidney failure,potassium,dialysis,peritoneal dialysis,catheter,cardiovascular disease,heart failure",
      "year": "2025",
      "organization": "Unknown"
    },
    {
      "source": "8205Oxford Handbook of Clinical Medicine 10th 2017 Edition_SamanSarKo - Copy.pdf",
      "chunk_id": 231,
      "content_type": "evidence",
      "content_type_confidence": 2,
      "word_count": 579,
      "entity_count": 6,
      "has_ckd": true,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": true,
      "medical_entities": "chronic kidney disease,renal function,dialysis,cardiovascular disease,heart failure,monitoring",
      "year": "2025",
      "organization": "Unknown",
      "section": "Temporary:"
    },
    {
      "source": "8205Oxford Handbook of Clinical Medicine 10th 2017 Edition_SamanSarKo - Copy.pdf",
      "chunk_id": 232,
      "content_type": "treatment",
      "content_type_confidence": 4,
      "word_count": 598,
      "entity_count": 10,
      "has_ckd": true,
      "has_gfr": true,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": true,
      "medical_entities": "chronic kidney disease,acute kidney injury,glomerular filtration rate,renal function,kidney failure,nephritis,proteinuria,creatinine,insulin,dialysis",
      "year": "2025",
      "organization": "Unknown"
    },
    {
      "source": "8205Oxford Handbook of Clinical Medicine 10th 2017 Edition_SamanSarKo - Copy.pdf",
      "chunk_id": 233,
      "content_type": "evidence",
      "content_type_confidence": 2,
      "word_count": 587,
      "entity_count": 10,
      "has_ckd": true,
      "has_gfr": true,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": true,
      "medical_entities": "chronic kidney disease,acute kidney injury,glomerular filtration rate,renal function,renal failure,nephropathy,nephritis,proteinuria,creatinine,dialysis",
      "year": "2025",
      "organization": "Unknown"
    },
    {
      "source": "8205Oxford Handbook of Clinical Medicine 10th 2017 Edition_SamanSarKo - Copy.pdf",
      "chunk_id": 234,
      "content_type": "dietary",
      "content_type_confidence": 3,
      "word_count": 597,
      "entity_count": 8,
      "has_ckd": false,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "acute kidney injury,renal failure,nephropathy,nephritis,proteinuria,creatinine,diuretics,loop diuretics",
      "year": "2025",
      "organization": "Unknown",
      "section": "Diagnosis:"
    },
    {
      "source": "8205Oxford Handbook of Clinical Medicine 10th 2017 Edition_SamanSarKo - Copy.pdf",
      "chunk_id": 235,
      "content_type": "dietary",
      "content_type_confidence": 2,
      "word_count": 592,
      "entity_count": 8,
      "has_ckd": true,
      "has_gfr": true,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "chronic kidney disease,glomerular filtration rate,renal failure,kidney failure,nephropathy,proteinuria,creatinine,statins",
      "year": "2025",
      "organization": "Unknown"
    },
    {
      "source": "8205Oxford Handbook of Clinical Medicine 10th 2017 Edition_SamanSarKo - Copy.pdf",
      "chunk_id": 236,
      "content_type": "dietary",
      "content_type_confidence": 4,
      "word_count": 578,
      "entity_count": 10,
      "has_ckd": false,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "renal function,renal failure,kidney failure,nephropathy,nephritis,albuminuria,creatinine,sodium,potassium,chloride",
      "year": "2025",
      "organization": "Unknown",
      "section": "Treatment:"
    },
    {
      "source": "8205Oxford Handbook of Clinical Medicine 10th 2017 Edition_SamanSarKo - Copy.pdf",
      "chunk_id": 237,
      "content_type": "treatment",
      "content_type_confidence": 2,
      "word_count": 593,
      "entity_count": 8,
      "has_ckd": false,
      "has_gfr": true,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "acute kidney injury,glomerular filtration rate,renal function,renal failure,proteinuria,hemoglobin,antihypertensive,heart failure",
      "year": "2025",
      "organization": "Unknown"
    },
    {
      "source": "8205Oxford Handbook of Clinical Medicine 10th 2017 Edition_SamanSarKo - Copy.pdf",
      "chunk_id": 238,
      "content_type": "treatment",
      "content_type_confidence": 4,
      "word_count": 579,
      "entity_count": 10,
      "has_ckd": true,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "chronic kidney disease,acute kidney injury,renal function,renal failure,nephropathy,nephron,albuminuria,proteinuria,creatinine,sodium",
      "year": "2025",
      "organization": "Unknown",
      "section": "Biopsy:"
    },
    {
      "source": "8205Oxford Handbook of Clinical Medicine 10th 2017 Edition_SamanSarKo - Copy.pdf",
      "chunk_id": 239,
      "content_type": "treatment",
      "content_type_confidence": 5,
      "word_count": 597,
      "entity_count": 10,
      "has_ckd": true,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "chronic kidney disease,acute kidney injury,nephropathy,nephritis,sodium,potassium,calcium,bicarbonate,uric acid,diuretics",
      "year": "2025",
      "organization": "Unknown"
    },
    {
      "source": "8205Oxford Handbook of Clinical Medicine 10th 2017 Edition_SamanSarKo - Copy.pdf",
      "chunk_id": 240,
      "content_type": "treatment",
      "content_type_confidence": 5,
      "word_count": 600,
      "entity_count": 10,
      "has_ckd": true,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "chronic kidney disease,acute kidney injury,nephropathy,nephritis,proteinuria,sodium,potassium,phosphate,chloride,bicarbonate",
      "year": "2025",
      "organization": "Unknown"
    },
    {
      "source": "8205Oxford Handbook of Clinical Medicine 10th 2017 Edition_SamanSarKo - Copy.pdf",
      "chunk_id": 241,
      "content_type": "evidence",
      "content_type_confidence": 3,
      "word_count": 590,
      "entity_count": 10,
      "has_ckd": true,
      "has_gfr": true,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "chronic kidney disease,glomerular filtration rate,renal failure,nephropathy,nephritis,proteinuria,calcium,phosphate,uric acid,diet",
      "year": "2025",
      "organization": "Unknown"
    },
    {
      "source": "8205Oxford Handbook of Clinical Medicine 10th 2017 Edition_SamanSarKo - Copy.pdf",
      "chunk_id": 242,
      "content_type": "treatment",
      "content_type_confidence": 3,
      "word_count": 579,
      "entity_count": 7,
      "has_ckd": false,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "kidney function,renal failure,kidney failure,proteinuria,iron,diet,screening",
      "year": "2025",
      "organization": "Unknown"
    },
    {
      "source": "8205Oxford Handbook of Clinical Medicine 10th 2017 Edition_SamanSarKo - Copy.pdf",
      "chunk_id": 244,
      "content_type": "treatment",
      "content_type_confidence": 2,
      "word_count": 583,
      "entity_count": 7,
      "has_ckd": false,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "renal failure,potassium,hemoglobin,iron,ferritin,fatigue,heart failure",
      "year": "2025",
      "organization": "Unknown"
    },
    {
      "source": "8205Oxford Handbook of Clinical Medicine 10th 2017 Edition_SamanSarKo - Copy.pdf",
      "chunk_id": 245,
      "content_type": "reference",
      "content_type_confidence": 3,
      "word_count": 594,
      "entity_count": 7,
      "has_ckd": false,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "hemoglobin,iron,ferritin,diet,supplements,diuretics,heart failure",
      "year": "2025",
      "organization": "Unknown"
    },
    {
      "source": "8205Oxford Handbook of Clinical Medicine 10th 2017 Edition_SamanSarKo - Copy.pdf",
      "chunk_id": 246,
      "content_type": "treatment",
      "content_type_confidence": 3,
      "word_count": 593,
      "entity_count": 6,
      "has_ckd": false,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "renal failure,hemoglobin,iron,ferritin,erythropoietin,quality of life",
      "year": "2025",
      "organization": "Unknown"
    },
    {
      "source": "8205Oxford Handbook of Clinical Medicine 10th 2017 Edition_SamanSarKo - Copy.pdf",
      "chunk_id": 247,
      "content_type": "recommendation",
      "content_type_confidence": 1,
      "word_count": 579,
      "entity_count": 3,
      "has_ckd": false,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "hemoglobin,iron,ferritin",
      "year": "2025",
      "organization": "Unknown"
    },
    {
      "source": "8205Oxford Handbook of Clinical Medicine 10th 2017 Edition_SamanSarKo - Copy.pdf",
      "chunk_id": 248,
      "content_type": "treatment",
      "content_type_confidence": 3,
      "word_count": 598,
      "entity_count": 1,
      "has_ckd": false,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": true,
      "medical_entities": "dialysis",
      "year": "2025",
      "organization": "Unknown",
      "section": "Target cells:"
    },
    {
      "source": "8205Oxford Handbook of Clinical Medicine 10th 2017 Edition_SamanSarKo - Copy.pdf",
      "chunk_id": 249,
      "content_type": "treatment",
      "content_type_confidence": 2,
      "word_count": 597,
      "entity_count": 1,
      "has_ckd": false,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "neuropathy",
      "year": "2025",
      "organization": "Unknown"
    },
    {
      "source": "8205Oxford Handbook of Clinical Medicine 10th 2017 Edition_SamanSarKo - Copy.pdf",
      "chunk_id": 250,
      "content_type": "definition",
      "content_type_confidence": 2,
      "word_count": 584,
      "entity_count": 3,
      "has_ckd": false,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": true,
      "medical_entities": "diet,dialysis,neuropathy",
      "year": "2025",
      "organization": "Unknown",
      "section": "It is likely to show one of the following four states:"
    },
    {
      "source": "8205Oxford Handbook of Clinical Medicine 10th 2017 Edition_SamanSarKo - Copy.pdf",
      "chunk_id": 251,
      "content_type": "dietary",
      "content_type_confidence": 4,
      "word_count": 599,
      "entity_count": 3,
      "has_ckd": false,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "hemoglobin,iron,neuropathy",
      "year": "2025",
      "organization": "Unknown"
    },
    {
      "source": "8205Oxford Handbook of Clinical Medicine 10th 2017 Edition_SamanSarKo - Copy.pdf",
      "chunk_id": 252,
      "content_type": "treatment",
      "content_type_confidence": 1,
      "word_count": 585,
      "entity_count": 3,
      "has_ckd": false,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "phosphate,hemoglobin,immunosuppressants",
      "year": "2025",
      "organization": "Unknown"
    },
    {
      "source": "8205Oxford Handbook of Clinical Medicine 10th 2017 Edition_SamanSarKo - Copy.pdf",
      "chunk_id": 253,
      "content_type": "evidence",
      "content_type_confidence": 1,
      "word_count": 587,
      "entity_count": 2,
      "has_ckd": false,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "phosphate,hemoglobin",
      "year": "2025",
      "organization": "Unknown"
    },
    {
      "source": "8205Oxford Handbook of Clinical Medicine 10th 2017 Edition_SamanSarKo - Copy.pdf",
      "chunk_id": 254,
      "content_type": "evidence",
      "content_type_confidence": 2,
      "word_count": 597,
      "entity_count": 3,
      "has_ckd": false,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "renal failure,hemoglobin,iron",
      "year": "2025",
      "organization": "Unknown"
    },
    {
      "source": "8205Oxford Handbook of Clinical Medicine 10th 2017 Edition_SamanSarKo - Copy.pdf",
      "chunk_id": 255,
      "content_type": "evidence",
      "content_type_confidence": 2,
      "word_count": 581,
      "entity_count": 3,
      "has_ckd": false,
      "has_gfr": true,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "glomerular filtration rate,hemoglobin,iron",
      "year": "2025",
      "organization": "Unknown",
      "section": "Lung damage:"
    },
    {
      "source": "8205Oxford Handbook of Clinical Medicine 10th 2017 Edition_SamanSarKo - Copy.pdf",
      "chunk_id": 256,
      "content_type": "dietary",
      "content_type_confidence": 2,
      "word_count": 599,
      "entity_count": 4,
      "has_ckd": false,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "hemoglobin,iron,diet,supplements",
      "year": "2025",
      "organization": "Unknown"
    },
    {
      "source": "8205Oxford Handbook of Clinical Medicine 10th 2017 Edition_SamanSarKo - Copy.pdf",
      "chunk_id": 258,
      "content_type": "treatment",
      "content_type_confidence": 2,
      "word_count": 598,
      "entity_count": 2,
      "has_ckd": false,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "urea,potassium",
      "year": "2025",
      "organization": "Unknown"
    },
    {
      "source": "8205Oxford Handbook of Clinical Medicine 10th 2017 Edition_SamanSarKo - Copy.pdf",
      "chunk_id": 260,
      "content_type": "recommendation",
      "content_type_confidence": 3,
      "word_count": 596,
      "entity_count": 2,
      "has_ckd": false,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "potassium,hemoglobin",
      "year": "2025",
      "organization": "Unknown"
    },
    {
      "source": "8205Oxford Handbook of Clinical Medicine 10th 2017 Edition_SamanSarKo - Copy.pdf",
      "chunk_id": 261,
      "content_type": "recommendation",
      "content_type_confidence": 2,
      "word_count": 566,
      "entity_count": 8,
      "has_ckd": false,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "potassium,hemoglobin,iron,erythropoietin,edema,heart failure,fluid overload,monitoring",
      "year": "2025",
      "organization": "Unknown"
    },
    {
      "source": "8205Oxford Handbook of Clinical Medicine 10th 2017 Edition_SamanSarKo - Copy.pdf",
      "chunk_id": 262,
      "content_type": "recommendation",
      "content_type_confidence": 3,
      "word_count": 595,
      "entity_count": 3,
      "has_ckd": false,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "renal failure,potassium,monitoring",
      "year": "2025",
      "organization": "Unknown"
    },
    {
      "source": "8205Oxford Handbook of Clinical Medicine 10th 2017 Edition_SamanSarKo - Copy.pdf",
      "chunk_id": 263,
      "content_type": "treatment",
      "content_type_confidence": 4,
      "word_count": 585,
      "entity_count": 1,
      "has_ckd": false,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "potassium",
      "year": "2025",
      "organization": "Unknown",
      "section": "CI:"
    },
    {
      "source": "8205Oxford Handbook of Clinical Medicine 10th 2017 Edition_SamanSarKo - Copy.pdf",
      "chunk_id": 264,
      "content_type": "dietary",
      "content_type_confidence": 4,
      "word_count": 599,
      "entity_count": 4,
      "has_ckd": false,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "acute kidney injury,renal failure,potassium,diet",
      "year": "2025",
      "organization": "Unknown"
    },
    {
      "source": "8205Oxford Handbook of Clinical Medicine 10th 2017 Edition_SamanSarKo - Copy.pdf",
      "chunk_id": 266,
      "content_type": "treatment",
      "content_type_confidence": 3,
      "word_count": 590,
      "entity_count": 2,
      "has_ckd": false,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "creatinine,hemoglobin",
      "year": "2025",
      "organization": "Unknown",
      "section": "Chemotherapy:"
    },
    {
      "source": "8205Oxford Handbook of Clinical Medicine 10th 2017 Edition_SamanSarKo - Copy.pdf",
      "chunk_id": 267,
      "content_type": "treatment",
      "content_type_confidence": 3,
      "word_count": 597,
      "entity_count": 3,
      "has_ckd": false,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "erythropoietin,fatigue,quality of life",
      "year": "2025",
      "organization": "Unknown"
    },
    {
      "source": "8205Oxford Handbook of Clinical Medicine 10th 2017 Edition_SamanSarKo - Copy.pdf",
      "chunk_id": 268,
      "content_type": "recommendation",
      "content_type_confidence": 4,
      "word_count": 600,
      "entity_count": 1,
      "has_ckd": false,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "hemoglobin",
      "year": "2025",
      "organization": "Unknown"
    },
    {
      "source": "8205Oxford Handbook of Clinical Medicine 10th 2017 Edition_SamanSarKo - Copy.pdf",
      "chunk_id": 269,
      "content_type": "treatment",
      "content_type_confidence": 4,
      "word_count": 594,
      "entity_count": 2,
      "has_ckd": false,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "hemoglobin,pruritus",
      "year": "2025",
      "organization": "Unknown"
    },
    {
      "source": "8205Oxford Handbook of Clinical Medicine 10th 2017 Edition_SamanSarKo - Copy.pdf",
      "chunk_id": 270,
      "content_type": "treatment",
      "content_type_confidence": 4,
      "word_count": 596,
      "entity_count": 1,
      "has_ckd": false,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "quality of life",
      "year": "2025",
      "organization": "Unknown"
    },
    {
      "source": "8205Oxford Handbook of Clinical Medicine 10th 2017 Edition_SamanSarKo - Copy.pdf",
      "chunk_id": 271,
      "content_type": "treatment",
      "content_type_confidence": 4,
      "word_count": 586,
      "entity_count": 1,
      "has_ckd": false,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "calcium",
      "year": "2025",
      "organization": "Unknown"
    },
    {
      "source": "8205Oxford Handbook of Clinical Medicine 10th 2017 Edition_SamanSarKo - Copy.pdf",
      "chunk_id": 272,
      "content_type": "treatment",
      "content_type_confidence": 2,
      "word_count": 590,
      "entity_count": 1,
      "has_ckd": false,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "hemoglobin",
      "year": "2025",
      "organization": "Unknown"
    },
    {
      "source": "8205Oxford Handbook of Clinical Medicine 10th 2017 Edition_SamanSarKo - Copy.pdf",
      "chunk_id": 273,
      "content_type": "reference",
      "content_type_confidence": 2,
      "word_count": 592,
      "entity_count": 3,
      "has_ckd": false,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "hemoglobin,iron,erythropoietin",
      "year": "2025",
      "organization": "Unknown"
    },
    {
      "source": "8205Oxford Handbook of Clinical Medicine 10th 2017 Edition_SamanSarKo - Copy.pdf",
      "chunk_id": 274,
      "content_type": "treatment",
      "content_type_confidence": 2,
      "word_count": 594,
      "entity_count": 4,
      "has_ckd": false,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "hemoglobin,hematocrit,iron,erythropoietin",
      "year": "2025",
      "organization": "Unknown"
    },
    {
      "source": "8205Oxford Handbook of Clinical Medicine 10th 2017 Edition_SamanSarKo - Copy.pdf",
      "chunk_id": 275,
      "content_type": "monitoring",
      "content_type_confidence": 3,
      "word_count": 590,
      "entity_count": 9,
      "has_ckd": false,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": true,
      "medical_entities": "acute kidney injury,renal failure,creatinine,urea,phosphate,hemoglobin,erythropoietin,dialysis,screening",
      "year": "2025",
      "organization": "Unknown"
    },
    {
      "source": "8205Oxford Handbook of Clinical Medicine 10th 2017 Edition_SamanSarKo - Copy.pdf",
      "chunk_id": 276,
      "content_type": "dietary",
      "content_type_confidence": 2,
      "word_count": 596,
      "entity_count": 4,
      "has_ckd": false,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": true,
      "medical_entities": "dialysis,bone disease,renal osteodystrophy,neuropathy",
      "year": "2025",
      "organization": "Unknown"
    },
    {
      "source": "8205Oxford Handbook of Clinical Medicine 10th 2017 Edition_SamanSarKo - Copy.pdf",
      "chunk_id": 277,
      "content_type": "recommendation",
      "content_type_confidence": 2,
      "word_count": 583,
      "entity_count": 3,
      "has_ckd": false,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "proteinuria,nutrition,neuropathy",
      "year": "2025",
      "organization": "Unknown",
      "section": "Nerves:"
    },
    {
      "source": "8205Oxford Handbook of Clinical Medicine 10th 2017 Edition_SamanSarKo - Copy.pdf",
      "chunk_id": 278,
      "content_type": "treatment",
      "content_type_confidence": 5,
      "word_count": 586,
      "entity_count": 2,
      "has_ckd": false,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "diuretics,erythropoietin",
      "year": "2025",
      "organization": "Unknown"
    },
    {
      "source": "8205Oxford Handbook of Clinical Medicine 10th 2017 Edition_SamanSarKo - Copy.pdf",
      "chunk_id": 279,
      "content_type": "recommendation",
      "content_type_confidence": 2,
      "word_count": 590,
      "entity_count": 2,
      "has_ckd": false,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "creatinine,potassium",
      "year": "2025",
      "organization": "Unknown"
    },
    {
      "source": "8205Oxford Handbook of Clinical Medicine 10th 2017 Edition_SamanSarKo - Copy.pdf",
      "chunk_id": 280,
      "content_type": "recommendation",
      "content_type_confidence": 3,
      "word_count": 599,
      "entity_count": 9,
      "has_ckd": false,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "nephritis,creatinine,calcium,vitamin D,supplements,heart failure,smoking cessation,exercise,monitoring",
      "year": "2025",
      "organization": "Unknown"
    },
    {
      "source": "8205Oxford Handbook of Clinical Medicine 10th 2017 Edition_SamanSarKo - Copy.pdf",
      "chunk_id": 283,
      "content_type": "dietary",
      "content_type_confidence": 3,
      "word_count": 564,
      "entity_count": 4,
      "has_ckd": false,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "potassium,nutrition,renal osteodystrophy,neuropathy",
      "year": "2025",
      "organization": "Unknown"
    },
    {
      "source": "8205Oxford Handbook of Clinical Medicine 10th 2017 Edition_SamanSarKo - Copy.pdf",
      "chunk_id": 284,
      "content_type": "dietary",
      "content_type_confidence": 3,
      "word_count": 578,
      "entity_count": 4,
      "has_ckd": false,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "potassium,nutrition,malnutrition,renal osteodystrophy",
      "year": "2025",
      "organization": "Unknown"
    },
    {
      "source": "8205Oxford Handbook of Clinical Medicine 10th 2017 Edition_SamanSarKo - Copy.pdf",
      "chunk_id": 285,
      "content_type": "treatment",
      "content_type_confidence": 5,
      "word_count": 592,
      "entity_count": 1,
      "has_ckd": false,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "renal function",
      "year": "2025",
      "organization": "Unknown"
    },
    {
      "source": "8205Oxford Handbook of Clinical Medicine 10th 2017 Edition_SamanSarKo - Copy.pdf",
      "chunk_id": 286,
      "content_type": "treatment",
      "content_type_confidence": 5,
      "word_count": 600,
      "entity_count": 2,
      "has_ckd": false,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "renal function,monitoring",
      "year": "2025",
      "organization": "Unknown"
    },
    {
      "source": "8205Oxford Handbook of Clinical Medicine 10th 2017 Edition_SamanSarKo - Copy.pdf",
      "chunk_id": 287,
      "content_type": "treatment",
      "content_type_confidence": 2,
      "word_count": 594,
      "entity_count": 4,
      "has_ckd": false,
      "has_gfr": true,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "glomerular filtration rate,creatinine,serum creatinine,statins",
      "year": "2025",
      "organization": "Unknown"
    },
    {
      "source": "8205Oxford Handbook of Clinical Medicine 10th 2017 Edition_SamanSarKo - Copy.pdf",
      "chunk_id": 288,
      "content_type": "dietary",
      "content_type_confidence": 2,
      "word_count": 589,
      "entity_count": 10,
      "has_ckd": false,
      "has_gfr": true,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": true,
      "medical_entities": "acute kidney injury,glomerular filtration rate,creatinine,potassium,serum creatinine,statins,dialysis,peritoneal dialysis,catheter,neuropathy",
      "year": "2025",
      "organization": "Unknown"
    },
    {
      "source": "8205Oxford Handbook of Clinical Medicine 10th 2017 Edition_SamanSarKo - Copy.pdf",
      "chunk_id": 289,
      "content_type": "treatment",
      "content_type_confidence": 2,
      "word_count": 593,
      "entity_count": 1,
      "has_ckd": false,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "creatinine",
      "year": "2025",
      "organization": "Unknown"
    },
    {
      "source": "8205Oxford Handbook of Clinical Medicine 10th 2017 Edition_SamanSarKo - Copy.pdf",
      "chunk_id": 290,
      "content_type": "reference",
      "content_type_confidence": 1,
      "word_count": 598,
      "entity_count": 2,
      "has_ckd": false,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "acute kidney injury,creatinine",
      "year": "2025",
      "organization": "Unknown"
    },
    {
      "source": "8205Oxford Handbook of Clinical Medicine 10th 2017 Edition_SamanSarKo - Copy.pdf",
      "chunk_id": 291,
      "content_type": "treatment",
      "content_type_confidence": 3,
      "word_count": 598,
      "entity_count": 4,
      "has_ckd": false,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "creatinine,urea,calcium,magnesium",
      "year": "2025",
      "organization": "Unknown",
      "section": "Pathogenic forms can cause:"
    },
    {
      "source": "8205Oxford Handbook of Clinical Medicine 10th 2017 Edition_SamanSarKo - Copy.pdf",
      "chunk_id": 292,
      "content_type": "dietary",
      "content_type_confidence": 3,
      "word_count": 598,
      "entity_count": 3,
      "has_ckd": false,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "creatinine,potassium,malnutrition",
      "year": "2025",
      "organization": "Unknown"
    },
    {
      "source": "8205Oxford Handbook of Clinical Medicine 10th 2017 Edition_SamanSarKo - Copy.pdf",
      "chunk_id": 293,
      "content_type": "dietary",
      "content_type_confidence": 3,
      "word_count": 596,
      "entity_count": 4,
      "has_ckd": true,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "chronic kidney disease,malnutrition,heart failure,neuropathy",
      "year": "2025",
      "organization": "Unknown"
    },
    {
      "source": "8205Oxford Handbook of Clinical Medicine 10th 2017 Edition_SamanSarKo - Copy.pdf",
      "chunk_id": 294,
      "content_type": "treatment",
      "content_type_confidence": 3,
      "word_count": 600,
      "entity_count": 3,
      "has_ckd": true,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": true,
      "medical_entities": "chronic kidney disease,dialysis,adherence",
      "year": "2025",
      "organization": "Unknown"
    },
    {
      "source": "8205Oxford Handbook of Clinical Medicine 10th 2017 Edition_SamanSarKo - Copy.pdf",
      "chunk_id": 295,
      "content_type": "evidence",
      "content_type_confidence": 2,
      "word_count": 587,
      "entity_count": 1,
      "has_ckd": false,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "creatinine",
      "year": "2025",
      "organization": "Unknown"
    },
    {
      "source": "8205Oxford Handbook of Clinical Medicine 10th 2017 Edition_SamanSarKo - Copy.pdf",
      "chunk_id": 298,
      "content_type": "treatment",
      "content_type_confidence": 3,
      "word_count": 600,
      "entity_count": 1,
      "has_ckd": false,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "creatinine",
      "year": "2025",
      "organization": "Unknown"
    },
    {
      "source": "8205Oxford Handbook of Clinical Medicine 10th 2017 Edition_SamanSarKo - Copy.pdf",
      "chunk_id": 299,
      "content_type": "dietary",
      "content_type_confidence": 2,
      "word_count": 591,
      "entity_count": 6,
      "has_ckd": false,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "acute kidney injury,creatinine,vitamin D,nutrition,bone disease,cardiovascular disease",
      "year": "2025",
      "organization": "Unknown",
      "section": "Prophylaxis:"
    },
    {
      "source": "8205Oxford Handbook of Clinical Medicine 10th 2017 Edition_SamanSarKo - Copy.pdf",
      "chunk_id": 300,
      "content_type": "treatment",
      "content_type_confidence": 4,
      "word_count": 598,
      "entity_count": 8,
      "has_ckd": true,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "chronic kidney disease,acute kidney injury,nephropathy,nephritis,proteinuria,neuropathy,adherence,monitoring",
      "year": "2025",
      "organization": "Unknown"
    },
    {
      "source": "8205Oxford Handbook of Clinical Medicine 10th 2017 Edition_SamanSarKo - Copy.pdf",
      "chunk_id": 301,
      "content_type": "treatment",
      "content_type_confidence": 5,
      "word_count": 582,
      "entity_count": 7,
      "has_ckd": false,
      "has_gfr": true,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "glomerular filtration rate,creatinine,insulin,acidosis,cardiovascular disease,adherence,monitoring",
      "year": "2025",
      "organization": "Unknown"
    },
    {
      "source": "8205Oxford Handbook of Clinical Medicine 10th 2017 Edition_SamanSarKo - Copy.pdf",
      "chunk_id": 302,
      "content_type": "treatment",
      "content_type_confidence": 2,
      "word_count": 584,
      "entity_count": 1,
      "has_ckd": false,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "creatinine",
      "year": "2025",
      "organization": "Unknown"
    },
    {
      "source": "8205Oxford Handbook of Clinical Medicine 10th 2017 Edition_SamanSarKo - Copy.pdf",
      "chunk_id": 303,
      "content_type": "evidence",
      "content_type_confidence": 2,
      "word_count": 588,
      "entity_count": 2,
      "has_ckd": false,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "nephropathy,creatinine",
      "year": "2025",
      "organization": "Unknown"
    },
    {
      "source": "8205Oxford Handbook of Clinical Medicine 10th 2017 Edition_SamanSarKo - Copy.pdf",
      "chunk_id": 304,
      "content_type": "reference",
      "content_type_confidence": 2,
      "word_count": 600,
      "entity_count": 4,
      "has_ckd": true,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "chronic kidney disease,creatinine,edema,retinopathy",
      "year": "2025",
      "organization": "Unknown"
    },
    {
      "source": "8205Oxford Handbook of Clinical Medicine 10th 2017 Edition_SamanSarKo - Copy.pdf",
      "chunk_id": 305,
      "content_type": "evidence",
      "content_type_confidence": 2,
      "word_count": 594,
      "entity_count": 2,
      "has_ckd": false,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "creatinine,pruritus",
      "year": "2025",
      "organization": "Unknown"
    },
    {
      "source": "8205Oxford Handbook of Clinical Medicine 10th 2017 Edition_SamanSarKo - Copy.pdf",
      "chunk_id": 306,
      "content_type": "treatment",
      "content_type_confidence": 3,
      "word_count": 590,
      "entity_count": 5,
      "has_ckd": false,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": true,
      "medical_entities": "creatinine,dialysis,vascular access,catheter,monitoring",
      "year": "2025",
      "organization": "Unknown"
    },
    {
      "source": "8205Oxford Handbook of Clinical Medicine 10th 2017 Edition_SamanSarKo - Copy.pdf",
      "chunk_id": 307,
      "content_type": "treatment",
      "content_type_confidence": 2,
      "word_count": 599,
      "entity_count": 5,
      "has_ckd": false,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "acute kidney injury,nutrition,vascular access,adherence,screening",
      "year": "2025",
      "organization": "Unknown"
    },
    {
      "source": "8205Oxford Handbook of Clinical Medicine 10th 2017 Edition_SamanSarKo - Copy.pdf",
      "chunk_id": 308,
      "content_type": "recommendation",
      "content_type_confidence": 2,
      "word_count": 590,
      "entity_count": 2,
      "has_ckd": false,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "creatinine,edema",
      "year": "2025",
      "organization": "Unknown"
    },
    {
      "source": "8205Oxford Handbook of Clinical Medicine 10th 2017 Edition_SamanSarKo - Copy.pdf",
      "chunk_id": 309,
      "content_type": "definition",
      "content_type_confidence": 2,
      "word_count": 600,
      "entity_count": 2,
      "has_ckd": false,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "creatinine,screening",
      "year": "2025",
      "organization": "Unknown",
      "section": "Gummatous syphilis:"
    },
    {
      "source": "8205Oxford Handbook of Clinical Medicine 10th 2017 Edition_SamanSarKo - Copy.pdf",
      "chunk_id": 310,
      "content_type": "dietary",
      "content_type_confidence": 2,
      "word_count": 599,
      "entity_count": 3,
      "has_ckd": false,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": true,
      "medical_entities": "creatinine,diet,dialysis",
      "year": "2025",
      "organization": "Unknown"
    },
    {
      "source": "8205Oxford Handbook of Clinical Medicine 10th 2017 Edition_SamanSarKo - Copy.pdf",
      "chunk_id": 311,
      "content_type": "dietary",
      "content_type_confidence": 4,
      "word_count": 596,
      "entity_count": 3,
      "has_ckd": false,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "creatinine,nutrition,fatigue",
      "year": "2025",
      "organization": "Unknown"
    },
    {
      "source": "8205Oxford Handbook of Clinical Medicine 10th 2017 Edition_SamanSarKo - Copy.pdf",
      "chunk_id": 312,
      "content_type": "reference",
      "content_type_confidence": 2,
      "word_count": 600,
      "entity_count": 3,
      "has_ckd": false,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "acute kidney injury,creatinine,acidosis",
      "year": "2025",
      "organization": "Unknown"
    },
    {
      "source": "8205Oxford Handbook of Clinical Medicine 10th 2017 Edition_SamanSarKo - Copy.pdf",
      "chunk_id": 313,
      "content_type": "treatment",
      "content_type_confidence": 4,
      "word_count": 598,
      "entity_count": 6,
      "has_ckd": false,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "acute kidney injury,renal failure,creatinine,hemoglobin,acidosis,monitoring",
      "year": "2025",
      "organization": "Unknown",
      "section": "In:"
    },
    {
      "source": "8205Oxford Handbook of Clinical Medicine 10th 2017 Edition_SamanSarKo - Copy.pdf",
      "chunk_id": 314,
      "content_type": "recommendation",
      "content_type_confidence": 3,
      "word_count": 597,
      "entity_count": 1,
      "has_ckd": false,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "monitoring",
      "year": "2025",
      "organization": "Unknown"
    },
    {
      "source": "8205Oxford Handbook of Clinical Medicine 10th 2017 Edition_SamanSarKo - Copy.pdf",
      "chunk_id": 315,
      "content_type": "evidence",
      "content_type_confidence": 2,
      "word_count": 596,
      "entity_count": 2,
      "has_ckd": false,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "acute kidney injury,creatinine",
      "year": "2025",
      "organization": "Unknown"
    },
    {
      "source": "8205Oxford Handbook of Clinical Medicine 10th 2017 Edition_SamanSarKo - Copy.pdf",
      "chunk_id": 316,
      "content_type": "treatment",
      "content_type_confidence": 3,
      "word_count": 594,
      "entity_count": 5,
      "has_ckd": true,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "chronic kidney disease,renal failure,proteinuria,edema,pruritus",
      "year": "2025",
      "organization": "Unknown"
    },
    {
      "source": "8205Oxford Handbook of Clinical Medicine 10th 2017 Edition_SamanSarKo - Copy.pdf",
      "chunk_id": 317,
      "content_type": "dietary",
      "content_type_confidence": 2,
      "word_count": 590,
      "entity_count": 2,
      "has_ckd": false,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "creatinine,malnutrition",
      "year": "2025",
      "organization": "Unknown",
      "section": "Diagnosis:"
    },
    {
      "source": "8205Oxford Handbook of Clinical Medicine 10th 2017 Edition_SamanSarKo - Copy.pdf",
      "chunk_id": 318,
      "content_type": "treatment",
      "content_type_confidence": 2,
      "word_count": 585,
      "entity_count": 4,
      "has_ckd": false,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "acute kidney injury,creatinine,hemoglobin,adherence",
      "year": "2025",
      "organization": "Unknown"
    },
    {
      "source": "8205Oxford Handbook of Clinical Medicine 10th 2017 Edition_SamanSarKo - Copy.pdf",
      "chunk_id": 319,
      "content_type": "evidence",
      "content_type_confidence": 2,
      "word_count": 590,
      "entity_count": 5,
      "has_ckd": false,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "acute kidney injury,renal failure,creatinine,fatigue,adherence",
      "year": "2025",
      "organization": "Unknown"
    },
    {
      "source": "8205Oxford Handbook of Clinical Medicine 10th 2017 Edition_SamanSarKo - Copy.pdf",
      "chunk_id": 320,
      "content_type": "recommendation",
      "content_type_confidence": 2,
      "word_count": 592,
      "entity_count": 3,
      "has_ckd": false,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "acute kidney injury,creatinine,heart failure",
      "year": "2025",
      "organization": "Unknown"
    },
    {
      "source": "8205Oxford Handbook of Clinical Medicine 10th 2017 Edition_SamanSarKo - Copy.pdf",
      "chunk_id": 321,
      "content_type": "evidence",
      "content_type_confidence": 4,
      "word_count": 556,
      "entity_count": 3,
      "has_ckd": false,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "creatinine,potassium,nutrition",
      "year": "2025",
      "organization": "Unknown",
      "section": "Diagnosis:"
    },
    {
      "source": "8205Oxford Handbook of Clinical Medicine 10th 2017 Edition_SamanSarKo - Copy.pdf",
      "chunk_id": 322,
      "content_type": "reference",
      "content_type_confidence": 2,
      "word_count": 597,
      "entity_count": 1,
      "has_ckd": false,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "edema",
      "year": "2025",
      "organization": "Unknown",
      "section": "Diarrhoea can be defi ned as:"
    },
    {
      "source": "8205Oxford Handbook of Clinical Medicine 10th 2017 Edition_SamanSarKo - Copy.pdf",
      "chunk_id": 323,
      "content_type": "dietary",
      "content_type_confidence": 3,
      "word_count": 598,
      "entity_count": 4,
      "has_ckd": true,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "chronic kidney disease,creatinine,sodium,renal osteodystrophy",
      "year": "2025",
      "organization": "Unknown",
      "section": "Duration of diarrhoea:"
    },
    {
      "source": "8205Oxford Handbook of Clinical Medicine 10th 2017 Edition_SamanSarKo - Copy.pdf",
      "chunk_id": 324,
      "content_type": "dietary",
      "content_type_confidence": 3,
      "word_count": 599,
      "entity_count": 6,
      "has_ckd": false,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "creatinine,potassium,nutrition,acidosis,metabolic acidosis,renal osteodystrophy",
      "year": "2025",
      "organization": "Unknown"
    },
    {
      "source": "8205Oxford Handbook of Clinical Medicine 10th 2017 Edition_SamanSarKo - Copy.pdf",
      "chunk_id": 325,
      "content_type": "evidence",
      "content_type_confidence": 2,
      "word_count": 591,
      "entity_count": 2,
      "has_ckd": false,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "creatinine,renal osteodystrophy",
      "year": "2025",
      "organization": "Unknown"
    },
    {
      "source": "8205Oxford Handbook of Clinical Medicine 10th 2017 Edition_SamanSarKo - Copy.pdf",
      "chunk_id": 326,
      "content_type": "reference",
      "content_type_confidence": 3,
      "word_count": 591,
      "entity_count": 4,
      "has_ckd": false,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "creatinine,pruritus,fatigue,neuropathy",
      "year": "2025",
      "organization": "Unknown"
    },
    {
      "source": "8205Oxford Handbook of Clinical Medicine 10th 2017 Edition_SamanSarKo - Copy.pdf",
      "chunk_id": 327,
      "content_type": "dietary",
      "content_type_confidence": 2,
      "word_count": 594,
      "entity_count": 1,
      "has_ckd": true,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "chronic kidney disease",
      "year": "2025",
      "organization": "Unknown",
      "section": "Presentation:"
    },
    {
      "source": "8205Oxford Handbook of Clinical Medicine 10th 2017 Edition_SamanSarKo - Copy.pdf",
      "chunk_id": 328,
      "content_type": "treatment",
      "content_type_confidence": 3,
      "word_count": 597,
      "entity_count": 4,
      "has_ckd": false,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "creatinine,magnesium,iron,monitoring",
      "year": "2025",
      "organization": "Unknown"
    },
    {
      "source": "8205Oxford Handbook of Clinical Medicine 10th 2017 Edition_SamanSarKo - Copy.pdf",
      "chunk_id": 329,
      "content_type": "treatment",
      "content_type_confidence": 2,
      "word_count": 589,
      "entity_count": 2,
      "has_ckd": false,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "creatinine,fatigue",
      "year": "2025",
      "organization": "Unknown"
    },
    {
      "source": "8205Oxford Handbook of Clinical Medicine 10th 2017 Edition_SamanSarKo - Copy.pdf",
      "chunk_id": 330,
      "content_type": "reference",
      "content_type_confidence": 2,
      "word_count": 600,
      "entity_count": 2,
      "has_ckd": false,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "nephropathy,creatinine",
      "year": "2025",
      "organization": "Unknown"
    },
    {
      "source": "8205Oxford Handbook of Clinical Medicine 10th 2017 Edition_SamanSarKo - Copy.pdf",
      "chunk_id": 332,
      "content_type": "dietary",
      "content_type_confidence": 3,
      "word_count": 598,
      "entity_count": 2,
      "has_ckd": false,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "creatinine,edema",
      "year": "2025",
      "organization": "Unknown"
    },
    {
      "source": "8205Oxford Handbook of Clinical Medicine 10th 2017 Edition_SamanSarKo - Copy.pdf",
      "chunk_id": 333,
      "content_type": "treatment",
      "content_type_confidence": 3,
      "word_count": 574,
      "entity_count": 2,
      "has_ckd": false,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "creatinine,diet",
      "year": "2025",
      "organization": "Unknown"
    },
    {
      "source": "8205Oxford Handbook of Clinical Medicine 10th 2017 Edition_SamanSarKo - Copy.pdf",
      "chunk_id": 334,
      "content_type": "dietary",
      "content_type_confidence": 3,
      "word_count": 596,
      "entity_count": 1,
      "has_ckd": false,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "creatinine",
      "year": "2025",
      "organization": "Unknown"
    },
    {
      "source": "8205Oxford Handbook of Clinical Medicine 10th 2017 Edition_SamanSarKo - Copy.pdf",
      "chunk_id": 335,
      "content_type": "evidence",
      "content_type_confidence": 2,
      "word_count": 579,
      "entity_count": 2,
      "has_ckd": false,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "magnesium,neuropathy",
      "year": "2025",
      "organization": "Unknown"
    },
    {
      "source": "8205Oxford Handbook of Clinical Medicine 10th 2017 Edition_SamanSarKo - Copy.pdf",
      "chunk_id": 341,
      "content_type": "treatment",
      "content_type_confidence": 3,
      "word_count": 595,
      "entity_count": 1,
      "has_ckd": false,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "creatinine",
      "year": "2025",
      "organization": "Unknown"
    },
    {
      "source": "8205Oxford Handbook of Clinical Medicine 10th 2017 Edition_SamanSarKo - Copy.pdf",
      "chunk_id": 342,
      "content_type": "treatment",
      "content_type_confidence": 4,
      "word_count": 593,
      "entity_count": 2,
      "has_ckd": false,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "edema,exercise",
      "year": "2025",
      "organization": "Unknown"
    },
    {
      "source": "8205Oxford Handbook of Clinical Medicine 10th 2017 Edition_SamanSarKo - Copy.pdf",
      "chunk_id": 344,
      "content_type": "treatment",
      "content_type_confidence": 2,
      "word_count": 594,
      "entity_count": 3,
      "has_ckd": false,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "antihypertensive,neuropathy,exercise",
      "year": "2025",
      "organization": "Unknown"
    },
    {
      "source": "8205Oxford Handbook of Clinical Medicine 10th 2017 Edition_SamanSarKo - Copy.pdf",
      "chunk_id": 346,
      "content_type": "evidence",
      "content_type_confidence": 1,
      "word_count": 594,
      "entity_count": 2,
      "has_ckd": false,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "diuretics,loop diuretics",
      "year": "2025",
      "organization": "Unknown"
    },
    {
      "source": "8205Oxford Handbook of Clinical Medicine 10th 2017 Edition_SamanSarKo - Copy.pdf",
      "chunk_id": 347,
      "content_type": "treatment",
      "content_type_confidence": 2,
      "word_count": 581,
      "entity_count": 1,
      "has_ckd": false,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "quality of life",
      "year": "2025",
      "organization": "Unknown"
    },
    {
      "source": "8205Oxford Handbook of Clinical Medicine 10th 2017 Edition_SamanSarKo - Copy.pdf",
      "chunk_id": 348,
      "content_type": "recommendation",
      "content_type_confidence": 1,
      "word_count": 588,
      "entity_count": 3,
      "has_ckd": false,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "fatigue,neuropathy,exercise",
      "year": "2025",
      "organization": "Unknown",
      "section": "Extrapyramidal:"
    },
    {
      "source": "8205Oxford Handbook of Clinical Medicine 10th 2017 Edition_SamanSarKo - Copy.pdf",
      "chunk_id": 349,
      "content_type": "dietary",
      "content_type_confidence": 2,
      "word_count": 598,
      "entity_count": 2,
      "has_ckd": false,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "kidney failure,sodium",
      "year": "2025",
      "organization": "Unknown",
      "section": "Causes:"
    },
    {
      "source": "8205Oxford Handbook of Clinical Medicine 10th 2017 Edition_SamanSarKo - Copy.pdf",
      "chunk_id": 350,
      "content_type": "evidence",
      "content_type_confidence": 2,
      "word_count": 598,
      "entity_count": 1,
      "has_ckd": false,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "phosphate",
      "year": "2025",
      "organization": "Unknown"
    },
    {
      "source": "8205Oxford Handbook of Clinical Medicine 10th 2017 Edition_SamanSarKo - Copy.pdf",
      "chunk_id": 351,
      "content_type": "evidence",
      "content_type_confidence": 3,
      "word_count": 593,
      "entity_count": 3,
      "has_ckd": false,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "nephropathy,retinopathy,exercise",
      "year": "2025",
      "organization": "Unknown"
    },
    {
      "source": "8205Oxford Handbook of Clinical Medicine 10th 2017 Edition_SamanSarKo - Copy.pdf",
      "chunk_id": 352,
      "content_type": "reference",
      "content_type_confidence": 3,
      "word_count": 600,
      "entity_count": 5,
      "has_ckd": false,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "nutrition,stage 1,stage 2,stage 3,stage 4",
      "year": "2025",
      "organization": "Unknown",
      "section": "Full recovery:"
    },
    {
      "source": "8205Oxford Handbook of Clinical Medicine 10th 2017 Edition_SamanSarKo - Copy.pdf",
      "chunk_id": 353,
      "content_type": "treatment",
      "content_type_confidence": 2,
      "word_count": 580,
      "entity_count": 1,
      "has_ckd": false,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "catheter",
      "year": "2025",
      "organization": "Unknown"
    },
    {
      "source": "8205Oxford Handbook of Clinical Medicine 10th 2017 Edition_SamanSarKo - Copy.pdf",
      "chunk_id": 354,
      "content_type": "recommendation",
      "content_type_confidence": 2,
      "word_count": 595,
      "entity_count": 1,
      "has_ckd": false,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "neuropathy",
      "year": "2025",
      "organization": "Unknown"
    },
    {
      "source": "8205Oxford Handbook of Clinical Medicine 10th 2017 Edition_SamanSarKo - Copy.pdf",
      "chunk_id": 355,
      "content_type": "recommendation",
      "content_type_confidence": 2,
      "word_count": 597,
      "entity_count": 1,
      "has_ckd": false,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "catheter",
      "year": "2025",
      "organization": "Unknown",
      "section": "Surgery:"
    },
    {
      "source": "8205Oxford Handbook of Clinical Medicine 10th 2017 Edition_SamanSarKo - Copy.pdf",
      "chunk_id": 357,
      "content_type": "dietary",
      "content_type_confidence": 3,
      "word_count": 589,
      "entity_count": 5,
      "has_ckd": false,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "sodium,hemoglobin,malnutrition,physical activity,monitoring",
      "year": "2025",
      "organization": "Unknown"
    },
    {
      "source": "8205Oxford Handbook of Clinical Medicine 10th 2017 Edition_SamanSarKo - Copy.pdf",
      "chunk_id": 358,
      "content_type": "treatment",
      "content_type_confidence": 4,
      "word_count": 580,
      "entity_count": 1,
      "has_ckd": false,
      "has_gfr": true,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "glomerular filtration rate",
      "year": "2025",
      "organization": "Unknown"
    },
    {
      "source": "8205Oxford Handbook of Clinical Medicine 10th 2017 Edition_SamanSarKo - Copy.pdf",
      "chunk_id": 359,
      "content_type": "evidence",
      "content_type_confidence": 3,
      "word_count": 599,
      "entity_count": 4,
      "has_ckd": false,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": true,
      "medical_entities": "dialysis,peritoneal dialysis,heart failure,blood pressure control",
      "year": "2025",
      "organization": "Unknown"
    },
    {
      "source": "8205Oxford Handbook of Clinical Medicine 10th 2017 Edition_SamanSarKo - Copy.pdf",
      "chunk_id": 360,
      "content_type": "dietary",
      "content_type_confidence": 4,
      "word_count": 598,
      "entity_count": 2,
      "has_ckd": false,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "potassium,supplements",
      "year": "2025",
      "organization": "Unknown"
    },
    {
      "source": "8205Oxford Handbook of Clinical Medicine 10th 2017 Edition_SamanSarKo - Copy.pdf",
      "chunk_id": 361,
      "content_type": "definition",
      "content_type_confidence": 2,
      "word_count": 595,
      "entity_count": 1,
      "has_ckd": false,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "sodium",
      "year": "2025",
      "organization": "Unknown"
    },
    {
      "source": "8205Oxford Handbook of Clinical Medicine 10th 2017 Edition_SamanSarKo - Copy.pdf",
      "chunk_id": 363,
      "content_type": "treatment",
      "content_type_confidence": 4,
      "word_count": 589,
      "entity_count": 4,
      "has_ckd": false,
      "has_gfr": true,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": true,
      "medical_entities": "glomerular filtration rate,sodium,dialysis,peritoneal dialysis",
      "year": "2025",
      "organization": "Unknown"
    },
    {
      "source": "8205Oxford Handbook of Clinical Medicine 10th 2017 Edition_SamanSarKo - Copy.pdf",
      "chunk_id": 364,
      "content_type": "treatment",
      "content_type_confidence": 6,
      "word_count": 599,
      "entity_count": 3,
      "has_ckd": false,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": true,
      "medical_entities": "dialysis,peritoneal dialysis,quality of life",
      "year": "2025",
      "organization": "Unknown"
    },
    {
      "source": "8205Oxford Handbook of Clinical Medicine 10th 2017 Edition_SamanSarKo - Copy.pdf",
      "chunk_id": 365,
      "content_type": "recommendation",
      "content_type_confidence": 2,
      "word_count": 600,
      "entity_count": 5,
      "has_ckd": false,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": true,
      "medical_entities": "vitamin D,dialysis,peritoneal dialysis,exercise,monitoring",
      "year": "2025",
      "organization": "Unknown"
    },
    {
      "source": "8205Oxford Handbook of Clinical Medicine 10th 2017 Edition_SamanSarKo - Copy.pdf",
      "chunk_id": 366,
      "content_type": "recommendation",
      "content_type_confidence": 1,
      "word_count": 584,
      "entity_count": 2,
      "has_ckd": false,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "fatigue,exercise",
      "year": "2025",
      "organization": "Unknown"
    },
    {
      "source": "8205Oxford Handbook of Clinical Medicine 10th 2017 Edition_SamanSarKo - Copy.pdf",
      "chunk_id": 367,
      "content_type": "treatment",
      "content_type_confidence": 4,
      "word_count": 587,
      "entity_count": 3,
      "has_ckd": true,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "chronic kidney disease,diuretics,loop diuretics",
      "year": "2025",
      "organization": "Unknown"
    },
    {
      "source": "8205Oxford Handbook of Clinical Medicine 10th 2017 Edition_SamanSarKo - Copy.pdf",
      "chunk_id": 369,
      "content_type": "dietary",
      "content_type_confidence": 1,
      "word_count": 591,
      "entity_count": 1,
      "has_ckd": false,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "edema",
      "year": "2025",
      "organization": "Unknown"
    },
    {
      "source": "8205Oxford Handbook of Clinical Medicine 10th 2017 Edition_SamanSarKo - Copy.pdf",
      "chunk_id": 370,
      "content_type": "dietary",
      "content_type_confidence": 2,
      "word_count": 576,
      "entity_count": 3,
      "has_ckd": true,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "chronic kidney disease,renal failure,neuropathy",
      "year": "2025",
      "organization": "Unknown"
    },
    {
      "source": "8205Oxford Handbook of Clinical Medicine 10th 2017 Edition_SamanSarKo - Copy.pdf",
      "chunk_id": 371,
      "content_type": "treatment",
      "content_type_confidence": 3,
      "word_count": 589,
      "entity_count": 1,
      "has_ckd": false,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "neuropathy",
      "year": "2025",
      "organization": "Unknown"
    },
    {
      "source": "8205Oxford Handbook of Clinical Medicine 10th 2017 Edition_SamanSarKo - Copy.pdf",
      "chunk_id": 372,
      "content_type": "recommendation",
      "content_type_confidence": 2,
      "word_count": 572,
      "entity_count": 2,
      "has_ckd": false,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "neuropathy,exercise",
      "year": "2025",
      "organization": "Unknown"
    },
    {
      "source": "8205Oxford Handbook of Clinical Medicine 10th 2017 Edition_SamanSarKo - Copy.pdf",
      "chunk_id": 374,
      "content_type": "recommendation",
      "content_type_confidence": 2,
      "word_count": 589,
      "entity_count": 2,
      "has_ckd": false,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "neuropathy,exercise",
      "year": "2025",
      "organization": "Unknown"
    },
    {
      "source": "8205Oxford Handbook of Clinical Medicine 10th 2017 Edition_SamanSarKo - Copy.pdf",
      "chunk_id": 375,
      "content_type": "dietary",
      "content_type_confidence": 3,
      "word_count": 591,
      "entity_count": 5,
      "has_ckd": false,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "potassium,magnesium,statins,fatigue,exercise",
      "year": "2025",
      "organization": "Unknown",
      "section": "Also:"
    },
    {
      "source": "8205Oxford Handbook of Clinical Medicine 10th 2017 Edition_SamanSarKo - Copy.pdf",
      "chunk_id": 376,
      "content_type": "treatment",
      "content_type_confidence": 3,
      "word_count": 596,
      "entity_count": 2,
      "has_ckd": false,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "magnesium,exercise",
      "year": "2025",
      "organization": "Unknown"
    },
    {
      "source": "8205Oxford Handbook of Clinical Medicine 10th 2017 Edition_SamanSarKo - Copy.pdf",
      "chunk_id": 377,
      "content_type": "monitoring",
      "content_type_confidence": 2,
      "word_count": 589,
      "entity_count": 2,
      "has_ckd": false,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "magnesium,screening",
      "year": "2025",
      "organization": "Unknown"
    },
    {
      "source": "8205Oxford Handbook of Clinical Medicine 10th 2017 Edition_SamanSarKo - Copy.pdf",
      "chunk_id": 378,
      "content_type": "reference",
      "content_type_confidence": 1,
      "word_count": 553,
      "entity_count": 2,
      "has_ckd": false,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "creatinine,neuropathy",
      "year": "2025",
      "organization": "Unknown"
    },
    {
      "source": "8205Oxford Handbook of Clinical Medicine 10th 2017 Edition_SamanSarKo - Copy.pdf",
      "chunk_id": 379,
      "content_type": "definition",
      "content_type_confidence": 2,
      "word_count": 592,
      "entity_count": 1,
      "has_ckd": false,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "heart failure",
      "year": "2025",
      "organization": "Unknown"
    },
    {
      "source": "8205Oxford Handbook of Clinical Medicine 10th 2017 Edition_SamanSarKo - Copy.pdf",
      "chunk_id": 382,
      "content_type": "recommendation",
      "content_type_confidence": 2,
      "word_count": 595,
      "entity_count": 4,
      "has_ckd": false,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "hemoglobin,iron,fatigue,screening",
      "year": "2025",
      "organization": "Unknown"
    },
    {
      "source": "8205Oxford Handbook of Clinical Medicine 10th 2017 Edition_SamanSarKo - Copy.pdf",
      "chunk_id": 384,
      "content_type": "treatment",
      "content_type_confidence": 4,
      "word_count": 599,
      "entity_count": 4,
      "has_ckd": false,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "edema,quality of life,screening,monitoring",
      "year": "2025",
      "organization": "Unknown"
    },
    {
      "source": "8205Oxford Handbook of Clinical Medicine 10th 2017 Edition_SamanSarKo - Copy.pdf",
      "chunk_id": 385,
      "content_type": "treatment",
      "content_type_confidence": 3,
      "word_count": 556,
      "entity_count": 3,
      "has_ckd": false,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "nutrition,quality of life,screening",
      "year": "2025",
      "organization": "Unknown",
      "section": "Nausea and Vomiting:"
    },
    {
      "source": "8205Oxford Handbook of Clinical Medicine 10th 2017 Edition_SamanSarKo - Copy.pdf",
      "chunk_id": 386,
      "content_type": "dietary",
      "content_type_confidence": 3,
      "word_count": 599,
      "entity_count": 7,
      "has_ckd": false,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "renal failure,sodium,potassium,calcium,phosphate,parathyroid hormone,neuropathy",
      "year": "2025",
      "organization": "Unknown"
    },
    {
      "source": "8205Oxford Handbook of Clinical Medicine 10th 2017 Edition_SamanSarKo - Copy.pdf",
      "chunk_id": 387,
      "content_type": "recommendation",
      "content_type_confidence": 2,
      "word_count": 508,
      "entity_count": 3,
      "has_ckd": false,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "calcium,screening,monitoring",
      "year": "2025",
      "organization": "Unknown"
    },
    {
      "source": "8205Oxford Handbook of Clinical Medicine 10th 2017 Edition_SamanSarKo - Copy.pdf",
      "chunk_id": 388,
      "content_type": "definition",
      "content_type_confidence": 2,
      "word_count": 600,
      "entity_count": 5,
      "has_ckd": true,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "chronic kidney disease,calcium,heart failure,quality of life,monitoring",
      "year": "2025",
      "organization": "Unknown"
    },
    {
      "source": "8205Oxford Handbook of Clinical Medicine 10th 2017 Edition_SamanSarKo - Copy.pdf",
      "chunk_id": 389,
      "content_type": "treatment",
      "content_type_confidence": 4,
      "word_count": 584,
      "entity_count": 2,
      "has_ckd": false,
      "has_gfr": true,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "glomerular filtration rate,renal failure",
      "year": "2025",
      "organization": "Unknown"
    },
    {
      "source": "8205Oxford Handbook of Clinical Medicine 10th 2017 Edition_SamanSarKo - Copy.pdf",
      "chunk_id": 390,
      "content_type": "treatment",
      "content_type_confidence": 6,
      "word_count": 591,
      "entity_count": 5,
      "has_ckd": false,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "renal failure,sodium,phosphate,magnesium,diuretics",
      "year": "2025",
      "organization": "Unknown",
      "section": "Rapid analgesia:"
    },
    {
      "source": "8205Oxford Handbook of Clinical Medicine 10th 2017 Edition_SamanSarKo - Copy.pdf",
      "chunk_id": 391,
      "content_type": "treatment",
      "content_type_confidence": 5,
      "word_count": 572,
      "entity_count": 3,
      "has_ckd": false,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "renal failure,catheter,pruritus",
      "year": "2025",
      "organization": "Unknown"
    },
    {
      "source": "8205Oxford Handbook of Clinical Medicine 10th 2017 Edition_SamanSarKo - Copy.pdf",
      "chunk_id": 393,
      "content_type": "monitoring",
      "content_type_confidence": 2,
      "word_count": 589,
      "entity_count": 2,
      "has_ckd": false,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "bone disease,screening",
      "year": "2025",
      "organization": "Unknown"
    },
    {
      "source": "8205Oxford Handbook of Clinical Medicine 10th 2017 Edition_SamanSarKo - Copy.pdf",
      "chunk_id": 394,
      "content_type": "monitoring",
      "content_type_confidence": 2,
      "word_count": 597,
      "entity_count": 2,
      "has_ckd": false,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "edema,screening",
      "year": "2025",
      "organization": "Unknown"
    },
    {
      "source": "8205Oxford Handbook of Clinical Medicine 10th 2017 Edition_SamanSarKo - Copy.pdf",
      "chunk_id": 395,
      "content_type": "reference",
      "content_type_confidence": 2,
      "word_count": 600,
      "entity_count": 2,
      "has_ckd": false,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "creatinine,potassium",
      "year": "2025",
      "organization": "Unknown"
    },
    {
      "source": "8205Oxford Handbook of Clinical Medicine 10th 2017 Edition_SamanSarKo - Copy.pdf",
      "chunk_id": 396,
      "content_type": "recommendation",
      "content_type_confidence": 2,
      "word_count": 597,
      "entity_count": 2,
      "has_ckd": false,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "calcium,exercise",
      "year": "2025",
      "organization": "Unknown"
    },
    {
      "source": "8205Oxford Handbook of Clinical Medicine 10th 2017 Edition_SamanSarKo - Copy.pdf",
      "chunk_id": 397,
      "content_type": "treatment",
      "content_type_confidence": 5,
      "word_count": 598,
      "entity_count": 3,
      "has_ckd": false,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "edema,exercise,quality of life",
      "year": "2025",
      "organization": "Unknown"
    },
    {
      "source": "8205Oxford Handbook of Clinical Medicine 10th 2017 Edition_SamanSarKo - Copy.pdf",
      "chunk_id": 398,
      "content_type": "treatment",
      "content_type_confidence": 3,
      "word_count": 594,
      "entity_count": 3,
      "has_ckd": false,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "renal failure,diuretics,heart failure",
      "year": "2025",
      "organization": "Unknown"
    },
    {
      "source": "8205Oxford Handbook of Clinical Medicine 10th 2017 Edition_SamanSarKo - Copy.pdf",
      "chunk_id": 399,
      "content_type": "treatment",
      "content_type_confidence": 2,
      "word_count": 592,
      "entity_count": 2,
      "has_ckd": false,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "cardiovascular disease,neuropathy",
      "year": "2025",
      "organization": "Unknown",
      "section": "Alternatives to NSAIDs:"
    },
    {
      "source": "8205Oxford Handbook of Clinical Medicine 10th 2017 Edition_SamanSarKo - Copy.pdf",
      "chunk_id": 400,
      "content_type": "evidence",
      "content_type_confidence": 3,
      "word_count": 600,
      "entity_count": 5,
      "has_ckd": false,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "edema,retinopathy,quality of life,screening,monitoring",
      "year": "2025",
      "organization": "Unknown"
    },
    {
      "source": "8205Oxford Handbook of Clinical Medicine 10th 2017 Edition_SamanSarKo - Copy.pdf",
      "chunk_id": 401,
      "content_type": "treatment",
      "content_type_confidence": 4,
      "word_count": 591,
      "entity_count": 8,
      "has_ckd": true,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "chronic kidney disease,renal function,renal failure,nephritis,diuretics,edema,cardiovascular disease,heart failure",
      "year": "2025",
      "organization": "Unknown"
    },
    {
      "source": "8205Oxford Handbook of Clinical Medicine 10th 2017 Edition_SamanSarKo - Copy.pdf",
      "chunk_id": 402,
      "content_type": "reference",
      "content_type_confidence": 1,
      "word_count": 596,
      "entity_count": 3,
      "has_ckd": false,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "calcium,uric acid,exercise",
      "year": "2025",
      "organization": "Unknown"
    },
    {
      "source": "8205Oxford Handbook of Clinical Medicine 10th 2017 Edition_SamanSarKo - Copy.pdf",
      "chunk_id": 403,
      "content_type": "dietary",
      "content_type_confidence": 2,
      "word_count": 586,
      "entity_count": 2,
      "has_ckd": false,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "fatigue,exercise",
      "year": "2025",
      "organization": "Unknown"
    },
    {
      "source": "8205Oxford Handbook of Clinical Medicine 10th 2017 Edition_SamanSarKo - Copy.pdf",
      "chunk_id": 404,
      "content_type": "recommendation",
      "content_type_confidence": 1,
      "word_count": 597,
      "entity_count": 1,
      "has_ckd": false,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "renal function",
      "year": "2025",
      "organization": "Unknown"
    },
    {
      "source": "8205Oxford Handbook of Clinical Medicine 10th 2017 Edition_SamanSarKo - Copy.pdf",
      "chunk_id": 405,
      "content_type": "dietary",
      "content_type_confidence": 2,
      "word_count": 595,
      "entity_count": 3,
      "has_ckd": false,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "potassium,calcium,statins",
      "year": "2025",
      "organization": "Unknown",
      "section": "Gottrons papules:"
    },
    {
      "source": "8205Oxford Handbook of Clinical Medicine 10th 2017 Edition_SamanSarKo - Copy.pdf",
      "chunk_id": 406,
      "content_type": "treatment",
      "content_type_confidence": 3,
      "word_count": 600,
      "entity_count": 5,
      "has_ckd": false,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "nephritis,fatigue,cardiovascular disease,blood pressure control,monitoring",
      "year": "2025",
      "organization": "Unknown"
    },
    {
      "source": "8205Oxford Handbook of Clinical Medicine 10th 2017 Edition_SamanSarKo - Copy.pdf",
      "chunk_id": 407,
      "content_type": "reference",
      "content_type_confidence": 1,
      "word_count": 587,
      "entity_count": 4,
      "has_ckd": false,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "nephritis,proteinuria,fatigue,neuropathy",
      "year": "2025",
      "organization": "Unknown"
    },
    {
      "source": "8205Oxford Handbook of Clinical Medicine 10th 2017 Edition_SamanSarKo - Copy.pdf",
      "chunk_id": 408,
      "content_type": "recommendation",
      "content_type_confidence": 1,
      "word_count": 600,
      "entity_count": 6,
      "has_ckd": false,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "renal failure,proteinuria,creatinine,calcium,hemoglobin,heart failure",
      "year": "2025",
      "organization": "Unknown"
    },
    {
      "source": "8205Oxford Handbook of Clinical Medicine 10th 2017 Edition_SamanSarKo - Copy.pdf",
      "chunk_id": 409,
      "content_type": "recommendation",
      "content_type_confidence": 2,
      "word_count": 580,
      "entity_count": 4,
      "has_ckd": false,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "renal failure,proteinuria,creatinine,fatigue",
      "year": "2025",
      "organization": "Unknown",
      "section": "Renal:"
    },
    {
      "source": "8205Oxford Handbook of Clinical Medicine 10th 2017 Edition_SamanSarKo - Copy.pdf",
      "chunk_id": 410,
      "content_type": "recommendation",
      "content_type_confidence": 4,
      "word_count": 543,
      "entity_count": 2,
      "has_ckd": false,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "fatigue,exercise",
      "year": "2025",
      "organization": "Unknown",
      "section": "Management:"
    },
    {
      "source": "8205Oxford Handbook of Clinical Medicine 10th 2017 Edition_SamanSarKo - Copy.pdf",
      "chunk_id": 411,
      "content_type": "evidence",
      "content_type_confidence": 3,
      "word_count": 596,
      "entity_count": 1,
      "has_ckd": false,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "retinopathy",
      "year": "2025",
      "organization": "Unknown"
    },
    {
      "source": "8205Oxford Handbook of Clinical Medicine 10th 2017 Edition_SamanSarKo - Copy.pdf",
      "chunk_id": 412,
      "content_type": "treatment",
      "content_type_confidence": 2,
      "word_count": 600,
      "entity_count": 1,
      "has_ckd": false,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "retinopathy",
      "year": "2025",
      "organization": "Unknown"
    },
    {
      "source": "8205Oxford Handbook of Clinical Medicine 10th 2017 Edition_SamanSarKo - Copy.pdf",
      "chunk_id": 413,
      "content_type": "treatment",
      "content_type_confidence": 3,
      "word_count": 600,
      "entity_count": 1,
      "has_ckd": false,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "diet",
      "year": "2025",
      "organization": "Unknown"
    },
    {
      "source": "8205Oxford Handbook of Clinical Medicine 10th 2017 Edition_SamanSarKo - Copy.pdf",
      "chunk_id": 415,
      "content_type": "treatment",
      "content_type_confidence": 4,
      "word_count": 595,
      "entity_count": 3,
      "has_ckd": false,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "potassium,bicarbonate,diuretics",
      "year": "2025",
      "organization": "Unknown"
    },
    {
      "source": "8205Oxford Handbook of Clinical Medicine 10th 2017 Edition_SamanSarKo - Copy.pdf",
      "chunk_id": 416,
      "content_type": "treatment",
      "content_type_confidence": 5,
      "word_count": 589,
      "entity_count": 4,
      "has_ckd": false,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "hemoglobin,diuretics,exercise,monitoring",
      "year": "2025",
      "organization": "Unknown"
    },
    {
      "source": "8205Oxford Handbook of Clinical Medicine 10th 2017 Edition_SamanSarKo - Copy.pdf",
      "chunk_id": 417,
      "content_type": "recommendation",
      "content_type_confidence": 1,
      "word_count": 579,
      "entity_count": 1,
      "has_ckd": false,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "exercise",
      "year": "2025",
      "organization": "Unknown"
    },
    {
      "source": "8205Oxford Handbook of Clinical Medicine 10th 2017 Edition_SamanSarKo - Copy.pdf",
      "chunk_id": 419,
      "content_type": "recommendation",
      "content_type_confidence": 2,
      "word_count": 589,
      "entity_count": 1,
      "has_ckd": false,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "risk category",
      "year": "2025",
      "organization": "Unknown"
    },
    {
      "source": "8205Oxford Handbook of Clinical Medicine 10th 2017 Edition_SamanSarKo - Copy.pdf",
      "chunk_id": 421,
      "content_type": "treatment",
      "content_type_confidence": 3,
      "word_count": 587,
      "entity_count": 2,
      "has_ckd": false,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "acidosis,metabolic acidosis",
      "year": "2025",
      "organization": "Unknown"
    },
    {
      "source": "8205Oxford Handbook of Clinical Medicine 10th 2017 Edition_SamanSarKo - Copy.pdf",
      "chunk_id": 422,
      "content_type": "reference",
      "content_type_confidence": 3,
      "word_count": 586,
      "entity_count": 2,
      "has_ckd": false,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "magnesium,heart failure",
      "year": "2025",
      "organization": "Unknown",
      "section": "Recovery:"
    },
    {
      "source": "8205Oxford Handbook of Clinical Medicine 10th 2017 Edition_SamanSarKo - Copy.pdf",
      "chunk_id": 423,
      "content_type": "treatment",
      "content_type_confidence": 3,
      "word_count": 600,
      "entity_count": 1,
      "has_ckd": false,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "renal failure",
      "year": "2025",
      "organization": "Unknown"
    },
    {
      "source": "8205Oxford Handbook of Clinical Medicine 10th 2017 Edition_SamanSarKo - Copy.pdf",
      "chunk_id": 424,
      "content_type": "treatment",
      "content_type_confidence": 3,
      "word_count": 600,
      "entity_count": 6,
      "has_ckd": false,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "acute kidney injury,renal failure,sodium,catheter,edema,monitoring",
      "year": "2025",
      "organization": "Unknown"
    },
    {
      "source": "8205Oxford Handbook of Clinical Medicine 10th 2017 Edition_SamanSarKo - Copy.pdf",
      "chunk_id": 425,
      "content_type": "recommendation",
      "content_type_confidence": 2,
      "word_count": 598,
      "entity_count": 5,
      "has_ckd": false,
      "has_gfr": true,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "glomerular filtration rate,renal failure,edema,heart failure,monitoring",
      "year": "2025",
      "organization": "Unknown",
      "section": "Wells score:"
    },
    {
      "source": "8205Oxford Handbook of Clinical Medicine 10th 2017 Edition_SamanSarKo - Copy.pdf",
      "chunk_id": 426,
      "content_type": "recommendation",
      "content_type_confidence": 3,
      "word_count": 600,
      "entity_count": 2,
      "has_ckd": false,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "proteinuria,diuretics",
      "year": "2025",
      "organization": "Unknown"
    },
    {
      "source": "8205Oxford Handbook of Clinical Medicine 10th 2017 Edition_SamanSarKo - Copy.pdf",
      "chunk_id": 427,
      "content_type": "dietary",
      "content_type_confidence": 2,
      "word_count": 577,
      "entity_count": 3,
      "has_ckd": false,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "renal failure,potassium,nutrition",
      "year": "2025",
      "organization": "Unknown"
    },
    {
      "source": "8205Oxford Handbook of Clinical Medicine 10th 2017 Edition_SamanSarKo - Copy.pdf",
      "chunk_id": 429,
      "content_type": "dietary",
      "content_type_confidence": 6,
      "word_count": 600,
      "entity_count": 6,
      "has_ckd": false,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "potassium,nutrition,diet,malnutrition,renal osteodystrophy,screening",
      "year": "2025",
      "organization": "Unknown",
      "section": "Transanal endoscopic microsurgery:"
    },
    {
      "source": "8205Oxford Handbook of Clinical Medicine 10th 2017 Edition_SamanSarKo - Copy.pdf",
      "chunk_id": 430,
      "content_type": "dietary",
      "content_type_confidence": 5,
      "word_count": 592,
      "entity_count": 7,
      "has_ckd": false,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "sodium,potassium,chloride,nutrition,diet,malnutrition,monitoring",
      "year": "2025",
      "organization": "Unknown",
      "section": "Examination:"
    },
    {
      "source": "8205Oxford Handbook of Clinical Medicine 10th 2017 Edition_SamanSarKo - Copy.pdf",
      "chunk_id": 431,
      "content_type": "dietary",
      "content_type_confidence": 5,
      "word_count": 575,
      "entity_count": 7,
      "has_ckd": false,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "creatinine,calcium,phosphate,magnesium,nutrition,insulin,catheter",
      "year": "2025",
      "organization": "Unknown"
    },
    {
      "source": "8205Oxford Handbook of Clinical Medicine 10th 2017 Edition_SamanSarKo - Copy.pdf",
      "chunk_id": 432,
      "content_type": "dietary",
      "content_type_confidence": 6,
      "word_count": 587,
      "entity_count": 8,
      "has_ckd": false,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "sodium,potassium,calcium,phosphate,magnesium,hemoglobin,insulin,catheter",
      "year": "2025",
      "organization": "Unknown"
    },
    {
      "source": "8205Oxford Handbook of Clinical Medicine 10th 2017 Edition_SamanSarKo - Copy.pdf",
      "chunk_id": 433,
      "content_type": "dietary",
      "content_type_confidence": 4,
      "word_count": 575,
      "entity_count": 7,
      "has_ckd": false,
      "has_gfr": true,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "glomerular filtration rate,renal function,creatinine,serum creatinine,diet,insulin,heart failure",
      "year": "2025",
      "organization": "Unknown"
    },
    {
      "source": "8205Oxford Handbook of Clinical Medicine 10th 2017 Edition_SamanSarKo - Copy.pdf",
      "chunk_id": 434,
      "content_type": "dietary",
      "content_type_confidence": 4,
      "word_count": 593,
      "entity_count": 6,
      "has_ckd": false,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "renal function,renal failure,sodium,potassium,chloride,heart failure",
      "year": "2025",
      "organization": "Unknown"
    },
    {
      "source": "8205Oxford Handbook of Clinical Medicine 10th 2017 Edition_SamanSarKo - Copy.pdf",
      "chunk_id": 439,
      "content_type": "dietary",
      "content_type_confidence": 2,
      "word_count": 594,
      "entity_count": 2,
      "has_ckd": false,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "calcium,edema",
      "year": "2025",
      "organization": "Unknown"
    },
    {
      "source": "8205Oxford Handbook of Clinical Medicine 10th 2017 Edition_SamanSarKo - Copy.pdf",
      "chunk_id": 440,
      "content_type": "treatment",
      "content_type_confidence": 4,
      "word_count": 598,
      "entity_count": 1,
      "has_ckd": false,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "parathyroid hormone",
      "year": "2025",
      "organization": "Unknown"
    },
    {
      "source": "8205Oxford Handbook of Clinical Medicine 10th 2017 Edition_SamanSarKo - Copy.pdf",
      "chunk_id": 441,
      "content_type": "recommendation",
      "content_type_confidence": 2,
      "word_count": 591,
      "entity_count": 4,
      "has_ckd": false,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "stage 1,stage 2,stage 3,stage 4",
      "year": "2025",
      "organization": "Unknown"
    },
    {
      "source": "8205Oxford Handbook of Clinical Medicine 10th 2017 Edition_SamanSarKo - Copy.pdf",
      "chunk_id": 442,
      "content_type": "recommendation",
      "content_type_confidence": 2,
      "word_count": 600,
      "entity_count": 2,
      "has_ckd": false,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "edema,screening",
      "year": "2025",
      "organization": "Unknown"
    },
    {
      "source": "8205Oxford Handbook of Clinical Medicine 10th 2017 Edition_SamanSarKo - Copy.pdf",
      "chunk_id": 444,
      "content_type": "reference",
      "content_type_confidence": 2,
      "word_count": 587,
      "entity_count": 1,
      "has_ckd": false,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "edema",
      "year": "2025",
      "organization": "Unknown"
    },
    {
      "source": "8205Oxford Handbook of Clinical Medicine 10th 2017 Edition_SamanSarKo - Copy.pdf",
      "chunk_id": 445,
      "content_type": "reference",
      "content_type_confidence": 2,
      "word_count": 585,
      "entity_count": 1,
      "has_ckd": false,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "creatinine",
      "year": "2025",
      "organization": "Unknown"
    },
    {
      "source": "8205Oxford Handbook of Clinical Medicine 10th 2017 Edition_SamanSarKo - Copy.pdf",
      "chunk_id": 446,
      "content_type": "reference",
      "content_type_confidence": 2,
      "word_count": 590,
      "entity_count": 1,
      "has_ckd": false,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "calcium",
      "year": "2025",
      "organization": "Unknown"
    },
    {
      "source": "8205Oxford Handbook of Clinical Medicine 10th 2017 Edition_SamanSarKo - Copy.pdf",
      "chunk_id": 447,
      "content_type": "recommendation",
      "content_type_confidence": 2,
      "word_count": 592,
      "entity_count": 3,
      "has_ckd": false,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "hemoglobin,diet,stage 3",
      "year": "2025",
      "organization": "Unknown",
      "section": "The spermatic cord:"
    },
    {
      "source": "8205Oxford Handbook of Clinical Medicine 10th 2017 Edition_SamanSarKo - Copy.pdf",
      "chunk_id": 448,
      "content_type": "reference",
      "content_type_confidence": 3,
      "word_count": 581,
      "entity_count": 6,
      "has_ckd": false,
      "has_gfr": true,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "glomerular filtration rate,screening,stage 1,stage 2,stage 3,stage 4",
      "year": "2025",
      "organization": "Unknown"
    },
    {
      "source": "8205Oxford Handbook of Clinical Medicine 10th 2017 Edition_SamanSarKo - Copy.pdf",
      "chunk_id": 449,
      "content_type": "reference",
      "content_type_confidence": 2,
      "word_count": 599,
      "entity_count": 2,
      "has_ckd": false,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "diet,screening",
      "year": "2025",
      "organization": "Unknown"
    },
    {
      "source": "8205Oxford Handbook of Clinical Medicine 10th 2017 Edition_SamanSarKo - Copy.pdf",
      "chunk_id": 450,
      "content_type": "evidence",
      "content_type_confidence": 3,
      "word_count": 599,
      "entity_count": 6,
      "has_ckd": false,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "renal failure,hemoglobin,acidosis,metabolic acidosis,pruritus,quality of life",
      "year": "2025",
      "organization": "Unknown"
    },
    {
      "source": "8205Oxford Handbook of Clinical Medicine 10th 2017 Edition_SamanSarKo - Copy.pdf",
      "chunk_id": 452,
      "content_type": "dietary",
      "content_type_confidence": 4,
      "word_count": 597,
      "entity_count": 3,
      "has_ckd": false,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "phosphate,iron,insulin",
      "year": "2025",
      "organization": "Unknown",
      "section": "Physical complications of gastrectomy Abdominal fullness:"
    },
    {
      "source": "8205Oxford Handbook of Clinical Medicine 10th 2017 Edition_SamanSarKo - Copy.pdf",
      "chunk_id": 453,
      "content_type": "dietary",
      "content_type_confidence": 5,
      "word_count": 594,
      "entity_count": 3,
      "has_ckd": false,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "diet,quality of life,monitoring",
      "year": "2025",
      "organization": "Unknown"
    },
    {
      "source": "8205Oxford Handbook of Clinical Medicine 10th 2017 Edition_SamanSarKo - Copy.pdf",
      "chunk_id": 454,
      "content_type": "dietary",
      "content_type_confidence": 5,
      "word_count": 589,
      "entity_count": 4,
      "has_ckd": false,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "stage 1,stage 2,stage 3,stage 4",
      "year": "2025",
      "organization": "Unknown"
    },
    {
      "source": "8205Oxford Handbook of Clinical Medicine 10th 2017 Edition_SamanSarKo - Copy.pdf",
      "chunk_id": 455,
      "content_type": "dietary",
      "content_type_confidence": 3,
      "word_count": 587,
      "entity_count": 4,
      "has_ckd": false,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "hemoglobin,diet,catheter,pruritus",
      "year": "2025",
      "organization": "Unknown",
      "section": "Fistulae:"
    },
    {
      "source": "8205Oxford Handbook of Clinical Medicine 10th 2017 Edition_SamanSarKo - Copy.pdf",
      "chunk_id": 456,
      "content_type": "treatment",
      "content_type_confidence": 3,
      "word_count": 593,
      "entity_count": 1,
      "has_ckd": false,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "fistula",
      "year": "2025",
      "organization": "Unknown"
    },
    {
      "source": "8205Oxford Handbook of Clinical Medicine 10th 2017 Edition_SamanSarKo - Copy.pdf",
      "chunk_id": 457,
      "content_type": "treatment",
      "content_type_confidence": 2,
      "word_count": 600,
      "entity_count": 2,
      "has_ckd": false,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "edema,pruritus",
      "year": "2025",
      "organization": "Unknown"
    },
    {
      "source": "8205Oxford Handbook of Clinical Medicine 10th 2017 Edition_SamanSarKo - Copy.pdf",
      "chunk_id": 458,
      "content_type": "treatment",
      "content_type_confidence": 2,
      "word_count": 595,
      "entity_count": 2,
      "has_ckd": false,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "calcium,hemoglobin",
      "year": "2025",
      "organization": "Unknown"
    },
    {
      "source": "8205Oxford Handbook of Clinical Medicine 10th 2017 Edition_SamanSarKo - Copy.pdf",
      "chunk_id": 459,
      "content_type": "definition",
      "content_type_confidence": 2,
      "word_count": 590,
      "entity_count": 1,
      "has_ckd": false,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "nutrition",
      "year": "2025",
      "organization": "Unknown"
    },
    {
      "source": "8205Oxford Handbook of Clinical Medicine 10th 2017 Edition_SamanSarKo - Copy.pdf",
      "chunk_id": 460,
      "content_type": "recommendation",
      "content_type_confidence": 2,
      "word_count": 560,
      "entity_count": 5,
      "has_ckd": false,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "renal failure,nutrition,insulin,catheter,monitoring",
      "year": "2025",
      "organization": "Unknown"
    },
    {
      "source": "8205Oxford Handbook of Clinical Medicine 10th 2017 Edition_SamanSarKo - Copy.pdf",
      "chunk_id": 461,
      "content_type": "dietary",
      "content_type_confidence": 3,
      "word_count": 596,
      "entity_count": 10,
      "has_ckd": false,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "renal function,nephritis,proteinuria,creatinine,urea,sodium,calcium,phosphate,magnesium,bicarbonate",
      "year": "2025",
      "organization": "Unknown",
      "section": "Mnemonic:"
    },
    {
      "source": "8205Oxford Handbook of Clinical Medicine 10th 2017 Edition_SamanSarKo - Copy.pdf",
      "chunk_id": 462,
      "content_type": "dietary",
      "content_type_confidence": 5,
      "word_count": 586,
      "entity_count": 10,
      "has_ckd": false,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "acute kidney injury,proteinuria,sodium,potassium,calcium,phosphate,magnesium,bicarbonate,vitamin D,diet",
      "year": "2025",
      "organization": "Unknown"
    },
    {
      "source": "8205Oxford Handbook of Clinical Medicine 10th 2017 Edition_SamanSarKo - Copy.pdf",
      "chunk_id": 463,
      "content_type": "monitoring",
      "content_type_confidence": 3,
      "word_count": 598,
      "entity_count": 4,
      "has_ckd": false,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "renal function,renal failure,creatinine,catheter",
      "year": "2025",
      "organization": "Unknown"
    },
    {
      "source": "8205Oxford Handbook of Clinical Medicine 10th 2017 Edition_SamanSarKo - Copy.pdf",
      "chunk_id": 464,
      "content_type": "dietary",
      "content_type_confidence": 2,
      "word_count": 588,
      "entity_count": 10,
      "has_ckd": false,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "nephropathy,creatinine,sodium,chloride,bicarbonate,serum creatinine,sodium bicarbonate,catheter,acidosis,metabolic acidosis",
      "year": "2025",
      "organization": "Unknown"
    },
    {
      "source": "8205Oxford Handbook of Clinical Medicine 10th 2017 Edition_SamanSarKo - Copy.pdf",
      "chunk_id": 465,
      "content_type": "definition",
      "content_type_confidence": 2,
      "word_count": 600,
      "entity_count": 3,
      "has_ckd": false,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "creatinine,urea,sodium",
      "year": "2025",
      "organization": "Unknown",
      "section": "SE:"
    },
    {
      "source": "8205Oxford Handbook of Clinical Medicine 10th 2017 Edition_SamanSarKo - Copy.pdf",
      "chunk_id": 466,
      "content_type": "treatment",
      "content_type_confidence": 3,
      "word_count": 586,
      "entity_count": 4,
      "has_ckd": false,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "renal function,nephron,erythropoietin,screening",
      "year": "2025",
      "organization": "Unknown",
      "section": "Epidemiology:"
    },
    {
      "source": "8205Oxford Handbook of Clinical Medicine 10th 2017 Edition_SamanSarKo - Copy.pdf",
      "chunk_id": 467,
      "content_type": "recommendation",
      "content_type_confidence": 3,
      "word_count": 585,
      "entity_count": 1,
      "has_ckd": false,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "screening",
      "year": "2025",
      "organization": "Unknown"
    },
    {
      "source": "8205Oxford Handbook of Clinical Medicine 10th 2017 Edition_SamanSarKo - Copy.pdf",
      "chunk_id": 468,
      "content_type": "treatment",
      "content_type_confidence": 3,
      "word_count": 597,
      "entity_count": 1,
      "has_ckd": false,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "renal failure",
      "year": "2025",
      "organization": "Unknown"
    },
    {
      "source": "8205Oxford Handbook of Clinical Medicine 10th 2017 Edition_SamanSarKo - Copy.pdf",
      "chunk_id": 469,
      "content_type": "evidence",
      "content_type_confidence": 4,
      "word_count": 597,
      "entity_count": 4,
      "has_ckd": false,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "diuretics,catheter,exercise,monitoring",
      "year": "2025",
      "organization": "Unknown"
    },
    {
      "source": "8205Oxford Handbook of Clinical Medicine 10th 2017 Edition_SamanSarKo - Copy.pdf",
      "chunk_id": 470,
      "content_type": "treatment",
      "content_type_confidence": 5,
      "word_count": 591,
      "entity_count": 6,
      "has_ckd": false,
      "has_gfr": true,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "glomerular filtration rate,sodium,diuretics,catheter,heart failure,quality of life",
      "year": "2025",
      "organization": "Unknown",
      "section": "Other causes:"
    },
    {
      "source": "8205Oxford Handbook of Clinical Medicine 10th 2017 Edition_SamanSarKo - Copy.pdf",
      "chunk_id": 471,
      "content_type": "dietary",
      "content_type_confidence": 2,
      "word_count": 594,
      "entity_count": 2,
      "has_ckd": false,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "catheter,edema",
      "year": "2025",
      "organization": "Unknown"
    },
    {
      "source": "8205Oxford Handbook of Clinical Medicine 10th 2017 Edition_SamanSarKo - Copy.pdf",
      "chunk_id": 472,
      "content_type": "treatment",
      "content_type_confidence": 2,
      "word_count": 598,
      "entity_count": 1,
      "has_ckd": false,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "stage 1",
      "year": "2025",
      "organization": "Unknown",
      "section": "Risk factors:"
    },
    {
      "source": "8205Oxford Handbook of Clinical Medicine 10th 2017 Edition_SamanSarKo - Copy.pdf",
      "chunk_id": 473,
      "content_type": "treatment",
      "content_type_confidence": 2,
      "word_count": 596,
      "entity_count": 2,
      "has_ckd": false,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "screening,monitoring",
      "year": "2025",
      "organization": "Unknown",
      "section": "Cryptorchidism:"
    },
    {
      "source": "8205Oxford Handbook of Clinical Medicine 10th 2017 Edition_SamanSarKo - Copy.pdf",
      "chunk_id": 474,
      "content_type": "recommendation",
      "content_type_confidence": 1,
      "word_count": 599,
      "entity_count": 3,
      "has_ckd": false,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "calcium,hemoglobin,monitoring",
      "year": "2025",
      "organization": "Unknown",
      "section": "Rupture is more likely if:"
    },
    {
      "source": "8205Oxford Handbook of Clinical Medicine 10th 2017 Edition_SamanSarKo - Copy.pdf",
      "chunk_id": 475,
      "content_type": "recommendation",
      "content_type_confidence": 3,
      "word_count": 589,
      "entity_count": 1,
      "has_ckd": false,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "exercise",
      "year": "2025",
      "organization": "Unknown"
    },
    {
      "source": "8205Oxford Handbook of Clinical Medicine 10th 2017 Edition_SamanSarKo - Copy.pdf",
      "chunk_id": 476,
      "content_type": "recommendation",
      "content_type_confidence": 3,
      "word_count": 593,
      "entity_count": 2,
      "has_ckd": false,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "catheter,quality of life",
      "year": "2025",
      "organization": "Unknown"
    },
    {
      "source": "8205Oxford Handbook of Clinical Medicine 10th 2017 Edition_SamanSarKo - Copy.pdf",
      "chunk_id": 477,
      "content_type": "treatment",
      "content_type_confidence": 3,
      "word_count": 598,
      "entity_count": 3,
      "has_ckd": false,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "edema,quality of life,monitoring",
      "year": "2025",
      "organization": "Unknown"
    },
    {
      "source": "8205Oxford Handbook of Clinical Medicine 10th 2017 Edition_SamanSarKo - Copy.pdf",
      "chunk_id": 478,
      "content_type": "recommendation",
      "content_type_confidence": 2,
      "word_count": 596,
      "entity_count": 3,
      "has_ckd": false,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "nutrition,neuropathy,screening",
      "year": "2025",
      "organization": "Unknown"
    },
    {
      "source": "8205Oxford Handbook of Clinical Medicine 10th 2017 Edition_SamanSarKo - Copy.pdf",
      "chunk_id": 479,
      "content_type": "reference",
      "content_type_confidence": 3,
      "word_count": 587,
      "entity_count": 4,
      "has_ckd": false,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "calcium,phosphate,magnesium,neuropathy",
      "year": "2025",
      "organization": "Unknown"
    },
    {
      "source": "8205Oxford Handbook of Clinical Medicine 10th 2017 Edition_SamanSarKo - Copy.pdf",
      "chunk_id": 480,
      "content_type": "reference",
      "content_type_confidence": 2,
      "word_count": 516,
      "entity_count": 8,
      "has_ckd": true,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "chronic kidney disease,creatinine,potassium,calcium,hemoglobin,catheter,screening,monitoring",
      "year": "2025",
      "organization": "Unknown"
    },
    {
      "source": "8205Oxford Handbook of Clinical Medicine 10th 2017 Edition_SamanSarKo - Copy.pdf",
      "chunk_id": 481,
      "content_type": "dietary",
      "content_type_confidence": 4,
      "word_count": 585,
      "entity_count": 10,
      "has_ckd": true,
      "has_gfr": true,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "chronic kidney disease,acute kidney injury,glomerular filtration rate,kidney function,renal failure,creatinine,urea,sodium,potassium,phosphate",
      "year": "2025",
      "organization": "Unknown"
    },
    {
      "source": "8205Oxford Handbook of Clinical Medicine 10th 2017 Edition_SamanSarKo - Copy.pdf",
      "chunk_id": 482,
      "content_type": "dietary",
      "content_type_confidence": 4,
      "word_count": 587,
      "entity_count": 7,
      "has_ckd": false,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "creatinine,sodium,potassium,calcium,chloride,hemoglobin,acidosis",
      "year": "2025",
      "organization": "Unknown"
    },
    {
      "source": "8205Oxford Handbook of Clinical Medicine 10th 2017 Edition_SamanSarKo - Copy.pdf",
      "chunk_id": 483,
      "content_type": "dietary",
      "content_type_confidence": 3,
      "word_count": 592,
      "entity_count": 5,
      "has_ckd": false,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "sodium,potassium,chloride,bicarbonate,heart failure",
      "year": "2025",
      "organization": "Unknown"
    },
    {
      "source": "8205Oxford Handbook of Clinical Medicine 10th 2017 Edition_SamanSarKo - Copy.pdf",
      "chunk_id": 484,
      "content_type": "dietary",
      "content_type_confidence": 3,
      "word_count": 544,
      "entity_count": 10,
      "has_ckd": true,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "chronic kidney disease,renal failure,kidney failure,sodium,potassium,phosphate,vitamin D,erythropoietin,catheter,heart failure",
      "year": "2025",
      "organization": "Unknown",
      "section": "Elderly:"
    },
    {
      "source": "8205Oxford Handbook of Clinical Medicine 10th 2017 Edition_SamanSarKo - Copy.pdf",
      "chunk_id": 485,
      "content_type": "dietary",
      "content_type_confidence": 2,
      "word_count": 587,
      "entity_count": 8,
      "has_ckd": true,
      "has_gfr": true,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "chronic kidney disease,glomerular filtration rate,creatinine,urea,sodium,potassium,serum creatinine,insulin",
      "year": "2025",
      "organization": "Unknown"
    },
    {
      "source": "8205Oxford Handbook of Clinical Medicine 10th 2017 Edition_SamanSarKo - Copy.pdf",
      "chunk_id": 486,
      "content_type": "dietary",
      "content_type_confidence": 3,
      "word_count": 596,
      "entity_count": 9,
      "has_ckd": false,
      "has_gfr": true,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": true,
      "medical_entities": "glomerular filtration rate,renal function,creatinine,serum creatinine,diet,insulin,dialysis,screening,monitoring",
      "year": "2025",
      "organization": "Unknown"
    },
    {
      "source": "8205Oxford Handbook of Clinical Medicine 10th 2017 Edition_SamanSarKo - Copy.pdf",
      "chunk_id": 487,
      "content_type": "treatment",
      "content_type_confidence": 4,
      "word_count": 598,
      "entity_count": 9,
      "has_ckd": false,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "renal failure,sodium,potassium,phosphate,chloride,bicarbonate,diuretics,acidosis,metabolic acidosis",
      "year": "2025",
      "organization": "Unknown"
    },
    {
      "source": "8205Oxford Handbook of Clinical Medicine 10th 2017 Edition_SamanSarKo - Copy.pdf",
      "chunk_id": 488,
      "content_type": "dietary",
      "content_type_confidence": 6,
      "word_count": 598,
      "entity_count": 7,
      "has_ckd": false,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "urea,sodium,potassium,bicarbonate,diuretics,acidosis,heart failure",
      "year": "2025",
      "organization": "Unknown"
    },
    {
      "source": "8205Oxford Handbook of Clinical Medicine 10th 2017 Edition_SamanSarKo - Copy.pdf",
      "chunk_id": 489,
      "content_type": "treatment",
      "content_type_confidence": 6,
      "word_count": 597,
      "entity_count": 9,
      "has_ckd": false,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": true,
      "medical_entities": "renal failure,urea,sodium,potassium,calcium,diuretics,dialysis,acidosis,metabolic acidosis",
      "year": "2025",
      "organization": "Unknown"
    },
    {
      "source": "8205Oxford Handbook of Clinical Medicine 10th 2017 Edition_SamanSarKo - Copy.pdf",
      "chunk_id": 490,
      "content_type": "dietary",
      "content_type_confidence": 4,
      "word_count": 586,
      "entity_count": 9,
      "has_ckd": false,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "potassium,calcium,phosphate,magnesium,bicarbonate,parathyroid hormone,vitamin D,calcitriol,diuretics",
      "year": "2025",
      "organization": "Unknown"
    },
    {
      "source": "8205Oxford Handbook of Clinical Medicine 10th 2017 Edition_SamanSarKo - Copy.pdf",
      "chunk_id": 491,
      "content_type": "dietary",
      "content_type_confidence": 5,
      "word_count": 599,
      "entity_count": 10,
      "has_ckd": false,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "renal failure,urea,potassium,calcium,phosphate,magnesium,bicarbonate,parathyroid hormone,vitamin D,thiazides",
      "year": "2025",
      "organization": "Unknown"
    },
    {
      "source": "8205Oxford Handbook of Clinical Medicine 10th 2017 Edition_SamanSarKo - Copy.pdf",
      "chunk_id": 492,
      "content_type": "dietary",
      "content_type_confidence": 5,
      "word_count": 587,
      "entity_count": 10,
      "has_ckd": true,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "chronic kidney disease,renal failure,potassium,calcium,phosphate,magnesium,vitamin D,nutrition,diet,phosphate binders",
      "year": "2025",
      "organization": "Unknown"
    },
    {
      "source": "8205Oxford Handbook of Clinical Medicine 10th 2017 Edition_SamanSarKo - Copy.pdf",
      "chunk_id": 493,
      "content_type": "treatment",
      "content_type_confidence": 5,
      "word_count": 594,
      "entity_count": 10,
      "has_ckd": true,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "chronic kidney disease,acute kidney injury,renal failure,nephropathy,potassium,bicarbonate,uric acid,diuretics,loop diuretics,thiazides",
      "year": "2025",
      "organization": "Unknown"
    },
    {
      "source": "8205Oxford Handbook of Clinical Medicine 10th 2017 Edition_SamanSarKo - Copy.pdf",
      "chunk_id": 494,
      "content_type": "dietary",
      "content_type_confidence": 4,
      "word_count": 591,
      "entity_count": 9,
      "has_ckd": false,
      "has_gfr": true,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "glomerular filtration rate,calcium,phosphate,parathyroid hormone,vitamin D,diet,supplements,cardiovascular disease,exercise",
      "year": "2025",
      "organization": "Unknown"
    },
    {
      "source": "8205Oxford Handbook of Clinical Medicine 10th 2017 Edition_SamanSarKo - Copy.pdf",
      "chunk_id": 495,
      "content_type": "evidence",
      "content_type_confidence": 3,
      "word_count": 600,
      "entity_count": 9,
      "has_ckd": false,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "renal failure,calcium,phosphate,parathyroid hormone,vitamin D,diet,bone disease,renal osteodystrophy,screening",
      "year": "2025",
      "organization": "Unknown"
    },
    {
      "source": "8205Oxford Handbook of Clinical Medicine 10th 2017 Edition_SamanSarKo - Copy.pdf",
      "chunk_id": 496,
      "content_type": "dietary",
      "content_type_confidence": 2,
      "word_count": 595,
      "entity_count": 5,
      "has_ckd": false,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "renal failure,calcium,phosphate,vitamin D,calcitriol",
      "year": "2025",
      "organization": "Unknown"
    },
    {
      "source": "8205Oxford Handbook of Clinical Medicine 10th 2017 Edition_SamanSarKo - Copy.pdf",
      "chunk_id": 497,
      "content_type": "reference",
      "content_type_confidence": 2,
      "word_count": 597,
      "entity_count": 6,
      "has_ckd": false,
      "has_gfr": true,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "glomerular filtration rate,renal failure,albuminuria,creatinine,malnutrition,screening",
      "year": "2025",
      "organization": "Unknown"
    },
    {
      "source": "8205Oxford Handbook of Clinical Medicine 10th 2017 Edition_SamanSarKo - Copy.pdf",
      "chunk_id": 498,
      "content_type": "evidence",
      "content_type_confidence": 2,
      "word_count": 598,
      "entity_count": 5,
      "has_ckd": true,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "chronic kidney disease,statins,bone disease,cardiovascular disease,screening",
      "year": "2025",
      "organization": "Unknown"
    },
    {
      "source": "8205Oxford Handbook of Clinical Medicine 10th 2017 Edition_SamanSarKo - Copy.pdf",
      "chunk_id": 499,
      "content_type": "recommendation",
      "content_type_confidence": 2,
      "word_count": 577,
      "entity_count": 5,
      "has_ckd": true,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "chronic kidney disease,renal failure,statins,cardiovascular disease,exercise",
      "year": "2025",
      "organization": "Unknown"
    },
    {
      "source": "8205Oxford Handbook of Clinical Medicine 10th 2017 Edition_SamanSarKo - Copy.pdf",
      "chunk_id": 500,
      "content_type": "treatment",
      "content_type_confidence": 4,
      "word_count": 596,
      "entity_count": 5,
      "has_ckd": false,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "proteinuria,sodium,potassium,iron,neuropathy",
      "year": "2025",
      "organization": "Unknown"
    },
    {
      "source": "8205Oxford Handbook of Clinical Medicine 10th 2017 Edition_SamanSarKo - Copy.pdf",
      "chunk_id": 501,
      "content_type": "definition",
      "content_type_confidence": 2,
      "word_count": 574,
      "entity_count": 3,
      "has_ckd": false,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "calcium,iron,statins",
      "year": "2025",
      "organization": "Unknown"
    },
    {
      "source": "8205Oxford Handbook of Clinical Medicine 10th 2017 Edition_SamanSarKo - Copy.pdf",
      "chunk_id": 502,
      "content_type": "recommendation",
      "content_type_confidence": 4,
      "word_count": 585,
      "entity_count": 5,
      "has_ckd": false,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "renal failure,nephropathy,proteinuria,edema,screening",
      "year": "2025",
      "organization": "Unknown"
    },
    {
      "source": "8205Oxford Handbook of Clinical Medicine 10th 2017 Edition_SamanSarKo - Copy.pdf",
      "chunk_id": 503,
      "content_type": "recommendation",
      "content_type_confidence": 2,
      "word_count": 583,
      "entity_count": 3,
      "has_ckd": false,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "sodium,neuropathy,quality of life",
      "year": "2025",
      "organization": "Unknown"
    },
    {
      "source": "8205Oxford Handbook of Clinical Medicine 10th 2017 Edition_SamanSarKo - Copy.pdf",
      "chunk_id": 504,
      "content_type": "treatment",
      "content_type_confidence": 2,
      "word_count": 596,
      "entity_count": 2,
      "has_ckd": false,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "renal failure,quality of life",
      "year": "2025",
      "organization": "Unknown"
    },
    {
      "source": "8205Oxford Handbook of Clinical Medicine 10th 2017 Edition_SamanSarKo - Copy.pdf",
      "chunk_id": 506,
      "content_type": "definition",
      "content_type_confidence": 1,
      "word_count": 580,
      "entity_count": 4,
      "has_ckd": false,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "renal failure,calcium,iron,neuropathy",
      "year": "2025",
      "organization": "Unknown",
      "section": "Symptoms:"
    },
    {
      "source": "8205Oxford Handbook of Clinical Medicine 10th 2017 Edition_SamanSarKo - Copy.pdf",
      "chunk_id": 507,
      "content_type": "treatment",
      "content_type_confidence": 2,
      "word_count": 593,
      "entity_count": 1,
      "has_ckd": false,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "exercise",
      "year": "2025",
      "organization": "Unknown"
    },
    {
      "source": "8205Oxford Handbook of Clinical Medicine 10th 2017 Edition_SamanSarKo - Copy.pdf",
      "chunk_id": 509,
      "content_type": "dietary",
      "content_type_confidence": 3,
      "word_count": 595,
      "entity_count": 1,
      "has_ckd": false,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "potassium",
      "year": "2025",
      "organization": "Unknown"
    },
    {
      "source": "8205Oxford Handbook of Clinical Medicine 10th 2017 Edition_SamanSarKo - Copy.pdf",
      "chunk_id": 510,
      "content_type": "definition",
      "content_type_confidence": 2,
      "word_count": 596,
      "entity_count": 6,
      "has_ckd": false,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "potassium,diet,statins,fatigue,heart failure,exercise",
      "year": "2025",
      "organization": "Unknown"
    },
    {
      "source": "8205Oxford Handbook of Clinical Medicine 10th 2017 Edition_SamanSarKo - Copy.pdf",
      "chunk_id": 512,
      "content_type": "recommendation",
      "content_type_confidence": 2,
      "word_count": 587,
      "entity_count": 3,
      "has_ckd": false,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "acute kidney injury,edema,exercise",
      "year": "2025",
      "organization": "Unknown"
    },
    {
      "source": "8205Oxford Handbook of Clinical Medicine 10th 2017 Edition_SamanSarKo - Copy.pdf",
      "chunk_id": 513,
      "content_type": "recommendation",
      "content_type_confidence": 2,
      "word_count": 600,
      "entity_count": 2,
      "has_ckd": false,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "potassium,calcium",
      "year": "2025",
      "organization": "Unknown"
    },
    {
      "source": "8205Oxford Handbook of Clinical Medicine 10th 2017 Edition_SamanSarKo - Copy.pdf",
      "chunk_id": 514,
      "content_type": "dietary",
      "content_type_confidence": 3,
      "word_count": 589,
      "entity_count": 3,
      "has_ckd": false,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "potassium,neuropathy,exercise",
      "year": "2025",
      "organization": "Unknown"
    },
    {
      "source": "8205Oxford Handbook of Clinical Medicine 10th 2017 Edition_SamanSarKo - Copy.pdf",
      "chunk_id": 515,
      "content_type": "treatment",
      "content_type_confidence": 3,
      "word_count": 596,
      "entity_count": 4,
      "has_ckd": false,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "immunosuppressants,edema,fatigue,neuropathy",
      "year": "2025",
      "organization": "Unknown"
    },
    {
      "source": "8205Oxford Handbook of Clinical Medicine 10th 2017 Edition_SamanSarKo - Copy.pdf",
      "chunk_id": 516,
      "content_type": "treatment",
      "content_type_confidence": 2,
      "word_count": 589,
      "entity_count": 2,
      "has_ckd": false,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "potassium,blood pressure control",
      "year": "2025",
      "organization": "Unknown"
    },
    {
      "source": "8205Oxford Handbook of Clinical Medicine 10th 2017 Edition_SamanSarKo - Copy.pdf",
      "chunk_id": 518,
      "content_type": "dietary",
      "content_type_confidence": 5,
      "word_count": 595,
      "entity_count": 5,
      "has_ckd": false,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "nephritis,proteinuria,creatinine,malnutrition,neuropathy",
      "year": "2025",
      "organization": "Unknown"
    },
    {
      "source": "8205Oxford Handbook of Clinical Medicine 10th 2017 Edition_SamanSarKo - Copy.pdf",
      "chunk_id": 519,
      "content_type": "recommendation",
      "content_type_confidence": 3,
      "word_count": 592,
      "entity_count": 1,
      "has_ckd": false,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "creatinine",
      "year": "2025",
      "organization": "Unknown"
    },
    {
      "source": "8205Oxford Handbook of Clinical Medicine 10th 2017 Edition_SamanSarKo - Copy.pdf",
      "chunk_id": 520,
      "content_type": "recommendation",
      "content_type_confidence": 2,
      "word_count": 591,
      "entity_count": 2,
      "has_ckd": false,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "creatinine,hemoglobin",
      "year": "2025",
      "organization": "Unknown"
    },
    {
      "source": "8205Oxford Handbook of Clinical Medicine 10th 2017 Edition_SamanSarKo - Copy.pdf",
      "chunk_id": 522,
      "content_type": "recommendation",
      "content_type_confidence": 1,
      "word_count": 596,
      "entity_count": 2,
      "has_ckd": false,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "calcium,heart failure",
      "year": "2025",
      "organization": "Unknown",
      "section": "Inspiration:"
    },
    {
      "source": "8205Oxford Handbook of Clinical Medicine 10th 2017 Edition_SamanSarKo - Copy.pdf",
      "chunk_id": 523,
      "content_type": "recommendation",
      "content_type_confidence": 2,
      "word_count": 506,
      "entity_count": 1,
      "has_ckd": false,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "catheter",
      "year": "2025",
      "organization": "Unknown"
    },
    {
      "source": "8205Oxford Handbook of Clinical Medicine 10th 2017 Edition_SamanSarKo - Copy.pdf",
      "chunk_id": 524,
      "content_type": "recommendation",
      "content_type_confidence": 2,
      "word_count": 600,
      "entity_count": 1,
      "has_ckd": false,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "catheter",
      "year": "2025",
      "organization": "Unknown"
    },
    {
      "source": "8205Oxford Handbook of Clinical Medicine 10th 2017 Edition_SamanSarKo - Copy.pdf",
      "chunk_id": 526,
      "content_type": "monitoring",
      "content_type_confidence": 2,
      "word_count": 599,
      "entity_count": 3,
      "has_ckd": false,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": true,
      "medical_entities": "dialysis,peritoneal dialysis,monitoring",
      "year": "2025",
      "organization": "Unknown"
    },
    {
      "source": "8205Oxford Handbook of Clinical Medicine 10th 2017 Edition_SamanSarKo - Copy.pdf",
      "chunk_id": 527,
      "content_type": "monitoring",
      "content_type_confidence": 2,
      "word_count": 594,
      "entity_count": 2,
      "has_ckd": false,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "renal failure,screening",
      "year": "2025",
      "organization": "Unknown"
    },
    {
      "source": "8205Oxford Handbook of Clinical Medicine 10th 2017 Edition_SamanSarKo - Copy.pdf",
      "chunk_id": 528,
      "content_type": "definition",
      "content_type_confidence": 1,
      "word_count": 584,
      "entity_count": 3,
      "has_ckd": false,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": true,
      "medical_entities": "hemoglobin,dialysis,peritoneal dialysis",
      "year": "2025",
      "organization": "Unknown"
    },
    {
      "source": "8205Oxford Handbook of Clinical Medicine 10th 2017 Edition_SamanSarKo - Copy.pdf",
      "chunk_id": 531,
      "content_type": "evidence",
      "content_type_confidence": 2,
      "word_count": 597,
      "entity_count": 4,
      "has_ckd": false,
      "has_gfr": true,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": true,
      "medical_entities": "glomerular filtration rate,renal function,nephropathy,dialysis",
      "year": "2025",
      "organization": "Unknown"
    },
    {
      "source": "8205Oxford Handbook of Clinical Medicine 10th 2017 Edition_SamanSarKo - Copy.pdf",
      "chunk_id": 532,
      "content_type": "treatment",
      "content_type_confidence": 2,
      "word_count": 600,
      "entity_count": 3,
      "has_ckd": false,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "renal function,catheter,exercise",
      "year": "2025",
      "organization": "Unknown"
    },
    {
      "source": "8205Oxford Handbook of Clinical Medicine 10th 2017 Edition_SamanSarKo - Copy.pdf",
      "chunk_id": 533,
      "content_type": "evidence",
      "content_type_confidence": 2,
      "word_count": 563,
      "entity_count": 3,
      "has_ckd": false,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "potassium,catheter,exercise",
      "year": "2025",
      "organization": "Unknown"
    },
    {
      "source": "8205Oxford Handbook of Clinical Medicine 10th 2017 Edition_SamanSarKo - Copy.pdf",
      "chunk_id": 534,
      "content_type": "recommendation",
      "content_type_confidence": 1,
      "word_count": 580,
      "entity_count": 4,
      "has_ckd": true,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "chronic kidney disease,renal function,calcium,catheter",
      "year": "2025",
      "organization": "Unknown"
    },
    {
      "source": "8205Oxford Handbook of Clinical Medicine 10th 2017 Edition_SamanSarKo - Copy.pdf",
      "chunk_id": 535,
      "content_type": "monitoring",
      "content_type_confidence": 2,
      "word_count": 598,
      "entity_count": 3,
      "has_ckd": false,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "catheter,kidney transplant,monitoring",
      "year": "2025",
      "organization": "Unknown"
    },
    {
      "source": "8205Oxford Handbook of Clinical Medicine 10th 2017 Edition_SamanSarKo - Copy.pdf",
      "chunk_id": 536,
      "content_type": "evidence",
      "content_type_confidence": 2,
      "word_count": 590,
      "entity_count": 2,
      "has_ckd": false,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "hemoglobin,catheter",
      "year": "2025",
      "organization": "Unknown"
    },
    {
      "source": "8205Oxford Handbook of Clinical Medicine 10th 2017 Edition_SamanSarKo - Copy.pdf",
      "chunk_id": 537,
      "content_type": "treatment",
      "content_type_confidence": 2,
      "word_count": 589,
      "entity_count": 6,
      "has_ckd": false,
      "has_gfr": true,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "glomerular filtration rate,renal function,erythropoietin,acidosis,exercise,adherence",
      "year": "2025",
      "organization": "Unknown"
    },
    {
      "source": "8205Oxford Handbook of Clinical Medicine 10th 2017 Edition_SamanSarKo - Copy.pdf",
      "chunk_id": 538,
      "content_type": "reference",
      "content_type_confidence": 3,
      "word_count": 591,
      "entity_count": 1,
      "has_ckd": false,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "acute kidney injury",
      "year": "2025",
      "organization": "Unknown"
    },
    {
      "source": "8205Oxford Handbook of Clinical Medicine 10th 2017 Edition_SamanSarKo - Copy.pdf",
      "chunk_id": 539,
      "content_type": "treatment",
      "content_type_confidence": 3,
      "word_count": 584,
      "entity_count": 3,
      "has_ckd": false,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "calcium,chloride,hemoglobin",
      "year": "2025",
      "organization": "Unknown",
      "section": "Further lack of evidence to support Wagners hypothesis came when Gauss brain was weighed:"
    },
    {
      "source": "8205Oxford Handbook of Clinical Medicine 10th 2017 Edition_SamanSarKo - Copy.pdf",
      "chunk_id": 540,
      "content_type": "dietary",
      "content_type_confidence": 3,
      "word_count": 592,
      "entity_count": 10,
      "has_ckd": false,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "creatinine,sodium,potassium,phosphate,magnesium,hemoglobin,parathyroid hormone,vitamin D,iron,ferritin",
      "year": "2025",
      "organization": "Unknown"
    },
    {
      "source": "8205Oxford Handbook of Clinical Medicine 10th 2017 Edition_SamanSarKo - Copy.pdf",
      "chunk_id": 541,
      "content_type": "treatment",
      "content_type_confidence": 6,
      "word_count": 598,
      "entity_count": 6,
      "has_ckd": false,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "renal function,renal failure,magnesium,diuretics,loop diuretics,monitoring",
      "year": "2025",
      "organization": "Unknown"
    },
    {
      "source": "8205Oxford Handbook of Clinical Medicine 10th 2017 Edition_SamanSarKo - Copy.pdf",
      "chunk_id": 542,
      "content_type": "treatment",
      "content_type_confidence": 3,
      "word_count": 599,
      "entity_count": 5,
      "has_ckd": false,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "potassium,chloride,diuretics,insulin,acidosis",
      "year": "2025",
      "organization": "Unknown"
    },
    {
      "source": "8205Oxford Handbook of Clinical Medicine 10th 2017 Edition_SamanSarKo - Copy.pdf",
      "chunk_id": 544,
      "content_type": "treatment",
      "content_type_confidence": 3,
      "word_count": 596,
      "entity_count": 1,
      "has_ckd": false,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "catheter",
      "year": "2025",
      "organization": "Unknown"
    },
    {
      "source": "8205Oxford Handbook of Clinical Medicine 10th 2017 Edition_SamanSarKo - Copy.pdf",
      "chunk_id": 546,
      "content_type": "recommendation",
      "content_type_confidence": 3,
      "word_count": 598,
      "entity_count": 2,
      "has_ckd": false,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "potassium,catheter",
      "year": "2025",
      "organization": "Unknown"
    },
    {
      "source": "8205Oxford Handbook of Clinical Medicine 10th 2017 Edition_SamanSarKo - Copy.pdf",
      "chunk_id": 547,
      "content_type": "monitoring",
      "content_type_confidence": 2,
      "word_count": 589,
      "entity_count": 2,
      "has_ckd": false,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "catheter,neuropathy",
      "year": "2025",
      "organization": "Unknown"
    },
    {
      "source": "8205Oxford Handbook of Clinical Medicine 10th 2017 Edition_SamanSarKo - Copy.pdf",
      "chunk_id": 548,
      "content_type": "recommendation",
      "content_type_confidence": 2,
      "word_count": 590,
      "entity_count": 3,
      "has_ckd": false,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "acute kidney injury,renal failure,catheter",
      "year": "2025",
      "organization": "Unknown"
    },
    {
      "source": "8205Oxford Handbook of Clinical Medicine 10th 2017 Edition_SamanSarKo - Copy.pdf",
      "chunk_id": 549,
      "content_type": "recommendation",
      "content_type_confidence": 1,
      "word_count": 578,
      "entity_count": 1,
      "has_ckd": false,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "catheter",
      "year": "2025",
      "organization": "Unknown"
    },
    {
      "source": "8205Oxford Handbook of Clinical Medicine 10th 2017 Edition_SamanSarKo - Copy.pdf",
      "chunk_id": 557,
      "content_type": "recommendation",
      "content_type_confidence": 3,
      "word_count": 579,
      "entity_count": 2,
      "has_ckd": false,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "nutrition,adherence",
      "year": "2025",
      "organization": "Unknown"
    },
    {
      "source": "8205Oxford Handbook of Clinical Medicine 10th 2017 Edition_SamanSarKo - Copy.pdf",
      "chunk_id": 559,
      "content_type": "monitoring",
      "content_type_confidence": 4,
      "word_count": 599,
      "entity_count": 1,
      "has_ckd": false,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "screening",
      "year": "2025",
      "organization": "Unknown"
    },
    {
      "source": "8205Oxford Handbook of Clinical Medicine 10th 2017 Edition_SamanSarKo - Copy.pdf",
      "chunk_id": 562,
      "content_type": "treatment",
      "content_type_confidence": 3,
      "word_count": 568,
      "entity_count": 1,
      "has_ckd": false,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "proteinuria",
      "year": "2025",
      "organization": "Unknown"
    },
    {
      "source": "8205Oxford Handbook of Clinical Medicine 10th 2017 Edition_SamanSarKo - Copy.pdf",
      "chunk_id": 563,
      "content_type": "treatment",
      "content_type_confidence": 2,
      "word_count": 600,
      "entity_count": 5,
      "has_ckd": false,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "proteinuria,calcium,acidosis,metabolic acidosis,heart failure",
      "year": "2025",
      "organization": "Unknown"
    },
    {
      "source": "8205Oxford Handbook of Clinical Medicine 10th 2017 Edition_SamanSarKo - Copy.pdf",
      "chunk_id": 565,
      "content_type": "monitoring",
      "content_type_confidence": 2,
      "word_count": 596,
      "entity_count": 2,
      "has_ckd": false,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "acidosis,retinopathy",
      "year": "2025",
      "organization": "Unknown"
    },
    {
      "source": "8205Oxford Handbook of Clinical Medicine 10th 2017 Edition_SamanSarKo - Copy.pdf",
      "chunk_id": 567,
      "content_type": "treatment",
      "content_type_confidence": 3,
      "word_count": 572,
      "entity_count": 4,
      "has_ckd": false,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "acute kidney injury,sodium,heart failure,monitoring",
      "year": "2025",
      "organization": "Unknown"
    },
    {
      "source": "8205Oxford Handbook of Clinical Medicine 10th 2017 Edition_SamanSarKo - Copy.pdf",
      "chunk_id": 569,
      "content_type": "recommendation",
      "content_type_confidence": 3,
      "word_count": 581,
      "entity_count": 4,
      "has_ckd": false,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "diuretics,cardiovascular disease,heart failure,monitoring",
      "year": "2025",
      "organization": "Unknown",
      "section": "Morphine:"
    },
    {
      "source": "8205Oxford Handbook of Clinical Medicine 10th 2017 Edition_SamanSarKo - Copy.pdf",
      "chunk_id": 570,
      "content_type": "treatment",
      "content_type_confidence": 4,
      "word_count": 596,
      "entity_count": 4,
      "has_ckd": true,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "chronic kidney disease,renal function,cardiovascular disease,heart failure",
      "year": "2025",
      "organization": "Unknown",
      "section": "Aspirin:"
    },
    {
      "source": "8205Oxford Handbook of Clinical Medicine 10th 2017 Edition_SamanSarKo - Copy.pdf",
      "chunk_id": 571,
      "content_type": "treatment",
      "content_type_confidence": 3,
      "word_count": 594,
      "entity_count": 6,
      "has_ckd": true,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "chronic kidney disease,renal function,calcium,heart failure,fluid overload,monitoring",
      "year": "2025",
      "organization": "Unknown"
    },
    {
      "source": "8205Oxford Handbook of Clinical Medicine 10th 2017 Edition_SamanSarKo - Copy.pdf",
      "chunk_id": 572,
      "content_type": "treatment",
      "content_type_confidence": 4,
      "word_count": 594,
      "entity_count": 5,
      "has_ckd": false,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "renal failure,urea,acidosis,heart failure,monitoring",
      "year": "2025",
      "organization": "Unknown",
      "section": "7. Begin treatment before investigations"
    },
    {
      "source": "8205Oxford Handbook of Clinical Medicine 10th 2017 Edition_SamanSarKo - Copy.pdf",
      "chunk_id": 573,
      "content_type": "monitoring",
      "content_type_confidence": 3,
      "word_count": 596,
      "entity_count": 5,
      "has_ckd": false,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "urea,potassium,magnesium,catheter,monitoring",
      "year": "2025",
      "organization": "Unknown",
      "section": "Causes:"
    },
    {
      "source": "8205Oxford Handbook of Clinical Medicine 10th 2017 Edition_SamanSarKo - Copy.pdf",
      "chunk_id": 574,
      "content_type": "evidence",
      "content_type_confidence": 2,
      "word_count": 598,
      "entity_count": 3,
      "has_ckd": false,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "potassium,magnesium,heart failure",
      "year": "2025",
      "organization": "Unknown"
    },
    {
      "source": "8205Oxford Handbook of Clinical Medicine 10th 2017 Edition_SamanSarKo - Copy.pdf",
      "chunk_id": 576,
      "content_type": "dietary",
      "content_type_confidence": 2,
      "word_count": 600,
      "entity_count": 3,
      "has_ckd": false,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "potassium,fatigue,heart failure",
      "year": "2025",
      "organization": "Unknown"
    },
    {
      "source": "8205Oxford Handbook of Clinical Medicine 10th 2017 Edition_SamanSarKo - Copy.pdf",
      "chunk_id": 577,
      "content_type": "treatment",
      "content_type_confidence": 4,
      "word_count": 600,
      "entity_count": 3,
      "has_ckd": false,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "potassium,calcium,heart failure",
      "year": "2025",
      "organization": "Unknown"
    },
    {
      "source": "8205Oxford Handbook of Clinical Medicine 10th 2017 Edition_SamanSarKo - Copy.pdf",
      "chunk_id": 578,
      "content_type": "treatment",
      "content_type_confidence": 3,
      "word_count": 600,
      "entity_count": 4,
      "has_ckd": false,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "potassium,magnesium,smoking cessation,exercise",
      "year": "2025",
      "organization": "Unknown"
    },
    {
      "source": "8205Oxford Handbook of Clinical Medicine 10th 2017 Edition_SamanSarKo - Copy.pdf",
      "chunk_id": 579,
      "content_type": "treatment",
      "content_type_confidence": 4,
      "word_count": 585,
      "entity_count": 1,
      "has_ckd": false,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "monitoring",
      "year": "2025",
      "organization": "Unknown"
    },
    {
      "source": "8205Oxford Handbook of Clinical Medicine 10th 2017 Edition_SamanSarKo - Copy.pdf",
      "chunk_id": 580,
      "content_type": "treatment",
      "content_type_confidence": 3,
      "word_count": 597,
      "entity_count": 3,
      "has_ckd": false,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "acute kidney injury,creatinine,urea",
      "year": "2025",
      "organization": "Unknown"
    },
    {
      "source": "8205Oxford Handbook of Clinical Medicine 10th 2017 Edition_SamanSarKo - Copy.pdf",
      "chunk_id": 581,
      "content_type": "evidence",
      "content_type_confidence": 2,
      "word_count": 592,
      "entity_count": 3,
      "has_ckd": false,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "potassium,hemoglobin,catheter",
      "year": "2025",
      "organization": "Unknown"
    },
    {
      "source": "8205Oxford Handbook of Clinical Medicine 10th 2017 Edition_SamanSarKo - Copy.pdf",
      "chunk_id": 582,
      "content_type": "treatment",
      "content_type_confidence": 4,
      "word_count": 587,
      "entity_count": 3,
      "has_ckd": false,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "potassium,hemoglobin,edema",
      "year": "2025",
      "organization": "Unknown"
    },
    {
      "source": "8205Oxford Handbook of Clinical Medicine 10th 2017 Edition_SamanSarKo - Copy.pdf",
      "chunk_id": 583,
      "content_type": "treatment",
      "content_type_confidence": 3,
      "word_count": 600,
      "entity_count": 2,
      "has_ckd": false,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "creatinine,monitoring",
      "year": "2025",
      "organization": "Unknown"
    },
    {
      "source": "8205Oxford Handbook of Clinical Medicine 10th 2017 Edition_SamanSarKo - Copy.pdf",
      "chunk_id": 584,
      "content_type": "treatment",
      "content_type_confidence": 3,
      "word_count": 570,
      "entity_count": 1,
      "has_ckd": false,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "creatinine",
      "year": "2025",
      "organization": "Unknown"
    },
    {
      "source": "8205Oxford Handbook of Clinical Medicine 10th 2017 Edition_SamanSarKo - Copy.pdf",
      "chunk_id": 585,
      "content_type": "monitoring",
      "content_type_confidence": 3,
      "word_count": 597,
      "entity_count": 2,
      "has_ckd": false,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "acidosis,monitoring",
      "year": "2025",
      "organization": "Unknown"
    },
    {
      "source": "8205Oxford Handbook of Clinical Medicine 10th 2017 Edition_SamanSarKo - Copy.pdf",
      "chunk_id": 587,
      "content_type": "treatment",
      "content_type_confidence": 4,
      "word_count": 588,
      "entity_count": 8,
      "has_ckd": false,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "renal function,creatinine,sodium,potassium,bicarbonate,insulin,acidosis,monitoring",
      "year": "2025",
      "organization": "Unknown"
    },
    {
      "source": "8205Oxford Handbook of Clinical Medicine 10th 2017 Edition_SamanSarKo - Copy.pdf",
      "chunk_id": 588,
      "content_type": "treatment",
      "content_type_confidence": 3,
      "word_count": 586,
      "entity_count": 5,
      "has_ckd": false,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "potassium,bicarbonate,insulin,catheter,acidosis",
      "year": "2025",
      "organization": "Unknown"
    },
    {
      "source": "8205Oxford Handbook of Clinical Medicine 10th 2017 Edition_SamanSarKo - Copy.pdf",
      "chunk_id": 589,
      "content_type": "treatment",
      "content_type_confidence": 4,
      "word_count": 600,
      "entity_count": 5,
      "has_ckd": false,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "sodium,potassium,insulin,acidosis,heart failure",
      "year": "2025",
      "organization": "Unknown"
    },
    {
      "source": "8205Oxford Handbook of Clinical Medicine 10th 2017 Edition_SamanSarKo - Copy.pdf",
      "chunk_id": 590,
      "content_type": "treatment",
      "content_type_confidence": 4,
      "word_count": 591,
      "entity_count": 4,
      "has_ckd": false,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "sodium,potassium,calcium,monitoring",
      "year": "2025",
      "organization": "Unknown"
    },
    {
      "source": "8205Oxford Handbook of Clinical Medicine 10th 2017 Edition_SamanSarKo - Copy.pdf",
      "chunk_id": 591,
      "content_type": "treatment",
      "content_type_confidence": 4,
      "word_count": 596,
      "entity_count": 5,
      "has_ckd": false,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "acute kidney injury,sodium,insulin,acidosis,metabolic acidosis",
      "year": "2025",
      "organization": "Unknown"
    },
    {
      "source": "8205Oxford Handbook of Clinical Medicine 10th 2017 Edition_SamanSarKo - Copy.pdf",
      "chunk_id": 592,
      "content_type": "treatment",
      "content_type_confidence": 3,
      "word_count": 588,
      "entity_count": 2,
      "has_ckd": false,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "iron,screening",
      "year": "2025",
      "organization": "Unknown"
    },
    {
      "source": "8205Oxford Handbook of Clinical Medicine 10th 2017 Edition_SamanSarKo - Copy.pdf",
      "chunk_id": 593,
      "content_type": "treatment",
      "content_type_confidence": 3,
      "word_count": 585,
      "entity_count": 4,
      "has_ckd": false,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "sodium,hemoglobin,iron,screening",
      "year": "2025",
      "organization": "Unknown"
    },
    {
      "source": "8205Oxford Handbook of Clinical Medicine 10th 2017 Edition_SamanSarKo - Copy.pdf",
      "chunk_id": 594,
      "content_type": "dietary",
      "content_type_confidence": 2,
      "word_count": 600,
      "entity_count": 6,
      "has_ckd": false,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "renal failure,potassium,hemoglobin,iron,acidosis,metabolic acidosis",
      "year": "2025",
      "organization": "Unknown"
    },
    {
      "source": "8205Oxford Handbook of Clinical Medicine 10th 2017 Edition_SamanSarKo - Copy.pdf",
      "chunk_id": 595,
      "content_type": "treatment",
      "content_type_confidence": 3,
      "word_count": 596,
      "entity_count": 7,
      "has_ckd": false,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "acute kidney injury,potassium,bicarbonate,edema,acidosis,metabolic acidosis,monitoring",
      "year": "2025",
      "organization": "Unknown"
    },
    {
      "source": "8205Oxford Handbook of Clinical Medicine 10th 2017 Edition_SamanSarKo - Copy.pdf",
      "chunk_id": 596,
      "content_type": "treatment",
      "content_type_confidence": 4,
      "word_count": 599,
      "entity_count": 9,
      "has_ckd": false,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": true,
      "medical_entities": "acute kidney injury,sodium,potassium,bicarbonate,sodium bicarbonate,dialysis,acidosis,metabolic acidosis,heart failure",
      "year": "2025",
      "organization": "Unknown"
    },
    {
      "source": "8205Oxford Handbook of Clinical Medicine 10th 2017 Edition_SamanSarKo - Copy.pdf",
      "chunk_id": 598,
      "content_type": "treatment",
      "content_type_confidence": 4,
      "word_count": 597,
      "entity_count": 6,
      "has_ckd": false,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": true,
      "medical_entities": "renal function,diuretics,dialysis,catheter,heart failure,neuropathy",
      "year": "2025",
      "organization": "Unknown"
    },
    {
      "source": "8205Oxford Handbook of Clinical Medicine 10th 2017 Edition_SamanSarKo - Copy.pdf",
      "chunk_id": 599,
      "content_type": "reference",
      "content_type_confidence": 2,
      "word_count": 591,
      "entity_count": 2,
      "has_ckd": false,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": true,
      "medical_entities": "acute kidney injury,dialysis",
      "year": "2025",
      "organization": "Unknown"
    },
    {
      "source": "8205Oxford Handbook of Clinical Medicine 10th 2017 Edition_SamanSarKo - Copy.pdf",
      "chunk_id": 600,
      "content_type": "reference",
      "content_type_confidence": 4,
      "word_count": 595,
      "entity_count": 2,
      "has_ckd": false,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "acute kidney injury,potassium",
      "year": "2025",
      "organization": "Unknown"
    },
    {
      "source": "8205Oxford Handbook of Clinical Medicine 10th 2017 Edition_SamanSarKo - Copy.pdf",
      "chunk_id": 620,
      "content_type": "reference",
      "content_type_confidence": 3,
      "word_count": 599,
      "entity_count": 7,
      "has_ckd": false,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "nephritis,albuminuria,creatinine,ACE inhibitors,acidosis,heart failure,screening",
      "year": "2025",
      "organization": "Unknown",
      "section": "Abbreviations:"
    },
    {
      "source": "8205Oxford Handbook of Clinical Medicine 10th 2017 Edition_SamanSarKo - Copy.pdf",
      "chunk_id": 621,
      "content_type": "reference",
      "content_type_confidence": 3,
      "word_count": 553,
      "entity_count": 5,
      "has_ckd": false,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "nephropathy,potassium,iron,catheter,heart failure",
      "year": "2025",
      "organization": "Unknown"
    },
    {
      "source": "8205Oxford Handbook of Clinical Medicine 10th 2017 Edition_SamanSarKo - Copy.pdf",
      "chunk_id": 623,
      "content_type": "reference",
      "content_type_confidence": 2,
      "word_count": 298,
      "entity_count": 1,
      "has_ckd": false,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "nephropathy",
      "year": "2025",
      "organization": "Unknown"
    },
    {
      "source": "8205Oxford Handbook of Clinical Medicine 10th 2017 Edition_SamanSarKo - Copy.pdf",
      "chunk_id": 624,
      "content_type": "monitoring",
      "content_type_confidence": 3,
      "word_count": 579,
      "entity_count": 4,
      "has_ckd": false,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "calcium,calcitriol,heart failure,screening",
      "year": "2025",
      "organization": "Unknown"
    },
    {
      "source": "8205Oxford Handbook of Clinical Medicine 10th 2017 Edition_SamanSarKo - Copy.pdf",
      "chunk_id": 626,
      "content_type": "evidence",
      "content_type_confidence": 3,
      "word_count": 577,
      "entity_count": 2,
      "has_ckd": false,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "creatinine,heart failure",
      "year": "2025",
      "organization": "Unknown"
    },
    {
      "source": "8205Oxford Handbook of Clinical Medicine 10th 2017 Edition_SamanSarKo - Copy.pdf",
      "chunk_id": 627,
      "content_type": "treatment",
      "content_type_confidence": 4,
      "word_count": 586,
      "entity_count": 9,
      "has_ckd": false,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": true,
      "medical_entities": "nephropathy,diet,diuretics,insulin,dialysis,acidosis,neuropathy,retinopathy,monitoring",
      "year": "2025",
      "organization": "Unknown"
    },
    {
      "source": "8205Oxford Handbook of Clinical Medicine 10th 2017 Edition_SamanSarKo - Copy.pdf",
      "chunk_id": 629,
      "content_type": "dietary",
      "content_type_confidence": 4,
      "word_count": 592,
      "entity_count": 5,
      "has_ckd": false,
      "has_gfr": true,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "glomerular filtration rate,potassium,fistula,fatigue,exercise",
      "year": "2025",
      "organization": "Unknown"
    },
    {
      "source": "8205Oxford Handbook of Clinical Medicine 10th 2017 Edition_SamanSarKo - Copy.pdf",
      "chunk_id": 630,
      "content_type": "treatment",
      "content_type_confidence": 3,
      "word_count": 572,
      "entity_count": 4,
      "has_ckd": false,
      "has_gfr": true,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "glomerular filtration rate,phosphate,diet,monitoring",
      "year": "2025",
      "organization": "Unknown"
    },
    {
      "source": "8205Oxford Handbook of Clinical Medicine 10th 2017 Edition_SamanSarKo - Copy.pdf",
      "chunk_id": 631,
      "content_type": "dietary",
      "content_type_confidence": 3,
      "word_count": 575,
      "entity_count": 3,
      "has_ckd": false,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "bicarbonate,hemoglobin,heart failure",
      "year": "2025",
      "organization": "Unknown"
    },
    {
      "source": "8205Oxford Handbook of Clinical Medicine 10th 2017 Edition_SamanSarKo - Copy.pdf",
      "chunk_id": 632,
      "content_type": "treatment",
      "content_type_confidence": 3,
      "word_count": 557,
      "entity_count": 6,
      "has_ckd": false,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "nephropathy,nephritis,iron,insulin,heart failure,retinopathy",
      "year": "2025",
      "organization": "Unknown"
    },
    {
      "source": "8205Oxford Handbook of Clinical Medicine 10th 2017 Edition_SamanSarKo - Copy.pdf",
      "chunk_id": 633,
      "content_type": "dietary",
      "content_type_confidence": 2,
      "word_count": 588,
      "entity_count": 2,
      "has_ckd": false,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "potassium,acidosis",
      "year": "2025",
      "organization": "Unknown"
    },
    {
      "source": "8205Oxford Handbook of Clinical Medicine 10th 2017 Edition_SamanSarKo - Copy.pdf",
      "chunk_id": 634,
      "content_type": "treatment",
      "content_type_confidence": 5,
      "word_count": 595,
      "entity_count": 6,
      "has_ckd": false,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "nephropathy,nephritis,phosphate,magnesium,diuretics,heart failure",
      "year": "2025",
      "organization": "Unknown"
    },
    {
      "source": "8205Oxford Handbook of Clinical Medicine 10th 2017 Edition_SamanSarKo - Copy.pdf",
      "chunk_id": 635,
      "content_type": "evidence",
      "content_type_confidence": 1,
      "word_count": 593,
      "entity_count": 4,
      "has_ckd": false,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "nephritis,acidosis,neuropathy,screening",
      "year": "2025",
      "organization": "Unknown"
    },
    {
      "source": "8205Oxford Handbook of Clinical Medicine 10th 2017 Edition_SamanSarKo - Copy.pdf",
      "chunk_id": 636,
      "content_type": "dietary",
      "content_type_confidence": 3,
      "word_count": 554,
      "entity_count": 5,
      "has_ckd": false,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "nephropathy,nutrition,supplements,diuretics,neuropathy",
      "year": "2025",
      "organization": "Unknown"
    },
    {
      "source": "8205Oxford Handbook of Clinical Medicine 10th 2017 Edition_SamanSarKo - Copy.pdf",
      "chunk_id": 637,
      "content_type": "dietary",
      "content_type_confidence": 2,
      "word_count": 578,
      "entity_count": 5,
      "has_ckd": false,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": true,
      "medical_entities": "parathyroid hormone,nutrition,dialysis,peritoneal dialysis,monitoring",
      "year": "2025",
      "organization": "Unknown"
    },
    {
      "source": "8205Oxford Handbook of Clinical Medicine 10th 2017 Edition_SamanSarKo - Copy.pdf",
      "chunk_id": 638,
      "content_type": "treatment",
      "content_type_confidence": 3,
      "word_count": 590,
      "entity_count": 5,
      "has_ckd": false,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "potassium,calcium,phosphate,iron,diuretics",
      "year": "2025",
      "organization": "Unknown"
    },
    {
      "source": "8205Oxford Handbook of Clinical Medicine 10th 2017 Edition_SamanSarKo - Copy.pdf",
      "chunk_id": 639,
      "content_type": "evidence",
      "content_type_confidence": 2,
      "word_count": 545,
      "entity_count": 6,
      "has_ckd": false,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "nephropathy,nephritis,proteinuria,creatinine,acidosis,pruritus",
      "year": "2025",
      "organization": "Unknown"
    },
    {
      "source": "8205Oxford Handbook of Clinical Medicine 10th 2017 Edition_SamanSarKo - Copy.pdf",
      "chunk_id": 640,
      "content_type": "evidence",
      "content_type_confidence": 1,
      "word_count": 575,
      "entity_count": 4,
      "has_ckd": false,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "nephropathy,acidosis,neuropathy,screening",
      "year": "2025",
      "organization": "Unknown"
    },
    {
      "source": "8205Oxford Handbook of Clinical Medicine 10th 2017 Edition_SamanSarKo - Copy.pdf",
      "chunk_id": 641,
      "content_type": "treatment",
      "content_type_confidence": 2,
      "word_count": 594,
      "entity_count": 3,
      "has_ckd": false,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": true,
      "medical_entities": "sodium,statins,dialysis",
      "year": "2025",
      "organization": "Unknown"
    },
    {
      "source": "8205Oxford Handbook of Clinical Medicine 10th 2017 Edition_SamanSarKo - Copy.pdf",
      "chunk_id": 642,
      "content_type": "treatment",
      "content_type_confidence": 2,
      "word_count": 447,
      "entity_count": 1,
      "has_ckd": false,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "diuretics",
      "year": "2025",
      "organization": "Unknown"
    },
    {
      "source": "8205Oxford Handbook of Clinical Medicine 10th 2017 Edition_SamanSarKo - Copy.pdf",
      "chunk_id": 644,
      "content_type": "reference",
      "content_type_confidence": 2,
      "word_count": 571,
      "entity_count": 6,
      "has_ckd": false,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "nephropathy,albuminuria,proteinuria,phosphate,uric acid,catheter",
      "year": "2025",
      "organization": "Unknown"
    },
    {
      "source": "8205Oxford Handbook of Clinical Medicine 10th 2017 Edition_SamanSarKo - Copy.pdf",
      "chunk_id": 646,
      "content_type": "recommendation",
      "content_type_confidence": 3,
      "word_count": 596,
      "entity_count": 1,
      "has_ckd": false,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "monitoring",
      "year": "2025",
      "organization": "Unknown"
    },
    {
      "source": "8205Oxford Handbook of Clinical Medicine 10th 2017 Edition_SamanSarKo - Copy.pdf",
      "chunk_id": 647,
      "content_type": "evidence",
      "content_type_confidence": 3,
      "word_count": 592,
      "entity_count": 8,
      "has_ckd": true,
      "has_gfr": true,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "chronic kidney disease,acute kidney injury,glomerular filtration rate,renal function,sodium,phosphate,heart failure,quality of life",
      "year": "2025",
      "organization": "Unknown"
    },
    {
      "source": "8205Oxford Handbook of Clinical Medicine 10th 2017 Edition_SamanSarKo - Copy.pdf",
      "chunk_id": 648,
      "content_type": "treatment",
      "content_type_confidence": 4,
      "word_count": 329,
      "entity_count": 2,
      "has_ckd": false,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "renal function,insulin",
      "year": "2025",
      "organization": "Unknown"
    }
  ],
  "ids": [
    "8205oxford handbook of clinical medicine 10th 2017 edition_samansarko _ copy_0",
    "8205oxford handbook of clinical medicine 10th 2017 edition_samansarko _ copy_1",
    "8205oxford handbook of clinical medicine 10th 2017 edition_samansarko _ copy_3",
    "8205oxford handbook of clinical medicine 10th 2017 edition_samansarko _ copy_4",
    "8205oxford handbook of clinical medicine 10th 2017 edition_samansarko _ copy_5",
    "8205oxford handbook of clinical medicine 10th 2017 edition_samansarko _ copy_6",
    "8205oxford handbook of clinical medicine 10th 2017 edition_samansarko _ copy_10",
    "8205oxford handbook of clinical medicine 10th 2017 edition_samansarko _ copy_15",
    "8205oxford handbook of clinical medicine 10th 2017 edition_samansarko _ copy_17",
    "8205oxford handbook of clinical medicine 10th 2017 edition_samansarko _ copy_19",
    "8205oxford handbook of clinical medicine 10th 2017 edition_samansarko _ copy_20",
    "8205oxford handbook of clinical medicine 10th 2017 edition_samansarko _ copy_21",
    "8205oxford handbook of clinical medicine 10th 2017 edition_samansarko _ copy_22",
    "8205oxford handbook of clinical medicine 10th 2017 edition_samansarko _ copy_25",
    "8205oxford handbook of clinical medicine 10th 2017 edition_samansarko _ copy_26",
    "8205oxford handbook of clinical medicine 10th 2017 edition_samansarko _ copy_28",
    "8205oxford handbook of clinical medicine 10th 2017 edition_samansarko _ copy_29",
    "8205oxford handbook of clinical medicine 10th 2017 edition_samansarko _ copy_30",
    "8205oxford handbook of clinical medicine 10th 2017 edition_samansarko _ copy_31",
    "8205oxford handbook of clinical medicine 10th 2017 edition_samansarko _ copy_32",
    "8205oxford handbook of clinical medicine 10th 2017 edition_samansarko _ copy_33",
    "8205oxford handbook of clinical medicine 10th 2017 edition_samansarko _ copy_34",
    "8205oxford handbook of clinical medicine 10th 2017 edition_samansarko _ copy_35",
    "8205oxford handbook of clinical medicine 10th 2017 edition_samansarko _ copy_36",
    "8205oxford handbook of clinical medicine 10th 2017 edition_samansarko _ copy_38",
    "8205oxford handbook of clinical medicine 10th 2017 edition_samansarko _ copy_39",
    "8205oxford handbook of clinical medicine 10th 2017 edition_samansarko _ copy_40",
    "8205oxford handbook of clinical medicine 10th 2017 edition_samansarko _ copy_41",
    "8205oxford handbook of clinical medicine 10th 2017 edition_samansarko _ copy_44",
    "8205oxford handbook of clinical medicine 10th 2017 edition_samansarko _ copy_45",
    "8205oxford handbook of clinical medicine 10th 2017 edition_samansarko _ copy_47",
    "8205oxford handbook of clinical medicine 10th 2017 edition_samansarko _ copy_48",
    "8205oxford handbook of clinical medicine 10th 2017 edition_samansarko _ copy_49",
    "8205oxford handbook of clinical medicine 10th 2017 edition_samansarko _ copy_51",
    "8205oxford handbook of clinical medicine 10th 2017 edition_samansarko _ copy_52",
    "8205oxford handbook of clinical medicine 10th 2017 edition_samansarko _ copy_54",
    "8205oxford handbook of clinical medicine 10th 2017 edition_samansarko _ copy_56",
    "8205oxford handbook of clinical medicine 10th 2017 edition_samansarko _ copy_58",
    "8205oxford handbook of clinical medicine 10th 2017 edition_samansarko _ copy_59",
    "8205oxford handbook of clinical medicine 10th 2017 edition_samansarko _ copy_61",
    "8205oxford handbook of clinical medicine 10th 2017 edition_samansarko _ copy_62",
    "8205oxford handbook of clinical medicine 10th 2017 edition_samansarko _ copy_65",
    "8205oxford handbook of clinical medicine 10th 2017 edition_samansarko _ copy_68",
    "8205oxford handbook of clinical medicine 10th 2017 edition_samansarko _ copy_71",
    "8205oxford handbook of clinical medicine 10th 2017 edition_samansarko _ copy_73",
    "8205oxford handbook of clinical medicine 10th 2017 edition_samansarko _ copy_74",
    "8205oxford handbook of clinical medicine 10th 2017 edition_samansarko _ copy_75",
    "8205oxford handbook of clinical medicine 10th 2017 edition_samansarko _ copy_76",
    "8205oxford handbook of clinical medicine 10th 2017 edition_samansarko _ copy_77",
    "8205oxford handbook of clinical medicine 10th 2017 edition_samansarko _ copy_78",
    "8205oxford handbook of clinical medicine 10th 2017 edition_samansarko _ copy_79",
    "8205oxford handbook of clinical medicine 10th 2017 edition_samansarko _ copy_80",
    "8205oxford handbook of clinical medicine 10th 2017 edition_samansarko _ copy_81",
    "8205oxford handbook of clinical medicine 10th 2017 edition_samansarko _ copy_82",
    "8205oxford handbook of clinical medicine 10th 2017 edition_samansarko _ copy_83",
    "8205oxford handbook of clinical medicine 10th 2017 edition_samansarko _ copy_84",
    "8205oxford handbook of clinical medicine 10th 2017 edition_samansarko _ copy_85",
    "8205oxford handbook of clinical medicine 10th 2017 edition_samansarko _ copy_86",
    "8205oxford handbook of clinical medicine 10th 2017 edition_samansarko _ copy_87",
    "8205oxford handbook of clinical medicine 10th 2017 edition_samansarko _ copy_88",
    "8205oxford handbook of clinical medicine 10th 2017 edition_samansarko _ copy_89",
    "8205oxford handbook of clinical medicine 10th 2017 edition_samansarko _ copy_90",
    "8205oxford handbook of clinical medicine 10th 2017 edition_samansarko _ copy_91",
    "8205oxford handbook of clinical medicine 10th 2017 edition_samansarko _ copy_92",
    "8205oxford handbook of clinical medicine 10th 2017 edition_samansarko _ copy_93",
    "8205oxford handbook of clinical medicine 10th 2017 edition_samansarko _ copy_94",
    "8205oxford handbook of clinical medicine 10th 2017 edition_samansarko _ copy_95",
    "8205oxford handbook of clinical medicine 10th 2017 edition_samansarko _ copy_96",
    "8205oxford handbook of clinical medicine 10th 2017 edition_samansarko _ copy_97",
    "8205oxford handbook of clinical medicine 10th 2017 edition_samansarko _ copy_98",
    "8205oxford handbook of clinical medicine 10th 2017 edition_samansarko _ copy_100",
    "8205oxford handbook of clinical medicine 10th 2017 edition_samansarko _ copy_101",
    "8205oxford handbook of clinical medicine 10th 2017 edition_samansarko _ copy_102",
    "8205oxford handbook of clinical medicine 10th 2017 edition_samansarko _ copy_103",
    "8205oxford handbook of clinical medicine 10th 2017 edition_samansarko _ copy_104",
    "8205oxford handbook of clinical medicine 10th 2017 edition_samansarko _ copy_105",
    "8205oxford handbook of clinical medicine 10th 2017 edition_samansarko _ copy_106",
    "8205oxford handbook of clinical medicine 10th 2017 edition_samansarko _ copy_107",
    "8205oxford handbook of clinical medicine 10th 2017 edition_samansarko _ copy_108",
    "8205oxford handbook of clinical medicine 10th 2017 edition_samansarko _ copy_109",
    "8205oxford handbook of clinical medicine 10th 2017 edition_samansarko _ copy_110",
    "8205oxford handbook of clinical medicine 10th 2017 edition_samansarko _ copy_111",
    "8205oxford handbook of clinical medicine 10th 2017 edition_samansarko _ copy_112",
    "8205oxford handbook of clinical medicine 10th 2017 edition_samansarko _ copy_113",
    "8205oxford handbook of clinical medicine 10th 2017 edition_samansarko _ copy_114",
    "8205oxford handbook of clinical medicine 10th 2017 edition_samansarko _ copy_115",
    "8205oxford handbook of clinical medicine 10th 2017 edition_samansarko _ copy_116",
    "8205oxford handbook of clinical medicine 10th 2017 edition_samansarko _ copy_117",
    "8205oxford handbook of clinical medicine 10th 2017 edition_samansarko _ copy_118",
    "8205oxford handbook of clinical medicine 10th 2017 edition_samansarko _ copy_119",
    "8205oxford handbook of clinical medicine 10th 2017 edition_samansarko _ copy_123",
    "8205oxford handbook of clinical medicine 10th 2017 edition_samansarko _ copy_124",
    "8205oxford handbook of clinical medicine 10th 2017 edition_samansarko _ copy_125",
    "8205oxford handbook of clinical medicine 10th 2017 edition_samansarko _ copy_127",
    "8205oxford handbook of clinical medicine 10th 2017 edition_samansarko _ copy_128",
    "8205oxford handbook of clinical medicine 10th 2017 edition_samansarko _ copy_129",
    "8205oxford handbook of clinical medicine 10th 2017 edition_samansarko _ copy_130",
    "8205oxford handbook of clinical medicine 10th 2017 edition_samansarko _ copy_131",
    "8205oxford handbook of clinical medicine 10th 2017 edition_samansarko _ copy_132",
    "8205oxford handbook of clinical medicine 10th 2017 edition_samansarko _ copy_133",
    "8205oxford handbook of clinical medicine 10th 2017 edition_samansarko _ copy_134",
    "8205oxford handbook of clinical medicine 10th 2017 edition_samansarko _ copy_135",
    "8205oxford handbook of clinical medicine 10th 2017 edition_samansarko _ copy_136",
    "8205oxford handbook of clinical medicine 10th 2017 edition_samansarko _ copy_137",
    "8205oxford handbook of clinical medicine 10th 2017 edition_samansarko _ copy_138",
    "8205oxford handbook of clinical medicine 10th 2017 edition_samansarko _ copy_139",
    "8205oxford handbook of clinical medicine 10th 2017 edition_samansarko _ copy_140",
    "8205oxford handbook of clinical medicine 10th 2017 edition_samansarko _ copy_141",
    "8205oxford handbook of clinical medicine 10th 2017 edition_samansarko _ copy_142",
    "8205oxford handbook of clinical medicine 10th 2017 edition_samansarko _ copy_143",
    "8205oxford handbook of clinical medicine 10th 2017 edition_samansarko _ copy_144",
    "8205oxford handbook of clinical medicine 10th 2017 edition_samansarko _ copy_145",
    "8205oxford handbook of clinical medicine 10th 2017 edition_samansarko _ copy_146",
    "8205oxford handbook of clinical medicine 10th 2017 edition_samansarko _ copy_147",
    "8205oxford handbook of clinical medicine 10th 2017 edition_samansarko _ copy_148",
    "8205oxford handbook of clinical medicine 10th 2017 edition_samansarko _ copy_149",
    "8205oxford handbook of clinical medicine 10th 2017 edition_samansarko _ copy_150",
    "8205oxford handbook of clinical medicine 10th 2017 edition_samansarko _ copy_151",
    "8205oxford handbook of clinical medicine 10th 2017 edition_samansarko _ copy_152",
    "8205oxford handbook of clinical medicine 10th 2017 edition_samansarko _ copy_153",
    "8205oxford handbook of clinical medicine 10th 2017 edition_samansarko _ copy_154",
    "8205oxford handbook of clinical medicine 10th 2017 edition_samansarko _ copy_155",
    "8205oxford handbook of clinical medicine 10th 2017 edition_samansarko _ copy_156",
    "8205oxford handbook of clinical medicine 10th 2017 edition_samansarko _ copy_157",
    "8205oxford handbook of clinical medicine 10th 2017 edition_samansarko _ copy_158",
    "8205oxford handbook of clinical medicine 10th 2017 edition_samansarko _ copy_159",
    "8205oxford handbook of clinical medicine 10th 2017 edition_samansarko _ copy_161",
    "8205oxford handbook of clinical medicine 10th 2017 edition_samansarko _ copy_162",
    "8205oxford handbook of clinical medicine 10th 2017 edition_samansarko _ copy_163",
    "8205oxford handbook of clinical medicine 10th 2017 edition_samansarko _ copy_164",
    "8205oxford handbook of clinical medicine 10th 2017 edition_samansarko _ copy_165",
    "8205oxford handbook of clinical medicine 10th 2017 edition_samansarko _ copy_166",
    "8205oxford handbook of clinical medicine 10th 2017 edition_samansarko _ copy_167",
    "8205oxford handbook of clinical medicine 10th 2017 edition_samansarko _ copy_168",
    "8205oxford handbook of clinical medicine 10th 2017 edition_samansarko _ copy_170",
    "8205oxford handbook of clinical medicine 10th 2017 edition_samansarko _ copy_171",
    "8205oxford handbook of clinical medicine 10th 2017 edition_samansarko _ copy_172",
    "8205oxford handbook of clinical medicine 10th 2017 edition_samansarko _ copy_173",
    "8205oxford handbook of clinical medicine 10th 2017 edition_samansarko _ copy_175",
    "8205oxford handbook of clinical medicine 10th 2017 edition_samansarko _ copy_176",
    "8205oxford handbook of clinical medicine 10th 2017 edition_samansarko _ copy_178",
    "8205oxford handbook of clinical medicine 10th 2017 edition_samansarko _ copy_179",
    "8205oxford handbook of clinical medicine 10th 2017 edition_samansarko _ copy_180",
    "8205oxford handbook of clinical medicine 10th 2017 edition_samansarko _ copy_181",
    "8205oxford handbook of clinical medicine 10th 2017 edition_samansarko _ copy_183",
    "8205oxford handbook of clinical medicine 10th 2017 edition_samansarko _ copy_184",
    "8205oxford handbook of clinical medicine 10th 2017 edition_samansarko _ copy_185",
    "8205oxford handbook of clinical medicine 10th 2017 edition_samansarko _ copy_186",
    "8205oxford handbook of clinical medicine 10th 2017 edition_samansarko _ copy_187",
    "8205oxford handbook of clinical medicine 10th 2017 edition_samansarko _ copy_188",
    "8205oxford handbook of clinical medicine 10th 2017 edition_samansarko _ copy_189",
    "8205oxford handbook of clinical medicine 10th 2017 edition_samansarko _ copy_190",
    "8205oxford handbook of clinical medicine 10th 2017 edition_samansarko _ copy_191",
    "8205oxford handbook of clinical medicine 10th 2017 edition_samansarko _ copy_193",
    "8205oxford handbook of clinical medicine 10th 2017 edition_samansarko _ copy_194",
    "8205oxford handbook of clinical medicine 10th 2017 edition_samansarko _ copy_195",
    "8205oxford handbook of clinical medicine 10th 2017 edition_samansarko _ copy_196",
    "8205oxford handbook of clinical medicine 10th 2017 edition_samansarko _ copy_197",
    "8205oxford handbook of clinical medicine 10th 2017 edition_samansarko _ copy_198",
    "8205oxford handbook of clinical medicine 10th 2017 edition_samansarko _ copy_199",
    "8205oxford handbook of clinical medicine 10th 2017 edition_samansarko _ copy_200",
    "8205oxford handbook of clinical medicine 10th 2017 edition_samansarko _ copy_201",
    "8205oxford handbook of clinical medicine 10th 2017 edition_samansarko _ copy_202",
    "8205oxford handbook of clinical medicine 10th 2017 edition_samansarko _ copy_203",
    "8205oxford handbook of clinical medicine 10th 2017 edition_samansarko _ copy_204",
    "8205oxford handbook of clinical medicine 10th 2017 edition_samansarko _ copy_205",
    "8205oxford handbook of clinical medicine 10th 2017 edition_samansarko _ copy_206",
    "8205oxford handbook of clinical medicine 10th 2017 edition_samansarko _ copy_207",
    "8205oxford handbook of clinical medicine 10th 2017 edition_samansarko _ copy_208",
    "8205oxford handbook of clinical medicine 10th 2017 edition_samansarko _ copy_209",
    "8205oxford handbook of clinical medicine 10th 2017 edition_samansarko _ copy_210",
    "8205oxford handbook of clinical medicine 10th 2017 edition_samansarko _ copy_213",
    "8205oxford handbook of clinical medicine 10th 2017 edition_samansarko _ copy_214",
    "8205oxford handbook of clinical medicine 10th 2017 edition_samansarko _ copy_215",
    "8205oxford handbook of clinical medicine 10th 2017 edition_samansarko _ copy_216",
    "8205oxford handbook of clinical medicine 10th 2017 edition_samansarko _ copy_218",
    "8205oxford handbook of clinical medicine 10th 2017 edition_samansarko _ copy_219",
    "8205oxford handbook of clinical medicine 10th 2017 edition_samansarko _ copy_220",
    "8205oxford handbook of clinical medicine 10th 2017 edition_samansarko _ copy_221",
    "8205oxford handbook of clinical medicine 10th 2017 edition_samansarko _ copy_222",
    "8205oxford handbook of clinical medicine 10th 2017 edition_samansarko _ copy_223",
    "8205oxford handbook of clinical medicine 10th 2017 edition_samansarko _ copy_224",
    "8205oxford handbook of clinical medicine 10th 2017 edition_samansarko _ copy_225",
    "8205oxford handbook of clinical medicine 10th 2017 edition_samansarko _ copy_226",
    "8205oxford handbook of clinical medicine 10th 2017 edition_samansarko _ copy_227",
    "8205oxford handbook of clinical medicine 10th 2017 edition_samansarko _ copy_228",
    "8205oxford handbook of clinical medicine 10th 2017 edition_samansarko _ copy_229",
    "8205oxford handbook of clinical medicine 10th 2017 edition_samansarko _ copy_230",
    "8205oxford handbook of clinical medicine 10th 2017 edition_samansarko _ copy_231",
    "8205oxford handbook of clinical medicine 10th 2017 edition_samansarko _ copy_232",
    "8205oxford handbook of clinical medicine 10th 2017 edition_samansarko _ copy_233",
    "8205oxford handbook of clinical medicine 10th 2017 edition_samansarko _ copy_234",
    "8205oxford handbook of clinical medicine 10th 2017 edition_samansarko _ copy_235",
    "8205oxford handbook of clinical medicine 10th 2017 edition_samansarko _ copy_236",
    "8205oxford handbook of clinical medicine 10th 2017 edition_samansarko _ copy_237",
    "8205oxford handbook of clinical medicine 10th 2017 edition_samansarko _ copy_238",
    "8205oxford handbook of clinical medicine 10th 2017 edition_samansarko _ copy_239",
    "8205oxford handbook of clinical medicine 10th 2017 edition_samansarko _ copy_240",
    "8205oxford handbook of clinical medicine 10th 2017 edition_samansarko _ copy_241",
    "8205oxford handbook of clinical medicine 10th 2017 edition_samansarko _ copy_242",
    "8205oxford handbook of clinical medicine 10th 2017 edition_samansarko _ copy_244",
    "8205oxford handbook of clinical medicine 10th 2017 edition_samansarko _ copy_245",
    "8205oxford handbook of clinical medicine 10th 2017 edition_samansarko _ copy_246",
    "8205oxford handbook of clinical medicine 10th 2017 edition_samansarko _ copy_247",
    "8205oxford handbook of clinical medicine 10th 2017 edition_samansarko _ copy_248",
    "8205oxford handbook of clinical medicine 10th 2017 edition_samansarko _ copy_249",
    "8205oxford handbook of clinical medicine 10th 2017 edition_samansarko _ copy_250",
    "8205oxford handbook of clinical medicine 10th 2017 edition_samansarko _ copy_251",
    "8205oxford handbook of clinical medicine 10th 2017 edition_samansarko _ copy_252",
    "8205oxford handbook of clinical medicine 10th 2017 edition_samansarko _ copy_253",
    "8205oxford handbook of clinical medicine 10th 2017 edition_samansarko _ copy_254",
    "8205oxford handbook of clinical medicine 10th 2017 edition_samansarko _ copy_255",
    "8205oxford handbook of clinical medicine 10th 2017 edition_samansarko _ copy_256",
    "8205oxford handbook of clinical medicine 10th 2017 edition_samansarko _ copy_258",
    "8205oxford handbook of clinical medicine 10th 2017 edition_samansarko _ copy_260",
    "8205oxford handbook of clinical medicine 10th 2017 edition_samansarko _ copy_261",
    "8205oxford handbook of clinical medicine 10th 2017 edition_samansarko _ copy_262",
    "8205oxford handbook of clinical medicine 10th 2017 edition_samansarko _ copy_263",
    "8205oxford handbook of clinical medicine 10th 2017 edition_samansarko _ copy_264",
    "8205oxford handbook of clinical medicine 10th 2017 edition_samansarko _ copy_266",
    "8205oxford handbook of clinical medicine 10th 2017 edition_samansarko _ copy_267",
    "8205oxford handbook of clinical medicine 10th 2017 edition_samansarko _ copy_268",
    "8205oxford handbook of clinical medicine 10th 2017 edition_samansarko _ copy_269",
    "8205oxford handbook of clinical medicine 10th 2017 edition_samansarko _ copy_270",
    "8205oxford handbook of clinical medicine 10th 2017 edition_samansarko _ copy_271",
    "8205oxford handbook of clinical medicine 10th 2017 edition_samansarko _ copy_272",
    "8205oxford handbook of clinical medicine 10th 2017 edition_samansarko _ copy_273",
    "8205oxford handbook of clinical medicine 10th 2017 edition_samansarko _ copy_274",
    "8205oxford handbook of clinical medicine 10th 2017 edition_samansarko _ copy_275",
    "8205oxford handbook of clinical medicine 10th 2017 edition_samansarko _ copy_276",
    "8205oxford handbook of clinical medicine 10th 2017 edition_samansarko _ copy_277",
    "8205oxford handbook of clinical medicine 10th 2017 edition_samansarko _ copy_278",
    "8205oxford handbook of clinical medicine 10th 2017 edition_samansarko _ copy_279",
    "8205oxford handbook of clinical medicine 10th 2017 edition_samansarko _ copy_280",
    "8205oxford handbook of clinical medicine 10th 2017 edition_samansarko _ copy_283",
    "8205oxford handbook of clinical medicine 10th 2017 edition_samansarko _ copy_284",
    "8205oxford handbook of clinical medicine 10th 2017 edition_samansarko _ copy_285",
    "8205oxford handbook of clinical medicine 10th 2017 edition_samansarko _ copy_286",
    "8205oxford handbook of clinical medicine 10th 2017 edition_samansarko _ copy_287",
    "8205oxford handbook of clinical medicine 10th 2017 edition_samansarko _ copy_288",
    "8205oxford handbook of clinical medicine 10th 2017 edition_samansarko _ copy_289",
    "8205oxford handbook of clinical medicine 10th 2017 edition_samansarko _ copy_290",
    "8205oxford handbook of clinical medicine 10th 2017 edition_samansarko _ copy_291",
    "8205oxford handbook of clinical medicine 10th 2017 edition_samansarko _ copy_292",
    "8205oxford handbook of clinical medicine 10th 2017 edition_samansarko _ copy_293",
    "8205oxford handbook of clinical medicine 10th 2017 edition_samansarko _ copy_294",
    "8205oxford handbook of clinical medicine 10th 2017 edition_samansarko _ copy_295",
    "8205oxford handbook of clinical medicine 10th 2017 edition_samansarko _ copy_298",
    "8205oxford handbook of clinical medicine 10th 2017 edition_samansarko _ copy_299",
    "8205oxford handbook of clinical medicine 10th 2017 edition_samansarko _ copy_300",
    "8205oxford handbook of clinical medicine 10th 2017 edition_samansarko _ copy_301",
    "8205oxford handbook of clinical medicine 10th 2017 edition_samansarko _ copy_302",
    "8205oxford handbook of clinical medicine 10th 2017 edition_samansarko _ copy_303",
    "8205oxford handbook of clinical medicine 10th 2017 edition_samansarko _ copy_304",
    "8205oxford handbook of clinical medicine 10th 2017 edition_samansarko _ copy_305",
    "8205oxford handbook of clinical medicine 10th 2017 edition_samansarko _ copy_306",
    "8205oxford handbook of clinical medicine 10th 2017 edition_samansarko _ copy_307",
    "8205oxford handbook of clinical medicine 10th 2017 edition_samansarko _ copy_308",
    "8205oxford handbook of clinical medicine 10th 2017 edition_samansarko _ copy_309",
    "8205oxford handbook of clinical medicine 10th 2017 edition_samansarko _ copy_310",
    "8205oxford handbook of clinical medicine 10th 2017 edition_samansarko _ copy_311",
    "8205oxford handbook of clinical medicine 10th 2017 edition_samansarko _ copy_312",
    "8205oxford handbook of clinical medicine 10th 2017 edition_samansarko _ copy_313",
    "8205oxford handbook of clinical medicine 10th 2017 edition_samansarko _ copy_314",
    "8205oxford handbook of clinical medicine 10th 2017 edition_samansarko _ copy_315",
    "8205oxford handbook of clinical medicine 10th 2017 edition_samansarko _ copy_316",
    "8205oxford handbook of clinical medicine 10th 2017 edition_samansarko _ copy_317",
    "8205oxford handbook of clinical medicine 10th 2017 edition_samansarko _ copy_318",
    "8205oxford handbook of clinical medicine 10th 2017 edition_samansarko _ copy_319",
    "8205oxford handbook of clinical medicine 10th 2017 edition_samansarko _ copy_320",
    "8205oxford handbook of clinical medicine 10th 2017 edition_samansarko _ copy_321",
    "8205oxford handbook of clinical medicine 10th 2017 edition_samansarko _ copy_322",
    "8205oxford handbook of clinical medicine 10th 2017 edition_samansarko _ copy_323",
    "8205oxford handbook of clinical medicine 10th 2017 edition_samansarko _ copy_324",
    "8205oxford handbook of clinical medicine 10th 2017 edition_samansarko _ copy_325",
    "8205oxford handbook of clinical medicine 10th 2017 edition_samansarko _ copy_326",
    "8205oxford handbook of clinical medicine 10th 2017 edition_samansarko _ copy_327",
    "8205oxford handbook of clinical medicine 10th 2017 edition_samansarko _ copy_328",
    "8205oxford handbook of clinical medicine 10th 2017 edition_samansarko _ copy_329",
    "8205oxford handbook of clinical medicine 10th 2017 edition_samansarko _ copy_330",
    "8205oxford handbook of clinical medicine 10th 2017 edition_samansarko _ copy_332",
    "8205oxford handbook of clinical medicine 10th 2017 edition_samansarko _ copy_333",
    "8205oxford handbook of clinical medicine 10th 2017 edition_samansarko _ copy_334",
    "8205oxford handbook of clinical medicine 10th 2017 edition_samansarko _ copy_335",
    "8205oxford handbook of clinical medicine 10th 2017 edition_samansarko _ copy_341",
    "8205oxford handbook of clinical medicine 10th 2017 edition_samansarko _ copy_342",
    "8205oxford handbook of clinical medicine 10th 2017 edition_samansarko _ copy_344",
    "8205oxford handbook of clinical medicine 10th 2017 edition_samansarko _ copy_346",
    "8205oxford handbook of clinical medicine 10th 2017 edition_samansarko _ copy_347",
    "8205oxford handbook of clinical medicine 10th 2017 edition_samansarko _ copy_348",
    "8205oxford handbook of clinical medicine 10th 2017 edition_samansarko _ copy_349",
    "8205oxford handbook of clinical medicine 10th 2017 edition_samansarko _ copy_350",
    "8205oxford handbook of clinical medicine 10th 2017 edition_samansarko _ copy_351",
    "8205oxford handbook of clinical medicine 10th 2017 edition_samansarko _ copy_352",
    "8205oxford handbook of clinical medicine 10th 2017 edition_samansarko _ copy_353",
    "8205oxford handbook of clinical medicine 10th 2017 edition_samansarko _ copy_354",
    "8205oxford handbook of clinical medicine 10th 2017 edition_samansarko _ copy_355",
    "8205oxford handbook of clinical medicine 10th 2017 edition_samansarko _ copy_357",
    "8205oxford handbook of clinical medicine 10th 2017 edition_samansarko _ copy_358",
    "8205oxford handbook of clinical medicine 10th 2017 edition_samansarko _ copy_359",
    "8205oxford handbook of clinical medicine 10th 2017 edition_samansarko _ copy_360",
    "8205oxford handbook of clinical medicine 10th 2017 edition_samansarko _ copy_361",
    "8205oxford handbook of clinical medicine 10th 2017 edition_samansarko _ copy_363",
    "8205oxford handbook of clinical medicine 10th 2017 edition_samansarko _ copy_364",
    "8205oxford handbook of clinical medicine 10th 2017 edition_samansarko _ copy_365",
    "8205oxford handbook of clinical medicine 10th 2017 edition_samansarko _ copy_366",
    "8205oxford handbook of clinical medicine 10th 2017 edition_samansarko _ copy_367",
    "8205oxford handbook of clinical medicine 10th 2017 edition_samansarko _ copy_369",
    "8205oxford handbook of clinical medicine 10th 2017 edition_samansarko _ copy_370",
    "8205oxford handbook of clinical medicine 10th 2017 edition_samansarko _ copy_371",
    "8205oxford handbook of clinical medicine 10th 2017 edition_samansarko _ copy_372",
    "8205oxford handbook of clinical medicine 10th 2017 edition_samansarko _ copy_374",
    "8205oxford handbook of clinical medicine 10th 2017 edition_samansarko _ copy_375",
    "8205oxford handbook of clinical medicine 10th 2017 edition_samansarko _ copy_376",
    "8205oxford handbook of clinical medicine 10th 2017 edition_samansarko _ copy_377",
    "8205oxford handbook of clinical medicine 10th 2017 edition_samansarko _ copy_378",
    "8205oxford handbook of clinical medicine 10th 2017 edition_samansarko _ copy_379",
    "8205oxford handbook of clinical medicine 10th 2017 edition_samansarko _ copy_382",
    "8205oxford handbook of clinical medicine 10th 2017 edition_samansarko _ copy_384",
    "8205oxford handbook of clinical medicine 10th 2017 edition_samansarko _ copy_385",
    "8205oxford handbook of clinical medicine 10th 2017 edition_samansarko _ copy_386",
    "8205oxford handbook of clinical medicine 10th 2017 edition_samansarko _ copy_387",
    "8205oxford handbook of clinical medicine 10th 2017 edition_samansarko _ copy_388",
    "8205oxford handbook of clinical medicine 10th 2017 edition_samansarko _ copy_389",
    "8205oxford handbook of clinical medicine 10th 2017 edition_samansarko _ copy_390",
    "8205oxford handbook of clinical medicine 10th 2017 edition_samansarko _ copy_391",
    "8205oxford handbook of clinical medicine 10th 2017 edition_samansarko _ copy_393",
    "8205oxford handbook of clinical medicine 10th 2017 edition_samansarko _ copy_394",
    "8205oxford handbook of clinical medicine 10th 2017 edition_samansarko _ copy_395",
    "8205oxford handbook of clinical medicine 10th 2017 edition_samansarko _ copy_396",
    "8205oxford handbook of clinical medicine 10th 2017 edition_samansarko _ copy_397",
    "8205oxford handbook of clinical medicine 10th 2017 edition_samansarko _ copy_398",
    "8205oxford handbook of clinical medicine 10th 2017 edition_samansarko _ copy_399",
    "8205oxford handbook of clinical medicine 10th 2017 edition_samansarko _ copy_400",
    "8205oxford handbook of clinical medicine 10th 2017 edition_samansarko _ copy_401",
    "8205oxford handbook of clinical medicine 10th 2017 edition_samansarko _ copy_402",
    "8205oxford handbook of clinical medicine 10th 2017 edition_samansarko _ copy_403",
    "8205oxford handbook of clinical medicine 10th 2017 edition_samansarko _ copy_404",
    "8205oxford handbook of clinical medicine 10th 2017 edition_samansarko _ copy_405",
    "8205oxford handbook of clinical medicine 10th 2017 edition_samansarko _ copy_406",
    "8205oxford handbook of clinical medicine 10th 2017 edition_samansarko _ copy_407",
    "8205oxford handbook of clinical medicine 10th 2017 edition_samansarko _ copy_408",
    "8205oxford handbook of clinical medicine 10th 2017 edition_samansarko _ copy_409",
    "8205oxford handbook of clinical medicine 10th 2017 edition_samansarko _ copy_410",
    "8205oxford handbook of clinical medicine 10th 2017 edition_samansarko _ copy_411",
    "8205oxford handbook of clinical medicine 10th 2017 edition_samansarko _ copy_412",
    "8205oxford handbook of clinical medicine 10th 2017 edition_samansarko _ copy_413",
    "8205oxford handbook of clinical medicine 10th 2017 edition_samansarko _ copy_415",
    "8205oxford handbook of clinical medicine 10th 2017 edition_samansarko _ copy_416",
    "8205oxford handbook of clinical medicine 10th 2017 edition_samansarko _ copy_417",
    "8205oxford handbook of clinical medicine 10th 2017 edition_samansarko _ copy_419",
    "8205oxford handbook of clinical medicine 10th 2017 edition_samansarko _ copy_421",
    "8205oxford handbook of clinical medicine 10th 2017 edition_samansarko _ copy_422",
    "8205oxford handbook of clinical medicine 10th 2017 edition_samansarko _ copy_423",
    "8205oxford handbook of clinical medicine 10th 2017 edition_samansarko _ copy_424",
    "8205oxford handbook of clinical medicine 10th 2017 edition_samansarko _ copy_425",
    "8205oxford handbook of clinical medicine 10th 2017 edition_samansarko _ copy_426",
    "8205oxford handbook of clinical medicine 10th 2017 edition_samansarko _ copy_427",
    "8205oxford handbook of clinical medicine 10th 2017 edition_samansarko _ copy_429",
    "8205oxford handbook of clinical medicine 10th 2017 edition_samansarko _ copy_430",
    "8205oxford handbook of clinical medicine 10th 2017 edition_samansarko _ copy_431",
    "8205oxford handbook of clinical medicine 10th 2017 edition_samansarko _ copy_432",
    "8205oxford handbook of clinical medicine 10th 2017 edition_samansarko _ copy_433",
    "8205oxford handbook of clinical medicine 10th 2017 edition_samansarko _ copy_434",
    "8205oxford handbook of clinical medicine 10th 2017 edition_samansarko _ copy_439",
    "8205oxford handbook of clinical medicine 10th 2017 edition_samansarko _ copy_440",
    "8205oxford handbook of clinical medicine 10th 2017 edition_samansarko _ copy_441",
    "8205oxford handbook of clinical medicine 10th 2017 edition_samansarko _ copy_442",
    "8205oxford handbook of clinical medicine 10th 2017 edition_samansarko _ copy_444",
    "8205oxford handbook of clinical medicine 10th 2017 edition_samansarko _ copy_445",
    "8205oxford handbook of clinical medicine 10th 2017 edition_samansarko _ copy_446",
    "8205oxford handbook of clinical medicine 10th 2017 edition_samansarko _ copy_447",
    "8205oxford handbook of clinical medicine 10th 2017 edition_samansarko _ copy_448",
    "8205oxford handbook of clinical medicine 10th 2017 edition_samansarko _ copy_449",
    "8205oxford handbook of clinical medicine 10th 2017 edition_samansarko _ copy_450",
    "8205oxford handbook of clinical medicine 10th 2017 edition_samansarko _ copy_452",
    "8205oxford handbook of clinical medicine 10th 2017 edition_samansarko _ copy_453",
    "8205oxford handbook of clinical medicine 10th 2017 edition_samansarko _ copy_454",
    "8205oxford handbook of clinical medicine 10th 2017 edition_samansarko _ copy_455",
    "8205oxford handbook of clinical medicine 10th 2017 edition_samansarko _ copy_456",
    "8205oxford handbook of clinical medicine 10th 2017 edition_samansarko _ copy_457",
    "8205oxford handbook of clinical medicine 10th 2017 edition_samansarko _ copy_458",
    "8205oxford handbook of clinical medicine 10th 2017 edition_samansarko _ copy_459",
    "8205oxford handbook of clinical medicine 10th 2017 edition_samansarko _ copy_460",
    "8205oxford handbook of clinical medicine 10th 2017 edition_samansarko _ copy_461",
    "8205oxford handbook of clinical medicine 10th 2017 edition_samansarko _ copy_462",
    "8205oxford handbook of clinical medicine 10th 2017 edition_samansarko _ copy_463",
    "8205oxford handbook of clinical medicine 10th 2017 edition_samansarko _ copy_464",
    "8205oxford handbook of clinical medicine 10th 2017 edition_samansarko _ copy_465",
    "8205oxford handbook of clinical medicine 10th 2017 edition_samansarko _ copy_466",
    "8205oxford handbook of clinical medicine 10th 2017 edition_samansarko _ copy_467",
    "8205oxford handbook of clinical medicine 10th 2017 edition_samansarko _ copy_468",
    "8205oxford handbook of clinical medicine 10th 2017 edition_samansarko _ copy_469",
    "8205oxford handbook of clinical medicine 10th 2017 edition_samansarko _ copy_470",
    "8205oxford handbook of clinical medicine 10th 2017 edition_samansarko _ copy_471",
    "8205oxford handbook of clinical medicine 10th 2017 edition_samansarko _ copy_472",
    "8205oxford handbook of clinical medicine 10th 2017 edition_samansarko _ copy_473",
    "8205oxford handbook of clinical medicine 10th 2017 edition_samansarko _ copy_474",
    "8205oxford handbook of clinical medicine 10th 2017 edition_samansarko _ copy_475",
    "8205oxford handbook of clinical medicine 10th 2017 edition_samansarko _ copy_476",
    "8205oxford handbook of clinical medicine 10th 2017 edition_samansarko _ copy_477",
    "8205oxford handbook of clinical medicine 10th 2017 edition_samansarko _ copy_478",
    "8205oxford handbook of clinical medicine 10th 2017 edition_samansarko _ copy_479",
    "8205oxford handbook of clinical medicine 10th 2017 edition_samansarko _ copy_480",
    "8205oxford handbook of clinical medicine 10th 2017 edition_samansarko _ copy_481",
    "8205oxford handbook of clinical medicine 10th 2017 edition_samansarko _ copy_482",
    "8205oxford handbook of clinical medicine 10th 2017 edition_samansarko _ copy_483",
    "8205oxford handbook of clinical medicine 10th 2017 edition_samansarko _ copy_484",
    "8205oxford handbook of clinical medicine 10th 2017 edition_samansarko _ copy_485",
    "8205oxford handbook of clinical medicine 10th 2017 edition_samansarko _ copy_486",
    "8205oxford handbook of clinical medicine 10th 2017 edition_samansarko _ copy_487",
    "8205oxford handbook of clinical medicine 10th 2017 edition_samansarko _ copy_488",
    "8205oxford handbook of clinical medicine 10th 2017 edition_samansarko _ copy_489",
    "8205oxford handbook of clinical medicine 10th 2017 edition_samansarko _ copy_490",
    "8205oxford handbook of clinical medicine 10th 2017 edition_samansarko _ copy_491",
    "8205oxford handbook of clinical medicine 10th 2017 edition_samansarko _ copy_492",
    "8205oxford handbook of clinical medicine 10th 2017 edition_samansarko _ copy_493",
    "8205oxford handbook of clinical medicine 10th 2017 edition_samansarko _ copy_494",
    "8205oxford handbook of clinical medicine 10th 2017 edition_samansarko _ copy_495",
    "8205oxford handbook of clinical medicine 10th 2017 edition_samansarko _ copy_496",
    "8205oxford handbook of clinical medicine 10th 2017 edition_samansarko _ copy_497",
    "8205oxford handbook of clinical medicine 10th 2017 edition_samansarko _ copy_498",
    "8205oxford handbook of clinical medicine 10th 2017 edition_samansarko _ copy_499",
    "8205oxford handbook of clinical medicine 10th 2017 edition_samansarko _ copy_500",
    "8205oxford handbook of clinical medicine 10th 2017 edition_samansarko _ copy_501",
    "8205oxford handbook of clinical medicine 10th 2017 edition_samansarko _ copy_502",
    "8205oxford handbook of clinical medicine 10th 2017 edition_samansarko _ copy_503",
    "8205oxford handbook of clinical medicine 10th 2017 edition_samansarko _ copy_504",
    "8205oxford handbook of clinical medicine 10th 2017 edition_samansarko _ copy_506",
    "8205oxford handbook of clinical medicine 10th 2017 edition_samansarko _ copy_507",
    "8205oxford handbook of clinical medicine 10th 2017 edition_samansarko _ copy_509",
    "8205oxford handbook of clinical medicine 10th 2017 edition_samansarko _ copy_510",
    "8205oxford handbook of clinical medicine 10th 2017 edition_samansarko _ copy_512",
    "8205oxford handbook of clinical medicine 10th 2017 edition_samansarko _ copy_513",
    "8205oxford handbook of clinical medicine 10th 2017 edition_samansarko _ copy_514",
    "8205oxford handbook of clinical medicine 10th 2017 edition_samansarko _ copy_515",
    "8205oxford handbook of clinical medicine 10th 2017 edition_samansarko _ copy_516",
    "8205oxford handbook of clinical medicine 10th 2017 edition_samansarko _ copy_518",
    "8205oxford handbook of clinical medicine 10th 2017 edition_samansarko _ copy_519",
    "8205oxford handbook of clinical medicine 10th 2017 edition_samansarko _ copy_520",
    "8205oxford handbook of clinical medicine 10th 2017 edition_samansarko _ copy_522",
    "8205oxford handbook of clinical medicine 10th 2017 edition_samansarko _ copy_523",
    "8205oxford handbook of clinical medicine 10th 2017 edition_samansarko _ copy_524",
    "8205oxford handbook of clinical medicine 10th 2017 edition_samansarko _ copy_526",
    "8205oxford handbook of clinical medicine 10th 2017 edition_samansarko _ copy_527",
    "8205oxford handbook of clinical medicine 10th 2017 edition_samansarko _ copy_528",
    "8205oxford handbook of clinical medicine 10th 2017 edition_samansarko _ copy_531",
    "8205oxford handbook of clinical medicine 10th 2017 edition_samansarko _ copy_532",
    "8205oxford handbook of clinical medicine 10th 2017 edition_samansarko _ copy_533",
    "8205oxford handbook of clinical medicine 10th 2017 edition_samansarko _ copy_534",
    "8205oxford handbook of clinical medicine 10th 2017 edition_samansarko _ copy_535",
    "8205oxford handbook of clinical medicine 10th 2017 edition_samansarko _ copy_536",
    "8205oxford handbook of clinical medicine 10th 2017 edition_samansarko _ copy_537",
    "8205oxford handbook of clinical medicine 10th 2017 edition_samansarko _ copy_538",
    "8205oxford handbook of clinical medicine 10th 2017 edition_samansarko _ copy_539",
    "8205oxford handbook of clinical medicine 10th 2017 edition_samansarko _ copy_540",
    "8205oxford handbook of clinical medicine 10th 2017 edition_samansarko _ copy_541",
    "8205oxford handbook of clinical medicine 10th 2017 edition_samansarko _ copy_542",
    "8205oxford handbook of clinical medicine 10th 2017 edition_samansarko _ copy_544",
    "8205oxford handbook of clinical medicine 10th 2017 edition_samansarko _ copy_546",
    "8205oxford handbook of clinical medicine 10th 2017 edition_samansarko _ copy_547",
    "8205oxford handbook of clinical medicine 10th 2017 edition_samansarko _ copy_548",
    "8205oxford handbook of clinical medicine 10th 2017 edition_samansarko _ copy_549",
    "8205oxford handbook of clinical medicine 10th 2017 edition_samansarko _ copy_557",
    "8205oxford handbook of clinical medicine 10th 2017 edition_samansarko _ copy_559",
    "8205oxford handbook of clinical medicine 10th 2017 edition_samansarko _ copy_562",
    "8205oxford handbook of clinical medicine 10th 2017 edition_samansarko _ copy_563",
    "8205oxford handbook of clinical medicine 10th 2017 edition_samansarko _ copy_565",
    "8205oxford handbook of clinical medicine 10th 2017 edition_samansarko _ copy_567",
    "8205oxford handbook of clinical medicine 10th 2017 edition_samansarko _ copy_569",
    "8205oxford handbook of clinical medicine 10th 2017 edition_samansarko _ copy_570",
    "8205oxford handbook of clinical medicine 10th 2017 edition_samansarko _ copy_571",
    "8205oxford handbook of clinical medicine 10th 2017 edition_samansarko _ copy_572",
    "8205oxford handbook of clinical medicine 10th 2017 edition_samansarko _ copy_573",
    "8205oxford handbook of clinical medicine 10th 2017 edition_samansarko _ copy_574",
    "8205oxford handbook of clinical medicine 10th 2017 edition_samansarko _ copy_576",
    "8205oxford handbook of clinical medicine 10th 2017 edition_samansarko _ copy_577",
    "8205oxford handbook of clinical medicine 10th 2017 edition_samansarko _ copy_578",
    "8205oxford handbook of clinical medicine 10th 2017 edition_samansarko _ copy_579",
    "8205oxford handbook of clinical medicine 10th 2017 edition_samansarko _ copy_580",
    "8205oxford handbook of clinical medicine 10th 2017 edition_samansarko _ copy_581",
    "8205oxford handbook of clinical medicine 10th 2017 edition_samansarko _ copy_582",
    "8205oxford handbook of clinical medicine 10th 2017 edition_samansarko _ copy_583",
    "8205oxford handbook of clinical medicine 10th 2017 edition_samansarko _ copy_584",
    "8205oxford handbook of clinical medicine 10th 2017 edition_samansarko _ copy_585",
    "8205oxford handbook of clinical medicine 10th 2017 edition_samansarko _ copy_587",
    "8205oxford handbook of clinical medicine 10th 2017 edition_samansarko _ copy_588",
    "8205oxford handbook of clinical medicine 10th 2017 edition_samansarko _ copy_589",
    "8205oxford handbook of clinical medicine 10th 2017 edition_samansarko _ copy_590",
    "8205oxford handbook of clinical medicine 10th 2017 edition_samansarko _ copy_591",
    "8205oxford handbook of clinical medicine 10th 2017 edition_samansarko _ copy_592",
    "8205oxford handbook of clinical medicine 10th 2017 edition_samansarko _ copy_593",
    "8205oxford handbook of clinical medicine 10th 2017 edition_samansarko _ copy_594",
    "8205oxford handbook of clinical medicine 10th 2017 edition_samansarko _ copy_595",
    "8205oxford handbook of clinical medicine 10th 2017 edition_samansarko _ copy_596",
    "8205oxford handbook of clinical medicine 10th 2017 edition_samansarko _ copy_598",
    "8205oxford handbook of clinical medicine 10th 2017 edition_samansarko _ copy_599",
    "8205oxford handbook of clinical medicine 10th 2017 edition_samansarko _ copy_600",
    "8205oxford handbook of clinical medicine 10th 2017 edition_samansarko _ copy_620",
    "8205oxford handbook of clinical medicine 10th 2017 edition_samansarko _ copy_621",
    "8205oxford handbook of clinical medicine 10th 2017 edition_samansarko _ copy_623",
    "8205oxford handbook of clinical medicine 10th 2017 edition_samansarko _ copy_624",
    "8205oxford handbook of clinical medicine 10th 2017 edition_samansarko _ copy_626",
    "8205oxford handbook of clinical medicine 10th 2017 edition_samansarko _ copy_627",
    "8205oxford handbook of clinical medicine 10th 2017 edition_samansarko _ copy_629",
    "8205oxford handbook of clinical medicine 10th 2017 edition_samansarko _ copy_630",
    "8205oxford handbook of clinical medicine 10th 2017 edition_samansarko _ copy_631",
    "8205oxford handbook of clinical medicine 10th 2017 edition_samansarko _ copy_632",
    "8205oxford handbook of clinical medicine 10th 2017 edition_samansarko _ copy_633",
    "8205oxford handbook of clinical medicine 10th 2017 edition_samansarko _ copy_634",
    "8205oxford handbook of clinical medicine 10th 2017 edition_samansarko _ copy_635",
    "8205oxford handbook of clinical medicine 10th 2017 edition_samansarko _ copy_636",
    "8205oxford handbook of clinical medicine 10th 2017 edition_samansarko _ copy_637",
    "8205oxford handbook of clinical medicine 10th 2017 edition_samansarko _ copy_638",
    "8205oxford handbook of clinical medicine 10th 2017 edition_samansarko _ copy_639",
    "8205oxford handbook of clinical medicine 10th 2017 edition_samansarko _ copy_640",
    "8205oxford handbook of clinical medicine 10th 2017 edition_samansarko _ copy_641",
    "8205oxford handbook of clinical medicine 10th 2017 edition_samansarko _ copy_642",
    "8205oxford handbook of clinical medicine 10th 2017 edition_samansarko _ copy_644",
    "8205oxford handbook of clinical medicine 10th 2017 edition_samansarko _ copy_646",
    "8205oxford handbook of clinical medicine 10th 2017 edition_samansarko _ copy_647",
    "8205oxford handbook of clinical medicine 10th 2017 edition_samansarko _ copy_648"
  ]
}